PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	PROPST, T; PROPST, A; DIETZE, O; JUDMAIER, G; BRAUNSTEINER, H; VOGEL, W				PROPST, T; PROPST, A; DIETZE, O; JUDMAIER, G; BRAUNSTEINER, H; VOGEL, W			HIGH PREVALENCE OF VIRAL-INFECTION IN ADULTS WITH HOMOZYGOUS AND HETEROZYGOUS ALPHA(1)-ANTITRYPSIN DEFICIENCY AND CHRONIC LIVER-DISEASE	ANNALS OF INTERNAL MEDICINE			English	Article						ALPHA-1-ANTITRYPSIN; HEPATITIS, CHRONIC ACTIVE; LIVER CIRRHOSIS; HEPATITIS ANTIBODIES; HEPATITIS-C VIRUS	HEPATITIS-C VIRUS; ALPHA-ANTITRYPSIN DEFICIENCY; CHRONIC ACTIVE HEPATITIS; ALPHA-1-ANTITRYPSIN DEFICIENCY; MALIGNANT HEPATOMA; CYTO-TOXICITY; CIRRHOSIS; ANTIBODIES; EMPHYSEMA; PROTEIN	Objective: To determine the prevalence of chronic liver disease in adults with homozygous (Pi ZZ) and heterozygous (Pi Z) alpha1-antitrypsin deficiency and to assess the presence of other possible risk factors for the development of chronic active hepatitis and cirrhosis of the liver in these patients. Design: Cross-sectional study. Setting: A referral-based university hospital. Patients: Consecutive patients (164) with the Pi ZZ and Pi Z phenotype with and without chronic liver disease. Measurements: The presence of antibody to hepatitis C virus (anti-HCV) was determined using an assay incorporating synthetic peptide antigen from capsid protein (United Biomedical [UBI] assay) and a second-generation enzyme immunoassay (Abbott test); the presence of antibody to hepatitis B virus (anti-HBV) was determined using radioimmunoassays incorporating hepatitis B surface antigen (HBsAg) and hepatitis B core antigen (HBcAg); assays for antinuclear antibody and antimitochondrial antibody (M2 subtype) were also done, and alcohol abuse was assessed by history. Results: Among patients with cirrhosis (32%), 62% were anti-HCV positive by the Abbott test (P = 0.006), and 41% were anti-HCV positive by the UBI assay (P = 0.007). Thirty-three percent of patients with cirrhosis had hepatitis B virus (HBV) infection (P = 0.01); 41% had a history of alcoholism; and 12% had features of autoimmune liver disease. Only five patients (9%) with cirrhosis had no other risk factor for chronic liver disease. Among patients with chronic active hepatitis (7%), 80% were anti-HCV positive by the Abbott test (P = 0.002), and 75% were anti-HCV positive by the UBI assay (P < 0.001). Thirty percent of patients with chronic active hepatitis had HBV infection (P = 0.023); 18% had autoimmune hepatitis; and 8% abused alcohol. Only two patients (17%) had no additional risk factor for the development of chronic active hepatitis. Among patients with steatosis of the liver (48%), 5% were anti-HCV positive by the Abbott test, and none were anti-HCV positive by the UBI assay; 18% had serologic evidence of past HBV infection, and 28% abused alcohol. Among patients without chronic liver disease (13%), no viral infection could be found; 9% were alcoholics. Conclusions: Chronic liver disease in patients with alpha1-antitrypsin deficiency is associated with a high prevalence of viral infection; this infection, rather than alpha1-antitrypsin deficiency alone, may be the cause of the liver disease in such patients.	UNIV INNSBRUCK, DEPT INTERNAL MED, A-6020 INNSBRUCK, AUSTRIA; UNIV INNSBRUCK, DEPT PATHOL, A-6020 INNSBRUCK, AUSTRIA	University of Innsbruck; University of Innsbruck	PROPST, T (corresponding author), UNIV HOSP INNSBRUCK, DEPT INTERNAL MED, ANICHSTR 35, A-6020 INNSBRUCK, AUSTRIA.							ADES EW, 1982, SCAND J IMMUNOL, V15, P109, DOI 10.1111/j.1365-3083.1982.tb00628.x; BRANTLY M, 1988, SCIENCE, V242, P1700, DOI 10.1126/science.2904702; BREIT SN, 1985, CLIN IMMUNOL IMMUNOP, V35, P363, DOI 10.1016/0090-1229(85)90097-2; BRILLANTI S, 1989, LANCET, V2, P1390; CARLSON J, 1985, SCAND J GASTROENTERO, V20, P835, DOI 10.3109/00365528509088831; CARLSON JA, 1989, J CLIN INVEST, V83, P1183, DOI 10.1172/JCI113999; COX DW, 1980, HUM GENET, V53, P429, DOI 10.1007/BF00287070; CRELL RW, 1979, ESSAYS MED BIOCH, V4, P83; ERIKSSON S, 1974, ACTA MED SCAND, V195, P451; ERIKSSON S, 1986, NEW ENGL J MED, V314, P736, DOI 10.1056/NEJM198603203141202; FATTOVICH G, 1989, LANCET, V2, P797; FISHER RL, 1976, GASTROENTEROLOGY, V71, P646; GADEK JE, 1981, J CLIN INVEST, V68, P889, DOI 10.1172/JCI110344; GELLER SA, 1990, HEPATOLOGY, V12, P40, DOI 10.1002/hep.1840120108; HODGES JR, 1981, NEW ENGL J MED, V304, P557, DOI 10.1056/NEJM198103053041001; HOSEIN B, 1991, P NATL ACAD SCI USA, V88, P3647, DOI 10.1073/pnas.88.9.3647; HUDIG D, 1981, J IMMUNOL, V126, P1569; LENZI M, 1990, LANCET, V335, P258, DOI 10.1016/0140-6736(90)90070-L; LENZI M, 1991, LANCET, V338, P277, DOI 10.1016/0140-6736(91)90418-O; MORIN T, 1975, LANCET, V1, P250; PERLMUTTER DH, 1989, AM J PHYSIOL, V257, pL147, DOI 10.1152/ajplung.1989.257.4.L147; PERLMUTTER DH, 1991, HEPATOLOGY, V13, P172, DOI 10.1002/hep.1840130125; ROGET M, 1990, HEPATOLOGY, V11, P333, DOI 10.1002/hep.1840110234; SANCHEZTAPIAS JM, 1990, ANN INTERN MED, V112, P921, DOI 10.7326/0003-4819-112-12-921; SCHROEDER WT, 1985, AM J HUM GENET, V37, P868; SHARP HL, 1971, J LAB CLIN MED, V78, P1012; SHARP HL, 1969, J LAB CLIN MED, V73, P934; SHARP HL, 1982, SEMIN LIVER DIS, V2, P314, DOI 10.1055/s-2008-1040718; SVEGER T, 1976, NEW ENGL J MED, V294, P1316, DOI 10.1056/NEJM197606102942404; TILG H, 1992, GASTROENTEROLOGY, V103, P264, DOI 10.1016/0016-5085(92)91122-K; WEWERS MD, 1987, NEW ENGL J MED, V316, P1055, DOI 10.1056/NEJM198704233161704	31	81	84	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1992	117	8					641	645		10.7326/0003-4819-117-8-641	http://dx.doi.org/10.7326/0003-4819-117-8-641			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JR861	1530195				2022-12-01	WOS:A1992JR86100003
J	THOMPSON, LT; MOSKAL, JR; DISTERHOFT, JF				THOMPSON, LT; MOSKAL, JR; DISTERHOFT, JF			HIPPOCAMPUS-DEPENDENT LEARNING FACILITATED BY A MONOCLONAL-ANTIBODY OR D-CYCLOSERINE	NATURE			English	Article							D-ASPARTATE RECEPTOR; LONG-TERM POTENTIATION; NICTITATING-MEMBRANE RESPONSE; RAT-BRAIN; ALZHEIMERS-DISEASE; MODULATORY SITE; PARTIAL AGONIST; GLYCINE; RABBITS; COMPLEX	PERSISTENT neuronal plasticity, including that observed at some hippocampal synapses, requires N-methyl-D-aspartate (NMDA)-mediated transmission. NMDA receptor activation may be necessary for hippocampus-dependent learning as antagonists block acquisition in many such tasks. The behavioural effects of NMDA agonists are less well defined. We have shown that a monoclonal antibody (B6B21) displaced [H-3]-glycine that was bound specifically to the NMDA receptor, and enhanced the opening of its integral cation channel in a glycine-like fashion, effects that were competitively antagonized by 7-chlorokynurenic acid1. B6B21 also enhanced long-term potentiation in hippocampal slices1. We report here that intraventricular infusions of B6B21 significantly enhances acquisition rates in hippocampus-dependent trace eye blink conditioning in rabbits, halving the number of trials required to reach a criterion of 80% conditioned responses. Peripheral injections Of D-cycloserine, a partial agonist of the glycine site on the NMDA receptor which crosses the blood-brain barrier, also doubles rabbits' learning rates. Pseudoconditioning control experiments indicated a lack of nonspecific behavioural sensitization effects. Our data suggest that enhanced activation of the glycine coagonist site on the NMDA receptor/channel complex facilitates one form of associative learning and may be used in other learning tasks.	CHICAGO INST NEUROSURG & NEURORES,CHICAGO,IL 60614		THOMPSON, LT (corresponding author), NORTHWESTERN UNIV,SCH MED,DEPT CELL MOLEC & STRUCT BIOL,303 E CHICAGO AVE,CHICAGO,IL 60611, USA.		Thompson, Lucien/F-3496-2012; Moskal, Joseph/B-7628-2009; moskal, joseph/K-8431-2014	Thompson, Lucien/0000-0001-8878-0221; Disterhoft, John/0000-0002-8817-7913				ANDERSON P, 1991, EXCITATORY AMINO ACI, P463; BERGER TW, 1983, J NEUROPHYSIOL, V50, P1197, DOI 10.1152/jn.1983.50.5.1197; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; CONTRERAS PC, 1990, NEUROPHARMACOLOGY, V29, P291, DOI 10.1016/0028-3908(90)90015-J; DEDRICK RL, 1989, IMMUNITY CANCER, V2, P429; DEJONGE MC, 1990, EXP BRAIN RES, V80, P456, DOI 10.1007/BF00227987; DEYO RA, 1989, SCIENCE, V243, P809, DOI 10.1126/science.2916127; DISTERHOFT JF, 1986, P NATL ACAD SCI USA, V83, P2733, DOI 10.1073/pnas.83.8.2733; FOSTER AC, 1990, EUR J NEUROSCI, V2, P270, DOI 10.1111/j.1460-9568.1990.tb00418.x; GAFFAN D, 1991, BRAIN, V114, P2611, DOI 10.1093/brain/114.6.2611; GOLUB ES, 1987, IMMUNOLOGY SYNTHESIS; Hanngren H, 1961, ANTIBIOT CHEMOTHER, V12, P46; HARING R, 1991, J NEUROCHEM, V57, P323, DOI 10.1111/j.1471-4159.1991.tb02131.x; HOOD WF, 1989, NEUROSCI LETT, V98, P91, DOI 10.1016/0304-3940(89)90379-0; MIYOSHI R, 1990, SYNAPSE, V6, P338, DOI 10.1002/syn.890060405; MONAGHAN DT, 1985, J NEUROSCI, V5, P2909; MONAHAN JB, 1989, PHARMACOL BIOCHEM BE, V34, P649, DOI 10.1016/0091-3057(89)90571-6; MONAHAN JB, 1989, J NEUROCHEM, V53, P370; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; MOSKAL JR, 1986, J NEUROSCI, V6, P2045; MOYER JR, 1990, BEHAV NEUROSCI, V104, P243, DOI 10.1037/0735-7044.104.2.243; NAPIER RM, 1992, J EXP PSYCHOL ANIM B, V18, P182, DOI 10.1037/0097-7403.18.2.182; OLIVER MW, 1990, SYNAPSE, V5, P265, DOI 10.1002/syn.890050403; PATEL J, 1990, J NEUROCHEM, V54, P849, DOI 10.1111/j.1471-4159.1990.tb02329.x; PROCTER AW, 1989, NEUROSCI LETT, V101, P62, DOI 10.1016/0304-3940(89)90441-2; ROBINSON GS, 1989, PSYCHOBIOLOGY, V17, P156; SARAGOVI HU, 1991, SCIENCE, V253, P792, DOI 10.1126/science.1876837; SCHWARTZ BL, 1991, NEUROLOGY, V41, P1341, DOI 10.1212/WNL.41.9.1341; SOLOMON PR, 1991, NEUROBIOL AGING, V12, P283, DOI 10.1016/0197-4580(91)90004-4; SOLOMON PR, 1986, BEHAV NEUROSCI, V100, P729, DOI 10.1037/0735-7044.100.5.729; Squire L.R., 1987, MEMORY BRAIN; THIELS E, 1992, NEUROSCIENCE, V46, P501, DOI 10.1016/0306-4522(92)90139-S; THOMSON AM, 1989, NATURE, V338, P422, DOI 10.1038/338422a0; VARTANIAN MG, 1991, NEUROSCI LETT, V133, P109, DOI 10.1016/0304-3940(91)90069-6; WATSON GB, 1990, BRAIN RES, V510, P158, DOI 10.1016/0006-8993(90)90745-W; WINTER G, 1991, NATURE, V349, P293, DOI 10.1038/349293a0; WOODRUFFPAK DS, 1988, PSYCHOL AGING, V3, P219, DOI 10.1037/0882-7974.3.3.219	37	154	174	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 15	1992	359	6396					638	641		10.1038/359638a0	http://dx.doi.org/10.1038/359638a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JT824	1406995				2022-12-01	WOS:A1992JT82400058
J	AMOS, CI; SHAW, GL; TUCKER, MA; HARTGE, P				AMOS, CI; SHAW, GL; TUCKER, MA; HARTGE, P			AGE AT ONSET FOR FAMILIAL EPITHELIAL OVARIAN-CANCER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PROPHYLACTIC OOPHORECTOMY; BREAST; CARCINOMA; LINKAGE; PRONE	Objective.-To provide age-specific risks for ovarian cancer for relatives of ovarian cancer case patients. To characterize the age at onset for ovarian cancer for women with a single relative vs several relatives affected with ovarian cancer. Design.-Three previous studies were reexamined. The cumulative probability of ovarian cancer in first-degree relatives of women with histologically confirmed epithelial ovarian cancer and matched control subjects who participated in the Cancer and Steroid Hormone (CASH) Study was determined. The age of onset of ovarian cancer in women with and without relatives with ovarian cancer in a Washington, DC, case-control study was contrasted with that of women with at least two first-degree relatives studied at the National Cancer Institute (NCI). Results.-The CASH Study data showed that first-degree relatives of women with ovarian cancer had an increased risk for ovarian cancer, especially at older ages, when compared with relatives of control subjects. However, the median age at onset was the same among women in the Washington, DC, study with and without an affected relative. Among the women with an extensive family history of ovarian cancer studied at the NCI, the age at onset was considerably younger (47 years) than is typical for this disease (59 years). Of these, 17% had been diagnosed as having primary ovarian cancer by age 40 years. Conclusions.-Women who have one first-degree relative affected by ovarian cancer are at greater risk for ovarian cancer but not at an age earlier than the general population. The small proportion of women who have several affected relatives are, however, at a greater risk of early onset of ovarian cancer. Prophylactic oophorectomy may be reasonable for these women.	NCI, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	AMOS, CI (corresponding author), NIAMSD, LSB, GENET STUDIES SECT, BLDG 6, ROOM 249, BETHESDA, MD 20892 USA.		Tucker, Margaret A/B-4297-2015		PHS HHS [3-Y01-8-1037] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AMOS CI, IN PRESS CANCER; BERLIN NI, 1966, ANN INTERN MED, V64, P403, DOI 10.7326/0003-4819-64-2-403; Cox DR, 1984, ANAL SURVIVAL DATA, P48; CREASMAN WT, 1991, AM J OBSTET GYNECOL, V165, P7, DOI 10.1016/0002-9378(91)90213-B; DOZOIS RR, 1970, ANN SURG, V172, P233, DOI 10.1097/00000658-197008000-00009; FERRELL RE, 1989, CANCER GENET CYTOGEN, V38, P241, DOI 10.1016/0165-4608(89)90665-1; FRAUMENI JF, 1975, CANCER-AM CANCER SOC, V36, P364, DOI 10.1002/1097-0142(197508)36:2<364::AID-CNCR2820360211>3.0.CO;2-C; GREGGI S, 1990, GYNECOL ONCOL, V39, P300, DOI 10.1016/0090-8258(90)90256-K; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; Harrel F, 1986, SUGI SUPPLEMENTAL LI, P437; HARTGE P, 1989, AM J OBSTET GYNECOL, V161, P10, DOI 10.1016/0002-9378(89)90221-4; JACOBS I, 1989, BRIT J OBSTET GYNAEC, V96, P510, DOI 10.1111/j.1471-0528.1989.tb03248.x; LURAIN JR, 1979, GYNECOL ONCOL, V8, P185, DOI 10.1016/0090-8258(79)90024-6; LURAIN JR, 1991, JAMA-J AM MED ASSOC, V266, P3343; LYNCH HT, 1991, CANCER, V67, P1460, DOI 10.1002/1097-0142(19910301)67:5<1460::AID-CNCR2820670534>3.0.CO;2-S; LYNCH HT, 1985, BRIT J CANCER, V52, P271, DOI 10.1038/bjc.1985.187; LYNCH HT, 1982, OBSTET GYNECOL, V59, P589; LYNCH HT, 1981, JAMA-J AM MED ASSOC, V245, P261, DOI 10.1001/jama.245.3.261; NAROD SA, 1991, LANCET, V338, P82; PIVER MS, 1982, OBSTET GYNECOL, V60, P397; PIVER MS, 1991, SEMIN ONCOL, V18, P177; SCHILDKRAUT JM, 1989, AM J HUM GENET, V45, P521; SCHILDKRAUT JM, 1988, AM J EPIDEMIOL, V128, P456, DOI 10.1093/oxfordjournals.aje.a114994; SPEROFF T, 1991, AM J OBSTET GYNECOL, V164, P165, DOI 10.1016/0002-9378(91)90649-C; TETER J, 1967, CANCER-AM CANCER SOC, V20, P1301, DOI 10.1002/1097-0142(196708)20:8<1301::AID-CNCR2820200814>3.0.CO;2-4; TOBACMAN JK, 1982, LANCET, V2, P795; WINGO PA, 1988, AM J EPIDEMIOL, V128, P206, DOI 10.1093/oxfordjournals.aje.a114942; [No title captured]	28	55	55	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 14	1992	268	14					1896	1899		10.1001/jama.268.14.1896	http://dx.doi.org/10.1001/jama.268.14.1896			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JR439	1404714				2022-12-01	WOS:A1992JR43900039
J	HANDEL, N; SILVERSTEIN, MJ; GAMAGAMI, P; JENSEN, JA; COLLINS, A				HANDEL, N; SILVERSTEIN, MJ; GAMAGAMI, P; JENSEN, JA; COLLINS, A			FACTORS AFFECTING MAMMOGRAPHIC VISUALIZATION OF THE BREAST AFTER AUGMENTATION MAMMAPLASTY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CANCER; MAMMOPLASTY; IMPLANTS; PROSTHESES; MORTALITY; DIAGNOSIS; LESIONS; BIOPSY	Objective.-To measure the effect of various parameters on mammographic visualization of the breast after augmentation mammaplasty. Design.-Preoperative and postoperative mammography was performed in patients undergoing augmentation mammaplasty. The area of breast tissue visualized on each film was measured. Changes in the area visualized were correlated with a variety of different parameters. Setting.-The Breast Center, Van Nuys, Calif, a free-standing multidisciplinary breast diagnostic and treatment facility. Patients.-The 68 women (126 breasts) represent a consecutive sample of patients undergoing augmentation mammaplasty for whom preoperative and postoperative mammograms were available. Main Outcome Measures.-Area visualized was correlated with degree of capsular contracture, implant position, type of mammography, preoperative breast size, implant size, and implant type. Results.-The major factor affecting mammography is capsular contracture. Little or no capsular contracture results in a 30% reduction in the area visualized; moderate or severe contracture results in a 50% reduction. Other important factors include implant position (improved visualization with implant beneath pectoral muscle) and type of mammography performed (slightly more tissue seen with displacement technique). Very small preoperative breast size yields increased visualization. Implant size and type have little or no effect. Conclusions.-In most women with breast implants, there is a decrease in measurable breast tissue on the postaugmentation mammogram. Capsular contracture and implant position exert a profound effect; type of mammography performed and preoperative breast size are also significant.			HANDEL, N (corresponding author), BREAST CTR,14624 SHERMAN WAY,VAN NUYS,CA 91405, USA.			Jensen, Jay/0000-0002-2369-8291				BAKER JL, 1975, OCT AESTH BREAST S S; BEISANG AA, 1991, PLAST RECONSTR SURG, V87, P855; BORGEN PI, 1991, AM SURGEON, V57, P8; CATHCART RS, 1989, ANN PLAS SURG, V22, P533, DOI 10.1097/00000637-198906000-00011; DERSHAW DD, 1989, RADIOLOGY, V170, P69, DOI 10.1148/radiology.170.1.2909122; DOUGLAS KP, 1991, SOUTH MED J, V84, P49, DOI 10.1097/00007611-199101000-00013; EKLUND GW, 1988, AM J ROENTGENOL, V151, P469, DOI 10.2214/ajr.151.3.469; ERSEK RA, 1991, PLAST RECONSTR SURG, V87, P879, DOI 10.1097/00006534-199105000-00012; GALLAGER HS, 1971, CANCER, V28, P1505, DOI 10.1002/1097-0142(197112)28:6<1505::AID-CNCR2820280624>3.0.CO;2-W; GRACE GT, 1990, ANN PLAS SURG, V25, P119, DOI 10.1097/00000637-199008000-00008; GUMUCIO CA, 1989, PLAST RECONSTR SURG, V84, P772, DOI 10.1097/00006534-198911000-00008; HAYES H, 1988, PLAST RECONSTR SURG, V82, P1, DOI 10.1097/00006534-198882010-00001; HERMAN S, 1984, PLAST RECONSTR SURG, V73, P411, DOI 10.1097/00006534-198403000-00012; HESTER TR, 1990, PLASTIC RECONSTRUCTI, P131; Hester TR, 1988, PERSPECT PLAST SURG, V2, P135; LEIBMAN AJ, 1990, RADIOLOGY, V174, P195, DOI 10.1148/radiology.174.1.2152981; LEIS HP, 1989, BREAST CANCER CONSER, P3; LEIS HP, 1986, SURGERY BREAST DIAGN, P100; LITTLE G, 1980, PLAST RECONSTR SURG, V65, P30, DOI 10.1097/00006534-198001000-00006; McCurdy JA, 1990, AM J COSMETIC SURG, V7, P235; MELMED EP, 1988, PLAST RECONSTR SURG, V82, P285, DOI 10.1097/00006534-198808000-00013; MITNICK JS, 1989, SURG GYNECOL OBSTET, V168, P30; MONSEES BS, 1991, PERSPECT PLAST SURG, V5, P103; RINTALA AE, 1974, PLAST RECONSTR SURG, V54, P390, DOI 10.1097/00006534-197410000-00002; SCHWARTZ GF, 1978, CANCER, V41, P1147, DOI 10.1002/1097-0142(197803)41:3<1147::AID-CNCR2820410352>3.0.CO;2-9; SHAPIRO S, 1982, JNCI-J NATL CANCER I, V69, P349; SILVERSTEIN MJ, 1988, ARCH SURG-CHICAGO, V123, P681; SILVERSTEIN MJ, 1992, EUR J CANCER, V28A, P635, DOI 10.1016/S0959-8049(05)80115-7; SILVERSTEIN MJ, 1989, RADIOLOGY, V171, P633, DOI 10.1148/radiology.171.3.2717734; SILVERSTEIN MJ, 1987, CANCER, V59, P715, DOI 10.1002/1097-0142(19870215)59:4<715::AID-CNCR2820590409>3.0.CO;2-C; SILVERSTEIN MJ, 1990, PLAST RECONSTR SURG, V86, P1126, DOI 10.1097/00006534-199012000-00014; STRAX P, 1990, CANCER, V66, P1136; TABAR L, 1985, LANCET, V1, P829, DOI 10.1016/S0140-6736(85)92204-4; VANA J, 1981, CANCER, V48, P1043, DOI 10.1002/1097-0142(19810815)48:4<1043::AID-CNCR2820480432>3.0.CO;2-K; Walt A J, 1990, Bull Am Coll Surg, V75, P6; WERTHEIMER MD, 1986, JAMA-J AM MED ASSOC, V255, P1311, DOI 10.1001/jama.255.10.1311; Whidden PG, 1986, TRANSPLANT IMPLANT T, V3, P43	37	72	73	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 14	1992	268	14					1913	1917		10.1001/jama.268.14.1913	http://dx.doi.org/10.1001/jama.268.14.1913			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JR439	1404718				2022-12-01	WOS:A1992JR43900043
J	HORTOBAGYI, GN				HORTOBAGYI, GN			DIAGNOSTIC BREAST IMAGING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											HORTOBAGYI, GN (corresponding author), TEXAS MED CTR,MD ANDERSON CANC CTR,HOUSTON,TX 77025, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 14	1992	268	14					1926	1926						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JR439	1404721				2022-12-01	WOS:A1992JR43900047
J	KENDLER, KS; HEATH, AC; NEALE, MC; KESSLER, RC; EAVES, LJ				KENDLER, KS; HEATH, AC; NEALE, MC; KESSLER, RC; EAVES, LJ			A POPULATION-BASED TWIN STUDY OF ALCOHOLISM IN WOMEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ENVIRONMENTAL-FACTORS; DEPRESSION; GENETICS; SCHIZOPHRENIA; TRANSMISSION; INHERITANCE; SIMILARITY; CONTACT; MODELS; LISREL	Objective.-To clarify the role of genetic factors in the etiology of alcoholism in women. Design and Setting.-Personal structured psychiatric interviews conducted by researchers "blinded" to the status of the co-twin in an epidemiologic sample of 1030 female-female twin pairs of known zygosity from the population-based Virginia Twin Registry. Measures.-Three definitions of lifetime prevalence of alcoholism based on Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised criteria: (1) alcoholism with tolerance or dependence; (2) alcoholism with or without tolerance-dependence; and (3) alcoholism with or without tolerance-dependence or problem drinking. Results.-Using narrow, intermediate, or broad definitions, the probandwise concordance for alcoholism was consistently higher in monozygotic than in dizygotic twin pairs. Multifactorial threshold models suggested that the heritability of liability to alcoholism in women is in the range of 50% to 60%. Conclusions.-The results support the hypothesis that genetic factors play a major role in the etiology of alcoholism in women. Women should be well represented in the efforts currently under way to elucidate the molecular basis of the genetic susceptibility to alcoholism.	WASHINGTON UNIV,SCH MED,DEPT PSYCHIAT,ST LOUIS,MO 63110; UNIV MICHIGAN,INST SOCIAL RES,ANN ARBOR,MI 48109; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT HUMAN GENET,RICHMOND,VA 23298	Washington University (WUSTL); University of Michigan System; University of Michigan; Virginia Commonwealth University	KENDLER, KS (corresponding author), VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PSYCHIAT,BOX 710,RICHMOND,VA 23298, USA.		Neale, Michael C/B-1418-2008; Neale, Michael/AAD-5056-2020; Kendler, Kenneth/AAF-2876-2019		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD026746] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH040828] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA009095] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA-09095] Funding Source: Medline; NICHD NIH HHS [HD-26746] Funding Source: Medline; NIMH NIH HHS [MH-40828] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AKAIKE H, 1987, PSYCHOMETRIKA, V52, P317, DOI 10.1007/BF02294359; BEARDSLEE WR, 1986, BRIT J PSYCHIAT, V149, P584, DOI 10.1192/bjp.149.5.584; BOHMAN M, 1981, ARCH GEN PSYCHIAT, V38, P965; BROMET EJ, 1986, ARCH GEN PSYCHIAT, V43, P435; CADORET RJ, 1985, ARCH GEN PSYCHIAT, V42, P161, DOI 10.1001/archpsyc.1985.01790250055007; CLONINGER CR, 1991, JAMA-J AM MED ASSOC, V266, P1833; CLONINGER CR, 1981, ARCH GEN PSYCHIAT, V38, P861; CLONINGER CR, 1988, ALCOHOLISM ORIGINS O; DEVOR EJ, 1989, ANNU REV GENET, V23, P19, DOI 10.1146/annurev.ge.23.120189.000315; Eaves L, 1989, GENES CULTURE PERSON; FALCONER DS, 1965, ANN HUM GENET, V29, P51, DOI 10.1111/j.1469-1809.1965.tb00500.x; GOODWIN DW, 1977, ARCH GEN PSYCHIAT, V34, P751; GOODWIN DW, 1973, ARCH GEN PSYCHIAT, V28, P238; GURLING HMD, 1984, ACTA GENET MED GEMEL, V33, P333, DOI 10.1017/S0001566000007376; HEATH AC, 1989, BEHAV GENET, V19, P9, DOI 10.1007/BF01065881; HELLER RF, 1988, GENET EPIDEMIOL, V5, P311, DOI 10.1002/gepi.1370050503; HELZER JE, 1991, PSYCHIATRIC DISORDER; HOLDEN C, 1991, SCIENCE, V251, P163, DOI 10.1126/science.1824800; HOLMES SJ, 1988, PSYCHIATRY, V51, P24, DOI 10.1080/00332747.1988.11024377; HRUBEC Z, 1981, ALCOHOL CLIN EXP RES, V5, P207, DOI 10.1111/j.1530-0277.1981.tb04890.x; Joreskog KG, 1986, PRELIS PREPROCESSOR; Joreskog KG, 1989, LISREL7 GUIDE PROGRA; KAIJ L, 1960, ALCOHOLISM TWINS; KENDLER KS, 1992, ARCH GEN PSYCHIAT, V49, P257; KENDLER KS, 1986, ARCH GEN PSYCHIAT, V43, P213; KENDLER KS, 1983, AM J PSYCHIAT, V140, P1551; KENDLER KS, 1983, AM J PSYCHIAT, V140, P1413; KENDLER KS, 1986, ANN HUM GENET, V50, P83, DOI 10.1111/j.1469-1809.1986.tb01941.x; LELAND J, 1982, GENDER PSYCHOPATHOLO; Loehlin J., 1976, HEREDITY ENV PERSONA, DOI DOI 10.7560/730038; LYKKEN DT, 1990, BEHAV GENET, V20, P547, DOI 10.1007/BF01065871; MARTIN NG, 1978, HEREDITY, V40, P97, DOI 10.1038/hdy.1978.10; MCGUE M, 1992, J ABNORM PSYCHOL, V101, P3, DOI 10.1037/0021-843X.101.1.3; MCGUFFIN P, 1989, BRIT J PSYCHIAT, V155, P294, DOI 10.1192/bjp.155.3.294; MERIKANGAS KR, 1990, PSYCHOL MED, V20, P11, DOI 10.1017/S0033291700013192; MORRISYATES A, 1990, ACTA PSYCHIAT SCAND, V81, P322, DOI 10.1111/j.1600-0447.1990.tb05457.x; NEALE MC, 1989, BEHAV GENET, V19, P37, DOI 10.1007/BF01065882; NEALE MC, 1991, STATISTICAL MODELLIN; PARSIAN A, 1991, ARCH GEN PSYCHIAT, V48, P655; PEARSON K, 1901, P R SOC, V66, P241; PICKENS RW, 1991, ARCH GEN PSYCHIAT, V48, P19; REICH T, 1988, ALCOHOL CLIN EXP RES, V12, P458, DOI 10.1111/j.1530-0277.1988.tb00227.x; REICH T, 1972, ANN HUM GENET, V36, P163, DOI 10.1111/j.1469-1809.1972.tb00767.x; ROSE RJ, 1990, BEHAV GENET, V20, P763, DOI 10.1007/BF01065919; SPENCE J E, 1988, American Journal of Human Genetics, V43, pA159; Spitzer R. L., 1987, STRUCTURED CLIN INTE; WANBERG KW, 1970, Q J STUD ALCOHOL, V31, P40; ZUCKER RA, 1986, AM PSYCHOL, V41, P783, DOI 10.1037/0003-066X.41.7.783; 1987, DIAGNOSTIC STATISTIC; 1985, SAS USERS GUIDE STAT	50	343	346	1	20	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 14	1992	268	14					1877	1882		10.1001/jama.268.14.1877	http://dx.doi.org/10.1001/jama.268.14.1877			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JR439	1404711				2022-12-01	WOS:A1992JR43900036
J	NIGHTINGALE, SL				NIGHTINGALE, SL			FDA PROPOSES TO PROHIBIT 415 INGREDIENTS FROM OTC DRUG PRODUCTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 14	1992	268	14					1828	1828		10.1001/jama.268.14.1828	http://dx.doi.org/10.1001/jama.268.14.1828			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JR439	1404696				2022-12-01	WOS:A1992JR43900009
J	NIGHTINGALE, SL				NIGHTINGALE, SL			UPDATE ON EMS AND L-TRYPTOPHAN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 14	1992	268	14					1828	1828		10.1001/jama.268.14.1828	http://dx.doi.org/10.1001/jama.268.14.1828			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JR439	1404696				2022-12-01	WOS:A1992JR43900008
J	NIGHTINGALE, SL				NIGHTINGALE, SL			FDAS ELECTRONIC BULLETIN BOARD	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 14	1992	268	14					1828	1828		10.1001/jama.268.14.1828	http://dx.doi.org/10.1001/jama.268.14.1828			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JR439	1404696				2022-12-01	WOS:A1992JR43900010
J	SPECTOR, SL				SPECTOR, SL			ORAL STEROID-THERAPY FOR ASTHMA AND CONTACT-DERMATITIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											SPECTOR, SL (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,LOS ANGELES,CA 90024, USA.							EPSTEIN E, 1973, CUTIS, V12, P47; FISHER AA, 1973, CONTACT DERMATITIS, P10; SPECTOR SL, 1985, CHEST, V87, pS73; SPECTOR SL, 1989, ANN ALLERGY, V63, P591	4	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 14	1992	268	14					1926	1926						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JR439	1404722				2022-12-01	WOS:A1992JR43900046
J	WEISNER, C; SCHMIDT, L				WEISNER, C; SCHMIDT, L			GENDER DISPARITIES IN TREATMENT FOR ALCOHOL-PROBLEMS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							WOMEN; DEPENDENCE; PREVALENCE; HEALTH	Objective.-To examine women's access to treatment for alcohol problems in terms of the prevalence, characteristics, and treatment-seeking patterns of problem drinkers in a range of alcohol-specific and nonspecialized health care systems. Design.-In-person survey. Setting.-A Northern California county. Participants.-Consecutive samples of admissions in public alcohol treatment (n=381), drug treatment (n=210), mental health treatment (n=406), emergency health services (n=2626), primary health clinics (n=394), and adults in the county general population (n=3069). Primary Outcome Measures.-Prevalence and relative risk (RR) of problem drinking and rates of alcohol-related treatment episodes. Results.-Rates of problem drinking were higher among men than women across all samples. However, after accounting for gender differences in general population rates, women in all of the non-alcohol-specific clinical samples were at greater risk than men for problem drinking (eg, RR=5.6 for women and RR=2.1 for men in the mental health sample). Men reported a greater variety in types of services sought in past alcohol-related treatment encounters, but women experienced greater symptom severity. Conclusions.-Female problem drinkers were more likely than male problem drinkers to use non-alcohol-specific health care settings, particularly mental health treatment services, and to report greater symptom severity. Future research on women's access to services for alcohol problems should consider a range of health care systems and gender differences in seeking help.	UNIV CALIF BERKELEY,SCH PUBL HLTH,BERKELEY,CA 94720; UNIV CALIF BERKELEY,DEPT SOCIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley; University of California System; University of California Berkeley	WEISNER, C (corresponding author), ALCOHOL RES GRP,2000 HEARST AVE,BERKELEY,CA 94709, USA.				NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [P30AA005595, P50AA005595] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA-05595] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ARMITAGE P, 1971, STATISTICAL METHODS; Baily S, 1990, Drug Alcohol Rev, V9, P125, DOI 10.1080/09595239000185181; BECKMAN LJ, 1986, J STUD ALCOHOL, V47, P135, DOI 10.15288/jsa.1986.47.135; BLUME SB, 1986, JAMA-J AM MED ASSOC, V256, P1467; BLUME SB, 1982, ALCOHOLISM CLIN PSYC, pCH13; CAETANO R, 1990, ALCOHOL ALCOHOLISM, V25, P303, DOI 10.1093/oxfordjournals.alcalc.a045004; CAETANO R, 1988, STUDY DIMENSIONS DEP; CELENTANO DD, 1980, J CHRON DIS, V33, P383, DOI 10.1016/0021-9681(80)90048-X; Cherpitel C, 1989, DRINKING CASUALTIES, P288; CHERPITEL CS, 1989, PRIMARY CARE STUDY; CHERPITEL CS, 1991, ALCOHOL ALCOHOLISM, V5, P627; Clark WB, 1982, ALCOHOL CONSUMPTION, P3; Clark WB, 1991, ALCOHOL AM DRINKING; CURLEE J, 1970, J PSYCHOL, V74, P239, DOI 10.1080/00223980.1970.9923735; FERRENCE RG, 1980, SERVICES ALCOHOLICS; FERRENCE RG, 1980, RES ADV ALCOHOL DRUG, V5, P69; Fillmore K.M., 1984, ALCOHOL PROBLEMS WOM, P7; FURST C, 1981, UTILIZATION ALCOHOL; GLASS IB, 1988, BRIT J ADDICT, V83, P1105; GOMBERG E, 1974, WOMEN THERAPY, pCH7; HILTON M, 1991, ALCOHOL AM DRINKING, P256; HORN JL, 1970, Q J STUD ALCOHOL, V31, P40; Jones K R, 1979, Med Care, V17, P1; MARSH JC, 1982, J SOC ISSUES, V38, P1, DOI 10.1111/j.1540-4560.1982.tb00114.x; MCINTOSH ID, 1982, INT J ADDICT, V17, P609, DOI 10.3109/10826088209053007; MECHANIC D, 1979, J HEALTH SOC BEHAV, V20, P387, DOI 10.2307/2955413; MOORE RD, 1989, JAMA-J AM MED ASSOC, V261, P403, DOI 10.1001/jama.261.3.403; REED BG, 1987, J PSYCHOACTIVE DRUGS, V19, P151, DOI 10.1080/02791072.1987.10472399; RODIN J, 1990, AM PSYCHOL, V45, P1018, DOI 10.1037/0003-066X.45.9.1018; ROMAN PM, 1988, ADM881574US DEP HLTH; ROOM R, 1988, 14TH ANN ALC EP S BE; RUSH B, 1983, CAN J PUBLIC HEALTH, V74, P270; SANDMAIER M, 1980, INVISIBLE ALCOHOLICS; SCHMIDT L, 1992, HOSP COMMUNITY PSYCH, V43, P245; SCHMIDT L, 1988, COSTA COUNTRY MENTAL; SCHUCKIT M A, 1979, American Journal of Psychiatry, V136, P611; STEPHENS C, 1987, COSTA COUNTY 4 HOSPI; THOM B, 1986, BRIT J ADDICT, V81, P777; Weisner C, 1987, Recent Dev Alcohol, V5, P203; WEISNER C, IN PRESS AM J DRUG A; WEISNER C, IN PRESS J STUD ALCO; WEISNER C, 1988, COMMUNITY RESPONSE S; WILSNACK SC, 1991, AM J PUBLIC HEALTH, V81, P305, DOI 10.2105/AJPH.81.3.305; ZUNG BJ, 1982, PSYCHIAT FORUM, V11, P32; 1990, HIGHLIGHTS 1989 NATI; 1990, BROADENING BASE ALCO, P23; 1991, C ASSESSING FUTURE R	47	233	234	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 14	1992	268	14					1872	1876		10.1001/jama.268.14.1872	http://dx.doi.org/10.1001/jama.268.14.1872			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JR439	1328695				2022-12-01	WOS:A1992JR43900035
J	WING, RR; MATTHEWS, KA; KULLER, LH; SMITH, D; BECKER, D; PLANTINGA, PL; MEILAHN, EN				WING, RR; MATTHEWS, KA; KULLER, LH; SMITH, D; BECKER, D; PLANTINGA, PL; MEILAHN, EN			ENVIRONMENTAL AND FAMILIAL CONTRIBUTIONS TO INSULIN LEVELS AND CHANGE IN INSULIN LEVELS IN MIDDLE-AGED WOMEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; CARDIOVASCULAR RISK-FACTORS; BODY-MASS INDEX; BLOOD-PRESSURE; PREMENOPAUSAL WOMEN; PLASMA-INSULIN; ESSENTIAL-HYPERTENSION; GLUCOSE-INTOLERANCE; DIABETES-MELLITUS; PHYSICAL-ACTIVITY	Objective.-To examine familial and environmental variables associated with elevated insulin levels and changes in insulin levels in healthy, premenopausal women. Methods.-A population-based sample of 518 women (aged 42 to 50 years) completed baseline assessments of weight, cardiovascular risk factors, exercise behaviors, and glucose and insulin levels (fasting and 2 hours after a glucose load); 495 of the women were reevaluated after 3 years. Results.-Plasma insulin levels were related to weight, activity level, race, body fat distribution, and weight gain since age 20 years. Parental history of either diabetes or hypertension was also related to elevated insulin levels, independent of body mass index, with the highest insulin levels occurring in those women with a parental history of both diseases. Increases in plasma insulin levels over the years of follow-up were related to weight gain. Conclusions.-This study suggests the importance of using family history to identify women who may have elevated insulin levels and of intervening to prevent weight gain during middle age.	CHILDRENS HOSP PITTSBURGH, DIV ENDOCRINE, PITTSBURGH, PA USA; UNIV PITTSBURGH, DEPT PSYCHIAT, PITTSBURGH, PA 15260 USA; UNIV PITTSBURGH, GRAD SCH PUBL HLTH, DEPT EPIDEMIOL, PITTSBURGH, PA 15260 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh			West, Delia Smith/GWV-5839-2022	West, Delia Smith/0000-0002-4375-2785	NHLBI NIH HHS [HL28266] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028266] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLAIN CC, 1974, CLIN CHEM, V20, P470; BOGARDUS C, 1989, DIABETES, V38, P1423, DOI 10.2337/diabetes.38.11.1423; BUCOLO G, 1973, CLIN CHEM, V19, P476; DEFRONZO RA, 1991, DIABETES CARE, V14, P173, DOI 10.2337/diacare.14.3.173; DISCHINGER P, 1986, CONTROL CLIN TRIALS, V7, pS137; DONAHUE RP, 1987, AM J EPIDEMIOL, V125, P650, DOI 10.1093/oxfordjournals.aje.a114578; DONAHUE RP, 1990, AM J EPIDEMIOL, V132, P827, DOI 10.1093/oxfordjournals.aje.a115725; DUCIMETIERE P, 1980, DIABETOLOGIA, V19, P205, DOI 10.1007/BF00275270; ERIKSSON J, 1989, NEW ENGL J MED, V321, P337, DOI 10.1056/NEJM198908103210601; FERRANNINI E, 1987, NEW ENGL J MED, V317, P350, DOI 10.1056/NEJM198708063170605; FOURNIER AM, 1986, AM J MED, V80, P861, DOI 10.1016/0002-9343(86)90629-7; FUH MMT, 1987, ARCH INTERN MED, V147, P1035, DOI 10.1001/archinte.147.6.1035; GARCIAWEBB P, 1983, SCAND J CLIN LAB INV, V43, P677; GIDEZ JI, 1978, HIGH DENSITY LIPOPRO, P328; HAFFNER SM, 1988, NEW ENGL J MED, V319, P1297, DOI 10.1056/NEJM198811173192001; HERBERT V, 1965, J CLIN ENDOCR METAB, V25, P1375, DOI 10.1210/jcem-25-10-1375; HOLBROOK TL, 1989, INT J OBESITY, V13, P723; HORTON E S, 1986, Diabetes Metabolism Reviews, V2, P1; KAPLAN NM, 1989, ARCH INTERN MED, V149, P1514, DOI 10.1001/archinte.149.7.1514; KOLTERMAN OG, 1980, J CLIN INVEST, V65, P1272, DOI 10.1172/JCI109790; KROTKIEWSKI M, 1979, METABOLISM, V28, P650, DOI 10.1016/0026-0495(79)90018-0; LESLIE RDG, 1986, BRIT MED J, V293, P840, DOI 10.1136/bmj.293.6551.840; MANSON JAE, 1990, NEW ENGL J MED, V322, P882, DOI 10.1056/NEJM199003293221303; MARKOVITZ JH, 1991, J HYPERTENS, V9, P399, DOI 10.1097/00004872-199105000-00003; MATTHEWS KA, 1989, AM J EPIDEMIOL, V129, P1132, DOI 10.1093/oxfordjournals.aje.a115235; MODAN M, 1985, J CLIN INVEST, V75, P809, DOI 10.1172/JCI111776; ORCHARD TJ, 1983, AM J EPIDEMIOL, V118, P326, DOI 10.1093/oxfordjournals.aje.a113639; OWENS JF, 1990, PREV MED, V19, P147, DOI 10.1016/0091-7435(90)90016-D; PAFFENBARGER RS, 1978, AM J EPIDEMIOL, V108, P161, DOI 10.1093/oxfordjournals.aje.a112608; Pyorala K, 1979, Diabetes Care, V2, P131, DOI 10.2337/diacare.2.2.131; REAVEN GM, 1991, DIABETES CARE, V14, P195, DOI 10.2337/diacare.14.3.195; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; SAAD MF, 1991, NEW ENGL J MED, V324, P733, DOI 10.1056/NEJM199103143241105; SINGER P, 1985, HYPERTENSION, V7, P182, DOI 10.1161/01.HYP.7.2.182; WARNICK GR, 1978, J LIPID RES, V19, P65; Welborn T A, 1979, Diabetes Care, V2, P154, DOI 10.2337/diacare.2.2.154; WING RR, 1989, ARTERIOSCLEROSIS, V9, P479, DOI 10.1161/01.ATV.9.4.479; ZAVARONI I, 1990, DIABETIC MED, V7, P494, DOI 10.1111/j.1464-5491.1990.tb01430.x; ZIMMET P, 1989, DIABETIC MED, V6, P728, DOI 10.1111/j.1464-5491.1989.tb01266.x	39	44	44	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 14	1992	268	14					1890	1895		10.1001/jama.268.14.1890	http://dx.doi.org/10.1001/jama.268.14.1890			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JR439	1404713				2022-12-01	WOS:A1992JR43900038
J	CARME, B				CARME, B			PSEUDORESISTANT MALARIA IN TROPICAL COUNTRIES	LANCET			English	Editorial Material							PLASMODIUM-FALCIPARUM; CHEMOSENSITIVITY		FAC MED AMIENS,F-800054 AMIENS,FRANCE		CARME, B (corresponding author), CTR HOSP REG UNIV AMIENS,SERV PARASITOL,F-800054 AMIENS,FRANCE.							CARME B, 1991, LANCET, V338, P582, DOI 10.1016/0140-6736(91)91158-Q; CARME B, 1991, J INFECT DIS, V164, P828, DOI 10.1093/infdis/164.4.828; HOFFMAN SL, 1984, T ROY SOC TROP MED H, V78, P175, DOI 10.1016/0035-9203(84)90271-2; 1989, UN DIENSA STESA112 U; 1984, WHO TECH REP SER, V711	5	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 10	1992	340	8824					896	897		10.1016/0140-6736(92)93296-Y	http://dx.doi.org/10.1016/0140-6736(92)93296-Y			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT327	1357307				2022-12-01	WOS:A1992JT32700015
J	CLARK, IA; ROCKETT, KA; COWDEN, WB				CLARK, IA; ROCKETT, KA; COWDEN, WB			POSSIBLE CENTRAL ROLE OF NITRIC-OXIDE IN CONDITIONS CLINICALLY SIMILAR TO CEREBRAL MALARIA	LANCET			English	Article							TUMOR-NECROSIS-FACTOR; ETHANOL; MORPHINE; CALCIUM; INHIBITION; WITHDRAWAL; RECEPTORS; TOLERANCE; SEIZURES; RELEASE	The changes in mental status during cerebral malaria, heat stroke, and recovery from major surgery are clinically similar, and are associated with high circulating concentrations of cytokines that can induce nitric oxide generation in vascular walls. This vascular nitric oxide could diffuse across the blood-brain barrier, causing functional changes that include inhibition of glutamate-induced calcium entry, reduced activity of the calcium-dependent nitric oxide synthase, and thus reduced nitric oxide formation, in post-synaptic neurons. Certain general anaesthetics and ethanol reduce glutamate-induced calcium entry into post-synaptic cells, and so would also reduce the rate of formation of neuronal nitric oxide. In view of the apparent importance of glutamate-induced nitric oxide in excitatory neurotransmission, a reduction in neuronal nitric oxide could help explain why these otherwise unrelated influences alter central nervous system function in a similar manner. In particular, this reduction could rationalise why heat stroke, ethanol excess, morphine poisoning, and conditions with high blood ammonia concentrations are easily confused clinically with cerebral malaria.	AUSTRALIAN NATL UNIV,JOHN CURTIN SCH MED RES,DIV CELL BIOL,CANBERRA,ACT 2601,AUSTRALIA	Australian National University; John Curtin School of Medical Research	CLARK, IA (corresponding author), AUSTRALIAN NATL UNIV,SCH LIFE SCI,DIV BIOCHEM & MOLEC BIOL,GPO BOX 4,CANBERRA,ACT 2601,AUSTRALIA.		Clark, Ian A./K-2069-2012					ARN PH, 1990, NEW ENGL J MED, V322, P1652, DOI 10.1056/NEJM199006073222307; BAIGRIE RJ, 1991, LYMPHOKINE CYTOK RES, V10, P253; BIANCHI M, 1991, NEUROCHEM RES, V16, P443, DOI 10.1007/BF00965564; BOUCHAMA A, 1991, J APPL PHYSIOL, V70, P2640, DOI 10.1152/jappl.1991.70.6.2640; CLARK IA, 1991, PARASITOL TODAY, V7, P205, DOI 10.1016/0169-4758(91)90142-B; COTMAN CW, 1987, TRENDS NEUROSCI, V10, P263, DOI 10.1016/0166-2236(87)90170-6; DENICOFF KD, 1987, ANN INTERN MED, V107, P293, DOI 10.7326/0003-4819-107-2-293; DESARRO GB, 1991, FUNDAM CLIN PHARM, V5, P503; DILDYMAYFIELD JE, 1991, J NEUROCHEM, V56, P1536, DOI 10.1111/j.1471-4159.1991.tb02048.x; ECCLES JC, 1946, J NEUROPHYSIOL, V9, P87, DOI 10.1152/jn.1946.9.2.87; FIDECKA S, 1986, POL J PHARMACOL PHAR, V38, P277; FIDECKA S, 1989, POL J PHARMACOL PHAR, V41, P23; FRASER CL, 1985, NEW ENGL J MED, V313, P865, DOI 10.1056/NEJM198510033131406; GRANT KA, 1990, EUR J PHARMACOL, V176, P289, DOI 10.1016/0014-2999(90)90022-X; HARRIS RA, 1977, LIFE SCI, V20, P501; HEGESCHEUING G, 1989, ANAESTHESIST, V38, P443; HIBBS JB, 1992, J CLIN INVEST, V89, P867, DOI 10.1172/JCI115666; HOFFMAN PL, 1989, J NEUROCHEM, V52, P1937, DOI 10.1111/j.1471-4159.1989.tb07280.x; JOHNS RA, 1991, ANESTHESIOLOGY, V75, P927; KWIATKOWSKI D, 1990, LANCET, V336, P1201, DOI 10.1016/0140-6736(90)92827-5; LOVINGER DM, 1989, SCIENCE, V243, P1721, DOI 10.1126/science.2467382; MANZONI O, 1992, NEURON, V8, P653, DOI 10.1016/0896-6273(92)90087-T; PUIL E, 1990, J PHARMACOL EXP THER, V255, P955; ROCKETT KA, 1992, INFECT IMMUN, V60, P3725, DOI 10.1128/IAI.60.9.3725-3730.1992; SIMSON PE, 1991, J PHARMACOL EXP THER, V257, P225; SPRIGGS DR, 1988, J NATL CANCER I, V80, P1039, DOI 10.1093/jnci/80.13.1039; SZERB JC, 1992, PROG NEUROBIOL, V39, P135, DOI 10.1016/0301-0082(92)90008-3; TANG TT, 1975, JAMA-J AM MED ASSOC, V232, P1339, DOI 10.1001/jama.232.13.1339; TANGANELLI S, 1991, NEUROSCI LETT, V122, P270, DOI 10.1016/0304-3940(91)90875-T; 1942, MEMORANDUM 24 MED DI, P154	30	120	122	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 10	1992	340	8824					894	896		10.1016/0140-6736(92)93295-X	http://dx.doi.org/10.1016/0140-6736(92)93295-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT327	1383658				2022-12-01	WOS:A1992JT32700014
J	CROS, P; ALLIBERT, P; MANDRAND, B; TIERCY, JM; MACH, B				CROS, P; ALLIBERT, P; MANDRAND, B; TIERCY, JM; MACH, B			OLIGONUCLEOTIDE GENOTYPING OF HLA POLYMORPHISM ON MICROTITRE PLATES	LANCET			English	Article							LINKAGE DISEQUILIBRIUM; TYPING ANALYSIS; CLASS-II; HYBRIDIZATION; DNA; IDENTIFICATION; PROBES	Molecular analysis of mutations and polymorphisms that are of medical importance requires both accuracy and simplicity. In organ transplantation there is a need for an HLA typing procedure that combines the remarkable accuracy of oligonucleotide genotyping with the simplicity of conventional serological typing. We describe a simple semiautomated method of HLA class II typing consisting of an oligonucleotide hybridisation assay done on microtitre plates followed by automatic colorimetric reading. Individual HLA-DR generic typing for 30 DR specificities, including subtypes of DR1, DR2, DR13, DR14, and DR52, is done on a single plate. The entire typing assay can be completed in less than 4 hours. The procedure has been validated on more than a thousand haplotypes in prospective DR typing of kidney transplant patients, leukaemic patients, and their potential donors. The simplicity of this assay makes it suitable for routine laboratory use. It can be applied to genetic testing in general, including the testing of patients with multiple mutations.	BIOMERIEUX,NUCLEIC ACID PROBES LAB,LYON,FRANCE; HOP CANTONAL GENEVA,DIV IMMUNOL & ALLERGOL,TRANSPLANTAT IMMUNOL UNIT,CH-1211 GENEVA 4,SWITZERLAND; UNIV GENEVA,SCH MED,DEPT GENET & MICROBIOL,CH-1211 GENEVA 4,SWITZERLAND	bioMerieux; University of Geneva; University of Geneva								ANGELINI G, 1986, P NATL ACAD SCI USA, V83, P4489, DOI 10.1073/pnas.83.12.4489; BODMER JG, 1992, TISSUE ANTIGENS, V39, P161, DOI 10.1111/j.1399-0039.1992.tb01932.x; DUNN AR, 1977, CELL, V12, P23, DOI 10.1016/0092-8674(77)90182-9; GRIMBERG J, 1989, NUCLEIC ACIDS RES, V17, P8390, DOI 10.1093/nar/17.20.8390; KELLER GH, 1989, DNA PROBES, P141; MACH B, 1991, HUM IMMUNOL, V30, P278, DOI 10.1016/0198-8859(91)90007-V; MACH B, 1990, MOL BIOL HLA CLASS 2, P201; MOREL C, 1990, HUM IMMUNOL, V29, P64, DOI 10.1016/0198-8859(90)90070-6; SAIKI RK, 1986, NATURE, V324, P163, DOI 10.1038/324163a0; SAIKI RK, 1989, P NATL ACAD SCI USA, V86, P6230, DOI 10.1073/pnas.86.16.6230; TIERCY JM, 1991, TISSUE ANTIGENS, V37, P161, DOI 10.1111/j.1399-0039.1991.tb01865.x; TIERCY JM, 1991, P NATL ACAD SCI USA, V88, P7121, DOI 10.1073/pnas.88.16.7121; TIERCY JM, 1988, P NATL ACAD SCI USA, V85, P198, DOI 10.1073/pnas.85.1.198; TIERCY JM, 1990, EUR J IMMUNOL, V20, P237, DOI 10.1002/eji.1830200202; TIERCY JM, 1991, TRANSPLANTATION, V51, P1110, DOI 10.1097/00007890-199105000-00034; WAKE CT, 1982, NATURE, V300, P372, DOI 10.1038/300372a0	16	67	72	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 10	1992	340	8824					870	873		10.1016/0140-6736(92)93284-T	http://dx.doi.org/10.1016/0140-6736(92)93284-T			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT327	1357296				2022-12-01	WOS:A1992JT32700003
J	ILLINGWORTH, C				ILLINGWORTH, C			THE ARGUMENT FOR HELMETS	BRITISH MEDICAL JOURNAL			English	Article							BICYCLE INJURIES; CHILDREN; ACCIDENTS		CHILDRENS HOSP,PAEDIAT ACCID & EMERGENCY,SHEFFIELD S10 2TH,S YORKSHIRE,ENGLAND	Sheffield Children's NHS Foundation Trust; Sheffield Children's Hospital								AHLSTROM I, 1990, HJALM ALLA; BALLANTYNE R, 1975, RICHARDS BICYCLE BOO; Bouvier R, 1984, Aust Fam Physician, V13, P287; CASS DT, 1989, AUST NZ J SURG, V59, P719, DOI 10.1111/j.1445-2197.1989.tb01664.x; GUICHON DMP, 1975, J TRAUMA, V15, P504, DOI 10.1097/00005373-197506000-00009; ILLINGWORTH CM, 1979, ACTA PAEDIATR SCAND, V68, P869; ILLINGWORTH CM, 1981, INJURY, V13, P7, DOI 10.1016/0020-1383(81)90083-8; ILLINGWORTH CM, 1985, ARCH DIS CHILD, V60, P461, DOI 10.1136/adc.60.5.461; ILLINGWORTH CM, 1984, BRIT MED J, V289, P956, DOI 10.1136/bmj.289.6450.956; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; SELBST SM, 1987, AM J DIS CHILD, V141, P140, DOI 10.1001/archpedi.1987.04460020030021; THOMPSON RS, 1989, NEW ENGL J MED, V320, P1361, DOI 10.1056/NEJM198905253202101; WILLIAMS M, 1989, PROTECTIVE PERFORMAN; 1987, AM J DIS CHILD, V141, P135; 1986, ROAD ACCIDENTS GREAT	15	8	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 10	1992	305	6858					882	883		10.1136/bmj.305.6858.882	http://dx.doi.org/10.1136/bmj.305.6858.882			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT777	1422408	Bronze, Green Published, Green Submitted			2022-12-01	WOS:A1992JT77700036
J	MCCARTHY, M				MCCARTHY, M			DO CYCLE HELMETS PREVENT SERIOUS HEAD-INJURY - CYCLING WITHOUT HELMETS	BRITISH MEDICAL JOURNAL			English	Article							BICYCLE				MCCARTHY, M (corresponding author), BLOOMSBURY & ISLINGTON HLTH AUTHOR,PUBL HLTH,LONDON NW1 2LJ,ENGLAND.		McCarthy, Mark/C-1117-2009					ADAMS M, 1990, CAPITAL KILLER AIR P; BULL JP, 1988, BRIT MED J, V296, P1144, DOI 10.1136/bmj.296.6630.1144; DIGUISEPPI CG, 1989, JAMA-J AM MED ASSOC, V262, P2256, DOI 10.1001/jama.262.16.2256; HAMMER M, 1987, WHEELS WHEELS STUDY; MCCARTHY M, 1991, PUBLIC HEALTH, V105, P327, DOI 10.1016/S0033-3506(05)80218-5; Rogers R, 1992, NEW LONDON; THOMPSON RS, 1989, NEW ENGL J MED, V320, P1361, DOI 10.1056/NEJM198905253202101; 1991, HLTH MOVE POLICIES P; 1991, ROAD ACCIDENTS GREAT; 1990, CATALOGUE, P328; 1992, CYCLING HLTH SAFETY; 1988, LANCET, V1, P159	12	23	23	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 10	1992	305	6858					881	882		10.1136/bmj.305.6858.881	http://dx.doi.org/10.1136/bmj.305.6858.881			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT777	1422407	Green Published, Bronze, Green Submitted			2022-12-01	WOS:A1992JT77700035
J	RODRIGUEZ, LAG; GUTTHANN, SP; WALKER, AM; LUECK, L				RODRIGUEZ, LAG; GUTTHANN, SP; WALKER, AM; LUECK, L			THE ROLE OF NONSTEROIDAL ANTIINFLAMMATORY DRUGS IN ACUTE LIVER-INJURY	BRITISH MEDICAL JOURNAL			English	Article							PROGRAM	Objective-To investigate the association between use of non-steroidal anti-inflammatory drugs and serious, acute non-infectious liver injury. Design-Retrospective cohort study, cross over design. Setting-Health records from provincial database in Saskatchewan, Canada, 1982-6. Subjects-228392 adults who contributed 645456 person years. All were either using or had used non-steroidal anti-inflammatory drugs. Main outcome measures-Number and type of prescriptions for non-steroidal anti-inflammatory drugs. Admission to hospital for newly diagnosed acute liver injury. Results-There were 34 admissions to hospital; 16 among subjects currently using non-steroidal anti-inflammatory drugs and 18 among subjects who were not. The incidence rate among current users was 9 per 100 000 person years (95% confidence interval 6 to 15 per 100000 person years). Subjects currently using non-steroidal anti-inflammatory drugs had twice the risk of newly diagnosed liver injury as those not currently taking these drugs (rate ratio 2.3; 95% confidence interval 1.1 to 4.9) and an excess risk of 5 per 100000 person years. The age and sex adjusted risk ratio was 1.7 (0.8 to 3.7). The strength of the association increased when only cases with no concomitant use of other hepatotoxic drugs were considered (4.0; 0.9 to 19.0). The rate ratio for people having received one to nine prescriptions was constant. There was no increased risk with long duration of treatment (1.0; 0.3 to 3.5). Conclusions-There is a small excess risk of serious, acute non-infectious liver injury associated with the use of non-steroidal anti-inflammatory drugs.	CIBA GEIGY AG,PHARMACOEPIDEMIOL UNIT,CH-4002 BASEL,SWITZERLAND; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115; GDS & ASSOCIATES SYSTEMS LTD,REGINA,SASKATCHEWAN,CANADA	Novartis; Harvard University; Harvard T.H. Chan School of Public Health			rodriguez, luis a garcia/B-1980-2010	Perez-Gutthann, Susana/0000-0001-5798-3691				BEARD K, 1986, J CLIN PHARMACOL, V26, P633, DOI 10.1002/j.1552-4604.1986.tb02963.x; BJORNEBOE M, 1967, ACTA MED SCAND, V182, P491; Davis M., 1989, ADVERSE DRUG REACT B, V139, P520; JICK H, 1992, PHARMACOTHERAPY, V12, P207; LEWIS JH, 1984, CLIN PHARMACY, V3, P128; MARTIN D, 1991, EPIDEMIOLOGY, V2, P359, DOI 10.1097/00001648-199109000-00008; PESSAYRE D, 1988, BAILLIERE CLIN GASTR, V2, P385, DOI 10.1016/0950-3528(88)90009-7; RAVIOLO P, 1991, Recenti Progressi in Medicina, V82, P319; RAY WA, 1989, AM J EPIDEMIOL, V129, P837, DOI 10.1093/oxfordjournals.aje.a115198; RODRIGUEZ LAG, 1992, EPIDEMIOLOGY, V3, P337, DOI 10.1097/00001648-199207000-00008; ROSS RM, 1981, AM J GASTROENTEROL, V76, P511; ROTHMAN KJ, 1988, INT J EPIDEMIOL, V17, P955, DOI 10.1093/ije/17.4.955; SANCHO CG, 1988, MED CLIN-BARCELONA, V90, P579; SHERLOCK S, 1981, DISEASES LIVER BILIA; STRAND LM, 1989, PHARMACOEPIDEM DR S, P189; STRICKER BHC, 1985, DRUG INDUCED HEPATIC; VANNESS MM, 1989, ANN INTERN MED, V111, P473, DOI 10.7326/0003-4819-111-6-473; Walker AM, 1991, OBSERVATION INFERENC; ZIMMERMAN HJ, 1981, ARCH INTERN MED, V141, P333, DOI 10.1001/archinte.141.3.333; 1990, J HEPATOL, V11, P272	20	81	84	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 10	1992	305	6858					865	868		10.1136/bmj.305.6858.865	http://dx.doi.org/10.1136/bmj.305.6858.865			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT777	1422399	Green Published, Green Submitted, Bronze			2022-12-01	WOS:A1992JT77700024
J	SILAGY, C; MUIR, J; COULTER, A; THOROGOOD, M; YUDKIN, P; ROE, L				SILAGY, C; MUIR, J; COULTER, A; THOROGOOD, M; YUDKIN, P; ROE, L			LIFE-STYLE ADVICE IN GENERAL-PRACTICE - RATES RECALLED BY PATIENTS	BRITISH MEDICAL JOURNAL			English	Article							PRIMARY CARE; HEALTH PROMOTION; CONTROLLED TRIAL; PRACTITIONERS; PREVENTION; SMOKING; VIEWS; AUDIT	Objective-To document how often patients with varying cardiovascular risk levels reported receiving lifestyle advice from general practice. Design-Cross sectional descriptive survey by postal questionnaire. Setting-5 general practices in Bedfordshire. Subjects-4941 people aged 35-64 years who had consulted a general practitioner at least once during the 12 months before completing the questionnaire and who subsequently attended for a health check as part of the OXCHECK trial. Main outcome measures-Report of having received advice from a general practitioner or practice nurse about smoking, alcohol consumption, exercise, or diet during the 12 months before completing the questionnaire. Cardiovascular risk assessed by a nurse during structured health check. Results-The overall reported rate of advice was 27% for smoking, 4.5% for exercise, 12% for diet, and 3% for alcohol consumption. Those with unhealthy behaviour profile or at increased cardiovascular risk received more advice-for example, 47% of smokers with a history of cardiovascular disease received advice on smoking. Among those at increased risk, men were more likely than women to receive advice about exercise (11% v 4%, p = 0.04) and alcohol consumption (10% v 4%, p = 0.007), while women received more advice about weight (17% v 23%, p < 0.001). The rate of receiving advice was unaffected by age, marital status, or social class. Conclusion-The low rate of lifestyle advice reported by patients implies that more preventive advice could be provided in primary care.	RADCLIFFE INFIRM,DEPT PUBL HLTH & PRIMARY CARE,HLTH SERV RES UNIT,OXFORD OX2 6HE,ENGLAND	Radcliffe Infirmary; University of Oxford	SILAGY, C (corresponding author), UNIV OXFORD,RADCLIFFE INFIRM,DEPT PUBL HLTH & PRIMARY CARE,OXFORD OX2 6HE,ENGLAND.		Coulter, Angela/N-6998-2019	Coulter, Angela/0000-0002-6308-8375				[Anonymous], 1980, CLASSIFICATION OCCUP; ARMITAGE P, 1987, STATISTICAL METHODS, P372; CATFORD JC, 1984, BRIT MED J, V288, P832, DOI 10.1136/bmj.288.6420.832; COULTER A, 1987, J ROY COLL GEN PRACT, V37, P533; COULTER A, 1991, BRIT J GEN PRACT, V41, P140; DICKINSON JA, 1989, MED J AUSTRALIA, V150, P420, DOI 10.5694/j.1326-5377.1989.tb136560.x; Fleming D M, 1981, J R Coll Gen Pract, V31, P615; FLEMING DM, 1983, BRIT MED J, V287, P1852, DOI 10.1136/bmj.287.6408.1852; FORD AS, 1983, SOC SCI MED, V17, P1505, DOI 10.1016/0277-9536(83)90095-3; FREELING P, 1989, MATERNAL CHILD HLTH, V14, P394; FREER C B, 1986, Health Bulletin (Edinburgh), V44, P75; FULLARD E, 1987, BRIT MED J, V294, P1080, DOI 10.1136/bmj.294.6579.1080; FULLARD E, 1984, BRIT MED J, V289, P1585, DOI 10.1136/bmj.289.6458.1585; JAMROZIK K, 1984, BRIT MED J, V288, P1499, DOI 10.1136/bmj.288.6429.1499; LAWRENCE M, 1990, BRIT MED J, V300, P1501, DOI 10.1136/bmj.300.6738.1501; ORLEANS CT, 1985, PREV MED, V14, P636, DOI 10.1016/0091-7435(85)90083-0; PILL R, 1988, J ROY COLL GEN PRACT, V38, P53; PILL RM, 1989, J ROY COLL GEN PRACT, V39, P196; ROSE G, 1977, BRIT J PREV SOC MED, V31, P42; RUSSELL MAH, 1987, BRIT MED J, V295, P1240, DOI 10.1136/bmj.295.6608.1240; STOATE HG, 1989, J ROY COLL GEN PRACT, V39, P193; STONE DH, 1987, J ROY COLL GEN PRACT, V37, P218; Stott N C, 1979, J R Coll Gen Pract, V29, P201; STOTT NCH, 1990, FAM PRACT, V7, P125, DOI 10.1093/fampra/7.2.125; TUCKETT D, 1985, M EXPERTS APPRAOCH S; WALLACE PG, 1987, BRIT MED J, V294, P940, DOI 10.1136/bmj.294.6577.940; 1989, GENERAL PRACTICE NAT; 1984, 28 COMM MED ASP FOOD; 1991, BMJ, V302, P1057; 1981, RCGP18 ROYAL COLL GE	30	83	85	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 10	1992	305	6858					871	874		10.1136/bmj.305.6858.871	http://dx.doi.org/10.1136/bmj.305.6858.871			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT777	1422405	Green Submitted, Green Published, Bronze			2022-12-01	WOS:A1992JT77700031
J	STARZL, TE; DEMETRIS, AJ; TRUCCO, M; RAMOS, H; ZEEVI, A; RUDERT, WA; KOCOVA, M; RICORDI, C; ILDSTAD, S; MURASE, N				STARZL, TE; DEMETRIS, AJ; TRUCCO, M; RAMOS, H; ZEEVI, A; RUDERT, WA; KOCOVA, M; RICORDI, C; ILDSTAD, S; MURASE, N			SYSTEMIC CHIMERISM IN HUMAN FEMALE RECIPIENTS OF MALE LIVERS	LANCET			English	Note							PCR	We have previously reported data from clinical and laboratory animal observations which suggest that organ tolerance after transplantation depends on a state of balanced lymphodendritic cell chimerism between the host and donor graft. We have sought further evidence to support this hypothesis by investigating HLA-mismatched liver allograft recipients. 9 of 9 female recipients of livers from male donors had chimerism in their allografts and extrahepatic tissues, according to in-situ hybridisation and molecular techniques 10 to 19 years post-transplantation. In 8 women with good graft function, evidence of the Y chromosome was found in the blood (6/8), skin (8/8), and lymph nodes (7/8). A ninth patient whose transplant failed after 12 years from recurrent chronic viral hepatitis had chimerism in her lymph nodes, skin, jejunum, and aorta at the time of retransplantation. Although cell migration is thought to take place after all types of transplantation, the large population of migratory cells in, and the extent of their seeding from, hepatic grafts may explain the privileged tolerogenicity of the liver compared with other organs.	UNIV PITTSBURGH,HLTH SCI CTR,PITTSBURGH TRANSPLANT INST,PITTSBURGH,PA 15213; UNIV PITTSBURGH,HLTH SCI CTR,DEPT PATHOL,PITTSBURGH,PA 15213; UNIV PITTSBURGH,HLTH SCI CTR,DEPT PEDIAT,PITTSBURGH,PA 15213	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	STARZL, TE (corresponding author), UNIV PITTSBURGH,HLTH SCI CTR,DEPT SURG,3601 5TH AVE,5C FALK CLIN,PITTSBURGH,PA 15213, USA.		RICORDI, CAMILLO/AAA-4740-2019	Ricordi, Camillo/0000-0001-8092-7153	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK029961, R37DK029961] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 29961] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CALNE RY, 1969, NATURE, V223, P472, DOI 10.1038/223472a0; KASHIWAGI N, 1969, Surgical Forum (Chicago), V20, P374; NAKAGOME Y, 1991, AM J MED GENET, V41, P112, DOI 10.1002/ajmg.1320410127; STARZL TE, 1992, LANCET, V339, P1579, DOI 10.1016/0140-6736(92)91840-5; STARZL TE, IN PRESS TRANSPLANT; STARZL TE, IN PRESS N ENGL J ME; STARZL TE, 1969, EXPERIENCE HEPATIC T, P184; WARBURTON PE, 1991, GENOMICS, V11, P324, DOI 10.1016/0888-7543(91)90139-6	8	324	333	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 10	1992	340	8824					876	877		10.1016/0140-6736(92)93286-V	http://dx.doi.org/10.1016/0140-6736(92)93286-V			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT327	1357298	Green Accepted			2022-12-01	WOS:A1992JT32700005
J	TULINIUS, H; EGILSSON, V; OLAFSDOTTIR, GH; SIGVALDASON, H				TULINIUS, H; EGILSSON, V; OLAFSDOTTIR, GH; SIGVALDASON, H			RISK OF PROSTATE, OVARIAN, AND ENDOMETRIAL CANCER AMONG RELATIVES OF WOMEN WITH BREAST-CANCER	BRITISH MEDICAL JOURNAL			English	Article							FAMILIAL ASSOCIATION; CARCINOMA; LOCUS	Objective-To investigate the risk of prostate, ovarian, and endometrial cancer among relatives of patients with breast cancer. Design-Cohort study of 947 pedigrees in which the proband had breast cancer, linked with the Icelandic cancer registry. Setting-Iceland. Subjects-The 947 pedigrees included 29725 people, of whom 1539 had breast cancer, 467 had prostate cancer, 135 ovarian cancer, and 105 endometrial cancer. Main outcome measures-Risk of prostate, ovarian, and endometrial cancer among blood relatives of women with breast cancer compared with risk in spouses. Results-The risk of prostate cancer was significantly raised for all relatives (1.5), first degree relatives (1.4), and second degree relatives (1.3) of women with breast cancer. Risk of ovarian cancer was raised for all relatives (1.9) and first degree relatives (1.9) and risk of endometrial cancer was raised for all relatives only (1.9). The risk of prostate cancer was raised if the proband with breast cancer had a first degree relative with prostate cancer. Conclusions-Coaggreption exists between breast cancer and cancers of the prostate, ovaries, and endometrium. This risk relation is probably based on genes which act by increasing the risk for cancer at these sites. Environmental factors that are common among relatives may also play a part. Continued research is required into pathophysiological mechanisms that could explain these observations.	UNIV ICELAND,DEPT PATHOL,REYKJAVIK,ICELAND	University of Iceland	TULINIUS, H (corresponding author), ICELAND CANC REGISTRY,SKOGARHLID 8,IS-125 REYKJAVIK,ICELAND.							Cannon L., 1982, CANCER SURV, V1, P47; FERRELL RE, 1989, CANCER GENET CYTOGEN, V38, P241, DOI 10.1016/0165-4608(89)90665-1; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; KING MC, 1980, SCIENCE, V208, P406, DOI 10.1126/science.7367867; LYNCH HT, 1978, CANCER-AM CANCER SOC, V41, P1543, DOI 10.1002/1097-0142(197804)41:4<1543::AID-CNCR2820410444>3.0.CO;2-Y; LYNCH HT, 1982, OBSTET GYNECOL, V59, P589; NAROD SA, 1991, LANCET, V338, P82; NOMURA AMY, 1991, EPIDEMIOL REV, V13, P200, DOI 10.1093/oxfordjournals.epirev.a036069; SCHILDKRAUT JM, 1989, AM J HUM GENET, V45, P521; THIESSEN EU, 1974, CANCER, V34, P1102, DOI 10.1002/1097-0142(197410)34:4<1102::AID-CNCR2820340421>3.0.CO;2-5; THOMPSON WD, 1991, INT J EPIDEMIOL, V20, P595, DOI 10.1093/ije/20.3.595; TULINIUS H, 1992, J MED GENET, V29, P158, DOI 10.1136/jmg.29.3.158; TULINIUS H, 1985, INT C SERIES, V685; TULINIUS H, 1985, NARINGSFORSKNING, V29, P17; VATTEN LJ, 1990, INT J CANCER, V45, P440, DOI 10.1002/ijc.2910450311; WILLIAMS W R, 1984, Genetic Epidemiology, V1, P7, DOI 10.1002/gepi.1370010104; 1990, EGRET REFERENCE MANU	17	149	152	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 10	1992	305	6858					855	857		10.1136/bmj.305.6858.855	http://dx.doi.org/10.1136/bmj.305.6858.855			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT777	1422397	Green Published, Bronze, Green Submitted			2022-12-01	WOS:A1992JT77700021
J	VERITY, CM; ROSS, EM; GOLDING, J				VERITY, CM; ROSS, EM; GOLDING, J			EPILEPSY IN THE 1ST 10 YEARS OF LIFE - FINDINGS OF THE CHILD HEALTH AND EDUCATION STUDY	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CONVULSIVE DISORDERS; FEBRILE CONVULSIONS; UNPROVOKED SEIZURE; NATIONAL COHORT; RISK-FACTORS; FOLLOW-UP; RECURRENCE; POPULATION; PREVALENCE; PROGNOSIS	Objectives-To identify children with afebrile seizures in a national cohort, classify the seizures, and document progress in the first 10 years of life. Design-Population based birth cohort study. Setting-The child health and education study, which includes 16004 neonatal survivors (98.5% of infants born in the United Kingdom during one week of April 1970). Subjects-14676 children for whom relevant information was available. Main outcome measures-Responses to parental and general practitioner questionnaires and hospital records at 5 and 10 years after birth. Results-84 children (42 boys, 42 girls) had had one or more afebrile seizure (incidence 5.7/1000). 63 children (31 boys, 32 girls) had epilepsy (incidence 4.3/1000). 49 of 55 children had a second seizure within a year of the first. The commonest seizure types were tonic-clonic (42) and complex partial (25). A greater proportion of children with complex partial seizures had recurrences. Children who had infantile spasms or a mixed seizure disorder had a poor outcome. All six children who died had symptomatic seizures in the first year, but seizures were not the direct cause of death. Conclusions-The results of this study are probably representative of seizure patterns in the general population. Outcome after seizures is determined more by the underlying disease than by the seizures themselves.	UNIV LONDON KINGS COLL HOSP, DEPT COMMUNITY PAEDIAT, LONDON SE5 8RX, ENGLAND; UNIV BRISTOL, INST CHILD HLTH, DEPT PAEDIAT & PERINATAL, BRISTOL BS8 1TH, AVON, ENGLAND	King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London; University of Bristol	VERITY, CM (corresponding author), ADDENBROOKES HOSP, DEPT PAEDIAT, CAMBRIDGE CB2 2QQ, ENGLAND.			Golding, Jean/0000-0003-2826-3307				ANNEGERS JF, 1979, EPILEPSIA, V20, P729, DOI 10.1111/j.1528-1157.1979.tb04857.x; ANNEGERS JF, 1986, EPILEPSIA, V27, P43, DOI 10.1111/j.1528-1157.1986.tb03499.x; [Anonymous], 1981, Epilepsia, V22, P489; BERG AT, 1991, NEUROLOGY, V41, P965, DOI 10.1212/WNL.41.7.965; CAVAZZUTI GB, 1984, DEV MED CHILD NEUROL, V26, P425; CHADWICK D, 1991, J NEUROL NEUROSUR PS, V54, P385, DOI 10.1136/jnnp.54.5.385; CHAMBERLAIN R, 1978, BRIT BIRTHS 1970, V1; CHEVRIE JJ, 1979, EPILEPSIA, V20, P643, DOI 10.1111/j.1528-1157.1979.tb04848.x; CHEVRIE JJ, 1978, EPILEPSIA, V19, P67; COOPER JE, 1965, BRIT MED J, V1, P1020, DOI 10.1136/bmj.1.5441.1020; ELLENBERG JH, 1984, ANN NEUROL, V15, P127, DOI 10.1002/ana.410150204; FALCONER MA, 1964, ARCH NEUROL-CHICAGO, V10, P233, DOI 10.1001/archneur.1964.00460150003001; GOODRIDGE DMG, 1983, BRIT MED J, V287, P645, DOI 10.1136/bmj.287.6393.645; GOODRIDGE DMG, 1983, BMJ-BRIT MED J, V287, P641, DOI 10.1136/bmj.287.6393.641; HART YM, 1990, LANCET, V336, P1271, DOI 10.1016/0140-6736(90)92960-P; HAUSER WA, 1990, NEUROLOGY, V40, P1163, DOI 10.1212/WNL.40.8.1163; NELSON KB, 1976, NEW ENGL J MED, V295, P1029, DOI 10.1056/NEJM197611042951901; ROCCA WA, 1987, ANN NEUROL, V21, P22, DOI 10.1002/ana.410210106; ROCCA WA, 1987, NEUROLOGY, V37, P1315, DOI 10.1212/WNL.37.8.1315; ROSS EM, 1980, BRIT MED J, V280, P207, DOI 10.1136/bmj.280.6209.207; SANDER JWAS, 1987, J NEUROL NEUROSUR PS, V50, P829, DOI 10.1136/jnnp.50.7.829; SHORVON SD, 1984, J NEUROL NEUROSUR PS, V47, P1157, DOI 10.1136/jnnp.47.11.1157; SILLANPAA M, 1973, ACTA PAEDIATR SC   S, V273, P1; TAYLOR DC, 1971, EPILEPSIA, V12, P33, DOI 10.1111/j.1528-1157.1971.tb03913.x; VANDENBERG BJ, 1969, PEDIATR RES, V3, P298, DOI 10.1203/00006450-196907000-00005; VERITY CM, 1985, BRIT MED J, V290, P1307, DOI 10.1136/bmj.290.6478.1307; VERITY CM, 1985, BMJ-BRIT MED J, V290, P1311, DOI 10.1136/bmj.290.6478.1311; VERITY CM, 1991, BMJ-BRIT MED J, V303, P1373, DOI 10.1136/bmj.303.6814.1373	28	60	61	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 10	1992	305	6858					857	861		10.1136/bmj.305.6858.857	http://dx.doi.org/10.1136/bmj.305.6858.857			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT777	1384897	Bronze, Green Published, Green Submitted			2022-12-01	WOS:A1992JT77700022
J	AKABAS, MH; STAUFFER, DA; XU, M; KARLIN, A				AKABAS, MH; STAUFFER, DA; XU, M; KARLIN, A			ACETYLCHOLINE-RECEPTOR CHANNEL STRUCTURE PROBED IN CYSTEINE-SUBSTITUTION MUTANTS	SCIENCE			English	Article							SITE-DIRECTED MUTAGENESIS; AFFINITY BINDING-SITE; DELTA-SUBUNIT; H-3 CHLORPROMAZINE; ALPHA-SUBUNIT; TORPEDO-CALIFORNICA; NICOTINIC RECEPTOR; ION CHANNEL; NONCOMPETITIVE BLOCKERS; GAMMA-SUBUNIT	In order to understand the structural bases of ion conduction, ion selectivity, and gating in the nicotinic acetylcholine receptor, mutagenesis and covalent modification were combined to identify the amino acid residues that line the channel. The side chains of alternate residues-Ser248, Leu250, Ser252, and Thr254-in M2, a membrane-spanning segment of the alpha subunit, are exposed in the closed channel. Thus alpha248-254 probably forms a beta strand, and the gate is closer to the cytoplasmic end of the channel than any of these residues. On channel opening, Leu251 is also exposed. These results lead to a revised view of the closed and open channel structures.	COLUMBIA UNIV COLL PHYS & SURG,CTR MOLEC RECOGNIT,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT BIOCHEM,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT PHYSIOL,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT NEUROL,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032	Columbia University; Columbia University; Columbia University; Columbia University; Columbia University				KARLIN, ARTHUR/0000-0002-4813-752X; Akabas, Myles/0000-0001-8781-7846	NINDS NIH HHS [NS07065, NS07258] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTENBACH C, 1990, SCIENCE, V248, P1088, DOI 10.1126/science.2160734; ANDERSON DJ, 1981, P NATL ACAD SCI-BIOL, V78, P5598, DOI 10.1073/pnas.78.9.5598; ARNOLD E, 1990, J MOL BIOL, V211, P763, DOI 10.1016/0022-2836(90)90076-X; BERTRAND D, 1992, P NATL ACAD SCI USA, V89, P1261, DOI 10.1073/pnas.89.4.1261; CHARNET P, 1990, NEURON, V2, P87; CHAVEZ RA, 1991, J BIOL CHEM, V266, P15532; CLAUDIO T, 1983, P NATL ACAD SCI-BIOL, V80, P1111, DOI 10.1073/pnas.80.4.1111; COHEN BN, 1992, J GEN PHYSIOL, V99, P545, DOI 10.1085/jgp.99.4.545; COLQUHOUN D, 1981, NATURE, V294, P464, DOI 10.1038/294464a0; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; DANI JA, 1989, J NEUROSCI, V9, P884; DIPAOLA M, 1989, J BIOL CHEM, V264, P15457; DIPAOLA M, 1990, J BIOL CHEM, V265, P11017; DWYER TM, 1980, J GEN PHYSIOL, V75, P469, DOI 10.1085/jgp.75.5.469; FALKE JJ, 1988, J BIOL CHEM, V263, P14850; FATT P, 1951, J PHYSIOL-LONDON, V115, P320, DOI 10.1113/jphysiol.1951.sp004675; GIRAUDAT J, 1986, P NATL ACAD SCI USA, V83, P2719, DOI 10.1073/pnas.83.8.2719; GIRAUDAT J, 1987, BIOCHEMISTRY-US, V26, P2410, DOI 10.1021/bi00383a003; GIRAUDAT J, 1989, FEBS LETT, V253, P190, DOI 10.1016/0014-5793(89)80957-3; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; HUCHO F, 1986, FEBS LETT, V205, P137, DOI 10.1016/0014-5793(86)80881-X; IMOTO K, 1986, NATURE, V324, P670, DOI 10.1038/324670a0; IMOTO K, 1988, NATURE, V335, P645, DOI 10.1038/335645a0; JAKES KS, 1990, J BIOL CHEM, V265, P6984; JONES TA, 1988, EMBO J, V7, P1597, DOI 10.1002/j.1460-2075.1988.tb02985.x; KAO PN, 1984, J BIOL CHEM, V259, P1662; Kenyon G L, 1977, Methods Enzymol, V47, P407; KONNO T, 1991, P ROY SOC B-BIOL SCI, V244, P69, DOI 10.1098/rspb.1991.0053; KUIPERS OP, 1991, NUCLEIC ACIDS RES, V19, P4558, DOI 10.1093/nar/19.16.4558; LASTERS I, 1988, P NATL ACAD SCI USA, V85, P3338, DOI 10.1073/pnas.85.10.3338; LEATHY DJ, 1992, CELL, V68, P1145; LEONARD RJ, 1988, SCIENCE, V242, P1578, DOI 10.1126/science.2462281; LO DC, 1991, NEURON, V6, P31, DOI 10.1016/0896-6273(91)90119-K; MCCREA PD, 1987, EMBO J, V6, P3619, DOI 10.1002/j.1460-2075.1987.tb02693.x; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; NODA M, 1983, NATURE, V302, P528, DOI 10.1038/302528a0; OBERTHUR W, 1986, EMBO J, V5, P1815, DOI 10.1002/j.1460-2075.1986.tb04431.x; PAKULA AA, 1992, P NATL ACAD SCI USA, V89, P4144, DOI 10.1073/pnas.89.9.4144; PEDERSEN SE, 1992, J BIOL CHEM, V267, P10489; POPOT JL, 1984, PHYSIOL REV, V64, P1162, DOI 10.1152/physrev.1984.64.4.1162; REVAH F, 1990, P NATL ACAD SCI USA, V87, P4675, DOI 10.1073/pnas.87.12.4675; REVAH F, 1991, NATURE, V353, P846, DOI 10.1038/353846a0; REYNOLDS JA, 1978, BIOCHEMISTRY-US, V17, P2035, DOI 10.1021/bi00604a001; STAUFFER D, UNPUB; TODD AP, 1989, PROTEINS, V6, P294, DOI 10.1002/prot.340060312; UNWIN N, 1989, NEURON, V3, P65; VILLARROEL A, 1991, P ROY SOC B-BIOL SCI, V243, P69, DOI 10.1098/rspb.1991.0012; WEISS MS, 1991, SCIENCE, V254, P1627, DOI 10.1126/science.1721242; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; YOOL AJ, 1991, NATURE, V349, P700, DOI 10.1038/349700a0	50	611	619	0	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 9	1992	258	5080					307	310		10.1126/science.1384130	http://dx.doi.org/10.1126/science.1384130			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JR860	1384130				2022-12-01	WOS:A1992JR86000037
J	BOITANO, S; DIRKSEN, ER; SANDERSON, MJ				BOITANO, S; DIRKSEN, ER; SANDERSON, MJ			INTERCELLULAR PROPAGATION OF CALCIUM WAVES MEDIATED BY INOSITOL TRISPHOSPHATE	SCIENCE			English	Article							INTRACELLULAR CA-2+; GAP-JUNCTIONS; MECHANICAL STIMULATION; CILIATED CELLS; OSCILLATIONS; COMMUNICATION; THAPSIGARGIN; ACTIVATION; GENERATION; MOBILIZATION	Two types of calcium (Ca2+) signaling-propagating intercellular Ca2+ waves of increasing intracellular Ca2+ concentration ([Ca2+]i) and nonpropagating oscillations in [Ca2+]i-co-exist in a variety of cell types. To investigate this difference in Ca2+ signaling, airway epithelial cells were loaded with heparin, an inositol 1,4,5-trisphosphate (IP3) receptor antagonist, by pulsed, high-frequency electroporation. Heparin inhibited propagation of intercellular Ca2+ waves but not oscillations of [Ca2+]i. In heparin-free cells, Ca2+ waves propagated through cells displaying [Ca2+]i oscillations. Depletion of intracellular Ca2+ pools with the Ca2+-pump inhibitor thapsigargin also inhibited the propagation of Ca2+ waves. These studies demonstrate that the release of Ca2+ by IP3 is necessary for the propagation of intercellular Ca2+ waves and suggest that IP3 moves through gap junctions to communicate intercellular Ca2+ waves.	UNIV CALIF LOS ANGELES,SCH MED,DEPT ANAT & CELL BIOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA								BENNETT MVL, 1988, GAP JUNCTIONS, P167; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BREHM P, 1989, NEURON, V3, P191, DOI 10.1016/0896-6273(89)90032-9; CHANG DC, 1989, ELECTROPORATION ELEC, P215; CHARLES AC, 1991, NEURON, V6, P983, DOI 10.1016/0896-6273(91)90238-U; CHARLES AC, 1992, J CELL BIOL, V118, P195, DOI 10.1083/jcb.118.1.195; CHARLES AC, IN PRESS GLIA; CORNELLBELL AH, 1990, SCIENCE, V247, P470, DOI 10.1126/science.1967852; DEMER LL, UNPUB; ELY JA, 1991, J BIOL CHEM, V266, P18635; FOSKETT JK, 1989, SCIENCE, V244, P1582, DOI 10.1126/science.2500708; FOSKETT JK, 1991, J BIOL CHEM, V266, P2778; GHOSH TK, 1988, J BIOL CHEM, V263, P11075; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUTHRIE SC, 1989, TRENDS NEUROSCI, V12, P12, DOI 10.1016/0166-2236(89)90150-1; HAROOTUNIAN AT, 1991, SCIENCE, V251, P75, DOI 10.1126/science.1986413; HILL TD, 1987, BIOCHEM BIOPH RES CO, V149, P897, DOI 10.1016/0006-291X(87)90492-X; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; JACOB R, 1990, BIOCHIM BIOPHYS ACTA, V1052, P427, DOI 10.1016/0167-4889(90)90152-4; KASAI H, 1990, NATURE, V348, P735, DOI 10.1038/348735a0; PETERSEN OH, 1990, J MEMBRANE BIOL, V118, P93, DOI 10.1007/BF01868467; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; ROONEY TA, 1989, J BIOL CHEM, V264, P17131; SAEZ JC, 1989, P NATL ACAD SCI USA, V86, P2708, DOI 10.1073/pnas.86.8.2708; SANDBERG K, 1992, J CELL BIOL, V117, P157, DOI 10.1083/jcb.117.1.157; SANDBERG K, 1990, SCIENCE, V249, P298, DOI 10.1126/science.2374929; SANDERSON MJ, 1990, CELL REGUL, V1, P585, DOI 10.1091/mbc.1.8.585; SANDERSON MJ, 1988, AM J PHYSIOL, V254, pC63, DOI 10.1152/ajpcell.1988.254.1.C63; SANDERSON MJ, 1986, P NATL ACAD SCI USA, V83, P7302, DOI 10.1073/pnas.83.19.7302; SNEYD J, UNPUB; SPRAY DC, 1985, ANNU REV PHYSIOL, V47, P281, DOI 10.1146/annurev.ph.47.030185.001433; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; THASTRUP O, 1991, J BIOL CHEM, V266, P17067; TSE A, 1992, SCIENCE, V255, P462, DOI 10.1126/science.1734523; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; WONG MMY, 1991, NATURE, V254, P1014; WORLEY PF, 1987, J BIOL CHEM, V262, P12132; ZHENG Q, 1991, BIOCHIM BIOPHYS ACTA, V1088, P104, DOI 10.1016/0167-4781(91)90158-I	39	450	455	0	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 9	1992	258	5080					292	295		10.1126/science.1411526	http://dx.doi.org/10.1126/science.1411526			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JR860	1411526				2022-12-01	WOS:A1992JR86000032
J	CHOI, DW				CHOI, DW			BENCH TO BEDSIDE - THE GLUTAMATE CONNECTION	SCIENCE			English	Editorial Material							MOLECULAR-CLONING; NMDA RECEPTOR; NITRIC-OXIDE; ACID; ANIRACETAM; ENCEPHALOPATHY; NEUROTOXICITY; MODULATION; ISCHEMIA; CHANNEL				CHOI, DW (corresponding author), WASHINGTON UNIV,SCH MED,DEPT NEUROL,ST LOUIS,MO 63110, USA.							ALBERS GW, 1992, ARCH NEUROL-CHICAGO, V49, P418, DOI 10.1001/archneur.1992.00530280112031; BUCHAN AM, 1991, NEUROSCI LETT, V132, P255, DOI 10.1016/0304-3940(91)90314-J; BURNASHEV N, 1992, SCIENCE, V257, P1415, DOI 10.1126/science.1382314; CHENG B, 1991, NEURON, V7, P1; CHOI DW, 1990, J NEUROSCI, V10, P2493; GARTHWAITE J, 1991, TRENDS NEUROSCI, V14, P60, DOI 10.1016/0166-2236(91)90022-M; GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0; HEYES MP, 1991, ANN NEUROL, V29, P202, DOI 10.1002/ana.410290215; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; Hory-Lee F., 1992, Society for Neuroscience Abstracts, V18, P46; HUME RI, 1991, SCIENCE, V253, P1028, DOI 10.1126/science.1653450; ISAACSON JS, 1991, P NATL ACAD SCI USA, V88, P10936, DOI 10.1073/pnas.88.23.10936; ITO I, 1990, J PHYSIOL-LONDON, V424, P533, DOI 10.1113/jphysiol.1990.sp018081; KOH JY, 1990, BRAIN RES, V533, P315, DOI 10.1016/0006-8993(90)91355-K; LIPTON SA, 1991, NEURON, V7, P111, DOI 10.1016/0896-6273(91)90079-F; LOWENSTEIN DH, 1991, NEURON, V7, P1053, DOI 10.1016/0896-6273(91)90349-5; MATTSON MP, 1992, J NEUROSCI, V12, P376, DOI 10.1523/jneurosci.12-02-00376.1992; MCNAMARA JO, 1992, J NEUROSCI, V12, P1555; MONYER H, 1991, NEURON, V6, P799, DOI 10.1016/0896-6273(91)90176-Z; MORI H, 1992, NATURE, V358, P673, DOI 10.1038/358673a0; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; OLNEY JW, 1976, NATURE, V264, P659, DOI 10.1038/264659a0; PAVLAKIS SG, 1984, ANN NEUROL, V16, P481, DOI 10.1002/ana.410160409; PELLEGRINIGIAMP.DE, 1992, FIDIA S EXCITATORY A, P35; PERL TM, 1990, NEW ENGL J MED, V322, P1775, DOI 10.1056/NEJM199006213222504; PIOMELLI D, 1987, NATURE, V328, P38, DOI 10.1038/328038a0; PUCKETT C, 1991, P NATL ACAD SCI USA, V88, P7557, DOI 10.1073/pnas.88.17.7557; RORDORF G, 1991, NEURON, V7, P1043, DOI 10.1016/0896-6273(91)90348-4; ROTHSTEIN JD, 1992, NEW ENGL J MED, V326, P1464, DOI 10.1056/NEJM199205283262204; SHEARDOWN MJ, 1990, SCIENCE, V247, P571, DOI 10.1126/science.2154034; SNYDER SH, 1991, TRENDS PHARMACOL SCI, V12, P125, DOI 10.1016/0165-6147(91)90526-X; SOMMER B, 1992, TRENDS PHARMACOL SCI, V13, P291, DOI 10.1016/0165-6147(92)90088-N; SPENCER PS, 1987, SCIENCE, V237, P517, DOI 10.1126/science.3603037; SUN W, 1992, P NATL ACAD SCI USA, V89, P1143; TANABE Y, 1992, NEURON, V8, P169, DOI 10.1016/0896-6273(92)90118-W; TANG CM, 1991, SCIENCE, V254, P288, DOI 10.1126/science.1681589; TANG CM, 1990, P NATL ACAD SCI USA, V87, P6445, DOI 10.1073/pnas.87.16.6445; TURSKI L, 1991, NATURE, V349, P414, DOI 10.1038/349414a0; YAMADA K A, 1991, Society for Neuroscience Abstracts, V17, P896	39	169	221	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 9	1992	258	5080					241	243		10.1126/science.1357748	http://dx.doi.org/10.1126/science.1357748			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JR860	1357748				2022-12-01	WOS:A1992JR86000019
J	DASILVA, LB; TREBES, JE; BALHORN, R; MROWKA, S; ANDERSON, E; ATTWOOD, DT; BARBEE, TW; BRASE, J; CORZETT, M; GRAY, J; KOCH, JA; LEE, C; KERN, D; LONDON, RA; MACGOWAN, BJ; MATTHEWS, DL; STONE, G				DASILVA, LB; TREBES, JE; BALHORN, R; MROWKA, S; ANDERSON, E; ATTWOOD, DT; BARBEE, TW; BRASE, J; CORZETT, M; GRAY, J; KOCH, JA; LEE, C; KERN, D; LONDON, RA; MACGOWAN, BJ; MATTHEWS, DL; STONE, G			X-RAY LASER MICROSCOPY OF RAT SPERM NUCLEI	SCIENCE			English	Article								The development of high brightness and short pulse width (<200 picoseconds) x-ray lasers now offers biologists the possibility of high-resolution imaging of specimens in an aqueous environment without the blurring effects associated with natural motions and chemical erosion. As a step toward developing the capabilities of this type of x-ray microscopy, a tantalum x-ray laser at 44.83 angstrom wavelength was used together with an x-ray zone plate lens to image both unlabeled and selectively gold-labeled dried rat sperm nuclei. The observed images show approximately 500 angstrom features, illustrate the importance of x-ray microscopy in determining chemical composition, and provide information about the uniformity of sperm chromatin organization and the extent of sperm chromatin hydration.	LAWRENCE LIVERMORE NATL LAB,LIVERMORE,CA 94550; LAWRENCE BERKELEY LAB,CTR XRAY OPT,BERKELEY,CA 94720; UNIV CALIF SAN FRANCISCO,DIV MOLEC CYTOMETRY,SAN FRANCISCO,CA 94143; IBM CORP,THOMAS J WATSON RES CTR,YORKTOWN HTS,NY 10598	United States Department of Energy (DOE); Lawrence Livermore National Laboratory; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California San Francisco; International Business Machines (IBM)	DASILVA, LB (corresponding author), UNIV CALIF BERKELEY,DEPT PHYS,BERKELEY,CA 94720, USA.		Kern, Dieter P/A-3109-2011					ALLEN MJ, 1991, J CELL BIOL, V15, P50; ALLEN MJ, 1990, J CELL BIOL, V111, P110; ANDERSON EH, 1991, XRAY MICROSCOPY, V3, P75; BALHORN R, 1977, BIOCHEMISTRY-US, V16, P4704; BARBEE TW, 1990, OPT ENG, V29, P581; DASILVA LB, 1992, OPT LETT, V17, P754, DOI 10.1364/OL.17.000754; DOOHER GB, 1973, AM J ANAT, V136, P339, DOI 10.1002/aja.1001360307; HUNT J, 1991, SPIE P, V1410, P2; JACOBSEN C, 1991, OPT COMMUN, V86, P351, DOI 10.1016/0030-4018(91)90016-7; KOEHLER J K, 1970, Journal of Ultrastructure Research, V33, P598, DOI 10.1016/S0022-5320(70)90184-X; KOEHLER JK, 1983, GAMETE RES, V8, P357, DOI 10.1002/mrd.1120080406; MacGowan B. J., 1990, X-Ray Lasers 1990. Proceedings of the 2nd International Colloquium, P221; MACGOWAN BJ, 1990, PHYS REV LETT, V65, P420, DOI 10.1103/PhysRevLett.65.420; MEYERILSE W, 1991, XRAY MICROSCOPY, V3, P284; ROSEN MD, 1985, PHYS REV LETT, V54, P106, DOI 10.1103/PhysRevLett.54.106; SKINNER CH, 1990, J MICROSC-OXFORD, V159, P51, DOI 10.1111/j.1365-2818.1990.tb03018.x; TOMIE T, 1991, SCIENCE, V252, P691, DOI 10.1126/science.2024121	17	137	137	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 9	1992	258	5080					269	271		10.1126/science.1411525	http://dx.doi.org/10.1126/science.1411525			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JR860	1411525				2022-12-01	WOS:A1992JR86000025
J	DESIMONE, R				DESIMONE, R			THE PHYSIOLOGY OF MEMORY - RECORDINGS OF THINGS PAST	SCIENCE			English	Editorial Material							INFERIOR TEMPORAL CORTEX; SHORT-TERM-MEMORY; HIPPOCAMPAL-FORMATION; RECOGNITION MEMORY; NEURONS; LESIONS; ASSOCIATION; RESPONSES; MACAQUE; PRIMATE				DESIMONE, R (corresponding author), NIMH,NEUROPSYCHOL LAB,BETHESDA,MD 20892, USA.		Desimone, Robert/G-1121-2018					BAKIN JS, 1990, BRAIN RES, V536, P271, DOI 10.1016/0006-8993(90)90035-A; BAYLIS GC, 1987, EXP BRAIN RES, V65, P614; COLOMBO M, 1990, SCIENCE, V247, P336, DOI 10.1126/science.2296723; EICHENBAUM H, 1992, BEHAV NEURAL BIOL, V57, P2, DOI 10.1016/0163-1047(92)90724-I; ESKANDAR EN, IN PRESS J NEUROPHYS; FUSTER JM, 1981, SCIENCE, V212, P952, DOI 10.1126/science.7233192; GALFAN D, 1992, BEHAV NEUROSCI, V106, P30; GNADT JW, 1988, EXP BRAIN RES, V70, P216; GOLDMANRAKIC PS, 1990, COLD SPRING HARB SYM, V55, P1025; GRAFTON ST, 1992, J NEUROSCI, V12, P2542; MAUNSELL JHR, 1991, VISUAL NEUROSCI, V7, P561, DOI 10.1017/S095252380001035X; MERZENICH MM, 1990, COLD SPRING HARB SYM, V55, P873; MIHASHITA Y, 1988, NATURE, V335, P817; MILLER EK, 1991, SCIENCE, V254, P1377, DOI 10.1126/science.1962197; MISHKIN M, 1991, 1990 YAK INT S PERC, P7; MISHKIN M, 1982, PHILOS T R SOC LOND, V298, P83; MITZ AR, 1991, J NEUROSCI, V11, P1855; MIYASHITA Y, 1988, NATURE, V331, P68, DOI 10.1038/331068a0; MURRAY EA, 1985, SCIENCE, V228, P604, DOI 10.1126/science.3983648; NADEL L, 1992, J COGNITIVE NEUROSCI, V4, P179, DOI 10.1162/jocn.1992.4.3.179; PACKARD MG, 1989, J NEUROSCI, V9, P1465; POLSTER MR, 1991, J COGNITIVE NEUROSCI, V3, P95, DOI 10.1162/jocn.1991.3.2.95; PONS TP, 1991, SCIENCE, V252, P1857, DOI 10.1126/science.1843843; RICHES IP, 1991, J NEUROSCI, V11, P1763; ROLLS ET, 1989, EXP BRAIN RES, V76, P153; SAKAI K, 1991, NATURE, V354, P152, DOI 10.1038/354152a0; SQUIRE LR, 1991, SCIENCE, V253, P1380, DOI 10.1126/science.1896849; SQUIRE LR, 1992, P NATL ACAD SCI USA, V89, P1837, DOI 10.1073/pnas.89.5.1837; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; THOMPSON RF, 1991, NEUROPSYCHOLOGIA, V29, P571, DOI 10.1016/0028-3932(91)90011-V; ZOLAMORGAN S, 1989, J NEUROSCI, V9, P4355; ZOLAMORGAN S, IN PRESS J NEUROSCI	32	59	60	1	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 9	1992	258	5080					245	246		10.1126/science.1411523	http://dx.doi.org/10.1126/science.1411523			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JR860	1411523				2022-12-01	WOS:A1992JR86000021
J	GARCIA, I; MARTINOU, I; TSUJIMOTO, Y; MARTINOU, JC				GARCIA, I; MARTINOU, I; TSUJIMOTO, Y; MARTINOU, JC			PREVENTION OF PROGRAMMED CELL-DEATH OF SYMPATHETIC NEURONS BY THE BCL-2 PROTOONCOGENE	SCIENCE			English	Article							GROWTH-FACTOR DEPRIVATION; FOLLICULAR LYMPHOMA; B-CELLS; EXPRESSION; SURVIVAL; TRANSLOCATION; ENDONUCLEASE; MOTONEURONS; ACTIVATION; DEPENDENCE	Approximately half of the neurons produced during embryogenesis normally die before adulthood. Although target-derived neurotrophic factors are known to be major determinants of programmed cell death-apoptosis-the molecular mechanisms by which trophic factors interfere with cell death regulation are largely unknown. Overexpression of the bcl-2 proto-oncogene in cultured sympathetic neurons has now been shown to prevent apoptosis normally induced by deprivation of nerve growth factor. This finding, together with the previous demonstration of bcl-2 expression in the nervous system, suggests that the Bcl-2 protein may be a major mediator of the effects of neurotrophic factors on neuronal survival.	UNIV GENEVA,MED CTR,DEPT PHARMACOL & CLIN NEUROPHYSIOL,CH-1211 GENEVA 4,SWITZERLAND; UNIV GENEVA,MED CTR,DEPT PATHOL,CH-1211 GENEVA 4,SWITZERLAND; WISTAR INST,PHILADELPHIA,PA 19104	University of Geneva; University of Geneva; The Wistar Institute				martinou, Jean-claude/0000-0002-9847-2051	NCI NIH HHS [CA-51864, CA-50551] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051864, R01CA050551] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], [No title captured]; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BATISTATOU A, 1991, J CELL BIOL, V115, P461, DOI 10.1083/jcb.115.2.461; BORZILLO VG, 1992, ONCOGENE, V7, P869; CHUWANG IW, 1978, J COMP NEUROL, V177, P33, DOI 10.1002/cne.901770105; COHEN JJ, 1984, J IMMUNOL, V132, P38; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; FORSSPETTER S, 1990, NEURON, V5, P187, DOI 10.1016/0896-6273(90)90308-3; GARCIA I, 1986, MOL CELL BIOL, V51, P294; GLUCKSMANN A, 1951, BIOL REV, V26, P59, DOI 10.1111/j.1469-185X.1951.tb00774.x; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; JOHNSON LV, 1980, P NATL ACAD SCI-BIOL, V77, P990, DOI 10.1073/pnas.77.2.990; KOIKE T, 1989, P NATL ACAD SCI USA, V86, P6421, DOI 10.1073/pnas.86.16.6421; LAZARUS KJ, 1976, BRAIN RES, V113, P159, DOI 10.1016/0006-8993(76)90013-5; MARTIN DP, 1988, J CELL BIOL, V106, P829, DOI 10.1083/jcb.106.3.829; MARTINOU JC, 1989, J NEUROSCI, V9, P3645; MARTINOU JC, UNPUB; NEGRINI M, 1987, CELL, V49, P455, DOI 10.1016/0092-8674(87)90448-X; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.neuro.14.1.453; PEZZELLA F, 1990, AM J PATHOL, V137, P225; PILAR G, 1976, J CELL BIOL, V68, P339, DOI 10.1083/jcb.68.2.339; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; SCHWARTZ LM, 1990, P NATL ACAD SCI USA, V87, P6594, DOI 10.1073/pnas.87.17.6594; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SINGH NP, 1986, STAIN TECHNOL, V61, P315, DOI 10.3109/10520298609109959; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WALLACE DC, 1992, SCIENCE, V256, P628, DOI 10.1126/science.1533953; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112	34	719	743	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 9	1992	258	5080					302	304		10.1126/science.1411528	http://dx.doi.org/10.1126/science.1411528			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JR860	1411528				2022-12-01	WOS:A1992JR86000035
J	GHO, M; MCDONALD, K; GANETZKY, B; SAXTON, WM				GHO, M; MCDONALD, K; GANETZKY, B; SAXTON, WM			EFFECTS OF KINESIN MUTATIONS ON NEURONAL FUNCTIONS	SCIENCE			English	Article							TRANSMITTER RELEASE; AXONAL-TRANSPORT; HEAVY-CHAIN; C-ELEGANS; DROSOPHILA; SQUID; MICROTUBULES; IDENTIFICATION; MOTILITY; PROTEINS	Kinesin is believed to generate force for the movement of organelles in anterograde axonal transport. The identification of genes that encode kinesin-like proteins suggests that other motors may provide anterograde force instead of or in addition to kinesin. To gain insight into the specific functions of kinesin, the effects of mutations in the kinesin heavy chain gene (khc) on the physiology and ultrastructure of Drosophila larval neurons were studied. Mutations in khc impair both action potential propagation in axons and neurotransmitter release at nerve terminals but have no apparent effect on the concentration of synaptic vesicles in nerve terminal cytoplasm. Thus kinesin is required in vivo for normal neuronal function and may be active in the transport of ion channels and components of the synaptic release machinery to their appropriate cellular locations. Kinesin appears not to be required for the anterograde transport of synaptic vesicles or their components.	UNIV WISCONSIN,GENET LAB,MADISON,WI 53706; UNIV COLORADO,DEPT MOLEC CELLULAR & DEV BIOL,BOULDER,CO 80309; INDIANA UNIV,DEPT BIOL,BLOOMINGTON,IN 47405	University of Wisconsin System; University of Wisconsin Madison; University of Colorado System; University of Colorado Boulder; Indiana University System; Indiana University Bloomington					NIGMS NIH HHS [R01 GM046295, R01 GM046295-09] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046295] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUGUSTINE GJ, 1985, J PHYSIOL-LONDON, V367, P163, DOI 10.1113/jphysiol.1985.sp015819; BRADY ST, 1990, P NATL ACAD SCI USA, V87, P1061, DOI 10.1073/pnas.87.3.1061; BRADY ST, 1991, NEURON, V7, P521, DOI 10.1016/0896-6273(91)90365-7; BRISMAR T, 1987, P NATL ACAD SCI USA, V84, P1459, DOI 10.1073/pnas.84.5.1459; Goldstein L S, 1991, Trends Cell Biol, V1, P93, DOI 10.1016/0962-8924(91)90036-9; GYOEVA FK, 1991, NATURE, V353, P445, DOI 10.1038/353445a0; HALL DH, 1991, CELL, V65, P837, DOI 10.1016/0092-8674(91)90391-B; HEUSER JE, 1979, J CELL BIOL, V81, P275, DOI 10.1083/jcb.81.2.275; HOLLENBECK PJ, 1990, NATURE, V346, P864, DOI 10.1038/346864a0; JAN LY, 1976, J PHYSIOL-LONDON, V262, P189, DOI 10.1113/jphysiol.1976.sp011592; JOHANSEN J, 1989, J NEUROSCI, V9, P710; MCDONALD K, 1984, J ULTRA MOL STRUCT R, V86, P107, DOI 10.1016/S0022-5320(84)80051-9; OTSUKA AJ, 1991, NEURON, V6, P113, DOI 10.1016/0896-6273(91)90126-K; SAXTON WM, 1991, CELL, V64, P1093, DOI 10.1016/0092-8674(91)90264-Y; STEWART RJ, 1991, P NATL ACAD SCI USA, V88, P8470, DOI 10.1073/pnas.88.19.8470; VALE RD, 1990, CELL, V60, P883, DOI 10.1016/0092-8674(90)90334-B; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; VALE RD, 1985, CELL, V43, P623, DOI 10.1016/0092-8674(85)90234-X; VALLEE RB, 1990, ANNU REV BIOCHEM, V59, P909, DOI 10.1146/annurev.biochem.59.1.909; WONDERLIN WF, 1991, P NATL ACAD SCI USA, V88, P4391, DOI 10.1073/pnas.88.10.4391; WU CF, 1978, P NATL ACAD SCI USA, V75, P4047, DOI 10.1073/pnas.75.8.4047; YANG JT, 1990, SCIENCE, V249, P42, DOI 10.1126/science.2142332	22	107	108	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 9	1992	258	5080					313	316		10.1126/science.1384131	http://dx.doi.org/10.1126/science.1384131			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JR860	1384131	Green Accepted			2022-12-01	WOS:A1992JR86000039
J	HENDEY, B; KLEE, CB; MAXFIELD, FR				HENDEY, B; KLEE, CB; MAXFIELD, FR			INHIBITION OF NEUTROPHIL CHEMOKINESIS ON VITRONECTIN BY INHIBITORS OF CALCINEURIN	SCIENCE			English	Article							FREE CALCIUM; POLYMORPHONUCLEAR LEUKOCYTES; CELLULAR-REGULATION; CYCLOSPORINE-A; PROTEIN; DOMAIN; FIBRONECTIN; RECEPTORS; CELLS; IDENTIFICATION	Migration of human polymorphonuclear neutrophils on vitronectin is dependent on repeated transient increases in the concentration of intracellular free calcium ([Ca2+]i). A specific peptide inhibitor of the Ca2+-calmodulin-dependent phosphatase calcineurin was introduced into the cytoplasm of neutrophils. The peptide inhibited neutrophil migration on vitronectin by interfering with the release of the cells from sites of attachment. A similar reduction in motility on vitronectin occurred when cells were treated with the immunosuppressant FK506, which also inhibits calcineurin when bound to its binding protein, FKBP. These results indicate that a rise in [Ca2+]i reduces integrin-mediated adhesion to vitronectin by a mechanism that requires calcineurin activity.	COLUMBIA UNIV COLL PHYS & SURG,DEPT PATHOL,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT PHYSIOL,NEW YORK,NY 10032; NCI,BIOCHEM LAB,BETHESDA,MD 20892	Columbia University; Columbia University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Maxfield, Fred/A-1718-2011; Maxfield, Fred/M-6747-2019	Maxfield, Fred/0000-0003-4396-8866	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM014150, R01GM034770] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34770, GM14150] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHANTLER PD, 1985, J CELL BIOL, V101, P207, DOI 10.1083/jcb.101.1.207; CHATILA TA, 1989, J CELL BIOL, V109, P3435, DOI 10.1083/jcb.109.6.3435; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; GRESHAM HD, 1989, J CELL BIOL, V108, P1935, DOI 10.1083/jcb.108.5.1935; GUERINI D, 1989, P NATL ACAD SCI USA, V86, P9183, DOI 10.1073/pnas.86.23.9183; HASHIMOTO Y, 1990, J BIOL CHEM, V265, P1924; HAYMAN EG, 1985, J CELL BIOL, V100, P1948, DOI 10.1083/jcb.100.6.1948; HAYMAN EG, 1983, P NATL ACAD SCI-BIOL, V80, P4003, DOI 10.1073/pnas.80.13.4003; HUBBARD MJ, 1989, BIOCHEMISTRY-US, V28, P1868, DOI 10.1021/bi00430a066; HUBBARD MJ, 1991, MOL NEUROBIOL, P135; INGEBRITSEN TS, 1983, EUR J BIOCHEM, V132, P255, DOI 10.1111/j.1432-1033.1983.tb07357.x; JACONI MEE, 1991, J CELL BIOL, V112, P1249, DOI 10.1083/jcb.112.6.1249; KINCAID RL, 1988, P NATL ACAD SCI USA, V85, P8983, DOI 10.1073/pnas.85.23.8983; KLEE CB, 1988, ADV ENZYMOL RAMB, V61, P149; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU J, 1992, BIOCHEMISTRY-US, V31, P3896, DOI 10.1021/bi00131a002; LO SK, 1989, J EXP MED, V169, P1779, DOI 10.1084/jem.169.5.1779; MARKS PW, 1990, J CELL BIOL, V110, P43, DOI 10.1083/jcb.110.1.43; MARKS PW, 1991, J CELL BIOL, V112, P149, DOI 10.1083/jcb.112.1.149; OSTERGAARD HL, 1991, SCIENCE, V253, P1423, DOI 10.1126/science.1654595; RATAN RR, 1986, P NATL ACAD SCI USA, V83, P5136, DOI 10.1073/pnas.83.14.5136; RECHSTEINER M, 1987, METHOD ENZYMOL, V149, P42; SIEKIERKA JJ, 1989, J IMMUNOL, V143, P1580; SINGER II, 1989, J CELL BIOL, V109, P3169, DOI 10.1083/jcb.109.6.3169; TOMASINI BR, 1990, PROG HEMOSTASIS THRO, V10, P269; WRIGHT SD, 1986, J IMMUNOL, V136, P1759; WRIGHT SD, 1988, J CELL SCI S, V9, P99; YAMASHIRO DJ, 1983, J CELL BIOL, V97, P929, DOI 10.1083/jcb.97.3.929	29	183	183	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 9	1992	258	5080					296	299		10.1126/science.1384129	http://dx.doi.org/10.1126/science.1384129			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JR860	1384129				2022-12-01	WOS:A1992JR86000033
J	KANDEL, ER; ODELL, TJ				KANDEL, ER; ODELL, TJ			ARE ADULT LEARNING-MECHANISMS ALSO USED FOR DEVELOPMENT	SCIENCE			English	Editorial Material							LONG-TERM POTENTIATION; REQUIRES NEURAL ACTIVITY; 3-EYED RANA-PIPIENS; NITRIC-OXIDE; CELLULAR MECHANISM; ARACHIDONIC-ACID; DEPRESSION; HIPPOCAMPUS; ENHANCEMENT; APLYSIA		COLUMBIA UNIV COLL PHYS & SURG,HOWARD HUGHES MED INST,NEW YORK,NY 10032	Columbia University; Howard Hughes Medical Institute	KANDEL, ER (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,CTR NEUROBIOL & BEHAV,722 W 168 ST,NEW YORK,NY 10032, USA.							ARTOLA A, 1990, NATURE, V347, P69, DOI 10.1038/347069a0; BAILEY CH, 1992, SCIENCE, V256, P645, DOI 10.1126/science.1585177; BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BOHME GA, 1991, EUR J PHARMACOL, V199, P379, DOI 10.1016/0014-2999(91)90505-K; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CLINE HT, 1987, P NATL ACAD SCI USA, V84, P4342, DOI 10.1073/pnas.84.12.4342; CONSTANTINEPATON M, 1990, ANNU REV NEUROSCI, V13, P129, DOI 10.1146/annurev.neuro.13.1.129; GALLY JA, 1990, P NATL ACAD SCI USA, V87, P3547, DOI 10.1073/pnas.87.9.3547; GOODMAN CS, 1984, SCIENCE, V225, P1271, DOI 10.1126/science.6474176; GRANT SGN, 1992, SOC NEUR ABSTR, V18, P639; HALEY JE, 1992, NEURON, V8, P211, DOI 10.1016/0896-6273(92)90288-O; HAWKINS RD, 1983, SCIENCE, V219, P400, DOI 10.1126/science.6294833; HOER M, 1992, SOC NEUR ABSTR, V18, P1311; ITO M, 1989, ANNU REV NEUROSCI, V12, P85, DOI 10.1146/annurev.neuro.12.1.85; IUMI Y, 1992, SCIENCE, V257, P1273; JESSELL TM, 1988, NEURON, V1, P3, DOI 10.1016/0896-6273(88)90204-8; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MAYFORD M, 1992, SCIENCE, V256, P638, DOI 10.1126/science.1585176; MERZENICH MM, 1988, NEUROBIOLOGY NEOCORT, P41; MILLER KD, 1989, SCIENCE, V245, P605, DOI 10.1126/science.2762813; ODELL TJ, 1991, P NATL ACAD SCI USA, V88, P11285, DOI 10.1073/pnas.88.24.11285; PIOMELLI D, 1987, NATURE, V328, P38, DOI 10.1038/328038a0; PRISKY G, 1992, SOC NEUR ABSTR, V18, P1311; RAKIC P, 1992, CURR CONTENTS   0127; REH TA, 1985, J NEUROSCI, V5, P1132; Schatz C. J., 1992, SCI AM, V267, P60; SCHMIDT JT, 1983, BRAIN RES, V269, P29, DOI 10.1016/0006-8993(83)90959-9; SCHMIDT JT, 1990, J NEUROSCI, V10, P233; SCHWATZ CJ, 1990, NEURON, V5, P745; SHIBUKI K, 1991, NATURE, V349, P326, DOI 10.1038/349326a0; SHUMAN EM, 1991, SCIENCE, V254, P1503; SILVA AJ, 1992, P NATL ACAD SCI USA, V257, P201; Small S. A., 1992, Society for Neuroscience Abstracts, V18, P639; SPERRY RW, 1963, P NATL ACAD SCI USA, V50, P703, DOI 10.1073/pnas.50.4.703; WALTERS ET, 1983, SCIENCE, V219, P405, DOI 10.1126/science.6294834; WILLIAMS JH, 1989, NATURE, V341, P739, DOI 10.1038/341739a0; [No title captured]	37	147	149	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 9	1992	258	5080					243	245		10.1126/science.1411522	http://dx.doi.org/10.1126/science.1411522			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	JR860	1411522				2022-12-01	WOS:A1992JR86000020
J	MILLER, C				MILLER, C			ION CHANNEL STRUCTURE AND FUNCTION	SCIENCE			English	Editorial Material							ACETYLCHOLINE-RECEPTOR; K+ CHANNELS; INACTIVATION				MILLER, C (corresponding author), BRANDEIS UNIV,HOWARD HUGHES MED INST,WALTHAM,MA 02254, USA.							DEMO SD, 1991, NEURON, V7, P743, DOI 10.1016/0896-6273(91)90277-7; HEGINBOTHAM L, 1992, NEURON, V8, P483, DOI 10.1016/0896-6273(92)90276-J; HEINEMANN SH, 1992, NATURE, V356, P441, DOI 10.1038/356441a0; HOSHI T, 1991, NEURON, V7, P547, DOI 10.1016/0896-6273(91)90367-9; IMOTO K, 1988, NATURE, V335, P645, DOI 10.1038/335645a0; KAVANAUGH MP, 1992, NEURON, V8, P493, DOI 10.1016/0896-6273(92)90277-K; LI M, 1992, NEURON, V8, P1151, DOI 10.1016/0896-6273(92)90135-Z; LISTERUD M, 1991, SCIENCE, V254, P1518, DOI 10.1126/science.1720573; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; MURRELL-LAGNADO R D, 1992, Biophysical Journal, V61, pA290; SINE SM, 1991, J BIOL CHEM, V266, P19369; TOMASELLI GF, 1991, BIOPHYS J, V60, P721, DOI 10.1016/S0006-3495(91)82102-6; UNWIN N, 1989, NEURON, V3, P665, DOI 10.1016/0896-6273(89)90235-3; WEST JW, 1991, SCIENCE, V254, P866, DOI 10.1126/science.1658937; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520	15	21	22	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 9	1992	258	5080					240	241		10.1126/science.1384128	http://dx.doi.org/10.1126/science.1384128			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JR860	1384128				2022-12-01	WOS:A1992JR86000018
J	NITSCH, RM; SLACK, BE; WURTMAN, RJ; GROWDON, JH				NITSCH, RM; SLACK, BE; WURTMAN, RJ; GROWDON, JH			RELEASE OF ALZHEIMER AMYLOID PRECURSOR DERIVATIVES STIMULATED BY ACTIVATION OF MUSCARINIC ACETYLCHOLINE-RECEPTORS	SCIENCE			English	Article							PROTEIN KINASE-C; DISEASE; DOMAIN; PHOSPHORYLATION; LOCALIZATION; CLEAVAGE; SUBTYPES; PEPTIDE	Altered processing of the amyloid precursor protein (APP) is a central event in the formation of amyloid deposits in the brains of individuals with Alzheimer's disease. To investigate whether cellular APP processing is controlled by cell-surface neurotransmitter receptors, human embryonic kidney (293) cell lines were transfected with the genes for human brain muscarinic acetylcholine receptors. Stimulation of m1 and m3 receptor subtypes with carbachol increased the basal release of APP derivatives within minutes of treatment, indicating that preexisting APP is released in response to receptor activation. Receptor-activated APP release was blocked by staurosporine, suggesting that protein kinases mediate neurotransmitter receptor-controlled APP processing.	MASSACHUSETTS GEN HOSP,DEPT NEUROL,BOSTON,MA 02114; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	NITSCH, RM (corresponding author), MIT,DEPT BRAIN & COGNIT SCI,E25-604,CAMBRIDGE,MA 02139, USA.		Slack, Barbara/AAU-9917-2021	Slack, Barbara/0000-0002-7619-410X				ANDERSON JP, 1991, NEUROSCI LETT, V128, P126, DOI 10.1016/0304-3940(91)90775-O; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BUXBAUM JD, 1990, P NATL ACAD SCI USA, V87, P6003, DOI 10.1073/pnas.87.15.6003; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P3055, DOI 10.1073/pnas.89.7.3055; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; ESTUS S, 1992, SCIENCE, V255, P726, DOI 10.1126/science.1738846; GANDY S, 1988, P NATL ACAD SCI USA, V85, P6218, DOI 10.1073/pnas.85.16.6218; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; HAASS C, 1991, J NEUROSCI, V11, P3783; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; KONIG G, 1992, J BIOL CHEM, V267, P10804; KOWALL NW, 1991, P NATL ACAD SCI USA, V88, P7247, DOI 10.1073/pnas.88.16.7247; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; NITSCH RM, UNPUB; OLTERSDORF T, 1990, J BIOL CHEM, V265, P4492; OLTERSDORF T, 1989, NATURE, V341, P144, DOI 10.1038/341144a0; PALMERT MR, 1989, P NATL ACAD SCI USA, V86, P6338, DOI 10.1073/pnas.86.16.6338; PERALTA EG, 1988, NATURE, V334, P434, DOI 10.1038/334434a0; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; SANDMANN J, 1991, J BIOL CHEM, V266, P6031; SELKOE DJ, 1986, J NEUROCHEM, V46, P1820; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; SELKOE DJ, 1988, P NATL ACAD SCI USA, V85, P7341, DOI 10.1073/pnas.85.19.7341; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; SUZUKI T, 1992, NEUROSCIENCE, V48, P755, DOI 10.1016/0306-4522(92)90264-3; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; WANG R, 1991, J BIOL CHEM, V266, P16960; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; 1989, TRENDS PHARM SCI S, pR7	33	846	880	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 9	1992	258	5080					304	307		10.1126/science.1411529	http://dx.doi.org/10.1126/science.1411529			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JR860	1411529				2022-12-01	WOS:A1992JR86000036
J	OROURKE, NA; DAILEY, ME; SMITH, SJ; MCCONNELL, SK				OROURKE, NA; DAILEY, ME; SMITH, SJ; MCCONNELL, SK			DIVERSE MIGRATORY PATHWAYS IN THE DEVELOPING CEREBRAL-CORTEX	SCIENCE			English	Article							VISUAL CORTICAL-NEURONS; FETAL MONKEY NEOCORTEX; GLIAL-CELLS; CULTURES; TRANSFORMATION; NEUROGENESIS; ASTROCYTES; ORIGIN; FERRET; BRAIN	During early development of the mammalian cerebral cortex, young neurons migrate outward from the site of their final mitosis in the ventricular zone into the cortical plate, where they form the adult cortex. Time-lapse confocal microscopy was used to observe directly the dynamic behaviors of migrating cells in living slices of developing cortex. The majority of cells migrated along a radial pathway, consistent with the view that cortical neurons migrate along radial glial fibers. A fraction of cells, however, turned within the intermediate zone and migrated orthogonal to the radial fibers. This orthogonal migration may contribute to the tangential dispersion of clonally related cortical neurons.	STANFORD UNIV,SCH MED,DEPT MOLEC & CELLULAR PHYSIOL,STANFORD,CA 94305	Stanford University	OROURKE, NA (corresponding author), STANFORD UNIV,DEPT BIOL SCI,STANFORD,CA 94305, USA.				NEI NIH HHS [EY06314] Funding Source: Medline; NINDS NIH HHS [NS09027, NS28587] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028587] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANGEVINE JB, 1961, NATURE, V192, P766, DOI 10.1038/192766b0; AUSTIN CP, 1990, DEVELOPMENT, V110, P713; BOLZ J, 1990, NATURE, V346, P359, DOI 10.1038/346359a0; COOPER M W, 1989, Society for Neuroscience Abstracts, V15, P808; EDMONDSON JC, 1987, J NEUROSCI, V7, P1928; Fishell G., 1992, Society for Neuroscience Abstracts, V18, P926; GADISSEUX JF, 1989, DEV BRAIN RES, V50, P55, DOI 10.1016/0165-3806(89)90126-0; GAHWILER BH, 1981, J NEUROSCI METH, V4, P329, DOI 10.1016/0165-0270(81)90003-0; GRAY GE, 1991, NEURON, V6, P211, DOI 10.1016/0896-6273(91)90357-6; HATTEN ME, 1990, TRENDS NEUROSCI, V13, P179, DOI 10.1016/0166-2236(90)90044-B; HONIG MG, 1986, J CELL BIOL, V103, P171, DOI 10.1083/jcb.103.1.171; JACKSON CA, 1989, J NEUROSCI, V9, P1242; KATZ LC, 1987, J NEUROSCI, V7, P1223; LUSKIN MB, 1985, J COMP NEUROL, V242, P611, DOI 10.1002/cne.902420409; MCCONNELL SK, 1988, J NEUROSCI, V8, P945; MCCONNELL SK, 1989, SCIENCE, V245, P978, DOI 10.1126/science.2475909; Misson JP, 1991, CEREB CORTEX, V1, P221, DOI 10.1093/cercor/1.3.221; MOREST DK, 1970, Z ANAT ENTWICKLUNGS, V130, P265, DOI 10.1007/BF00520999; RAKIC P, 1988, SCIENCE, V241, P170, DOI 10.1126/science.3291116; RAKIC P, 1974, SCIENCE, V183, P425, DOI 10.1126/science.183.4123.425; RAKIC P, 1972, J COMP NEUROL, V145, P61, DOI 10.1002/cne.901450105; RAKIC P, 1971, BRAIN RES, V33, P471, DOI 10.1016/0006-8993(71)90119-3; ROBERTS JS, IN PRESS DEV BIOL; SANDELL JH, 1988, J HISTOCHEM CYTOCHEM, V36, P555, DOI 10.1177/36.5.3356898; SCHMECHEL DE, 1979, ANAT EMBRYOL, V156, P115, DOI 10.1007/BF00300010; SHOUKIMAS GM, 1978, J COMP NEUROL, V179, P795, DOI 10.1002/cne.901790407; SMITH SJ, 1988, SCIENCE, V242, P708, DOI 10.1126/science.3055292; SMITH SJ, 1990, BIOL MEMORY, V23, P49; STENSAAS LJ, 1967, J COMP NEUROL, V131, P423, DOI 10.1002/cne.901310403; STENSAAS LJ, 1967, J COMP NEUROL, V131, P409, DOI 10.1002/cne.901310402; VOIGT T, 1989, J COMP NEUROL, V289, P74, DOI 10.1002/cne.902890106; WALSH C, 1992, SCIENCE, V255, P434, DOI 10.1126/science.1734520; 1970, ANAT REC, V166, P257	33	385	386	1	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 9	1992	258	5080					299	302		10.1126/science.1411527	http://dx.doi.org/10.1126/science.1411527			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JR860	1411527				2022-12-01	WOS:A1992JR86000034
J	SHATZ, CJ				SHATZ, CJ			DIVIDING UP THE NEOCORTEX	SCIENCE			English	Editorial Material							CAT STRIATE CORTEX; CORTICAL AREAS; CONNECTIONS; NEURONS; SEGMENTATION; SPECIFICITY; HINDBRAIN				SHATZ, CJ (corresponding author), UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, DIV NEUROBIOL, BERKELEY, CA 94720 USA.							BARBE MF, 1991, J NEUROSCI, V11, P519; BOLTZ J, 1990, NATURE, V346, P359; CALLAWAY EM, 1990, J NEUROSCI, V10, P1134; FISHELL CA, 1992, SOC NEUR ABSTR, V18, P926; Frantz G. D., 1992, Society for Neuroscience Abstracts, V18, P957; FRASER S, 1990, NATURE, V344, P431, DOI 10.1038/344431a0; GHOSH A, 1990, NATURE, V347, P179, DOI 10.1038/347179a0; GRAHAM A, 1989, CELL, V57, P367, DOI 10.1016/0092-8674(89)90912-4; GUTHRIE S, 1992, NATURE, V356, P157, DOI 10.1038/356157a0; KATZ LC, 1991, EUR J NEUROSCI, V3, P1, DOI 10.1111/j.1460-9568.1991.tb00805.x; KEYNES R, 1990, NEURON, V4, P1, DOI 10.1016/0896-6273(90)90438-L; MCCONNELL SK, 1991, SCIENCE, V254, P282, DOI 10.1126/science.1925583; MOLNAR Z, 1991, NATURE, V351, P475, DOI 10.1038/351475a0; OLEARY DDM, 1989, J NEUROSCI, V9, P2230; OLEARY DDM, 1989, TRENDS NEUROSCI, V12, P400, DOI 10.1016/0166-2236(89)90080-5; OROURKE NA, 1992, SCIENCE, V258, P299, DOI 10.1126/science.1411527; PORTEUS MH, 1991, NEURON, V7, P221, DOI 10.1016/0896-6273(91)90260-7; PRICE M, 1992, NEURON, V8, P241, DOI 10.1016/0896-6273(92)90291-K; RAKIC P, 1988, SCIENCE, V241, P170, DOI 10.1126/science.3291116; SCHLAGGAR BL, 1991, SCIENCE, V252, P1556, DOI 10.1126/science.2047863; SHATZ CJ, 1990, NEURON, V5, P745, DOI 10.1016/0896-6273(90)90333-B; SIMEONE A, 1992, EMBO J, V11, P2541, DOI 10.1002/j.1460-2075.1992.tb05319.x; STERN CD, 1988, TRENDS NEUROSCI, V11, P190, DOI 10.1016/0166-2236(88)90120-8; TAO W, 1992, NEURON, V8, P957, DOI 10.1016/0896-6273(92)90210-5; WALSH C, 1992, SCIENCE, V255, P434, DOI 10.1126/science.1734520; WILKINSON DG, 1990, TRENDS NEUROSCI, V13, P335, DOI 10.1016/0166-2236(90)90145-Z; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0	27	31	32	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 9	1992	258	5080					237	238		10.1126/science.1357747	http://dx.doi.org/10.1126/science.1357747			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JR860	1357747				2022-12-01	WOS:A1992JR86000016
J	TAKAHASHI, JS				TAKAHASHI, JS			CIRCADIAN CLOCK GENES ARE TICKING	SCIENCE			English	Editorial Material							VISUAL-SYSTEM; DNA-BINDING; DROSOPHILA; PERIOD; RHYTHMS; PROTEIN; TRANSCRIPTION; OSCILLATOR; PRODUCT; MYOD		NORTHWESTERN UNIV, DEPT NEUROBIOL & PHYSIOL, EVANSTON, IL 60208 USA	Northwestern University	TAKAHASHI, JS (corresponding author), NORTHWESTERN UNIV, NATL SCI FDN, CTR BIOL TIMING, EVANSTON, IL 60208 USA.		Takahashi, Joseph S/E-8482-2012; Takahashi, Joseph S./Y-2781-2019	Takahashi, Joseph S/0000-0003-0384-8878; Takahashi, Joseph S./0000-0003-0384-8878				BARGIELLO TA, IN PRESS BIOL B; BAYLIES MK, IN PRESS MOL GENETIC; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; DUNLAP JC, 1989, IN PRESS ANN REV PHY, V45; EWER J, 1992, J NEUROSCI, V12, P3321; HALL JC, 1990, ANNU REV GENET, V24, P659; HARDIN DE, 1991, IN PRESS P NATL ACAD, V88; HARDIN PE, 1990, NATURE, V343, P536, DOI 10.1038/343536a0; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; KONOPKA RJ, 1971, P NATL ACAD SCI USA, V68, P2112, DOI 10.1073/pnas.68.9.2112; KORNHAUSER JM, 1992, SCIENCE, V255, P1581, DOI 10.1126/science.1549784; KORNHAUSER JM, IN PRESS MOL GENETIC; LIU X, 1992, J NEUROSCI, V12, P2735; MILLAR AJ, 1991, PLANT CELL, V3, P541, DOI 10.1105/tpc.3.5.541; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NAMBU JR, 1991, CELL, V67, P1157, DOI 10.1016/0092-8674(91)90292-7; RAJU U, 1991, SCIENCE, V253, P673, DOI 10.1126/science.1871602; RALPH MR, 1988, SCIENCE, V241, P1225, DOI 10.1126/science.3413487; ROSBASH M, 1989, NEURON, V3, P387, DOI 10.1016/0896-6273(89)90199-2; ROSBASH M, COMMUNICATION; SIWICKI KK, 1988, NEURON, V1, P141, DOI 10.1016/0896-6273(88)90198-5; Takahashi J S, 1991, Curr Opin Neurobiol, V1, P556, DOI 10.1016/S0959-4388(05)80028-5; TAKAHASHI JS, 1989, RECENT PROG HORM RES, V45, P279; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WUARIN J, 1990, CELL, V63, P1257, DOI 10.1016/0092-8674(90)90421-A; YOUNG MW, COMMUNICATION; YU Q, 1987, NATURE, V326, P765, DOI 10.1038/326765a0; ZERR DM, 1990, J NEUROSCI, V10, P2749; ZWIEBEL LJ, 1991, P NATL ACAD SCI USA, V88, P3882, DOI 10.1073/pnas.88.9.3882	30	64	66	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 9	1992	258	5080					238	240		10.1126/science.1384127	http://dx.doi.org/10.1126/science.1384127			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JR860	1384127				2022-12-01	WOS:A1992JR86000017
J	TURNER, TJ; ADAMS, ME; DUNLAP, K				TURNER, TJ; ADAMS, ME; DUNLAP, K			CALCIUM CHANNELS COUPLED TO GLUTAMATE RELEASE IDENTIFIED BY OMEGA-AGA-IVA	SCIENCE			English	Article							CA2+ CHANNELS; CONOTOXIN GVIA; NERVE-ENDINGS; NEURONS; SYNAPTOSOMES; CURRENTS; BLOCKING; PEPTIDE	Presynaptic calcium channels are crucial elements of neuronal excitation-secretion coupling. In mammalian brain, they have been difficult to characterize because most presynaptic terminals are too small to probe with electrodes, and available pharmacological tools such as dihydropyridines and omega-conotoxin are largely ineffective. Subsecond measurements of synaptosomal glutamate release have now been used to assess presynaptic calcium channel activity in order to study the action of peptide toxins from the venom of the funnel web spider Agelenopsis aperta, which is known to inhibit dihydropyridine and omega-conotoxin-resistant neuronal calcium currents. A presynaptic calcium channel important in glutamate release is shown to be omega-Aga-IVA sensitive and omega-conotoxin resistant.	UNIV CALIF RIVERSIDE, DEPT ENTOMOL, RIVERSIDE, CA 92521 USA; UNIV CALIF RIVERSIDE, DEPT NEUROSCI, RIVERSIDE, CA 92521 USA	University of California System; University of California Riverside; University of California System; University of California Riverside	TURNER, TJ (corresponding author), TUFTS UNIV, SCH MED, DEPT PHYSIOL, BOSTON, MA 02111 USA.		Adams, Michael/ABF-6728-2020	Adams, Michael/0000-0003-0519-6113; Turner, Timothy/0000-0001-9770-2647				AUGUSTINE GJ, 1987, ANNU REV NEUROSCI, V10, P633, DOI 10.1146/annurev.ne.10.030187.003221; HOFMANN F, 1990, N-S ARCH PHARMACOL, V341, P200; HORNE AL, 1991, BRIT J PHARMACOL, V103, P1733, DOI 10.1111/j.1476-5381.1991.tb09855.x; KERR LM, 1984, NATURE, V308, P282, DOI 10.1038/308282a0; LEMOS JR, 1989, NEURON, V2, P1419, DOI 10.1016/0896-6273(89)90187-6; LINDGREN CA, 1989, J PHYSIOL-LONDON, V414, P201, DOI 10.1113/jphysiol.1989.sp017684; LLINAS R, 1989, P NATL ACAD SCI USA, V86, P1689, DOI 10.1073/pnas.86.5.1689; LUNDY PM, 1991, EUR J PHARM-MOLEC PH, V206, P61, DOI 10.1016/0922-4106(91)90147-A; MACKINNON R, 1988, J GEN PHYSIOL, V91, P335, DOI 10.1085/jgp.91.3.335; Mintz I. M., 1992, Society for Neuroscience Abstracts, V18, P9; MINTZ IM, 1991, P NATL ACAD SCI USA, V88, P6628, DOI 10.1073/pnas.88.15.6628; MINTZ IM, 1992, NATURE, V355, P827, DOI 10.1038/355827a0; MOGUL DJ, 1991, J PHYSIOL-LONDON, V433, P259, DOI 10.1113/jphysiol.1991.sp018425; NOWYCKY MC, 1985, NATURE, V316, P440, DOI 10.1038/316440a0; OLIVERA BM, 1991, ANN NY ACAD SCI, V635, P114, DOI 10.1111/j.1749-6632.1991.tb36486.x; REGAN LJ, 1991, NEURON, V6, P269, DOI 10.1016/0896-6273(91)90362-4; REGAN LJ, 1991, J NEUROSCI, V11, P2259; REYNOLDS IJ, 1986, P NATL ACAD SCI USA, V83, P8804, DOI 10.1073/pnas.83.22.8804; RIVIER J, 1987, J BIOL CHEM, V262, P1194; STANLEY EF, 1991, J NEUROSCI, V11, P985; SUSZKIW JB, 1989, J NEUROCHEM, V52, P1260, DOI 10.1111/j.1471-4159.1989.tb01874.x; TURNER T J, 1991, Society for Neuroscience Abstracts, V17, P577; TURNER TJ, 1989, ANAL BIOCHEM, V178, P8, DOI 10.1016/0003-2697(89)90347-3; TURNER TJ, 1989, BIOCHEMISTRY-US, V28, P586, DOI 10.1021/bi00428a026; TURNER TJ, 1992, J CELL BIOCHEM, V16, P225; TURNER TJ, UNPUB; UCHITEL OD, 1992, P NATL ACAD SCI USA, V89, P3330, DOI 10.1073/pnas.89.8.3330; VENEMA VJ, 1992, J BIOL CHEM, V267, P2610	28	288	290	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 9	1992	258	5080					310	313		10.1126/science.1357749	http://dx.doi.org/10.1126/science.1357749			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JR860	1357749				2022-12-01	WOS:A1992JR86000038
J	BILOUS, RW; MURTY, G; PARKINSON, DB; THAKKER, RV; COULTHARD, MG; BURN, J; MATHIAS, D; KENDALLTAYLOR, P				BILOUS, RW; MURTY, G; PARKINSON, DB; THAKKER, RV; COULTHARD, MG; BURN, J; MATHIAS, D; KENDALLTAYLOR, P			AUTOSOMAL DOMINANT FAMILIAL HYPOPARATHYROIDISM, SENSORINEURAL DEAFNESS, AND RENAL DYSPLASIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							HUMAN PARATHYROID-HORMONE; IDIOPATHIC HYPOPARATHYROIDISM; RECESSIVE INHERITANCE; GENE; NEPHROPATHY		UNIV NEWCASTLE UPON TYNE,DEPT EAR NOSE & THROAT SURG,NEWCASTLE TYNE NE1 7RU,TYNE & WEAR,ENGLAND; UNIV NEWCASTLE UPON TYNE,DEPT MED,NEWCASTLE TYNE NE1 7RU,TYNE & WEAR,ENGLAND; UNIV NEWCASTLE UPON TYNE,DEPT PAEDIAT,NEWCASTLE TYNE NE1 7RU,TYNE & WEAR,ENGLAND; UNIV NEWCASTLE UPON TYNE,DEPT HUMAN GENET,NEWCASTLE TYNE NE1 7RU,TYNE & WEAR,ENGLAND; MRC,CLIN RES CTR,DIV MOLEC MED,HARROW HA1 3UJ,MIDDX,ENGLAND	Newcastle University - UK; Newcastle University - UK; Newcastle University - UK; Newcastle University - UK; Medical Research Council Clinical Trials Unit				Thakker, Rajesh/0000-0002-1438-3220; Burn, John/0000-0002-9823-2322				AHN TG, 1986, MEDICINE, V65, P73, DOI 10.1097/00005792-198603000-00001; AHONEN P, 1985, CLIN GENET, V27, P535, DOI 10.1111/j.1399-0004.1985.tb02037.x; Albright F, 1929, J CLIN INVEST, V7, P183, DOI 10.1172/JCI100224; ARNOLD A, 1990, J CLIN INVEST, V86, P1084, DOI 10.1172/JCI114811; BARAKAT AY, 1977, J PEDIATR-US, V91, P61, DOI 10.1016/S0022-3476(77)80445-9; BOONSTRA CE, 1965, ANN INTERN MED, V63, P468, DOI 10.7326/0003-4819-63-3-468; BRONSKY D, 1968, J CLIN ENDOCR METAB, V28, P61, DOI 10.1210/jcem-28-1-61; CHU HY, 1964, CHINESE MED J-PEKING, V83, P723; COUNAHAN R, 1976, ARCH DIS CHILD, V51, P875, DOI 10.1136/adc.51.11.875; DAHLBERG PJ, 1983, AM J MED GENET, V16, P99, DOI 10.1002/ajmg.1320160115; DECAMPO C, 1988, J ENDOCRINOL INVEST, V11, P91, DOI 10.1007/BF03350111; EDWARDS BD, 1989, J MED GENET, V26, P289, DOI 10.1136/jmg.26.5.289; ELLIS HA, 1969, PEDIATRICS, V44, P225; GEERTINGER P, 1967, PEDIATRICS, V39, P43; GEERTINGER P, 1969, ACTA PATHOL MIC SC, V75, P270; HUNTER AGW, 1981, J MED GENET, V18, P431, DOI 10.1136/jmg.18.6.431; IKEDA K, 1987, LARYNGOSCOPE, V97, P1075; KRUSE K, 1987, EUR J PEDIATR, V146, P373, DOI 10.1007/BF00444941; KUNSTADTER RH, 1963, AM J DIS CHILD, V105, P499, DOI 10.1001/archpedi.1963.02080040501014; LEHNHARDT E, 1986, CLIN ASPECTS INNER E, P57; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MCELDUFF A, 1989, AUST NZ J MED, V19, P22, DOI 10.1111/j.1445-5994.1989.tb01668.x; MILLER M J, 1972, Henry Ford Hospital Medical Journal, V20, P3; NAYLOR SL, 1983, SOMAT CELL GENET, V9, P609, DOI 10.1007/BF01574261; NUSYNOWITZ ML, 1976, MEDICINE, V55, P105, DOI 10.1097/00005792-197603000-00001; PARKINSON DB, 1992, NAT GENET, V1, P149, DOI 10.1038/ng0592-149; PEDEN VH, 1960, AM J HUM GENET, V12, P323; PHILIPSON B, 1978, ACTA MED SCAND, V203, P223; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAO SD, 1981, ANN INTERN MED, V95, P655, DOI 10.7326/0003-4819-95-5-655_1; RICHTER PL, 1968, NEUROLOGY, V18, P75, DOI 10.1212/WNL.18.1_Part_1.75; SHAW NJ, 1991, ARCH DIS CHILD, V66, P1191, DOI 10.1136/adc.66.10.1191; THAKKER RV, 1990, J CLIN INVEST, V86, P40, DOI 10.1172/JCI114712; VALDESDAPENA MA, 1971, ACTA PATH MICRO IM A, VA 79, P228; WEIDAUER H, 1981, ARCH OTO-RHINO-LARYN, V231, P677, DOI 10.1007/BF00501699; WHYTE MP, 1981, J PEDIATR-US, V99, P608, DOI 10.1016/S0022-3476(81)80272-7; WINTER WE, 1983, J PEDIATR-US, V103, P387, DOI 10.1016/S0022-3476(83)80408-9; YUMITA S, 1986, TOHOKU J EXP MED, V148, P135, DOI 10.1620/tjem.148.135	38	118	121	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 8	1992	327	15					1069	1074		10.1056/NEJM199210083271506	http://dx.doi.org/10.1056/NEJM199210083271506			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JR321	1522843				2022-12-01	WOS:A1992JR32100006
J	BISSONNETTE, RP; ECHEVERRI, F; MAHBOUBI, A; GREEN, DR				BISSONNETTE, RP; ECHEVERRI, F; MAHBOUBI, A; GREEN, DR			APOPTOTIC CELL-DEATH INDUCED BY C-MYC IS INHIBITED BY BCL-2	NATURE			English	Article							TRANSGENIC MICE; GENE-EXPRESSION; LYMPHOID-CELLS; B-CELLS; GROWTH; DIFFERENTIATION; ONCOGENE; SURVIVAL; PROTEIN; INDUCTION	APOPTOSIS is a form of physiological cell death, characterized by chromatin condensation, cytoplasmic blebbing and DNA fragmentation1, which often depends on RNA and protein synthesis by the dying cell2-4. The c-myc proto-oncogene, usually implicated in cell transformation, differentiation and cell-cycle progression5-9 also has a central role in some forms of apoptosis10-13. These opposing roles of myc in cell growth and death require that other gene products dictate the outcome of c-Myc expression on a cell. A candidate for such a modifying gene is bcl-2, whose product prolongs cell survival14-16 and blocks apoptosis in some systems17-21. Here we demonstrate that Bcl-2 prevents apoptotic death induced by c-Myc, provide a mechanism whereby cells can express c-Myc without undergoing apoptosis, and give a possible explanation for the ability of Bcl-2 to synergize with c-Myc in cell transformation21-23.			BISSONNETTE, RP (corresponding author), LA JOLLA INST ALLERGY & IMMUNOL,DIV CELLULAR IMMUNOL,11149 N TORREY PINES RD,LA JOLLA,CA 92037, USA.		Green, Douglas R/N-8083-2018	Green, Douglas R/0000-0002-7332-1417				ASKEW DS, 1991, ONCOGENE, V6, P1915; BUKH A, 1990, J IMMUNOL, V144, P4835; COHEN JJ, 1984, J IMMUNOL, V132, P38; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; DEGOLS G, 1991, NUCLEIC ACIDS RES, V19, P945, DOI 10.1093/nar/19.4.945; DUKE RC, 1986, LYMPHOKINE RES, V5, P289; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; KACZMAREK L, 1985, SCIENCE, V228, P1313, DOI 10.1126/science.4001943; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; NUNEZ G, 1991, NATURE, V353, P71, DOI 10.1038/353071a0; NUNEZ G, 1990, J IMMUNOL, V144, P3602; ONCLERCQ R, 1989, ONCOGENE RES, V4, P293; PALLAVICINI MG, 1990, J CELL PHYSIOL, V143, P372, DOI 10.1002/jcp.1041430223; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; REED JC, 1990, P NATL ACAD SCI USA, V348, P331; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; STRASSER A, 1991, P NATL ACAD SCI USA, V88, P8661, DOI 10.1073/pnas.88.19.8661; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VOGT M, 1987, ONCOGENE RES, V2, P49; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; WURM FM, 1986, P NATL ACAD SCI USA, V83, P5414, DOI 10.1073/pnas.83.15.5414; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1987, BRIT J CANCER, V56, P251, DOI 10.1038/bjc.1987.186; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112	29	967	1001	0	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 8	1992	359	6395					552	554		10.1038/359552a0	http://dx.doi.org/10.1038/359552a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JR859	1406975				2022-12-01	WOS:A1992JR85900065
J	FANIDI, A; HARRINGTON, EA; EVAN, GI				FANIDI, A; HARRINGTON, EA; EVAN, GI			COOPERATIVE INTERACTION BETWEEN C-MYC AND BCL-2 PROTOONCOGENES	NATURE			English	Article							PROGRAMMED CELL-DEATH; APOPTOSIS; MICE; GENE	THE bcl-2 proto-oncogene is activated by translocation in a variety of B-lymphoid tumours and synergizes with the c-myc oncogene in tumour progression1. The mechanism of synergy is unclear but bcl-2 expression inhibits apoptosis2-6, a property presumably pertinent to its proto-oncogenic mode of action4. We have shown that the c-myc gene is a potent inducer of apoptosis, in addition to its established role in mitogenesis7. Here we show that expression of the bcl-2 protein, Bcl-2, specifically abrogates c-myc-induced apoptosis without affecting the c-myc mitogenic function. This provides a novel mechanism for oncogene cooperation, of potential importance both in carcinogenesis and in the evolution of drug resistance in tumours.	IMPERIAL CANC RES FUND, BIOCHEM CELL NUCLEUS LAB, 44 LINCOLNS INN FIELDS, LONDON WC2A 3PX, ENGLAND	Cancer Research UK								ASKEW DS, 1991, ONCOGENE, V6, P1915; BURSCH W, 1990, BIOCHEM CELL BIOL, V68, P1071, DOI 10.1139/o90-160; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; LENNON SV, 1990, BIOCHEM SOC T, V18, P343, DOI 10.1042/bst0180343; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; PEZZELLA F, 1990, AM J PATHOL, V137, P225; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SPENCER CA, 1991, ADV CANCER RES, V56, P1; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WYLLIE AH, 1987, J PATHOL, V153, P313, DOI 10.1002/path.1711530404	16	765	802	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 8	1992	359	6395					554	556		10.1038/359554a0	http://dx.doi.org/10.1038/359554a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JR859	1406976				2022-12-01	WOS:A1992JR85900066
J	HEATH, WR; ALLISON, J; HOFFMANN, MW; SCHONRICH, G; HAMMERLING, G; ARNOLD, B; MILLER, JFAP				HEATH, WR; ALLISON, J; HOFFMANN, MW; SCHONRICH, G; HAMMERLING, G; ARNOLD, B; MILLER, JFAP			AUTOIMMUNE DIABETES AS A CONSEQUENCE OF LOCALLY PRODUCED INTERLEUKIN-2	NATURE			English	Article							RECEPTOR TRANSGENIC MICE; VIRUS-INFECTION; T-CELLS; TOLERANCE; MOLECULES; MECHANISM; INDUCTION	DURING cell differentiation in the thymus, self-reactive T cells can be generated. The majority of these seem to be deleted after intrathymic encounter with the relevant autoantigen1. As all self antigens are unlikely to be present in the thymus, some autoreactive T cells may escape censorship. Here we study the fate of these cells using transgenic mice expressing the class I molecule H-2K(b) (K(b)) in the insulin-producing beta-cells of the pancreas2,3. These mice were crossed with mice transgenic for genes encoding a K(b)-specific T-cell antigen receptor (TCR)4 which could be detected using a clonotype-specific monoclonal antibody5. Although T cells expressing the highest level of transgenic TCR were deleted intrathymically in double-transgenic mice, K(b)-specific T cells were detected in the periphery. These cells caused the rejection of K(b)-expressing skin grafts, but ignored islet K(b) antigens even after priming. But when double-transgenic mice were crossed with transgenic mice expressing the lymphokine interleukin-2 in the pancreatic beta-cells6, there was a rapid onset of diabetes. These results indicate that autoreactive T cells that ignore self antigens may cause autoimmune diabetes when provided with exogenous 'help' in the form of interleukin-2.	ROYAL MELBOURNE HOSP, WALTER & ELIZA HALL INST MED RES, PARKVILLE, VIC 3050, AUSTRALIA; GERMAN CANC RES CTR, INST IMMUNOL & GENET, W-6900 HEIDELBERG 1, GERMANY	Royal Melbourne Hospital; Walter & Eliza Hall Institute; Helmholtz Association; German Cancer Research Center (DKFZ)				Schonrich, Gunther/0000-0002-5346-5704; Heath, William/0000-0001-9670-259X				ALLISON J, 1992, EUR J IMMUNOL, V22, P1115, DOI 10.1002/eji.1830220503; ALLISON J, 1988, NATURE, V333, P529, DOI 10.1038/333529a0; DENNERT G, 1980, CELL IMMUNOL, V53, P350, DOI 10.1016/0008-8749(80)90335-4; HUA C, 1986, J IMMUNOL, V136, P1937; LO D, 1992, EUR J IMMUNOL, V22, P1013, DOI 10.1002/eji.1830220421; MILLER JFAP, 1991, IMMUNOL REV, V122, P103, DOI 10.1111/j.1600-065X.1991.tb00599.x; MILLER JFAP, 1989, COLD SPRING HARB SYM, V54, P807; MORAHAN G, 1989, NATURE, V339, P622, DOI 10.1038/339622a0; MORAHAN G, 1991, P NATL ACAD SCI USA, V88, P11421, DOI 10.1073/pnas.88.24.11421; OHASHI PS, 1991, CELL, V65, P305, DOI 10.1016/0092-8674(91)90164-T; OLDSTONE MBA, 1991, CELL, V65, P319, DOI 10.1016/0092-8674(91)90165-U; SCHONRICH G, 1992, INT IMMUNOL, V4, P581, DOI 10.1093/intimm/4.5.581; SCHONRICH G, 1991, CELL, V65, P293, DOI 10.1016/0092-8674(91)90163-S; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531	14	243	250	0	3	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	OCT 8	1992	359	6395					547	549		10.1038/359547a0	http://dx.doi.org/10.1038/359547a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JR859	1406974				2022-12-01	WOS:A1992JR85900063
J	HEGDE, RS; GROSSMAN, SR; LAIMINS, LA; SIGLER, PB				HEGDE, RS; GROSSMAN, SR; LAIMINS, LA; SIGLER, PB			CRYSTAL-STRUCTURE AT 1.7-ANGSTROM OF THE BOVINE PAPILLOMAVIRUS-1 E2 DNA-BINDING DOMAIN BOUND TO ITS DNA TARGET	NATURE			English	Article							PROTEIN STRUCTURES; TERMINAL DOMAIN; NUCLEIC-ACIDS; REPRESSOR; RECOGNITION; RESOLUTION; COMPLEX; OPERATOR; ACTIVATION; E2-PROTEIN	The dominant transcriptional regulator of the papillomaviruses, E2, binds to its specific DNA target through a previously unobserved dimeric antiparallel beta-barrel. The DNA is severely but smoothly bent over the barrel by the interaction of successive major grooves with a pair of symmetrically disposed alpha-helices. The specific interface is an 'interwoven' network of interactions where the identifying base pairs of the target contact more than one amino-acid side chain and the discriminating amino acids interact with more than one base pair.	YALE UNIV,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06510; UNIV CHICAGO,DEPT MOLEC GENET & CELL BIOL,CHICAGO,IL 60637; UNIV CHICAGO,HOWARD HUGHES MED INST,CHICAGO,IL 60637	Yale University; University of Chicago; Howard Hughes Medical Institute; University of Chicago	HEGDE, RS (corresponding author), YALE UNIV,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510, USA.							ADMAN E, 1975, P NATL ACAD SCI USA, V72, P4854, DOI 10.1073/pnas.72.12.4854; AGGARWAL AK, 1988, SCIENCE, V242, P899, DOI 10.1126/science.3187531; ANDROPHY EJ, 1987, NATURE, V325, P70, DOI 10.1038/325070a0; BLUNDELL TL, 1971, NATURE, V231, P506, DOI 10.1038/231506a0; BREG JN, 1990, NATURE, V346, P586, DOI 10.1038/346586a0; BRUNGER AT, 1990, XPLOR VERSION 2 1 MA; DOSTATNI N, 1988, EMBO J, V7, P3807, DOI 10.1002/j.1460-2075.1988.tb03265.x; FINZEL BC, 1987, J APPL CRYSTALLOGR, V20, P53, DOI 10.1107/S0021889887087144; GIRI I, 1988, EMBO J, V7, P2823, DOI 10.1002/j.1460-2075.1988.tb03138.x; HAM J, 1991, TRENDS BIOCHEM SCI, V16, P440, DOI 10.1016/0968-0004(91)90172-R; HANDSCHUMACHER MD, 1983, ACCESS YALE U; Hendrickson W. A., 1981, BIOMOLECULAR STRUCTU, V1, P43; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JORDAN SR, 1988, SCIENCE, V242, P893, DOI 10.1126/science.3187530; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KNIGHT JD, 1991, P NATL ACAD SCI USA, V88, P3204, DOI 10.1073/pnas.88.8.3204; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAVERY R, 1988, J BIOMOL STRUCT DYN, V6, P63, DOI 10.1080/07391102.1988.10506483; LI R, 1989, GENE DEV, V3, P510, DOI 10.1101/gad.3.4.510; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MARMORSTEIN R, 1992, NATURE, V356, P408, DOI 10.1038/356408a0; MCBRIDE AA, 1988, EMBO J, V7, P533, DOI 10.1002/j.1460-2075.1988.tb02842.x; MCBRIDE AA, 1989, P NATL ACAD SCI USA, V86, P510, DOI 10.1073/pnas.86.2.510; MCBRIDE AA, 1989, COMMON MECHANISMS TR, P115; MONINI P, 1991, J VIROL, V65, P2124, DOI 10.1128/JVI.65.4.2124-2130.1991; MOSKALUK C, 1988, P NATL ACAD SCI USA, V85, P1826, DOI 10.1073/pnas.85.6.1826; OHLENDORF DH, 1982, NATURE, V298, P718, DOI 10.1038/298718a0; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; OTWINOWSKI Z, 1991, MLPHARE CCP4 P, P80; Phillips SEV, 1991, CURR OPIN STRUC BIOL, V1, P89, DOI 10.1016/0959-440X(91)90016-M; PRAKASH SS, 1992, GENE DEV, V6, P105, DOI 10.1101/gad.6.1.105; PRESTA LG, 1988, SCIENCE, V240, P1632, DOI 10.1126/science.2837824; RICHARDSON JS, 1988, SCIENCE, V240, P1648, DOI 10.1126/science.3381086; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; SOUSA R, 1990, BIOCHIM BIOPHYS ACTA, V1032, P19, DOI 10.1016/0304-419X(90)90010-X; Travers AA, 1991, CURR OPIN STRUC BIOL, V1, P114, DOI 10.1016/0959-440X(91)90019-P; USTAV M, 1991, EMBO J, V10, P445; WESTHOF E, 1985, J MOL BIOL, V184, P119, DOI 10.1016/0022-2836(85)90048-8; YANG L, 1991, NATURE, V353, P628, DOI 10.1038/353628a0	40	309	317	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 8	1992	359	6395					505	512		10.1038/359505a0	http://dx.doi.org/10.1038/359505a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JR859	1328886				2022-12-01	WOS:A1992JR85900050
J	HYMAN, AA; MIDDLETON, K; CENTOLA, M; MITCHISON, TJ; CARBON, J				HYMAN, AA; MIDDLETON, K; CENTOLA, M; MITCHISON, TJ; CARBON, J			MICROTUBULE-MOTOR ACTIVITY OF A YEAST CENTROMERE-BINDING PROTEIN COMPLEX	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; CYTOPLASMIC DYNEIN; KINETOCHORES; SPINDLE; MITOSIS; INVITRO; CELLS	DURING cell division, sister chromosomes segregate from each other on a microtubule-based structure called the mitotic spindle. Proteins bind to the centromere, a region of chromosomal DNA, to form the kinetochore, which mediates chromosome attachment to the mitotic spindle microtubules1,2. In the budding yeast Saccharomyces cerevisiae, genetic analysis has shown that the 28-base-pair (bp) CDEIII region of the 125-bp centromere DNA sequence (CEN sequence) is the main region controlling chromosome segregation in vivo3,4. Therefore it is likely that proteins binding to the CDEIII region link the centromeres to the microtubules during mitosis. A complex of proteins (CBF3) that binds specifically to the CDEIII DNA sequence has been isolated by affinity chromatography5. Here we describe kinetochore function in vitro. The CBF3 complex can link DNA to microtubules, and the complex contains a minus-end-directed microtubule-based motor. We suggest that microtubule-based motors form the fundamental link between microtubules and chromosomes at mitosis.	UNIV CALIF SANTA BARBARA, DEPT BIOL SCI, SANTA BARBARA, CA 93106 USA	University of California System; University of California Santa Barbara	HYMAN, AA (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT PHARMACOL, SAN FRANCISCO, CA 94143 USA.		Hyman, Tony/F-1923-2011; Hyman, Anthony A/B-3917-2017	Hyman, Anthony A/0000-0003-3664-154X				BLOCK SM, 1990, NATURE, V348, P348, DOI 10.1038/348348a0; CLARKE L, 1990, TRENDS GENET, V6, P150, DOI 10.1016/0168-9525(90)90149-Z; EUTENEUER U, 1982, J CELL BIOL, V94, P644, DOI 10.1083/jcb.94.3.644; HYMAN AA, 1991, NATURE, V351, P206, DOI 10.1038/351206a0; HYMAN AA, 1991, J CELL SCI, P125; LECHNER J, 1991, CELL, V64, P717, DOI 10.1016/0092-8674(91)90501-O; MCGREW J, 1986, MOL CELL BIOL, V6, P530, DOI 10.1128/MCB.6.2.530; NG R, 1987, MOL CELL BIOL, V7, P4522, DOI 10.1128/MCB.7.12.4522; PALMER RE, 1989, J CELL BIOL, V109, P3355, DOI 10.1083/jcb.109.6.3355; PETERSON JB, 1976, J CELL SCI, V22, P219; PFARR CM, 1990, NATURE, V345, P263, DOI 10.1038/345263a0; RIEDER CL, 1981, CHROMOSOMA, V84, P145, DOI 10.1007/BF00293368; RIEDER CL, 1990, J CELL BIOL, V110, P81, DOI 10.1083/jcb.110.1.81; ROOS UP, 1973, CHROMOSOMA, V41, P195, DOI 10.1007/BF00319696; SHIMIZU T, 1991, J CELL BIOL, V112, P1189, DOI 10.1083/jcb.112.6.1189; STEUER ER, 1990, NATURE, V345, P266, DOI 10.1038/345266a0; SWITZER RC, 1979, ANAL BIOCHEM, V98, P231, DOI 10.1016/0003-2697(79)90732-2; VALLEE RB, 1990, ANNU REV BIOCHEM, V59, P909, DOI 10.1146/annurev.biochem.59.1.909; WALKER JW, 1989, METHOD ENZYMOL, V172, P288; YAMAMOTO A, 1990, CELL STRUCT FUNCT, V15, P221, DOI 10.1247/csf.15.221	20	104	104	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 8	1992	359	6395					533	536		10.1038/359533a0	http://dx.doi.org/10.1038/359533a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JR859	1406970				2022-12-01	WOS:A1992JR85900059
J	NISLOW, C; LOMBILLO, VA; KURIYAMA, R; MCINTOSH, JR				NISLOW, C; LOMBILLO, VA; KURIYAMA, R; MCINTOSH, JR			A PLUS-END-DIRECTED MOTOR ENZYME THAT MOVES ANTIPARALLEL MICROTUBULES INVITRO LOCALIZES TO THE INTERZONE OF MITOTIC SPINDLES	NATURE			English	Article							PROTEINS; KINESIN; PROGRESSION; SEQUENCE; CELLS	MITOSIS comprises a complex set of overlapping motile events, many of which involve microtubule-dependent motor enzymes1,2. Here we describe a new member of the kinesin superfamily. The protein was originally identified as a spindle antigen by the CHO1 monoclonal antibody3 and shown to be required for mitotic progression4,5. We have cloned the gene that encodes this antigen and found that its sequence contains a domain with strong sequence similarity to the motor domain of kinesin-like proteins. The product of this gene, expressed in bacteria, can cross-bridge antiparallel microtubules in vitro, and in the presence of Mg-ATP, microtubules slide over one another in a fashion reminiscent of microtubule movements during spindle elongation.	UNIV MINNESOTA,DEPT CELL BIOL & NEUROANAT,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities	NISLOW, C (corresponding author), UNIV COLORADO,DEPT MOLEC CELLULAR & DEV BIOL,BOULDER,CO 80309, USA.		McIntosh, Richard/GLN-3533-2022	Nislow, Corey/0000-0002-4016-8874				CANDE WZ, 1978, J CELL BIOL, V79, P573, DOI 10.1083/jcb.79.2.573; CANDE WZ, 1989, CELL MOVEMENT, V2, P441; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; COLE DG, 1992, J CELL SCI, V101, P291; ENDOW SA, 1991, TRENDS BIOCHEM SCI, V16, P221, DOI 10.1016/0968-0004(91)90089-E; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; Goldstein L S, 1991, Trends Cell Biol, V1, P93, DOI 10.1016/0962-8924(91)90036-9; HAGAN I, 1992, NATURE, V356, P74, DOI 10.1038/356074a0; HEIDEMANN SR, 1980, NATURE, V286, P517, DOI 10.1038/286517a0; HOLLENBECK PJ, 1989, J CELL BIOL, V108, P2335, DOI 10.1083/jcb.108.6.2335; HUANG B, 1979, J BIOL CHEM, V254, P3091; JANS DA, 1991, J CELL BIOL, V115, P1203, DOI 10.1083/jcb.115.5.1203; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KURIYAMA R, 1992, BIOESSAYS, V14, P81, DOI 10.1002/bies.950140203; LIN KH, 1991, BIOTECHNIQUES, V11, P748; LOMBILLO VA, IN PRESS METHODS CEL; MACDONALD RJ, 1987, METHOD ENZYMOL, V152, P219; MCINTOSH JR, 1991, J CELL BIOL, V115, P577, DOI 10.1083/jcb.115.3.577; MCLACHLAN AD, 1983, J MOL BIOL, V164, P605, DOI 10.1016/0022-2836(83)90053-0; NISLOW C, 1990, J CELL BIOL, V111, P511, DOI 10.1083/jcb.111.2.511; PFARR CM, 1990, NATURE, V345, P263, DOI 10.1038/345263a0; ROBERTS B, 1989, BIOCHIM BIOPHYS ACTA, V1008, P263, DOI 10.1016/0167-4781(89)90016-X; RODIONOV VI, 1991, P NATL ACAD SCI USA, V88, P4956, DOI 10.1073/pnas.88.11.4956; ROOF DM, 1991, COLD SPRING HARB SYM, V56, P693; SAUNDERS WS, 1992, CELL, V70, P451, DOI 10.1016/0092-8674(92)90169-D; Sawin K E, 1991, Trends Cell Biol, V1, P122, DOI 10.1016/0962-8924(91)90117-R; SAWIN KE, 1992, J CELL SCI, V101, P303; SELLITTO C, 1988, J CELL BIOL, V106, P431, DOI 10.1083/jcb.106.2.431; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; WILLIAMS RC, 1979, BIOCHEMISTRY-US, V18, P2499, DOI 10.1021/bi00579a010; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2; YANG JT, 1990, SCIENCE, V249, P42, DOI 10.1126/science.2142332; YEN TJ, 1991, EMBO J, V10, P1245, DOI 10.1002/j.1460-2075.1991.tb08066.x	33	303	312	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 8	1992	359	6395					543	547		10.1038/359543a0	http://dx.doi.org/10.1038/359543a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JR859	1406973				2022-12-01	WOS:A1992JR85900062
J	RESNICK, JL; BIXLER, LS; CHENG, LZ; DONOVAN, PJ				RESNICK, JL; BIXLER, LS; CHENG, LZ; DONOVAN, PJ			LONG-TERM PROLIFERATION OF MOUSE PRIMORDIAL GERM-CELLS IN CULTURE	NATURE			English	Article							DIFFERENTIATION INHIBITING ACTIVITY; EMBRYOS; GROWTH	PRIMORDIAL germ cells(PGCs) are first identifiable as a population of about eight alkaline phosphatase-positive cells in the 7.0 days postcoitum mouse embryo1. During the next 6 days of development they proliferate to give rise to the 25,000 cells that will establish the meiotic population2. Steel factor is required for PGC survival both in vivo3 and in vitro4,5 and together with leukaemia inhibitory factor stimulates PGC proliferation in vitro6. In feeder-dependent culture, PGCs will proliferate for up to 7 days, but their numbers eventually decline and their proliferative capacity is only a fraction of that seen in vivo6,7. Here we report a further factor that stimulates PGC proliferation in vitro, basic fibroblast growth factor (bFGF). Furthermore, bFGF, in the presence of steel factor and leukaemia inhibitory factor, stimulates long-term proliferation of PGCs, leading to the derivation of large colonies of cells. These embryonic germ cells resemble embryonic stem cells, pluripotent cells derived from preimplantation embryos, or feeder-dependent embryonal carcinoma cells, pluripotent stem cells of PGC-derived tumours (teratomas and teratocarcinomas)8. To our knowledge, these results provide the first system for long-term culture of PGCs.	NCI,FREDERICK CANC RES & DEV CTR,PRI DYNCORP,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	RESNICK, JL (corresponding author), NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,MAMMALIAN GENET LAB,POB B,FREDERICK,MD 21702, USA.							BENNETT DOROTHEA, 1956, J MORPH, V98, P199, DOI 10.1002/jmor.1050980202; DOLCI S, 1991, NATURE, V352, P809, DOI 10.1038/352809a0; DONOVAN PJ, 1986, CELL, V44, P831, DOI 10.1016/0092-8674(86)90005-X; FOX N, 1981, DEV BIOL, V83, P391, DOI 10.1016/0012-1606(81)90487-5; GINSBURG M, 1990, DEVELOPMENT, V110, P521; GODIN I, 1991, NATURE, V352, P807, DOI 10.1038/352807a0; KOOPMAN P, 1984, EXP CELL RES, V154, P233, DOI 10.1016/0014-4827(84)90683-9; MARTIN GR, 1983, TERATOCARCINOMA STEM, P635; MATSUI Y, 1991, NATURE, V353, P750, DOI 10.1038/353750a0; MATSUI Y, 1992, CELL, V70, P841, DOI 10.1016/0092-8674(92)90317-6; RATHJEN PD, 1990, CELL, V62, P1105, DOI 10.1016/0092-8674(90)90387-T; RATHJEN PD, 1990, GENE DEV, V4, P2308, DOI 10.1101/gad.4.12b.2308; STEVENS LC, 1967, J NATL CANCER I, V38, P549; STEVENS LC, 1961, J NATL CANCER I, V27, P443; TAM PPL, 1981, J EMBRYOL EXP MORPH, V64, P133; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299	16	680	767	1	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 8	1992	359	6395					550	551		10.1038/359550a0	http://dx.doi.org/10.1038/359550a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JR859	1383830				2022-12-01	WOS:A1992JR85900064
J	SAWIN, KE; LEGUELLEC, K; PHILIPPE, M; MITCHISON, TJ				SAWIN, KE; LEGUELLEC, K; PHILIPPE, M; MITCHISON, TJ			MITOTIC SPINDLE ORGANIZATION BY A PLUS-END-DIRECTED MICROTUBULE MOTOR	NATURE			English	Article							KINESIN-LIKE PROTEIN; CHROMOSOME SEGREGATION; DROSOPHILA; INVITRO; GENE; EXTRACTS; FLUX; IDENTIFICATION; MOTILITY; ENCODES	INTRACELLULAR microtubule motor proteins1,2 may direct the motile properties and/or morphogenesis of the mitotic spindle (reviewed in ref. 3). The recent identification of kinesin-like proteins important for mitosis or meiosis4-9 indicates that kinesin-related proteins may play a universal role in eukaryotic cell division, but the precise function of such proteins in mitosis remains unknown. Here we use an in vitro assay for spindle assembly, derived from Xenopus egg extracts10,11, to investigate the role of Eg5, a kinesin-like protein in Xenopus eggs12. Eg5 is localized along spindle microtubules, and particularly enriched near spindle poles. Immunodepletion of Eg5 from egg extracts markedly reduces the extent of spindle formation in extracts, as does direct addition of anti-Eg5 antibodies. We also demonstrate that Eg5 is a plus-end-directed microtubule motor in vitro. Our results suggest a novel mechanism for the dynamic self-organization of spindle poles in mitosis.	UNIV CALIF SAN FRANCISCO,DEPT PHARMACOL,SAN FRANCISCO,CA 94143; UNIV RENNES 1,CNRS,URA 256,DEPT BIOL & GENET DEV,F-35042 RENNES,FRANCE	University of California System; University of California San Francisco; Centre National de la Recherche Scientifique (CNRS); Universite de Rennes 1	SAWIN, KE (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.			Sawin, Kenneth/0000-0002-2607-2219	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039565] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELMONT LD, 1990, CELL, V62, P579, DOI 10.1016/0092-8674(90)90022-7; COMPTON DA, 1992, J CELL BIOL, V116, P1395, DOI 10.1083/jcb.116.6.1395; ENDOW SA, 1990, NATURE, V345, P81, DOI 10.1038/345081a0; ENOS AP, 1990, CELL, V60, P1019, DOI 10.1016/0092-8674(90)90350-N; HAGAN I, 1992, NATURE, V356, P74, DOI 10.1038/356074a0; HAGAN I, 1990, NATURE, V347, P563, DOI 10.1038/347563a0; HOYT MA, 1992, J CELL BIOL, V118, P109, DOI 10.1083/jcb.118.1.109; HYMAN AA, 1991, J CELL SCI S, V14, P125; KITANISHIYUMURA T, 1987, CELL MOTIL CYTOSKEL, V8, P106, DOI 10.1002/cm.970080203; LEGUELLEC R, 1991, MOL CELL BIOL, V11, P3395, DOI 10.1128/MCB.11.6.3395; LOHKA MJ, 1985, J CELL BIOL, V101, P518, DOI 10.1083/jcb.101.2.518; MACKETT M, 1990, NUCLEIC ACIDS RES, V18, P1082, DOI 10.1093/nar/18.4.1082; MCDONALD HB, 1990, CELL, V63, P1159, DOI 10.1016/0092-8674(90)90412-8; MCDONALD HB, 1990, CELL, V61, P991, DOI 10.1016/0092-8674(90)90064-L; MCINTOSH JR, 1981, INT CELLBIOL 1980 19; MELUH PB, 1990, CELL, V60, P1029, DOI 10.1016/0092-8674(90)90351-E; MITCHISON TJ, 1990, CELL MOTIL CYTOSKEL, V16, P93, DOI 10.1002/cm.970160202; MITCHISON TJ, 1989, J CELL BIOL, V109, P637, DOI 10.1083/jcb.109.2.637; MURRAY AW, 1952, METHOD CELL BIOL, P581; PASCHAL BM, 1987, J CELL BIOL, V105, P1273, DOI 10.1083/jcb.105.3.1273; PICKETTHEAPS JD, 1982, CELL, V29, P729, DOI 10.1016/0092-8674(82)90435-4; REBHUN LI, 1988, CELL MOTIL CYTOSKEL, V10, P197, DOI 10.1002/cm.970100124; ROOF DM, 1992, J CELL BIOL, V118, P95, DOI 10.1083/jcb.118.1.95; Sawin K E, 1991, Trends Cell Biol, V1, P122, DOI 10.1016/0962-8924(91)90117-R; SAWIN KE, 1992, J CELL SCI, V101, P303; SAWIN KE, 1991, J CELL BIOL, V112, P941, DOI 10.1083/jcb.112.5.941; SAWIN KE, 1991, J CELL BIOL, V112, P925, DOI 10.1083/jcb.112.5.925; SHAMU CE, 1992, J CELL BIOL, V117, P921, DOI 10.1083/jcb.117.5.921; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; VALE RD, 1985, CELL, V40, P559, DOI 10.1016/0092-8674(85)90204-1; VERDE F, 1991, J CELL BIOL, V112, P1177, DOI 10.1083/jcb.112.6.1177; WALKER RA, 1990, NATURE, V347, P780, DOI 10.1038/347780a0; WOLF KW, 1991, EUR J CELL BIOL, V55, P235; YANG CH, 1992, J CELL BIOL, V116, P1303, DOI 10.1083/jcb.116.6.1303; YANG JT, 1990, SCIENCE, V249, P42, DOI 10.1126/science.2142332; ZHANG P, 1990, CELL, V62, P1053, DOI 10.1016/0092-8674(90)90383-P	38	549	560	3	22	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 8	1992	359	6395					540	543		10.1038/359540a0	http://dx.doi.org/10.1038/359540a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JR859	1406972				2022-12-01	WOS:A1992JR85900061
J	YEN, TJ; LI, G; SCHAAR, BT; SZILAK, I; CLEVELAND, DW				YEN, TJ; LI, G; SCHAAR, BT; SZILAK, I; CLEVELAND, DW			CENP-E IS A PUTATIVE KINETOCHORE MOTOR THAT ACCUMULATES JUST BEFORE MITOSIS	NATURE			English	Article							KINESIN HEAVY-CHAIN; PROTEIN; SEQUENCE; GENE; ENCODES; DOMAINS	THE mechanics of chromosome movement, mitotic spindle assembly and spindle elongation have long been central questions of cell biology1. After attachment in prometaphase of a microtubule from one pole, duplicated chromosome pairs travel towards the pole in a rapid but discontinuous motion2,3. This is followed by a slower congression towards the midplate as the chromosome pair orients with each kinetochore attached to the microtubules f rom the nearest pole. The pairs disjoin at anaphase and translocate to opposite poles and the interpolar distance increases. Here we identify CENP-E as a kinesin-like motor protein (M(r) 312,000) that accumulates in the G2 phase of the cell cycle. CENP-E associates with kinetochores during congression, relocates to the spindle midzone at anaphase, and is quantitatively discarded at the end of the cell division. CENP-E is likely to be one of the motors responsible for mammalian chromosome movement and/or spindle elongation.	UNIV PENN,CELL BIOL GRAD GRP,PHILADELPHIA,PA 19104; JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL SCI,BALTIMORE,MD 21205	University of Pennsylvania; Johns Hopkins University	YEN, TJ (corresponding author), FOX CHASE CANC CTR,7701 BURHOLME AVE,PHILADELPHIA,PA 19111, USA.		Cleveland, Don/AAN-9783-2021	Yen, Tim/0000-0003-2159-0997; Cleveland, Don/0000-0002-1934-3682				CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; ENDOW SA, 1990, NATURE, V345, P81, DOI 10.1038/345081a0; ENDOW SA, 1991, TRENDS BIOCHEM SCI, V16, P221, DOI 10.1016/0968-0004(91)90089-E; HAGAN I, 1990, NATURE, V347, P563, DOI 10.1038/347563a0; HAYDEN JH, 1990, J CELL BIOL, V111, P1039, DOI 10.1083/jcb.111.3.1039; HIROKAWA N, 1989, CELL, V56, P867, DOI 10.1016/0092-8674(89)90691-0; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KOSIK KS, 1990, J BIOL CHEM, V265, P3278; LANFORD RE, 1984, CELL, V37, P801, DOI 10.1016/0092-8674(84)90415-X; LEGUELLEC R, 1991, MOL CELL BIOL, V11, P3395, DOI 10.1128/MCB.11.6.3395; LEWIS SA, 1988, SCIENCE, V242, P936, DOI 10.1126/science.3142041; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MACDONALD HB, 1990, CELL, V61, P991; MELUH PB, 1990, CELL, V60, P1029, DOI 10.1016/0092-8674(90)90351-E; NAVONE F, 1992, J CELL BIOL, V117, P1263, DOI 10.1083/jcb.117.6.1263; OTSUKA AJ, 1991, NEURON, V6, P113, DOI 10.1016/0896-6273(91)90126-K; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; van Beneden E., 1883, ARCH BIOL, V4, P265; WRIGHT BD, 1991, J CELL BIOL, V113, P817, DOI 10.1083/jcb.113.4.817; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2; YEN TJ, 1991, EMBO J, V10, P1245, DOI 10.1002/j.1460-2075.1991.tb08066.x	21	351	363	0	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 8	1992	359	6395					536	539		10.1038/359536a0	http://dx.doi.org/10.1038/359536a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JR859	1406971				2022-12-01	WOS:A1992JR85900060
J	SIEGEL, D; GOLDEN, E; WASHINGTON, AE; MORSE, SA; FULLILOVE, MT; CATANIA, JA; MARIN, B; HULLEY, SB				SIEGEL, D; GOLDEN, E; WASHINGTON, AE; MORSE, SA; FULLILOVE, MT; CATANIA, JA; MARIN, B; HULLEY, SB			PREVALENCE AND CORRELATES OF HERPES-SIMPLEX INFECTIONS - THE POPULATION-BASED AIDS IN MULTIETHNIC NEIGHBORHOODS STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							VIRUS TYPE-2 INFECTION; GENITAL HERPES; GLYCOPROTEIN-G; UNITED-STATES; ANTIBODIES; EPIDEMIOLOGY; RISK; IDENTIFICATION; CHILDREN; GENE	Objective.-To examine the extent and correlates of infection with herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) in an inner-city community, we studied the prevalence of antibodies to these viruses and their association with risk behaviors in a representative sample of unmarried white, black, and Hispanic adults living in San Francisco, Calif. Design.-Cross-sectional, community-based, random household survey. Participants.-In 1988 and 1989, we surveyed 1770 unmarried men and women aged 20 to 44 years from three San Francisco neighborhoods of varying geographic and cultural characteristics. Main Outcome Measures.-HSV-1 and HSV-2 antibodies based on an immunodot assay using type-specific glycoproteins gG-1 and gG-2. Results.- blood samples from 1212 participants available for testing, 750 (62%) had HSV-1 antibodies and 400 (33%) had HSV-2 antibodies. After controlling for other variables, HSV-1 antibody was significantly correlated (P<.05) with older age (in heterosexual men, women, and homosexually active men), less education (in heterosexual men and women), and Hispanic (especially those not born in the United States) or black race. HSV-2 antibody was significantly correlated (P<.05) with female gender, number of lifetime sexual partners and older age (in heterosexual men and women), and low levels of education and black or Hispanic race (in women). Among those with antibody to HSV-2, only 28 (19%) of 149 men and 32 (13%) of 251 women reported a history of genital herpes. However, most men (62%) and women (84%) who reported a history of genital herpes had HSV-2 antibodies. We observed a similar pattern (low sensitivity and moderate specificity) for a history of facial herpes and the presence of HSV-1 antibodies. After controlling for other variables, HSV-2 antibodies were associated with a lower frequency of HSV-1 antibodies among homosexual men infected with the human immunodeficiency virus. Conclusions.-HSV-1 antibodies were found in nearly two thirds of single urban adults and were most common among Hispanics not born in the United States. HSV-2 antibodies were found in one third of this population and were associated with risk behaviors for sexually transmitted diseases. For both facial and genital herpes infections, self-reporting of infection was very insensitive and moderately specific.	NEW YORK STATE PSYCHIAT INST & HOSP,HIV CTR CLIN & BEHAV STUDIES,NEW YORK,NY 10032; UNIV CALIF SAN FRANCISCO,DEPT EPIDEMIOL & BIOSTAT,DIV CLIN EPIDEMIOL,SAN FRANCISCO,CA 94143; COLUMBIA UNIV,NEW YORK,NY 10027; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; CTR DIS CONTROL,DIV SEXUALLY TRANSMITTED DIS LAB RES,ATLANTA,GA 30333; UNIV CALIF SAN FRANCISCO,CTR AIDS PREVENT STUDIES,SAN FRANCISCO,CA 94143	New York State Psychiatry Institute; University of California System; University of California San Francisco; Columbia University; University of California System; University of California San Francisco; Centers for Disease Control & Prevention - USA; University of California System; University of California San Francisco			Fullilove, Mindy Thompson/AAI-4919-2020		NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH042459] Funding Source: NIH RePORTER; NIMH NIH HHS [MH42459] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ACKERMANN M, 1986, VIROLOGY, V150, P207, DOI 10.1016/0042-6822(86)90280-1; ADLERSTORTHZ K, 1985, AM J OBSTET GYNECOL, V151, P582, DOI 10.1016/0002-9378(85)90143-7; ASHLEY RL, 1988, J CLIN MICROBIOL, V26, P662, DOI 10.1128/JCM.26.4.662-667.1988; BECKER TM, 1985, JAMA-J AM MED ASSOC, V253, P1601, DOI 10.1001/jama.253.11.1601; BECKER TM, 1988, AM J EPIDEMIOL, V127, P1071, DOI 10.1093/oxfordjournals.aje.a114883; BLACK FL, 1970, AM J EPIDEMIOL, V91, P430, DOI 10.1093/oxfordjournals.aje.a121153; BLACK FL, 1975, SCIENCE, V187, P515, DOI 10.1126/science.163483; BLACK FL, 1974, AM J EPIDEMIOL, V100, P230, DOI 10.1093/oxfordjournals.aje.a112032; BREINIG MK, 1990, J INFECT DIS, V162, P299, DOI 10.1093/infdis/162.2.299; CATANIA JA, 1992, AM J PUBLIC HEALTH, V82, P284, DOI 10.2105/AJPH.82.2.284; COREY L, 1986, NEW ENGL J MED, V314, P686, DOI 10.1056/NEJM198603133141105; COREY L, 1986, NEW ENGL J MED, V314, P749, DOI 10.1056/NEJM198603203141205; FULLILOVE MT, 1992, WESTERN J MED, V157, P32; FULLILOVE RE, 1990, JAMA-J AM MED ASSOC, V263, P851, DOI 10.1001/jama.263.6.851; GALLO D, 1986, J CLIN MICROBIOL, V23, P1049, DOI 10.1128/JCM.23.6.1049-1051.1986; GIBSON JJ, 1990, J INFECT DIS, V162, P306, DOI 10.1093/infdis/162.2.306; GUINAN ME, 1985, EPIDEMIOL REV, V7, P127, DOI 10.1093/oxfordjournals.epirev.a036279; HOLMBERG SD, 1988, JAMA-J AM MED ASSOC, V259, P1048, DOI 10.1001/jama.259.7.1048; ISAGER H, 1983, ACTA PATH MICRO IM B, V91, P339; JOHNSON RE, 1989, NEW ENGL J MED, V321, P7, DOI 10.1056/NEJM198907063210102; JOSEY WE, 1972, OBSTET GYNECOL SURV, V27, P295; KIEFF E, 1972, J VIROL, V9, P738, DOI 10.1128/JVI.9.5.738-745.1972; KJAER SK, 1990, AM J EPIDEMIOL, V131, P669, DOI 10.1093/oxfordjournals.aje.a115551; KOUTSKY LA, 1990, SEX TRANSM DIS, V17, P90, DOI 10.1097/00007435-199004000-00009; LEE FK, 1986, J VIROL METHODS, V14, P111, DOI 10.1016/0166-0934(86)90041-8; LEE FK, 1985, J CLIN MICROBIOL, V22, P641, DOI 10.1128/JCM.22.4.641-644.1985; LOWHAGEN GB, 1990, ACTA DERM-VENEREOL, V70, P330; MARSDEN HS, 1984, J VIROL, V50, P547, DOI 10.1128/JVI.50.2.547-554.1984; MURRAY JL, 1988, NEW ENGL J MED, V319, P1385, DOI 10.1056/NEJM198811243192105; NAHMIAS AJ, 1973, NEW ENGL J MED, V289, P781, DOI 10.1056/NEJM197310112891505; NAHMIAS AJ, 1973, NEW ENGL J MED, V289, P719, DOI 10.1056/NEJM197310042891404; NAHMIAS AJ, 1973, NEW ENGL J MED, V289, P667, DOI 10.1056/NEJM197309272891305; NAHMIAS AJ, 1970, AM J EPIDEMIOL, V91, P539, DOI 10.1093/oxfordjournals.aje.a121165; OBERLE MV, 1989, AM J TROP MED HYG, V4, P224; PASQUINI P, 1988, EUR J CLIN MICROBIOL, V7, P54, DOI 10.1007/BF01962174; RAWLS WE, 1971, AM J OBSTET GYNECOL, V110, P682, DOI 10.1016/0002-9378(71)90254-7; RAWLS WE, 1981, HUMAN HERPESVIRUSES, P137; RICHMAN DD, 1986, J VIROL, V57, P647, DOI 10.1128/JVI.57.2.647-655.1986; ROIZMAN B, 1984, VIROLOGY, V133, P242, DOI 10.1016/0042-6822(84)90447-1; SANCHEZMARTINEZ D, 1991, J INFECT DIS, V164, P1196, DOI 10.1093/infdis/164.6.1196; SETH P, 1981, INDIAN J MED RES, V73, P475; STAVRAKY KM, 1983, AM J EPIDEMIOL, V118, P109, DOI 10.1093/oxfordjournals.aje.a113612	42	121	123	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 7	1992	268	13					1702	1708		10.1001/jama.268.13.1702	http://dx.doi.org/10.1001/jama.268.13.1702			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JQ376	1326673				2022-12-01	WOS:A1992JQ37600032
J	TRICHOPOULOS, D; MOLLO, F; TOMATIS, L; AGAPITOS, E; DELSEDIME, L; ZAVITSANOS, X; KALANDIDI, A; KATSOUYANNI, K; RIBOLI, E; SARACCI, R				TRICHOPOULOS, D; MOLLO, F; TOMATIS, L; AGAPITOS, E; DELSEDIME, L; ZAVITSANOS, X; KALANDIDI, A; KATSOUYANNI, K; RIBOLI, E; SARACCI, R			ACTIVE AND PASSIVE SMOKING AND PATHOLOGICAL INDICATORS OF LUNG-CANCER RISK IN AN AUTOPSY STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AIR-POLLUTION; CIGARETTE-SMOKING; TOBACCO-SMOKE; BRONCHIAL EPITHELIUM; SMALL AIRWAYS; COUNTY; ASSOCIATION; EXPOSURE; DISEASE; WOMEN	Objective.-The association between involuntary smoking and lung cancer has been supported by most epidemiologic studies, but a number of authors and interest groups claim that the possibility of bias has not been excluded. Few autopsy-based studies have explored the role of active smoking and other exposures in lung carcinogenesis, and none has been previously done to examine the role of passive smoking. We have undertaken such an autopsy-based study in Athens, Greece. Design.-Lung specimens were taken at autopsy from 400 persons 35 years of age or older, of both genders, who had died within 4 hours from a cause other than respiratory or cancer in Athens or the surrounding area. For each person at least seven tissue blocks were taken from the main and lobar bronchi and at least five blocks from the parenchyma, including an average of about 20 smaller cartilaginous bronchi and membranous bronchioles. The specimens were examined without knowledge of the exposures of the particular subject in Turin, Italy. For 283 (71%) of the subjects the preservation of the bronchial epithelium was satisfactory for pathological examination, and for 206 among them (73%) an interview could be arranged with their next of kin, focusing on smoking habits of the deceased and their spouses, as well as other variables. The interviewers were not aware of the results of the pathological examinations. Main Outcome Measure.-Specimens were examined for basal cell hyperplasia, squamous cell metaplasia, cell atypia, and (in membranous bronchioles and bronchiolo-alveolar airways) mucous cell metaplasia, ie, pathological entities that may be lung cancer risk indicators or epithelial, possibly precancerous, lesions (EPPL). The gland and wall thicknesses were also measured and their ratio calculated (Reid Index). Results.-In comparison with nonsmokers, EPPL values were significantly higher among current smokers and higher, but not significantly so, among former smokers. Furthermore, EPPL values were significantly higher among deceased nonsmoking women married to smokers rather than to nonsmokers. In this set of data neither occupation nor residence was associated with EPPL, but this could be due to the poor correlation of residential history with exposure to air pollution and the lack of adequate standardization of contemporary Greek occupations. The Reid Index was higher among smokers and former smokers in comparison with nonsmokers, among subjects with mainly urban residence in comparison with those with mainly rural residence, and among nonsmoking women married to smokers in comparison with those married to nonsmokers, but none of these differences was statistically significant. Conclusion.-These results provide support to the body of evidence linking passive smoking to lung-cancer, even though they are based on a study methodologically different from those that have previously examined this association.	UNIV ATHENS,SCH MED,DEPT PATHOL,ATHENS,GREECE; UNIV ATHENS,SCH MED,DEPT HYG & EPIDEMIOL,ATHENS,GREECE; WHO,INT AGCY RES CANC,LYON,FRANCE; UNIV TURIN,DEPT BIOMED SCI & HUMAN ONCOL,I-10124 TURIN,ITALY	Athens Medical School; National & Kapodistrian University of Athens; Athens Medical School; National & Kapodistrian University of Athens; World Health Organization; International Agency for Research on Cancer (IARC); University of Turin	TRICHOPOULOS, D (corresponding author), HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,677 HUNTINGTON AVE,BOSTON,MA 02115, USA.		Katsouyanni, Klea/D-4856-2014	Katsouyanni, Klea/0000-0002-0132-9575; Riboli, Elio/0000-0001-6795-6080				AGAPITOS E, 1991, AUTOPSY EPIDEMIOLOGY, P263; [Anonymous], 1986, IARC MONOGRAPHS EVAL; [Anonymous], 1985, EPIDEMIOLOGY AIR POL; AUERBACH O, 1962, NEW ENGL J MED, V267, P111, DOI 10.1056/NEJM196207192670301; AUERBACH O, 1962, NEW ENGL J MED, V267, P119, DOI 10.1056/NEJM196207192670302; AUERBACH O, 1957, NEW ENGL J MED, V256, P97, DOI 10.1056/NEJM195701172560301; AUERBACH O, 1956, CANCER, V9, P76, DOI 10.1002/1097-0142(195601/02)9:1<76::AID-CNCR2820090106>3.0.CO;2-D; AUERBACH O, 1979, NEW ENGL J MED, V300, P381, DOI 10.1056/NEJM197902223000801; BLOT WJ, 1976, AM J EPIDEMIOL, V103, P539, DOI 10.1093/oxfordjournals.aje.a112258; BOSKEN CH, 1990, AM REV RESPIR DIS, V142, P563, DOI 10.1164/ajrccm/142.3.563; BUFFLER PA, 1988, AM J EPIDEMIOL, V128, P683, DOI 10.1093/oxfordjournals.aje.a115022; CANVOW BW, 1978, ENV HLTH PERSPECT, V22, P17; CARROLL R, 1961, BRIT J CANCER, V15, P215, DOI 10.1038/bjc.1961.27; COSIO MG, 1980, AM REV RESPIR DIS, V122, P265; Cosio MG, 1977, NEW ENGL J MED, V298, P1277; EVERINGHAM R, 1991, TOBACCO LITIGATION A; Field W E, 1966, Br J Dis Chest, V60, P66, DOI 10.1016/S0007-0971(66)80002-5; FORD AB, 1980, ARCH ENVIRON HEALTH, V35, P350; GLANTZ SA, 1991, CIRCULATION, V83, P1, DOI 10.1161/01.CIR.83.1.1; HAMMOND EC, 1980, PREV MED, V9, P206, DOI 10.1016/0091-7435(80)90077-8; HENDERSON BE, 1975, AM J EPIDEMIOL, V101, P477, DOI 10.1093/oxfordjournals.aje.a112118; HIRAYAMA T, 1981, BRIT MED J, V282, P183, DOI 10.1136/bmj.282.6259.183; JANERICH DT, 1990, NEW ENGL J MED, V323, P632, DOI 10.1056/NEJM199009063231003; KALANDIDI A, 1990, CANCER CAUSE CONTROL, V1, P15, DOI 10.1007/BF00053179; KATSOUYANNI K, 1991, PREV MED, V20, P271, DOI 10.1016/0091-7435(91)90026-Z; LEE PN, 1987, TOXICOL LETT, V35, P157, DOI 10.1016/0378-4274(87)90102-0; LEE PN, 1987, HUM TOXICOL, V6, P517, DOI 10.1177/096032718700600612; MATANOSKI GM, 1981, ENVIRON RES, V25, P8, DOI 10.1016/0013-9351(81)90076-1; Mollo F, 1981, Pathologica, V73, P185; MULLEN JBM, 1986, AM REV RESPIR DIS, V133, P120, DOI 10.1164/arrd.1986.133.1.120; Pershagen G, 1990, EUROPEAN SCH ONCOLOG, P63; REID LYNNE, 1960, THORAX, V15, P132, DOI 10.1136/thx.15.2.132; RIBOLI E, 1990, CANCER CAUSE CONTROL, V1, P243, DOI 10.1007/BF00117476; SARACCI R, 1989, MUTAT RES, V22, P117; SOLOMON MD, 1990, MODERN PATHOL, V3, P684; TANNENBAUM A, 1970, INT J CANCER, V5, P282, DOI 10.1002/ijc.2910050217; THURLBECK WM, 1988, PATHOLOGY LUNG, P529; TRICHOPOULOS D, 1981, INT J CANCER, V27, P1, DOI 10.1002/ijc.2910270102; TRICHOPOULOS D, 1988, SCAND J SOC MED, V16, P75, DOI 10.1177/140349488801600203; VENA JE, 1982, AM J EPIDEMIOL, V116, P42, DOI 10.1093/oxfordjournals.aje.a113401; VINE MF, 1990, AM J EPIDEMIOL, V131, P781, DOI 10.1093/oxfordjournals.aje.a115569; VUTUC C, 1984, PREV MED, V13, P698, DOI 10.1016/S0091-7435(84)80019-5; WALD NJ, 1986, BMJ-BRIT MED J, V293, P1217, DOI 10.1136/bmj.293.6556.1217; WEINBERG GB, 1982, AM J EPIDEMIOL, V115, P40, DOI 10.1093/oxfordjournals.aje.a113278; WELLS AJ, 1991, AM J EPIDEMIOL, V133, P208, DOI 10.1093/oxfordjournals.aje.a115859; WHIMSTER W F, 1988, Applied Pathology, V6, P241; WRIGHT JL, 1984, AM REV RESPIR DIS, V129, P989; WRIGHT JL, 1985, ARCH PATHOL LAB MED, V109, P163; ZU ZY, 1989, J NATL CANCER I, V81, P1800; 1985, PHS DHHS CDC87839833	50	48	49	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 7	1992	268	13					1697	1701		10.1001/jama.268.13.1697	http://dx.doi.org/10.1001/jama.268.13.1697			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JQ376	1527879				2022-12-01	WOS:A1992JQ37600031
J	BAIRD, EA; MCHENRY, PM; MACKIE, RM				BAIRD, EA; MCHENRY, PM; MACKIE, RM			EFFECT OF MAINTENANCE CHEMOTHERAPY IN CHILDHOOD ON NUMBERS OF MELANOCYTIC NEVI	BRITISH MEDICAL JOURNAL			English	Article							MALIGNANT-MELANOMA; RISK-FACTOR; NEVI	Objective-(a) To determine whether children given chemotherapy for haematological malignancy have significantly more melanocytic naevi than age matched children in the local population; (b) to establish whether any observed variation in naevus counts from normal is seen at the start of maintenance chemotherapy. Design-Follow up of 29 consecutive children starting maintenance chemotherapy, with parental interview and count of all melanocytic naevi greater-than-or-equal-to 2 mm on the child's skin. Assessment repeated three years later after completion of maintenance chemotherapy. Other dermatological problems identified at either visit were also recorded. Setting-Royal Hospital for Sick Children, Glasgow. Results-At the start of maintenance chemotherapy all children had total body counts of melanocytic naevi within the normal range established for age matched children in the local population. Three years later total body naevus counts were significantly increased, the median increase being 66 naevi per child (95% confidence interval 57 to 94). The only other problem noted in these children was relatively poor regrowth of scalp hair. Conclusion-Children on maintenance chemotherapy for haematological malignancies develop an excessive number of melanocytic naevi. Excessive numbers of melanocytic naevi are the most important risk factor for melanoma in the general population. These children should have periodic skin examinations at their follow up visits, and both child and parent should be educated about clinical features of early melanoma.	UNIV GLASGOW,ROYAL HOSP SICK CHILDREN,DEPT DERMATOL,GLASGOW G12 8QQ,SCOTLAND	University of Glasgow								DEWIT PEJ, 1990, MED PEDIATR ONCOL, V18, P336, DOI 10.1002/mpo.2950180417; GALLAGHER RP, 1990, ARCH DERMATOL, V126, P770, DOI 10.1001/archderm.126.6.770; HOLLY EA, 1987, J AM ACAD DERMATOL, V17, P459, DOI 10.1016/S0190-9622(87)70230-8; HUGHES BR, 1989, BMJ-BRIT MED J, V299, P88, DOI 10.1136/bmj.299.6691.88; MACKIE RM, 1985, BRIT J DERMATOL, V113, P167, DOI 10.1111/j.1365-2133.1985.tb02060.x; MACKIE RM, 1989, LANCET, V2, P487; OSTERLIND A, 1988, INT J CANCER, V42, P200, DOI 10.1002/ijc.2910420210; SWERDLOW AJ, 1986, BRIT MED J, V292, P1555, DOI 10.1136/bmj.292.6535.1555	8	39	39	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 3	1992	305	6857					799	801		10.1136/bmj.305.6857.799	http://dx.doi.org/10.1136/bmj.305.6857.799			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT256	1422359	Green Submitted, Green Published, Bronze			2022-12-01	WOS:A1992JT25600019
J	CRAIG, PS; LIU, DS; MACPHERSON, CNL; SHI, DZ; REYNOLDS, D; BARNISH, G; GOTTSTEIN, B; WANG, ZR				CRAIG, PS; LIU, DS; MACPHERSON, CNL; SHI, DZ; REYNOLDS, D; BARNISH, G; GOTTSTEIN, B; WANG, ZR			A LARGE FOCUS OF ALVEOLAR ECHINOCOCCOSIS IN CENTRAL CHINA	LANCET			English	Article							HYDATID-DISEASE; CYSTIC ECHINOCOCCOSIS; MULTILOCULARIS; ALBENDAZOLE; INFECTION; POPULATION; REGION	Human alveolar echinococcosis (AE) is a rare and highly pathogenic helminthic zoonosis due to infection with the intermediate stage of the small fox tapeworm, Echinococcus multilocularis. Parasite transmission is restricted to northern latitudes, including central and north China, from where few clinical and no detailed community studies have been reported. In August, 1991, 65 (5%) of 1312 people residing in three rural communes of Zhang County, Gansu Province, China were diagnosed as having hepatic AE after mass ultrasound scanning with serological back-up. This represents one of the highest prevalence rates of AE ever recorded. It is also the first time that mass ultrasound scanning and serology have been used together in an AE endemic region. The region was selected one year earlier, when a preliminary serosurvey on 606 unselected people in the same locality resulted in an 8.8% serum antibody positive rate with a 76% rate of confirmation of hepatic AE in 37 individuals who could be followed up in 1991. Seropositivity rates varied for villages between 0 and 20.5%. Overall, females (7.8%) had a significantly greater risk of infection than males (2.5%), especially in the 31-50 age group, a difference which may be related to contact with dogs and dog faeces over many years. Age-specific prevalence of AE increased from 0% in the under-5-year group to 8.2% in those aged 31-50. The youngest case was 11 years and the mean age of diagnosis was 40 years. Adult tapeworms of E multilocularis were identified from the small intestines of 10% of domestic dogs. Sylvatic animal hosts of the parasite have not yet been identified. The high prevalence of human AE in this region of central China is most probably due to semi-domestic transmission of E multilocularis between wild rodents and dogs, together with the poverty and poor hygiene in these rural communities.	LANZHOU MED COLL, DEPT PARASITOL, LANZHOU, PEOPLES R CHINA; UNIV W INDIES, FAC MED, SCH VET MED, ST AUGUSTINE, TRINIDAD TOBAGO; UNIV LIVERPOOL, LIVERPOOL SCH TROP MED, LIVERPOOL L3 5QA, ENGLAND; UNIV ZURICH, INST PARASITOL, CH-8006 ZURICH, SWITZERLAND; PUBL HLTH BUR, Ganzhou, PEOPLES R CHINA	Lanzhou University; University West Indies Mona Jamaica; University West Indies Saint Augustine; Liverpool School of Tropical Medicine; University of Liverpool; University of Zurich	CRAIG, PS (corresponding author), UNIV SALFORD, DEPT BIOL SCI, SALFORD M5 4WT, LANCS, ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AUER H, 1991, PARASITOL RES, V77, P430, DOI 10.1007/BF00931640; BCHIR A, 1991, ACTA TROP, V49, P149, DOI 10.1016/0001-706X(91)90062-O; BRESSONHADNI S, 1991, HEPATOLOGY, V13, P1061, DOI 10.1002/hep.1840130610; CHI P, 1990, TROP MED PARASITOL, V41, P157; COLTORTI E, 1988, T ROY SOC TROP MED H, V82, P607, DOI 10.1016/0035-9203(88)90527-5; CRAIG PS, 1991, PARASITOL TODAY, V7, P46, DOI 10.1016/0169-4758(91)90188-T; DIDIER D, 1985, RADIOLOGY, V154, P179, DOI 10.1148/radiology.154.1.3880602; GOTTSTEIN B, 1987, T ROY SOC TROP MED H, V81, P960, DOI 10.1016/0035-9203(87)90365-8; GOTTSTEIN B, 1985, LANCET, V1, P1097; GOTTSTEIN B, 1991, 15TH EXTR C CEL 50 Y, P831; GROVE DI, 1990, HIST HUMAN HELMINTHO, P343; Habluetzel A., 1989, Transactions of the Royal Society of Tropical Medicine and Hygiene, V83, P15, DOI 10.1016/0035-9203(89)90597-X; HORTON RJ, 1989, T ROY SOC TROP MED H, V83, P97, DOI 10.1016/0035-9203(89)90724-4; JIANG C, 1991, CHIN END DIS B, V6, P82; JIANG CP, 1981, CHINESE MED J-PEKING, V94, P771; LU YQ, 1988, CHIN J ULTRASOUND ME, V4, P78; MACPHERSON CNL, 1987, LANCET, V2, P259; MATOSSIAN RM, 1977, B WORLD HEALTH ORGAN, V55, P499; PODOPRIGORA GI, UNPUB WHO GUIDELINES; Rausch R.L., 1986, P44; RAUSCH RL, 1990, ANN TROP MED PARASIT, V84, P239, DOI 10.1080/00034983.1990.11812463; ROGAN MT, 1991, T ROY SOC TROP MED H, V85, P773, DOI 10.1016/0035-9203(91)90451-4; Schantz P.M., 1986, P69; SCHANTZ PM, 1991, PARASITOL TODAY, V7, P35, DOI 10.1016/0169-4758(91)90185-Q; STEHRGREEN JK, 1988, AM J TROP MED HYG, V38, P380, DOI 10.4269/ajtmh.1988.38.380; TODOROV T, 1988, T ROY SOC TROP MED H, V82, P453, DOI 10.1016/0035-9203(88)90161-7; Vuitton D, 1990, Hepatology, V12, P617, DOI 10.1002/hep.1840120329; WATSONJONES DL, 1988, ANN TROP MED PARASIT, V82, P343, DOI 10.1080/00034983.1988.11812256; WEN H, 1990, CHIN MED J, V70, P47; WILSON JF, 1987, AM J TROP MED HYG, V37, P162, DOI 10.4269/ajtmh.1987.37.162; WILSON JF, 1980, AM J TROP MED HYG, V29, P1340, DOI 10.4269/ajtmh.1980.29.1340; YAO P, 1965, CHINESE J SURG, V13, P461; 1987, LANCET, V1, P21; 1981, GUIDELINES ECHINOCOC	34	147	157	1	16	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 3	1992	340	8823					826	831		10.1016/0140-6736(92)92693-A	http://dx.doi.org/10.1016/0140-6736(92)92693-A			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JR168	1357252				2022-12-01	WOS:A1992JR16800012
J	FARQUHARSON, J; COCKBURN, F; PATRICK, WA; JAMIESON, EC; LOGAN, RW				FARQUHARSON, J; COCKBURN, F; PATRICK, WA; JAMIESON, EC; LOGAN, RW			INFANT CEREBRAL-CORTEX PHOSPHOLIPID FATTY-ACID COMPOSITION AND DIET	LANCET			English	Article							MEMBRANE PHOSPHOLIPIDS; HUMAN-BRAIN; LINOLENATE; RATS	It has not been established whether nutrition in early infancy affects subsequent neurodevelopment and function. If there is an effect, it seems probable that the essential fatty acids and their metabolites, the major constituents of brain structure, will be the most susceptible to dietary influence. We determined the phospholipid fatty-acid composition of cerebral cortex grey matter obtained from 20 term and 2 preterm infants who had died of "cot deaths" and related results to the milk diet the infants had received. Tissues were analysed by gas chromotography. The mean weight percentage of docosahexaenoic acid was significantly greater (p < 0.02) in 5 breast-milk-fed infants (9.7%) than in 5 age-comparable formula-milk-fed infants (7.6%). In these formula-fed babies, the overall percentage of long-chain polyunsaturated fatty acids was maintained by increased incorporation of the major n-6 series fatty acids. In 1 formula-fed preterm infant, in whom the lowest concentration of cortical docosahexaenoic acid was found, the compensatory effect was only partial with both n-9 series eicosatrienoic acid or Mead acid and docosatrienoic acid also detected in the phospholipid. Supplementation of formula milks for term infants with docosahexaenoic acid and those for preterm infants with both docosahexaenoic and arachidonic acid could prove beneficial to subsequent neurodevelopment.	UNIV GLASGOW,DEPT CHILD HLTH,GLASGOW G12 8QQ,SCOTLAND; UNIV GLASGOW,DEPT BIOCHEM,GLASGOW G12 8QQ,SCOTLAND; ROYAL HOSP SICK CHILDREN,DEPT PATHOL,GLASGOW G3 8SJ,SCOTLAND	University of Glasgow; University of Glasgow; University of Glasgow								ANDERSON GJ, 1990, PEDIATR RES, V27, P89, DOI 10.1203/00006450-199001000-00023; ANDING RH, 1986, LIPIDS, V21, P697, DOI 10.1007/BF02537243; CARLSON SE, 1986, J NUTR, V116, P718, DOI 10.1093/jn/116.5.718; CLANDININ M T, 1981, Progress in Lipid Research, V20, P901, DOI 10.1016/0163-7827(81)90168-5; CLANDININ MT, 1980, EARLY HUM DEV, V4, P121, DOI 10.1016/0378-3782(80)90015-8; Crawford M A, 1977, Adv Exp Med Biol, V83, P135; FOLCH J, 1957, J BIOL CHEM, V226, P497; HARANT I, 1990, JPEN-PARENTER ENTER, V14, P42, DOI 10.1177/014860719001400142; LUCAS A, 1992, LANCET, V339, P261, DOI 10.1016/0140-6736(92)91329-7; MARTINEZ M, 1974, PEDIATR RES, V8, P93, DOI 10.1203/00006450-197402000-00005; OBRIEN JS, 1965, J LIPID RES, V6, P545; SVENNERHOLM L, 1973, BRAIN RES, V50, P341, DOI 10.1016/0006-8993(73)90735-X; YAMAMOTO N, 1987, J LIPID RES, V28, P144; 1991, ACTA PAEDIATR SCAND, V80, P887; 1977, DHSS12 REP	15	453	478	0	28	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 3	1992	340	8823					810	813		10.1016/0140-6736(92)92684-8	http://dx.doi.org/10.1016/0140-6736(92)92684-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JR168	1357244				2022-12-01	WOS:A1992JR16800003
J	KEANE, DP; ECKFORD, SD; SHEPHERD, AM; ABRAMS, P				KEANE, DP; ECKFORD, SD; SHEPHERD, AM; ABRAMS, P			REFERRAL PATTERNS AND DIAGNOSES IN WOMEN ATTENDING A URODYNAMIC UNIT	BRITISH MEDICAL JOURNAL			English	Article							INCONTINENCE				KEANE, DP (corresponding author), SOUTHMEAD GEN HOSP,URODYNAM UNIT,BRISTOL BS10 5NB,AVON,ENGLAND.							ABRAMS P, 1990, BRIT J OBSTET GYN  S, V6, P1; CARTER PG, 1991, BRIT J UROL, V67, P40, DOI 10.1111/j.1464-410X.1991.tb15066.x; SORENSEN S, 1988, SCAND J UROL NEPHR S, V114, P35; THOMAS TM, 1980, BRIT MED J, V281, P1243, DOI 10.1136/bmj.281.6250.1243; VERSI E, 1991, BRIT J OBSTET GYNAEC, V98, P815, DOI 10.1111/j.1471-0528.1991.tb13488.x	5	17	17	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 3	1992	305	6857					808	808		10.1136/bmj.305.6857.808	http://dx.doi.org/10.1136/bmj.305.6857.808			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT256	1422361	Green Published, Green Submitted, Bronze			2022-12-01	WOS:A1992JT25600022
J	KINSELLA, JP; NEISH, SR; SHAFFER, E; ABMAN, SH				KINSELLA, JP; NEISH, SR; SHAFFER, E; ABMAN, SH			LOW-DOSE INHALATIONAL NITRIC-OXIDE IN PERSISTENT PULMONARY-HYPERTENSION OF THE NEWBORN	LANCET			English	Note								We studied the effects of inhaled nitric oxide (NO) in 9 newborn infants with severe persistent pulmonary hypertension (PPHN) who were candidates for extracorporeal membrane oxygenation treatment. With low doses of NO (10-20 ppm) all showed rapid improvement in oxygenation without reduction of systemic blood pressure. In 6 infants treated with inhaled NO for 24 h, clinical improvement was sustained at 6 ppm.	CHILDRENS HOSP,DEPT PEDIAT,DIV CARDIOL,DENVER,CO 80218; CHILDRENS HOSP,DEPT PEDIAT,DIV PULM MED,DENVER,CO 80218; UNIV COLORADO,SCH MED,DENVER,CO 80202	Children's Hospital Colorado; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	KINSELLA, JP (corresponding author), CHILDRENS HOSP,DEPT PEDIAT,DIV NEONATOL,BOX B-070,1056 E 19TH AVE,DENVER,CO 80218, USA.		Neish, Steven/AAJ-7974-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL046481, R29HL041012, R01HL041012] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-46481, HL-01932, HL-41012] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABMAN SH, 1990, AM J PHYSIOL, V259, pH1921, DOI 10.1152/ajpheart.1990.259.6.H1921; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; IGNARRO LJ, 1989, CIRC RES, V65, P1, DOI 10.1161/01.RES.65.1.1; KINSELLA JP, 1992, J PEDIATR SURG, V27, P44, DOI 10.1016/0022-3468(92)90102-D; KINSELLA JP, AM J PHYSL, V32; LEVIN DL, 1976, J PEDIATR-US, V89, P626, DOI 10.1016/S0022-3476(76)80405-2; PEPKEZABA J, 1991, LANCET, V338, P1173, DOI 10.1016/0140-6736(91)92033-X; ROBERTS JD, 1991, CIRCULATION S2, V84, pA1279	8	592	613	0	10	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 3	1992	340	8823					819	820		10.1016/0140-6736(92)92687-B	http://dx.doi.org/10.1016/0140-6736(92)92687-B			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JR168	1357246				2022-12-01	WOS:A1992JR16800006
J	LEANING, MS; GALLIVAN, S; NEWLANDS, ES; DENT, J; BRAMPTON, M; SMITH, DB; BAGSHAWE, KD				LEANING, MS; GALLIVAN, S; NEWLANDS, ES; DENT, J; BRAMPTON, M; SMITH, DB; BAGSHAWE, KD			COMPUTER-SYSTEM FOR ASSISTING WITH CLINICAL INTERPRETATION OF TUMOR-MARKER DATA	BRITISH MEDICAL JOURNAL			English	Article							HUMAN CHORIONIC-GONADOTROPIN; GERM-CELL TUMORS; HALF-LIFE; PROGNOSTIC-SIGNIFICANCE; INDUCTION CHEMOTHERAPY; OVARIAN-CARCINOMA; CANCER; CA-125; SURVIVAL	Objective-To design and evaluate a computer advisory system for the treatment of gestational trophoblastic tumour. Design-A comparison of clinicians' treatment decisions with those of the computer system. Two datasets were used: one to calibrate the system and one to independently evaluate it. Setting-Department of medical oncology. Patients-Computerised records of 290 patients with low risk gestational trophoblastic tumour for whom the advisory system could predict the adequacy of treatment. The calibration set comprised patients admitted during 1979-86 (227) and the test set patients during 1986-89 (63). Main outcome measures-The system's accuracy in predicting need to change treatment compared with clinicians' actions. The mean time faster that the system was in predicting the need to change treatment. Results-On the calibration dataset the system was 94% (164/174) accurate in predicting patients whose treatment was adequate, recommending change when none occurred in only 10 (6%) patients. In patients whose treatment was changed the system recommended change earlier than clinicians in 39/53 cases (74%), with a mean time advantage of 14.9 (SE 2.02) days. On the test dataset the system had an accuracy of 91% (31/34) in predicting treatment adequacy and a false positive rate of 9% (3/34). The system recommended change earlier than clinicians in 22/29 cases (76%), with a mean time advantage of 12.5 (2.22) days. Conclusions-The computer advisory system could improve patient management by reducing the time spent receiving ineffective treatment. This has implications for both patient time and clinical costs.	CHARING CROSS HOSP,DEPT MED ONCOL,LONDON W6 8RF,ENGLAND	Imperial College London	LEANING, MS (corresponding author), UNIV LONDON UNIV COLL,DEPT STAT SCI,CLIN OPERAT RES UNIT,LONDON WC1E 6BT,ENGLAND.							ARMITAGE P, 1987, STATISTICAL METHODS; BAGSHAWE KD, 1989, BRIT J OBSTET GYNAEC, V96, P795, DOI 10.1111/j.1471-0528.1989.tb03318.x; BAGSHAWE KD, 1976, CANCER, V38, P1373, DOI 10.1002/1097-0142(197609)38:3<1373::AID-CNCR2820380342>3.0.CO;2-E; BARTELS C, 1987, P ECCO, P179; HAWKINS RE, 1989, BRIT J OBSTET GYNAEC, V96, P1395, DOI 10.1111/j.1471-0528.1989.tb06301.x; HUNTER VJ, 1990, AM J OBSTET GYNECOL, V163, P1164, DOI 10.1016/0002-9378(90)90680-6; LANGE PH, 1982, J UROLOGY, V128, P708, DOI 10.1016/S0022-5347(17)53149-3; PICOZZI V, 1985, P AM SOC CLIN ONCOL, V910, P102; PICOZZI VJ, 1984, ANN INTERN MED, V100, P183, DOI 10.7326/0003-4819-100-2-183; RUSTIN GJS, 1989, J CLIN ONCOL, V7, P1667, DOI 10.1200/JCO.1989.7.11.1667; TONER GC, 1990, CANCER RES, V50, P5904; VANDERBURG MEL, 1988, GYNECOL ONCOL, V30, P307, DOI 10.1016/0090-8258(88)90244-2; VOGELZANG NJ, 1982, CANCER RES, V42, P4855	13	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 3	1992	305	6857					804	807		10.1136/bmj.305.6857.804	http://dx.doi.org/10.1136/bmj.305.6857.804			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT256	1330140	Bronze, Green Published, Green Submitted			2022-12-01	WOS:A1992JT25600021
J	LINDSTEDT, S; HOLME, E; LOCK, EA; HJALMARSON, O; STRANDVIK, B				LINDSTEDT, S; HOLME, E; LOCK, EA; HJALMARSON, O; STRANDVIK, B			TREATMENT OF HEREDITARY TYROSINEMIA TYPE-I BY INHIBITION OF 4-HYDROXYPHENYLPYRUVATE DIOXYGENASE	LANCET			English	Article							TYROSINEMIA; SUCCINYLACETONE; DEFICIENCY; LIVER; FORM; ACID	Liver transplantation is the only effective treatment for hereditary tyrosinaemia type I (McKusick 276700). We have treated one acute and four subacute-chronic cases with 2-(2-nitro-4-trifluoro-methylbenzoyl)-1,3-cyclohexanedione (NTBC), a potent inhibitor of 4-hydroxyphenylpyruvate dioxygenase (EC 1.13.11.27), to prevent the formation of maleylacetoacetate and fumarylaceto-acetate and their saturated derivatives. The oral daily dose was 0.1-0.6 mg/kg. The excretion of succinylacetoacetate and succinylacetone decreased from 15-103 mmol/mol creatinine to the detection limit or slightly above (ie, to 20-150 mumol/mol creatinine). The concentration of succinylacetone in plasma decreased from 5.8-43-mumol/l to the detection limit (0.1 mumol/l) over 2-5 months of treatment. The almost complete inhibition of porphobilinogen synthase in erythrocytes was abolished and the excretion of 5-aminolevulinate decreased to within or slightly above the reference range. The concentration of alpha-fetoprotein decreased in four patients to 1.3-7.5% of initially high values over 6-8 months. Improved liver function was reflected by normal concentrations of prothrombin complex and in decreased activities of alkaline phosphatase and gamma-glutamyltransferase in serum. Computed tomography revealed regression of hepatic abnormalities in three patients. One patient developed rickets 6 months before treatment and had excreted high concentrations of markers of tubular dysfunction-after 3 weeks of treatment, this excretion had disappeared. No side-effects were encountered. Inhibition of 4-hydroxyphenylpyruvate dioxygenase may prevent the development of liver cirrhosis and abolish or diminish the risk of liver cancer. Normalisation of porphyrin synthesis will eliminate the risk of porphyric crises. This type of treatment may thus offer an alternative to liver transplantation in hereditary tryosinaemia.	ICI PLC, CENT TOXICOL LAB, MACCLESFIELD SK10 4TG, CHESHIRE, ENGLAND; GOTHENBURG UNIV, DEPT PAEDIAT, S-41124 GOTHENBURG, SWEDEN	University of Gothenburg	LINDSTEDT, S (corresponding author), GOTHENBURG UNIV, SAHLGRENS HOSP, DEPT CLIN CHEM, S-41345 GOTHENBURG, SWEDEN.		Lock, Edward/AAJ-1334-2020					COLLIER HB, 1971, CLIN BIOCHEM, V4, P222, DOI 10.1016/S0009-9120(71)91692-4; Danks DM, 1989, METABOLIC BASIS INHE, P1411; DEBRAEKELEER M, 1990, AM J HUM GENET, V47, P302; ENDO F, 1983, PEDIATR RES, V17, P92, DOI 10.1203/00006450-198302000-00002; GENTZ J, 1969, CLIN CHIM ACTA, V23, P257, DOI 10.1016/0009-8981(69)90040-0; GENTZ J, 1965, J PEDIATR-US, V66, P670, DOI 10.1016/S0022-3476(65)80002-6; GIARDINI O, 1983, PEDIATR RES, V17, P25, DOI 10.1203/00006450-198301000-00005; GRENIER A, 1982, CLIN CHIM ACTA, V123, P93, DOI 10.1016/0009-8981(82)90117-6; GRETER J, 1987, CLIN CHEM, V33, P473; HOLME E, 1992, LANCET, V340, P850, DOI 10.1016/0140-6736(92)92724-T; KUHLER TC, 1985, THESIS GOTHENBURG U; KVITTINGEN EA, 1986, SCAND J CLIN LAB INV, V46, P27; LAHDENNE P, 1991, J PEDIATR-US, V118, P272, DOI 10.1016/S0022-3476(05)80501-3; LINDBLAD B, 1977, P NATL ACAD SCI USA, V74, P4641, DOI 10.1073/pnas.74.10.4641; LINDSTEDT S, 1987, METHOD ENZYMOL, V142, P139; MANOWSKI Z, 1990, MODERN PATHOL, V3, P694; MITCHELL G, 1990, NEW ENGL J MED, V322, P432, DOI 10.1056/NEJM199002153220704; TSCHUDY DP, 1981, J BIOL CHEM, V256, P9915; TUCHMAN M, 1984, J CHROMATOGR SCI, V22, P211, DOI 10.1093/chromsci/22.5.211; VANSPRONSEN FJ, 1991, 29TH P SSIEM ANN S L; WEINBERG AG, 1976, J PEDIATR-US, V88, P434, DOI 10.1016/S0022-3476(76)80259-4	21	475	493	2	27	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 3	1992	340	8823					813	817		10.1016/0140-6736(92)92685-9	http://dx.doi.org/10.1016/0140-6736(92)92685-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JR168	1383656				2022-12-01	WOS:A1992JR16800004
J	MCKEGANEY, N; BARNARD, M; LEYLAND, A; COOTE, I; FOLLET, E				MCKEGANEY, N; BARNARD, M; LEYLAND, A; COOTE, I; FOLLET, E			FEMALE STREETWORKING PROSTITUTION AND HIV-INFECTION IN GLASGOW	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PREVALENCE	Objectives-To identify the extent of HIV infection and injecting drug use among female street-working prostitutes in Glasgow; to estimate the size of the female streetworking prostitute population in the city; and to estimate the number of HIV positive women working as prostitutes on the streets in Glasgow. Design-Observation and interviewing of female prostitutes over seven months in red light district; analysis of sativa samples for presence of antibodies to HIV; capture-recapture approach to estimating the size of the female streetworking prostitute population. Setting-Glasgow. Subjects-206 female streetworking prostitutes. Main outcome measures-Number of women with antibodies to HIV, self reported use of injecting drugs, history of contact with 206 women. Results-Saliva samples were requested from 197 women; 159 (81%) provided samples. Four (2.5%, 95% confidence interval 0.7%-6.3%) of the samples were positive for HIV, all of which had been provided by women who injected drugs. Of the 206 streetworking women contacted 147 (71%) were injecting drug users. About 1150 women are estimated to work on the streets in Glasgow over a 12 month period. Conclusions-HIV is not as widespread among female prostitutes as many reports in the tabloid press suggest. A greater proportion of female street-working prostitutes in Glasgow are injecting drugs than has been reported for other British cities.	RUCHILL HOSP, REG VIRUS LAB, HEPATITIS HIV REFERENCE LAB, GLASGOW G20 9NB, SCOTLAND		MCKEGANEY, N (corresponding author), UNIV GLASGOW, PUBL HLTH RES UNIT, GLASGOW G12 8RZ, SCOTLAND.		Leyland, Alastair/C-6069-2011	Leyland, Alastair/0000-0003-3741-7099				BLOOR M, 1991, BRIT J ADDICT, V86, P1477; CAMERON W, 1990, HETEROSEXUAL TRANSMI; CORMACK RM, 1989, BIOMETRICS, V45, P395, DOI 10.2307/2531485; DAY S, 1988, BRIT MED J, V297, P1585, DOI 10.1136/bmj.297.6663.1585; FRISCHER M, 1991, INT J EPIDEMIOL, V20, P997, DOI 10.1093/ije/20.4.997; FRISCHER M, 1992, LANCET, V339, P995, DOI 10.1016/0140-6736(92)91577-U; HOOK EB, 1992, LANCET, V339, P742, DOI 10.1016/0140-6736(92)90639-K; KINNELL H, 1989, PROSTITUTES THEIR CL; LAPORTE RE, 1992, LANCET, V339, P494, DOI 10.1016/0140-6736(92)91103-F; LEYLAND AH, 1992, JUN INT C SOCIAL SCI; MCKEGANEY N, 1990, AIDS, V4, P1153, DOI 10.1097/00002030-199011000-00017; MCKEGANEY NP, IN PRESS AIDS CARE; PARRY JV, 1987, LANCET, V2, P72, DOI 10.1016/S0140-6736(87)92737-1; TAPPIN DM, 1991, LANCET, V337, P1565; THOMAS RM, 1989, BMJ-BRIT MED J, V299, P148, DOI 10.1136/bmj.299.6692.148; TIRELLI U, 1989, AIDS, V3, P547, DOI 10.1097/00002030-198908000-00015	16	79	80	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 3	1992	305	6857					801	804		10.1136/bmj.305.6857.801	http://dx.doi.org/10.1136/bmj.305.6857.801			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT256	1422360	Green Accepted, Green Published, Bronze, Green Submitted			2022-12-01	WOS:A1992JT25600020
J	MONTEIRO, CA; TORRES, AM				MONTEIRO, CA; TORRES, AM			CAN SECULAR TRENDS IN CHILD GROWTH BE ESTIMATED FROM A SINGLE CROSS-SECTIONAL SURVEY	BRITISH MEDICAL JOURNAL			English	Article							HEIGHT; BOYS	Objective-To formulate and evaluate a new method to measure secular trends in child growth based on the cross sectional collection of heights of children and young adults. Design-Trends in child growth obtained from comparison of two national surveys made with an interval of 15 years were compared with estimates obtained from comparison of height deficits of children and young adults in the more recent survey. Setting-Brazil. Subjects-Random sample of children (6 and 7 years old) and young adults (21 and 22 years old) living in Brazil in 1974 and 1989 (a total of 23 271 subjects in 1974 and 5479 in 1989). Main outcome measures-Increments in average heights of 6 and 7 year old children in a 15 year period. Results-Mean height of 6 year old children increased 4.0 cm (boys) and 3.3 cm (girls) from 1974 to 1989. Similar results were obtained by subtracting, in the 1989 survey, mean height deficits found at ages 21 and 6 (3.8 cm for males and 3.5 cm for females). Positive changes in the mean height of 7 year old children could also be predicted by subtracting, in the 1989 survey, height deficits found at ages 7 and 22. Conclusions-Findings of this study support the hypothesis that secular trends in child growth can be estimated by comparing height deficits observed in children and young adults.	WHO,NUTR UNIT,CH-1211 GENEVA 27,SWITZERLAND; UNIV GENEVA,COMMUNITY HLTH UNIT,CH-1211 GENEVA 4,SWITZERLAND	World Health Organization; University of Geneva			Monteiro, Carlos Augusto/F-9892-2012	Monteiro, Carlos Augusto/0000-0002-3777-1533; Torres-Cantero, Alberto M./0000-0001-5402-1016				BILLEWICZ WZ, 1982, ANN HUM BIOL, V9, P309, DOI 10.1080/03014468200005811; DIBLEY MJ, 1987, AM J CLIN NUTR, V46, P749, DOI 10.1093/ajcn/46.5.749; Eveleth P.B., 1976, WORLDWIDE VARIATION, V8; HAUSPIE RC, 1980, ANN HUM BIOL, V7, P429, DOI 10.1080/03014468000004541; Martorell R., 1990, ANN NESTLE, V48, P85; MONTEIRO CA, 1989, IN PRESS B WHO; SATYANARAYANA K, 1989, ANN HUM BIOL, V16, P289, DOI 10.1080/03014468900000422; Van Wieringen J., 1978, HUMAN GROWTH, P445, DOI [10.1007/978-1-4684-2622-9_16, DOI 10.1007/978-1-4684-2622-9_16]; WATERLOW JC, 1988, NUTRITION WORKSHOP S, V14; 1989, PERFIL ESTATISTICO C; 1989, GLOBAL NUTRITION STA; 1990, APPROPRIATE USES ANT	12	7	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 3	1992	305	6857					797	799		10.1136/bmj.305.6857.797	http://dx.doi.org/10.1136/bmj.305.6857.797			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT256	1422358	Green Published, Green Submitted, Bronze			2022-12-01	WOS:A1992JT25600018
J	MUIR, KW; RODGER, JC; DEBONO, JS; MCDONALD, H; IRVING, JB				MUIR, KW; RODGER, JC; DEBONO, JS; MCDONALD, H; IRVING, JB			DRUGS AND THE EXERCISE TEST	BRITISH MEDICAL JOURNAL			English	Article									MONKLANDS DIST GEN HOSP,AIRDRIE ML6 0JS,LANARK,SCOTLAND; ST JOHNS HOSP,LIVINGSTON,W LOTHIAN,SCOTLAND				Muir, Keith W/A-7670-2011	Muir, Keith W/0000-0001-9535-022X; de Bono, Johann S/0000-0002-2034-595X				AKHRAS F, 1991, LANCET, V338, P1036, DOI 10.1016/0140-6736(91)91900-F; CURTIS JL, 1991, AM HEART J, V121, P1655, DOI 10.1016/0002-8703(91)90009-7; Lollgen H, 1988, Eur Heart J, V9 Suppl K, P3; SCHLANT RC, 1986, CIRCULATION, V74, P653; 1990, ANN INTERN MED, V113, P703	5	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 3	1992	305	6857					808	809		10.1136/bmj.305.6857.808-a	http://dx.doi.org/10.1136/bmj.305.6857.808-a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT256	1301028	Bronze, Green Published, Green Submitted			2022-12-01	WOS:A1992JT25600023
J	ROBERTS, JD; POLANER, DM; LANG, P; ZAPOL, WM				ROBERTS, JD; POLANER, DM; LANG, P; ZAPOL, WM			INHALED NITRIC-OXIDE IN PERSISTENT PULMONARY-HYPERTENSION OF THE NEWBORN	LANCET			English	Note							RELAXING FACTOR	Nitric oxide (NO) has vasodilatory effects on the pulmonary vasculature in adults and animals. We examined the effects on systemic oxygenation and blood pressure of inhaling up to 80 parts per million by volume of NO at F(i)O2 0.9 for up to 30 minutes by 6 infants with persistent pulmonary hypertension of the newborn (PPHN). In all infants this treatment rapidly and significantly increased preductal oxygen saturation (SpO2); in 5 infants postductal SpO2 and oxygen tensions also increased. Inhalation of NO did not cause systemic hypotension or raise methaemoglobin. These data suggest that low levels of inhaled NO have an important role in the reversal of hypoxaemia due to PPHN.	MASSACHUSETTS GEN HOSP,DEPT PEDIAT,BOSTON,MA 02114	Harvard University; Massachusetts General Hospital	ROBERTS, JD (corresponding author), MASSACHUSETTS GEN HOSP,DEPT ANESTHESIA,BOSTON,MA 02114, USA.		Polaner, David M/AAX-2514-2021	Polaner, David M/0000-0001-8716-6289	NHLBI NIH HHS [HL 42397] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042397] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CLUTTONBROCK J, 1967, BRIT J ANAESTH, V39, P388, DOI 10.1093/bja/39.5.388; FROSTELL C, 1991, CIRCULATION, V83, P2038, DOI 10.1161/01.CIR.83.6.2038; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; JANSSENS SP, 1992, J BIOL CHEM, V267, P14519; PALMER RMJ, 1988, NATURE, V333, P664, DOI 10.1038/333664a0; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PEPKEZABA J, 1991, LANCET, V338, P1173, DOI 10.1016/0140-6736(91)92033-X; ROBERTS J D JR, 1992, American Review of Respiratory Disease, V145, pA208	8	693	719	0	14	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 3	1992	340	8823					818	819		10.1016/0140-6736(92)92686-A	http://dx.doi.org/10.1016/0140-6736(92)92686-A			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JR168	1357245				2022-12-01	WOS:A1992JR16800005
J	ALCAMI, A; SMITH, GL				ALCAMI, A; SMITH, GL			A SOLUBLE RECEPTOR FOR INTERLEUKIN-1-BETA ENCODED BY VACCINIA VIRUS - A NOVEL MECHANISM OF VIRUS MODULATION OF THE HOST RESPONSE TO INFECTION	CELL			English	Article							TUMOR-NECROSIS-FACTOR; INVERTED TERMINAL REPEAT; IL-1 RECEPTOR; BIOLOGICAL CHARACTERIZATION; IMMUNOGLOBULIN SUPERFAMILY; NUCLEOTIDE-SEQUENCE; B-CELLS; ANTAGONIST; EXPRESSION; BINDING	Vaccinia virus gene B15R is shown to encode an abundant, secretory glycoprotein that functions as a soluble interleukin-1 (IL-1) receptor. This IL-1 receptor has novel specificity since, in contrast with cellular counterparts, it binds only IL-1beta and not IL-1alpha or the natural competitor IL-1 receptor antagonist. The vaccinia IL-1beta receptor is secreted when expressed in a baculovirus system and competitively inhibited binding of IL-1beta to the natural receptor on T cells. Deletion of B15R from vaccinia virus accelerated the appearance of symptoms of illness and mortality in intranasally infected mice, suggesting that the blockade of IL-1beta by vaccinia virus can diminish the systemic acute phase response to infection and modulate the severity of the disease. The IL-1beta binding activity is present in other orthopoxviruses.			ALCAMI, A (corresponding author), UNIV OXFORD, SIR WILLIAM DUNN SCH PATHOL, OXFORD OX1 3RE, ENGLAND.		Smith, Geoffrey L/G-2894-2012; Alcami, Antonio/F-8512-2015	Alcami, Antonio/0000-0002-3333-6016; Smith, Geoffrey L/0000-0002-3730-9955	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AGUADO B, 1992, CELL, V73; ALEXANDER HR, 1991, J EXP MED, V173, P1029, DOI 10.1084/jem.173.4.1029; BENJAMIN D, 1990, J BIOL CHEM, V265, P9943; BREDER CD, 1988, SCIENCE, V240, P321, DOI 10.1126/science.3258444; BROWN M, 1977, J GEN VIROL, V36, P361, DOI 10.1099/0022-1317-36-2-361; BULLER RML, 1991, MICROBIOL REV, V55, P80, DOI 10.1128/MMBR.55.1.80-122.1991; BUSBRIDGE NJ, 1989, BIOCHEM BIOPH RES CO, V162, P591, DOI 10.1016/0006-291X(89)92351-6; CARTER DB, 1990, NATURE, V344, P633, DOI 10.1038/344633a0; DIGIOVINE FS, 1990, IMMUNOL TODAY, V11, P13; DINARELLO CA, 1989, ADV IMMUNOL, V44, P153, DOI 10.1016/S0065-2776(08)60642-2; DINARELLO CA, 1991, IMMUNOL TODAY, V12, P404, DOI 10.1016/0167-5699(91)90142-G; DINARELLO CA, 1988, FASEB J, V2, P108, DOI 10.1096/fasebj.2.2.3277884; DOWER SK, 1985, J EXP MED, V162, P501, DOI 10.1084/jem.162.2.501; DOWER SK, 1989, J IMMUNOL, V142, P4314; DOWER SK, 1987, IMMUNOL TODAY, V8, P46, DOI 10.1016/0167-5699(87)90238-6; DRIPPS DJ, 1991, J BIOL CHEM, V266, P20311; DUFF GW, 1983, NATURE, V304, P449, DOI 10.1038/304449a0; EISENBERG SP, 1990, NATURE, V343, P341, DOI 10.1038/343341a0; ESPOSITO J, 1981, J VIROL METHODS, V2, P175, DOI 10.1016/0166-0934(81)90036-7; FALKNER FG, 1990, J VIROL, V64, P3108, DOI 10.1128/JVI.64.6.3108-3111.1990; FANSLOW WC, 1990, SCIENCE, V248, P739, DOI 10.1126/science.2139736; Fenner F., 1988, SMALLPOX ITS ERADICA; GERSHENWALD JE, 1990, P NATL ACAD SCI USA, V87, P4966, DOI 10.1073/pnas.87.13.4966; GINSBERG HS, 1989, P NATL ACAD SCI USA, V86, P3823, DOI 10.1073/pnas.86.10.3823; GIRI JG, 1990, J BIOL CHEM, V265, P17416; GOEBEL SJ, 1990, VIROLOGY, V179, P247, DOI 10.1016/0042-6822(90)90294-2; GOODING LR, 1988, CELL, V53, P341, DOI 10.1016/0092-8674(88)90154-7; GRANOWITZ EV, 1991, J BIOL CHEM, V266, P14147; HANNUM CH, 1990, NATURE, V343, P336, DOI 10.1038/343336a0; HARLOW E, 1988, ANTIBODIES LABORATOR; HAZUDA DJ, 1988, J BIOL CHEM, V263, P8473; HOWARD ST, 1991, VIROLOGY, V180, P633, DOI 10.1016/0042-6822(91)90077-O; HSU DH, 1990, SCIENCE, V250, P830, DOI 10.1126/science.2173142; HUGHES SJ, 1991, J BIOL CHEM, V266, P20103; IKUTA K, 1980, J GEN VIROL, V47, P227, DOI 10.1099/0022-1317-47-1-227; ISAACS SN, 1990, VIROLOGY, V178, P626, DOI 10.1016/0042-6822(90)90367-Z; KATSUURA G, 1988, BIOCHEM BIOPH RES CO, V156, P61, DOI 10.1016/S0006-291X(88)80805-2; KENT RK, 1988, THESIS U CAMBRIDGE C; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARRICK JW, 1989, IMMUNOL TODAY, V10, P61, DOI 10.1016/0167-5699(89)90308-3; LUCKOW VA, 1988, BIO-TECHNOL, V6, P47, DOI 10.1038/nbt0188-47; MACDONALD HR, 1985, J IMMUNOL, V135, P3944; Mackett M., 1985, DNA CLONING PRACTICA, P191; MCINTYRE KW, 1991, J EXP MED, V173, P931, DOI 10.1084/jem.173.4.931; MCMAHAN CJ, 1991, EMBO J, V10, P2821, DOI 10.1002/j.1460-2075.1991.tb07831.x; MOORE JB, 1992, EMBO J, V11, P1973, DOI 10.1002/j.1460-2075.1992.tb05251.x; MOSS B, 1990, ANNU REV BIOCHEM, V59, P661, DOI 10.1146/annurev.biochem.59.1.661; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NEURATH AR, 1992, J EXP MED, V175, P461, DOI 10.1084/jem.175.2.461; OHLSSON K, 1990, NATURE, V348, P550, DOI 10.1038/348550a0; PERKUS ME, 1991, VIROLOGY, V180, P406, DOI 10.1016/0042-6822(91)90047-F; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; ROMANCZUK H, 1992, P NATL ACAD SCI USA, V89, P3159, DOI 10.1073/pnas.89.7.3159; Sambrook J., 1989, MOL CLONING LAB MANU; SHIELDS J, 1991, CLIN BIOTECHNOL, V3, P81; SIMS JE, 1989, P NATL ACAD SCI USA, V86, P8946, DOI 10.1073/pnas.86.22.8946; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; SMITH CA, 1991, BIOCHEM BIOPH RES CO, V176, P335, DOI 10.1016/0006-291X(91)90929-2; SMITH GL, 1991, J GEN VIROL, V72, P511, DOI 10.1099/0022-1317-72-3-511; SMITH GL, 1991, J GEN VIROL, V72, P1349, DOI 10.1099/0022-1317-72-6-1349; SPRIGGS MK, 1992, CELL, V71, P145, DOI 10.1016/0092-8674(92)90273-F; SYMONS J A, 1990, Cytokine, V2, P190, DOI 10.1016/1043-4666(90)90015-L; SYMONS JA, 1991, J EXP MED, V174, P1251, DOI 10.1084/jem.174.5.1251; SYMONS JA, 1990, FEBS LETT, V272, P133, DOI 10.1016/0014-5793(90)80466-V; TAGA T, 1987, J EXP MED, V166, P967, DOI 10.1084/jem.166.4.967; TRAKTMAN P, 1990, CURR TOP MICROBIOL, V163, P93; Turner G S, 1967, J Gen Virol, V1, P399, DOI 10.1099/0022-1317-1-3-399; TURNER PC, 1990, CURR TOP MICROBIOL, V163, P125; UEDA Y, 1972, VIROLOGY, V49, P794, DOI 10.1016/0042-6822(72)90535-1; UEDA Y, 1990, VIROLOGY, V177, P588, DOI 10.1016/0042-6822(90)90524-U; UEHARA A, 1987, BIOCHEM BIOPH RES CO, V146, P1286, DOI 10.1016/0006-291X(87)90788-1; UPTON C, 1991, VIROLOGY, V184, P370, DOI 10.1016/0042-6822(91)90853-4; URDAL DL, 1988, J BIOL CHEM, V263, P2870; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; WILLIAMSON JD, 1990, J GEN VIROL, V71, P2761, DOI 10.1099/0022-1317-71-11-2761; ZUIDEMA D, 1990, J GEN VIROL, V71, P2201, DOI 10.1099/0022-1317-71-10-2201; [No title captured]	78	425	439	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 2	1992	71	1					153	167		10.1016/0092-8674(92)90274-G	http://dx.doi.org/10.1016/0092-8674(92)90274-G			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JQ623	1394428				2022-12-01	WOS:A1992JQ62300015
J	BORGSTAHL, GEO; PARGE, HE; HICKEY, MJ; BEYER, WF; HALLEWELL, RA; TAINER, JA				BORGSTAHL, GEO; PARGE, HE; HICKEY, MJ; BEYER, WF; HALLEWELL, RA; TAINER, JA			THE STRUCTURE OF HUMAN MITOCHONDRIAL MANGANESE SUPEROXIDE-DISMUTASE REVEALS A NOVEL TETRAMERIC INTERFACE OF 2 4-HELIX BUNDLES	CELL			English	Article							TUMOR NECROSIS FACTOR; OXIDATIVE DAMAGE; ESCHERICHIA-COLI; THERMUS-THERMOPHILUS; PSEUDOMONAS-OVALIS; OXYGEN RADICALS; CDNA SEQUENCE; CYTO-TOXICITY; RESOLUTION; EXPRESSION	The 2.2 angstrom resolution crystal structure of recombinant human manganese superoxide dismutase, a homotetrameric enzyme that protects mitochondria against oxygen-mediated free radical damage, has been determined. Within each subunit, both the N-terminal helical hairpin and C-terminal alpha/beta domains contribute ligands to the catalytic manganese site. Two identical 4-helix bundles, symmetrically assembled from the N-terminal helical hairpins, form novel tetrameric interfaces that stabilize the active sites. Structurally altered polymorphic variants with reduced activity, such as tetrameric interface mutant Ile-58 to Thr, may produce not only an early selective advantage, through enhanced cytotoxicity of tumor necrosis factor for virus-infected cells, but also detrimental effects from increased mitochondrial oxidative damage, contributing to degenerative conditions, including diabetes, aging, and Parkinson's and Alzheimer's diseases.	DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA	Duke University	BORGSTAHL, GEO (corresponding author), SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA.		Borgstahl, Gloria/AAZ-4114-2020; Tainer, John/GWQ-4878-2022	Tainer, John/0000-0003-1659-2429	NIGMS NIH HHS [GM39345] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039345] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADELMAN R, 1988, P NATL ACAD SCI USA, V85, P2706, DOI 10.1073/pnas.85.8.2706; ALLISON AC, 1956, SCI AM, V195, P87, DOI 10.1038/scientificamerican0856-87; AMES BN, 1983, SCIENCE, V221, P1256, DOI 10.1126/science.6351251; BALLINGER SW, 1992, NAT GENET, V1, P11, DOI 10.1038/ng0492-11; BANNER DW, 1987, J MOL BIOL, V196, P657, DOI 10.1016/0022-2836(87)90039-8; BECK Y, 1987, NUCLEIC ACIDS RES, V15, P9076, DOI 10.1093/nar/15.21.9076; BECK Y, 1988, BIO-TECHNOL, V6, P930, DOI 10.1038/nbt0888-930; BEEM KM, 1976, J MOL BIOL, V105, P327, DOI 10.1016/0022-2836(76)90115-7; BELL GI, 1986, NUCLEIC ACIDS RES, V14, P5561; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BEYER W, 1991, PROG NUCLEIC ACID RE, V40, P221; BEYER WF, 1987, BIOCHEMISTRY-US, V26, P1251, DOI 10.1021/bi00379a008; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CAMPBELL IL, 1988, J IMMUNOL, V141, P2325; CARLIOZ A, 1988, J BIOL CHEM, V263, P1555; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CERUTTI PA, 1985, SCIENCE, V227, P375, DOI 10.1126/science.2981433; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; CHURCH SL, 1990, BIOCHIM BIOPHYS ACTA, V1087, P250, DOI 10.1016/0167-4781(90)90213-L; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985; CROUCH RK, 1981, DIABETES, V30, P235, DOI 10.2337/diab.30.3.235; DEUTSCH HF, 1991, J MOL BIOL, V219, P103, DOI 10.1016/0022-2836(91)90860-9; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; FLOYD RA, 1991, SCIENCE, V254, P1597, DOI 10.1126/science.1684251; FRAGA CG, 1990, P NATL ACAD SCI USA, V87, P4533, DOI 10.1073/pnas.87.12.4533; FRIDOVICH I, 1986, ADV ENZYMOL RAMB, V58, P61; GETZOFF ED, 1992, NATURE, V358, P347, DOI 10.1038/358347a0; GORECKI M, 1991, FREE RADICAL RES COM, V12-3, P401, DOI 10.3109/10715769109145810; HALLEWELL RA, 1989, J BIOL CHEM, V264, P5260; HALLEWELL RA, 1985, NUCLEIC ACIDS RES, V13, P2017, DOI 10.1093/nar/13.6.2017; HALLEWELL RA, 1986, NUCLEIC ACIDS RES, V14, P9539, DOI 10.1093/nar/14.23.9539; HALLIWELL B, 1985, PHILOS T ROY SOC B, V311, P659, DOI 10.1098/rstb.1985.0171; Halliwell B, 1989, FREE RADICAL BIO MED, P22; HARMAN D, 1981, P NATL ACAD SCI-BIOL, V78, P7124, DOI 10.1073/pnas.78.11.7124; HASSAN HM, 1988, FREE RADICAL BIO MED, V5, P377, DOI 10.1016/0891-5849(88)90111-6; HECKL K, 1988, NUCLEIC ACIDS RES, V16, P6224, DOI 10.1093/nar/16.13.6224; HO YS, 1988, FEBS LETT, V229, P256, DOI 10.1016/0014-5793(88)81136-0; HO YS, 1991, AM J RESP CELL MOL, V4, P278, DOI 10.1165/ajrcmb/4.3.278; HOUSSET B, 1981, CLIN RES PROC, V17, P107; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; INGRAM VM, 1957, NATURE, V180, P326, DOI 10.1038/180326a0; KIRBY TW, 1981, ARCH BIOCHEM BIOPHYS, V210, P140, DOI 10.1016/0003-9861(81)90174-0; KRALL J, 1988, J BIOL CHEM, V263, P1910; LUDWIG ML, 1991, J MOL BIOL, V219, P335, DOI 10.1016/0022-2836(91)90569-R; MALAISSE WJ, 1982, P NATL ACAD SCI-BIOL, V79, P927, DOI 10.1073/pnas.79.3.927; MASUDA A, 1988, FASEB J, V2, P3087, DOI 10.1096/fasebj.2.15.3263930; MATSUDA Y, 1990, EUR J BIOCHEM, V194, P713, DOI 10.1111/j.1432-1033.1990.tb19461.x; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MCREE DE, 1990, J BIOL CHEM, V265, P14234; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; MUROHARA Y, 1991, AM J CARDIOL, V67, P765, DOI 10.1016/0002-9149(91)90538-V; NAIN M, 1990, J IMMUNOL, V145, P1921; NAKAZONO K, 1991, P NATL ACAD SCI USA, V88, P10045, DOI 10.1073/pnas.88.22.10045; NAMBA K, 1989, J MOL BIOL, V208, P307, DOI 10.1016/0022-2836(89)90391-4; NATH N, 1984, DIABETES, V33, P586, DOI 10.2337/diabetes.33.6.586; NATVIG DO, 1987, J BIOL CHEM, V262, P14697; NIWA Y, 1990, BLOOD, V76, P835; NOMIKOS IN, 1989, IMMUNOL CELL BIOL, V67, P85, DOI 10.1038/icb.1989.12; OBERLEY LW, 1987, ARCH BIOCHEM BIOPHYS, V254, P69, DOI 10.1016/0003-9861(87)90082-8; ODA T, 1989, SCIENCE, V244, P974, DOI 10.1126/science.2543070; PARGE HE, 1992, P NATL ACAD SCI USA, V89, P6109, DOI 10.1073/pnas.89.13.6109; PARKER MW, 1988, J MOL BIOL, V199, P649, DOI 10.1016/0022-2836(88)90308-7; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; REVEILLAUD I, 1991, MOL CELL BIOL, V11, P632, DOI 10.1128/MCB.11.2.632; Richardson J.S., 1990, PREDICTION PROTEIN S, P1; RICHTER C, 1988, P NATL ACAD SCI USA, V85, P6465, DOI 10.1073/pnas.85.17.6465; SATO S, 1978, J BIOCHEM-TOKYO, V83, P1165, DOI 10.1093/oxfordjournals.jbchem.a132007; SATO S, 1977, EUR J BIOCHEM, V73, P373, DOI 10.1111/j.1432-1033.1977.tb11328.x; SMITH MW, 1992, J MOL EVOL, V34, P175; STALLINGS WC, 1984, J BIOL CHEM, V259, P695; STCLAIR DK, 1991, CANCER RES, V51, P939; STINE OC, 1992, J MOL EVOL, V34, P336; STODDARD BL, 1990, PROTEIN ENG, V4, P113, DOI 10.1093/protein/4.2.113; STODDARD BL, 1990, BIOCHEMISTRY-US, V29, P8885, DOI 10.1021/bi00490a002; TAINER JA, 1982, J MOL BIOL, V160, P181, DOI 10.1016/0022-2836(82)90174-7; TAINER JA, 1991, STUDY ENZYMES, V2, P499; TAYLOR R, 1992, J NIH RES, V4, P62; TOUATI D, 1988, FREE RADICAL BIO MED, V5, P393, DOI 10.1016/0891-5849(88)90113-X; WAGNER UG, 1989, J MOL BIOL, V206, P787, DOI 10.1016/0022-2836(89)90586-X; WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523; WHITE CW, 1991, J CLIN INVEST, V87, P2162, DOI 10.1172/JCI115249; WISPE JR, 1989, BIOCHIM BIOPHYS ACTA, V994, P30, DOI 10.1016/0167-4838(89)90058-7; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; Yoon JW, 1990, CURR TOP MICROBIOL I, V164, P95; ZWEIER JL, 1987, P NATL ACAD SCI USA, V84, P1404, DOI 10.1073/pnas.84.5.1404	86	410	421	2	25	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 2	1992	71	1					107	118		10.1016/0092-8674(92)90270-M	http://dx.doi.org/10.1016/0092-8674(92)90270-M			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JQ623	1394426				2022-12-01	WOS:A1992JQ62300011
J	CLARK, DJ; FELSENFELD, G				CLARK, DJ; FELSENFELD, G			A NUCLEOSOME CORE IS TRANSFERRED OUT OF THE PATH OF A TRANSCRIBING POLYMERASE	CELL			English	Article							RNA-POLYMERASE; TRANSCRIPTIONALLY COMPETENT; CHROMATIN STRUCTURE; DNA-TEMPLATE; II INVITRO; 5S RNA; INITIATION; HISTONES; DISPLACEMENT; ELONGATION	We have determined the fate of a nucleosome core on transcription. A nucleosome core was assembled on a short DNA fragment and ligated into a plasmid containing a promoter and terminators for SP6 RNA polymerase. The nucleosome core was stable in the absence of transcription. The distribution of nucleosome cores after transcription was examined. The histone octamer was displaced from its original site and reformed a nucleosome core at a new site within the same plasmid molecule, with some preference for the untranscribed region behind the promoter. These observations eliminate several models that have been proposed for transcription through a nucleosome core. Our results suggest that a nucleosome core in the path of a transcribing polymerase is displaced by transfer to the closest acceptor DNA.			CLARK, DJ (corresponding author), NIH,MOLEC BIOL LAB,BETHESDA,MD 20892, USA.							BERG OG, 1982, TRENDS BIOCHEM SCI, V7, P52, DOI 10.1016/0968-0004(82)90075-5; BJORKROTH B, 1988, CHROMOSOMA, V96, P333, DOI 10.1007/BF00330699; BONNEANDREA C, 1990, NATURE, V343, P719, DOI 10.1038/343719a0; CAMERON V, 1977, BIOCHEMISTRY-US, V16, P5120, DOI 10.1021/bi00642a027; CARON F, 1981, J MOL BIOL, V146, P513, DOI 10.1016/0022-2836(81)90045-0; CLARK DJ, 1991, EMBO J, V10, P387, DOI 10.1002/j.1460-2075.1991.tb07960.x; DEBERNARDIN W, 1986, J MOL BIOL, V191, P469, DOI 10.1016/0022-2836(86)90142-7; EICKBUSH TH, 1978, BIOCHEMISTRY-US, V17, P4955, DOI 10.1021/bi00616a016; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; FELTS SJ, 1990, MOL CELL BIOL, V10, P2390, DOI 10.1128/MCB.10.5.2390; GIAEVER GN, 1988, CELL, V55, P849, DOI 10.1016/0092-8674(88)90140-7; HAYES JJ, 1990, P NATL ACAD SCI USA, V87, P7405, DOI 10.1073/pnas.87.19.7405; HOROWITZ DS, 1984, J MOL BIOL, V173, P75, DOI 10.1016/0022-2836(84)90404-2; IZBAN MG, 1991, GENE DEV, V5, P683, DOI 10.1101/gad.5.4.683; KAMAKAKA RT, 1990, EMBO J, V9, P3997, DOI 10.1002/j.1460-2075.1990.tb07621.x; KIROV N, 1992, EMBO J, V11, P1941, DOI 10.1002/j.1460-2075.1992.tb05247.x; KNEZETIC JA, 1986, CELL, V45, P95, DOI 10.1016/0092-8674(86)90541-6; KNEZETIC JA, 1988, MOL CELL BIOL, V8, P3114, DOI 10.1128/MCB.8.8.3114; KORNBERG RD, 1991, CELL, V67, P833, DOI 10.1016/0092-8674(91)90354-2; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; LORCH Y, 1987, CELL, V49, P203, DOI 10.1016/0092-8674(87)90561-7; LORCH Y, 1988, CELL, V55, P743, DOI 10.1016/0092-8674(88)90128-6; LOSA R, 1987, CELL, V50, P801, DOI 10.1016/0092-8674(87)90338-2; McKnight S L, 1978, Cold Spring Harb Symp Quant Biol, V42 Pt 2, P741; MCMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835, DOI 10.1073/pnas.74.11.4835; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MORSE RH, 1989, EMBO J, V8, P2343, DOI 10.1002/j.1460-2075.1989.tb08362.x; MORSE RH, 1992, TRENDS BIOCHEM SCI, V17, P23, DOI 10.1016/0968-0004(92)90422-6; NACHEVA GA, 1989, CELL, V58, P27, DOI 10.1016/0092-8674(89)90399-1; ONEILL TE, 1992, J MOL BIOL, V223, P67, DOI 10.1016/0022-2836(92)90716-W; PFAFFLE P, 1990, J BIOL CHEM, V265, P16830; RHODES D, 1985, EMBO J, V4, P3473, DOI 10.1002/j.1460-2075.1985.tb04106.x; RICHMOND TJ, 1984, NATURE, V311, P532, DOI 10.1038/311532a0; RUUSALA T, 1992, P NATL ACAD SCI USA, V89, P4903, DOI 10.1073/pnas.89.11.4903; SHORE D, 1983, J MOL BIOL, V170, P957, DOI 10.1016/S0022-2836(83)80198-3; SPADAFORA C, 1979, EUR J BIOCHEM, V100, P225, DOI 10.1111/j.1432-1033.1979.tb02053.x; STEIN A, 1979, J MOL BIOL, V130, P103, DOI 10.1016/0022-2836(79)90421-2; TENHEGGELERBORDIER B, 1992, EMBO J, V11, P667, DOI 10.1002/j.1460-2075.1992.tb05098.x; THOMA F, 1991, TRENDS GENET, V7, P175, DOI 10.1016/0168-9525(91)90429-T; THOMAS JO, 1975, P NATL ACAD SCI USA, V72, P2626, DOI 10.1073/pnas.72.7.2626; TSAO YP, 1989, CELL, V56, P111, DOI 10.1016/0092-8674(89)90989-6; VANHOLDE KE, 1992, J BIOL CHEM, V267, P2837; VOORDOUW G, 1978, NATURE, V273, P446, DOI 10.1038/273446a0; WILLIAMSON P, 1978, BIOCHEMISTRY-US, V17, P5695, DOI 10.1021/bi00619a015; WOLFFE AP, 1989, P NATL ACAD SCI USA, V86, P9817, DOI 10.1073/pnas.86.24.9817; WOLFFE AP, 1986, CELL, V44, P381, DOI 10.1016/0092-8674(86)90459-9; WOLFFE AP, 1992, CHROMATIN STRUCTURE; WU HY, 1988, CELL, V53, P433, DOI 10.1016/0092-8674(88)90163-8	48	132	133	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 2	1992	71	1					11	22		10.1016/0092-8674(92)90262-B	http://dx.doi.org/10.1016/0092-8674(92)90262-B			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JQ623	1394427				2022-12-01	WOS:A1992JQ62300003
J	CLARK, MR; CAMPBELL, KS; KAZLAUSKAS, A; JOHNSON, SA; HERTZ, M; POTTER, TA; PLEIMAN, C; CAMBIER, JC				CLARK, MR; CAMPBELL, KS; KAZLAUSKAS, A; JOHNSON, SA; HERTZ, M; POTTER, TA; PLEIMAN, C; CAMBIER, JC			THE B-CELL ANTIGEN RECEPTOR COMPLEX - ASSOCIATION OF IG-ALPHA AND IG-BETA WITH DISTINCT CYTOPLASMIC EFFECTORS	SCIENCE			English	Article							PROTEIN TYROSINE PHOSPHORYLATION; SIGNAL TRANSDUCTION; LYMPHOCYTES-B; PDGF RECEPTOR; MEMBRANE IMMUNOGLOBULIN; KINASE; STIMULATION; ANTIIMMUNOGLOBULIN; GENE	The B cell antigen receptor complex is a hetero-oligomeric structure composed of antigen binding, membrane immunoglobulin, and transducer-transporter substructures. The transducer-transporter substructure is composed of disulfide-linked dimers of immunoglobulin (Ig)-alpha and Ig-beta/gamma subunits that are products of the mb-1(alpha) and B29 (beta/gamma) genes. Although the receptor complex associates with Src family kinases that are activated after receptor ligation, the site of interaction of these and other cytoplasmic effector molecules with receptor subunits is unknown. The cytoplasmic tails of Ig-alpha and Ig-beta chains were found to associate with distinct sets of effector molecules. The Ig-alpha chain cytoplasmic domain bound to the Src family kinases Lyn and Fyn, phosphatidylinositol-3 kinase (PI-3 kinase), and an unidentified 38-kilodalton phosphoprotein; the cytoplasmic tail of Ig-beta bound PI-3 kinase and unidentified 40- and 42-kilodalton phosphoproteins. Binding activity was found to occur within a 26-amino acid sequence of Ig-alpha and Ig-beta that contains a motif [(Asp or Glu)-(any amino acid)7-(Asp or Glu)-Tyr-(any amino acid)3-Leu-(any amino acid)7-Tyr-(any amino acid)2-(Leu or Ile)] previously implicated in signal transduction via other receptors including the Fc(epsilon) receptor I and the T cell antigen receptor. These findings indicate that the subunits act independently to activate distinct second messenger pathways.	NATL JEWISH CTR IMMUNOL & RESP MED,DIV BASIC SCI,DENVER,CO 80206; UNIV COLORADO,HLTH SCI CTR,DEPT MICROBIOL & IMMUNOL,DENVER,CO 80206	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver			Campbell, Kerry S./T-1381-2019	Cambier, John/0000-0002-7803-242X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020519, R01AI021768] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K08AR001864] Funding Source: NIH RePORTER; NIAID NIH HHS [AI20519, AI21768] Funding Source: Medline; NIAMS NIH HHS [AR01864] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALARCON B, 1991, EMBO J, V10, P903, DOI 10.1002/j.1460-2075.1991.tb08023.x; Ausubel FM, 1992, CURRENT PROTOCOLS MO; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; CAMBIER J, 1988, P NATL ACAD SCI USA, V85, P6493, DOI 10.1073/pnas.85.17.6493; CAMBIER JC, IN PRESS CURR OPIN I; CAMPBELL K, UNPUB; CAMPBELL KS, 1990, EMBO J, V9, P441, DOI 10.1002/j.1460-2075.1990.tb08129.x; CAMPBELL KS, 1991, P NATL ACAD SCI USA, V88, P3982, DOI 10.1073/pnas.88.9.3982; CAMPBELL KS, 1990, LIGANDS RECEPTORS SI, pCH1; CAMPBELL MA, 1990, EMBO J, V9, P2125, DOI 10.1002/j.1460-2075.1990.tb07381.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARTER RH, 1991, P NATL ACAD SCI USA, V88, P2745, DOI 10.1073/pnas.88.7.2745; CHIEN N, UNPUB; CLARK MW, UNPUB; COGGESHALL KM, IN PRESS P NATL ACAD; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; COUGHLIN SR, 1989, SCIENCE, V243, P1191; FINKEL TH, 1991, IMMUNOL TODAY, V12, P79, DOI 10.1016/0167-5699(91)90162-M; GOLD MR, 1990, NATURE, V345, P810, DOI 10.1038/345810a0; GOLD MR, 1992, J IMMUNOL, V148, P2012; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; JENSEN W, UNPUB J C CAMBIER; JULIUS MH, 1984, EUR J IMMUNOL, V14, P753, DOI 10.1002/eji.1830140816; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KAWAKAMI T, 1988, P NATL ACAD SCI USA, V85, P3870, DOI 10.1073/pnas.85.11.3870; KAZLAUSKAS A, 1991, CELL REGUL, V2, P413, DOI 10.1091/mbc.2.6.413; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; PLEIMAN CM, UNPUB; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; RETH M, 1991, IMMUNOL TODAY, V12, P196, DOI 10.1016/0167-5699(91)90053-V; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; VENKITARAMAN AR, 1991, NATURE, V352, P777, DOI 10.1038/352777a0; WEGENER AMK, 1992, CELL, V68, P83, DOI 10.1016/0092-8674(92)90208-T; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YAMANASHI Y, 1992, P NATL ACAD SCI USA, V89, P1118, DOI 10.1073/pnas.89.3.1118	38	300	311	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 2	1992	258	5079					123	126		10.1126/science.1439759	http://dx.doi.org/10.1126/science.1439759			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JQ619	1439759				2022-12-01	WOS:A1992JQ61900033
J	DURAND, B; SAUNDERS, M; LEROY, P; LEID, M; CHAMBON, P				DURAND, B; SAUNDERS, M; LEROY, P; LEID, M; CHAMBON, P			ALL-TRANS AND 9-CIS RETINOIC ACID INDUCTION OF CRABPII TRANSCRIPTION IS MEDIATED BY RAR-RXR HETERODIMERS BOUND TO DR1 AND DR2 REPEATED MOTIFS	CELL			English	Article							BINDING-PROTEIN GENE; HORMONE RECEPTOR SUPERFAMILY; RESPONSE ELEMENT; MOLECULAR-CLONING; NUCLEAR RECEPTORS; TERATOCARCINOMA CELLS; DIFFERENTIAL PATTERN; NEGATIVE REGULATION; THYROID-HORMONE; MESSENGER-RNA	Two cooperating retinoic acid response elements (RAREs) in the cellular retinoic acid-binding protein II (CRABPII) gene mediate differential transcriptional transactivation by retinoic acid receptors (RARs) and retinoid X receptors (RXRs) in P19 embryonal carcinoma cells. RARE1 and RARE2 are direct repeats (DR) of two motifs separated by 2 bp (DR2) and 1 bp (DR1), respectively, and bind RAR-RXR heterodimers more efficiently than homodimers. Using all-trans and 9-cis RA, which differentially activate RARs and RXRs, and RAR and RXR dominant-negative mutants, RAR-RXR heterodimers bound to RARE1 and RARE2 are shown to be responsible for CRABPII promoter transactivation, arguing against a unique DR spacing specifying recognition by RARs. Within heterodimers, RAR and RXR independently and differentially transactivate, depending on the specific RARE. Consistent with these results, 9-cis RA increases CRABPII mRNA levels more efficiently than all-trans RA. In contrast, all-trans and 9-cis RA have identical effects on induction of RARbeta2 transcripts.			DURAND, B (corresponding author), FAC MED STRASBOURG, INST CHIM BIOL,INSERM,GENET MOLEC EUCARYOTES LAB, CNRS, UNITE 184, F-67085 STRASBOURG, FRANCE.		DURAND, Beatrice C/J-6387-2015	DURAND, Beatrice C/0000-0002-0047-288X				ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ASTROM A, 1991, J BIOL CHEM, V266, P17662; BAILEY JS, 1988, J BIOL CHEM, V263, P9326; BALLING R, 1991, TRENDS GENET, V7, P35; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BLOMHOFF R, 1991, PHYSIOL REV, V71, P951, DOI 10.1152/physrev.1991.71.4.951; BLUMBERG B, 1992, P NATL ACAD SCI USA, V89, P2321, DOI 10.1073/pnas.89.6.2321; BOCQUEL MT, IN PRESS; BOYLAN JF, 1991, J CELL BIOL, V112, P965, DOI 10.1083/jcb.112.5.965; BREITMAN TR, 1981, BLOOD, V57, P1000; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BROCKES J, 1990, NATURE, V345, P766, DOI 10.1038/345766a0; BROCKES JP, 1989, NEURON, V2, P1285, DOI 10.1016/0896-6273(89)90066-4; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; CHAMBON P, 1991, RETINOIDS : 10 YEARS ON, P10; CHODOSH LA, 1988, CELL, V53, P25, DOI 10.1016/0092-8674(88)90484-9; CHYTIL F, 1991, RETINOIDS : 10 YEARS ON, P38; CORDEN J, 1980, SCIENCE, V209, P1406, DOI 10.1126/science.6251548; DE LUCA LM, 1991, FASEB J, V5, P2924; DEMMER LA, 1987, J BIOL CHEM, V262, P2458; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DIDIERJEAN L, 1991, BIOCHEM BIOPH RES CO, V180, P204, DOI 10.1016/S0006-291X(05)81277-X; DOLLE P, 1989, NATURE, V342, P702, DOI 10.1038/342702a0; DOLLE P, 1990, DEVELOPMENT, V110, P1133; DOUER D, 1982, EXP CELL RES, V138, P193, DOI 10.1016/0014-4827(82)90105-7; DUESTER G, 1991, MOL CELL BIOL, V11, P1638, DOI 10.1128/MCB.11.3.1638; ELDER JT, 1992, J INVEST DERMATOL, V98, P673, DOI 10.1111/1523-1747.ep12499896; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GIGUERE V, 1990, P NATL ACAD SCI USA, V87, P6233, DOI 10.1073/pnas.87.16.6233; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HAMADA K, 1989, P NATL ACAD SCI USA, V86, P8289, DOI 10.1073/pnas.86.21.8289; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; KADOWAKI Y, 1992, BIOCHEM BIOPH RES CO, V183, P492, DOI 10.1016/0006-291X(92)90509-J; KASTNER P, 1992, DEV PATTERNING VERTE, P75; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448, DOI 10.1073/pnas.89.4.1448; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KUMAR V, 1986, EMBO J, V5, P2231, DOI 10.1002/j.1460-2075.1986.tb04489.x; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEROY P, 1991, EMBO J, V10, P59, DOI 10.1002/j.1460-2075.1991.tb07921.x; LEROY P, 1991, P NATL ACAD SCI USA, V88, P10138, DOI 10.1073/pnas.88.22.10138; LEROY P, 1992, RETINOIDS NORMAL DEV, P7; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LIBBY PR, 1982, CARCINOGENESIS, V3, P481, DOI 10.1093/carcin/3.5.481; LOTAN R, 1980, BIOCHIM BIOPHYS ACTA, V605, P33, DOI 10.1016/0304-419X(80)90021-9; LUCAS PC, 1991, P NATL ACAD SCI USA, V88, P2184, DOI 10.1073/pnas.88.6.2184; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MADEN M, 1988, NATURE, V335, P733, DOI 10.1038/335733a0; MADEN M, 1989, DEVELOPMENT, V107, P109; Maden M., 1991, SEMIN DEV BIOL, V2, P161; MADER S, 1992, IN PRESS J BIOL CHEM, V267; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MENDELSOHN C, 1992, DEV BIOL, V152, P50, DOI 10.1016/0012-1606(92)90155-A; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; NAGPAL S, 1992, IN PRESS CELL, V70; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; ROBERTSON M, 1987, NATURE, V330, P420, DOI 10.1038/330420a0; ROCHETTEEGLY C, 1991, J CELL BIOL, V115, P535, DOI 10.1083/jcb.115.2.535; ROSENBERGER M, 1992, IN PRESS P NATL ACAD, V89; ROTTMAN JN, 1991, MOL CELL BIOL, V11, P3814, DOI 10.1128/MCB.11.7.3814; ROWE A, 1991, DEVELOPMENT, V111, P771; RUBERTE E, 1991, DEVELOPMENT, V111, P45; Ruberte E., 1991, SEMIN DEV BIOL, V2, P153; RUBERTE E, 1992, IN PRESS DEVELOPMENT; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SAURAT JH, 1990, RETINOIDS 10 YEARS; SHERMAN MI, 1986, RETINOIDS CELL DIFFE; SIEGENTHALER G, 1990, RETINOIDS 10 YEARS, P56; SMITH SM, 1989, DEVELOPMENT, V107, P121; SMITH WC, 1991, EMBO J, V10, P2223, DOI 10.1002/j.1460-2075.1991.tb07758.x; STONER CM, 1989, CANCER RES, V49, P1497; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; SUMMERBELL D, 1990, TRENDS NEUROSCI, V13, P142, DOI 10.1016/0166-2236(90)90006-V; TABIN CJ, 1991, CELL, V66, P199, DOI 10.1016/0092-8674(91)90612-3; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VASIOS G, 1991, EMBO J, V10, P1149, DOI 10.1002/j.1460-2075.1991.tb08055.x; VASIOS GW, 1989, P NATL ACAD SCI USA, V86, P9099, DOI 10.1073/pnas.86.23.9099; WEI LN, 1989, MOL ENDOCRINOL, V3, P454, DOI 10.1210/mend-3-3-454; WEI LN, 1990, DNA CELL BIOL, V9, P471, DOI 10.1089/dna.1990.9.471; WEI LN, 1991, DEVELOPMENT, V112, P847; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZELENT A, 1991, EMBO J, V10, P71, DOI 10.1002/j.1460-2075.1991.tb07922.x; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	91	409	417	2	23	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 2	1992	71	1					73	85		10.1016/0092-8674(92)90267-G	http://dx.doi.org/10.1016/0092-8674(92)90267-G			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JQ623	1327537	Green Published			2022-12-01	WOS:A1992JQ62300008
J	FARCI, P; ALTER, HJ; GOVINDARAJAN, S; WONG, DC; ENGLE, R; LESNIEWSKI, RR; MUSHAHWAR, IK; DESAI, SM; MILLER, RH; OGATA, N; PURCELL, RH				FARCI, P; ALTER, HJ; GOVINDARAJAN, S; WONG, DC; ENGLE, R; LESNIEWSKI, RR; MUSHAHWAR, IK; DESAI, SM; MILLER, RH; OGATA, N; PURCELL, RH			LACK OF PROTECTIVE IMMUNITY AGAINST REINFECTION WITH HEPATITIS-C VIRUS	SCIENCE			English	Article							NON-B-HEPATITIS; EXPERIMENTALLY INFECTED CHIMPANZEES; TRANSFUSION-ASSOCIATED HEPATITIS; NON-A-HEPATITIS; VIRAL-HEPATITIS; ENVELOPE PROTEIN; LONG-TERM; POSTTRANSFUSION HEPATITIS; CROSS-CHALLENGE; HUMAN CARRIERS	Some individuals infected with hepatitis C virus (HCV) experience multiple episodes of acute hepatitis. It is unclear whether these episodes are due to reinfection with HCV or to reactivation of the original virus infection. Markers of viral replication and host immunity were studied in five chimpanzees sequentially inoculated over a period of 3 years with different HCV strains of proven infectivity. Each rechallenge of a convalescent chimpanzee with the same or a different HCV strain resulted in the reappearance of viremia, which was due to infection with the subsequent challenge virus. The evidence indicates that HCV infection does not elicit protective immunity against reinfection with homologous or heterologous strains, which raises concerns for the development of effective vaccines against HCV.	NIH,WARREN G MARGNUSON CLIN CTR,DEPT TRANSFUS MED,BETHESDA,MD 20892; RANCHO LOS AMIGOS MED CTR,DOWNEY,CA 90242; GEORGETOWN UNIV,DEPT MICROBIOL,DIV MOLEC VIROL & IMMUNOL,ROCKVILLE,MD 20852; ABBOTT LABS,EXPTL BIOL RES,N CHICAGO,IL 60064	National Institutes of Health (NIH) - USA; Georgetown University; Abbott Laboratories	FARCI, P (corresponding author), NIAID,INFECT DIS LAB,HEPATITIS VIRUSES SECT,BETHESDA,MD 20892, USA.							AACH RD, 1991, NEW ENGL J MED, V325, P1325, DOI 10.1056/NEJM199111073251901; Aach RD, 1978, VIRAL HEPATITIS, P383; ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; ALTER HJ, 1978, LANCET, V1, P459; Alter HJ, 1978, VIRAL HEPATITIS, P359; ALTER HJ, 1989, CURRENT PERSPECTIVES, P83; BACHMANN B, 1990, NUCLEIC ACIDS RES, V18, P1309, DOI 10.1093/nar/18.5.1309; BENN S, 1985, SCIENCE, V230, P949, DOI 10.1126/science.2997922; BRADLEY DW, 1980, J MED VIROL, V6, P185, DOI 10.1002/jmv.1890060302; BRADLEY DW, 1979, J MED VIROL, V3, P253, DOI 10.1002/jmv.1890030403; BRADLEY DW, 1981, J INFECT DIS, V143, P210, DOI 10.1093/infdis/143.2.210; BROTMAN B, 1985, J INFECT DIS, V151, P618, DOI 10.1093/infdis/151.4.618; BURK KH, 1984, HEPATOLOGY, V4, P808, DOI 10.1002/hep.1840040502; BUUKH J, 1992, P NATL ACAD SCI USA, V89, P187; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; CHOO QL, 1991, P NATL ACAD SCI USA, V88, P2451, DOI 10.1073/pnas.88.6.2451; CRASKE J, 1978, LANCET, V2, P1051; DIENES HP, 1990, J HEPATOL, V10, P77, DOI 10.1016/0168-8278(90)90076-4; DIENSTAG JL, 1983, GASTROENTEROLOGY, V85, P439; Eder G, 1988, VIRAL HEPATITIS LIVE, P550; ESTEBAN JI, 1990, NEW ENGL J MED, V323, P1107, DOI 10.1056/NEJM199010183231605; FARCI P, 1991, NEW ENGL J MED, V325, P98, DOI 10.1056/NEJM199107113250205; FARCI P, 1992, J INFECT DIS, V165, P1006, DOI 10.1093/infdis/165.6.1006; FARCI P, UNPUB; FEINSTONE SM, 1981, J INFECT DIS, V144, P588, DOI 10.1093/infdis/144.6.588; FEINSTONE SM, 1975, NEW ENGL J MED, V292, P767, DOI 10.1056/NEJM197504102921502; GALBRAITH RM, 1979, LANCET, V1, P951; GOVINDARAJAN S, UNPUB; HAN JH, 1991, P NATL ACAD SCI USA, V88, P1711, DOI 10.1073/pnas.88.5.1711; HIJIKATA M, 1991, BIOCHEM BIOPH RES CO, V175, P220, DOI 10.1016/S0006-291X(05)81223-9; HIJIKATA M, 1990, JPN J CANCER RES, V81, P1195, DOI 10.1111/j.1349-7006.1990.tb02676.x; HOLLAND J, 1982, SCIENCE, V215, P1577, DOI 10.1126/science.7041255; HOLLINGER FB, 1980, J INFECT DIS, V142, P400, DOI 10.1093/infdis/142.3.400; HOUGHTON M, 1991, HEPATOLOGY, V14, P381, DOI 10.1016/0270-9139(91)91430-9; HRUBY MA, 1978, JAMA-J AM MED ASSOC, V240, P1355; JAVAHERIAN K, 1989, P NATL ACAD SCI USA, V86, P6768, DOI 10.1073/pnas.86.17.6768; KATO N, 1990, P NATL ACAD SCI USA, V87, P9524, DOI 10.1073/pnas.87.24.9524; KNODELL RG, 1976, LANCET, V1, P557; KORETZ RL, 1985, GASTROENTEROLOGY, V88, P1251, DOI 10.1016/S0016-5085(85)80087-1; KOZIOL DE, 1986, ANN INTERN MED, V104, P488, DOI 10.7326/0003-4819-104-4-488; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; MODROW S, 1987, J VIROL, V61, P570, DOI 10.1128/JVI.61.2.570-578.1987; MOSLEY JW, 1990, JAMA-J AM MED ASSOC, V263, P77, DOI 10.1001/jama.263.1.77; MOSLEY JW, 1977, NEW ENGL J MED, V296, P75, DOI 10.1056/NEJM197701132960204; NORKRANS G, 1980, JAMA-J AM MED ASSOC, V243, P1056, DOI 10.1001/jama.243.10.1056; OGATA N, 1991, P NATL ACAD SCI USA, V88, P3392, DOI 10.1073/pnas.88.8.3392; OKAMOTO H, 1990, JPN J EXP MED, V60, P167; PRINCE AM, 1992, J INFECT DIS, V165, P438, DOI 10.1093/infdis/165.3.438; PURCELL RH, 1985, HEPATOLOGY, V5, P1091, DOI 10.1002/hep.1840050606; REALDI G, 1982, GUT, V23, P270, DOI 10.1136/gut.23.4.270; RIZZETTO M, 1986, PROG LIVER DIS, V8, P417; SEEFF LB, 1978, VIRAL HEPATITIS, P371; SHIMIZU YK, 1990, P NATL ACAD SCI USA, V87, P6441, DOI 10.1073/pnas.87.16.6441; TABOR E, 1984, TRANSFUSION, V24, P224, DOI 10.1046/j.1537-2995.1984.24384225027.x; TAEBOR E, 1979, J INFECT DIS, V140, P789; TAKAMIZAWA A, 1991, J VIROL, V65, P1105, DOI 10.1128/JVI.65.3.1105-1113.1991; TAKEUCHI K, 1990, GENE, V91, P287, DOI 10.1016/0378-1119(90)90102-W; TAKEUCHI K, 1990, J GEN VIROL, V71, P3027, DOI 10.1099/0022-1317-71-12-3027; TSIQUAYE KN, 1979, LANCET, V1, P1135; WARE AJ, 1979, ANN INTERN MED, V91, P364, DOI 10.7326/0003-4819-91-3-364; WEINER AJ, 1991, VIROLOGY, V180, P842, DOI 10.1016/0042-6822(91)90104-J; WEINER AJ, 1990, LANCET, V335, P1, DOI 10.1016/0140-6736(90)90134-Q; YOSHIZAWA H, 1981, GASTROENTEROLOGY, V81, P107; 883109225	64	663	705	1	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 2	1992	258	5079					135	140		10.1126/science.1279801	http://dx.doi.org/10.1126/science.1279801			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JQ619	1279801				2022-12-01	WOS:A1992JQ61900036
J	FARR, CJ; GOODFELLOW, PN				FARR, CJ; GOODFELLOW, PN			HIDDEN MESSAGES IN GENETIC MAPS	SCIENCE			English	Editorial Material											FARR, CJ (corresponding author), UNIV CAMBRIDGE,DEPT GENET,CAMBRIDGE CB2 3EH,ENGLAND.			Farr, Christine/0000-0002-5357-5962				BRENNER S, 1992, NATURE, V356, P27; COLOMBO P, 1992, P NATL ACAD SCI USA, V89, P6358, DOI 10.1073/pnas.89.14.6358; DISTECHE CM, 1992, NAT GENET, V1, P333, DOI 10.1038/ng0892-333; Fisher R., 2005, TEACHING CHILDREN TH; FOSTER JW, IN PRESS NATURE; GAUNT SJ, 1991, BIOESSAYS, V13, P505, DOI 10.1002/bies.950131004; HANCOMBE O, 1991, GENE DEV, V5, P1387; MIYAJIMA N, 1989, CELL, V57, P31, DOI 10.1016/0092-8674(89)90169-4; Trowsdale J, 1992, CURR OPIN GENET DEV, V2, P492, DOI 10.1016/S0959-437X(05)80163-7; VISKOCHIL D, 1991, MOL CELL BIOL, V11, P906, DOI 10.1128/MCB.11.2.906; 1991, CYTOGENET CELL GENET, V58, P1	11	14	15	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 2	1992	258	5079					49	49		10.1126/science.1439767	http://dx.doi.org/10.1126/science.1439767			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JQ619	1439767				2022-12-01	WOS:A1992JQ61900022
J	FOOTE, S; VOLLRATH, D; HILTON, A; PAGE, DC				FOOTE, S; VOLLRATH, D; HILTON, A; PAGE, DC			THE HUMAN Y-CHROMOSOME - OVERLAPPING DNA CLONES SPANNING THE EUCHROMATIC REGION	SCIENCE			English	Article							YEAST ARTIFICIAL CHROMOSOMES; HUMAN X-CHROMOSOME; SEX-DETERMINING REGION; HUMAN GENOME; PSEUDOAUTOSOMAL REGION; ENZYMATIC AMPLIFICATION; DROSOPHILA GENOME; PHYSICAL MAP; SHORT ARM; LONG ARM	The human Y chromosome was physically mapped by assembling 196 recombinant DNA clones, each containing a segment of the chromosome, into a single overlapping array. This array included more than 98 percent of the euchromatic portion of the Y chromosome. First, a library of yeast artificial chromosome (YAC) clones was prepared from the genomic DNA of a human XYYYY male. The library was screened to identify clones containing 160 sequence-tagged sites and the map was then constructed from this information. In all, 207 Y-chromosomal DNA loci were assigned to 127 ordered intervals on the basis of their presence or absence in the YAC's, yielding ordered landmarks at an average spacing of 220 kilobases across the euchromatic region. The map reveals that Y-chromosomal genes are scattered among a patchwork of X-homologous, Y-specific repetitive, and single-copy DNA sequences. This map of overlapping clones and ordered, densely spaced markers should accelerate studies of the chromosome.	MIT,DEPT BIOL,CAMBRIDGE,MA 02142	Massachusetts Institute of Technology (MIT)	FOOTE, S (corresponding author), MIT,WHITEHEAD INST,HOWARD HUGHES RES LABS,9 CAMBRIDGE CTR,CAMBRIDGE,MA 02142, USA.		Foote, Simon J/F-2802-2013	Foote, Simon/0000-0002-9142-2107				ABIDI FE, 1990, GENOMICS, V7, P363, DOI 10.1016/0888-7543(90)90170-Y; AJIOKA JW, 1991, CHROMOSOMA, V100, P495, DOI 10.1007/BF00352200; ALBERTSEN HM, 1990, P NATL ACAD SCI USA, V87, P4256, DOI 10.1073/pnas.87.11.4256; ARRATIA R, 1991, GENOMICS, V11, P806, DOI 10.1016/0888-7543(91)90004-X; BROWN WRA, 1988, EMBO J, V7, P2377, DOI 10.1002/j.1460-2075.1988.tb03082.x; BURKE DT, 1987, SCIENCE, V236, P806, DOI 10.1126/science.3033825; CHU G, 1986, SCIENCE, V234, P1582, DOI 10.1126/science.3538420; COOKE HJ, 1984, NATURE, V311, P259, DOI 10.1038/311259a0; COOKE HJ, 1985, NATURE, V317, P687, DOI 10.1038/317687a0; COOKE HJ, 1979, NUCLEIC ACIDS RES, V6, P3177, DOI 10.1093/nar/6.10.3177; COULSON A, 1986, P NATL ACAD SCI USA, V83, P7821, DOI 10.1073/pnas.83.20.7821; COULSON A, 1988, NATURE, V335, P184, DOI 10.1038/335184a0; DEININGER PL, 1981, J MOL BIOL, V151, P17, DOI 10.1016/0022-2836(81)90219-9; FISHER EMC, 1990, CELL, V63, P1205, DOI 10.1016/0092-8674(90)90416-C; FROMMER M, 1984, NUCLEIC ACIDS RES, V12, P2887, DOI 10.1093/nar/12.6.2887; GARZA D, 1989, SCIENCE, V246, P641, DOI 10.1126/science.2510296; GELIN C, 1989, EMBO J, V8, P3253, DOI 10.1002/j.1460-2075.1989.tb08485.x; GOODFELLOW PJ, 1986, SCIENCE, V234, P740, DOI 10.1126/science.2877492; GOUGH NM, 1990, NATURE, V345, P734, DOI 10.1038/345734a0; Green E D, 1991, PCR Methods Appl, V1, P77; GREEN ED, 1991, GENOMICS, V11, P658, DOI 10.1016/0888-7543(91)90073-N; GREEN ED, 1990, SCIENCE, V250, P94, DOI 10.1126/science.2218515; GUIOLI S, 1992, NAT GENET, V1, P337, DOI 10.1038/ng0892-337; HENKE A, 1991, AM J HUM GENET, V49, P811; INCERTI B, IN PRESS NATURE GENE; KNOWLTON RG, 1989, NUCLEIC ACIDS RES, V17, P423, DOI 10.1093/nar/17.1.423; KUSPA A, 1989, P NATL ACAD SCI USA, V86, P8917, DOI 10.1073/pnas.86.22.8917; LAU EC, 1989, GENOMICS, V4, P162, DOI 10.1016/0888-7543(89)90295-4; LITTLE RD, 1992, P NATL ACAD SCI USA, V89, P177, DOI 10.1073/pnas.89.1.177; MAIER E, 1992, NAT GENET, V1, P273, DOI 10.1038/ng0792-273; MORTON NE, 1991, P NATL ACAD SCI USA, V88, P7474, DOI 10.1073/pnas.88.17.7474; NAKAHORI Y, 1986, NUCLEIC ACIDS RES, V14, P7569, DOI 10.1093/nar/14.19.7569; NAKAHORI Y, 1991, GENOMICS, V9, P264, DOI 10.1016/0888-7543(91)90251-9; NEIL DL, 1990, NUCLEIC ACIDS RES, V18, P1421, DOI 10.1093/nar/18.6.1421; OAKEY R, 1990, GENOMICS, V7, P325, DOI 10.1016/0888-7543(90)90165-Q; OLSON M, 1989, SCIENCE, V245, P1434, DOI 10.1126/science.2781285; OLSON MV, 1987, CELL, V50, P495; PAGE D C, 1987, Genomics, V1, P243, DOI 10.1016/0888-7543(87)90051-6; PAGE DC, 1987, CELL, V51, P1091, DOI 10.1016/0092-8674(87)90595-2; PAGE DC, 1984, NATURE, V311, P119, DOI 10.1038/311119a0; PEDICINI A, 1991, GENOMICS, V11, P482, DOI 10.1016/0888-7543(91)90167-D; PETIT C, 1988, EMBO J, V7, P2369, DOI 10.1002/j.1460-2075.1988.tb03081.x; RAPPOLD G, 1988, NUCLEIC ACIDS RES, V16, P5631; RILEY J, 1990, NUCLEIC ACIDS RES, V18, P2887, DOI 10.1093/nar/18.10.2887; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANDBERG AA, 1985, Y CHROMOSOME A; SCHLESSINGER D, 1991, GENOMICS, V11, P783, DOI 10.1016/0888-7543(91)90001-U; SCHNEIDERGADICKE A, 1989, CELL, V57, P1247, DOI 10.1016/0092-8674(89)90061-5; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; SIROTA L, 1981, CLIN GENET, V19, P87; SMITH DR, IN PRESS METHODS ENZ; SMITH KD, 1987, DEVELOPMENT, V101, P77; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; VERGNAUD G, 1986, AM J HUM GENET, V38, P109; VOLLRATH D, 1992, SCIENCE, V258, P52, DOI 10.1126/science.1439769; YEN PH, 1988, CELL, V55, P1123, DOI 10.1016/0092-8674(88)90257-7	57	403	415	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 2	1992	258	5079					60	66		10.1126/science.1359640	http://dx.doi.org/10.1126/science.1359640			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JQ619	1359640				2022-12-01	WOS:A1992JQ61900025
J	GILL, DR; HYDE, SC; HIGGINS, CF; VALVERDE, MA; MINTENIG, GM; SEPULVEDA, FV				GILL, DR; HYDE, SC; HIGGINS, CF; VALVERDE, MA; MINTENIG, GM; SEPULVEDA, FV			SEPARATION OF DRUG TRANSPORT AND CHLORIDE CHANNEL FUNCTIONS OF THE HUMAN MULTIDRUG RESISTANCE P-GLYCOPROTEIN	CELL			English	Article							NUCLEOTIDE-BINDING FOLD; CYSTIC-FIBROSIS; ATP-BINDING; ADENYLATE KINASE; DEPENDENT TRANSPORT; STRUCTURAL MODEL; EPITHELIAL-CELLS; ESCHERICHIA-COLI; R-DOMAIN; EXPRESSION	The human multidrug resistance P-glycoprotein is an active transporter that pumps cytotoxic drugs out of cells. Expression of P-glycoprotein is also associated with a volume-activated chloride channel. Here we address the relationship between these two functions. Drug transport requires ATP hydrolysis while, in contrast, ATP binding is sufficient to enable activation of the chloride channel. The chloride channel and drug transport activities of P-glycoprotein appear to reflect two distinct functional states of the protein that can be interconverted by changes in tonicity. Transportable drugs prevent channel activation but have no effect on channel activity once it has been preactivated by hypotonicity. The transport and channel functions of P-glycoprotein have been separated by directed mutations in the nucleotide-binding domains of the protein. These data provide further evidence that P-glycoprotein is bifunctional with both transport and channel activities. Implications for the design of chemotherapeutic drugs and for the function of the related cystic fibrosis gene product, CFTR, are discussed.	AFRC,INST ANIM PHYSIOL & GENET RES,CAMBRIDGE CB2 4AT,ENGLAND	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute	GILL, DR (corresponding author), UNIV OXFORD,JOHN RADCLIFFE HOSP,INST MOLEC MED,IMPERIAL CANC RES FUND LABS,OXFORD OX3 9DU,ENGLAND.			Valverde, Miguel A./0000-0002-6961-3361; Gill, Deborah/0000-0002-5264-054X; Hyde, Stephen/0000-0002-8877-4005				ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ARCECI RJ, 1988, P NATL ACAD SCI USA, V85, P4350, DOI 10.1073/pnas.85.12.4350; ASHCROFT FM, 1989, J PHYSIOL-LONDON, V416, P349, DOI 10.1113/jphysiol.1989.sp017765; AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; BAAS F, 1990, CANCER RES, V50, P5392; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BISHOP L, 1989, P NATL ACAD SCI USA, V86, P6953, DOI 10.1073/pnas.86.18.6953; CANOGAUCI DF, 1990, BIOCHEM BIOPH RES CO, V167, P48, DOI 10.1016/0006-291X(90)91728-B; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; CORDONCARDO C, 1990, J HISTOCHEM CYTOCHEM, V38, P1277, DOI 10.1177/38.9.1974900; CORNWELL MM, 1987, FASEB J, V1, P51, DOI 10.1096/fasebj.1.1.2886389; CUTTING GR, 1990, NATURE, V346, P366, DOI 10.1038/346366a0; DIAZ M, 1992, UNPUB EUR J PHYSL; ECKSTEIN F, 1985, ANNU REV BIOCHEM, V54, P367, DOI 10.1146/annurev.bi.54.070185.002055; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; GARBOCZI DN, 1990, J BIOL CHEM, V265, P14632; GOTTESMAN MM, 1988, TRENDS PHARMACOL SCI, V9, P54, DOI 10.1016/0165-6147(88)90117-4; GREGORY RJ, 1991, MOL CELL BIOL, V11, P3886, DOI 10.1128/MCB.11.8.3886; GROS P, 1986, NATURE, V323, P728, DOI 10.1038/323728a0; HAMADA H, 1988, J BIOL CHEM, V263, P1454; HIGGINS CF, 1992, TRENDS BIOCHEM SCI, V17, P18, DOI 10.1016/0968-0004(92)90419-A; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cellbio.8.1.67; HIGGINS CF, 1986, NATURE, V323, P448, DOI 10.1038/323448a0; HOFFMANN EK, 1989, PHYSIOL REV, V69, P315, DOI 10.1152/physrev.1989.69.2.315; HORIO M, 1988, P NATL ACAD SCI USA, V85, P3580, DOI 10.1073/pnas.85.10.3580; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; KEREM BS, 1990, P NATL ACAD SCI USA, V87, P8445; MCNAUGHTON PA, 1986, NATURE, V322, P261, DOI 10.1038/322261a0; MIMMACK ML, 1989, P NATL ACAD SCI USA, V86, P8257, DOI 10.1073/pnas.86.21.8257; MIMURA CS, 1991, P NATL ACAD SCI USA, V88, P84, DOI 10.1073/pnas.88.1.84; MOOS C, 1960, ARCH BIOCHEM BIOPHYS, V88, P183, DOI 10.1016/0003-9861(60)90220-4; OBRIEN JA, 1991, BIOCHIM BIOPHYS ACTA, V1070, P501, DOI 10.1016/0005-2736(91)90093-N; OKADA Y, 1989, NEWS PHYSIOL SCI, V4, P238; PASTAN I, 1988, P NATL ACAD SCI USA, V85, P4486, DOI 10.1073/pnas.85.12.4486; REINSTEIN J, 1990, BIOCHEMISTRY-US, V29, P7451, DOI 10.1021/bi00484a014; REINSTEIN J, 1988, BIOCHEMISTRY-US, V27, P4712, DOI 10.1021/bi00413a020; RICH DP, 1991, SCIENCE, V253, P205, DOI 10.1126/science.1712985; RONINSON IB, 1990, PEDIATR PULM, V5, P138; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SARKADI B, 1992, J BIOL CHEM, V267, P4854; SHEN DW, 1986, SCIENCE, V232, P643, DOI 10.1126/science.3457471; SHEPPARD DN, 1991, J PHYSIOL-LONDON, V433, P663, DOI 10.1113/jphysiol.1991.sp018449; SHIMABUKU AM, 1992, J BIOL CHEM, V267, P4305; SMITH JS, 1985, NATURE, V316, P446, DOI 10.1038/316446a0; SOLC CK, 1991, AM J PHYSIOL, V261, pC658, DOI 10.1152/ajpcell.1991.261.4.C658; SUNG P, 1988, EMBO J, V7, P3263, DOI 10.1002/j.1460-2075.1988.tb03193.x; SUZUKI S, 1990, J PHYSIOL-LONDON, V421, P645, DOI 10.1113/jphysiol.1990.sp017967; THIEBAUT F, 1987, P NATL ACAD SCI USA, V84, P7735, DOI 10.1073/pnas.84.21.7735; TIAN G, 1990, BIOCHEMISTRY-US, V29, P4296, DOI 10.1021/bi00470a006; UEDA K, 1987, P NATL ACAD SCI USA, V84, P3004, DOI 10.1073/pnas.84.9.3004; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WORRELL RT, 1989, AM J PHYSIOL, V256, pC1111, DOI 10.1152/ajpcell.1989.256.6.C1111; YOUNT RG, 1971, BIOCHEMISTRY-US, V10, P2490, DOI 10.1021/bi00789a010	55	366	371	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 2	1992	71	1					23	32		10.1016/0092-8674(92)90263-C	http://dx.doi.org/10.1016/0092-8674(92)90263-C			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JQ623	1382860				2022-12-01	WOS:A1992JQ62300004
J	JEUNEMAITRE, X; SOUBRIER, F; KOTELEVTSEV, YV; LIFTON, RP; WILLIAMS, CS; CHARRU, A; HUNT, SC; HOPKINS, PN; WILLIAMS, RR; LALOUEL, JM; CORVOL, P				JEUNEMAITRE, X; SOUBRIER, F; KOTELEVTSEV, YV; LIFTON, RP; WILLIAMS, CS; CHARRU, A; HUNT, SC; HOPKINS, PN; WILLIAMS, RR; LALOUEL, JM; CORVOL, P			MOLECULAR-BASIS OF HUMAN HYPERTENSION - ROLE OF ANGIOTENSINOGEN	CELL			English	Article							BLOOD-PRESSURE; MESSENGER-RNA; RENIN GENE; LINKAGE; RAT; SYSTEM; IDENTIFICATION; POLYMORPHISMS; SUBSTRATE; FAMILIES	Essential hypertension is a common human disease believed to result from the interplay of multiple genetic and environmental determinants. In genetic studies of two large panels of hypertensive sibships from widely separated geographical areas, we obtained evidence of genetic linkage between the angiotensinogen gene (AGT) and hypertension, demonstrated association of AGT molecular variants with the disease, and found significant differences in plasma concentrations of angiotensinogen among hypertensive subjects with different AGT genotypes. The corroboration and replication afforded by these results support the interpretation that molecular variants of AGT constitute inherited predispositions to essential hypertension in humans.	UNIV UTAH, HLTH SCI CTR, ECCLES INST HUMAN GENET, DEPT HUMAN GENET, SALT LAKE CITY, UT 84112 USA; COLL FRANCE, INSERM U36, F-75005 PARIS, FRANCE; BRIGHAM & WOMENS HOSP, DIV ENDOCRINE HYPERTENS, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; UNIV UTAH, HLTH SCI CTR, CARDIOVASC GENET RES CLIN, SALT LAKE CITY, UT 84112 USA	Utah System of Higher Education; University of Utah; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Utah System of Higher Education; University of Utah	JEUNEMAITRE, X (corresponding author), UNIV UTAH, HLTH SCI CTR, ECCLES INST HUMAN GENET, HOWARD HUGHES MED INST, SALT LAKE CITY, UT 84112 USA.		JEUNEMAITRE, Xavier/AAQ-4853-2021; Williams, christopher S/A-1186-2009; Kotelevtsev, Yuri V/R-1772-2016	JEUNEMAITRE, Xavier/0000-0001-5925-381X; Kotelevtsev, Yuri/0000-0002-7255-7794; Williams, Christopher/0000-0002-1541-579X	NHLBI NIH HHS [HL24855, HL45325] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL024855, R01HL045325] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARNAL JF, 1991, AM J MED, V90, P17, DOI 10.1016/0002-9343(91)90501-N; BACHMANN J, 1991, J STEROID BIOCHEM, V40, P511, DOI 10.1016/0960-0760(91)90270-F; BISHOP DT, 1990, AM J HUM GENET, V46, P254; BLACKWELDER W C, 1985, Genetic Epidemiology, V2, P85, DOI 10.1002/gepi.1370020109; BROWN AJ, 1981, AM J PHYSIOL, V241, pH381, DOI 10.1152/ajpheart.1981.241.3.H381; CAIN MD, 1971, J CLIN ENDOCR METAB, V33, P671, DOI 10.1210/jcem-33-4-671; CAMPBELL DJ, 1986, J CLIN INVEST, V78, P31, DOI 10.1172/JCI112566; Carrell R.W, 1986, PROTEINASE INHIBITOR, P403; CLAUSER E, 1989, AM J HYPERTENS, V2, P403, DOI 10.1093/ajh/2.5.403; CORVOL P, 1989, CLIN EXP HYPERTENS A, V11, P1053, DOI 10.3109/10641968909035391; CUDWORTH AG, 1975, BRIT MED J, V3, P133, DOI 10.1136/bmj.3.5976.133; DAUSSET J, 1990, GENOMICS, V6, P575, DOI 10.1016/0888-7543(90)90491-C; DENG YL, 1992, NAT GENET, V1, P267, DOI 10.1038/ng0792-267; FASOLA AF, 1968, J APPL PHYSIOL, V25, P410, DOI 10.1152/jappl.1968.25.4.410; FROGUEL P, 1992, NATURE, V356, P162, DOI 10.1038/356162a0; FUKAMIZU A, 1990, J BIOL CHEM, V265, P7576; GAILLARD I, 1989, DNA-J MOLEC CELL BIO, V8, P87, DOI 10.1089/dna.1.1989.8.87; GARDES J, 1982, HYPERTENSION, V4, P185, DOI 10.1161/01.HYP.4.2.185; GOULD AB, 1971, CARDIOVASC RES, V5, P86, DOI 10.1093/cvr/5.1.86; Hall JE, 1990, HYPERTENSION PATHOPH, P1105; HATA A, 1990, NUCLEIC ACIDS RES, V18, P5407, DOI 10.1093/nar/18.18.5407; HILBERT P, 1991, NATURE, V353, P521, DOI 10.1038/353521a0; HODGE S E, 1984, Genetic Epidemiology, V1, P109, DOI 10.1002/gepi.1370010203; JACOB HJ, 1991, CELL, V67, P213, DOI 10.1016/0092-8674(91)90584-L; JEUNEMAITRE X, 1992, HUM GENET, V88, P301; JEUNEMAITRE X, 1992, NAT GENET, V1, P72, DOI 10.1038/ng0492-72; KIMURA S, 1992, EMBO J, V11, P821, DOI 10.1002/j.1460-2075.1992.tb05119.x; KOTELEVTSEV YV, 1991, NUCLEIC ACIDS RES, V19, P6978, DOI 10.1093/nar/19.24.6978; KUNAPULI SP, 1986, NUCLEIC ACIDS RES, V14, P7509, DOI 10.1093/nar/14.18.7509; KURTZ TW, 1990, J CLIN INVEST, V85, P1328, DOI 10.1172/JCI114572; LALOUEL JM, 1990, DRUGS AFFECTING LIPI, V10, P11; LANDER ES, 1989, GENETICS, V121, P185; LANDER ES, 1986, COLD SPRING HARB SYM, V51, P49, DOI 10.1101/SQB.1986.051.01.007; LANGE K, 1986, ANN HUM GENET, V50, P283, DOI 10.1111/j.1469-1809.1986.tb01049.x; LATHROP GM, 1991, HDB STATISTICS, V8, P81; LIFTON RP, 1992, NATURE, V355, P262, DOI 10.1038/355262a0; MENARD J, 1991, HYPERTENSION, V18, P705, DOI 10.1161/01.HYP.18.5.705; MENARD J, 1973, ENDOCRINOLOGY, V92, P1382, DOI 10.1210/endo-92-5-1382; MULLINS JJ, 1990, NATURE, V344, P541, DOI 10.1038/344541a0; OHKUBO H, 1990, P NATL ACAD SCI USA, V87, P5153, DOI 10.1073/pnas.87.13.5153; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; PLOUIN PF, 1989, PRESSE MED, V18, P917; PRATT RE, 1989, AM J PHYSIOL, V256, pF469, DOI 10.1152/ajprenal.1989.256.3.F469; RAPP JP, 1989, SCIENCE, V243, P542, DOI 10.1126/science.2563177; RISCH N, 1990, AM J HUM GENET, V46, P242; ROCCELLA EJ, 1985, HYPERTENSION, V7, P457; Sealey JE, 1990, HYPERTENSION PATHOPH, P1287; SOUBRIER F, 1990, HYPERTENSION, V16, P712, DOI 10.1161/01.HYP.16.6.712; SUAREZ BK, 1984, AM J MED GENET, V18, P135, DOI 10.1002/ajmg.1320180117; SUAREZ BK, 1978, ANN HUM GENET, V42, P87, DOI 10.1111/j.1469-1809.1978.tb00933.x; TEWKSBURY DA, 1990, HYPERTENSION PATHOPH, P1197; WALKER WG, 1979, HYPERTENSION, V1, P287, DOI 10.1161/01.HYP.1.3.287; WARD R, 1990, HYPERTENSION PATHOPH, P81; WATT GCM, 1992, J HYPERTENS, V10, P473, DOI 10.1097/00004872-199205000-00011; WHITE R, 1987, ADV HUM GENET, V16, P121; WILLIAMS RR, 1988, JAMA-J AM MED ASSOC, V259, P3579, DOI 10.1001/jama.259.24.3579; WILLIAMS RR, 1989, HYPERTENSION, V14, P610, DOI 10.1161/01.HYP.14.6.610; YONGUE BG, 1991, HYPERTENSION, V17, P485, DOI 10.1161/01.HYP.17.4.485	58	1612	1687	0	30	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 2	1992	71	1					169	180		10.1016/0092-8674(92)90275-H	http://dx.doi.org/10.1016/0092-8674(92)90275-H			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JQ623	1394429				2022-12-01	WOS:A1992JQ62300016
J	KNIGHTON, DR; PEARSON, RB; SOWADSKI, JM; MEANS, AR; TENEYCK, LF; TAYLOR, SS; KEMP, BE				KNIGHTON, DR; PEARSON, RB; SOWADSKI, JM; MEANS, AR; TENEYCK, LF; TAYLOR, SS; KEMP, BE			STRUCTURAL BASIS OF THE INTRASTERIC REGULATION OF MYOSIN LIGHT CHAIN KINASES	SCIENCE			English	Article							DEPENDENT PROTEIN-KINASE; CATALYTIC SUBUNIT; CALMODULIN BINDING; CONSERVED FEATURES; SYNTHETIC PEPTIDES; RESIDUES; SEQUENCE; PHOSPHORYLATION; DOMAIN; SITE	The smooth muscle myosin light chain kinase (smMLCK) catalytic core was modeled by using the crystallographic coordinates of the cyclic AMP-dependent protein kinase catalytic subunit (cAPK) and a bound pseudosubstrate inhibitor peptide, PKI(5-24). Despite only 30% identity in amino acid sequence, the MLCK sequence can be readily accommodated in this structure. With the exception of the short B-helix, all major elements of secondary structure in the core are very likely conserved. The active site of the modeled MLCK complements the known requirements for peptide substrate recognition. MLCK contains a pseudosubstrate sequence that overlaps the calmodulin binding domain and has been proposed to act as an intrasteric inhibitor and occupy the substrate binding site in the absence of Ca2+-calmodulin. The pseudosubstrate sequence can be modeled easily into the entire backbone of PKI(5-24). The results demonstrate that the intrasteric model for regulation of MLCK by intramolecular competitive inhibition is structurally plausible.	ST VINCENTS INST MED RES, 41 VICTORIA PARADE, FITZROY, VIC 3065, AUSTRALIA; UNIV CALIF SAN DIEGO, DEPT CHEM, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT MED, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA; DUKE UNIV, DEPT PHARMACOL, DURHAM, NC 27706 USA	St. Vincent's Institute of Medical Research; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Duke University			Kemp, Bruce E/L-2633-2014; Pearson, Richard Bruce/I-1451-2013; Kemp, Bruce/G-9602-2019	Kemp, Bruce E/0000-0001-6735-5082; Pearson, Richard Bruce/0000-0001-5919-5090; Kemp, Bruce/0000-0001-6735-5082	NATIONAL CANCER INSTITUTE [T32CA009523] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007233] Funding Source: NIH RePORTER; NCI NIH HHS [T32CA09523] Funding Source: Medline; NIDDK NIH HHS [T32DK07233] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAGCHI IC, 1992, MOL ENDOCRINOL, V6, P621, DOI 10.1210/me.6.4.621; CHENG HC, 1986, J BIOL CHEM, V261, P989; GLASS DB, 1989, J BIOL CHEM, V264, P14579; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HERRING BP, 1991, J BIOL CHEM, V266, P11838; HERRING BP, 1990, J BIOL CHEM, V265, P16588; ITO M, 1991, BIOCHEMISTRY-US, V30, P3498, DOI 10.1021/bi00228a021; KEMP BE, 1983, P NATL ACAD SCI-BIOL, V80, P7471, DOI 10.1073/pnas.80.24.7471; KEMP BE, 1985, J BIOL CHEM, V260, P3355; KEMP BE, 1991, BIOCHIM BIOPHYS ACTA, V1094, P67, DOI 10.1016/0167-4889(91)90027-U; KEMP BE, 1987, J BIOL CHEM, V262, P2542; KEMP BE, 1990, PEPTIDES PROTEIN PHO; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; LEACHMAN SA, 1992, J BIOL CHEM, V267, P4930; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; MICHNOFF CH, 1986, J BIOL CHEM, V261, P8320; OLSON NJ, 1990, P NATL ACAD SCI USA, V87, P2284, DOI 10.1073/pnas.87.6.2284; PEARSON RB, 1988, SCIENCE, V241, P970, DOI 10.1126/science.3406746; PEARSON RB, 1986, J BIOL CHEM, V261, P25; PEARSON RB, 1991, EUR J BIOCHEM, V200, P723, DOI 10.1111/j.1432-1033.1991.tb16237.x; PEARSON RW, UNPUB; SHOEMAKER MO, 1990, J CELL BIOL, V111, P1107, DOI 10.1083/jcb.111.3.1107; SHOJI S, 1979, J BIOL CHEM, V254, P6211; SOBIESZEK A, 1991, EUR J BIOCHEM, V199, P735, DOI 10.1111/j.1432-1033.1991.tb16178.x	26	114	129	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 2	1992	258	5079					130	135		10.1126/science.1439761	http://dx.doi.org/10.1126/science.1439761			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JQ619	1439761				2022-12-01	WOS:A1992JQ61900035
J	KRETSINGER, RH				KRETSINGER, RH			CALMODULIN AND MYOSIN LIGHT CHAIN KINASE - HOW HELICES ARE BENT	SCIENCE			English	Editorial Material							DEPENDENT PROTEIN-KINASE; CATALYTIC SUBUNIT; MONOPHOSPHATE				KRETSINGER, RH (corresponding author), UNIV VIRGINIA,DEPT BIOL,CHARLOTTESVILLE,VA 22901, USA.							IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1992, SCIENCE, V258, P130, DOI 10.1126/science.1439761; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KRETSINGER RH, 1975, BIOCHIM BIOPHYS ACTA, V405, P40, DOI 10.1016/0005-2795(75)90312-8; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; PERSECHINI A, 1988, J BIOL CHEM, V263, P12175; Raghunathan S., UNPUB	8	22	22	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 2	1992	258	5079					50	51		10.1126/science.1439768	http://dx.doi.org/10.1126/science.1439768			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JQ619	1439768				2022-12-01	WOS:A1992JQ61900023
J	LEE, JJ; VONKESSLER, DP; PARKS, S; BEACHY, PA				LEE, JJ; VONKESSLER, DP; PARKS, S; BEACHY, PA			SECRETION AND LOCALIZED TRANSCRIPTION SUGGEST A ROLE IN POSITIONAL SIGNALING FOR PRODUCTS OF THE SEGMENTATION GENE HEDGEHOG	CELL			English	Article							DROSOPHILA HEAD DEVELOPMENT; ANTENNA IMAGINAL DISK; POLARITY GENE; PATTERN-FORMATION; ENGRAILED GENE; MESSENGER-RNA; FUSHI-TARAZU; MOLECULAR-GENETICS; EMBRYONIC PATTERN; LARVAL CUTICLE	The segment polarity genes engrailed and wingless are expressed in neighboring stripes of cells on opposite sides of the Drosophila parasegment boundary. Each gene is mutually required for maintenance of the other's expression; continued expression of both also requires several other segment polarity genes. We show here that one such gene, hedgehog, encodes a protein targeted to the secretory pathway and is expressed coincidently with engrailed in embryos and in imaginal discs; maintenance of the hedgehog expression pattern is itself dependent upon other segment polarity genes including engrailed and wingless. Expression of hedgehog thus functions in, and is sensitive to, positional signaling. These properties are consistent with the non-cell autonomous requirement for hedgehog in cuticular patterning and in maintenance of wingless expression.			LEE, JJ (corresponding author), JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT MOLEC BIOL & GENET,BALTIMORE,MD 21205, USA.							AKAM M, 1987, DEVELOPMENT, V101, P1; ARIAS AM, 1988, DEVELOPMENT, V103, P157; ARIAS AM, 1985, NATURE, V313, P639; Ausubel FM., 2006, ENZYMATIC MANIPULATI; BAKER NE, 1988, DEVELOPMENT, V102, P489; BELLEN HJ, 1989, GENE DEV, V3, P1288, DOI 10.1101/gad.3.9.1288; BIGGIN MD, 1989, TRENDS GENET, V5, P377, DOI 10.1016/0168-9525(89)90173-X; BISHOP JG, 1988, GENE DEV, V2, P567, DOI 10.1101/gad.2.5.567; BROWER DL, 1986, EMBO J, V5, P2649, DOI 10.1002/j.1460-2075.1986.tb04547.x; BROWER DL, 1981, DEV BIOL, V86, P448, DOI 10.1016/0012-1606(81)90203-7; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; BRYANT PJ, 1975, J EXP ZOOL, V193, P49, DOI 10.1002/jez.1401930106; CAVENER DR, 1991, NUCLEIC ACIDS RES, V19, P3185, DOI 10.1093/nar/19.12.3185; COHEN S, 1991, TRENDS GENET, V7, P267; COHEN SM, 1990, NATURE, V346, P482, DOI 10.1038/346482a0; DINARDO S, 1987, GENE DEV, V1, P1212, DOI 10.1101/gad.1.10.1212; DINARDO S, 1985, CELL, V43, P59, DOI 10.1016/0092-8674(85)90012-1; DINARDO S, 1988, NATURE, V332, P604, DOI 10.1038/332604a0; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; EKKER SC, 1991, EMBO J, V10, P1179, DOI 10.1002/j.1460-2075.1991.tb08058.x; EKKER SC, 1992, IN PRESS EMBO J; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FINKELSTEIN R, 1991, DEVELOPMENT, V112, P899; FINKELSTEIN R, 1990, NATURE, V346, P485, DOI 10.1038/346485a0; FJOSE A, 1985, NATURE, V313, P284, DOI 10.1038/313284a0; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; FLORENCE B, 1991, MOL CELL BIOL, V11, P3613, DOI 10.1128/MCB.11.7.3613; FROHMAN MA, 1990, AMPLIFICATIONS, V5, P11; GONZALEZ F, 1991, MECH DEVELOP, V35, P43, DOI 10.1016/0925-4773(91)90040-D; HAMA C, 1990, GENE DEV, V4, P1079, DOI 10.1101/gad.4.7.1079; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; HAYNIE JL, 1986, J EXP ZOOL, V237, P293, DOI 10.1002/jez.1402370302; HEEMSKERK J, 1991, NATURE, V352, P404, DOI 10.1038/352404a0; HIDALGO A, 1990, DEVELOPMENT, V110, P291; HOLLAND EC, 1984, P NATL ACAD SCI-BIOL, V81, P7338, DOI 10.1073/pnas.81.23.7338; HOLMGREN R, 1981, P NATL ACAD SCI-BIOL, V78, P3775, DOI 10.1073/pnas.78.6.3775; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; HOWARD K, 1986, CELL, V44, P949, DOI 10.1016/0092-8674(86)90018-8; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; INGHAM PW, 1992, CELL, V68, P221, DOI 10.1016/0092-8674(92)90467-Q; IVES B, 1950, DROS INF SERV, V24, P58; JOYNER AL, 1985, CELL, V43, P29, DOI 10.1016/0092-8674(85)90009-1; JURGENS G, 1986, ROUX ARCH DEV BIOL, V195, P359, DOI 10.1007/BF00402870; JURGENS G, 1984, ROUX ARCH DEV BIOL, V193, P283, DOI 10.1007/BF00848157; KARPEN G, 1992, IN PRESS GENETICS; KASSIS JA, 1990, GENE DEV, V4, P433, DOI 10.1101/gad.4.3.433; KEITH TP, 1987, GENETICS, V116, P67; KORNBERG T, 1985, CELL, V40, P45, DOI 10.1016/0092-8674(85)90307-1; KORNBERG T, 1981, P NATL ACAD SCI-BIOL, V78, P1095, DOI 10.1073/pnas.78.2.1095; KORNFELD K, 1989, GENE DEV, V3, P243, DOI 10.1101/gad.3.2.243; KRIEGLER M, 1988, CELL, V53, P45, DOI 10.1016/0092-8674(88)90486-2; KYTE J, 1982, J MOL BIOL, V157, P133; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDRY SJ, 1991, TRENDS BIOCHEM SCI, V16, P159, DOI 10.1016/0968-0004(91)90060-9; LANGERSAFER PR, 1982, P NATL ACAD SCI-BIOL, V79, P4381, DOI 10.1073/pnas.79.14.4381; LIMBOURGBOUCHON B, 1991, DEVELOPMENT, V112, P417; LIS JT, 1983, CELL, V35, P403, DOI 10.1016/0092-8674(83)90173-3; MANIATIS T, 1978, CELL, V15, P687, DOI 10.1016/0092-8674(78)90036-3; MASSAGUE J, 1990, J BIOL CHEM, V265, P21393; MLODZIK M, 1992, METHODS NEUROSCIENCE, V9, P397; MOHLER J, 1988, GENETICS, V120, P1061; MORATA G, 1979, DEV BIOL, V70, P355, DOI 10.1016/0012-1606(79)90033-2; NAKANO Y, 1989, NATURE, V341, P508, DOI 10.1038/341508a0; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156; OHARE K, 1983, CELL, V34, P25, DOI 10.1016/0092-8674(83)90133-2; PANKRATZ MJ, 1990, TRENDS GENET, V6, P287, DOI 10.1016/0168-9525(90)90234-W; PATEL NH, 1989, GENE DEV, V3, P890, DOI 10.1101/gad.3.6.890; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; PEIFER M, 1991, DEVELOPMENT, V111, P1029; PENNICA D, 1984, NATURE, V312, P724, DOI 10.1038/312724a0; PHILLIPS RG, 1990, DEVELOPMENT, V110, P105; POOLE SJ, 1985, CELL, V40, P37, DOI 10.1016/0092-8674(85)90306-X; PREAT T, 1990, NATURE, V347, P87, DOI 10.1038/347087a0; PROUDFOOT N, 1991, CELL, V64, P671, DOI 10.1016/0092-8674(91)90495-K; RAO JKM, 1986, BIOCHIM BIOPHYS ACTA, V869, P197, DOI 10.1016/0167-4838(86)90295-5; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; ROOP DR, 1978, CELL, V15, P671, DOI 10.1016/0092-8674(78)90035-1; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEIDER C, 1984, NATURE, V311, P675, DOI 10.1038/311675b0; SCHROTH GP, 1992, J BIOL CHEM, V267, P11846; SCHUBIGER G, 1971, DEV BIOL, V26, P277, DOI 10.1016/0012-1606(71)90127-8; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SHAW AS, 1988, P NATL ACAD SCI USA, V85, P7592, DOI 10.1073/pnas.85.20.7592; SPIESS M, 1986, CELL, V44, P177, DOI 10.1016/0092-8674(86)90496-4; STEIN J, 1990, BLOOD, V76, P1308, DOI 10.1182/blood.V76.7.1308.bloodjournal7671308; STEINER E, 1976, ROUX ARCH DEV BIOL, V180, P9, DOI 10.1007/BF00848882; STRUBIN M, 1984, EMBO J, V3, P869, DOI 10.1002/j.1460-2075.1984.tb01898.x; TARTOF KD, 1991, CELL, V65, P201, DOI 10.1016/0092-8674(91)90153-P; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TURNER FR, 1979, DEV BIOL, V68, P96, DOI 10.1016/0012-1606(79)90246-X; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; VINCENT JP, 1992, CELL, V68, P923, DOI 10.1016/0092-8674(92)90035-B; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WALLACE JC, 1992, COMPUT APPL BIOSCI, V8, P249; WEIR MP, 1985, NATURE, V318, P433, DOI 10.1038/318433a0; Wieschaus E., 1986, P199; WILKINS AS, 1991, DEV BIOL, V145, P1, DOI 10.1016/0012-1606(91)90208-K	101	500	525	2	23	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 2	1992	71	1					33	50		10.1016/0092-8674(92)90264-D	http://dx.doi.org/10.1016/0092-8674(92)90264-D			18	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JQ623	1394430				2022-12-01	WOS:A1992JQ62300005
J	MANDEL, JL; MONACO, AP; NELSON, DL; SCHLESSINGER, D; WILLARD, H				MANDEL, JL; MONACO, AP; NELSON, DL; SCHLESSINGER, D; WILLARD, H			GENOME ANALYSIS AND THE HUMAN X-CHROMOSOME	SCIENCE			English	Article							DUCHENNE MUSCULAR-DYSTROPHY; POLYMERASE CHAIN-REACTION; YEAST ARTIFICIAL CHROMOSOMES; FIELD GEL-ELECTROPHORESIS; GENETIC-LINKAGE MAP; HUMAN XQ24-XQ28 DNA; FRAGILE-X; SHORT ARM; INACTIVATION CENTER; CAENORHABDITIS-ELEGANS	A unified genetic, physical, and functional map of the human X chromosome is being built through a concerted, international effort. About 40 percent of the 160 million base pairs of the X chromosome DNA have been cloned in overlapping, ordered contigs derived from yeast artificial chromosomes. This rapid progress toward a physical map is accelerating the identification of inherited disease genes, 26 of which are already cloned and more than 50 others regionally localized by linkage analysis. This article summarizes the mapping strategies now used and the impact of genome research on the understanding of X chromosome inactivation and X-linked diseases.	JOHN RADCLIFFE HOSP,IMPERIAL CANC RES FUND,HUMAN GENET LAB,OXFORD OX3 9DU,ENGLAND; BAYLOR COLL MED,INST MOLEC GENET,HOUSTON,TX 77030; WASHINGTON UNIV,SCH MED,DEPT MOLEC MICROBIOL,ST LOUIS,MO 63110	University of Oxford; Baylor College of Medicine; Washington University (WUSTL)	MANDEL, JL (corresponding author), CNRS,INSERM,GENET MOLEC EUCARYOTES LAB,F-67085 STRASBOURG,FRANCE.		Gilna, Paul/I-3608-2016; Monaco, Anthony P/A-4495-2010	Gilna, Paul/0000-0002-6542-0191; Monaco, Anthony P/0000-0001-7480-3197				ABBS S, 1990, GENOMICS, V7, P602, DOI 10.1016/0888-7543(90)90205-9; ABIDI FE, 1990, GENOMICS, V7, P363, DOI 10.1016/0888-7543(90)90170-Y; ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; ALBERTSEN HM, 1990, P NATL ACAD SCI USA, V87, P4256, DOI 10.1073/pnas.87.11.4256; ALITALO T, 1991, HUM GENET, V86, P599, DOI 10.1007/BF00201548; ANAND R, 1990, NUCLEIC ACIDS RES, V18, P1951, DOI 10.1093/nar/18.8.1951; ARCHIDIACONO N, 1991, HUM GENET, V86, P604; ARVEILER B, 1990, AM J HUM GENET, V46, P906; ASHWORTH A, 1991, NATURE, V351, P406, DOI 10.1038/351406a0; ATTREE O, 1992, NATURE, V358, P239, DOI 10.1038/358239a0; BACH I, IN PRESS HUM GENET; BAKKER E, 1989, J MED GENET, V26, P553, DOI 10.1136/jmg.26.9.553; BALLABIO A, 1990, GENOMICS, V8, P263, DOI 10.1016/0888-7543(90)90281-X; Ballabio A, 1992, CURR OPIN GENET DEV, V2, P439, DOI 10.1016/S0959-437X(05)80155-8; Ballabio A, 1991, CURR OPIN GENET DEV, V1, P25, DOI 10.1016/0959-437X(91)80036-L; BARKER DF, 1991, HUM GENET, V88, P189; BARLOW DP, 1987, TRENDS GENET, V3, P167, DOI 10.1016/0168-9525(87)90219-8; BAXENDALE S, 1991, NUCLEIC ACIDS RES, V19, P6651, DOI 10.1093/nar/19.23.6651; BENHAM F, 1989, GENOMICS, V4, P509, DOI 10.1016/0888-7543(89)90274-7; BERGER W, 1992, NAT GENET, V1, P199, DOI 10.1038/ng0692-199; BERGER W, 1992, NAT GENET, V1, P204; BLONDEN LAJ, 1991, GENOMICS, V10, P631, DOI 10.1016/0888-7543(91)90445-K; BORSANI G, 1991, NATURE, V351, P325, DOI 10.1038/351325a0; BOTTEMA CDK, 1991, AM J HUM GENET, V49, P839; BOYD Y, 1990, GENOMICS, V7, P182, DOI 10.1016/0888-7543(90)90539-7; BROCKDORFF N, 1991, MAMM GENOME, V1, P152, DOI 10.1007/BF00351061; BROCKDORFF N, 1991, NATURE, V351, P329, DOI 10.1038/351329a0; BROCKDORFF N, IN PRESS CELL; BROWN CJ, 1989, SOMAT CELL MOLEC GEN, V15, P173, DOI 10.1007/BF01535079; BROWN CJ, 1991, NATURE, V349, P82, DOI 10.1038/349082a0; BROWN CJ, 1989, CYTOGENET CELL GENET, V51, P970; BROWN CJ, 1991, NATURE, V349, P38, DOI 10.1038/349038a0; BROWN CJ, IN PRESS CELL; BROWN S, IN PRESS MAMM GENOME; BROWNSTEIN BH, 1989, SCIENCE, V244, P1348, DOI 10.1126/science.2544027; BUCKLER AJ, 1991, P NATL ACAD SCI USA, V88, P4005, DOI 10.1073/pnas.88.9.4005; BURKE DT, 1987, SCIENCE, V236, P806, DOI 10.1126/science.3033825; CANGIANO G, 1990, NUCLEIC ACIDS RES, V18, P5077, DOI 10.1093/nar/18.17.5077; CASKEY CT, 1992, SCIENCE, V256, P784, DOI 10.1126/science.1589758; CATTANACH BM, 1991, CYTOGENET CELL GENET, V56, P137, DOI 10.1159/000133070; CLARKE TR, 1992, AM J HUM GENET, V51, P316; COFFEY AJ, 1992, GENOMICS, V12, P474, DOI 10.1016/0888-7543(92)90437-W; COHEN D, 1992, COLD SPRING HARBOR M, P32; COLE CG, 1991, GENOMICS, V10, P816, DOI 10.1016/0888-7543(91)90468-T; COLLINS FS, 1992, NAT GENET, V1, P3, DOI 10.1038/ng0492-3; COULSON A, 1986, P NATL ACAD SCI USA, V83, P7821, DOI 10.1073/pnas.83.20.7821; COULSON A, 1986, P NATL ACAD SCI USA, V83, P7826; COX DR, 1990, SCIENCE, V250, P245, DOI 10.1126/science.2218528; CREMERS FP, 1990, NATURE, V347, P347; CREMERS FPM, 1988, AM J HUM GENET, V43, P452; DAVIES KE, 1991, CYTOGENET CELL GENET, V58, P853, DOI 10.1159/000133183; DENDUNNEN JT, 1989, AM J HUM GENET, V45, P835; DENDUNNEN JT, 1992, HUM MOL GENET, V1, P19; DOMBROSKI BA, 1991, SCIENCE, V254, P1805, DOI 10.1126/science.1662412; DRAYNA D, 1984, P NATL ACAD SCI-BIOL, V81, P2836, DOI 10.1073/pnas.81.9.2836; DRAYNA D, 1985, SCIENCE, V230, P753, DOI 10.1126/science.4059909; DUYK GM, 1990, P NATL ACAD SCI USA, V87, P8995, DOI 10.1073/pnas.87.22.8995; ELVIN P, 1990, NUCLEIC ACIDS RES, V18, P3913, DOI 10.1093/nar/18.13.3913; FAIN P, 1992, 3RD X CHROM WORKSH A; FARR C, 1991, P NATL ACAD SCI USA, V88, P7006, DOI 10.1073/pnas.88.16.7006; FOOTE S, 1992, SCIENCE, V258, P60, DOI 10.1126/science.1359640; FRANCKE U, 1985, AM J HUM GENET, V37, P250; FRANCO B, 1991, NATURE, V353, P529, DOI 10.1038/353529a0; FU YH, 1991, NEW ENGL J MED, V65, P905; GEDEON AK, 1992, AM J MED GENET, V43, P255, DOI 10.1002/ajmg.1320430140; GIANNELLI F, 1991, NUCLEIC ACIDS RES, V19, P2193, DOI 10.1093/nar/19.suppl.2193; GOLEMAN MP, 1991, GENOMICS, V11, P991; GORSKI JL, 1991, AM J HUM GENET, V48, P53; GOSS SJ, 1975, NATURE, V255, P680, DOI 10.1038/255680a0; Green E D, 1991, PCR Methods Appl, V1, P77; GREEN ED, 1990, P NATL ACAD SCI USA, V87, P1213, DOI 10.1073/pnas.87.3.1213; HADANO S, 1991, GENOMICS, V11, P364, DOI 10.1016/0888-7543(91)90144-4; HENDRIKS RW, 1992, HUM MOL GENET, V1, P187, DOI 10.1093/hmg/1.3.187; HIGUCHI M, 1991, P NATL ACAD SCI USA, V88, P8307, DOI 10.1073/pnas.88.19.8307; HIGUCHI M, 1991, P NATL ACAD SCI USA, V88, P405; HIRST MC, 1991, GENOMICS, V10, P243, DOI 10.1016/0888-7543(91)90506-A; HO M, 1991, CYTOGENET CELL GENET, V58, P2067; HO MF, 1992, AM J HUM GENET, V50, P317; HU XY, 1990, AM J HUM GENET, V46, P682; HUANG THM, 1992, GENOMICS, V13, P375, DOI 10.1016/0888-7543(92)90256-R; KERE J, IN PRESS GENOMICS; KERR B, 1991, J MED GENET, V28, P378, DOI 10.1136/jmg.28.6.378; KOENIG M, 1989, AM J HUM GENET, V45, P489; KORN B, 1991, HUM MOL GENET, V1, P235; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; KUPKE KG, 1992, AM J HUM GENET, V50, P808; LAFRENIERE RG, 1991, GENOMICS, V11, P352, DOI 10.1016/0888-7543(91)90143-3; LAFRENIERE RG, 1992, COLD SPRING HARBOR M; LARIN Z, 1991, P NATL ACAD SCI USA, V88, P4123, DOI 10.1073/pnas.88.10.4123; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; LEE JT, 1992, GENOMICS, V12, P526, DOI 10.1016/0888-7543(92)90444-W; LEGOUIS R, 1991, CELL, V67, P423, DOI 10.1016/0092-8674(91)90193-3; LEHRACH H, 1990, CENOME ANAL, V1, P39; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; LITT M, 1989, AM J HUM GENET, V44, P397; LITTLE RD, 1992, P NATL ACAD SCI USA, V89, P177, DOI 10.1073/pnas.89.1.177; LITTLEFIELD JW, 1964, SCIENCE, V145, P709, DOI 10.1126/science.145.3633.709; LLISON KA, 1992, AM J HUM GENET, V50, P278; LOVETT M, 1991, P NATL ACAD SCI USA, V88, P9628, DOI 10.1073/pnas.88.21.9628; LUDECKE HJ, 1989, NATURE, V338, P348, DOI 10.1038/338348a0; LYON MF, 1988, AM J HUM GENET, V42, P8; MAESTRINI E, 1990, GENOMICS, V8, P664, DOI 10.1016/0888-7543(90)90253-Q; MAESTRINI E, 1992, HUM MOL GENET, V1, P2775; MAHTANI MM, 1991, GENOMICS, V10, P849, DOI 10.1016/0888-7543(91)90172-B; MAZZARELLA R, 1992, P NATL ACAD SCI USA, V89, P3681, DOI 10.1073/pnas.89.9.3681; McKusick V.A., 1992, MENDELIAN INHERITANC; MIGEON BR, 1990, GENET RES, V56, P91, DOI 10.1017/S0016672300035151; MONACO AP, 1986, NATURE, V323, P646, DOI 10.1038/323646a0; MONACO AP, 1992, GENOMICS, V12, P465, DOI 10.1016/0888-7543(92)90436-V; MONACO AP, 1985, NATURE, V316, P842, DOI 10.1038/316842a0; MONACO AP, 1991, NUCLEIC ACIDS RES, V19, P3315, DOI 10.1093/nar/19.12.3315; MONACO AP, 1986, NATURE, V322, P32; MONACO AP, UNPUB; MONTANARO V, 1991, AM J HUM GENET, V48, P183; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; MUSARELLA MA, 1991, GENOMICS, V11, P263, DOI 10.1016/0888-7543(91)90132-X; NELSON DL, 1989, P NATL ACAD SCI USA, V86, P6686, DOI 10.1073/pnas.86.17.6686; NELSON DL, 1991, P NATL ACAD SCI USA, V88, P6157, DOI 10.1073/pnas.88.14.6157; NERI G, 1992, AM J MED GENET, V43, P373, DOI 10.1002/ajmg.1320430158; NIZETIC D, 1991, P NATL ACAD SCI USA, V88, P3233, DOI 10.1073/pnas.88.8.3233; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; Ohno S., 1967, SEX CHROMOSOMES SEX; OLSON M, 1989, SCIENCE, V245, P1434, DOI 10.1126/science.2781285; OUDET C, IN PRESS HUM MOL GEN; PALAZZOLO MJ, 1991, P NATL ACAD SCI USA, V88, P8034, DOI 10.1073/pnas.88.18.8034; PARIMOO S, 1991, P NATL ACAD SCI USA, V88, P9623, DOI 10.1073/pnas.88.21.9623; PETIT C, 1988, EMBO J, V7, P2369, DOI 10.1002/j.1460-2075.1988.tb03081.x; PETIT C, 1990, P NATL ACAD SCI USA, V87, P3680, DOI 10.1073/pnas.87.10.3680; PETIT C, 1991, P NATL ACAD SCI USA, V88, P8302; POUSTKA A, 1991, P NATL ACAD SCI USA, V88, P8302, DOI 10.1073/pnas.88.19.8302; RASTAN S, 1990, GENET RES, V56, P99, DOI 10.1017/S0016672300035163; RICHARDS RI, 1991, J MED GENET, V28, P818, DOI 10.1136/jmg.28.12.818; RICHARDS RI, 1992, NAT GENET, V1, P7, DOI 10.1038/ng0492-7; ROBERTS RG, 1992, P NATL ACAD SCI USA, V89, P2331, DOI 10.1073/pnas.89.6.2331; ROBERTS RG, 1992, GENOMICS, V13, P942, DOI 10.1016/0888-7543(92)90005-D; ROSS MT, 1992, NAT GENET, V1, P284, DOI 10.1038/ng0792-284; ROUSSEAU F, 1991, AM J HUM GENET, V48, P108; ROUSSEAU F, 1991, NEW ENGL J MED, V325, P1673, DOI 10.1056/NEJM199112123252401; ROUYER F, 1986, NATURE, V319, P291, DOI 10.1038/319291a0; ROYLE NJ, 1988, GENOMICS, V3, P325; SACCONE S, 1992, P NATL ACAD SCI USA, V89, P4913, DOI 10.1073/pnas.89.11.4913; SCHLESSINGER D, 1991, GENOMICS, V11, P783, DOI 10.1016/0888-7543(91)90001-U; SCHMIDT M, 1992, AM J MED GENET, V43, P279, DOI 10.1002/ajmg.1320430143; SEFIANI A, 1991, HUM GENET, V86, P297; SINKALA EM, 1989, HUM GENET, V84, P66; SUTHERS GK, 1991, GENOMICS, V9, P37, DOI 10.1016/0888-7543(91)90218-4; SUTHERS GK, 1990, AM J HUM GENET, V47, P187; TUDDENHAM EGD, 1991, NUCLEIC ACIDS RES, V19, P4821, DOI 10.1093/nar/19.18.4821; UBERBACHER EC, 1991, P NATL ACAD SCI USA, V88, P11261, DOI 10.1073/pnas.88.24.11261; VERGA V, 1992, HUM GENET, V88, P668; VIDAUD D, IN PRESS EUR J HUM G; VOLLRATH D, 1992, SCIENCE, V258, P52, DOI 10.1126/science.1439769; VULLIAMY P, 1992, TRENDS GENET, V8, P138; WADA M, 1990, AM J HUM GENET, V46, P95; WARREN ST, 1990, P NATL ACAD SCI USA, V87, P3856, DOI 10.1073/pnas.87.10.3856; WATSON JM, 1991, P NATL ACAD SCI USA, V88, P11256, DOI 10.1073/pnas.88.24.11256; WEBER JL, 1989, AM J HUM GENET, V44, P388; WILLARD HF, 1985, HUM GENET, V71, P138; YEN PH, 1990, CELL, V61, P603, DOI 10.1016/0092-8674(90)90472-Q; ZONANA J, IN PRESS AM J HUM GE; ZUCCHI I, 1992, GENOMICS, V12, P264, DOI 10.1016/0888-7543(92)90373-Z	161	48	51	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 2	1992	258	5079					103	109		10.1126/science.1439756	http://dx.doi.org/10.1126/science.1439756			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JQ619	1439756				2022-12-01	WOS:A1992JQ61900027
J	MANDEL, MA; BOWMAN, JL; KEMPIN, SA; MA, H; MEYEROWITZ, EM; YANOFSKY, MF				MANDEL, MA; BOWMAN, JL; KEMPIN, SA; MA, H; MEYEROWITZ, EM; YANOFSKY, MF			MANIPULATION OF FLOWER STRUCTURE IN TRANSGENIC TOBACCO	CELL			English	Article							MOSAIC VIRUS-35S PROMOTER; ARABIDOPSIS-THALIANA; FLORAL DEVELOPMENT; ANTIRRHINUM-MAJUS; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION FACTORS; GENETIC INTERACTIONS; HOMEOTIC GENES; MORPHOGENESIS; EXPRESSION	Genetic studies suggest that three homeotic functions, designated A, B, and C, act alone and together to specify the fate of floral organ primordia in distantly related dicotyledonous plant species. To test the genetic model, we have generated transgenic tobacco plants that ectopically express the AGAMOUS gene from Brassica napus, which is necessary for the C function. Flowers on the resulting plants showed homeotic transformations of sepals into carpels and petals into stamens. These phenotypes are consistent with predictions from the genetic model, show that expression of AGAMOUS is sufficient to provide ectopic C function, and demonstrate that the structure of flowers can be manipulated in a predictable manner by altering the expression of a single regulatory gene. Furthermore, the generation of the predicted transformations by ectopic expression of the Brassica gene in transgenic tobacco indicates that gene functions are interchangable between phylogenetically distant species.	UNIV CALIF SAN DIEGO,CTR MOLEC GENET,LA JOLLA,CA 92093; CALTECH,DIV BIOL,PASADENA,CA 91125	University of California System; University of California San Diego; California Institute of Technology	MANDEL, MA (corresponding author), UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093, USA.		Ma, Hong/W-5251-2018; Meyerowitz, Elliot M/A-7118-2009	Ma, Hong/0000-0001-8717-4422; Bowman, John/0000-0001-7347-3691	NIGMS NIH HHS [5T32-GM07616, GM45697] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007616] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENFEY PN, 1990, SCIENCE, V250, P959, DOI 10.1126/science.250.4983.959; BOWMAN JL, 1991, DEVELOPMENT, V112, P1; BOWMAN JL, 1991, PLANT CELL, V3, P749, DOI 10.1105/tpc.3.8.749; BOWMAN JL, 1989, PLANT CELL, V1, P37, DOI 10.1105/tpc.1.1.37; BOWMAN JL, 1988, OXFORD SURV PLANT MO, V5, P57; CHANG C, 1988, P NATL ACAD SCI USA, V85, P6856, DOI 10.1073/pnas.85.18.6856; CHRIST C, 1991, GENE DEV, V5, P751, DOI 10.1101/gad.5.5.751; COEN ES, 1991, NATURE, V353, P31, DOI 10.1038/353031a0; COEN ES, 1990, CELL, V63, P1311, DOI 10.1016/0092-8674(90)90426-F; CRAWFORD NM, 1986, P NATL ACAD SCI USA, V83, P8073, DOI 10.1073/pnas.83.21.8073; DREWS GN, 1991, CELL, V65, P991, DOI 10.1016/0092-8674(91)90551-9; DUBOIS E, 1987, GENE, V55, P265, DOI 10.1016/0378-1119(87)90286-1; EVANS PT, 1989, DEV BIOL, V136, P273, DOI 10.1016/0012-1606(89)90148-6; HAUGHN GW, 1988, DEV GENET, V9, P73, DOI 10.1002/dvg.1020090202; HICKS GS, 1970, CAN J BOTANY, V48, P133, DOI 10.1139/b70-017; HILL JP, 1989, CAN J BOT, V67, P2922, DOI 10.1139/b89-375; HORSCH RB, 1985, SCIENCE, V227, P1229, DOI 10.1126/science.227.4691.1229; HUIJSER P, 1992, EMBO J, V11, P1239, DOI 10.1002/j.1460-2075.1992.tb05168.x; IRISH VF, 1990, PLANT CELL, V2, P741, DOI 10.1105/tpc.2.8.741; JACK T, 1992, CELL, V68, P683, DOI 10.1016/0092-8674(92)90144-2; JARVIS EE, 1989, GENE DEV, V3, P936, DOI 10.1101/gad.3.7.936; KOLTUNOW AM, 1990, PLANT CELL, V2, P1201, DOI 10.1105/tpc.2.12.1201; KOMAKI MK, 1988, DEVELOPMENT, V104, P195; KUNST L, 1989, PLANT CELL, V1, P1195, DOI 10.1105/tpc.1.12.1195; MEYEROWITZ EM, 1989, DEVELOPMENT, V106, P209; MEYEROWITZ EM, 1987, ANNU REV GENET, V21, P93, DOI 10.1146/annurev.genet.21.1.93; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; ODELL JT, 1985, NATURE, V313, P810, DOI 10.1038/313810a0; PASSMORE S, 1988, J MOL BIOL, V204, P593, DOI 10.1016/0022-2836(88)90358-0; Pruitt RE, 1987, GENETIC REGULATION D, P327; ROGERS SG, 1987, METHOD ENZYMOL, V153, P253; SCHWARZSOMMER Z, 1990, SCIENCE, V250, P931, DOI 10.1126/science.250.4983.931; SMYTH DR, 1990, PLANT CELL, V2, P755, DOI 10.1105/tpc.2.8.755; SOMMER H, 1990, EMBO J, V9, P605, DOI 10.1002/j.1460-2075.1990.tb08152.x; WEIGEL D, 1992, CELL, V69, P843, DOI 10.1016/0092-8674(92)90295-N; YANOFSKY MF, 1990, NATURE, V346, P35, DOI 10.1038/346035a0	36	194	216	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 2	1992	71	1					133	143		10.1016/0092-8674(92)90272-E	http://dx.doi.org/10.1016/0092-8674(92)90272-E			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JQ623	1356631				2022-12-01	WOS:A1992JQ62300013
J	MIZUKAMI, Y; MA, H				MIZUKAMI, Y; MA, H			ECTOPIC EXPRESSION OF THE FLORAL HOMEOTIC GENE AGAMOUS IN TRANSGENIC ARABIDOPSIS PLANTS ALTERS FLORAL ORGAN IDENTITY	CELL			English	Article							FLOWER DEVELOPMENT; ANTIRRHINUM-MAJUS; TRANSCRIPTION FACTORS; THALIANA; TRANSFORMATION; MORPHOGENESIS; SEQUENCES; PRODUCT	The Arabidopsis floral homeotic gene AGAMOUS (AG) is required for development of the reproductive organs (stamens and carpels). In ag mutants, the loss of AG function leads to the conversion of these organs to the perianth organs (petals and sepals). In contrast, mutations in another floral homeotic gene, APETALA2 (AP2), result in the replacement of the perianth organs by the reproductive organs. On the basis of these observations, it has been proposed that AG and AP2 act in an antagonistic fashion. To test this hypothesis, we have studied the effects of ectopically expressed AG in transgenic Arabidopsis plants. The flowers of the transgenic plants exhibit a range of phenotypes mirroring those of ap2 mutants. These experiments provide direct evidence of the proposed antagonism between AG and AP2 functions, and the results strongly suggest that AG does indeed inhibit AP2 function.			MIZUKAMI, Y (corresponding author), COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA.		Ma, Hong/W-5251-2018	Ma, Hong/0000-0001-8717-4422				ALVAREZ J, 1992, PLANT J, V2, P103, DOI 10.1111/j.1365-313X.1992.00103.x; BOWMAN JL, 1991, DEVELOPMENT, V112, P1; BOWMAN JL, 1992, DEVELOPMENT, V114, P599; BOWMAN JL, 1991, PLANT CELL, V3, P749, DOI 10.1105/tpc.3.8.749; BOWMAN JL, 1989, PLANT CELL, V1, P37, DOI 10.1105/tpc.1.1.37; COEN ES, 1991, NATURE, V353, P31, DOI 10.1038/353031a0; COEN ES, 1990, CELL, V63, P1311, DOI 10.1016/0092-8674(90)90426-F; DREWS GN, 1991, CELL, V65, P991, DOI 10.1016/0092-8674(91)90551-9; HAUGHN GW, 1988, DEV GENET, V9, P73, DOI 10.1002/dvg.1020090202; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; HILL JP, 1989, CAN J BOT, V67, P2922, DOI 10.1139/b89-375; HUIJSER P, 1992, EMBO J, V11, P1239, DOI 10.1002/j.1460-2075.1992.tb05168.x; IRISH VF, 1990, PLANT CELL, V2, P741, DOI 10.1105/tpc.2.8.741; JACK T, 1992, CELL, V68, P683, DOI 10.1016/0092-8674(92)90144-2; KOMAKI MK, 1988, DEVELOPMENT, V104, P195; KUNST L, 1989, PLANT CELL, V1, P1195, DOI 10.1105/tpc.1.12.1195; MA H, 1991, GENE DEV, V5, P484, DOI 10.1101/gad.5.3.484; MANDEL MA, 1992, CELL, V71, P133, DOI 10.1016/0092-8674(92)90272-E; MATZKE MA, 1990, DEV GENET, V11, P214, DOI 10.1002/dvg.1020110307; MEYEROWITZ EM, 1989, DEVELOPMENT, V106, P209; MEYEROWITZ EM, 1991, DEVELOPMENT, P157; NAPOLI C, 1990, PLANT CELL, V2, P279, DOI 10.1105/tpc.2.4.279; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; ODELL JT, 1985, NATURE, V313, P810, DOI 10.1038/313810a0; PASSMORE S, 1988, J MOL BIOL, V204, P593, DOI 10.1016/0022-2836(88)90358-0; PNUELI L, 1991, PLANT J, V1, P255, DOI 10.1111/j.1365-313X.1991.00255.x; Pruitt RE, 1987, GENETIC REGULATION D, P327; ROGERS SG, 1987, METHOD ENZYMOL, V153, P253; SCHULTZ EA, 1991, PLANT CELL, V3, P1221, DOI 10.1105/tpc.3.11.1221; SCHULTZ EA, 1991, PLANT CELL, V3, P771, DOI 10.1105/tpc.3.8.771; SCHWARZSOMMER Z, 1990, SCIENCE, V250, P931, DOI 10.1126/science.250.4983.931; SHANNON S, 1991, PLANT CELL, V3, P877, DOI 10.1105/tpc.3.9.877; SMYTH DR, 1990, PLANT CELL, V2, P755, DOI 10.1105/tpc.2.8.755; SOMMER H, 1990, EMBO J, V9, P605, DOI 10.1002/j.1460-2075.1990.tb08152.x; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; VALVEKENS D, 1988, P NATL ACAD SCI USA, V85, P5536, DOI 10.1073/pnas.85.15.5536; WEIGEL D, 1992, CELL, V69, P843, DOI 10.1016/0092-8674(92)90295-N; YANOFSKY MF, 1990, NATURE, V346, P35, DOI 10.1038/346035a0	38	355	387	1	36	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 2	1992	71	1					119	131		10.1016/0092-8674(92)90271-D	http://dx.doi.org/10.1016/0092-8674(92)90271-D			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JQ623	1356630				2022-12-01	WOS:A1992JQ62300012
J	MONTELL, DJ; RORTH, P; SPRADLING, AC				MONTELL, DJ; RORTH, P; SPRADLING, AC			SLOW BORDER CELLS, A LOCUS REQUIRED FOR A DEVELOPMENTALLY REGULATED CELL-MIGRATION DURING OOGENESIS, ENCODES DROSOPHILA C/EBP	CELL			English	Article							ENHANCER-BINDING-PROTEIN; GENE; EXPRESSION; ELEMENTS	During Drosophila oogenesis six to ten follicle cells, the border cells, undergo a dramatic and stereotypic migration through the developing egg chamber. We identified four independent P element insertion mutations that specifically blocked border cell migration. They defined a single, novel locus that was named slow border cells (slbo), because hypomorphic alleles caused delayed onset of the migration. Laser ablation of the border cells, or failure of their migration, caused improper morphogenesis of the micropyle, the eggshell structure through which the sperm enters at fertilization. The slbo locus was found to encode a product homologous to the CCAAT/enhancer-binding protein (C/EBP), a basic region-leucine zipper transcription factor. Drosophila C/EBP may be required for the expression of gene products mediating border cell migration.	CARNEGIE INST WASHINGTON, HOWARD HUGHES MED INST, DEPT EMBRYOL, BALTIMORE, MD 21210 USA	Carnegie Institution for Science; Howard Hughes Medical Institute			Rørth, Pernille/H-3020-2011		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM046425] Funding Source: NIH RePORTER; Howard Hughes Medical Institute Funding Source: Medline; NIGMS NIH HHS [R29GM46425] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELLEN HJ, 1989, GENE DEV, V3, P1288, DOI 10.1101/gad.3.9.1288; BERG CA, 1991, GENETICS, V127, P515; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; COHEN B, 1992, GENE DEV, V6, P715, DOI 10.1101/gad.6.5.715; COOLEY L, 1988, SCIENCE, V239, P1121, DOI 10.1126/science.2830671; FALB D, 1992, GENE DEV, V6, P454, DOI 10.1101/gad.6.3.454; FRIEDMAN AD, 1990, GENE DEV, V4, P1416, DOI 10.1101/gad.4.8.1416; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GUTZEIT HO, 1982, J EMBRYOL EXP MORPH, V67, P101; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; KAESTNER KH, 1990, P NATL ACAD SCI USA, V87, P251, DOI 10.1073/pnas.87.1.251; KALT MR, 1971, J ULTRA MOL STRUCT R, V36, P633, DOI 10.1016/S0022-5320(71)90020-7; KIMBLE M, 1990, GENETICS, V126, P991; King RC., 1970, OVARIAN DEV DROSOPHI; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LIN FT, 1992, GENE DEV, V6, P533, DOI 10.1101/gad.6.4.533; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MILLER DM, 1992, NATURE, V355, P841, DOI 10.1038/355841a0; MLODZIK M, 1992, GENE EXPRESSION NEUR, V9, P397; MONTELL DJ, 1991, SCIENCE, V254, P290, DOI 10.1126/science.1925585; OKANE CJ, 1987, P NATL ACAD SCI USA, V84, P9123, DOI 10.1073/pnas.84.24.9123; SALSER SJ, 1992, NATURE, V355, P255, DOI 10.1038/355255a0; Sambrook J., 1989, MOL CLONING LAB MANU; SPRADLING AC, 1992, IN PRESS DROSOPHILA; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; THIERY JP, 1988, CIBA F SYMP, V141, P48; Tressler R J, 1989, Cancer Commun, V1, P55; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; ZARANI FE, 1986, CAN J ZOOL, V64, P2509, DOI 10.1139/z86-372	31	269	273	0	18	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 2	1992	71	1					51	62		10.1016/0092-8674(92)90265-E	http://dx.doi.org/10.1016/0092-8674(92)90265-E			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JQ623	1394432				2022-12-01	WOS:A1992JQ62300006
J	NELSON, RJ; ZIEGELHOFFER, T; NICOLET, C; WERNERWASHBURNE, M; CRAIG, EA				NELSON, RJ; ZIEGELHOFFER, T; NICOLET, C; WERNERWASHBURNE, M; CRAIG, EA			THE TRANSLATION MACHINERY AND 70 KD HEAT-SHOCK PROTEIN COOPERATE IN PROTEIN-SYNTHESIS	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; HSP70 FAMILY; YEAST; MEMBER; TRANSLOCATION; MITOCHONDRIA; SEQUENCE; CLONING; MUTANT; GENES	The function of the yeast SSB 70 kd heatshock proteins (hsp70s) was investigated by a variety of approaches. The SSB hsp70s (Ssb1/2p) are associated with translating ribosomes. This association is disrupted by puromycin, suggesting that Ssb1/2p may bind directly to the nascent polypeptide. Mutant ssb1 ssb2 strains grow slowly, contain a low number of translating ribosomes, and are hypersensitive to several inhibitors of protein synthesis. The slow growth phenotype of ssb1 ssb2 mutants is suppressed by increased copy number of a gene encoding a novel translation elongation factor 1alpha (EF-1alpha)-like protein. We suggest that cytosolic hsp70 aids in the passage of the nascent polypeptide chain through the ribosome in a manner analogous to the role played by organelle-localized hsp70 in the transport of proteins across membranes.	UNIV WISCONSIN,PROGRAM CELLULAR & MOLEC BIOL,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison	NELSON, RJ (corresponding author), UNIV WISCONSIN,DEPT BIOMOLEC CHEM,MADISON,WI 53706, USA.							BAYLISS FT, 1971, SCIENCE, V174, P1339, DOI 10.1126/science.174.4016.1339; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BLOBEL G, 1971, P NATL ACAD SCI USA, V68, P390, DOI 10.1073/pnas.68.2.390; BLOBEL G, 1970, J CELL BIOL, V45, P130, DOI 10.1083/jcb.45.1.130; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; CARTER CJ, 1980, EUR J BIOCHEM, V107, P173, DOI 10.1111/j.1432-1033.1980.tb04638.x; CRAIG EA, 1985, MOL CELL BIOL, V5, P3517, DOI 10.1128/MCB.5.12.3517; CRAIG EA, 1989, MOL CELL BIOL, V9, P3000, DOI 10.1128/MCB.9.7.3000; CRAIG EA, 1985, CRC CR REV BIOCH MOL, V18, P239, DOI 10.3109/10409238509085135; CULBERTSON MR, 1982, GENETICS, V102, P361; DEVER TE, 1987, P NATL ACAD SCI USA, V84, P1814, DOI 10.1073/pnas.84.7.1814; ENGMAN DM, 1989, MOL CELL BIOL, V9, P5163, DOI 10.1128/MCB.9.11.5163; FORCHHAMMER J, 1971, J MOL BIOL, V55, P563, DOI 10.1016/0022-2836(71)90337-8; FRIED HM, 1981, P NATL ACAD SCI-BIOL, V78, P238, DOI 10.1073/pnas.78.1.238; Gale E. F., 1981, MOL BASIS ANTIBIOTIC; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; GONZALEZ A, 1978, BIOCHIM BIOPHYS ACTA, V521, P459, DOI 10.1016/0005-2787(78)90287-3; GRIBSKOV M, 1986, NUCLEIC ACIDS RES, V14, P6745, DOI 10.1093/nar/14.16.6745; Hawthorne D C, 1974, Curr Top Microbiol Immunol, V64, P1; HEMMINGS BA, 1981, P NATL ACAD SCI-BIOL, V78, P435, DOI 10.1073/pnas.78.1.435; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KITAKAWA M, 1990, NUCLEIC ACIDS RES, V18, P1521, DOI 10.1093/nar/18.6.1521; LEUSTEK T, 1989, P NATL ACAD SCI USA, V86, P7805, DOI 10.1073/pnas.86.20.7805; MALKIN LI, 1967, J MOL BIOL, V26, P329, DOI 10.1016/0022-2836(67)90301-4; Maniatis T., 1982, MOL CLONING; MARSHALL JS, 1990, P NATL ACAD SCI USA, V87, P374, DOI 10.1073/pnas.87.1.374; MASUREKAR M, 1981, J MOL BIOL, V147, P381, DOI 10.1016/0022-2836(81)90490-3; MILLIGAN RA, 1986, NATURE, V319, P693, DOI 10.1038/319693a0; MIZZEN LA, 1989, J BIOL CHEM, V264, P20664; NAGATA S, 1984, EMBO J, V3, P1825, DOI 10.1002/j.1460-2075.1984.tb02053.x; NGUYEN TH, 1991, P NATL ACAD SCI USA, V88, P1565, DOI 10.1073/pnas.88.4.1565; NORMINGTON K, 1989, CELL, V57, P1223, DOI 10.1016/0092-8674(89)90059-7; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHERER PE, 1990, EMBO J, V9, P4315, DOI 10.1002/j.1460-2075.1990.tb07880.x; SMITH JD, 1965, J MOL BIOL, V13, P617, DOI 10.1016/S0022-2836(65)80130-9; STOCKLEIN W, 1981, FEBS LETT, V136, P265, DOI 10.1016/0014-5793(81)80632-1; Surguchovs AP, 1984, PHYSICOCHEMICAL BIOL, V4, P147; VANHOLDE KE, 1974, RIBOSOMES, P53; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; WETTSTEIN FO, 1964, BIOCHIM BIOPHYS ACTA, V87, P525, DOI 10.1016/0926-6550(64)90131-8	47	448	473	1	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 2	1992	71	1					97	105		10.1016/0092-8674(92)90269-I	http://dx.doi.org/10.1016/0092-8674(92)90269-I			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JQ623	1394434				2022-12-01	WOS:A1992JQ62300010
J	OOI, CE; WEISS, J				OOI, CE; WEISS, J			BIDIRECTIONAL MOVEMENT OF A NASCENT POLYPEPTIDE ACROSS MICROSOMAL-MEMBRANES REVEALS REQUIREMENTS FOR VECTORIAL TRANSLOCATION OF PROTEINS	CELL			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; SIGNAL RECOGNITION PARTICLE; PERMEABILITY-INCREASING PROTEIN; POLYMORPHONUCLEAR LEUKOCYTES; ROUGH MICROSOMES; ER MEMBRANE; RECEPTOR; SEQUENCE; TRANSLATION; IDENTIFICATION	The translocation of polypeptides across the endoplasmic reticulum is a vectorial process that occurs probably through a protein channel by a mechanism as yet undetermined. Here, we demonstrate bidirectional movement of a 221 residue nascent polypeptide across microsomal membranes and provide evidence suggesting that the retrograde movement is through the translocation channel. Retrograde movement is observed only when the polypeptide is generated from a truncated transcript; addition of a stop codon after codon 221 confers vectorial movement. Retrograde movement can also be prevented by glycosylation of the nascent polypeptide, as well as by inclusion of 32 additional amino acids that may promote folding of the translocated chain. We propose that the protein translocation channel is a passive pore that does not create a directional bias in polypeptide movement and that vectorial translocation is driven by nascent chain elongation and sustained by posttranslocation events that prevent retrograde movement.			OOI, CE (corresponding author), NYU, SCH MED, DEPT MICROBIOL, NEW YORK, NY 10016 USA.			Weiss, Jerrold/0000-0003-1476-4485	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK005472] Funding Source: NIH RePORTER; NIDDK NIH HHS [R37 DK 05472] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAUSE E, 1983, BIOCHEM J, V209, P331, DOI 10.1042/bj2090331; BLOBEL G, 1970, J CELL BIOL, V45, P130, DOI 10.1083/jcb.45.1.130; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; Blobel G., 1971, BIOMEMBRANE, P193, DOI DOI 10.1007/978-1-4684-3330-2_16; CASKEY CT, 1980, TRENDS BIOCHEM SCI, V5, P234, DOI 10.1016/S0968-0004(80)80809-7; CHUCK SL, 1990, NATURE, V346, P382, DOI 10.1038/346382a0; CONNOLLY T, 1989, J CELL BIOL, V108, P299, DOI 10.1083/jcb.108.2.299; CONNOLLY T, 1991, SCIENCE, V252, P1171, DOI 10.1126/science.252.5009.1171; CONNOLLY T, 1989, CELL, V57, P599, DOI 10.1016/0092-8674(89)90129-3; CONNOLLY T, 1986, J CELL BIOL, V103, P2253, DOI 10.1083/jcb.103.6.2253; DOOHAN JP, 1992, VIROLOGY, V186, P409, DOI 10.1016/0042-6822(92)90006-B; ELSBACH P, 1990, TRENDS BIOTECHNOL, V8, P26, DOI 10.1016/0167-7799(90)90127-J; Elsbach P., 1988, INFLAMMATION BASIC P, P445; GILMORE R, 1983, CELL, V35, P677, DOI 10.1016/0092-8674(83)90100-9; GILMORE R, 1982, J CELL BIOL, V95, P463, DOI 10.1083/jcb.95.2.463; GILMORE R, 1985, CELL, V42, P497, DOI 10.1016/0092-8674(85)90107-2; GILMORE R, 1982, J CELL BIOL, V95, P470, DOI 10.1083/jcb.95.2.470; GORLICH D, 1992, NATURE, V357, P47, DOI 10.1038/357047a0; GRAY PW, 1989, J BIOL CHEM, V264, P9505; HIGH S, 1991, J CELL BIOL, V113, P35, DOI 10.1083/jcb.113.1.35; HOFFMAN KE, 1988, J BIOL CHEM, V263, P4381; KELLARIS KV, 1991, J CELL BIOL, V114, P21, DOI 10.1083/jcb.114.1.21; KRIEG UC, 1989, J CELL BIOL, V109, P2033, DOI 10.1083/jcb.109.5.2033; KURZCHALIA TV, 1986, NATURE, V320, P634, DOI 10.1038/320634a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINGAPPA VR, 1991, CELL, V65, P527, DOI 10.1016/0092-8674(91)90081-9; MALKIN LI, 1967, J MOL BIOL, V26, P329, DOI 10.1016/0022-2836(67)90301-4; MANNION BA, 1990, J CLIN INVEST, V86, P631, DOI 10.1172/JCI114755; MARRA MN, 1990, J IMMUNOL, V144, P662; MEYER DI, 1982, NATURE, V297, P647, DOI 10.1038/297647a0; NICCHITTA CV, 1990, CELL, V60, P259, DOI 10.1016/0092-8674(90)90741-V; OOI CE, 1987, J BIOL CHEM, V262, P14891; OOI CE, 1991, J EXP MED, V174, P649, DOI 10.1084/jem.174.3.649; PERARA E, 1986, SCIENCE, V232, P348, DOI 10.1126/science.3961485; RABINOVICH YM, 1991, BIOCHIM BIOPHYS ACTA, V1089, P193, DOI 10.1016/0167-4781(91)90007-9; RAPOPORT TA, 1990, TRENDS BIOCHEM SCI, V15, P355, DOI 10.1016/0968-0004(90)90076-N; REDMAN CM, 1966, P NATL ACAD SCI USA, V56, P608, DOI 10.1073/pnas.56.2.608; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SHAW AS, 1988, P NATL ACAD SCI USA, V85, P7592, DOI 10.1073/pnas.85.20.7592; SIMON SM, 1992, P NATL ACAD SCI USA, V89, P3770, DOI 10.1073/pnas.89.9.3770; SIMON SM, 1992, CELL, V69, P677, DOI 10.1016/0092-8674(92)90231-Z; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; TRAUT RR, 1964, J MOL BIOL, V10, P63, DOI 10.1016/S0022-2836(64)80028-0; WALTER P, 1980, P NATL ACAD SCI-BIOL, V77, P7112, DOI 10.1073/pnas.77.12.7112; WALTER P, 1986, ANNU REV CELL BIOL, V2, P499, DOI 10.1146/annurev.cellbio.2.1.499; WEISS J, 1978, J BIOL CHEM, V253, P2664; WELPLY JK, 1983, J BIOL CHEM, V258, P1856; WIEDMANN M, 1987, NATURE, V328, P830, DOI 10.1038/328830a0; WOLIN SL, 1988, EMBO J, V7, P3559, DOI 10.1002/j.1460-2075.1988.tb03233.x; YU YH, 1989, P NATL ACAD SCI USA, V86, P9931, DOI 10.1073/pnas.86.24.9931	50	77	77	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 2	1992	71	1					87	96		10.1016/0092-8674(92)90268-H	http://dx.doi.org/10.1016/0092-8674(92)90268-H			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JQ623	1394433				2022-12-01	WOS:A1992JQ62300009
J	SANO, T; SMITH, CL; CANTOR, CR				SANO, T; SMITH, CL; CANTOR, CR			IMMUNO-PCR - VERY SENSITIVE ANTIGEN-DETECTION BY MEANS OF SPECIFIC ANTIBODY-DNA CONJUGATES	SCIENCE			English	Article							POLYMERASE CHAIN-REACTION; CATALYTIC ANTIBODIES; ESCHERICHIA-COLI; AMPLIFICATION; MOLECULES; CHEMISTRY	An antigen detection system, termed immuno-polymerase chain reaction (immuno-PCR), was developed in which a specific DNA molecule is used as the marker. A streptavidin-protein A chimera that possesses tight and specific binding affinity both for biotin and immunoglobulin G was used to attach a biotinylated DNA specifically to antigen-monoclonal antibody complexes that had been immobilized on microtiter plate wells. Then, a segment of the attached DNA was amplified by PCR. Analysis of the PCR products by agarose gel electrophoresis after staining with ethidium bromide allowed as few as 580 antigen molecules (9.6 x 10(-22) moles) to be readily and reproducibly detected. Direct comparison with enzyme-linked immunosorbent assay with the use of a chimera-alkaline phosphatase conjugate demonstrates that enhancement (approximately x 10(5)) in detection sensitivity was obtained with the use of immuno-PCR. Given the enormous amplification capability and specificity of PCR, this immuno-PCR technology has a sensitivity greater than any existing antigen detection system and, in principle, could be applied to the detection of single antigen molecules.	LAWRENCE BERKELEY LAB, DIV STRUCT BIOL, BERKELEY, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory	SANO, T (corresponding author), UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA.		Abrams, William R/A-5782-2008	Smith, Cassandra/0000-0002-0346-8907	NCI NIH HHS [CA39782] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA039782] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENKOVIC SJ, 1990, SCIENCE, V250, P1135, DOI 10.1126/science.2251500; BLOCH W, 1991, BIOCHEMISTRY-US, V30, P2735, DOI 10.1021/bi00225a001; BOLHUIS RLH, 1991, J CELL BIOCHEM, V47, P306, DOI 10.1002/jcb.240470404; CHISWELL DJ, 1992, TRENDS BIOTECHNOL, V10, P80, DOI 10.1016/0167-7799(92)90178-X; CIMINO GD, 1990, NATURE, V345, P773, DOI 10.1038/345773b0; ERLICH HA, 1991, SCIENCE, V252, P1643, DOI 10.1126/science.2047872; FEBER JP, 1976, LANCET, V2, P406; FEBER JP, 1978, ADV CIN CHEM, V20, P129; GEISOW MJ, 1992, TRENDS BIOTECHNOL, V10, P75, DOI 10.1016/0167-7799(92)90175-U; GIBBS RA, 1990, ANAL CHEM, V62, P1202, DOI 10.1021/ac00212a004; GIBBS RA, 1991, CURR OPIN BIOTECH, V2, P69, DOI 10.1016/0958-1669(91)90063-B; Hales C N, 1980, Methods Enzymol, V70, P334; LERNER RA, 1987, TRENDS BIOCHEM SCI, V12, P427, DOI 10.1016/0968-0004(87)90208-8; LERNER RA, 1991, SCIENCE, V252, P659, DOI 10.1126/science.2024118; MORRISON SL, 1988, CLIN CHEM, V34, P1668; MORRISON SL, 1989, ADV IMMUNOL, V44, P65; NOLAN O, 1990, BIOCHIM BIOPHYS ACTA, V1040, P1, DOI 10.1016/0167-4838(90)90139-7; PLUCKTHUN A, 1990, NATURE, V347, P497, DOI 10.1038/347497a0; PLUCKTHUN A, 1991, BIO-TECHNOL, V9, P545, DOI 10.1038/nbt0691-545; REYES GR, CA39782 NIH GRANT; RODWELL JD, 1989, NATURE, V342, P99, DOI 10.1038/342099a0; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SANO T, 1991, BIO-TECHNOL, V9, P1378, DOI 10.1038/nbt1291-1378; SARKAR G, 1990, NATURE, V343, P27, DOI 10.1038/343027a0; SCHULTZ PG, 1988, SCIENCE, V240, P426, DOI 10.1126/science.2833815; SHOKAT KM, 1990, ANNU REV IMMUNOL, V8, P335; VANVUNAKIS H, 1980, METHOD ENZYMOL, V770, P201; WAGNER MF, 1991, TRENDS BIOTECHNOL, V3, P375; WETZEL R, 1991, PROTEIN ENG, V4, P371, DOI 10.1093/protein/4.4.371; WHITE TJ, 1989, TRENDS GENET, V5, P185, DOI 10.1016/0168-9525(89)90073-5; WINTER G, 1991, NATURE, V349, P293, DOI 10.1038/349293a0	31	637	850	10	163	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 2	1992	258	5079					120	122		10.1126/science.1439758	http://dx.doi.org/10.1126/science.1439758			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JQ619	1439758				2022-12-01	WOS:A1992JQ61900032
J	SHOJI, M; GOLDE, TE; GHISO, J; CHEUNG, TT; ESTUS, S; SHAFFER, LM; CAI, XD; MCKAY, DM; TINTNER, R; FRANGIONE, B; YOUNKIN, SG				SHOJI, M; GOLDE, TE; GHISO, J; CHEUNG, TT; ESTUS, S; SHAFFER, LM; CAI, XD; MCKAY, DM; TINTNER, R; FRANGIONE, B; YOUNKIN, SG			PRODUCTION OF THE ALZHEIMER AMYLOID-BETA PROTEIN BY NORMAL PROTEOLYTIC PROCESSING	SCIENCE			English	Article							ADRDA WORK GROUP; SOLUBLE DERIVATIVES; CLINICAL-DIAGNOSIS; DISEASE; PRECURSOR; PEPTIDE; LOCALIZATION; DEGRADATION; FRAGMENTS; CRITERIA	The 4-kilodalton (39 to 43 amino acids) amyloid beta protein (betaAP), which is deposited as amyloid in the brains of patients with Alzheimer's disease, is derived from a large protein, the amyloid beta protein precursor (betaAPP). Human mononuclear leukemic (K562) cells expressing a betaAP-bearing, carboxyl-terminal betaAPP derivative released significant amounts of a soluble 4-kilodalton betaAPP derivative essentially identical to the betaAP deposited in Alzheimer's disease. Human neuroblastoma (M17) cells transfected with constructs expressing full-length betaAPP and M17 cells expressing only endogenous betaAPP also released soluble 4-kilodalton betaAP, and a similar, if not identical, fragment was readily detected in cerebrospinal fluid from individuals with Alzheimer's disease and normal individuals. Thus cells normally produce and release soluble 4-kilodalton betaAP that is essentially identical to the 4-kilodalton betaAP deposited as insoluble amyloid fibrils in Alzheimer's disease.	CASE WESTERN RESERVE UNIV,INST PATHOL,DIV NEUROPATHOL,CLEVELAND,OH 44106; UNIV TEXAS,SW MED CTR,DEPT NEUROL,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,ALZHEIMERS DIS RES CTR,DALLAS,TX 75235; GUNMA UNIV,DEPT NEUROL,MAEBASHI,GUNMA 371,JAPAN; NYU MED CTR,DEPT PATHOL,NEW YORK,NY 10016; WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,ST LOUIS,MO 63110	Case Western Reserve University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Gunma University; New York University; Washington University (WUSTL)			McKay, Derek/HCH-3240-2022; Shoji, Mikio/F-2841-2013	Shoji, Mikio/0000-0003-1027-1712	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR002594, R01AR002594] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG005891, R01AG006656, R37AG005891] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR02594] Funding Source: Medline; NIA NIH HHS [AG06656, AG05891] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BARROW CJ, 1991, SCIENCE, V253, P179, DOI 10.1126/science.1853202; BUKTENICA S, 1987, J BIOL CHEM, V262, P9469; BURDICK D, 1992, J BIOL CHEM, V267, P546; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P2252, DOI 10.1073/pnas.89.6.2252; CASTANO EM, 1986, BIOCHEM BIOPH RES CO, V141, P782, DOI 10.1016/S0006-291X(86)80241-8; COLE GM, 1989, NEUROCHEM RES, V14, P933, DOI 10.1007/BF00965926; COLE GM, 1990, MOL BIOL GENETICS AL, P113; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; ESTUS S, 1992, SCIENCE, V255, P726, DOI 10.1126/science.1738846; FRANGIONE B, IN PRESS ALZHEIMERS; FRUCHT SJ, 1992, J NEUROPATH EXP NEUR, V51, P369; GLENNER G, 1983, BRANBURY REPORT, V15, P137; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V122, P1131, DOI 10.1016/0006-291X(84)91209-9; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; HAMBOR JE, 1988, P NATL ACAD SCI USA, V85, P4010, DOI 10.1073/pnas.85.11.4010; HILBICH C, 1991, J MOL BIOL, V218, P149, DOI 10.1016/0022-2836(91)90881-6; ISENMAN LD, 1989, J BIOL CHEM, V264, P21591; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KIDD M, 1964, BRAIN, V87, P307, DOI 10.1093/brain/87.2.307; Kim K., 1988, NEUROSCI RES COMMUN, V2, P121; KIRSCHNER DA, 1987, P NATL ACAD SCI USA, V84, P6953, DOI 10.1073/pnas.84.19.6953; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MORRIS JC, 1988, ANN NEUROL, V24, P17, DOI 10.1002/ana.410240105; PALMERT MR, 1989, BIOCHEM BIOPH RES CO, V165, P182, DOI 10.1016/0006-291X(89)91052-8; PALMERT MR, 1989, P NATL ACAD SCI USA, V86, P6338, DOI 10.1073/pnas.86.16.6338; PRELLI F, 1988, J NEUROCHEM, V51, P648, DOI 10.1111/j.1471-4159.1988.tb01087.x; ROBAKIS NK, 1987, LANCET, V1, P384; SCHUBERT D, 1989, P NATL ACAD SCI USA, V86, P2066, DOI 10.1073/pnas.86.6.2066; SELKOE DJ, 1986, J NEUROCHEM, V46, P1820; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; TERRY RD, 1963, BRAIN, V311, P528; TIERNEY MC, 1988, NEUROLOGY, V38, P359, DOI 10.1212/WNL.38.3.359; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3	37	1385	1453	2	68	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 2	1992	258	5079					126	129		10.1126/science.1439760	http://dx.doi.org/10.1126/science.1439760			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JQ619	1439760				2022-12-01	WOS:A1992JQ61900034
J	SPRIGGS, MK; HRUBY, DE; MALISZEWSKI, CR; PICKUP, DJ; SIMS, JE; BULLER, RML; VANSLYKE, J				SPRIGGS, MK; HRUBY, DE; MALISZEWSKI, CR; PICKUP, DJ; SIMS, JE; BULLER, RML; VANSLYKE, J			VACCINIA AND COWPOX VIRUSES ENCODE A NOVEL SECRETED INTERLEUKIN-1-BINDING PROTEIN	CELL			English	Article							INVERTED TERMINAL REPEAT; EPIDERMAL GROWTH-FACTOR; OPEN READING FRAME; B-CELL GROWTH; IMMUNOGLOBULIN SUPERFAMILY; EXPRESSION VECTORS; INFLUENZA-VIRUS; IL-1 RECEPTOR; T-CELLS; INFECTION	Supernatants from vaccinia virus (VV)-infected CV-1 cells were examined and found to contain a 33 kd protein capable of binding murine interleukin-1beta (mIL-1beta). A VV open reading frame (ORF) that exhibits 30% amino acid identity to the type II IL-1 receptor was expressed in CV-1-EBNA cells and shown specifically to bind mIL-1beta. A similar ORF from cowpox virus was expressed and also specifically bound mIL-1beta. A recombinant VV was constructed in which this ORF was disrupted (vB15RKO). Supernatants from vB15RKO-infected cells did not contain an IL-1-binding protein. Supernatants from VV-infected CV-1 cells were capable of inhibiting IL-1-induced murine lymphocyte proliferation in vitro while supernatants from vB15RKO infected cells did not. Intracranial inoculation of mice with vB15RKO suggests that this ORF is involved in VV virulence. The possible role of a virus-encoded IL-1-binding protein in the pathology of a poxvirus infection and its relationship to other poxvirus-encoded immune modulators is discussed.	IMMUNEX RES & DEV CORP,DEPT IMMUNOL,SEATTLE,WA 98101; OREGON STATE UNIV,DEPT MICROBIOL,CORVALLIS,OR 97331; DUKE UNIV,MED CTR,DEPT MICROBIOL & IMMUNOL,DURHAM,NC 27710; NIAID,VIRAL DIS LAB,BETHESDA,MD 20892	Oregon State University; Duke University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	SPRIGGS, MK (corresponding author), IMMUNEX RES & DEV CORP,DEPT MOLEC BIOL,SEATTLE,WA 98101, USA.			Sims, John/0000-0002-5667-9185	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021335] Funding Source: NIH RePORTER; NIAID NIH HHS [AI21335-06] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALCAMI A, 1992, CELL, V71; BECKER S, 1991, J IMMUNOL, V147, P4307; BEUTLER B, 1989, ANNU REV IMMUNOL, V7, P625, DOI 10.1146/annurev.immunol.7.1.625; BLANDEN RV, 1975, NATURE, V254, P269, DOI 10.1038/254269a0; BLANDEN RV, 1974, TRANSPLANT REV, V19, P56; BLOMQUIST MC, 1984, P NATL ACAD SCI-BIOL, V81, P7363, DOI 10.1073/pnas.81.23.7363; BOOTH RJ, 1984, J IMMUNOL, V133, P1346; BROWN JP, 1985, NATURE, V313, P491, DOI 10.1038/313491a0; BULLER RML, 1985, NATURE, V317, P813, DOI 10.1038/317813a0; BULLER RML, 1991, MICROBIOL REV, V55, P80, DOI 10.1128/MMBR.55.1.80-122.1991; DAYHOFF MO, 1983, METHOD ENZYMOL, V91, P524; DEYERLE KL, 1992, IN PRESS J IMMUNOL; DOWER SK, 1990, CELLULAR MOL MECHANI, V1, P137; EICHELBERGER M, 1991, J EXP MED, V174, P875, DOI 10.1084/jem.174.4.875; ELANGO N, 1986, P NATL ACAD SCI USA, V83, P1906, DOI 10.1073/pnas.83.6.1906; FALKNER FG, 1988, J VIROL, V62, P1849, DOI 10.1128/JVI.62.6.1849-1854.1988; FARRAR WL, 1987, J IMMUNOL, V139, P459; Fenner F., 1989, MONKEYPOX VIRUS ORTH, P227; FLAMAND L, 1991, J VIROL, V65, P5105, DOI 10.1128/JVI.65.9.5105-5110.1991; FRANKE CA, 1985, MOL CELL BIOL, V5, P1918, DOI 10.1128/MCB.5.8.1918; GOEBEL SJ, 1990, VIROLOGY, V179, P247, DOI 10.1016/0042-6822(90)90294-2; HOWARD M, 1983, J EXP MED, V157, P1529, DOI 10.1084/jem.157.5.1529; HOWARD ST, 1991, VIROLOGY, V180, P633, DOI 10.1016/0042-6822(91)90077-O; HRUBY DE, 1990, CLIN MICROBIOL REV, V3, P153, DOI 10.1128/CMR.3.2.153-170.1990; KOTWAL GJ, 1988, NATURE, V335, P176, DOI 10.1038/335176a0; KOTWAL GJ, 1990, SCIENCE, V250, P827, DOI 10.1126/science.2237434; LAW KM, 1992, J GEN VIROL, V73, P549, DOI 10.1099/0022-1317-73-3-549; LUGMAN M, 1992, EUR J IMMUNOL, V22, P95; MALISZEWSKI CR, 1990, J IMMUNOL, V144, P3028; MARTIN M, 1988, TRENDS PHARMACOL SCI, V9, P171, DOI 10.1016/0165-6147(88)90033-8; McFadden G., 1988, Virus diseases in laboratory and captive animals, P37; MCMAHAN CJ, 1991, EMBO J, V10, P2821, DOI 10.1002/j.1460-2075.1991.tb07831.x; OLIFF A, 1988, CELL, V54, P141, DOI 10.1016/0092-8674(88)90543-0; OPPENHEIM JJ, 1986, IMMUNOL TODAY, V7, P45, DOI 10.1016/0167-5699(86)90124-6; PALUMBO GJ, 1989, VIROLOGY, V172, P262, DOI 10.1016/0042-6822(89)90128-1; PICKUP DJ, 1986, P NATL ACAD SCI USA, V83, P7698, DOI 10.1073/pnas.83.20.7698; PICKUP DJ, 1984, P NATL ACAD SCI-BIOL, V81, P6817, DOI 10.1073/pnas.81.21.6817; PIKE BL, 1985, P NATL ACAD SCI USA, V82, P8153, DOI 10.1073/pnas.82.23.8153; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; REISNER AH, 1985, NATURE, V313, P801, DOI 10.1038/313801a0; Sambrook J., 1989, MOL CLONING LAB MANU; SIMS JE, 1989, P NATL ACAD SCI USA, V86, P8946, DOI 10.1073/pnas.86.22.8946; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; SMITH CA, 1991, BIOCHEM BIOPH RES CO, V176, P335, DOI 10.1016/0006-291X(91)90929-2; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SMITH GL, 1991, J GEN VIROL, V72, P511, DOI 10.1099/0022-1317-72-3-511; SMITH GL, 1991, J GEN VIROL, V72, P1349, DOI 10.1099/0022-1317-72-6-1349; SPRIGGS MK, 1990, J BIOL CHEM, V265, P22499; SPRIGGS MK, 1992, P NATL ACAD SCI USA, V89, P6070, DOI 10.1073/pnas.89.13.6070; TRACEY KJ, 1988, J EXP MED, V167, P1211, DOI 10.1084/jem.167.3.1211; TWARDZIK DR, 1985, P NATL ACAD SCI USA, V82, P5300, DOI 10.1073/pnas.82.16.5300; UPTON C, 1991, VIROLOGY, V184, P370, DOI 10.1016/0042-6822(91)90853-4; VACHERON F, 1990, J GEN VIROL, V71, P477, DOI 10.1099/0022-1317-71-2-477	53	293	302	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 2	1992	71	1					145	152		10.1016/0092-8674(92)90273-F	http://dx.doi.org/10.1016/0092-8674(92)90273-F			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JQ623	1339315				2022-12-01	WOS:A1992JQ62300014
J	VOLLRATH, D; FOOTE, S; HILTON, A; BROWN, LG; BEERROMERO, P; BOGAN, JS; PAGE, DC				VOLLRATH, D; FOOTE, S; HILTON, A; BROWN, LG; BEERROMERO, P; BOGAN, JS; PAGE, DC			THE HUMAN Y-CHROMOSOME - A 43-INTERVAL MAP BASED ON NATURALLY-OCCURRING DELETIONS	SCIENCE			English	Article							HUMAN X-CHROMOSOME; CONTIGUOUS GENE SYNDROMES; SEX-DETERMINING REGION; DISTAL SHORT ARM; ENZYMATIC AMPLIFICATION; MOLECULAR-DETECTION; TURNER SYNDROME; PAIRING REGION; DNA-SEQUENCES; HUMAN GENOME	A deletion map of the human Y chromosome was constructed by testing 96 individuals with partial Y chromosomes for the presence or absence of many DNA loci. The individuals studied included XX males, XY females, and persons in whom chromosome banding had revealed translocated, deleted, isodicentric, or ring Y chromosomes. Most of the 132 Y chromosomal loci mapped were sequence-tagged sites, detected by means of the polymerase chain reaction. These studies resolved the euchromatic region (short arm, centromere, and proximal long arm) of the Y chromosome into 43 ordered intervals, all defined by naturally occurring chromosomal breakpoints and averaging less than 800 kilobases in length. This deletion map should be useful in identifying Y chromosomal genes, in exploring the origin of chromosomal disorders, and in tracing the evolution of the Y chromosome.	MIT, DEPT BIOL, CAMBRIDGE, MA 02142 USA	Massachusetts Institute of Technology (MIT)	VOLLRATH, D (corresponding author), MIT, WHITEHEAD INST, HOWARD HUGHES RES LABS, 9 CAMBRIDGE CTR, CAMBRIDGE, MA 02142 USA.		Foote, Simon J/F-2802-2013; Bogan, Jonathan S/A-1575-2010	Bogan, Jonathan S/0000-0001-6463-8466; Foote, Simon/0000-0002-9142-2107				AFFARA NA, 1987, NUCLEIC ACIDS RES, V15, P7325, DOI 10.1093/nar/15.18.7325; AFFARA NA, 1986, NUCLEIC ACIDS RES, V14, P5353, DOI 10.1093/nar/14.13.5353; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ALVESALO L, 1981, ANN HUM GENET, V45, P49, DOI 10.1111/j.1469-1809.1981.tb00305.x; ANDERSSON M, 1988, HUM GENET, V79, P2, DOI 10.1007/BF00291700; BALLABIO A, 1989, P NATL ACAD SCI USA, V86, P10001, DOI 10.1073/pnas.86.24.10001; BARDONI B, 1991, GENOMICS, V11, P443, DOI 10.1016/0888-7543(91)90153-6; BISHOP C, 1984, J MOL BIOL, V173, P403, DOI 10.1016/0022-2836(84)90388-7; BLAGOWIDOW N, 1989, AM J MED GENET, V34, P159, DOI 10.1002/ajmg.1320340204; BORGAONKAR DS, 1985, Y CHROMOSOME B, P15; BROWN CJ, 1990, AM J HUM GENET, V46, P273; BUHLER EM, 1980, HUM GENET, V55, P145, DOI 10.1007/BF00291764; CANTRELL MA, 1992, GENOMICS, V13, P1255, DOI 10.1016/0888-7543(92)90043-R; CHARLESWORTH B, 1991, SCIENCE, V251, P1030, DOI 10.1126/science.1998119; COOKE HJ, 1984, NATURE, V311, P259, DOI 10.1038/311259a0; COOKE HJ, 1985, NATURE, V317, P687, DOI 10.1038/317687a0; DAVIS RM, 1981, J MED GENET, V18, P161, DOI 10.1136/jmg.18.3.161; DISTECHE CM, 1986, P NATL ACAD SCI USA, V83, P7841, DOI 10.1073/pnas.83.20.7841; DISTECHE CM, 1986, HUM GENET, V74, P372, DOI 10.1007/BF00280488; FERGUSONSMITH MA, 1987, DEVELOPMENT, V101, P41; FISHER EMC, 1990, CELL, V63, P1205, DOI 10.1016/0092-8674(90)90416-C; FOOTE S, 1992, GENOMICS, V258, P60; FUSCOE JC, 1986, CYTOGENET CELL GENET, V43, P79, DOI 10.1159/000132301; GOULMY E, 1983, IMMUNOGENETICS, V17, P523, DOI 10.1007/BF00696875; GREEN ED, 1990, P NATL ACAD SCI USA, V87, P1213, DOI 10.1073/pnas.87.3.1213; GREEN ED, 1991, GENOMICS, V11, P548, DOI 10.1016/0888-7543(91)90062-J; GRIFO JA, 1992, JAMA-J AM MED ASSOC, V268, P727, DOI 10.1001/jama.268.6.727; GUIOLI S, 1992, NAT GENET, V1, P337, DOI 10.1038/ng0892-337; INCERTI B, UNPUB NATURE GENET; JACOBS PA, 1966, NATURE, V210, P352, DOI 10.1038/210352a0; KOENIG M, 1985, NUCLEIC ACIDS RES, V13, P5485, DOI 10.1093/nar/13.15.5485; KOTECKI M, 1991, HUM GENET, V87, P234, DOI 10.1007/BF00204192; LINCOLN S, COMMUNICATION; MA K, 1992, HUM MOL GENET, V1, P29, DOI 10.1093/hmg/1.1.29; MARCUS M, 1976, NATURE, V262, P63, DOI 10.1038/262063a0; MORTON NE, 1991, P NATL ACAD SCI USA, V88, P7474, DOI 10.1073/pnas.88.17.7474; MULLER U, 1990, HUM GENET, V85, P205; MUNKE M, 1988, HUM GENET, V80, P219, DOI 10.1007/BF01790089; NAKAHORI Y, 1991, GENOMICS, V9, P765, DOI 10.1016/0888-7543(91)90373-M; NUSSBAUM RL, 1986, AM J MED GENET, V23, P457, DOI 10.1002/ajmg.1320230137; OLSON M, 1989, SCIENCE, V245, P1434, DOI 10.1126/science.2781285; OREILLY AM, UNPUB; PAGE DC, 1987, DEVELOPMENT, V101, P151; PAGE DC, 1984, NATURE, V311, P119, DOI 10.1038/311119a0; PAGE DC, 1990, NATURE, V346, P279, DOI 10.1038/346279a0; PAGE DC, 1986, COLD SPRING HARB SYM, V51, P229, DOI 10.1101/SQB.1986.051.01.028; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; ROUYER F, 1987, CELL, V51, P417, DOI 10.1016/0092-8674(87)90637-4; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SHARP CB, 1990, HUM GENET, V85, P330; SILVER J, 1987, MOL CELL BIOL, V7, P1559, DOI 10.1128/MCB.7.4.1559; SIMMLER MC, 1985, NATURE, V317, P692, DOI 10.1038/317692a0; SIMPSON E, 1987, NATURE, V326, P876, DOI 10.1038/326876a0; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; SKARE J, 1990, AM J MED GENET, V36, P394, DOI 10.1002/ajmg.1320360405; TIEPOLO L, 1976, HUM GENET, V34, P119, DOI 10.1007/BF00278879; VERGNAUD G, 1986, AM J HUM GENET, V38, P109; VOGT P, 1991, HUM GENET, V86, P341; WEISSENBACH J, 1991, CYTOGENET CELL GENET, V58, P967, DOI 10.1159/000133184; YEN PH, 1991, P NATL ACAD SCI USA, V88, P8944, DOI 10.1073/pnas.88.20.8944	61	416	456	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 2	1992	258	5079					52	59		10.1126/science.1439769	http://dx.doi.org/10.1126/science.1439769			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JQ619	1439769				2022-12-01	WOS:A1992JQ61900024
J	YAO, TP; SEGRAVES, WA; ORO, AE; MCKEOWN, M; EVANS, RM				YAO, TP; SEGRAVES, WA; ORO, AE; MCKEOWN, M; EVANS, RM			DROSOPHILA ULTRASPIRACLE MODULATES ECDYSONE RECEPTOR FUNCTION VIA HETERODIMER FORMATION	CELL			English	Article							THYROID-HORMONE RECEPTOR; RETINOIC ACID RECEPTOR; RESPONSE ELEMENT; ESTROGEN-RECEPTOR; TRANS-ACTIVATION; BETA-GENE; SUPERFAMILY; IDENTIFICATION; BINDING; MEMBER	The vertebrate retinoid X receptor (RXR) has been implicated in the regulation of multiple hormonal signaling pathways through the formation of heteromeric receptor complexes that bind DNA with high affinity. We now demonstrate that ultraspiracle (usp), a Drosophila RXR homolog, can substitute for RXR in stimulating the DNA binding of receptors for retinoic acid, T3, vitamin D, and peroxisome proliferator activators. These observations led to the search and ultimate identification of the ecdysone receptor (EcR) as a Drosophila partner of usp. Together, usp and EcR bind DNA in a highly cooperative fashion. Cotransfection of both EcR and usp expression vectors is required to render cultured mammalian cells ecdysone responsive. These results implicate usp as an integral component of the functional EcR. By demonstrating that receptor heterodimer formation precedes the divergence of vertebrate and invertebrate lineages, these data underscore a central role for RXR and its homolog usp in the evolution and control of the nuclear receptor-based endocrine system.	UNIV CALIF SAN DIEGO, DEPT BIOL, GRAD PROGRAM BIOMED SCI, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego	YAO, TP (corresponding author), SALK INST BIOL STUDIES, HOWARD HUGHES MED INST, LA JOLLA, CA 92037 USA.		Evans, Ronald/AAF-4001-2019	Evans, Ronald/0000-0002-9986-5965				ANDRES AJ, 1992, TRENDS GENET, V8, P132, DOI 10.1016/0168-9525(92)90371-A; ASHBURNER M, 1990, CELL, V61, P1, DOI 10.1016/0092-8674(90)90205-S; Ashburner M, 1974, Cold Spring Harb Symp Quant Biol, V38, P655; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; CHERBAS L, 1991, GENE DEV, V5, P120, DOI 10.1101/gad.5.1.120; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; FORMAN BM, 1989, MOL ENDOCRINOL, V3, P1610, DOI 10.1210/mend-3-10-1610; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GLASS CK, 1990, CELL, V63, P729, DOI 10.1016/0092-8674(90)90139-6; HENRICH VC, 1990, NUCLEIC ACIDS RES, V18, P4143, DOI 10.1093/nar/18.14.4143; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KOELLE MR, 1991, CELL, V67, P59, DOI 10.1016/0092-8674(91)90572-G; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LAUDET V, 1992, EMBO J, V11, P1003, DOI 10.1002/j.1460-2075.1992.tb05139.x; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LIAO J, 1990, P NATL ACAD SCI USA, V87, P9751, DOI 10.1073/pnas.87.24.9751; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MANGELSDORF DJ, 1992, IN PRESS TRANSCRIPTI; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MLODZIK M, 1990, CELL, V60, P211, DOI 10.1016/0092-8674(90)90737-Y; MURRAY MB, 1989, MOL ENDOCRINOL, V3, P1434, DOI 10.1210/mend-3-9-1434; NODA M, 1990, P NATL ACAD SCI USA, V87, P9995, DOI 10.1073/pnas.87.24.9995; ORO AE, 1990, NATURE, V347, P298, DOI 10.1038/347298a0; ORO AE, 1992, DEVELOPMENT, V115, P449; ORO AE, 1991, THESIS U CALIFORNIA; Oro AE, 1992, CURR OPIN GENET DEV, V2, P269, DOI 10.1016/S0959-437X(05)80284-9; PICARD D, 1988, CELL, V54, P170; Ragsdale CW, 1991, CURR OPIN CELL BIOL, V3, P928, DOI 10.1016/0955-0674(91)90109-C; RICHARDS G, 1981, MOL CELL ENDOCRINOL, V21, P181, DOI 10.1016/0303-7207(81)90013-7; RIDDIFORD LM, 1985, COMPREHENSIVE INSECT, V8, P38; RIDDIHOUGH G, 1987, EMBO J, V6, P3729, DOI 10.1002/j.1460-2075.1987.tb02707.x; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SEGRAVES WA, 1991, CELL, V67, P225, DOI 10.1016/0092-8674(91)90172-U; SHEA MJ, 1990, GENE DEV, V4, P1128, DOI 10.1101/gad.4.7.1128; SLITER TJ, 1992, GENETICS, V130, P555; SOELLER WC, 1988, GENE DEV, V2, P68, DOI 10.1101/gad.2.1.68; STEEL CGH, 1985, COMPREHENSIVE INSECT, V8, P1; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; TABIN CJ, 1991, CELL, V66, P199, DOI 10.1016/0092-8674(91)90612-3; THOMPSON CC, 1989, P NATL ACAD SCI USA, V86, P3494, DOI 10.1073/pnas.86.10.3494; TSAI SY, 1988, CELL, V55, P361, DOI 10.1016/0092-8674(88)90059-1; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VAUGHAN JM, 1989, METHOD ENZYMOL, V168, P588; YANG N, 1991, P NATL ACAD SCI USA, V88, P3559, DOI 10.1073/pnas.88.9.3559; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	61	614	685	4	23	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 2	1992	71	1					63	72		10.1016/0092-8674(92)90266-F	http://dx.doi.org/10.1016/0092-8674(92)90266-F			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JQ623	1327536				2022-12-01	WOS:A1992JQ62300007
J	AMATI, B; DALTON, S; BROOKS, MW; LITTLEWOOD, TD; EVAN, GI; LAND, H				AMATI, B; DALTON, S; BROOKS, MW; LITTLEWOOD, TD; EVAN, GI; LAND, H			TRANSCRIPTIONAL ACTIVATION BY THE HUMAN C-MYC ONCOPROTEIN IN YEAST REQUIRES INTERACTION WITH MAX	NATURE			English	Article							DNA-BINDING; PROTEIN; GENE; FOS; SEQUENCE; JUN; TRANSFORMATION; CEREVISIAE; ZIPPER; COMMON	THE c-myc protein (Myc) contains an amino-terminal transcriptional activation domain1 and a carboxy-terminal basic helix-loop-helix-leucine zipper (bHLH-Z) domain 2-5 that directs dimerization of Myc with its partner, the max protein (Max), and promotes DNA binding to sites containing a CACGTG core consensus sequence6-9. Despite these characteristics and the observation that Myc can modulate gene expression4,5,10, a direct role for Myc or Max as transcription factors has never been demonstrated. Here we use Saccharomyces cerevisiae as an in vivo model system to show that the Myc protein is a sequence-specific transcriptional activator whose DNA binding is strictly dependent on dimerization with Max. Transactivation is mediated by the amino-terminal domain of Myc. We find that Max homodimers bind to the same DNA sequence as Myc + Max but that they fail to transactivate and thus can antagonize Myc + Max function. We also show that the Max HLH-Z domain has a higher affinity for the Myc HLH-Z domain than for itself, and suggest that the heterodimeric Myc + Max activator forms preferentially at equilibrium.	IMPERIAL CANC RES FUND,GROWTH CONTROL & DEV LAB,LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND; IMPERIAL CANC RES FUND,TRANSCRIPTION LAB,LONDON WC2A 3PX,ENGLAND; IMPERIAL CANC RES FUND,BIOCHEM CELL NUCLEUS LAB,LONDON WC2A 3PX,ENGLAND	Cancer Research UK; Cancer Research UK; Cancer Research UK			Amati, Bruno/AAM-3418-2020	Amati, Bruno/0000-0002-2958-1799				BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FISHER F, 1991, ONCOGENE, V6, P1099; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; GUARENTE L, 1983, CELL, V32, P1279, DOI 10.1016/0092-8674(83)90309-4; HARSHMAN KD, 1988, CELL, V53, P321, DOI 10.1016/0092-8674(88)90393-5; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KELLY K, 1986, ANNU REV IMMUNOL, V4, P317, DOI 10.1146/annurev.immunol.4.1.317; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LECH K, 1988, CELL, V52, P179, DOI 10.1016/0092-8674(88)90506-5; LITTLEWOOD TD, 1992, ONCOGENE, V7, P1783; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MAKELA TP, 1992, SCIENCE, V256, P373, DOI 10.1126/science.256.5055.373; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; OSHEA EK, 1989, SCIENCE, V245, P646, DOI 10.1126/science.2503872; Penn L J, 1990, Semin Cancer Biol, V1, P69; PENN LJZ, 1990, MOL CELL BIOL, V10, P4961, DOI 10.1128/MCB.10.9.4961; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; SMITH M, 1979, CELL, V16, P753, DOI 10.1016/0092-8674(79)90091-6; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; VORONOVA A, 1990, P NATL ACAD SCI USA, V87, P4277	31	424	431	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 1	1992	359	6394					423	426		10.1038/359423a0	http://dx.doi.org/10.1038/359423a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JQ624	1406955				2022-12-01	WOS:A1992JQ62400059
J	BENFENATI, F; VALTORTA, F; RUBENSTEIN, JL; GORELICK, FS; GREENGARD, P; CZERNIK, AJ				BENFENATI, F; VALTORTA, F; RUBENSTEIN, JL; GORELICK, FS; GREENGARD, P; CZERNIK, AJ			SYNAPTIC VESICLE-ASSOCIATED CA2+/CALMODULIN-DEPENDENT PROTEIN KINASE-II IS A BINDING-PROTEIN FOR SYNAPSIN-I	NATURE			English	Article							POSTSYNAPTIC DENSITY PROTEIN; BRAIN; FRAGMENTS; CLEAVAGE; RELEASE; ASSAY	SYNAPSIN I is a synaptic vesicle-associated phosphoprotein that is involved in the modulation of neurotransmitter release1. Ca2+ calmodulin-dependent protein kinase II, which phosphorylates two sites in the carboxy-terminal region of synapsin I, causes synapsin I to dissociate from synaptic vesicles2 and increases nerotransmitter release3,4. Conversely, the dephosphorylated form of synapsin I, but not the form phosphorylated by Ca2+/calmodulin-dependent protein kinase II, inhibits neurotransmitter release4-6. The amino-terminal region of synapsin I interacts with membrane phospholipids, whereas the C-terminal region binds to a protein component of synaptic vesicles7,8. Here we demonstrate that the binding of the C-terminal region of synapsin I involves the regulatory domain of a synaptic vesicle-associated form of Ca2+/calmodulin-dependent protein kinase II. Our results indicate that this form of the kinase functions both as a binding protein for synapsin I, and as an enzyme that phosphorylates synapsin I and promotes its dissociation from the vesicles.	UNIV MILAN,CNR,CTR CYTOPHARMACOL,BRUNO CECCARELLI CTR,S RAFFAELE SCI INST,I-20122 MILAN,ITALY; ROCKEFELLER UNIV,MOLEC & CELLULAR NEUROSCI LAB,NEW YORK,NY 10021	Consiglio Nazionale delle Ricerche (CNR); University of Milan; Rockefeller University	BENFENATI, F (corresponding author), UNIV MODENA,INST HUMAN PHYSIOL,VIA CAMPI 287,I-41100 MODENA,ITALY.		Flavia, Valtorta/F-3450-2012	Flavia, Valtorta/0000-0001-9556-4746; Gorelick, Fred/0000-0001-8293-6803	Telethon [112] Funding Source: Medline	Telethon(Fondazione Telethon)		BAHLER M, 1989, J CELL BIOL, V108, P1841, DOI 10.1083/jcb.108.5.1841; BENFENATI F, 1989, J CELL BIOL, V108, P1863, DOI 10.1083/jcb.108.5.1863; BENFENATI F, 1989, J CELL BIOL, V108, P1851, DOI 10.1083/jcb.108.5.1851; BULLEIT RF, 1988, NEURON, V1, P63, DOI 10.1016/0896-6273(88)90210-3; COLBRAN RJ, 1989, BIOCHEM J, V258, P313, DOI 10.1042/bj2580313; DECAMILLI P, 1990, ANNU REV CELL BIOL, V6, P433, DOI 10.1146/annurev.cellbio.6.1.433; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; GOELZ SE, 1981, P NATL ACAD SCI-BIOL, V78, P2130, DOI 10.1073/pnas.78.4.2130; HACKETT JT, 1990, J NEUROPHYSIOL, V63, P701, DOI 10.1152/jn.1990.63.4.701; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; IMADA M, 1980, BIOCHIM BIOPHYS ACTA, V625, P179, DOI 10.1016/0005-2795(80)90282-2; JAHN R, 1984, P NATL ACAD SCI-BIOL, V81, P1684, DOI 10.1073/pnas.81.6.1684; JI TH, 1982, ANAL BIOCHEM, V121, P286, DOI 10.1016/0003-2697(82)90481-X; KELLY PT, 1984, P NATL ACAD SCI-BIOL, V81, P945, DOI 10.1073/pnas.81.3.945; KENNEDY MB, 1983, P NATL ACAD SCI-BIOL, V80, P7357, DOI 10.1073/pnas.80.23.7357; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LLINAS R, 1991, J PHYSIOL-LONDON, V436, P257, DOI 10.1113/jphysiol.1991.sp018549; MARKWELL MAK, 1982, ANAL BIOCHEM, V125, P427, DOI 10.1016/0003-2697(82)90025-2; MCGUINNESS TL, 1985, J BIOL CHEM, V260, P1696; MCGUINNESS TL, 1983, FEBS LETT, V163, P329, DOI 10.1016/0014-5793(83)80846-1; NICHOLS RA, 1990, NATURE, V343, P647, DOI 10.1038/343647a0; NICHOLS RA, 1992, J NEUROCHEM, V58, P783, DOI 10.1111/j.1471-4159.1992.tb09788.x; SCHIEBLER W, 1986, J BIOL CHEM, V261, P8383; SCHULMAN H, 1989, TRENDS BIOCHEM SCI, V14, P62, DOI 10.1016/0968-0004(89)90045-5; TOBIMATSU T, 1989, J BIOL CHEM, V264, P17907; WU K, 1992, P NATL ACAD SCI USA, V89, P3015, DOI 10.1073/pnas.89.7.3015	26	242	246	1	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 1	1992	359	6394					417	420		10.1038/359417a0	http://dx.doi.org/10.1038/359417a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JQ624	1328883				2022-12-01	WOS:A1992JQ62400057
J	DERAY, G; BENHMIDA, M; LEHOANG, P; MAKSUD, P; AUPETIT, B; BAUMELOU, A; JACOBS, C				DERAY, G; BENHMIDA, M; LEHOANG, P; MAKSUD, P; AUPETIT, B; BAUMELOU, A; JACOBS, C			RENAL-FUNCTION AND BLOOD-PRESSURE IN PATIENTS RECEIVING LONG-TERM, LOW-DOSE CYCLOSPORINE THERAPY FOR IDIOPATHIC AUTOIMMUNE UVEITIS	ANNALS OF INTERNAL MEDICINE			English	Article						CYCLOSPORINE; UVEITIS; AUTOIMMUNE DISEASES; KIDNEY DISEASES; HYPERTENSION	GLOMERULAR-FILTRATION RATE; RHEUMATOID-ARTHRITIS; DOUBLE-BLIND; INTERSTITIAL NEPHRITIS; TRANSPLANT RECIPIENTS; ANTERIOR UVEITIS; CONTROLLED TRIAL; HYPERTENSION; PLACEBO; NEPHROTOXICITY	Objective: To determine the renal side effects of long-term, low-dose cyclosporine therapy (initial dose, 5 mg/kg body weight per day) in patients with autoimmune idiopathic uveitis. Design: Cohort study with at least 2 years of follow-up. Setting: A teaching hospital in Paris, France (Hospital Pitie-Salpetriere). Patients: Sixteen patients with idiopathic autoimmune uveitis who were normotensive and had normal renal function before treatment. Cyclosporine was administered orally for at least 2 years at an initial dosage of 5 mg/kg body weight per day. Results: After 2 years of treatment, the serum creatinine level increased by 35 +/- 5 mumol/L (0.40 +/- 0.06 mg/dL) (95% Cl, 25 to 46 mumol/L, [73 +/- 4 to 108 +/- 4 mumol/L]). Creatinine clearance decreased significantly from 120 +/- 5 mL/min to 75 +/- 4 mL/min. Glomerular filtration rate decreased from 116 +/- 8 mL/min to 75 +/- 3 mL/min, and effective renal plasma flow decreased from 455 +/- 24 mL/min to 338 +/- 30 mL/min (P < 0.05). Cyclosporine induced a significant increase in serum uric acid, total cholesterol, and serum potassium levels. Blood pressure was normal in all patients before treatment; 81% (95% Cl, 64% to 98%) of these patients developed hypertension after 24 months of treatment. Blood pressure was controlled with a single drug in all but two patients. Conclusions: In patients with healthy native kidneys, long-term cyclosporine therapy, even at a low dose (5 mg/kg per day), is nephrotoxic and is associated with a high incidence of hypertension.			DERAY, G (corresponding author), HOP PITIE, SERV NEPHROL, 83 BLVD HOP, F-75013 PARIS, FRANCE.			Ben Hmida, Mohamed/0000-0002-0997-6136				BENNETT WM, 1988, AM J MED, V85, P131, DOI 10.1016/S0002-9343(88)80330-9; BRYNSKOV J, 1989, NEW ENGL J MED, V321, P845, DOI 10.1056/NEJM198909283211301; COHEN SL, 1989, NEPHROL DIAL TRANSPL, V4, P201, DOI 10.1093/oxfordjournals.ndt.a091856; CURTIS JJ, 1988, AM J MED, V85, P134; DERAY G, 1988, EUR J CLIN PHARMACOL, V34, P601, DOI 10.1007/BF00615224; DERAY G, 1987, LANCET, V1, P158; DERAY G, 1989, CLIN NEPHROL, V32, P47; DIETERLE A, 1988, TRANSPLANT P, V20, P349; DOBRIN RS, 1975, AM J MED, V59, P325, DOI 10.1016/0002-9343(75)90390-3; DOUGADOS M, 1988, ANN RHEUM DIS, V47, P127, DOI 10.1136/ard.47.2.127; GAFTER U, 1986, NEPHRON, V42, P249, DOI 10.1159/000183675; GURECKI J, 1985, TRANSPLANT P, V17, P1997; LAMB FS, 1987, LIFE SCI, V40, P2571, DOI 10.1016/0024-3205(87)90080-4; LEVEY AS, 1988, ANNU REV MED, V39, P465, DOI 10.1146/annurev.me.39.020188.002341; LIN HY, 1989, NEW ENGL J MED, V321, P287, DOI 10.1056/NEJM198908033210504; LUDWIN D, 1988, TRANSPLANT P, V20, P367; MCDIARMID SV, 1990, TRANSPLANTATION, V49, P81, DOI 10.1097/00007890-199001000-00018; MIHATSCH MJ, 1988, KLIN WOCHENSCHR, V66, P43, DOI 10.1007/BF01713009; MORGAN BJ, 1989, FASEB J, V3, pA1145; POWLES AV, 1990, BRIT J DERMATOL, V122, P665, DOI 10.1111/j.1365-2133.1990.tb07288.x; RAINE AEG, 1988, NEPHROL DIAL TRANSPL, V3, P458, DOI 10.1093/oxfordjournals.ndt.a091698; RUSSELL CD, 1985, J NUCL MED, V26, P1243; SCHERRER U, 1990, NEW ENGL J MED, V323, P693, DOI 10.1056/NEJM199009133231101; SCHMITZSCHUMANN M, 1986, PROG ALLERGY, V38, P436; SINCLAIR NR, 1986, NEW ENGL J MED, V314, P1219; STILLER CR, 1983, NEW ENGL J MED, V309, P809; TAUXE WN, 1982, EUR J NUCL MED, V7, P51; TAUXE WN, 1971, MAYO CLIN PROC, V46, P524; TINDALL RSA, 1987, NEW ENGL J MED, V316, P719, DOI 10.1056/NEJM198703193161205; TUGWELL P, 1987, J RHEUMATOL, V14, P1108; TUGWELL P, 1990, LANCET, V335, P1051, DOI 10.1016/0140-6736(90)92630-Z; VANRIJTHOVEN AWAM, 1991, J RHEUMATOL, V18, P19; WEIDLE PJ, 1988, DRUG INTEL CLIN PHAR, V22, P443, DOI 10.1177/106002808802200601; WIESNER RH, 1990, NEW ENGL J MED, V322, P1419, DOI 10.1056/NEJM199005173222003; WOLINSKY JS, 1990, ANN NEUROL, V27, P591; YOCUM DE, 1988, ANN INTERN MED, V109, P863, DOI 10.7326/0003-4819-109-11-863; ZACHARIAE H, 1990, BRIT J DERMATOL, V122, P677, DOI 10.1111/j.1365-2133.1990.tb07290.x	37	87	88	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1992	117	7					578	583		10.7326/0003-4819-117-7-578	http://dx.doi.org/10.7326/0003-4819-117-7-578			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JQ226	1524331				2022-12-01	WOS:A1992JQ22600006
J	HAAS, OA; ARGYRIOUTIRITA, A; LION, T				HAAS, OA; ARGYRIOUTIRITA, A; LION, T			PARENTAL ORIGIN OF CHROMOSOMES INVOLVED IN THE TRANSLOCATION T(9 22)	NATURE			English	Article							NUCLEOLUS ORGANIZER REGIONS; DNA METHYLATION; HUMAN LEUKEMIA; GENE ACTIVITY; WILMS-TUMOR; ALLELES; CANCER; TRANSGENES	FUNCTIONALLY equivalent genetic material can be labelled by an epigenetic marking process and used differentially depending on whether its origin is maternal or paternal1. This phenomenon is known as genomic imprinting and is manifested at either the chromosomal or gene level. Genomic imprinting seems to play an important role in cancer predisposition syndromes2-5 , and phenotypic consequences are evident in constitutional deletion syndromes and uniparental disomies1. Moreover, there seems to be a preferential retention of paternal alleles in sporadic tumours such as Wilms' tumour6, rhabdomyosarcoma7, osteosarcoma8 and retinoblastoma9. To investigate whether chromosomes involved in acquired abnormalities of haematologic neoplasms show a similar 'parent of origin' bias, we studied the inheritance of the translocated chromosomes 9 and 22 in cases of Philadelphia-chromosome-positive leukaemia, using unique specific chromosome band polymorphisms. Here we show that the translocated chromosome 9 was of paternal origin, whereas the translocated chromosomes 22 were derived exclusively from the maternal copy, in 11 cases with reliable polymorphisms. Our data therefore provide evidence that imprinting phenomena may play an important role in acquired tumour-specific chromosome rearrangements.			HAAS, OA (corresponding author), ST ANNA CHILDRENS HOSP, CHILDRENS CANC RES INST, KINDERSPITALGASSE 6, A-1090 VIENNA, AUSTRIA.		Haas, Oskar/AAM-5794-2020; Lion, MD, PhD, Professor, Thomas/C-3241-2016	Lion, MD, PhD, Professor, Thomas/0000-0001-9346-0994				ANTONARAKIS SE, 1991, NEW ENGL J MED, V324, P872, DOI 10.1056/NEJM199103283241302; CAMPBELL ML, 1991, ADV CANCER RES, V57, P227; CEDAR H, 1988, CELL, V53, P3, DOI 10.1016/0092-8674(88)90479-5; COTE GB, 1989, ANN GENET-PARIS, V32, P69; DALEY GQ, 1991, ADV CANCER RES, V57, P151; DOERFLER W, 1983, ANNU REV BIOCHEM, V52, P93, DOI 10.1146/annurev.bi.52.070183.000521; FERGUSONSMITH AC, 1990, CANCER SURV, V9, P487; HALL JG, 1990, AM J HUM GENET, V46, P857; HASSOLD TJ, 1984, ANNU REV GENET, V18, P69, DOI 10.1146/annurev.genet.18.1.69; HENRY I, 1991, NATURE, V351, P665, DOI 10.1038/351665a0; HOWELL WM, 1980, EXPERIENTIA, V36, P1014, DOI 10.1007/BF01953855; JADAYEL D, 1990, NATURE, V343, P558, DOI 10.1038/343558a0; Jones P A, 1990, Adv Cancer Res, V54, P1, DOI 10.1016/S0065-230X(08)60806-4; LEACH RJ, 1990, CELL GROWTH DIFFER, V1, P401; LETTMANN C, 1991, NUCLEIC ACIDS RES, V19, P7131, DOI 10.1093/nar/19.25.7131; LION T, 1991, LEUKEMIA, V5, P156; MARKOVIC VD, 1978, HUM GENET, V41, P181, DOI 10.1007/BF00273100; MULLER H, 1975, CYTOGENET CELL GENET, V15, P239, DOI 10.1159/000130522; OLSON SB, 1988, CYTOGENETICS MAMMALI, P583; PAL N, 1990, ONCOGENE, V5, P1665; PANTHIER JJ, 1991, BIOESSAYS, V13, P351, DOI 10.1002/bies.950130709; REIK W, 1987, NATURE, V328, P248, DOI 10.1038/328248a0; REIK W, 1989, NATURE, V338, P112, DOI 10.1038/338112a0; SAPIENZA C, 1987, NATURE, V328, P251, DOI 10.1038/328251a0; SAPIENZA C, 1991, BIOCHIM BIOPHYS ACTA, V1072, P51, DOI 10.1016/0304-419X(91)90006-7; SCHAEFERREGO KE, 1990, ONCOGENE, V5, P1669; SCHWEIZER D, 1980, CYTOGENET CELL GENET, V27, P190, DOI 10.1159/000131482; SCRABLE H, 1989, P NATL ACAD SCI USA, V86, P7480, DOI 10.1073/pnas.86.19.7480; SMITH SS, 1991, MOL CARCINOGEN, V4, P91, DOI 10.1002/mc.2940040202; SURANI MA, 1988, TRENDS GENET, V4, P59, DOI 10.1016/0168-9525(88)90040-6; TOGUCHIDA J, 1989, NATURE, V338, P156, DOI 10.1038/338156a0; VERMA RS, 1989, HUMAN CHROMOSOMES MA; YAMADA T, 1990, LEUKEMIA, V4, P341	33	88	93	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 1	1992	359	6394					414	416		10.1038/359414a0	http://dx.doi.org/10.1038/359414a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JQ624	1406953				2022-12-01	WOS:A1992JQ62400056
J	HECHT, SR; BERGER, M				HECHT, SR; BERGER, M			RIGHT-SIDED ENDOCARDITIS IN INTRAVENOUS-DRUG-USERS - PROGNOSTIC FEATURES IN 102 EPISODES	ANNALS OF INTERNAL MEDICINE			English	Article						ENDOCARDITIS, BACTERIAL; SUBSTANCE ABUSE, INTRAVENOUS; STAPHYLOCOCCUS-AUREUS; PULMONARY VALVE; TRICUSPID VALVE	TRICUSPID-VALVE ENDOCARDITIS; STAPHYLOCOCCUS-AUREUS ENDOCARDITIS; ACTIVE INFECTIVE ENDOCARDITIS; VEGETATION SIZE; ECHOCARDIOGRAPHIC FINDINGS; PROSTHETIC REPLACEMENT; CLINICAL IMPLICATIONS; COMBINATION THERAPY; ADDICTS; DIAGNOSIS	Objective: To describe the clinical, laboratory, and echocardiographic findings in a large group of patients with right-sided endocarditis and to determine whether any of these findings is predictive of prognosis. Design: Retrospective survey of medical records to evaluate the course of hospitalization with follow-up on 6-month survival. Review of two-dimensional echocardiograms by an observer blinded to clinical information. Setting: Large, metropolitan, voluntary hospital. Patients: One hundred twenty-one intravenous drug users with clinical and bacteriologic evidence of 132 episodes of endocarditis. The presence ot a right-sided valvular vegetation detected by two-dimensional echocardiography was required for entry into the study. Measurements and Results: Staphylococcus aureus was the most common infecting organism (82%, 108 of 132). Vegetations involved the tricuspid valve in 127 episodes, the pulmonic in 4, and both in 1; they ranged in size from 0.4 to 4.3 cm (mean, 1.5 +/- 0.7 cm). Vegetations greater than 1.0 cm were present in 106 cases (80%). Among patients with isolated native right-sided endocarditis who reached a definite end point in treatment, mortality was 7% (7 of 98). Vegetations greater than 2.0 cm were associated with a significantly higher mortality compared with vegetations of 2.0 cm or less (33% compared with 1.3%, P < 0.001). Conclusions: Overall, right-sided endocarditis has a favorable prognosis. Although complications and prolonged fever are common, most cases respond to medical therapy. Our findings suggest that vegetation size may be an important predictor of outcome and that vegetations greater than 2.0 cm are associated with increased mortality.	CUNY MT SINAI SCH MED, NEW YORK, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	HECHT, SR (corresponding author), BETH ISRAEL MED CTR, 1ST AVE & 16TH ST, NEW YORK, NY 10003 USA.							ABRAMS B, 1979, ANN INTERN MED, V90, P789, DOI 10.7326/0003-4819-90-5-789; ANDY JJ, 1977, AM J CARDIOL, V40, P17, DOI 10.1016/0002-9149(77)90094-7; ARBULU A, 1981, J THORAC CARDIOV SUR, V82, P684; BARBOUR DJ, 1986, AM J CARDIOL, V57, P475, DOI 10.1016/0002-9149(86)90776-9; BAYER AS, 1988, CHEST, V93, P247, DOI 10.1378/chest.93.2.247; BERGER M, 1984, AM HEART J, V107, P391, DOI 10.1016/0002-8703(84)90393-4; BERGER M, 1980, CIRCULATION, V61, P855, DOI 10.1161/01.CIR.61.4.855; CHAMBERS HF, 1983, MEDICINE, V62, P170, DOI 10.1097/00005792-198305000-00004; CHAMBERS HF, 1988, ANN INTERN MED, V109, P619, DOI 10.7326/0003-4819-109-8-619; CHAN PK, 1989, AM HEART J, V117, P1140, DOI 10.1016/0002-8703(89)90874-0; DINUBILE M, 1987, AM J MED, V82, P811, DOI 10.1016/0002-9343(87)90019-2; GINZTON LE, 1982, AM J CARDIOL, V49, P1853, DOI 10.1016/0002-9149(82)90202-8; HUBBELL G, 1981, AM HEART J, V102, P85, DOI 10.1016/0002-8703(81)90418-X; JAFFE WM, 1990, J AM COLL CARDIOL, V15, P1227, DOI 10.1016/S0735-1097(10)80005-1; LEVINE DP, 1986, REV INFECT DIS, V8, P374; LUTAS EM, 1986, AM HEART J, V112, P107, DOI 10.1016/0002-8703(86)90687-3; MANOLIS AS, 1988, ARCH INTERN MED, V148, P2461, DOI 10.1001/archinte.148.11.2461; MUGGE A, 1989, J AM COLL CARDIOL, V14, P631; OBRIEN JT, 1984, AM HEART J, V108, P386, DOI 10.1016/0002-8703(84)90630-6; RACKLEY CE, 1990, HEART ARTERIES VEINS, P855; REISBERG BE, 1979, PROG CARDIOVASC DIS, V22, P193, DOI 10.1016/0033-0620(79)90023-9; ROBBINS MJ, 1986, AM J MED, V80, P165, DOI 10.1016/0002-9343(86)90004-5; ROBIN E, 1975, AM J CARDIOL, V35, P481, DOI 10.1016/0002-9149(75)90830-9; SANABRIA TJ, 1990, ARCH INTERN MED, V150, P1305, DOI 10.1001/archinte.150.6.1305; SHEIKH MU, 1979, AM J MED, V66, P283, DOI 10.1016/0002-9343(79)90546-1; SHENOY MM, 1984, AM J CARDIOL, V54, P1374, DOI 10.1016/S0002-9149(84)80106-X; SHIVELY BK, 1991, J AM COLL CARDIOL, V18, P391, DOI 10.1016/0735-1097(91)90591-V; SKEHAN JD, 1988, BRIT HEART J, V59, P62; STAFFORD A, 1979, AM J CARDIOL, V44, P754, DOI 10.1016/0002-9149(79)90298-4; STAFFORD WJ, 1985, BRIT HEART J, V53, P310; STEWART JA, 1980, CIRCULATION, V61, P374, DOI 10.1161/01.CIR.61.2.374; TAAMS MA, 1990, BRIT HEART J, V63, P109; WONG D, 1983, ARCH INTERN MED, V143, P1874, DOI 10.1001/archinte.143.10.1874; YEE ES, 1988, J THORAC CARDIOV SUR, V96, P133	34	182	190	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1992	117	7					560	566		10.7326/0003-4819-117-7-560	http://dx.doi.org/10.7326/0003-4819-117-7-560			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JQ226	1524330				2022-12-01	WOS:A1992JQ22600003
J	KRETZNER, L; BLACKWOOD, EM; EISENMAN, RN				KRETZNER, L; BLACKWOOD, EM; EISENMAN, RN			MYC AND MAX PROTEINS POSSESS DISTINCT TRANSCRIPTIONAL ACTIVITIES	NATURE			English	Article							C-MYC; DNA-BINDING; ACTIVATES TRANSCRIPTION; GENE-EXPRESSION; CELLS; ONCOGENE; PRODUCT; SITES; RNA	THE MyC family proteins are thought to be involved in transcription1,2 because they have both a carboxy-terminal basic-helix-loop-helix-zipper (bHLH-Z) domain, common to a large class of transcription factors, and an amino-terminal fragment which, for c-Myc, has transactivating function when assayed in chimaeric constructs4. In addition, c-, N- and L-Myc proteins heterodimerize, in vitro and in vivo, with the bHLH-Z protein Max5-8. In vitro, Max homodimerizes but preferentially associates with Myc, which homodimerizes poorly5,6. Furthermore Myc-Max heterodimers specifically bind the nucleotide sequence CACGTG9 with higher affinity than either homodimer alone5. The identification of Max and the specific DNA-binding activities of Myc and Max provides an opportunity for directly testing the transcriptional activities of these proteins in mammalian cells. We report here that Myc overexpression activates, whereas Max overexpression represses, transcription of a reporter gene. Max-induced repression is relieved by overexpression of c-Myc. Repression requires the DNA-binding domain of Max, whereas relief of repression requires the dimerization and transcriptional activation activities of Myc. Both effects require Myc-Max-binding sites in the reporter gene.	UNIV WASHINGTON,SCH MED,DEPT PATHOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle	KRETZNER, L (corresponding author), FRED HUTCHINSON CANC RES CTR,DIV BASIC SCI,1124 COLUMBIA ST,SEATTLE,WA 98104, USA.							BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; DEAN M, 1986, J BIOL CHEM, V261, P9161; GEBALLE AP, 1988, J VIROL, V62, P3334, DOI 10.1128/JVI.62.9.3334-3340.1988; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HALAZONETIS TD, 1991, P NATL ACAD SCI USA, V88, P6162, DOI 10.1073/pnas.88.14.6162; HANN SR, 1985, NATURE, V314, P366, DOI 10.1038/314366a0; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; HARLAND R, 1985, J CELL BIOL, V101, P1094, DOI 10.1083/jcb.101.3.1094; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; KADDURAHDAOUK R, 1987, GENE DEV, V1, P347, DOI 10.1101/gad.1.4.347; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KINGSTON RE, 1985, CELL, V41, P3, DOI 10.1016/0092-8674(85)90049-2; NYBORG JK, 1990, J BIOL CHEM, V265, P8237; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; WATERS CM, 1991, ONCOGENE, V6, P797; WENZEL A, 1991, EMBO J, V10, P3703, DOI 10.1002/j.1460-2075.1991.tb04938.x	26	458	466	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 1	1992	359	6394					426	429		10.1038/359426a0	http://dx.doi.org/10.1038/359426a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JQ624	1406956				2022-12-01	WOS:A1992JQ62400060
J	MISIANI, R; BELLAVITA, P; FENILI, D; BORELLI, G; MARCHESI, D; MASSAZZA, M; VENDRAMIN, G; COMOTTI, B; TANZI, E; SCUDELLER, G; ZANETTI, A				MISIANI, R; BELLAVITA, P; FENILI, D; BORELLI, G; MARCHESI, D; MASSAZZA, M; VENDRAMIN, G; COMOTTI, B; TANZI, E; SCUDELLER, G; ZANETTI, A			HEPATITIS-C VIRUS-INFECTION IN PATIENTS WITH ESSENTIAL MIXED CRYOGLOBULINEMIA	ANNALS OF INTERNAL MEDICINE			English	Article						HEPATITIS-C; CRYOGLOBULINEMIA; GLOMERULONEPHRITIS; HEPATITIS ANTIBODIES; RHEUMATOID FACTOR	LONG-TERM; B VIRUS; GLOMERULONEPHRITIS; VASCULITIS	Objective: To study the association between hepatitis C virus (HCV) infection and essential mixed cryoglobulinemia. Setting: Wards and clinics of the Ospedali Riuniti di Bergamo and Ospedale di Treviglio e Caravaggio, Italy. Patients: Fifty-one patients with essential mixed cryoglobulinemia associated with glomerulonephritis and 45 controls with noncryoglobulinemic glomerulopathies. Measurements: Antibodies to hepatitis C virus (anti-HCV) in sera from patients with essential mixed cryoglobulinemia and from controls, using two enzyme-linked immunosorbent assays (C100 ELISA and c22/c200 ELISA) and a recombinant immunoblot assay (4-RIBA); cryoprecipitate anti-HCV before and after use of dithiothreitol, a substance able to destroy IgM antibodies with rheumatoid factor activity, in patients with essential mixed cryoglobulinemia; serum HCV RNA by polymerase chain reaction in patients with essential mixed cryoglobulinemia. Results: In patients with essential mixed cryoglobulinemia, the c22/c200 ELISA detected anti-HCV in 98% of serum samples (95% Cl, 90% to 100%), whereas the rate of reactivity remained at 2% (Cl, 0% to 12%) in the control group (P < 0.0001). These results were confirmed by the 4-RIBA in 66% of patients with essential mixed cryoglobulinemia. The study of cryoprecipitate by c100 ELISA showed anti-HCV in 41% (Cl, 28% to 56%) of patients. After dithiothreitol, the rate of reactivity increased to 94% (Cl, 84% to 99%; P < 0.0001 by the McNemar paired chi-square test), suggesting that the elimination of rheumatoid factor leads to unmasking of anti-HCV in cryoprecipitate. Polymerase chain reaction detected HCV RNA in 13 of 16 sera from patients with essential mixed cryoglobulinemia. Conclusions: The extremely high prevalence of anti-HCV in serum and cryoprecipitate along with the frequently associated serum HCV RNA suggests a close relation between essential mixed cryoglobulinemia and chronic HCV infection.	OSPED RIUNITI BERGAMO, DEPT IMMUNOHEMATOL, LARGO BAROZZI 1, I-24100 BERGAMO, ITALY; OSPED TREVIGLIO & CARAVAGGIO, TREVIGLIO, SPAIN; UNIV MILAN, I-20122 MILAN, ITALY; UNIV CAMERINO, I-62032 CAMERINO, ITALY	Ospedali Riuniti di Bergamo; University of Milan; University of Camerino			Tanzi, Elisabetta/M-9066-2016	Tanzi, Elisabetta/0000-0002-4119-701X				BONOMO L, 1987, AM J MED, V83, P726, DOI 10.1016/0002-9343(87)90904-1; BONOMO L, 1971, CLIN EXP IMMUNOL, V9, P175; BOUDART D, 1990, LANCET, V336, P63, DOI 10.1016/0140-6736(90)91585-X; CASATO M, 1991, LANCET, V337, P1047, DOI 10.1016/0140-6736(91)92715-E; CORDONNIER D, 1975, AM J MED, V59, P867, DOI 10.1016/0002-9343(75)90480-5; CREAM JJ, 1971, BRIT J DERMATOL, V84, P48, DOI 10.1111/j.1365-2133.1971.tb14196.x; DURAND JM, 1991, LANCET, V337, P499, DOI 10.1016/0140-6736(91)93443-D; DUSSAIX E, 1990, LANCET, V335, P1160, DOI 10.1016/0140-6736(90)91163-5; FARCI P, 1991, NEW ENGL J MED, V325, P98, DOI 10.1056/NEJM199107113250205; GARSON JA, 1990, LANCET, V335, P1419, DOI 10.1016/0140-6736(90)91446-H; GOREVIC PD, 1980, AM J MED, V69, P287, DOI 10.1016/0002-9343(80)90390-3; HOUGHTON M, 1989, Patent No. 883109225; HURWITZ D, 1975, CLIN EXP IMMUNOL, V19, P131; JORI GP, 1977, GUT, V18, P245, DOI 10.1136/gut.18.3.245; LEVO Y, 1977, NEW ENGL J MED, V296, P1501, DOI 10.1056/NEJM197706302962605; LEVO Y, 1977, ANN INTERN MED, V87, P287, DOI 10.7326/0003-4819-87-3-287; MAGGIORE Q, 1982, KIDNEY INT, V21, P387, DOI 10.1038/ki.1982.34; Masson P L, 1981, Methods Enzymol, V74 Pt C, P106; MCFARLANE IG, 1990, LANCET, V335, P754, DOI 10.1016/0140-6736(90)90870-B; MCINTOSH RM, 1976, Q J MED, V45, P23; MELTZER M, 1966, AM J MED, V40, P837, DOI 10.1016/0002-9343(66)90200-2; MELTZER M, 1966, AM J MED, V40, P828, DOI 10.1016/0002-9343(66)90199-9; PASCUAL M, 1990, J INFECT DIS, V162, P569, DOI 10.1093/infdis/162.2.569; POPP JW, 1980, ANN INTERN MED, V92, P379, DOI 10.7326/0003-4819-92-3-379; REALDI G, 1974, Z IMMUNITATSFORSCH, V147, P114; Riethmuller G, 1966, Clin Exp Immunol, V1, P337; SINICO RA, 1988, KIDNEY INT, V34, P109, DOI 10.1038/ki.1988.152; SPALLUTO JL, 1962, AM J MED, V32, P142; TARANTINO A, 1978, CLIN EXP IMMUNOL, V32, P77; THEILMANN L, 1990, LANCET, V335, P1345; VANDERPOEL CL, 1991, LANCET, V337, P317, DOI 10.1016/0140-6736(91)90942-I	31	516	521	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1992	117	7					573	577		10.7326/0003-4819-117-7-573	http://dx.doi.org/10.7326/0003-4819-117-7-573			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JQ226	1326246				2022-12-01	WOS:A1992JQ22600005
J	ROWLAND, AS; BAIRD, DD; WEINBERG, CR; SHORE, DL; SHY, CM; WILCOX, AJ				ROWLAND, AS; BAIRD, DD; WEINBERG, CR; SHORE, DL; SHY, CM; WILCOX, AJ			REDUCED FERTILITY AMONG WOMEN EMPLOYED AS DENTAL ASSISTANTS EXPOSED TO HIGH-LEVELS OF NITROUS-OXIDE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SPRAGUE-DAWLEY RATS; SPONTANEOUS-ABORTION; DELAYED CONCEPTION; CIGARETTE-SMOKING; ANESTHETIC-GASES; PREGNANCY; EXPOSURES; WORKPLACE; DENTISTS; TOXICITY	Background. Fertility is reduced in female rats exposed to levels of nitrous oxide similar to those found in some dental offices. Epidemiologic studies have suggested an association between exposure to mixed anesthetic gases and impaired fertility. We investigated the effects of occupational exposure to nitrous oxide on the fertility of female dental assistants. Methods. Screening questionnaires were mailed to 7000 female dental assistants, ages 18 to 39, registered by the California Department of Consumer Affairs. Sixty-nine percent responded. Four hundred fifty-nine women were determined to be eligible, having become pregnant during the previous four years for reasons unrelated to the failure of birth control, and 91 percent of these women completed telephone interviews. Detailed information was collected on exposure to nitrous oxide and fertility (measured by the number of menstrual cycles without contraception that the women required to become pregnant). Results. After controlling for covariates, we found that women exposed to high levels of nitrous oxide were significantly less fertile than women who were unexposed or exposed to lower levels of nitrous oxide. The effect was evident only in the 19 women with five or more hours of exposure per week. These women were only 41 percent (95 percent confidence interval, 23 to 74 percent; P<0.003) as likely as unexposed women to conceive during each menstrual cycle. Conclusions. Occupational exposure to high levels of nitrous oxide may adversely affect a woman's ability to become pregnant.	NIEHS,DIV BIOMETRY & RISK ASSESSMENT,STAT & BIOMATH BRANCH,RES TRIANGLE PK,NC 27709; UNIV N CAROLINA,SCH PUBL HLTH,DEPT EPIDEMIOL,CHAPEL HILL,NC 27514	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of North Carolina; University of North Carolina Chapel Hill	ROWLAND, AS (corresponding author), NIEHS,EPIDEMIOL BRANCH,A3-05,POB 12233,RES TRIANGLE PK,NC 27709, USA.		Baird, Donna D/D-5214-2017; Rowland, Andy/AAH-4049-2019; Wilcox, Allen J/C-7723-2019	Baird, Donna D/0000-0002-5544-2653; Wilcox, Allen J/0000-0002-3376-1311; Weinberg, Clarice/0000-0002-7713-8556				AXELSSON G, 1982, INT J EPIDEMIOL, V11, P250, DOI 10.1093/ije/11.3.250; BAIRD DD, 1985, JAMA-J AM MED ASSOC, V253, P2979, DOI 10.1001/jama.253.20.2979; BAIRD DD, 1986, AM J EPIDEMIOL, V124, P470, DOI 10.1093/oxfordjournals.aje.a114417; BARLOW SM, 1982, REPRODUCTIVE HAZARDS, P386; COATE WB, 1979, ANESTHESIOLOGY, V50, P310, DOI 10.1097/00000542-197904000-00006; COHEN EN, 1971, ANESTHESIOLOGY, V35, P343; COHEN EN, 1980, J AM DENT ASSOC, V101, P21, DOI 10.14219/jada.archive.1980.0345; COHEN EN, 1975, J AM DENT ASSOC, V90, P1291, DOI 10.14219/jada.archive.1975.0270; FERSTANDIG LL, 1978, ANESTH ANALG, V57, P328; FUJINAGA M, 1991, TERATOLOGY, V43, P151, DOI 10.1002/tera.1420430207; HENRY RJ, 1991, J DENT RES, V70, P1286, DOI 10.1177/00220345910700091001; JASTAK JT, 1989, INT ANESTHESIOL CLIN, V27, P92, DOI 10.1097/00004311-198902720-00005; KNILLJON.RP, 1972, LANCET, V1, P1326; KUGEL G, 1989, Journal of Dental Research, V68, P313; Kugel G, 1990, Anesth Prog, V37, P176; LEMASTERS GK, 1989, J CLIN EPIDEMIOL, V42, P975, DOI 10.1016/0895-4356(89)90162-5; LINN S, 1982, JAMA-J AM MED ASSOC, V247, P629; MAZZE RI, 1988, TERATOLOGY, V38, P121, DOI 10.1002/tera.1420380204; MAZZE RI, 1987, BRIT J ANAESTH, V59, P1291, DOI 10.1093/bja/59.10.1291; McCullagh P., 1983, GEN LINEAR MODELS, DOI [10.1007/978-1-4899-3244-0, DOI 10.1007/978-1-4899-3244-0]; McGlothlin JD, 1988, STUDY PROTOCOL CONTR; NUNN JF, 1985, NITROUS OXIDE N2O, P211; RACHOOTIN P, 1983, J OCCUP ENVIRON MED, V25, P394; ROYSTON BD, 1988, ANESTHESIOLOGY, V68, P213, DOI 10.1097/00000542-198802000-00006; SPENCE AA, 1977, JAMA-J AM MED ASSOC, V238, P955, DOI 10.1001/jama.238.9.955; SURUDA AJ, 1990, J OCCUP ENVIRON MED, V32, P682; SWEENEY B, 1985, BRIT MED J, V291, P567, DOI 10.1136/bmj.291.6495.567; TIETZE C, 1968, INT J FERTIL, V13, P385; VESSEY MP, 1978, ANAESTHESIA, V33, P430, DOI 10.1111/j.1365-2044.1978.tb12461.x; WEINBERG CR, 1989, AM J EPIDEMIOL, V129, P1072, DOI 10.1093/oxfordjournals.aje.a115211; WEINBERG CR, IN PRESS STAT MED; WHITCHER CE, 1977, J AM DENT ASSOC, V95, P763, DOI 10.14219/jada.archive.1977.0493; 1977, DHEW NIOSH77140 NAT; 1992, EMPLOY EARN, V39, P185; 1981, DENTISTS DESK REFERE, P23	35	220	221	0	13	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 1	1992	327	14					993	997		10.1056/NEJM199210013271405	http://dx.doi.org/10.1056/NEJM199210013271405			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JQ225	1298226				2022-12-01	WOS:A1992JQ22500005
J	RUDENSKY, AY; PRESTONHURLBURT, P; ALRAMADI, BK; ROTHBARD, J; JANEWAY, CA				RUDENSKY, AY; PRESTONHURLBURT, P; ALRAMADI, BK; ROTHBARD, J; JANEWAY, CA			TRUNCATION VARIANTS OF PEPTIDES ISOLATED FROM MHC CLASS-II MOLECULES SUGGEST SEQUENCE MOTIFS	NATURE			English	Article							B-CELL INTERACTION; IA MOLECULE; IDENTIFICATION; ANTIGEN; SELF; IMMUNOGLOBULIN; PROTEIN; RECOGNITION; EPITOPE; CLONES	T CELLS recognize foreign protein antigens in the form of peptide fragments bound tightly to the outer aspect of molecules encoded by the major histocompatibility complex (MHC). Most of the amino-acid differences that distinguish MHC allelic variants line the peptide-binding cleft, and different allelic forms of MHC molecules bind distinct peptides1,2. It has been demonstrated that peptide-binding to MHC class I involves anchor residues in certain positions and that antigenic peptides associated with MHC class I exhibit allele-specific structural motifs3. We have previously reported an analysis of MHC class II-associated peptide sequences4. Here we extend this analysis and show that certain amino-acid residues occur at particular positions in the sequence of peptides binding to a given MHC class II molecule. These sequence motifs require the amino terminus to be shifted one or two positions to obtain alignment; such shifts occur naturally for a single peptide sequence without qualitatively altering CD4 T-cell recognition.	YALE UNIV,SCH MED,IMMUNOBIOL SECT,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510	Yale University; Howard Hughes Medical Institute; Yale University	RUDENSKY, AY (corresponding author), IMMULOG PHARMACEUT CORP,PALO ALTO,CA 94304, USA.							BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; CHEN JS, 1991, J IMMUNOL, V147, P3672; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FINNEGAN A, 1986, J EXP MED, V164, P897, DOI 10.1084/jem.164.3.897; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; HEBERKATZ E, 1983, J MOL CELL IMMUNOL, V1, P3; HUNT DF, 1992, SCIENCE, V256, P1817, DOI 10.1126/science.1319610; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; JARDETZKY TS, 1990, EMBO J, V9, P1797, DOI 10.1002/j.1460-2075.1990.tb08304.x; KABAT EA, 1991, NIH913242 US DEP HLT; KAPPLER J, 1982, P NATL ACAD SCI-BIOL, V79, P3604, DOI 10.1073/pnas.79.11.3604; MARGULIES D H, 1992, Current Biology, V2, P211, DOI 10.1016/0960-9822(92)90542-I; MATSUMURA M, 1992, SCIENCE, V257, P927, DOI 10.1126/science.1323878; MURRAY JS, 1992, EUR J IMMUNOL, V22, P559, DOI 10.1002/eji.1830220239; OSULLIVAN D, 1991, J IMMUNOL, V147, P2663; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; R/tzschke O., 1990, NATURE, V348, P253; RATH S, IN PRESS EUR J IMMUN; ROTHBARD JB, 1991, ANNU REV IMMUNOL, V9, P527, DOI 10.1146/annurev.iy.09.040191.002523; RUDENSKY AY, 1991, NATURE, V353, P622, DOI 10.1038/353622a0; RUDENSKY AY, 1991, NATURE, V353, P660, DOI 10.1038/353660a0; RUDENSKY AY, 1989, EUR J IMMUNOL, V19, P1677, DOI 10.1002/eji.1830190923; SAKAI K, 1988, J NEUROIMMUNOL, V19, P21, DOI 10.1016/0165-5728(88)90032-X; SHASTRI N, 1986, J EXP MED, V164, P882, DOI 10.1084/jem.164.3.882; SHUMACHER TNM, 1991, NATURE, V350, P703; TUOHY VK, 1989, J IMMUNOL, V142, P1523; VANBLEEK GM, 1990, NATURE, V348, P213; WEISS S, 1989, P NATL ACAD SCI USA, V86, P282, DOI 10.1073/pnas.86.1.282; YURIN VL, 1989, EUR J IMMUNOL, V19, P1685, DOI 10.1002/eji.1830190924	29	247	255	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 1	1992	359	6394					429	431		10.1038/359429a0	http://dx.doi.org/10.1038/359429a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JQ624	1328884				2022-12-01	WOS:A1992JQ62400061
J	SOMERS, WS; PHILLIPS, SEV				SOMERS, WS; PHILLIPS, SEV			CRYSTAL-STRUCTURE OF THE MET REPRESSOR-OPERATOR COMPLEX AT 2.8 A-ANGSTROM RESOLUTION REVEALS DNA RECOGNITION BY BETA-STRANDS	NATURE			English	Article							ESCHERICHIA-COLI; METHIONINE BIOSYNTHESIS; ARC REPRESSOR; PROTEIN; BINDING; COREPRESSOR; PHAGE-434; PROGRAM; REGION; FAMILY	The crystal structure of the met repressor-operator complex shows two dimeric repressor molecules bound to adjacent sites 8 base pairs apart on an 18-base-pair DNA fragment. Sequence specificity is achieved by insertion of double-stranded antiparallel protein beta-ribbons into the major groove of B-form DNA, with direct hydrogen-bonding between amino-acid side chains and the base pairs. The repressor also recognizes sequence-dependent distortion or flexibility of the operator phosphate backbone, conferring specificity even for inaccessible base pairs.	UNIV LEEDS,DEPT BIOCHEM & MOLEC BIOL,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND	University of Leeds				Phillips, Simon/0000-0001-8922-0250				AGGARWAL AK, 1988, SCIENCE, V242, P899, DOI 10.1126/science.3187531; BELFAIZA J, 1986, P NATL ACAD SCI USA, V83, P867, DOI 10.1073/pnas.83.4.867; BOWIE JU, 1990, J MOL BIOL, V211, P5, DOI 10.1016/0022-2836(90)90004-6; BREG JN, 1990, NATURE, V346, P586, DOI 10.1038/346586a0; BRENNAN RG, 1990, P NATL ACAD SCI USA, V87, P8165, DOI 10.1073/pnas.87.20.8165; Brennan RG, 1991, CURR OPIN STRUC BIOL, V1, P80, DOI 10.1016/0959-440X(91)90015-L; BROWN BM, 1990, BIOCHEMISTRY-US, V29, P11189, DOI 10.1021/bi00503a006; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CARTER CW, 1974, P NATL ACAD SCI USA, V71, P283, DOI 10.1073/pnas.71.2.283; CHURCH GM, 1977, P NATL ACAD SCI USA, V74, P1458, DOI 10.1073/pnas.74.4.1458; CLARKE ND, 1991, SCIENCE, V254, P267, DOI 10.1126/science.1833818; DAVIDSON BE, 1989, MOL MICROBIOL, V3, P1639, DOI 10.1111/j.1365-2958.1989.tb00149.x; DREW HR, 1985, J MOL BIOL, V186, P773, DOI 10.1016/0022-2836(85)90396-1; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; FLOWER DR, 1991, J MOL GRAPHICS, V9, P257, DOI 10.1016/0263-7855(91)80021-Q; FREEMONT PS, 1991, BIOCHEM J, V278, P1; HARRISON SC, 1991, NATURE, V353, P715, DOI 10.1038/353715a0; HARRISON SC, 1990, REV BIOCH, V59, P933; HE YY, 1992, NATURE, V359, P431, DOI 10.1038/359431a0; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JORDAN SR, 1988, SCIENCE, V242, P893, DOI 10.1126/science.3187530; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KLUG A, 1979, J MOL BIOL, V131, P669, DOI 10.1016/0022-2836(79)90196-7; KNIGHT KL, 1989, J BIOL CHEM, V264, P3639; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; LUISI BF, 1990, BIOCHIM BIOPHYS ACTA, V1048, P113, DOI 10.1016/0167-4781(90)90047-6; MONDRAGON A, 1991, J MOL BIOL, V219, P321, DOI 10.1016/0022-2836(91)90568-Q; OLD IG, 1991, PROG BIOPHYS MOL BIO, V56, P145, DOI 10.1016/0079-6107(91)90012-H; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PHILLIPS SEV, 1989, NATURE, V341, P711, DOI 10.1038/341711a0; PRIESTLE JP, 1988, J APPL CRYSTALLOGR, V21, P572, DOI 10.1107/S0021889888005746; QUINTANA JR, 1992, J MOL BIOL, V225, P379, DOI 10.1016/0022-2836(92)90928-D; RAFFERTY JB, 1989, NATURE, V341, P705, DOI 10.1038/341705a0; RHODES D, 1980, NATURE, V286, P573, DOI 10.1038/286573a0; SAENGER W, 1984, PRINCIPLES NUCLEIC A, P226; SAINTGIRONS I, 1986, J BIOL CHEM, V261, P936; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; SIM GA, 1960, ACTA CRYSTALLOGR, V13, P511, DOI 10.1107/S0365110X60001266; STEITZ TA, 1990, Q REV BIOPHYS, V23, P205, DOI 10.1017/S0033583500005552; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5; YOON C, 1988, P NATL ACAD SCI USA, V85, P6332, DOI 10.1073/pnas.85.17.6332; 1979, 4 DAR LAB SERC COLL	46	284	290	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 1	1992	359	6394					387	393		10.1038/359387a0	http://dx.doi.org/10.1038/359387a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JQ624	1406951				2022-12-01	WOS:A1992JQ62400046
J	TATE, ME; ENNEKING, D				TATE, ME; ENNEKING, D			A MESS OF RED POTTAGE	NATURE			English	Editorial Material											TATE, ME (corresponding author), UNIV ADELAIDE,WAITE AGR RES INST,DEPT PLANT SCI,GLEN OSMOND,SA 5064,AUSTRALIA.							BARULINA H, 1930, T PRIKL BOT GENET S, V40, P302; Candolle AD, 1886, ORIGIN CULTIVATED PL; COKE LA, 1992, PLANT VAR SEEDS, V5, P1; DANCKWORTT PW, 1935, Z UNTERSUCHUNG LEBEN, V69, P458; HARPER JA, 1962, POULTRY SCI, V41, P1968, DOI 10.3382/ps.0411968; Hegi, 1925, ILLUSTRIERTE FLORA M; RESSLER C, 1969, J AM CHEM SOC, V91, P2758, DOI 10.1021/ja01038a058; 1959, FAO TABULATED INFORM, P297	8	36	36	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 1	1992	359	6394					357	358		10.1038/359357a0	http://dx.doi.org/10.1038/359357a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JQ624	1406942				2022-12-01	WOS:A1992JQ62400023
J	TORNOS, MP; PERMANYERMIRALDA, G; OLONA, M; GIL, M; GALVE, E; ALMIRANTE, B; SOLERSOLER, J				TORNOS, MP; PERMANYERMIRALDA, G; OLONA, M; GIL, M; GALVE, E; ALMIRANTE, B; SOLERSOLER, J			LONG-TERM COMPLICATIONS OF NATIVE VALVE INFECTIVE ENDOCARDITIS IN NONADDICTS - A 15-YEAR FOLLOW-UP-STUDY	ANNALS OF INTERNAL MEDICINE			English	Article						ENDOCARDITIS; HEART VALVE DISEASE; AORTIC VALVE; DEATH, SUDDEN, CARDIAC; HEART VALVE PROSTHESIS	DISEASE	Objective: To describe the incidence and clinical manifestations of long-term cardiac complications of endocarditis. Design: Cohort study. Setting: University-affiliated tertiary medical center. Patients: One hundred twelve consecutive patients, survivors from a series of 140 non-addicted patients with a first episode of infective endocarditis on native valves hospitalized from 1975 to 1990. Thirty-two patients had had valve replacement during the active phase of the infection, and the remaining 80 patients received medical treatment alone. Measurements: Relapse, recurrence, need for late cardiac surgery, and cardiac mortality. Results: Relapses occurred in three patients (2.7%) and recurrences in five patients (4.5%, incidence density at 15 years, 0.0030 per patient-year). Late cardiac surgery was needed by 47% of the patients treated medically during the active phase, and most had surgery in the first 2 years of follow-up (incidence density, 0.25 per patient-year at 2 years). Aortic valve involvement (relative risk, 2.66; 95% Cl, 1.15 to 6.17) and end-diastolic diameter greater than 60 mm (relative risk, 1.04; 95% Cl, 1.03 to 2.43) were associated with the need for late surgery in univariate analysis. Multiple logistic regression analysis showed aortic valve involvement to be an independent predictor of the need for late surgery (relative risk, 3.04; Cl, 1.23 to 7.54). Only 2 of the 32 patients who had surgery during the active infection needed a second operation during follow-up. At the end of follow-up, the number of patients who had surgery after the onset of the infection was 86 (60% of the whole series). Cardiac death occurred in 16 patients; most deaths were sudden or postoperative and occurred in the first 2 years of follow-up (incidence density, 0.047 per patient-year at 2 years). Independent predictors of death were not found. Survival was 90% at 2 years, 88% at 5 years, 81 % at 10 years, and 61 % at 15 years. Conclusions: Survival after infective endocarditis is fair (81% probability of survival at 10 years), and the most common types of cardiac death are sudden and postoperative. Aortic valve involvement is an independent predictor of the need for late cardiac surgery. The rate of recurrences is not negligible (incidence density at 15 years, 0.0030 per patient-year).			TORNOS, MP (corresponding author), UNIV BARCELONA, HOSP GEN VALL DHEBRON, P VALL DHEBRON SN, E-08035 BARCELONA, SPAIN.			Almirante, Benito/0000-0002-1189-2361				BADDOUR LM, 1988, REV INFECT DIS, V10, P1163; BAYLISS R, 1983, BRIT HEART J, V50, P513, DOI 10.1136/hrt.50.6.513; CALDERWOOD SB, 1986, J THORAC CARDIOV SUR, V92, P776; CHAMBERS HF, 1983, MEDICINE, V62, P170, DOI 10.1097/00005792-198305000-00004; DAVID TE, 1990, ANN THORAC SURG, V49, P701, DOI 10.1016/0003-4975(90)90006-R; DELAHAYE JP, 1989, ARCH MAL COEUR VAISS, V82, P543; DURACK DT, 1990, HEART, P1230; GERACI JE, 1982, MAYO CLIN PROC, V57, P145; IVERT TSA, 1984, CIRCULATION, V69, P223, DOI 10.1161/01.CIR.69.2.223; JAFFE WM, 1990, J AM COLL CARDIOL, V15, P1227, DOI 10.1016/S0735-1097(10)80005-1; KAYE D, 1991, HARRISONS PRINCIPLES, P508; KAYE D, 1976, INFECTIVE ENDOCARDIT, P201; Kleimbaum DG., 1982, EPIDEMIOLOGIC RES PR, P96; KOMSHIAN SV, 1990, REV INFECT DIS, V12, P693; MCANULTY JH, 1979, JAMA-J AM MED ASSOC, V242, P77, DOI 10.1001/jama.242.1.77; ORMISTON JA, 1981, AUST NZ J MED, V11, P620, DOI 10.1111/j.1445-5994.1981.tb03536.x; PRINGLE SD, 1989, INT J CARDIOL, V24, P179, DOI 10.1016/0167-5273(89)90302-1; RICE LB, 1991, REV INFECT DIS, V13, P1; SCHELD WM, 1990, PRINCIPLES PRACTICE, P670; STECKELBERG JM, 1991, ANN INTERN MED, V114, P635, DOI 10.7326/0003-4819-114-8-635; STECKELBERG JM, 1990, AM J MED, V88, P582, DOI 10.1016/0002-9343(90)90521-E; STEIN DS, 1987, REV INFECT DIS, V9, P908; TORNOSMAS MP, 1984, EUR HEART J, V5, P107, DOI 10.1093/eurheartj/5.suppl_C.107; VONREYN CF, 1981, ANN INTERN MED, V94, P505, DOI 10.7326/0003-4819-94-4-505; WEINSTEIN L, 1988, HEART DISEASE TXB CA, P1093	25	123	124	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1992	117	7					567	572		10.7326/0003-4819-117-7-567	http://dx.doi.org/10.7326/0003-4819-117-7-567			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JQ226	1306055				2022-12-01	WOS:A1992JQ22600004
J	TYTGAT, J; HESS, P				TYTGAT, J; HESS, P			EVIDENCE FOR COOPERATIVE INTERACTIONS IN POTASSIUM CHANNEL GATING	NATURE			English	Article							XENOPUS-OOCYTES; SHAKER; DROSOPHILA; EXPRESSION; CDNA	CLONING and expression of voltage-activated potassium ionchannel complementary DNAs1-4 has confirmed that these channels are composed of four identical subunits5, each containing a voltage sensor. It has been generally accepted that the voltage sensors must reach a permissive state through one or more conformational ('gating') transitions before the channel can open6,7. To test whether each subunit gates independently, we have constructed cDNAs encoding four subunits on a single polypeptide chain, enabling us to specify the subunit stoichiometry. The gating of heterotetramers made up from combinations of subunits with different gating phenotypes strongly suggests that individual subunits gate cooperatively, rather than independently8. Nonindependent subunit gating is consistent with measurements of the kinetics of K+-channel gating currents9-13 and in line with the widespread subunit cooperativity observed in other multisubunit proteins14.	HARVARD UNIV, SCH MED, DEPT CELLULAR & MOLEC PHYSIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, PROGRAM NEUROSCI, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School			Tytgat, Jan/F-1560-2010	Tytgat, Jan/0000-0003-1778-6022				BAUMANN A, 1988, EMBO J, V7, P2457, DOI 10.1002/j.1460-2075.1988.tb03092.x; BEZANILLA F, 1991, SCIENCE, V254, P679, DOI 10.1126/science.1948047; CHRISTIE MJ, 1989, SCIENCE, V244, P221, DOI 10.1126/science.2539643; GILLY WF, 1982, J GEN PHYSIOL, V79, P965, DOI 10.1085/jgp.79.6.965; HEGINBOTHAM L, 1992, NEURON, V8, P483, DOI 10.1016/0896-6273(92)90276-J; HILLE B, 1992, IONIC CHANNELS EXCIT, P1; HODGKIN AL, 1952, J PHYSIOL-LONDON, V117, P500, DOI 10.1113/jphysiol.1952.sp004764; HURST R S, 1992, Biophysical Journal, V61, pA425; ISACOFF EY, 1990, NATURE, V345, P530, DOI 10.1038/345530a0; IVERSON LE, 1988, P NATL ACAD SCI USA, V85, P5723, DOI 10.1073/pnas.85.15.5723; KAVANAUGH MP, 1992, NEURON, V8, P493, DOI 10.1016/0896-6273(92)90277-K; KOREN G, 1990, NEURON, V4, P39, DOI 10.1016/0896-6273(90)90442-I; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LIMAN ER, 1991, NATURE, V353, P752, DOI 10.1038/353752a0; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; PAPAZIAN DM, 1987, SCIENCE, V237, P749, DOI 10.1126/science.2441470; PAPAZIAN DM, 1991, NATURE, V349, P305, DOI 10.1038/349305a0; PONGS O, 1988, EMBO J, V7, P1087, DOI 10.1002/j.1460-2075.1988.tb02917.x; SCHOPPA NE, 1992, SCIENCE, V255, P1712, DOI 10.1126/science.1553560; STUHMER W, 1991, PFLUG ARCH EUR J PHY, V418, P423, DOI 10.1007/BF00550881; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; TIMPE LC, 1988, NATURE, V331, P143, DOI 10.1038/331143a0; TYTGAT J, 1992, Biophysical Journal, V61, pA426; VANDENBERG CA, 1991, BIOPHYS J, V60, P1511, DOI 10.1016/S0006-3495(91)82186-5; ZAGOTTA WN, 1990, J GEN PHYSIOL, V95, P29, DOI 10.1085/jgp.95.1.29	26	126	126	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 1	1992	359	6394					420	423		10.1038/359420a0	http://dx.doi.org/10.1038/359420a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JQ624	1406954				2022-12-01	WOS:A1992JQ62400058
J	WALD, A; COYLE, MB; CARLSON, LC; THOMPSON, RL; HOOTON, TM				WALD, A; COYLE, MB; CARLSON, LC; THOMPSON, RL; HOOTON, TM			INFECTION WITH A FASTIDIOUS MYCOBACTERIUM RESEMBLING MYCOBACTERIUM-SIMIAE IN 7 PATIENTS WITH AIDS	ANNALS OF INTERNAL MEDICINE			English	Note								We report the clinical features of seven patients with the acquired immunodeficiency syndrome (AIDS) who were infected with a new, fastidious mycobacterium, and we describe the microbiologic properties of the isolates. All patients but one had had a previous AIDS-defining illness; the median CD4 lymphocyte count was 7/muL. Fevers and wasting were the most common signs and symptoms, followed by abdominal pain and diarrhea. The mycobacterium grew fastidiously on solid media and resembled Mycobacterium simiae on chromatography. We conclude that this mycobacterium infects profoundly immunosuppressed patients with AIDS. The clinical features at presentation are comparable to those reported in patients with disseminated Mycobacterium avium complex infection.	UNIV WASHINGTON, HARBORVIEW MED CTR, SEATTLE, WA 98104 USA; UNIV WASHINGTON, SEATTLE, WA 98195 USA; GRP HLTH COOPERAT PUGET SOUND, SEATTLE, WA USA	Harborview Medical Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Group Health Cooperative			Wald, Anna/B-6272-2012	Wald, Anna/0000-0003-3486-6438				AGY MB, 1989, DIAGN MICR INFEC DIS, V12, P303, DOI 10.1016/0732-8893(89)90094-1; BOTTGER EC, 1991, 31ST P INT C ANT AG; BUTLER WR, 1991, J CLIN MICROBIOL, V29, P2468, DOI 10.1128/JCM.29.11.2468-2472.1991; HIRSCHEL B, 1990, NEW ENGL J MED, V323, P109, DOI 10.1056/NEJM199007123230207; MINNIKIN DE, 1985, ZBL BAKT-INT J MED M, V259, P446	5	37	37	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1992	117	7					586	589		10.7326/0003-4819-117-7-586	http://dx.doi.org/10.7326/0003-4819-117-7-586			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JQ226	1524333				2022-12-01	WOS:A1992JQ22600008
J	WOLFF, JO				WOLFF, JO			PARENTS SUPPRESS REPRODUCTION AND STIMULATE DISPERSAL IN OPPOSITE-SEX JUVENILE WHITE-FOOTED MICE	NATURE			English	Article							INBREEDING AVOIDANCE; PEROMYSCUS-MANICULATUS; NATAL DISPERSAL; MAMMALS; LEUCOPUS; BIRDS; COMPETITION; RELATEDNESS; HYPOTHESIS; SUCCESS	JUVENILE dispersal is sex-biased in many mammals and birds: one sex often disperses more often or farther than the other. Two hypotheses are generally presented for sex-biased dispersal. The first holds that juvenile dispersal reduces reproductive and/or resource competition between parents and same-sexed offspring1-5. If so, presence of a parent on the natal home range should both promote dispersal of same-sex offspring and suppress reproduction of those that remain. The second is that juvenile dispersal reduces matings between parents and offspring6-10, thus decreasing the likelihood of inbreeding depression11-13. If so, presence of a parent should favour dispersal and reproductive suppression of offspring of the opposite sex. Here I present evidence that juvenile dispersal in white-footed mice, Peromyscus leucopus, is due to inbreeding avoidance. When population density was high, experimental removal of one parent delayed dispersal of opposite-sexed offspring and only the presence of the parents of opposite sex suppressed juvenile reproduction.	US EPA,CORVALLIS,OR 97333	United States Environmental Protection Agency	WOLFF, JO (corresponding author), OREGON STATE UNIV,DEPT FISHERIES & WILDLIFE,NASH HALL 104,CORVALLIS,OR 97331, USA.							Anderson P.K, 1989, DISPERSAL RODENTS RE; CLUTTONBROCK TH, 1989, NATURE, V337, P70, DOI 10.1038/337070a0; COCKBURN A, 1985, ANIM BEHAV, V33, P908, DOI 10.1016/S0003-3472(85)80025-7; DOBSON FS, 1982, ANIM BEHAV, V30, P1183; GREENWOOD PJ, 1980, ANIM BEHAV, V28, P1140, DOI 10.1016/S0003-3472(80)80103-5; HAIGH GR, 1983, J MAMMAL, V64, P48, DOI 10.2307/1380749; HARVEY PH, 1986, NATURE, V320, P675; HESTBECK JB, 1982, OIKOS, V39, P157, DOI 10.2307/3544480; HOAGLAND JL, 1979, SCIENCE, V215, P1639; HOLZENBEIN S, 1992, J WILDLIFE MANAGE, V56, P147, DOI 10.2307/3808802; KEANE B, 1990, ANIM BEHAV, V39, P264, DOI 10.1016/S0003-3472(05)80870-X; KOENIG WD, 1979, SCIENCE, V206, P1103, DOI 10.1126/science.206.4422.1103; LIBERG P, 1986, AM NAT, V126, P129; MARKS JS, 1987, AM NAT, V129, P158, DOI 10.1086/284627; MCCRAVY KW, 1992, J MAMMAL, V73, P151, DOI 10.2307/1381877; MOORE J, 1984, ANIM BEHAV, V32, P94, DOI 10.1016/S0003-3472(84)80328-0; PACKER C, 1985, ANIM BEHAV, V33, P676, DOI 10.1016/S0003-3472(85)80096-8; PUSEY AE, 1987, TRENDS ECOL EVOL, V2, P295, DOI 10.1016/0169-5347(87)90081-4; Ralls K., 1986, P35; WASER PM, 1985, ECOLOGY, V66, P1170, DOI 10.2307/1939169; Wolff J.O., 1989, P271; Wolff JO, 1991, BEHAV ECOL, V2, P38, DOI 10.1093/beheco/2.1.38; WOLFF JO, 1985, CAN J ZOOL, V63, P2657, DOI 10.1139/z85-397; WOLFF JO, 1988, ANIM BEHAV, V36, P456, DOI 10.1016/S0003-3472(88)80016-2; WOLFF JO, 1983, BEHAV ECOL SOCIOBIOL, V12, P237, DOI 10.1007/BF00290776; WOLFF JO, 1985, CAN J ZOOL, V63, P1548, DOI 10.1139/z85-230; WOLFF JO, 1986, VA J SCI, V37, P209	27	129	131	0	27	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 1	1992	359	6394					409	410		10.1038/359409a0	http://dx.doi.org/10.1038/359409a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JQ624	1406952				2022-12-01	WOS:A1992JQ62400053
J	ZOUROS, E; FREEMAN, KR; BALL, AO; POGSON, GH				ZOUROS, E; FREEMAN, KR; BALL, AO; POGSON, GH			DIRECT EVIDENCE FOR EXTENSIVE PATERNAL MITOCHONDRIAL-DNA INHERITANCE IN THE MARINE MUSSEL MYTILUS	NATURE			English	Article							MATERNAL INHERITANCE; HETEROPLASMY; POPULATIONS; DROSOPHILA; MICE	INHERITANCE of Mitochondrial DNA in animals was thought to be strictly maternal1,2. Recently, evidence for incidental paternal mtDNA leakage was obtained in hybrid crosses of Drosophila3,4 and mice5. In mice, the frequency of paternal mtDNA contributions was estimated at 10(-4), Compared with maternal contributions. The common occurrence in the marine mussel Mytilus of heteroplasmic individuals with two or more types of highly diverged mtDNA molecules was interpreted as strong evidence for biparental mtDNA inheritance by some6, but not by others7. We report here results from pair-matings involving two species of mussels, Mytilus edulis and Mytilus trossulus. Extensive contribution of paternal mtDNA, amounting to several orders of magnitude higher than that inferred for Drosophila or mice, was observed in both intra- and interspecific crosses.	DALHOUSIE UNIV, MARINE GENE PROBE LAB, HALIFAX B3H 4J1, NS, CANADA; UNIV CRETE, DEPT BIOL, IRAKLION, GREECE; INST MARINE BIOL CRETE, IRAKLION, GREECE; FISHERIES & OCEANS CANADA, HALIFAX FISHERIES RES LAB, HALIFAX B3J 2S7, NS, CANADA	Dalhousie University; University of Crete; Fisheries & Oceans Canada	ZOUROS, E (corresponding author), DALHOUSIE UNIV, DEPT BIOL, HALIFAX B3H 4J1, NS, CANADA.							CHAPMAN RW, 1984, METHOD RAPID ISOLATI; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FISHER C, 1990, P ROY SOC B-BIOL SCI, V242, P149, DOI 10.1098/rspb.1990.0118; GJETVAJ B, 1992, MOL BIOL EVOL, V9, P106; GYLLENSTEN U, 1985, J HERED, V76, P321, DOI 10.1093/oxfordjournals.jhered.a110103; GYLLENSTEN U, 1991, NATURE, V352, P255, DOI 10.1038/352255a0; HOEH WR, 1991, SCIENCE, V251, P1488, DOI 10.1126/science.1672472; HOFFMANN RJ, 1992, GENETICS, V131, P397; KOEHLER CM, 1991, GENETICS, V129, P247; KOEHN RK, 1991, AQUACULTURE, V94, P125, DOI 10.1016/0044-8486(91)90114-M; KONDO R, 1990, GENETICS, V126, P657; LANSMAN RA, 1981, J MOL EVOL, V17, P214, DOI 10.1007/BF01732759; LANSMAN RA, 1983, P NATL ACAD SCI-BIOL, V80, P1969, DOI 10.1073/pnas.80.7.1969; LONGO FJ, 1969, J EXP ZOOL, V172, P97, DOI 10.1002/jez.1401720108; MAGOULAS A, IN PRESS MOL BIOL EV; MALLET AL, 1985, MAR BIOL, V87, P165, DOI 10.1007/BF00539424; MCDONALD JH, 1991, MAR BIOL, V111, P323, DOI 10.1007/BF01319403; MCDONALD JH, 1988, MAR BIOL, V99, P111, DOI 10.1007/BF00644984; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; SATTA Y, 1988, GENET RES, V52, P1, DOI 10.1017/S0016672300027245; WESTNEAT DF, 1988, NUCLEIC ACIDS RES, V16, P4161, DOI 10.1093/nar/16.9.4161	22	168	173	0	17	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	OCT 1	1992	359	6394					412	414		10.1038/359412a0	http://dx.doi.org/10.1038/359412a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JQ624	1357555				2022-12-01	WOS:A1992JQ62400055
J	FOTHERBY, MD; HARPER, GD; POTTER, JF				FOTHERBY, MD; HARPER, GD; POTTER, JF			GENERAL-PRACTITIONERS MANAGEMENT OF HYPERTENSION IN ELDERLY PATIENTS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BLOOD-PRESSURE; STROKE; TRIAL; MORTALITY; MORBIDITY; THERAPY	Objective-To assess general practitioners' attitudes to the diagnosis and management of hypertension in elderly patients. Design - Postal questionnaire to all general practitioners in Leicestershire. Results-360 of 451 general practitioners (80%) responded. 81% (292) reported rechecking an initially high blood pressure on two or three occasions before starting treatment, 56% (202) measured sitting blood pressure only, and just 28% (100) took sitting and standing levels. 36% (128) had no upper age limit for starting anti-hypertensive treatment; of the 58% (206) who did, the median was 80 (range 70-99) years. Blood pressure levels reported for starting treatment in patients aged 70-79 years were 180 (150-240)/106 (90-120) mm Hg. 34% of general practitioners (121) would not treat isolated systolic hypertension. The most popular first line treatment for an elderly hypertensive patient was a thiazide diuretic; only 17% of general practitioners (61) initially tried non-pharmacological methods. 34% (122) would continue anti-hypertensive treatment unchanged in the period immediately after stroke. Conclusions-The variation among general practitioners in the criteria for the measurement, diagnosis, and treatment of hypertension in elderly patients emphasises the need for clear management guidelines in this age group.			FOTHERBY, MD (corresponding author), UNIV LEICESTER, LEICESTER GEN HOSP, DEPT MED ELDERLY, LEICESTER LE5 4PW, ENGLAND.							AMERY A, 1985, LANCET, V1, P1349; [Anonymous], 1991, JAMA, V265, P3255; [Anonymous], 1988, ARCH INTERN MED, V148, P1023; BEARD K, 1992, BMJ-BRIT MED J, V304, P412, DOI 10.1136/bmj.304.6824.412; BRITTON M, 1980, ACTA MED SCAND, V207, P253; BULPITT CJ, 1989, HDB HYPERTENSION, V12, P153; CAIRD FI, 1973, BRIT HEART J, V35, P527; CARTER AB, 1970, LANCET, V1, P485; COOPE J, 1986, BRIT MED J, V293, P1145, DOI 10.1136/bmj.293.6555.1145; DAHLOF B, 1991, LANCET, V338, P1281, DOI 10.1016/0140-6736(91)92589-T; KOOPMAN H, 1990, J HUM HYPERTENS, V4, P368; MADER SL, 1987, JAMA-J AM MED ASSOC, V258, P1511, DOI 10.1001/jama.258.11.1511; MEADE TW, 1992, BMJ-BRIT MED J, V304, P405; Meyer JS, 1973, STROKE, V4, P169, DOI 10.1161/01.STR.4.2.169; PATTERSON HR, 1984, J ROY COLL GEN PRACT, V34, P97; SMITH TDW, 1990, BMJ-BRIT MED J, V300, P74, DOI 10.1136/bmj.300.6717.74; SMITH WCS, 1985, BRIT MED J, V291, P1483, DOI 10.1136/bmj.291.6507.1483; WALLACE JD, 1981, JAMA-J AM MED ASSOC, V246, P2177, DOI 10.1001/jama.246.19.2177; WALLER PC, 1990, J HUM HYPERTENS, V4, P509; 1989, BMJ, V298, P294; 1987, DAN MED B S1, V34, P5; 1974, JAMA-J AM MED ASSOC, V229, P409; 1989, J HYPERTENS, V7, P689	23	49	49	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 26	1992	305	6856					750	752		10.1136/bmj.305.6856.750	http://dx.doi.org/10.1136/bmj.305.6856.750			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JQ520	1358373	Green Published, Green Submitted, Bronze			2022-12-01	WOS:A1992JQ52000024
J	LEWIS, SJ; DAVIDSON, RN; ROSS, EJ; HALL, AP				LEWIS, SJ; DAVIDSON, RN; ROSS, EJ; HALL, AP			SEVERITY OF IMPORTED FALCIPARUM-MALARIA - EFFECT OF TAKING ANTIMALARIAL PROPHYLAXIS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							TRAVELERS	Objective-To investigate the effects of antimalarial chemoprophylaxis and other variables on the severity of falciparum malaria. Design-Review of consecutive malaria cases between 1987 and 1991. Setting-The Hospital for Tropical Diseases, London. Subjects-250 consecutive cases of mild and 51 consecutive cases of severe falciparum malaria. Results-Prophylaxis was taken in 52.4% (131/250) of the cases of mild malaria and 21.6% (11/51) of cases of severe malaria. Severe malaria was more common in white patients than in those of African origin and was also seen more commonly in people returning from central, southern, and east Africa than in those returning from west Africa. Patients with severe malaria presented sooner than patients with mild malaria. Conclusions-Prior chemoprophylaxis led to a reduction in the severity of falciparum malaria. Ethnic origin, time to presentation, and sex were also associated with the severity of malaria.	HOSP TROP DIS, LONDON NW1 0PE, ENGLAND; MIDDLESEX HOSP, ACAD DEPT GENITOURINARY MED, LONDON NW1, ENGLAND	University College London Hospitals NHS Foundation Trust; University of London; London School of Hygiene & Tropical Medicine; University of London; University College London								BEHRENS RH, 1991, IN PRESS 2ND P INT C; BRADLEY DJ, 1989, J ROY SOC MED, V82, P8; GREENBERG AE, 1990, ANN INTERN MED, V113, P326, DOI 10.7326/0003-4819-113-4-326; HALL AP, 1972, P HELM SOC WASH, V39, P66; LACKRITZ EM, 1991, JAMA-J AM MED ASSOC, V265, P383, DOI 10.1001/jama.265.3.383; PHILLIPSHOWARD PA, 1990, BMJ-BRIT MED J, V300, P499, DOI 10.1136/bmj.300.6723.499; WESTEYN JCF, 1985, B WORLD HEALTH ORGAN, V63, P101; [No title captured]	8	61	62	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 26	1992	305	6856					741	743		10.1136/bmj.305.6856.741	http://dx.doi.org/10.1136/bmj.305.6856.741			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JQ520	1422328	Bronze, Green Published, Green Submitted			2022-12-01	WOS:A1992JQ52000019
J	MADERAZO, EG; SUN, H; JAY, GT				MADERAZO, EG; SUN, H; JAY, GT			SIMPLIFICATION OF ANTIBIOTIC DOSE ADJUSTMENTS IN RENAL-INSUFFICIENCY - THE DREM SYSTEM	LANCET			English	Article							DOSING GUIDELINES; DRUG-THERAPY; GENTAMICIN; PHARMACOKINETICS; FAILURE; ADULTS; AGENTS	Many clinicians, unassisted by reference books, are unable to make the required dose adjustment of antibiotics needed when a patient has renal insufficiency. We describe the DREM (dosing in renopathy by easy-to-use multipliers) system, which simplifies the understanding and the process of dose adjustment. DREM is a two-step process: Cockcroft and Gault estimation of creatinine clearance (CLcr) from age, sex, and serum creatinine and calculation of the adjusted dose or dosing interval by multipliers. If the normal dose is multiplied by the dose multiplier (CLcr/100) and the dosing interval by the interval multiplier (100/CLcr), the adjusted dose and interval, respectively, are obtained. Theoretical trough concentrations calculated with the DREM system correlated closely (r=0.9) with actual concentrations obtained from doses calculated by the Hull and Sarubbi method in 23 patients. With DREM, gentamicin or tobramycin trough concentrations above 2 mug/ml were less likely to occur. The DREM system is a simple and easily remembered method for dose adjustments of certain anti-infective agents in renal insufficiency. Dose estimates with this method are reasonably accurate and compare favourably with other standard methods of correction.	HARTFORD HOSP,DEPT MED,ANTIBIOT MANAGEMENT PROGRAM,HARTFORD,CT 06115; HARTFORD HOSP,DEPT MED,DIV INFECT DIS,HARTFORD,CT 06115; HARTFORD HOSP,DEPT PHARM SERV,CTR DRUG INFORMAT,HARTFORD,CT 06115; UNIV CONNECTICUT,SCH MED,FARMINGTON,CT 06032; UNIV CONNECTICUT,SCH PHARM,FARMINGTON,CT 06032; UNIV CONNECTICUT,SCH MED,STORRS,CT 06268; UNIV CONNECTICUT,SCH PHARM,STORRS,CT 06268	Hartford Hospital; Hartford Hospital; Hartford Hospital; University of Connecticut; University of Connecticut; University of Connecticut; University of Connecticut	MADERAZO, EG (corresponding author), HARTFORD HOSP,MED RES LAB,HARTFORD,CT 06115, USA.							BENNETT WM, 1980, ANN INTERN MED, V93, P62, DOI 10.7326/0003-4819-93-1-62; BENNETT WM, 1980, ANN INTERN MED, V93, P286, DOI 10.7326/0003-4819-111-3-286; BOUCHER BA, 1992, REV INFECT DIS, V14, P458; BRATER DC, 1984, PHARMACOKINETIC BASI, P111; CHOW MSS, 1986, DRUG INTELL CLIN PHA, V9, P385; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; DAHLGREN JG, 1975, ANTIMICROB AGENTS CH, V8, P58, DOI 10.1128/AAC.8.1.58; GAMBERTOGLIO JG, 1984, PHARMACOKINETIC BASI, P149; GIBSON TP, 1986, APPLIED PHARMACOKINE, P83; HULL JH, 1976, ANN INTERN MED, V85, P183, DOI 10.7326/0003-4819-85-2-183; MATZKE GR, 1984, ANTIMICROB AGENTS CH, V25, P433, DOI 10.1128/AAC.25.4.433; MAWER GE, 1974, BRIT J CLIN PHARMACO, V1, P45, DOI 10.1111/j.1365-2125.1974.tb00205.x; NORRIS S, 1990, PRINCIPLES PRACTICE, P434; PATEL IH, 1984, ANTIMICROB AGENTS CH, V25, P438, DOI 10.1128/AAC.25.4.438; SANFORD JP, 1991, GUIDE ANTIMICROBIAL; 1991, PHYSICIANS DESK REFE	16	13	14	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 26	1992	340	8822					767	770		10.1016/0140-6736(92)92302-V	http://dx.doi.org/10.1016/0140-6736(92)92302-V			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JP869	1356185				2022-12-01	WOS:A1992JP86900011
J	OLSSON, S; EDWARDS, IR				OLSSON, S; EDWARDS, IR			TACHYCARDIA DURING CISAPRIDE TREATMENT	BRITISH MEDICAL JOURNAL			English	Article							METOCLOPRAMIDE				OLSSON, S (corresponding author), WHO,COLLABORATING CTR INT DRUG MONITORING,BOX 26,S-75103 UPPSALA,SWEDEN.							BEVACQUA BK, 1988, ANESTHESIOLOGY, V68, P124, DOI 10.1097/00000542-198801000-00021; CHERON G, 1991, PRESSE MED, V20, P1138; MCCALLUM RW, 1988, DRUGS, V36, P652, DOI 10.2165/00003495-198836060-00002; SHAKLAI M, 1974, BRIT MED J, V2, P385, DOI 10.1136/bmj.2.5915.385-a	4	77	78	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 26	1992	305	6856					748	749		10.1136/bmj.305.6856.748-a	http://dx.doi.org/10.1136/bmj.305.6856.748-a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JQ520	1384896	Bronze, Green Published, Green Submitted			2022-12-01	WOS:A1992JQ52000023
J	PIETERSZ, RNI; REESINK, HW; PAUW, W; DEKKER, WJA; BUISMAN, L				PIETERSZ, RNI; REESINK, HW; PAUW, W; DEKKER, WJA; BUISMAN, L			PREVENTION OF YERSINIA-ENTEROCOLITICA GROWTH IN RED-BLOOD-CELL CONCENTRATES	LANCET			English	Note							PHAGOCYTOSIS; TEMPERATURE; STORAGE	In response to concern about Yersinia enterocolitica contamination of blood products, we have studied the effects on Y enterocolitica growth of holding whole blood at 22-degrees-C for 20 h and then removing leucocytes. Thirty pools of three bags of blood were inoculated with Y enterocolitica (2 x 10(1)-3 x 10(4) colony-forming units/ml). One bag in each pool was processed to red-blood-cell concentrate after 6 h at 4-degrees-C (RBC); the other two were held at 22-degrees-C for 20 h before processing to buffy-coat-depleted RBC (BCd-RBC). One of these bags was then depleted of leucocytes by filtration (Ld-RBC). All bags were stored at 4-degrees-C for 5 weeks. R B C bags showed Y enterocolitica growth after the shortest storage times, followed by BCd-RBC then Ld-RBC (p < 0.03-0.001). We recommend that whole blood should be held at 22-degrees-C to make use of inherent bactericidal activity; leucocytes should then be removed.	SLOTERVAART HOSP,DEPT MICROBIOL,AMSTERDAM,NETHERLANDS	Slotervaart Hospital	PIETERSZ, RNI (corresponding author), RED CROSS BLOOD BANK,POSTBOX 9137,1006 AC AMSTERDAM,NETHERLANDS.							GOLDMAN M, 1991, Transfusion Medicine Reviews, V5, P73, DOI 10.1016/S0887-7963(91)70194-6; HOGMAN CF, 1991, TRANSFUSION, V31, P620, DOI 10.1046/j.1537-2995.1991.31791368338.x; HOPPE PA, 1992, TRANSFUSION, V32, P199, DOI 10.1046/j.1537-2995.1992.32392213799.x; MANARA FS, 1985, BIOCHEM BIOPH RES CO, V132, P696, DOI 10.1016/0006-291X(85)91188-X; PETERSON PK, 1977, INFECT IMMUN, V15, P175, DOI 10.1128/IAI.15.1.175-179.1977; PIETERSZ RNI, 1987, VOX SANG, V53, P203, DOI 10.1111/j.1423-0410.1987.tb05067.x; PIETERSZ RNI, 1989, VOX SANG, V56, P145, DOI 10.1111/j.1423-0410.1989.tb02017.x; PIETERSZ RNI, 1989, VOX SANG, V57, P29, DOI 10.1111/j.1423-0410.1989.tb04980.x; STOSSEL TP, 1975, SEMIN HEMATOL, V12, P83; 1991, MORBID MORTAL WEEKLY, V40, P176	10	63	63	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 26	1992	340	8822					755	756		10.1016/0140-6736(92)92296-R	http://dx.doi.org/10.1016/0140-6736(92)92296-R			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JP869	1356179				2022-12-01	WOS:A1992JP86900005
J	STEINETZ, BG; WHITAKER, PG; EDWARDS, JRG				STEINETZ, BG; WHITAKER, PG; EDWARDS, JRG			MATERNAL RELAXIN CONCENTRATIONS IN DIABETIC PREGNANCY	LANCET			English	Article							HUMAN CHORIONIC-GONADOTROPIN; INSULIN BINDING; RECEPTOR-BINDING; PORCINE RELAXIN; ADIPOCYTES; MOTHERS; RADIOIMMUNOASSAY; PROGESTERONE; INFANTS; WOMEN	Maternal serum concentrations of relaxin, an insulin homologue produced both by the corpus luteum of pregnancy and by the fetoplacental unit, are highest in the first trimester and fall to their lowest level in the third trimester. Relaxin is thought to influence carbohydrate metabolism in the uterus, and it has been suggested that serum concentrations of relaxin in diabetic women are higher than those of non-diabetic women. We show that maternal serum relaxin concentrations are significantly higher at each stage of pregnancy in insulin-dependent diabetic mothers than in non-diabetic mothers. This elevation in relaxin concentrations is not related to other indices of diabetic control. The physiological importance of the higher concentrations of relaxin in the serum of diabetic women-in particular, whether they contribute to the higher incidence of major anomalies in the fetuses of diabetic mothers-is yet to be determined.	UNIV NEWCASTLE UPON TYNE,CLEFT PALATE RES UNIT,1-4 CLAREMONT TERRACE,NEWCASTLE TYNE NE1 7RU,TYNE & WEAR,ENGLAND; UNIV NEWCASTLE UPON TYNE,PRINCESS MARY MATERN HOSP,DEPT OBSTET,NEWCASTLE TYNE NE1 7RU,TYNE & WEAR,ENGLAND; NYU,MED CTR,EXPTL MED & SURG PRIMATES LAB,TUXEDO PK,NY	Newcastle University - UK; Newcastle University - UK; New York University								BELL RJ, 1989, FERTIL STERIL, V52, P85; BELL RJ, 1987, OBSTET GYNECOL, V69, P585; CRELIN ES, 1969, T NEW YORK ACAD SCI, V31, P1049, DOI 10.1111/j.2164-0947.1969.tb02024.x; EDWARDS JRG, 1988, LANCET, V1, P1428; HANING RV, 1985, OBSTET GYNECOL, V66, P42; JARRETT JC, 1984, AM J OBSTET GYNECOL, V149, P250, DOI 10.1016/0002-9378(84)90223-0; JOHNSON MR, 1991, J CLIN ENDOCR METAB, V72, P1042, DOI 10.1210/jcem-72-5-1042; LADENHEIM RG, 1984, ENDOCRINOLOGY, V115, P752, DOI 10.1210/endo-115-2-752; LOUMAYE E, 1978, GYNECOL OBSTET INVES, V9, P262, DOI 10.1159/000300993; MILLER E, 1981, NEW ENGL J MED, V304, P1331, DOI 10.1056/NEJM198105283042204; MILLS JL, 1988, NEW ENGL J MED, V318, P671, DOI 10.1056/NEJM198803173181104; NEUFELD ND, 1978, J CLIN ENDOCR METAB, V47, P590, DOI 10.1210/jcem-47-3-590; OBYRNE EM, 1976, P SOC EXP BIOL MED, V152, P272, DOI 10.3181/00379727-152-39377; OBYRNE EM, 1978, J CLIN ENDOCR METAB, V47, P1106, DOI 10.1210/jcem-47-5-1106; OLEFSKY JM, 1982, ANN NY ACAD SCI, V380, P200, DOI 10.1111/j.1749-6632.1982.tb18043.x; PAGANO G, 1980, HORM METAB RES, V12, P177, DOI 10.1055/s-2007-996237; PAWLINA W, 1990, MOL CELL ENDOCRINOL, V72, P55, DOI 10.1016/0303-7207(90)90239-5; PEDERSEN J, 1980, PREGNANT DIABETIC HE; PEDERSEN O, 1981, J CLIN ENDOCR METAB, V53, P1160, DOI 10.1210/jcem-53-6-1160; QUAGLIARELLO J, 1980, J CLIN ENDOCR METAB, V51, P74, DOI 10.1210/jcem-51-1-74; QUAGLIARELLO J, 1979, AM J OBSTET GYNECOL, V135, P43; Sherwood O.D., 1988, P585; STEINETZ BG, IN PRESS ENDOCRINOLO; STEWART DR, 1990, J CLIN ENDOCR METAB, V70, P1771, DOI 10.1210/jcem-70-6-1771; STEWART MO, 1989, BRIT J OBSTET GYNAEC, V96, P415, DOI 10.1111/j.1471-0528.1989.tb02415.x; SUTTERDUB MT, 1973, HORM METAB RES, V5, P18, DOI 10.1055/s-0028-1093994; SUTTERDUB MT, 1984, J ENDOCRINOL, V102, P209, DOI 10.1677/joe.0.1020209; SZLACHTER BN, 1982, OBSTET GYNECOL, V59, P167; TOYODA N, 1985, ENDOCRINOLOGY, V116, P998, DOI 10.1210/endo-116-3-998; VASILENKO P, 1982, P SOC EXP BIOL MED, V169, P376; WEISS G, 1976, SCIENCE, V194, P948, DOI 10.1126/science.982052; WHITTAKER PG, 1990, OBSTET GYNECOL, V76, P223; WITT BR, 1990, FERTIL STERIL, V53, P1029	33	16	16	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 26	1992	340	8822					752	755		10.1016/0140-6736(92)92295-Q	http://dx.doi.org/10.1016/0140-6736(92)92295-Q			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JP869	1356178				2022-12-01	WOS:A1992JP86900004
J	THORPEBEESTON, JG; BANFIELD, PJ; SAUNDERS, NJS				THORPEBEESTON, JG; BANFIELD, PJ; SAUNDERS, NJS			OUTCOME OF BREECH DELIVERY AT TERM	BRITISH MEDICAL JOURNAL			English	Article							CESAREAN-SECTION; RANDOMIZED MANAGEMENT; MODE	Objective-To compare neonatal mortality and morbidity in term infants presenting by the breech and delivered vaginally or by caesarean section. Design-Population based comparison of outcomes. Data derived from the St Mary's maternity information system. Setting-North West Thames Regional Health Authority, 1988-90. Subjects-3447 singleton fetuses presenting by the breech at term. Main outcome measures-Intrapartum and neonatal mortality, low Apgar scores, intubation at birth, and admission to special care baby units. Results-After the exclusion of babies with congenital anomalies the incidence of intrapartum and neonatal death associated with vaginal birth was 8/961 (0.83%) compared with 1/2486 (0.03%) in babies born by caesarean section (relative risk 20, 95% confidence interval 2.5 to 163). The numbers of low Apgar scores and neonatal intubation were doubled in babies born vaginally or by emergency caesarean section compared with those delivered by elective operation. Conclusions-The good neonatal outcome associated with elective caesarean delivery of the term breech fetus may influence the decision of women and their obstetricians about mode of delivery.	ST MARYS HOSP,DEPT OBSTET,LONDON W2 1PG,ENGLAND	Imperial College London								BINGHAM P, 1987, OBSTET GYNECOL, V69, P965; BINGHAM P, 1987, BRIT J OBSTET GYNAEC, V94, P746, DOI 10.1111/j.1471-0528.1987.tb03720.x; BITHELL JF, 1975, BRIT J CANCER, V31, P271, DOI 10.1038/bjc.1975.62; CHRISTIAN SS, 1990, AM J OBSTET GYNECOL, V163, P848; COLLEA JV, 1980, AM J OBSTET GYNECOL, V137, P235, DOI 10.1016/0002-9378(80)90780-2; FELDMAN GB, 1985, NEW ENGL J MED, V312, P1264, DOI 10.1056/NEJM198505093121926; GARDNER MJ, 1989, BMJ; GIMOVSKY ML, 1983, AM J OBSTET GYNECOL, V146, P34, DOI 10.1016/0002-9378(83)90923-7; HYTTEN FE, 1982, BRIT J OBSTET GYNAEC, V89, P879, DOI 10.1111/j.1471-0528.1982.tb05049.x; KIELY JL, 1991, BRIT J OBSTET GYNAEC, V98, P898, DOI 10.1111/j.1471-0528.1991.tb13512.x; PATERSON CM, 1991, BRIT MED J, V303, P818, DOI 10.1136/bmj.303.6806.818; REDIE D, 1967, BRIT J RADIOL, V40, P489; ROSEN MG, 1990, OBSTET GYNECOL, V76, P865, DOI 10.1097/00006250-199011000-00029; SACHS BP, 1983, JAMA-J AM MED ASSOC, V250, P2157, DOI 10.1001/jama.250.16.2157	14	85	86	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 26	1992	305	6856					746	747		10.1136/bmj.305.6856.746	http://dx.doi.org/10.1136/bmj.305.6856.746			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JQ520	1422330	Green Published, Green Submitted, Bronze			2022-12-01	WOS:A1992JQ52000021
J	YATES, DW; WOODFORD, M; HOLLIS, S				YATES, DW; WOODFORD, M; HOLLIS, S			PRELIMINARY-ANALYSIS OF THE CARE OF INJURED PATIENTS IN 33 BRITISH HOSPITALS - 1ST REPORT OF THE UNITED-KINGDOM MAJOR TRAUMA OUTCOME STUDY	BRITISH MEDICAL JOURNAL			English	Article							SEVERITY SCORE	Objective-To measure the effectiveness of management of major trauma in the United Kingdom. Design-Review of the care of all seriously injured patients seen over two years. Setting-33 hospitals which receive patients who have sustained major trauma. Subjects-14 648 injured patients admitted for more than three days, transferred or admitted into an intensive care bed, or dying from their injuries. Main outcome measure-Death or survival in hospital within three months of the injury. Results-21% of seriously injured patients (1299) took longer than one hour to reach hospital. Time before arrival at hospital was not related to severity of injury. A senior house officer was in charge of initial hospital resuscitation in 57% (826/1445) of patients with an injury severity score greater-than-or-equal-to 16. More senior staff were commonly responsible for definitive operations, but only 46% (165/355) of patients judged to require early operation arrived in theatre within two hours. Mortality for 6111 patients sustaining blunt trauma and treated in the 14 busiest hospitals was significantly higher (actual 408, predicted 295.6, p<0.001) than in a comparable North American dataset. Large differences in the 14 hospitals assessed could not be explained by variations in case load or facilities. In contrast, the outcome of the 4.1% (597) of patients with penetrating injuries was better than that of a comparable group in the United States. Analysis of the 415 penetrating injuries with complete data showed that 15 patients died (19.3 predicted; p=0.04). Conclusions-The initial management of major trauma in the United Kingdom remains unsatisfactory. There are delays in providing experienced staff and timely operations. Mortality varies inexplicably between hospitals and, for blunt trauma, is generally higher than in the United States.			YATES, DW (corresponding author), UNIV MANCHESTER,HOPE HOSP,SALFORD M6 8HD,LANCS,ENGLAND.			Hollis, Sally/0000-0003-0156-9189				BAKER SP, 1976, J TRAUMA, V16, P882, DOI 10.1097/00005373-197611000-00006; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; CHAMPION HR, 1989, J TRAUMA, V29, P623, DOI 10.1097/00005373-198905000-00017; CHAMPION HR, 1990, J TRAUMA, V30, P1356, DOI 10.1097/00005373-199011000-00008; SMITH EJ, 1990, BRIT J HOSP MED, V44, P114; YATES DW, 1990, BRIT MED J, V301, P1090, DOI 10.1136/bmj.301.6760.1090; YATES DW, 1991, ACCIDENT ANAL PREV, V23, P323, DOI 10.1016/0001-4575(91)90010-3; YATES DW, 1990, INTENS THER CLIN MON, V10, P38; 1988, REPORT WORKING PARTY; 1986, MORTALITY STATISTICS; 1991, CMD1523	12	137	138	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 26	1992	305	6856					737	740		10.1136/bmj.305.6856.737	http://dx.doi.org/10.1136/bmj.305.6856.737			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JQ520	1422327	Green Published, Bronze, Green Submitted			2022-12-01	WOS:A1992JQ52000018
J	CHAIT, BT; KENT, SBH				CHAIT, BT; KENT, SBH			WEIGHING NAKED PROTEINS - PRACTICAL, HIGH-ACCURACY MASS MEASUREMENT OF PEPTIDES AND PROTEINS	SCIENCE			English	Article							ASSISTED LASER-DESORPTION; ELECTROSPRAY-IONIZATION; CONFORMATIONAL-CHANGES; PLASMINOGEN-ACTIVATOR; NUCLEOTIDE-SEQUENCE; RECOMBINANT-DNA; SPECTROMETRY; MATRIX; SPECTRA; LIPOPROTEINS	Two new technologies have made the study of proteins by mass spectrometry straight-forward. Proteins with molecular masses of up to more than 100 kilodaltons can be analyzed at picomole sensitivities to give simple mass spectra corresponding to the intact molecule. This development has allowed unprecedented accuracy in the determination of the molecular weights of proteins. A number of "case studies" are used to present the revolutionary impact that these powerful new ways of looking at proteins are having on biological research.	SCRIPPS RES INST, LA JOLLA, CA 92037 USA	Scripps Research Institute	CHAIT, BT (corresponding author), ROCKEFELLER UNIV, NEW YORK, NY 10021 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000862] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038274] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00862] Funding Source: Medline; NIGMS NIH HHS [GM38274] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN MH, 1992, J AM SOC MASS SPECTR, V3, P18, DOI 10.1016/1044-0305(92)85014-B; ALPIN RT, 1990, FEBS LETT, V277, P212; ANNAN RS, 1992, RAPID COMMUN MASS SP, V6, P298, DOI 10.1002/rcm.1290060415; ASHTON DS, 1991, FEBS LETT, V292, P201, DOI 10.1016/0014-5793(91)80867-3; BACA M, 1992, J AM CHEM SOC, V114, P3992, DOI 10.1021/ja00036a066; BALDWIN M, UNPUB; BAPTISTA GB, 1991, RAPID COMMUN MASS SP, V5, P632, DOI 10.1002/rcm.1290051214; Barber M, 1987, Rapid Commun Mass Spectrom, V1, P80, DOI 10.1002/rcm.1290010505; BARBER M, 1981, J CHEM SOC CHEM COMM, P325, DOI 10.1039/c39810000325; BEAVIS R, UNPUB; Beavis R C, 1989, Rapid Commun Mass Spectrom, V3, P432, DOI 10.1002/rcm.1290031207; Beavis R C, 1989, Rapid Commun Mass Spectrom, V3, P233, DOI 10.1002/rcm.1290030708; BEAVIS RC, 1991, CHEM PHYS LETT, V181, P479, DOI 10.1016/0009-2614(91)90384-L; BEAVIS RC, 1990, ANAL CHEM, V62, P1836, DOI 10.1021/ac00216a020; BEAVIS RC, 1990, P NATL ACAD SCI USA, V87, P6873, DOI 10.1073/pnas.87.17.6873; BEAVIS RC, 1992, ORG MASS SPECTROM, V27, P156, DOI 10.1002/oms.1210270217; BEAVIS RC, 1991, NATO ASI SERIES B, V209; BIEMANN K, 1992, ANNU REV BIOCHEM, V61, P977, DOI 10.1146/annurev.bi.61.070192.004553; BIEMANN K, 1987, SCIENCE, V237, P992, DOI 10.1126/science.3303336; BIER ME, IN PRESS 40TH P ASMS; BOARD PG, 1986, GENE, V44, P127, DOI 10.1016/0378-1119(86)90051-X; BURLINGAME AL, 1992, ANAL CHEM, V64, pR467, DOI 10.1021/ac00036a025; CAPRIOLI RM, 1991, TECHNIQUES PROTEIN C, V2, P497; CASTRO JA, 1992, RAPID COMMUN MASS SP, V6, P239, DOI 10.1002/rcm.1290060403; CHAIT BT, IN PRESS 40TH P ASMS; CHOLOUPEK RC, 1989, J CHROMATOGR, V463, P375; CHOWDHURY SK, 1990, RAPID COMMUN MASS SP, V4, P81, DOI 10.1002/rcm.1290040305; CHOWDHURY SK, 1990, J AM CHEM SOC, V112, P9012, DOI 10.1021/ja00180a074; CHRIVIA JC, 1988, J BIOL CHEM, V263, P5739; COLLEN D, 1984, J PHARMACOL EXP THER, V231, P146; COTTER RJ, 1988, ANAL CHEM, V60, pA781, DOI 10.1021/ac00164a002; Covey T R, 1988, Rapid Commun Mass Spectrom, V2, P249, DOI 10.1002/rcm.1290021111; COX KA, 1992, BIOL MASS SPECTROM, V21, P226, DOI 10.1002/bms.1200210503; Dawson P. H, 1995, QUADRUPOLE MASS SPEC; DEEB SS, 1991, J BIOL CHEM, V266, P13654; DELAETER JR, 1988, J PHYS CHEM REF DATA, V17, P1791, DOI 10.1063/1.555816; DESIDERIO DM, 1991, MASS SPECTROMETRY PE; EHRING H, 1992, ORG MASS SPECTROM, V27, P472, DOI 10.1002/oms.1210270419; Elder J. H., UNPUB; FALICK AM, IN PRESS 40TH P ASMS; FENG R, IN PRESS ANAL CHEM; FENN JB, 1990, MASS SPECTROM REV, V9, P37, DOI 10.1002/mas.1280090103; FENN JB, 1989, SCIENCE, V246, P64, DOI 10.1126/science.2675315; FOWLER VM, 1990, J CELL BIOL, V111, P471, DOI 10.1083/jcb.111.2.471; GANEM B, 1991, J AM CHEM SOC, V113, P7818, DOI 10.1021/ja00020a085; GANEM B, 1991, J AM CHEM SOC, V113, P6294, DOI 10.1021/ja00016a069; GANGULY AK, 1992, J AM CHEM SOC, V114, P6559, DOI 10.1021/ja00042a046; GIMON ME, 1992, ORG MASS SPECTROM, V27, P827, DOI 10.1002/oms.1210270711; GOTTO AM, 1986, METHOD ENZYMOL, V128, P3; GUEVREMONT R, 1992, J AM SOC MASS SPECTR, V3, P216, DOI 10.1016/1044-0305(92)87005-J; HENDERSON LE, 1983, P NATL ACAD SCI-BIOL, V80, P339, DOI 10.1073/pnas.80.2.339; HENRY KD, 1991, J AM CHEM SOC, V113, P5447, DOI 10.1021/ja00014a043; HERBERG F, UNPUB; HILL JA, 1991, RAPID COMMUN MASS SP, V5, P395, DOI 10.1002/rcm.1290050905; HILLENKAMP F, 1991, ANAL CHEM, V63, pA1193; HORIUCHI A, 1990, J BIOL CHEM, V265, P9576; HOU J, IN PRESS BIOCHEMISTR; HUNT DF, 1986, P NATL ACAD SCI USA, V83, P6233, DOI 10.1073/pnas.83.17.6233; KARAS M, 1991, MASS SPECTROM REV, V10, P335, DOI 10.1002/mas.1280100503; KARAS M, 1988, ANAL CHEM, V60, P2299, DOI 10.1021/ac00171a028; KATTA V, 1991, J AM CHEM SOC, V113, P8534, DOI 10.1021/ja00022a058; KATTA V, 1991, RAPID COMMUN MASS SP, V5, P214, DOI 10.1002/rcm.1290050415; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; LEBLANC JCY, 1991, ORG MASS SPECTROM, V26, P831; LING V, 1991, ANAL CHEM, V63, P2909, DOI 10.1021/ac00024a020; Loo J.A., 1988, RAPID COMMUN MASS SP, V2, P207; LOO JA, 1991, RAPID COMMUN MASS SP, V5, P101, DOI 10.1002/rcm.1290050303; MACFARLANE RD, 1976, SCIENCE, V191, P920, DOI 10.1126/science.1251202; MANN M, 1989, ANAL CHEM, V61, P1702, DOI 10.1021/ac00190a023; MCCLOSKEY JA, 1990, METHODS ENZYMOLOGY, V193; MCEWEN CN, 1992, RAPID COMMUN MASS SP, V6, P173, DOI 10.1002/rcm.1290060304; MENARD R, 1991, FEBS LETT, V295, P27, DOI 10.1016/0014-5793(91)81376-J; MENG CK, 1988, Z PHYS D ATOM MOL CL, V10, P361, DOI 10.1007/BF01384871; MIRZA UA, UNPUB; NELSON RW, 1990, RAPID COMMUN MASS SP, V4, P348, DOI 10.1002/rcm.1290040911; PALEZEWSKI K, UNPUB; PEDERSEN NC, 1987, SCIENCE, V235, P790, DOI 10.1126/science.3643650; PENNICA D, 1983, NATURE, V301, P214, DOI 10.1038/301214a0; REINHOLD BB, 1992, J AM SOC MASS SPECTR, V3, P207, DOI 10.1016/1044-0305(92)87004-I; SCHAR M, 1991, RAPID COMMUN MASS SP, V5, P319, DOI 10.1002/rcm.1290050705; SCHMID K, 1973, BIOCHEMISTRY-US, V12, P2711, DOI 10.1021/bi00738a026; SEE YP, 1990, PROTEIN STRUCTURE PR; SEPNGLER B, 1992, ANALYSIS, V20, P91; SMITH RD, 1990, J AM SOC MASS SPECTR, V1, P53, DOI 10.1016/1044-0305(90)80006-9; SMITH RD, 1991, MASS SPECTROM REV, V10, P359, DOI 10.1002/mas.1280100504; SPENGLER B, 1991, RAPID COMMUN MASS SP, V5, P198, DOI 10.1002/rcm.1290050412; STRUPAT K, 1991, INT J MASS SPECTROM, V111, P89, DOI 10.1016/0168-1176(91)85050-V; SUNG LA, 1992, J BIOL CHEM, V267, P2616; TALBOTT RL, 1989, P NATL ACAD SCI USA, V86, P5743, DOI 10.1073/pnas.86.15.5743; Tanaka K, 1988, RAPID COMMUN MASS SP, V2, P151, DOI 10.1002/rcm.1290020802; VANBERKEL GJ, 1990, ANAL CHEM, V62, P1284, DOI 10.1021/ac00212a016; WHITEHOUSE CM, 1985, ANAL CHEM, V57, P675, DOI 10.1021/ac00280a023; WILKENS CL, IN PRESS 40TH P ASMS; WILKINS CL, IN PRESS 40TH P ASMS; YONEMOTO W, UNPUB	95	408	425	0	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 25	1992	257	5078					1885	1894		10.1126/science.1411504	http://dx.doi.org/10.1126/science.1411504			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JP594	1411504				2022-12-01	WOS:A1992JP59400020
J	DULIC, V; LEES, E; REED, SI				DULIC, V; LEES, E; REED, SI			ASSOCIATION OF HUMAN CYCLIN-E WITH A PERIODIC G(1)-S PHASE PROTEIN-KINASE	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; CDC28 MUTATION; YEAST; GENE; COMPLEMENTATION; HOMOLOG; POLYMERASE; MITOSIS; FAMILY	G1 cyclins control the G1 to S phase transition in the budding yeast, Saccharomyces cerevisiae. Cyclin E was discovered in the course of a screen for human complementary DNAs that rescue a deficiency of G1 cyclin function in budding yeast. The amounts of both the cyclin E protein and an associated protein kinase activity fluctuated periodically through the human cell cycle; both were maximal in late G1 and early S phases. Cyclin E-associated kinase activity was correlated with the appearance of complexes containing cyclin E and the cyclin-dependent kinase Cdk2. Thus, the cyclin E-Cdk2 complex may constitute a human G1-S phase-specific regulatory protein kinase.	Scripps Res Inst, RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; MASSACHUSETTS GEN HOSP, CTR CANC, BOSTON, MA 02129 USA	Scripps Research Institute; Harvard University; Massachusetts General Hospital				Dulic, Vjekoslav/0000-0003-1201-3901	NCI NIH HHS [CA55339] Funding Source: Medline; NIGMS NIH HHS [GM46006, GM38328] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055339] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038328, P01GM046006, R37GM038328] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DULIC V, UNPUB; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; ELLIOTT SG, 1978, P NATL ACAD SCI USA, V75, P4384, DOI 10.1073/pnas.75.9.4384; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HARLOW E, 1988, ANTIBODIES LABORATOR; HINDS P, IN PRESS CELL; KLEID DG, 1981, SCIENCE, V214, P1125, DOI 10.1126/science.6272395; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEES E, IN PRESS GENES DEVD; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; NINOMIYATSUJI J, 1991, P NATL ACAD SCI USA, V88, P9006, DOI 10.1073/pnas.88.20.9006; Pines J, 1991, Trends Cell Biol, V1, P117, DOI 10.1016/0962-8924(91)90116-Q; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; RAO PN, 1970, NATURE, V225, P159, DOI 10.1038/225159a0; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	27	878	905	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 25	1992	257	5078					1958	1961		10.1126/science.1329201	http://dx.doi.org/10.1126/science.1329201			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JP594	1329201				2022-12-01	WOS:A1992JP59400035
J	GOGOS, JA; HSU, T; BOLTON, J; KAFATOS, FC				GOGOS, JA; HSU, T; BOLTON, J; KAFATOS, FC			SEQUENCE DISCRIMINATION BY ALTERNATIVELY SPLICED ISOFORMS OF A DNA-BINDING ZINC FINGER DOMAIN	SCIENCE			English	Article							SITE SELECTION ANALYSIS; OLIGONUCLEOTIDE MIXTURES; PROTEIN; RECOGNITION; DROSOPHILA; COMPLEX; MYOD; FORM	Two major developmentally regulated isoforms of the Drosophila chorion transcription factor CF2 differ by an extra zinc finger within the DNA binding domain. The preferred DNA binding sites were determined and are distinguished by an internal duplication of TAT in the site recognized by the isoform with the extra finger. The results are consistent with modular interactions between zinc fingers and trinucleotides and also suggest rules for recognition of AT-rich DNA sites by zinc finger proteins. The results show how modular finger interactions with trinucleotides can be used, in conjunction with alternative splicing, to alter the binding specificity and increase the spectrum of sites recognized by a DNA binding domain. Thus, CF2 may potentially regulate distinct sets of target genes during development.	HARVARD UNIV,DEPT CELLULAR & DEV BIOL,CAMBRIDGE,MA 02138; UNIV CRETE,FORTH,INST MOLEC BIOL & BIOTECHNOL,GR-71110 IRAKLION,GREECE; UNIV CRETE,DEPT BIOL,GR-71110 IRAKLION,GREECE	Harvard University; Foundation for Research & Technology - Hellas (FORTH); University of Crete; University of Crete								BALDWIN AS, 1987, CURRENT PROTOCOLS MO; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; EKKER SC, 1991, EMBO J, V10, P1179, DOI 10.1002/j.1460-2075.1991.tb08058.x; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; GOGOS JA, 1991, NUCLEIC ACIDS RES, V19, P1449, DOI 10.1093/nar/19.7.1449; GOGOS JA, UNPUB; HSU T, 1992, SCIENCE, V257, P1946, DOI 10.1126/science.1411512; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; LEE DK, 1991, CELL, V67, P1241, DOI 10.1016/0092-8674(91)90300-N; LIU AL, 1981, J BIOL CHEM, V256, P13200; MAINA CV, 1988, GENE, V74, P355; MARSTON FA, 1987, DNA CLONING PRACTICA, P65; MCCLARIN JA, 1986, SCIENCE, V234, P1526, DOI 10.1126/science.3024321; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; NARDELLI J, 1991, NATURE, V349, P175, DOI 10.1038/349175a0; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; POLLOCK R, 1990, NUCLEIC ACIDS RES, V18, P6197, DOI 10.1093/nar/18.21.6197; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; ROMAN C, 1991, SCIENCE, V254, P94, DOI 10.1126/science.1840705; SAENGER W, 1984, PRINCIPLES NUCLEIC A; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; SHEA MJ, 1990, GENE DEV, V4, P1128, DOI 10.1101/gad.4.7.1128; THIESEN HJ, 1990, NUCLEIC ACIDS RES, V18, P3203, DOI 10.1093/nar/18.11.3203; TRUSS M, 1990, P NATL ACAD SCI USA, V87, P7180, DOI 10.1073/pnas.87.18.7180; UEDA H, 1991, NUCLEIC ACIDS RES, V19, P3689, DOI 10.1093/nar/19.13.3689; YOON C, 1988, P NATL ACAD SCI USA, V85, P6332, DOI 10.1073/pnas.85.17.6332	27	91	98	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 25	1992	257	5078					1951	1955		10.1126/science.1290524	http://dx.doi.org/10.1126/science.1290524			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JP594	1290524				2022-12-01	WOS:A1992JP59400033
J	HENDERSON, E; HAYDON, PG; SAKAGUCHI, DS				HENDERSON, E; HAYDON, PG; SAKAGUCHI, DS			ACTIN FILAMENT DYNAMICS IN LIVING GLIAL-CELLS IMAGED BY ATOMIC FORCE MICROSCOPY	SCIENCE			English	Article							LANGMUIR-BLODGETT-FILMS; MOLECULAR-RESOLUTION; DNA	Observation of filamentous actin (F-actin) in living cells is currently limited to the resolution of the light microscope. Higher resolution procedures require sample fixation and preclude dynamic studies. The atomic force microscope (AFM) can image and manipulate samples at very high, sometimes atomic resolution by scanning a fine tip over the surface of interest and detecting physical interactions between the tip and sample. This study demonstrates that F-actin can be readily resolved in living cells with the AFM and that the dynamic properties of F-actin are easily observed.			HENDERSON, E (corresponding author), IOWA STATE UNIV SCI & TECHNOL,DEPT ZOOL & GENET,SIGNAL TRANSDUCT TRAINING GRP,AMES,IA 50011, USA.			Sakaguchi, Donald/0000-0003-4537-0972				BINNIG G, 1986, PHYS REV LETT, V56, P930, DOI 10.1103/PhysRevLett.56.930; BUSTAMANTE C, 1992, BIOCHEMISTRY-US, V31, P22, DOI 10.1021/bi00116a005; BUTT HJ, 1990, BIOPHYS J, V58, P1473, DOI 10.1016/S0006-3495(90)82492-9; BUTT HJ, 1990, J STRUCT BIOL, V105, P54, DOI 10.1016/1047-8477(90)90098-W; DRAKE B, 1989, SCIENCE, V243, P1586, DOI 10.1126/science.2928794; EDSTROM RD, 1990, FASEB J, V4, P3144, DOI 10.1096/fasebj.4.13.2120098; GOULD SAC, 1990, J VAC SCI TECHNOL A, V8, P369, DOI 10.1116/1.576398; HENDERSON E, 1992, NUCLEIC ACIDS RES, V20, P445, DOI 10.1093/nar/20.3.445; HOH J H, 1992, Trends in Cell Biology, V2, P208, DOI 10.1016/0962-8924(92)90248-L; HOH JH, 1991, SCIENCE, V253, P1405, DOI 10.1126/science.1910206; KELLER D, 1992, SPIE P, V1639, P91; MARTI O, 1988, J MICROSC-OXFORD, V152, P803, DOI 10.1111/j.1365-2818.1988.tb01452.x; OMIE J, 1991, SCIENCE, V252, P691; PARPURA V, COMMUNICATION; PUTMAN CAJ, IN PRESS ULTRAMICROS; PUTNAM CAJ, 1992, REV SCI INSTRUM, V63, P1914; RADMACHER M, 1992, STRUCTURE CONFORMATI, V66, P24; SAKAGUCHI DS, 1989, DEV BIOL, V134, P158, DOI 10.1016/0012-1606(89)90086-9; SMITH SJ, 1988, SCIENCE, V242, P708, DOI 10.1126/science.3055292; VESENKA J, IN PRESS ULTRAMICROS; VESENKA J, 1992, SPIE P, V1639, P38; WEISENHORN AL, 1990, BIOPHYS J, V58, P1251, DOI 10.1016/S0006-3495(90)82465-6; WEISENHORN AL, 1990, SCANNING MICROSCOPY, V4, P511; WEISENHORN AL, 1991, LANGMUIR, V7, P8, DOI 10.1021/la00049a003	24	375	393	4	85	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 25	1992	257	5078					1944	1946		10.1126/science.1411511	http://dx.doi.org/10.1126/science.1411511			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JP594	1411511				2022-12-01	WOS:A1992JP59400031
J	KLEINERT, HD; ROSENBERG, SH; BAKER, WR; STEIN, HH; KLINGHOFER, V; BARLOW, J; SPINA, K; POLAKOWSKI, J; KOVAR, P; COHEN, J; DENISSEN, J				KLEINERT, HD; ROSENBERG, SH; BAKER, WR; STEIN, HH; KLINGHOFER, V; BARLOW, J; SPINA, K; POLAKOWSKI, J; KOVAR, P; COHEN, J; DENISSEN, J			DISCOVERY OF A PEPTIDE-BASED RENIN INHIBITOR WITH ORAL BIOAVAILABILITY AND EFFICACY	SCIENCE			English	Article							CONVERTING-ENZYME; BLOOD-PRESSURE; BIOLOGICAL-ACTIVITY; DIPEPTIDE ANALOGS; PROFILE; POTENT; HYPERTENSION; RO-42-5892; ENALKIREN; SITE	Peptidic renin inhibitors have been poorly absorbed across the intestine or rapidly eliminated by the liver and have been reported to have oral bioavailabilities of less than 2%. A peptide-based renin inhibitor, A-72517 (molecular mass of 706 daltons), was devised that has oral bioavailabilities of 8, 24, 32, and 53% in the monkey, rat, ferret, and dog, respectively. Dose-related reductions in blood pressure, plasma renin activity, and plasma angiotensin II in parallel with increased plasma drug concentrations were observed after oral administration of A-72517 to conscious, salt-depleted dogs. Thus, peptide-based molecules of sizable molecular mass can be absorbed intact into the systemic circulation of animals. These findings support the potential of peptide-based drugs for oral administration.			KLEINERT, HD (corresponding author), ABBOTT LABS, ABBOTT PK, IL 60064 USA.							ALDERMAN MH, 1991, NEW ENGL J MED, V324, P1098, DOI 10.1056/NEJM199104183241605; BLAINE EH, 1984, HYPERTENSION, V6, pI111, DOI 10.1161/01.HYP.6.2_Pt_2.I111; BOGER J, 1983, NATURE, V303, P81, DOI 10.1038/303081a0; BRUNNER HR, 1979, ANN INTERN MED, V90, P19, DOI 10.7326/0003-4819-90-1-19; BRUNNER HR, 1972, NEW ENGL J MED, V286, P441, DOI 10.1056/NEJM197203022860901; BUHLMAYER P, 1988, J MED CHEM, V31, P1839; CAMENZIND E, 1991, J CARDIOVASC PHARM, V18, P299, DOI 10.1097/00005344-199109000-00001; CAVANAUGH J, 1989, J CLIN PHARMACOL, V29, P861; CODY RJ, 1985, AM J CARDIOL, V55, pA36, DOI 10.1016/0002-9149(85)90794-5; CUMIN F, 1990, DRUG METAB DISPOS, V18, P831; DEGASPARO M, 1989, BRIT J CLIN PHARMACO, V27, P587; ERDOS EG, 1990, HYPERTENSION, V16, P363, DOI 10.1161/01.HYP.16.4.363; FISCHLI W, 1991, HYPERTENSION, V18, P22, DOI 10.1161/01.HYP.18.1.22; GLASSMAN HN, 1990, J CARDIOVASC PHARM, V16, pS76, DOI 10.1097/00005344-199016004-00016; JEUNEMAITRE X, 1989, AM J HYPERTENS, V2, P819, DOI 10.1093/ajh/2.11.819; KLEINERT H, UNPUB; Kleinert H D, 1991, Adv Pharmacol, V22, P207, DOI 10.1016/S1054-3589(08)60036-8; KLEINERT HD, 1988, FEBS LETT, V230, P38, DOI 10.1016/0014-5793(88)80637-9; KLEINERT HD, 1990, CARDIOVASC DRUG REV, V8, P203, DOI 10.1111/j.1527-3466.1990.tb00393.x; LULY Jr, 1988, J MED CHEM, V31, P2264, DOI 10.1021/jm00120a005; NEUBERG GW, 1991, AM J CARDIOL, V67, P63, DOI 10.1016/0002-9149(91)90101-P; PALS DT, 1986, HYPERTENSION, V8, P1105, DOI 10.1161/01.HYP.8.12.1105; PANEK RL, 1991, CLIN EXP HYPERTENS A, V13, P1395, DOI 10.3109/10641969109048801; PLATTNER JJ, 1988, J MED CHEM, V31, P2277, DOI 10.1021/jm00120a006; PLATTNER JJ, 1990, DRUG DISCOVERY TECHN, pCH5; ROSENBERG SH, 1989, J MED CHEM, V32, P1371, DOI 10.1021/jm00126a038; RUSH BD, 1991, INT J PHARM, V73, P231, DOI 10.1016/0378-5173(91)90415-K; SCHAFFER LW, 1990, J HYPERTENS, V8, P251; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCROOP GC, 1968, NATURE, V220, P1331, DOI 10.1038/2201331a0; SLATER EE, 1988, JAMA-J AM MED ASSOC, V260, P967, DOI 10.1001/jama.260.7.967; SZELKE M, 1982, NATURE, V299, P555, DOI 10.1038/299555a0; VERBURG KM, 1989, HYPERTENSION, V13, P262, DOI 10.1161/01.HYP.13.3.262; Waeber BNJ, 1990, HYPERTENSION PATHOPH, P2209; WEISSMAN J, 1985, J MED CHEM, V28, P997, DOI 10.1021/jm00146a005; WONG PC, 1990, J PHARMACOL EXP THER, V252, P719; WOOD JM, 1989, J CARDIOVASC PHARM, V14, P221, DOI 10.1097/00005344-198908000-00006	37	105	107	1	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 25	1992	257	5078					1940	1943		10.1126/science.1411510	http://dx.doi.org/10.1126/science.1411510			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JP594	1411510				2022-12-01	WOS:A1992JP59400030
J	MCCONNELL, HM; OWICKI, JC; PARCE, JW; MILLER, DL; BAXTER, GT; WADA, HG; PITCHFORD, S				MCCONNELL, HM; OWICKI, JC; PARCE, JW; MILLER, DL; BAXTER, GT; WADA, HG; PITCHFORD, S			THE CYTOSENSOR MICROPHYSIOMETER - BIOLOGICAL APPLICATIONS OF SILICON TECHNOLOGY	SCIENCE			English	Article							CELL-AFFECTING AGENTS	A silicon-based device, dubbed a microphysiometer, can be used to detect and monitor the response of cells to a variety of chemical substances, especially ligands for specific plasma membrane receptors. The microphysiometer measures the rate of proton excretion from 104 to 106 cells. This article gives an overview of experiments currently being carried out with this instrument with emphasis on receptors with seven transmembrane helices and tyrosine kinase receptors. As a scientific instrument, the microphysiometer can be thought of as serving two distinct functions. In terms of detecting specific molecules, selected biological cells in this instrument serve as detectors and amplifiers. The microphysiometer can also investigate cell function and biochemistry. A major application of this instrument may prove to be screening for new receptor ligands. In this respect, the microphysiometer appears to offer significant advantages over other techniques.	MOLEC DEVICES CORP,4700 BOHANNAN DR,MENLO PK,CA 94025; STANFORD UNIV,DEPT CHEM,STANFORD,CA 94305	Stanford University								BAXTER GW, UNPUB; BRIGGS J, 1991, ANAL CHEM, V63, P850, DOI 10.1021/ac00009a003; FRASER CM, 1989, MOL PHARMACOL, V36, P840; HAFEMAN DG, 1988, SCIENCE, V240, P1182, DOI 10.1126/science.3375810; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; INDELICATO SR, 1991, 5TH INT C IMM TAMP; McConnell HM, 1991, CURR OPIN STRUC BIOL, V1, P647, DOI 10.1016/S0959-440X(05)80091-0; MILLER DL, 1991, FASEB J, V5, pA1014; NAG B, 1992, J IMMUNOL, V148, P2040; OWICKI JC, 1992, BIOSENS BIOELECTRON, V7, P255, DOI 10.1016/0956-5663(92)87004-9; OWICKI JC, 1990, P NATL ACAD SCI USA, V87, P4007, DOI 10.1073/pnas.87.10.4007; PARCE JW, 1990, ANN BIOL CLIN-PARIS, V48, P639; PARCE JW, 1989, SCIENCE, V246, P243, DOI 10.1126/science.2799384; RALEYSUSMAN KM, 1992, J NEUROSCI, V12, P773; RICE PA, 1991, FASEB J, V5, pA1014; RICE PA, 1991, THESIS STANFORD U ST; ROSSER M P, 1991, Society for Neuroscience Abstracts, V17, P818; SALON J A, 1991, Society for Neuroscience Abstracts, V17, P86; WADA HG, IN PRESS J CELL PHYS; WADA HG, 1990, MAY NAT I ALL INF DI	20	564	651	0	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 25	1992	257	5078					1906	1912		10.1126/science.1329199	http://dx.doi.org/10.1126/science.1329199			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JP594	1329199				2022-12-01	WOS:A1992JP59400023
J	PARKER, LL; PIWNICAWORMS, H				PARKER, LL; PIWNICAWORMS, H			INACTIVATION OF THE P34(CDC2)-CYCLIN-B COMPLEX BY THE HUMAN WEE1 TYROSINE KINASE	SCIENCE			English	Article							FISSION YEAST; CELL-CYCLE; P34CDC2 KINASE; SCHIZOSACCHAROMYCES-POMBE; PHOSPHORYLATION SITES; ACTIVATES P34CDC2; MITOTIC INDUCER; CDC25 PROTEIN; GENE; DEPHOSPHORYLATION	Entry into mitosis in Schizosaccharomyces pombe is negatively regulated by the wee1+ gene, which encodes a protein kinase with serine-, theonine-, and tyrosine-phosphorylating activities. The wee1+ kinase negatively regulates mitosis by phosphorylating p34cdc2 on tyrosine 15, thereby inactivating the p34cdc2-cyclin B complex. The human homolog of the wee1+ gene (WEE1Hu) was overproduced in bacteria and assayed in an in vitro system. Unlike its fission yeast homolog, the product of the WEE1Hu gene encoded a tyrosine-specific protein kinase. The human WEE1 kinase phosphorylated the p34cdc2-cyclin B complex on tyrosine 15 but not on threonine 14 in vitro and inactivated the p34cdc2-cyclin B kinase. This inhibition was reversed by the human Cdc25C protein, which catalyzed the dephosphorylation of p34cdc2. These results indicate that the product of the WEE1Hu gene directly regulates the p34cdc2-cyclin B complex in human cells and that a kinase other than that encoded by WEE1Hu phosphorylates p34cdc2 on threonine 14.	TUFTS UNIV, DEPT PHYSIOL, BOSTON, MA 02111 USA	Tufts University			Piwnica-Worms, Helen/C-5214-2012					BOOHER R, 1986, MOL CELL BIOL, V6, P3523, DOI 10.1128/MCB.6.10.3523; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; IGARASHI M, 1991, NATURE, V353, P80, DOI 10.1038/353080a0; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; LEE MS, 1992, MOL BIOL CELL, V3, P73, DOI 10.1091/mbc.3.1.73; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LINDBERG RA, 1992, TRENDS BIOCHEM SCI, V17, P114, DOI 10.1016/0968-0004(92)90248-8; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MILLAR JBA, 1991, EMBO J, V10, P4301, DOI 10.1002/j.1460-2075.1991.tb05008.x; MURRAY AW, 1989, NATURE, V342, P14, DOI 10.1038/342014a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PARKER L, UNPUB; PARKER LL, 1991, EMBO J, V10, P1255, DOI 10.1002/j.1460-2075.1991.tb08067.x; PARKER LL, 1992, P NATL ACAD SCI USA, V89, P2917, DOI 10.1073/pnas.89.7.2917; PINES J, 1990, New Biologist, V2, P389; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	26	546	569	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 25	1992	257	5078					1955	1957		10.1126/science.1384126	http://dx.doi.org/10.1126/science.1384126			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JP594	1384126				2022-12-01	WOS:A1992JP59400034
J	PUGLIANO, N; SAYKALLY, RJ				PUGLIANO, N; SAYKALLY, RJ			MEASUREMENT OF QUANTUM TUNNELING BETWEEN CHIRAL ISOMERS OF THE CYCLIC WATER TRIMER	SCIENCE			English	Article							VANDERWAALS COMPLEXES; SPECTROSCOPY; DYNAMICS; CLUSTERS	A detailed experimental study of the water trimer is reported. A vibration-rotation-tunneling band of the perdeuterated cluster has been measured near 89.6 wavenumbers by tunable far infrared laser absorption spectroscopy. The data indicate a chiral six-membered ring structure with rapid quantum tunneling occurring between the enantiomers. The observed vibration involves torsional motion of the water subunits about each hydrogen bond axis. It is speculated that larger water clusters would also exhibit transient chirality and that similar effects may be found in liquid water.	UNIV CALIF BERKELEY,DEPT CHEM,BERKELEY,CA 94720	University of California System; University of California Berkeley				SAYKALLY, RICHARD/0000-0001-8942-3656	NCRR NIH HHS [850RR05651A] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BALASUBRAMANIAN K, 1984, J PHYS CHEM-US, V88, P4688, DOI 10.1021/j150664a049; BLAKE GA, 1991, REV SCI INSTRUM, V62, P1701, DOI 10.1063/1.1142410; COHEN RC, 1992, J PHYS CHEM-US, V96, P1024, DOI 10.1021/j100182a006; COHEN RC, 1991, ANNU REV PHYS CHEM, V42, P369, DOI 10.1146/annurev.pc.42.100191.002101; FRANKS F, 1976, WATER COMPREHENSIVE; FRASER GT, 1991, INT REV PHYS CHEM, V10, P189, DOI 10.1080/01442359109353257; HALLER EE, 1985, INFRARED PHYS, V25, P257, DOI 10.1016/0020-0891(85)90088-0; HONEGGER E, 1988, J CHEM PHYS, V88, P2582, DOI 10.1063/1.454038; HUTSON JM, 1990, ANNU REV PHYS CHEM, V41, P123, DOI 10.1146/annurev.pc.41.100190.001011; LOESER JG, IN PRESS J CHEM PHYS; OWICKI JC, 1975, J PHYS CHEM-US, V79, P1794, DOI 10.1021/j100584a010; PUGLIANO N, 1992, J CHEM PHYS, V96, P1832, DOI 10.1063/1.462084	12	397	403	1	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 25	1992	257	5078					1937	1940		10.1126/science.1411509	http://dx.doi.org/10.1126/science.1411509			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JP594	1411509				2022-12-01	WOS:A1992JP59400029
J	WASSARMAN, DA; STEITZ, JA				WASSARMAN, DA; STEITZ, JA			INTERACTIONS OF SMALL NUCLEAR RNAS WITH PRECURSOR MESSENGER-RNA DURING INVITRO SPLICING	SCIENCE			English	Article							PSORALEN CROSS-LINKING; GROUP-II INTRON; RIBONUCLEOPROTEIN-PARTICLES; SITE SELECTION; 2'-OME RNA; U6 SNRNA; U2 SNRNP; YEAST; U1; SPLICEOSOME	Precursor messenger RNA splicing requires multiple factors including U1, U2, U4, U5, and U6 small nuclear RNA's. The crosslinking reagent psoralen was used to analyze the interactions of these RNA's with an adenovirus precursor messenger RNA in HeLa nuclear extract. An endogenous U2-U4-U6 crosslinkable complex dissociated upon incubation with precursor messenger RNA. During splicing, U1, U2, U5, and U6 became crosslinked to precursor messenger RNA and U2, U5, and U6 became crosslinked to excised lariat intron. U2 also formed a doubly crosslinked complex with U6 and precursor messenger RNA. The U1, U5, and U6 crosslinks to the precursor messenger RNA mapped to intron sequences near the 5' splice site, whereas the U2 crosslink mapped to the branch site. The kinetics of crosslink formation and disappearance delineates a temporal pathway for the action of small RNA's in the spliceosome. Potential base pairing interactions between conserved sequences in the small nuclear RNA's and precursor messenger RNA at the sites of crosslinking suggest that the 5' splice site is defined in several steps prior to the first cleavage event.			WASSARMAN, DA (corresponding author), YALE UNIV, SCH MED, DEPT MOLEC BIOPHYS & BIOCHEM, HOWARD HUGHES MED INST, 295 CONGRESS AVE, NEW HAVEN, CT 06536 USA.				NIGMS NIH HHS [GM26154] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026154, R37GM026154] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABMAYR SM, 1988, P NATL ACAD SCI USA, V85, P7216, DOI 10.1073/pnas.85.19.7216; BARABINO SML, 1989, EMBO J, V8, P4171, DOI 10.1002/j.1460-2075.1989.tb08602.x; BLACK DL, 1989, MOL CELL BIOL, V9, P3350, DOI 10.1128/MCB.9.8.3350; BLENCOWE BJ, 1989, CELL, V59, P531, DOI 10.1016/0092-8674(89)90036-6; BROW DA, 1988, NATURE, V334, P213, DOI 10.1038/334213a0; BRUZIK JP, 1990, CELL, V62, P889, DOI 10.1016/0092-8674(90)90264-F; CALVET JP, 1987, J MOL BIOL, V197, P543, DOI 10.1016/0022-2836(87)90563-8; CALVET JP, 1982, SCIENCE, V217, P456, DOI 10.1126/science.6178162; CALVET JP, 1981, CELL, V26, P363, DOI 10.1016/0092-8674(81)90205-1; CECH TR, 1986, CELL, V44, P207, DOI 10.1016/0092-8674(86)90751-8; CHAPDELAINE Y, 1991, CELL, V65, P465, DOI 10.1016/0092-8674(91)90464-A; CIMINO GD, 1985, ANNU REV BIOCHEM, V54, P1151, DOI 10.1146/annurev.bi.54.070185.005443; COPERTINO DW, 1991, EMBO J, V10, P433, DOI 10.1002/j.1460-2075.1991.tb07965.x; DATTA B, 1991, NATURE, V352, P821, DOI 10.1038/352821a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; England T E, 1980, Methods Enzymol, V65, P65; FABRIZIO P, 1990, SCIENCE, V250, P404, DOI 10.1126/science.2145630; GARRETTWHEELER E, 1984, NUCLEIC ACIDS RES, V12, P3405, DOI 10.1093/nar/12.7.3405; GE H, 1990, CELL, V62, P25, DOI 10.1016/0092-8674(90)90236-8; GOLDSCHMIDTCLERMONT M, 1991, CELL, V65, P135, DOI 10.1016/0092-8674(91)90415-U; GRABOWSKI PJ, 1986, SCIENCE, V233, P1294, DOI 10.1126/science.3638792; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; GUPTA S, 1991, NUCLEIC ACIDS RES, V19, P2073, DOI 10.1093/nar/19.suppl.2073; GUTHRIE C, 1989, AM ZOOL, V29, P557; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; HAUSNER TP, 1990, GENE DEV, V4, P2146, DOI 10.1101/gad.4.12a.2146; JACQUIER A, 1991, J MOL BIOL, V219, P415, DOI 10.1016/0022-2836(91)90183-7; JACQUIER A, 1990, TRENDS BIOCHEM SCI, V15, P351, DOI 10.1016/0968-0004(90)90075-M; JARRELL KA, 1988, MOL CELL BIOL, V8, P2361, DOI 10.1128/MCB.8.6.2361; KNOOP V, 1991, EMBO J, V10, P3483, DOI 10.1002/j.1460-2075.1991.tb04912.x; KOCH JL, 1992, MOL CELL BIOL, V12, P1950, DOI 10.1128/MCB.12.5.1950; KRAINER AR, 1985, CELL, V42, P725, DOI 10.1016/0092-8674(85)90269-7; KRAINER AR, 1990, CELL, V62, P35, DOI 10.1016/0092-8674(90)90237-9; LAMOND AI, 1989, CELL, V58, P383, DOI 10.1016/0092-8674(89)90852-0; LERNER EA, 1981, P NATL ACAD SCI-BIOL, V78, P2737, DOI 10.1073/pnas.78.5.2737; LUND E, 1992, SCIENCE, V255, P327, DOI 10.1126/science.1549778; MADHANI HD, 1990, GENE DEV, V4, P2264, DOI 10.1101/gad.4.12b.2264; MADHANI HD, COMMUNICATION; MANIATIS T, 1987, NATURE, V325, P673, DOI 10.1038/325673a0; MICHEL F, 1989, GENE, V82, P5, DOI 10.1016/0378-1119(89)90026-7; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NAKASHIMA K, 1980, NATURE, V286, P226, DOI 10.1038/286226a0; NEWMAN A, 1991, CELL, V65, P115, DOI 10.1016/0092-8674(91)90413-S; NEWMAN AJ, 1992, CELL, V68, P743, DOI 10.1016/0092-8674(92)90149-7; OSHIM AY, 1987, J MOL BIOL, V195, P297; PATTERSON B, 1987, CELL, V49, P613, DOI 10.1016/0092-8674(87)90537-X; REICH C, 1990, MOL CELL BIOL, V10, P5548, DOI 10.1128/MCB.10.10.5548; REICH CI, 1992, CELL, V69, P1159, DOI 10.1016/0092-8674(92)90637-R; RINKE J, 1985, J MOL BIOL, V185, P721, DOI 10.1016/0022-2836(85)90057-9; ROSBASH M, 1991, TRENDS BIOCHEM SCI, V16, P187, DOI 10.1016/0968-0004(91)90073-5; RUBY SW, 1991, TRENDS GENET, V7, P79; RYMOND BC, 1988, GENE DEV, V2, P428, DOI 10.1101/gad.2.4.428; RYMOND BC, 1985, NATURE, V317, P735, DOI 10.1038/317735a0; SAWA H, 1992, GENE DEV, V6, P244, DOI 10.1101/gad.6.2.244; SERAPHIN B, 1990, CELL, V63, P619, DOI 10.1016/0092-8674(90)90457-P; SHARP PA, 1985, CELL, V42, P397, DOI 10.1016/0092-8674(85)90092-3; SHARP PA, 1991, SCIENCE, V254, P663, DOI 10.1126/science.1948046; SHUSTER EO, 1990, NATURE, V345, P270, DOI 10.1038/345270a0; SILICIANO PG, 1988, GENE DEV, V2, P1258, DOI 10.1101/gad.2.10.1258; SINGH R, 1989, P NATL ACAD SCI USA, V86, P8280, DOI 10.1073/pnas.86.21.8280; SMITH CWJ, 1989, NATURE, V342, P243, DOI 10.1038/342243a0; SOLNICK D, 1985, CELL, V42, P157, DOI 10.1016/S0092-8674(85)80111-2; SPROAT BS, 1989, NUCLEIC ACIDS RES, V17, P3373, DOI 10.1093/nar/17.9.3373; Steitz J. A., 1988, STRUCTURE FUNCTION M, P115; STEITZ JA, 1992, SCIENCE, V257, P888, DOI 10.1126/science.1386941; STEITZ JA, 1989, METHOD ENZYMOL, V180, P468; TANI T, 1991, GENE DEV, V5, P1022, DOI 10.1101/gad.5.6.1022; TANI T, 1989, NATURE, V337, P87, DOI 10.1038/337087a0; WASSARMAN D, UNPUB; WISSINGER B, 1991, CELL, V65, P473, DOI 10.1016/0092-8674(91)90465-B; WOLFF T, 1992, EMBO J, V11, P345, DOI 10.1002/j.1460-2075.1992.tb05057.x; WU J, 1991, NATURE, V352, P818, DOI 10.1038/352818a0; WYATT J, UNPUB; YEAN SL, 1991, MOL CELL BIOL, V11, P5571, DOI 10.1128/MCB.11.11.5571; ZAUG AJ, 1984, SCIENCE, V224, P574, DOI 10.1126/science.6200938	75	326	326	1	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 25	1992	257	5078					1918	1925		10.1126/science.1411506	http://dx.doi.org/10.1126/science.1411506			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JP594	1411506				2022-12-01	WOS:A1992JP59400025
J	BIX, M; RAULET, D				BIX, M; RAULET, D			INEFFICIENT POSITIVE SELECTION OF T-CELLS DIRECTED BY HEMATOPOIETIC-CELLS	NATURE			English	Article							THYMUS	SUCCESSFUL intrathymic differentiation of alpha-beta-TCR+ T cells depends on positive selection of CD4+CD8+ thymocytes by thymic major histocompatibility complex (MHC) molecules1-9. Positive selection allows the maturation of only those T cells capable of restricted antigen recognition in the context of the hosts' MHC alleles. Studies of normal or T-cell receptor-transgenic mice engrafted with MHC-different bone marrow or thymuses support the conclusion that positive selection is directed by MHC molecules expressed on non-haematopoietic cells, presumably thymic epithelial cells1-3,8-10. Here we present contrary evidence that class I MHC molecules expressed by haematopoietic cell types direct positive selection of CD8+ T cells, though at a reduced rate compared with positive selection directed by thymic epithelial cells. The identity of cell types that direct positive selection bears directly on mechanistic models of the process, including the idea that thymic epithelial cell MHC molecules uniquely present specialized peptides that mediate positive selection, and the notion that thymic epithelial cells express unique differentiation-inducing cell surface molecules.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,DIV IMMUNOL,489 LIFE SCI ADDIT,BERKELEY,CA 94720	University of California System; University of California Berkeley				Raulet, David/0000-0002-1257-8649; Bix, Mark/0000-0003-4617-0497				BEVAN MJ, 1978, IMMUNOL REV, V42, P3, DOI 10.1111/j.1600-065X.1978.tb00256.x; SPRENT J, 1978, J EXP MED, V147, P1159, DOI 10.1084/jem.147.4.1159; ZINKERNAGEL RM, 1978, J EXP MED, V147, P882, DOI 10.1084/jem.147.3.882	3	142	144	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 24	1992	359	6393					330	333		10.1038/359330a0	http://dx.doi.org/10.1038/359330a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JP503	1406938				2022-12-01	WOS:A1992JP50300060
J	CHAPMAN, AB; RUBINSTEIN, D; HUGHES, R; STEARS, JC; EARNEST, MP; JOHNSON, AM; GABOW, PA; KAEHNY, WD				CHAPMAN, AB; RUBINSTEIN, D; HUGHES, R; STEARS, JC; EARNEST, MP; JOHNSON, AM; GABOW, PA; KAEHNY, WD			INTRACRANIAL ANEURYSMS IN AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COMPUTED-TOMOGRAPHY; RISK-FACTORS; DIAGNOSIS	Background and Methods. Intracranial aneurysms are a feature of autosomal dominant polycystic kidney disease, but their prevalence is uncertain. We studied 92 subjects with autosomal dominant polycystic kidney disease who had no symptoms or signs of any neurologic disorder. To determine the prevalence of intracranial aneurysms, we performed high-resolution computed tomography (CT) in 60 subjects, four-vessel cerebral angiography in 21, and both procedures in 11. Results. Four of the 88 subjects in whom the radiologic studies were successfully completed had intracranial aneurysms (4 percent; 95 percent confidence interval, 0.1 to 9 percent), as compared with the prevalence of 1 percent reported for an angiographic study of the general population. Three of the four subjects had multiple aneurysms. Seven subjects for whom the results of CT studies were suspicious underwent cerebral angiography: two had aneurysms, and five had normal vascular structures that accounted for the suspicious results of tomography. Four subjects who had normal CT imaging studies also had normal angiographic examinations. Eight of the 32 subjects who underwent angiography (25 percent) had transient complications, as compared with 22 of 220 control subjects (10 percent) who did not have polycystic kidney disease (P<0.05). We could not identify any risk factor in these subjects that was related to the occurrence of aneurysm. Conclusions. Asymptomatic intracranial aneurysms appear to be more frequent in people with polycystic kidney disease than in the general population, although our 95 percent confidence interval includes the possibility of no difference. Because cerebral angiography is associated with increased morbidity in people with polycystic kidney disease, we recommend high-resolution CT as a screening test.	UNIV HOSP DENVER, DENVER, CO USA; DEPT VET AFFAIRS MED CTR, DENVER, CO USA; DENVER GEN HOSP, DENVER, CO 80204 USA; UNIV COLORADO, SCH MED, DEPT MED, DENVER, CO 80202 USA; UNIV COLORADO, SCH MED, DEPT RADIOL, DENVER, CO 80202 USA; UNIV COLORADO, SCH MED, DEPT NEUROL, DENVER, CO 80202 USA	University of Colorado System; University of Colorado Hospital; Denver Health Medical Center; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver				Johnson, Anne/0000-0003-1330-7100	NCRR NIH HHS [MO-RR00051] Funding Source: Medline; NIDDK NIH HHS [DK34039] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACOSTARUA GJ, 1978, ARCH NEUROL-CHICAGO, V35, P675, DOI 10.1001/archneur.1978.00500340051010; ASKUPMARK E, 1950, ACTA MED SCAND, V138, P15; ATKINSON JLD, 1989, J NEUROSURG, V70, P551, DOI 10.3171/jns.1989.70.4.0551; BIGELOW NH, 1953, AM J MED SCI, V225, P485, DOI 10.1097/00000441-195305000-00004; Braasch WF, 1933, SURG GYNECOL OBSTET, V57, P467; BROWN R A P, 1951, Glasgow Med J, V32, P333; DALGAARD O Z, 1957, Acta Med Scand Suppl, V328, P1; DELAMONTE SM, 1985, AM J MED, V78, P957, DOI 10.1016/0002-9343(85)90218-9; DITLEFSEN EML, 1960, ACTA MED SCAND, V168, P51; Dunger R, 1904, BEITR PATHOL ANAT AL, V35, P445; EADIE MJ, 1964, J NEUROL SCI, V1, P501, DOI 10.1016/0022-510X(64)90170-4; EARNEST MP, 1987, STROKE, V18, P292; GABOW PA, 1984, ANN INTERN MED, V101, P238, DOI 10.7326/0003-4819-101-2-238; GABOW PA, 1990, HEPATOLOGY, V11, P1033, DOI 10.1002/hep.1840110619; HASSLER OVE, 1959, ACTA PATHOL ET MICROBIOL SCAND, V46, P305; HOSSACK KF, 1988, NEW ENGL J MED, V319, P907, DOI 10.1056/NEJM198810063191404; ISHIBASHI A, 1981, JPN J NEPHROL, V23, P1003; JAIN KK, 1974, ACTA NEUROCHIR, V30, P129, DOI 10.1007/BF01405761; KOBAYASHI H, 1984, SURG NEUROL, V21, P258, DOI 10.1016/0090-3019(84)90198-8; LEVEY AS, 1983, NEW ENGL J MED, V308, P986, DOI 10.1056/NEJM198304283081702; MATSUMURA M, 1986, ACTA NEUROCHIR, V79, P94, DOI 10.1007/BF01407451; NORRGARD O, 1987, NEUROSURGERY, V20, P236, DOI 10.1227/00006123-198702000-00006; PHILLIPS LH, 1980, NEUROLOGY, V30, P1034, DOI 10.1212/WNL.30.10.1034; SALTZMAN GF, 1959, ACTA RADIOL, V51, P415, DOI 10.3109/00016925909171114; SCHMID UD, 1987, NEURORADIOLOGY, V29, P152, DOI 10.1007/BF00327540; TABONE J, 1949, CR HEBD ACAD SCI, V229, P471; TORRES VE, 1990, J AM SOC NEPHROL, V1, P84; WAKABAYASHI T, 1983, J NEUROSURG, V58, P488, DOI 10.3171/jns.1983.58.4.0488	28	239	247	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 24	1992	327	13					916	920		10.1056/NEJM199209243271303	http://dx.doi.org/10.1056/NEJM199209243271303			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JP014	1513348				2022-12-01	WOS:A1992JP01400003
J	CLARKE, AR; MAANDAG, ER; VANROON, M; VANDERLUGT, NMT; VANDERVALK, M; HOOPER, ML; BERNS, A; RIELE, HT				CLARKE, AR; MAANDAG, ER; VANROON, M; VANDERLUGT, NMT; VANDERVALK, M; HOOPER, ML; BERNS, A; RIELE, HT			REQUIREMENT FOR A FUNCTIONAL RB-1 GENE IN MURINE DEVELOPMENT	NATURE			English	Article							EMBRYONIC STEM-CELLS; LEUKEMIA INHIBITORY FACTOR; MOUSE PGK-1 GENE; RETINOBLASTOMA GENE; ALTERED EXPRESSION; DIFFERENTIATION; DISRUPTION; CARCINOMA; MUTATIONS; SARCOMAS	HUMAN retinoblastomas can occur both as hereditary and as sporadic cases. Knudson's proposal1 that they result from two mutational events, of which one is present in the germ line in hereditary cases, has been confirmed by more recent molecular analysis, which has shown both events to involve loss or mutational inactivation of the same gene, RB-1 (ref. 2). RB-1 heterozygosity also predisposes to osteosarcoma, and RB-1 allele losses are seen in sporadic lung, breast, prostate and bladder carcinomas3-7. RB-1 is expressed in most, if not all, tissues and codes for a nuclear phosphoprotein which becomes hypophosphorylated in the G0 growth arrest state and in the G1 phase of the cell cycle2. To gain a further insight ino the role of RB-1 we and other groups8,9 have generated mice carrying an inactivated allele of the homologous gene, Rb-1 (ref. 10), by gene targeting". We report here that young heterozygous mice do not appear abnormal and do not develop retinoblastoma at a detectable frequency. However, homozygous mutant embryos fail to reach term and show a number of abnormalities in neural and haematopoietic development. Broadly similar results are reported by the other groups8,9.	UNIV EDINBURGH, DEPT PATHOL, CANC RES, CAMPAIGN LABS, EDINBURGH EH8 9YL, MIDLOTHIAN, SCOTLAND; UNIV EDINBURGH, AFRC, CTR GENOME RES, EDINBURGH EH8 9YL, MIDLOTHIAN, SCOTLAND; UNIV AMSTERDAM, DEPT BIOCHEM, AMSTERDAM, NETHERLANDS; NETHERLANDS CANC INST, DIV MOLEC GENET, 1066 CX AMSTERDAM, NETHERLANDS	University of Edinburgh; University of Edinburgh; University of Amsterdam; Netherlands Cancer Institute			Clarke, Alan R/A-6256-2008; clarke, alan r/P-2820-2014	Clarke, Alan/0000-0002-4281-426X				ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; CANCE WG, 1990, NEW ENGL J MED, V323, P1457, DOI 10.1056/NEJM199011223232105; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; COLBEREGARAPIN F, 1979, P NATL ACAD SCI USA, V76, P3755, DOI 10.1073/pnas.76.8.3755; DIVE C, IN PRESS FRONTIERS P; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; KASTER KR, 1983, NUCLEIC ACIDS RES, V11, P6895, DOI 10.1093/nar/11.19.6895; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; MOORE GE, 1967, J AMER MED ASSOC, V199, P519, DOI 10.1001/jama.199.8.519; MOREAU JF, 1988, NATURE, V336, P690, DOI 10.1038/336690a0; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; RIELE HT, 1990, NATURE, V348, P649, DOI 10.1038/348649a0; RIELE HT, 1992, P NATL ACAD SCI USA, V89, P5128, DOI 10.1073/pnas.89.11.5128; SHEW JY, 1989, ONCOGENE RES, V4, P205; SMITH AG, 1987, DEV BIOL, V121, P1, DOI 10.1016/0012-1606(87)90132-1; SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0; STRATTON MR, 1989, BRIT J CANCER, V60, P202, DOI 10.1038/bjc.1989.251; SZEKELY L, 1992, CELL GROWTH DIFFER, V3, P149; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; VANDERLUGT N, 1991, GENE, V105, P263, DOI 10.1016/0378-1119(91)90161-4; WEINBERG RA, 1990, TRENDS BIOCHEM SCI, V15, P199, DOI 10.1016/0968-0004(90)90162-5; WILLIAMS RL, 1988, NATURE, V336, P684, DOI 10.1038/336684a0; YOKOTA J, 1988, ONCOGENE, V3, P471	30	913	927	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 24	1992	359	6393					328	330		10.1038/359328a0	http://dx.doi.org/10.1038/359328a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JP503	1406937				2022-12-01	WOS:A1992JP50300059
J	FRANZOSO, G; BOURS, V; PARK, S; TOMITAYAMAGUCHI, M; KELLY, K; SIEBENLIST, U				FRANZOSO, G; BOURS, V; PARK, S; TOMITAYAMAGUCHI, M; KELLY, K; SIEBENLIST, U			THE CANDIDATE ONCOPROTEIN BCL-3 IS AN ANTAGONIST OF P50/NF-KAPPA-B-MEDIATED INHIBITION	NATURE			English	Article							NF-KAPPA-B; DNA-BINDING SUBUNIT; REL-ASSOCIATED PP40; CELL-CYCLE CONTROL; HUMAN T-CELLS; P65 SUBUNIT; TRANSCRIPTION; CLONING; HOMOLOGY; PROTEIN	THE candidate oncogene bcl-3 was discovered as a translocation into the immunoglobulin alpha-locus in some cases of B-cell chronic lymphocytic leukaemias1. The protein Bcl-3 contains seven so-called ankyrin repeats. Similar repeat motifs are found in a number of diverse regulatory proteins but the motifs of Bcl-3 are most closely related to those found in I-kappa-B proteins in which the ankyrin repeat domain is thought to be directly involved in inhibition of NF-kappa-B activity. No biological function has yet been described for Bcl-3, but it was noted recently2 that Bcl-3 interferes with DNA-binding of the p50 subunit of NF-kappa-B in vitro. Here we demonstrate that Bcl-3 can aid kappa-B site-dependent transcription in vivo by counteracting the inhibitory effects of p50/NF-kappa-B homodimers. Bcl-3 may therefore aid activation of select NF-kappa-B-regulated genes, including those of the human immunodeficiency virus.	NIAID,IMMUNOREGULAT LAB,BETHESDA,MD 20892; NCI,PATHOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Franzoso, Guido/GRR-8628-2022	Franzoso, Guido/0000-0002-0778-988X				BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BLANK V, 1991, EMBO J, V10, P4159, DOI 10.1002/j.1460-2075.1991.tb04994.x; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GENDELMAN HE, 1986, P NATL ACAD SCI USA, V83, P9759, DOI 10.1073/pnas.83.24.9759; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HATADA EN, 1992, P NATL ACAD SCI USA, V89, P2489, DOI 10.1073/pnas.89.6.2489; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; ISRAEL DI, 1989, NUCLEIC ACIDS RES, V17, P4589, DOI 10.1093/nar/17.12.4589; KANG SM, 1992, SCIENCE, V256, P1452, DOI 10.1126/science.1604322; KERR LD, 1991, GENE DEV, V5, P1464, DOI 10.1101/gad.5.8.1464; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KRETZSCHMAR M, 1992, GENE DEV, V6, P761, DOI 10.1101/gad.6.5.761; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LU D, 1991, ONCOGENE, V6, P1235; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; MEYER R, 1991, P NATL ACAD SCI USA, V88, P966, DOI 10.1073/pnas.88.3.966; MOLITOR JA, 1990, P NATL ACAD SCI USA, V87, P10028, DOI 10.1073/pnas.87.24.10028; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; RIVIERE Y, 1991, NATURE, V350, P625, DOI 10.1038/350625a0; RUBEN SM, 1992, MOL CELL BIOL, V12, P444, DOI 10.1128/MCB.12.2.444; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; URBAN MB, 1991, EMBO J, V10, P1817, DOI 10.1002/j.1460-2075.1991.tb07707.x; WULCZYN FG, 1992, NATURE, V358, P597, DOI 10.1038/358597a0; ZIPFEL PF, 1989, MOL CELL BIOL, V9, P1041, DOI 10.1128/MCB.9.3.1041	35	291	296	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 24	1992	359	6393					339	342		10.1038/359339a0	http://dx.doi.org/10.1038/359339a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JP503	1406939	Green Published			2022-12-01	WOS:A1992JP50300063
J	HAASS, C; SCHLOSSMACHER, MG; HUNG, AY; VIGOPELFREY, C; MELLON, A; OSTASZEWSKI, BL; LIEBERBURG, I; KOO, EH; SCHENK, D; TEPLOW, DB; SELKOE, DJ				HAASS, C; SCHLOSSMACHER, MG; HUNG, AY; VIGOPELFREY, C; MELLON, A; OSTASZEWSKI, BL; LIEBERBURG, I; KOO, EH; SCHENK, D; TEPLOW, DB; SELKOE, DJ			AMYLOID BETA-PEPTIDE IS PRODUCED BY CULTURED-CELLS DURING NORMAL METABOLISM	NATURE			English	Article							ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; IDENTIFICATION; LOCALIZATION; TISSUES; BRAIN	ALZHEIMER's disease is characterized by the extracellular deposition in the brain and its blood vessels of insoluble aggregates of the amyloid beta-peptide (A-beta), a fragment, of about 40 amino acids in length, of the integral membrane protein beta-amyloid precursor protein (beta-APP)1. The mechanism of extracellular accumulation of A-beta in brain is unknown and no simple in vitro or in vivo model systems that produce extracellular A-beta have been described. We report here the unexpected identification of the 4K (M(r) 4,000) A-beta and a truncated form of A-beta (approximately 3K) in media from cultures of primary cells and untransfected and beta-APP-transfected cell lines grown under normal conditions. These peptides were immunoprecipitated readily from culture medium by A-beta-specific antibodies and their identities confirmed by sequencing. The concept that pathological processes are responsible for the production of A-beta must now be reassessed in light of the observation that A-beta is produced in soluble form in vitro and in vivo2 during normal cellular metabolism. Further, these findings provide the basis for using simple cell culture systems to identify drugs that block the formation or release of A-beta, the primary protein constituent of the senile plaques of Alzheimer's disease.	HARVARD UNIV,SCH MED,PROGRAM NEUROSCI,BOSTON,MA 02155; BRIGHAM & WOMENS HOSP,CTR NEUROL DIS,DEPT MED NEUROL,BOSTON,MA 02155; ATHENA NEUROSCI INC,S SAN FRANCISCO,CA 94090	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	HAASS, C (corresponding author), HARVARD UNIV,SCH MED,DEPT NEUROL,BOSTON,MA 02155, USA.			Schlossmacher, Michael/0000-0002-0394-0300				ANDERSON JP, IN PRESS J NEUROCHEM; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; ESTUS S, 1992, SCIENCE, V255, P726, DOI 10.1126/science.1738846; GABUZDA D H, 1992, Neurology, V42, P304; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; GREENBERG SM, 1988, BLOOD, V72, P1968; HAASS C, 1991, J NEUROSCI, V11, P3783; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; JOACHIM CL, 1989, NATURE, V341, P226, DOI 10.1038/341226a0; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; MORI H, 1992, J BIOL CHEM, V267, P17082; NORDSTEDT C, 1991, P NATL ACAD SCI USA, V88, P8910, DOI 10.1073/pnas.88.20.8910; OLTERSDORF T, 1990, J BIOL CHEM, V265, P4492; PODLISNY MB, 1991, AM J PATHOL, V138, P1423; SELKOE DJ, 1989, NEUROBIOL AGING, V10, P387, DOI 10.1016/0197-4580(89)90072-9; SELKOE DJ, 1988, P NATL ACAD SCI USA, V85, P7341, DOI 10.1073/pnas.85.19.7341; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; TAMAOKA A, 1992, P NATL ACAD SCI USA, V89, P1345, DOI 10.1073/pnas.89.4.1345; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3	20	1738	1829	0	130	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 24	1992	359	6393					322	325		10.1038/359322a0	http://dx.doi.org/10.1038/359322a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JP503	1383826				2022-12-01	WOS:A1992JP50300057
J	JACKS, T; FAZELI, A; SCHMITT, EM; BRONSON, RT; GOODELL, MA; WEINBERG, RA				JACKS, T; FAZELI, A; SCHMITT, EM; BRONSON, RT; GOODELL, MA; WEINBERG, RA			EFFECTS OF AN RB MUTATION IN THE MOUSE	NATURE			English	Article							RETINOBLASTOMA SUSCEPTIBILITY GENE; HUMAN PROSTATE CARCINOMA; SV40-TRANSFORMED CELLS; ENCODED PROTEIN; T-ANTIGEN; PRODUCT; EXPRESSION; TUMORS; CANCER; PHOSPHORYLATION	The retinoblastoma gene is mutated in several types of human cancer and is the best characterized of the tumour-suppressor genes. A mouse strain has been constructed in which one allele of Rb is disrupted. These heterozygous animals are not predisposed to retinoblastoma, but some display pituitary tumours arising from cells in which the wild-type Rb allele is absent. Embryos homozygous for the mutation die between days 14 and 15 of gestation, exhibiting neuronal cell death and defective erythropoiesis.	MIT,WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02139; TUFTS UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02111; TUFTS UNIV,SCH VET MED,BOSTON,MA 02111	Massachusetts Institute of Technology (MIT); Whitehead Institute; Tufts University; Tufts University	JACKS, T (corresponding author), MIT,DEPT BIOL,CTR CANC RES,CAMBRIDGE,MA 02139, USA.			Goodell, Margaret A./0000-0003-1111-2932				ABRAMSON DH, 1984, OPHTHALMOLOGY, V91, P1351; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BOOKSTEIN R, 1990, P NATL ACAD SCI USA, V87, P7762, DOI 10.1073/pnas.87.19.7762; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BRADLEY A, 1987, TERATOCARCINOMAS EMB, P113; BRONSTEIN I, 1992, BIOTECHNIQUES, V12, P748; BUCHKOVICH K, 1989, CELL, V46, P447; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HENSEL CH, 1990, CANCER RES, V50, P3067; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MATSUNAGA E, 1980, HUM GENET, V56, P127; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; TANG A, 1988, SCIENCE, V241, P1797; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VARLEY JM, 1989, ONCOGENE, V4, P725; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WINDLE JJ, 1990, NATURE, V343, P665, DOI 10.1038/343665a0; WONG PMC, 1986, P NATL ACAD SCI USA, V83, P3851, DOI 10.1073/pnas.83.11.3851; YOKOTA J, 1988, ONCOGENE, V3, P471	46	1541	1590	0	35	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 24	1992	359	6393					295	300		10.1038/359295a0	http://dx.doi.org/10.1038/359295a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JP503	1406933				2022-12-01	WOS:A1992JP50300046
J	LAND, MF				LAND, MF			PREDICTABLE EYE HEAD COORDINATION DURING DRIVING	NATURE			English	Article							MOVEMENTS	LARGE changes in the direction of gaze are made with a combination of fast saccadic eye movements and rather slower head movements. Since the first study on freely moving subjects1, most authors have agreed that the head movement component of gaze is very variable, with a high 'volitional' component2. But in some circumstances head and eye movements can be quite predictable, for example when a subject is asked to shift gaze as quickly as possible3. Under these conditions, laboratory studies have shown that the eye and head motor-systems both receive gaze-change commands, although they execute them in rather different ways3-6. Here I reconsider the way gaze direction is changed during free movement, but in the performance of a task where the subject is too busy to exert conscious control over head or eye movements. Using a new portable and inexpensive method for recording head and eye movements, I examine the oculomotor behaviour of car drivers, particularly during the large gaze changes made at road junctions. The results show that the pattern of eye and head movements is highly preditable, given only the sequence of gaze targets.			LAND, MF (corresponding author), UNIV SUSSEX,SCH BIOL SCI,CTR NEUROSCI,BRIGHTON BN1 9QG,E SUSSEX,ENGLAND.							BECKER W, 1991, VISION VISUAL DYSFUN, P95; BIZZI E, 1971, SCIENCE, V173, P452, DOI 10.1126/science.173.3995.452; Carpenter RHS, 1988, MOVEMENTS EYES; Collewijn H., 1977, CONTROL GAZE BRAIN S, P13; Delreux V., 1991, BRAIN SPACE, P38; GUITTON D, 1992, TRENDS NEUROSCI, V15, P174, DOI 10.1016/0166-2236(92)90169-9; LAND MF, 1990, J COMP PHYSIOL A, V167, P155; LAURUTIS VP, 1986, J PHYSIOL-LONDON, V373, P209, DOI 10.1113/jphysiol.1986.sp016043; MORASSO P, 1973, EXP BRAIN RES, V16, P492, DOI 10.1007/BF00234475; TOMLINSON RD, 1990, J NEUROPHYSIOL, V64, P1873, DOI 10.1152/jn.1990.64.6.1873; Yarbus A. L., 1967, EYE MOVEMENTS VISION; ZANGEMEISTER WH, 1982, EXP NEUROL, V77, P563, DOI 10.1016/0014-4886(82)90228-X; ZANGEMEISTER WH, 1981, EXP NEUROL, V71, P76, DOI 10.1016/0014-4886(81)90072-8	13	117	117	1	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 24	1992	359	6393					318	320		10.1038/359318a0	http://dx.doi.org/10.1038/359318a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JP503	1406934				2022-12-01	WOS:A1992JP50300055
J	LEE, EYHP; CHANG, CY; HU, NP; WANG, YCJ; LAI, CC; HERRUP, K; LEE, WH; BRADLEY, A				LEE, EYHP; CHANG, CY; HU, NP; WANG, YCJ; LAI, CC; HERRUP, K; LEE, WH; BRADLEY, A			MICE DEFICIENT FOR RB ARE NONVIABLE AND SHOW DEFECTS IN NEUROGENESIS AND HEMATOPOIESIS	NATURE			English	Article							RETINOBLASTOMA GENE-PRODUCT; LARGE T-ANTIGEN; CELL-CYCLE; SUSCEPTIBILITY GENE; TRANSCRIPTION FACTOR; MOUSE EMBRYO; ENCODED PROTEIN; CARCINOMA-CELLS; STEM-CELLS; BINDING	The retinoblastoma gene, a prototypic tumour-suppressor gene, encodes a nuclear phosphoprotein (Rb). To understand better the role of Rb in development and in tumorigenesis, mice with an insertional mutation in exon 20 of the Rb-1 locus were generated. Homozygous mutants die before the 16th embryonic day with multiple defects. The haematopoietic system is abnormal; there is a significant increase in the number of immature nucleated erythrocytes. In the nervous system, ectopic mitoses and massive cell death are found, particularly in the hindbrain. All spinal ganglion cells die, but the neural retina is unaffected. Transfer of the human retinoblastoma (RB) mini-transgene into the mutant mice corrects the developmental defects. Thus, Rb is essential for normal mouse development.	UNIV TEXAS, HLTH SCI CTR, INST BIOTECHNOL, SAN ANTONIO, TX 78284 USA; CASE WESTERN RESERVE UNIV, SCH MED, ALZHEIMER RES LAB, CLEVELAND, OH 44106 USA; BAYLOR COLL MED, INST MOLEC GENET, HOUSTON, TX 77030 USA	University of Texas System; University of Texas Health San Antonio; Case Western Reserve University; Baylor College of Medicine	LEE, EYHP (corresponding author), UNIV TEXAS, HLTH SCI CTR, CTR MOLEC MED, SAN ANTONIO, TX 78284 USA.		; Herrup, Karl/C-5313-2014	Bradley, Allan/0000-0002-2349-8839; Herrup, Karl/0000-0001-7786-5844				ABRAMSON DH, 1984, OPHTHALMOLOGY, V91, P1351; ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DRYJA TP, 1986, P NATL ACAD SCI USA, V83, P7391, DOI 10.1073/pnas.83.19.7391; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GOODRICH DW, 1992, CANCER RES, V52, P1968; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG S, 1991, NATURE, V350, P160, DOI 10.1038/350160a0; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; Knudson A G Jr, 1989, Birth Defects Orig Artic Ser, V25, P15; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; LEE EYHP, 1991, PROG CLIN BIOL RES, V362, P221; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LEE WH, 1990, TUMOUR SUPPRESSOR GE, P159; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MOORE MAS, 1970, BRIT J HAEMATOL, V18, P279, DOI 10.1111/j.1365-2141.1970.tb01443.x; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SUMEGI J, 1990, CELL GROWTH DIFFER, V1, P247; TAKAHASHI R, 1991, P NATL ACAD SCI USA, V88, P5257, DOI 10.1073/pnas.88.12.5257; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; VOGEL F, 1979, HUM GENET, V52, P1; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; XU HJ, 1989, ONCOGENE, V4, P807	49	1150	1170	0	13	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	SEP 24	1992	359	6393					288	294		10.1038/359288a0	http://dx.doi.org/10.1038/359288a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JP503	1406932				2022-12-01	WOS:A1992JP50300045
J	LINDGREN, S; LOKSHIN, B; STROMQUIST, A; WEINBERGER, M; NASSIF, E; MCCUBBIN, M; FRASHER, R				LINDGREN, S; LOKSHIN, B; STROMQUIST, A; WEINBERGER, M; NASSIF, E; MCCUBBIN, M; FRASHER, R			DOES ASTHMA OR TREATMENT WITH THEOPHYLLINE LIMIT CHILDRENS ACADEMIC-PERFORMANCE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							AMBULATORY PATIENTS; SCHOOL PERFORMANCE; CHILDHOOD ASTHMA; UNITED-STATES; BEHAVIOR; HOSPITALIZATION; PREVALENCE; PREDNISONE; CAFFEINE; THERAPY	Background. Asthma is a major cause of morbidity in childhood, restricting activity and causing absences from school. Theophylline, although effective in managing chronic asthma, has been reported to cause deficits in cognitive functioning and school performance. We therefore examined the effect of asthma and its treatment on academic achievement in a large, representative population of school-age children; matched sibling controls were used for comparison. Methods. We identified 255 consecutive children with asthma (mean age, 12.0 years) who had taken nationally standardized scholastic achievement tests administered routinely by the schools. One hundred one of these children had siblings without asthma with whom comparisons Gould be made in reading, mathematics, and a composite measure of achievement. Results. Academic achievement among the children with asthma was similar to normative standards in Iowa and higher than national standards, as reflected in a mean composite T-score of 57.1 (expected mean [+/-SD], 50+/-10). For the 101 children with sibling controls, composite T-scores were 58.3 for the children with asthma and 57.5 for the siblings. Eighty-five of these 101 children with asthma were receiving daily maintenance medication for chronic asthma; 72 of these were receiving theophylline. The mean composite T-scores were 58.5 for the theophylline-treated patients and 58.4 for their siblings without asthma. None of the differences between the children with asthma and the sibling controls were statistically significant. Conclusions. Academic achievement among children with asthma, at least those whose status is closely monitored in a structured treatment program, generally appears to be unaffected by asthma or by its treatment with appropriate doses of theophylline.	MCFARLAND CLIN,AMES,IA; UNIV IOWA,COLL MED,DEPT PREVENT MED,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT ENVIRONM HLTH,IOWA CITY,IA 52242; UNIV MISSOURI,DEPT CHILD HLTH,COLUMBIA,MO 65201; UNIV MISSOURI,DEPT PEDIAT,COLUMBIA,MO 65201	University of Iowa; University of Iowa; University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia	LINDGREN, S (corresponding author), UNIV IOWA,COLL MED,DEPT PEDIAT,IOWA CITY,IA 52242, USA.		Weinberger, Miles/H-6743-2019					BENDER B, 1992, JAMA-J AM MED ASSOC, V267, P2621; BENDER B G, 1991, Annals of Allergy, V66, P65; CREER TL, 1989, J PEDIATR, V15, P850; Crowder M.J., 1990, ANAL REPEATED MEASUR; EKWO E, 1978, J ALLERGY CLIN IMMUN, V61, P240, DOI 10.1016/0091-6749(78)90198-7; ELKINS RN, 1981, AM J PSYCHIAT, V138, P178; FELDT LS, 1989, IOWA TESTS ED DEV; FURUKAWA CT, 1984, LANCET, V1, P621; FURUKAWA CT, 1988, J ALLERGY CLIN IMMUN, V81, P83, DOI 10.1016/0091-6749(88)90224-2; GELLIS SS, 1986, PEDIATRIC NOTES, V10, P207; GERGEN PJ, 1988, PEDIATRICS, V81, P1; GUTSTADT LB, 1989, AM J DIS CHILD, V143, P471, DOI 10.1001/archpedi.1989.02150160101020; HARRIS JB, 1987, J PEDIATR-US, V110, P627, DOI 10.1016/S0022-3476(87)80567-X; HIERONYMUS AN, 1989, IOWA TESTS BASIC SKI; LINDGREN SD, 1985, CHILD DEV, V56, P1404, DOI 10.1111/j.1467-8624.1985.tb00206.x; MCNEMAR Q, 1969, PSYCHOL STATISTICS; MILAVETZ G, 1986, J PEDIATR-US, V109, P351, DOI 10.1016/S0022-3476(86)80403-6; NASSIF E, 1987, J ALLERGY CLIN IMMUN, V80, P518, DOI 10.1016/0091-6749(87)90002-9; PERRIN JM, 1989, NEW ENGL J MED, V320, P1183, DOI 10.1056/NEJM198905043201805; RACHELEFSKY GS, 1986, PEDIATRICS, V78, P1133; RAPOPORT JL, 1984, ARCH GEN PSYCHIAT, V41, P1073; RAPPAPORT L, 1989, AM J DIS CHILD, V143, P368, DOI 10.1001/archpedi.1989.02150150126032; SCHLIEPER A, 1991, J PEDIATR-US, V118, P449, DOI 10.1016/S0022-3476(05)82167-5; SHAYWITZ SE, 1990, JAMA-J AM MED ASSOC, V264, P998, DOI 10.1001/jama.264.8.998; SPRINGER C, 1985, J ALLERGY CLIN IMMUN, V76, P64, DOI 10.1016/0091-6749(85)90806-1; SUESS WM, 1986, J ASTHMA, V23, P291, DOI 10.3109/02770908609073175; TWAROG FJ, 1987, PEDIATR ALERT, V12, P17; WEINBERGER M, 1987, J PEDIATR-US, V111, P471, DOI 10.1016/S0022-3476(87)80483-3; WEINBERGER M, 1990, MANAGING ASTHMA; WISSOW LS, 1988, AM J PUBLIC HEALTH, V78, P777, DOI 10.2105/AJPH.78.7.777; WOLKOWITZ OM, 1990, AM J PSYCHIAT, V147, P1297; 1962, AM REV RESPIR DIS, V85, P762	32	60	60	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 24	1992	327	13					926	930		10.1056/NEJM199209243271305	http://dx.doi.org/10.1056/NEJM199209243271305			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JP014	1513349				2022-12-01	WOS:A1992JP01400005
J	MATSUMURA, K; TOME, FMS; COLLIN, H; AZIBI, K; CHAOUCH, M; KAPLAN, JC; FARDEAU, M; CAMPBELL, KP				MATSUMURA, K; TOME, FMS; COLLIN, H; AZIBI, K; CHAOUCH, M; KAPLAN, JC; FARDEAU, M; CAMPBELL, KP			DEFICIENCY OF THE 50K DYSTROPHIN-ASSOCIATED GLYCOPROTEIN IN SEVERE CHILDHOOD AUTOSOMAL RECESSIVE MUSCULAR-DYSTROPHY	NATURE			English	Article							SKELETAL-MUSCLE; COMPLEX; PROTEIN	X-LINKED recessive Duchenne muscular dystrophy (DMD) is caused by the absence of dystrophin, a membrane cytoskeletal protein1,2. Dystrophin is associated with a large oligomeric complex of sarcolemmal glycoproteins3-10. The dystrophin-glycoprotein complex has been proposed to span the sarcolemma to provide a link between the subsarcolemmal cytoskeleton and the extracellular matrix component, laminin7,9. In DMD, the absence of dystrophin leads to a large reduction in all of the dystrophin-associated proteins4,9,10. We have investigated the possibility that a deficiency of a dystrophin-associated protein could be the cause of severe childhood autosomal recessive muscular dystrophy (SCARMD) with a DMD-like phenotype11-14. Here we report the specific deficiency of the 50K dystrophin-associated glycoprotein (M(r) 50,000) in sarcolemma of SCARMD patients. Therefore, the loss of this glycoprotein is a common denominator of the pathological process leading to muscle cell necrosis in two forms of muscular dystrophy, DMD and SCARMD.	UNIV IOWA, COLL MED, HOWARD HUGHES MED INST, IOWA CITY, IA 52242 USA; UNIV IOWA, COLL MED, DEPT PHYSIOL & BIOPHYS, IOWA CITY, IA 52242 USA; INSERM, U153, F-75005 PARIS, FRANCE; HOP BOLOGHINE, BIOL LAB, ALGIERS, ALGERIA; HOP BEN AKNOUN, SERV NEUROL, ALGIERS, ALGERIA; INST COCHIN GENET MOLEC, INSERM, U129, F-75014 PARIS, FRANCE	Howard Hughes Medical Institute; University of Iowa; University of Iowa; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm)				Campbell, Kevin/0000-0003-2066-5889				BENHAMIDA M, 1992, J NEUROL SCI, V107, P60; BENJELLOUNDELLAGI S, 1990, NEUROLOGY, V40, P1903; CAMPBELL KP, 1989, NATURE, V338, P259, DOI 10.1038/338259a0; ERVASTI JM, 1991, J BIOL CHEM, V266, P9161; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; HAMIDA MB, 1983, MUSCLE NERVE, V6, P469, DOI 10.1002/mus.880060702; HEMMINGS L, 1992, J CELL BIOL, V116, P1369, DOI 10.1083/jcb.116.6.1369; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; Khurana T S, 1991, Neuromuscul Disord, V1, P185, DOI 10.1016/0960-8966(91)90023-L; KOENIG M, 1988, CELL, V53, P219, DOI 10.1016/0092-8674(88)90383-2; LOVE DR, 1989, NATURE, V339, P55, DOI 10.1038/339055a0; McKusick V. A. E., 1991, MENDELIAN INHERITANC; OHLENDIECK K, 1991, J CELL BIOL, V112, P135, DOI 10.1083/jcb.112.1.135; OHLENDIECK K, 1991, J CELL BIOL, V115, P1685, DOI 10.1083/jcb.115.6.1685; OHLENDIECK K, IN PRESS NEUROLOGY	17	256	258	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 24	1992	359	6393					320	322		10.1038/359320a0	http://dx.doi.org/10.1038/359320a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JP503	1406935				2022-12-01	WOS:A1992JP50300056
J	PEREIRA, BJG; MILFORD, EL; KIRKMAN, RL; QUAN, S; SAYRE, KR; JOHNSON, PJ; WILBER, JC; LEVEY, AS				PEREIRA, BJG; MILFORD, EL; KIRKMAN, RL; QUAN, S; SAYRE, KR; JOHNSON, PJ; WILBER, JC; LEVEY, AS			PREVALENCE OF HEPATITIS-C VIRUS-RNA IN ORGAN DONORS POSITIVE FOR HEPATITIS-C ANTIBODY AND IN THE RECIPIENTS OF THEIR ORGANS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NON-B-HEPATITIS; CHRONIC NON-A; LONG-TERM; LIVER-DISEASE; RENAL-TRANSPLANTATION; VIRAL-HEPATITIS; SGOT ACTIVITY; TRANSMISSION; SERUM; COMPLICATIONS	Background. There is a high prevalence of liver disease among the recipients of organs from donors with antibodies to hepatitis C virus (HCV). We undertook a study to determine the frequency of persistent HCV infection, as indicated by the presence of HCV RNA, among both cadaveric organ donors positive for antibodies to HCV (anti-HCV) and the recipients of organs from these donors. Methods. Serum samples from donors and recipients were tested for HCV RNA with the reverse transcriptase polymerase chain reaction, with use of primers from the 5' untranslated region of the HCV genome, and for anti-HCV with the first-generation enzyme-linked immunosorbent assay (ELISA) and two second-generation tests. Results. HCV RNA was detected in 9 of the 11 organ donors (82 percent) with a positive first-generation ELISA for anti-HCV. Among the organ recipients, the prevalence of HCV RNA increased after transplantation: 7 of 26 patients (27 percent) had positive samples before transplantation, as compared with 23 of 24 patients (96 percent) after transplantation (P<0.001). Among 13 recipients who were HCV RNA-negative before receiving organs from the nine HCV RNA-positive donors, HCV infection was detected in all 13 after transplantation, and anti-HCV developed in 8 (62 percent). On the basis of a positive test for HCV RNA, the maximal sensitivity of the three anti-HCV tests was 57 percent (positive in 4 of 7 patients with end-stage organ failure) before transplantation and 70 percent (positive in 16 of 23 patients) after transplantation. Conclusions. Nearly all the recipients of organs from anti-HCV-positive donors become infected with HCV. The current tests for anti-HCV antibodies underestimate the incidence of transmission and the prevalence of HCV infection among immunosuppressed organ recipients.	NEW ENGLAND ORGAN BANK INC,1 GATEWAY CTR,WASHINGTON ST & NEWTON CORNER,NEWTON,MA 02158; ORTHO DIAGNOST SYST INC,RARITAN,NJ; CHIRON CORP,EMERYVILLE,CA	Novartis								ABBOTT MA, 1988, J INFECT DIS, V158, P1158, DOI 10.1093/infdis/158.6.1158; ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; BRAUN WE, 1990, KIDNEY INT, V37, P1363, DOI 10.1038/ki.1990.123; CHA TA, 1991, J CLIN MICROBIOL, V29, P2528, DOI 10.1128/JCM.29.11.2528-2534.1991; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; COHEN GA, 1976, ANN INTERN MED, V84, P275, DOI 10.7326/0003-4819-84-3-275; Debure A, 1988, Adv Nephrol Necker Hosp, V17, P375; DIETHELM AG, 1992, NEW ENGL J MED, V326, P410, DOI 10.1056/NEJM199202063260612; ESTEBAN JI, 1990, NEW ENGL J MED, V323, P1107, DOI 10.1056/NEJM199010183231605; EVANS CS, 1992, TRANSFUSION, V32, P408, DOI 10.1046/j.1537-2995.1992.32592327712.x; FARCI P, 1991, NEW ENGL J MED, V325, P98, DOI 10.1056/NEJM199107113250205; GIOVANNINI M, 1990, LANCET, V335, P1166, DOI 10.1016/0140-6736(90)91174-9; HESS G, 1989, LANCET, V2, P987; KORETZ RL, 1985, GASTROENTEROLOGY, V88, P1251, DOI 10.1016/S0016-5085(85)80087-1; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; LAQUAGLIA MP, 1981, TRANSPLANTATION, V32, P504, DOI 10.1097/00007890-198112000-00011; MAHONY JF, 1989, TRANSPLANT P, V21, P1433; PEREIRA BJG, 1991, NEW ENGL J MED, V325, P454, DOI 10.1056/NEJM199108153250702; PEREIRA BJG, 1992, 11 ANN M AM SOC TRAN, P322; PEREZROMERO M, 1990, ANN INTERN MED, V113, P411, DOI 10.7326/0003-4819-113-5-411; PIRSCH JD, 1992, NEW ENGL J MED, V326, P412; RAKELA J, 1979, GASTROENTEROLOGY, V77, P1200; REALDI G, 1982, GUT, V23, P270, DOI 10.1136/gut.23.4.270; RIESTRA S, 1990, ANN INTERN MED, V113, P411; ROTH D, 1991, Journal of the American Society of Nephrology, V2, P815; WARE AJ, 1979, ANN INTERN MED, V91, P364, DOI 10.7326/0003-4819-91-3-364; WARNOCK LG, 1974, CLIN CHEM, V20, P1213; WEIR MR, 1985, KIDNEY INT, V28, P839, DOI 10.1038/ki.1985.206; WOLF PL, 1972, CLIN CHEM, V18, P567; 1991, MMWR MORB MORTAL W S, V40, P1	32	235	236	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 24	1992	327	13					910	915		10.1056/NEJM199209243271302	http://dx.doi.org/10.1056/NEJM199209243271302			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JP014	1325035				2022-12-01	WOS:A1992JP01400002
J	SEUBERT, P; VIGOPELFREY, C; ESCH, F; LEE, M; DOVEY, H; DAVIS, D; SINHA, S; SCHLOSSMACHER, M; WHALEY, J; SWINDLEHURST, C; MCCORMACK, R; WOLFERT, R; SELKOE, D; LIEBERBURG, I; SCHENK, D				SEUBERT, P; VIGOPELFREY, C; ESCH, F; LEE, M; DOVEY, H; DAVIS, D; SINHA, S; SCHLOSSMACHER, M; WHALEY, J; SWINDLEHURST, C; MCCORMACK, R; WOLFERT, R; SELKOE, D; LIEBERBURG, I; SCHENK, D			ISOLATION AND QUANTIFICATION OF SOLUBLE ALZHEIMERS BETA-PEPTIDE FROM BIOLOGICAL-FLUIDS	NATURE			English	Article							AMYLOID PRECURSOR PROTEIN; DISEASE; MUTATION; GENE; CLEAVAGE; CELLS	CEREBRAL deposition of the beta-amyloid peptide (A-beta) is an invariant feature of Alzheimer's disease. Since the original isolation and characterization of A-beta (ref. 1) and the subsequent cloning of its precursor protein2-5, no direct evidence for the actual production of discrete A-beta has been reported6-11. Here we investigate whether A-beta is present in human biological fluids using antibodies specific for an epitope within A-beta that spans the site of normal constitutive cleavage12,13. These antibodies were used to construct a sandwich-type enzyme-linked immunosorbent assay that detects A-beta in cerebrospinal fluid, plasma and conditioned medium of human mixed-brain cells grown in vitro (see also ref. 14). By affinity chromatography, we have purified and sequenced A-beta and a novel A-beta fragment from human cerebrospinal fluid and conditioned medium of human mixed-brain cell cultures. These findings demonstrate that A-beta is produced and released both in vivo and in vitro. These observations offer new opportunities for developing diagnostic tests for Alzheimer's disease and therapeutic strategies aimed at reducing the cerebral deposition of A-beta.	ATHENA NEUROSCI INC, 800F GATEWAY BLVD, San Francisco, CA 94080 USA; HARVARD UNIV, SCH MED, DEPT NEUROL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, PROGRAM NEUROSCI, BOSTON, MA 02115 USA; HYBRITECH INC, SAN DIEGO, CA 92196 USA; BRIGHAM & WOMENS HOSP, CTR NEUROL DIS, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital				Schlossmacher, Michael/0000-0002-0394-0300				ANDERSON JP, 1991, NEUROSCI LETT, V128, P126, DOI 10.1016/0304-3940(91)90775-O; BUXBAUM JD, 1990, P NATL ACAD SCI USA, V87, P6003, DOI 10.1073/pnas.87.15.6003; CHARTIERHARLIN MC, 1991, NATURE, V353, P844, DOI 10.1038/353844a0; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; ESTUS S, 1992, SCIENCE, V255, P726, DOI 10.1126/science.1738846; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HILBICH C, 1991, J MOL BIOL, V218, P149, DOI 10.1016/0022-2836(91)90881-6; HYMAN BT, 1992, J NEUROPATH EXP NEUR, V51, P76, DOI 10.1097/00005072-199201000-00009; JOACHIM CL, 1988, BRAIN RES, V474, P100, DOI 10.1016/0006-8993(88)90673-7; JOHNSTONE EM, 1991, MOL BRAIN RES, V10, P299, DOI 10.1016/0169-328X(91)90088-F; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; LEVY E, 1990, SCIENCE, V248, P1124, DOI 10.1126/science.2111584; MORI H, 1992, J BIOL CHEM, V267, P17082; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; NORDSTEDT C, 1991, P NATL ACAD SCI USA, V88, P8910, DOI 10.1073/pnas.88.20.8910; OI VT, 1990, METHODS CELLULAR IMM; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; PRELLI F, 1988, J NEUROCHEM, V51, P648, DOI 10.1111/j.1471-4159.1988.tb01087.x; TAMAOKA A, 1992, P NATL ACAD SCI USA, V89, P1345, DOI 10.1073/pnas.89.4.1345; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; WANG RW, 1984, J IMMUNOL METHODS, V18, P157; ZAGORSKI MG, 1992, BIOCHEMISTRY-US, V31, P5621, DOI 10.1021/bi00139a028	27	1638	1790	1	87	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 24	1992	359	6393					325	327		10.1038/359325a0	http://dx.doi.org/10.1038/359325a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JP503	1406936				2022-12-01	WOS:A1992JP50300058
J	TATSUKA, M; MITSUI, H; WADA, M; NAGATA, A; NOJIMA, H; OKAYAMA, H				TATSUKA, M; MITSUI, H; WADA, M; NAGATA, A; NOJIMA, H; OKAYAMA, H			ELONGATION FACTOR-1-ALPHA GENE DETERMINES SUSCEPTIBILITY TO TRANSFORMATION	NATURE			English	Article							NEOPLASTIC TRANSFORMATION; GROWTH-FACTOR; CELLS; PROTEIN; LINE	ELONGATION factor-1-alpha (EF-1-alpha), an essential component of the eukaryotic translational apparatus, is a GTP-binding protein that catalyses the binding of aminoacyl-transfer RNAs to the ribosome1-3. Expression of the EF-1-alpha gene decreases towards the end of the lifespans of mouse and human fibroblasts4,5, but forced expression of EF-1-alpha prolongs the lifespan of Drosophila melanogaster6. Eukaryotic initiation factor-4E, another component of the translational machinery, is mitogenic or oncogenic when constitutively expressed in some mammalian cells7-9. Thus, components of the protein synthesis apparatus seem to be involved in the control of cell proliferation. Using expression cloning, we have isolated a complementary DNA clone from a BALB/c 3T3 mouse fibroblast variant, A31-I-13 (ref. 10), which specifies a factor determining the susceptibility of BALB/c 3T3 to chemically and physically induced transformation. Here we report that the factor is EF-1-alpha and that its constitutive expression causes BALB/c 3T3 A31-I-1 (ref. 10), C3H10T1/2 (ref. 11) and Syrian hamster SHOK12 fibroblasts to become highly susceptible to transformation induced by 3-methylcholanthrene and ultraviolet light. EF-1-alpha messenger RNA is also constitutively expressed in a quiescent culture of the highly susceptible variant A31-I-13. We conclude that the removal of regulation of the expression of these components of the translational machinery may predispose cells to become more susceptible to malignant transformation.	OSAKA UNIV,MICROBIAL DIS RES INST,DEPT MOLEC GENET,SUITA,OSAKA 565,JAPAN; KYOTO PHARMACEUT UNIV,INST MOLEC & CELLULAR BIOL PHARMACEUT SCI,DEPT MOLEC BIOREGULAT,KYOTO 607,JAPAN	Osaka University; Kyoto Pharmaceutical University								AUSABEL FM, 1987, CURRENT PROTOCOLS MO; BENEDETTI AD, 1990, P NATL ACAD SCI USA, V87, P8212; BOCKUS BJ, 1984, EXP CELL RES, V153, P186, DOI 10.1016/0014-4827(84)90460-9; BREITMAN ML, 1982, MOL CELL BIOL, V2, P966, DOI 10.1128/MCB.2.8.966; CAVALLIUS J, 1986, EXP GERONTOL, V21, P149, DOI 10.1016/0531-5565(86)90068-9; CHEM C, 1987, MOL CELL BIOL, V7, P2745; CURRAN T, 1982, J VIROL, V44, P672; HERMAN B, 1985, J CELL BIOL, V100, P1031, DOI 10.1083/jcb.100.4.1031; HERSHEY JWB, 1980, BIOL COMPREHENSIVE T, V4; HIGASHI T, 1990, P NATL ACAD SCI USA, V87, P2409, DOI 10.1073/pnas.87.7.2409; HIRAKAWA T, 1982, SCIENCE, V216, P527, DOI 10.1126/science.6280280; KAKUNAGA T, 1980, SCIENCE, V209, P505, DOI 10.1126/science.7394516; Kakunaga T., 1985, IARC SCI PUBLICATION, V67; KARIRO T, 1978, BIOCHIM BIOPHYS ACTA, V505, P95; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; LO KY, 1982, CANCER RES, V42, P2644; LU X, 1989, Nucleic Acids Research, V17, P442, DOI 10.1093/nar/17.1.442; MOLDAVE K, 1985, ANNU REV BIOCHEM, V54, P1109, DOI 10.1146/annurev.bi.54.070185.005333; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; REZNIKOFF CA, 1973, CANCER RES, V33, P3231; SHEPHERD JCW, 1989, P NATL ACAD SCI USA, V86, P7520, DOI 10.1073/pnas.86.19.7520; SMITH M R, 1990, New Biologist, V2, P648; TANIGUCHI S, 1991, NUCLEIC ACIDS RES, V19, P6949, DOI 10.1093/nar/19.24.6949; TATAUKA M, 1992, CANCER RES, V52, P4232; TATSUKA M, 1989, J CELL PHYSIOL, V139, P18, DOI 10.1002/jcp.1041390104; TATSUKA M, 1988, EXP CELL RES, V178, P154, DOI 10.1016/0014-4827(88)90386-2; WEBSTER GC, 1985, MOL BIOL AGING GENE, P263; YAGI T, 1989, MOL CARCINOGEN, V1, P222, DOI 10.1002/mc.2940010404; YAMASAKI H, 1985, CANCER RES, V45, P637; YANG F, 1990, NATURE, V347, P494, DOI 10.1038/347494a0	30	155	163	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 24	1992	359	6393					333	336		10.1038/359333a0	http://dx.doi.org/10.1038/359333a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JP503	1383827				2022-12-01	WOS:A1992JP50300061
J	ZHENG, XM; WANG, Y; PALLEN, CJ				ZHENG, XM; WANG, Y; PALLEN, CJ			CELL-TRANSFORMATION AND ACTIVATION OF PP60(C-SRC) BY OVEREXPRESSION OF A PROTEIN TYROSINE PHOSPHATASE	NATURE			English	Article							MITOTIC ACTIVATION; PP60C-SRC; KINASE; PHOSPHORYLATION; MITOSIS; GENE; DEPHOSPHORYLATION; EXPRESSION; P60C-SRC; CLONING	THE kinase activity of pp60c-src is specifically and transiently increased during mitosis and repressed during interphase1. Loss of cell-cycle control of pp60c-src occurs on mutation of Tyr 527 to Phe or when pp60c-src is associated with polyoma middle-T-antigen, and these conditions result in cell transformation or tumorigenesis2,3. In both cases, pp60c-src has elevated kinase activity which is maintained throughout the cell cycle and accompanied by dephosphorylation of the carboxy-terminal negative regulatory4-7 Tyr 527 site, or mimicry of Tyr 527 dephosphorylation in the case of the mutant. Here we report that overexpression of the receptor-like protein tyrosine phosphatase PTP-alpha-8-10 results in persistent activation of pp60c-src kinase, with concomitant cell transformation and tumorigenesis. In PTP-alpha-overexpressing cells the pp60c-src kinase activation is accompanied by dephosphorylation at Tyr 527, and direct dephosphorylation of this site by purified PTP-alpha occurs in vitro. Our results suggest that PTP-alpha is involved in the regulation of cell proliferation, exerting at least some of its effects through pp60c-src kinase, and has oncogenic capability when overexpressed.	NATL UNIV SINGAPORE,INST MOLEC & CELL BIOL,CELL REGULAT LAB,10 KENT RIDGE CRESCENT,SINGAPORE 0511,SINGAPORE	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore			Wang, Yue/H-2107-2011; Wang, Yue/AGN-6053-2022	Wang, Yue/0000-0002-1211-2822; Pallen, Catherine/0000-0002-3576-5295				AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; BAGRODIA S, 1991, NATURE, V349, P172, DOI 10.1038/349172a0; BOLEN JB, 1987, ONCOGENE RES, V1, P149; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COTTON PC, 1983, MOL CELL BIOL, V3, P1157, DOI 10.1128/MCB.3.6.1157; COURTNEIDGE SA, 1980, P NATL ACAD SCI-BIOL, V77, P3783, DOI 10.1073/pnas.77.7.3783; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRUEGER NX, 1990, EMBO J, V9, P3241; KAECH S, 1991, NATURE, V350, P431, DOI 10.1038/350431a0; KAWAKAMI T, 1988, P NATL ACAD SCI USA, V85, P3870, DOI 10.1073/pnas.85.11.3870; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; LAFORGIA S, 1991, P NATL ACAD SCI USA, V88, P5036, DOI 10.1073/pnas.88.11.5036; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MATTHEWS RJ, 1990, P NATL ACAD SCI USA, V87, P4444, DOI 10.1073/pnas.87.12.4444; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OKADA M, 1989, J BIOL CHEM, V264, P20886; PARKER RC, 1984, CELL, V37, P131, DOI 10.1016/0092-8674(84)90308-8; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; SAP J, 1990, P NATL ACAD SCI USA, V87, P6112, DOI 10.1073/pnas.87.16.6112; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; WANG Y, 1991, EMBO J, V10, P3231, DOI 10.1002/j.1460-2075.1991.tb04886.x; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G	30	437	462	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 24	1992	359	6393					336	339		10.1038/359336a0	http://dx.doi.org/10.1038/359336a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JP503	1383828				2022-12-01	WOS:A1992JP50300062
J	FRANK, E; WINKLEBY, MA; FORTMANN, SP; ROCKHILL, B; FARQUHAR, JW				FRANK, E; WINKLEBY, MA; FORTMANN, SP; ROCKHILL, B; FARQUHAR, JW			IMPROVED CHOLESTEROL-RELATED KNOWLEDGE AND BEHAVIOR AND PLASMA-CHOLESTEROL LEVELS IN ADULTS DURING THE 1980S	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							STANFORD 5-CITY PROJECT; COMMUNITY-HEALTH EDUCATION; 2 NATIONAL SURVEYS; HEART-DISEASE; RISK-FACTORS; SOCIAL-CLASS; PERSPECTIVE; PHYSICIAN	Objectives.-To determine whether cholesterol-related knowledge and behavior and plasma cholesterol levels were stable until the inception of large-scale national interventions in the middle to late 1980s, whether they subsequently improved, and whether these levels varied by subgroups. Design, Setting, and Participants.-Data were collected from 4173 adults aged 25 through 74 years in the two control cities (San Luis Obispo and Modesto, Calif) of the Stanford Five-City Project. Five separate, community-based surveys were conducted in 1979-1980, 1981-1982, 1983-1984, 1985-1986, and 1989-1990. Results.-Cholesterol-related knowledge and behavior and plasma cholesterol levels improved (P=.0001) in both cities after the early 1980s. Those who were more educated, female, older, or nonsmokers had significantly higher knowledge and behavior scores, and those who were younger, more educated, or normotensive had significantly lower plasma cholesterol levels. Conclusion.-Improvements in this population's cholesterol-related knowledge and behavior and plasma cholesterol levels began in 1985-1986, suggesting that the extensive cholesterol interventions that began in the middle 1980s in the United States created positive cholesterol-related changes at the community level.	STANFORD UNIV, SCH MED, STANFORD CTR RES DIS PREVENT, 1000 WELCH RD, PALO ALTO, CA 94304 USA; STANFORD UNIV, SCH MED, DEPT MED, PALO ALTO, CA 94304 USA	Stanford University; Stanford University				Frank, Erica/0000-0001-7159-5417	NHLBI NIH HHS [5T32-HL-07034, 1R01-HL-21906] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007034, R01HL021906] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERNSTEIN MJ, 1985, JAMA-J AM MED ASSOC, V253, P2080; BURKE GL, 1991, NEW ENGL J MED, V324, P941, DOI 10.1056/NEJM199104043241402; CLEEMAN JI, 1988, ARCH INTERN MED, V148, P36, DOI 10.1001/archinte.148.1.36; FARQUHAR JW, 1985, AM J EPIDEMIOL, V122, P323, DOI 10.1093/oxfordjournals.aje.a114104; FARQUHAR JW, 1990, JAMA-J AM MED ASSOC, V264, P359, DOI 10.1001/jama.264.3.359; FORTMANN SP, 1990, AM J EPIDEMIOL, V132, P629, DOI 10.1093/oxfordjournals.aje.a115705; LENFANT C, 1986, CIRCULATION, V73, P855, DOI 10.1161/01.CIR.73.5.855; LIBERATOS P, 1988, EPIDEMIOL REV, V10, P87, DOI 10.1093/oxfordjournals.epirev.a036030; McKibben B., 1989, END NATURE; NIKNIAN M, 1991, AM J PUBLIC HEALTH, V81, P203, DOI 10.2105/AJPH.81.2.205; Olien C. N., 1983, MASS COMMUNICATION R, V4, P455; RIFKIN J, 1992, BEEF RISE FALL CATTL; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P365; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; SCHUCKER B, 1987, JAMA-J AM MED ASSOC, V258, P3527, DOI 10.1001/jama.258.24.3527; SCHUCKER B, 1991, ARCH INTERN MED, V151, P666, DOI 10.1001/archinte.151.4.666; SCHUCKER B, 1987, JAMA-J AM MED ASSOC, V258, P3521, DOI 10.1001/jama.258.24.3521; TAYLOR CB, 1991, AM J EPIDEMIOL, V134, P235, DOI 10.1093/oxfordjournals.aje.a116077; WILLIAMS F, 1977, J COMMUN, V27, P95, DOI 10.1111/j.1460-2466.1977.tb01803.x; WINKLEBY MA, 1990, PREV MED, V19, P1, DOI 10.1016/0091-7435(90)90001-Z; WINKLEBY MA, 1992, AM J PUBLIC HEALTH, V82, P816, DOI 10.2105/AJPH.82.6.816; WINKLEBY MA, IN PRESS HISP J BEHA; 1974, US DHEW NIH75628 PUB, P1	23	44	44	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 23	1992	268	12					1566	1572		10.1001/jama.268.12.1566	http://dx.doi.org/10.1001/jama.268.12.1566			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN256	1518111				2022-12-01	WOS:A1992JN25600027
J	JOHNSON, E				JOHNSON, E			EVIDENCE OF SUBSTANCE-ABUSE FOUND WITH POSTTRAUMATIC-STRESS-DISORDER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											JOHNSON, E (corresponding author), US ALCOHOL DRUG ABUSE & MENTAL HLTH ADM,ROCKVILLE,MD 20857, USA.							COTTLER LB, 1992, AM J PSYCHIAT, V149, P664	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 23	1992	268	12					1518	1518						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN256	1325568				2022-12-01	WOS:A1992JN25600006
J	JOHNSON, E				JOHNSON, E			MEMORY CIRCUIT AND SCHIZOPHRENIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											JOHNSON, E (corresponding author), US ALCOHOL DRUG ABUSE & MENTAL HLTH ADM,ROCKVILLE,MD 20857, USA.							1992, AM J PSYCHIAT, V149, P890	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 23	1992	268	12					1518	1518						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN256	1325568				2022-12-01	WOS:A1992JN25600007
J	JOHNSON, E				JOHNSON, E			RECALL OF DRINKING PATTERNS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											JOHNSON, E (corresponding author), US ALCOHOL DRUG ABUSE & MENTAL HLTH ADM,ROCKVILLE,MD 20857, USA.							GLADSJO JA, 1992, ADDICT BEHAV, V17, P347, DOI 10.1016/0306-4603(92)90040-3	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 23	1992	268	12					1518	1518						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN256	1325568				2022-12-01	WOS:A1992JN25600005
J	MACKOWIAK, PA; WASSERMAN, SS; LEVINE, MM				MACKOWIAK, PA; WASSERMAN, SS; LEVINE, MM			A CRITICAL-APPRAISAL OF 98.6-DEGREES-F, THE UPPER LIMIT OF THE NORMAL BODY-TEMPERATURE, AND OTHER LEGACIES OF WUNDERLICH,CARL,REINHOLD,AUGUST	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note								Objective.-To evaluate critically Carl Wundedich's axioms on clinical thermometry. Design.-Descriptive analysis of baseline oral temperature data from volunteers participating in Shigella vaccine trials conducted at the University of Maryland Center for Vaccine Development, Baltimore. Setting.-Inpatient clinical research unit. Participants.-One hundred forty-eight healthy men and women aged 18 through 40 years. Main Measurements.-Oral temperatures were measured one to four times daily for 3 consecutive days using an electronic digital thermometer. Results.-Our findings conflicted with Wunderlich's in that 36.8-degrees-C (98.2-degrees-F) rather than 37.0-degrees-C (98.6-degrees-F) was the mean oral temperature of our subjects; 37.7-degrees-C (99.9-degrees-F) rather than 38.0-degrees-C (100.4-degrees-F) was the upper limit of the normal temperature range; maximum temperatures, like mean temperatures, varied with time of day; and men and women exhibited comparable thermal variability. Our data corroborated Wunderlich's in that mean temperature varied diurnally, with a 6 AM nadir, a 4 to 6 PM zenith, and a mean amplitude of variability of 0.5-degrees-C (0.9-degrees-F); women had slightly higher normal temperatures than men; and there was a trend toward higher temperatures among black than among white subjects. Conclusions.-Thirty-seven degrees centigrade (98.6-degrees-F) should be abandoned as a concept relevant to clinical thermometry; 37.2-degrees-C (98.9-degrees-F) in the early morning and 37.7-degrees-C (99.9-degrees-F) overall should be regarded as the upper limit of the normal oral temperature range in healthy adults aged 40 years or younger, and several of Wundedich's other cherished dictums should be revised.	UNIV MARYLAND,SCH MED,CTR VACCINE DEV,BALTIMORE,MD 21218; UNIV MARYLAND,SCH MED,DEPT MED,BALTIMORE,MD 21218	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	MACKOWIAK, PA (corresponding author), UNIV MARYLAND,VET AFFAIRS MED CTR,SCH MED,MED SERV 111,3900 LOCH RAVEN BLVD,BALTIMORE,MD 21218, USA.							[Anonymous], 1871, MED THERMOMETRY HUMA; Beutler B, 1992, CECIL TXB MED, P1568; BRENGELMANN GL, 1989, TXB PHYSL, P1584; DINARELLO CA, 1978, NEW ENGL J MED, V298, P607, DOI 10.1056/NEJM197803162981107; DINARELLO CA, 1990, PRINCIPLES PRACTICE, P462; Dominguez E, 1991, FEVER BASIC MECH MAN, P71; GARRISON FH, 1929, INTRO HIST MED, P757; GUYTON AC, 1991, TXB MED PHYSL, P6; HENSYL WR, 1990, STEDMANS MED DICT, P574; HORVATH STEVEN M., 1950, JOUR AMER MED ASSOC, V144, P1562; IVY AC, 1944, B NW U MED SCH, V18, P22; Linder F.E., 1935, HUM BIOL, V7, P24; PETERSDORF RG, 1991, HARRISONS PRINCIPLES, P2194; TANNER JM, 1951, J PHYSIOL-LONDON, V115, P391, DOI 10.1113/jphysiol.1951.sp004677; TAUBER MG, 1990, INTERNAL MED, P1240; THOMAS CL, 1989, TABERS CYCLOPEDIC ME, P665; Whiting MH, 1915, BIOMETRIKA, V11, P1; Wunderlich C.A., 1869, AM J MED SCI, V57, P425, DOI DOI 10.1097/00000441-186904000-00021; WUNDERLICH CA, 1871, TEMPERATURE DISEASES, P71; Wunderlich CA, 1868, VERHALTEN EIAENWARME; 1982, HLTH DEVICES, V12, P3	21	328	333	1	28	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 23	1992	268	12					1578	1580		10.1001/jama.268.12.1578	http://dx.doi.org/10.1001/jama.268.12.1578			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN256	1302471				2022-12-01	WOS:A1992JN25600029
J	ALBERTI, A; MORSICA, G; CHEMELLO, L; CAVALLETTO, D; NOVENTA, F; PONTISSO, P; RUOL, A				ALBERTI, A; MORSICA, G; CHEMELLO, L; CAVALLETTO, D; NOVENTA, F; PONTISSO, P; RUOL, A			HEPATITIS-C VIREMIA AND LIVER-DISEASE IN SYMPTOM-FREE INDIVIDUALS WITH ANTI-HCV	LANCET			English	Note							NON-B-HEPATITIS; NON-A; BLOOD-DONORS; VIRUS; ANTIBODIES; GENOME	There is controversy about clinical management of patients who persistently have antibodies to hepatitis C virus (anti-HCV) but who have no symptoms and signs of liver disease. We have taken liver biopsy samples from 23 such patients (1 6 of whom had normal alanine aminotransferase [ALT] values) to assess prevalence of liver disease and to see whether anti-HCV and HCV-RNA correlated with histological findings. 16 patients had histological evidence of chronic hepatitis, which was not predicted by serum ALT or by the pattern of specificity of anti-HCV. All 16 cases with hepatitis C viraemia (HCV-RNA detected by polymerase chain reaction), including 9 with normal ALT, had chronic hepatitis on biopsy (p<0.001), whereas 7 HCV-RNA-negative cases had normal liver histology. These findings indicate that serum HCV-RNA is a sensitive and specific marker of liver disease in anti-HCV-positive subjects, independent of ALT values, and challenge the idea of the existence of "true" healthy carriers of HCV.	UNIV PADUA,DEPT INTERNAL MED 2,I-35100 PADUA,ITALY	University of Padua			chemello, liliana/AAU-9414-2020; Morsica, Giulia/AAC-4993-2019; Noventa, Franco/C-1202-2008; PONTISSO, PATRIZIA/K-3574-2018	Morsica, Giulia/0000-0003-4891-5376; Noventa, Franco/0000-0003-4622-5523; ALBERTI, ALFREDO/0000-0001-9926-2382; PONTISSO, PATRIZIA/0000-0003-2077-9202				AACH RD, 1991, NEW ENGL J MED, V325, P1325, DOI 10.1056/NEJM199111073251901; ALBERTI A, 1991, ANN INTERN MED, V114, P1010, DOI 10.7326/0003-4819-114-12-1010; ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; [Anonymous], 1977, Lancet, V2, P914; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; DAVIS GL, 1989, NEW ENGL J MED, V321, P1501, DOI 10.1056/NEJM198911303212203; ESTEBAN JI, 1991, ANN INTERN MED, V115, P443, DOI 10.7326/0003-4819-115-6-443; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; OKAMOTO H, 1990, JPN J EXP MED, V60, P167	9	423	422	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 19	1992	340	8821					697	698		10.1016/0140-6736(92)92234-7	http://dx.doi.org/10.1016/0140-6736(92)92234-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN780	1355801				2022-12-01	WOS:A1992JN78000006
J	BERGMAN, U; ROSA, FW; BAUM, C; WIHOLM, BE; FAICH, GA				BERGMAN, U; ROSA, FW; BAUM, C; WIHOLM, BE; FAICH, GA			EFFECTS OF EXPOSURE TO BENZODIAZEPINE DURING FETAL LIFE	LANCET			English	Article							PREGNANCY; INUTERO	Dysmorphism and mental retardation have been reported in 7 Swedish children born of mothers who had taken high doses of benzodiazepines regularly during pregnancy. To explore this association further, we examined benzodiazepine use during pregnancy in 104 000 women whose deliveries were registered by the US public health insurance system, Medicaid, during 1980-83. Fetal outcomes were assessed from the health claims profiles of their offspring, up to 6-9 years after delivery. 80 pregnant women had received 10 or more benzodiazepine prescriptions during the 4 years. Their records showed heavy general use of health care and frequent alcohol and substance abuse, and other disorders that could confound any effect of the benzodiazepines. For the 80 pregnancies, 3 intrauterine deaths were identified as well as 2 infants with congenital abnormalities whose curtailed records suggested neonatal death. Records of 64 surviving children could be linked to these 80 pregnancies whilst records for 11 apparent survivors could not be located. 6 of the 64 survivors had diagnoses consistent with teratogenic abnormalities. The high rate of teratogenicity after heavy maternal benzodiazepine use occurs with multiple alcohol and substance exposure and thus may not be due to benzodiazepine exposure.	US FDA, OFF EPIDEMIOL & BIOSTAT, ROCKVILLE, MD 20857 USA; MED PROD AGCY, UPPSALA, SWEDEN	US Food & Drug Administration (FDA); Medical Products Agency	BERGMAN, U (corresponding author), KAROLINSKA INST, HUDDINGE HOSP, DEPT CLIN PHARMACOL, S-14186 HUDDINGE, SWEDEN.							BARRY WS, 1987, LANCET, V1, P1436; BERGMAN U, 1990, J PEDIATR-US, V116, P490, DOI 10.1016/S0022-3476(05)82853-7; Bergman U, 1991, Bratisl Lek Listy, V92, P560; DUKES MNG, 1986, SIDE EFFECTS DRUGS A, V10, P50; FAICH GA, 1989, CLIN PHARMACOL THER, V46, P387, DOI 10.1038/clpt.1989.155; LAEGREID L, 1987, LANCET, V2, P1405; LAEGREID L, 1987, LANCET, V1, P108; LAEGREID L, 1989, J PEDIATR-US, V114, P126, DOI 10.1016/S0022-3476(89)80619-5; LAEGREID L, 1992, NEUROPEDIATRICS, V23, P18, DOI 10.1055/s-2008-1071305; NELSON LB, 1987, AM J DIS CHILD, V141, P175, DOI 10.1001/archpedi.1987.04460020065028; OLEGARD R, 1979, ACTA PAEDIATR SCAND, P112; PIPER JM, 1987, AM J OBSTET GYNECOL, V157, P148, DOI 10.1016/S0002-9378(87)80368-X; STROM BL, 1991, STAT MED, V10, P565, DOI 10.1002/sim.4780100408; WEBER LWD, 1985, BIOL RES PREG PERIN, V6, P151; WINTER RM, 1987, LANCET, V1, P627	15	77	77	4	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 19	1992	340	8821					694	696		10.1016/0140-6736(92)92232-5	http://dx.doi.org/10.1016/0140-6736(92)92232-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN780	1355799				2022-12-01	WOS:A1992JN78000004
J	COCHRANE, RA; MANDAL, AR; LEDGERSCOTT, M; WALKER, R				COCHRANE, RA; MANDAL, AR; LEDGERSCOTT, M; WALKER, R			CHANGES IN DRUG-TREATMENT AFTER DISCHARGE FROM HOSPITAL IN GERIATRIC-PATIENTS	BRITISH MEDICAL JOURNAL			English	Article								Objectives-To ascertain changes in drug treatment of elderly patients after discharge from hospital and to identify areas of communication which may require improvement. Design-Follow up of patients six to 14 days after discharge, when the drugs supplied by the hospital should have run out and a further supply obtained from the general practitioner. Patients were also asked about information supplied to them by health care professionals during their hospital stay. Subjects - 50 elderly patients discharged from five geriatric wards (mean age 76.9 years). Setting- Sunderland District Health Authority. Main outcome measure-Drugs taken after discharge from hospital. Results-After returning home the drug regimen of 45 patients differed from that prescribed on discharge from hospital, with 11 patients taking a different dose, 10 having stopped drugs, and 20 taking new drugs. Possible influencing factors included an incomplete drug history, the continuation of drugs taken before hospital admission, and changes in the prescription not attributable to a conscious clinical decision. Lack of information also contributed; 46 patients could not recall being told when to take drugs before discharge. Conclusion-Closer communication is needed between hospital and community health care professionals to ensure that patients are informed about their discharge prescription and continuation of treatment.	SUNDERLAND DIST GEN HOSP,SUNDERLAND SR4 7TP,ENGLAND; ROYAL INFIRM,SUNDERLAND SR2 7JE,ENGLAND; SUNDERLAND POLYTECH,SCH PHARMACEUT & CHEM SCI,SUNDERLAND SR2 7EE,DURHAM,ENGLAND	Sunderland Royal Hospital; University of Sunderland								Davidson J R, 1974, Nurs Times, V70, P391; Hatch A M, 1982, Nurs Times, V78, P1773; MACDONALD ET, 1977, BMJ-BRIT MED J, V2, P618, DOI 10.1136/bmj.2.6087.618; MOTTRAM DR, 1989, PHARM J, V243, P458; PARKIN DM, 1976, BMJ-BRIT MED J, V2, P686, DOI 10.1136/bmj.2.6037.686; Sweeney SJ, 1989, PHARM J, V242; WALKER CA, 1987, BRIT J PHARM PRACTIC, V9, P47; WINFIELD AJ, 1990, BR J PHARM PRACT, V12, P206	8	86	89	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 19	1992	305	6855					694	696		10.1136/bmj.305.6855.694	http://dx.doi.org/10.1136/bmj.305.6855.694			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JP511	1393119	Bronze, Green Submitted, Green Published			2022-12-01	WOS:A1992JP51100028
J	COUTURIER, E; BROSSARD, Y; LARSEN, C; LARSEN, M; DUMAZAUBRUN, C; PARISLLADO, J; GILLOT, R; HENRION, R; BREART, G; BRUNET, JB				COUTURIER, E; BROSSARD, Y; LARSEN, C; LARSEN, M; DUMAZAUBRUN, C; PARISLLADO, J; GILLOT, R; HENRION, R; BREART, G; BRUNET, JB			HIV-INFECTION AT OUTCOME OF PREGNANCY IN THE PARIS AREA, FRANCE	LANCET			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; PREVALENCE; NEWBORNS; WOMEN	The prevalence of H IV infection in women at end of pregnancy, irrespective of outcome, was determined in a comprehensive survey of both women and medical centres during successive 4-week periods in four areas of the Paris region, France. Blood samples were tested anonymously for antibodies to human immunodeficiency virus (HIV)-1 and HIV-2. Of the 11 593 blood samples 0.40% (95% confidence interval [CI] 0.28-0.51) were positive for HIV-1 and 0-02% (95% binomial interval [BI] 0.002-0.065) for HIV-2. Seroprevalence was higher among women with ectopic pregnancy (2%) (95% BI 0.24-7.04); the rate in women having an elective or therapeutic abortion was more than twice that in those delivering babies (0.70% vs O.28%, p<0.05, relative risk 2.54, 95% CI 1.36-4.75). Studies with neonatal HIV seroprevalence as a surrogate for HIV prevalence in pregnant women would underestimate prevalence in these women.	CLIN UNIV PORT ROYAL,PARIS,FRANCE; HOP ST ANTOINE,CTR PERINATOL HAEMATOL,F-75571 PARIS 12,FRANCE; INSERM,U149,F-75005 PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm)	COUTURIER, E (corresponding author), HOP NATL ST MAURICE,EUROPEAN CTR EPIDEMIOL MONITORING AIDS,14 RUE VAL DOSNE,F-94410 ST MAURICE,FRANCE.							ADES AE, 1991, LANCET, V337, P1562, DOI 10.1016/0140-6736(91)93260-G; FAUR B, 1985, COLLECTIONS INSEE D, V106, P109; HOFF R, 1988, NEW ENGL J MED, V318, P525, DOI 10.1056/NEJM198803033180901; IPPOLITO G, 1991, J ACQ IMMUN DEF SYND, V4, P402; SELWYN PA, 1989, JAMA-J AM MED ASSOC, V261, P1289, DOI 10.1001/jama.261.9.1289; TAPPIN DM, 1991, LANCET, V337, P1565; 1991, B EPIDEMIOL HEBDOMAD, V32, P131; 1991, LANCET, V337, P253	8	26	27	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 19	1992	340	8821					707	709		10.1016/0140-6736(92)92241-7	http://dx.doi.org/10.1016/0140-6736(92)92241-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN780	1355808				2022-12-01	WOS:A1992JN78000013
J	ESMAIL, A; ANDERSON, HR; RAMSEY, JD; TAYLOR, J; POTTIER, A				ESMAIL, A; ANDERSON, HR; RAMSEY, JD; TAYLOR, J; POTTIER, A			CONTROLLING DEATHS FROM VOLATILE SUBSTANCE-ABUSE IN UNDER 18S - THE EFFECTS OF LEGISLATION	BRITISH MEDICAL JOURNAL			English	Article									ST GEORGE HOSP,TOXICOL UNIT,LONDON SW17 0RE,ENGLAND	St Georges University London	ESMAIL, A (corresponding author), ST GEORGE HOSP,SCH MED,DEPT PUBL HLTH SCI,LONDON SW17 0RE,ENGLAND.		Esmail, Aneez/I-6903-2013					ANDERSON HR, 1985, BRIT MED J, V290, P304, DOI 10.1136/bmj.290.6464.304; FLANAGAN RJ, 1990, DRUG SAFETY, V5, P359, DOI 10.2165/00002018-199005050-00005; LISS BI, 1989, HUM TOXICOL, V8, P327, DOI 10.1177/096032718900800413; WRIGHT SP, 1991, TRENDS DEATHS ASS AB; 1986, GENERALISED LINEAR I	5	21	21	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 19	1992	305	6855					692	692		10.1136/bmj.305.6855.692	http://dx.doi.org/10.1136/bmj.305.6855.692			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JP511	1393114	Green Submitted, Green Published, Bronze			2022-12-01	WOS:A1992JP51100023
J	HARRIS, PL				HARRIS, PL			REDUCING THE MORTALITY FROM ABDOMINAL AORTIC-ANEURYSMS - NEED FOR A NATIONAL SCREENING-PROGRAM	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SURGICAL-TREATMENT; POPULATION				HARRIS, PL (corresponding author), BROADGREEN HOSP, LIVERPOOL L14 3LB, MERSEYSIDE, ENGLAND.							ARMOUR RH, 1977, BRIT MED J, V2, P1055, DOI 10.1136/bmj.2.6094.1055; BARODOI JC, 1991, ANN VASC SURG, V5, P491; BENGTSSON H, 1989, BRIT J SURG, V76, P589, DOI 10.1002/bjs.1800760620; Bengtsson H, 1989, Eur J Vasc Surg, V3, P497, DOI 10.1016/S0950-821X(89)80123-9; BERGQVIST D, 1992, ANN CHIR GYNAECOL FE, V81, P205; BLAMEY RW, 1986, RECENT ADV SURGERY, V12, P29; COLLIN J, 1989, SURG GYNECOL OBSTET, V169, P527; COLLIN J, 1988, LANCET, V2, P613; COLLIN J, 1990, CAUSE MANAGEMENT ANE; COLLIN J, 1989, BMJ-BRIT MED J, V299, P49; ELLIS M, 1991, BRIT J SURG, V78, P614, DOI 10.1002/bjs.1800780529; FOWKES FGR, 1989, BRIT MED J, V298, P33, DOI 10.1136/bmj.298.6665.33; INGOLDBY CJH, 1986, BRIT J SURG, V73, P551, DOI 10.1002/bjs.1800730711; JOHANSSON G, 1986, BRIT J SURG, V73, P101, DOI 10.1002/bjs.1800730205; MCGREGOR JC, 1975, SCOT MED J, V20, P133, DOI 10.1177/003693307502000313; MELTON LJ, 1984, AM J EPIDEMIOL, V120, P379, DOI 10.1093/oxfordjournals.aje.a113902; OKELLY TJ, 1989, BRIT J SURG, V76, P479, DOI 10.1002/bjs.1800760517; POWELL JT, 1990, CLIN SCI, V78, P13, DOI 10.1042/cs0780013; SCOTT RAP, 1986, BRIT J SURG, V73, P318; SCOTT RAP, 1988, BRIT MED J, V296, P1709, DOI 10.1136/bmj.296.6638.1709-a; SMITH FCT, 1992, BRIT J SURG, V79, P358; SZILAGYI DE, 1972, ARCH SURG-CHICAGO, V104, P600; TURK KAD, 1965, P ROY SOC MED, V58, P869, DOI 10.1177/003591576505811P109; 1984, MORTALITY STATISTICS; 1992, HLTH NATION STRATEGY; 1986, ENGLAND WALES MORTAL	26	55	55	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 19	1992	305	6855					697	699		10.1136/bmj.305.6855.697	http://dx.doi.org/10.1136/bmj.305.6855.697			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JP511	1296605	Green Published, Green Submitted, Bronze			2022-12-01	WOS:A1992JP51100029
J	LINDEMANN, F; SCHLIMOK, G; DIRSCHEDL, P; WITTE, J; RIETHMULLER, G				LINDEMANN, F; SCHLIMOK, G; DIRSCHEDL, P; WITTE, J; RIETHMULLER, G			PROGNOSTIC-SIGNIFICANCE OF MICROMETASTATIC TUMOR-CELLS IN BONE-MARROW OF COLORECTAL-CANCER PATIENTS	LANCET			English	Article							LARGE BOWEL-CANCER; MONOCLONAL-ANTIBODIES; MULTIVARIATE-ANALYSIS; MICRO-METASTESES; BREAST-CANCER; RECTAL-CANCER; CARCINOMA; CYTOKERATIN; METASTASES; EXPRESSION	Much of the information recorded at the time of surgery for malignant disease has been used, alone or in combination, to indicate the outlook for that patient, including probability of metastasis. However, direct evidence of tumour seeding in distant organs at that time is not available. An immunocytochemical assay for the epithelial cytokeratin protein (CK18) may fill this gap since it is a feature of epithelial cells but would not normally be in bone marrow. We looked for disseminated tumour cells preoperatively in bone marrow from 88 patients with radically resected colorectal carcinomas. Smears for 28 (32%) patients were positive for cells of epithelial origin, which were absent from aspirates taken from 102 controls with non-malignant disease. The prognostic value was assessed in a follow-up study with a median observation time of 35 (12-58) months. Patients who had bone marrow tumour cells in the aspirate showed a significantly shorter disease-free survival than those without tumour cells (p = 0.0084). In a Cox regression model multivariate analysis demonstrated that the finding of tumour cells in bone marrow is an independent, significant (p = 0.0035) determinant of relapse. Although the skeleton is not a preferred site of overt metastasis in colorectal cancer the demonstration of tumour cells in bone marrow has to be taken as evidence of the general disseminative capability of an individual tumour.	UNIV MUNICH, INST IMMUNOL, W-8000 MUNICH 2, GERMANY; UNIV MUNICH, INST MED INFORMAT BIOMETRY & EPIDEMIOL, W-8000 MUNICH 2, GERMANY; ZENT KLINIKUM, MED CLIN 2, W-8900 AUGSBURG, GERMANY	University of Munich; University of Munich	LINDEMANN, F (corresponding author), ZENT KLINIKUM, ALLGEMEIN & ABDOMINALCHIRURG KLIN, DEPT GEN SURG, STENGLINSTR 2, W-8900 AUGSBURG, GERMANY.							BONNHEIM DC, 1986, AM J SURG, V151, P457, DOI 10.1016/0002-9610(86)90102-9; BURKHARDT R, 1980, B CANCER, V67, P291; CHAPUIS PH, 1985, BRIT J SURG, V72, P698, DOI 10.1002/bjs.1800720909; CORDELL JL, 1984, J HISTOCHEM CYTOCHEM, V32, P219, DOI 10.1177/32.2.6198355; COTE RJ, 1991, J CLIN ONCOL, V9, P1749, DOI 10.1200/JCO.1991.9.10.1749; COX DR, 1972, J R STAT SOC B, V34, P187; DEBUS E, 1984, AM J PATHOL, V114, P121; FIELDING LP, 1986, LANCET, V2, P904; FREEDMAN LS, 1984, LANCET, V2, P733; HERMANEK P, 1989, DIS COLON RECTUM, V32, P593, DOI 10.1007/BF02554180; JASS JR, 1986, HISTOPATHOLOGY, V10, P437, DOI 10.1111/j.1365-2559.1986.tb02497.x; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KILLION JJ, 1989, SEMIN ONCOL, V16, P106; KNAPP AC, 1989, CELL, V59, P67, DOI 10.1016/0092-8674(89)90870-2; MANSI JL, 1987, BRIT MED J, V295, P1093, DOI 10.1136/bmj.295.6606.1093; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; Paget S, 1989, LANCET, V8, P98, DOI DOI 10.1016/S0140-6736(00)49915-0; PANTEL K, 1991, CANCER RES, V51, P4712; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; RIETHMULLER G, 1989, PROGR IMMUNOLOGY, V7, P1079; Schlimok G, 1990, Semin Cancer Biol, V1, P207; SCHLIMOK G, 1987, P NATL ACAD SCI USA, V84, P8672, DOI 10.1073/pnas.84.23.8672; SCHLIMOK G, 1990, J CLIN ONCOL, V8, P831, DOI 10.1200/JCO.1990.8.5.831; SCHLIMOK G, 1985, BLUT, V51, P203; SCHMITZMOORMANN P, 1987, J CANCER RES CLIN, V113, P586, DOI 10.1007/BF00390871; TALBOT RW, 1989, EUR J SURG ONCOL, V15, P449; WEISS L, 1986, J PATHOL, V150, P195, DOI 10.1002/path.1711500308; WELCH JP, 1979, ANN SURG, V189, P496; WIGGERS T, 1988, CANCER, V61, P386, DOI 10.1002/1097-0142(19880115)61:2<386::AID-CNCR2820610231>3.0.CO;2-J; ZETTER BR, 1990, NEW ENGL J MED, V322, P605; 1991, JAMA-J AM MED ASSOC, V264, P1444	31	506	517	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 19	1992	340	8821					685	689		10.1016/0140-6736(92)92230-D	http://dx.doi.org/10.1016/0140-6736(92)92230-D			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN780	1381801				2022-12-01	WOS:A1992JN78000002
J	MCKEITH, I; FAIRBAIRN, A; PERRY, R; THOMPSON, P; PERRY, E				MCKEITH, I; FAIRBAIRN, A; PERRY, R; THOMPSON, P; PERRY, E			NEUROLEPTIC SENSITIVITY IN PATIENTS WITH SENILE DEMENTIA OF LEWY BODY TYPE	BRITISH MEDICAL JOURNAL			English	Article							DISEASE	Objective-To determine the outcome of administration of neuroleptics to patients with senile dementia of Lewy body type confirmed at necropsy. Design-Retrospective analysis of clinical notes blind to neuropathological diagnosis. Setting-Specialist psychogeriatric assessment units referring cases for necropsy to a teaching hospital neuropathology service. Patients-41 elderly patients with diagnosis of either Alzheimer type dementia (n=21) or Lewy body type dementia (n=20) confirmed at necropsy. Main outcome measures-Clinical state including extrapyramidal features before and after neuroleptic treatment and survival analysis of patients showing severe neuroleptic sensitivity compared with the remainder in the group. Results-16 (80%) patients with Lewy body type dementia received neuroleptics, 13 (81%) of whom reacted adversely; in seven (54%) the reactions were severe. Survival analysis showed an increased mortality in the year after presentation to psychiatric services compared with patients with mild or no neuroleptic sensitivity (hazard ratio 2.70 (95% confidence interval 2.50-8.99); (chi-2=2.68, p=0.05). By contrast, only one (7%) of 14 patients with Alzheimer type dementia given neuroleptics showed severe neuroleptic sensitivity. Conclusions-Severe, and often fatal, neuroleptic sensitivity may occur in elderly patients with confusion, dementia, or behavioural disturbance. Its occurrence may indicate senile dementia of Lewy body type and this feature has been included in clinical diagnostic criteria for this type of dementia.	GATESHEAD MENTAL HLTH UNIT,OLD AGE PSYCHIAT,GATESHEAD,ENGLAND; NEWCASTLE GEN HOSP,MRC,NEUROCHEM PATHOL UNIT,NEWCASTLE TYNE NE4 6BE,TYNE & WEAR,ENGLAND	Newcastle General Hospital	MCKEITH, I (corresponding author), NEWCASTLE GEN HOSP,OLD AGE PSYCHIAT,NEWCASTLE TYNE NE4 6BE,TYNE & WEAR,ENGLAND.		McKeith, Ian/AAH-3382-2021	McKeith, Ian/0000-0002-9250-0568				ADOZZONIZIO G, 1991, INT J GERIATRIC PSYC, V6, P547; GILLEARD CJ, 1983, ACTA PSYCHIAT SCAND, V68, P419, DOI 10.1111/j.1600-0447.1983.tb00950.x; HANSEN L, 1990, NEUROLOGY, V40, P1; LENNOX G, 1989, J NEUROL NEUROSUR PS, V52, P1236, DOI 10.1136/jnnp.52.11.1236; MCKEITH IG, IN PRESS PSYCHOL MED; PERRY EK, 1991, ANN NY ACAD SCI, V640, P197; PERRY RH, 1990, J NEUROL SCI, V95, P119, DOI 10.1016/0022-510X(90)90236-G; ZIMMER JG, 1984, AM J PUBLIC HEALTH, V74, P1118, DOI 10.2105/AJPH.74.10.1118	8	446	451	1	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 19	1992	305	6855					673	678		10.1136/bmj.305.6855.673	http://dx.doi.org/10.1136/bmj.305.6855.673			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JP511	1356550	Green Submitted, Green Published, Bronze			2022-12-01	WOS:A1992JP51100018
J	NICOLAIDES, KH; SNIJDERS, RJM; GOSDEN, CM; BERRY, C; CAMPBELL, S				NICOLAIDES, KH; SNIJDERS, RJM; GOSDEN, CM; BERRY, C; CAMPBELL, S			ULTRASONOGRAPHICALLY DETECTABLE MARKERS OF FETAL CHROMOSOMAL-ABNORMALITIES	LANCET			English	Article							DOWNS-SYNDROME; AGE	Screening for fetal chromosomal abnormalities on the basis of maternal age has not resulted in a substantial fall in the Proportion of infants born with an abnormal karyotype. Most fetuses with major chromosomal abnormalities have defects that can be recognised on detailed ultrasonographic examination. Therefore, provided the cardinal signs of each chromosomal syndrome are recognised, it is possible that screening by ultrasound examination could have a greater impact. We karyotyped 2086 fetuses after ultrasonographic examination had revealed fetal malformations, growth retardation, or both. Chromosomal abnormalities were detected in 301 (14%) cases and were more common among fetuses with multisystem malformations (29%) than among those with isolated defects (2%). The commonest chromosomal abnormality was trisomy 18, followed by trisomy 21, triploidy, Turner's syndrome, unbalanced chromosomal rearrangements, and trisomy 13. Trisomy 18 was associated with strawberry-shaped head, choroid plexus cysts, facial cleft, micrognathia, heart defects, exomphalos, malformations of hands and feet, and growth retardation. In trisomy 21, the associated defects were subtle and included nuchal oedema, macroglossia, atrioventricular septal defects, mild hydronephrosis, clinodactyly, and sandal gap. The frequency of autosomal abnormalities increased with maternal age, but if fetal karyotyping had been restricted to mothers older than 35 years, large proportions of chromosomally abnormal fetuses would not have been diagnosed prenatally (64-97%). Our findings provide guidelines as to which defects to search for in screening studies for the detection of chromosomal abnormalities.	GUYS HOSP,SE THAMES REG GENET CTR,PAEDIAT RES UNIT,LONDON SE1 9RT,ENGLAND; WESTERN GEN HOSP,MRC,HUMAN GENET UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND	Guy's & St Thomas' NHS Foundation Trust; University of Edinburgh	NICOLAIDES, KH (corresponding author), UNIV LONDON KINGS COLL HOSP,HARRIS BIRTHRIGHT RES CTR FETAL MED,DENMARK HILL,LONDON SE5 8RX,ENGLAND.			Snijders, Rosalinde/0000-0003-1809-7886; Nicolaides, Kypros/0000-0003-1266-0711				AZAR G B, 1991, Fetal Diagnosis and Therapy, V6, P46; BENACERRAF BR, 1990, OBSTET GYNECOL, V976, P59; BERRY S M, 1990, Fetal Diagnosis and Therapy, V5, P92; CUCKLE H, 1991, PRENATAL DIAG, V11, P29, DOI 10.1002/pd.1970110106; DRIFE JO, 1991, 18TH P STUDY GROUP R; FERGUSONSMITH MA, 1984, PRENATAL DIAG, V4, P5, DOI 10.1002/pd.1970040704; HSU LYF, 1986, GENETIC DISORDERS FE, P115; Lyons Jones K., 1988, SMITHS RECOGNIZABLE; NICOLAIDES K H, 1992, Fetal Diagnosis and Therapy, V7, P1; NICOLAIDES K H, 1990, Fetal Diagnosis and Therapy, V5, P5; NICOLAIDES KH, 1992, FETAL DIAGN THER, V7, P123, DOI 10.1159/000263659; NICOLAIDES KH, 1986, LANCET, V1, P283; NICOLAIDES KH, 1992, FETAL DIAGN THER, V7, P132, DOI 10.1159/000263660; NICOLAIDES KH, 1992, FETAL DIAGN THER, V7, P102, DOI 10.1159/000263657; NICOLAIDES KH, IN PRESS FETAL DIAGN; NYBERG DA, 1989, J ULTRAS MED, V8, P299; RODECK CH, 1984, 11TH P STUD GROUP RO; Thorpe-Beeston G, 1989, FETAL THER, V4, P21; THORPEBEESTON JG, 1990, BRIT J RADIOL, V63, P783, DOI 10.1259/0007-1285-63-754-783; WALD NJ, 1988, BRIT MED J, V297, P883, DOI 10.1136/bmj.297.6653.883; YOUINGS S, 1991, PRENATAL DIAG, V11, P419, DOI 10.1002/pd.1970110703; ZEITUNE M, 1991, PRENATAL DIAG, V11, P847, DOI 10.1002/pd.1970111106	22	227	245	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 19	1992	340	8821					704	707		10.1016/0140-6736(92)92240-G	http://dx.doi.org/10.1016/0140-6736(92)92240-G			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN780	1355807				2022-12-01	WOS:A1992JN78000012
J	PATEL, V; RASSAM, S; NEWSOM, R; WIEK, J; KOHNER, E				PATEL, V; RASSAM, S; NEWSOM, R; WIEK, J; KOHNER, E			RETINAL BLOOD-FLOW IN DIABETIC-RETINOPATHY	BMJ-BRITISH MEDICAL JOURNAL			English	Article							LASER DOPPLER VELOCIMETRY; AUTO-REGULATION; FUNDUS CAMERA; MELLITUS; PRESSURE; CIRCULATION	Objectives - (a) To report on the basic parameters of retinal blood flow in a population of diabetic patients with and without retinopathy and nondiabetic controls; (b) to formulate a haemodynamic model for the pathogenesis of diabetic retinopathy from this and other studies. Design-Laser-Doppler velocimetry and computerised image analysis to determine retinal blood flow in a large cross sectional study. Setting-Diabetic retinopathy outpatient clinic. Subjects-24 non-diabetic controls and 76 diabetic subjects were studied (63 patients with insulin dependent diabetes, 13 with non-insulin dependent diabetes). Of the diabetic subjects, 12 had no diabetic retinopathy, 27 had background retinopathy, 13 had pre-proliferative retinopathy, 12 had proliferative retinopathy, and 12 had had pan-retinal photocoagulation for proliferative retinopathy. Main outcome measures-Retinal blood flow (mu-l/min) and conductance (rate of flow per unit of perfusion pressure). Results-In comparison with non-diabetic controls (9.52-mu-l/min) and diabetic patients with no diabetic retinopathy (9.12-mu-l/min) retinal blood flow was significantly increased in all grades of untreated diabetic retinopathy (background 12.13-mu-l/min, preproliferative 15.27-mu-l/min, proliferative 13.88-mu-l/min). There was a significant decrease in flow after pan-retinal photocoagulation in comparison with all the other groups studied (4-48-mu-l/min). Conductance of the retinal circulation was higher in the untreated diabetic retinopathy groups. These results were independent of age, sex, type of diabetes, duration of diabetes, glycated haemoglobin concentration, blood glucose concentration, blood pressure, and intraocular pressure. Conclusions-Retinal blood flow is significantly increased in diabetic retinopathy in comparison with non-diabetic controls and diabetic subjects with no retinopathy. This has implications for controlling hypertension and hyperglycaemia as a strategy in reducing morbidity from diabetic retinopathy.	HAMMERSMITH HOSP, ROYAL POSTGRAD MED SCH, DEPT MED, DIABET RETINOPATHY UNIT, LONDON W12 0NN, ENGLAND	Imperial College London				newsom, Richard/0000-0002-2221-0653				BAUDOIN C, 1989, DIABETES, V38, P491; Behrendt T, 1970, Trans Am Acad Ophthalmol Otolaryngol, V74, P28; BENGTSSON B, 1977, ACTA OPHTHALMOL, V55, P123; BERKMAN J, 1973, METABOLISM, V21, P715, DOI 10.1016/0026-0495(73)90243-6; BRENNER BM, 1982, NEW ENGL J MED, V307, P652, DOI 10.1056/NEJM198209093071104; BRINCHMANN HO, 1986, ACTA OPHTHALMOL, V95, P861; BURTON AC, 1954, PHYSIOL REV, V34, P619, DOI 10.1152/physrev.1954.34.4.619; CALDWELL G, 1990, DIABETOLOGIA, V33, P262, DOI 10.1007/BF00403318; CHEN HC, 1992, INVEST OPHTH VIS SCI, V33, P811; CUNHAVAZ JG, 1978, ARCH OPHTHALMOL-CHIC, V96, P809, DOI 10.1001/archopht.1978.03910050415001; DAMON DN, 1979, MICROVASC RES, V17, P330, DOI 10.1016/S0026-2862(79)80008-4; DELORI FC, 1988, GRAEF ARCH CLIN EXP, V226, P393, DOI 10.1007/BF02172974; FEKE GT, 1989, INVEST OPHTH VIS SCI, V30, P58; FRY DL, 1969, CIRC RES, V24, P93, DOI 10.1161/01.RES.24.1.93; GAY AJ, 1966, ARCH OPHTHALMOL-CHIC, V75, P78; GRUNWALD JE, 1992, INVEST OPHTH VIS SCI, V33, P356; GRUNWALD JE, 1984, OPHTHALMOLOGY, V91, P1447; GRUNWALD JE, 1987, OPHTHALMOLOGY, V94, P1614; GRUNWALD JE, 1986, ARCH OPHTHALMOL-CHIC, V104, P991; JUHAN I, 1982, LANCET, V1, P535; KLEIN BEK, 1990, DIABETES CARE, V13, P34, DOI 10.2337/diacare.13.1.34; KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P527, DOI 10.1001/archopht.1984.01040030405011; KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P520, DOI 10.1001/archopht.1984.01040030398010; KNOWLER WC, 1980, NEW ENGL J MED, V302, P645, DOI 10.1056/NEJM198003203021201; KOHNER EM, 1975, DIABETOLOGIA, V11, P27, DOI 10.1007/BF00422814; KUWABARA T, 1963, ARCH OPHTHALMOL-CHIC, V69, P492, DOI 10.1001/archopht.1963.00960040498013; LANIGAN LP, 1989, EYE, V3, P39, DOI 10.1038/eye.1989.6; MCMILLAN DE, 1983, DIABETES, V32, P56, DOI 10.2337/diab.32.2.S56; Milnor W, 1989, HEMODYNAMICS, P140; MORGENSEN CE, 1982, BRIT MED J, V285, P685; MOSS SE, 1988, OPHTHALMOLOGY, V95, P1340; Oakley N, 1967, Diabetologia, V3, P402, DOI 10.1007/BF02342633; OGASAWARA H, 1991, INVEST OPHTH VIS SCI, V32, P864; PARVING HH, 1983, METABOLISM, V32, P943, DOI 10.1016/0026-0495(83)90210-X; PATZ A, 1984, BRIT J OPHTHALMOL, V68, P42, DOI 10.1136/bjo.68.1.42; RIVA CE, 1981, APPL OPTICS, V20, P117, DOI 10.1364/AO.20.000117; ROBINSON F, 1986, INVEST OPHTH VIS SCI, V27, P722; ROSS J, 1990, BEST TAYLORS PHYSL B, P138; SINCLAIR SH, 1982, OPHTHALMOLOGY, V89, P748, DOI 10.1016/s0161-6420(82)34720-x; STRAUSS AL, 1987, MED INSTRUM, V21, P255; SULLIVAN P, 1990, Folia Ophthalmologica (Leipzig), V15, P99; TAKAHASHI K, 1989, DIABETES, V38, P1200, DOI 10.2337/diabetes.38.9.1200; TOOKE JE, 1986, CLIN SCI, V70, P119, DOI 10.1042/cs0700119; 1987, ARCH INTERN MED, V147, P830; 1990, ARCH OPHTHALMOL-CHIC, V108, P1577	45	258	263	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 19	1992	305	6855					678	683		10.1136/bmj.305.6855.678	http://dx.doi.org/10.1136/bmj.305.6855.678			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JP511	1393111	Green Submitted, Bronze, Green Published			2022-12-01	WOS:A1992JP51100019
J	ROWE, WJ				ROWE, WJ			EXTRAORDINARY UNREMITTING ENDURANCE EXERCISE AND PERMANENT INJURY TO NORMAL HEART	LANCET			English	Article							MYOCARDIAL NECROSIS; SERUM MAGNESIUM; VARIANT ANGINA; CATECHOLAMINES; PATHOGENESIS; ISCHEMIA; DAMAGE; SPASM	This hypothesis is that permanent cardiac injury could develop in some endurance athletes despite the absence of coronary atherosclerosis and ventricular hypertrophy. The proposed mechanism by which this injury could arise involves two physiological "vicious cycles". The first vicious cycle would occur between severe ischaemia and high catecholamines, the second would be between coronary vasospasm (induced by high catecholamines) and endothelial injury. The likelihood of the injury becoming permanent might increase if there is insufficient time between bouts of endurance exercise for regression of ischaemia and endothelial repair. Furthermore, magnesium ion deficiency, which can be induced by exercise, could exacerbate these vicious cycles and also contribute to catecholamine-induced thrombogenesis. In addition to ischaemia, there are several mechanisms, including the effect of free fatty acids liberated by the lipolytic effect of high catecholamines, that could cause direct myocardial injury.										ASTRAND PO, 1986, TXB WORK PHYSL PHYSL, P685; BADIMON L, 1992, THROMBOSIS CARDIOVAS, P17; BELLER GA, 1975, AVIAT SPACE ENVIR MD, V46, P709; BENNET WC, 1935, TARAHUMARA INDIAN TR, P113; CHILIAN WM, 1986, CIRC RES, V58, P68, DOI 10.1161/01.RES.58.1.68; DEARMAN J, 1983, J SPORT MED PHYS FIT, V23, P30; EATON SB, 1988, PALEOLITHIC PRESCRIP, P32; EBEL H, 1980, J CLIN CHEM CLIN BIO, V18, P257; ESCOURROU P, 1984, J APPL PHYSIOL, V57, P1507, DOI 10.1152/jappl.1984.57.5.1507; FACTOR SM, 1985, PROG CARDIOVASC DIS, V27, P395, DOI 10.1016/0033-0620(85)90002-7; FURCHGOTT RF, 1983, CIRC RES, V53, P557, DOI 10.1161/01.RES.53.5.557; GEFT IL, 1982, CIRCULATION, V66, P1150, DOI 10.1161/01.CIR.66.6.1150; GERTZ SD, 1981, CIRCULATION, V63, P476, DOI 10.1161/01.CIR.63.3.476; GOTO K, 1990, AM J CARDIOL, V65, P709, DOI 10.1016/0002-9149(90)91375-G; GREEN LH, 1976, ANN INTERN MED, V84, P704, DOI 10.7326/0003-4819-84-6-704; HIRAMATSU K, 1984, CLIN EXP PHARMACOL P, V11, P171, DOI 10.1111/j.1440-1681.1984.tb00254.x; KNOCHEL JP, 1961, AM J MED, V30, P299, DOI 10.1016/0002-9343(61)90101-2; KONDO T, 1987, CARDIOVASC RES, V21, P248, DOI 10.1093/cvr/21.4.248; LAKS MM, 1991, CATECHOLAMINES HEART, P103; MAJUMDER S, 1991, CATECHOLAMINES HEART, P267; MARON MB, 1977, EUR J APPL PHYSIOL O, V36, P231, DOI 10.1007/BF00423048; MCKECHNIE JK, 1979, S AFR MED J, V56, P261; PRASAD DM, 1980, SCIENCE, V208, P198; PREVITALI M, 1989, AM HEART J, V117, P92, DOI 10.1016/0002-8703(89)90661-3; RONA G, 1985, J MOL CELL CARDIOL, V17, P291, DOI 10.1016/S0022-2828(85)80130-9; ROWE WJ, 1991, CHEST, V99, P1306, DOI 10.1378/chest.99.5.1306; RYZEN E, 1990, J AM COLL NUTR, V9, P114; SCHWARTZ SM, 1975, AM J PATHOL, V81, P15; SEELIG MS, 1974, AM J CLIN NUTR, V27, P59, DOI 10.1093/ajcn/27.1.59; STENDIGLINDBERG G, 1987, J AM COLL NUTR, V6, P35; TODD GL, 1985, J MOL CELL CARDIOL, V17, P647, DOI 10.1016/S0022-2828(85)80064-X; WENGER NK, 1974, HEART ARTERIES VEINS, P1546; YASUE H, 1978, CIRCULATION, V58, P56, DOI 10.1161/01.CIR.58.1.56	33	55	57	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 19	1992	340	8821					712	714		10.1016/0140-6736(92)92243-9	http://dx.doi.org/10.1016/0140-6736(92)92243-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN780	1355810				2022-12-01	WOS:A1992JN78000015
J	STOSCHITZKY, K; LINDNER, W; KLEIN, W				STOSCHITZKY, K; LINDNER, W; KLEIN, W			STEREOSELECTIVE RELEASE OF (S)-ATENOLOL FROM ADRENERGIC-NERVE ENDINGS AT EXERCISE	LANCET			English	Note							ATENOLOL; PHARMACOKINETICS; PROPRANOLOL; ENANTIOMERS	In-vitro studies have shown that atenolol, a beta-blocking agent, is stereoselectively taken up by and released from adrenergic nerve endings by membrane depolarisation. To investigate the potential importance of these findings, blood samples were taken at rest and after exercise testing from 10 patients (mean [SE] age 60 [3] years) receiving long-term treatment with racemic atenolol. At rest, mean plasma concentration of (R)-atenolol was higher than that of (S)-atenolol (ratio 1.14, p<0.01), but after exercise there was a stereoselective increase in (S)-atenolol concentration, which changed the ratio to 0.66 (p<0.01 ). Since (S)-atenolol but not (R)-atenolol causes clinically relevant beta-blockade, our findings may have importance for the management of patients receiving beta-blocking drugs.	GRAZ UNIV,INST PHARMACEUT CHEM,A-8036 GRAZ,AUSTRIA	University of Graz	STOSCHITZKY, K (corresponding author), GRAZ UNIV,DEPT MED,DIV CARDIOL,AUANBRUGGERPL 15,A-8036 GRAZ,AUSTRIA.							BAGWELL EE, 1989, J PHARMACOL EXP THER, V249, P476; BOYD RA, 1989, CLIN PHARMACOL THER, V45, P403, DOI 10.1038/clpt.1989.47; BRIGHT PS, 1985, BRIT J PHARMACOL, V84, P499, DOI 10.1111/j.1476-5381.1985.tb12934.x; HURWITZ GA, 1983, BRIT J CLIN PHARMACO, V16, P599, DOI 10.1111/j.1365-2125.1983.tb02228.x; LINDNER W, 1991, 2ND P INT S CHIR DIS, P238; MEHVAR R, 1990, J PHARM SCI, V79, P881, DOI 10.1002/jps.2600791007; STOSCHITZKY K, 1992, CLIN PHARMACOL THER, V51, P445, DOI 10.1038/clpt.1992.45; WALLE T, 1988, BIOCHEM PHARMACOL, V37, P115, DOI 10.1016/0006-2952(88)90763-0; WEBB JG, 1988, J PHARMACOL EXP THER, V247, P958	9	22	23	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 19	1992	340	8821					696	697		10.1016/0140-6736(92)92233-6	http://dx.doi.org/10.1016/0140-6736(92)92233-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN780	1355800				2022-12-01	WOS:A1992JN78000005
J	ANDERSON, MP; WELSH, MJ				ANDERSON, MP; WELSH, MJ			REGULATION BY ATP AND ADP OF CFTR CHLORIDE CHANNELS THAT CONTAIN MUTANT NUCLEOTIDE-BINDING DOMAINS	SCIENCE			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; CYSTIC-FIBROSIS GENE; MULTIDRUG RESISTANCE; R-DOMAIN; EXPRESSION; MUTATIONS; IDENTIFICATION; TRANSPORT; CELLS; PHOSPHORYLATION	Regulation of the cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel is unusual in that phosphorylated channels require cytosolic adenosine triphosphate (ATP) to open. The CFTR contains two regions predicted to be nucleotide-binding domains (NBDs); site-directed mutations in each NBD have now been shown to alter the relation between ATP concentration and channel activity, which indicates that ATP stimulates the channel by direct interaction with both NBDs. The two NBDs are not, however, functionally equivalent: adenosine diphosphate (ADP) competitively inhibited the channel by interacting with NBD2 but not by interacting with NBD1. Four cystic fibrosis-associated mutations in the NBDs reduced absolute chloride channel activity, and one mutation also decreased the potency with which ATP stimulates channel activity. Dysfunction of ATP-dependent stimulation through the NBDs may be the basis for defective CFTR chloride channel activity in some cystic fibrosis patients.	UNIV IOWA, COLL MED, HOWARD HUGHES MED INST, DEPT PHYSIOL & BIOPHYS, IOWA CITY, IA 52242 USA	Howard Hughes Medical Institute; University of Iowa	ANDERSON, MP (corresponding author), UNIV IOWA, COLL MED, HOWARD HUGHES MED INST, DEPT INTERNAL MED, IOWA CITY, IA 52242 USA.			Anderson, Matthew/0000-0003-4602-1811; Welsh, Michael/0000-0002-1646-6206				AMES GF, 1990, FEMS MICROBIOL LETT, V75, P429, DOI 10.1016/S0168-6445(05)80008-7; ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BEAUDET A, COMMUNICATION; BERGER HA, 1991, J CLIN INVEST, V88, P1422, DOI 10.1172/JCI115450; BERKOWER C, 1991, EMBO J, V10, P3777, DOI 10.1002/j.1460-2075.1991.tb04947.x; BLACK ME, 1990, J BIOL CHEM, V265, P17584; BLOXMAN DP, 1973, ENZYMES, P262; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; DENNING GM, 1992, J CELL BIOL, V118, P551, DOI 10.1083/jcb.118.3.551; DEVOTO M, 1991, AM J HUM GENET, V48, P1127; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; GREGORY RJ, 1991, MOL CELL BIOL, V11, P3886, DOI 10.1128/MCB.11.8.3886; HARTMAN J, 1992, J BIOL CHEM, V267, P6455; HORN R, 1991, BIOPHYS J, V60, P433, DOI 10.1016/S0006-3495(91)82069-0; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; LISSENS W, COMMUNICATION; NEET KE, 1983, CONT ENZYME KINETICS, P267; PASTAN I, 1991, FASEB J, V5, P2523, DOI 10.1096/fasebj.5.11.1868977; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; RICH DP, 1991, SCIENCE, V253, P205, DOI 10.1126/science.1712985; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SHYAMALA V, 1991, J BIOL CHEM, V266, P18714; Smith R.M., 1975, CRITICAL STABILITY C; STRONG TV, 1991, NEW ENGL J MED, V325, P1630, DOI 10.1056/NEJM199112053252307; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; THOMAS PJ, 1991, SCIENCE, V251, P555, DOI 10.1126/science.1703660; Tsui L C, 1991, Adv Hum Genet, V20, P153; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x	37	202	208	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 18	1992	257	5077					1701	1704		10.1126/science.1382316	http://dx.doi.org/10.1126/science.1382316			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JN501	1382316				2022-12-01	WOS:A1992JN50100036
J	BELLANNECHANTELOT, C; LACROIX, B; OUGEN, P; BILLAULT, A; BEAUFILS, S; BERTRAND, S; GEORGES, I; GLIBERT, F; GROS, I; LUCOTTE, G; SUSINI, L; CODANI, JJ; GESNOUIN, P; POOK, S; VAYSSEIX, G; LUKUO, J; RIED, T; WARD, D; CHUMAKOV, I; LEPASLIER, D; BARILLOT, E; COHEN, D				BELLANNECHANTELOT, C; LACROIX, B; OUGEN, P; BILLAULT, A; BEAUFILS, S; BERTRAND, S; GEORGES, I; GLIBERT, F; GROS, I; LUCOTTE, G; SUSINI, L; CODANI, JJ; GESNOUIN, P; POOK, S; VAYSSEIX, G; LUKUO, J; RIED, T; WARD, D; CHUMAKOV, I; LEPASLIER, D; BARILLOT, E; COHEN, D			MAPPING THE WHOLE HUMAN GENOME BY FINGERPRINTING YEAST ARTIFICIAL CHROMOSOMES	CELL			English	Article							PHYSICAL MAP; CAENORHABDITIS-ELEGANS; DNA; CONSTRUCTION; SEQUENCE; STRATEGY; LIBRARY; CLONES; HYBRIDIZATION; GENES	Physical mapping of the human genome has until now been envisioned through single chromosome strategies. We demonstrate that by using large insert yeast artificial chromosomes (YACs) a whole genome approach becomes feasible. YACs (22,000) of 810 kb mean size (5 genome equivalents) have been fingerprinted to obtain individual patterns of restriction fragments detected by a LINE-1 (L1) probe. More than 1000 contigs were assembled. Ten randomly chosen contigs were validated by metaphase chromosome fluorescence in situ hybridization, as well as by analyzing the inter-Alu PCR patterns of their constituent YACs. We estimate that 15% to 20% of the human genome, mainly the L1-rich regions, is already covered with contigs larger than 3 Mb.	GENETHON, F-91000 EVRY, FRANCE; INST NATL RECH INFORMAT & AUTOMAT, F-78153 LE CHESNAY, FRANCE; YALE UNIV, SCH MED, DEPT GENET, NEW HAVEN, CT 06510 USA; YALE UNIV, SCH MED, DEPT MOLEC BIOPHYS & BIOCHEM, NEW HAVEN, CT 06510 USA	Yale University; Yale University	BELLANNECHANTELOT, C (corresponding author), CTR ETUD POLYMORPHISME HUMAIN, F-75010 PARIS, FRANCE.		susini, laurent/N-7913-2019; Susini, Laurent/O-4227-2016	Susini, Laurent/0000-0002-5164-2770; Le Paslier, Denis/0000-0003-4335-9956; BARILLOT, Emmanuel/0000-0003-2724-2002				ALBERTSEN HM, 1990, P NATL ACAD SCI USA, V87, P4256, DOI 10.1073/pnas.87.11.4256; ANAND R, 1989, NUCLEIC ACIDS RES, V17, P3425, DOI 10.1093/nar/17.9.3425; ARNOLD N, 1992, IN PRESS TECHNIQUES; BALDING DJ, 1991, B MATH BIOL, V53, P853, DOI 10.1016/S0092-8240(05)80411-2; BATES GP, 1992, NAT GENET, V1, P180, DOI 10.1038/ng0692-180; BELLANNECHANTELOT C, 1991, NUCLEIC ACIDS RES, V19, P505, DOI 10.1093/nar/19.3.505; BOTSTEIN D, 1980, AM J HUM GENET, V32, P314; BROWNSTEIN BH, 1989, SCIENCE, V244, P1348, DOI 10.1126/science.2544027; BURKE DT, 1987, SCIENCE, V236, P806, DOI 10.1126/science.3033825; CANGIANO G, 1990, NUCLEIC ACIDS RES, V18, P5077, DOI 10.1093/nar/18.17.5077; CHUMAKOV IM, 1992, NAT GENET, V1, P222, DOI 10.1038/ng0692-222; COLLEAUX L, 1992, YEAST, V8, P325, DOI 10.1002/yea.320080410; COULSON A, 1986, P NATL ACAD SCI USA, V83, P7821, DOI 10.1073/pnas.83.20.7821; COX DR, 1990, SCIENCE, V250, P245, DOI 10.1126/science.2218528; CRAIG AG, 1990, NUCLEIC ACIDS RES, V18, P2653; EVANS GA, 1989, P NATL ACAD SCI USA, V86, P5030, DOI 10.1073/pnas.86.13.5030; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GREEN ED, 1991, GENOMICS, V11, P658, DOI 10.1016/0888-7543(91)90073-N; JEFFREYS AJ, 1987, BIOCHEM SOC T, V15, P309, DOI 10.1042/bst0150309; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; KORENBERG JR, 1992, TRENDS BIOTECHNOL, V10, P27, DOI 10.1016/0167-7799(92)90163-P; KORENBERG JR, 1988, CELL, V53, P391, DOI 10.1016/0092-8674(88)90159-6; LACROIX B, 1992, IN PRESS WORLD SCI; LANDER E S, 1988, Genomics, V2, P231; LARIN Z, 1991, P NATL ACAD SCI USA, V88, P4123, DOI 10.1073/pnas.88.10.4123; MATERA AG, 1990, NUCLEIC ACIDS RES, V18, P6019, DOI 10.1093/nar/18.20.6019; MONTANARO V, 1991, AM J HUM GENET, V48, P183; OLSON MV, 1986, P NATL ACAD SCI USA, V83, P7826, DOI 10.1073/pnas.83.20.7826; RIED T, 1992, P NATL ACAD SCI USA, V89, P1388, DOI 10.1073/pnas.89.4.1388; RIED T, 1992, GENE CHROMOSOME CANC, V4, P69, DOI 10.1002/gcc.2870040109; SHAFITZAGARDO B, 1982, NUCLEIC ACIDS RES, V10, P3175, DOI 10.1093/nar/10.10.3175; STALLINGS RL, 1990, P NATL ACAD SCI USA, V87, P6218, DOI 10.1073/pnas.87.16.6218; THIERRY A, 1990, YEAST, V6, P521, DOI 10.1002/yea.320060609	33	169	175	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 18	1992	70	6					1059	1068		10.1016/0092-8674(92)90254-A	http://dx.doi.org/10.1016/0092-8674(92)90254-A			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JN781	1525822				2022-12-01	WOS:A1992JN78100019
J	BODOR, N; PROKAI, L; WU, WM; FARAG, H; JONALAGADDA, S; KAWAMURA, M; SIMPKINS, J				BODOR, N; PROKAI, L; WU, WM; FARAG, H; JONALAGADDA, S; KAWAMURA, M; SIMPKINS, J			A STRATEGY FOR DELIVERING PEPTIDES INTO THE CENTRAL-NERVOUS-SYSTEM BY SEQUENTIAL METABOLISM	SCIENCE			English	Article							BLOOD-BRAIN-BARRIER; RAT-BRAIN; ENKEPHALIN; AMINOPEPTIDASE	Most peptides do not enter the central nervous system because of their hydrophilic character and the presence of peptidolytic enzymes in the lipoidal blood-brain barrier. To achieve brain delivery of a peptide conjugate, an opioid peptide (enkephalin) was placed in a molecular environment that disguises its peptide nature and provides biolabile, lipophilic functions to penetrate the blood-brain barrier by passive transport. The strategy also incorporates a 1,4-dihydrotrigonellinate targetor that undergoes an enzymatically mediated oxidation to a hydrophilic, membrane-impermeable trigonellinate salt. The polar targetor-peptide conjugate that is trapped behind the lipoidal blood-brain barrier is deposited in the central nervous system. Analgesia was observed with "packaged" enkephalin but not with the unmodified peptide or lipophilic peptide precursors.			BODOR, N (corresponding author), UNIV FLORIDA,J HILLIS MILLER HLTH CTR,COLL PHARM,CTR DRUG DISCOVERY,GAINESVILLE,FL 32610, USA.			Prokai, Laszlo/0000-0002-4559-3458	NIA NIH HHS [1 PO AG10485] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG010485] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BEGLEY DJ, 1990, J NEUROCHEM, V55, P1222, DOI 10.1111/j.1471-4159.1990.tb03128.x; BODOR N, 1983, SCIENCE, V221, P65, DOI 10.1126/science.6857264; Bodor N., 1983, PHARMACOL THERAPEUT, V19, P337; BRIGHTMAN MW, 1977, EXP EYE RES, V25, P1, DOI 10.1016/S0014-4835(77)80008-0; GIBSON AM, 1989, NEUROPEPTIDES, V13, P259, DOI 10.1016/0143-4179(89)90079-6; GORENSTEIN C, 1980, PROC R SOC SER B-BIO, V210, P123, DOI 10.1098/rspb.1980.0123; HAMBROOK JM, 1976, NATURE, V262, P782, DOI 10.1038/262782a0; HERSH LB, 1987, PEPTIDES, V8, P523, DOI 10.1016/0196-9781(87)90019-2; HOEK JB, 1988, BIOCHEM J, V254, P1; ITO F, 1984, MOL CELL ENDOCRINOL, V36, P165, DOI 10.1016/0303-7207(84)90032-7; McKelvy J.F., 1983, P117; NEUWELT EA, 1984, FED PROC, V43, P214; OLDENDORF WH, 1971, AM J PHYSIOL, V221, P1629, DOI 10.1152/ajplegacy.1971.221.6.1629; PARDRIDGE WM, 1981, ENDOCRINOLOGY, V109, P1138, DOI 10.1210/endo-109-4-1138; PARDRIDGE WM, 1986, ENDOCR REV, V7, P314, DOI 10.1210/edrv-7-3-314; PARDRIDGE WM, 1991, PEPTIDE DRUG DELIVER, P244; POPLACK DG, 1981, NEUROBIOLOGY CEREBRO, P561; TSUZUKI N, 1991, BIOCHEM PHARMACOL, V41, pR5, DOI 10.1016/0006-2952(91)90616-D	18	128	139	1	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 18	1992	257	5077					1698	1700		10.1126/science.1529356	http://dx.doi.org/10.1126/science.1529356			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JN501	1529356				2022-12-01	WOS:A1992JN50100035
J	CERAMI, C; FREVERT, U; SINNIS, P; TAKACS, B; CLAVIJO, P; SANTOS, MJ; NUSSENZWEIG, V				CERAMI, C; FREVERT, U; SINNIS, P; TAKACS, B; CLAVIJO, P; SANTOS, MJ; NUSSENZWEIG, V			THE BASOLATERAL DOMAIN OF THE HEPATOCYTE PLASMA-MEMBRANE BEARS RECEPTORS FOR THE CIRCUMSPOROZOITE PROTEIN OF PLASMODIUM-FALCIPARUM SPOROZOITES	CELL			English	Article							HUMAN MALARIA PARASITES; VACCINE DEVELOPMENT; SYNTHETIC PEPTIDES; SURFACE-ANTIGEN; MONOCLONAL-ANTIBODIES; SULFATED GLYCOLIPIDS; VONWILLEBRAND-FACTOR; PROTECTIVE ANTIGEN; SEQUENCE HOMOLOGY; CELL EPITOPES	Minutes after injection into the circulation, malaria sporozoites enter hepatocytes. The speed and specificity of the invasion process suggest that it is receptor mediated. We show here that recombinant Plasmodium falciparum circumsporozoite protein (CS) binds specifically to regions of the plasma membrane of hepatocytes exposed to circulating blood in the Disse space. No binding has been detected in other organs, or even in other regions of the hepatocyte membrane. The interaction of CS with hepatocytes, as well as sporozoite invasion of HepG2 cells, is inhibited by synthetic peptides representing the evolutionarily conserved region II of CS. We conclude that region II is a sporozoite ligand for hepatocyte receptors localized to the basolateral domain of the plasma membrane. Our findings provide a rational explanation for the target cell specificity of malaria sporozoites.	NYU MED CTR, DEPT MED & MOLEC PARASITOL, NEW YORK, NY 10016 USA; F HOFFMANN LA ROCHE & CO LTD, PHARMACEUT RES NEW TECHNOL, CH-4002 BASEL, SWITZERLAND; CATHOLIC UNIV CHILE, SANTIAGO, CHILE	New York University; Roche Holding; Pontificia Universidad Catolica de Chile	CERAMI, C (corresponding author), NYU MED CTR, KAPLAN CANC CTR, DEPT PATHOL, MICHAEL HEIDELBERGER DIV IMMUNOL, NEW YORK, NY 10016 USA.			Frevert, Ute/0000-0001-9556-7330; Cerami, Carla/0000-0002-7634-0955	NATIONAL CANCER INSTITUTE [T32CA009161] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007308] Funding Source: NIH RePORTER; NCI NIH HHS [5T32CA9161-16] Funding Source: Medline; NIGMS NIH HHS [5T32GM07308] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIKAWA M, 1981, J IMMUNOL, V126, P2494; ALEY SB, 1986, J EXP MED, V164, P1915, DOI 10.1084/jem.164.6.1915; BALLOU WR, 1985, SCIENCE, V228, P996, DOI 10.1126/science.2988126; BEIER JC, 1991, MED VET ENTOMOL, V5, P71, DOI 10.1111/j.1365-2915.1991.tb00523.x; BURKOT TR, 1991, PARASITE IMMUNOL, V13, P161, DOI 10.1111/j.1365-3024.1991.tb00272.x; CERAMI C, 1992, MOL BIOCHEM PARASIT, V54, P1, DOI 10.1016/0166-6851(92)90089-3; CLARKE LE, 1990, MOL BIOCHEM PARASIT, V41, P269, DOI 10.1016/0166-6851(90)90190-W; COCHRANE AH, 1976, J IMMUNOL, V116, P859; DAME JB, 1984, SCIENCE, V225, P593, DOI 10.1126/science.6204383; DELACRUZ VF, 1987, J BIOL CHEM, V262, P11935; DOOLAN DL, 1992, INFECT IMMUN, V60, P675, DOI 10.1128/IAI.60.2.675-682.1992; DUKOR P, 1970, P NATL ACAD SCI USA, V67, P991, DOI 10.1073/pnas.67.2.991; EICHINGER DJ, 1986, MOL CELL BIOL, V6, P3965, DOI 10.1128/MCB.6.11.3965; Frazier WA, 1991, CURR OPIN CELL BIOL, V3, P792, DOI 10.1016/0955-0674(91)90052-Z; FREVERT U, 1992, IN PRESS INFECT IMMU; GALINSKI MR, 1987, CELL, V48, P311, DOI 10.1016/0092-8674(87)90434-X; GODSON GN, 1983, NATURE, V305, P29, DOI 10.1038/305029a0; GOOD MF, 1988, ANNU REV IMMUNOL, V6, P663, DOI 10.1146/annurev.iy.06.040188.003311; GOUNDIS D, 1988, NATURE, V335, P82, DOI 10.1038/335082a0; GUO NH, 1992, P NATL ACAD SCI USA, V89, P3040, DOI 10.1073/pnas.89.7.3040; HARLOW E, 1988, ANTIBODIES LABORATOR; HEDSTROM RC, 1990, WHO B OMS S, V68, P152; HOFFMAN SL, 1987, SCIENCE, V237, P639, DOI 10.1126/science.3299709; HOLLINGDALE MR, 1981, SCIENCE, V213, P1021, DOI 10.1126/science.7022652; HOLT GD, 1989, J BIOL CHEM, V264, P12138; HOLT GD, 1990, J BIOL CHEM, V265, P2852; HOUGHTEN RA, 1985, P NATL ACAD SCI USA, V82, P5131, DOI 10.1073/pnas.82.15.5131; HUBBARD AL, 1983, J CELL BIOL, V96, P217, DOI 10.1083/jcb.96.1.217; IMAI Y, 1990, J CELL BIOL, V111, P1225, DOI 10.1083/jcb.111.3.1225; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; LAL AA, 1987, J BIOL CHEM, V262, P2937; LAL AA, 1988, J BIOL CHEM, V263, P5495; LAL AA, 1988, MOL BIOCHEM PARASIT, V30, P291, DOI 10.1016/0166-6851(88)90099-0; LAMBERT JM, 1978, BIOCHEMISTRY-US, V17, P5406, DOI 10.1021/bi00618a014; LOCKYER MJ, 1989, MOL BIOCHEM PARASIT, V37, P275, DOI 10.1016/0166-6851(89)90159-X; MCCUTCHAN TF, 1985, SCIENCE, V230, P1381, DOI 10.1126/science.2416057; MEIS JFGM, 1983, PARASITOLOGY, V86, P231, DOI 10.1017/S003118200005040X; MOROOSE R, 1986, ANNU REV MED, V37, P157; NARDIN EH, 1982, J EXP MED, V156, P20, DOI 10.1084/jem.156.1.20; NUSSENZWEIG V, 1989, ADV IMMUNOL, V45, P283, DOI 10.1016/S0065-2776(08)60695-1; OKADA H, 1989, BIOCHEM BIOPH RES CO, V162, P1553, DOI 10.1016/0006-291X(89)90852-8; PANCAKE SJ, 1992, J CELL BIOL, V117, P1351, DOI 10.1083/jcb.117.6.1351; POTOCNJAK P, 1980, J EXP MED, V151, P1504, DOI 10.1084/jem.151.6.1504; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; RICH KA, 1990, SCIENCE, V249, P1574, DOI 10.1126/science.2120774; RIVIER J, 1984, J CHROMATOGR, V288, P303, DOI 10.1016/S0021-9673(01)93709-4; ROBERTS DD, 1985, J BIOL CHEM, V260, P9405; ROBERTS DD, 1986, J BIOL CHEM, V261, P6872; ROBSON KJH, 1988, NATURE, V335, P79, DOI 10.1038/335079a0; ROSENBERG R, 1990, T ROY SOC TROP MED H, V84, P209, DOI 10.1016/0035-9203(90)90258-G; RUSSELL DG, 1983, PARASITOLOGY, V87, P199, DOI 10.1017/S0031182000052562; SANTORO F, 1983, J BIOL CHEM, V258, P3341; SHIN SCJ, 1982, J PROTOZOOL, V29, P448, DOI 10.1111/j.1550-7408.1982.tb05431.x; Sinden R. E., 1981, Parasitological topics -- a presentation volume to P.C.C. Garnham, F.R.S. on the occasion of his 80th birthday, 1981., P242; SINDEN RE, 1990, WHO B S, V68, P115; SINGER SJ, 1992, SCIENCE, V255, P1671, DOI 10.1126/science.1313187; STEWART MJ, 1986, INFECT IMMUN, V51, P859, DOI 10.1128/IAI.51.3.859-864.1986; STUBER D, 1990, EUR J IMMUNOL, V20, P819, DOI 10.1002/eji.1830200416; TAKACS BJ, 1991, J IMMUNOL METHODS, V143, P231, DOI 10.1016/0022-1759(91)90048-K; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TUSZYNSKI GP, 1989, EXP CELL RES, V182, P473, DOI 10.1016/0014-4827(89)90251-6; VANDERBERG J, 1969, MIL MED, V134, P1183; VANDERBERG JP, 1974, J PROTOZOOL, V21, P527, DOI 10.1111/j.1550-7408.1974.tb03693.x; YOSHIDA N, 1981, J EXP MED, V154, P1225, DOI 10.1084/jem.154.4.1225; ZAVALA F, 1985, SCIENCE, V228, P1436, DOI 10.1126/science.2409595	65	306	315	0	15	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 18	1992	70	6					1021	1033		10.1016/0092-8674(92)90251-7	http://dx.doi.org/10.1016/0092-8674(92)90251-7			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JN781	1326407				2022-12-01	WOS:A1992JN78100016
J	GEGNER, JA; GRAHAM, DR; ROTH, AF; DAHLQUIST, FW				GEGNER, JA; GRAHAM, DR; ROTH, AF; DAHLQUIST, FW			ASSEMBLY OF AN MCP RECEPTOR, CHEW, AND KINASE CHEA COMPLEX IN THE BACTERIAL CHEMOTAXIS SIGNAL TRANSDUCTION PATHWAY	CELL			English	Article							DIRECTED CROSS-LINKING; ESCHERICHIA-COLI; PROTEIN-PHOSPHORYLATION; METHYLESTERASE; SITE; OVEREXPRESSION; DEMETHYLATION; ATTRACTANTS; METHYLATION; REPELLENTS	We examined the binding interactions of the methylation-dependent chemotaxis receptors Tsr and Tar with the chemotaxis-specific protein kinase CheA and the coupling factor CheW. Receptor directly bound CheW, but receptor-CheA binding was dependent upon the presence of CheW. These observations in combination with our previous identification of a CheW-CheA complex suggest that CheW physically links the kinase to the receptor. The ternary complex of receptor, CheW, and CheA is both kinetically and thermodynamically stable at physiological concentrations. Stability is not significantly altered by changes associated with attractant or repellent binding to the receptor. Such binding greatly modulates the kinase activity of CheA. Our results demonstrate that modulation of the kinase activity does not require association-dissociation of the ternary complex. This suggests that the receptor signal is transduced through conformational changes in the ternary complex rather than through changes in the association of the kinase CheA with receptor and/or CheW.	UNIV OREGON, INST MOLEC BIOL, EUGENE, OR 97403 USA; UNIV OREGON, DEPT CHEM, EUGENE, OR 97403 USA	University of Oregon; University of Oregon					NIGMS NIH HHS [GM33677, GM07759] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007759, R01GM033677, R37GM033677] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERG HC, 1975, P NATL ACAD SCI USA, V72, P3235, DOI 10.1073/pnas.72.8.3235; BORKOVICH KA, 1989, P NATL ACAD SCI USA, V86, P1208, DOI 10.1073/pnas.86.4.1208; BORKOVICH KA, 1990, CELL, V63, P1339, DOI 10.1016/0092-8674(90)90429-I; BOURRET RB, 1991, ANNU REV BIOCHEM, V60, P401, DOI 10.1146/annurev.bi.60.070191.002153; BOURRET RB, 1989, J BIOL CHEM, V264, P7085; FALKE JJ, 1987, SCIENCE, V237, P1596, DOI 10.1126/science.2820061; GEGNER JA, 1991, P NATL ACAD SCI USA, V88, P750, DOI 10.1073/pnas.88.3.750; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HESS JF, 1988, CELL, V53, P79, DOI 10.1016/0092-8674(88)90489-8; HESS JF, 1987, P NATL ACAD SCI USA, V84, P7609, DOI 10.1073/pnas.84.21.7609; KEHRY MR, 1985, J BACTERIOL, V161, P105, DOI 10.1128/JB.161.1.105-112.1985; KEHRY MR, 1985, J BACTERIOL, V163, P983, DOI 10.1128/JB.163.3.983-990.1985; KLEENE SJ, 1979, P NATL ACAD SCI USA, V76, P6309, DOI 10.1073/pnas.76.12.6309; LIU JD, 1989, P NATL ACAD SCI USA, V86, P8703, DOI 10.1073/pnas.86.22.8703; LUPAS A, 1989, J BIOL CHEM, V264, P17337; Macnab R. M., 1987, ESCHERICHIA COLI SAL, V1, P732; MATSUMURA P, 1984, J BACTERIOL, V160, P36, DOI 10.1128/JB.160.1.36-41.1984; MCNALLY DF, 1991, P NATL ACAD SCI USA, V88, P6269, DOI 10.1073/pnas.88.14.6269; MESIBOV R, 1972, J BACTERIOL, V112, P315, DOI 10.1128/JB.112.1.315-326.1972; MILLIGAN DL, 1988, J BIOL CHEM, V263, P6268; MUCHMORE DC, 1989, METHOD ENZYMOL, V177, P44; NINFA EG, 1991, J BIOL CHEM, V266, P9764; Osborn M J, 1974, Methods Enzymol, V31, P642; ROLLINS C, 1981, CELL, V25, P333, DOI 10.1016/0092-8674(81)90051-9; SANDERS DA, 1989, J BACTERIOL, V171, P6271, DOI 10.1128/jb.171.11.6271-6278.1989; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SEGALL JE, 1982, NATURE, V296, P855, DOI 10.1038/296855a0; SIMMS SA, 1985, J BIOL CHEM, V260, P161; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SMITH RA, 1980, P NATL ACAD SCI-BIOL, V77, P5370, DOI 10.1073/pnas.77.9.5370; STEWART RC, 1987, CHEM REV, V87, P997, DOI 10.1021/cr00081a007; STEWART RC, 1988, J BACTERIOL, V170, P5728, DOI 10.1128/jb.170.12.5728-5738.1988; STOCK A, 1987, J BIOL CHEM, V262, P535; TSANG N, 1973, SCIENCE, V181, P60, DOI 10.1126/science.181.4094.60; TSO WW, 1974, J BACTERIOL, V118, P560, DOI 10.1128/JB.118.2.560-576.1974	35	317	320	0	21	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 18	1992	70	6					975	982		10.1016/0092-8674(92)90247-A	http://dx.doi.org/10.1016/0092-8674(92)90247-A			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JN781	1326408				2022-12-01	WOS:A1992JN78100012
J	GEORGIADIS, MM; KOMIYA, H; CHAKRABARTI, P; WOO, D; KORNUC, JJ; REES, DC				GEORGIADIS, MM; KOMIYA, H; CHAKRABARTI, P; WOO, D; KORNUC, JJ; REES, DC			CRYSTALLOGRAPHIC STRUCTURE OF THE NITROGENASE IRON PROTEIN FROM AZOTOBACTER-VINELANDII	SCIENCE			English	Article							AMINO-ACID-SEQUENCE; MAGNESIUM ADENOSINE 5'-TRIPHOSPHATE; ELECTRON-PARAMAGNETIC RESONANCE; CLOSTRIDIUM-PASTEURIANUM; FE-PROTEIN; KLEBSIELLA-PNEUMONIAE; NUCLEOTIDE-BINDING; MACROMOLECULAR CRYSTALLOGRAPHY; MOLYBDENUM COFACTOR; CRYSTAL-STRUCTURE	The nitrogenase enzyme system catalyzes the ATP (adenosine triphosphate)-dependent reduction of dinitrogen to ammonia during the process of nitrogen fixation. Nitrogenase consists of two proteins: the iron (Fe)-protein, which couples hydrolysis of ATP to electron transfer, and the molybdenum-iron (MoFe)-protein, which contains the dinitrogen binding site. In order to address the role of ATP in nitrogen fixation, the crystal structure of the nitrogenase Fe-protein from Azotobacter vinelandii has been determined at 2.9 angstrom (angstrom) resolution. Fe-protein is a dimer of two identical subunits that coordinate a single 4Fe:4S cluster. Each subunit folds as a single alpha/beta-type domain, which together symmetrically ligate the surface exposed 4Fe:4S cluster through two cysteines from each subunit. A single bound ADP (adenosine diphosphate) molecule is located in the interface region between the two subunits. Because the phosphate groups of this nucleotide are approximately 20 angstrom from the 4Fe:4S cluster, it is unlikely that ATP hydrolysis and electron transfer are directly coupled. Instead, it appears that interactions between the nucleotide and cluster sites must be indirectly coupled by allosteric changes occurring at the subunit interface. The coupling between protein conformation and nucleotide hydrolysis in Fe-protein exhibits general similarities to the H-Ras p21 and recA proteins that have been recently characterized structurally. The Fe-protein structure may be relevant to the functioning of other biochemical energy-transducing systems containing two nucleotide-binding sites, including membrane transport proteins.	CALTECH,DEPT CHEM & CHEM ENGN,147-75CH,PASADENA,CA 91125	California Institute of Technology					NIGMS NIH HHS [GM45162] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045162, R37GM045162] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADMAN E, 1975, P NATL ACAD SCI USA, V72, P4854, DOI 10.1073/pnas.72.12.4854; ALLEN JP, 1987, P NATL ACAD SCI USA, V84, P5730, DOI 10.1073/pnas.84.16.5730; ANDERSON GL, 1984, BIOCHEMISTRY-US, V23, P2118, DOI 10.1021/bi00305a002; BERNSTEIN HD, 1989, NATURE, V340, P482, DOI 10.1038/340482a0; BETHGE PH, 1984, J APPL CRYSTALLOGR, V17, P215, DOI 10.1107/S0021889884011365; BETHGE PH, CCP4 DAR LAB PROJ; Bishop P. E., 1988, Nitrogen fixation: Hundred years after. Proceedings of the 7th International Congress on Nitrogen Fixation, Koln (Cologne), FRG, March 13-20, 1988., P71; BRICOGNE G, 1976, ACTA CRYSTALLOGR A, V32, P832, DOI 10.1107/S0567739476001691; BRUNGER AT, 1990, P NATL ACAD SCI USA, V87, P4849, DOI 10.1073/pnas.87.12.4849; Burgess B. K., 1984, Advances in nitrogen fixation research, P103; BURGESS BK, 1980, BIOCHIM BIOPHYS ACTA, V614, P196, DOI 10.1016/0005-2744(80)90180-1; BURKE DG, UNPUB; BURRIS RH, 1991, J BIOL CHEM, V266, P9339; CARSON M, 1986, J MOL GRAPHICS, V4, P121, DOI 10.1016/0263-7855(86)80010-8; CORK C, 1985, METHOD ENZYMOL, V114, P452; Crowther R. A., 1972, MOL REPLACEMENT METH, P173; DAESCH G, 1968, J BACTERIOL, V96, P346, DOI 10.1128/JB.96.2.346-351.1968; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; DEITS TL, 1989, J BIOL CHEM, V264, P6619; DRENTH J, 1975, J BIOL CHEM, V250, P5268; EMERICH DW, 1976, P NATL ACAD SCI USA, V73, P4369, DOI 10.1073/pnas.73.12.4369; GAVINI N, 1992, IN PRESS J BIOL CHEM; GELLMAN SH, 1991, BIOCHEMISTRY-US, V30, P6633, DOI 10.1021/bi00241a001; GEORGIADIS M, UNPUB; GEORGIADIS MM, 1990, NITROGEN FIXATION : ACHIEVEMENTS AND OBJECTIVES, P111; GODDEN JW, 1991, SCIENCE, V253, P438, DOI 10.1126/science.1862344; HAGEMAN RV, 1978, BIOCHEMISTRY-US, V17, P4117, DOI 10.1021/bi00613a002; HAGEMAN RV, 1980, BIOCHEMISTRY-US, V19, P2333, DOI 10.1021/bi00552a009; HAGEN WR, 1985, FEBS LETT, V189, P250, DOI 10.1016/0014-5793(85)81033-4; HAUSINGER RP, 1983, J BIOL CHEM, V258, P3486; HAUSINGER RP, 1982, J BIOL CHEM, V257, P2483; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; HOPE H, 1988, ACTA CRYSTALLOGR B, V44, P22, DOI 10.1107/S0108768187008632; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; HOWARD JB, 1989, J BIOL CHEM, V264, P11270; HOWARD KS, 1986, J BIOL CHEM, V261, P772; JACOBSON MR, 1990, J BIOL CHEM, V265, P19429; JOERGER RD, 1991, J BACTERIOL, V173, P4440, DOI 10.1128/JB.173.14.4440-4446.1991; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KARKARIA CE, 1990, J BIOL CHEM, V265, P7832; KIM JS, 1992, SCIENCE, V257, P1677, DOI 10.1126/science.1529354; LINDAHL PA, 1987, J BIOL CHEM, V262, P14945; LINDAHL PA, 1985, J BIOL CHEM, V260, P1160; LJONES T, 1978, BIOCHEMISTRY-US, V17, P1866, DOI 10.1021/bi00603a010; MEYER J, 1988, BIOCHEMISTRY-US, V27, P6150, DOI 10.1021/bi00416a048; MORGAN TV, 1986, FEBS LETT, V206, P4, DOI 10.1016/0014-5793(86)81329-1; MORGAN TV, 1990, BIOCHEMISTRY-US, V29, P3077, DOI 10.1021/bi00464a026; MURRELL SA, 1988, BIOCHEM J, V251, P609, DOI 10.1042/bj2510609; NELSON MJ, 1983, P NATL ACAD SCI-BIOL, V80, P147, DOI 10.1073/pnas.80.1.147; NORMAND P, 1989, J MOL EVOL, V29, P436, DOI 10.1007/BF02602914; ORMEJOHNSON WH, 1985, ANNU REV BIOPHYS BIO, V14, P419, DOI 10.1146/annurev.biophys.14.1.419; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PAUL W, 1989, EUR J BIOCHEM, V178, P675, DOI 10.1111/j.1432-1033.1989.tb14497.x; PERUTZ MF, 1989, Q REV BIOPHYS, V22, P139, DOI 10.1017/S0033583500003826; POPE MR, 1985, P NATL ACAD SCI USA, V82, P3173, DOI 10.1073/pnas.82.10.3173; REEKE GN, 1984, J APPL CRYSTALLOGR, V17, P125, DOI 10.1107/S0021889884011171; REES DC, 1983, J BIOL CHEM, V258, P2733; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROBINSON AC, 1989, J BIOL CHEM, V264, P10088; ROBINSON AC, 1987, J BIOL CHEM, V262, P14327; ROBSON RL, 1984, FEBS LETT, V173, P394, DOI 10.1016/0014-5793(84)80812-1; Rossmann M. G., 1972, MOL REPLACEMENT METH; ROSSMANN MG, 1962, ACTA CRYSTALLOGR, V15, P24, DOI 10.1107/S0365110X62000067; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; SCHULZ GE, 1974, NATURE, V250, P120, DOI 10.1038/250120a0; SCHULZ GE, 1992, CURR OPIN STRUC BIOL, V2, P61; SEEFELDT LC, 1992, J BIOL CHEM, V267, P6680; SIMPSON FB, 1984, SCIENCE, V224, P1095, DOI 10.1126/science.6585956; SMITH BE, 1992, EUR J BIOCHEM, V205, P1, DOI 10.1111/j.1432-1033.1992.tb16746.x; STIEFEL EI, 1988, ACS SYM SER, V372, P372; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; TAL S, 1991, J BIOL CHEM, V266, P10654; TANAKA M, 1977, J BIOL CHEM, V252, P7093; TANAKA M, 1977, J BIOL CHEM, V252, P7089; TANAKA M, 1977, J BIOL CHEM, V252, P7081; THORNELEY RNF, 1984, BIOCHEM J, V224, P887, DOI 10.1042/bj2240887; THORNELEY RNF, 1983, BIOCHEM J, V215, P393, DOI 10.1042/bj2150393; THORNELEY RNF, 1992, PHILOS T R SOC B, V336, P73, DOI 10.1098/rstb.1992.0046; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; WALKER GA, 1973, BIOCHEM BIOPH RES CO, V53, P904, DOI 10.1016/0006-291X(73)90177-0; WALKER GA, 1974, BIOCHEMISTRY-US, V13, P2382, DOI 10.1021/bi00708a023; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WANG ZC, 1985, BIOCHEMISTRY-US, V24, P214, DOI 10.1021/bi00322a031; WATT GD, 1986, BIOCHEMISTRY-US, V25, P8156, DOI 10.1021/bi00373a005; WATT GD, 1985, BIOCHEMISTRY-US, V24, P7226, DOI 10.1021/bi00346a031; WILLING A, 1990, J BIOL CHEM, V265, P6596; WILLING AH, 1989, J BIOL CHEM, V264, P8499; WOLLE D, 1992, J BIOL CHEM, V267, P3667; WOLLE D, IN PRESS SCIENCE; ZUMFT WG, 1973, BIOCHIM BIOPHYS ACTA, V292, P413, DOI 10.1016/0005-2728(73)90047-9	91	572	586	2	116	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 18	1992	257	5077					1653	1659		10.1126/science.1529353	http://dx.doi.org/10.1126/science.1529353			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JN501	1529353				2022-12-01	WOS:A1992JN50100022
J	GESTELAND, RF; WEISS, RB; ATKINS, JF				GESTELAND, RF; WEISS, RB; ATKINS, JF			RECODING - REPROGRAMMED GENETIC DECODING	SCIENCE			English	Article							POLYMERASE-III HOLOENZYME; RELEASE FACTOR-II; ESCHERICHIA-COLI; READING FRAME; GAMMA-SUBUNIT; MESSENGER-RNA; SELENOCYSTEINE; CODON; PSEUDOKNOT; PEPTIDE		UNIV UTAH,ECCLES INST HUMAN GENET,DEPT HUMAN GENET,SALT LAKE CITY,UT 84112	Utah System of Higher Education; University of Utah	GESTELAND, RF (corresponding author), UNIV UTAH,HOWARD HUGHES MED INST,SALT LAKE CITY,UT 84112, USA.			Atkins, John/0000-0001-7933-0165				ATKINS JF, 1990, CELL, V62, P413, DOI 10.1016/0092-8674(90)90007-2; BELCOURT MF, 1990, CELL, V62, P339, DOI 10.1016/0092-8674(90)90371-K; BERRY MJ, 1991, NATURE, V353, P273, DOI 10.1038/353273a0; BLINKOWA AL, 1990, NUCLEIC ACIDS RES, V18, P1725, DOI 10.1093/nar/18.7.1725; BOCK A, 1991, MOL MICROBIOL, V5, P515, DOI 10.1111/j.1365-2958.1991.tb00722.x; BRIERLEY I, 1989, CELL, V57, P537, DOI 10.1016/0092-8674(89)90124-4; CRAIGEN WJ, 1986, NATURE, V322, P273, DOI 10.1038/322273a0; CURRAN JF, 1988, J MOL BIOL, V203, P75, DOI 10.1016/0022-2836(88)90092-7; FLOWER AM, 1990, P NATL ACAD SCI USA, V87, P3713, DOI 10.1073/pnas.87.10.3713; HATFIELD DL, 1992, ADV VIRUS RES, V41, P193, DOI 10.1016/S0065-3527(08)60037-8; HILL KE, 1991, J BIOL CHEM, V266, P10050; HUANG WM, 1988, SCIENCE, V239, P1005, DOI 10.1126/science.2830666; JACKS T, 1988, CELL, V55, P447, DOI 10.1016/0092-8674(88)90031-1; MATSUFUJI S, UNPUB; TSUCHIHASHI Z, 1990, P NATL ACAD SCI USA, V87, P2516, DOI 10.1073/pnas.87.7.2516; WEISS RB, 1990, CELL, V62, P117, DOI 10.1016/0092-8674(90)90245-A; WEISS RB, 1987, COLD SPRING HARB SYM, V52, P687, DOI 10.1101/SQB.1987.052.01.078; WEISS RB, 1988, EMBO J, V7, P1503, DOI 10.1002/j.1460-2075.1988.tb02969.x; WILLS NM, 1991, P NATL ACAD SCI USA, V88, P6991, DOI 10.1073/pnas.88.16.6991; ZINONI F, 1990, P NATL ACAD SCI USA, V87, P4660, DOI 10.1073/pnas.87.12.4660	20	159	162	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 18	1992	257	5077					1640	1641		10.1126/science.1529352	http://dx.doi.org/10.1126/science.1529352			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JN501	1529352				2022-12-01	WOS:A1992JN50100019
J	HINDS, PW; MITTNACHT, S; DULIC, V; ARNOLD, A; REED, SI; WEINBERG, RA				HINDS, PW; MITTNACHT, S; DULIC, V; ARNOLD, A; REED, SI; WEINBERG, RA			REGULATION OF RETINOBLASTOMA PROTEIN FUNCTIONS BY ECTOPIC EXPRESSION OF HUMAN CYCLINS	CELL			English	Article							LARGE-T-ANTIGEN; ADENOVIRUS E1A PROTEINS; CELL-CYCLE; GENE-PRODUCT; SUSCEPTIBILITY GENE; SACCHAROMYCES-CEREVISIAE; G1-SPECIFIC CYCLINS; CANDIDATE ONCOGENE; KINASE COMPLEX; G1 PHASE	The retinoblastoma susceptibility gene (RB) product, the retinoblastoma protein (pRb), functions as a regulator of cell proliferation. Introduction of the RB gene into SAOS-2 osteosarcoma cells, which lack functional pRb, prevents cell cycle progression. Such growth-suppressive functions can be modulated by phosphorylation of pRb, which occurs via cell cycle-regulated kinases. We show that constitutively expressed cyclins A and E can overcome pRb-mediated suppression of proliferation. pRb becomes hyperphosphorylated in cells overexpressing these cyclins, and this phosphorylation is essential for cyclin A- and cyclin E-mediated rescue of pRb-blocked cells. This suggests that G1 and S phase cyclins can act as regulators of pRb function in the cell cycle by promoting pRb phosphorylation.	SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; MASSACHUSETTS GEN HOSP, ENDOCRINE UNIT, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02114 USA	Scripps Research Institute; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	HINDS, PW (corresponding author), WHITEHEAD INST, 9 CAMBRIDGE CTR, CAMBRIDGE, MA 02142 USA.			Dulic, Vjekoslav/0000-0003-1201-3901	NATIONAL CANCER INSTITUTE [R01CA055909] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038328, P01GM046006, R01GM038328] Funding Source: NIH RePORTER; NCI NIH HHS [CA55909] Funding Source: Medline; NIGMS NIH HHS [GM46006, GM38328] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; BUENO A, 1991, CELL, V66, P149, DOI 10.1016/0092-8674(91)90147-Q; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHERINGTON V, 1988, MOL CELL BIOL, V8, P1380, DOI 10.1128/MCB.8.3.1380; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; DULIC V, 1992, IN PRESS SCIENCE; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FURUKAWA Y, 1991, ONCOGENE, V6, P1343; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HARTWELL LH, 1974, SCIENCE, V183, P46, DOI 10.1126/science.183.4120.46; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; Hunt T, 1989, CURR OPIN CELL BIOL, V1, P268, DOI 10.1016/0955-0674(89)90099-9; IMAI Y, 1991, J VIROL, V65, P4966, DOI 10.1128/JVI.65.9.4966-4972.1991; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; LAMMIE GA, 1991, ONCOGENE, V6, P439; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; Maller JL, 1991, CURR OPIN CELL BIOL, V3, P269; MENDENHALL MD, 1987, CELL, V50, P927, DOI 10.1016/0092-8674(87)90519-8; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; MITTNACHT S, 1991, COLD SPRING HARB SYM, V56, P197; MORAN E, 1988, NATURE, V334, P168, DOI 10.1038/334168a0; MORAN E, 1986, MOL CELL BIOL, V6, P3470, DOI 10.1128/MCB.6.10.3470; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MOTOKURA T, 1992, IN PRESS J BIOL CHEM; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; Nigg E A, 1991, Semin Cell Biol, V2, P261; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; REED SI, 1991, TRENDS GENET, V7, P95, DOI 10.1016/0168-9525(91)90064-W; REED SI, 1980, GENETICS, V95, P561; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; ROSENBERG CL, 1991, ONCOGENE, V6, P449; ROSENBERG CL, 1991, P NATL ACAD SCI USA, V88, P9638, DOI 10.1073/pnas.88.21.9638; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; SHEW JY, 1989, ONCOGENE RES, V4, P205; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SMITH DH, 1988, MOL CELL BIOL, V8, P3882, DOI 10.1128/MCB.8.9.3882; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; VARLEY JM, 1989, ONCOGENE, V4, P725; WANG HGH, 1991, MOL CELL BIOL, V11, P4253, DOI 10.1128/MCB.11.8.4253; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WILLIAMS RT, 1992, ONCOGENE, V7, P423; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; WITTENBERG C, 1988, CELL, V54, P1061, DOI 10.1016/0092-8674(88)90121-3; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	68	1007	1022	0	24	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 18	1992	70	6					993	1006		10.1016/0092-8674(92)90249-C	http://dx.doi.org/10.1016/0092-8674(92)90249-C			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JN781	1388095				2022-12-01	WOS:A1992JN78100014
J	KIM, JS; REES, DC				KIM, JS; REES, DC			STRUCTURAL MODELS FOR THE METAL CENTERS IN THE NITROGENASE MOLYBDENUM-IRON PROTEIN	SCIENCE			English	Article							AZOTOBACTER-VINELANDII NITROGENASE; KLEBSIELLA-PNEUMONIAE NITROGENASE; SUBSTRATE REDUCTION PROPERTIES; CONSERVED CYSTEINE RESIDUES; MOFE PROTEIN; ALPHA-SUBUNIT; FEMO-COFACTOR; BETA-SUBUNIT; MACROMOLECULAR CRYSTALLOGRAPHY; CLUSTER	Structural models for the nitrogenase FeMo-cofactor and P-clusters are proposed based on crystallographic analysis of the nitrogenase molybdenum-iron (MoFe)-protein from Azotobacter vinelandii at 2.7 angstrom resolution. Each center consists of two bridged clusters; the FeMo-cofactor has 4Fe:3S and 1Mo:3Fe:3S clusters bridged by three non-protein ligands, and the P-clusters contain two 4Fe:4S clusters bridged by two cysteine thiol ligands. Six of the seven Fe sites in the FeMo-cofactor appear to have trigonal coordination geometry, including one ligand provided by a bridging group. The remaining Fe site has tetrahedral geometry and is liganded to the side chain of Cys(alpha-275). The Mo site exhibits approximate octahedral coordination geometry and is liganded by three sulfurs in the cofactor, two oxygens from homocitrate, and the imidazole side chain of His(alpha-442). The P-clusters are liganded by six cysteine thiol groups, two which bridge the two clusters, alpha-88 and beta-95, and four which singly coordinate the remaining Fe sites, alpha-62, alpha-154, beta-70, and beta-153. The side chain of Ser(beta-188) may also coordinate one iron. The polypeptide folds of the homologous alpha and beta-subunits surrounding the P-clusters are approximately related by a twofold rotation that may be utilized in the binding interactions between the MoFe-protein and the nitrogenase Fe-protein. Neither the FeMo-cofactor nor the P-clusters are exposed to the surface, suggesting that substrate entry, electron transfer, and product release must involve a carefully regulated sequence of interactions between the MoFe-protein and Fe-protein of nitrogenase.	CALTECH,DIV CHEM & CHEM ENGN 14775CH,PASADENA,CA 91125	California Institute of Technology								ALLEN JP, 1987, P NATL ACAD SCI USA, V84, P5730, DOI 10.1073/pnas.84.16.5730; ARBER JM, 1988, BIOCHEM J, V252, P421, DOI 10.1042/bj2520421; BOLIN JT, 1990, NITROGEN FIXATION : ACHIEVEMENTS AND OBJECTIVES, P117; BRIGLE KE, 1985, GENE, V37, P37, DOI 10.1016/0378-1119(85)90255-0; Burgess B. K., 1984, Advances in nitrogen fixation research, P103; BURGESS BK, 1980, BIOCHIM BIOPHYS ACTA, V614, P196, DOI 10.1016/0005-2744(80)90180-1; BURGESS BK, 1990, CHEM REV, V90, P1377, DOI 10.1021/cr00106a002; BURRIS RH, 1991, J BIOL CHEM, V266, P9339; CHU CTW, 1977, INORG CHEM, V16, P3245, DOI 10.1021/ic50178a052; CONRADSON SD, 1987, J AM CHEM SOC, V109, P7507, DOI 10.1021/ja00258a042; COUCOUVANIS D, 1991, ACCOUNTS CHEM RES, V24, P1, DOI 10.1021/ar00001a001; Crowther R. A., 1972, MOL REPLACEMENT METH, P173; CROWTHER RA, 1967, ACTA CRYSTALLOGR, V23, P544, DOI 10.1107/S0365110X67003172; DEAN DR, 1990, MOL MICROBIOL, V4, P1505, DOI 10.1111/j.1365-2958.1990.tb02061.x; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; DRENTH J, 1975, J BIOL CHEM, V250, P5268; EIDSNESS MK, 1986, J AM CHEM SOC, V108, P2746, DOI 10.1021/ja00270a039; GEORGIADIS M, UNPUB; GEORGIADIS MM, 1992, SCIENCE, V257, P1653, DOI 10.1126/science.1529353; HAGEN WR, 1987, EUR J BIOCHEM, V169, P457, DOI 10.1111/j.1432-1033.1987.tb13633.x; HAWKES TR, 1984, BIOCHEM J, V217, P317, DOI 10.1042/bj2170317; HEDMAN B, 1988, J AM CHEM SOC, V110, P3798, DOI 10.1021/ja00220a013; HERSKOVITZ T, 1972, P NATL ACAD SCI USA, V69, P2437, DOI 10.1073/pnas.69.9.2437; Holm R. H., 1985, MOLYBDENUM ENZYMES; HOLMES S, 1990, COMPOS SCI TECHNOL, V38, P1, DOI 10.1016/0266-3538(90)90068-G; HOOVER TR, 1987, NATURE, V329, P855, DOI 10.1038/329855a0; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; HUYNH BH, 1980, BIOCHIM BIOPHYS ACTA, V623, P124, DOI 10.1016/0005-2795(80)90015-X; IMPERIAL J, 1989, BIOCHEMISTRY-US, V28, P7796, DOI 10.1021/bi00445a040; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KENT HM, 1990, MOL MICROBIOL, V4, P1497, DOI 10.1111/j.1365-2958.1990.tb02060.x; KENT HM, 1989, BIOCHEM J, V264, P257, DOI 10.1042/bj2640257; KURTZ DM, 1979, P NATL ACAD SCI USA, V76, P4986, DOI 10.1073/pnas.76.10.4986; LAMMERS PJ, 1983, P NATL ACAD SCI-BIOL, V80, P4723, DOI 10.1073/pnas.80.15.4723; LAUBLE H, 1992, BIOCHEMISTRY-US, V31, P2735, DOI 10.1021/bi00125a014; LINDAHL PA, 1988, J BIOL CHEM, V263, P19412; LINDAHL PA, 1987, J BIOL CHEM, V262, P12900; MADDEN MS, 1990, P NATL ACAD SCI USA, V87, P6517, DOI 10.1073/pnas.87.17.6517; MARCUS RN, 1992, SCIENCE, V256, P1007; MAY HD, 1991, BIOCHEM J, V277, P457, DOI 10.1042/bj2770457; NELSON MJ, 1983, P NATL ACAD SCI-BIOL, V80, P147, DOI 10.1073/pnas.80.1.147; ORMEJOHNSON WH, 1985, ANNU REV BIOPHYS BIO, V14, P419, DOI 10.1146/annurev.biophys.14.1.419; POWER PP, 1991, ANGEW CHEM INT EDIT, V30, P330, DOI 10.1002/anie.199103301; RAWLINGS J, 1978, J BIOL CHEM, V253, P1001; Rossmann M. G., 1972, MOL REPLACEMENT METH; ROSSMANN MG, 1962, ACTA CRYSTALLOGR, V15, P24, DOI 10.1107/S0365110X62000067; SCOTT DJ, 1990, NATURE, V343, P188, DOI 10.1038/343188a0; SCOTT DJ, 1990, NITROGEN FIXATION AC, P169; SHAH VK, 1977, P NATL ACAD SCI USA, V74, P3249, DOI 10.1073/pnas.74.8.3249; SMITH BE, 1992, EUR J BIOCHEM, V205, P1, DOI 10.1111/j.1432-1033.1992.tb16746.x; STIEFEL EI, 1988, ACS SYM SER, V372, P372; SURERUS KK, IN PRESS J AM CHEM S; THOMANN H, 1987, J AM CHEM SOC, V109, P7913, DOI 10.1021/ja00259a067; THOMANN H, 1991, P NATL ACAD SCI USA, V88, P6620, DOI 10.1073/pnas.88.15.6620; THORNELEY RNF, 1984, BIOCHEM J, V224, P887, DOI 10.1042/bj2240887; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; TRUE AE, 1988, J AM CHEM SOC, V110, P1935, DOI 10.1021/ja00214a045; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WANG SZ, 1988, BIOCHEMISTRY-US, V27, P2800, DOI 10.1021/bi00408a021; WEININGER MS, 1982, P NATL ACAD SCI-BIOL, V79, P378, DOI 10.1073/pnas.79.2.378; ZIMMERMANN R, 1978, BIOCHIM BIOPHYS ACTA, V537, P185, DOI 10.1016/0005-2795(78)90504-4	61	743	769	2	211	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 18	1992	257	5077					1677	1682		10.1126/science.1529354	http://dx.doi.org/10.1126/science.1529354			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JN501	1529354				2022-12-01	WOS:A1992JN50100030
J	KOFF, A; GIORDANO, A; DESAI, D; YAMASHITA, K; HARPER, JW; ELLEDGE, S; NISHIMOTO, T; MORGAN, DO; FRANZA, BR; ROBERTS, JM				KOFF, A; GIORDANO, A; DESAI, D; YAMASHITA, K; HARPER, JW; ELLEDGE, S; NISHIMOTO, T; MORGAN, DO; FRANZA, BR; ROBERTS, JM			FORMATION AND ACTIVATION OF A CYCLIN E-CDK2 COMPLEX DURING THE G(1)-PHASE OF THE HUMAN CELL-CYCLE	SCIENCE			English	Article							CLN FUNCTION; YEAST; GENE	Human cyclin E, originally identified on the basis of its ability to function as a G1 cyclin in budding yeast, associated with a cell cycle-regulated protein kinase in human cells. The cyclin E-associated kinase activity peaked during G1, before the appearance of cyclin A, and was diminished during exit from the cell cycle after differentiation or serum withdrawal. The major cyclin E-associated kinase in human cells was Cdk2 (cyclin-dependent kinase 2). The abundance of the cyclin E protein and the cyclin E-Cdk2 complex was maximal in G1 cells. These results provide further evidence that in all eukaryotes assembly of a cyclin-Cdk complex is an important step in the biochemical pathway that controls cell proliferation during G1.	COLD SPRING HARBOR LAB, FREEMAN LAB CANC CELL BIOL, COLD SPRING HARBOR, NY 11724 USA; UNIV CALIF SAN FRANCISCO, DEPT PHYSIOL, SAN FRANCISCO, CA 94143 USA; KYUSHU UNIV, GRAD SCH MED SCI, DEPT MOLEC BIOL, FUKUOKA 812, JAPAN; BAYLOR COLL MED, VERNA & MARRS MCLEAN DEPT BIOCHEM, HOUSTON, TX 77030 USA	Cold Spring Harbor Laboratory; University of California System; University of California San Francisco; Kyushu University; Baylor College of Medicine	KOFF, A (corresponding author), FRED HUTCHINSON CANC RES CTR, DEPT BASIC SCI, 1124 COLUMBIA ST, SEATTLE, WA 98104 USA.		Giordano, Antonio/F-1927-2010	Giordano, Antonio/0000-0002-5959-016X; Harper, Jeffrey/0000-0002-6944-7236; Morgan, David/0000-0001-8753-4416				DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; FRANZA BR, UNPUB; GARRELS JI, 1989, J BIOL CHEM, V264, P5823; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GIORDANO A, 1991, SCIENCE, V253, P1271, DOI 10.1126/science.1653969; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, UNPUB; LAHUE EE, 1991, GENE DEV, V5, P2166, DOI 10.1101/gad.5.12a.2166; LEOPOLD P, 1991, CELL, V66, P1207, DOI 10.1016/0092-8674(91)90043-X; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; MARRACCINO RL, 1992, MOL BIOL CELL, V3, P389, DOI 10.1091/mbc.3.4.389; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; OHTSUBO M, UNPUB; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	20	1023	1058	1	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 18	1992	257	5077					1689	1694		10.1126/science.1388288	http://dx.doi.org/10.1126/science.1388288			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JN501	1388288				2022-12-01	WOS:A1992JN50100033
J	KOROMILAS, AE; ROY, S; BARBER, GN; KATZE, MG; SONENBERG, N				KOROMILAS, AE; ROY, S; BARBER, GN; KATZE, MG; SONENBERG, N			MALIGNANT TRANSFORMATION BY A MUTANT OF THE IFN-INDUCIBLE DSRNA-DEPENDENT PROTEIN-KINASE	SCIENCE			English	Article							DOUBLE-STRANDED-RNA; NF-KAPPA-B; EIF-2-ALPHA KINASE; 3T3-F442A CELLS; INTERFERON; RECEPTOR; BINDING; AUTOPHOSPHORYLATION; INITIATION; EXPRESSION	The double-stranded RNA-dependent protein kinase (dsRNA-PK) is thought to be a key mediator of the antiviral and antiproliferative effects of interferons (IFNs). Studies examining the physiological function of the kinase suggest that it participates in cell growth and differentiation by regulating protein synthesis. Autophosphorylation and consequent activation of dsRNA-PK in vitro and in vivo result in phosphorylation of the alpha-subunit of eukaryotic initiation factor-2 (eIF-2) and inhibition of protein synthesis. Expression of a functionally defective mutant of human dsRNA-PK in NIH 3T3 cells resulted in malignant transformation, suggesting that dsRNA-PK may function as a suppressor of cell proliferation and tumorigenesis.	MCGILL UNIV, FAC MED, DEPT BIOCHEM, MONTREAL H3G 1Y6, QUEBEC, CANADA; MCGILL UNIV, FAC MED, MCGILL CANC CTR, MONTREAL H3G 1Y6, QUEBEC, CANADA; UNIV WASHINGTON, SCH MED, DEPT MICROBIOL, SEATTLE, WA 98195 USA	McGill University; McGill University; University of Washington; University of Washington Seattle					NCRR NIH HHS [RR00166] Funding Source: Medline; NIAID NIH HHS [AI22646] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000166] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022646] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BELL JS, COMMUNICATION; CHEN JJ, 1991, P NATL ACAD SCI USA, V88, P7729, DOI 10.1073/pnas.88.17.7729; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FENG GS, 1992, P NATL ACAD SCI USA, V89, P5447, DOI 10.1073/pnas.89.12.5447; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FLEURY S, 1991, CELL, V66, P1037, DOI 10.1016/0092-8674(91)90447-7; GALABRU J, 1989, EUR J BIOCHEM, V178, P581, DOI 10.1111/j.1432-1033.1989.tb14485.x; GALABRU J, 1987, J BIOL CHEM, V262, P15538; HAMMACHER A, 1989, EMBO J, V8, P2489, DOI 10.1002/j.1460-2075.1989.tb08385.x; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; HONEGGER A, 1988, EMBO J, V7, P3053, DOI 10.1002/j.1460-2075.1988.tb03170.x; HONEGGER A, 1990, J CELL BIOL, V10, P1541; HONEGGER AM, 1990, MOL CELL BIOL, V10, P4035, DOI 10.1128/MCB.10.8.4035; HOVANESSIAN AG, 1987, EUR J BIOCHEM, V167, P467, DOI 10.1111/j.1432-1033.1987.tb13360.x; HOVANESSIAN AG, 1989, J INTERFERON RES, V9, P641, DOI 10.1089/jir.1989.9.641; Jagus R, 1981, Prog Nucleic Acid Res Mol Biol, V25, P127, DOI 10.1016/S0079-6603(08)60484-5; KATZE MG, 1991, MOL CELL BIOL, V11, P5497, DOI 10.1128/MCB.11.11.5497; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KOROMILAS AE, UNPUB; KOSTURA M, 1989, MOL CELL BIOL, V9, P1576, DOI 10.1128/MCB.9.4.1576; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LANGLAND JO, 1992, J BIOL CHEM, V267, P10729; LAURENT AG, 1984, BIOCHEM BIOPH RES CO, V125, P1, DOI 10.1016/S0006-291X(84)80324-1; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; LENARDO MJ, 1989, CELL, V57, P287, DOI 10.1016/0092-8674(89)90966-5; LI JH, 1991, EUR J BIOCHEM, V195, P41, DOI 10.1111/j.1432-1033.1991.tb15673.x; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; NIELSCH U, 1991, EMBO J, V10, P4169, DOI 10.1002/j.1460-2075.1991.tb04995.x; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; PETRYSHYN R, 1984, J BIOL CHEM, V259, P4736; PETRYSHYN R, 1988, P NATL ACAD SCI USA, V85, P1427, DOI 10.1073/pnas.85.5.1427; RAMIREZ M, 1991, MOL CELL BIOL, V11, P3027, DOI 10.1128/MCB.11.6.3027; RAMIREZ M, 1992, CELL, V68, P585; REIS LFL, 1992, EMBO J, V11, P185, DOI 10.1002/j.1460-2075.1992.tb05041.x; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEN GC, 1992, J BIOL CHEM, V267, P5017; VISVANATHAN KV, 1989, EMBO J, V8, P1129, DOI 10.1002/j.1460-2075.1989.tb03483.x; WEINBERG RA, 1989, CANCER RES, V49, P3713; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741	45	530	543	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 18	1992	257	5077					1685	1689		10.1126/science.1382315	http://dx.doi.org/10.1126/science.1382315			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JN501	1382315				2022-12-01	WOS:A1992JN50100032
J	LAYBOURN, PJ; KADONAGA, JT				LAYBOURN, PJ; KADONAGA, JT			THRESHOLD PHENOMENA AND LONG-DISTANCE ACTIVATION OF TRANSCRIPTION BY RNA POLYMERASE-II	SCIENCE			English	Article							GAL4 DERIVATIVES; HYPERSENSITIVE SITES; INVITRO; GENE; NUCLEOSOME; PROTEINS	To explore the underlying mechanisms by which genes are regulated in eukaryotes, long-distance transcriptional activation and threshold effects were reconstituted in vitro. Long-range activation of transcription by GAL4-VP16 protein located 1300 base pairs upstream of the RNA start site was dependent on packaging of the template into histone H1-containing chromatin. A transcriptional threshold effect by GAL4-VP16 was observed with repressed chromatin templates but not naked DNA templates. The experimental data with the chromatin templates were similar to the theoretical activation profile that is predicted if the action of each DNA bound protomer of GAL4-VP16 were independent and additive in terms of free energy.	UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, CTR MOLEC GENET, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego								BULGER MD, UNPUB; CAREY M, 1990, SCIENCE, V247, P710, DOI 10.1126/science.2405489; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; Croston G.E., 1991, Protein Expression and Purification, V2, P162, DOI 10.1016/1046-5928(91)90066-R; CROSTON GE, 1991, SCIENCE, V251, P643, DOI 10.1126/science.1899487; CROSTON GE, UNPUB; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; ELGIN SCR, 1988, J BIOL CHEM, V263, P19259; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; GRUNSTEIN M, 1990, ANNU REV CELL BIOL, V6, P643, DOI 10.1146/annurev.cellbio.6.1.643; HOUGH PVC, 1982, J MOL BIOL, V160, P375, DOI 10.1016/0022-2836(82)90183-8; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KORNBERG RD, 1991, CELL, V67, P833, DOI 10.1016/0092-8674(91)90354-2; LAYBOURN PJ, 1991, SCIENCE, V254, P238, DOI 10.1126/science.1718039; LAYBOURN PJ, UNPUB; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; PTASHNE M, 1986, NATURE, V322, P697, DOI 10.1038/322697a0; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; PUGH BF, 1992, J BIOL CHEM, V267, P679; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SALTZMAN AG, 1989, FASEB J, V3, P1723, DOI 10.1096/fasebj.3.6.2649403; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SERFLING E, 1985, TRENDS GENET, V1, P224, DOI 10.1016/0168-9525(85)90088-5; SIMPSON RT, 1991, PROG NUCLEIC ACID RE, V40, P143; SINHA SN, 1982, NUCLEIC ACIDS RES, V10, P5533, DOI 10.1093/nar/10.18.5533; STJOHNSTON D, 1992, CELL, V68, P201; TAMAKA RT, 1991, P NATL ACAD SCI USA, V88, P1024; van Holde K.E., 1989, CHROMATIN; WEINTRAUB H, 1985, CELL, V42, P705, DOI 10.1016/0092-8674(85)90267-3; WOLFFE A P, 1990, New Biologist, V2, P211; ZAWEL L, IN PRESS PROG NUCLEI	36	96	97	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 18	1992	257	5077					1682	1685		10.1126/science.1388287	http://dx.doi.org/10.1126/science.1388287			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JN501	1388287				2022-12-01	WOS:A1992JN50100031
J	LIVINGSTONE, LR; WHITE, A; SPROUSE, J; LIVANOS, E; JACKS, T; TISTY, TD				LIVINGSTONE, LR; WHITE, A; SPROUSE, J; LIVANOS, E; JACKS, T; TISTY, TD			ALTERED CELL-CYCLE ARREST AND GENE AMPLIFICATION POTENTIAL ACCOMPANY LOSS OF WILD-TYPE P53	CELL			English	Article							NUCLEOTIDE-SEQUENCE; DNA AMPLIFICATION; CANCER SYNDROME; HAMSTER-CELLS; CAD GENE; TRANSFORMATION; PROTEIN; MUTATIONS; ONCOGENE; LINES	Gene amplification occurs at high frequency in transformed cells (10(-3)-10(-5)), but is undetectable in normal diploid fibroblasts (<10(-9)). This study examines whether alterations of one or both p53 alleles were sufficient to allow gene amplification to occur. Cells retaining one wild-type p53 allele mimicked the behavior of primary diploid cells: they arrested growth in the presence of drug and failed to demonstrate amplification. Cells losing the second p53 allele failed to arrest when placed in drug and displayed the ability to amplify at a high frequency. Thus, loss of wild-type p53 may lead to amplification, possibly caused by changes in cell cycle progression. Other determinants can bypass this p53 function, however, since tumor cells with wild-type p53 have the ability to amplify genes.	MIT,CTR CANC RES,CAMBRIDGE,MA 02139; UNIV N CAROLINA,SCH MED,CURRICULUM GENET,CHAPEL HILL,NC 27599	Massachusetts Institute of Technology (MIT); University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	LIVINGSTONE, LR (corresponding author), UNIV N CAROLINA,SCH MED,LINEBERGER COMPREHENS CANC CTR,DEPT PATHOL,CHAPEL HILL,NC 27599, USA.				NATIONAL CANCER INSTITUTE [R01CA051912] Funding Source: NIH RePORTER; NCI NIH HHS [CA51912] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARKER D, 1984, AM J HUM GENET, V36, P1159; BIENZ B, 1984, EMBO J, V3, P2179, DOI 10.1002/j.1460-2075.1984.tb02110.x; BISCHOFF FZ, 1990, CANCER RES, V50, P7979; BISCHOFF FZ, 1991, ONCOGENE, V6, P183; BUCHMAN VL, 1988, GENE, V70, P245, DOI 10.1016/0378-1119(88)90196-5; CHEN YM, 1991, ONCOGENE, V6, P1799; DAVIDSON JN, 1990, DNA CELL BIOL, V9, P667, DOI 10.1089/dna.1990.9.667; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; EFFERT P, 1992, J VIROL, V66, P3768, DOI 10.1128/JVI.66.6.3768-3775.1992; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FIDLER IJ, 1982, ONCODEV BIOL MED, V4, P161; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FOULDS L, 1959, NEOPLASTIC DEV, V2; GIULOTTO E, 1987, CELL, V48, P837, DOI 10.1016/0092-8674(87)90080-8; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JOHNSTON RN, 1983, P NATL ACAD SCI-BIOL, V80, P3711, DOI 10.1073/pnas.80.12.3711; KASTAN MB, 1991, CANCER RES, V51, P6304; KAVATHAS P, 1983, NATURE, V306, P385, DOI 10.1038/306385a0; KUERBITZ SJ, 1992, IN PRESS P NATL ACAD; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OTTO E, 1989, J BIOL CHEM, V264, P3390; POSTE G, 1986, CANCER TREAT REP, V70, P183; ROBERTSON EJ, 1987, STEM CELLS; ROWLEY JD, 1983, CHROMOSOMES CANCER; SAGER R, 1985, P NATL ACAD SCI USA, V82, P7015, DOI 10.1073/pnas.82.20.7015; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STURZBECHER HW, 1987, ONCOGENE, V1, P201; TIsty T.D., 1989, P NATL ACAD SCI USA, V86, P9441; TISTY TD, 1990, P NATL ACAD SCI USA, V87, P3132; TISTY TD, 1992, SCIENCE, V255, P1425; TRASK BJ, 1989, GENE DEV, V3, P1913, DOI 10.1101/gad.3.12a.1913; VOGELSTEIN B, 1990, NATURE, V348, P681, DOI 10.1038/348681a0; WAHL GM, 1979, J BIOL CHEM, V254, P8679; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WRIGHT JA, 1990, P NATL ACAD SCI USA, V87, P1791, DOI 10.1073/pnas.87.5.1791; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YOUNG JL, 1981, NCI MONOGRAPH, V57; ZIEG J, 1983, MOL CELL BIOL, V3, P2089, DOI 10.1128/MCB.3.11.2089	52	1408	1423	0	22	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 18	1992	70	6					923	935		10.1016/0092-8674(92)90243-6	http://dx.doi.org/10.1016/0092-8674(92)90243-6			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JN781	1356076				2022-12-01	WOS:A1992JN78100008
J	MADDEN, DR; GORGA, JC; STROMINGER, JL; WILEY, DC				MADDEN, DR; GORGA, JC; STROMINGER, JL; WILEY, DC			THE 3-DIMENSIONAL STRUCTURE OF HLA-B27 AT 2.1 ANGSTROM RESOLUTION SUGGESTS A GENERAL MECHANISM FOR TIGHT PEPTIDE BINDING TO MHC	CELL			English	Article							I HISTOCOMPATIBILITY ANTIGENS; SELF-PEPTIDES; HLA-A; ALPHA-3 DOMAIN; ANKYLOSING-SPONDYLITIS; LYMPHOCYTES-T; MOLECULES; RECOGNITION; PROTEIN; SITE	Cell surface complexes of class I MHC molecules and bound peptide antigens serve as specific recognition elements controlling the cytotoxic immune response. The 2.1 angstrom structure of the human class I MHC molecule HLA-B27 provides a detailed composite image of a co-crystallized collection of HLA-B27-bound peptides, indicating that they share a common main-chain structure and length. It also permits direct visualization of the conservation of arginine as an "anchor" side chain at the second peptide position, which is bound in a potentially HLA-B27-specific pocket and may therefore have a role in the association of HLA-B27 with several diseases. Tight peptide binding to class I MHC molecules appears to result from the extensive contacts found at the ends of the cleft between peptide main-chain atoms and conserved MHC side chains, which also involve the peptide in stabilizing the three-dimensional fold of HLA-B27. The concentration of binding interactions at the peptide termini permits extensive sequence (and probably some length) variability in the center of the peptide, where it is exposed for T cell recognition.	HARVARD UNIV,COMM HIGHER DEGREES BIOPHYS,CAMBRIDGE,MA 02138; HARVARD UNIV,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02138	Harvard University; Harvard University; Howard Hughes Medical Institute	MADDEN, DR (corresponding author), HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138, USA.							BENJAMIN R, 1990, IMMUNOL TODAY, V11, P137, DOI 10.1016/0167-5699(90)90051-A; BJORKMAN PJ, 1990, ANNU REV BIOCHEM, V59, P253, DOI 10.1146/annurev.biochem.59.1.253; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BLU M, 1990, THESIS HARVARD U CAM; BLUM M, 1987, J APPL CRYSTALLOGR, V20, P235, DOI 10.1107/S0021889887086783; BREURVRIESENDORP BS, 1987, ANN RHEUM DIS, V46, P353, DOI 10.1136/ard.46.5.353; BRICOGNE G, 1976, ACTA CRYSTALLOGR A, V32, P832, DOI 10.1107/S0567739476001691; BRODSKY FM, 1991, ANNU REV IMMUNOL, V9, P707; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1990, X PLOR; BUXTON SE, 1992, J EXP MED, V175, P809, DOI 10.1084/jem.175.3.809; CALVO V, 1990, J IMMUNOL, V144, P4038; CERUNDOLO V, 1991, EUR J IMMUNOL, V21, P2069, DOI 10.1002/eji.1830210915; CHEN BP, 1989, NATURE, V337, P743, DOI 10.1038/337743a0; CHOO SY, 1991, J IMMUNOL, V147, P174; CONNOLLY JM, 1990, P NATL ACAD SCI USA, V87, P2137, DOI 10.1073/pnas.87.6.2137; CROWTHER RA, 1967, ACTA CRYSTALLOGR, V23, P544, DOI 10.1107/S0365110X67003172; DAVIS MM, 1990, ANNU REV BIOCHEM, V59, P475, DOI 10.1146/annurev.biochem.59.1.475; DECASTRO JAL, 1989, IMMUNOL TODAY, V10, P239, DOI 10.1016/0167-5699(89)90261-2; DECASTRO JAL, 1984, METHOD ENZYMOL, V108, P582; DeMars R, 1992, Trends Cell Biol, V2, P81, DOI 10.1016/0962-8924(92)90077-Z; DURBIN RM, 1986, SCIENCE, V232, P1127, DOI 10.1126/science.3704639; EZQUERRA A, 1985, BIOCHEMISTRY-US, V24, P1733, DOI 10.1021/bi00328a025; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; FOX GC, 1966, ACTA CRYSTALLOGR, V20, P886, DOI 10.1107/S0365110X66002007; FREMONT DH, 1992, IN PRESS SCIENCE; FRENCH S, 1978, ACTA CRYSTALLOGR A, V34, P517, DOI 10.1107/S0567739478001114; GARRETT TPJ, 1989, NATURE, V342, P692, DOI 10.1038/342692a0; GORGA JC, 1987, J BIOL CHEM, V262, P16087; GORGA JC, 1992, PROTEINS, V12, P87, DOI 10.1002/prot.340120110; HAMMER RE, 1990, CELL, V63, P1099, DOI 10.1016/0092-8674(90)90512-D; HEDRICK PW, 1991, P NATL ACAD SCI USA, V88, P5897, DOI 10.1073/pnas.88.13.5897; HENDERSON RA, 1992, SCIENCE, V255, P1264, DOI 10.1126/science.1546329; HERMANS J, 1974, ACTA CRYSTALLOGR A, VA 30, P730, DOI 10.1107/S056773947400180X; HILL AVS, 1991, LANCET, V337, P640, DOI 10.1016/0140-6736(91)92452-8; HUET SH, 1990, INT IMMUNOL, V4, P311; HUNT DF, 1992, SCIENCE, V255, P1261, DOI 10.1126/science.1546328; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; Johnson CK, 1965, 3794 ONRL; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1978, ACTA CRYSTALLOGR A, V34, P827, DOI 10.1107/S0567739478001680; KHAN MA, 1987, ANKYLOSING SPONDYLIT, V1, P23; KRISHNA S, 1992, NATURE, V357, P164, DOI 10.1038/357164a0; LATRON F, 1992, IN PRESS SCIENCE; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LOPEZ D, 1992, J IMMUNOL, V148, P996; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; MADDEN DR, 1992, CURR OPIN STRUC BIOL, V2, P300; MARQUART M, 1980, J MOL BIOL, V141, P369, DOI 10.1016/0022-2836(80)90252-1; MATSUMURA M, 1992, IN PRESS SCIENCE; MCLACHLAN AD, 1979, J MOL BIOL, V128, P49, DOI 10.1016/0022-2836(79)90308-5; PARHAM P, 1988, P NATL ACAD SCI USA, V85, P4005, DOI 10.1073/pnas.85.11.4005; PARHAM P, 1977, J BIOL CHEM, V252, P7555; PONDER JW, 1987, J MOL BIOL, V193, P775, DOI 10.1016/0022-2836(87)90358-5; POTTER TA, 1989, NATURE, V337, P73, DOI 10.1038/337073a0; POWIS SJ, 1992, NATURE, V357, P211, DOI 10.1038/357211a0; ROSSMANN MG, 1962, ACTA CRYSTALLOGR, V15, P24, DOI 10.1107/S0365110X62000067; SALTER RD, 1990, NATURE, V345, P41, DOI 10.1038/345041a0; SALTER RD, 1989, NATURE, V338, P345, DOI 10.1038/338345a0; SAPER MA, 1991, J MOL BIOL, V219, P277, DOI 10.1016/0022-2836(91)90567-P; SCHULZ GE, 1979, PRINCIPALS PROTEIN S, P3; TENG TY, 1990, J APPL CRYSTALLOGR, V23, P387, DOI 10.1107/S0021889890005568; TILTON RF, 1992, BIOCHEMISTRY-US, V31, P2469, DOI 10.1021/bi00124a006; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; TURNER MJ, 1975, J BIOL CHEM, V250, P4512; VANBLEEK GM, 1991, P NATL ACAD SCI USA, V88, P11032, DOI 10.1073/pnas.88.24.11032; VILLADANGOS JA, 1992, J IMMUNOL, V149, P505; WEI ML, 1992, NATURE, V356, P443, DOI 10.1038/356443a0; ZHANG W, 1992, IN PRESS P NATL ACAD	75	643	663	0	15	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 18	1992	70	6					1035	1048		10.1016/0092-8674(92)90252-8	http://dx.doi.org/10.1016/0092-8674(92)90252-8			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JN781	1525820				2022-12-01	WOS:A1992JN78100017
J	NAGPAL, S; SAUNDERS, M; KASTNER, P; DURAND, B; NAKSHATRI, H; CHAMBON, P				NAGPAL, S; SAUNDERS, M; KASTNER, P; DURAND, B; NAKSHATRI, H; CHAMBON, P			PROMOTER CONTEXT-DEPENDENT AND RESPONSE ELEMENT-DEPENDENT SPECIFICITY OF THE TRANSCRIPTIONAL ACTIVATION AND MODULATING FUNCTIONS OF RETINOIC ACID RECEPTORS	CELL			English	Article							HUMAN ESTROGEN-RECEPTOR; HUMAN PROGESTERONE-RECEPTOR; DIFFERENTIAL PATTERN; NUCLEAR RECEPTORS; BINDING-PROTEINS; BETA-GENE; MOUSE; GAMMA; IDENTIFICATION; DOMAINS	Using several naturally occurring and synthetic retinoic acid (RA)-responsive reporter genes, we show that the patterns of transcriptional activation by various retinoic acid receptor (RAR) and retinoid X receptor (RXR) forms vary according to the nature of the RA response element and the context of the stimulated promoter. We demonstrate the presence of autonomous, ligand-inducible, and promoter context-dependent transactivation functions (AF-2s) located in the C-terminal region of all RARs and RXRs. In addition, promoter context-specific modulating transactivation functions are associated with the N-terminal A and B regions of RARs and RXRs. We also show that these transactivation and modulating functions exhibit response-element specificity. The modulating functions display a marked specificity in their cooperation with the AF-2 transactivation functions, cooperation that depends on the receptor origin of the modulating and transactivation functions and the promoter context of the RA-responsive gene, thus accounting for the specific transactivation properties of RAR and RXR types.			NAGPAL, S (corresponding author), FAC MED STRASBOURG,INST CHIM BIOL,INSERM,U184,UNITE BIOL MOLEC & GENIE GENET,CNRS,F-67085 STRASBOURG,FRANCE.		DURAND, Beatrice C/J-6387-2015; Nagpal, Sunil/A-8007-2009	DURAND, Beatrice C/0000-0002-0047-288X; Nakshatri, Harikrishna/0000-0001-8876-0052				BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BENBROOK D, 1988, NATURE, V333, P669, DOI 10.1038/333669a0; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; BLUMBERG B, 1992, P NATL ACAD SCI USA, V89, P2321, DOI 10.1073/pnas.89.6.2321; BOCQUEL MT, 1989, NUCLEIC ACIDS RES, V17, P2581, DOI 10.1093/nar/17.7.2581; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; BROCKES J, 1990, NATURE, V345, P766, DOI 10.1038/345766a0; BROCKES JP, 1989, NEURON, V2, P1285, DOI 10.1016/0896-6273(89)90066-4; CHAMBON P, 1991, RETINOIDS : 10 YEARS ON, P10; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DEVERNEUIL H, 1990, NUCLEIC ACIDS RES, V18, P4489; DOLLE P, 1989, NATURE, V342, P702, DOI 10.1038/342702a0; DOLLE P, 1990, DEVELOPMENT, V110, P1133; EVANS RM, 1988, SCIENCE, V240, P89; GAUB MP, 1992, IN PRESS EXP CELL RE, V201; GIGUERE V, 1990, MOL CELL BIOL, V10, P2335, DOI 10.1128/MCB.10.5.2335; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; GRONEMEYER H, 1991, ANNU REV GENET, V25, P89, DOI 10.1146/annurev.ge.25.120191.000513; HAMADA K, 1989, P NATL ACAD SCI USA, V86, P8289, DOI 10.1073/pnas.86.21.8289; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HUSMANN M, 1991, MOL CELL BIOL, V11, P4097, DOI 10.1128/MCB.11.8.4097; KASTNER P, 1990, P NATL ACAD SCI USA, V87, P2700, DOI 10.1073/pnas.87.7.2700; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; KLEINHITPASS L, 1988, NUCLEIC ACIDS RES, V16, P647, DOI 10.1093/nar/16.2.647; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448, DOI 10.1073/pnas.89.4.1448; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; KUMAR V, 1986, EMBO J, V5, P2231, DOI 10.1002/j.1460-2075.1986.tb04489.x; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEROY P, 1991, EMBO J, V10, P59, DOI 10.1002/j.1460-2075.1991.tb07921.x; LEROY P, 1991, P NATL ACAD SCI USA, V88, P10138, DOI 10.1073/pnas.88.22.10138; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LOTAN R, 1980, BIOCHIM BIOPHYS ACTA, V605, P33, DOI 10.1016/0304-419X(80)90021-9; MADER S, 1992, IN PRESS J BIOL CHEM, V267; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MATTEI MG, 1991, GENOMICS, V10, P1061, DOI 10.1016/0888-7543(91)90199-O; MENDELSOHN C, 1992, DEV BIOL, V152, P50, DOI 10.1016/0012-1606(92)90155-A; MENDELSOHN C, 1991, DEVELOPMENT, V113, P723; METZGER D, 1988, NATURE, V334, P31, DOI 10.1038/334031a0; MEYER ME, 1990, EMBO J, V9, P3923, DOI 10.1002/j.1460-2075.1990.tb07613.x; MEYER ME, 1992, J BIOL CHEM, V267, P10882; NAGATA T, 1992, P NATL ACAD SCI USA, V89, P937, DOI 10.1073/pnas.89.3.937; NAGPAL S, 1992, P NATL ACAD SCI USA, V89, P2718, DOI 10.1073/pnas.89.7.2718; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; ROCHETTEEGLY C, 1991, J CELL BIOL, V115, P535, DOI 10.1083/jcb.115.2.535; ROWE A, 1991, DEVELOPMENT, V111, P771; RUBERTE E, 1990, DEVELOPMENT, V108, P213; RUBERTE E, 1991, DEVELOPMENT, V111, P45; Ruberte E., 1991, SEMIN DEV BIOL, V2, P153; SAURAT JH, 1990, RETINOIDS 10 YEARS O; SHERMAN MI, 1986, RETINOIDS CELL DIFFE; SMITH WC, 1991, EMBO J, V10, P2223, DOI 10.1002/j.1460-2075.1991.tb07758.x; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; SUMMERBELL D, 1990, TRENDS NEUROSCI, V13, P142, DOI 10.1016/0166-2236(90)90006-V; TABIN CJ, 1991, CELL, V66, P199, DOI 10.1016/0092-8674(91)90612-3; TASSET D, 1990, CELL, V62, P1177, DOI 10.1016/0092-8674(90)90394-T; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TORA L, 1988, NATURE, V333, P185, DOI 10.1038/333185a0; TURCOTTE B, 1991, J BIOL CHEM, V266, P2582; VASIOS G, 1991, EMBO J, V10, P1149, DOI 10.1002/j.1460-2075.1991.tb08055.x; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; WHITE JH, 1988, COLD SPRING HARB SYM, V53, P819, DOI 10.1101/SQB.1988.053.01.093; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZELENT A, 1991, EMBO J, V10, P71, DOI 10.1002/j.1460-2075.1991.tb07922.x; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	71	336	342	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 18	1992	70	6					1007	1019		10.1016/0092-8674(92)90250-G	http://dx.doi.org/10.1016/0092-8674(92)90250-G			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JN781	1326406	Green Published			2022-12-01	WOS:A1992JN78100015
J	ORMEJOHNSON, WH				ORMEJOHNSON, WH			NITROGENASE STRUCTURE - WHERE TO NOW	SCIENCE			English	Article							IRON-MOLYBDENUM COFACTOR; AZOTOBACTER-VINELANDII; MOFE PROTEIN; CLUSTERS; METAL; SITE				ORMEJOHNSON, WH (corresponding author), MIT,DEPT CHEM,CAMBRIDGE,MA 02139, USA.							BOLIN JT, 1990, NITROGEN FIXATION : ACHIEVEMENTS AND OBJECTIVES, P117; BURGESS BK, 1990, CHEM REV, V90, P1377, DOI 10.1021/cr00106a002; CHISNELL JR, 1988, J BACTERIOL, V170, P27, DOI 10.1128/jb.170.1.27-33.1988; CHRISTOU G, 1982, J AM CHEM SOC, V104, P2820, DOI 10.1021/ja00374a021; CONRADSON SD, 1987, J AM CHEM SOC, V109, P7507, DOI 10.1021/ja00258a042; COUCOUVANIS D, 1991, ACCOUNTS CHEM RES, V24, P1, DOI 10.1021/ar00001a001; DEAN DR, 1990, NITROGEN FIXATION : ACHIEVEMENTS AND OBJECTIVES, P95; GEORGIADIS MM, 1990, NITROGEN FIXATION : ACHIEVEMENTS AND OBJECTIVES, P111; GEORGIADIS MM, 1992, SCIENCE, V257, P1653, DOI 10.1126/science.1529353; GRESSHOFF PM, 1990, NITROGEN FIXATION AC; HAUSINGER RP, 1983, J BIOL CHEM, V258, P3486; HAWKES TR, 1984, BIOCHEM J, V217, P317, DOI 10.1042/bj2170317; HOLM RH, 1977, IRON SULFUR PROTEINS, V3, P206; HOOVER TR, 1989, BIOCHEMISTRY-US, V28, P2768, DOI 10.1021/bi00433a004; HUGHES DL, 1988, NITROGEN FIXATION 10, P66; Jolly W. L., 1964, INORGANIC CHEM NITRO; KAUL BB, 1990, J AM CHEM SOC, V112, P2002, DOI 10.1021/ja00161a058; KIM JS, 1992, SCIENCE, V257, P1677, DOI 10.1126/science.1529354; LINDAHL PA, 1987, J BIOL CHEM, V262, P14945; LOWE DJ, 1984, BIOCHEM J, V24, P887; LOWE DJ, 1984, BIOCHEM J, V224, P909; MAY HD, 1990, NITROGEN FIXATION AC, P162; NELSON MJ, 1983, P NATL ACAD SCI-BIOL, V80, P147, DOI 10.1073/pnas.80.1.147; ORMEJOHNSON WH, 1985, ANNU REV BIOPHYS BIO, V14, P419, DOI 10.1146/annurev.biophys.14.1.419; RAWLINGS J, 1978, J BIOL CHEM, V253, P1001; SCHROCK RR, 1991, J AM CHEM SOC, V113, P725, DOI 10.1021/ja00002a079; SHAH VK, 1977, P NATL ACAD SCI USA, V74, P3249, DOI 10.1073/pnas.74.8.3249; SURERUS KK, IN PRESS J AM CHEM S; THORNELEY RNF, 1990, NITROGEN FIXATION : ACHIEVEMENTS AND OBJECTIVES, P103; TRUE AE, 1988, J AM CHEM SOC, V110, P1935, DOI 10.1021/ja00214a045; WINK DA, 1989, BIOCHEMISTRY-US, V28, P9407, DOI 10.1021/bi00450a024; ZIMMERMANN R, 1978, BIOCHIM BIOPHYS ACTA, V537, P185, DOI 10.1016/0005-2795(78)90504-4; 1979, AMMONIA	33	70	72	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 18	1992	257	5077					1639	1640		10.1126/science.1529351	http://dx.doi.org/10.1126/science.1529351			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JN501	1529351				2022-12-01	WOS:A1992JN50100018
J	PIERRE, P; SCHEEL, J; RICKARD, JE; KREIS, TE				PIERRE, P; SCHEEL, J; RICKARD, JE; KREIS, TE			CLIP-170 LINKS ENDOCYTIC VESICLES TO MICROTUBULES	CELL			English	Article							SEQUENCE-ANALYSIS; DROSOPHILA-MELANOGASTER; MECHANOCHEMICAL ENZYME; TRANSFERRIN RECEPTOR; CYTOPLASMIC DYNEIN; MOLECULAR-CLONING; BINDING-PROTEINS; CARRIER VESICLES; FUSION INVITRO; HEAVY-CHAIN	Binding of endocytic carrier vesicles to microtubules depends on the microtubule-binding protein CLIP-170 in vitro. In vivo, CLIP-170 colocalizes with a subset of transferrin receptor-positive endocytic structures and, more extensively, with endosomal tubules induced by brefeldin A. The structure of CLIP-170 has been analyzed by cloning its cDNA. The predicted non-helical C- and N-terminal domains of the homodimeric protein are connected by a long coiled-coil domain. We have identified a novel motif present in a tandem repeat in the N-terminal domain of CLIP-170 that is involved in binding to microtubules. This motif is also found in the Drosophila Glued and yeast BIK1 proteins. These features, together with its very elongated structure, suggest that CLIP-170 belongs to a novel class of proteins, cytoplasmic linker proteins (CLIPs), mediating interactions of organelles with microtubules.	UNIV GENEVA,DEPT CELL BIOL,SCI 3,30 QUAI ERNEST ANSERMET,CH-1211 GENEVA 4,SWITZERLAND	University of Geneva	PIERRE, P (corresponding author), EUROPEAN MOLEC BIOL LAB,W-6900 HEIDELBERG,GERMANY.			pierre, philippe/0000-0003-0863-8255				AIZAWA H, 1990, J BIOL CHEM, V265, P13849; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARGOS P, 1987, J MOL BIOL, V193, P385, DOI 10.1016/0022-2836(87)90226-9; BAIROCH A, 1989, EMBL4 EUR MOL BIOL L; BERG JM, 1986, SCIENCE, V232, P485, DOI 10.1126/science.2421409; BERLIN V, 1990, J CELL BIOL, V111, P2573, DOI 10.1083/jcb.111.6.2573; BLOOM GS, 1988, BIOCHEMISTRY-US, V27, P3409, DOI 10.1021/bi00409a043; BOMSEL M, 1990, CELL, V62, P719, DOI 10.1016/0092-8674(90)90117-W; BRESSAN GM, 1987, NUCLEIC ACIDS RES, V15, P10056, DOI 10.1093/nar/15.23.10056; CHEN MS, 1991, NATURE, V351, P583, DOI 10.1038/351583a0; CHENEY R E, 1992, Current Opinion in Cell Biology, V4, P27, DOI 10.1016/0955-0674(92)90055-H; DEBRABANDER M, 1988, CELL MOTIL CYTOSKEL, V9, P30, DOI 10.1002/cm.970090105; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIBB NJ, 1989, J MOL BIOL, V205, P603, DOI 10.1016/0022-2836(89)90229-5; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GELFAND VI, 1991, ANNU REV CELL BIOL, V7, P93, DOI 10.1146/annurev.cb.07.110191.000521; GIBBONS IR, 1991, NATURE, V352, P640, DOI 10.1038/352640a0; GILL SR, 1991, J CELL BIOL, V115, P1639, DOI 10.1083/jcb.115.6.1639; GRUENBERG J, 1989, J CELL BIOL, V108, P1301, DOI 10.1083/jcb.108.4.1301; GRUENBERG J, 1989, ANNU REV CELL BIOL, V5, P453; HERMAN B, 1984, J CELL BIOL, V98, P565, DOI 10.1083/jcb.98.2.565; HINZIKER W, 1991, CELL, V67, P5617; HOLLENBECK PJ, 1990, NATURE, V346, P864, DOI 10.1038/346864a0; HOLZBAUR ELF, 1991, NATURE, V351, P579, DOI 10.1038/351579a0; HOPKINS CR, 1983, J CELL BIOL, V97, P508, DOI 10.1083/jcb.97.2.508; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; INGOLD AL, 1988, J CELL BIOL, V107, P2659; IRMINGERFINGER I, 1990, J CELL BIOL, V111, P2563, DOI 10.1083/jcb.111.6.2563; KIRSCHNER M, 1986, CELL, V45, P329, DOI 10.1016/0092-8674(86)90318-1; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KOSAKA T, 1983, J CELL BIOL, V97, P499, DOI 10.1083/jcb.97.2.499; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LEE G, 1988, SCIENCE, V239, P285, DOI 10.1126/science.3122323; LEWIS SA, 1988, SCIENCE, V242, P936, DOI 10.1126/science.3142041; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MATTEONI R, 1987, J CELL BIOL, V105, P1253, DOI 10.1083/jcb.105.3.1253; MITHIEUX G, 1989, J BIOL CHEM, V264, P4664; NOBLE M, 1989, J CELL BIOL, V109, P3367, DOI 10.1083/jcb.109.6.3367; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PEPPERKOK R, 1990, J CELL BIOL, V111, P3003, DOI 10.1083/jcb.111.6.3003; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; RECHID R, 1989, COMPUT APPL BIOSCI, V5, P107; RICKARD JE, 1991, J BIOL CHEM, V266, P17597; RICKARD JE, 1990, J CELL BIOL, V110, P1623, DOI 10.1083/jcb.110.5.1623; Rodman JS, 1990, CURR OPIN CELL BIOL, V2, P664, DOI 10.1016/0955-0674(90)90108-Q; Sambrook J., 1989, MOL CLONING LAB MANU; SCHEEL J, 1991, J BIOL CHEM, V266, P18141; SCHEEL J, 1990, J CELL SCI, V96, P711; SCHLIWA M, 1989, CELL, V56, P719, DOI 10.1016/0092-8674(89)90672-7; SCHNEIDER A, 1988, SCIENCE, V241, P459, DOI 10.1126/science.3393912; SCHROER TA, 1991, ANNU REV PHYSIOL, V53, P629, DOI 10.1146/annurev.ph.53.030191.003213; SHPETNER HS, 1989, CELL, V59, P421, DOI 10.1016/0092-8674(89)90027-5; SIBBALD PR, 1990, COMPUT APPL BIOSCI, V6, P279; SWAROOP A, 1987, P NATL ACAD SCI USA, V84, P6501, DOI 10.1073/pnas.84.18.6501; TRUEHEART J, 1987, MOL CELL BIOL, V7, P2316, DOI 10.1128/MCB.7.7.2316; VALE RD, 1990, CELL, V60, P883, DOI 10.1016/0092-8674(90)90334-B; VALE RD, 1992, IN PRESS GUIDEBOOK C; VALLEE RB, 1990, ANNU REV BIOCHEM, V59, P909, DOI 10.1146/annurev.biochem.59.1.909; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; VANDERSLUIJS P, 1990, J CELL SCI, V95, P545; WACKER IU, 1992, J CELL BIOL, V117, P813, DOI 10.1083/jcb.117.4.813; WEST RR, 1991, J BIOL CHEM, V266, P21886; WOOD SA, 1991, CELL, V67, P591, DOI 10.1016/0092-8674(91)90533-5	67	328	340	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 18	1992	70	6					887	900		10.1016/0092-8674(92)90240-D	http://dx.doi.org/10.1016/0092-8674(92)90240-D			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JN781	1356075				2022-12-01	WOS:A1992JN78100005
J	ROTH, DB; MENETSKI, JP; NAKAJIMA, PB; BOSMA, MJ; GELLERT, M				ROTH, DB; MENETSKI, JP; NAKAJIMA, PB; BOSMA, MJ; GELLERT, M			V(D)J RECOMBINATION - BROKEN DNA-MOLECULES WITH COVALENTLY SEALED (HAIRPIN) CODING ENDS IN SCID MOUSE THYMOCYTES	CELL			English	Article							SITE-SPECIFIC RECOMBINATION; COMBINED IMMUNE-DEFICIENCY; ANTIGEN RECEPTOR GENES; SUPERCOILED DNA; DELTA-GENES; MICE; REARRANGEMENT; MUTATION; PROTEIN; REPAIR	Lymphoid cells from scid mice initiate V(D)J recombination normally but have a severely reduced ability to join coding segments. Thymocytes from scid mice contain broken DNA molecules at the TCR-delta locus that have coding ends, as well as molecules with signal ends, whereas in normal mice we previously detected only signal ends. Remarkably, these coding (but not signal) ends are sealed into hairpin structures. The formation of hairpins at coding ends may be a universal, early step in V(D)J recombination; this would provide a simple explanation for the origin of P nucleotides in coding joints. These findings may shed light on the mechanism of cleavage and suggest a possible role for the scid factor.	FOX CHASE CANC CTR, INST CANC RES, PHILADELPHIA, PA 19111 USA	Fox Chase Cancer Center	ROTH, DB (corresponding author), NIDDKD, MOLEC BIOL LAB, BETHESDA, MD 20892 USA.				NATIONAL CANCER INSTITUTE [R37CA004946, R01CA004946] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI013323] Funding Source: NIH RePORTER; NCI NIH HHS [CA-04946] Funding Source: Medline; NCRR NIH HHS [RR-05539] Funding Source: Medline; NIAID NIH HHS [AI-13323] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGUILAR LK, 1991, J IMMUNOL, V146, P1348; BIEDERMANN KA, 1991, P NATL ACAD SCI USA, V88, P1394, DOI 10.1073/pnas.88.4.1394; BLACKWELL TK, 1989, EMBO J, V8, P735, DOI 10.1002/j.1460-2075.1989.tb03433.x; BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; BOSMA MJ, 1991, ANNU REV IMMUNOL, V9, P323, DOI 10.1146/annurev.iy.09.040191.001543; CARROLL AM, 1991, GENE DEV, V5, P1357, DOI 10.1101/gad.5.8.1357; CARROLL AM, 1989, CURR TOP MICROBIOL, V152, P63; CHEN JW, 1992, CELL, V69, P647, DOI 10.1016/0092-8674(92)90228-5; CHIEN YH, 1987, NATURE, V330, P722, DOI 10.1038/330722a0; COEN ES, 1986, CELL, V47, P285, DOI 10.1016/0092-8674(86)90451-4; ELLIOTT JF, 1988, NATURE, V331, P627; FEENEY AJ, 1992, J IMMUNOL, V149, P222; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FULOP GM, 1990, NATURE, V347, P479, DOI 10.1038/347479a0; HENDRICKSON EA, 1991, P NATL ACAD SCI USA, V88, P4061, DOI 10.1073/pnas.88.10.4061; KIENKER LJ, 1991, J IMMUNOL, V147, P4351; LAFAILLE JJ, 1989, CELL, V59, P859, DOI 10.1016/0092-8674(89)90609-0; LEWIS S, 1989, CELL, V59, P585, DOI 10.1016/0092-8674(89)90002-0; LIEBER MR, 1991, FASEB J, V5, P2934, DOI 10.1096/fasebj.5.14.1752360; LIEBER MR, 1988, CELL, V55, P7, DOI 10.1016/0092-8674(88)90004-9; LILLEY DMJ, 1980, P NATL ACAD SCI-BIOL, V77, P6468, DOI 10.1073/pnas.77.11.6468; MCCORMACK WT, 1989, CELL, V56, P785, DOI 10.1016/0092-8674(89)90683-1; MEYERLEON L, 1988, MOL CELL BIOL, V8, P3784, DOI 10.1128/MCB.8.9.3784; NASH HA, 1989, EMBO J, V8, P3523, DOI 10.1002/j.1460-2075.1989.tb08518.x; PANAYOTATOS N, 1981, NATURE, V289, P466, DOI 10.1038/289466a0; REDDY MK, 1989, J BIOL CHEM, V264, P443; RICHET E, 1988, CELL, V52, P9, DOI 10.1016/0092-8674(88)90526-0; ROTH DB, 1992, CELL, V69, P41, DOI 10.1016/0092-8674(92)90117-U; Sambrook J., 1989, MOL CLONING LAB MANU; SCHULER W, 1991, EUR J IMMUNOL, V21, P589, DOI 10.1002/eji.1830210309; SCHULER W, 1988, EMBO J, V7, P2019, DOI 10.1002/j.1460-2075.1988.tb03041.x; SCHULER W, 1986, CELL, V46, P963, DOI 10.1016/0092-8674(86)90695-1; SUN H, 1991, CELL, V64, P1155, DOI 10.1016/0092-8674(91)90270-9; VANDERENDE A, 1981, NUCLEIC ACIDS RES, V9, P2037, DOI 10.1093/nar/9.9.2037; WHITE CI, 1990, EMBO J, V9, P663, DOI 10.1002/j.1460-2075.1990.tb08158.x	35	391	393	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 18	1992	70	6					983	991		10.1016/0092-8674(92)90248-B	http://dx.doi.org/10.1016/0092-8674(92)90248-B			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JN781	1356077				2022-12-01	WOS:A1992JN78100013
J	SACHS, AB; DEARDORFF, JA				SACHS, AB; DEARDORFF, JA			TRANSLATION INITIATION REQUIRES THE PAB-DEPENDENT POLY(A) RIBONUCLEASE IN YEAST	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; MESSENGER-RNA; PROTEIN-KINASE; REGULATORY SUBUNIT; TRANSFORMATION; DEADENYLATION; SEQUENCE; BINDING; SYSTEM; TAIL	Messenger RNA translation initiation and cytoplasmic poly(A) tail shortening require the poly(A)-binding protein (PAB) in yeast. The PAB-dependent poly(A) ribonuclease (PAN) has been purified to near homogeneity from S. cerevisiae based upon its PAB requirement, and its gene has been cloned. The essential PAN1 gene encodes a 161 kd protein organized into distinct domains containing repeated sequence elements. Deletion analysis of the gene revealed that only one-third of the protein is needed to maintain cell viability. Conditional mutations in PAN1 lead to an arrest of translation initiation and alterations in mRNA poly(A) tail lengths. These data suggest that PAN could mediate each of the PAB-dependent reactions within the cell, and they provide evidence for a direct relationship between translation initiation and mRNA metabolism.	WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142	Massachusetts Institute of Technology (MIT); Whitehead Institute	SACHS, AB (corresponding author), UNIV CALIF BERKELEY,DEPT BIOCHEM & MOLEC BIOL,BERKELEY,CA 94720, USA.				NIGMS NIH HHS [R29 GM43164] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM043164] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; ASTROM J, 1991, EMBO J, V10, P3067, DOI 10.1002/j.1460-2075.1991.tb07858.x; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BOEKE JD, 1987, 5 FLUOROOROTIC ACID; CANNON JF, 1987, MOL CELL BIOL, V7, P2653, DOI 10.1128/MCB.7.8.2653; ELLEDGE SJ, 1988, GENE, V70, P303, DOI 10.1016/0378-1119(88)90202-8; GIBBS JB, 1991, CELL, V65, P1, DOI 10.1016/0092-8674(91)90352-Y; Guthrie C, 1991, GUIDE YEAST GENETICS; HARLOW E, 1988, ANTIBODIES LABORATOR; HARTWELL LH, 1967, J BACTERIOL, V93, P1662, DOI 10.1128/JB.93.5.1662-1670.1967; HERRICK D, 1990, MOL CELL BIOL, V10, P2269, DOI 10.1128/MCB.10.5.2269; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KUNISAWA R, 1987, NUCLEIC ACIDS RES, V15, P368, DOI 10.1093/nar/15.1.368; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; MOLDAVE K, 1985, ANNU REV BIOCHEM, V54, P1109, DOI 10.1146/annurev.bi.54.070185.005333; MUNROE D, 1990, MOL CELL BIOL, V10, P3441, DOI 10.1128/MCB.10.7.3441; ORRWEAVER TL, 1981, P NATL ACAD SCI-BIOL, V78, P6354, DOI 10.1073/pnas.78.10.6354; PELTZ S W, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P99; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; RHOADS RE, 1988, TRENDS BIOCHEM SCI, V13, P52, DOI 10.1016/0968-0004(88)90028-X; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; Sachs A, 1990, CURR OPIN CELL BIOL, V2, P1092, DOI 10.1016/0955-0674(90)90161-7; SACHS AB, 1990, SCIENCE, V247, P1077, DOI 10.1126/science.2408148; SACHS AB, 1987, MOL CELL BIOL, V7, P3268, DOI 10.1128/MCB.7.9.3268; SACHS AB, 1989, CELL, V58, P857, DOI 10.1016/0092-8674(89)90938-0; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sherman F., 1986, METHODS YEAST GENETI; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; TODA T, 1987, MOL CELL BIOL, V7, P1371, DOI 10.1128/MCB.7.4.1371; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P320, DOI 10.1016/0968-0004(90)90022-4; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P277, DOI 10.1016/0968-0004(90)90054-F	32	184	190	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 18	1992	70	6					961	973		10.1016/0092-8674(92)90246-9	http://dx.doi.org/10.1016/0092-8674(92)90246-9			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JN781	1339314				2022-12-01	WOS:A1992JN78100011
J	SAWYERS, CL; CALLAHAN, W; WITTE, ON				SAWYERS, CL; CALLAHAN, W; WITTE, ON			DOMINANT NEGATIVE MYC BLOCKS TRANSFORMATION BY ABL ONCOGENES	CELL			English	Article							HUMAN C-MYC; CHRONIC MYELOGENOUS LEUKEMIA; GTPASE-ACTIVATING PROTEIN; TYROSINE KINASE-ACTIVITY; DNA-BINDING; PHILADELPHIA-CHROMOSOME; LYMPHOID-CELLS; V-SRC; RAS; SEQUENCES	A link between ABL oncogenes and MYC is suggested by the transformation synergy that is observed when MYC is expressed at high levels. Dominant negative MYC proteins were overexpressed in fibroblasts to determine if MYC complements ABL oncogene transformation or is essential for this process. Transformation by both v-abl and BCR-ABL oncogenes was reduced 5- to 10-fold, whereas transformation by the serine/threonine kinase oncogene v-mos was unaffected. Using a retrovirus construct modified to express BCR-ABL and MYC genes simultaneously, we show that dominant negative MYC suppressed transformation of primary mouse bone marrow pre-B cells by BCR-ABL. These observations demonstrate that c-MYC is essential for transformation and help define the pathway by which these proteins cause transformation.	UNIV CALIF LOS ANGELES, HOWARD HUGHES MED INST, DEPT MICROBIOL, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, HOWARD HUGHES MED INST, DEPT MOLEC GENET, LOS ANGELES, CA 90024 USA	Howard Hughes Medical Institute; University of California System; University of California Los Angeles; Howard Hughes Medical Institute; University of California System; University of California Los Angeles	SAWYERS, CL (corresponding author), UNIV CALIF LOS ANGELES, HOWARD HUGHES MED INST, DEPT MED, LOS ANGELES, CA 90024 USA.		Sawyers, Charles/G-5327-2016					BAICHWAL VR, 1991, NATURE, V352, P165, DOI 10.1038/352165a0; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BLICK M, 1987, CANCER GENET CYTOGEN, V27, P349, DOI 10.1016/0165-4608(87)90018-5; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CLEVELAND JL, 1989, MOL CELL BIOL, V9, P5685, DOI 10.1128/MCB.9.12.5685; DANG CV, 1989, NATURE, V337, P664, DOI 10.1038/337664a0; DEAN M, 1987, ONCOGENE RES, V1, P279; DECLUE JE, 1991, MOL CELL BIOL, V11, P2819, DOI 10.1128/MCB.11.5.2819; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FUJII M, 1989, MOL CELL BIOL, V9, P2493, DOI 10.1128/MCB.9.6.2493; HALAZONETIS TD, 1991, P NATL ACAD SCI USA, V88, P6162, DOI 10.1073/pnas.88.14.6162; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KIRSCHMEIER PT, 1988, DNA-J MOLEC CELL BIO, V7, P219, DOI 10.1089/dna.1988.7.219; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KONOPKA JB, 1985, MOL CELL BIOL, V5, P3116, DOI 10.1128/MCB.5.11.3116; KURZROCK R, 1988, NEW ENGL J MED, V319, P990; LIU E, 1988, P NATL ACAD SCI USA, V85, P1952, DOI 10.1073/pnas.85.6.1952; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; LUGO TG, 1989, MOL CELL BIOL, V9, P1263, DOI 10.1128/MCB.9.3.1263; MCCARTHY DM, 1984, LANCET, V2, P1362; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; MCLAUGHLIN J, 1989, MOL CELL BIOL, V9, P1866, DOI 10.1128/MCB.9.5.1866; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; NORI M, 1991, MOL CELL BIOL, V11, P2812, DOI 10.1128/MCB.11.5.2812; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; ROSENBAUM H, 1990, EMBO J, V9, P897, DOI 10.1002/j.1460-2075.1990.tb08187.x; ROSENBERG N, 1978, J EXP MED, V147, P1126, DOI 10.1084/jem.147.4.1126; ROSENBERG N, 1988, ADV VIRUS RES, V35, P39; ROUSSEL MF, 1991, NATURE, V353, P361, DOI 10.1038/353361a0; SCHWARTZ RC, 1986, MOL CELL BIOL, V6, P3221, DOI 10.1128/MCB.6.9.3221; SKLAR MD, 1991, MOL CELL BIOL, V11, P3699, DOI 10.1128/MCB.11.7.3699; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STACEY DW, 1991, ONCOGENE, V6, P2297; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; WHITLOCK CA, 1982, P NATL ACAD SCI-BIOL, V79, P3608, DOI 10.1073/pnas.79.11.3608	43	358	368	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 18	1992	70	6					901	910		10.1016/0092-8674(92)90241-4	http://dx.doi.org/10.1016/0092-8674(92)90241-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JN781	1525828				2022-12-01	WOS:A1992JN78100006
J	SEABRA, MC; BROWN, MS; SLAUGHTER, CA; SUDHOF, TC; GOLDSTEIN, JL				SEABRA, MC; BROWN, MS; SLAUGHTER, CA; SUDHOF, TC; GOLDSTEIN, JL			PURIFICATION OF COMPONENT-A OF RAB GERANYLGERANYL TRANSFERASE - POSSIBLE IDENTITY WITH THE CHOROIDEREMIA GENE-PRODUCT	CELL			English	Article							GTP-BINDING PROTEIN; SMG P25A; REGULATORY PROTEIN; SYNAPTIC VESICLES; PEPTIDE-BINDING; ALPHA-SUBUNIT; FARNESYLTRANSFERASE; CLONING; EXPRESSION; DEPENDENCE	Rab geranylgeranyl transferase (GG transferase) from rat brain contains two components, A and B. Component B comprises polypeptides of 60 and 38 kd. Here we report the purification of component A, a single 95 kd polypeptide. The holoenzyme attaches H-3-geranyl-geranyl to cysteines in two GTP-binding proteins, Rab3A and Rab1A. The reaction is abolished when both cysteines in the COOH-terminal CysCys sequence of Rab1A are mutated to serines. The mutant protein inhibits transfer of H-3-geranylgeranyl to wild-type Rab1A and Rab3A, suggesting that the enzyme recognizes conserved sequences distinct from the COOH-terminus. Six peptides from rat component A show striking similarity to the product of the defective gene in choroideremia, an X-linked retinal degeneration disease. The choroideremia protein resembles Rab3A GDI, which binds Rab3A. We hypothesize that component A binds conserved sequences in Rab and that component B transfers geranylgeranyl. A defect in this reaction may cause choroideremia.	UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	SEABRA, MC (corresponding author), UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235, USA.		Seabra, Miguel/AAC-3099-2019; Seabra, Miguel C/M-3280-2013	Seabra, Miguel C/0000-0002-6404-4892	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 20948] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; ARAKI S, 1990, J BIOL CHEM, V265, P13007; BALCH WE, 1990, TRENDS BIOCHEM SCI, V15, P473, DOI 10.1016/0968-0004(90)90301-Q; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASEY PJ, 1991, P NATL ACAD SCI USA, V88, P8631, DOI 10.1073/pnas.88.19.8631; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; CHEN WJ, 1991, CELL, V66, P327, DOI 10.1016/0092-8674(91)90622-6; CHEN WJ, 1991, P NATL ACAD SCI USA, V88, P11368, DOI 10.1073/pnas.88.24.11368; CREMERS FPM, 1990, NATURE, V347, P674, DOI 10.1038/347674a0; Cremers Frans P. M., 1992, Human Molecular Genetics, V1, P71, DOI 10.1093/hmg/1.2.71; FARNSWORTH CC, 1991, P NATL ACAD SCI USA, V88, P6196, DOI 10.1073/pnas.88.14.6196; FODOR E, 1991, NATURE, V351, P614, DOI 10.1038/351614b0; Heckenlively J. R., 1988, RETINITIS PIGMENTOSA; HECKENLIVELY JR, 1988, CHOROIDEREMIA RETINI, P176; HORIUCHI H, 1991, J BIOL CHEM, V266, P16981; KHOSRAVIFAR R, 1991, P NATL ACAD SCI USA, V88, P6264, DOI 10.1073/pnas.88.14.6264; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUI Y, 1990, MOL CELL BIOL, V10, P4116, DOI 10.1128/MCB.10.8.4116; MATTEOLI M, 1991, J CELL BIOL, V115, P625, DOI 10.1083/jcb.115.3.625; MERRY DE, 1992, P NATL ACAD SCI USA, V89, P2135, DOI 10.1073/pnas.89.6.2135; MOORES SL, 1991, J BIOL CHEM, V266, P14603; Pfeffer S R, 1992, Trends Cell Biol, V2, P41, DOI 10.1016/0962-8924(92)90161-F; POMPLIANO DL, 1992, BIOCHEMISTRY-US, V31, P3800, DOI 10.1021/bi00130a010; REISS Y, 1992, J BIOL CHEM, V267, P6403; REISS Y, 1991, P NATL ACAD SCI USA, V88, P732, DOI 10.1073/pnas.88.3.732; REISS Y, 1991, J BIOL CHEM, V266, P10672; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; ROSSI G, 1991, NATURE, V351, P158, DOI 10.1038/351158a0; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; SEABRA MC, 1992, J BIOL CHEM, V267, P14497; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; VONMOLLARD GF, 1990, P NATL ACAD SCI USA, V87, P1988, DOI 10.1073/pnas.87.5.1988; YOKOYAMA K, 1991, P NATL ACAD SCI USA, V88, P5302, DOI 10.1073/pnas.88.12.5302	34	258	261	1	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 18	1992	70	6					1049	1057		10.1016/0092-8674(92)90253-9	http://dx.doi.org/10.1016/0092-8674(92)90253-9			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JN781	1525821				2022-12-01	WOS:A1992JN78100018
J	SOLARO, CR; LINGLE, CJ				SOLARO, CR; LINGLE, CJ			TRYPSIN-SENSITIVE, RAPID INACTIVATION OF A CALCIUM-ACTIVATED POTASSIUM CHANNEL	SCIENCE			English	Article							CA-2+-ACTIVATED K+ CHANNELS; PITUITARY CELL-LINE; RAT MUSCLE; DROSOPHILA MUSCLE; SMALL CONDUCTANCE; SODIUM-CHANNEL; CURRENTS; BLOCKADE; NEURONS; SECRETION	Most calcium-activated potassium channels couple changes in intracellular calcium to membrane excitability by conducting a current with a probability that depends directly on submembrane calcium concentration. In rat adrenal chromaffin cells, however, a large conductance, voltage- and calcium-activated potassium channel (BK) undergoes rapid inactivation, suggesting that this channel has a physiological role different than that of other BK channels. The inactivation of the BK channel, like that of the voltage-gated Shaker B potassium channel, is removed by trypsin digestion and channels are blocked by th Shaker B amino-terminal inactivating domain. Thus, this BK channel shares functional and possibly structural homologies with other inactivating voltage-gated potassium channels.	WASHINGTON UNIV,SCH MED,DEPT ANESTHESIOL,ST LOUIS,MO 63110	Washington University (WUSTL)				Lingle, Christopher/0000-0002-9916-3795				ALDRICH RW, 1983, NATURE, V306, P436, DOI 10.1038/306436a0; AUGUSTINE GJ, 1992, J PHYSIOL-LONDON, V450, P247, DOI 10.1113/jphysiol.1992.sp019126; BARRETT JN, 1982, J PHYSIOL-LONDON, V331, P211, DOI 10.1113/jphysiol.1982.sp014370; BEZANILLA F, 1977, J GEN PHYSIOL, V70, P549, DOI 10.1085/jgp.70.5.549; BEZANILLA F, 1977, J GEN PHYSIOL, V70, P567; BLATZ AL, 1986, NATURE, V323, P718, DOI 10.1038/323718a0; CHUNG S K, 1991, Society for Neuroscience Abstracts, V17, P777; DECOURSEY TE, 1990, J GEN PHYSIOL, V95, P617, DOI 10.1085/jgp.95.4.617; FINDLAY I, 1985, FEBS LETT, V185, P4, DOI 10.1016/0014-5793(85)80729-8; GOH JW, 1987, J PHYSIOL-LONDON, V394, P315, DOI 10.1113/jphysiol.1987.sp016872; GONOI T, 1987, J GEN PHYSIOL, V89, P253, DOI 10.1085/jgp.89.2.253; HAMILL OP, 1981, PFLUGERS ARCH, V393, P254; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; IKEMOTO Y, 1989, BIOPHYS J, V56, P207, DOI 10.1016/S0006-3495(89)82665-7; IWATSUKI N, 1985, BIOCHIM BIOPHYS ACTA, V819, P249, DOI 10.1016/0005-2736(85)90180-4; KIDOKORO Y, 1980, J PHYSIOL-LONDON, V307, P199, DOI 10.1113/jphysiol.1980.sp013431; LANCASTER B, 1987, J PHYSIOL-LONDON, V387, P519, DOI 10.1113/jphysiol.1987.sp016587; LANG DG, 1990, J PHYSIOL-LONDON, V425, P117, DOI 10.1113/jphysiol.1990.sp018095; LANG DG, 1987, PFLUG ARCH EUR J PHY, V410, P614, DOI 10.1007/BF00581321; LATORRE R, 1983, J MEMBRANE BIOL, V71, P11, DOI 10.1007/BF01870671; LATTORE R, 1990, ANN REV PHYSL, V51, P385; MACDERMOTT AB, 1982, NATURE, V300, P185, DOI 10.1038/300185a0; MARTY A, 1983, TRENDS NEUROSCI, V6, P262, DOI 10.1016/0166-2236(83)90115-7; MARTY A, 1989, TRENDS NEUROSCI, V12, P420, DOI 10.1016/0166-2236(89)90090-8; MILLER C, 1987, J GEN PHYSIOL, V90, P427, DOI 10.1085/jgp.90.3.427; MURRELLLAGNADO R, COMMUNICATION; NEELY A, 1992, J PHYSIOL-LONDON, V453, P97, DOI 10.1113/jphysiol.1992.sp019220; NOHMI M, 1984, BRAIN RES, V301, P146, DOI 10.1016/0006-8993(84)90412-8; PALLOTTA BS, 1985, J PHYSIOL-LONDON, V363, P501, DOI 10.1113/jphysiol.1985.sp015724; PALLOTTA BS, 1981, NATURE, V293, P471, DOI 10.1038/293471a0; PETERSEN OH, 1984, NATURE, V307, P693, DOI 10.1038/307693a0; ROMEY G, 1984, BIOCHEM BIOPH RES CO, V118, P669, DOI 10.1016/0006-291X(84)91355-X; RUPPERSBERG JP, 1990, NATURE, V345, P535, DOI 10.1038/345535a0; RUPPERSBERG JP, 1991, NATURE, V353, P657, DOI 10.1038/353657a0; SALA F, 1990, BIOPHYS J, V57, P313, DOI 10.1016/S0006-3495(90)82533-9; STUHMER W, 1989, EMBO J, V8, P3235, DOI 10.1002/j.1460-2075.1989.tb08483.x; THOMPSON SH, 1977, J PHYSIOL-LONDON, V265, P465, DOI 10.1113/jphysiol.1977.sp011725; TORO L, 1992, Biophysical Journal, V61, pA379; VERGARA C, 1983, J GEN PHYSIOL, V82, P543, DOI 10.1085/jgp.82.4.543; YELLEN G, 1984, J GEN PHYSIOL, V84, P157, DOI 10.1085/jgp.84.2.157; ZAGOTTA WN, 1990, J GEN PHYSIOL, V95, P29, DOI 10.1085/jgp.95.1.29; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520; ZAGOTTA WN, 1989, P NATL ACAD SCI USA, V86, P7243, DOI 10.1073/pnas.86.18.7243	43	100	100	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 18	1992	257	5077					1694	1698		10.1126/science.1529355	http://dx.doi.org/10.1126/science.1529355			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JN501	1529355				2022-12-01	WOS:A1992JN50100034
J	YIN, YX; TAINSKY, MA; BISCHOFF, FZ; STRONG, LC; WAHL, GM				YIN, YX; TAINSKY, MA; BISCHOFF, FZ; STRONG, LC; WAHL, GM			WILD-TYPE P53 RESTORES CELL-CYCLE CONTROL AND INHIBITS GENE AMPLIFICATION IN CELLS WITH MUTANT P53 ALLELES	CELL			English	Article							CHINESE-HAMSTER CELLS; DNA POLYMERASE-ALPHA; MAMMALIAN-CELLS; T-ANTIGEN; COLORECTAL TUMORIGENESIS; HIGH-SENSITIVITY; CANCER SYNDROME; OVARY CELLS; CAD GENE; PROTEIN	Loss of cell cycle control and acquisition of chromosomal rearrangements such as gene amplification often occur during tumor progression, suggesting that they may be correlated. We show here that the wild-type p53 allele is lost when fibroblasts from patients with the Li-Fraumeni syndrome (LFS) are passaged in vitro. Normal and LFS cells containing wild-type p53 arrested in G1 when challenged with the uridine biosynthesis inhibitor PALA and did not undergo PALA-selected gene amplification. The converse occurred in cells lacking wild-type p53 expression. Expression of wild-type p53 in transformants of immortal and tumor cells containing mutant p53 alleles restored G1 control and reduced the frequency of gene amplification to undetectable levels. These studies reveal that p53 contributes to a metabolically regulated G1 checkpoint, and they provide a model for understanding how abnormal cell cycle progression leads to the genetic rearrangements involved in tumor progression.	UNIV TEXAS, MD ANDERSON CANC CTR, DEPT EXPTL PEDIAT, HOUSTON, TX 77030 USA; UNIV TEXAS, MD ANDERSON CANC CTR, DEPT TUMOR BIOL, HOUSTON, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	YIN, YX (corresponding author), SALK INST, SAN DIEGO, CA 92186 USA.			Tainsky, Michael/0000-0002-0261-831X	NCI NIH HHS [P01CA34936] Funding Source: Medline; NIGMS NIH HHS [GM27754] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA034936] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027754] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], 1985, DNA REPAIR; ARMITAGE P, 1954, BRIT J CANCER, V8, P1, DOI 10.1038/bjc.1954.1; AYUSAWA D, 1983, J BIOL CHEM, V258, P2448; BAKER SJ, 1990, CANCER RES, V50, P7717; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BALABAN GB, 1986, CANCER GENET CYTOGEN, V19, P113, DOI 10.1016/0165-4608(86)90378-X; BEISKER W, 1987, CYTOMETRY, V8, P235, DOI 10.1002/cyto.990080218; BIEDLER JL, 1988, CANCER RES, V48, P3179; BISCHOFF FZ, 1990, CANCER RES, V50, P7979; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; BROWN PC, 1983, MOL CELL BIOL, V3, P1097, DOI 10.1128/MCB.3.6.1097; CHEN KC, 1989, HUM GENET, V82, P40, DOI 10.1007/BF00288269; CHENG J, 1992, CANCER RES, V52, P222; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; Cleaver J E, 1989, Birth Defects Orig Artic Ser, V25, P61; DAVIDSON JN, 1990, DNA CELL BIOL, V9, P667, DOI 10.1089/dna.1990.9.667; DEAN PN, 1974, J CELL BIOL, V60, P523, DOI 10.1083/jcb.60.2.523; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; EKI T, 1987, CANCER RES, V47, P5162; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FLINTOFF WF, 1984, MOL CELL BIOL, V4, P69, DOI 10.1128/MCB.4.1.69; FULTS D, 1992, CANCER RES, V52, P674; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GOZ B, 1989, MOL PHARMACOL, V36, P360; HAHN P, 1986, CANCER RES, V46, P4607; HAMLIN JL, 1984, INT REV CYTOL, V90, P31, DOI 10.1016/S0074-7696(08)61487-4; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HUNT JD, 1990, MOL CELL BIOL, V10, P823, DOI 10.1128/MCB.10.2.823; JAMES CD, 1988, CANCER RES, V48, P5546; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KOYAMA H, 1982, MUTAT RES, V105, P433, DOI 10.1016/0165-7992(82)90190-7; LALANDE M, 1990, EXP CELL RES, V186, P332, DOI 10.1016/0014-4827(90)90313-Y; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LAVIGUEUR A, 1991, ONCOGENE, V6, P2197; LAVIGUEUR A, 1989, MOL CELL BIOL, V9, P3982, DOI 10.1128/MCB.9.9.3982; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LI FP, 1988, CANCER RES, V48, P5358; LI FP, 1969, J NATL CANCER I, V43, P1365; LITTLE JB, 1987, CANCER RES, V47, P4229; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MILNER J, 1990, EMBO J, V9, P2885, DOI 10.1002/j.1460-2075.1990.tb07478.x; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MORGAN WE, 1986, CHROMOSOMA, V93, P191, DOI 10.1007/BF00292737; MOYER JD, 1982, CANCER RES, V42, P4525; MULLIGAN LM, 1990, P NATL ACAD SCI USA, V87, P5863, DOI 10.1073/pnas.87.15.5863; NAKAMURA Y, 1988, NUCLEIC ACIDS RES, V16, P1507; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NOWELL PC, 1982, TUMOR CELL HETEROGEN, P351; OTTO E, 1989, J BIOL CHEM, V264, P3390; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; RABINOVITCH PS, 1989, LAB INVEST, V60, P65; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; RICE GC, 1987, P NATL ACAD SCI USA, V84, P9261, DOI 10.1073/pnas.84.24.9261; RICE GC, 1986, P NATL ACAD SCI USA, V83, P5978, DOI 10.1073/pnas.83.16.5978; SCHIMKE RT, 1988, J BIOL CHEM, V263, P5989; SHERLEY JL, 1991, J BIOL CHEM, V266, P24815; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STARK GR, 1986, CANCER SURV, V5, P1; STARK GR, 1984, ANNU REV BIOCHEM, V53, P447, DOI 10.1146/annurev.bi.53.070184.002311; STEIN WD, 1991, ADV CANCER RES, V56, P161; STURZBECHER HW, 1990, ONCOGENE, V5, P795; STURZBECHER HW, 1988, ONCOGENE, V3, P405; SWYRYD EA, 1974, J BIOL CHEM, V249, P6945; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TISTY T, 1982, GENE AMPLIFICATION, P231; TIsty T.D., 1989, P NATL ACAD SCI USA, V86, P9441; TISTY TD, 1990, P NATL ACAD SCI USA, V87, P3132; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WAHL GM, 1979, J BIOL CHEM, V254, P8679; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WANG Y, 1992, P NATL ACAD SCI USA, V89, P4231, DOI 10.1073/pnas.89.10.4231; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WINDLE B, 1991, GENE DEV, V5, P160, DOI 10.1101/gad.5.2.160; WINDLE BE, 1992, MUTAT RES, V276, P199, DOI 10.1016/0165-1110(92)90009-X; WRIGHT JA, 1990, P NATL ACAD SCI USA, V87, P1791, DOI 10.1073/pnas.87.5.1791; YEARGIN J, 1992, LEUKEMIA, V6, pS85; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0	89	1172	1183	0	21	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 18	1992	70	6					937	948		10.1016/0092-8674(92)90244-7	http://dx.doi.org/10.1016/0092-8674(92)90244-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JN781	1525830				2022-12-01	WOS:A1992JN78100009
J	YOUNGERSHEPHERD, S; VAESSIN, H; BIER, E; JAN, LY; JAN, YN				YOUNGERSHEPHERD, S; VAESSIN, H; BIER, E; JAN, LY; JAN, YN			DEADPAN, AN ESSENTIAL PAN-NEURAL GENE ENCODING AN HLH PROTEIN, ACTS AS A DENOMINATOR IN DROSOPHILA SEX DETERMINATION	CELL			English	Article							ACHAETE-SCUTE COMPLEX; LOOP-HELIX PROTEINS; PERIPHERAL NERVOUS-SYSTEM; X-A RATIO; DOSAGE COMPENSATION; DNA-BINDING; DETERMINATION SIGNAL; NEGATIVE REGULATOR; PRONEURAL CLUSTERS; NUMERATOR ELEMENT	In Drosophila, sex is determined by the X:A ratio. One major numerator element on the X chromosome is sisterless-b (sis-b), also called scute, which encodes an HLH-type transcription factor. We report here that an essential pan-neural gene, the autosomal HLH gene deadpan (dpn), acts as a denominator element. As revealed by dosage-dependent dominant interactions, males die with too high a ratio of sc+ to dpn+, caused by misexpression of Sex lethal (Sxl) in embryos, and females die with too low a ratio of sc+ to dpn+, because of altered embryonic Sxl expression. In addition, we found that the HLH gene extramacrochaetae (emc), like daughterless (da), is needed maternally for proper communication of the X:A ratio, thus supporting the idea that a set of HLH genes comprises a functional cassette that makes a sensitive and stable genetic switch used in both neural determination and sex determination.	UNIV CALIF SAN FRANCISCO, DEPT PHYSIOL & BIOCHEM, SAN FRANCISCO, CA 94143 USA; OHIO STATE UNIV, DEPT MOLEC GENET, COLUMBUS, OH 43210 USA; OHIO STATE UNIV, OHIO STATE BIOTECHNOL CTR, COLUMBUS, OH 43210 USA; UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, CTR MOLEC GENET, LA JOLLA, CA 92093 USA	University of California System; University of California San Francisco; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University of California System; University of California San Diego; University of California System; University of California San Diego	YOUNGERSHEPHERD, S (corresponding author), UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, SAN FRANCISCO, CA 94143 USA.			Jan, Yuh Nung/0000-0003-1367-6299; Jan, Lily/0000-0003-3938-8498				BAKER BS, 1989, GENOME, V31, P638, DOI 10.1139/g89-117; BAKER BS, 1989, NATURE, V340, P521, DOI 10.1038/340521a0; BELL AE, 1954, GENETICS, V39, P958; BELL LR, 1991, CELL, V65, P229, DOI 10.1016/0092-8674(91)90157-T; BELL LR, 1988, CELL, V55, P1037, DOI 10.1016/0092-8674(88)90248-6; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; BODMER R, 1987, ROUX ARCH DEV BIOL, V196, P69, DOI 10.1007/BF00402027; BODMER R, 1989, NEURON, V3, P21, DOI 10.1016/0896-6273(89)90112-8; BOGGS RT, 1987, CELL, V50, P739, DOI 10.1016/0092-8674(87)90332-1; BOPP D, 1991, GENE DEV, V5, P403, DOI 10.1101/gad.5.3.403; BOTAS J, 1982, EMBO J, V1, P307, DOI 10.1002/j.1460-2075.1982.tb01165.x; BRAND M, 1988, ROUX ARCH DEV BIOL, V197, P457, DOI 10.1007/BF00385679; Bridges CB, 1925, AM NAT, V59, P127, DOI 10.1086/280023; Bridges CB, 1921, SCIENCE, V54, P252, DOI 10.1126/science.54.1394.252; CABRERA CV, 1990, DEVELOPMENT, V109, P733; CABRERA CV, 1991, EMBO J, V10, P2965, DOI 10.1002/j.1460-2075.1991.tb07847.x; Campos-Ortega JA., 1997, EMBRYONIC DEV DROSOP; CARROLL SB, 1989, GENE DEV, V3, P905, DOI 10.1101/gad.3.6.905; CAUDY M, 1988, CELL, V55, P1061, DOI 10.1016/0092-8674(88)90250-4; CAUDY M, 1988, GENE DEV, V2, P843, DOI 10.1101/gad.2.7.843; CLINE TW, 1986, GENETICS, V113, P641; CLINE TW, 1978, GENETICS, V90, P683; CLINE TW, 1984, GENETICS, V107, P231; CLINE TW, 1976, GENETICS, V84, P723; CLINE TW, 1980, GENETICS, V96, P903; CLINE TW, 1988, GENETICS, V119, P829; CLINE TW, 1983, DEV BIOL, V95, P260, DOI 10.1016/0012-1606(83)90027-1; CLINE TW, 1979, DEV BIOL, V72, P266, DOI 10.1016/0012-1606(79)90117-9; CLINE TW, 1989, CELL, V59, P231, DOI 10.1016/0092-8674(89)90280-8; CLINE TW, 1983, GENETICS, V104, P516; CORBIN V, 1991, CELL, V67, P311, DOI 10.1016/0092-8674(91)90183-Y; CRONMILLER C, 1987, CELL, V48, P479, DOI 10.1016/0092-8674(87)90198-X; CRONMILLER C, 1988, GENE DEV, V2, P1666, DOI 10.1101/gad.2.12a.1666; CRONMILLER C, 1986, DEV GENET, V7, P205, DOI 10.1002/dvg.1020070406; CUBAS P, 1991, GENE DEV, V5, P996, DOI 10.1101/gad.5.6.996; DAMBLYCHAUDIERE C, 1987, GENE DEV, V1, P297, DOI 10.1101/gad.1.3.297; DAMBLYCHAUDIERE C, 1988, ROUX ARCH DEV BIOL, V197, P419, DOI 10.1007/BF00398993; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DELPRADO JM, 1984, W ROUX ARCH DEV BIOL, V193, P242; Dobzhansky T, 1934, J GENET, V28, P349, DOI 10.1007/BF02981760; DUFFY JB, 1991, GENE DEV, V5, P2176, DOI 10.1101/gad.5.12a.2176; ELLIS HM, 1990, CELL, V61, P27, DOI 10.1016/0092-8674(90)90212-W; ERICKSON JW, 1991, SCIENCE, V251, P1071, DOI 10.1126/science.1900130; FOE VE, 1983, J CELL SCI, V61, P31; GARRELL J, 1990, CELL, V61, P39, DOI 10.1016/0092-8674(90)90213-X; GERGEN JP, 1987, GENETICS, V117, P477; GHYSEN A, 1989, TRENDS GENET, V5, P251, DOI 10.1016/0168-9525(89)90097-8; HODGKIN J, 1990, NATURE, V344, P721, DOI 10.1038/344721a0; INGHAM PW, 1985, GENETICS, V111, P463; JAN YN, 1990, TRENDS NEUROSCI, V13, P493, DOI 10.1016/0166-2236(90)90083-M; KEYES LN, 1992, CELL, V68, P933, DOI 10.1016/0092-8674(92)90036-C; LINDSLEY D, 1987, DROS INF SERV, V65; LUCCHESI JC, 1981, CHROMOSOMA, V82, P217, DOI 10.1007/BF00286106; MANGE AP, 1973, GENETICS, V73, P73; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NAGOSHI RN, 1988, CELL, V53, P229, DOI 10.1016/0092-8674(88)90384-4; PARKHURST SM, 1990, CELL, V63, P1179, DOI 10.1016/0092-8674(90)90414-A; RUOHOLA H, 1991, CELL, V66, P433, DOI 10.1016/0092-8674(81)90008-8; RUSHLOW CA, 1989, EMBO J, V8, P3095, DOI 10.1002/j.1460-2075.1989.tb08461.x; SALZ HK, 1989, GENE DEV, V3, P708, DOI 10.1101/gad.3.5.708; SANCHEZ L, 1983, EMBO J, V2, P485, DOI 10.1002/j.1460-2075.1983.tb01451.x; SCHUPBACH T, 1985, GENETICS, V109, P529; SCHUPBACH T, 1982, DEV BIOL, V89, P117, DOI 10.1016/0012-1606(82)90300-1; SIMPSON P, 1990, DEVELOPMENT, V110, P927; SKEATH JB, 1991, GENE DEV, V5, P984, DOI 10.1101/gad.5.6.984; SLEE R, 1990, Q REV BIOL, V65, P175, DOI 10.1086/416718; Steinmann-Zwicky M, 1990, Adv Genet, V27, P189; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TORRES M, 1989, EMBO J, V8, P3079, DOI 10.1002/j.1460-2075.1989.tb08459.x; TORRES M, 1991, DEVELOPMENT, V113, P715; VAESSIN H, 1991, CELL, V67, P941, DOI 10.1016/0092-8674(91)90367-8; VAESSIN H, 1990, COLD SH Q B, V55, P239; VANDOREN M, 1991, DEVELOPMENT, V113, P245; VILLARES R, 1987, CELL, V50, P415, DOI 10.1016/0092-8674(87)90495-8	76	112	114	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 18	1992	70	6					911	922		10.1016/0092-8674(92)90242-5	http://dx.doi.org/10.1016/0092-8674(92)90242-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JN781	1525829				2022-12-01	WOS:A1992JN78100007
J	CLARK, SW; MEYER, DI				CLARK, SW; MEYER, DI			CENTRACTIN IS AN ACTIN HOMOLOG ASSOCIATED WITH THE CENTROSOME	NATURE			English	Article							GAMMA-TUBULIN; ASPERGILLUS-NIDULANS; BINDING PROTEINS; IDENTIFICATION; CONSTRUCTION; EXPRESSION; COMPONENT; RNA; TRANSLOCATION; MEMBRANE	ACTIN is one of the most ubiquitous, abundant and well-conserved proteins of eukaryotes, participating in many crucial cellular processes including the maintenance of cell shape, motility and cell division1,2. Actins from the most divergent sources still share amino-acid identities in excess of 70% (ref. 3). This may well explain why low-abundance homologues of actin have been difficult to isolate. Genes encoding distant relatives of actin in budding and fission yeast have now been cloned3,4. We report here the discovery of a vertebrate actin-like protein, which we name centractin. A full-length complementary DNA clone was isolated whose sequence reveals amino-acid identities with actin of over 50%, increasing to more than 70% when conservative amino-acid changes are considered. Northern analysis and western blotting indicate a ubiquitous tissue and species distribution. Morphological and biochemical criteria show that centractin is associated with centrosomes.	UNIV CALIF LOS ANGELES,SCH MED,DEPT BIOL CHEM,LOS ANGELES,CA 90024; MOLEC BIOL INST,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA								ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; ANSORGE W, 1985, J BIOCHEM BIOPH METH, V11, P13, DOI 10.1016/0165-022X(85)90037-5; BORNENS M, 1987, CELL MOTIL CYTOSKEL, V8, P238, DOI 10.1002/cm.970080305; BUCKINGHAM ME, 1985, ESSAYS BIOCHEM, V20, P77; BUSH GL, 1991, J BIOL CHEM, V266, P13811; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GILL SR, 1991, J CELL BIOL, V115, P1639, DOI 10.1083/jcb.115.6.1639; GOSTITESTU F, 1986, EMBO J, V5, P2545, DOI 10.1002/j.1460-2075.1986.tb04533.x; HERZ J, 1990, FEBS LETT, V276, P103, DOI 10.1016/0014-5793(90)80518-N; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; HORTSCH M, 1986, J CELL BIOL, V103, P241, DOI 10.1083/jcb.103.1.241; JOSHI HC, 1992, NATURE, V356, P80, DOI 10.1038/356080a0; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KUENZEL EA, 1987, J BIOL CHEM, V262, P9136; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEESMILLER JP, 1992, NATURE, V359, P244, DOI 10.1038/359244a0; LEESMILLER JP, 1992, P NATL ACAD SCI USA, V89, P80, DOI 10.1073/pnas.89.1.80; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MARO B, 1980, BIOL CELLULAIRE, V39, P287; MINTY AJ, 1981, J BIOL CHEM, V256, P1008; MITCHISON T, 1984, NATURE, V312, P232, DOI 10.1038/312232a0; OAKLEY BR, 1990, CELL, V61, P1289, DOI 10.1016/0092-8674(90)90693-9; OAKLEY CE, 1989, NATURE, V338, P662, DOI 10.1038/338662a0; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OSBORN M, 1976, P NATL ACAD SCI USA, V73, P867, DOI 10.1073/pnas.73.3.867; Pollard TD, 1990, CURR OPIN CELL BIOL, V2, P33, DOI 10.1016/S0955-0674(05)80028-6; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; PONTE P, 1983, MOL CELL BIOL, V3, P1783, DOI 10.1128/MCB.3.10.1783; Sambrook J., 1989, MOL CLONING LAB MANU; SCHWOB E, 1992, NATURE, V355, P179, DOI 10.1038/355179a0; STANLEY KK, 1984, EMBO J, V3, P1429, DOI 10.1002/j.1460-2075.1984.tb01988.x; STEARNS T, 1991, CELL, V65, P825, DOI 10.1016/0092-8674(91)90390-K; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ZHENG YX, 1991, CELL, V65, P817, DOI 10.1016/0092-8674(91)90389-G	35	161	167	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 17	1992	359	6392					246	250		10.1038/359246a0	http://dx.doi.org/10.1038/359246a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JN944	1356230				2022-12-01	WOS:A1992JN94400065
J	DEBOER, P; CROSSLEY, R; ROTHFIELD, L				DEBOER, P; CROSSLEY, R; ROTHFIELD, L			THE ESSENTIAL BACTERIAL CELL-DIVISION PROTEIN FTSZ IS A GTPASE	NATURE			English	Article							ESCHERICHIA-COLI; GENE-FTSZ; BACILLUS-SUBTILIS; SEPTATION; CLONING; SITE	CYTOKINESIS defines the last stage in the division cycle, in which cell constriction leads to the formation of daughter cells. The biochemical mechanisms responsible for this process are poorly understood. In bacteria, the ftsZ gene product, FtsZ, is required for cell division1-3,17, playing a prominent role in cytokinesis. The cellular concentration of FtsZ regulates the frequency of division4 and genetic studies have indicated that it is the target of several endogenous division inhibitors5. At the time of onset of septal invagination, the FtsZ protein is recruited from the cytoplasm to the division site, where it assembles into a ring that remains associated with the leading edge of the invaginating septum until septation is completed 6. Here we report that FtsZ specifically binds and hydrolyses GTP. The reaction can be dissociated into a GTP-dependent activation stage that is markedly affected by the concentration of FtsZ, and a hydrolysis stage in which GTP is hydrolysed to GDP. The results indicate that GTP binding and hydrolysis are important in enabling FtsZ to support bacterial cytokinesis, either by facilitating the assembly of the FtsZ ring and/or by catalysing an essential step in the cytokinetic process itself.			DEBOER, P (corresponding author), UNIV CONNECTICUT, CTR HLTH, DEPT MICROBIOL, FARMINGTON, CT 06030 USA.			de Boer, Piet/0000-0002-5375-6317				BAIROCH A, 1991, NUCLEIC ACIDS RES, V19, P2241, DOI 10.1093/nar/19.suppl.2241; BEALL B, 1988, J BACTERIOL, V170, P4855, DOI 10.1128/jb.170.10.4855-4864.1988; BEALL B, 1991, GENE DEV, V5, P447, DOI 10.1101/gad.5.3.447; BI E, 1990, J BACTERIOL, V172, P5602, DOI 10.1128/jb.172.10.5602-5609.1990; BI E, 1991, NATURE, V354, P161, DOI 10.1038/354161a0; CARLIER MF, 1989, INT REV CYTOL, V115, P139; DAI K, 1991, J BACTERIOL, V173, P3500, DOI 10.1128/jb.173.11.3500-3506.1991; DEBOER PAJ, 1990, ANNU REV GENET, V24, P249, DOI 10.1146/annurev.genet.24.1.249; DEBOER PAJ, 1991, EMBO J, V10, P4371, DOI 10.1002/j.1460-2075.1991.tb05015.x; HESSE J, 1987, J BIOL CHEM, V262, P15472; LUTKENHAUS JF, 1980, J BACTERIOL, V142, P615, DOI 10.1128/JB.142.2.615-620.1980; MARGOLIN W, 1991, J BACTERIOL, V173, P5822, DOI 10.1128/jb.173.18.5822-5830.1991; PLA J, 1991, MOL MICROBIOL, V5, P1681, DOI 10.1111/j.1365-2958.1991.tb01915.x; STERNLICHT H, 1987, FEBS LETT, V214, P226, DOI 10.1016/0014-5793(87)80061-3; WANG XD, 1991, EMBO J, V10, P3363, DOI 10.1002/j.1460-2075.1991.tb04900.x; WARD JE, 1985, CELL, V42, P941, DOI 10.1016/0092-8674(85)90290-9; YI QM, 1985, GENE, V36, P241	17	445	458	1	50	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 17	1992	359	6392					254	256		10.1038/359254a0	http://dx.doi.org/10.1038/359254a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JN944	1528268				2022-12-01	WOS:A1992JN94400067
J	DORIN, JR; DICKINSON, P; ALTON, EWFW; SMITH, SN; GEDDES, DM; STEVENSON, BJ; KIMBER, WL; FLEMING, S; CLARKE, AR; HOOPER, ML; ANDERSON, L; BEDDINGTON, RSP; PORTEOUS, DJ				DORIN, JR; DICKINSON, P; ALTON, EWFW; SMITH, SN; GEDDES, DM; STEVENSON, BJ; KIMBER, WL; FLEMING, S; CLARKE, AR; HOOPER, ML; ANDERSON, L; BEDDINGTON, RSP; PORTEOUS, DJ			CYSTIC-FIBROSIS IN THE MOUSE BY TARGETED INSERTIONAL MUTAGENESIS	NATURE			English	Article							EMBRYONIC STEM-CELLS; POTENTIAL DIFFERENCE; GENE; IDENTIFICATION; REGULATOR	Cystic fibrosis is a fatal genetic disorder which afflicts 50,000 people worldwide. A viable animal model would be invaluable for investigating and combating this disease. The mouse cystic fibrosis transmembrane conductance regulator gene was disrupted in embryonal stem cells using an insertional gene targeting vector. Germ-line chimaeras were derived and the off spring of heterozygous crosses studied. These homozygous mutant mice survive beyond weaning. In vivo electrophysiology demonstrates the predicted defect in chloride ion transport in these mice and can distinguish between each genotype. Histological analysis detects important hallmarks of human disease pathology, including abnormalities of the colon, lung and vas deferens. This insertional mouse mutation provides a valid model system for the development and testing of therapies for cystic fibrosis patients.	WESTERN GEN HOSP,MRC,HUMAN GENET UNIT,CREWE RD,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND; NATL HEART & LUNG INST,ION TRANSPORT LAB,LONDON SW3 6LR,ENGLAND; UNIV EDINBURGH,SCH MED,DEPT PATHOL,CANC RES CAMPAIGN LABS,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND; AFRC,CTR GENOME RES,EDINBURGH EH9 3JQ,MIDLOTHIAN,SCOTLAND	University of Edinburgh; Imperial College London; University of Edinburgh			Dickinson, Paul/B-7598-2014; Clarke, Alan R/A-6256-2008; Porteous, David J/C-7289-2013; clarke, alan r/P-2820-2014; Porteous, David/AAA-3446-2021	Porteous, David J/0000-0003-1249-6106; Porteous, David/0000-0003-1249-6106; Clarke, Alan/0000-0002-4281-426X; Alton, Eric WFW/0000-0003-3852-6764				ALTON EWF, IN PRESS THORAX; ALTON EWFW, 1991, EUR RESPIR J, V4, P5; ALTON EWFW, 1990, EUR RESPIR J, V3, P922; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; Boat TF., 1989, CYSTIC FIBROSIS META, V6th, P2649; CLARKE LL, 1992, SCIENCE, V257, P1125, DOI 10.1126/science.257.5073.1125; COLLINS FS, 1992, SCIENCE, V256, P774, DOI 10.1126/science.1375392; CUTTING GR, 1990, NEW ENGL J MED, V323, P1685, DOI 10.1056/NEJM199012133232407; DENG CX, 1992, MOL CELL BIOL, V12, P3365, DOI 10.1128/MCB.12.8.3365; DIAMOND G, 1991, J BIOL CHEM, V266, P22761; Dorin Julia R., 1992, Transgenic Research, V1, P101, DOI 10.1007/BF02513027; EGAN M, 1992, NATURE, V358, P581, DOI 10.1038/358581a0; GOLDSTEIN JL, 1988, AM J PHYSIOL, V254, P718; HASTY P, 1991, NATURE, V350, P243, DOI 10.1038/350243a0; HASTY P, 1992, MOL CELL BIOL, V12, P1464; IVANSCHENKO T, 1991, GENOMICS, V10, P298; JACKSON ADM, 1989, CYSTIC FIBROSIS, P1; JONES CT, 1992, HUM MOL GENET, V1, P11, DOI 10.1093/hmg/1.1.11; KAPLAN E, 1968, NEW ENGL J MED, V279, P65, DOI 10.1056/NEJM196807112790203; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KNOWLES M, 1981, NEW ENGL J MED, V305, P1489, DOI 10.1056/NEJM198112173052502; KOLLER BH, 1991, P NATL ACAD SCI USA, V88, P10730, DOI 10.1073/pnas.88.23.10730; KRISTIDIS P, 1992, AM J HUM GENET, V50, P1178; MOENS CB, 1992, GENE DEV, V6, P691, DOI 10.1101/gad.6.5.691; Oppenheimer E H, 1975, Perspect Pediatr Pathol, V2, P241; QUINTON PM, 1990, NATURE, V347, P226, DOI 10.1038/347226a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SCHWACHMAN H, 1965, PEDIATRICS, V36, P689; SHOSHANI T, 1992, AM J HUM GENET, V50, P222; SMITH SN, 1992, CLIN SCI, V82, P667, DOI 10.1042/cs0820667; SNOUWAERT JN, 1992, SCIENCE, V257, P1083, DOI 10.1126/science.257.5073.1083; WIDDICOMBE JH, 1985, P NATL ACAD SCI USA, V82, P6167, DOI 10.1073/pnas.82.18.6167; WILLUMSEN NJ, 1991, AM J PHYSIOL, V261, P319; WINE JJ, 1992, NAT GENET, V1, P10, DOI 10.1038/ng0492-10	35	253	263	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 17	1992	359	6392					211	215		10.1038/359211a0	http://dx.doi.org/10.1038/359211a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JN944	1382232	Green Submitted			2022-12-01	WOS:A1992JN94400051
J	HOGAN, BLM; THALLER, C; EICHELE, G				HOGAN, BLM; THALLER, C; EICHELE, G			EVIDENCE THAT HENSEN NODE IS A SITE OF RETINOIC ACID SYNTHESIS	NATURE			English	Article							DEVELOPING CHICK LIMB; LOCAL APPLICATION; XENOPUS EMBRYOS; NERVOUS-SYSTEM; MOUSE EMBRYOS; EXPRESSION; PATTERN; GENES; BUD; TRANSFORMATION	HENSEN'S node of amniotes, like the Spemann organizer of amphibians, can induce a second body axis when grafted into a host embryo1. The avian node, as well as several midline structures originating from it (notochord, floor plate), can also induce digit pattern duplications when grafted into the chick wing bud2,3. We report here that the equivalent of Hensen's node from mouse is an effective inducer of digits in the chick wing bud. Tissues anterior and posterior to the node also evoke pattern duplications, but with a significantly lower efficiency. The finding that the murine node operates in an avian wing bud suggests that the same inducing agent(s) function in both primary and secondary embryonic fields and have been conserved during vertebrate evolution. Digit pattern duplications are also evoked by local administration of all-transretinoic acid4,5. This similarity raises the possibility that Hensen's node is a source of retinoic acid. The mouse node is capable of synthesizing retinoic acid from its biosynthetic precursor all-transretinol at a substantially higher rate than either anterior or posterior tissues.	BAYLOR COLL MED,V&M MCLEAN DEPT BIOCHEM,HOUSTON,TX 77030; VANDERBILT UNIV,MED CTR,SCH MED,DEPT CELL BIOL,NASHVILLE,TN 37232	Baylor College of Medicine; Vanderbilt University								ALTABA ARI, 1991, GENE DEV, V5, P175, DOI 10.1101/gad.5.2.175; [Anonymous], 1952, EPIGENETICS BIRDS; CONLON RA, IN PRESS DEVELOPMENT; DURSTON AJ, 1989, NATURE, V340, P140, DOI 10.1038/340140a0; EICHELE G, 1989, TRENDS GENET, V5, P246, DOI 10.1016/0168-9525(89)90096-6; GAUNT SJ, 1990, TRENDS GENET, V6, P208; HORNBRUCH A, 1986, J EMBRYOL EXP MORPH, V94, P257; JESSELL TM, 1992, CELL, V68, P257, DOI 10.1016/0092-8674(92)90469-S; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LAWSON KA, 1992, CIBA F SYMP, V165, P3; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MORRISSKAY GM, 1991, EMBO J, V10, P2985, DOI 10.1002/j.1460-2075.1991.tb07849.x; MURPHY P, 1991, DEVELOPMENT, V111, P61; PAPALOPULU N, 1991, NUCLEIC ACIDS RES, V19, P5497, DOI 10.1093/nar/19.20.5497; Romijn HJ, 1982, DEV BRAIN RES, V2, P583; ROSSANT J, 1991, GENE DEV, V5, P1333, DOI 10.1101/gad.5.8.1333; RUBERTE E, 1991, DEVELOPMENT, V111, P45; SCHOENWOLF GC, 1992, DEV DYNAM, V193, P235, DOI 10.1002/aja.1001930304; SELLECK MAJ, 1991, DEVELOPMENT, V112, P615; SHARPE CR, 1991, NEURON, V7, P239, DOI 10.1016/0896-6273(91)90262-X; SIMEONE A, 1990, NATURE, V346, P763, DOI 10.1038/346763a0; SIMEONE A, 1991, MECH DEVELOP, V33, P215, DOI 10.1016/0925-4773(91)90029-6; SIVE HL, 1990, GENE DEV, V4, P932, DOI 10.1101/gad.4.6.932; SMITH SM, 1991, DEVELOPMENT, V111, P245; STERN CD, 1979, ANAT EMBRYOL, V156, P319, DOI 10.1007/BF00299630; SUMMERBELL D, 1983, J EMBRYOL EXP MORPH, V78, P269; SUNDIN O, 1992, DEVELOPMENT, V114, P841; THALLER C, 1990, NATURE, V345, P815, DOI 10.1038/345815a0; THALLER C, 1988, DEVELOPMENT, V103, P473; TICKLE C, 1982, NATURE, V296, P564, DOI 10.1038/296564a0; TICKLE C, 1975, NATURE, V254, P199, DOI 10.1038/254199a0; WAGNER M, 1990, NATURE, V345, P819, DOI 10.1038/345819a0	33	205	206	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 17	1992	359	6392					237	241		10.1038/359237a0	http://dx.doi.org/10.1038/359237a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JN944	1528265				2022-12-01	WOS:A1992JN94400062
J	OSIPCHUK, Y; CAHALAN, M				OSIPCHUK, Y; CAHALAN, M			CELL-TO-CELL SPREAD OF CALCIUM SIGNALS MEDIATED BY ATP RECEPTORS IN MAST-CELLS	NATURE			English	Article							MECHANICAL STIMULATION; G-PROTEINS; SECRETION; CA-2+; OSCILLATIONS; IONOPHORES; GLUTAMATE; GRANULES; MEMBRANE; WAVES	RAT basophilic leukaemia cells, like mast cells from which they are derived, have surface Fc-epsilon receptors that trigger secretion of inflammatory mediators when crosslinked. Both GTP-binding proteins and a rise in cytosolic calcium concentration ([Ca2+]i) are implicated in the secretory mechanism1-5. Here we use a video-imaging technique to report that transient rises in [Ca2+]i initiated in an individual cell can spread from cell to cell in a wave-like pattern by means of a secreted intermediate, in the absence of gap-junctional communication. We find that the leukaemia cells, peritoneal mast cells and mucosal mast cells have cell-surface P2-type purinergic receptors that can trigger similar [Ca2+]i transients. We provide evidence that ATP is rapidly released, and that it can amplify [Ca2+]i signals and initial secretory responses during antigen-stimulation of rat basophilic leukaemia cells.			OSIPCHUK, Y (corresponding author), UNIV CALIF IRVINE,DEPT PHYSIOL & BIOPHYS,IRVINE,CA 92717, USA.							ALI H, 1989, J IMMUNOL, V143, P2626; ALMERS W, 1985, FEBS LETT, V192, P13, DOI 10.1016/0014-5793(85)80033-8; ALTER SC, 1989, BIOCHIM BIOPHYS ACTA, V991, P426, DOI 10.1016/0304-4165(89)90068-8; BORN GVR, 1984, J PHYSIOL-LONDON, V354, P419, DOI 10.1113/jphysiol.1984.sp015385; BROIDE DH, 1988, J IMMUNOL, V141, P4298; BURNSTOCK G, 1990, ANN NY ACAD SCI, V603, P1; CHAKRAVARTY N, 1980, ACTA PHARMACOL TOX, V47, P223; CHARLES AC, 1991, NEURON, V6, P983, DOI 10.1016/0896-6273(91)90238-U; CHEEK TR, 1989, J CELL BIOL, V109, P1219, DOI 10.1083/jcb.109.3.1219; COCHRANE DE, 1974, P NATL ACAD SCI USA, V71, P408, DOI 10.1073/pnas.71.2.408; CORNELLBELL AH, 1990, SCIENCE, V247, P470, DOI 10.1126/science.1967852; DEMATTEIS MA, 1991, J BIOL CHEM, V266, P10452; DUBYAK GR, 1990, ANN NY ACAD SCI, V603, P227; FERNANDEZ JM, 1984, NATURE, V312, P453, DOI 10.1038/312453a0; GRISSMER S, 1992, J GEN PHYSIOL, V99, P63, DOI 10.1085/jgp.99.1.63; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HOWELL TW, 1987, J CELL BIOL, V105, P191, DOI 10.1083/jcb.105.1.191; JOHNSON RG, 1980, FEBS LETT, V120, P75, DOI 10.1016/0014-5793(80)81050-7; LEFF P, 1990, BRIT J PHARMACOL, V101, P645, DOI 10.1111/j.1476-5381.1990.tb14134.x; LEVISCHAFFER F, 1985, J IMMUNOL, V135, P3454; MCCLOSKEY MA, 1990, J GEN PHYSIOL, V95, P205, DOI 10.1085/jgp.95.2.205; MILLARD PJ, 1989, J BIOL CHEM, V264, P19730; NEHER E, 1988, J PHYSIOL-LONDON, V395, P193, DOI 10.1113/jphysiol.1988.sp016914; PLAUT M, 1989, NATURE, V339, P64, DOI 10.1038/339064a0; SANDERSON MJ, 1990, CELL REGUL, V1, P585, DOI 10.1091/mbc.1.8.585; TATHAM PER, 1988, EUR J PHARMACOL, V147, P13, DOI 10.1016/0014-2999(88)90628-0; TATHAM PER, 1990, J GEN PHYSIOL, V95, P459, DOI 10.1085/jgp.95.3.459; UVNAS B, 1974, LIFE SCI, V14, P2355, DOI 10.1016/0024-3205(74)90131-3; WOLDEMUSSIE E, 1986, J IMMUNOL, V137, P1674	29	337	342	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 17	1992	359	6392					241	244		10.1038/359241a0	http://dx.doi.org/10.1038/359241a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JN944	1388246				2022-12-01	WOS:A1992JN94400063
J	POWELL, SM; ZILZ, N; BEAZERBARCLAY, Y; BRYAN, TM; HAMILTON, SR; THIBODEAU, SN; VOGELSTEIN, B; KINZLER, KW				POWELL, SM; ZILZ, N; BEAZERBARCLAY, Y; BRYAN, TM; HAMILTON, SR; THIBODEAU, SN; VOGELSTEIN, B; KINZLER, KW			APC MUTATIONS OCCUR EARLY DURING COLORECTAL TUMORIGENESIS	NATURE			English	Article							GENES; IDENTIFICATION; CHROMOSOME-5Q21; CANCERS; LOCUS; FAP	HUMAN tumorigenesis is associated with the accumulation of mutations both in oncogenes and in tumour suppressor genes1-3. But in no common adult cancer have the mutations that are critical in the early stages of the tumorigenic process been defined. We have attempted to determine if mutations of the APC gene play such a role in human colorectal tumours, which evolve from small benign tumours (adenomas) to larger malignant tumours (carcinomas) over the course of several decades. Here we report that sequence analysis of 41 colorectal tumours revealed that the majority of colorectal carcinomas (60%) and adenomas (63%) contained a mutated APC gene. Furthermore, the APC gene met two criteria of importance for tumour initiation. First, mutations of this gene were found in the earliest tumours that could be analysed, including adenomas as small as 0.5 cm in diameter. Second, the frequency of such mutations remained constant as tumours progressed from benign to malignant stages. These data provide strong evidence that mutations of the APC gene play a major role in the early development of colorectal neoplasms.	JOHNS HOPKINS ONCOL CTR,424 N BOND ST,BALTIMORE,MD 21231; JOHNS HOPKINS UNIV,SCH MED,DEPT PATHOL,BALTIMORE,MD 21205; MAYO CLIN & MAYO FDN,DEPT LAB MED,ROCHESTER,MN 55905	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Mayo Clinic			Bryan, Tracy M/B-8468-2014; Pillay, Nischalan/F-9536-2012	Bryan, Tracy/0000-0002-7990-5501				BAKER SJ, 1990, CANCER RES, V50, P7717; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BOYNTON RF, 1992, P NATL ACAD SCI USA, V89, P3385, DOI 10.1073/pnas.89.8.3385; CANNONALBRIGHT LA, 1988, NEW ENGL J MED, V319, P533, DOI 10.1056/NEJM198809013190902; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; KINZLER KW, 1991, SCIENCE, V251, P1366, DOI 10.1126/science.1848370; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; MIYOSHI Y, 1992, P NATL ACAD SCI USA, V89, P4452, DOI 10.1073/pnas.89.10.4452; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; RIDEOUT WM, 1990, SCIENCE, V249, P1288, DOI 10.1126/science.1697983; SIDRANSKY D, 1992, SCIENCE, V256, P102, DOI 10.1126/science.1566048; SPIRIO L, 1991, NUCLEIC ACIDS RES, V19, P6348, DOI 10.1093/nar/19.22.6348; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; TURNBULL RB, 1967, ANN SURG, V166, P420; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WADDELL WR, 1989, AM J SURG, V157, P175, DOI 10.1016/0002-9610(89)90442-X; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WIJNEN J, 1991, NUCLEIC ACIDS RES, V19, P6965, DOI 10.1093/nar/19.24.6965-a	22	1588	1635	0	60	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 17	1992	359	6392					235	237		10.1038/359235a0	http://dx.doi.org/10.1038/359235a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JN944	1528264				2022-12-01	WOS:A1992JN94400061
J	RAYCHAUDHURI, D; PARK, JT				RAYCHAUDHURI, D; PARK, JT			ESCHERICHIA-COLI CELL-DIVISION GENE FTSZ ENCODES A NOVEL GTP-BINDING PROTEIN	NATURE			English	Article							BUD SITE SELECTION; MOLECULAR CHARACTERIZATION; BIOCHEMICAL-PROPERTIES; YEAST; SEQUENCE; MEMBRANE; PRODUCT; SUPERFAMILY; MUTATIONS; MUTANTS	ESCHERICHIA COLI divides by forming a septum across the middle of the cell. The biochemical mechanism underlying this process is unknown. Genetic evidence suggests that of all the fts (filamentation temperature sensitive) genes1,2 involved in E. coli cell division, ftsZ plays a central role at the earliest known step of septation3-5. Here we show that FtsZ protein binds GTP in vitro using unusual sequence elements6-8. In contrast, such binding to the product of the conditional-lethal ftsZ84 allele is impaired. purified FtsZ displays a Mg2+-dependent GTPase activity which is markedly reduced in the FtsZ84 protein. FtsZ copurifies with near stoichiometric amounts of noncovalently-bound GDP, implying the presence of a GTPase cycle in vivo, similar to that known for signal-transducing GTP-binding proteins8,9. We also show that a small fraction of FtsZ exists as a distinct membrane-associated species that binds GTP. The membrane association of FtsZ and the known ability of GTPases to act as molecular switches8,9 implicate FtsZ in a GTP-activated signal transduction pathway that may regulate the start of septation in E. coli.			RAYCHAUDHURI, D (corresponding author), TUFTS UNIV,SCH MED,DEPT MOLEC BIOL & MICROBIOL,BOSTON,MA 02111, USA.							BEALL B, 1988, J BACTERIOL, V170, P4855, DOI 10.1128/jb.170.10.4855-4864.1988; BEALL B, 1991, J BACTERIOL, V173, P5822; BEGG KJ, 1985, J BACTERIOL, V163, P615, DOI 10.1128/JB.163.2.615-622.1985; BENDER A, 1989, P NATL ACAD SCI USA, V86, P9976, DOI 10.1073/pnas.86.24.9976; BI E, 1990, J BACTERIOL, V172, P5602, DOI 10.1128/jb.172.10.5602-5609.1990; BI E, 1991, NATURE, V354, P161, DOI 10.1038/354161a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CHANT J, 1991, CELL, V65, P1213, DOI 10.1016/0092-8674(91)90016-R; CHANT J, 1991, CELL, V65, P1203, DOI 10.1016/0092-8674(91)90015-Q; CONNOLLY T, 1989, CELL, V57, P599, DOI 10.1016/0092-8674(89)90129-3; CORTON JC, 1987, J BACTERIOL, V169, P1; DEBOER PAJ, 1990, ANNU REV GENET, V24, P249, DOI 10.1146/annurev.genet.24.1.249; DONACHIE WD, 1984, MICROBIAL DEV, P27; FARNSWORTH CL, 1991, CELL, V64, P625, DOI 10.1016/0092-8674(91)90246-U; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; HALL A, 1986, J BIOL CHEM, V261, P963; Hershey JW., 1987, ESCHERICHIA COLI SAL, P613; ITO K, 1977, CELL, V11, P551, DOI 10.1016/0092-8674(77)90073-3; JANMEY PA, 1990, NATURE, V347, P95, DOI 10.1038/347095a0; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; KIM HB, 1991, J CELL BIOL, V112, P535, DOI 10.1083/jcb.112.4.535; KRAUHS E, 1981, P NATL ACAD SCI-BIOL, V78, P4156, DOI 10.1073/pnas.78.7.4156; LAPETINA EG, 1987, P NATL ACAD SCI USA, V84, P2261, DOI 10.1073/pnas.84.8.2261; LUTKENHAUS J, 1990, TRENDS GENET, V6, P22, DOI 10.1016/0168-9525(90)90045-8; MARGOLIN W, 1991, J BACTERIOL, V173, P5822, DOI 10.1128/jb.173.18.5822-5830.1991; MCENTEE K, 1981, J BIOL CHEM, V256, P8835; MCGRATH JP, 1984, NATURE, V310, P644, DOI 10.1038/310644a0; OAKLEY CE, 1989, NATURE, V338, P662, DOI 10.1038/338662a0; POE M, 1985, J BIOL CHEM, V260, P3906; ROSEN BP, 1988, J BIOL CHEM, V263, P3067; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHMITT HD, 1986, CELL, V47, P401, DOI 10.1016/0092-8674(86)90597-0; SNYDER JA, 1976, ANNU REV BIOCHEM, V45, P699, DOI 10.1146/annurev.bi.45.070176.003411; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TASCHNER PEM, 1988, J BACTERIOL, V170, P1533, DOI 10.1128/jb.170.4.1533-1540.1988; TEMELES GL, 1985, NATURE, V313, P700, DOI 10.1038/313700a0; YI QM, 1985, GENE, V36, P241	38	355	365	1	26	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 17	1992	359	6392					251	254		10.1038/359251a0	http://dx.doi.org/10.1038/359251a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JN944	1528267				2022-12-01	WOS:A1992JN94400066
J	ROSENTHAL, W; SEIBOLD, A; ANTARAMIAN, A; LONERGAN, M; ARTHUS, MF; HENDY, GN; BIRNBAUMER, M; BICHET, DG				ROSENTHAL, W; SEIBOLD, A; ANTARAMIAN, A; LONERGAN, M; ARTHUS, MF; HENDY, GN; BIRNBAUMER, M; BICHET, DG			MOLECULAR-IDENTIFICATION OF THE GENE RESPONSIBLE FOR CONGENITAL NEPHROGENIC DIABETES-INSIPIDUS	NATURE			English	Article							DNA; VASOPRESSIN; POLYMERASE; RECEPTORS; LOCUS	ANTIDIURETIC hormone (arginine vasopressin) binds to and activates V2 receptors in renal collecting tubule cells. Subsequent stimulation of the G(s)/adenylyl cyclase system promotes insertion of water pores into the luminal membrane and thereby reabsorption of fluid. In congenital nephrogenic diabetes insipidus (CNDI)1, an X-linked recessive disorder, the kidney fails to respond to arginine vasopressin. Here we report that an affected male of a family with CNDI2,3 has a deletion in the open reading frame of the V2 receptor gene, causing a frame shift and premature termination of translation in the third intracellular loop of the receptor protein. A normal receptor gene was found in the patient's brother. Both the normal and the mutant allele were detected in his mother. A different mutation, causing a codon change in the third transmembrane domain of the V2 receptor, was found in the open reading frame of an affected male but not in the unaffected brother belonging to another family suffering from CNDI.	BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; HOP SACRE COEUR,CTR RECH,SERV NEPHROL,MONTREAL H4J 1C5,QUEBEC,CANADA; UNIV MONTREAL,DEPT MED,MONTREAL H3C 3J7,QUEBEC,CANADA	Baylor College of Medicine; Universite de Montreal; Universite de Montreal				BICHET, DANIEL-G/0000-0003-2856-6850				BICHET DG, 1989, KIDNEY INT, V36, P859, DOI 10.1038/ki.1989.272; BICHET DG, 1988, NEW ENGL J MED, V318, P881, DOI 10.1056/NEJM198804073181403; BICHET DG, IN PRESS AM J HUM GE; BIRNBAUMER M, 1992, NATURE, V357, P333, DOI 10.1038/357333a0; DILELLA AG, 1987, METHOD ENZYMOL, V152, P199; GIBBS RA, 1991, METHOD MOL BIOL, V8, P9; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; Hanahan D., 1985, DNA CLONING PRACTICA, V1, P109; JANS DA, 1990, J BIOL CHEM, V265, P15379; KARNIK SS, 1988, P NATL ACAD SCI USA, V85, P8459, DOI 10.1073/pnas.85.22.8459; KNOERS N, 1988, NEPHRON, V50, P187, DOI 10.1159/000185155; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MOSES AM, 1982, J CLIN ENDOCR METAB, V55, P699, DOI 10.1210/jcem-55-4-699; PATTEN JL, 1990, NEW ENGL J MED, V322, P1412, DOI 10.1056/NEJM199005173222002; PEREZREYES E, 1990, J BIOL CHEM, V265, P20430; REEVES WB, 1989, METABOLIC BASIS INHE, P1985; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J., 1989, MOL CLONING; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEIBOLD A, IN PRESS AM J HUM GE; SUNG CH, 1991, P NATL ACAD SCI USA, V88, P8840, DOI 10.1073/pnas.88.19.8840	22	260	263	1	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 17	1992	359	6392					233	235		10.1038/359233a0	http://dx.doi.org/10.1038/359233a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JN944	1356229				2022-12-01	WOS:A1992JN94400060
J	TAKEMOTO, S; TERASAKI, PI; CECKA, JM; CHO, YW; GJERTSON, DW				TAKEMOTO, S; TERASAKI, PI; CECKA, JM; CHO, YW; GJERTSON, DW			SURVIVAL OF NATIONALLY SHARED, HLA-MATCHED KIDNEY-TRANSPLANTS FROM CADAVERIC DONORS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RENAL-TRANSPLANTATION; BENEFITS	Background. The importance of HLA histocompatibility typing to the outcome of transplantation of cadaveric kidneys has been controversial. Four years ago, a prospective trial began in all U.S. transplantation centers to determine whether the results of transplantation would improve with the nationwide shipment of kidneys from cadaveric donors to waiting patients undergoing dialysis when there was a match at the HLA-A, B, and DR loci. Methods. A total of 1386 cadaveric kidneys were shipped from 108 organ centers to 198 transplantation centers and distributed among HLA-matched recipients, 1004 of whom were receiving a first transplant and 382 of whom were receiving a subsequent transplant. Graft survival in these recipients was compared with that in 22,188 recipients of first transplants and 3950 recipients of subsequent transplants whose HLA antigens differed from those of the donor. Results. The rate of graft survival at one year in recipients of HLA-matched first transplants was 88 percent, as compared with 79 percent in the recipients of mismatched grafts (P<0.001). The estimated half-life of the kidney after the first year was 17.3 years for matched grafts, as compared with 7.8 years for mismatched grafts (P = 0.003). Among paired kidneys from 470 donors, one-year graft survival was 87 percent in the recipients of matched first grafts, as compared with 80 percent in the recipients of the contralateral kidneys, who did not have HLA matches with the donors. In donors and recipients matched for the more highly defined split Class I and Class II HLA antigens, the rate of graft survival after one year was as high as 90 percent. Conclusions. The collaborative renal-transplantation program for HLA matching of donors and recipients yielded an increased rate of one-year graft survival and an estimated half-life for matched grafts twice that for mismatched grafts. An increased role for HLA matching in kidney allocation is therefore indicated.			TAKEMOTO, S (corresponding author), UNIV CALIF LOS ANGELES,DEPT SURG,TISSUE TYPING LAB,950 VET AVE,LOS ANGELES,CA 90024, USA.							Cho Y W, 1988, Clin Transpl, P277; CICCIARELLI J, 1987, TRANSPLANTATION, V43, P636, DOI 10.1097/00007890-198705000-00006; COX DR, 1972, J R STAT SOC B, V34, P187; Dixon W. J., 1990, BMDP STATISTICAL SOF; GILKS WR, 1987, TRANSPLANTATION, V43, P669, DOI 10.1097/00007890-198705000-00013; GJERTSON DW, 1991, NEW ENGL J MED, V324, P1032, DOI 10.1056/NEJM199104113241505; Lau M, 1991, Clin Transpl, P385; MICKEY MR, 1989, TRANSPLANTATION, V47, P401; OPELZ G, 1991, LANCET, V338, P461, DOI 10.1016/0140-6736(91)90540-6; OPELZ G, 1988, LANCET, V2, P61; OPELZ G, 1988, NEW ENGL J MED, V318, P1289, DOI 10.1056/NEJM198805193182001; Persijn G G, 1988, Clin Transpl, P237; SANFILIPPO F, 1984, NEW ENGL J MED, V311, P358, DOI 10.1056/NEJM198408093110603; STARZL TE, 1987, JAMA-J AM MED ASSOC, V57, P3073; TAKIFF H, 1988, TRANSPLANTATION, V45, P410, DOI 10.1097/00007890-198802000-00033; TERASAKI PI, 1991, KIDNEY INT, V39, P557, DOI 10.1038/ki.1991.64; TERASAKI PI, 1990, CLIN TRANSPLANTS 199, P585	17	184	187	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 17	1992	327	12					834	839		10.1056/NEJM199209173271202	http://dx.doi.org/10.1056/NEJM199209173271202			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN120	1508242				2022-12-01	WOS:A1992JN12000002
J	VINCENT, GM; TIMOTHY, KW; LEPPERT, M; KEATING, M				VINCENT, GM; TIMOTHY, KW; LEPPERT, M; KEATING, M			THE SPECTRUM OF SYMPTOMS AND QT INTERVALS IN CARRIERS OF THE GENE FOR THE LONG-QT SYNDROME	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEART-RATE; LINKAGE	Background. The familial long-QT syndrome is characterized by a prolonged QT interval on the electro-cardiogram, ventricular arrhythmias, and sudden death. It is not certain, however, that the length of the QT interval is a sensitive or a specific diagnostic criterion. Recently, we identified genetic markers on chromosome 11 that distinguished between carriers and noncarriers of the gene for the long-QT syndrome in three families. In this study, we compared the clinical features of carriers and noncarriers and assessed the diagnostic accuracy of the QT interval. Methods. We obtained medical histories and electro-cardiograms from 199 family members. OT intervals corrected for heart rate (QT(c)) were determined independently by two blinded investigators. Carriers of the long-QT gene (83 subjects) and noncarriers (1 16 subjects) were distinguished by genetic-linkage analysis. Results. Fifty-two of the carriers of the long-QT gene (63 percent) had a history of syncope, whereas four 5 percent had a history of aborted sudden death. The QT(c) intervals of the gene carriers ranged from 0.41 to 0.59 second (mean, 0.49). By contrast, the QT(c) intervals of the noncarriers ranged from 0.38 to 0.47 second (mean, 0.42). On average, carriers of the gene for the long-QT syndrome had longer QT(c) intervals than noncarriers, but there was substantial overlap (in 126 of the 199 subjects, or 63 percent). The use of a QT(c) interval above 0.44 second as a diagnostic criterion resulted in 22 misclassifications among the 199 family members (11 percent). QT(c) intervals of 0.47 second or longer in males and 0.48 second or longer in females were completely predictive but resulted in false negative diagnoses in 40 percent of the males and 20 percent of the females. Conclusions. In families affected by the long-QT syndrome, measurement of the QT(c) interval may not permit an accurate diagnosis. DNA markers make it possible to make a genetic diagnosis in some families, but not all gene carriers have symptoms.	UNIV UTAH,HLTH SCI CTR,ECCLES PROGRAM HUMAN MOLEC BIOL & GENET,SALT LAKE CITY,UT 84112; UNIV UTAH,HLTH SCI CTR,DEPT MED,SALT LAKE CITY,UT 84112; UNIV UTAH,HLTH SCI CTR,DEPT HUMAN GENET,SALT LAKE CITY,UT 84112; UNIV UTAH,HLTH SCI CTR,HOWARD HUGHES MED INST,SALT LAKE CITY,UT 84112	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah	VINCENT, GM (corresponding author), UNIV UTAH,LATTER DAY ST HOSP,HLTH SCI CTR,DEPT MED,SALT LAKE CITY,UT 84143, USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000064] Funding Source: NIH RePORTER; NCRR NIH HHS [MO1-RR00064] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Bazett HC, 1920, HEART-J STUD CIRC, V7, P353; Hashiba K, 1987, Heart Vessels Suppl, V2, P47; HASHIBA K, 1978, JPN CIRC J, V42, P1133, DOI 10.1253/jcj.42.1133; KEATING M, 1991, AM J HUM GENET, V49, P1335; KEATING M, 1992, CIRCULATION, V85, P1973, DOI 10.1161/01.CIR.85.6.1973; KEATING M, 1991, SCIENCE, V252, P704, DOI 10.1126/science.1673802; LIPMAN BS, 1973, CLIN SCALAR ELECTROC, P670; MOSS AJ, 1986, JAMA-J AM MED ASSOC, V256, P2985; MOSS AJ, 1991, CIRCULATION, V84, P1136, DOI 10.1161/01.CIR.84.3.1136; MOSS AJ, 1985, CIRCULATION, V71, P17, DOI 10.1161/01.CIR.71.1.17; MOSS AJ, 1987, JAMA-J AM MED ASSOC, V257, P487; ROMANO C, 1963, Clin Pediatr (Bologna), V45, P656; SCHWARTZ PJ, 1975, AM HEART J, V89, P378, DOI 10.1016/0002-8703(75)90089-7; SCHWARTZ PJ, 1985, AM HEART J, V109, P399, DOI 10.1016/0002-8703(85)90626-X; VINCENT G M, 1974, Progress in Cardiovascular Diseases, V16, P523; VINCENT GM, 1991, AM J CARDIOL, V68, P498, DOI 10.1016/0002-9149(91)90785-J; VINCENT GM, 1986, AM HEART J, V112, P61, DOI 10.1016/0002-8703(86)90678-2; VINCENT GM, 1989, CLIN ASPECTS VENTRIC, P411; VINCENT GM, 1989, CIRCULATION S2, V80, P654; WARD O C, 1964, J Ir Med Assoc, V54, P103; WEINSTEIN MV, 1980, CLIN DECISION ANAL, P79; WEINTRAUB RG, 1990, J AM COLL CARDIOL, V16, P674, DOI 10.1016/0735-1097(90)90359-W; Zar JH., 1999, BIOSTAT ANAL, V4	23	487	498	0	10	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 17	1992	327	12					846	852		10.1056/NEJM199209173271204	http://dx.doi.org/10.1056/NEJM199209173271204			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN120	1508244	Bronze			2022-12-01	WOS:A1992JN12000004
J	FRANCIS, DP				FRANCIS, DP			TOWARD A COMPREHENSIVE HIV PREVENTION PROGRAM FOR THE CDC AND THE NATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTERVENTION				FRANCIS, DP (corresponding author), CTR DIS CONTROL,NATL CTR PREVENT SERV,REG AIDS DIV,ATLANTA,GA 30333, USA.							[Anonymous], 1978, Bull World Health Organ, V56, P247; FRANCIS DP, 1989, JAMA-J AM MED ASSOC, V262, P2572, DOI 10.1001/jama.262.18.2572; KELLY JA, 1991, AM J PUBLIC HEALTH, V81, P168, DOI 10.2105/AJPH.81.2.168; RUTHERFORD GW, 1990, BRIT MED J, V301, P1183, DOI 10.1136/bmj.301.6762.1183; SCITOVSKY AA, 1987, PUBLIC HLTH REPORTS, V102, P1; Shilts R., 1987, BAND PLAYED ON, P273; STALL R, 1989, EPIDEMIOLOGY AIDS EX, P266; WEINSTEIN I, 1947, AM J PUBLIC HEALTH, V37, P1376; ZWEIGHAFT RM, 1977, NEW ENGL J MED, V297, P803, DOI 10.1056/NEJM197710132971504; 1986, CONFRONTING AIDS DIR, P10; 1981, STATISTICAL ABSTRACT; 1990, MMWR, V39, P110	12	20	20	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 16	1992	268	11					1444	1447		10.1001/jama.268.11.1444	http://dx.doi.org/10.1001/jama.268.11.1444			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JM849	1324996				2022-12-01	WOS:A1992JM84900028
J	GURWITZ, JH; COL, NF; AVORN, J				GURWITZ, JH; COL, NF; AVORN, J			THE EXCLUSION OF THE ELDERLY AND WOMEN FROM CLINICAL-TRIALS IN ACUTE MYOCARDIAL-INFARCTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEART-DISEASE; PROPHYLACTIC LIDOCAINE; MORTALITY; AGE; HYPERTENSION; MORBIDITY; PATTERNS; THERAPY; MEN	Objective.-To determine the extent to which the elderly have been excluded from trials of drug therapies used in the treatment of acute myocardial infarction, to identify factors associated with such exclusions, and to explore the relationship between the exclusion of elderly and the representation of women. Data Sources.-We conducted a systematic search of the English-language literature from January 1960 through September 1991 to identify all relevant studies of specific pharmacotherapies employed in the treatment of acute myocardial infarction. To accomplish this, we searched MEDLINE, major cardiology textbooks, meta-analyses, reviews, editorials, and the bibliographies of all identified articles. Study Selection.-Only trials in which patients were randomly allocated to receive a specific therapeutic regimen or a placebo or nonplacebo control regimen were included for review. Data Extraction.-Studies were abstracted for year of publication, source of support, performance location, drug therapies to which patients were randomized, use of invasive diagnostic tests or therapeutic procedures, exclusion criteria, size and demographic characteristics of the randomized study population, and principal outcome measures. Data Synthesis.-A total of 214 trials met inclusion criteria, involving 150 920 study subjects. Over 60% of trials excluded persons over the age of 75 years. Studies published after 1980 were more likely to have age-based exclusions compared with studies published before 1980 (adjusted odds ratio, 4.92; 95% confidence interval, 2.33 to 10.54). Trials of thrombolytic therapy involving an invasive procedure were more likely to exclude elderly patients compared with other studies (adjusted odds ratio, 2.45; 95% confidence interval, 1.10 to 5.47). Studies with age-based exclusions had a smaller percentage of women compared with those without such exclusions (18% vs 23%; P=.0002), with the mean age of the study population significantly associated with the proportion of women participants (P=.0001, R2=.29). Conclusions.-Age-based exclusions are frequently used in clinical trials of medications used in the treatment of acute myocardial infarction. Such exclusions limit the ability to generalize study findings to the patient population that experiences the most morbidity and mortality from acute myocardial infarction.	HARVARD RES & TRAINING CTR, BOSTON, MA USA; HEBREW REHABIL CTR AGED, BOSTON, MA USA; UNIV MASSACHUSETTS, SCH MED, DEPT FAMILY & COMMUNITY MED, WORCESTER, MA 01605 USA	Harvard University; Harvard Medical School; University of Massachusetts System; University of Massachusetts Worcester	GURWITZ, JH (corresponding author), BRIGHAM & WOMENS HOSP, DIV GERONTOL, PROGRAM ANAL CLIN STRATEGIES, 221 LONGWOOD AVE, BOSTON, MA 02115 USA.		Col, Nananda/AAE-3445-2019	Col, Nananda/0000-0001-7106-662X	NIA NIH HHS [KO8 AG00510-01] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [K08AG000510] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ADOLPH RJ, 1990, J AM COLL CARDIOL, V16, P793, DOI 10.1016/S0735-1097(10)80323-7; AMERY A, 1985, LANCET, V1, P1349; [Anonymous], 1991, JAMA, V265, P3255; [Anonymous], 1990, Lancet, V336, P65; [Anonymous], 1986, Lancet, V1, P397; [Anonymous], 1989, GUIDELINE STUDY DRUG; COTTON P, 1990, JAMA-J AM MED ASSOC, V263, P1049, DOI 10.1001/jama.263.8.1049; DAHLOF B, 1991, LANCET, V338, P1281, DOI 10.1016/0140-6736(91)92589-T; DOUGLAS PS, 1986, CIRCULATION, V74, P917, DOI 10.1161/01.CIR.74.5.917; DUNN HM, 1985, AM HEART J, V110, P353, DOI 10.1016/0002-8703(85)90156-5; EVEMY KL, 1978, EUR J CARDIOL, V7, P391; FISHER LD, 1989, INT J CARDIOL, V24, P317, DOI 10.1016/0167-5273(89)90011-9; FULTON JP, 1989, VITAL HLTH STAT 10, V167; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; GRAVES EJ, 1991, VITAL HLTH STAT, V13; GURWITZ JH, 1991, JAMA-J AM MED ASSOC, V265, P1720, DOI 10.1001/jama.265.13.1720; GURWITZ JH, 1991, ANN INTERN MED, V114, P956, DOI 10.7326/0003-4819-114-11-956; JECKER NS, 1991, JAMA-J AM MED ASSOC, V266, P3012, DOI 10.1001/jama.266.21.3012; KAPANTAIS G, 1989, ADV DATA VITAL HLTH, V172; Kleinbaum D.G, 1988, APPL REGRESSION ANAL; KLINKENBERGKNOL EC, 1987, LANCET, V1, P349; LAKATTA EG, 1982, AM J PHYSIOL, V242, pH927, DOI 10.1152/ajpheart.1982.242.6.H927; LEVEY BA, 1991, CLIN PHARMACOL THER, V50, P641, DOI 10.1038/clpt.1991.201; MACMAHON S, 1988, JAMA-J AM MED ASSOC, V260, P1910, DOI 10.1001/jama.260.13.1910; MANOLIO TA, 1992, AM J MED, V92, P1, DOI 10.1016/0002-9343(92)90007-X; MONTAGUE TJ, 1991, AM J CARDIOL, V68, P843, DOI 10.1016/0002-9149(91)90397-4; MONTAMAT SC, 1989, NEW ENGL J MED, V321, P303; RICH MW, 1992, AM J MED, V92, P7, DOI 10.1016/0002-9343(92)90008-Y; ROSS AM, 1990, J MYO ISCH, V2, P65; SMITH SC, 1990, J AM COLL CARDIOL, V16, P784, DOI 10.1016/S0735-1097(10)80322-5; WARNES CA, 1984, AM HEART J, V108, P431, DOI 10.1016/0002-8703(84)90404-6; WEAVER WD, 1991, J AM COLL CARDIOL, V18, P657, DOI 10.1016/0735-1097(91)90784-7; WILHELMSEN L, 1988, EUR HEART J, V9, P207, DOI 10.1093/oxfordjournals.eurheartj.a062484; WILHELMSSON C, 1974, LANCET, V2, P1157; YUSUF S, 1988, JAMA-J AM MED ASSOC, V260, P2088, DOI 10.1001/jama.260.14.2088; YUSUF S, 1990, STAT MED, V9, P73, DOI 10.1002/sim.4780090114; YUSUF S, 1991, AM J CARDIOL, V68, P954, DOI 10.1016/0002-9149(91)90416-I; YUSUF S, 1988, LANCET, V1, P1088; 1991, VITAL STATISTICS U A, V2; 1987, SAS RELEAS 604; 1987, VITAL HLTH STAT, V3; 1990, STATISTICAL ABSTRACT	42	381	388	0	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 16	1992	268	11					1417	1422		10.1001/jama.268.11.1417	http://dx.doi.org/10.1001/jama.268.11.1417			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JM849	1512909				2022-12-01	WOS:A1992JM84900023
J	NIGHTINGALE, SL				NIGHTINGALE, SL			DRUG APPROVED TO TREAT BENIGN PROSTATIC HYPERPLASIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	8	10	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 16	1992	268	11					1390	1390						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JM849	1380995				2022-12-01	WOS:A1992JM84900004
J	NIGHTINGALE, SL				NIGHTINGALE, SL			TREATMENT IND GROUP-C DISTRIBUTION FOR ADVANCED METASTATIC OVARIAN-CANCER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	8	10	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 16	1992	268	11					1390	1390						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JM849	1380995				2022-12-01	WOS:A1992JM84900003
J	NIGHTINGALE, SL				NIGHTINGALE, SL			WIDE ACCESS PROTOCOLS FOR BREAST IMPLANTS APPROVED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	8	10	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 16	1992	268	11					1390	1390						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JM849	1380995				2022-12-01	WOS:A1992JM84900005
J	POWE, NR; GRIFFITHS, RI; DELISSOVOY, G; ANDERSON, GF; WATSON, AJ; GREER, JW; HERBERT, RJ; EGGERS, PW; MILAM, RA; WHELTON, PK				POWE, NR; GRIFFITHS, RI; DELISSOVOY, G; ANDERSON, GF; WATSON, AJ; GREER, JW; HERBERT, RJ; EGGERS, PW; MILAM, RA; WHELTON, PK			ACCESS TO RECOMBINANT ERYTHROPOIETIN BY MEDICARE-ENTITLED DIALYSIS PATIENTS IN THE 1ST YEAR AFTER FDA APPROVAL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEMODIALYSIS-PATIENTS; HEART-DISEASE; MASSACHUSETTS; CAPACITY; THERAPY; QUALITY; WHITES; TRIAL; COST; LIFE	Objective.-Examine access to recombinant human erythropoietin (rHuEPO) by dialysis-dependent end-stage renal disease (ESRD) patients during the first year after FDA approval for use in clinical practice and Medicare coverage. Design.-Longitudinal and cross-sectional claims data analyses. Setting.-All US providers of outpatient dialysis treatment. Patients.-126 201 Medicare-entitled dialysis patients (almost-equal-to 93% of all US dialysis patients). Outcome Measures.-Percentage of patients who received rHuEPO, odds of receiving rHuEPO according to patient characteristics, and cost of rHuEPO to Medicare. Results.-One year after FDA approval, 52% of all dialysis and 60% of in-center hemodialysis patients who regularly had Medicare-paid dialysis services received rHuEPO at a monthly cost to Medicare of $19 million (18% of Medicare ESRD out-patient expenditures and 6% of all ESRD program expenditures). Blacks were less likely than whites to receive rHuEPO (odds ratio, 0.88; 95% confidence interval, 0.86 to 0.91). Home peritoneal and hemodialysis patients were less likely than in-center hemodialysis patients to receive rHuEPO (odds ratios, 0.17 and 0.22, respectively; 95% confidence intervals, 0.16 to 0.17 and 0.20 to 0.24, respectively). Use of rHuEPO varied across geographic regions. The odds of receiving rHuEPO were lower for patients of male vs female sex, of ages 35 through 64 years vs less than 35 years and greater than 65 years, with a longer history of ESRD, with polycystic kidney disease vs other causes of ESRD, and receiving care in nonprofit vs for-profit facilities. First-month hematocrits were slightly higher (1.2 percentage points) for patients starting rHuEPO in the 12th month than in the first month after FDA approval. Conclusions.-With prompt insurance coverage, the majority of Medicare-entitled dialysis patients received rHuEPO following widespread availability. Factors that may not be related to clinical need (race, setting of care, and geography) possibly influenced early patient access. More attention should be paid to monitoring the appropriate use of high-cost biotechnologic therapy.	JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,BALTIMORE,MD 21218; JOHNS HOPKINS PROGRAM MED TECHNOL & PRACTICE ASSESSMENT,BALTIMORE,MD; WELCH CTR PREVENT CLIN RES & EPIDEMIOL,BALTIMORE,MD; JOHNS HOPKINS HLTH INST,BALTIMORE,MD; JOHNS HOPKINS UNIV,SCH MED,DIV NEPHROL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,DEPT EPIDEMIOL,BALTIMORE,MD 21218; US HLTH CARE FINANCING ADM,BALTIMORE,MD	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	POWE, NR (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DIV INTERNAL MED,ROOM 8061,1830 E MONUMENT ST,BALTIMORE,MD 21205, USA.							AYANIAN JZ, 1991, NEW ENGL J MED, V325, P221, DOI 10.1056/NEJM199107253250401; Bunn H. F., 1991, HARRISONS PRINCIPLES, P344; CHASSIN MR, 1986, NEW ENGL J MED, V314, P285, DOI 10.1056/NEJM198601303140505; DOOLITTLE RF, 1991, NEW ENGL J MED, V324, P1360, DOI 10.1056/NEJM199105093241910; EIEENBERG JM, 1986, DOCTORS DECISIONS CO, P5; ERSLEV AJ, 1991, NEW ENGL J MED, V324, P1339, DOI 10.1056/NEJM199105093241907; ESCHBACH JW, 1989, ANN INTERN MED, V111, P992, DOI 10.7326/0003-4819-111-12-992; EVANS RW, 1990, JAMA-J AM MED ASSOC, V263, P825; FORD E, 1989, AM J PUBLIC HEALTH, V79, P437, DOI 10.2105/AJPH.79.4.437; GOTCH FA, 1990, AM J KIDNEY DIS, V15, P511, DOI 10.1016/S0272-6386(12)70369-4; HADLEY J, 1991, JAMA-J AM MED ASSOC, V265, P374, DOI 10.1001/jama.265.3.374; HELD PJ, 1991, JAMA-J AM MED ASSOC, V265, P871, DOI 10.1001/jama.265.7.871; JAVITT JC, 1991, NEW ENGL J MED, V325, P1418, DOI 10.1056/NEJM199111143252005; LAUPACIS A, 1990, SEMIN NEPHROL, V10, P11; NEWHOUSE JP, 1981, NEW ENGL J MED, V305, P1501, DOI 10.1056/NEJM198112173052504; Rettig RA, 1991, KIDNEY FAILURE FEDER; ROBERTSON HT, 1990, AM J KIDNEY DIS, V15, P325, DOI 10.1016/S0272-6386(12)80079-5; SISK JE, 1991, JAMA-J AM MED ASSOC, V266, P247, DOI 10.1001/jama.266.2.247; STROGATZ DS, 1990, AM J PUBLIC HEALTH, V80, P290, DOI 10.2105/AJPH.80.3.290; WATSON AJ, 1989, SEMIN NEPHROL, V9, P30; WENNEKER MB, 1989, JAMA-J AM MED ASSOC, V261, P253, DOI 10.1001/jama.261.2.253; WENNEKER MB, 1990, JAMA-J AM MED ASSOC, V264, P1255, DOI 10.1001/jama.264.10.1255; [No title captured]; 1990, 03272 HLTH CAR FIN A; 1992, 03319 HLTH CAR FIN A; 1991, AM J KIDNEY DIS S2, V18, P96	26	35	35	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 16	1992	268	11					1434	1440		10.1001/jama.268.11.1434	http://dx.doi.org/10.1001/jama.268.11.1434			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JM849	1512912				2022-12-01	WOS:A1992JM84900026
J	ANAISSIE, E; KONTOYIANNIS, DP; KANTARJIAN, H; ELTING, L; ROBERTSON, LE; KEATING, M				ANAISSIE, E; KONTOYIANNIS, DP; KANTARJIAN, H; ELTING, L; ROBERTSON, LE; KEATING, M			LISTERIOSIS IN PATIENTS WITH CHRONIC LYMPHOCYTIC-LEUKEMIA WHO WERE TREATED WITH FLUDARABINE AND PREDNISONE	ANNALS OF INTERNAL MEDICINE			English	Article						LISTERIA INFECTIONS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; FLUDARABINE; PREDNISONE; ANTIGENS, CD4; ACQUIRED IMMUNODEFICIENCY SYNDROME; HUMAN IMMUNODEFICIENCY VIRUS	INFECTIONS; THERAPY; AGENT	Objective. To determine whether therapy with fludarabine plus prednisone in patients with chronic lymphocytic leukemia increases the risk for developing listeriosis. Design: Retrospective cohort study based on hospital surveillance data. Setting: Referral cancer center. Participants: A total of 795 patients with chronic lymphocytic leukemia who received care at The University of Texas M. D. Anderson Cancer Center between 1980 and 1990. Interventions: Patients were treated with fludarabine alone or fludarabine and prednisone. Measurements: The listeriosis attack rate was analyzed according to the type of treatment received. Results: Seven of 408 patients in the fludarabine group developed listeriosis (1.7%; 95% Cl, 0.2% to 6%) compared with 0 of 387 patients who received conventional chemotherapy alone (0% to 0.9%; P = 0.015). The 7 patients were among 248 patients who were treated with both fludarabine and prednisone; none of 160 patients treated with fludarabine alone developed listeriosis (P = 0.045 by the Fisher exact test). A dramatic reduction in CD4 counts occurred in patients after fludarabine and prednisone treatment and coincided with the development of listeriosis. Conclusion: The administration of fludarabine plus prednisone is associated with an increased incidence of listeriosis in patients with chronic lymphocytic leukemia. The depletion of CD4 cells may underlie the pathogenesis.			ANAISSIE, E (corresponding author), UNIV TEXAS, MD ANDERSON CANC CTR, 1515 HOLCOMBE BLVD, BOX 47, HOUSTON, TX 77030 USA.							AMPEL MN, 1990, 30TH P INT C ANT AG; ARMSTRONG D, 1990, PRINCIPLES PRACTICE, P1587; AROESTY JM, 1962, NEW YORK STATE J MED, V62, P1946; Bille J, 1988, B BUNDESAMTES GESUND, V3, P28; BOLDT DH, 1984, CANCER RES, V44, P4661; COX DR, 1953, BIOMETRIKA, V40, P354, DOI 10.1093/biomet/40.3-4.354; FAUCI AS, 1976, ANN INTERN MED, V84, P304, DOI 10.7326/0003-4819-84-3-304; HANSEN MM, 1973, SCAND J HAEMATOL, P1; HANTEL A, 1989, CANCER, V64, P516, DOI 10.1002/1097-0142(19890715)64:2<516::AID-CNCR2820640226>3.0.CO;2-I; HEATH ME, 1985, AM J HEMATOL, V19, P63, DOI 10.1002/ajh.2830190109; KEATING MJ, 1988, LEUKEMIA, V2, P157; KEATING MJ, 1989, BLOOD, V74, P19; LINNAN MJ, 1988, NEW ENGL J MED, V319, P823, DOI 10.1056/NEJM198809293191303; LOURIA DB, 1970, ANN NY ACAD SCI, V174, P545, DOI 10.1111/j.1749-6632.1970.tb45580.x; LOURIA DB, 1967, ANN INTERN MED, V67, P261, DOI 10.7326/0003-4819-67-2-261; MONSERRATCOSTA E, 1977, SANGRE, V22, P968; MYERS TJ, 1980, CANCER, V46, P619, DOI 10.1002/1097-0142(19800801)46:3<619::AID-CNCR2820460332>3.0.CO;2-I; NIEMAN RE, 1980, REV INFECT DIS, V2, P207; PISCIOTTA AV, 1957, ARCH INTERN MED, V99, P334, DOI 10.1001/archinte.1957.00260030012002; REVOL L, 1974, ENCY MED CHIRURGICAL; ROBERTSON LE, 1990, BLOOD, V76, pA314; SAMRA Y, 1984, POSTGRAD MED J, V60, P267, DOI 10.1136/pgmj.60.702.267; SCHILLING PJ, 1990, NEW ENGL J MED, V323, P833, DOI 10.1056/NEJM199009203231216; SCHLECH WF, 1983, NEW ENGL J MED, V308, P203, DOI 10.1056/NEJM198301273080407; SCHWARTZ B, 1988, LANCET, V2, P779; SHAW RK, 1960, ARCH INTERN MED, V106, P467, DOI 10.1001/archinte.1960.03820040005002; SPITZER PG, 1986, REV INFECT DIS, V8, P427; TRAVADE P, 1986, PRESSE MED, V15, P1715; TWOMEY JJ, 1973, ARCH INTERN MED, V132, P562, DOI 10.1001/archinte.132.4.562; UTMANN JE, 1959, ANN INTERN MED, V51, P501; WINSLOW DL, 1982, ANTIMICROB AGENTS CH, V22, P51, DOI 10.1128/AAC.22.1.51; 1989, MMWR, V38, P267	32	110	111	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1992	117	6					466	469		10.7326/0003-4819-117-6-466	http://dx.doi.org/10.7326/0003-4819-117-6-466			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN257	1354425				2022-12-01	WOS:A1992JN25700004
J	DITULLIO, M; SACCO, RL; GOPAL, A; MOHR, JP; HOMMA, S				DITULLIO, M; SACCO, RL; GOPAL, A; MOHR, JP; HOMMA, S			PATENT FORAMEN OVALE AS A RISK FACTOR FOR CRYPTOGENIC STROKE	ANNALS OF INTERNAL MEDICINE			English	Article						HEART SEPTAL DEFECTS, ATRIAL; CEREBROVASCULAR DISORDERS; RISK FACTORS; ECHOCARDIOGRAPHY; CEREBRAL INFARCTION	ATRIAL SEPTAL-DEFECTS; TWO-DIMENSIONAL ECHOCARDIOGRAPHY; TRANSCRANIAL DOPPLER ULTRASOUND; CONTRAST ECHOCARDIOGRAPHY; DIAGNOSIS; EMBOLISM; EMBOLIZATION; PREVALENCE; ISCHEMIA; SHUNTS	Objective: To determine and compare the prevalence of patent foramen ovale in patients with stroke of undetermined origin (cryptogenic) and in patients with stroke of determined origin to assess the possible role of patent foramen ovale as a risk factor for cryptogenic stroke. Design: Cross-sectional study with nested case-control analysis. M Patients: A total of 146 patients (73 men, 73 women) with acute ischemic stroke referred to the echocardiography laboratory for evaluation. Setting: Neurovascular Unit and Echocardiography Laboratory, Columbia-Presbyterian Medical Center, New York, New York. Measurements: Patients were considered to have strokes of determined origin or cryptogenic strokes according to National Institute of Neurological Disorders and Stroke (NINDS) Stroke Data Bank criteria. The presence of patent foramen ovale was assessed by contrast echocardiography, performed blinded for type of stroke. The association between patent foramen ovale and type of stroke was tested after correcting for patients' demographic variables and stroke risk factors. Results: The overall prevalence of patent foramen ovale was 26 of 146 patients (18%; 95% CI, 11.4% to 24.6%). Patients with cryptogenic stroke (31%) had a significantly higher prevalence of patent foramen ovale than did patients with an identifiable cause of stroke (69%) in both the younger (< 55 years; 48% compared with 4%; P < 0.001) and the older (greater-than-or-equal-to 55 years; 38% compared with 8%; P < 0.001) age groups. Multiple logistic regression analysis was used to identify the presence of a patent foramen ovale as strongly associated with the diagnosis of cryptogenic stroke (odds ratio, 7.2; Cl, 2.4 to 21.7), irrespective of patient age and other stroke risk factors. Conclusions: Patients with cryptogenic stroke have a higher prevalence of patent foramen ovale than patients with stroke of determined cause in all age groups, even after correcting for the presence of recognized stroke risk factors. This identifies patent foramen ovale as a risk factor for cryptogenic stroke. Regardless of patient age, contrast echocardiography should be considered when the cause of stroke is unknown.	COLUMBIA PRESBYTERIAN MED CTR,DIV CARDIOL,P&S 9-441,630 W 168TH ST,NEW YORK,NY 10032	Columbia University; NewYork-Presbyterian Hospital			Mohr, J/AAO-9694-2020; Sacco, Ralph/Y-9278-2019		NINDS NIH HHS [R01NS27517] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027517] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BERGER M, 1985, J AM COLL CARDIOL, V6, P359, DOI 10.1016/S0735-1097(85)80172-8; BILLER J, 1987, ARCH NEUROL-CHICAGO, V44, P740, DOI 10.1001/archneur.1987.00520190046016; BOMMER WJ, 1984, J AM COLL CARDIOL, V3, P6, DOI 10.1016/S0735-1097(84)80423-4; BOROW KM, 1990, NEW ENGL J MED, V323, P1698, DOI 10.1056/NEJM199012133232409; BRESLOW N. E., 1980, STATISTICAL METHODS; DITULLIO M, 1991, CIRCULATION, V84, P451; DUBOURG O, 1986, ARCH MAL COEUR VAISS, V79, P193; GROSS CR, 1986, ARCH NEUROL-CHICAGO, V43, P893, DOI 10.1001/archneur.1986.00520090031012; HAGEN PT, 1984, MAYO CLIN PROC, V59, P17, DOI 10.1016/S0025-6196(12)60336-X; HART RG, 1983, STROKE, V14, P110, DOI 10.1161/01.STR.14.1.110; HARVEY JR, 1986, ANN INTERN MED, V105, P695, DOI 10.7326/0003-4819-105-5-695; HOFMANN T, 1990, LANCET, V336, P1421; JEANRENAUD X, 1990, SCHWEIZ MED WSCHR, V120, P823; JONES HR, 1983, ANN NEUROL, V13, P314, DOI 10.1002/ana.410130315; LECHAT P, 1988, NEW ENGL J MED, V318, P1148, DOI 10.1056/NEJM198805053181802; LOSCALZO J, 1986, AM HEART J, V112, P141, DOI 10.1016/0002-8703(86)90692-7; LYNCH JJ, 1984, AM J CARDIOL, V53, P1478, DOI 10.1016/S0002-9149(84)91617-5; MOHR JP, 1988, NEW ENGL J MED, V318, P1197, DOI 10.1056/NEJM198805053181810; MOHR JP, 1984, INT ANGIOL, V3, P431; NEMEC JJ, 1991, AM J CARDIOL, V68, P1498, DOI 10.1016/0002-9149(91)90285-S; PEARSON AC, 1991, J AM COLL CARDIOL, V17, P66, DOI 10.1016/0735-1097(91)90705-E; ROCCHINI AP, 1990, CIRCULATION, V82, P1044, DOI 10.1161/01.CIR.82.3.1044; ROSENOW EC, 1981, MAYO CLIN PROC, V56, P161; SACCO RL, 1989, ANN NEUROL, V25, P382, DOI 10.1002/ana.410250410; SHUB C, 1983, J AM COLL CARDIOL, V2, P127, DOI 10.1016/S0735-1097(83)80385-4; STRUNK BL, 1987, AM J CARDIOL, V60, P413, DOI 10.1016/0002-9149(87)90271-2; TEAGUE SM, 1991, STROKE, V22, P740, DOI 10.1161/01.STR.22.6.740; VANHARE GF, 1989, J AM COLL CARDIOL, V13, P673, DOI 10.1016/0735-1097(89)90610-4; WEBSTER MWI, 1988, LANCET, V2, P11	29	448	453	1	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572	0003-4819			ANN INTERN MED	Ann. Intern. Med.	SEP 15	1992	117	6					461	465		10.7326/0003-4819-117-6-461	http://dx.doi.org/10.7326/0003-4819-117-6-461			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN257	1503349				2022-12-01	WOS:A1992JN25700003
J	EDLIN, BR; STCLAIR, MH; PITHA, PM; WHALING, SM; KING, DM; BITRAN, JD; WEINSTEIN, RA				EDLIN, BR; STCLAIR, MH; PITHA, PM; WHALING, SM; KING, DM; BITRAN, JD; WEINSTEIN, RA			INVITRO RESISTANCE TO ZIDOVUDINE AND ALPHA-INTERFERON IN HIV-1 ISOLATES FROM PATIENTS - CORRELATIONS WITH TREATMENT DURATION AND RESPONSE	ANNALS OF INTERNAL MEDICINE			English	Article						INTERFERON-ALPHA; HUMAN IMMUNODEFICIENCY VIRUS; ZIDOVUDINE; DRUG RESISTANCE; ACQUIRED IMMUNODEFICIENCY SYNDROME	HUMAN-IMMUNODEFICIENCY-VIRUS; KAPOSIS-SARCOMA; AIDS; SENSITIVITY; INFECTION; TYPE-1; THERAPY	Objective: To measure in-vitro antiviral drug susceptibilities of human immunodeficiency virus type 1 (HIV-1) isolates recovered from patients treated with alpha-interferon or zidovudine and patients not treated with these drugs and to examine the relation of these susceptibility measurements to duration of therapy, disease stage, and response to alpha-interferon therapy. Design: Cross-sectional study. Setting: Outpatient HIV clinic. Patients: Twenty-six ambulatory HIV-1-infected patients: Fifteen of these patients were receiving alpha-interferon therapy, and 11 had never received such therapy. Nine patients were participating in a clinical trial of combination therapy with zidovudine and alpha-interferon. Measurements: The 50% inhibitory concentration (IC50) of zidovudine and alpha-interferon was determined for HIV-1 isolates recovered from each patient. Plasma concentrations of HIV-1 p24 antigen in the nine patients in the clinical trial were measured monthly after alpha-interferon was added to zidovudine monotherapy. Results: Zidovudine IC50 (range, 0.01 to 4.87-mu-M) increased steadily with duration of zidovudine therapy (r = 0.57, P = 0.003). In contrast, alpha-interferon IC50 (range, 0.8 to 415 units/mL) was not related to duration of alpha-interferon treatment; in fact, high IC50s were found in isolates from patients who had never received exogenous alpha-interferon therapy. Resistance to alpha-interferon was greater in isolates from the 15 patients with the acquired immunodeficiency syndrome (AIDS) (median, 104 units/mL) than in those from the 10 patients without AIDS (median, 50 units/mL). Interferon activity was detected in plasma samples from 23 of 24 patients and was also at higher levels in patients with AIDS than in HIV-infected patients without AIDS. Reductions in plasma concentrations of HIV-1 p24 antigen in nine patients after beginning alpha-interferon therapy were greater in those with more susceptible isolates (r = -0.72, P = 0.03). Conclusions: Interferon resistance, possibly due to endogenous interferon, is not related to duration of interferon therapy but may limit the effectiveness of interferon therapy. Determinations of interferon susceptibility may identify patients most likely to benefit from this agent.			EDLIN, BR (corresponding author), CTR DIS CONTROL, DIV HIV AIDS, 1600 CLIFTON RD, E-45, ATLANTA, GA 30333 USA.		Edlin, Brian R/F-2966-2018	Edlin, Brian R/0000-0001-8172-8797				BERGLUND O, 1991, J INFECT DIS, V163, P710, DOI 10.1093/infdis/163.4.710; BOUCHER CAB, 1990, LANCET, V336, P585, DOI 10.1016/0140-6736(90)93391-2; DESTEFANO E, 1982, J INFECT DIS, V146, P451, DOI 10.1093/infdis/146.4.451; DEWIT R, 1988, LANCET, V2, P1214; DEWIT R, 1991, J INTERN MED, V229, P35; EDLIN BR, 1989, LANCET, V1, P156; EDLIN BR, 1992, J INFECT DIS, V165, P793, DOI 10.1093/infdis/165.5.793; EVANS LA, 1987, J IMMUNOL, V138, P3415; FISCHL MA, 1991, J ACQ IMMUN DEF SYND, V4, P1; FRANCIS ML, 1992, AIDS RES HUM RETROV, V8, P199, DOI 10.1089/aid.1992.8.199; HARPER HD, 1973, BIOCHEM BIOPH RES CO, V53, P1220, DOI 10.1016/0006-291X(73)90595-0; HO DD, 1985, LANCET, V1, P602; JACKSON JB, 1988, J CLIN MICROBIOL, V26, P1416, DOI 10.1128/JCM.26.7.1416-1418.1988; JOKLIK WK, 1985, VIROLOGY, P283; KROWN SE, 1990, ANN INTERN MED, V112, P812, DOI 10.7326/0003-4819-112-11-812; LAND S, 1990, J INFECT DIS, V161, P326, DOI 10.1093/infdis/161.2.326; LANE HC, 1990, ANN INTERN MED, V112, P805, DOI 10.7326/0003-4819-112-11-805; LANE HC, 1988, LANCET, V2, P1218; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; PITHA PM, 1991, J INTERFERON RES, V11, P313, DOI 10.1089/jir.1991.11.313; RICHMAN DD, 1990, J ACQ IMMUN DEF SYND, V3, P743; SAAG MS, 1988, NATURE, V334, P440, DOI 10.1038/334440a0; SAKAI K, 1988, J VIROL, V62, P4078, DOI 10.1128/JVI.62.11.4078-4085.1988; STCLAIR MH, 1991, SCIENCE, V253, P1557, DOI 10.1126/science.1716788; TUDORWILLIAMS G, 1992, LANCET, V339, P15, DOI 10.1016/0140-6736(92)90140-X	25	36	36	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1992	117	6					457	460		10.7326/0003-4819-117-6-457	http://dx.doi.org/10.7326/0003-4819-117-6-457			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN257	1503348				2022-12-01	WOS:A1992JN25700002
J	FAHS, MC; MANDELBLATT, J; SCHECHTER, C; MULLER, C				FAHS, MC; MANDELBLATT, J; SCHECHTER, C; MULLER, C			COST-EFFECTIVENESS OF CERVICAL-CANCER SCREENING FOR THE ELDERLY	ANNALS OF INTERNAL MEDICINE			English	Article						CERVIX NEOPLASMS; COST-BENEFIT ANALYSIS; VAGINAL SMEARS; MASS SCREENING; MEDICARE	PREVENTIVE HEALTH-CARE; PNEUMOCOCCAL IMMUNIZATION; NATIONAL TRENDS; FOLLOW-UP; WOMEN; CYTOLOGY; SMEARS; VACCINATION; MAMMOGRAPHY; PHYSICIANS	Objective: To analyze the costs and benefits of alternate cervical cancer screening schedules among elderly women. Setting: Population-based screening programs. Design: A Markov model predicts the outcomes of periodic screening, diagnosis, and treatment for cervical cancer among women from 65 to 109 years of age. Patients: A hypothetical cohort of one million 65-year-old women, representative of the U.S. population. Measurements: The costs and yields of screening. Results: Triennial screening reduced mortality from cervical cancer among the elderly by 74% at a cost of $2254 per year of life saved. Annual screening increased costs to $7345 per year of life saved; less frequent schedules yielded lower costs but decreased savings in life. These results were most sensitive to the quality of the Papanicolaou smear and the characteristics of the women using the benefit. If the sensitivity of the Papanicolaou smear was reduced from a baseline estimate of 75% to 50% and the specificity was decreased to 87% from 95%, the cost effectiveness ratio increased by nearly $7000 per year of life saved. If triennial screening is targeted to women who have not had regular screening, the program will save money as well as years of life; however, screening women who have been screened regularly is considerably less efficient, increasing costs to $33 572 per year of life saved. Conclusion: The success of the new Medicare benefit depends substantially on physicians assuring that their elderly patients, particularly women without regular prior screening, obtain high quality Papanicolaou smears. The data also show that after a woman 65 years of age or older has a history of regular negative smears, screening is inefficient and can cease.	MEM SLOAN KETTERING CANC CTR, DEPT EPIDEMIOL & BIOSTAT, NEW YORK, NY 10021 USA	Memorial Sloan Kettering Cancer Center	FAHS, MC (corresponding author), MT SINAI MED CTR, DEPT COMMUNITY MED, BOX 1043, 1 GUSTAVE LEVY PL, NEW YORK, NY 10029 USA.				PHS HHS [J3-4130.0] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BAQUET C, 1987, MILBANK Q, V65, P322, DOI 10.2307/3349994; BATTISTA RN, 1983, AM J PUBLIC HEALTH, V73, P1036, DOI 10.2105/AJPH.73.9.1036; BECK JR, 1983, MED DECIS MAKING, V3, P419, DOI 10.1177/0272989X8300300403; BEILBY JOW, 1982, OBSTET GYNECOL, V60, P46; BERGET A, 1977, DAN MED BULL, V24, P26; BOYES DA, 1982, CLIN INVEST MED, V5, P1; CAMPION MJ, 1986, LANCET, V2, P237; CELENTANO DD, 1989, PREV MED, V18, P411, DOI 10.1016/0091-7435(89)90001-7; CELENTANO DD, 1982, PREV MED, V11, P454, DOI 10.1016/0091-7435(82)90048-2; CHRISTOPHERSON WM, 1969, CANCER-AM CANCER SOC, V24, P64, DOI 10.1002/1097-0142(196907)24:1<64::AID-CNCR2820240108>3.0.CO;2-Y; COPPLESON LW, 1974, AM J OBSTET GYNECOL, V119, P953, DOI 10.1016/0002-9378(74)90013-1; COPPLESON LW, 1975, AM J OBSTET GYNECOL, V122, P127, DOI 10.1016/0002-9378(75)90627-4; CREASMAN WT, 1981, GYNECOL ONCOL, V12, pS306, DOI 10.1016/0090-8258(81)90084-6; DAVIS JR, 1981, ACTA CYTOL, V25, P533; DICKINSON L, 1972, MAYO CLIN PROC, V47, P534; DUNN JE, 1959, J NATL CANCER I, V23, P507; DUNN JE, 1981, AM J OBSTET GYNECOL, V139, P868, DOI 10.1016/0002-9378(81)90951-0; EDDY D, 1987, BREAST CANCER SCREEN; EDELSON JT, 1990, JAMA-J AM MED ASSOC, V263, P407, DOI 10.1001/jama.263.3.407; FAHS MC, 1991, WOMEN POPULATION AGI, P1; FEDSON DS, 1987, CHEST, V91, P436, DOI 10.1378/chest.91.3.436; FIDLER H. K., 1968, J OBSTET GYNAECOL BRIT COMMONW, V75, P392; FINK DJ, 1988, CA-CANCER J CLIN, V38, P127, DOI 10.3322/canjclin.38.2.127; FOX CH, 1967, AM J OBSTET GYNECOL, V99, P960, DOI 10.1016/0002-9378(67)90251-7; FOX SA, 1991, ARCH INTERN MED, V151, P50, DOI 10.1001/archinte.151.1.50; GAY JD, 1985, ACTA CYTOL, V29, P1043; GILES JA, 1988, BRIT MED J, V296, P1099, DOI 10.1136/bmj.296.6629.1099; HARLAN LC, 1991, AM J PUBLIC HEALTH, V81, P885, DOI 10.2105/AJPH.81.7.885; HARRIS RP, 1991, CANCER, V67, P2010, DOI 10.1002/1097-0142(19910401)67:7<2010::AID-CNCR2820670730>3.0.CO;2-8; HUSAIN OAN, 1974, J CLIN PATHOL, V27, P935, DOI 10.1136/jcp.27.12.935; HUSAIN OAN, 1984, BRIT MED J, V289, P50, DOI 10.1136/bmj.289.6436.50; KASHGARI.M, 1970, AM J EPIDEMIOL, V92, P211, DOI 10.1093/oxfordjournals.aje.a121201; KINLEN LJ, 1978, LANCET, V2, P463; KLEINMAN JC, 1981, AM J PUBLIC HEALTH, V71, P73, DOI 10.2105/AJPH.71.1.73; MACCORMAC L, 1988, MED J AUSTRALIA, V149, P530, DOI 10.5694/j.1326-5377.1988.tb120761.x; MAKUC DM, 1989, AM J PUBLIC HEALTH, V79, P21, DOI 10.2105/AJPH.79.1.21; MAMON JA, 1990, PREV MED, V19, P363, DOI 10.1016/0091-7435(90)90036-J; MANDELBLATT J, 1991, AM J OBSTET GYNECOL, V164, P644, DOI 10.1016/S0002-9378(11)80040-2; MANDELBLATT J, 1986, JAMA-J AM MED ASSOC, V256, P367, DOI 10.1001/jama.256.3.367; MANDELBLATT JS, 1988, JAMA-J AM MED ASSOC, V259, P2409, DOI 10.1001/jama.259.16.2409; MCPHEE SJ, 1987, AM J PUBLIC HEALTH, V77, P780, DOI 10.2105/AJPH.77.7.780; MCPHEE SJ, 1986, J GEN INTERN MED, V1, P275, DOI 10.1007/BF02596202; MILLER AB, 1991, CAN MED ASSOC J, V145, P1301; MORRISON EAB, 1991, INT J CANCER, V49, P6, DOI 10.1002/ijc.2910490103; MULLER C, 1990, COSTS EFFECTIVENESS; NASIELL K, 1983, OBSTET GYNECOL, V61, P609; NELSON JH, 1989, CA-CANCER J CLIN, V39, P157, DOI 10.3322/canjclin.39.3.157; PETERSEN O, 1956, AM J OBSTET GYNECOL, V72, P1063, DOI 10.1016/0002-9378(56)90072-2; RICHART RM, 1969, AM J OBSTET GYNECOL, V105, P386, DOI 10.1016/0002-9378(69)90268-3; RIDDIOUGH MA, 1983, JAMA-J AM MED ASSOC, V249, P3189; RIOTTON G, 1986, COMMUNICATION   0306; ROBERTSON JH, 1988, RISK CERVICAL CANCER; RYLANDER E, 1977, ACTA OBSTET GYN SCAN, V56, P115, DOI 10.3109/00016347709158352; SCHWARTZ B, 1990, JAMA-J AM MED ASSOC, V264, P1154; SILVERBERG E, 1984, CA-CANCER J CLIN, V34, P7; SPRIGGS AI, 1977, BRIT MED J, V1, P1516; STAUB JJ, 1976, NEW ENGL J MED, V294, P223; STENKVIST B, 1984, JAMA-J AM MED ASSOC, V252, P1423, DOI 10.1001/jama.252.11.1423; STERN E, 1959, CANCER, V12, P933, DOI 10.1002/1097-0142(195909/10)12:5<933::AID-CNCR2820120513>3.0.CO;2-2; Stern E, 1969, Obstet Gynecol Surv, V24, P711, DOI 10.1097/00006254-196907001-00005; WEISMAN CS, 1989, PUBLIC HEALTH REP, V104, P209; WILLEMS JS, 1980, NEW ENGL J MED, V303, P553, DOI 10.1056/NEJM198009043031004; WILLIAMS WW, 1988, ANN INTERN MED, V108, P616, DOI 10.7326/0003-4819-108-4-616; 1987, NATIONAL HOSPITAL DI; 1989, GUIDE CLIN PREVENTIV, P26; 1990, JAMA-J AM MED ASSOC, V264, P54; 1985, CHEM ABSTR, V35, P197; 1976, VITAL STATISTICS US, V2; 1989, WASHINGTON REPORT, V7, P1; 1985, CANCER INCIDENCE 197; 1976, CAN MED ASSOC J, V114, P1003; 1980, CHEM ABSTR, V30, P215; 1988, PRESS RELEASE; 1981, SO MED J, V74, P87; 1984, VITAL STATISTICS U A, V2; 1991, NCI912789 NIH DIV CA; 1988, 2ND P C STAT ART QUA	77	110	111	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1992	117	6					520	527		10.7326/0003-4819-117-6-520	http://dx.doi.org/10.7326/0003-4819-117-6-520			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN257	1503355				2022-12-01	WOS:A1992JN25700012
J	KUPFER, Y; NAMBA, T; KALDAWI, E; TESSLER, S				KUPFER, Y; NAMBA, T; KALDAWI, E; TESSLER, S			PROLONGED WEAKNESS AFTER LONG-TERM INFUSION OF VECURONIUM BROMIDE	ANNALS OF INTERNAL MEDICINE			English	Note						VECURONIUM; RESPIRATORY INSUFFICIENCY; MUSCULAR WEAKNESS; DOSE-RESPONSE RELATIONSHIP, DRUG; ASTHMA; STATUS ASTHMATICUS	NEUROMUSCULAR BLOCKADE; PATIENT	Neuromuscular blocking agents, increasingly used in intensive care units, have been retrospectively reported to cause weakness after prolonged use. This study prospectively compared ten patients with respiratory failure requiring prolonged muscle relaxation using vecuronium and 18 asthmatic patients with respiratory failure requiring mechanical ventilation without vecuronium. Serial neurologic and electrodiagnostic studies were done. Seven of ten patients (70%; 95% CI, 35% to 93%) experienced weakness 24 hours after discontinuation of vecuronium. The weakness was due to prolonged neuromuscular blockade for up to 3 days in two patients and to polyneuropathy characterized by weakness of all extremities, loss of tendon reflexes, and muscle atrophy lasting 5 days to 6 months in five patients. The only factors that correlated with the development of polyneuropathy were the dose (P = 0.047) and duration (P = 0.047) of vecuronium use, None of the control patients with asthma developed weakness. Caution must be exercised when using large doses of vecuronium for a prolonged period.	MAIMONIDES HOSP, DIV PULM & CRIT CARE MED, 4802 10TH AVE, BROOKLYN, NY 11219 USA; MAIMONIDES HOSP, DIV NEUROMUSCULAR DIS, BROOKLYN, NY 11219 USA	Maimonides Medical Center; Maimonides Medical Center								GOOCH JL, 1991, CRIT CARE MED, V19, P1125, DOI 10.1097/00003246-199109000-00006; KUPFER Y, 1987, CRIT CARE MED, V15, P795, DOI 10.1097/00003246-198708000-00019; MORRIS RB, 1983, ANESTHESIOLOGY, V58, P438, DOI 10.1097/00000542-198305000-00008; PARTRIDGE BL, 1990, CRIT CARE MED, V18, P1177, DOI 10.1097/00003246-199010000-00025; SEGREDO V, 1990, ANESTHESIOLOGY, V72, P566, DOI 10.1097/00000542-199003000-00030; SHANKS AB, 1985, BRIT J ANAESTH, V57, P807, DOI 10.1093/bja/57.8.807; SLATER RM, 1988, ANAESTHESIA, V43, P250; STARSNIC MA, 1989, CAN J ANAESTH, V36, P35, DOI 10.1007/BF03010884; VANMARLE W, 1980, BRIT MED J, V281, P271, DOI 10.1136/bmj.281.6235.271-a; ZOCHODNE DW, 1987, BRAIN, V110, P819, DOI 10.1093/brain/110.4.819	10	91	91	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1992	117	6					484	486		10.7326/0003-4819-117-6-484	http://dx.doi.org/10.7326/0003-4819-117-6-484			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN257	1354426				2022-12-01	WOS:A1992JN25700008
J	MATCHAR, DB; DIVINE, GW; HEYMAN, A; FEUSSNER, JR				MATCHAR, DB; DIVINE, GW; HEYMAN, A; FEUSSNER, JR			THE INFLUENCE OF HYPERGLYCEMIA ON OUTCOME OF CEREBRAL INFARCTION	ANNALS OF INTERNAL MEDICINE			English	Article						HYPERGLYCEMIA; CEREBRAL INFARCTION; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); BLOOD GLUCOSE; CEREBROVASCULAR DISORDERS	ACUTE STROKE; DIABETES-MELLITUS; BLOOD-GLUCOSE; PROGNOSTIC VALUE; CEREBROVASCULAR ACCIDENT; GLYCOSYLATED HEMOGLOBIN; NATURAL-HISTORY; BARTHEL INDEX; RECOVERY; ISCHEMIA	Objective: To determine whether hyperglycemia in the acute stroke period is associated with worse survival and functional outcome after accounting for acute stress response and chronic hyperglycemia. Design: Prospective, county-wide, multicenter cohort study. Setting: A community hospital, a university hospital, and a Veterans Affairs hospital. Patients: A cohort of 146 patients hospitalized with new atherothrombotic stroke. Measurements: Admission blood glucose concentration, demographic characteristics of patients, 24-hour urinary catecholamine, serum cortisol, and glycosylated hemoglobin levels; outcomes included mortality and functional outcome (Barthel index and Fugl-Meyer score) at 5, 30, 90, and 180 days after stroke. Results: Of the 996 patients with possible acute stroke who were screened, 146 (15%) were eligible for and consented to participate in the study; in most cases, exclusion from study was based on the absence of acute, atherothrombotic stroke. Overall, no evidence was found of a significant univariate association between admission blood glucose level and survival (relative risk, 1.02; 95% CI, 0.94 to 1.09) or functional outcome (univariate regression coefficient for adjusted Fugl-Meyer score at day 30, - 0.36; CI, - 1.08 to 0.27). This absence of an association persisted after adjustment for significant predictors of outcome in a multivariate model. Conclusions: These data do not support an association between level of glycemia and outcome from acute stroke.	DUKE UNIV, MED CTR, DEPT MED, DIV NEUROL, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT MED, DIV GEN INTERNAL MED, DURHAM, NC 27710 USA; VET AFFAIRS MED CTR, DURHAM, NC USA	Duke University; Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	MATCHAR, DB (corresponding author), DUKE UNIV, CTR HLTH POLICY RES & EDUC, SUITE 125, OLD CHEM BLDG, DURHAM, NC 27706 USA.		Matchar, David/M-3951-2019	Matchar, David/0000-0003-3020-2108	NINDS NIH HHS [NS 06233] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS006233] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABUZEID HAH, 1978, ARCH NEUROL-CHICAGO, V35, P213, DOI 10.1001/archneur.1978.00500280031005; ACHESON J, 1971, Q J MED, V40, P25; ARONSON SM, 1973, J NEUROPATH EXP NEUR, V32, P183, DOI 10.1097/00005072-197304000-00001; ASPLUND K, 1980, ACTA MED SCAND, V207, P417; BARNES AJ, 1977, LANCET, V2, P789; BENTSEN N, 1975, STROKE, V6, P497, DOI 10.1161/01.STR.6.5.497; BERGER L, 1986, STROKE, V17, P865, DOI 10.1161/01.STR.17.5.865; BUTTERFIELD WJH, 1955, LANCET, V1, P489; CANDELISE L, 1985, ARCH NEUROL-CHICAGO, V42, P661, DOI 10.1001/archneur.1985.04060070051014; COX NH, 1986, POSTGRAD MED J, V62, P7, DOI 10.1136/pgmj.62.723.7; CRUICKSHANK JM, 1974, BRIT HEART J, V36, P697; DUNCAN PW, 1983, PHYS THER, V63, P1606, DOI 10.1093/ptj/63.10.1606; ENTMACHER PS, 1964, DIABETES, V13, P373, DOI 10.2337/diab.13.4.373; FEIBEL JH, 1977, JAMA-J AM MED ASSOC, V238, P1374, DOI 10.1001/jama.238.13.1374; FRITHZ G, 1976, ACTA MED SCAND, V199, P133; FUGLMEYER AR, 1975, SCAND J REHABIL MED, V7, P13; FULLERTON KJ, 1988, Q J MED, V66, P147; GINSBERG MD, 1987, STROKE, V18, P570, DOI 10.1161/01.STR.18.3.570; GINSBERG MD, 1980, STROKE, V11, P347, DOI 10.1161/01.STR.11.4.347; GIROUD M, 1987, PRESSE MED, V16, P1079; GRANGER CV, 1979, ARCH PHYS MED REHAB, V60, P14; GRANGER CV, 1979, ARCH PHYS MED REHAB, V60, P145; GRAY CS, 1987, DIABETIC MED, V4, P237, DOI 10.1111/j.1464-5491.1987.tb00870.x; GRAY CS, 1989, POSTGRAD MED J, V65, P720, DOI 10.1136/pgmj.65.768.720; GRUNNET ML, 1963, NEUROLOGY, V13, P486, DOI 10.1212/WNL.13.6.486; HAMMOND EC, 1969, ARCH ENVIRON HEALTH, V19, P167, DOI 10.1080/00039896.1969.10666825; HELGASON CM, 1988, STROKE, V19, P1049, DOI 10.1161/01.STR.19.8.1049; Huff TA, 1972, STROKE, V3, P543, DOI 10.1161/01.STR.3.5.543; JACHUCK SJ, 1975, BRIT MED J, V1, P242, DOI 10.1136/bmj.1.5952.242; Kannel WB, 1971, STROKE, V2, P295, DOI 10.1161/01.STR.2.4.295; KESSLER II, 1971, AM J MED, V51, P715, DOI 10.1016/0002-9343(71)90299-3; KUSHNER M, 1990, ANN NEUROL, V28, P129, DOI 10.1002/ana.410280204; LAVY S, 1968, J NEUROL SCI, V7, P409, DOI 10.1016/0022-510X(68)90049-X; LAVY S, 1974, STROKE, V5, P775, DOI 10.1161/01.STR.5.6.775; LEBOVITZ HE, 1969, CIRCULATION, V39, P171, DOI 10.1161/01.CIR.39.2.171; MAHONEY F I, 1965, Md State Med J, V14, P61; MARSH WR, 1986, J NEUROSURG, V65, P693, DOI 10.3171/jns.1986.65.5.0693; MATCHAR DB, 1989, CLIN RES, V37, pA84; MCDONALD L, 1969, LANCET, V2, P1021; MCMILLAN DE, 1978, DIABETES, V27, P895, DOI 10.2337/diab.27.9.895; MELAMED E, 1976, J NEUROL SCI, V29, P267, DOI 10.1016/0022-510X(76)90176-3; MEYER JS, 1973, BRAIN, V96, P277, DOI 10.1093/brain/96.2.277; MIAH K, 1983, J CHRON DIS, V36, P279, DOI 10.1016/0021-9681(83)90063-2; MYERS MG, 1981, STROKE, V12, P200, DOI 10.1161/01.STR.12.2.200; MYERS RE, 1976, NEUROLOGY, V26, P345; NEDERGAARD M, 1986, J CEREBR BLOOD F MET, V6, P607, DOI 10.1038/jcbfm.1986.108; ONEILL PA, 1991, STROKE, V22, P842, DOI 10.1161/01.STR.22.7.842; OPPENHEIMER SM, 1985, BRIT MED J, V291, P1014, DOI 10.1136/bmj.291.6501.1014-a; OXBURY JM, 1975, BRIT MED J, V3, P125, DOI 10.1136/bmj.3.5976.125; POWER MJ, 1988, AGE AGEING, V17, P164, DOI 10.1093/ageing/17.3.164; PULSINELLI WA, 1983, AM J MED, V74, P540, DOI 10.1016/0002-9343(83)91007-0; PULSINELLI WA, 1982, NEUROLOGY, V32, P1239, DOI 10.1212/WNL.32.11.1239; RIDDLE MC, 1982, STROKE, V13, P356, DOI 10.1161/01.STR.13.3.356; SCHOENBERG BS, 1980, ANN NEUROL, V8, P101; SELYE H, 1946, J CLIN ENDOCR METAB, V6, P117, DOI 10.1210/jcem-6-2-117; SIEMKOWICZ E, 1981, ACTA NEUROL SCAND, V64, P207; SIEMKOWICZ E, 1978, ACTA NEUROL SCAND, V58, P1; SILBERBAUER K, 1979, NEW ENGL J MED, V300, P366; TOMOMATSU T, 1964, JPN CIRC J, V28, P884; TOPIC E, 1989, DIABETIC MED, V6, P12, DOI 10.1111/j.1464-5491.1989.tb01131.x; WAUTIER JL, 1981, NEW ENGL J MED, V305, P237, DOI 10.1056/NEJM198107303050501; WEIDLER DJ, 1974, STROKE, V5, P759, DOI 10.1161/01.STR.5.6.759; WOO E, 1988, STROKE, V19, P185, DOI 10.1161/01.STR.19.2.185; [No title captured]	64	60	61	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1992	117	6					449	456		10.7326/0003-4819-117-6-449	http://dx.doi.org/10.7326/0003-4819-117-6-449			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN257	1503347				2022-12-01	WOS:A1992JN25700001
J	ROTH, D; FERNANDEZ, JA; BABISCHKIN, S; DEMATTOS, A; BUCK, BE; QUAN, S; OLSON, L; BURKE, GW; NERY, JR; ESQUENAZI, V; SCHIFF, ER; MILLER, J				ROTH, D; FERNANDEZ, JA; BABISCHKIN, S; DEMATTOS, A; BUCK, BE; QUAN, S; OLSON, L; BURKE, GW; NERY, JR; ESQUENAZI, V; SCHIFF, ER; MILLER, J			DETECTION OF HEPATITIS-C VIRUS-INFECTION AMONG CADAVER ORGAN DONORS - EVIDENCE FOR LOW TRANSMISSION OF DISEASE	ANNALS OF INTERNAL MEDICINE			English	Article						HEPATITIS-C; ORGAN TRANSPLANTATION; CADAVER	NON-B-HEPATITIS; NON-A; LIVER-DISEASE; TRANSPLANT RECIPIENTS; BLOOD-DONORS; ANTIBODIES; ASSAY; RNA	Objective: To determine the prevalence of antibodies to hepatitis C virus (anti-HCV) and HCV RNA among cadaver organ donors and to correlate these results with donor liver histologic abnormalities and evidence for transmission of disease through organ transplantation. Design: Retrospective testing of stored serum samples from cadaver organ donors for anti-HCV and HCV RNA. Setting: Transplantation service of the University of Miami/Jackson Memorial Medical Center and other cooperative medical centers furnishing follow-up data. Subjects: Of 1096 cadaver organ donors harvested between 1 January 1979 and 28 February 1991, 484 had stored serum samples available for analysis. Recipients of organs from recombinant immunoblot assay (RIBA)-positive donors for whom adequate follow-up was available were also included in the analysis. Measurements: Samples were tested for anti-HCV by enzyme-linked immunosorbent assay (ELISA). Confirmatory testing was done using a second-generation RIBA. Hepatitis C viral RNA was detected in serum using the polymerase chain reaction. Liver biopsies were obtained from the organ donor and interpreted blindly by a pathologist unaware of the clinical data. Liver chemistry profiles and serum sample analysis for HCV RNA were done for transplant recipients. Results: From the 484 cadaver organ donors, 89 samples (18%; 95% CI, 15% to 21%) were reactive by ELISA. Of these, 33 (6.8%; CI, 4.6% to 9%) were RIBA seropositive. Hepatitis C viral RNA sequences were detected in 50% of the RIBA-positive serum samples tested. Liver tissue was available from 24 of the 33 RIBA-positive donors and showed chronic active hepatitis in 16, chronic persistent hepatitis in 2, and no abnormality in 6. Among the 46 recipients of a kidney from a RIBA-positive donor, 13 (28%; CI, 15% to 41%) developed post-transplant liver disease, of which only 4 cases were highly suggestive of viral transmission from the donor. Little morbidity and no mortality could be attributed to liver disease in this cohort of recipients. Conclusions: These data suggest that HCV transmission by organ transplantation is low and that the consequences of infection are small. If the medical condition of the potential recipient is so serious that other options no longer exist, the use of an organ from an anti-HCV-seropositive donor should be considered.							NIDDK NIH HHS [R01DK25243] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK025243] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBERTI A, 1991, ANN INTERN MED, V114, P1010, DOI 10.7326/0003-4819-114-12-1010; ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; CHA TA, 1991, J CLIN MICROBIOL, V29, P2528, DOI 10.1128/JCM.29.11.2528-2534.1991; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; CZAFA AJ, 1990, MAYO CLIN P, V65, P1303; ESTEBAN JI, 1990, NEW ENGL J MED, V323, P1107, DOI 10.1056/NEJM199010183231605; ESTEBAN JI, 1991, ANN INTERN MED, V115, P443, DOI 10.7326/0003-4819-115-6-443; ESTEBAN JI, 1989, LANCET, V2, P294; FARCI P, 1991, NEW ENGL J MED, V325, P98, DOI 10.1056/NEJM199107113250205; GARSON JA, 1990, LANCET, V335, P1419, DOI 10.1016/0140-6736(90)91446-H; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; MADDREY WC, 1990, HEPATOLOGY TXB LIVER, P1025; MILGROM M, 1989, TRANSPLANT P, V21, P3934; PEREIRA BJG, 1991, NEW ENGL J MED, V325, P454, DOI 10.1056/NEJM199108153250702; PONZ E, 1991, KIDNEY INT, V40, P748, DOI 10.1038/ki.1991.270; QUAN S, 1990, 2ND P INT S HEP C VI; ROTH D, 1991, TRANSPLANTATION, V51, P396, DOI 10.1097/00007890-199102000-00024; TREMOLADA F, 1991, ANN INTERN MED, V114, P277, DOI 10.7326/0003-4819-114-4-277; VANDERPOEL CL, 1991, LANCET, V337, P317, DOI 10.1016/0140-6736(91)90942-I; WARE AJ, 1979, ANN INTERN MED, V91, P364, DOI 10.7326/0003-4819-91-3-364; 1989, 1ST P INT S HEP C VI, P25	23	93	94	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1992	117	6					470	475		10.7326/0003-4819-117-6-470	http://dx.doi.org/10.7326/0003-4819-117-6-470			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN257	1323944				2022-12-01	WOS:A1992JN25700005
J	BURNETT, SD; WOOLF, CM; YUDKIN, JS				BURNETT, SD; WOOLF, CM; YUDKIN, JS			DEVELOPING A DISTRICT DIABETIC REGISTER	BRITISH MEDICAL JOURNAL			English	Article							CARE	Objectives-To compile a district wide diabetic register of all diabetic patients registered with general practitioners in the catchment area of a single district general hospital and to compare different approaches to identifying patients. Design-Information for a register was obtained from general practitioners' practice registers, the Prescription Pricing Authority, and hospital diabetic clinic records. Setting-Catchment area of an inner London district general hospital with a large diabetic clinic. Subjects-All patients with a diagnosis of diabetes resident in or attending general practitioners or hospital clinics in the district or its catchment area. Main outcome measures-Prevalence of diabetes, population of patients elicited by different approaches, proportion attending the local district general hospital, cost of using prescription returns for identifying diabetic patients. Results-4674 patients with diabetes were identified from all sources of information, which corresponds to a mean of 22.4 patients per general practitioner and the prevalence of known diabetes of 1.17%. 39.4% of patients identified had Prescription Pricing Authority returns and 42.8% of patients appeared on practices' diabetic registers. Only 56.5% of patients identified attended the district general hospital. For practices where all sources of information were available, practice registers included 60.4% of all patients, and prescription returns and the clinic register identified 64.9% and 40.6% respectively. The cost of using prescription returns to identify patients not detected in other ways was Pound 6-37 per patient. Conclusion-The task of developing district diabetic registers may prove, even in one cross sectional attempt, a major task in many inner city health districts.			BURNETT, SD (corresponding author), WHITTINGTON HOSP,UNIV COLL & MIDDLESEX SCH MED,DEPT MED,LONDON N19 5NF,ENGLAND.		Yudkin, John S/C-1988-2008					COULTER A, 1989, J EPIDEMIOL COMMUN H, V43, P25, DOI 10.1136/jech.43.1.25; HURWITZ B, 1990, DIABETES CLIN MANAGE, P110; JONES RB, 1989, PRACTICAL DIABETES, V3, P129; KOPELMAN P, 1990, DIABETIC MED, V7, P558, DOI 10.1111/j.1464-5491.1990.tb01446.x; MCMAHON C, 1991, DIABETIC MED, V8, P770, DOI 10.1111/j.1464-5491.1991.tb01698.x; NABARRO J, 1987, J ROY COLL GEN PRACT, V37, P389; YUDKIN JS, 1980, J EPIDEMIOL COMMUN H, V34, P277, DOI 10.1136/jech.34.4.277; 1991, RECOMMENDATIONS DIAB	8	30	29	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 12	1992	305	6854					627	630		10.1136/bmj.305.6854.627	http://dx.doi.org/10.1136/bmj.305.6854.627			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN698	1294089	Green Submitted, Green Published, Bronze			2022-12-01	WOS:A1992JN69800022
J	COTTRELL, S; BICKNELL, D; KAKLAMANIS, L; BODMER, WF				COTTRELL, S; BICKNELL, D; KAKLAMANIS, L; BODMER, WF			MOLECULAR ANALYSIS OF APC MUTATIONS IN FAMILIAL ADENOMATOUS POLYPOSIS AND SPORADIC COLON CARCINOMAS	LANCET			English	Article							CELL-LINES; PRESYMPTOMATIC DIAGNOSIS; DNA MARKERS; GENE; IDENTIFICATION; CHROMOSOME-5Q21; ESTABLISHMENT; MISMATCHES; LOCUS; FAP	Mutations in the APC gene give rise to familial adenomatous polyposis (FAP) and also occur in many, perhaps most, sporadic colon cancers. By screening with single-strand conformation polymorphism analysis we identified several mutations in a small region of the APC gene in both FAP and sporadic cancers. These mutations were either point mutations or small deletions or insertions causing frameshifts, and all generated stop codons. One 5 base-pair deletion was found in a sporadic colon tumour, a colorectal cancer cell line derived from a sporadic colon tumour, and in four unrelated FAP patients. This mutation produces distinctive heteroduplex bands, which can be detected with a simple non-radioactive assay. Our findings suggest that highly localised short sequences, essentially runs that code for adenine and thymine, may account for up to 20% of all observed APC mutations.	IMPERIAL CANC RES FUND,CANC GENET LAB,POB 123,LONDON WC2A 3PX,ENGLAND; JOHN RADCLIFFE HOSP,INST MOLEC MED,IMPERIAL CANC RES FUND,CANC IMMUNOL LAB,OXFORD OX3 9DU,ENGLAND; JOHN RADCLIFFE HOSP,NUFFIELD DEPT PATHOL,OXFORD OX3 9DU,ENGLAND	Cancer Research UK; University of Oxford; University of Oxford				Bodmer, Walter/0000-0001-6244-9792				BISHOP DT, 1990, HEREDITARY COLORECTA, P423; BODMER W, 1992, CANCER SURV, V13, P1; BODMER WF, 1987, NATURE, V328, P614, DOI 10.1038/328614a0; BODMER WF, 1990, HEREDITARY COLORECTA, P37; BOYNTON RF, 1992, P NATL ACAD SCI USA, V89, P3385, DOI 10.1073/pnas.89.8.3385; COTTON RGH, 1988, P NATL ACAD SCI USA, V85, P4397, DOI 10.1073/pnas.85.12.4397; Cottrel S., 1992, Human Molecular Genetics, V1, P352, DOI 10.1093/hmg/1.5.352-a; DAMICO D, 1992, CANCER RES, V52, P1996; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; DREWINKO B, 1976, CANCER RES, V36, P467; DUNLOP MG, 1991, LANCET, V337, P313, DOI 10.1016/0140-6736(91)90940-Q; GREENWALD BD, 1992, CANCER RES, V52, P741; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HEIGHWAY J, 1991, NUCLEIC ACIDS RES, V19, P6966, DOI 10.1093/nar/19.24.6966; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; KEEN J, 1991, TRENDS GENET, V7, P5; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KRAUS C, 1992, HUM GENET, V88, P705, DOI 10.1007/BF02265305; LEIBOVITZ A, 1976, CANCER RES, V36, P4562; LEPPERT M, 1987, SCIENCE, V238, P1411, DOI 10.1126/science.3479843; MCBAIN JA, 1984, CANCER RES, V44, P5813; MITELMAN F, 1991, CYTOGENET CELL GENET, V58, P1053, DOI 10.1159/000133721; MIYOSHI Y, 1992, P NATL ACAD SCI USA, V89, P4452, DOI 10.1073/pnas.89.10.4452; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; PARASKEVA C, 1984, INT J CANCER, V34, P49, DOI 10.1002/ijc.2910340109; SPIRIO L, 1991, NUCLEIC ACIDS RES, V19, P6348, DOI 10.1093/nar/19.22.6348; SUARDET L, 1992, CANCER RES, V52, P3705; TOPS CMJ, 1989, LANCET, V2, P1361; WHITE MB, 1992, GENOMICS, V12, P301, DOI 10.1016/0888-7543(92)90377-5	30	207	208	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 12	1992	340	8820					626	630		10.1016/0140-6736(92)92169-G	http://dx.doi.org/10.1016/0140-6736(92)92169-G			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JM851	1355210				2022-12-01	WOS:A1992JM85100002
J	WEETMAN, AP; TANDON, N; MORGAN, BP				WEETMAN, AP; TANDON, N; MORGAN, BP			ANTITHYROID DRUGS AND RELEASE OF INFLAMMATORY MEDIATORS BY COMPLEMENT-ATTACKED THYROID-CELLS	LANCET			English	Article							GRAVES-DISEASE; HASHIMOTOS THYROIDITIS; MEMBRANE ATTACK; GROWTH-FACTOR; T-CELLS; INTERLEUKIN-6; LYMPHOCYTES; METHIMAZOLE; SURFACE	Thyroid cells are exposed to complement attack in Graves' disease and Hashimoto's thyroiditis, but are resistant to killing by homologous complement. We have examined the effects of sublethal complement attack on thyroid cells in vitro. Extracellular reactive oxygen metabolites were produced and prostaglandin E2, interleukin-1-alpha, and interleukin-6 were released after complement attack. Cells pretreated with interferon-gamma and interleukin-1-alpha, which increase expression of CD59, were more resistant to these effects of complement. Conversely, blockade of CD59 with monoclonal antibody increased complement-mediated oxygen radical production and release of prostaglandin E2, interleukin-1-alpha, and interleukin-6. The antithyroid drugs methimazole and propylthiouracil abolished or reduced oxygen radical production by complement-attacked thyroid cells and reduced cytokine release. These results suggest that sublethal complement attack in autoimmune thyroid diseases exacerbates tissue injury by causing thyroid cells to release potent phlogistic mediators, although some degree of protection may be afforded in vivo by cytokine-mediated upregulation of CD59. Antithyroid drugs, concentrated within thyroid cells, will prevent the release of these inflammatory molecules, which may in turn explain the amelioration of thyroiditis and remission of Graves' disease after such treatment.	UNIV WALES COLL MED,DEPT MED BIOCHEM,CARDIFF CF4 4XN,S GLAM,WALES	Cardiff University	WEETMAN, AP (corresponding author), UNIV SHEFFIELD,NO GEN HOSP,CTR CLIN SCI,DEPT MED,SHEFFIELD S5 7AU,ENGLAND.			Morgan, Paul/0000-0003-4075-7676	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AKIRA S, 1990, FASEB J, V4, P2860, DOI 10.1096/fasebj.4.11.2199284; ALLEN EM, 1986, AM J MED SCI, V29, P267; BANGA JP, 1991, AUTOIMMUNITY, V8, P335, DOI 10.3109/08916939109007642; BELLUR S, 1990, ENDOCRINOLOGY, V127, P1526, DOI 10.1210/endo-127-3-1526; BROWN TR, 1991, J CLIN INVEST, V88, P106, DOI 10.1172/JCI115265; GRUBECKLOEBENSTEIN B, 1989, CLIN EXP IMMUNOL, V77, P324; JANSSON R, 1985, BRIT MED J, V290, P11, DOI 10.1136/bmj.290.6461.11; KALDERON AE, 1977, AM J MED, V63, P729, DOI 10.1016/0002-9343(77)90159-0; KASAI K, 1987, LIFE SCI, V41, P241, DOI 10.1016/0024-3205(87)90499-1; KHOURY EL, 1984, J EXP MED, V159, P577, DOI 10.1084/jem.159.2.577; KHOURY EL, 1981, CLIN EXP IMMUNOL, V45, P316; MARCHANT B, 1972, J CLIN ENDOCR METAB, V34, P847, DOI 10.1210/jcem-34-5-847; MARGOLICK JB, 1988, CLIN IMMUNOL IMMUNOP, V47, P208, DOI 10.1016/0090-1229(88)90073-6; MCGREGOR AM, 1982, BRIT MED J, V284, P1750, DOI 10.1136/bmj.284.6331.1750; MCGREGOR AM, 1980, BRIT MED J, V281, P968, DOI 10.1136/bmj.281.6246.968; MCLACHLAN SM, 1986, CLIN ENDOCRINOL, V24, P223, DOI 10.1111/j.1365-2265.1986.tb00766.x; MORGAN BP, 1989, BIOCHEM J, V264, P1; OLEESKY DA, 1985, CLIN ENDOCRINOL, V25, P623; ROMALDINI JH, 1986, J ENDOCRINOL INVEST, V9, P233, DOI 10.1007/BF03348107; ROMALDINI JH, 1983, J CLIN ENDOCR METAB, V57, P563, DOI 10.1210/jcem-57-3-563; TANDON N, 1992, IMMUNOLOGY, V75, P372; TOTTERMAN TH, 1987, NEW ENGL J MED, V316, P15, DOI 10.1056/NEJM198701013160104; VOLPE R, 1987, NEW ENGL J MED, V316, P44, DOI 10.1056/NEJM198701013160109; WEETMAN AP, 1990, J ENDOCRINOL, V127, P357, DOI 10.1677/joe.0.1270357; WEETMAN AP, 1990, CLIN EXP IMMUNOL, V82, P69; WEETMAN AP, 1982, CLIN EXP IMMUNOL, V48, P196; WEETMAN AP, 1989, CLIN EXP IMMUNOL, V77, P25; WEETMAN AP, 1984, CLIN ENDOCRINOL, V21, P163, DOI 10.1111/j.1365-2265.1984.tb03456.x; WERNER SC, 1972, NEW ENGL J MED, V287, P421, DOI 10.1056/NEJM197208312870901; WOOD LC, 1979, J CLIN INVEST, V64, P1429, DOI 10.1172/JCI109601; YOUNG RJ, 1976, J CLIN PATHOL, V29, P398, DOI 10.1136/jcp.29.5.398; ZHENG RQH, 1991, CLIN EXP IMMUNOL, V83, P314	32	83	84	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 12	1992	340	8820					633	636						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JM851	1381035				2022-12-01	WOS:A1992JM85100004
J	HOLDEN, C				HOLDEN, C			CRIME CONFERENCE - BACK TO THE DRAWING BOARD, SAYS NIH	SCIENCE			English	Editorial Material																		WALTERS R, 1992, SCIENCE, V257, P739	1	4	4	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 11	1992	257	5076					1474	1474		10.1126/science.1523404	http://dx.doi.org/10.1126/science.1523404			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JM570	1523404				2022-12-01	WOS:A1992JM57000012
J	HWANG, C; SINSKEY, AJ; LODISH, HF				HWANG, C; SINSKEY, AJ; LODISH, HF			OXIDIZED REDOX STATE OF GLUTATHIONE IN THE ENDOPLASMIC-RETICULUM	SCIENCE			English	Article							PROTEIN-DISULFIDE-ISOMERASE; MICROSOMAL-MEMBRANES; RAT-LIVER; CATALYZED FORMATION; BOND FORMATION; SYSTEM; THIOL; TRANSLOCATION; RIBONUCLEASE; TRANSPORT	The redox state of the endoplasmic reticulum (ER) was measured with the peptide N-Ace-tyl-Asn-Tyr-Thr-Cys-NH2. The peptide diffused across cellular membranes; some became glycosylated and thus trapped within the secretory pathway, and its cysteine residue underwent reversible thiol-disulfide exchanges with the surrounding redox buffer. Glycosylated peptides from cells were disulfide-linked to glutathione, indicating that glutathione is the major redox buffer in the secretory pathway. The redox state of the secretory pathway was more oxidative than that of the cytosol; the ratio of reduced glutathione to the disulfide form (GSH/GSSG) within the secretory pathway ranged from 1:1 to 3:1, whereas the overall cellular GSH/GSSG ratio ranged from 30:1 to 100:1. Cytosolic glutathione was also transported into the lumen of microsomes in a cell-free system. Although how the ER maintains an oxidative environment is not known, these results suggest that the demonstrated preferential transport of GSSG compared to GSH into the ER lumen may contribute to this redox compartmentation.	MIT, WHITEHEAD INST BIOMED RES, DEPT BIOL, CAMBRIDGE, MA 02142 USA; MIT, CTR BIOTECH PROC ENGN, CAMBRIDGE, MA 02142 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)								ANDERSON ME, 1985, METHOD ENZYMOL, V113, P548; ANIYA Y, 1989, ARCH BIOCHEM BIOPHYS, V270, P330, DOI 10.1016/0003-9861(89)90035-0; BANNAI S, 1980, J CELL PHYSIOL, V104, P215, DOI 10.1002/jcp.1041040211; BISCHOFF J, 1983, J BIOL CHEM, V258, P7907; BULLEID NJ, 1988, NATURE, V335, P649, DOI 10.1038/335649a0; COTGREAVE IA, 1989, SULPHUR CONTAINING B, V2, P101; Dolphin D., 1989, GLUTATHIONE CHEM BIO; FAHEY RC, 1987, METHOD ENZYMOL, V143, P85; GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69; HAWKINS HC, 1991, BIOCHEM J, V275, P341, DOI 10.1042/bj2750341; HOLMGREN A, 1968, EUR J BIOCHEM, V6, P475, DOI 10.1111/j.1432-1033.1968.tb00470.x; HWANG C, UNPUB; ISAACS J, 1977, BIOCHIM BIOPHYS ACTA, V497, P192, DOI 10.1016/0304-4165(77)90152-0; JANOLINO VG, 1987, ARCH BIOCHEM BIOPHYS, V258, P265, DOI 10.1016/0003-9861(87)90344-4; KADERBHAI MA, 1984, BIOCHEM J, V217, P145, DOI 10.1042/bj2170145; KADERBHAI MA, 1985, EUR J BIOCHEM, V153, P167, DOI 10.1111/j.1432-1033.1985.tb09283.x; KOIVU J, 1987, J BIOL CHEM, V262, P6159; Kosower N S, 1978, Int Rev Cytol, V54, P109, DOI 10.1016/S0074-7696(08)60166-7; KUROSAWA K, 1990, BIOCHEM BIOPH RES CO, V167, P367, DOI 10.1016/0006-291X(90)91774-M; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBERT N, 1983, BIOCHEM J, V213, P235, DOI 10.1042/bj2130235; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P613, DOI 10.1021/bi00217a004; MARTENSSON J, 1990, P NATL ACAD SCI USA, V87, P7185, DOI 10.1073/pnas.87.18.7185; NILSSON R, 1973, J CELL BIOL, V56, P762, DOI 10.1083/jcb.56.3.762; ONDARZA RN, 1989, BIOSCIENCE REP, V9, P593, DOI 10.1007/BF01119803; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; PETERSEN JG, 1974, J BIOL CHEM, V249, P5633; SAXENA VP, 1970, BIOCHEMISTRY-US, V9, P5015; SCHEELE G, 1982, J BIOL CHEM, V257, P2277; SCHEELE G, 1983, METHOD ENZYMOL, V96, P94; SCHEELE G, 1983, J BIOL CHEM, V258, P2005; Torchinsky Y, 1981, SULFUR PROTEINS; VERMEER C, 1990, BIOCHEM J, V266, P625, DOI 10.1042/bj2660625; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WELPLY JK, 1983, J BIOL CHEM, V258, P1856; WETLAUFER DB, 1987, PROTEIN ENG, V1, P141, DOI 10.1093/protein/1.2.141; WIELAND FT, 1987, CELL, V50, P289, DOI 10.1016/0092-8674(87)90224-8; WIKSTROM L, 1991, J CELL BIOL, V113, P997, DOI 10.1083/jcb.113.5.997; ZIEGLER DM, 1977, TRENDS BIOCHEM SCI, V2, P79, DOI 10.1016/0968-0004(77)90042-1; ZIEGLER DM, 1985, ANNU REV BIOCHEM, V54, P305, DOI 10.1146/annurev.bi.54.070185.001513	40	1596	1633	5	211	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 11	1992	257	5076					1496	1502		10.1126/science.1523409	http://dx.doi.org/10.1126/science.1523409			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JM570	1523409				2022-12-01	WOS:A1992JM57000021
J	NERI, D; BILLETER, M; WIDER, G; WUTHRICH, K				NERI, D; BILLETER, M; WIDER, G; WUTHRICH, K			NMR DETERMINATION OF RESIDUAL STRUCTURE IN A UREA-DENATURED PROTEIN, THE 434-REPRESSOR	SCIENCE			English	Article							NUCLEAR-MAGNETIC-RESONANCE; DNA-BINDING DOMAIN; PHAGE-434 REPRESSOR; PROTON; SPECTROSCOPY; CONFORMATIONS; FILTERS; LEUCINE; VALINE	A nuclear magnetic resonance (NMR) structure determination is reported for the polypeptide chain of a globular protein in strongly denaturing solution. Nuclear Overhauser effect (NOE) measurements with a 7 molar urea solution of the amino-terminal 63-residue domain of the 434-repressor and distance geometry calculations showed that the polypeptide segment 54 to 59 forms a hydrophobic cluster containing the side chains of Val54, Val56, Trp58, and Leu59. This residual structure in the urea-unfolded protein is related to the corresponding region of the native, folded protein by simple rearrangements of the residues 58 to 60. Based on these observations a model for the early phase of refolding of the 434-repressor(1-63) is proposed.	SWISS FED INST TECHNOL,INST MOLEK BIOL & BIOPHYS,CH-8092 ZURICH,SWITZERLAND	Swiss Federal Institutes of Technology Domain; ETH Zurich			Neri, Dario/P-4368-2016; Billeter, Martin/A-8293-2010	Neri, Dario/0000-0001-5234-7370; Wider, Gerhard/0000-0001-9366-7645				ANDERSON J, 1984, P NATL ACAD SCI-BIOL, V81, P1307, DOI 10.1073/pnas.81.5.1307; BILLETER M, 1990, BIOPOLYMERS, V29, P695, DOI 10.1002/bip.360290404; BRAUN W, 1981, BIOCHIM BIOPHYS ACTA, V667, P377, DOI 10.1016/0005-2795(81)90205-1; BUNDI A, 1979, BIOPOLYMERS, V18, P285, DOI 10.1002/bip.1979.360180206; CHAN HS, 1990, P NATL ACAD SCI USA, V87, P6388, DOI 10.1073/pnas.87.16.6388; Dobson CM, 1991, CURR OPIN STRUC BIOL, V1, P22, DOI 10.1016/0959-440X(91)90006-F; FESIK SW, 1988, NATURE, V332, P865, DOI 10.1038/332865a0; GRIFFEY RH, 1987, Q REV BIOPHYS, V19, P51, DOI 10.1017/S0033583500004029; GUNTERT P, 1991, J MOL BIOL, V217, P517, DOI 10.1016/0022-2836(91)90754-T; MONDRAGON A, 1989, J MOL BIOL, V205, P189, DOI 10.1016/0022-2836(89)90375-6; NERI D, 1992, J MOL BIOL, V223, P743, DOI 10.1016/0022-2836(92)90987-U; NERI D, 1989, BIOCHEMISTRY-US, V28, P7510, DOI 10.1021/bi00445a003; NERI D, 1992, P NATL ACAD SCI USA, V89, P4397, DOI 10.1073/pnas.89.10.4397; NERI D, 1992, FEBS LETT, V303, P129, DOI 10.1016/0014-5793(92)80504-A; OTTING G, 1988, J MAGN RESON, V76, P569, DOI 10.1016/0022-2364(88)90361-7; OTTING G, 1986, J MAGN RESON, V70, P500, DOI 10.1016/0022-2364(86)90144-7; OTTING G, 1990, Q REV BIOPHYS, V23, P39, DOI 10.1017/S0033583500005412; OTTING G, 1991, SCIENCE, V254, P974, DOI 10.1126/science.1948083; RICHARDS FM, 1991, SCI AM, V264, P54, DOI 10.1038/scientificamerican0191-54; RODER H, 1986, Proteins Structure Function and Genetics, V1, P34, DOI 10.1002/prot.340010107; RODER H, 1988, NATURE, V335, P700, DOI 10.1038/335700a0; SENN H, 1989, FEBS LETT, V249, P113, DOI 10.1016/0014-5793(89)80027-4; SINGH UC, 1986, AMBER30 U CAL; UDGAONKAR JB, 1988, NATURE, V335, P694, DOI 10.1038/335694a0; WIDER G, 1991, J AM CHEM SOC, V113, P4676, DOI 10.1021/ja00012a044; WUTHRICH K, 1989, SCIENCE, V243, P45, DOI 10.1126/science.2911719; WUTHRICH K, 1983, J MOL BIOL, V169, P949, DOI 10.1016/S0022-2836(83)80144-2; Wuthrich K., 1986, NMR PROTEINS NUCL AC	28	494	498	0	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 11	1992	257	5076					1559	1563		10.1126/science.1523410	http://dx.doi.org/10.1126/science.1523410			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JM570	1523410				2022-12-01	WOS:A1992JM57000036
J	SEIDEL, HM; POMPLIANO, DL; KNOWLES, JR				SEIDEL, HM; POMPLIANO, DL; KNOWLES, JR			EXONS AS MICROGENES	SCIENCE			English	Editorial Material							SPLICE JUNCTIONS; EVOLUTION; TETRAHYMENA; CODONS; INTRON; GENES		HARVARD UNIV, DEPT CHEM, 12 OXFORD ST, CAMBRIDGE, MA 02138 USA; HARVARD UNIV, DEPT BIOCHEM, CAMBRIDGE, MA 02138 USA	Harvard University; Harvard University								Anfinsen C.B., 1971, ENZYMES, V4; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; CRAIK CS, 1982, NATURE, V299, P180, DOI 10.1038/299180a0; GALAKATOS NG, 1987, BIOCHEMISTRY-US, V26, P8475, DOI 10.1021/bi00399a066; GILBERT W, 1985, SCIENCE, V228, P823, DOI 10.1126/science.4001923; GILBERT W, 1978, NATURE, V271, P501, DOI 10.1038/271501a0; GO M, 1987, COLD SPRING HARB SYM, V52, P915, DOI 10.1101/SQB.1987.052.01.100; GO M, 1981, NATURE, V291, P90, DOI 10.1038/291090a0; HANYU N, 1986, EMBO J, V5, P1307, DOI 10.1002/j.1460-2075.1986.tb04360.x; Hori T., 1984, BIOCH NATURAL C P CO; LI CH, 1976, P NATL ACAD SCI USA, V73, P1476, DOI 10.1073/pnas.73.5.1476; MARTINDALE DW, 1989, J PROTOZOOL, V36, P29; NAITO Y, 1991, P NATL ACAD SCI USA, V88, P6672, DOI 10.1073/pnas.88.15.6672; ORGEL LE, 1987, COLD SPRING HARB SYM, V52, P9, DOI 10.1101/SQB.1987.052.01.004; OSAWA S, 1990, P ROY SOC B-BIOL SCI, V241, P19, DOI 10.1098/rspb.1990.0060; RICHARDS FM, 1971, ENZYMES, V4, P647; SEIDEL HM, 1992, BIOCHEMISTRY-US, V31, P2598, DOI 10.1021/bi00124a021; SENAPATHY P, 1988, P NATL ACAD SCI USA, V85, P1129, DOI 10.1073/pnas.85.4.1129; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SHARP PA, 1981, CELL, V23, P643, DOI 10.1016/0092-8674(81)90425-6; [No title captured]	21	29	31	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 11	1992	257	5076					1489	1490		10.1126/science.1523407	http://dx.doi.org/10.1126/science.1523407			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JM570	1523407				2022-12-01	WOS:A1992JM57000019
J	SMITH, EF; SALE, WS				SMITH, EF; SALE, WS			REGULATION OF DYNEIN-DRIVEN MICROTUBULE SLIDING BY THE RADIAL SPOKES IN FLAGELLA	SCIENCE			English	Article							SWIMMING SPERM FLAGELLA; CHLAMYDOMONAS-FLAGELLA; GENETIC-ANALYSIS; SEA-URCHIN; INNER-ARM; MUTANTS; OUTER; REINHARDTII; COMPONENTS; DIRECTION	The regulation of microtubule sliding in flagellar axonemes was studied with the use of Chlamydomonas mutants and in vitro assays. Microtubule sliding velocities were diminished in axonemes from mutant cells missing radial spoke structures but could be restored upon reconstitution with dynein from axonemes with wild-type radial spokes. These experiments demonstrate that the radial spokes activate dynein's microtubule sliding activity.			SMITH, EF (corresponding author), EMORY UNIV,SCH MED,DEPT ANAT & CELL BIOL,ATLANTA,GA 30322, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD020497] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008367] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 20497] Funding Source: Medline; NIGMS NIH HHS [GM 08367] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLOOM G S, 1992, Current Opinion in Cell Biology, V4, P66, DOI 10.1016/0955-0674(92)90060-P; BROKAW CJ, 1991, J CELL BIOL, V114, P1201, DOI 10.1083/jcb.114.6.1201; BROKAW CJ, 1980, SCIENCE, V207, P1365, DOI 10.1126/science.6898364; BROKAW CJ, 1982, J CELL BIOL, V92, P722, DOI 10.1083/jcb.92.3.722; BROKAW CJ, 1987, CELL MOTIL CYTOSKEL, V8, P68, DOI 10.1002/cm.970080110; BROKAW CJ, 1989, SCIENCE, V243, P1593, DOI 10.1126/science.2928796; DIENER DR, 1990, P NATL ACAD SCI USA, V87, P5739, DOI 10.1073/pnas.87.15.5739; FOX LA, 1987, J CELL BIOL, V105, P1781, DOI 10.1083/jcb.105.4.1781; HUANG B, 1982, CELL, V28, P115, DOI 10.1016/0092-8674(82)90381-6; HUANG B, 1981, J CELL BIOL, V88, P80, DOI 10.1083/jcb.88.1.80; HUANG BPH, 1986, INT REV CYTOL, V99, P181; JOHNSON KA, 1985, ANNU REV BIOPHYS BIO, V14, P161, DOI 10.1146/annurev.bb.14.060185.001113; KAMIYA R, 1989, CELL MOVEMENT DYNEIN, V1, pCH15; KURIMOTO E, 1991, CELL MOTIL CYTOSKEL, V19, P275, DOI 10.1002/cm.970190406; LUCK D, 1977, P NATL ACAD SCI USA, V74, P3456, DOI 10.1073/pnas.74.8.3456; LUCK DJL, 1989, CELL MOVEMENT DYNEIN, V1, pCH4; MUTO E, 1991, J CELL SCI, V99, P57; OKAGAKI T, 1986, J CELL BIOL, V103, P1895, DOI 10.1083/jcb.103.5.1895; OMOTO CK, 1980, J CELL BIOL, V87, P33, DOI 10.1083/jcb.87.1.33; PIPERNO G, 1991, J CELL BIOL, V112, P701, DOI 10.1083/jcb.112.4.701; PIPERNO G, 1981, CELL, V27, P331, DOI 10.1016/0092-8674(81)90416-5; PIPERNO G, 1990, J CELL BIOL, V110, P379, DOI 10.1083/jcb.110.2.379; PIPERNO G, 1981, J CELL BIOL, V88, P73, DOI 10.1083/jcb.88.1.73; SALE WS, 1977, P NATL ACAD SCI USA, V74, P2045, DOI 10.1073/pnas.74.5.2045; SATIR P, 1968, J CELL BIOL, V39, P77, DOI 10.1083/jcb.39.1.77; SMITH EF, 1992, J CELL BIOL, V117, P573, DOI 10.1083/jcb.117.3.573; SUMMERS KE, 1971, P NATL ACAD SCI USA, V68, P3092, DOI 10.1073/pnas.68.12.3092; WARNER FD, 1974, J CELL BIOL, V63, P35, DOI 10.1083/jcb.63.1.35; WITMAN GB, 1978, J CELL BIOL, V76, P729, DOI 10.1083/jcb.76.3.729; WITMAN GB, 1992, CURR OPIN CELL BIOL, V4, P77	30	151	153	1	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 11	1992	257	5076					1557	1559		10.1126/science.1387971	http://dx.doi.org/10.1126/science.1387971			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JM570	1387971				2022-12-01	WOS:A1992JM57000035
J	ALLISON, MC; HOWATSON, AG; TORRANCE, CJ; LEE, FD; RUSSELL, RI				ALLISON, MC; HOWATSON, AG; TORRANCE, CJ; LEE, FD; RUSSELL, RI			GASTROINTESTINAL DAMAGE ASSOCIATED WITH THE USE OF NONSTEROIDAL ANTIINFLAMMATORY DRUGS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ANTI-INFLAMMATORY DRUGS; SMALL-BOWEL ULCERATION; SMALL-INTESTINE; PEPTIC-ULCER; RHEUMATOID-ARTHRITIS; ELDERLY PERSONS; DISEASE; PERMEABILITY; THERAPY; PERFORATION	Background. Long-term use of nonsteroidal antiinflammatory drugs (NSAIDs) may lead to inflammation of the small intestine associated with occult blood and protein loss. The aim of this study was to investigate the prevalence and structural correlates of this enteropathy. Methods. We examined the stomach, duodenum, and small intestine of 713 patients post mortem. Of these patients, 249 had had NSAIDs prescribed during the six months before death and 464 patients had not. All visible small intestinal lesions were removed for histologic examination, and specific etiologic factors were sought. The prevalence of nonspecific small-intestinal ulcers and ulcers of the stomach and duodenum was compared in the two groups of patients. Results. Nonspecific small-intestinal ulceration was found in 21 (8.4 percent) of the users of NSAIDs and 3 (0.6 percent) of the nonusers (difference, 7.8 percent; 95 percent confidence interval, 5.0 to 10.6 percent; P<0.001). Three patients who were long-term users of NSAIDs were found to have died of perforated nonspecific small-intestinal ulcers. Ulcers of the stomach or duodenum were found in 54 (21.7 percent) of the patients who used these drugs and 57 (12.3 percent) of those who had not (difference, 9.4 percent; 95 percent confidence interval, 3.9 to 15.1 percent; P<0.001). Conclusions. Patients who take NSAIDs have an increased risk of nonspecific ulceration of the small-intestinal mucosa. These ulcers are less common than ulcers ot the stomach or duodenum, but can lead to life-threatening complications.	GLASGOW ROYAL INFIRM,DEPT PATHOL,GLASGOW G4 0SF,SCOTLAND; GLASGOW ROYAL INFIRM,GASTROENTEROL UNIT,GLASGOW G4 0SF,SCOTLAND	University of Glasgow; University of Glasgow								ARMSTRONG CP, 1987, GUT, V28, P527, DOI 10.1136/gut.28.5.527; BEARDON PHG, 1989, Q J MED, V71, P497; BJARNASON I, 1986, GUT, V27, P1292, DOI 10.1136/gut.27.11.1292; BJARNASON I, 1988, GASTROENTEROLOGY, V94, P1070, DOI 10.1016/0016-5085(88)90568-9; BJARNASON I, 1987, GASTROENTEROLOGY, V93, P480, DOI 10.1016/0016-5085(87)90909-7; BJARNASON I, 1984, LANCET, V2, P1171; BJARNASON I, 1987, LANCET, V2, P711; Bjarnason I., 1988, RECENT ADV GASTROENT, P23; BOYDSTUN JS, 1981, DIGEST DIS SCI, V26, P911, DOI 10.1007/BF01309496; COLLINS AJ, 1987, BRIT J RHEUMATOL, V26, P295; DAY TK, 1983, BRIT MED J, V287, P1671, DOI 10.1136/bmj.287.6406.1671-a; DEAKIN M, 1988, BRIT MED J, V297, P488, DOI 10.1136/bmj.297.6646.488-b; GRAHAM DY, 1988, LANCET, V2, P1277; GRIFFIN MR, 1988, ANN INTERN MED, V109, P359, DOI 10.7326/0003-4819-109-5-359; GRIFFIN MR, 1991, ANN INTERN MED, V114, P257, DOI 10.7326/0003-4819-114-4-257; HOLVOET J, 1991, GUT, V32, P730, DOI 10.1136/gut.32.7.730; JENKINS RT, 1987, BRIT J RHEUMATOL, V26, P103; LANG J, 1988, J CLIN PATHOL, V41, P516, DOI 10.1136/jcp.41.5.516; LANGMAN MJS, 1985, BRIT MED J, V290, P347, DOI 10.1136/bmj.290.6465.347; LEIJONMARCK CE, 1985, ACTA CHIR SCAND, V151, P273; MADHOK R, 1986, Q J MED, V58, P53; MORRIS AJ, 1991, LANCET, V337, P520, DOI 10.1016/0140-6736(91)91300-J; NEOPTOLEMOS JP, 1983, BRIT J SURG, V70, P244, DOI 10.1002/bjs.1800700422; SAVERYMUTTU SH, 1986, POSTGRAD MED J, V62, P967, DOI 10.1136/pgmj.62.732.967; SAW KC, 1990, J ROY SOC MED, V83, P114, DOI 10.1177/014107689008300219; SILVOSO GR, 1979, ANN INTERN MED, V91, P517, DOI 10.7326/0003-4819-91-4-517; SOLL AH, 1991, ANN INTERN MED, V114, P307, DOI 10.7326/0003-4819-114-4-307; SOMERVILLE K, 1986, LANCET, V1, P462; STURGES HF, 1973, AM J GASTROENTEROL, V59, P162; UPADHYAY R, 1990, ANN RHEUM DIS, V49, P359, DOI 10.1136/ard.49.6.359; WAYTE DM, 1968, AM J CLIN PATHOL, V49, P26	31	846	884	0	20	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 10	1992	327	11					749	754		10.1056/NEJM199209103271101	http://dx.doi.org/10.1056/NEJM199209103271101			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JL661	1501650				2022-12-01	WOS:A1992JL66100001
J	BERGSTEIN, JM; RILEY, M; BANG, NU				BERGSTEIN, JM; RILEY, M; BANG, NU			ROLE OF PLASMINOGEN-ACTIVATOR INHIBITOR TYPE-1 IN THE PATHOGENESIS AND OUTCOME OF THE HEMOLYTIC UREMIC SYNDROME	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ENDOTHELIAL-CELLS; PLASMA INHIBITOR; PLATELETS	Background. Deposition of fibrin in glomeruli and renal failure are characteristic features of the hemolytic uremic syndrome. An inhibitor of glomerular fibrinolysis has been detected in plasma from children with this disorder. In this study, we define the inhibitor and show that its plasma level is correlated with the outcome of the disease. Methods and Results. Plasminogen-activator inhibitor type 1 (PAI-1) in plasma was measured with an assay employing a specific monoclonal antibody in 40 consecutive children hospitalized with the hemolytic uremic syndrome: 12 who recovered adequate renal function (serum creatinine, less-than-or-equal-to 2.0 mg per deciliter [177-mu-mol per liter]) without dialysis, 23 who recovered adequate renal function after peritoneal dialysis, and 5 who did not recover adequate renal function after undergoing dialysis. At presentation, plasma PAI-1 levels were higher in the patients with the hemolytic uremic syndrome than in nine children with other forms of acute renal failure. That the inhibitor was PAI-1 was indicated by the fact that it was a potent inhibitor of tissue plasminogen activator, was acid-resistant, and was not inhibited by denaturation (all unique traits of PAI-1) and that it was neutralized by an antibody specific for PAI-1. Multivariate discriminant-function analysis revealed that the duration of elevated PAI-1 activity was strongly correlated with the outcome of the disease (P<0.001). Peritoneal dialysis reduced plasma PAI-1 levels dramatically. Conclusions. Our studies suggest that PAI-1 is the circulating inhibitor of fibrinolysis in the hemolytic uremic syndrome. Normalization of plasma PAI-1 levels (e.g., by peritoneal dialysis) is correlated with improvement in renal function. However, the possibility that increased plasma levels of PAI-1 are either causes or effects of the hemolytic uremic syndrome is not unequivocally established by these studies.	INDIANA UNIV, SCH MED, LILLY RES LABS, INDIANAPOLIS, IN 46202 USA; INDIANA UNIV, SCH MED, DEPT PEDIAT, INDIANAPOLIS, IN 46202 USA; INDIANA UNIV, SCH MED, DEPT MED, INDIANAPOLIS, IN 46202 USA	Eli Lilly; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis								[Anonymous], 1987, PEDIATRICS, V79, P1; BANCROFT H, 1962, INTRO BIOSTATISTICS; BERGSTEIN JM, 1988, KIDNEY INT, V33, P868, DOI 10.1038/ki.1988.78; BERGSTEIN JM, 1982, AM J MED, V73, P322, DOI 10.1016/0002-9343(82)90717-3; BOOTH NA, 1988, BRIT J HAEMATOL, V70, P327, DOI 10.1111/j.1365-2141.1988.tb02490.x; DECLERCK PJ, 1988, BLOOD, V71, P220; ERICKSON LA, 1984, J CLIN INVEST, V74, P1465, DOI 10.1172/JCI111559; ERICKSON LA, 1986, BLOOD, V68, P1298; HEKMAN CM, 1987, SEMIN THROMB HEMOST, V13, P514, DOI 10.1055/s-2007-1003527; KREDIET RT, 1986, NEPHRON, V42, P133, DOI 10.1159/000183652; KRUITHOF EKO, 1986, THROMB HAEMOSTASIS, V55, P65; LOSKUTOFF DJ, 1977, P NATL ACAD SCI USA, V74, P3903, DOI 10.1073/pnas.74.9.3903; Rosner B., 1986, FUNDAMENTALS BIOSTAT, V2nd, P442; SPRENGERS ED, 1987, BLOOD, V69, P381; 1990, AM J KIDNEY DIS S2, V16, P65	15	84	85	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 10	1992	327	11					755	759		10.1056/NEJM199209103271102	http://dx.doi.org/10.1056/NEJM199209103271102			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JL661	1501651				2022-12-01	WOS:A1992JL66100002
J	DELATTRE, O; ZUCMAN, J; PLOUGASTEL, B; DESMAZE, C; MELOT, T; PETER, M; KOVAR, H; JOUBERT, I; DEJONG, P; ROULEAU, G; AURIAS, A; THOMAS, G				DELATTRE, O; ZUCMAN, J; PLOUGASTEL, B; DESMAZE, C; MELOT, T; PETER, M; KOVAR, H; JOUBERT, I; DEJONG, P; ROULEAU, G; AURIAS, A; THOMAS, G			GENE FUSION WITH AN ETS DNA-BINDING DOMAIN CAUSED BY CHROMOSOME-TRANSLOCATION IN HUMAN TUMORS	NATURE			English	Article							EWINGS-SARCOMA; RECIPROCAL TRANSLOCATION; MYXOID CHONDROSARCOMA; PROTEINS; ERYTHROLEUKEMIA; REARRANGEMENTS; CONSISTENCY; T(11-22); VIRUS	EWING'S sarcoma and related subtypes of primitive neuroectodermal tumours share a recurrent and specific t(11; 22) (q24; q12) chromosome translocation1-8, the breakpoints of which have recently been cloned9. Phylogenetically conserved restriction fragments in the vicinity of EWSR1 and EWSR2, the genomic regions where the breakpoints of chromosome 22 and chromosome 11 are, respectively, have allowed identification of transcribed sequences from these regions and has indicated that a hybrid transcript might be generated by the translocation9. Here we use these fragments to screen human complementary DNA libraries to show that the translocation alters the open reading frame of an expressed gene on chromosome 22 gene by substituting a sequence encoding a putative RNA-binding domain for that of the DNA-binding domain of the human homologue of murine Fli-1.	INST CURIE,GENET TUMEURS LAB,26 RUE ULM,F-75231 PARIS 05,FRANCE; ST ANNA CHILDRENS HOSP,CHILDRENS CANC RES INST,A-1090 VIENNA,AUSTRIA; MCGILL UNIV,CTR RECH NEUROSCI,MONTREAL H3G 1A4,QUEBEC,CANADA; LAWRENCE LIVERMORE NATL LAB,CTR HUMAN GENOME,LIVERMORE,CA 94550; INST CURIE,CNRS,URA 620,F-75231 PARIS 05,FRANCE	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Saint Anna Children's Hospital; McGill University; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie			j, zucman-rossi/AAV-3594-2021; Plougastel-Douglas, Beatrice/Q-3186-2019; zucman-rossi, Jessica/B-5098-2009	j, zucman-rossi/0000-0002-5687-0334; Plougastel-Douglas, Beatrice/0000-0002-6389-561X; zucman-rossi, Jessica/0000-0002-5687-0334; delattre, olivier/0000-0002-8730-2276; Desmaze, Chantal/0000-0003-0777-8854; Kovar, Heinrich/0000-0001-6873-9109				AURIAS A, 1983, NEW ENGL J MED, V309, P496; BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431; BAUD V, 1991, GENOMICS, V11, P223, DOI 10.1016/0888-7543(91)90124-W; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BIAMONTI G, 1989, J MOL BIOL, V207, P491, DOI 10.1016/0022-2836(89)90459-2; BURD CG, 1989, P NATL ACAD SCI USA, V86, P9788, DOI 10.1073/pnas.86.24.9788; CAVAZZANA AO, 1988, ADV NEUROBLASTOMA RE, V2, P463; CORDEN JL, 1990, TRENDS BIOCHEM SCI, V15, P383, DOI 10.1016/0968-0004(90)90236-5; DECHADAREVIAN JP, 1984, NEW ENGL J MED, V311, P1702; DOUGLASS EC, 1986, J NATL CANCER I, V77, P1211; FRANKEL AD, 1991, CELL, V67, P1041, DOI 10.1016/0092-8674(91)90282-4; GRANGE T, 1987, NUCLEIC ACIDS RES, V15, P4771, DOI 10.1093/nar/15.12.4771; HAYNES SR, 1987, P NATL ACAD SCI USA, V84, P1819, DOI 10.1073/pnas.84.7.1819; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KUMAR A, 1990, J BIOL CHEM, V265, P17094; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MUNROE SH, 1992, P NATL ACAD SCI USA, V89, P895, DOI 10.1073/pnas.89.3.895; ROULEAU GA, 1990, AM J HUM GENET, V46, P323; SHEN WPV, 1990, CANCER GENET CYTOGEN, V45, P207, DOI 10.1016/0165-4608(90)90084-N; SPRITZ RA, 1987, NUCLEIC ACIDS RES, V15, P10173; SRIVASTAVA M, 1990, J BIOL CHEM, V265, P14922; SUZUKI M, 1990, NATURE, V344, P562, DOI 10.1038/344562a0; TRENT JM, 1989, CYTOGENET CELL GENET, V51, P533, DOI 10.1159/000132807; TURCCAREL C, 1983, NEW ENGL J MED, V309, P497; TURCCAREL C, 1984, CANCER GENET CYTOGEN, V12, P1, DOI 10.1016/0165-4608(84)90002-5; TURCCAREL C, 1988, CANCER GENET CYTOGEN, V30, P145, DOI 10.1016/0165-4608(88)90103-3; TURCCAREL C, 1988, CANCER GENET CYTOGEN, V32, P229, DOI 10.1016/0165-4608(88)90285-3; VIGFUSSON NV, 1986, CANCER GENET CYTOGEN, V22, P211, DOI 10.1016/0165-4608(86)90157-3; WATSON D K, 1990, Critical Reviews in Oncogenesis, V1, P409; WHANGPENG J, 1984, NEW ENGL J MED, V311, P584, DOI 10.1056/NEJM198408303110907; WHANGPENG J, 1987, CANCER GENET CYTOGEN, V29, P155, DOI 10.1016/0165-4608(87)90043-4; ZUCMAN J, IN PRESS GENES CHROM	34	1474	1505	6	54	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 10	1992	359	6391					162	165		10.1038/359162a0	http://dx.doi.org/10.1038/359162a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JM494	1522903				2022-12-01	WOS:A1992JM49400058
J	EDWARDS, FA; GIBB, AJ; COLQUHOUN, D				EDWARDS, FA; GIBB, AJ; COLQUHOUN, D			ATP RECEPTOR-MEDIATED SYNAPTIC CURRENTS IN THE CENTRAL-NERVOUS-SYSTEM	NATURE			English	Article							ADENOSINE-TRIPHOSPHATE; HIPPOCAMPAL SLICES; DORSAL HORN; NEURONS; CHANNELS; RELEASE; CELLS	UNTIL now, the only well documented, fast excitatory neurotransmitter in the brain has been glutamate. Although there is evidence for adenosine 5'-triphosphate (ATP) acting as a transmitter in the peripheral nervous system1-4, suggestions for such a role in the central nervous system1,5-11 have so far not been supported by any direct evidence. Here we report the recording of evoked and miniature synaptic currents in the rat medial habenula. The fast rise time of the currents showed that they were mediated by a ligand-activated ion channel rather than a second messenger system, thus limiting the known transmitter candidates. Evidence was found for the presence on the cells of glutamate, gamma-aminobutyric acid, acetylcholine and ATP receptors, but not for 5-hydroxytryptamine (5HT3) or glycine receptors. The evoked currents were unaffected by blockers of glutamate, gamma-aminobutyric acid or acetylcholine receptors but were blocked by the ATP receptor-blocker, suramin and the desensitizing ATP receptor-agonist alpha,beta-methylene-ATP. Our evidence identifies for the first time synaptic currents in the brain, mediated directly by ATP receptors.	UNIV LONDON UNIV COLL,DEPT PHARMACOL,LONDON WC1E 6BT,ENGLAND	University of London; University College London			Gibb, Alasdair/AAL-1605-2020; Colquhoun, David/C-1664-2008; Edwards, Frances/AAE-1755-2019	Colquhoun, David/0000-0002-4263-017X; Gibb, Alasdair/0000-0002-2145-1615	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BEAN BP, 1992, TRENDS PHARMACOL SCI, V13, P87, DOI 10.1016/0165-6147(92)90032-2; BURNSTOCK G, 1985, GEN PHARMACOL, V16, P433, DOI 10.1016/0306-3623(85)90001-1; EDWARDS FA, 1989, PFLUG ARCH EUR J PHY, V414, P600, DOI 10.1007/BF00580998; EVANS RJ, 1992, NATURE, V357, P503, DOI 10.1038/357503a0; FIEBER LA, 1991, J PHYSIOL-LONDON, V434, P239, DOI 10.1113/jphysiol.1991.sp018467; FYFFE REW, 1984, P NATL ACAD SCI-BIOL, V81, P6890, DOI 10.1073/pnas.81.21.6890; HOYLE CHV, 1991, ADENOSINE NERVOUS SY, pCH3; INOUE K, 1992, NEUROSCI LETT, V134, P215, DOI 10.1016/0304-3940(92)90520-H; JAHR CE, 1983, NATURE, V304, P730, DOI 10.1038/304730a0; KRISHTAL OA, 1988, NEUROSCIENCE, V27, P995, DOI 10.1016/0306-4522(88)90203-5; NAKAZAWA K, 1991, J PHYSIOL-LONDON, V434, P647, DOI 10.1113/jphysiol.1991.sp018491; NEUHAUS R, 1991, J NEUROSCI, V11, P3984; PHILLIS JW, 1974, CAN J PHYSIOL PHARM, V52, P1226, DOI 10.1139/y74-162; POTTER P, 1980, NEUROSCIENCE, V5, P1351, DOI 10.1016/0306-4522(80)90207-9; RICHARDSON PJ, 1986, BIOCHEM SOC T, V14, P1250, DOI 10.1042/bst0141250; SALTER MW, 1985, NEUROSCIENCE, V15, P815, DOI 10.1016/0306-4522(85)90080-6; SCHUBERT P, 1979, BRAIN RES, V168, P419, DOI 10.1016/0006-8993(79)90186-0; SILINSKY EM, 1992, BRIT J PHARMACOL, V106, P762, DOI 10.1111/j.1476-5381.1992.tb14408.x; TOKUNAGA A, 1978, BRAIN RES, V150, P600, DOI 10.1016/0006-8993(78)90823-5; TSCHOPL M, 1992, EUR J PHARMACOL, V213, P71, DOI 10.1016/0014-2999(92)90234-U; WHITE TD, 1978, J NEUROCHEM, V30, P329, DOI 10.1111/j.1471-4159.1978.tb06534.x; WIERASZKO A, 1989, BRAIN RES, V491, P356, DOI 10.1016/0006-8993(89)90070-X; WIERASZKO A, 1989, BRAIN RES, V485, P244, DOI 10.1016/0006-8993(89)90567-2; WILLIAMS M, 1987, PSYCHOPHARMACOLOGY 3, pCH30	24	729	738	1	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 10	1992	359	6391					144	147		10.1038/359144a0	http://dx.doi.org/10.1038/359144a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JM494	1381811				2022-12-01	WOS:A1992JM49400051
J	FUKAMI, K; FURUHASHI, K; INAGAKI, M; ENDO, T; HATANO, S; TAKENAWA, T				FUKAMI, K; FURUHASHI, K; INAGAKI, M; ENDO, T; HATANO, S; TAKENAWA, T			REQUIREMENT OF PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE FOR ALPHA-ACTININ FUNCTION	NATURE			English	Article							CAPPING PROTEIN; SMOOTH-MUSCLE; POLYPHOSPHOINOSITIDE; COMPLEXES; GELSOLIN	INOSITOL phospholipid turnover is enhanced during mitogenic stimulation of cells by growth factors1 and the breakdown of phosphatidylinositol 4,5-bisphosphate (PtdInsP2) may be important in triggering cell proliferation. PtdInsP2 also binds actin-binding proteins to regulate their activity2-7, but it is not yet understood how this control is achieved. The protein alpha-actinin from striated muscle contains large amounts of endogenous PtdInsP2, whereas that from smooth muscle has only a little but will bind exogenously added PtdInsP2. In vitro alpha-actinin binds to F-actin and will crosslink actin filaments, increasing the viscosity of F-actin solutions8,9. We report here that alpha-actinin from striated muscle is an endogenous PtdInsP2-bound protein and that the specific interaction between alpha-actinin and PtdInsP2 regulates the F-actin-gelating activity of alpha-actinin. Although the F-actin-gelating activity of alpha-actinin from smooth muscle is much reduced compared with that from striated muscle, exogenous PtdInsP2 can enhance the activity of smooth muscle alpha-actinin to the level seen in striated muscles. These results show that PtdInsP2 is present in striated muscle alpha-actinin and that it is necessary for alpha-actinin to realize its maximum gelating activity.	TOKYO METROPOLITAN GERIATR HOSP & INST GERONTOL,DEPT BIOSIGNAL RES,SAKAE CHO,ITABASHI KU,TOKYO 173,JAPAN; CHIBA UNIV,DEPT BIOL,YAYOI,CHIBA 260,JAPAN; AICHI CANC CTR,RES INST,EXPTL RADIOL LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN; NAGOYA UNIV,SCH SCI,DEPT MOLEC BIOL,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN	Chiba University; Aichi Cancer Center; Nagoya University			Inagaki, Masaki/B-9920-2016					ANDERSON RA, 1985, NATURE, V318, P295, DOI 10.1038/318295a0; BENNETT JP, 1984, BIOCHEMISTRY-US, V23, P5081, DOI 10.1021/bi00316a039; BURN P, 1985, NATURE, V314, P469, DOI 10.1038/314469a0; EBASHI S, 1964, NATURE, V203, P645, DOI 10.1038/203645a0; ENDO T, 1982, BIOCHEM BIOPH RES CO, V107, P1467, DOI 10.1016/S0006-291X(82)80164-2; ENDO T, 1982, J BIOCHEM, V92, P1457, DOI 10.1093/oxfordjournals.jbchem.a134070; FERAMISCO JR, 1980, J BIOL CHEM, V255, P1194; FURUHASHI K, 1992, BIOCHEM BIOPH RES CO, V184, P121; HEISS SG, 1991, BIOCHEMISTRY-US, V30, P8753, DOI 10.1021/bi00100a006; JANMEY PA, 1987, J BIOL CHEM, V262, P12228; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; KHYSEANDERSON J, 1984, J BIOCHEM BIOPH METH, V10, P203; KOBAYASHI R, 1984, EUR J BIOCHEM, V143, P125, DOI 10.1111/j.1432-1033.1984.tb08351.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDON F, 1985, EUR J BIOCHEM, V153, P231, DOI 10.1111/j.1432-1033.1985.tb09291.x; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; MARUYAMA K, 1965, J BIOCH, V58, P7; MASAKI T, 1967, J BIOCHEM-TOKYO, V62, P630, DOI 10.1093/oxfordjournals.jbchem.a128717; MATUOKA K, 1988, SCIENCE, V239, P640, DOI 10.1126/science.2829356; MEYER RK, 1982, P NATL ACAD SCI-BIOL, V79, P4280, DOI 10.1073/pnas.79.14.4280; POLLARD TD, 1982, METHOD ENZYMOL, V85, P211; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; YU FX, 1990, SCIENCE, V250, P1413, DOI 10.1126/science.2255912	23	310	316	0	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 10	1992	359	6391					150	152		10.1038/359150a0	http://dx.doi.org/10.1038/359150a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JM494	1326084				2022-12-01	WOS:A1992JM49400053
J	GURSOY, S; STEURER, G; BRUGADA, J; ANDRIES, E; BRUGADA, P				GURSOY, S; STEURER, G; BRUGADA, J; ANDRIES, E; BRUGADA, P			THE HEMODYNAMIC MECHANISM OF POUNDING IN THE NECK IN ATRIOVENTRICULAR NODAL REENTRANT TACHYCARDIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							SUPRAVENTRICULAR TACHYCARDIA		ONZE LIEVE VROUW HOSP, CTR CARDIOVASC, MOORSELBAAN 164, B-9300 AALST, BELGIUM; UNIV BARCELONA, HOSP CLIN, ARRHYTHMIA UNIT, BARCELONA 7, SPAIN	University of Barcelona; Hospital Clinic de Barcelona				BRUGADA, JOSEP/0000-0002-5662-8302				AKHTAR M, 1978, AM HEART J, V95, P22, DOI 10.1016/0002-8703(78)90394-0; FERRER MI, 1949, AM J MED, V6, P725, DOI 10.1016/0002-9343(49)90308-3; GOLDREYER BN, 1976, CIRCULATION, V54, P783, DOI 10.1161/01.CIR.54.5.783; NAITO M, 1983, AM HEART J, V105, P295, DOI 10.1016/0002-8703(83)90530-6; SGANZERLA P, 1989, EUR HEART J, V10, P32, DOI 10.1093/oxfordjournals.eurheartj.a059378; SWINSCOW TDV, 1980, STATISTICS SQUARE ON	6	51	53	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 10	1992	327	11					772	774		10.1056/NEJM199209103271105	http://dx.doi.org/10.1056/NEJM199209103271105			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JL661	1501653				2022-12-01	WOS:A1992JL66100005
J	INGLESE, J; KOCH, WJ; CARON, MG; LEFKOWITZ, RJ				INGLESE, J; KOCH, WJ; CARON, MG; LEFKOWITZ, RJ			ISOPRENYLATION IN REGULATION OF SIGNAL TRANSDUCTION BY G-PROTEIN-COUPLED RECEPTOR KINASES	NATURE			English	Article							GAMMA SUBUNITS CONTAIN; RAS PROTEINS; TRANSLOCATION; FARNESYL; FAMILY; CELLS; ACID; P21	RHODOPSIN kinase1 and beta-adrenergic receptor kinase (beta-ARK)2 are related members of a serine/threonine kinase family that specifically initiate deactivation of G-protein-coupled receptors. After stimulus-mediated receptor activation, these cytoplasmic kinases translocate to the plasma membrane3,4. Here we show that the molecular basis for this event involves a class of unsaturated lipids called isoprenoids. Covalent modification in vivo of rhodopsin kinase by a 15-C (farnesyl) isoprenoid5 enables the kinase to anchor to photon-activated rhodopsin. Mutations that alter or eliminate the isoprenoid, fully disable light-specific Rhodopsin kinase translocation. Other receptor kinases (such as beta-ARK), which lack an intrinsic lipid, are activated6 on exposure to brain beta-gamma-subunits of the signal-transducing G proteins, the gamma-subunit of which bears a 20-C (geranylgeranyl) isoprenoid7,8. Using chimaeric beta-ARKs that undergo isoprenylation in vitro, we demonstrate that membrane association and activation of these kinases can occur in the absence of beta-gamma. These results indicate that rhodopsin kinase (by means of an integral isoprenoid) and beta-ARK (through its association with beta-gamma) both rely on the function of isoprenyl moieties for their translocation and activity, illustrating distinct, though related, modes of biological regulation of receptor function.	DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DEPT BIOCHEM,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710	Duke University; Howard Hughes Medical Institute; Duke University; Duke University			Lefkowitz, Robert/AAW-2649-2021					ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ARRIZA JL, IN PRESS J NEUROSCI; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; BENOVIC JL, 1986, NATURE, V322, P869; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CASEY PJ, 1991, P NATL ACAD SCI USA, V88, P8631, DOI 10.1073/pnas.88.19.8631; COX AD, IN PRESS CRIT REV ON; FARNSWORTH C C, 1990, Methods (Orlando), V1, P231, DOI 10.1016/S1046-2023(05)80322-6; GLOMSET JA, 1990, TRENDS BIOCHEM SCI, V15, P139, DOI 10.1016/0968-0004(90)90213-U; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; HAGA K, 1992, J BIOL CHEM, V267, P2222; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; INGLESE J, 1992, J BIOL CHEM, V267, P1422; JACKSON JH, 1990, P NATL ACAD SCI USA, V87, P3042, DOI 10.1073/pnas.87.8.3042; KINSELLA BT, 1991, P NATL ACAD SCI USA, V88, P8934, DOI 10.1073/pnas.88.20.8934; KUHN H, 1978, BIOCHEMISTRY-US, V17, P4389; LORENZ W, 1991, P NATL ACAD SCI USA, V88, P8715, DOI 10.1073/pnas.88.19.8715; MAYOR F, 1987, J BIOL CHEM, V262, P6468; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; PITCHER J, IN PRESS SCIENCE; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SIMONDS WF, 1991, J BIOL CHEM, V266, P5363; STRASSER RH, 1986, P NATL ACAD SCI USA, V83, P6362, DOI 10.1073/pnas.83.17.6362; WILLUMSEN BM, 1984, EMBO J, V3, P2581, DOI 10.1002/j.1460-2075.1984.tb02177.x; YAMANE HK, 1990, P NATL ACAD SCI USA, V87, P5868, DOI 10.1073/pnas.87.15.5868	26	267	272	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 10	1992	359	6391					147	150		10.1038/359147a0	http://dx.doi.org/10.1038/359147a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JM494	1522899				2022-12-01	WOS:A1992JM49400052
J	MALONE, RE; BULLARD, S; LUNDQUIST, S; KIM, S; TARKOWSKI, T				MALONE, RE; BULLARD, S; LUNDQUIST, S; KIM, S; TARKOWSKI, T			A MEIOTIC GENE CONVERSION GRADIENT OPPOSITE TO THE DIRECTION OF TRANSCRIPTION	NATURE			English	Article							INITIATION SITE; SACCHAROMYCES-CEREVISIAE; ARG4 LOCUS; DECREASING GRADIENTS; YEAST; RECOMBINATION; REPLACEMENT; SEQUENCES; SIDES	GENETIC recombination involves classical crossing-over and gene conversion (aberrant segregation). In fungi that produce an ascus containing four spores, a gene conversion event is manifested as 3:1 or 1:3 (or more rarely 4:0 or 0:4) segregations, in contrast to the normal mendelian 2:2 segregation1,2. Polarity is one of the properties of gene conversion; in almost all cases the frequency of conversion exhibits a gradient across the gene monitored1. The frequency of conversion is usually independent of the specific allele used as a marker, but dependent on its location. An interpretation of conversion polarity is that it is caused by the existence of specific initiation sites for meiotic recombination, located at the high end of the polarity gradient. Here we show that the polarity gradient for the HIS2 gene of Saccharomyces cerevisiae is high at the 3' end of the gene, implying that the promoter of HIS2 is not the initiation site.			MALONE, RE (corresponding author), UNIV IOWA, DEPT BIOL, IOWA CITY, IA 52242 USA.							DICAPRIO L, 1976, GENETICS, V84, P697; FOGEL S, 1979, COLD SPRING HARB SYM, V43, P1325, DOI 10.1101/SQB.1979.043.01.152; NICOLAS A, 1989, NATURE, V338, P35, DOI 10.1038/338035a0; Petes T. D., 1991, MOL CELLULAR BIOL YE, P407; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; SCHERER S, 1979, P NATL ACAD SCI USA, V76, P4951, DOI 10.1073/pnas.76.10.4951; SCHULTES NP, 1990, GENETICS, V126, P813; SCHULTES NP, 1991, MOL CELL BIOL, V11, P322, DOI 10.1128/MCB.11.1.322; STRUHL K, 1985, P NATL ACAD SCI USA, V82, P8419, DOI 10.1073/pnas.82.24.8419; WHITE MA, 1992, CURR GENET, V21, P109, DOI 10.1007/BF00318468; WHITE MA, 1991, P NATL ACAD SCI USA, V88, P9755, DOI 10.1073/pnas.88.21.9755	11	38	38	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 10	1992	359	6391					154	155		10.1038/359154a0	http://dx.doi.org/10.1038/359154a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JM494	1355857				2022-12-01	WOS:A1992JM49400055
J	ROTHE, M; PEHL, M; TAUBERT, H; JACKLE, H				ROTHE, M; PEHL, M; TAUBERT, H; JACKLE, H			LOSS OF GENE-FUNCTION THROUGH RAPID MITOTIC-CYCLES IN THE DROSOPHILA EMBRYO	NATURE			English	Article							PATTERN; KNIRPS; SEGMENTATION; SUPERFAMILY	THE early developmental period in Drosophila is characterized by rapid mitotic divisions, when the body pattern becomes organized by a cascade of segmentation gene activity1,2. During this process localized expression of the gap gene knirps (kni) is required to establish abdomen segmentation3,4. The knirps-related gene (knrl) encodes a kni-homologous nuclear hormone receptor-like protein5,6 and shares the spatial patterns of kni expression. The two genes differ with respect to the size of their transcription units; kni contains 1 kilobase and knrl 19 kilobases of intron sequences. The consequence of this difference in intron size is that knrl cannot substitute for kni segmentation function, although it gains this ability when expressed from an intronless transgene. Here we show that the length of mitotic cycles provides a physiological barrier to transcript size, and is therefore a significant factor in controlling developmental gene activity during short 'phenocritical' periods. The required coordination of cycle length and gene size provides severe constraints towards the evolution of rapid development.	MAX PLANCK INST BIOPHYS CHEM,MOLEK ENTWICKLUNGSBIOL ABT,W-3400 GOTTINGEN,GERMANY	Max Planck Society								AKAM M, 1987, DEVELOPMENT, V101, P1; Campos-Ortega JA., 1997, EMBRYONIC DEV DROSOP; EDGAR B, 1990, CELL, V52, P469; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FOE VE, 1983, J CELL SCI, V61, P31; FOE VE, 1989, DEVELOPMENT, V107, P1; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; HOCH M, 1992, SCIENCE, V256, P94, DOI 10.1126/science.1348871; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; LEHMANN R, 1988, DEVELOPMENT, V104, P17; LEHMANN R, 1985, THESIS U TUBINGEN; MACDONALD PM, 1986, NATURE, V324, P537, DOI 10.1038/324537a0; NAUBER U, 1988, NATURE, V336, P489, DOI 10.1038/336489a0; ORO AE, 1988, NATURE, V336, P493, DOI 10.1038/336493a0; ORO AE, 1989, DEVELOPMENT, V107, P133; PANKRATZ MJ, 1990, CELL, V61, P309, DOI 10.1016/0092-8674(90)90811-R; ROTHE M, 1989, EMBO J, V8, P3087, DOI 10.1002/j.1460-2075.1989.tb08460.x; SHERMOEN AW, 1991, CELL, V67, P303, DOI 10.1016/0092-8674(91)90182-X; STRECKER TR, 1986, DEV BIOL, V113, P64, DOI 10.1016/0012-1606(86)90108-9; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041	20	120	121	1	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 10	1992	359	6391					156	159		10.1038/359156a0	http://dx.doi.org/10.1038/359156a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JM494	1522901				2022-12-01	WOS:A1992JM49400056
J	SANDEMAN, DD; SHORE, AC; TOOKE, JE				SANDEMAN, DD; SHORE, AC; TOOKE, JE			RELATION OF SKIN CAPILLARY-PRESSURE IN PATIENTS WITH INSULIN-DEPENDENT DIABETES-MELLITUS TO COMPLICATIONS AND METABOLIC CONTROL	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IMPAIRED AUTO-REGULATION; BLOOD-FLOW; MICROANGIOPATHY; PERMEABILITY; NEPHROPATHY; PREVALENCE; DURATION; RATS	Background. Microvascular disease is a major problem in patients with diabetes mellitus. It has been suggested that diabetic microangiopathy may result from an increase in capillary blood flow and capillary hypertension, but direct evidence of capillary hypertension in such patients is lacking. Methods. We measured capillary pressure at the summit of the capillary loop by direct microcannulation of skin nail-fold capillaries and a dynamic method of pressure measurement in 29 patients with insulin-dependent (Type 1) diabetes and 29 normal subjects matched for age and sex. Among the diabetic patients, 7 had had diabetes for less than one year, 12 had incipient nephropathy (albumin excretion, 20 to 200-mu-g per minute), and 10 had overt nephropathy (albumin excretion, >200-mu-g per minute). In addition, seven patients with no evidence of nephropathy were studied before and after three months of improved glycemic control. Results. The median capillary pressure in the diabetic patients was 20.4 mm Hg (range, 13.6 to 25.3), as compared with 16.7 mm Hg (range, 12.8 to 22.8; P<0.001) in the normal subjects. The values were higher in each subgroup of diabetic patients than in the corresponding group of normal subjects, but the values did not differ among the three subgroups of diabetic patients. In the seven patients who were studied before and after three months of improved glycemic control, the median capillary pressure fell from 20.0 mm Hg (range, 18.5 to 21.7) to 17.8 mm Hg (range, 14.1 to 20.3; P = 0.02). Conclusions. Nail-fold capillary hypertension may develop early in the course of diabetes, before the emergence of microvascular disease, and may be influenced by changes in metabolic control.			SANDEMAN, DD (corresponding author), UNIV EXETER,POSTGRAD MED SCH,BARRACK RD,EXETER EX2 5EQ,ENGLAND.			Shore, Angela/0000-0003-3039-308X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALTURA BM, 1979, ADV MICROCIRCULAT, V8, P118; CHASE HP, 1989, JAMA-J AM MED ASSOC, V261, P1155, DOI 10.1001/jama.261.8.1155; Christiansen J S, 1985, Diabet Med, V2, P235; DARTON K, 1991, RAYNAUDS SYNDROME, P69; DITZEL J, 1968, DIABETES, V17, P388, DOI 10.2337/diab.17.6.388; FLAVELL HJ, 1988, CLIN CHEM, V34, P1506; FOLKOW B, 1983, CIBA F SYMP, V100, P56; GATLING W, 1988, DIABETIC MED, V5, P343, DOI 10.1111/j.1464-5491.1988.tb01002.x; GUNDERSEN HJ, 1974, DIABETOLOGIA, V10, P225, DOI 10.1007/BF00423039; HANSSEN KF, 1986, DIABETOLOGIA, V29, P901; HILL MA, 1990, FRONT DIABETES, V9, P118; KALEY G, 1989, AM J PHYSIOL, V256, pH720, DOI 10.1152/ajpheart.1989.256.3.H720; KASTRUP J, 1985, DIABETOLOGIA, V28, P711; KOHNER EM, 1975, DIABETOLOGIA, V11, P27, DOI 10.1007/BF00422814; LANSMAN JB, 1988, NATURE, V331, P481, DOI 10.1038/331481a0; MAUER SM, 1984, J CLIN INVEST, V74, P1143, DOI 10.1172/JCI111523; MCMILLAN DE, 1983, DIABETES, V32, P56, DOI 10.2337/diab.32.2.S56; MOGENSEN CE, 1988, TOPICS RENAL MED, V6, P7; MOGENSEN CE, 1989, DIABETES NUTR METAB, V2, P227; ORCHARD TJ, 1990, DIABETES, V39, P1116, DOI 10.2337/diabetes.39.9.1116; OSTERGREN J, 1982, INT J MICROCIRC, V1, P300; PARVING HH, 1984, DIABETOLOGIA, V27, P547, DOI 10.1007/BF00276965; PARVING HH, 1983, METABOLISM, V32, P943, DOI 10.1016/0026-0495(83)90210-X; RAYMAN G, 1984, INT J MICROCIRC, V3, P285; RIPPE B, 1977, ACTA PHYSIOL SCAND, V101, P72, DOI 10.1111/j.1748-1716.1977.tb05985.x; SANDEMAN DD, 1991, CLIN SCI S24, V80, pP13; SHORE AC, 1990, INT J MICROCIRC CLIN, V9, P136; SINCLAIR SH, 1982, OPHTHALMOLOGY, V89, P748, DOI 10.1016/s0161-6420(82)34720-x; TOOKE JE, 1980, DIABETES, V29, P815, DOI 10.2337/diabetes.29.10.815; TOOKE JE, 1986, CLIN SCI, V70, P119, DOI 10.1042/cs0700119; TOOKE JE, 1986, PROG APPL MICROCIRC, V11, P60; WILLIAMS SA, 1988, CLIN SCI, V74, P507, DOI 10.1042/cs0740507; WILLIAMSON JR, 1977, DIABETES, V26, P65, DOI 10.2337/diab.26.1.65; WILLIAMSON JR, 1985, DIABETES, V34, P703, DOI 10.2337/diabetes.34.7.703; WILLIAMSON JR, 1980, NEW ENGL J MED, V302, P399, DOI 10.1056/NEJM198002143020710; WILLIAMSON JR, 1990, J CLIN INVEST, V85, P1167, DOI 10.1172/JCI114549; YOSHIDA Y, 1989, KIDNEY INT, V35, P654, DOI 10.1038/ki.1989.35; ZATZ R, 1986, J CLIN INVEST, V77, P1925, DOI 10.1172/JCI112521; ZATZ R, 1986, AM J MED, V80, P443, DOI 10.1016/0002-9343(86)90719-9; ZIEGLER D, 1988, KLIN WOCHENSCHR, V66, P1085, DOI 10.1007/BF01711924	40	162	165	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 10	1992	327	11					760	764		10.1056/NEJM199209103271103	http://dx.doi.org/10.1056/NEJM199209103271103			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JL661	1501652				2022-12-01	WOS:A1992JL66100003
J	SETTLEMAN, J; ALBRIGHT, CF; FOSTER, LC; WEINBERG, RA				SETTLEMAN, J; ALBRIGHT, CF; FOSTER, LC; WEINBERG, RA			ASSOCIATION BETWEEN GTPASE ACTIVATORS FOR RHO AND RAS FAMILIES	NATURE			English	Article							ESCHERICHIA-COLI; TYROSINE KINASES; BINDING PROTEINS; PHOSPHORYLATION; IDENTIFICATION; PURIFICATION; RAS-P21; PRODUCT; GENE; SITE	THE ras-related low-molecular-mass GTPases participate in signal transduction involving a variety of cellular functions, including cell-cycle progression, cellular differentiation, cytoskeletal organization, protein transport and secretion1-2. The cycling of these proteins between GTP-bound and GDP-bound states is partially controlled by GTPase activating proteins (GAPs) which stimulate the intrinsic GTP-hydrolysing activity of specific GTPases1-6. The ras GTPase-activating protein (Ras-GAP) forms a complex with a second protein, p190 (M(r) 190,000), in growth-factor stimulated and tyrosine-kinase transformed cells7,8. At its carboxy-terminal end, p190 contains a region that is conserved in the breakpoint cluster region, n-chimaerin, and Rho-GAP9. Each of these three proteins exhibits GAP activity for at least one member of the rho family of small GTPases10. We have tested recombinant p190 protein for GAP activity on GTPases of the ras, rho and rab families, and show here that p190 can function as a GAP specifically for members of the rho family. Consequently, the formation of a complex between Ras-GAP and p190 in growth-factor stimulated cells may allow the coupling of signalling pathways that involve ras and rho GTPases.	MIT,DEPT BIOL,CAMBRIDGE,MA 02142	Massachusetts Institute of Technology (MIT)	SETTLEMAN, J (corresponding author), MIT,WHITEHEAD INST BIOMED RES,9 CAMBRIDGE CTR,CAMBRIDGE,MA 02142, USA.							ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; BAKER D, 1990, P NATL ACAD SCI USA, V87, P355, DOI 10.1073/pnas.87.1.355; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CHARDIN P, 1989, NUCLEIC ACIDS RES, V17, P4380, DOI 10.1093/nar/17.11.4380; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; Downward J, 1992, CURR OPIN GENET DEV, V2, P13, DOI 10.1016/S0959-437X(05)80315-6; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; Evans T, 1991, CURR OPIN CELL BIOL, V3, P185, DOI 10.1016/0955-0674(91)90137-N; FRECH M, 1990, J BIOL CHEM, V265, P6353; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; FRY M J, 1992, Current Biology, V2, P78, DOI 10.1016/0960-9822(92)90207-Q; GARRETT MD, 1989, J BIOL CHEM, V264, P10; GROSS M, 1985, MOL CELL BIOL, V5, P1015, DOI 10.1128/MCB.5.5.1015; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HART MJ, 1990, J BIOL CHEM, V265, P5990; LEROSEY I, 1991, J BIOL CHEM, V266, P4315; LOWY DR, 1991, TRENDS GENET, V7, P346, DOI 10.1016/0168-9525(91)90253-M; MCCOY MS, 1984, MOL CELL BIOL, V4, P1577, DOI 10.1128/MCB.4.8.1577; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; TRAHEY M, 1987, MOL CELL BIOL, V7, P541, DOI 10.1128/MCB.7.1.541; TUCKER J, 1986, EMBO J, V5, P1351, DOI 10.1002/j.1460-2075.1986.tb04366.x; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; ZAHRAOUI A, 1989, J BIOL CHEM, V264, P12394	30	297	302	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 10	1992	359	6391					153	154		10.1038/359153a0	http://dx.doi.org/10.1038/359153a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JM494	1522900				2022-12-01	WOS:A1992JM49400054
J	SHEA, S; MISRA, D; EHRLICH, MH; FIELD, L; FRANCIS, CK				SHEA, S; MISRA, D; EHRLICH, MH; FIELD, L; FRANCIS, CK			PREDISPOSING FACTORS FOR SEVERE, UNCONTROLLED HYPERTENSION IN AN INNER-CITY MINORITY POPULATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PUBLIC HOSPITAL EMERGENCY; ORAL CLONIDINE; HEART-DISEASE; STROKE; CARE; CONSEQUENCES; EXPERIENCE; URGENCIES; COST	Background. Hypertensive emergency and urgent hypertension are the most severe forms of uncontrolled hypertension and are now seen predominantly in poor, minority populations. We studied the characteristics of the medical care received by patients with these conditions in order to identify risk factors for severe, uncontrolled hypertension. Methods. Using a case-control study design, we interviewed 93 patients with severe, uncontrolled hypertension who presented in the hospital emergency room and 114 control patients with hypertension; both groups were seen at two New York City hospitals from 1989 through 1991. All the patients were black or Hispanic. Multiple logistic-regression models were used to adjust for age, sex, race or ethnic background, education, smoking status, alcohol-related problems, and use of illicit drugs during the previous year. Results. After additional adjustment for lack of health insurance, severe, uncontrolled hypertension was found to be more common among patients who had no primary care physician (adjusted odds ratio, 3.5; 95 percent confidence interval, 1.6 to 7.7) and among those who did not comply with treatment for their hypertension (adjusted odds ratio, 1.9; 95 percent confidence interval, 1.4 to 2.5). Lack of health insurance was marginally associated with severe, uncontrolled hypertension (adjusted odds ratio, 1.9; 95 percent confidence interval, 0.8 to 4.6) after adjustment for lack of a primary care physician and noncompliance with antihypertensive treatment. Patients without a primary care physician and without health insurance were more likely to have their blood pressure checked and receive prescriptions for blood-pressure medications in emergency rooms than in physicians' offices or clinics. Conclusions. Characteristics of both the health care system and patients' behavior are associated with severe, uncontrolled hypertension. Improving access to primary care physicians, through health insurance or other means, may be an effective strategy for improving control of hypertension in disadvantaged minority populations.	COLUMBIA UNIV COLL PHYS & SURG, DEPT MED, DIV GEN MED, NEW YORK, NY 10032 USA; COLUMBIA UNIV, SCH PUBL HLTH, DIV EPIDEMIOL, NEW YORK, NY 10027 USA; HARLEM HOSP MED CTR, DEPT MED, NEW YORK, NY 10037 USA	Columbia University; Columbia University					NHLBI NIH HHS [R01-HL38260] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038260] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1991, JAMA, V265, P3255; [Anonymous], 1988, ARCH INTERN MED, V148, P1023; BAKER DW, 1991, JAMA-J AM MED ASSOC, V266, P1085, DOI 10.1001/jama.266.8.1085; BENNETT NM, 1988, AM J PUBLIC HEALTH, V78, P636, DOI 10.2105/AJPH.78.6.636; BERKSON DM, 1980, AM J PUBLIC HEALTH, V70, P389, DOI 10.2105/AJPH.70.4.389; BINDMAN AB, 1991, JAMA-J AM MED ASSOC, V266, P1091, DOI 10.1001/jama.266.8.1091; BRAND FN, 1977, PUBLIC HEALTH REP, V92, P72; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; Cronbach LJ, 1951, PSYCHOMETRIKA, V16, P297; EISEN SA, 1990, ARCH INTERN MED, V150, P1881, DOI 10.1001/archinte.150.9.1881; FERGUSON RK, 1986, JAMA-J AM MED ASSOC, V255, P1607, DOI 10.1001/jama.255.12.1607; FOLSOM AR, 1983, JAMA-J AM MED ASSOC, V250, P916, DOI 10.1001/jama.250.7.916; GOLDMAN L, 1984, ANN INTERN MED, V101, P825, DOI 10.7326/0003-4819-101-6-825; GRANT BF, 1991, ALCOHOL HLTH RES WOR, V0015; HAYNES RB, 1980, NIH812102 PUBL; HOUSTON MC, 1986, ARCH INTERN MED, V146, P586, DOI 10.1001/archinte.146.3.586; JAKER M, 1989, ARCH INTERN MED, V149, P260, DOI 10.1001/archinte.149.2.260; KAPLAN NM, 1990, CLIN HYPERTENSION, P268; KEELER EB, 1985, JAMA-J AM MED ASSOC, V254, P1926; KELSEY JL, 1986, MONOGRAPHS EPIDEMIOL, V10, P109; KITTNER SJ, 1990, JAMA-J AM MED ASSOC, V264, P1267, DOI 10.1001/jama.264.10.1267; MORISKY DE, 1986, MED CARE, V24, P67, DOI 10.1097/00005650-198601000-00007; NORUSIS MJ, 1990, SPSS PCPLUS V40 IBM; OSTFELD AM, 1990, EPIDEMIOL REV, V12, P253, DOI 10.1093/oxfordjournals.epirev.a036059; Roccella E J, 1988, Health Psychol, V7 Suppl, P297, DOI 10.1037/0278-6133.7.Suppl.297; ROSTAND SG, 1982, NEW ENGL J MED, V306, P1276, DOI 10.1056/NEJM198205273062106; SHEA S, 1991, AM J EPIDEMIOL, V134, P567, DOI 10.1093/oxfordjournals.aje.a116130; SHULMAN NB, 1986, AM J PUBLIC HEALTH, V76, P1105, DOI 10.2105/AJPH.76.9.1105; STERN RS, 1991, JAMA-J AM MED ASSOC, V266, P2238, DOI 10.1001/jama.266.16.2238; THOM TJ, 1988, TRENDS CORONARY HEAR, P11; WILLIAMS GH, 1987, HARRISONS PRINCIPLES, V1, P1028; ZELLER KR, 1989, ARCH INTERN MED, V149, P2186, DOI 10.1001/archinte.149.10.2186; 1991, DHHS PHS9150213 DEP, P112; 1990, MMWR MORB MORTAL WKL, V39, P704; 1986, VITAL HLTH STATIS 11, V234; 1991, SAS SYSTEM REGRESSIO; 1987, MMWR MORB MORTAL WKL, V36, P144; 1984, ANN INTERN MED, V101, P393; 1980, DHHS PHS801260 DEP H	39	285	288	1	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 10	1992	327	11					776	781		10.1056/NEJM199209103271107	http://dx.doi.org/10.1056/NEJM199209103271107			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JL661	1501654				2022-12-01	WOS:A1992JL66100007
J	VANTILBEURGH, H; SARDA, L; VERGER, R; CAMBILLAU, C				VANTILBEURGH, H; SARDA, L; VERGER, R; CAMBILLAU, C			STRUCTURE OF THE PANCREATIC LIPASE PROCOLIPASE COMPLEX	NATURE			English	Article							REFINEMENT; COLIPASE	INTERFACIAL adsorption of pancreatic lipase is strongly dependent on the physical chemical properties of the lipid surface. These properties are affected by amphiphiles such as phospholipids and bile salts. In the presence of such amphiphiles, lipase binding to the interface requires a protein cofactor, colipase1-3. We obtained crystals of the pancreatic lipase-procolipase complex and solved the structure at 3.04 angstrom resolution. Here we describe the structure of procolipase, which essentially consists of three 'fingers' and is topologically comparable to snake toxins4,5. The tips of the fingers contain most of the hydrophobic amino acids and presumably form the interfacial binding site. Lipase binding occurs at the opposite side to this site and involves polar interactions. Determination of the three-dimensional structure of pancreatic lipase has revealed the presence of two domains: an amino-terminal domain, at residues 1-336 containing the active site and a carboxy-terminal domain at residues 337-449 (ref. 6). Procolipase binds exclusively to the C-terminal domain of lipase. No conformational change in the lipase molecule is induced by the binding of procolipase.	FAC ST CHARLES,INST CHIM BIOL,F-13331 MARSEILLE 3,FRANCE; CNRS,CTR BIOCHIM & BIOL MOLEC,F-13402 MARSEILLE,FRANCE	Centre National de la Recherche Scientifique (CNRS)	VANTILBEURGH, H (corresponding author), FAC MED NORD,LCCMB,CNRS,F-13326 MARSEILLE 15,FRANCE.							ABOUSALHAM A, 1992, PROTEIN ENG, V5, P105, DOI 10.1093/protein/5.1.105; Borgstrom B., 1984, P151; BOURNE PE, 1985, EUR J BIOCHEM, V153, P521, DOI 10.1111/j.1432-1033.1985.tb09333.x; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; BRZOZOWSKI AM, 1991, NATURE, V351, P491, DOI 10.1038/351491a0; COZZONE PJ, 1984, EUR J BIOCHEM, V114, P119; DEREWENDA U, 1992, BIOCHEMISTRY-US, V31, P1532, DOI 10.1021/bi00120a034; DONNER J, 1976, BIOCHEMISTRY-US, V15, P5413, DOI 10.1021/bi00669a031; ERLANSON C, 1974, BIOCHIM BIOPHYS ACTA, V259, P198; JANIN J, 1990, J BIOL CHEM, V265, P16027; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; MCINTYRE JC, 1987, BIOCHEM J, V245, P821, DOI 10.1042/bj2450821; RATHELOT J, 1981, BIOCHIMIE, V63, P227, DOI 10.1016/S0300-9084(81)80196-4; REES B, 1987, P NATL ACAD SCI USA, V84, P3132, DOI 10.1073/pnas.84.10.3132; ROUSSEL A, 1991, SILICON GRAPHICS DIR; SARDA L, 1991, LIPASES STRUCTURE ME, P145; Verger R., 1984, P83; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0	18	303	318	0	29	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 10	1992	359	6391					159	162		10.1038/359159a0	http://dx.doi.org/10.1038/359159a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JM494	1522902				2022-12-01	WOS:A1992JM49400057
J	BECKSAGUE, C; DOOLEY, SW; HUTTON, MD; OTTEN, J; BREEDEN, A; CRAWFORD, JT; PITCHENIK, AE; WOODLEY, C; CAUTHEN, G; JARVIS, WR				BECKSAGUE, C; DOOLEY, SW; HUTTON, MD; OTTEN, J; BREEDEN, A; CRAWFORD, JT; PITCHENIK, AE; WOODLEY, C; CAUTHEN, G; JARVIS, WR			HOSPITAL OUTBREAK OF MULTIDRUG-RESISTANT MYCOBACTERIUM-TUBERCULOSIS INFECTIONS - FACTORS IN TRANSMISSION TO STAFF AND HIV-INFECTED PATIENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To describe transmission of multidrug-resistant (MDR) Mycobacterium tuberculosis infection among patients and health care workers (HCWs) in a ward and clinic for human immunodeficiency virus (HIV)-infected patients in a hospital, four studies were conducted. Methods.-Case patients and control patients were persons who had been treated in the HIV ward or clinic, whose clinical course was consistent with tuberculosis and who had at least one positive culture for M tuberculosis between January 1, 1988, and January 31, 1990, resistant to at least isoniazid and rifampin (case patients), or whose isolates were susceptible to all drugs tested (control patients). In the first study, case patients and control patients were compared to identify risk factors for MDR tuberculosis. In the second study, inpatient and outpatient days of MDR tuberculosis case patients were compared to determine whether acid-fast bacillus (AFB) smear-positivity or aerosolized pentamidine use was associated with higher numbers of subsequent MDR tuberculosis cases among exposed patients. In the third study, restriction fragment length polymorphism analysis was performed on available MDR and sensitive M tuberculosis isolates. In the fourth study, skin test conversion rates among HCWs in the HIV ward and clinic were compared with those of HCWs in another ward, and the strength of the associations between skin test conversions among HCWs on the HIV ward and the number of person-days that AFB smear-positive case patients and control patients were on this ward was estimated. Results.-Case patients were more likely than control patients to have been exposed on the HIV ward or clinic to an AFB smear-positive case patient (P<.001). Inpatient and outpatient days of MDR tuberculosis case patients were associated with more subsequent cases of MDR tuberculosis if exposing case patients were smear-positive or if they received aerosolized pentamidine (P less-than-or-equal-to .01). Of 13 MDR isolates, all had one of two restriction fragment length polymorphism patterns; 10 sensitive isolates had restriction fragment length polymorphism patterns that were different from each other. The HCW skin test conversion rate was higher on the HIV ward and clinic than on the comparison ward (P<.01). The risk of occupational acquisition of infection increased in direct proportion to the number of person-days that AFB smear-positive case patients were on the HIV ward (r=.75; P=.005), but did not increase in proportion to the number of person-days that AFB smear-positive control patients were there (r=-.36; P=NS). After isolation measures for AFB smear-positive tuberculosis patients were improved, MDR tuberculosis cases decreased to seven of 214 tuberculosis patients. Conclusions.-Nosocomial transmission of MDR M tuberculosis infection to patients and HCWs occurred on the HIV ward and clinic. Infectiousness of MDR tuberculosis case patients was associated with AFB sputum-smear positivity. Case patients with MDR tuberculosis created a greater risk of skin test conversion for HCWs on the HIV ward than drug-susceptible control patients.	CTR DIS CONTROL,NATL CTR PREVENT SERV,DIV TB ELIMINAT,ATLANTA,GA 30333; CTR DIS CONTROL,NATL CTR INFECT DIS,DIV BACTERIAL & MYCOT DIS,ATLANTA,GA 30333; UNIV MIAMI,MIAMI,FL 33152; VET AFFAIRS MED CTR,MIAMI,FL; JACKSON MEM HOSP,MIAMI,FL 33136	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; University of Miami; US Department of Veterans Affairs; Veterans Health Administration (VHA)	BECKSAGUE, C (corresponding author), CTR DIS CONTROL,NATL CTR INFECT DIS,HOSP INFECT PROGRAM,ATLANTA,GA 30333, USA.			Beck-Sague, Consuelo/0000-0001-9082-0165				CAVE MD, 1991, MOL CELL PROBE, V5, P73, DOI 10.1016/0890-8508(91)90040-Q; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; Dean A. G., 1990, EPI INFO VERSION 5 W; DOOLEY SW, 1992, JAMA-J AM MED ASSOC, V267, P2632, DOI 10.1001/jama.267.19.2632; Jereb J A, 1991, MMWR CDC Surveill Summ, V40, P23; Kent PT, 1985, GUIDE LEVEL 3 LAB; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; SIEGEL S, 1981, NONPARAMETRIC STAT, P184; SNIDER DE, 1991, AM REV RESPIR DIS, V144, P732, DOI 10.1164/ajrccm/144.3_Pt_1.732; 1985, MMWR, V29, P429; 1985, SAS USERS GUIDE BASI, P861; 1990, AM REV RESPIR DIS, V142, P725; 1990, MMWR, V39, P718; 1991, MMWR, V40, P585; 1992, MMWR, V41, P61; 1991, MMWR, V40, P129; 1990, MMWR, V39, P1	17	395	401	0	12	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 9	1992	268	10					1280	1286		10.1001/jama.268.10.1280	http://dx.doi.org/10.1001/jama.268.10.1280			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JL608	1507374				2022-12-01	WOS:A1992JL60800028
J	COOPER, JR; CZECHOWICZ, DJ; PETERSEN, RC; MOLINARI, SP				COOPER, JR; CZECHOWICZ, DJ; PETERSEN, RC; MOLINARI, SP			PRESCRIPTION DRUG DIVERSION CONTROL AND MEDICAL-PRACTICE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CATCHMENT-AREA SITES; UNITED-STATES; CHRONIC PAIN; BENZODIAZEPINES; ABUSE; PREVALENCE; DEPRESSION; DISORDER; PROGRAM; QUALITY	Concern about the role of prescription drug diversion in drug abuse has led to demands for more stringent regulation and for better ways to detect prescription drug diversion. Advances in technology now allow point-of-sale computer systems to report prescriptions filled by pharmacies to state agencies rapidly and possibly more economically. However, the advantages of more comprehensive control systems must be balanced against their possible effects on medical practice and patient care. Our limited knowledge about prescription drug diversion and the impact of diversion control systems on medical practice is summarized. Needed research is outlined together with the components of a diversion control program that balances reducing drug diversion with minimizing adverse effects on medical practice and patient care. We stress the need for broadly defined practice parameters and peer review by medical experts thoroughly familiar with the complexities of medical practice.	NIDA,ROCKVILLE,MD	National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA)								ADAMS EH, 1991, NEW YORK STATE J MED, V91, P337; AMBRE JJ, 1991, MAY NAT I DRUG AB TE; BAIRD WP, 1990, BALANCING RESPONSE P, P65; BALTER MB, 1992, J PSYCHOACTIVE DRUGS, V24, P63, DOI 10.1080/02791072.1992.10471620; BARNETT GO, 1978, MED CARE, V16, P962, DOI 10.1097/00005650-197811000-00007; BATTEN HL, 1991, DRUG SERVICES RES SO; BERINA LF, 1985, AM J HOSP PHARM, V42, P857, DOI 10.1093/ajhp/42.4.857; Burton B T, 1991, NIDA Res Monogr, V115, P47; CHIARELLO RJ, 1987, ARCH GEN PSYCHIAT, V44, P286; CLEELAND CS, 1989, ADV PAIN RES THER, P81; COLE JO, 1990, J PSYCHIAT RES, V24, P135, DOI 10.1016/0022-3956(90)90045-R; DAHL J, 1991, MAY NAT I DRUG AB TE; Du Pont R.L., 1988, AM J DRUG ALCOHOL S1, V14, P1; DUBE CE, 1990, CURRICULUM PRIMARY C; EDWARDS CC, 1972, FED REG         0815, V37, P16503; FARNSWORTH P, 1990, BALANCING RESPONSE P, P103; FDA Drug Bulletin, 1982, FDA DRUG B, V12, P4; FRANCE RD, 1984, SOC SCI MED, V19, P1379, DOI 10.1016/0277-9536(84)90027-3; GARVEY MJ, 1986, AM J PSYCHIAT, V143, P1601; GLASS RM, 1991, JAMA-J AM MED ASSOC, V266, P2431, DOI 10.1001/jama.266.17.2431; Green J, 1989, PAIN MANAGE, V2, P241; HAISLIP GR, 1982, SUBST ABUS, V4, P4; HASH BM, 1984, J CLIN PSYCHOPHARM, V4, P298, DOI 10.1097/00004714-198410000-00022; HECHTMAN L, 1984, AM J ORTHOPSYCHIAT, V54, P415, DOI 10.1111/j.1939-0025.1984.tb01507.x; HILL CS, 1987, JAMA-J AM MED ASSOC, V257, P2081; HOLLISTER AS, 1991, SCIENCE, V252, P11, DOI 10.1126/science.252.5002.11-a; HOLLISTER AS, 1990, SUBST ABUSE, V11, P69; HORGAN C, 1991, REV PRESCRIPTION DRU; HUGHES PH, 1991, JAMA-J AM MED ASSOC, V265, P2069, DOI 10.1001/jama.265.16.2069; IRVINE GD, 1991, METHAMPHETAMINE ABUS, P33; Joranson D E, 1990, J Pain Symptom Manage, V5, pS12; JORANSON DE, 1992, B J MED LICENSURE DI, V79, P15; KALES A, 1983, J CLIN PSYCHOPHARM, V3, P140, DOI 10.1097/00004714-198304000-00038; KLEIN LE, 1981, J MED EDUC, V56, P504; LEVIN AA, 1992, JAMA-J AM MED ASSOC, V268, P473, DOI 10.1001/jama.268.4.473; LONEY J, 1988, ADOLESCENT DRUG ABUS, P19; LURIE P, 1992, JAMA-J AM MED ASSOC, V268, P472; MARKOWITZ JS, 1989, ARCH GEN PSYCHIAT, V46, P984; MAX MB, 1990, ANN INTERN MED, V113, P885, DOI 10.7326/0003-4819-113-11-885; MELLINGER GD, 1984, JAMA-J AM MED ASSOC, V251, P375, DOI 10.1001/jama.251.3.375; Mellinger Glen, 1981, EPIDEMIOLOGICAL IMPA, P117; MORGAN JP, 1986, AM OPIOPHOBIA CUSTOM, P163; NAGY A, 1987, ACTA PSYCHIAT SCAND, V765, P47; Nemeroff C B, 1990, N C Med J, V51, P240; PERRY S, 1982, PAIN, V13, P267, DOI 10.1016/0304-3959(82)90016-1; PISCOPO JA, 1991, MAY NAT I DRUG AB TE; PORTENOY R, 1990, J PAIN SYMPTOM MA S1, V5, P546; PORTER J, 1980, NEW ENGL J MED, V302, P123; PROTTAS J, 1991, MAY NAT I DRUG AB TE; PUDER KS, 1988, AM J DRUG ALCOHOL AB, V14, P463, DOI 10.3109/00952998809001564; REGIER DA, 1988, ARCH GEN PSYCHIAT, V45, P977; RICHARD BW, 1988, J CLIN PHARMACOL, V28, P395, DOI 10.1002/j.1552-4604.1988.tb05747.x; RICKELS K, 1972, CLIN PHARMACOL THER, V13, P595; RICKELS K, 1991, MAY NAT I DRUG AB TE; ROCK N, 1991, MAY AM AC CHILD AD P; SALZMAN C, 1991, NOV NIH CONS DEV C D; Sanders J H Jr, 1989, N C Med J, V50, P105; SATEL SL, 1989, J CLIN PSYCHIAT, V50, P241; SCHWARTZ HI, 1991, GEN HOSP PSYCHIAT, V13, P219, DOI 10.1016/0163-8343(91)90122-D; SCHWEIZER E, 1990, ARCH GEN PSYCHIAT, V47, P908; SHADER RI, 1991, J CLIN PHARMACOL, V31, P781, DOI 10.1002/j.1552-4604.1991.tb01910.x; SHAPIRO S, 1984, ARCH GEN PSYCHIAT, V41, P971; SIGLER KA, 1984, AM J HOSP PHARM, V41, P108, DOI 10.1093/ajhp/41.1.108; SMITH MC, 1983, SOC MED CONFLICTING, P259; STROSS JK, 1980, ARTHRITIS RHEUM, V23, P846, DOI 10.1002/art.1780230711; TEMIN P, 1981, DRUGS HLTH, P173; TENNANT FS, 1983, POSTGRAD MED, V73, P81, DOI 10.1080/00325481.1983.11698315; UHLENHUTH EH, 1988, J CLIN PSYCHOPHARM, V8, P161; UHLENHUTH EH, 1987, CURR MED RES OPIN, V765, P47; UNGERLEIDER JT, 1980, ARCH GEN PSYCHIAT, V37, P106; WEBB CE, 1991, MAY NAT I DRUG AB TE; WEINTRAUB M, 1991, JAMA-J AM MED ASSOC, V266, P2392, DOI 10.1001/jama.266.17.2392; WEINTRAUB M, 1992, CLIN PHARMACOL THER, V51, P642, DOI 10.1038/clpt.1992.76; Weissman D E, 1991, Wis Med J, V90, P671; WILFORD BB, 1991, J PSYCHOACTIVE DRUGS, V23, P343, DOI 10.1080/02791072.1991.10471605; WILFORD BB, 1983, NEW ENGL J MED, V308, P1457; WOLFE SM, 1990, HLTH LETT, V6, P6; WOODS JH, 1991, LANCET, V337, P295, DOI 10.1016/0140-6736(91)90902-2; WOODS JH, 1988, JAMA-J AM MED ASSOC, V260, P3476, DOI 10.1001/jama.260.23.3476; ZULLICH SG, 1992, ANN PHARMACOTHER, V26, P539; 1991, US DHHS ADM901839 PU; 1985, FED REG         1018, V50, P42184; 1991, J AM ACAD CHILD ADOL, V30, P1; 1991, US DHHS ADM911732 PU; 1982, GAOGGD832 GEN ACC OF; 1978, GAOGGD7822 GEN ACC O; 1990, PLAN CURB PRESCRIPTI; 1986, FED REG         0513, V51, P17476; 1992, OHIO STATE BOARD FEB, V13, P3; 1992, J NIH RES, V4, P27; 1990, EPIDEMIOL NOTES, V5, P1; 1990, BENZODIAZEPINE DEPEN; 1992, GAOHRD92115 GEN ACC	93	26	26	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 9	1992	268	10					1306	1310		10.1001/jama.268.10.1306	http://dx.doi.org/10.1001/jama.268.10.1306			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JL608	1507377				2022-12-01	WOS:A1992JL60800032
J	HOWEY, J				HOWEY, J			AIDS CARE CURRICULUM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 9	1992	268	10					1227	1227		10.1001/jama.268.10.1227	http://dx.doi.org/10.1001/jama.268.10.1227			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JL608	1507360				2022-12-01	WOS:A1992JL60800001
J	PSATY, BM; FURBERG, CD; KULLER, LH; BORHANI, NO; RAUTAHARJU, PM; OLEARY, DH; BILD, DE; ROBBINS, J; FRIED, LP; REID, C				PSATY, BM; FURBERG, CD; KULLER, LH; BORHANI, NO; RAUTAHARJU, PM; OLEARY, DH; BILD, DE; ROBBINS, J; FRIED, LP; REID, C			ISOLATED SYSTOLIC HYPERTENSION AND SUBCLINICAL CARDIOVASCULAR-DISEASE IN THE ELDERLY - INITIAL FINDINGS FROM THE CARDIOVASCULAR HEALTH STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNRECOGNIZED MYOCARDIAL-INFARCTION; CAROTID ATHEROSCLEROSIS; RISK-FACTORS; POPULATION; DETERMINANTS; HYPERTROPHY; PREVALENCE; MORTALITY; TRIAL	Objective.-To assess the association between isolated systolic hypertension (ISH) and subclinical disease in adults aged 65 years and above. Design.-Medicare eligibility lists were used to obtain a representative sample of 5201 community-dwelling elderly persons for the Cardiovascular Health Study, a National Heart, Lung, and Blood Institute-sponsored cohort study of risk factors for coronary heart disease and stroke. In this cross-sectional analysis of baseline data, we excluded 3012 participants who were receiving antihypertensive medications, had clinical cardiovascular disease, or had a diastolic blood pressure of at least 90 mm Hg. Main Outcome Measures.-For electrocardiogram: myocardial infarction, left ventricular hypertrophy, and left ventricular mass as measures of myocardial damage and strain; for echocardiography: left ventricular mass, fractional shortening, and Doppler flow velocities as measures of cardiac systolic and diastolic function; and for carotid sonography: carotid arterial intima-media thickness as a measure of atherosclerosis. Results.-Among the 2189 men and women in this analysis, 195 (9%) had ISH (systolic blood pressure, greater-than-or-equal-to 160 mm Hg) and 596 (23%) had borderline ISH (systolic blood pressure, 140 to 159 mm Hg). Systolic blood pressure was associated with myocardial infarction by electrocardiogram (P=.02). Borderline and definite ISH were strongly associated with left ventricular mass (P<.001). While there was little association with cardiac systolic function, borderline and definite ISH were associated with cardiac diastolic function (P<.001). Isolated systolic hypertension was also strongly associated with increased intima-media thickness of the carotid artery (P<.001). Conclusions.-While cohort analyses of future repeated measures will provide a better assessment of risk, both borderline and definite ISH were strongly related to a variety of measures of subclinical disease in elderly men and women.	UNIV WASHINGTON,DEPT EPIDEMIOL,SEATTLE,WA 98105; UNIV WASHINGTON,DEPT HLTH SERV,SEATTLE,WA 98105; WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT PUBL HLTH SCI,WINSTON SALEM,NC 27103; UNIV PITTSBURGH,DEPT EPIDEMIOL,PITTSBURGH,PA 15260; CARDIOVASC HLTH STUDY COORDINATING CTR,SEATTLE,WA; UNIV ALBERTA,DEPT MED,EDMONTON T6G 2E1,ALBERTA,CANADA; GEISINGER MED CTR,DANVILLE,PA 17822; NHLBI,DIV EPIDEMIOL & CLIN APPLICAT,EPIDEMIOL & BIOMETRY PROGRAM,BETHESDA,MD 20892; UNIV CALIF DAVIS,DEPT MED,DAVIS,CA 95616; JOHNS HOPKINS UNIV,DEPT MED,BALTIMORE,MD 21218; UNIV CALIF IRVINE,DEPT MED,IRVINE,CA 92717	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Wake Forest University; Wake Forest Baptist Medical Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Alberta; Geisinger Medical Center; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of California System; University of California Davis; Johns Hopkins University; University of California System; University of California Irvine	PSATY, BM (corresponding author), UNIV WASHINGTON,COORDINATING CTR,DEPT MED,JD-30,1107 NE 45TH ST,SUITE 530,SEATTLE,WA 98105, USA.				NHLBI NIH HHS [N01-HC-85079, N01-HC-85081, N01-HC-85080] Funding Source: Medline; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC085081, N01HC085079, N01HC085080] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Cochran W.G, 1957, STAT METHODS, V6th ed; COLANDREA MA, 1970, CIRCULATION, V41, P239, DOI 10.1161/01.CIR.41.2.239; DAHLOF B, 1986, J HYPERTENS, V4, P511, DOI 10.1097/00004872-198608000-00019; DEVEREUX RB, 1989, AM J HYPERTENS, V2, pS186, DOI 10.1093/ajh/2.6.186S; Fried Linda P., 1991, Annals of Epidemiology, V1, P263; Gardin J M, 1992, J Am Soc Echocardiogr, V5, P63; GARLAND C, 1983, AM J EPIDEMIOL, V118, P365, DOI 10.1093/oxfordjournals.aje.a113644; KANNEL WB, 1980, CIRCULATION, V61, P1179, DOI 10.1161/01.CIR.61.6.1179; KANNEL WB, 1985, AM HEART J, V109, P581, DOI 10.1016/0002-8703(85)90566-6; KITABATAKE A, 1989, Heart and Vessels, V5, P33, DOI 10.1007/BF02058356; LEVY D, 1988, ANN INTERN MED, V108, P7, DOI 10.7326/0003-4819-108-1-7; McCullagh P., 1983, GEN LINEAR MODELS, DOI [10.1007/978-1-4899-3244-0, DOI 10.1007/978-1-4899-3244-0]; NORUSIS MJ, 1990, SPSS PC PLUS 4 0 BAS; OLEARY DH, 1988, STROKE, V19, P143; OLEARY DH, 1991, STROKE, V22, P1155, DOI 10.1161/01.STR.22.9.1155; PSATY BM, 1992, J CLIN EPIDEMIOL, V45, P683, DOI 10.1016/0895-4356(92)90143-B; RAUTAHARJU PM, 1990, METHOD INFORM MED, V29, P362; RUTAN GH, 1988, CIRCULATION, V77, P504, DOI 10.1161/01.CIR.77.3.504; SALONEN R, 1991, ANN MED, V23, P23, DOI 10.3109/07853899109147926; SALONEN R, 1990, ATHEROSCLEROSIS, V81, P33, DOI 10.1016/0021-9150(90)90056-O; Schlesselman J.J., 1982, CASE CONTROL STUDIES; STAESSEN J, 1990, J HYPERTENS, V8, P393, DOI 10.1097/00004872-199005000-00001; Stamler J, 1989, Hypertension, V13, pI2; Stokes 3rd J, 1989, HYPERTENSION S1, V13, pI13; TELL GS, 1989, J CLIN EPIDEMIOL, V42, P551, DOI 10.1016/0895-4356(89)90151-0; VERDECCHIA P, 1990, EUR HEART J, V11, P679, DOI 10.1093/oxfordjournals.eurheartj.a059783; [No title captured]; 1985, BMJ, V291, P97; 1967, JAMA-J AM MED ASSOC, V202, P116; 1979, JAMA-J AM MED ASSOC, V242, P2562; 1991, JAMA-J AM MED ASSOC, V265, P3255; 1988, ARCH INTERN MED, V148, P1023	32	149	152	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 9	1992	268	10					1287	1291		10.1001/jama.268.10.1287	http://dx.doi.org/10.1001/jama.268.10.1287			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JL608	1387172				2022-12-01	WOS:A1992JL60800029
J	WORMSER, GP; FORSETER, G; COOPER, D; NOWAKOWSKI, J; NADELMAN, RB; HOROWITZ, H; SCHWARTZ, I; BOWEN, SL; CAMPBELL, GL; GOLDBERG, NS				WORMSER, GP; FORSETER, G; COOPER, D; NOWAKOWSKI, J; NADELMAN, RB; HOROWITZ, H; SCHWARTZ, I; BOWEN, SL; CAMPBELL, GL; GOLDBERG, NS			USE OF A NOVEL TECHNIQUE OF CUTANEOUS LAVAGE FOR DIAGNOSIS OF LYME-DISEASE ASSOCIATED WITH ERYTHEMA MIGRANS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							NEEDLE ASPIRATION; BORRELIA-BURGDORFERI; CELLULITIS; LIDOCAINE; LESIONS; ADULTS	Objective.-Determining the microbial cause of cellulitis is often difficult. In this study, a novel two-needle lavage technique was used to culture Borrelia burgdorferi from the skin of suspected erythema migrans lesions. Design.-The yield of lavage cultures for B burgdorferi was compared with that of a 2-mm skin biopsy sample. Setting.-A Lyme disease diagnostic center located in an area in which Lyme disease is epidemic. Patients.-Forty-five patients with suspected erythema migrans who had not been treated with antimicrobial agents. Intervention.-Cutaneous lavage of the advancing edge of a suspected primary erythema migrans lesion was done for all 45 participants, 33 of whom also had a skin biopsy of the same lesion at an identical (14) or an adjacent (19) site. Main Outcome Measures.-Growth of B burgdorferi in in vitro culture. Results.-Lavage fluid cultures grew B burgdorferi in 13 (29%) of the 45 cases (95% confidence interval [CI], 16% to 44%). Among the 33 cases in which both lavage and skin biopsy cultures were done, the yield of lavage culture was less than that of biopsy culture (P<.09, 12/33 vs 20/33). If contaminated cultures are excluded, this difference is significant (P<.05, 12/30 vs 20/27). Conclusion.-Cutaneous lavage is a new diagnostic technique for recovery of B burgdorferi from erythema migrans lesions that has potential applicability to other types of cutaneous infections.	NEW YORK MED COLL,WESTCHESTER CTY MED CTR,DEPT BIOCHEM & MOLEC BIOL,VALHALLA,NY 10595; NEW YORK MED COLL,WESTCHESTER CTY MED CTR,DEPT DERMATOL,VALHALLA,NY 10595; CTR DIS CONTROL,NATL CTR INFECT DIS,DIV VECTOR BORNE INFECT DIS,FT COLLINS,CO 80522	New York Medical College; Westchester Medical Center; New York Medical College; Westchester Medical Center	WORMSER, GP (corresponding author), NEW YORK MED COLL,WESTCHESTER CTY MED CTR,DEPT MED,DIV INFECT DIS,ROOM 209SE,MACY PAVIL,VALHALLA,NY 10595, USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041511] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR41511] Funding Source: Medline; PHS HHS [200-91-0912] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BARBOUR AG, 1984, YALE J BIOL MED, V57, P521; BERGER BW, 1983, AM J DERMATOPATH, V5, P111, DOI 10.1097/00000372-198304000-00008; HOOK EW, 1986, ARCH INTERN MED, V146, P295; MILLER MA, 1985, ARCH DERMATOL, V121, P1157, DOI 10.1001/archderm.121.9.1157; NADELMAN RB, 1990, AM J MED, V88, P21, DOI 10.1016/0002-9343(90)90122-T; NEWELL PM, 1988, J CLIN MICROBIOL, V26, P401, DOI 10.1128/JCM.26.3.401-404.1988; PAVIA CS, 1985, GENITOURIN MED, V61, P75; PIESMAN J, 1991, J INFECT DIS, V163, P895, DOI 10.1093/infdis/163.4.895; SCHMIDT RM, 1970, J INFECT DIS, V121, P597, DOI 10.1093/infdis/121.6.597; SCHWARTZ JJ, 1992, J BACTERIOL, V174, P3757, DOI 10.1128/JB.174.11.3757-3765.1992; SIGURDSSON AF, 1989, SCAND J INFECT DIS, V21, P537, DOI 10.3109/00365548909037882; UMAN SJ, 1975, ARCH INTERN MED, V135, P959, DOI 10.1001/archinte.135.7.959; 1990, MMWR, V39, P19	13	41	41	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 9	1992	268	10					1311	1313		10.1001/jama.268.10.1311	http://dx.doi.org/10.1001/jama.268.10.1311			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JL608	1507378				2022-12-01	WOS:A1992JL60800033
J	BATES, I; BEDUADDO, G; RUTHERFORD, T; BEVAN, DH				BATES, I; BEDUADDO, G; RUTHERFORD, T; BEVAN, DH			SPLENIC LYMPHOMA WITH VILLOUS LYMPHOCYTES IN TROPICAL WEST AFRICA	LANCET			English	Note							BLOOD	Splenic lymphoma with villous lymphocytes (SLVL) is a monoclonal B-lymphoproliferative disorder characterised by splenomegaly and distinctive villous lymphocytes in the peripheral blood. It has not previously been reported from Africa, but we describe ten Ghanaian patients with SLVL seen at one hospital during a 4-year period. The clinical presentation is similar in Africa and in temperate regions, though the lymphocyte count is higher in African patients and the disorder predominantly affects middle-aged women rather than elderly men. It is likely that SLVL has previously been classified as splenic chronic lymphocytic leukaemia or hyper-reactive malarial splenomegaly.	KOMFO ANOKYE TEACHING HOSP,KUMASI,GHANA	Kwame Nkrumah University Science & Technology	BATES, I (corresponding author), ST GEORGE HOSP,SCH MED,DIV HAEMATOL,CRANMER TERRACE,LONDON SW17 0RE,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BATES I, 1991, J CLIN PATHOL, V44, P605, DOI 10.1136/jcp.44.7.605; BATES I, 1991, LANCET, V337, P505, DOI 10.1016/0140-6736(91)91293-4; MELO JV, 1987, LEUKEMIA, V1, P294; SONNET J, 1966, TROP GEOGR MED, V18, P272; SPIRANO P, 1986, HEMATOLOGICA, V71, P25; 1990, BRIT J HAEMATOL, V75, P449	8	24	24	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 5	1992	340	8819					575	577		10.1016/0140-6736(92)92108-R	http://dx.doi.org/10.1016/0140-6736(92)92108-R			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JM334	1355156				2022-12-01	WOS:A1992JM33400005
J	DUNN, DT; NEWELL, ML; ADES, AE; PECKHAM, CS				DUNN, DT; NEWELL, ML; ADES, AE; PECKHAM, CS			RISK OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 TRANSMISSION THROUGH BREAST-FEEDING	LANCET			English	Article							POSTNATAL TRANSMISSION; INFECTION; HIV; INFANT; MOTHER; WOMEN; MILK	Detection of human immunodeficiency virus type 1 (HIV-1) in breast milk by culture and polymerase chain reaction does not necessarily mean that breastfeeding is a route of transmission, although evidence from several case-reports points in that direction. We undertook a systematic review of published studies meeting criteria that allowed determination of quantitative risk of transmission via breastfeeding. Based on four studies in which mothers acquired HIV-1 postnatally, the estimated risk of transmission is 29% (95% CI 16-42%). Analysis of five studies showed that when the mother was infected prenatally, the additional risk of transmission through breastfeeding, over and above transmission in utero or during delivery, is 14% (95% CI 7-22%). Where there are safe alternatives to breastfeeding, universal named testing of pregnant women would provide an opportunity to advise more infected women not to breastfeed and might thereby reduce the number of vertically infected children. Since breastfeeding protects against infant deaths from infectious diseases, breastfeeding is still recommended where infectious diseases are a common cause of death in childhood, despite the additional risk of HIV transmission.			DUNN, DT (corresponding author), INST CHILD HLTH,EPIDEMIOL & BIOSTAT UNIT,30 GUILFORD ST,LONDON WC1N 1EH,ENGLAND.		Newell, Marie-Louise/AAE-8222-2019	Newell, Marie-Louise/0000-0002-1074-7699; Dunn, David/0000-0003-1836-4446				ADES AE, 1991, LANCET, V337, P1562, DOI 10.1016/0140-6736(91)93260-G; BAUMSLAG N, 1987, LANCET, V2, P401; BLANCHE S, 1989, NEW ENGL J MED, V320, P1643, DOI 10.1056/NEJM198906223202502; COLEBUNDERS R, 1988, LANCET, V2, P1487; DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405; HEYMANN SJ, 1990, AM J PUBLIC HEALTH, V80, P1305, DOI 10.2105/AJPH.80.11.1305; HIRA SK, 1990, J PEDIATR-US, V117, P421, DOI 10.1016/S0022-3476(05)81084-4; HOLMBERG SD, 1989, J INFECT DIS, V160, P116, DOI 10.1093/infdis/160.1.116; HUTTO C, 1991, J PEDIATR-US, V118, P347, DOI 10.1016/S0022-3476(05)82145-6; JELLIFFE DB, 1992, NEW ENGL J MED, V326, P642; KIND C, 1992, EUR J PEDIATR, V151, P442, DOI 10.1007/BF01959360; KRIVINE A, 1992, LANCET, V339, P1187, DOI 10.1016/0140-6736(92)91131-Q; LEDERMAN SA, 1992, PEDIATRICS, V89, P290; NEWELL M-L, 1990, AIDS (London), V4, pS111; OXTOBY MJ, 1988, PEDIATR INFECT DIS J, V7, P825, DOI 10.1097/00006454-198807120-00001; PALASANTHIRAN P, IN PRESS J INFECT DI; ROGERS MF, 1987, LANCET, V2, P1278; RUFF A, 1992, 8 INT C AIDS AMST; RYDER RW, 1991, AIDS, V5, P709, DOI 10.1097/00002030-199106000-00010; SLOAND EM, 1991, JAMA-J AM MED ASSOC, V266, P2861, DOI 10.1001/jama.266.20.2861; THIRY L, 1985, LANCET, V2, P891; VANDEPERRE P, 1992, LANCET, V339, P1490; VANDEPERRE P, 1991, NEW ENGL J MED, V325, P593, DOI 10.1056/NEJM199108293250901; VICTORA CG, 1987, LANCET, V2, P319; ZIEGLER JB, 1985, LANCET, V1, P896; 1988, LANCET, V2, P1043; 1985, MMWR, V34, P721; 1991, LANCET, V337, P253; 1992, LANCET, V339, P1007; 1992, WEEKLY EPIDEMIOL REC, V67, P177	30	594	606	0	27	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 5	1992	340	8819					585	588		10.1016/0140-6736(92)92115-V	http://dx.doi.org/10.1016/0140-6736(92)92115-V			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JM334	1355163				2022-12-01	WOS:A1992JM33400012
J	HUNT, AJ; DAVIES, PM; MCMANUS, TJ; WEATHERBURN, P; HICKSON, FCI; CHRISTOFINIS, G; COXON, APM; SUTHERLAND, S				HUNT, AJ; DAVIES, PM; MCMANUS, TJ; WEATHERBURN, P; HICKSON, FCI; CHRISTOFINIS, G; COXON, APM; SUTHERLAND, S			HIV-INFECTION IN A COHORT OF HOMOSEXUAL AND BISEXUAL MEN	BRITISH MEDICAL JOURNAL			English	Article							SEXUAL-BEHAVIOR; GONORRHEA		UNIV ESSEX,DEPT SOCIOL,COLCHESTER CO4 3SQ,ESSEX,ENGLAND; UNIV LONDON KINGS COLL HOSP,DEPT GENITOURINARY MED,LONDON SE5 8RX,ENGLAND; DULWICH HOSP,PUBL HLTH LAB SERV,LONDON SE22 8PT,ENGLAND	University of Essex; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London; Public Health England	HUNT, AJ (corresponding author), S BANK UNIV,DEPT SOCIAL SCI,LONDON SE1 0AA,ENGLAND.		Weatherburn, Peter/AAC-2701-2019	Weatherburn, Peter/0000-0002-4950-6163				ADIB SM, 1991, AIDS, V5, P757, DOI 10.1097/00002030-199106000-00018; CARNE CA, 1987, LANCET, V1, P656; DAVIES PM, 1990, LONGITUDINAL STUDY S; STALL RD, 1988, AM PSYCHOL, V43, P878, DOI 10.1037/0003-066X.43.11.878; WAUGH MA, 1991, LANCET, V337, P375, DOI 10.1016/0140-6736(91)91017-O	5	17	17	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 5	1992	305	6853					561	562		10.1136/bmj.305.6853.561	http://dx.doi.org/10.1136/bmj.305.6853.561			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JM495	1393036	Green Submitted, Bronze, Green Published			2022-12-01	WOS:A1992JM49500018
J	KASPER, W; GEIBEL, A; TIEDE, N; JUST, H				KASPER, W; GEIBEL, A; TIEDE, N; JUST, H			PATENT FORAMEN OVALE IN PATIENTS WITH HEMODYNAMICALLY SIGNIFICANT PULMONARY-EMBOLISM	LANCET			English	Article							PARADOXICAL EMBOLISM; CONTRAST ECHOCARDIOGRAPHY; DIAGNOSIS; LIFE; PREVALENCE; HYPOXEMIA; STROKE	The prevalence of a patent foramen ovale is about 1 in 4. In cases with venous thromboembolism and raised right heart pressures, a patent foramen ovale may permit paradoxical emboli, which could complicate the course of patients with pulmonary embolism. Echocardiography enables detection of a patent foramen ovale in life. We have studied 85 patients who presented with haemodynamically significant pulmonary embolism as judged by clinical, echocardiographic, or haemodynamic indices and who had an echocardiographic evaluation for patent foramen ovale. 33 patients (39%) had a patent foramen ovale. Clinical symptoms suggestive of paradoxical embolism were more likely in patients with than in those without a patent foramen ovale (39% vs 6%, p=0.00034), with new neurological deficits occurring in 11 patients (9 vs 2, p=0.005) and a vascular occlusion in 8(7 vs 1, p=0.0096). Arterial oxygen tension was lower in patients with a patent foramen ovale (mean 55 [SD 14] vs 62 [16] mm Hg, p=0.038). Mortality was not different between the two groups (27% vs 19%). Cardiopulmonary complications in terms of resuscitation, intubation, or the use of catecholamines were more frequently observed in patients with a patent foramen ovale (48% vs 23%, p=0.028). Patients with a patent foramen ovale and haemodynamically significant pulmonary embolism are more likely to have arterial hypoxaemia and vascular occlusions, possibly due to paradoxical emboli.			KASPER, W (corresponding author), UNIV FREIBURG,MED CLIN 3,HUGSTETTERSTR 55,W-7800 FREIBURG,GERMANY.							BARNARD SP, 1991, EUR J CARDIO-THORAC, V5, P105, DOI 10.1016/1010-7940(91)90008-8; BILLER J, 1986, NEUROLOGY, V36, P1356, DOI 10.1212/WNL.36.10.1356; COME PC, 1985, DIAGNOSTIC CARDIOLOG, P281; CROSS SJ, 1992, BRIT MED J, V304, P481, DOI 10.1136/bmj.304.6825.481; CURRIE PJ, 1985, J AM COLL CARDIOL, V6, P750, DOI 10.1016/S0735-1097(85)80477-0; DALONZO GE, 1983, AM REV RESPIR DIS, V128, P170, DOI 10.1164/arrd.1983.128.1.170; HAGEN PT, 1984, MAYO CLIN PROC, V59, P17, DOI 10.1016/S0025-6196(12)60336-X; HALE GS, 1979, AUST NZ J MED, V9, P953; HIGGINS JR, 1984, AM HEART J, V107, P375, DOI 10.1016/0002-8703(84)90388-0; HOFMANN T, 1990, LANCET, V336, P1421; JARDIN F, 1979, CIRCULATION, V59, P909, DOI 10.1161/01.CIR.59.5.909; JOHNSON BI, 1951, J CLIN PATHOL, V4, P316, DOI 10.1136/jcp.4.3.316; KASPER W, 1989, HERZ, V14, P82; KASPER W, 1986, AM HEART J, V112, P1284, DOI 10.1016/0002-8703(86)90361-3; KRONIK G, 1989, EUR HEART J, V10, P1046; LANG I, 1988, EUR HEART J, V9, P678, DOI 10.1093/oxfordjournals.eurheartj.a062561; LECHAT P, 1988, NEW ENGL J MED, V318, P1148, DOI 10.1056/NEJM198805053181802; LEONARD RCF, 1982, EUR HEART J, V3, P362, DOI 10.1093/oxfordjournals.eurheartj.a061319; LOSCALZO J, 1986, AM HEART J, V112, P141, DOI 10.1016/0002-8703(86)90692-7; LYNCH JJ, 1984, AM J CARDIOL, V53, P1478, DOI 10.1016/S0002-9149(84)91617-5; MCNEIL BJ, 1980, J NUCL MED, V21, P319; MEISTER SG, 1972, AM J MED, V53, P292, DOI 10.1016/0002-9343(72)90171-4; MOON RE, 1989, LANCET, V1, P513; NELLESSEN U, 1985, J AM COLL CARDIOL, V5, P1002, DOI 10.1016/S0735-1097(85)80449-6; SEWARD JB, 1984, MAYO CLIN PROC, V59, P221, DOI 10.1016/S0025-6196(12)61253-1; STRUNK BL, 1987, AM J CARDIOL, V60, P413, DOI 10.1016/0002-9149(87)90271-2; Thompson T, 1930, Q J MED, V23, P135, DOI 10.1093/qjmed/os-23.90.135; WEBSTER MWI, 1988, LANCET, V2, P11; WILSON JE, 1971, J CLIN INVEST, V50, P481, DOI 10.1172/JCI106516	29	109	113	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 5	1992	340	8819					561	564		10.1016/0140-6736(92)92102-L	http://dx.doi.org/10.1016/0140-6736(92)92102-L			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JM334	1355152				2022-12-01	WOS:A1992JM33400001
J	KILIDIREAS, K; LATOV, N; STRAUSS, DH; GORIG, AD; HASHIM, GA; GORMAN, JM; SADIQ, SA				KILIDIREAS, K; LATOV, N; STRAUSS, DH; GORIG, AD; HASHIM, GA; GORMAN, JM; SADIQ, SA			ANTIBODIES TO THE HUMAN 60 KDA HEAT-SHOCK PROTEIN IN PATIENTS WITH SCHIZOPHRENIA	LANCET			English	Article							RHEUMATOID-ARTHRITIS; LYMPHOCYTE-T; MYCOBACTERIAL; CELLS; AUTOANTIBODIES; AUTOIMMUNITY; BACTERIAL; SURFACE; ANTIGEN; MYELIN	Immune mechanisms are thought to be important in a subpopulation of patients with schizophrenia. We examined the specificity of neural antibodies in patients with schizophrenia to identify a possible antigen. Serum antibodies from patients with schizophrenia and control subjects were tested for binding to protein extracts of human neuroblastoma cells by western blot. Protein antigens were characterised by aminoterminal and internal aminoacid sequence analysis. 14 of 32 (44%) otherwise healthy patients with schizophrenia had antibodies to a neuroblastoma protein of molecular weight 60 kDa. By partial sequence analysis, this protein was identified as the 60 kDa human heat-shock protein (hsp) that is the P1 mitochondrial protein, and which is 50% homologous to the mycobacterial 65 kDa hsp. Antigens that crossreact with hsp65 have been implicated in the pathogenesis of adjuvant-induced arthritis in rats and autoimmune diabetes in mice. Of 100 normal subjects or disease controls, antibodies to hsp60 were found in only 8 patients, all of whom had active infectious or inflammatory disease. Our results support the presence of abnormal immune reactivity involving hsp60 in a subset of patients with schizophrenia. The immune response may be related to the pathogenesis of the disease.	COLUMBIA UNIV COLL PHYS & SURG, DEPT NEUROL,BLACK BLDG,ROOM 3-323,630 W 168TH ST, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, DEPT PSYCHIAT, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, DEPT SURG, NEW YORK, NY 10032 USA; NEW YORK STATE PSYCHIAT INST & HOSP, DEPT CLIN PSYCHOBIOL, NEW YORK, NY 10032 USA	Columbia University; Columbia University; Columbia University; New York State Psychiatry Institute			Sadiq, Saud/AAA-9871-2020		NIMH NIH HHS [MH00416] Funding Source: Medline	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AGUAS AP, 1990, INFECT IMMUN, V58, P1461, DOI 10.1128/IAI.58.5.1461-1470.1990; BRUDZYNSKI K, 1992, DIABETOLOGIA, V35, P316, DOI 10.1007/BF00401198; COHEN IR, 1990, ISRAEL J MED SCI, V26, P673; COULIE PG, 1985, J EXP MED, V161, P88, DOI 10.1084/jem.161.1.88; DEGRAEFFMEEDER ER, 1990, AM J PATHOL, V137, P1013; ELIAS D, 1990, P NATL ACAD SCI USA, V87, P1576, DOI 10.1073/pnas.87.4.1576; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; JARJOUR W, 1990, J EXP MED, V172, P1857, DOI 10.1084/jem.172.6.1857; JARJOUR WN, 1991, ARTHRITIS RHEUM-US, V34, P1133, DOI 10.1002/art.1780340909; JINDAL S, 1989, MOL CELL BIOL, V9, P2279, DOI 10.1128/MCB.9.5.2279; KIRCH DG, 1985, BIOL PSYCHIAT, V20, P1039, DOI 10.1016/0006-3223(85)90002-2; KOGA T, 1989, SCIENCE, V245, P1112, DOI 10.1126/science.2788923; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; MCALLISTER CG, 1989, ARCH GEN PSYCHIAT, V46, P890; MUNK ME, 1989, J IMMUNOL, V143, P2844; READING DS, 1989, NATURE, V337, P655, DOI 10.1038/337655a0; SADIQ SA, 1991, J NEUROSCI RES, V29, P319, DOI 10.1002/jnr.490290307; SCHATTNER A, 1990, REV INFECT DIS, V12, P204; SIROTA P, 1990, ISRAEL J MED SCI, V26, P694; SPATZ LA, 1990, J IMMUNOL, V144, P2821; SPIVAK B, 1991, AM J PSYCHIAT, V148, P244; SUDDATH RL, 1990, NEW ENGL J MED, V322, P789, DOI 10.1056/NEJM199003223221201; SUNDIN U, 1989, Brain Behavior and Immunity, V3, P345, DOI 10.1016/0889-1591(89)90033-0; TSOULFA G, 1989, ANN RHEUM DIS, V48, P118, DOI 10.1136/ard.48.2.118; van Eden W, 1987, Concepts Immunopathol, V4, P144; VANDENBERG LH, 1990, J NEUROSCI RES, V25, P295, DOI 10.1002/jnr.490250305; VANEDEN W, 1985, P NATL ACAD SCI USA, V82, P5117; VILLEMAIN F, 1989, AM J PSYCHIAT, V2, P417; WANDWURTTENBERGER A, 1991, EUR J IMMUNOL, V21, P1089, DOI 10.1002/eji.1830210437; ZINKERNAGEL RM, 1990, NATURE, V345, P68, DOI 10.1038/345068a0	30	74	76	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 5	1992	340	8819					569	572		10.1016/0140-6736(92)92105-O	http://dx.doi.org/10.1016/0140-6736(92)92105-O			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JM334	1355154				2022-12-01	WOS:A1992JM33400003
J	PELTOLA, H; KILPI, T; ANTTILA, M				PELTOLA, H; KILPI, T; ANTTILA, M			RAPID DISAPPEARANCE OF HAEMOPHILUS-INFLUENZAE TYPE-B MENINGITIS AFTER ROUTINE CHILDHOOD IMMUNIZATION WITH CONJUGATE VACCINES	LANCET			English	Article							CAPSULAR POLYSACCHARIDE VACCINE; NEISSERIA-MENINGITIDIS; BACTERIAL-MENINGITIS; MEMBRANE-PROTEIN; FIELD TRIAL; EFFICACY; INFANTS; CHILDREN; FINLAND; AGE	Mortality from meningitis caused by Haemophilus influenzae type b (Hib), a disease that affects mainly infants and young children, can reach 5% in industrialised countries and ten times that in non-industrialised countries. To determine the efficacy of vaccination against Hib, we carried out a retrospective survey of the incidence of Hib meningitis over five decades in the Greater Helsinki area of Finland, where all children with bacterial meningitis are treated in one of three centres. Except for a meningococcal epidemic in the early 1970s, Hib was the leading cause of childhood bacterial meningitis until the Hib conjugate vaccines changed the picture profoundly. In 1986-87 the polysaccharide-diphtheria toxoid conjugate (PRP-D) was given experimentally to 50% of infants. In 1988-89 all infants were vaccinated, 50% with PRP-D, 50% with another conjugate vaccine, the oligosaccharide-CRM197 protein conjugate (HbOC). Since 1990 a third conjugate vaccine, the polysaccharide-tetanus toxoid (PRP-T), has been administered routinely to all infants. The vaccines were administered at age 3-6 months, with a booster dose at 14-18 months. In the first 5 years of the Hib vaccination programme the number of cases of Hib meningitis in children aged 0-4 years fell sharply, from 30 in 1986 (the first year of the programme) to none in 1991. The decline contrasts sharply with the rising trend up to the mid 1980s. Vaccination seems to be the only explanation for the observed change in the epidemiology of Hib meningitis.	AURORA CITY HOSP,HELSINKI,FINLAND; NATL PUBL HLTH INST,SF-00280 HELSINKI 28,FINLAND	Finland National Institute for Health & Welfare	PELTOLA, H (corresponding author), UNIV HELSINKI,CHILDRENS HOSP,11 STENBACKINKATU,SF-00290 HELSINKI 29,FINLAND.							ANDERSON PW, 1989, J IMMUNOL, V142, P2464; BIJLMER HA, 1991, VACCINE, V9, pS5, DOI 10.1016/0264-410X(91)90172-3; BLACK SB, 1991, PEDIATR INFECT DIS J, V10, P97, DOI 10.1097/00006454-199102000-00004; CHU CY, 1983, INFECT IMMUN, V40, P245, DOI 10.1128/IAI.40.1.245-256.1983; DECKER MD, 1992, J PEDIATR-US, V120, P184, DOI 10.1016/S0022-3476(05)80424-X; ESKOLA J, 1990, NEW ENGL J MED, V323, P1381, DOI 10.1056/NEJM199011153232004; ESKOLA J, 1987, NEW ENGL J MED, V317, P717, DOI 10.1056/NEJM198709173171201; ESKOLA J, 1991, VACCINE, V9, pS14, DOI 10.1016/0264-410X(91)90174-5; FERRECCIO C, 1991, PEDIATR INFECT DIS J, V10, P764, DOI 10.1097/00006454-199110000-00009; FORSSELL P, 1967, LEIRAKSEN JULKAISUJA, V17, P137; GORDON LK, 1984, MODERN APPROACHES VA, P393; KAUHTIO J, 1958, Ann Paediatr Fenn, V4, P42; KAYHTY H, 1991, AM J DIS CHILD, V145, P223; KILPI T, 1991, LANCET, V338, P406, DOI 10.1016/0140-6736(91)91032-P; KOSKINIEMI M, 1978, ACTA PAEDIATR SCAND, V67, P17, DOI 10.1111/j.1651-2227.1978.tb16271.x; MAKELA PH, 1977, J INFECT DIS, V136, pS43; MARBURG S, 1986, J AM CHEM SOC, V108, P5282, DOI 10.1021/ja00277a037; PELTOLA H, 1977, NEW ENGL J MED, V297, P686, DOI 10.1056/NEJM197709292971302; PELTOLA H, 1984, NEW ENGL J MED, V310, P1561, DOI 10.1056/NEJM198406143102404; PELTOLA H, 1977, PEDIATRICS, V60, P730; PELTOLA H, 1989, LANCET, V1, P1281; SANTOSHAM M, 1991, NEW ENGL J MED, V324, P1767, DOI 10.1056/NEJM199106203242503; SCHNEERSON R, 1980, J EXP MED, V152, P361, DOI 10.1084/jem.152.2.361; WARD J, 1990, NEW ENGL J MED, V323, P1393, DOI 10.1056/NEJM199011153232006; 1990, MORBID MORTAL WKLY R, V39, P924	25	284	290	0	10	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 5	1992	340	8819					592	594		10.1016/0140-6736(92)92117-X	http://dx.doi.org/10.1016/0140-6736(92)92117-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JM334	1355165				2022-12-01	WOS:A1992JM33400014
J	PIETRONI, PC				PIETRONI, PC			PARTNERS IN PRACTICE .7. BEYOND THE BOUNDARIES - RELATIONSHIP BETWEEN GENERAL-PRACTICE AND COMPLEMENTARY MEDICINE	BRITISH MEDICAL JOURNAL			English	Article											PIETRONI, PC (corresponding author), ST MARYS HOSP,SCH MED,LONDON,ENGLAND.							BEIER LM, 1987, SUFFERERS HEALERS EX, P38; DESSER A, IN PRESS J R COLL GE; FULDER S, 1981, STATUS COMPLEMENTARY; MCLEAN J, 1990, SOC SCI MED, V30, P591, DOI 10.1016/0277-9536(90)90157-N; PETERS D, IN PRESS J R COLL GE; PIETRONI PC, 1988, J R SOC ARTS, P791; REASON P, 1992, J ROY SOC MED, V85, P161; REASON P, 1991, J RES COUNCIL COMPLE, V5, P144; REILLY DT, 1983, BRIT MED J, V287, P337, DOI 10.1136/bmj.287.6388.337; WHARTON R, 1986, BRIT MED J, V292, P1498, DOI 10.1136/bmj.292.6534.1498; 1989, TIMES           1113; 1981, WHICH            AUG; 1991, REPORT OSTEOPATHY	13	28	28	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 5	1992	305	6853					564	566		10.1136/bmj.305.6853.564	http://dx.doi.org/10.1136/bmj.305.6853.564			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JM495	1393039	Green Published, Green Submitted, hybrid			2022-12-01	WOS:A1992JM49500021
J	THOMAS, SJ; MACLENNAN, R				THOMAS, SJ; MACLENNAN, R			SLAKED LIME AND BETEL NUT CANCER IN PAPUA-NEW-GUINEA	LANCET			English	Note							TOBACCO	Oral squamous cell cancer is the most common malignant tumour in Papua New Guinea. We have found that oral cancer in this region is concentrated at the corner of the mouth and cheek, by striking contrast with western populations, and corresponds precisely with the site of application of lime in 77% of 169 cases. Powdered slaked lime applied to the chewed Areca nut with Piper betle inflorescence at the comer of the mouth causes the mean pH to rise to 10, at which reactive oxygen species are generated from betel quid ingredients in vitro. Reactive oxygen species, together with sustained lime-induced cell proliferation, suggest a possible mechanism of carcinogenesis for this tumour.			THOMAS, SJ (corresponding author), QUEENSLAND INST MED RES,300 HERSTON RD,BRISBANE 4029,AUSTRALIA.							COHEN SM, 1990, SCIENCE, V249, P1007, DOI 10.1126/science.2204108; COOKE RA, 1969, CANCER, V24, P397, DOI 10.1002/1097-0142(196908)24:2<397::AID-CNCR2820240223>3.0.CO;2-6; Henderson BE, 1979, NATL CANCER I MONOGR, V53, P67; LANGDON JD, 1985, MALIGNANT TUMOURS OR, P3; MOORE C, 1967, AM J SURG, V114, P510, DOI 10.1016/0002-9610(67)90008-6; NAIR UJ, 1990, CARCINOGENESIS, V11, P2145, DOI 10.1093/carcin/11.12.2145; ROTHMAN K, 1972, J CHRON DIS, V25, P711, DOI 10.1016/0021-9681(72)90006-9; SCRIMGEOUR EM, 1983, BRIT MED J, V286, P1414, DOI 10.1136/bmj.286.6375.1414; STICH HF, 1989, MUTAT RES, V214, P47, DOI 10.1016/0027-5107(89)90197-8	9	106	110	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 5	1992	340	8819					577	578		10.1016/0140-6736(92)92109-S	http://dx.doi.org/10.1016/0140-6736(92)92109-S			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JM334	1355157				2022-12-01	WOS:A1992JM33400006
J	WAKABAYASHI, I; SAKAMOTO, K; YOSHIMOTO, S; MASUI, H				WAKABAYASHI, I; SAKAMOTO, K; YOSHIMOTO, S; MASUI, H			RELATION OF SERUM SIALIC-ACID TO LIPID CONCENTRATIONS	BRITISH MEDICAL JOURNAL			English	Article											WAKABAYASHI, I (corresponding author), HYOGO MED UNIV,DEPT HYG,1-1 MUKOGAWA CHO,NISHINOMIYA,HYOGO 663,JAPAN.							COMB DG, 1960, J BIOL CHEM, V235, P2529; LINDBERG G, 1991, BRIT MED J, V303, P1306, DOI 10.1136/bmj.303.6813.1306; LINDBERG G, 1991, BRIT MED J, V302, P143, DOI 10.1136/bmj.302.6769.143; RADHAKRISHNAMURTHY B, 1976, LAB INVEST, V34, P159; SHVARTZ OLS, 1971, PROBLEMY ENDOKRINOLO, V17, P37	5	35	35	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 5	1992	305	6853					562	563		10.1136/bmj.305.6853.562	http://dx.doi.org/10.1136/bmj.305.6853.562			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JM495	1393037	Green Published, Green Submitted			2022-12-01	WOS:A1992JM49500019
J	WIDGERY, D				WIDGERY, D			AIDS FAREWELLS	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 5	1992	305	6853					590	590						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JM495	1393064				2022-12-01	WOS:A1992JM49500072
J	WILSON, DI; GOODSHIP, JA; BURN, J; CROSS, IE; SCAMBLER, PJ				WILSON, DI; GOODSHIP, JA; BURN, J; CROSS, IE; SCAMBLER, PJ			DELETIONS WITHIN CHROMOSOME-22Q11 IN FAMILIAL CONGENITAL HEART-DISEASE	LANCET			English	Article							DIGEORGE SYNDROME	Because a locus on chromosome 22q11 is deleted in most individuals with DiGeorge and Shprintzen syndromes-conditions in which heart abnormalities are an important feature-we have looked for deletions in nine families with recurrent out flow-tract heart defects. In five families, chromosome 22 deletions were detected in all the living affected individuals studied and also in the clinically normal father of three affected children. The deletion was transmitted from parents to offspring and was associated with an increase in the severity of cardiac defects. No deletions were found in four families in which the parents were normal and affected siblings had anatomically identical defects. We propose that deletions within band q11 of chromosome 22 are an important cause of familial heart defects.	ST MARYS HOSP,SCH MED,DEPT BIOCHEM & MOLEC GENET,LONDON,ENGLAND	Imperial College London	WILSON, DI (corresponding author), UNIV NEWCASTLE UPON TYNE,DIV HUMAN GENET,NEWCASTLE TYNE NE2 4AA,ENGLAND.		Scambler, Peter J/C-4998-2008; Scambler, Peter/AAZ-6026-2020; Wilson, David I/A-6264-2010	Scambler, Peter J/0000-0002-1487-4628; Scambler, Peter/0000-0002-1487-4628; Wilson, David I/0000-0001-8779-2060; Burn, John/0000-0002-9823-2322				[Anonymous], 1985, INT SYSTEM HUMAN CYT; BURN J, 1990, AM J HUM GENET S, V47, pA121; CAREY AH, IN PRESS AM J HUM GE; CONLEY ME, 1979, J PEDIATR-US, V94, P883, DOI 10.1016/S0022-3476(79)80207-3; CZEIZEL A, 1982, BRIT HEART J, V47, P290; DENNIS NR, 1981, J MED GENET, V18, P8, DOI 10.1136/jmg.18.1.8; DRISCOLL AD, 1992, AM J HUM GENET, V50, P924; LIPSON AH, 1991, J MED GENET, V28, P596, DOI 10.1136/jmg.28.9.596; SCAMBLER PJ, 1992, LANCET, V339, P1138, DOI 10.1016/0140-6736(92)90734-K; SUTHERLAND GR, 1991, LANCET, V338, P289, DOI 10.1016/0140-6736(91)90426-P; WHITTEMORE R, 1982, AM J CARDIOL, V50, P641, DOI 10.1016/0002-9149(82)90334-4; WILSON DI, 1991, BRIT HEART J, V66, P308; WILSON DI, 1992, APR P BRIT PAED ASS; ZELLERS TM, 1990, AM J CARDIOL, V65, P523, DOI 10.1016/0002-9149(90)90825-L	14	158	162	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 5	1992	340	8819					573	575		10.1016/0140-6736(92)92107-Q	http://dx.doi.org/10.1016/0140-6736(92)92107-Q			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JM334	1355155				2022-12-01	WOS:A1992JM33400004
J	AHISSAR, E; VAADIA, E; AHISSAR, M; BERGMAN, H; ARIELI, A; ABELES, M				AHISSAR, E; VAADIA, E; AHISSAR, M; BERGMAN, H; ARIELI, A; ABELES, M			DEPENDENCE OF CORTICAL PLASTICITY ON CORRELATED ACTIVITY OF SINGLE NEURONS AND ON BEHAVIORAL CONTEXT	SCIENCE			English	Article							LONG-TERM POTENTIATION; VISUAL-CORTEX; HEBBIAN SYNAPSES; MECHANISMS; CONNECTIVITY; HIPPOCAMPUS; DEPRESSION; POSTULATE; MEMORY; SLICES	It has not been possible to analyze the cellular mechanisms underlying learning in behaving mammals because of the difficulties in recording intracellularly from awake animals. Therefore, in the present study of neuronal plasticity in behaving monkeys, the net effect of a single neuron on another neuron (the "functional connection") was evaluated by cross-correlating the times of firing of the two neurons. When two neurons were induced to fire together within a short time window, the functional connection between them was potentiated, and when simultaneous firing was prevented, the connection was depressed. These modifications were strongly dependent on the behavioral context of the stimuli that induced them. The results indicate that changes in the temporal contingency between neurons are often necessary, but not sufficient, for cortical plasticity in the adult monkey: behavioral relevance is required.	HEBREW UNIV JERUSALEM, HADASSAH MED SCH, DEPT PHYSIOL, IL-91010 JERUSALEM, ISRAEL	Hebrew University of Jerusalem			Vaadia, Eilon/E-9347-2011	Ahissar, Merav/0000-0001-7694-8111				ABELES M, 1977, P IEEE, V65, P762, DOI 10.1109/PROC.1977.10559; ABELES M, 1982, J NEUROSCI METH, V5, P317, DOI 10.1016/0165-0270(82)90002-4; Abeles M, 1991, CORTICONICS NEURAL C, DOI DOI 10.1017/CBO9780511574566; AERTSEN AMHJ, 1989, J NEUROPHYSIOL, V61, P900, DOI 10.1152/jn.1989.61.5.900; AHISSAR M, 1992, J NEUROPHYSIOL, V67, P203, DOI 10.1152/jn.1992.67.1.203; AOU SJ, 1992, J NEUROSCI, V12, P560; ARTOLA A, 1990, NATURE, V347, P69, DOI 10.1038/347069a0; BARANYI A, 1991, NEUROSCIENCE, V42, P321, DOI 10.1016/0306-4522(91)90378-2; BIENENSTOCK EL, 1982, J NEUROSCI, V2, P32, DOI 10.1523/jneurosci.02-01-00032.1982; BOWER GH, 1981, THEOR LEARN, P21; BROWN TH, 1990, ANNU REV NEUROSCI, V13, P475, DOI 10.1146/annurev.ne.13.030190.002355; CAREW TJ, 1984, J NEUROSCI, V4, P1217; DIPRISCO GV, 1984, PROG NEUROBIOL, V22, P89, DOI 10.1016/0301-0082(84)90021-2; Dudai Y., 1989, NEUROBIOLOGY MEMORY; FARLEY J, 1985, ANNU REV PSYCHOL, V36, P419; FREGNAC Y, 1988, NATURE, V333, P367, DOI 10.1038/333367a0; FROSTIG RD, 1983, BRAIN RES, V272, P211, DOI 10.1016/0006-8993(83)90567-X; GREUEL JM, 1988, SCIENCE, V242, P74, DOI 10.1126/science.2902687; GROSSBERG S, 1976, BIOL CYBERN, V23, P121, DOI 10.1007/BF00344744; GROSSBERG S, 1988, NEURAL NETWORKS NATU, P405; Hebb DO, 1949, ORG BEHAVIOR, P62; KANDEL ER, 1968, PHYSIOL REV, V48, P65, DOI 10.1152/physrev.1968.48.1.65; Kandel ER, 1976, CELLULAR BASIS BEHAV; KELSO SR, 1986, P NATL ACAD SCI USA, V83, P5326, DOI 10.1073/pnas.83.14.5326; KLOPF H, 1989, NEURAL MODELS PLASTI, P104; LEVY WB, 1979, BRAIN RES, V175, P233, DOI 10.1016/0006-8993(79)91003-5; LEVY WB, 1983, NEUROSCIENCE, V8, P791, DOI 10.1016/0306-4522(83)90010-6; Mackintosh N.J., 1983, CONDITIONING ASS LEA; PERKEL DH, 1967, BIOPHYS J, V7, P391, DOI 10.1016/S0006-3495(67)86596-2; RAUSCHECKER JP, 1991, PHYSIOL REV, V71, P587, DOI 10.1152/physrev.1991.71.2.587; RECANZONE GH, 1992, J NEUROPHYSIOL, V67, P1031, DOI 10.1152/jn.1992.67.5.1031; REITER HO, 1988, P NATL ACAD SCI USA, V85, P3623, DOI 10.1073/pnas.85.10.3623; RESCORLA RA, 1988, ANNU REV NEUROSCI, V11, P329, DOI 10.1146/annurev.ne.11.030188.001553; SEJNOWSKI TJ, 1977, J MATH BIOL, V4, P303, DOI 10.1007/BF00275079; STANTON PK, 1985, J NEUROSCI, V5, P2169; STENT GS, 1973, P NATL ACAD SCI USA, V70, P997, DOI 10.1073/pnas.70.4.997; SUTTON RS, 1981, PSYCHOL REV, V88, P135, DOI 10.1037/0033-295X.88.2.135; THORNDIKE EL, 1965, ANIMAL INTELLIGENCE, P244; VAADIA E, 1991, NEURONAL COOPERATIVI; von der Malsburg C, 1973, Kybernetik, V14, P85; Weinberger N. M., 1990, LEARNING COMPUTATION, P91	41	273	276	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 4	1992	257	5075					1412	1415		10.1126/science.1529342	http://dx.doi.org/10.1126/science.1529342			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL612	1529342				2022-12-01	WOS:A1992JL61200038
J	AMSTERCHODER, O; WRIGHT, A				AMSTERCHODER, O; WRIGHT, A			MODULATION OF THE DIMERIZATION OF A TRANSCRIPTIONAL ANTITERMINATOR PROTEIN BY PHOSPHORYLATION	SCIENCE			English	Article							DNA-BINDING PROTEINS; ESCHERICHIA-COLI; LEUCINE ZIPPER; BGL OPERON	The transcriptional antiterminator protein BgIG inhibits transcription termination of the bgl operon in Escherichia coli when it is in the nonphosphorylated state. The BgIG protein is now shown to exist in two configurations, an active, dimeric nonphosphorylated form and an inactive, monomeric phosphorylated form. The migration of BgIG on native polyacrylamide gels was consistent with it existing as a dimer when nonphosphorylated and as a monomer when phosphorylated. Only the nonphosphorylated dimer was found to bind to the target RNA. When the dimerization domain of the lambda-repressor was replaced with BgIG, the resulting chimera behaved like an intact lambda-repressor in its ability to repress lambda-gene expression, which suggests that BgIG dimerizes in vivo. Repression by the lambda-BgIG hybrid was significantly reduced by BgIF, the BgIG kinase, an effect that was relieved by conditions that stimulate dephosphorylation of BgIG by BgIF. These results suggest that the phosphorylation and the dephosphorylation of BgIG regulate its activity by controlling its dimeric state.			AMSTERCHODER, O (corresponding author), TUFTS UNIV,DEPT MOLEC BIOL & MICROBIOL,HLTH SCI CAMPUS,BOSTON,MA 02111, USA.							AMSTERCHODER O, 1990, SCIENCE, V249, P540, DOI 10.1126/science.2200123; AMSTERCHODER O, 1989, CELL, V58, P847, DOI 10.1016/0092-8674(89)90937-9; AMSTERCHODER O, UNPUB; BRYAN JK, 1977, ANAL BIOCHEM, V78, P523; DIAZTORRES MR, UNPUB; FRANKEL AD, 1991, CELL, V67, P1041, DOI 10.1016/0092-8674(91)90282-4; HOUMAN F, 1990, CELL, V62, P1153, DOI 10.1016/0092-8674(90)90392-R; HU JC, 1990, SCIENCE, V250, P1400, DOI 10.1126/science.2147779; Hu Jintao, COMMUNICATION; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; MAHADEVAN S, 1987, CELL, V50, P485, DOI 10.1016/0092-8674(87)90502-2; MENDEL DB, 1991, SCIENCE, V254, P1762, DOI 10.1126/science.1763325; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; REVEL HR, 1967, VIROLOGY, V31, P688, DOI 10.1016/0042-6822(67)90197-3; REYNOLDS AE, 1986, J MOL BIOL, V191, P85, DOI 10.1016/0022-2836(86)90424-9; RUDNER DZ, 1991, J BACTERIOL, V173, P1388, DOI 10.1128/jb.173.4.1388-1398.1991; STEINMETZ M, 1988, GENETICS BIOTECHNOLO, V2, P11; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ZAGURSKY RJ, 1984, GENE, V27, P183, DOI 10.1016/0378-1119(84)90139-2	21	122	122	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 4	1992	257	5075					1395	1398		10.1126/science.1382312	http://dx.doi.org/10.1126/science.1382312			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL612	1382312				2022-12-01	WOS:A1992JL61200032
J	APPLEBY, MW; GROSS, JA; COOKE, MP; LEVIN, SD; QIAN, X; PERLMUTTER, RM				APPLEBY, MW; GROSS, JA; COOKE, MP; LEVIN, SD; QIAN, X; PERLMUTTER, RM			DEFECTIVE T-CELL RECEPTOR SIGNALING IN MICE LACKING THE THYMIC ISOFORM OF P59(FYN)	CELL			English	Article							PROTEIN-TYROSINE KINASE; ANTIGEN RECEPTOR; PHOSPHOLIPASE C-GAMMA-1; CLONAL DELETION; CD4 RECEPTOR; PHOSPHORYLATION; ACTIVATION; P56LCK; STIMULATION; TRANSDUCTION	Considerable evidence supports the hypothesis that the nonreceptor protein tyrosine kinase p59fyn participates in signal transduction from the T cell receptor (TCR). To examine this hypothesis in detail, we have produced mice that lack the thymic isoform of p59fyn but retain expression of the brain isoform of the protein. fynT(null) mice exhibit a remarkably specific lymphoid defect: thymocytes are refractile to stimulation through the TCR with mitogen or antigen, while peripheral T cells, following what appears to be a normal maturation sequence, reacquire significant signaling capabilities. These data confirm that p59fynT plays a pivotal role in TCR signal transduction and demonstrate that additional developmentally regulated signaling components also contribute to TCR-induced lymphocyte activation.	UNIV WASHINGTON,HOWARD HUGHES MED INST,DEPT BIOCHEM,SEATTLE,WA 98195; UNIV WASHINGTON,HOWARD HUGHES MED INST,DEPT MED,SEATTLE,WA 98195	Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle	APPLEBY, MW (corresponding author), UNIV WASHINGTON,HOWARD HUGHES MED INST,DEPT IMMUNOL,SEATTLE,WA 98195, USA.				NATIONAL CANCER INSTITUTE [R01CA045682, T32CA009537] Funding Source: NIH RePORTER; NCI NIH HHS [CA09537, CA45682] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM KM, 1991, P NATL ACAD SCI USA, V88, P3977, DOI 10.1073/pnas.88.9.3977; ABRAHAM KM, 1991, J EXP MED, V173, P1421, DOI 10.1084/jem.173.6.1421; ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; BARBER EK, 1989, P NATL ACAD SCI USA, V86, P3277, DOI 10.1073/pnas.86.9.3277; BLACKMAN M, 1990, SCIENCE, V248, P1335, DOI 10.1126/science.1972592; BRADLEY A, 1987, TERATOCARCINOMAS EMB, P113; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOKE M P, 1989, New Biologist, V1, P66; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; FINKEL TH, 1991, IMMUNOL TODAY, V12, P79, DOI 10.1016/0167-5699(91)90162-M; GAZIT A, 1989, J MED CHEM, V32, P2344, DOI 10.1021/jm00130a020; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HAVRAN WL, 1987, NATURE, V330, P170, DOI 10.1038/330170a0; HSI ED, 1989, J BIOL CHEM, V264, P10836; HUANG MM, 1991, P NATL ACAD SCI USA, V88, P7844, DOI 10.1073/pnas.88.17.7844; JUNE CH, 1990, J IMMUNOL, V144, P1591; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; RABINOVITCH PS, 1986, J IMMUNOL, V137, P952; RAMSDELL F, 1991, J IMMUNOL, V147, P1779; RAMSDELL F, 1990, SCIENCE, V248, P1342, DOI 10.1126/science.1972593; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SECRIST JP, 1991, J BIOL CHEM, V266, P12135; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; STANLEY JB, 1990, J IMMUNOL, V145, P2189; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; SUGIE K, 1991, P NATL ACAD SCI USA, V88, P9132, DOI 10.1073/pnas.88.20.9132; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VANOERS NSC, 1992, IN PRESS MECHANISMS, V4; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WEGENER AMK, 1992, CELL, V68, P83, DOI 10.1016/0092-8674(92)90208-T; WEISS A, 1986, ANNU REV IMMUNOL, V4, P593, DOI 10.1146/annurev.iy.04.040186.003113; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484; WHITE J, 1989, CELL, V56, P27, DOI 10.1016/0092-8674(89)90980-X; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922	44	507	520	2	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 4	1992	70	5					751	763		10.1016/0092-8674(92)90309-Z	http://dx.doi.org/10.1016/0092-8674(92)90309-Z			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JL663	1516132				2022-12-01	WOS:A1992JL66300007
J	BUCCI, C; PARTON, RG; MATHER, IH; STUNNENBERG, H; SIMONS, K; HOFLACK, B; ZERIAL, M				BUCCI, C; PARTON, RG; MATHER, IH; STUNNENBERG, H; SIMONS, K; HOFLACK, B; ZERIAL, M			THE SMALL GTPASE RAB5 FUNCTIONS AS A REGULATORY FACTOR IN THE EARLY ENDOCYTIC PATHWAY	CELL			English	Article							CELL-FREE SYSTEM; RECEPTOR-MEDIATED ENDOCYTOSIS; RECOMBINANT VACCINIA VIRUS; BINDING YPT1 PROTEIN; COATED VESICLES; ENDOPLASMIC-RETICULUM; TRANSFERRIN RECEPTORS; VESICULAR TRANSPORT; GOLGI TRANSPORT; FUSION INVITRO	We have investigated the in vivo functional role of rab5, a small GTPase associated with the plasma membrane and early endosomes. Wild-type rab5 or rab5ile133, a mutant protein defective in GTP binding, was overexpressed in baby hamster kidney cells. In cells expressing the rab5ile133 protein, the rate of endocytosis was decreased by 50% compared with normal, while the rate of recycling was not significantly affected. The morphology of early endosomes was also drastically changed by the mutant protein, which induced accumulation of small tubules and vesicles at the periphery of the cell. Surprisingly, overexpression of wild-type rab5 accelerated the uptake of endocytic markers and led to the appearance of atypically large early endosomes. We conclude that rab5 is a rate-limiting component of the machinery regulating the kinetics of membrane traffic in the early endocytic pathway.	UNIV MARYLAND,DEPT ANIM SCI,COLL PK,MD 20742	University System of Maryland; University of Maryland College Park	BUCCI, C (corresponding author), EUROPEAN MOLEC BIOL LAB,MEYERHOFSTR 1,W-6900 HEIDELBERG,GERMANY.		Bucci, Cecilia/F-6699-2012; Stunnenberg, Hendrik G./D-6875-2012; Parton, Robert G/C-5673-2009; HOFLACK, Bernard/AAZ-6668-2020	Bucci, Cecilia/0000-0002-6232-6183; Stunnenberg, Hendrik G./0000-0002-0066-1576; Parton, Robert G/0000-0002-7494-5248; Simons, Kai/0000-0002-9231-9996				BADDELEY AJ, 1986, J MICROSC-OXFORD, V142, P259, DOI 10.1111/j.1365-2818.1986.tb04282.x; BAKER D, 1990, P NATL ACAD SCI USA, V87, P355, DOI 10.1073/pnas.87.1.355; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BECKERS CJM, 1989, NATURE, V339, P397, DOI 10.1038/339397a0; BOMSEL M, 1990, CELL, V62, P719, DOI 10.1016/0092-8674(90)90117-W; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1988, CELL, V53, P669, DOI 10.1016/0092-8674(88)90081-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAELL WA, 1987, P NATL ACAD SCI USA, V84, P1137, DOI 10.1073/pnas.84.5.1137; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; CHAVRIER P, 1991, NATURE, V353, P769, DOI 10.1038/353769a0; CIECHANOVER A, 1983, J BIOL CHEM, V258, P9681; COLOMBO MI, 1992, SCIENCE, V255, P1695, DOI 10.1126/science.1348148; CROWTHER RA, 1976, J MOL BIOL, V103, P785, DOI 10.1016/0022-2836(76)90209-6; DARCHEN F, 1990, P NATL ACAD SCI USA, V87, P5692, DOI 10.1073/pnas.87.15.5692; DAUTRYVARSAT A, 1983, P NATL ACAD SCI-BIOL, V80, P2258, DOI 10.1073/pnas.80.8.2258; DAVEY J, 1985, CELL, V43, P643, DOI 10.1016/0092-8674(85)90236-3; DAVISON AJ, 1989, J MOL BIOL, V210, P749, DOI 10.1016/0022-2836(89)90107-1; DIAZ R, 1989, NATURE, V339, P398, DOI 10.1038/339398a0; FALKNER FG, 1988, J VIROL, V62, P1849, DOI 10.1128/JVI.62.6.1849-1854.1988; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GLICK BS, 1987, NATURE, V326, P309, DOI 10.1038/326309a0; GODA Y, 1991, J CELL BIOL, V112, P823, DOI 10.1083/jcb.112.5.823; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; GOUD B, 1985, J CELL BIOL, V100, P521, DOI 10.1083/jcb.100.2.521; GOUD B, 1990, NATURE, V345, P553, DOI 10.1038/345553a0; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; GRIFFITHS G, 1989, J CELL BIOL, V109, P2703, DOI 10.1083/jcb.109.6.2703; GRUENBERG J, 1989, ANNU REV CELL BIOL, V5, P453; GRUENBERG JE, 1986, EMBO J, V5, P3091, DOI 10.1002/j.1460-2075.1986.tb04615.x; HANOVER JA, 1984, CELL, V39, P283, DOI 10.1016/0092-8674(84)90006-0; HOPKINS CR, 1990, NATURE, V346, P335, DOI 10.1038/346335a0; HOPKINS CR, 1983, CELL, V35, P321, DOI 10.1016/0092-8674(83)90235-0; Hubbard AL, 1989, CURR OPIN CELL BIOL, V1, P675, DOI 10.1016/0955-0674(89)90033-1; JANKNECHT R, 1991, P NATL ACAD SCI USA, V88, P8972, DOI 10.1073/pnas.88.20.8972; KLAUSNER RD, 1983, P NATL ACAD SCI-BIOL, V80, P2263, DOI 10.1073/pnas.80.8.2263; KOBAYASHI T, 1989, J BIOL CHEM, V264, P5966; KOBAYASHI T, 1992, FEBS LETT, V300, P227, DOI 10.1016/0014-5793(92)80851-7; LIN HC, 1991, J CELL BIOL, V114, P881, DOI 10.1083/jcb.114.5.881; MACKETT M, 1985, DNA CLONING PRACTICA, P191; MARSH M, 1987, J CELL BIOL, V104, P875, DOI 10.1083/jcb.104.4.875; MARSH M, 1980, J MOL BIOL, V142, P439, DOI 10.1016/0022-2836(80)90281-8; MAYORGA LS, 1989, SCIENCE, V244, P1475, DOI 10.1126/science.2499930; MILLER K, 1991, CELL, V65, P621, DOI 10.1016/0092-8674(91)90094-F; MIZOGUCHI A, 1990, J BIOL CHEM, V265, P11872; Murphy R F, 1991, Trends Cell Biol, V1, P77, DOI 10.1016/0962-8924(91)90022-2; NAKANO A, 1989, J CELL BIOL, V109, P2677, DOI 10.1083/jcb.109.6.2677; OKA T, 1991, J CELL BIOL, V114, P671, DOI 10.1083/jcb.114.4.671; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cellbio.6.1.151; PELHAM HRB, 1991, CELL, V67, P449, DOI 10.1016/0092-8674(91)90517-3; PODBILEWICZ B, 1990, EMBO J, V9, P3477, DOI 10.1002/j.1460-2075.1990.tb07556.x; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; ROBINSON MS, 1992, CELL, V69, P129, DOI 10.1016/0092-8674(92)90124-U; Rodman JS, 1990, CURR OPIN CELL BIOL, V2, P664, DOI 10.1016/0955-0674(90)90108-Q; RODRIGUEZ JF, 1985, J VIROL, V56, P482, DOI 10.1128/JVI.56.2.482-488.1985; SAHAGIAN GG, 1985, J BIOL CHEM, V260, P9838; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; SCHMID SL, 1991, J CELL BIOL, V114, P869, DOI 10.1083/jcb.114.5.869; SCHMITT HD, 1986, CELL, V47, P401, DOI 10.1016/0092-8674(86)90597-0; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; TOOZE J, 1991, J CELL BIOL, V115, P635, DOI 10.1083/jcb.115.3.635; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; VANDERSLUIJS P, 1992, CELL, V70, P729, DOI 10.1016/0092-8674(92)90307-X; VANDERSLUIJS P, 1991, P NATL ACAD SCI USA, V88, P6313, DOI 10.1073/pnas.88.14.6313; VONMOLLARD GF, 1990, P NATL ACAD SCI USA, V87, P1988, DOI 10.1073/pnas.87.5.1988; VOS JC, 1988, EMBO J, V7, P3487, DOI 10.1002/j.1460-2075.1988.tb03224.x; WALWORTH NC, 1989, EMBO J, V8, P1685, DOI 10.1002/j.1460-2075.1989.tb03560.x; WOODMAN PG, 1991, J CELL BIOL, V112, P1133, DOI 10.1083/jcb.112.6.1133; ZERIAL M, 1986, EMBO J, V5, P1543, DOI 10.1002/j.1460-2075.1986.tb04395.x	70	1152	1177	2	49	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 4	1992	70	5					715	728		10.1016/0092-8674(92)90306-W	http://dx.doi.org/10.1016/0092-8674(92)90306-W			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JL663	1516130	hybrid			2022-12-01	WOS:A1992JL66300004
J	BURNASHEV, N; SCHOEPFER, R; MONYER, H; RUPPERSBERG, JP; GUNTHER, W; SEEBURG, PH; SAKMANN, B				BURNASHEV, N; SCHOEPFER, R; MONYER, H; RUPPERSBERG, JP; GUNTHER, W; SEEBURG, PH; SAKMANN, B			CONTROL BY ASPARAGINE RESIDUES OF CALCIUM PERMEABILITY AND MAGNESIUM BLOCKADE IN THE NMDA RECEPTOR	SCIENCE			English	Article							MOUSE CENTRAL NEURONS; SPINAL-CORD NEURONS; GLUTAMATE-ACTIVATED CHANNELS; VOLTAGE-DEPENDENT BLOCK; LONG-TERM POTENTIATION; CENTRAL-NERVOUS-SYSTEM; D-ASPARTATE RESPONSES; AMINO-ACID RECEPTORS; MOLECULAR-CLONING; DIVALENT-CATIONS	The N-methyl-D-aspartate (NMDA) receptor forms a cation-selective channel with a high calcium permeability and sensitivity to channel block by extracellular magnesium. These properties, which are believed to be important for the induction of long-term changes in synaptic strength, are imparted by asparagine residues in a putative channel-forming segment of the protein, transmembrane 2 (TM2). In the NR1 subunit, replacement of this asparagine by a glutamine residue decreases calcium permeability of the channel and slightly reduces magnesium block. The same substitution in NR2 subunits strongly reduces magnesium block and increases the magnesium permeability but barely affects calcium permeability. These asparagines are in a position homologous to the site in the TM2 region (Q/R site) of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors that is occupied by either glutamine (Q) or arginine (R) and that controls divalent cation permeability of the AMPA receptor channel. Hence AMPA and NMDA receptor channels contain common structural motifs in their TM2 segments that are responsible for some of their ion selectivity and conductance properties.	MAX PLANCK INST MED RES, ZELLPHYSIOL ABT, JAHNSTR 29, W-6900 HEIDELBERG 1, GERMANY; UNIV HEIDELBERG, CTR MOLEC BIOL, W-6900 HEIDELBERG, GERMANY	Max Planck Society; Ruprecht Karls University Heidelberg			Burnashev, Nail/G-4056-2013	Monyer, Hannah/0000-0002-9332-5749				ASCHER P, 1988, J PHYSIOL-LONDON, V399, P247; BOULTER J, 1990, SCIENCE, V249, P1033, DOI 10.1126/science.2168579; BURNASHEV N, 1992, NEURON, V8, P189, DOI 10.1016/0896-6273(92)90120-3; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOI DW, 1988, J NEUROSCI, V8, P185; CHOL D, 1987, J NEUROSCI, V7, P369; CHOL DW, 1988, NEURON, V1, P623; COLLINGRIDGE GL, 1987, TRENDS NEUROSCI, V10, P288, DOI 10.1016/0166-2236(87)90175-5; COLLINGRIDGE GL, 1990, TRENDS PHARMACOL SCI, V11, P290, DOI 10.1016/0165-6147(90)90011-V; DINGLEDINE R, 1988, CRIT REV NEUROBIOL, V4, P1; GIBB AJ, IN PRESS J PHYSL LON; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HUME RI, 1991, SCIENCE, V253, P1028, DOI 10.1126/science.1653450; JAHR CE, 1987, NATURE, V325, P522, DOI 10.1038/325522a0; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; MACDERMOTT AB, 1986, NATURE, V321, P519, DOI 10.1038/321519a0; MAYER ML, 1985, J PHYSIOL-LONDON, V361, P65, DOI 10.1113/jphysiol.1985.sp015633; MAYER ML, 1987, PROG NEUROBIOL, V28, P197, DOI 10.1016/0301-0082(87)90011-6; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MEGURO H, 1992, NATURE, V357, P70, DOI 10.1038/357070a0; METHFESSEL C, 1986, PFLUG ARCH EUR J PHY, V407, P577, DOI 10.1007/BF00582635; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; NAKANISHI N, 1990, NEURON, V5, P569, DOI 10.1016/0896-6273(90)90212-X; NICOLL RA, 1988, NEURON, V1, P97, DOI 10.1016/0896-6273(88)90193-6; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; PRITCHETT DB, 1989, SCIENCE, V245, P1389, DOI 10.1126/science.2551039; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEEBURG PH, 1984, NATURE, V312, P71, DOI 10.1038/312071a0; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; SOMMER B, 1990, SCIENCE, V249, P1580, DOI 10.1126/science.1699275; UNWIN N, 1988, J CELL BIOL, V107, P1123, DOI 10.1083/jcb.107.3.1123; VERDOORN TA, 1991, SCIENCE, V252, P1715, DOI 10.1126/science.1710829; VILLARROEL A, IN PRESS P R SOC L B	36	346	351	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 4	1992	257	5075					1415	1419		10.1126/science.1382314	http://dx.doi.org/10.1126/science.1382314			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL612	1382314				2022-12-01	WOS:A1992JL61200039
J	DENT, P; HASER, W; HAYSTEAD, TAJ; VINCENT, LA; ROBERTS, TM; STURGILL, TW				DENT, P; HASER, W; HAYSTEAD, TAJ; VINCENT, LA; ROBERTS, TM; STURGILL, TW			ACTIVATION OF MITOGEN-ACTIVATED PROTEIN-KINASE KINASE BY V-RAF IN NIH 3T3 CELLS AND INVITRO	SCIENCE			English	Article							GROWTH; DEFINITION	Mitogen-activated protein (MAP) kinases are 42- and 44-kD serine-threonine protein kinases that are activated by tyrosine and threonine phosphorylation in cells stimulated with mitogens and growth factors. MAP kinase and the protein kinase that activates it (MAP kinase kinase) were constitutively activated in NIH 3T3 cells infected with viruses containing either of two oncogenic forms (p35EC12, p37(22W)) of the c-Raf-1 protein kinase. The v-Raf proteins purified from cells infected with ECl 2 or 22W viruses activated MAP kinase kinase from skeletal muscle in vitro. Furthermore, a bacterially expressed v-Raf fusion protein (glutathione S-transferase-p37(22W)) also activated MAP kinase kinase in vitro. These findings suggest that one function of c-Raf-1 in mitogenic signaling is to phosphorylate and activate MAP kinase kinase.	UNIV VIRGINIA,DEPT INTERNAL MED,CHARLOTTESVILLE,VA 22908; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115; UNIV VIRGINIA,DEPT PHARMACOL,CHARLOTTESVILLE,VA 22908	University of Virginia; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; University of Virginia					NCI NIH HHS [CA50661] Funding Source: Medline; NICHD NIH HHS [HD24926] Funding Source: Medline; NIDDK NIH HHS [DK41077] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD024926] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P01CA050661] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041077] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS PD, 1992, J BIOL CHEM, V267, P13135; AHN NG, 1990, J BIOL CHEM, V265, P11487; ALLEMAIN GL, 1992, J MOL CELL BIOL, V12, P2222; ANDERSON NG, 1991, BIOCHEM J, V277, P573, DOI 10.1042/bj2770573; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; DENT P, UNPUB; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; GALLEGO C, IN PRESS P NATL ACAD; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; HASER W, UNPUB; HEIDECKER G, 1992, ADV CANCER RES, V58, P53, DOI 10.1016/S0065-230X(08)60290-0; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KOSAKO H, 1992, EMBO J, V11, P2903, DOI 10.1002/j.1460-2075.1992.tb05359.x; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LEE RM, 1992, J BIOL CHEM, V267, P1088; NAKIELNY S, 1992, EMBO J, V11, P2123, DOI 10.1002/j.1460-2075.1992.tb05271.x; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; ROSSOMANDO A, 1992, P NATL ACAD SCI USA, V89, P5221, DOI 10.1073/pnas.89.12.5221; SEGER R, 1992, J BIOL CHEM, V267, P14373; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; WU J, 1992, BIOCHEM J, V285, P701, DOI 10.1042/bj2850701	27	666	683	1	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 4	1992	257	5075					1404	1407		10.1126/science.1326789	http://dx.doi.org/10.1126/science.1326789			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL612	1326789				2022-12-01	WOS:A1992JL61200035
J	FEANY, MB; LEE, S; EDWARDS, RH; BUCKLEY, KM				FEANY, MB; LEE, S; EDWARDS, RH; BUCKLEY, KM			THE SYNAPTIC VESICLE PROTEIN SV2 IS A NOVEL TYPE OF TRANSMEMBRANE TRANSPORTER	CELL			English	Article							SEROTONIN TRANSPORTER; RAT-BRAIN; CLONING; EXPRESSION; GLYCOPROTEIN	The primary function of synaptic vesicles is to store and release neurotransmitter. Synaptic vesicles are locally recycled following exocytosis and rapidly refilled with neurotransmitter from the cytoplasm by a process that depends on the electrochemical gradient generated by a proton pump. Little is known about the molecules that import neurotransmitter into synaptic vesicles. We report here that the sequence of the synaptic vesicle protein SV2 identifies this protein as a novel type of transmembrane transporter. The deduced amino acid sequence of SV2 contains two sets of six predicted transmembrane domains: the six most N-terminal transmembrane domains are highly homologous to a subfamily of transporters that includes the human glucose transporter, while the six most C-terminal domains are homologous to the plasma membrane transporters for neurotransmitters. We propose that SV2 mediates transport of neurotransmitters into synaptic vesicles.	HARVARD UNIV,SCH MED,DEPT NEUROBIOL,BOSTON,MA 02115	Harvard University; Harvard Medical School	FEANY, MB (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,DEPT NEUROL,LOS ANGELES,CA 90024, USA.			Feany, Mel/0000-0003-0315-7970; Buckley, Kathleen/0000-0003-0283-4917				AMES GF, 1992, FASEB J, V6, P2660, DOI 10.1096/fasebj.6.9.1377140; BAHR BA, 1992, BIOCHEMISTRY-US, V31, P5778, DOI 10.1021/bi00140a013; BLAKELY RD, 1991, NATURE, V354, P66, DOI 10.1038/354066a0; BUCKLEY K, 1985, J CELL BIOL, V100, P1284, DOI 10.1083/jcb.100.4.1284; BUCKLEY KM, 1987, J CELL BIOL, V105, P2447, DOI 10.1083/jcb.105.6.2447; CARLSON SS, 1983, J BIOL CHEM, V258, P1082; CARONI P, 1985, NATURE, V314, P441, DOI 10.1038/314441a0; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; Esko J D, 1986, Methods Enzymol, V129, P237; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; FREMEAU RT, 1992, NEURON, V8, P915, DOI 10.1016/0896-6273(92)90206-S; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; HIGGINS C, 1989, NATURE, V341, P103, DOI 10.1038/341103a0; HOFFMAN BJ, 1991, SCIENCE, V254, P579, DOI 10.1126/science.1948036; JAN LY, 1992, CELL, V69, P715, DOI 10.1016/0092-8674(92)90280-P; KILTY J, 1991, SCIENCE, V254, P579; LIU Y, 1992, IN PRESS P NATL ACAD; LIU YJ, 1992, CELL, V70, P539, DOI 10.1016/0092-8674(92)90425-C; PACHOLCZYK T, 1991, NATURE, V350, P350, DOI 10.1038/350350a0; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SHIMADA S, 1991, SCIENCE, V254, P576, DOI 10.1126/science.1948034; SMITH KE, 1992, NEURON, V8, P927, DOI 10.1016/0896-6273(92)90207-T; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0; WILLIAMS SA, 1988, J BIOL CHEM, V263, P19513	25	221	228	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 4	1992	70	5					861	867		10.1016/0092-8674(92)90319-8	http://dx.doi.org/10.1016/0092-8674(92)90319-8			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JL663	1355409				2022-12-01	WOS:A1992JL66300017
J	FERRIS, JP; ERTEM, G				FERRIS, JP; ERTEM, G			OLIGOMERIZATION OF RIBONUCLEOTIDES ON MONTMORILLONITE - REACTION OF THE 5'-PHOSPHORIMIDAZOLIDE OF ADENOSINE	SCIENCE			English	Article							BOND FORMATION; RNA; TETRAHYMENA; NUCLEOTIDES; CATALYSIS; ENZYME	The regiospecific formation of oligomers from unblocked monomers in aqueous solution is one of the central tenets in research on the.origins of life on earth. Direct experimental support for this hypothesis has been obtained in studies of the condensation of the 5'-phosphorimidazolide of adenosine (ImpA) with itself and with P1,P2-diadenosine-5',5'-pyrophosphate (AppA) in water in the presence of a montmorillonite clay. Oligomers of up to ten nucleotides in length are formed. Analysis of the trimers, tetramers, and pentamers formed from a 9:1 ImpA:AppA mixture has shown that 85% of the bonds formed are 3',5'-linked and that any 2',5'-linkages present are at the phosphodiester bond next to the 3'-terminus of the oligomers.			FERRIS, JP (corresponding author), RENSSELAER POLYTECH INST,DEPT CHEM,TROY,NY 12180, USA.							ASHIRBEKOVA DT, 1989, BIOORG KHIM+, V15, P166; BEEN MD, 1988, SCIENCE, V239, P1412, DOI 10.1126/science.2450400; BERNAL JD, 1949, P PHYS SOC LOND A, V62, P537, DOI 10.1088/0370-1298/62/9/301; CHEN CB, 1985, J MOL BIOL, V181, P271, DOI 10.1016/0022-2836(85)90091-9; ERTEM G, 1990, ORIGINS LIFE EVOL BI, V20, P279; FAKHRAI H, 1981, J MOL EVOL, V17, P295, DOI 10.1007/BF01795751; FERRIS JP, 1989, ORIGINS LIFE EVOL B, V19, P609, DOI 10.1007/BF01808121; FERRIS JP, 1989, ORIGINS LIFE EVOL B, V19, P165, DOI 10.1007/BF01808150; GRZESKOWIAK K, 1986, J MOL EVOL, V23, P287, DOI 10.1007/BF02100635; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; JOYCE GF, 1987, P NATL ACAD SCI USA, V84, P4398, DOI 10.1073/pnas.84.13.4398; KORNBERG A, 1991, DNA REPLICATION, P310; LOHRMANN R, 1979, J MOL EVOL, V14, P243, DOI 10.1007/BF01732491; LOHRMANN R, 1978, J MOL EVOL, V11, P17, DOI 10.1007/BF01768021; LUEBKE KJ, 1991, J AM CHEM SOC, V113, P7447, DOI 10.1021/ja00019a066; ORGEL LE, 1986, J THEOR BIOL, V123, P127, DOI 10.1016/S0022-5193(86)80149-7; PONNAMPERUMA C, 1982, ORIGINS LIFE, V12, P98; Reid T.W., 1971, ENZYMES, V4, P373; RODRIGUEZ L, 1991, J MOL EVOL, V32, P101, DOI 10.1007/BF02515382; SAWAI H, 1975, J AM CHEM SOC, V97, P3532, DOI 10.1021/ja00845a050; SAWAI H, 1989, B CHEM SOC JPN, V62, P2018, DOI 10.1246/bcsj.62.2018; SLEEPER HL, 1979, J MOL EVOL, V12, P357, DOI 10.1007/BF01732030; SOFFHILL R, 1970, J ORG CHEM, V35, P2881; STRIBLING R, 1991, J CHROMATOGR, V338, P474; SULSTON J, 1968, P NATL ACAD SCI USA, V59, P726, DOI 10.1073/pnas.59.3.726; YOUNG B, 1989, J MOL EVOL, V29, P480, DOI 10.1007/BF02602919; ZAUG AJ, 1986, SCIENCE, V231, P470, DOI 10.1126/science.3941911	27	210	212	0	42	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 4	1992	257	5075					1387	1389		10.1126/science.1529338	http://dx.doi.org/10.1126/science.1529338			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL612	1529338				2022-12-01	WOS:A1992JL61200029
J	LIN, AN; FROST, J; DENG, TL; SMEAL, T; ALALAWI, N; KIKKAWA, U; HUNTER, T; BRENNER, D; KARIN, M				LIN, AN; FROST, J; DENG, TL; SMEAL, T; ALALAWI, N; KIKKAWA, U; HUNTER, T; BRENNER, D; KARIN, M			CASEIN KINASE-II IS A NEGATIVE REGULATOR OF C-JUN DNA-BINDING AND AP-1 ACTIVITY	CELL			English	Article							EPIDERMAL GROWTH-FACTOR; TRANS-ACTING FACTOR; TRANSCRIPTIONAL ACTIVATION; STIMULATE TRANSCRIPTION; PROTO-ONCOGENE; PHOSPHORYLATION; GENE; ELEMENT; SERUM; FIBROBLASTS	c-Jun, a major component of the inducible transcription factor AP-1, is a phosphoprotein. In nonstimulated fibroblasts and epithelial cells, c-Jun is phosphorylated on a cluster of two to three sites abutting its DNA-binding domain. Phosphorylation of these sites inhibits DNA binding, and their dephosphorylation correlates with increased AP-1 activity. We show that two of these sites, Thr-231 and Ser-249, are phosphorylated by casein kinase II (CKII). Substitution of the third site, Ser-243, by Phe interferes with phosphorylation of the inhibitory sites in vivo and by purified CKII in vitro. Microinjection into living cells of synthetic peptides that are specific competitive substrates or inhibitors of CKII results in induction of AP-1 activity and c-Jun expression. Microinjection of CKII supresses induction of AP-1 by either phorbol ester or an inhibitory peptide. These results suggest that one of the roles of CKII, a major nuclear protein kinase with no known functions, is to attenuate AP-1 activity through phosphorylation of c-Jun.	UNIV CALIF SAN DIEGO, SCH MED, CTR MOLEC GENET, DEPT MED, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, SCH MED, CTR MOLEC GENET, DEPT BIOL, LA JOLLA, CA 92093 USA; SALK INST BIOL RES, LA JOLLA, CA 92037 USA; UNIV CALIF SAN DIEGO, SCH MED, CTR MOLEC GENET, CTR CANC, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Salk Institute; University of California System; University of California San Diego	LIN, AN (corresponding author), UNIV CALIF SAN DIEGO, SCH MED, CTR MOLEC GENET, DEPT PHARMACOL, LA JOLLA, CA 92093 USA.			Brenner, David/0000-0003-2573-525X; Frost, Jeffrey/0000-0001-9722-1536	NCI NIH HHS [CA39811, CA50528] Funding Source: Medline; NIEHS NIH HHS [ES04151] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA050528, R01CA039811] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES004151, R37ES004151] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ACKERMAN P, 1990, P NATL ACAD SCI USA, V87, P821, DOI 10.1073/pnas.87.2.821; ACKERMAN P, 1989, J BIOL CHEM, V264, P11958; ALANI R, 1991, MOL CELL BIOL, V11, P6286, DOI 10.1128/MCB.11.12.6286; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; ANGEL P, 1989, New Biologist, V1, P35; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BARBOSA MS, 1990, EMBO J, V9, P153, DOI 10.1002/j.1460-2075.1990.tb08091.x; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BODNER M, 1987, CELL, V50, P267, DOI 10.1016/0092-8674(87)90222-4; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CARROLL D, 1988, COLD SPRING HARB SYM, V53, P91, DOI 10.1101/SQB.1988.053.01.014; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CICIRELLI MF, 1988, J BIOL CHEM, V263, P2009; DENG T, 1992, IN PRESS P NATL ACAD, V89; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; FERAMISCO JR, 1986, MICROINJECTION ORGAN, P40; FIOL CJ, 1988, ARCH BIOCHEM BIOPHYS, V267, P797, DOI 10.1016/0003-9861(88)90089-6; FIRZLAFF J M, 1989, New Biologist, V1, P44; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; GAUTHIERROUVIERE C, 1991, EMBO J, V10, P2921, DOI 10.1002/j.1460-2075.1991.tb07842.x; GLINEUR C, 1989, ONCOGENE, V4, P1247; HATHAWAY GM, 1981, J BIOL CHEM, V256, P1442; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; HERRLICH P, 1989, TRENDS GENET, V5, P112, DOI 10.1016/0168-9525(89)90041-3; HUNTER T, 1984, NATURE, V311, P480, DOI 10.1038/311480a0; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; IMLER JL, 1988, NATURE, V332, P275, DOI 10.1038/332275a0; KARIN M, 1991, MOL ASPECTS CELLULAR, V6, P143; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KLARLUND JK, 1988, J BIOL CHEM, V263, P15872; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; KREK W, 1992, J CELL BIOL, V116, P43, DOI 10.1083/jcb.116.1.43; KUENZEL EA, 1985, P NATL ACAD SCI USA, V82, P737, DOI 10.1073/pnas.82.3.737; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CQ, 1990, EMBO J, V9, P4455, DOI 10.1002/j.1460-2075.1990.tb07896.x; LITCHFIELD DW, 1990, FEBS LETT, V261, P117, DOI 10.1016/0014-5793(90)80650-8; LITCHFIELD DW, 1990, J BIOL CHEM, V265, P7638; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MAHADEVAN LC, 1990, ONCOGENE, V5, P327; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MANAK JR, 1990, GENE DEV, V4, P955, DOI 10.1101/gad.4.6.955; MARAIS RM, 1992, EMBO J, V11, P97, DOI 10.1002/j.1460-2075.1992.tb05032.x; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MEINKOTH J, 1990, CIBA F SYMP, V150, P47; MEINKOTH JL, 1991, MOL CELL BIOL, V11, P1759, DOI 10.1128/MCB.11.3.1759; Meisner H, 1991, CURR OPIN CELL BIOL, V3, P474, DOI 10.1016/0955-0674(91)90076-B; PADMANABHA R, 1990, MOL CELL BIOL, V10, P4089, DOI 10.1128/MCB.10.8.4089; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; SOMMERCORN J, 1987, P NATL ACAD SCI USA, V84, P8834, DOI 10.1073/pnas.84.24.8834; Tooze J, 1980, DNA TUMOR VIRUSES; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; YANG-YEN H-F, 1990, New Biologist, V2, P351	65	368	374	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 4	1992	70	5					777	789		10.1016/0092-8674(92)90311-Y	http://dx.doi.org/10.1016/0092-8674(92)90311-Y			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JL663	1516134				2022-12-01	WOS:A1992JL66300009
J	MATSUI, Y; ZSEBO, K; HOGAN, BLM				MATSUI, Y; ZSEBO, K; HOGAN, BLM			DERIVATION OF PLURIPOTENTIAL EMBRYONIC STEM-CELLS FROM MURINE PRIMORDIAL GERM-CELLS IN CULTURE	CELL			English	Article							GROWTH-FACTOR; DIFFERENTIATION; PROLIFERATION	Steel factor (SF) and LIF (leukemia inhibitory factor) synergistically promote the proliferation and survival of mouse primordial germ cells (PGCs), but only for a limited time period in culture. We show here that addition of bFGF to cultures in the presence of membrane-associated SF and LIF enhances the growth of PGCs and allows their continued proliferation beyond the time when they normally stop dividing in vivo. They form colonies of densely packed, alkaline phosphatase-positive, SSEA-1-positive cells resembling undifferentiated embryonic stem (ES) cells in morphology. These cultures can be maintained on feeder layers for at least 20 passages, and under appropriate conditions give rise to embryoid bodies and to multiple differentiated cell phenotypes in monolayer culture and in tumors in nude mice. PGC-derived ES cells can also contribute to chimeras when injected into host blasto-cysts. The long-term culture of PGCs and their reprogramming to pluripotential ES cells has important implications for germ cell biology and the induction of teratocarcinomas.	VANDERBILT UNIV,MED CTR,SCH MED,DEPT CELL BIOL,NASHVILLE,TN 37232; AMGEN INC,AMGEN CTR,THOUSAND OAKS,CA 91320	Vanderbilt University; Amgen				Matsui, Yasuhisa/0000-0001-7026-6355				BOGLER O, 1990, P NATL ACAD SCI USA, V87, P6368, DOI 10.1073/pnas.87.16.6368; DOLCI S, 1991, NATURE, V352, P809, DOI 10.1038/352809a0; DONOVAN PJ, 1986, CELL, V44, P831, DOI 10.1016/0092-8674(86)90005-X; FFRENCHCONSTANT C, 1991, DEVELOPMENT, V113, P1365; GINSBURG M, 1990, DEVELOPMENT, V110, P521; GODIN I, 1991, DEVELOPMENT, V113, P1451; GODIN I, 1991, NATURE, V352, P807, DOI 10.1038/352807a0; LAWSON KA, 1992, CIBA F S, V165; MANN JR, 1990, CELL, V62, P251, DOI 10.1016/0092-8674(90)90363-J; MANOVA K, 1991, DEV BIOL, V146, P312, DOI 10.1016/0012-1606(91)90233-S; MATSUI Y, 1991, NATURE, V353, P750, DOI 10.1038/353750a0; MINTZ B, 1957, J EXP ZOOL, V134, P207, DOI 10.1002/jez.1401340202; NOBLE M, 1988, NATURE, V333, P560, DOI 10.1038/333560a0; NOGUCHI T, 1982, J NATL CANCER I, V69, P907; RAFF MC, 1988, NATURE, V333, P562, DOI 10.1038/333562a0; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; SOLTER D, 1978, P NATL ACAD SCI USA, V75, P5565, DOI 10.1073/pnas.75.11.5565; SOLTER D, 1975, TERATOMAS DIFFERENTI; SORIANO P, 1986, CELL, V46, P19, DOI 10.1016/0092-8674(86)90856-1; STEVENS LC, 1961, J NATL CANCER I, V27, P443; Stevens LC, 1983, COLD SPRING HARB C C, P23; SURANI MA, 1990, DEVELOPMENT S, V110, P89; TAM PPL, 1981, J EMBRYOL EXP MORPH, V64, P133; TOKSOZ D, 1992, IN PRESS P NATL ACAD, V89	24	962	1159	0	44	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 4	1992	70	5					841	847		10.1016/0092-8674(92)90317-6	http://dx.doi.org/10.1016/0092-8674(92)90317-6			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JL663	1381289				2022-12-01	WOS:A1992JL66300015
J	MORL, M; NIEMER, I; SCHMEIZER, C				MORL, M; NIEMER, I; SCHMEIZER, C			NEW REACTIONS CATALYZED BY A GROUP-II INTRON RIBOZYME WITH RNA AND DNA SUBSTRATES	CELL			English	Article							SELF-SPLICING RNA; TETRAHYMENA; INVITRO; ENDONUCLEASE; SELECTION; MATURASE; MOBILITY; ENZYME	Here we describe three novel reactions of the self-splicing group II intron bl1 (the first intron of the COB gene of yeast mitochondria) demonstrating its catalytic versatility: reversal of the first step of the self-splicing reaction catalyzed by a linear form of the intron utilizing the energy of a phosphoanhydride bond for transesterification, ligation of a single-stranded DNA to an RNA, and cleavage of a single-stranded DNA substrate. These results have the following evolutionary implications: use of the alpha-beta-bond of a terminal triphosphate for transesterification suggests that an RNA RNA replicase could use mononucleotide triphosphates as precursors, and cleavage of single-stranded DNA and DNA-RNA ligation suggests that excised group II introns might integrate directly into DNA without prior reverse transcription.			MORL, M (corresponding author), UNIV MUNICH,INST GENET & MIKROBIOL,MARIA WARD STR 1A,W-8000 MUNICH 19,GERMANY.			Morl, Mario/0000-0003-0972-9386				AUGUSTIN S, 1990, NATURE, V343, P383, DOI 10.1038/343383a0; BEEN MD, 1986, CELL, V47, P207, DOI 10.1016/0092-8674(86)90443-5; CECH TR, 1987, SCIENCE, V236, P1532, DOI 10.1126/science.2438771; COLLEAUX L, 1986, CELL, V44, P521, DOI 10.1016/0092-8674(86)90262-X; DELAHODDE A, 1989, CELL, V56, P431, DOI 10.1016/0092-8674(89)90246-8; HERSCHLAG D, 1990, NATURE, V344, P405, DOI 10.1038/344405a0; JACQUIER A, 1987, CELL, V50, P17, DOI 10.1016/0092-8674(87)90658-1; JACQUIER A, 1990, TRENDS BIOCHEM SCI, V15, P351, DOI 10.1016/0968-0004(90)90075-M; LAMBOWITZ AM, 1989, CELL, V56, P323, DOI 10.1016/0092-8674(89)90232-8; MORL M, 1990, NUCLEIC ACIDS RES, V18, P6545, DOI 10.1093/nar/18.22.6545; MORL M, 1990, CELL, V60, P629, DOI 10.1016/0092-8674(90)90666-3; MUSCARELLA DE, 1989, CELL, V56, P443, DOI 10.1016/0092-8674(89)90247-X; PYLE AM, 1991, NATURE, V350, P628, DOI 10.1038/350628a0; QUIRK SM, 1989, CELL, V56, P455, DOI 10.1016/0092-8674(89)90248-1; ROBERTSON DL, 1990, NATURE, V344, P467, DOI 10.1038/344467a0; WARING RB, 1986, NATURE, V321, P133, DOI 10.1038/321133a0; WENZLAU JM, 1989, CELL, V56, P421, DOI 10.1016/0092-8674(89)90245-6; WOODSON SA, 1989, CELL, V57, P335, DOI 10.1016/0092-8674(89)90971-9	18	53	56	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 4	1992	70	5					803	810		10.1016/0092-8674(92)90313-2	http://dx.doi.org/10.1016/0092-8674(92)90313-2			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JL663	1381286				2022-12-01	WOS:A1992JL66300011
J	PEARSON, M; BJORNSON, R; PEARSON, G; ROHRMANN, G				PEARSON, M; BJORNSON, R; PEARSON, G; ROHRMANN, G			THE AUTOGRAPHA-CALIFORNICA BACULOVIRUS GENOME - EVIDENCE FOR MULTIPLE REPLICATION ORIGINS	SCIENCE			English	Article							NUCLEAR POLYHEDROSIS-VIRUS; HOMOLOGOUS DNA; SEQUENCE; REGIONS; GENE	The Autographa californica multinucleocapsid nuclear polyhedrosis virus (AcMNPV), which is used for the overexpression of eukaryotic genes and is being engineered for possible use as a viral insecticide, has a circular, supercoiled genome of approximately 128 kilobases. Despite its widespread use, little is known about the mechanism by which AcMNPV replicates. Evidence is presented in this report that AcMNPV origins of DNA replication are repeated sequences each containing several closely related imperfect palindromes that are present in six regions distributed around the genome. Although AcMNPV infection-dependent plasmid replication was initiated by a single complete palindrome, the amount of replication was substantially increased in plasmids containing six or eight palindromes.	OREGON STATE UNIV,DEPT AGR CHEM,CORVALLIS,OR 97331; OREGON STATE UNIV,DEPT BIOCHEM & BIOPHYS,CORVALLIS,OR 97331	Oregon State University; Oregon State University					NIAID NIH HHS [AI21973] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021973] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		COCHRAN MA, 1983, J VIROL, V45, P961, DOI 10.1128/JVI.45.3.961-970.1983; FRIESEN PD, 1987, J VIROL, V61, P2264, DOI 10.1128/JVI.61.7.2264-2272.1987; GEIER GE, 1979, J BIOL CHEM, V254, P1408; GLOCKER B, 1992, J VIROL, V66, P3476, DOI 10.1128/JVI.66.6.3476-3484.1992; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUARINO LA, 1986, J VIROL, V60, P224, DOI 10.1128/JVI.60.1.224-229.1986; GUARINO LA, 1986, J VIROL, V60, P215, DOI 10.1128/JVI.60.1.215-223.1986; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; Kornberg A., 1992, DNA REPLICATION; LIU AF, 1986, J GEN VIROL, V67, P2565, DOI 10.1099/0022-1317-67-11-2565; PEDEN KWC, 1980, SCIENCE, V209, P1392, DOI 10.1126/science.6251547; Sambrook J., 1989, MOL CLONING LAB MANU; Summers M.D., 1987, B TEXAS AGR EXPT STA, V1555; [No title captured]	14	156	165	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 4	1992	257	5075					1382	1384		10.1126/science.1529337	http://dx.doi.org/10.1126/science.1529337			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL612	1529337				2022-12-01	WOS:A1992JL61200027
J	SMITH, JL; WILSON, JE; MACDONALD, PM				SMITH, JL; WILSON, JE; MACDONALD, PM			OVEREXPRESSION OF OSKAR DIRECTS ECTOPIC ACTIVATION OF NANOS AND PRESUMPTIVE POLE CELL-FORMATION IN DROSOPHILA EMBRYOS	CELL			English	Article							POSTERIOR DETERMINANT NANOS; MATERNAL-EFFECT MUTATIONS; DOUBLE-ABDOMEN EMBRYOS; GAP GENE GIANT; GERM PLASM; MESSENGER-RNA; ANTEROPOSTERIOR POLARITY; CAENORHABDITIS-ELEGANS; SEQUENCE SIMILARITY; BODY PATTERN	In Drosophila, a small group of maternal effect genes, including oskar, defines a shared pathway leading to the provision of two determinants at the posterior pole of the embryo. One determinant is the posterior body patterning morphogen nanos, and the other directs germ cell formation. Overexpression of oskar causes the shared pathway to be hyperactivated, with excess nanos activity present throughout the embryo and a superabundance of posterior pole cells. In addition, presumptive pole cells appear at a novel anterior position. Strikingly, formation of these ectopic pole cells is enhanced in nanos mutants. This observation may reflect competition between nanos and the germ cell determinant for a shared and limiting precursor.			SMITH, JL (corresponding author), STANFORD UNIV, DEPT BIOL SCI, STANFORD, CA 94305 USA.				NIGMS NIH HHS [GM42612] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042612] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; BOSWELL RE, 1985, CELL, V43, P97, DOI 10.1016/0092-8674(85)90015-7; BOSWELL RE, 1991, DEVELOPMENT, V113, P373; Davidson E. H., 1986, GENE ACTIVITY EARLY; EDDY EM, 1975, INT REV CYTOL, V43, P229; ELDON ED, 1991, DEVELOPMENT, V111, P367; EPHRUSSI A, 1991, CELL, V66, P37, DOI 10.1016/0092-8674(91)90137-N; FRIGERIO G, 1986, CELL, V47, P735, DOI 10.1016/0092-8674(86)90516-7; FROHNHOFER HG, 1987, GENE DEV, V1, P880, DOI 10.1101/gad.1.8.880; GOLUMBESKI GS, 1991, GENE DEV, V5, P2060, DOI 10.1101/gad.5.11.2060; HAY B, 1990, DEVELOPMENT, V109, P425; HAY B, 1988, CELL, V55, P577, DOI 10.1016/0092-8674(88)90216-4; HORVITZ HR, 1991, NATURE, V351, P535, DOI 10.1038/351535a0; HULSKAMP M, 1990, NATURE, V346, P577, DOI 10.1038/346577a0; ILLMENSEE K, 1974, P NATL ACAD SCI USA, V71, P1016, DOI 10.1073/pnas.71.4.1016; ILLMENSEE K, 1976, EXP CELL RES, V97, P127, DOI 10.1016/0014-4827(76)90662-5; KERR JB, 1974, J EMBRYOL EXP MORPH, V32, P573; KIMHA J, 1991, CELL, V66, P23, DOI 10.1016/0092-8674(91)90136-M; KRAUT R, 1991, DEVELOPMENT, V111, P601; KRAUT R, 1991, DEVELOPMENT, V111, P611; LASKO PF, 1990, GENE DEV, V4, P905, DOI 10.1101/gad.4.6.905; LASKO PF, 1988, NATURE, V335, P611, DOI 10.1038/335611a0; LEHMANN R, 1991, DEVELOPMENT, V112, P679; LEHMANN R, 1986, CELL, V47, P141, DOI 10.1016/0092-8674(86)90375-2; LEHMANN R, 1987, NATURE, V329, P167, DOI 10.1038/329167a0; Lindsley D.L., 1992, GENOME DROSOPHILA ME; MACDONALD PM, 1986, NATURE, V324, P537, DOI 10.1038/324537a0; MACDONALD PM, 1991, GENE DEV, V5, P2455, DOI 10.1101/gad.5.12b.2455; MACDONALD PM, 1990, DEVELOPMENT, V110, P161; MACDONALD PM, 1992, DEVELOPMENT, V114, P221; MAHOWALD AP, 1962, J EXP ZOOL, V151, P201, DOI 10.1002/jez.1401510302; MAHOWALD AP, 1977, AM ZOOL, V17, P551; MANSEAU LJ, 1989, GENE DEV, V3, P1437, DOI 10.1101/gad.3.9.1437; MOHLER J, 1986, GENETICS, V112, P803; NIKI Y, 1986, DEV BIOL, V113, P255, DOI 10.1016/0012-1606(86)90127-2; NUSSLEINVOLHARD C, 1987, SCIENCE, V238, P1675, DOI 10.1126/science.3686007; NUSSLEINVOLHARD C, 1991, DEVELOPMENT, P1; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SCHUPBACH T, 1986, ROUX ARCH DEV BIOL, V195, P302, DOI 10.1007/BF00376063; STJOHNSTON D, 1992, CELL, V68, P201; STJOHNSTON D, 1991, CELL, V66, P51, DOI 10.1016/0092-8674(91)90138-O; STROME S, 1982, P NATL ACAD SCI-BIOL, V79, P1558, DOI 10.1073/pnas.79.5.1558; STRUHL G, 1992, CELL, V69, P237, DOI 10.1016/0092-8674(92)90405-2; STRUHL G, 1989, CELL, V57, P1259, DOI 10.1016/0092-8674(89)90062-7; SUTER B, 1989, GENE DEV, V3, P1957, DOI 10.1101/gad.3.12a.1957; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; WANG C, 1991, CELL, V66, P637, DOI 10.1016/0092-8674(91)90110-K; WHARTON RP, 1989, CELL, V59, P881, DOI 10.1016/0092-8674(89)90611-9; WHARTON RP, 1991, CELL, V67, P955, DOI 10.1016/0092-8674(91)90368-9; Wieschaus E., 1986, P199	50	174	175	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 4	1992	70	5					849	859		10.1016/0092-8674(92)90318-7	http://dx.doi.org/10.1016/0092-8674(92)90318-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JL663	1516136				2022-12-01	WOS:A1992JL66300016
J	SMITH, WC; HARLAND, RM				SMITH, WC; HARLAND, RM			EXPRESSION CLONING OF NOGGIN, A NEW DORSALIZING FACTOR LOCALIZED TO THE SPEMANN ORGANIZER IN XENOPUS EMBRYOS	CELL			English	Article							MESSENGER-RNA; LAEVIS; AXIS; MESODERM; PATTERN; EMBRYOGENESIS; INDUCTION; ACTIVIN; XWNT-8; GENE	We have cloned a cDNA encoding a novel polypeptide capable of inducing dorsal development in Xenopus embryos. RNA transcripts from this clone rescue normal development when injected into ventralized embryos and result in excessive head development at high doses. Therefore, we have named the cDNA nog. gin. noggin cDNA contains a single reading frame encoding a 26 kd protein with a hydrophobic amino-terminal sequence, suggesting that it is secreted. In Northern blot analysis this cDNA hybridizes to two mRNAs that are expressed both maternally and zygotically. Although noggin transcript is not localized in the oocyte and cleavage stage embryo, zygotic transcripts are initially restricted to the presumptive dorsal mesoderm and reach their highest levels at the gastrula stage in the dorsal lip of the blastopore (Spemann organizer). In the neurula, noggin is transcribed in the notochord and prechordal mesoderm. The activity of exogenous noggin RNA in embryonic axis induction and the localized expression of endogenous noggin transcripts suggest that noggin plays a role in normal dorsal development.			SMITH, WC (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,DIV BIOCHEM & MOLEC BIOL,BERKELEY,CA 94720, USA.							ALTABA ARI, 1992, IN PRESS DEVELOPMENT; BLUMBERG B, 1991, NATURE, V253, P194; BOLCE ME, 1992, DEVELOPMENT, V115, P681; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; CHRISTIAN JL, 1992, EMBO J, V11, P33, DOI 10.1002/j.1460-2075.1992.tb05024.x; CHRISTIAN JL, 1991, DEVELOPMENT, V111, P1045; CONDIE BG, 1987, DEVELOPMENT, V101, P93; DIRKSEN ML, 1992, GENE DEV, V6, P599, DOI 10.1101/gad.6.4.599; FRANK D, 1992, DEVELOPMENT, V115, P439; FRANK D, 1991, DEVELOPMENT, V113, P1387; GERHART J, 1989, DEVELOPMENT, V107, P37; GIMLICH RL, 1986, DEV BIOL, V115, P340, DOI 10.1016/0012-1606(86)90254-X; GIMLICH RL, 1984, DEV BIOL, V104, P117, DOI 10.1016/0012-1606(84)90042-3; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; HEMMATIBRIVANLOU A, 1991, DEVELOPMENT, V111, P715; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; HOPWOOD ND, 1989, CELL, V59, P893, DOI 10.1016/0092-8674(89)90612-0; KAGEURA H, 1990, DEV BIOL, V142, P432, DOI 10.1016/0012-1606(90)90365-P; KAO KR, 1988, DEV BIOL, V127, P64, DOI 10.1016/0012-1606(88)90189-3; KIMELMAN D, 1992, DEVELOPMENT, V114, P261; KIMELMAN D, 1992, IN PRESS DEVELOPMENT; KLOC M, 1989, DEVELOPMENT, V107, P899; KRIEG PA, 1989, DEV BIOL, V133, P93, DOI 10.1016/0012-1606(89)90300-X; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MCMAHON AP, 1989, CELL, V58, P1075, DOI 10.1016/0092-8674(89)90506-0; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; Nieuwkoop P.D., 1994, NORMAL TABLES XENOPU; PENG HB, 1991, METHOD CELL BIOL, V36, P661; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHARF SR, 1980, DEV BIOL, V79, P181, DOI 10.1016/0012-1606(80)90082-2; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; SOKOL S, 1991, NATURE, V351, P409, DOI 10.1038/351409a0; SOKOL S, 1991, CELL, V67, P741, DOI 10.1016/0092-8674(91)90069-B; TAIRA M, 1992, GENE DEV, V6, P356, DOI 10.1101/gad.6.3.356; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; YAMADA T, 1991, CELL, V64, P635, DOI 10.1016/0092-8674(91)90247-V	37	987	1025	0	52	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 4	1992	70	5					829	840		10.1016/0092-8674(92)90316-5	http://dx.doi.org/10.1016/0092-8674(92)90316-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JL663	1339313				2022-12-01	WOS:A1992JL66300014
J	VANDERSLUIJS, P; HULL, M; WEBSTER, P; MALE, P; GOUD, B; MELLMAN, I				VANDERSLUIJS, P; HULL, M; WEBSTER, P; MALE, P; GOUD, B; MELLMAN, I			THE SMALL GTP-BINDING PROTEIN RAB4 CONTROLS AN EARLY SORTING EVENT ON THE ENDOCYTIC PATHWAY	CELL			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; SEMLIKI FOREST VIRUS; TRANSFERRIN RECEPTOR; MDCK CELLS; K562 CELLS; VESICULAR TRANSPORT; PLASMA-MEMBRANE; EARLY ENDOSOMES; DOMAIN; SECRETION	rab4 is a ras-like GTP-binding protein that associates with early endosomes in a cell cycle-dependent fashion. To determine its role during endocytosis, we generated stable cell lines that overexpressed mutant or wild-type rab4. By measuring endocytosis, transport to lysosomes, and recycling, we found that overexpression of wild-type rab4 had differential effects on the endocytic pathway. Although initial rates of internalization and degradation were not inhibited, the transfectants exhibited a 3-fold decrease in fluid phase endocytosis as well as an alteration in transferrin receptor (Tfn-R) recycling. Wild-type rab4 caused a re-distribution of Tfn-R's from endosomes to the plasma membrane. It also blocked iron discharge by preventing the delivery of Tfn to acidic early endosomes, instead causing Tfn accumulation in a population of nonacidic vesicles and tubules. rab4 thus appears to control the function or formation of endosomes involved in recycling.	INST PASTEUR,F-75724 PARIS,FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	VANDERSLUIJS, P (corresponding author), YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06510, USA.		Goud, Bruno/GWC-4807-2022; Mellman, Ira/ABG-5896-2020	Webster, Paul/0000-0002-1980-6931				BACON RA, 1989, J CELL BIOL, V109, P1015, DOI 10.1083/jcb.109.3.1015; BALCH WE, 1990, TRENDS BIOCHEM SCI, V15, P473, DOI 10.1016/0968-0004(90)90301-Q; BESTERMAN JM, 1981, J CELL BIOL, V91, P716, DOI 10.1083/jcb.91.3.716; BOURNE HR, 1988, CELL, V53, P669, DOI 10.1016/0092-8674(88)90081-5; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; CHAVRIER P, 1990, MOL CELL BIOL, V10, P6578, DOI 10.1128/MCB.10.12.6578; CIECHANOVER A, 1983, J BIOL CHEM, V258, P9681; DAUTRYVARSAT A, 1983, P NATL ACAD SCI-BIOL, V80, P2258, DOI 10.1073/pnas.80.8.2258; DEVER TE, 1987, P NATL ACAD SCI USA, V84, P1814, DOI 10.1073/pnas.84.7.1814; ENFERT C, 1991, J CELL BIOL, V114, P663; FUCHS R, 1989, P NATL ACAD SCI USA, V86, P539, DOI 10.1073/pnas.86.2.539; GEUZE HJ, 1987, J CELL BIOL, V104, P1715, DOI 10.1083/jcb.104.6.1715; GEUZE HJ, 1983, CELL, V32, P277, DOI 10.1016/0092-8674(83)90518-4; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; GOUD B, 1990, NATURE, V345, P553, DOI 10.1038/345553a0; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; GOUD B, 1991, Current Opinion in Cell Biology, V3, P626, DOI 10.1016/0955-0674(91)90033-U; GRIFFITHS G, 1989, J CELL BIOL, V109, P2703, DOI 10.1083/jcb.109.6.2703; GRUENBERG J, 1989, ANNU REV CELL BIOL, V5, P453; HARTER C, 1992, J CELL BIOL, V117, P311, DOI 10.1083/jcb.117.2.311; HELENIUS A, 1983, TRENDS BIOCHEM SCI, V8, P245, DOI 10.1016/0968-0004(83)90350-X; HOPKINS CR, 1992, TRENDS BIOCHEM SCI, V17, P27, DOI 10.1016/0968-0004(92)90423-7; HOPKINS CR, 1983, J CELL BIOL, V97, P508, DOI 10.1083/jcb.97.2.508; HOPKINS CR, 1990, NATURE, V346, P335, DOI 10.1038/346335a0; HORWICH AL, 1985, EMBO J, V4, P1129, DOI 10.1002/j.1460-2075.1985.tb03750.x; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; HUNZIKER W, 1991, CELL, V67, P617, DOI 10.1016/0092-8674(91)90535-7; KLAUSNER RD, 1984, J CELL BIOL, V98, P1098, DOI 10.1083/jcb.98.3.1098; KLAUSNER RD, 1983, P NATL ACAD SCI-BIOL, V80, P2263, DOI 10.1073/pnas.80.8.2263; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MARSH M, 1980, J MOL BIOL, V142, P439, DOI 10.1016/0022-2836(80)90281-8; MARSH M, 1986, P NATL ACAD SCI USA, V83, P2899, DOI 10.1073/pnas.83.9.2899; MARSH M, 1983, CELL, V32, P931, DOI 10.1016/0092-8674(83)90078-8; MCGRAW TE, 1987, J CELL BIOL, V105, P207, DOI 10.1083/jcb.105.1.207; MIETTINEN HM, 1989, CELL, V58, P317, DOI 10.1016/0092-8674(89)90846-5; Pfeffer S R, 1992, Trends Cell Biol, V2, P41, DOI 10.1016/0962-8924(92)90161-F; PLUTNER H, 1991, J CELL BIOL, V115, P31, DOI 10.1083/jcb.115.1.31; PLUTNER H, 1990, EMBO J, V9, P2375, DOI 10.1002/j.1460-2075.1990.tb07412.x; PODBILEWICZ B, 1990, EMBO J, V9, P3477, DOI 10.1002/j.1460-2075.1990.tb07556.x; ROFF CF, 1986, J CELL BIOL, V103, P2283, DOI 10.1083/jcb.103.6.2283; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMID S, 1989, J CELL BIOL, V108, P1291, DOI 10.1083/jcb.108.4.1291; SCHMID SL, 1988, CELL, V52, P73, DOI 10.1016/0092-8674(88)90532-6; STEIN BS, 1984, J BIOL CHEM, V259, P4762; STEINMAN RM, 1983, J CELL BIOL, V96, P1, DOI 10.1083/jcb.96.1.1; STOORVOGEL W, 1991, CELL, V65, P417, DOI 10.1016/0092-8674(91)90459-C; TOOZE J, 1991, J CELL BIOL, V115, P635, DOI 10.1083/jcb.115.3.635; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; VANDERSLUIJS P, 1991, P NATL ACAD SCI USA, V88, P6313, DOI 10.1073/pnas.88.14.6313; VANDERSLUIJS P, 1992, IN PRESS EMBO J; WALWORTH NC, 1989, EMBO J, V8, P1685, DOI 10.1002/j.1460-2075.1989.tb03560.x; WEISSMAN AM, 1986, J CELL BIOL, V102, P951, DOI 10.1083/jcb.102.3.951; YAMASHIRO DJ, 1984, CELL, V37, P789, DOI 10.1016/0092-8674(84)90414-8; ZAHRAOUI A, 1989, J BIOL CHEM, V264, P12394	56	531	536	0	19	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 4	1992	70	5					729	740		10.1016/0092-8674(92)90307-X	http://dx.doi.org/10.1016/0092-8674(92)90307-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JL663	1516131				2022-12-01	WOS:A1992JL66300005
J	WALENT, JH; PORTER, BW; MARTIN, TFJ				WALENT, JH; PORTER, BW; MARTIN, TFJ			A NOVEL 145-KD BRAIN CYTOSOLIC PROTEIN RECONSTITUTES CA2+-REGULATED SECRETION IN PERMEABLE NEUROENDOCRINE CELLS	CELL			English	Article							SEMI-INTACT CELLS; KINASE-C; VESICULAR TRANSPORT; MEMBRANE-FUSION; GOLGI-COMPLEX; MAST-CELLS; PC12 CELLS; EXOCYTOSIS; PURIFICATION; COMPONENTS	The regulated secretory pathway is activated by elevated cytoplasmic Ca2+; however, the components mediating Ca2+ regulation have not been identified. In semi-intact neuroendocrine cells, Ca2+-activated secretion is ATP- and cytosol protein-dependent. We have identified a novel brain protein, p145, as a cytosolic factor that reconstitutes Ca2+-activated secretion in two neuroendocrine cell types. The protein is a dimer of 145 kd subunits, exhibits Ca2+-dependent interaction with a hydrophobic matrix, and binds phospholipid vesicles, suggesting a membrane-associated function. A p145-specific antibody inhibits the reconstitution of Ca2+-activated secretion by cytosol, indicating an essential role for p145. The restricted expression of p145 in tissues exhibiting a regulated secretory pathway suggests a key role for this protein in the transduction of Ca2+ signals into vectorial membrane fusion events.			WALENT, JH (corresponding author), UNIV WISCONSIN,DEPT ZOOL,MADISON,WI 53706, USA.				NIDDK NIH HHS [DK 40428] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040428] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUGUSTINE GJ, 1992, J PHYSIOL-LONDON, V450, P247, DOI 10.1113/jphysiol.1992.sp019126; AUNIS D, 1988, J EXP BIOL, V139, P253; BECKERS CJM, 1987, CELL, V50, P523, DOI 10.1016/0092-8674(87)90025-0; BRAELL WA, 1987, P NATL ACAD SCI USA, V84, P1137, DOI 10.1073/pnas.84.5.1137; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; BURGOYNE RD, 1990, ANNU REV PHYSIOL, V52, P647; CHURCHER Y, 1990, CELL REGUL, V1, P337, DOI 10.1091/mbc.1.4.337; CLARY DO, 1990, J BIOL CHEM, V265, P10109; DELISLE RC, 1986, ANNU REV PHYSIOL, V48, P225; DUNPHY WG, 1986, P NATL ACAD SCI USA, V83, P1622, DOI 10.1073/pnas.83.6.1622; FRICKER LD, 1990, NEUROENDOCRINOLOGY, V51, P658, DOI 10.1159/000125407; GODA Y, 1989, FASEB J, V3, P2488, DOI 10.1096/fasebj.3.13.2680705; Greene LA., 1982, ADV CELL NEUROBIOL, V3, P373, DOI [10.1016/B978-0-12-008303-9.50016-5, DOI 10.1016/B978-0-12-008303-9.50016-5]; HARLOW E, 1988, ANTIBODIES LABORATOR; HAY JC, 1992, IN PRESS J CELL BIOL; KOFFER A, 1989, J CELL SCI, V94, P585; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOMNETH R, 1991, J NEUROCHEM, V57, P1413, DOI 10.1111/j.1471-4159.1991.tb08308.x; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; MARTIN TFJ, 1990, J BIOL CHEM, V265, P7623; MARTIN TFJ, 1989, J BIOL CHEM, V264, P10299; MARTIN TFJ, 1989, METHOD ENZYMOL, V168, P225; Miller SG, 1990, CURR OPIN CELL BIOL, V2, P642, DOI 10.1016/0955-0674(90)90105-N; MILLER SG, 1991, J CELL BIOL, V112, P39, DOI 10.1083/jcb.112.1.39; MORGAN A, 1992, NATURE, V355, P833, DOI 10.1038/355833a0; OBENDORF D, 1988, NEUROSCIENCE, V25, P343, DOI 10.1016/0306-4522(88)90030-9; OLMSTED JB, 1981, J BIOL CHEM, V256, P1955; PEPPERS SC, 1986, J BIOL CHEM, V261, P4665; Pfeffer S R, 1992, Trends Cell Biol, V2, P41, DOI 10.1016/0962-8924(92)90161-F; ROSSIER J, 1989, ANAL BIOCHEM, V178, P27, DOI 10.1016/0003-2697(89)90350-3; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SARAFIAN T, 1991, J CELL BIOL, V114, P1135, DOI 10.1083/jcb.114.6.1135; SARAFIAN T, 1987, J BIOL CHEM, V262, P16671; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; WATTENBERG BW, 1986, J BIOL CHEM, V261, P2208; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0	37	236	240	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 4	1992	70	5					765	775		10.1016/0092-8674(92)90310-9	http://dx.doi.org/10.1016/0092-8674(92)90310-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JL663	1516133				2022-12-01	WOS:A1992JL66300008
J	YANAGISAWAMIWA, A; UCHIDA, Y; NAKAMURA, F; TOMARU, T; KIDO, H; KAMIJO, T; SUGIMOTO, T; KAJI, K; UTSUYAMA, M; KURASHIMA, C; ITO, H				YANAGISAWAMIWA, A; UCHIDA, Y; NAKAMURA, F; TOMARU, T; KIDO, H; KAMIJO, T; SUGIMOTO, T; KAJI, K; UTSUYAMA, M; KURASHIMA, C; ITO, H			SALVAGE OF INFARCTED MYOCARDIUM BY ANGIOGENIC ACTION OF BASIC FIBROBLAST GROWTH-FACTOR	SCIENCE			English	Article							CORONARY COLLATERAL VESSELS; DNA-SYNTHESIS; FUNCTIONAL-SIGNIFICANCE; EXTRACELLULAR-MATRIX; CARDIAC MYOCYTES; HEPARIN; CIRCULATION; HEART; ARTERY; LOCALIZATION	Coronary collateral vessels reduce damage to ischemic myocardium after coronary obstruction. Factors that stimulate collateral formation are expected to have ameliorating effects on myocardial infarction. In a canine experimental myocardial infarct model, intracoronary injection of basic fibroblast growth factor (bFGF) improved cardiac systolic function and reduced infarct size. Treatment with bFGF increased the number of arterioles and capillaries in the infarct. Thus, the angiogenic action of bFGF might lead to a reduction in infarct size. The application of bFGF might bring about a therapeutic modality for the salvage of infarcted myocardium.	TOKYO METROPOLITAN GERIATR HOSP & INST GERONTOL, ENDOCRINOL & METAB SECT, ITABASHI KU, TOKYO 173, JAPAN; TOKYO METROPOLITAN GERIATR HOSP & INST GERONTOL, DEPT PATHOL, ITABASHI KU, TOKYO 173, JAPAN; TOKYO METROPOLITAN GERIATR HOSP & INST GERONTOL, DEPT BIOCHEM ISOTOPES, ITABASHI KU, TOKYO 173, JAPAN		YANAGISAWAMIWA, A (corresponding author), UNIV TOKYO, FAC MED, DEPT INTERNAL MED, 7-3-1 HONGO, BUNKYO KU, TOKYO 113, JAPAN.							BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CASSCELLS W, 1990, J CLIN INVEST, V85, P433, DOI 10.1172/JCI114456; COLLE JP, 1982, ARCH MAL COEUR VAISS, V75, P395; DAMORE PA, 1987, ANNU REV PHYSIOL, V49, P453; FLANAGAN MF, 1991, CIRC RES, V68, P1458, DOI 10.1161/01.RES.68.5.1458; FLAUMENHAFT R, 1989, J CELL PHYSIOL, V140, P75, DOI 10.1002/jcp.1041400110; FLAUMENHAFT R, 1990, J CELL BIOL, V111, P1651, DOI 10.1083/jcb.111.4.1651; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FUJITA M, 1991, AM HEART J, V122, P409, DOI 10.1016/0002-8703(91)90993-R; FUJITA M, 1988, CIRCULATION, V77, P1022, DOI 10.1161/01.CIR.77.5.1022; GOSPODAROWICZ D, 1989, J INVEST DERMATOL, V93, pS39, DOI 10.1111/1523-1747.ep12580907; GREGG DE, 1974, CIRC RES, V35, P335, DOI 10.1161/01.RES.35.3.335; HABIB GB, 1991, CIRCULATION, V83, P739, DOI 10.1161/01.CIR.83.3.739; KARDAMI E, 1989, J CELL BIOL, V109, P1865, DOI 10.1083/jcb.109.4.1865; KIDO H, 1991, J JPN COLL ANGIOL, V31, P753; KUMAR S, 1983, LANCET, V2, P364; LEVIN DC, 1974, CIRCULATION, V50, P831, DOI 10.1161/01.CIR.50.4.831; LINDNER V, 1991, CIRC RES, V68, P106, DOI 10.1161/01.RES.68.1.106; LINDNER V, 1991, P NATL ACAD SCI USA, V88, P3739, DOI 10.1073/pnas.88.9.3739; MOHRI M, 1989, CIRC RES, V64, P287, DOI 10.1161/01.RES.64.2.287; PASYK S, 1982, AM J PHYSIOL, V242, P1031; PIEK JJ, 1988, J AM COLL CARDIOL, V11, P1290, DOI 10.1016/0735-1097(88)90294-X; QUINKLER W, 1989, EUR J BIOCHEM, V181, P67, DOI 10.1111/j.1432-1033.1989.tb14694.x; RAKUSAN K, 1985, CIRC RES, V57, P393, DOI 10.1161/01.RES.57.3.393; SABRI MN, 1991, AM HEART J, V121, P876, DOI 10.1016/0002-8703(91)90202-S; SASAKI H, 1989, J BIOL CHEM, V264, P17606; SCHAPER W, 1990, J AM COLL CARDIOL, V15, P513, DOI 10.1016/0735-1097(90)90618-Y; SCHAPER W, 1978, BASIC RES CARDIOL, V73, P584, DOI 10.1007/BF01906796; SCHAPER W, 1988, PROG CARDIOVASC DIS, V31, P57, DOI 10.1016/0033-0620(88)90011-4; SCHAPER W, 1971, CIRC RES, V28, P671, DOI 10.1161/01.RES.28.6.671; SCHWARZ F, 1978, AM HEART J, V95, P570, DOI 10.1016/0002-8703(78)90298-3; THOMPSON JA, 1989, P NATL ACAD SCI USA, V86, P7928, DOI 10.1073/pnas.86.20.7928; THOMPSON JA, 1988, SCIENCE, V241, P1349, DOI 10.1126/science.2457952; UNGER EF, 1990, CIRCULATION, V82, P1449, DOI 10.1161/01.CIR.82.4.1449; WEINER HL, 1989, P NATL ACAD SCI USA, V86, P2683, DOI 10.1073/pnas.86.8.2683; YANAGISAWAMIWA A, UNPUB	36	432	468	1	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 4	1992	257	5075					1401	1403		10.1126/science.1382313	http://dx.doi.org/10.1126/science.1382313			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL612	1382313				2022-12-01	WOS:A1992JL61200034
J	DAVIES, K				DAVIES, K			MULLING OVER MOUSE MODELS	NATURE			English	Editorial Material																		BALDWIN CT, 1992, NATURE, V355, P637, DOI 10.1038/355637a0; COLLINS FS, 1992, NATURE, V358, P708, DOI 10.1038/358708a0; GARDNER JM, 1992, SCIENCE, V257, P1121, DOI 10.1126/science.257.5073.1121; GASCHEN PP, 1992, J NEUROL SCI, V110, P149; JORDAN T, 1992, NAT GENET, V1, P328, DOI 10.1038/ng0892-328; Morell Robert, 1992, Human Molecular Genetics, V1, P243, DOI 10.1093/hmg/1.4.243; PFAFFLE RW, 1992, SCIENCE, V257, P1118, DOI 10.1126/science.257.5073.1118; RADOVICK S, 1992, SCIENCE, V257, P1115, DOI 10.1126/science.257.5073.1115; SNOUWAERT JN, 1992, SCIENCE, V257, P1083, DOI 10.1126/science.257.5073.1083; STEDMAN HH, 1991, NATURE, V352, P536, DOI 10.1038/352536a0; STEEL KP, 1992, NAT GENET, V2, P75, DOI 10.1038/ng0992-75; TASSABEHJI M, 1992, NATURE, V355, P635, DOI 10.1038/355635a0; TATSUMI K, 1992, NAT GENET, V1, P56, DOI 10.1038/ng0492-56	13	4	4	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 3	1992	359	6390					86	86		10.1038/359086a0	http://dx.doi.org/10.1038/359086a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL662	1522893	Bronze			2022-12-01	WOS:A1992JL66200062
J	DERVAN, PB				DERVAN, PB			REAGENTS FOR THE SITE-SPECIFIC CLEAVAGE OF MEGABASE DNA	NATURE			English	Article							TRIPLE-HELIX FORMATION; RECOGNITION; MOTIF				DERVAN, PB (corresponding author), CALTECH, DEPT CHEM & CHEM ENGN, PASADENA, CA 91125 USA.							BEAL PA, 1992, J AM CHEM SOC, V114, P4976, DOI 10.1021/ja00039a004; BEAL PA, 1991, SCIENCE, V251, P1360, DOI 10.1126/science.2003222; COONEY M, 1988, SCIENCE, V241, P456, DOI 10.1126/science.3293213; FELSENFELD G, 1957, J AM CHEM SOC, V79, P2023, DOI 10.1021/ja01565a074; FERRIN LJ, 1991, SCIENCE, V254, P1494, DOI 10.1126/science.1962209; GRIFFIN LC, 1989, SCIENCE, V245, P967, DOI 10.1126/science.2549639; Home D. A., 1990, J AM CHEM SOC, V112, P2435; KOH JS, 1992, J AM CHEM SOC, V114, P1470, DOI 10.1021/ja00030a050; KOOB M, 1988, SCIENCE, V241, P1084, DOI 10.1126/science.2842862; LEDOAN T, 1987, NUCLEIC ACIDS RES, V15, P8643, DOI 10.1093/nar/15.21.8643; MAHER LJ, 1992, BIOCHEMISTRY-US, V31, P70, DOI 10.1021/bi00116a012; MOSER HE, 1987, SCIENCE, V238, P645, DOI 10.1126/science.3118463; PEI DH, 1990, P NATL ACAD SCI USA, V87, P9858, DOI 10.1073/pnas.87.24.9858; POVSIC TJ, 1992, J AM CHEM SOC, V114, P5934, DOI 10.1021/ja00041a005; RADHAKRISHNAN I, 1991, BIOCHEMISTRY-US, V30, P9022, DOI 10.1021/bi00101a016; RADHAKRISHNAN I, 1991, J MOL BIOL, V221, P1403, DOI 10.1016/0022-2836(91)90941-X; RAJAGOPAL P, 1989, BIOCHEMISTRY-US, V28, P7859, DOI 10.1021/bi00445a048; SINGLETON SF, IN PRESS J AM CHEM S; STOBEL SA, 1991, SCIENCE, V254, P1639; STROBEL SA, 1991, NATURE, V350, P172, DOI 10.1038/350172a0	20	70	73	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 3	1992	359	6390					87	88		10.1038/359087a0	http://dx.doi.org/10.1038/359087a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL662	1522894				2022-12-01	WOS:A1992JL66200063
J	HOULE, D; HOFFMASTER, DK; ASSIMACOPOULOS, S; CHARLESWORTH, B				HOULE, D; HOFFMASTER, DK; ASSIMACOPOULOS, S; CHARLESWORTH, B			THE GENOMIC MUTATION-RATE FOR FITNESS IN DROSOPHILA	NATURE			English	Article							AFFECTING VIABILITY; MELANOGASTER; POPULATIONS; EVOLUTION	THE mutation rate per genome for local affecting fitness is crucial in theories of the evolution of sex and recombination1,2 and of outbreeding mechanisms3. Mutational variation in fitness may also be important in the evolution of mate choice in animals2,4,5. No information is available on the rate at which spontaneous mutations with small effects on fitness arise, although viability (probability of survival to adulthood) has been studied in Drosophila melanogaster6-9. These experiments involved the accumulation of spontaneous mutations in the virtual absence of natural selection, in a set of independently maintained lines with a common origin. The rates of decline in mean and increase in variance among lines permit estimation of limits to the mean number of new mutations arising per generation (U) and the average homozygous effect of a new mutation of minor effect (s)7,9,10. For the second chromosome of D. melanogaster, the value of U is at least 0.17 (ref. 7), and (1 - h)s is less than 0.02, where hs is the average decline in fitness of heterozygotes. As the second chromosome is about 40% of the genome, these data indicate a mutation rate per haploid genome of at least 0.42 for viability. Here we present similar data on the effects of homozygous spontaneous mutations on a measure of fitness in D. melanogaster.	UNIV CHICAGO,DEPT ECOL & EVOLUT,CHICAGO,IL 60637	University of Chicago								ASHBURNER M, 1989, DROSOPHILA LABORATOR; BATEMAN A, 1959, INT J RADIAT BIOL, V2, P170; CARLSSON BG, 1987, ORNIS SCAND, V18, P237, DOI 10.2307/3676890; CHARLESWORTH B, 1990, NATURE, V347, P380, DOI 10.1038/347380a0; CHARLESWORTH B, 1985, HEREDITY, V54, P71, DOI 10.1038/hdy.1985.10; Charlesworth B, 1987, SEXUAL SELECTION TES, P21; CROW J. F., 1970, Biomathematics. Volume 1. Mathematical topics in population genetics., P128; Crow J.F., 1983, Genetics and Biology of Drosophila, V3c, P1; KIRKPATRICK M, 1991, NATURE, V350, P33, DOI 10.1038/350033a0; KONDRASHOV AS, 1988, NATURE, V336, P435, DOI 10.1038/336435a0; Lindsley D.L., 1968, GENETIC VARIATIONS D; MUKAI T, 1969, GENETICS, V61, P749; MUKAI T, 1971, GENETICS, V69, P385; MUKAI T, 1972, GENETICS, V72, P335; MUKAI T, 1964, GENETICS, V50, P1; OHNISHI O, 1977, GENETICS, V87, P529; SIMMONS MJ, 1980, GENETICS, V94, P467; Sokal R., 1981, BIOMETRY; SVED JA, 1971, GENET RES, V18, P97, DOI 10.1017/S0016672300012453; YOSHIMARU H, 1985, JPN J GENET, V60, P307, DOI 10.1266/jjg.60.307	20	108	108	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 3	1992	359	6390					58	60		10.1038/359058a0	http://dx.doi.org/10.1038/359058a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL662	1522887				2022-12-01	WOS:A1992JL66200052
J	LEGERSKI, R; PETERSON, C				LEGERSKI, R; PETERSON, C			EXPRESSION CLONING OF A HUMAN DNA-REPAIR GENE INVOLVED IN XERODERMA-PIGMENTOSUM GROUP-C	NATURE			English	Article							HIGH-EFFICIENCY TRANSFORMATION; MOLECULAR-CLONING; SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE-SEQUENCE; EXCISION REPAIR; RAD4 GENE; CELLS; COMPLEMENTATION; MUTANTS; DEFECT	XERODERMA pigmentosum (XP) is a rare human autosomal recessive disease characterized by solar sensitivity, high predisposition for developing cancers on areas exposed to sunlight, and, in some cases, neurological abnormalities1,2. XP cells are defective in DNA repair3, and complementation of this defect has been used to identify eight genetic groups (A-G and variant)4. We have developed a simple, highly efficient complementary DNA expression system for use in human cells5. Here we use this system to isolate a cDNA clone that restores the ultraviolet sensitivity and unscheduled DNA synthesis of XP-C cells to normal levels. The XP-C complementing clone XPCC encodes a highly hydrophilic protein which is composed of a predicted 823 amino acids and shares limited homology with the product of the yeast DNA repair gene RAD4. The XPCC transcript is undetectable by northern blotting in most XP-C cell lines examined.			LEGERSKI, R (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MOLEC GENET,1515 HOLCOMBE BLVD,HOUSTON,TX 77030, USA.							ANDREWS AD, 1978, P NATL ACAD SCI USA, V75, P1984, DOI 10.1073/pnas.75.4.1984; ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CLEAVER JE, 1968, NATURE, V218, P652, DOI 10.1038/218652a0; Cleaver JE, 1989, METABOLIC BASIS INHE, V6th, P2949; CLEAVER JE, 1975, REV GENET, V26, P365; COUTO LB, 1989, J BACTERIOL, V171, P1862, DOI 10.1128/jb.171.4.1862-1869.1989; DAYAGROSJEAN L, 1987, MUTAT RES, V183, P185, DOI 10.1016/0167-8817(87)90061-7; DOWER WJ, 1988, NUCLEIC ACIDS RES, V16, P6127, DOI 10.1093/nar/16.13.6127; FLEJTER WL, 1992, P NATL ACAD SCI USA, V89, P261, DOI 10.1073/pnas.89.1.261; GIETZ RD, 1988, GENE, V74, P535, DOI 10.1016/0378-1119(88)90186-2; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; KANTOR GJ, 1990, MUTAT RES, V235, P171, DOI 10.1016/0921-8777(90)90071-C; LEGERSKI RJ, 1984, P NATL ACAD SCI-BIOL, V81, P5676, DOI 10.1073/pnas.81.18.5676; PETERSON C, 1991, GENE, V107, P279, DOI 10.1016/0378-1119(91)90328-9; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; STORMO GD, 1987, NUCLEIC ACID PROTEIN, P231; TANAKA K, 1989, P NATL ACAD SCI USA, V86, P5512, DOI 10.1073/pnas.86.14.5512; THOMPSON LH, 1981, P NATL ACAD SCI-BIOL, V78, P3734, DOI 10.1073/pnas.78.6.3734; VENEMA J, 1991, MOL CELL BIOL, V11, P4128, DOI 10.1128/MCB.11.8.4128; VIRCA GD, 1990, BIOTECHNIQUES, V8, P370; WEBER CA, 1988, MOL CELL BIOL, V8, P1137, DOI 10.1128/MCB.8.3.1137; WEEDA G, 1990, CELL, V62, P777, DOI 10.1016/0092-8674(90)90122-U; WICKENS M, 1984, SCIENCE, V226, P1045, DOI 10.1126/science.6208611	25	208	211	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 3	1992	359	6390					70	73		10.1038/359070a0	http://dx.doi.org/10.1038/359070a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL662	1522891				2022-12-01	WOS:A1992JL66200056
J	LOUIE, GV; BROWNLIE, PD; LAMBERT, R; COOPER, JB; BLUNDELL, TL; WOOD, SP; WARREN, MJ; WOODCOCK, SC; JORDAN, PM				LOUIE, GV; BROWNLIE, PD; LAMBERT, R; COOPER, JB; BLUNDELL, TL; WOOD, SP; WARREN, MJ; WOODCOCK, SC; JORDAN, PM			STRUCTURE OF PORPHOBILINOGEN DEAMINASE REVEALS A FLEXIBLE MULTIDOMAIN POLYMERASE WITH A SINGLE CATALYTIC SITE	NATURE			English	Article							HYDROXYMETHYLBILANE SYNTHASE; DIPYRROMETHANE COFACTOR; RESOLUTION STRUCTURE; NUCLEOTIDE-SEQUENCE; SUBSTRATE BINDING; ARGININE RESIDUES; 2.3-A RESOLUTION; ACTIVE-TRANSPORT; PROTEIN; REFINEMENT	The three-domain structure of porphobilinogen deaminase, a key enzyme in the biosynthetic pathway of tetrapyrroles, has been defined by X-ray analysis at 1.9 angstrom resolution. Two of the domains structurally resemble the transferrins and periplasmic binding proteins. The dipyrromethane cofactor is covalently linked to domain 3 but is bound by extensive salt-bridges and hydrogen-bonds within the cleft between domains 1 and 2, at a position corresponding to the binding sites for small-molecule ligands in the analogous proteins. The X-ray structure and results from site-directed mutagenesis provide evidence for a single catalytic site. Interdomain flexibility may aid elongation of the polypyrrole product in the active-site cleft of the enzyme.	UNIV LONDON BIRKBECK COLL, IMPERIAL CANC RES FUND, STRUCT MOLEC BIOL UNIT, LONDON WC1E 7HX, ENGLAND; UNIV LONDON, QUEEN MARY & WESTFIELD COLL, SCH BIOL SCI, LONDON E1 4NS, ENGLAND	Cancer Research UK; University of London; Birkbeck University London; University of London; Queen Mary University London	LOUIE, GV (corresponding author), UNIV LONDON BIRKBECK COLL, DEPT CRISTALLOG, MOLEC BIOL LAB, MALET ST, LONDON WC1E 7HX, ENGLAND.		Wood, Stephen P/B-1438-2009	Warren, Martin/0000-0002-6028-6456				ANDERSON BF, 1990, NATURE, V344, P784, DOI 10.1038/344784a0; BAKER EN, 1987, TRENDS BIOCHEM SCI, V12, P350, DOI 10.1016/0968-0004(87)90163-0; BEAUMONT C, 1989, J BIOL CHEM, V264, P14829; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; DELFAU MH, 1990, J CLIN INVEST, V86, P1511, DOI 10.1172/JCI114869; EVANS SV, IN PRESS J MOL GRAPH; HADENER A, 1990, BIOCHEM J, V271, P487; HANEEF I, 1985, ACTA CRYSTALLOGR A, V41, P426, DOI 10.1107/S0108767385000915; HART GJ, 1987, J CHEM SOC CHEM COMM, P1762, DOI 10.1039/c39870001762; JONES C, 1984, J CHEM SOC PERK T 1, P2625, DOI 10.1039/p19840002625; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; Jordan P.M., 1991, NEW COMPREHENSIVE BI, V19, P1, DOI DOI 10.1016/S0167-7306(08)60108-8; JORDAN PM, 1987, FEBS LETT, V225, P87, DOI 10.1016/0014-5793(87)81136-5; JORDAN PM, 1992, J MOL BIOL, V224, P269, DOI 10.1016/0022-2836(92)90590-G; JORDAN PM, 1991, BIOCHEM J, V280, P445, DOI 10.1042/bj2800445; KAPPAS A, 1989, METABOLIC BASIS INHE, P1305; LANDER M, 1991, BIOCHEM J, V275, P447, DOI 10.1042/bj2750447; LOUIE GV, 1990, J MOL BIOL, V214, P527, DOI 10.1016/0022-2836(90)90197-T; LUECKE H, 1990, NATURE, V347, P402, DOI 10.1038/347402a0; MAUZERALL D, 1960, J AM CHEM SOC, V82, P2605, DOI 10.1021/ja01495a053; MGONE CS, IN PRESS HUM GENET; PETRICEK M, 1990, J BACTERIOL, V172, P2250, DOI 10.1128/jb.172.5.2250-2258.1990; PFLUGRATH JW, 1988, J MOL BIOL, V200, P163, DOI 10.1016/0022-2836(88)90341-5; RAICH N, 1986, NUCLEIC ACIDS RES, V14, P5955, DOI 10.1093/nar/14.15.5955; RAMAKRISHNAN C, 1965, BIOPHYS J, V5, P909, DOI 10.1016/S0006-3495(65)86759-5; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; SARRA R, 1990, ACTA CRYSTALLOGR B, V46, P763, DOI 10.1107/S0108768190006450; SCHAUDER JR, 1987, J CHEM SOC CHEM COMM, P436, DOI 10.1039/c39870000436; SCOTT AI, 1989, FEBS LETT, V242, P319, DOI 10.1016/0014-5793(89)80493-4; SHARIF AL, 1989, EUR J BIOCHEM, V184, P353, DOI 10.1111/j.1432-1033.1989.tb15026.x; SPURLINO JC, 1991, J BIOL CHEM, V266, P5202; STUBNICER AC, 1988, NUCLEIC ACIDS RES, V16, P3102, DOI 10.1093/nar/16.7.3102; SUTCLIFFE MJ, 1987, PROTEIN ENG, V1, P377, DOI 10.1093/protein/1.5.377; THOMAS SD, 1986, NUCLEIC ACIDS RES, V14, P6215, DOI 10.1093/nar/14.15.6215; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WARREN MJ, 1988, BIOCHEMISTRY-US, V27, P9020, DOI 10.1021/bi00425a021	38	177	181	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 3	1992	359	6390					33	39		10.1038/359033a0	http://dx.doi.org/10.1038/359033a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL662	1522882				2022-12-01	WOS:A1992JL66200044
J	ROCKEN, M; URBAN, JF; SHEVACH, EM				ROCKEN, M; URBAN, JF; SHEVACH, EM			INFECTION BREAKS T-CELL TOLERANCE	NATURE			English	Article							STAPHYLOCOCCAL ENTEROTOXIN-B; STIMULATORY FACTOR-I; TRANSGENIC MICE; CLONAL-DELETION; MONOCLONAL-ANTIBODY; SELF-TOLERANCE; RECEPTOR; ANERGY; INDUCTION; REACTIVITY	CLONAL deletion or clonal anergy establish tolerance in T cells that bear potentially autoreactive antigen receptors1-15. Here we report that concomitant infection with the nematode Nippostrongylus brasiliensis breaks an established T-cell tolerance induced by injection of mice with Staphylococcus enterotoxin B (SEB)16,17. CD4+ T cells from SEB-tolerant mice did not produce either interleukin-2 or interleukin-4 when challenged in vitro with SEB. N. brasiliensis infection of SEB-primed animals resulted in a normal expansion of SEB-tolerant CD4+V-beta-8+ T cells in vivo as well as an equivalent increase of SEB-reactive, interleukin-4-producing CD4+V-beta-8+ T cells both in SEB-tolerant and in normal animals. Thus, infection with N. brasiliensis circumvented the tolerance established with SEB. Activation of anergic, potentially autoreactive CD4+ T cells by infectious agents seems to be a major pathway for the initiation of autoimmune diseases15. Our results suggest that infectious agents may break tolerance in potentially autoreactive CD4+ T cells by activation of alternative reaction pathways.	USDA ARS, BELTSVILLE AGR RES CTR, INST LIVESTOCK & POULTRY SCI, HELMINTH DIS LAB, BELTSVILLE, MD 20705 USA	United States Department of Agriculture (USDA)	ROCKEN, M (corresponding author), NIAID, IMMUNOL LAB, BETHESDA, MD 20892 USA.			Urban, Joseph/0000-0002-1590-8869; Rocken, Martin/0000-0003-3795-7001				BENSASSON SZ, 1990, J IMMUNOL, V145, P1127; BLACKMAN MA, 1990, NATURE, V345, P540, DOI 10.1038/345540a0; BURKLY LC, 1989, NATURE, V342, P564, DOI 10.1038/342564a0; FINKELMAN FD, 1986, P NATL ACAD SCI USA, V83, P9675, DOI 10.1073/pnas.83.24.9675; FRY AM, 1989, SCIENCE, V246, P1044, DOI 10.1126/science.2511630; GOLDMAN M, 1991, IMMUNOL TODAY, V12, P223, DOI 10.1016/0167-5699(91)90034-Q; HODES RJ, 1989, SCIENCE, V246, P1041, DOI 10.1126/science.2587987; HULI J, 1989, J IMMUNOL, V142, P800; KAPPLER JW, 1988, NATURE, V332, P35, DOI 10.1038/332035a0; KAWABE Y, 1991, NATURE, V349, P245, DOI 10.1038/349245a0; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; MACDONALD HR, 1988, NATURE, V332, P40, DOI 10.1038/332040a0; MURPHY KM, 1989, P NATL ACAD SCI USA, V86, P10034, DOI 10.1073/pnas.86.24.10034; OHARA J, 1985, NATURE, V315, P333, DOI 10.1038/315333a0; OHASHI PS, 1991, CELL, V65, P305, DOI 10.1016/0092-8674(91)90164-T; QIN SX, 1989, J EXP MED, V169, P779, DOI 10.1084/jem.169.3.779; RAMMENSEE HG, 1989, NATURE, V339, P541, DOI 10.1038/339541a0; RAMSDELL F, 1989, SCIENCE, V246, P1038, DOI 10.1126/science.2511629; RELLAHAN BL, 1990, J EXP MED, V172, P1091, DOI 10.1084/jem.172.4.1091; ROCKEN M, 1992, J IMMUNOL, V148, P47; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SINHA AA, 1990, SCIENCE, V248, P1380, DOI 10.1126/science.1972595; SMITH H, 1989, SCIENCE, V245, P749, DOI 10.1126/science.2788921; SPEISER DE, 1990, J EXP MED, V172, P1305, DOI 10.1084/jem.172.5.1305; SPRENT J, 1990, SCIENCE, V248, P1357, DOI 10.1126/science.1694041; STAERZ UD, 1985, J IMMUNOL, V134, P3994; WEBB S, 1990, CELL, V63, P1249, DOI 10.1016/0092-8674(90)90420-J; WHITE J, 1989, CELL, V56, P27, DOI 10.1016/0092-8674(89)90980-X; YUI K, 1990, P NATL ACAD SCI USA, V87, P7135, DOI 10.1073/pnas.87.18.7135	29	147	147	0	2	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	SEP 3	1992	359	6390					79	82		10.1038/359079a0	http://dx.doi.org/10.1038/359079a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL662	1355854				2022-12-01	WOS:A1992JL66200059
J	SCHANTZ, PM; MOORE, AC; MUNOZ, JL; HARTMAN, BJ; SCHAEFER, JA; ARON, AM; PERSAUD, D; SARTI, E; WILSON, M; FLISSER, A				SCHANTZ, PM; MOORE, AC; MUNOZ, JL; HARTMAN, BJ; SCHAEFER, JA; ARON, AM; PERSAUD, D; SARTI, E; WILSON, M; FLISSER, A			NEUROCYSTICERCOSIS IN AN ORTHODOX JEWISH-COMMUNITY IN NEW-YORK-CITY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LINKED IMMUNOELECTROTRANSFER BLOT; CEREBRAL CYSTICERCOSIS; UNITED-STATES; DIAGNOSIS	Background and Methods. From June 1990 through July 1991, intracerebral infection with the larval stage of the pork tapeworm Taenia solium was diagnosed in four unrelated persons in an Orthodox Jewish community in New York City. None of the patients had eaten pork, and only one had traveled to a country in which T solium infection was endemic. We investigated this outbreak, screened serum samples from family members and household contacts for antibodies to cysticercosis, and examined stool specimens from household employees for eggs of taenia species. Results. The four patients had recurrent seizures and brain lesions that were radiologically consistent with the presence of cysticerci. The diagnosis was confirmed in two patients by a brain biopsy, and in two by immunoblot assays for cysticercus antibodies. Of 17 immediate family members screened serologically, 7 from two families had cysticercus antibodies. Magnetic resonance imaging of the brain showed cystic lesions in two of the seropositive family members, one of whom had had a seizure. Examinations of six domestic employees from all four households revealed an active infection with taenia species in one and a positive serologic test in another. Since these women had recently emigrated from Latin American countries where T. solium infection is endemic, they were the most likely sources of infection in the members of these households. Conclusions. A diagnosis of neurocysticercosis should be considered in patients with seizures and radiologic evidence of cystic brain lesions, even in those who do not eat pork and who have not traveled to a country in which T. solium infection is endemic. Recent emigrants from countries in which T. solium infection is endemic should be screened for tapeworm infection in their stools before they are employed as housekeepers or food handlers.	NYU MED CTR,DEPT PEDIAT,NEW YORK,NY 10016; CORNELL UNIV,SCH MED,DIV INFECT DIS,ITHACA,NY 14853; CORNELL UNIV,SCH MED,DEPT NEUROL,ITHACA,NY 14853; MT SINAI MED CTR,DIV PEDIAT NEUROL,NEW YORK,NY 10029; SECRETARIAT HLTH,GEN DIRECTORATE EPIDEMIOL,MEXICO CITY,MEXICO; BIOMED RES INST,MEXICO CITY,MEXICO	New York University; Cornell University; Cornell University; Icahn School of Medicine at Mount Sinai	SCHANTZ, PM (corresponding author), CTR DIS CONTROL,NATL CTR INFECT DIS,DIV PARASIT DIS F13,ATLANTA,GA 30333, USA.		Sarti, Elsa/ABB-8450-2021	Flisser, Ana/0000-0002-1744-8480				[Anonymous], 1992, MMWR MORB MORTAL WKL, V41, P1; Campagna M., 1954, Journal of Parasitology, V40, P46; COHEN B, 1962, SOUTHERN MED J, V55, P48, DOI 10.1097/00007611-196201000-00013; DEKAMINSKY RG, 1991, T ROY SOC TROP MED H, V85, P531, DOI 10.1016/0035-9203(91)90245-T; DIAZ JF, 1992, AM J TROP MED HYG, V46, P610, DOI 10.4269/ajtmh.1992.46.610; EARNEST MP, 1987, REV INFECT DIS, V9, P961; FLISSER A, 1988, PARASITOL TODAY, V4, P131, DOI 10.1016/0169-4758(88)90187-1; Garbutt G D, 1967, Bull Los Angeles Neurol Soc, V32, P6; GEMMELL M, 1983, WHO VPH8349 DOC; KEANE JR, 1980, ANN NEUROL, V8, P643, DOI 10.1002/ana.410080624; LOO L, 1982, MEDICINE, V61, P341, DOI 10.1097/00005792-198211000-00001; Mahajan R.C., 1982, P39; Mazzotti L., 1944, REV INST SALUBRIDAD Y ENFERM TROP, V5, P207; McCormick G F, 1985, Bull Clin Neurosci, V50, P76; MELVIN DM, 1982, DHHS CDC828282 CTR D; MITCHELL WG, 1988, PEDIATRICS, V82, P76; NASH TE, 1984, NEW ENGL J MED, V311, P1492, DOI 10.1056/NEJM198412063112307; PILCHER J B, 1991, American Journal of Tropical Medicine and Hygiene, V45, P131; Prevention and control of intestinal parasitic infections, 1987, WHO TECH REP SER, V749, P1; RICHARDS FO, 1985, JAMA-J AM MED ASSOC, V254, P3444, DOI 10.1001/jama.254.24.3444; SARTI E, 1992, AM J TROP MED HYG, V46, P677, DOI 10.4269/ajtmh.1992.46.677; Schantz P M, 1991, Southeast Asian J Trop Med Public Health, V22 Suppl, P65; SCHANTZ P M, 1989, Acta Leidensia, V57, P153; SCHARF D, 1988, ARCH NEUROL-CHICAGO, V45, P777, DOI 10.1001/archneur.1988.00520310087022; Schenone H., 1982, P25; SCHULTZ TS, 1978, NEUROSURGERY, V3, P164, DOI 10.1227/00006123-197809000-00006; SHANLEY JD, 1980, ARCH INTERN MED, V140, P1309, DOI 10.1001/archinte.140.10.1309; SORVILLO FJ, 1992, AM J TROP MED HYG, V47, P365, DOI 10.4269/ajtmh.1992.47.365; TASKER WG, 1979, PEDIATRICS, V63, P761; TSANG VCW, 1989, J INFECT DIS, V159, P50, DOI 10.1093/infdis/159.1.50; WILSON M, 1991, J INFECT DIS, V164, P1007, DOI 10.1093/infdis/164.5.1007; 1990, CALIFORNIA MORBIDITY; 1991, 1990 CENSUS PROFILE, P1; 1986, MED LETT DRUGS THER, V28, P9	34	309	321	0	13	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 3	1992	327	10					692	695		10.1056/NEJM199209033271004	http://dx.doi.org/10.1056/NEJM199209033271004			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JL235	1495521				2022-12-01	WOS:A1992JL23500004
J	SIBLEY, LD; BOOTHROYD, JC				SIBLEY, LD; BOOTHROYD, JC			VIRULENT-STRAINS OF TOXOPLASMA-GONDII COMPRISE A SINGLE CLONAL LINEAGE	NATURE			English	Article							CONGENITAL TOXOPLASMOSIS; DIAGNOSIS; ENCEPHALITIS	THE protozoan Toxoplasma gondii is a prevalent parasite in wild and domestic animals worldwide, being transmitted through the food chain by carnivorous feeding and scavenging1. Toxoplasma normally divides asexually to yield a haploid form that can infect virtually any vertebrate but it also has a well defined sexual cycle that occurs exclusively in cats1. Toxoplasma has become important as an often fatal opportunistic pathogen in patients with AIDS2,3, although the 15-85% of adult human populations that are chronically infected with T. gondii are typically asymptomatic4-7. Infections in immunocompromised hosts have variable outcomes. For example, only 30 to 50% of AIDS patients that are chronically infected with the parasite develop toxoplasmic encephalitis2,3 and only about half of acute maternal infections result in congenital disease of the newborn8. T. gondii strains differ in their virulence in animals1, but the extent to which different strains are related has not been determined. Here we analyse 28 strains from a variety of hosts on five continents and find that the ten virulent strains have an essentially identical genotype, whereas the nonvirulent strains are moderately polymorphic. These data strongly suggest that virulent strains of T. gondii originated from a single lineage which has remained genetically homogeneous despite being globally widespread, and despite the ability of this organism to reproduce sexually.	STANFORD UNIV,MED CTR,SCH MED,DEPT MICROBIOL & IMMUNOL,STANFORD,CA 94305	Stanford University			Sibley, L. David/C-4616-2008	Boothroyd, John C./0000-0001-9719-745X				APT WB, 1985, PARASITOL TODAY, V1, P44; BOOTHROYD JC, IN PRESS NATO ASI SE; BUELOW R, 1991, J IMMUNOL, V147, P3496; BURG JL, 1988, J IMMUNOL, V141, P3584; DANNEMANN BR, 1989, HOSP PRACT, V24, P139; DARDE ML, 1988, AM J TROP MED HYG, V39, P551, DOI 10.4269/ajtmh.1988.39.551; DARDE ML, IN PRESS J PARASIT; DESMONTS G, 1974, NEW ENGL J MED, V290, P1110, DOI 10.1056/NEJM197405162902003; Dubey J.P., 1977, P101; FELDMAN HA, 1965, AM J EPIDEMIOL, V81, P385, DOI 10.1093/oxfordjournals.aje.a120524; GROVER CM, 1990, J CLIN MICROBIOL, V28, P2297, DOI 10.1128/JCM.28.10.2297-2301.1990; Hughes H.P.A., 1985, Parasitology Today, V1, P41, DOI 10.1016/0169-4758(85)90112-7; KASPER LH, 1985, J CLIN INVEST, V75, P1570, DOI 10.1172/JCI111862; KIEHN TE, 1985, J CLIN MICROBIOL, V21, P168, DOI 10.1128/JCM.21.2.168-173.1985; LUFT BJ, 1988, J INFECT DIS, V157, P1, DOI 10.1093/infdis/157.1.1; PFEFFERKORN ER, 1977, J PARASITOL, V63, P158, DOI 10.2307/3280129; Sabin AB, 1941, J AMER MED ASSOC, V116, P801, DOI 10.1001/jama.1941.02820090001001; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SELANDER RK, 1980, SCIENCE, V210, P545, DOI 10.1126/science.6999623; SIBLEY LD, 1992, MOL BIOCHEM PARASIT, V51, P291, DOI 10.1016/0166-6851(92)90079-Y; SIBLEY LD, IN PRESS GENETICS; TIBAYRENC M, 1990, P NATL ACAD SCI USA, V87, P2414, DOI 10.1073/pnas.87.7.2414; TIBAYRENC M, 1991, P NATL ACAD SCI USA, V88, P5129, DOI 10.1073/pnas.88.12.5129; WILSON CB, 1980, AM J OBSTET GYNECOL, V138, P357, DOI 10.1016/0002-9378(80)90129-5	24	562	604	0	35	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 3	1992	359	6390					82	85		10.1038/359082a0	http://dx.doi.org/10.1038/359082a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL662	1355855				2022-12-01	WOS:A1992JL66200060
J	SIMONS, M; EDELMAN, ER; DEKEYSER, JL; LANGER, R; ROSENBERG, RD				SIMONS, M; EDELMAN, ER; DEKEYSER, JL; LANGER, R; ROSENBERG, RD			ANTISENSE C-MYB OLIGONUCLEOTIDES INHIBIT INTIMAL ARTERIAL SMOOTH-MUSCLE CELL ACCUMULATION INVIVO	NATURE			English	Article							FIBROBLAST GROWTH-FACTOR; VASCULAR INJURY; PROLIFERATION; HEPARIN; ANGIOPLASTY; EXPRESSION; ANTIBODY	SYNTHETIC antisense oligonucleotides have been used to dissect gene function in vitro. Technical difficulties prevented the use of this approach for investigating the effect of gene products in vivo. Here we report the use of local delivery of antisense c-myb oligonucleotide to suppress intimal accumulation of rat carotid arterial smooth muscle cells. Our results suggest that antisense oligonucleotides can be used to define the in vivo biological role of specific macromolecules in the blood vessel wall and could potentially serve as a new class of therapeutic agents for cardiovascular disorders.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139; MIT,DIV HLTH SCI TECHNOL,CAMBRIDGE,MA 02139; MIT,DEPT CHEM ENGN,CAMBRIDGE,MA 02139; HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DEPT MED,BOSTON,MA 02215	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School			Simons, Michael/G-8553-2014	Simons, Michael/0000-0003-0348-7734				AGRAWAL S, 1991, P NATL ACAD SCI USA, V88, P7595, DOI 10.1073/pnas.88.17.7595; ANFOSSI G, 1989, P NATL ACAD SCI USA, V86, P3379, DOI 10.1073/pnas.86.9.3379; BROWN KE, 1992, J BIOL CHEM, V267, P4625; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLOWES AW, 1983, LAB INVEST, V49, P327; DEUEL TF, 1984, J CLIN INVEST, V74, P669, DOI 10.1172/JCI111482; DILLEY RJ, 1987, ATHEROSCLEROSIS, V63, P99, DOI 10.1016/0021-9150(87)90109-2; EDELMAN ER, 1990, P NATL ACAD SCI USA, V87, P3773, DOI 10.1073/pnas.87.10.3773; EDELMAN ER, 1992, J CLIN INVEST, V89, P465, DOI 10.1172/JCI115607; FERNS GAA, 1991, SCIENCE, V253, P1129, DOI 10.1126/science.1653454; GUYTON JR, 1980, CIRC RES, V46, P625, DOI 10.1161/01.RES.46.5.625; HANSSON GK, 1988, CIRC RES, V63, P712, DOI 10.1161/01.RES.63.4.712; JAWIEN A, 1992, J CLIN INVEST, V89, P507, DOI 10.1172/JCI115613; JONASSON L, 1988, P NATL ACAD SCI USA, V85, P2303, DOI 10.1073/pnas.85.7.2303; LINDNER V, 1991, CIRC RES, V68, P106, DOI 10.1161/01.RES.68.1.106; LINDNER V, 1991, P NATL ACAD SCI USA, V88, P3739, DOI 10.1073/pnas.88.9.3739; LUSCHER B, 1990, GENE DEV, V4, P2235, DOI 10.1101/gad.4.12b.2235; NOBUYOSHI M, 1991, J AM COLL CARDIOL, V17, P433, DOI 10.1016/S0735-1097(10)80111-1; POWELL JS, 1989, SCIENCE, V245, P186, DOI 10.1126/science.2526370; PUKAC LA, 1991, AM J PATHOL, V139, P1501; REILLY CF, 1989, J BIOL CHEM, V264, P6990; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; SIMONS M, 1992, CIRC RES, V70, P835, DOI 10.1161/01.RES.70.4.835; THOMPSON CB, 1986, NATURE, V319, P374, DOI 10.1038/319374a0	24	680	821	0	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 3	1992	359	6390					67	70		10.1038/359067a0	http://dx.doi.org/10.1038/359067a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL662	1522889				2022-12-01	WOS:A1992JL66200055
J	STEWART, CL; KASPAR, P; BRUNET, LJ; BHATT, H; GADI, I; KONTGEN, F; ABBONDANZO, SJ				STEWART, CL; KASPAR, P; BRUNET, LJ; BHATT, H; GADI, I; KONTGEN, F; ABBONDANZO, SJ			BLASTOCYST IMPLANTATION DEPENDS ON MATERNAL EXPRESSION OF LEUKEMIA INHIBITORY FACTOR	NATURE			English	Article							COLONY-STIMULATING FACTOR; EMBRYONIC STEM-CELLS; PREIMPLANTATION DEVELOPMENT; PROTO-ONCOGENE; FACTOR LIF; MURINE; GENES; CSF-1; INTERLEUKIN-6; CYTOKINES	A CRITICAL point during mammalian pregnancy is the implantation of the blastocyst when the embryo attaches to the wall of the uterus. The autonomously developing preimplantation embryo then becomes dependent on the maternal environment for its continued development. Little is known about the regulation of implantation, except that a complex interaction between peptide and steroid hormones synchronizes the preparation of the uterus for implantation with the development of the embryo. Whether the implantation event is under maternal or embryonic control is also unclear (reviewed in refs 1, 2). We have previously shown that a cytokine, leukaemia inhibitory factor (LIF), is expressed in the uterine endometrial glands specifically on the fourth day of pregnancy3. This burst of expression is under maternal control and always precedes implantation of the blastocyst. Here we report that transient expression of LIF in mice is essential for implantation. Females lacking a functional LIF gene are fertile, but their blastocysts fail to implant and do not develop. The blastocysts, however, are viable and, when transferred to wild-type pseudopregnant recipients, they can implant and develop to term.	INST MOLEC GENET, PRAGUE 6, CZECHOSLOVAKIA; ROCHE BIOMED LABS INC, RARITAN, NJ USA; F HOFFMANN LA ROCHE & CO LTD, PHARMACEUT RES, BASEL NEW TECHNOL, CH-4002 BASEL, SWITZERLAND	Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences; Roche Holding	STEWART, CL (corresponding author), ROCHE INST MOLEC BIOL, ROCHE RES CTR, DEPT CELL & DEV BIOL, 340 KINGSLAND ST, NUTLEY, NJ 07110 USA.		Kaspar, Petr/G-5864-2014; Kaspar, Petr/J-1705-2014					BAZAN JF, 1991, NEURON, V7, P197, DOI 10.1016/0896-6273(91)90258-2; BHATT H, 1991, P NATL ACAD SCI USA, V88, P11408, DOI 10.1073/pnas.88.24.11408; BRADLEY A, 1987, TERATOCARCINOMAS EMB, P113; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CONQUET F, 1990, MOL CELL BIOL, V10, P3801, DOI 10.1128/MCB.10.7.3801; GEARING DP, 1987, EMBO J, V6, P3995, DOI 10.1002/j.1460-2075.1987.tb02742.x; GEARING DP, 1992, NEW BIOL, V4, P61; HILTON DJ, 1991, J CELL PHYSIOL, V148, P430, DOI 10.1002/jcp.1041480315; HILTON DJ, 1992, TRENDS BIOCHEM SCI, V17, P72, DOI 10.1016/0968-0004(92)90505-4; Hodgen G.D., 1988, P1995; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; KOENTGEN F, 1992, THESIS U FREIBOURG G; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MATSUI Y, 1991, NATURE, V353, P750, DOI 10.1038/353750a0; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MURRAY R, 1990, MOL CELL BIOL, V10, P4953, DOI 10.1128/MCB.10.9.4953; PAMPFER S, 1991, BIOESSAYS, V13, P535, DOI 10.1002/bies.950131007; POLALRD JW, 1987, NATURE, V390, P484; POLLARD JW, 1991, DEV BIOL, V148, P273, DOI 10.1016/0012-1606(91)90336-2; REGENSTREIF LJ, 1989, DEV BIOL, V133, P284, DOI 10.1016/0012-1606(89)90319-9; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; ROSE TM, 1991, P NATL ACAD SCI USA, V88, P8641, DOI 10.1073/pnas.88.19.8641; Sambrook J., 1989, MOL CLONING LAB MANU; SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0; STAHL J, 1990, J BIOL CHEM, V265, P8833; STEWART CL, 1987, EMBO J, V6, P383, DOI 10.1002/j.1460-2075.1987.tb04766.x; TARTAKOVSKY B, 1991, DEV BIOL, V146, P345, DOI 10.1016/0012-1606(91)90236-V; THOMPSON S, 1989, CELL, V56, P313, DOI 10.1016/0092-8674(89)90905-7; Weitlauf H.M., 1988, P231; WILLIAMS RL, 1988, NATURE, V336, P684, DOI 10.1038/336684a0; ZJILSTRA M, 1990, NATURE, V344, P742	31	1671	1763	2	73	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 3	1992	359	6390					76	79		10.1038/359076a0	http://dx.doi.org/10.1038/359076a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL662	1522892				2022-12-01	WOS:A1992JL66200058
J	VAZQUEZ, V; SOTELO, J				VAZQUEZ, V; SOTELO, J			THE COURSE OF SEIZURES AFTER TREATMENT FOR CEREBRAL CYSTICERCOSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PARENCHYMAL BRAIN CYSTICERCOSIS; LATE-ONSET EPILEPSY; NEUROCYSTICERCOSIS; PROGNOSIS; THERAPY; PRAZIQUANTEL; ALBENDAZOLE; CHILDHOOD; CT	Background. Worldwide, cerebral cysticercosis is one of the most common causes of seizure disorders. Modern cysticidal drugs can usually eliminate the parasite from the brain, but there have been doubts as to whether such treatment improves the seizure disorder. Methods. We studied 240 patients with seizures and cysticercosis of the brain parenchyma. Of these patients, 118 received cysticidal therapy (albendazole, praziquantel, or both) for lesions without inflammation on imaging studies (group 1); 49 patients with similar lesions either were not offered or refused cysticidal medication (group 2). Another 58 patients with inflammation around cysts (making spontaneous resolution more likely) also did not receive cysticidal medication (group 3), whereas cysticerci were removed surgically in 15 patients (group 4). The 240 patients were followed for a mean (+/-SE) of 92+/-7 months. Results. In the patients treated with cysticidal medications, there was an 82 percent reduction in the mean number of brain cysts (from 5.0 to 0.9) and a 95 percent reduction in the mean frequency of seizures (from 11.3 to 0.6 per year; P<0.001). After three years of follow-up, 64 patients in group 1 (54 percent) were seizure-free. By contrast, the untreated patients (group 2) averaged 10.9 seizures per year; none were seizure-free. Among those with inflamed cysts (group 3), there was a 74 percent reduction in the frequency of seizures (from 7.5 to 2.7 per year), and 18 patients (31 percent) became seizure-free. After surgical treatment (group 4), there was an 87 percent reduction in the frequency of seizures (from 12.8 to 1.7 per year), and six patients (40 percent) became seizure-free. Conclusions. After medical treatment of neurocysticercosis, there is usually remission or marked improvement in the associated seizure disorder.	INST NACL NEUROL & NEUROCIRUG MANUEL VELASCO SUARE, DIV RES, INSURGENTES 3877, MEXICO CITY 14269, MEXICO									AEBI C, 1991, EUR J PEDIATR, V150, P282, DOI 10.1007/BF01955533; [Anonymous], 1981, Epilepsia, V22, P489; [Anonymous], 1991, Lancet, V337, P1175; ARTS WFM, 1988, EPILEPSIA, V29, P244, DOI 10.1111/j.1528-1157.1988.tb03713.x; BHATTACHARYYA GK, 1977, STATISTICAL CONCEPTS; BRORSON LO, 1987, EPILEPSIA, V28, P324, DOI 10.1111/j.1528-1157.1987.tb03651.x; CALLAGHAN N, 1988, NEW ENGL J MED, V318, P942, DOI 10.1056/NEJM198804143181502; Del Brutto O. H., 1991, Journal of Tropical and Geographical Neurology, V1, P31; DELBRUTTO OH, 1992, NEUROLOGY, V42, P389, DOI 10.1212/WNL.42.2.389; DELBRUTTO OH, 1988, REV INFECT DIS, V10, P1075; Draper NR, 1981, APPL REGRESSION ANAL, DOI DOI 10.1002/9781118625590; EARNEST MP, 1987, REV INFECT DIS, V9, P961; Escobar A., 1983, CYSTICERCOSIS CENTRA, P27; ESCOBAR A, 1972, PATHOLOGY NERVOUS SY, V3, P2503; FISH DR, 1989, ACTA NEUROL SCAND, V80, P524, DOI 10.1111/j.1600-0404.1989.tb03921.x; HORNIG CR, 1990, EUR ARCH PSY CLIN N, V239, P379, DOI 10.1007/BF01734546; JUNG H, 1990, J NEUROL, V237, P279, DOI 10.1007/BF00314741; KATAOKA K, 1988, EUR NEUROL, V28, P279, DOI 10.1159/000116284; KERANEN T, 1988, ACTA NEUROL SCAND, V78, P7, DOI 10.1111/j.1600-0404.1988.tb07997.x; KLEINBAUM DG, 1978, APPLIED REGRESSION A; LOPEZ JLP, 1985, ACTA NEUROL SCAND, V72, P380; MEDINA MT, 1990, ARCH INTERN MED, V150, P325, DOI 10.1001/archinte.150.2.325; MILLER B, 1983, NEUROLOGY, V33, P1377, DOI 10.1212/WNL.33.10.1377; MOODLEY M, 1989, LANCET, V1, P262, DOI 10.1016/S0140-6736(89)91268-3; REYNOLDS EH, 1990, BRIT MED J, V301, P1112, DOI 10.1136/bmj.301.6761.1112; ROBITAILLE Y, 1987, CURRENT PROBLEMS EPI, V3, P95; ROBLES C, 1987, J NEUROSURG, V66, P359, DOI 10.3171/jns.1987.66.3.0359; RODRIGUEZCARBAJAL J, 1987, CHILD NERV SYST, V3, P199, DOI 10.1007/BF00274044; RODRIQUEZCARBAJAL J, 1983, AM J NEURORADIOL, V4, P51; SANTOYO H, 1991, NEW ENGL J MED, V324, P1137; SCHEUER ML, 1990, NEW ENGL J MED, V323, P1468; SHINTON RA, 1988, J NEUROL NEUROSUR PS, V51, P273, DOI 10.1136/jnnp.51.2.273; SOTELO J, 1990, J NEUROL, V237, P69, DOI 10.1007/BF00314663; SOTELO J, 1985, ARCH INTERN MED, V145, P442, DOI 10.1001/archinte.145.3.442; SOTELO J, 1988, ARCH NEUROL-CHICAGO, V45, P1130, DOI 10.1001/archneur.1988.00520340084017; SOTELO J, 1984, NEW ENGL J MED, V310, P1001, DOI 10.1056/NEJM198404193101601; SOTELO J, 1987, CURRENT THERAPY NEUR, P114; Sotelo-Morales J, 1989, Gac Med Mex, V125, P31; 1991, LANCET, V337, P1193	39	161	162	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 3	1992	327	10					696	701		10.1056/NEJM199209033271005	http://dx.doi.org/10.1056/NEJM199209033271005			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JL235	1495522				2022-12-01	WOS:A1992JL23500005
J	VOGELMANN, AM; ACKERMAN, TP; TURCO, RP				VOGELMANN, AM; ACKERMAN, TP; TURCO, RP			ENHANCEMENTS IN BIOLOGICALLY EFFECTIVE ULTRAVIOLET-RADIATION FOLLOWING VOLCANIC-ERUPTIONS	NATURE			English	Article							HETEROGENEOUS CHEMISTRY; PALMER-STATION; EL-CHICHON; OZONE; ANTARCTICA; SKIN	AEROSOLS injected into the stratosphere by large volcanic eruptions may induce ozone destruction through processes including heterogeneous chemical reactions. The effect of ozone reductions on surface ultraviolet irradiation is not obvious, however, because aerosols also increase the reflection of sunlight. Here we use a radiative transfer model to estimate the changes in biologically effective ultraviolet radiation (UV-BE) at the Earth's surface produced by the El Chichon (1982) and Mount Pinatubo (1991) eruptions. We find that in both cases surface UV-BE intensity can increase because the effect of ozone depletion outweighs the increased scattering.	UNIV CALIF LOS ANGELES,DEPT ATMOSPHER SCI,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles	VOGELMANN, AM (corresponding author), PENN STATE UNIV,DEPT METEOROL,UNIV PK,PA 16802, USA.		Vogelmann, Andrew M/M-8779-2014	Vogelmann, Andrew M/0000-0003-1918-5423				ACKERMAN TP, 1976, J APPL METEOROL, V15, P28, DOI 10.1175/1520-0450(1976)015<0028:IRTIPA>2.0.CO;2; ANGELL JK, 1985, MON WEATHER REV, V113, P641, DOI 10.1175/1520-0493(1985)113<0641:GBASEF>2.0.CO;2; ANGELL JK, 1988, J APPL METEOROL, V27, P91, DOI 10.1175/1520-0450(1988)027<0091:AUTOTV>2.0.CO;2; BERGER DS, 1976, PHOTOCHEM PHOTOBIOL, V24, P587, DOI 10.1111/j.1751-1097.1976.tb06877.x; BLUMTHALER M, 1988, PHOTOCHEM PHOTOBIOL, V48, P85, DOI 10.1111/j.1751-1097.1988.tb02790.x; BLUTH GJS, 1992, GEOPHYS RES LETT, V19, P151, DOI 10.1029/91GL02792; BOJKOV RD, 1987, MON WEATHER REV, V115, P2187, DOI 10.1175/1520-0493(1987)115<2187:TAAIOD>2.0.CO;2; BRASSEUR GP, 1990, NATURE, V348, P626, DOI 10.1038/348626a0; CALDWELL MM, 1986, STRATOSPHERIC OZONE, P87; CHANDRA S, 1991, GEOPHYS RES LETT, V18, P2277, DOI 10.1029/91GL02779; COOHILL TP, 1991, IMPACT GLOBAL CLIMAT; CUZZI JN, 1982, J ATMOS SCI, V39, P917, DOI 10.1175/1520-0469(1982)039<0917:TDFSAF>2.0.CO;2; FREDERICK JE, 1988, PHOTOCHEM PHOTOBIOL, V47, P571, DOI 10.1111/j.1751-1097.1988.tb08846.x; Goody R., 1964, ATMOSPHERIC RAD, V1; HOFMANN DJ, 1989, J GEOPHYS RES-ATMOS, V94, P5029, DOI 10.1029/JD094iD04p05029; HOFMANN DJ, 1987, REV GEOPHYS, V25, P743, DOI 10.1029/RG025i004p00743; Hunter J. R., 1982, ROLE SOLAR ULTRAVIOL, P459; LUBIN D, 1989, GEOPHYS RES LETT, V16, P783, DOI 10.1029/GL016i008p00783; LUBIN D, 1990, J GEOPHYS RES-ATMOS, V95, P13883, DOI 10.1029/JD095iD09p13883; MADRONICH S, 1992, GEOPHYS RES LETT, V19, P37, DOI 10.1029/91GL02954; McCormick M. P., 1984, GEOFISICA INT, V23, P187; MICHELANGELI DV, 1989, J GEOPHYS RES-ATMOS, V94, P18429, DOI 10.1029/JD094iD15p18429; MICHELANGELI DV, 1992, J GEOPHYS RES-ATMOS, V97, P865, DOI 10.1029/91JD01308; MOLINA LT, 1986, J GEOPHYS RES-ATMOS, V91, P14501, DOI 10.1029/JD091iD13p14501; PARRISH JA, 1982, PHOTOCHEM PHOTOBIOL, V36, P187, DOI 10.1111/j.1751-1097.1982.tb04362.x; PINTO JP, 1989, J GEOPHYS RES-ATMOS, V94, P11165, DOI 10.1029/JD094iD08p11165; PRATHER M, 1992, J GEOPHYS RES-ATMOS, V97, P10187, DOI 10.1029/92JD00845; SETLOW RB, 1974, P NATL ACAD SCI USA, V71, P3363, DOI 10.1073/pnas.71.9.3363; SHETTLE EP, 1979, ADA085951; SMITH RC, 1992, SCIENCE, V255, P952, DOI 10.1126/science.1546292; STAMNES K, 1990, GEOPHYS RES LETT, V17, P2181, DOI 10.1029/GL017i012p02181; TERAMURA AH, 1987, AM J BOT, V74, P975, DOI 10.2307/2443936; TOON OB, 1976, J APPL METEOROL, V15, P225, DOI 10.1175/1520-0450(1976)015<0225:AGAMOA>2.0.CO;2; TURCO RP, 1992, BER BUNSEN PHYS CHEM, V96, P323, DOI 10.1002/bbpc.19920960319; VALERO FPJ, 1992, GEOPHYS RES LETT, V19, P163, DOI 10.1029/92GL00074; Worrest R, 1982, ROLE SOLAR ULTRAVIOL, V7, P429; 1991, ENV EFFECTS OZONE DE; 1986, 16 WORLD MET ORG REP, V1; 1976, NOAAST761562 US STAN	39	34	34	1	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 3	1992	359	6390					47	49		10.1038/359047a0	http://dx.doi.org/10.1038/359047a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL662	1522884				2022-12-01	WOS:A1992JL66200048
J	WIEBEL, FF; KUNAU, WH				WIEBEL, FF; KUNAU, WH			THE PAS2 PROTEIN ESSENTIAL FOR PEROXISOME BIOGENESIS IS RELATED TO UBIQUITIN-CONJUGATING ENZYMES	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; ENCODES; GENE; DEGRADATION; MEMBER; FIBROBLASTS; FAMILY; SYSTEM	IN the yeast Saccharomyces cerevisiae, PAS genes are essential for the biogenesis and proliferation of peroxisomes1,2. Recently, the first two genes, PAS1 (ref. 3) and PAS3 (ref. 4), have been characterized. Here we report the cloning and sequencing of the PAS2 gene. It encodes a new member of the ubiquitin-conjugating (UBC) protein family5-7 and is the first member associated with peroxisomes. The proposed function of the Pas2 protein as a UBC enzyme (UBC10) is supported by the fact that site-directed mutagenesis of a strictly conserved and functionally essential cysteine residue of UBC proteins leads to mutant Pas2 proteins unable to complement pas2 mutant strains. Ubiquitination of proteins is known to play an important part in DNA repair, sporulation, cell cycle control and degradation of abnormal proteins5-8. We provide evidence for a crucial role of the ubiquitin-conjugation pathway in organelle formation.			WIEBEL, FF (corresponding author), RUHR UNIV BOCHUM,INST PHYSIOL CHEM,ZELLBIOCHEM ABT,W-4630 BOCHUM 1,GERMANY.							DESHAIES RJ, 1989, J CELL BIOL, V109, P2653, DOI 10.1083/jcb.109.6.2653; ERDMANN R, 1991, CELL, V64, P499, DOI 10.1016/0092-8674(91)90234-P; ERDMANN R, 1989, P NATL ACAD SCI USA, V86, P5419, DOI 10.1073/pnas.86.14.5419; ERDMANN R, IN PRESS CELL BIOCH; FINLEY D, 1991, ANNU REV CELL BIOL, V7, P25, DOI 10.1146/annurev.cb.07.110191.000325; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; GROPPER R, 1991, J BIOL CHEM, V266, P3602; HERSHKO A, 1991, TRENDS BIOCHEM SCI, V16, P265, DOI 10.1016/0968-0004(91)90101-Z; HOHFELD J, 1991, J CELL BIOL, V114, P1167, DOI 10.1083/jcb.114.6.1167; HOHFELD J, IN PRESS NEW COMPREH; Jentsch S, 1992, Trends Cell Biol, V2, P98, DOI 10.1016/0962-8924(92)90013-D; JENTSCH S, 1991, BIOCHIM BIOPHYS ACTA, V1089, P127, DOI 10.1016/0167-4781(91)90001-3; JENTSCH S, 1990, TRENDS BIOCHEM SCI, V15, P195, DOI 10.1016/0968-0004(90)90161-4; JOHNSON ES, 1992, EMBO J, V11, P497, DOI 10.1002/j.1460-2075.1992.tb05080.x; LASZLO L, 1990, FEBS LETT, V261, P365, DOI 10.1016/0014-5793(90)80593-8; QIN S, 1991, J BIOL CHEM, V266, P15549; REYNOLDS P, 1985, P NATL ACAD SCI USA, V82, P168, DOI 10.1073/pnas.82.1.168; ROSE MD, 1990, METHODS YEAST GENETI; SANTOS MJ, 1988, J BIOL CHEM, V263, P10502; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; SEUFERT W, 1990, EMBO J, V9, P4535, DOI 10.1002/j.1460-2075.1990.tb07905.x; SUNG P, 1990, P NATL ACAD SCI USA, V87, P2695, DOI 10.1073/pnas.87.7.2695; ZHUANG ZP, 1992, J BIOL CHEM, V267, P591	23	170	175	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 3	1992	359	6390					73	76		10.1038/359073a0	http://dx.doi.org/10.1038/359073a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL662	1326082				2022-12-01	WOS:A1992JL66200057
J	YOSHIKAWA, K; AIZAWA, T; HAYASHI, Y				YOSHIKAWA, K; AIZAWA, T; HAYASHI, Y			DEGENERATION INVITRO OF POSTMITOTIC NEURONS OVEREXPRESSING THE ALZHEIMER AMYLOID PROTEIN-PRECURSOR	NATURE			English	Article							CARCINOMA CELL-LINE; SENILE PLAQUES; DOWNS-SYNDROME; MESSENGER-RNA; DISEASE; DIFFERENTIATION; EXPRESSION; LOCALIZATION; MICROGLIA; PEPTIDE	A PATHOLOGICAL hallmark of Alzheimer's disease is the deposition of amyloid fibrils in the brain. The principal component of amyloid fibrils is beta/A4 amyloid protein1,2, which can be generated by the aberrant processing of a large membrane-bound glycoprotein, the beta/A4 amyloid protein precursor (App)3. To test whether overexpression of APP generates abnormally processed derivatives that affect the viability of neurons, we stably transfected full-length human APP complementary DNA into murine embryonal carcinoma P19 cells. These cells differentiate into post-mitotic neurons and astrocytes after exposure to retinoic acid4-6. When differentiation of the APP cDNA-transfected P19 cells was induced, all neurons showed severe degenerative changes and disappeared within a few days. The degenerating neurons contained large amounts of APP derivatives that were truncated at the amino terminus and encompassed the entire beta/A4 domain. These results suggest that post-mitotic neurons are vulnerable to overexpressed APP, which undergoes aberrant processing to generate potentially amyloidogenic fragments.	TOKYO INST PSYCHIAT, DEPT MOLEC BIOL, SETAGAYA KU, TOKYO 153, JAPAN; MORINAGA MILK IND CO LTD, BIOCHEM RES LAB, KANAGAWA 228, JAPAN	Tokyo Institute of Psychiatry; Morinaga Milk Industry Company, Ltd								AIZAWA T, 1991, DEV BRAIN RES, V59, P89, DOI 10.1016/0165-3806(91)90033-F; ALLSOP D, 1989, NEUROPATH APPL NEURO, V15, P531, DOI 10.1111/j.1365-2990.1989.tb01252.x; BELL JC, 1986, MOL CELL BIOL, V6, P617, DOI 10.1128/MCB.6.2.617; BENOWITZ LI, 1989, EXP NEUROL, V106, P237, DOI 10.1016/0014-4886(89)90156-8; CATALDO AM, 1990, P NATL ACAD SCI USA, V87, P3861, DOI 10.1073/pnas.87.10.3861; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; FUKUCHI K, 1992, BIOCHEM BIOPH RES CO, V182, P165, DOI 10.1016/S0006-291X(05)80126-3; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V122, P1131, DOI 10.1016/0006-291X(84)91209-9; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; HAASS C, 1991, J NEUROSCI, V11, P3783; JOHNSTONE EM, 1991, MOL BRAIN RES, V10, P299, DOI 10.1016/0169-328X(91)90088-F; JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; MARUYAMA K, 1991, BIOCHEM BIOPH RES CO, V178, P291, DOI 10.1016/0006-291X(91)91812-Q; MARUYAMA K, 1990, NATURE, V347, P566, DOI 10.1038/347566a0; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MCBURNEY MW, 1988, J NEUROSCI, V8, P1063; MCBURNEY MW, 1982, NATURE, V299, P165, DOI 10.1038/299165a0; NUKADA T, 1987, FEBS LETT, V211, P5, DOI 10.1016/0014-5793(87)81263-2; PALMERT MR, 1988, SCIENCE, V241, P1080, DOI 10.1126/science.2457949; PROBST A, 1991, ACTA NEUROPATHOL, V83, P21, DOI 10.1007/BF00294426; Runnicki M.A., 1987, TERATOCARCINOMAS EMB, P19; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; YAMADA T, 1989, BIOCHEM BIOPH RES CO, V158, P906, DOI 10.1016/0006-291X(89)92808-8; YANKNER BA, 1989, SCIENCE, V245, P417, DOI 10.1126/science.2474201; YOSHIKAWA K, 1990, BIOCHEM BIOPH RES CO, V171, P204, DOI 10.1016/0006-291X(90)91377-5	28	182	185	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 3	1992	359	6390					64	67		10.1038/359064a0	http://dx.doi.org/10.1038/359064a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL662	1301020				2022-12-01	WOS:A1992JL66200054
J	RESCH, KL; ERNST, E; MATRAI, A; PAULSEN, HF				RESCH, KL; ERNST, E; MATRAI, A; PAULSEN, HF			FIBRINOGEN AND VISCOSITY AS RISK-FACTORS FOR SUBSEQUENT CARDIOVASCULAR EVENTS IN STROKE SURVIVORS	ANNALS OF INTERNAL MEDICINE			English	Article						CEREBROVASCULAR DISORDERS; FIBRINOGEN; RHEOLOGY; CARDIOVASCULAR DISEASES; MYOCARDIAL INFARCTION	ISCHEMIC-HEART-DISEASE; PLASMA-FIBRINOGEN; MYOCARDIAL-INFARCTION; CEREBRAL INFARCTION; BLOOD	Objective: To investigate whether abnormalities in blood viscosity predict a poor prognosis for subsequent cardiovascular events in stroke survivors. Design: Nested case-control study among a cohort of survivors of a first stroke, followed for an average of 2 years. Patients with a second stroke, myocardial infarction, or cardiovascular death were matched with patients who did not have such events (control patients). Setting: Buchberg-Klinik, Bad Tolz, Germany, a specialized center for stroke rehabilitation. Patients: A total of 625 consecutive patients. Twenty-one patients (3.5%) were lost to follow-up. Sixty pairs were matched. Measurements: Native and hematocrit-standardized blood viscosity at three shear rates, hematocrit, plasma viscosity, fibrinogen, erythrocyte sedimentation rate, total leukocyte count, and the matching variables. Results: Eighty-five patients had a second stroke, myocardial infarction, or died due to a cardiovascular event. Patients with re-events had higher blood viscosity and fibrinogen levels than the control patients. In the 60 matched pairs, the mean of the paired differences between patients with re-events and control patients was 5.03 mPa . s (95% Cl, 1.262 to 8.941; P = 0.01) for native blood viscosity at shear rate 0.7 s-1, for plasma viscosity, 0.044 mPa . s (CI, 0.006 to 0.083; P > 0.02), and for fibrinogen, 0.056 g/L (CI, 0.010 to 0.101; P > 0.02). Odds ratios were significantly increased only for plasma viscosity (odds ratio, 2.86; CI, 1.06 to 8.43) and fibrinogen (odds ratio, 3.67; CI, 1.31 to 11.69). Conclusions: Hyperfibrinogenemia is an independent risk factor for cardiovascular events in stroke survivors. Intervention trials with fibrinogen lowering measures may be warranted.	UNIV VIENNA, DEPT PHYS MED & REHABIL, WAHRINGER GURTEL 18-20, A-1097 VIENNA, AUSTRIA; BUCHBERG KLIN, W-8170 BAD TOLZ, GERMANY	University of Vienna								BONITA R, 1992, LANCET, V339, P342, DOI 10.1016/0140-6736(92)91658-U; CHIEN S, 1987, CLIN HEMORHEOL, P125; COULL BM, 1991, STROKE, V22, P162, DOI 10.1161/01.STR.22.2.162; DIMINNO G, 1990, ARTERIOSCLEROSIS, V10, P1, DOI 10.1161/01.ATV.10.1.1; ERNST E, 1990, CLIN HEMORHEOL, V10, P525; ERNST E, 1988, STROKE, V19, P634, DOI 10.1161/01.STR.19.5.634; ERNST E, 1990, J INTERN MED, V227, P365, DOI 10.1111/j.1365-2796.1990.tb00174.x; ERNST E, 1991, BRIT MED J, V303, P596, DOI 10.1136/bmj.303.6803.596; ERNST E, 1986, HERZ KREISLAUF, V18, P30; ERNST E, 1989, HAMORHEOLOGIE THEORI, P247; ERNST E, 1992, IN PRESS J CLIN PATH; FISHER M, 1991, STROKE, V22, P1164, DOI 10.1161/01.STR.22.9.1164; GARDNER MJ, 1986, BMJ-BRIT MED J, V292, P746, DOI 10.1136/bmj.292.6522.746; GROTTA J, 1982, STROKE, V13, P296, DOI 10.1161/01.STR.13.3.296; HIER DB, 1991, STROKE, V22, P155, DOI 10.1161/01.STR.22.2.155; International Committee for Standardization in Haematology Expert Panel on Blood Cell Sizing, 1980, J CLIN PATHOL, V33, P1; JUNGQUIST G, 1991, J CLIN EPIDEMIOL, V44, P347, DOI 10.1016/0895-4356(91)90073-I; KANNEL WB, 1987, JAMA-J AM MED ASSOC, V258, P1183, DOI 10.1001/jama.258.9.1183; Lowe GDO, 1987, CLIN HEMORHEOL, P195; LOWE GOD, 1987, CEREBRAL ISCHEMIA HE, P496; MATRAD A, 1985, CLIN HEMORHEOL, V5, P622; MATRAI A, 1984, Biorheology, P99; MEADE TW, 1986, LANCET, V2, P533, DOI 10.1016/S0140-6736(86)90111-X; MERRILL EW, 1969, PHYSIOL REV, V49, P863, DOI 10.1152/physrev.1969.49.4.863; OTT EO, 1974, STROKE, V5, P330, DOI 10.1161/01.STR.5.3.330; PETERSEN WE, 1953, J LAB CLIN MED, V42, P641; RIDKER PM, 1991, CIRCULATION, V83, P1098, DOI 10.1161/01.CIR.83.3.1098; Schlesselman J. J, 1982, CASE CONTROL STUDIES, P207; SPINELLI F R, 1974, Biorheology, V11, P301; STONE MC, 1985, J ROY COLL GEN PRACT, V35, P565; SYRJANEN J, 1989, J CLIN PATHOL, V42, P63, DOI 10.1136/jcp.42.1.63; THOMAS DJ, 1987, CEREBRAL ISCHEMIA HE, P301; WILHELMSEN L, 1984, NEW ENGL J MED, V311, P501, DOI 10.1056/NEJM198408233110804; WOLF PA, 1991, STROKE, V22, P983, DOI 10.1161/01.STR.22.8.983; YARNELL JWG, 1991, CIRCULATION, V83, P836, DOI 10.1161/01.CIR.83.3.836; 1984, J CLIN PATHOL, V34, P1147	36	126	130	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1992	117	5					371	375		10.7326/0003-4819-117-5-371	http://dx.doi.org/10.7326/0003-4819-117-5-371			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JK678	1503327				2022-12-01	WOS:A1992JK67800004
J	CHOY, DSJ; ALTMAN, P				CHOY, DSJ; ALTMAN, P			THE CARDIOVASCULAR-SYSTEM OF BAROSAURUS - AN EDUCATED GUESS	LANCET			English	Article									COLUMBIA UNIV COLL PHYS & SURG,ST LUKES ROOSEVELT HOSP CTR,INVEST CARDIOL LAB,NEW YORK,NY 10032	Columbia University; Mount Sinai St. Luke's; Mount Sinai West								GOETZ R H, 1955, S Afr Med J, V29, P773; GOETZ RH, 1960, CIRC RES, V8, P1049, DOI 10.1161/01.RES.8.5.1049; LILLYWHITE HB, 1991, NAT HIST, V100, P33	3	17	17	0	13	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 29	1992	340	8818					534	536		10.1016/0140-6736(92)91722-K	http://dx.doi.org/10.1016/0140-6736(92)91722-K			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JL234	1354287				2022-12-01	WOS:A1992JL23400014
J	FERRO, D; VIOLI, F; QUINTARELLI, C; SEBASTIANELLI, A; DAMELIO, R; ZICHELLA, L; BALSANO, F				FERRO, D; VIOLI, F; QUINTARELLI, C; SEBASTIANELLI, A; DAMELIO, R; ZICHELLA, L; BALSANO, F			FIBRINOLYTIC BALANCE AND LUPUS ANTICOAGULANT IN PATIENTS WITH REPEATED SPONTANEOUS FETAL LOSS	BRITISH MEDICAL JOURNAL			English	Article							PREGNANCY		UNIV ROME,IST CLIN MED GEN & TERAPIA MED 1,VIALE POLICLIN,I-00185 ROME,ITALY; UNIV ROME LA SAPIENZA,IST CLIN MED 1,I-00185 ROME,ITALY	Sapienza University Rome; Sapienza University Rome			Violi, Francesco/K-1509-2016; ferro, domenico/AAT-5861-2020	Violi, Francesco/0000-0002-6610-7068; 				GRIS JC, 1990, BRIT MED J, V300, P1500, DOI 10.1136/bmj.300.6738.1500; JOHNSON PM, 1989, BRIT J OBSTET GYNAEC, V96, P1231, DOI 10.1111/j.1471-0528.1989.tb03203.x; LUBBE WF, 1984, BRIT J OBSTET GYNAEC, V91, P357, DOI 10.1111/j.1471-0528.1984.tb05923.x; TRIPLETT DA, 1989, AM J REPROD IMMUNOL, V20, P52, DOI 10.1111/j.1600-0897.1989.tb00639.x; VIOLI F, 1990, BRIT MED J, V300, P1099, DOI 10.1136/bmj.300.6732.1099	5	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 29	1992	305	6852					504	505		10.1136/bmj.305.6852.504	http://dx.doi.org/10.1136/bmj.305.6852.504			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JL609	1392996	Bronze, Green Published, Green Submitted			2022-12-01	WOS:A1992JL60900018
J	JOSEPH, CA; WATSON, JM; FERN, KJ				JOSEPH, CA; WATSON, JM; FERN, KJ			BCG IMMUNIZATION IN ENGLAND AND WALES - A SURVEY OF POLICY AND PRACTICE IN SCHOOLCHILDREN AND NEONATES	BRITISH MEDICAL JOURNAL			English	Article							VACCINATION; TUBERCULOSIS	Objective-To determine the policy and practice of district health authorities in England and Wales for BCG immunisation in schoolchildren and neonates. Design-Self completion postal questionnaire survey. Participants-District immunisation coordinators. Setting-199 district health authorities in England and Wales. Results-Questionnaires were received from 186 districts, a response rate of 94%. Considerable uniformity was observed in many aspects of BCG immunisation policy and practice but some important variations were found. 15 districts no longer carry out a routine schools programme. 148 districts offer BCG to selected groups of neonates and five to all neonates, but 31 districts do not offer BCG to this age group. The recommended action in response to different levels of tuberculin sensitivity in schoolchildren and neonates varied among districts. Conclusions-Despite the recommendations of the Joint Committee on Vaccination and Immunisation some districts do not offer BCG immunisation to neonates at high risk of tuberculosis and there are important variations in other aspects of BCG policy.			JOSEPH, CA (corresponding author), PUBL HLTH LAB SERV,CTR COMMUNICABLE DIS SURVEILLANCE,RESP DIS SECT,LONDON NW9 KEQ,ENGLAND.							CITRON KM, 1990, BRIT MED J, V301, P1275, DOI 10.1136/bmj.301.6763.1275; CUNDALL DB, 1988, ARCH DIS CHILD, V63, P964, DOI 10.1136/adc.63.8.964; CURTIS HM, 1984, LANCET, V1, P145; Dean A. G., 1990, EPI INFO VERSION 5 W; FRANKENBERG RA, 1991, J PUBLIC HEALTH MED, V13, P209, DOI 10.1093/oxfordjournals.pubmed.a042620; MILLER CL, 1984, BRIT MED J, V288, P564, DOI 10.1136/bmj.288.6416.564; PACKE GE, 1988, ARCH DIS CHILD, V63, P277, DOI 10.1136/adc.63.3.277; RODRIGUES LC, 1991, J EPIDEMIOL COMMUN H, V45, P78, DOI 10.1136/jech.45.1.78; SPRINGETT VH, 1990, THORAX, V45, P83, DOI 10.1136/thx.45.2.83; SUTHERLAND I, 1989, J EPIDEMIOL COMMUN H, V43, P15, DOI 10.1136/jech.43.1.15; Watson J M, 1991, CDR (Lond Engl Rev), V1, pR13; 1985, BMJ, V291, P658; IN PRESS IMMUNISATIO; 1974, COMMUNICABLE DISEASE; 1927, ANNUAL REPORT; 1985, SCH BCG VACCINATION	16	25	25	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 29	1992	305	6852					495	498		10.1136/bmj.305.6852.495	http://dx.doi.org/10.1136/bmj.305.6852.495			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JL609	1392994	Green Submitted, Green Published, Bronze			2022-12-01	WOS:A1992JL60900015
J	REES, MR; BROWNE, T; SIVANANTHAN, UM; WHITTAKER, S; HICK, D; VERMA, SP; TAN, LB; DAVIES, GA				REES, MR; BROWNE, T; SIVANANTHAN, UM; WHITTAKER, S; HICK, D; VERMA, SP; TAN, LB; DAVIES, GA			CARDIAC RESUSCITATION WITH PERCUTANEOUS CARDIOPULMONARY SUPPORT	LANCET			English	Note							ACUTE MYOCARDIAL-INFARCTION; BYPASS; SHOCK	Percutaneous cardiopulmonary support (CPS) was initiated in 9 patients to provide haemodynamic stability after failure of conventional resuscitation. 4 patients were in cardiogenic shock and 4 remained in asystole, with 1 in resistant ventricular fibrillation, after cardiac arrest. During CPS for those in cardiogenic shock, the mean intra-arterial pressures ranged from 65 to 100 mm Hg (mean 84), at flow rates of between 3 to 5 l/min (mean 3.9). 2 patients underwent technically successful coronary angioplasty. No patient in this group survived. In the cardiac arrest group, acceptable mean intra-arterial blood pressures were achieved (mean 95, range 90-100 mm Hg) at flow rates of between 2 to 3 l/min (mean 2.6). All 5 subjects underwent technically successful coronary angioplasty whilst on CPS. 4 survived. 2 were alive and well at 12 months follow-up, 1 of whom had returned to work; the third is alive and well at 4 months.			REES, MR (corresponding author), KILLINGBECK HOSP,REG CARDIOTHORAC CTR,CARDIAC RES UNIT,YORK RD,LEEDS LS14 6UQ,ENGLAND.		Rees, Michael/Y-4640-2019					AFIFI AA, 1974, AM J CARDIOL, V33, P826, DOI 10.1016/0002-9149(74)90628-6; DEBARD ML, 1981, ANN EMERG MED, V10, P408, DOI 10.1016/S0196-0644(81)80307-1; LITZIE AK, 1987, P AM ACAD CV PERFUSI, V8, P60; PROCTOR E., 1967, CARDIOVASC RES, V1, P189, DOI 10.1093/cvr/1.2.189; ROZENBAUM EA, 1988, CRIT CARE MED, V16, P583, DOI 10.1097/00003246-198806000-00003; SAFAR P, 1990, AM J EMERG MED, V8, P55, DOI 10.1016/0735-6757(90)90298-E; SHAWL FA, 1989, AM J CARDIOL, V64, P967, DOI 10.1016/0002-9149(89)90791-1; TOPOL E, 1988, ACUTE CORONARY INTER, P195	8	33	33	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 29	1992	340	8818					513	514		10.1016/0140-6736(92)91711-G	http://dx.doi.org/10.1016/0140-6736(92)91711-G			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JL234	1354278				2022-12-01	WOS:A1992JL23400005
J	SAVARIT, D; DECOCK, KM; SCHUTZ, R; KONATE, S; LACKRITZ, E; BONDURAND, A				SAVARIT, D; DECOCK, KM; SCHUTZ, R; KONATE, S; LACKRITZ, E; BONDURAND, A			RISK OF HIV-INFECTION FROM TRANSFUSION WITH BLOOD NEGATIVE FOR HIV ANTIBODY IN A WEST AFRICAN CITY	BRITISH MEDICAL JOURNAL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PREVALENCE; TRANSMISSION; AIDS	Objective-To estimate the risk of infection with HIV (HIV 1 or HIV 2, or both) from transfusion of a screened unit of blood in a high prevalence area in west Africa. Design-Retrospective cohort study for january-July 1991. Setting-National Blood Transfusion Centre, Abidjan, Cote d'Ivoire. Subjects-Repeat donors (5831 units of blood) and first time donors (5076 units) in the first five months of 1991. Main outcome measures-Prevalence and estimated incidence of HIV infection in repeat and first time donors; estimated rate of potentially infected, HIV antibody negative units; and rate of (false negative) potentially infected units assuming a laboratory test sensitivity of 99%. Results-Overall HIV prevalence was 11.0% in first time donors and 2.1% in repeat donors. In the first seven months of 1991, 29 HIV antibody positive (27 HIV 1, 1 HIV 2, 1 dually reactive) donors with a seronegative unit of blood earlier in the year were identified; 26 had donated blood eight weeks or less before their estimated dates of seroconversion and may have been infectious (minimum rate 26/5831 (4-5/1000 potentially infected units)). Estimated incidence of infection in repeat donors was 1.2-2.5%. Laboratory test insensitivity would result in an estimated 1.1/1000 false negative units from first time donors and 0.211000 units from regular donors. The overall rate of potentially infected units (all donors, seroconversions, and errors) was estimated at 5.4-10.6/1000. Conclusions-The risk of HIV infection from a single unit of blood remains substantial (5.4-10.6/1000 units). To prevent infection from blood transfusion in areas of high incidence and prevalence of HIV all but absolutely essential transfusions should be avoided, and donors with low incidence of HIV infection should be selected.	CTR NATL TRANSFUS SANGUINE,ABIDJAN,COTE IVOIRE; CTR DIS CONTROL,NATL CTR INFECT DIS,DIV HIV AIDS,ATLANTA,GA 30333; CTR DIS CONTROL,DIV PARASIT DIS,MALARIA BRANCH,ATLANTA,GA 30333	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA				Lackritz, Eve/0000-0002-5397-7291				ALTER HJ, 1990, NEW ENGL J MED, V323, P1312, DOI 10.1056/NEJM199011083231905; BROWN C, 1991, AIDS, V5, P89, DOI 10.1097/00002030-199101000-00013; BUSCH MP, 1991, NEW ENGL J MED, V325, P1, DOI 10.1056/NEJM199107043250101; CHIEWSILP P, 1991, LANCET, V338, P1341, DOI 10.1016/0140-6736(91)92650-Q; COUROUCE AM, 1990, REV FR TRANSFUS HEM, V33, P431, DOI 10.1016/S1140-4639(05)80060-7; CUMMING PD, 1989, NEW ENGL J MED, V321, P941, DOI 10.1056/NEJM198910053211405; DECOCK KM, 1988, AM J EPIDEMIOL, V127, P1250, DOI 10.1093/oxfordjournals.aje.a114917; DECOCK KM, 1990, AIDS, V4, P875, DOI 10.1097/00002030-199009000-00007; JULIEN AM, 1988, LANCET, V2, P1248; MARCUS R, 1988, NEW ENGL J MED, V319, P1118, DOI 10.1056/NEJM198810273191703; MILLER HG, 1990, AIDS 2ND DECADE, P289; NGALY B, 1988, NEW ENGL J MED, V319, P1123, DOI 10.1056/NEJM198810273191704; PIOT P, 1988, SCIENCE, V239, P573, DOI 10.1126/science.3277271; RUTHERFORD GW, 1990, BRIT MED J, V301, P1183, DOI 10.1136/bmj.301.6762.1183; WARD JW, 1988, NEW ENGL J MED, V318, P473, DOI 10.1056/NEJM198802253180803; ZUCK TF, 1988, NEW ENGL J MED, V318, P511, DOI 10.1056/NEJM198802253180809; 1990, B WORLD HEALTH ORGAN, V68, P262	17	35	35	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 29	1992	305	6852					498	502		10.1136/bmj.305.6852.498	http://dx.doi.org/10.1136/bmj.305.6852.498			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JL609	1327367	Green Published, Green Submitted, Bronze			2022-12-01	WOS:A1992JL60900016
J	TOMKINS, CM				TOMKINS, CM			HIV TRANSMISSION AND THE LAW	LANCET			English	Editorial Material							POLICY; AIDS				TOMKINS, CM (corresponding author), MED DEF UNION,LONDON,ENGLAND.							BAYER R, 1991, NEW ENGL J MED, V324, P1500, DOI 10.1056/NEJM199105233242111; GOSTIN LO, 1990, JAMA-J AM MED ASSOC, V263, P1951; KRASNIK A, 1989, SOC SCI MED, V29, P577, DOI 10.1016/0277-9536(89)90203-7; LANSDELL GT, 1991, MED J AUSTRALIA, V154, P61, DOI 10.5694/j.1326-5377.1991.tb112856.x; IN PRESS AUSTR HIV A	5	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 29	1992	340	8818					543	543		10.1016/0140-6736(92)91732-N	http://dx.doi.org/10.1016/0140-6736(92)91732-N			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JL234	1354289				2022-12-01	WOS:A1992JL23400017
J	AVNI, A; ANDERSON, JD; HOLLAND, N; ROCHAIX, JD; GROMETELHANAN, Z; EDELMAN, M				AVNI, A; ANDERSON, JD; HOLLAND, N; ROCHAIX, JD; GROMETELHANAN, Z; EDELMAN, M			TENTOXIN SENSITIVITY OF CHLOROPLASTS DETERMINED BY CODON-83 OF BETA-SUBUNIT OF PROTON-ATPASE	SCIENCE			English	Article							CHLAMYDOMONAS-REINHARDTII; RHODOSPIRILLUM-RUBRUM; COUPLING FACTOR-1; ESCHERICHIA-COLI; ATPB GENE; POLYPHENOL OXIDASE; H+-ATPASE; SYNTHASE; NICOTIANA; F1-ATPASE	Tentoxin is a naturally occurring phytotoxic peptide that causes seedling chlorosis and arrests growth in sensitive plants and algae. In vitro, it inhibits activity of the beta-subunit of the plastid proton-adenosine triphosphatase (ATPase) from sensitive species. Plastid atpB genes from six closely related, tentoxin-sensitive or -resistant Nicotiana species differ at codon 83, according to their response to the toxin: glutamate correlated with resistance and aspartate correlated with sensitivity. The genetic relevance of this site was confirmed in Chlamydomonas reinhardtii by chloroplast transformation. The alga, normally tentoxin-resistant, was rendered tentoxin-sensitive by mutagenesis of its plastid atpB gene at codon 83. Codon 83 may represent a critical site on the beta-subunit that does not compete with nucleotide binding or other catalytic activities.	WEIZMANN INST SCI,DEPT PLANT GENET,IL-76100 REHOVOT,ISRAEL; UNIV GENEVA,DEPT MOLEC BIOL,CH-1211 GENEVA,SWITZERLAND; WEIZMANN INST SCI,DEPT BIOCHEM,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science; University of Geneva; Weizmann Institute of Science			Rochaix, Jean-David/ABC-5243-2020					ALSHAWI MK, 1988, J BIOL CHEM, V263, P19633; ARNTZEN CJ, 1972, BIOCHIM BIOPHYS ACTA, V283, P539, DOI 10.1016/0005-2728(72)90273-3; AVITAL S, 1991, J BIOL CHEM, V266, P7067; AVIV D, 1980, THEOR APPL GENET, V56, P145, DOI 10.1007/BF00286675; AVNI A, 1991, J BIOL CHEM, V266, P7317; AVNI A, 1991, MOL GEN GENET, V225, P273, DOI 10.1007/BF00269859; AVNI A, UNPUB; AVRON M, 1960, BIOCHIM BIOPHYS ACTA, V40, P257, DOI 10.1016/0006-3002(60)91350-0; BENNETT J, 1976, PHYTOCHEMISTRY, V15, P263, DOI 10.1016/S0031-9422(00)89000-7; BOYNTON JE, 1988, SCIENCE, V240, P1534, DOI 10.1126/science.2897716; BURK LG, 1978, J HERED, V69, P117, DOI 10.1093/oxfordjournals.jhered.a108892; Clayton R. K., 1963, BACTERIAL PHOTOSYNTH, P495; DURBIN RD, 1977, PHYTOPATHOLOGY, V67, P602, DOI 10.1094/Phyto-67-602; FLICK CE, 1982, J HERED, V73, P264, DOI 10.1093/oxfordjournals.jhered.a109636; FLUHR R, 1981, MOL GEN GENET, V181, P484, DOI 10.1007/BF00428740; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; GALUN E, 1982, METHODS CHLOROPLAST, P139; GROMETELHANAN Z, 1985, J BIOL CHEM, V260, P2635; GROMETELHANAN Z, 1986, METHOD ENZYMOL, V126, P528; HOLLAND NB, UNPUB; JAGENDORF AT, 1991, CELL CULTURE SOMAT B, V7, P225; KLOTZ MG, 1988, PHYSIOL PLANTARUM, V74, P575, DOI 10.1111/j.1399-3054.1988.tb02021.x; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAX AR, 1986, PHYSIOL PLANTARUM, V66, P384, DOI 10.1111/j.1399-3054.1986.tb05939.x; LEMAIRE C, 1988, P NATL ACAD SCI USA, V85, P1344, DOI 10.1073/pnas.85.5.1344; MEYER WL, 1974, BIOCHEM BIOPH RES CO, V56, P234, DOI 10.1016/S0006-291X(74)80339-6; OHAD I, 1967, J CELL BIOL, V35, P521, DOI 10.1083/jcb.35.3.521; PARSONAGE D, 1988, J BIOL CHEM, V263, P4740; RICHTER ML, 1986, J BIOL CHEM, V261, P2109; ROBERTSON D, 1989, J BIOL CHEM, V264, P2331; Rochaix J. D., 1988, PLANT MOL BIOL PRACT, P253; SANGER F, 1981, SCIENCE, V214, P1205, DOI 10.1126/science.7302589; SELMAN BR, 1978, BIOCHIM BIOPHYS ACTA, V502, P29, DOI 10.1016/0005-2728(78)90128-7; SHINOZAKI K, 1983, GENE, V24, P147; STEELE JA, 1977, BIOCHIM BIOPHYS ACTA, V459, P347, DOI 10.1016/0005-2728(77)90036-6; STEELE JA, 1976, P NATL ACAD SCI USA, V73, P2245, DOI 10.1073/pnas.73.7.2245; STEELE JA, 1978, BIOCHIM BIOPHYS ACTA, V501, P72, DOI 10.1016/0005-2728(78)90096-8; TEMPLETON GE, 1972, MICROB TOXINS, V8, P160; VAUGHN KC, 1984, PHYSIOL PLANTARUM, V60, P257, DOI 10.1111/j.1399-3054.1984.tb04574.x; VAUGHN KC, 1981, PHYSIOL PLANTARUM, V53, P421, DOI 10.1111/j.1399-3054.1981.tb02725.x; WALKER JE, 1985, J MOL BIOL, V184, P677, DOI 10.1016/0022-2836(85)90313-4; WALLACH D, 1972, BIOCHIM BIOPHYS ACTA, V267, P124; WOESSNER JP, 1986, GENE, V44, P17; WOESSNER JP, 1984, PLANT MOL BIOL, V3, P177, DOI 10.1007/BF00016065; ZUMBRUNN G, 1989, TECHNIQUE, V1, P204; 1991, EMBL DATA LIBRARY RE	46	67	73	1	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 28	1992	257	5074					1245	1247		10.1126/science.1387730	http://dx.doi.org/10.1126/science.1387730			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL050	1387730				2022-12-01	WOS:A1992JL05000023
J	CHEN, J; MARTIN, BL; BRAUTIGAN, DL				CHEN, J; MARTIN, BL; BRAUTIGAN, DL			REGULATION OF PROTEIN SERINE-THREONINE PHOSPHATASE TYPE-2A BY TYROSINE PHOSPHORYLATION	SCIENCE			English	Article							EPIDERMAL GROWTH-FACTOR; CATALYTIC SUBUNIT ISOTYPES; RABBIT SKELETAL-MUSCLE; AMINO-ACID SEQUENCE; SEA STAR OOCYTES; S6 KINASE; PHOSPHOPROTEIN PHOSPHATASE; TRANSFORMING GENE; RAT-LIVER; INSULIN	Extracellular signals that promote cell growth activate cascades of protein kinases. The kinases are dephosphorylated and deactivated by a single type-2A protein phosphatase. The catalytic subunit of type-2A protein phosphatase was phosphorylated by tyrosine-specific protein kinases. Phosphorylation was enhanced in the presence of the phosphatase inhibitor okadaic acid, consistent with an autodephosphorylation reaction. More than 90% of the activity of phosphatase 2A was lost when thioadenosine triphosphate was used to produce a thiophosphorylated protein resistant to autodephosphorylation. Phosphorylation in vitro occurred exclusively on Tyr307. Phosphorylation was catalyzed by p60v-src, p56lck, epidermal growth factor receptors, and insulin receptors. Transient deactivation of phosphatase 2A might enhance transmission of cellular signals through kinase cascades within cells.	BROWN UNIV, DIV BIOL & MED, BIOCHEM SECT, PROVIDENCE, RI 02912 USA	Brown University								AHN NG, 1991, J BIOL CHEM, V266, P4220; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; ARINO J, 1988, P NATL ACAD SCI USA, V85, P4252, DOI 10.1073/pnas.85.12.4252; BALLOU LM, 1988, P NATL ACAD SCI USA, V85, P7154, DOI 10.1073/pnas.85.19.7154; BONISCHNETZLER M, 1987, P NATL ACAD SCI USA, V84, P7832, DOI 10.1073/pnas.84.22.7832; Chen J., UNPUB; CHUNG J, 1991, P NATL ACAD SCI USA, V88, P4981, DOI 10.1073/pnas.88.11.4981; CICRELLI MF, 1988, J BIOL CHEM, V263, P2009; COLLETT MS, 1980, NATURE, V285, P167, DOI 10.1038/285167a0; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GRATECOS D, 1974, BIOCHEM BIOPH RES CO, V58, P960, DOI 10.1016/S0006-291X(74)80237-8; HAYSTEAD TAJ, 1990, J BIOL CHEM, V265, P16571; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; IMAOKA T, 1983, J BIOL CHEM, V258, P1526; JENO P, 1988, P NATL ACAD SCI USA, V85, P406, DOI 10.1073/pnas.85.2.406; KAMIBAYASHI C, 1991, J BIOL CHEM, V266, P13251; KLARLUND JK, 1991, J BIOL CHEM, V266, P4052; KYRIAKIS JM, 1991, J BIOL CHEM, V266, P10043; LEE EYC, 1979, WIN MIAM S, V16, P483; LUTTRELL DK, 1988, MOL CELL BIOL, V8, P497, DOI 10.1128/MCB.8.1.497; MARTENSEN TM, 1982, J BIOL CHEM, V257, P9648; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; PRICE DJ, 1990, P NATL ACAD SCI USA, V87, P7944, DOI 10.1073/pnas.87.20.7944; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; REDDY SAG, 1990, J BIOL CHEM, V265, P7748; ROOME J, 1988, BIOCHEM J, V256, P493, DOI 10.1042/bj2560493; SANGHERA JS, 1991, J BIOL CHEM, V266, P6700; SHENOLIKAR S, 1991, ADV 2ND MESSENGER PH, V23, P1; SHRINER C, 1988, METHOD ENZYMOL, V159, P346; SILVA OBDC, 1987, FEBS LETT, V226, P176; SNEDDON AA, 1990, EMBO J, V9, P4339, DOI 10.1002/j.1460-2075.1990.tb07883.x; STONE SR, 1987, BIOCHEMISTRY-US, V26, P7215, DOI 10.1021/bi00397a003; TACHIBANA T, 1981, J AM CHEM SOC, V103, P2471; TAKEDA M, 1983, J BIOL CHEM, V258, P10453; TAMURA S, 1980, EUR J BIOCHEM, V104, P347, DOI 10.1111/j.1432-1033.1980.tb04435.x; TUNG HYL, 1985, EUR J BIOCHEM, V148, P253, DOI 10.1111/j.1432-1033.1985.tb08833.x; USUI H, 1988, J BIOL CHEM, V263, P3752; WALTER G, 1990, P NATL ACAD SCI USA, V87, P2521, DOI 10.1073/pnas.87.7.2521	41	551	563	1	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 28	1992	257	5074					1261	1264		10.1126/science.1325671	http://dx.doi.org/10.1126/science.1325671			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL050	1325671				2022-12-01	WOS:A1992JL05000028
J	ERICKSON, MA; ROBINSON, P; LISMAN, J				ERICKSON, MA; ROBINSON, P; LISMAN, J			DEACTIVATION OF VISUAL TRANSDUCTION WITHOUT GUANOSINE TRIPHOSPHATE HYDROLYSIS BY G-PROTEIN	SCIENCE			English	Article							CYCLIC-GMP PHOSPHODIESTERASE; GTP-BINDING PROTEIN; ROD OUTER SEGMENTS; LIGHT-ACTIVATED PHOSPHODIESTERASE; FROG PHOTORECEPTOR-MEMBRANES; RETINAL RODS; CGMP PHOSPHODIESTERASE; MECHANISM; SUBUNIT; GDP	G proteins couple receptors to their target enzymes in many signal transduction cascades. It has generally been thought that deactivation of such cascades cannot occur without the hydrolysis of guanosine triphosphate (GTP) by G protein. This requirement has now been reexamined in both vertebrate and invertebrate phototransduction. Results indicate that GTP hydrolysis is not required for deactivation. Evidence is presented for an alternative model in which the target enzyme is deactivated by an inhibitory factor that is available even when GTP hydrolysis is blocked.	BRANDEIS UNIV,DEPT BIOCHEM,BIOPHYS PROGRAM,WALTHAM,MA 02254; BRANDEIS UNIV,CTR COMPLEX SYST,WALTHAM,MA 02254	Brandeis University; Brandeis University					NATIONAL EYE INSTITUTE [R01EY001496, R37EY001496] Funding Source: NIH RePORTER; NEI NIH HHS [EY 01496] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ADOLPH AR, 1964, J GEN PHYSIOL, V48, P297, DOI 10.1085/jgp.48.2.297; BAEHR W, 1979, J BIOL CHEM, V254, P1669; BARKDOLL AE, 1989, J GEN PHYSIOL, V93, P1091, DOI 10.1085/jgp.93.6.1091; BENNETT N, 1989, BIOCHEMISTRY-US, V28, P7418, DOI 10.1021/bi00444a040; BIERNBAUM MS, 1985, J GEN PHYSIOL, V85, P83, DOI 10.1085/jgp.85.1.83; BOLSOVER SR, 1982, J PHYSIOL-LONDON, V332, P325, DOI 10.1113/jphysiol.1982.sp014416; BROWN RL, 1989, P NATL ACAD SCI USA, V86, P4922, DOI 10.1073/pnas.86.13.4922; CLACK JW, 1983, NATURE, V305, P50, DOI 10.1038/305050a0; DETERRE P, 1986, Proteins Structure Function and Genetics, V1, P188, DOI 10.1002/prot.340010210; DETERRE P, 1988, P NATL ACAD SCI USA, V85, P2424, DOI 10.1073/pnas.85.8.2424; FATHI M, 1991, J CHROMATOGR-BIOMED, V563, P356, DOI 10.1016/0378-4347(91)80042-B; GILLESPIE PG, 1989, J BIOL CHEM, V264, P12187; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.biochem.56.1.615; HOFFMANN KP, 1983, BIOCHIM BIOPHYS ACTA, V725, P60; HURLEY JB, 1982, J BIOL CHEM, V257, P8188; HURLEY JM, UNPUB; KAWAMURA S, 1991, NATURE, V349, P420, DOI 10.1038/349420a0; KAWAMURA S, 1981, J GEN PHYSIOL, V77, P571, DOI 10.1085/jgp.77.5.571; KIRKWOOD A, 1989, P NATL ACAD SCI USA, V86, P3872, DOI 10.1073/pnas.86.10.3872; KONDO H, 1988, P NATL ACAD SCI USA, V85, P1322, DOI 10.1073/pnas.85.4.1322; KROLL S, 1989, J BIOL CHEM, V264, P4490; LAMB TD, 1988, J PHYSIOL-LONDON, V407, P463, DOI 10.1113/jphysiol.1988.sp017426; LIEBMAN PA, 1980, NATURE, V287, P734, DOI 10.1038/287734a0; LISMAN J, 1985, J GEN PHYSIOL, V85, P171, DOI 10.1085/jgp.85.2.171; MIKI N, 1975, J BIOL CHEM, V250, P6320; ROBINSON PH, UNPUB; ROBINSON PR, 1980, J GEN PHYSIOL, V76, P631, DOI 10.1085/jgp.76.5.631; SITARAMAYYA A, 1986, BIOCHEMISTRY-US, V25, P651, DOI 10.1021/bi00351a021; SITARAMAYYA A, 1983, J BIOL CHEM, V258, P1205; STRYER L, 1981, TRENDS BIOCHEM SCI, V6, P245, DOI 10.1016/0968-0004(81)90089-X; STRYER L, 1986, ANNU REV CELL BIOL, V2, P391, DOI 10.1146/annurev.cb.02.110186.002135; WENSEL T G, 1986, Proteins Structure Function and Genetics, V1, P90, DOI 10.1002/prot.340010114; WHEELER GL, 1977, P NATL ACAD SCI USA, V74, P4238, DOI 10.1073/pnas.74.10.4238; YAMANAKA G, 1986, BIOCHEMISTRY-US, V25, P6149, DOI 10.1021/bi00368a048; YAMANAKA G, 1985, BIOCHEMISTRY-US, V24, P8094, DOI 10.1021/bi00348a039; YAMAZAKI A, 1983, J BIOL CHEM, V258, P8188; YEE R, 1978, J BIOL CHEM, V253, P8902	37	37	37	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 28	1992	257	5074					1255	1258		10.1126/science.1519062	http://dx.doi.org/10.1126/science.1519062			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL050	1519062				2022-12-01	WOS:A1992JL05000026
J	GARFINKEL, A; SPANO, ML; DITTO, WL; WEISS, JN				GARFINKEL, A; SPANO, ML; DITTO, WL; WEISS, JN			CONTROLLING CARDIAC CHAOS	SCIENCE			English	Article							DYNAMICS; CELLS	The extreme sensitivity to initial conditions that chaotic systems display makes them unstable and unpredictable. Yet that same sensitivity also makes them highly susceptible to control, provided that the developing chaos can be analyzed in real time and that analysis is then used to make small control interventions. This strategy has been used here to stabilize cardiac arrhythmias induced by the drug ouabain in rabbit ventricle. By administering electrical stimuli to the heart at irregular times determined by chaos theory, the arrhythmia was converted to periodic beating.	USN,CTR SURFACE WARFARE,SILVER SPRING,MD 20903; COLL WOOSTER,DEPT PHYS,WOOSTER,OH 44691; UNIV CALIF LOS ANGELES,DEPT MED CARDIOL,LOS ANGELES,CA 90024	United States Department of Defense; United States Navy; College of Wooster; University of California System; University of California Los Angeles	GARFINKEL, A (corresponding author), UNIV CALIF LOS ANGELES,DEPT PHYSIOL SCI,LOS ANGELES,CA 90024, USA.		Ditto, William/AAK-9827-2020; Spano, Mark L/B-6883-2011	Ditto, William/0000-0002-7416-8012; 	NHLBI NIH HHS [R01 HL44880, R01 HL36729, KO4 HL01890] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036729, R01HL044880, K04HL001890] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARNSDORF MF, 1991, CURR OPIN CARDIOL, V6, P3, DOI 10.1097/00001573-199102000-00002; BOWEN R, 1971, T AM MATH SOC, V154, P377, DOI 10.2307/1995452; CHIALVO DR, 1990, NATURE, V343, P653, DOI 10.1038/343653a0; COLQUHOUN D, 1981, NATURE, V294, P752, DOI 10.1038/294752a0; CRUTCHFIELD JP, 1986, SCI AM, V255, P46, DOI 10.1038/scientificamerican1286-46; DITTO WL, 1990, PHYS REV LETT, V65, P3211, DOI 10.1103/PhysRevLett.65.3211; FEDIDA D, 1987, J PHYSIOL-LONDON, V392, P523, DOI 10.1113/jphysiol.1987.sp016795; GARFINKEL AJ, 1991, LIFE SCI, V48, P2189, DOI 10.1016/0024-3205(91)90153-3; GOLLUB JP, 1975, PHYS REV LETT, V35, P927, DOI 10.1103/PhysRevLett.35.927; GREBOGI C, 1988, PHYS REV A, V37, P1711, DOI 10.1103/PhysRevA.37.1711; GUCKENHEIMER J, 1983, NONLINEAR OSCILLATIO, P105; GUEVARA MR, 1981, SCIENCE, V214, P1350, DOI 10.1126/science.7313693; HUNT ER, 1991, PHYS REV LETT, V67, P53; KAPLAN JL, 1979, LECT NOTES MATH, V730, P228, DOI DOI 10.1007/BFB0064320; Moon F.C., 1987, CHAOTIC VIBRATIONS; OLSEN LF, 1990, SCIENCE, V249, P499, DOI 10.1126/science.2382131; OTT E, 1990, PHYS REV LETT, V64, P1196, DOI 10.1103/PhysRevLett.64.1196; ROSSLER OE, 1978, NATURE, V271, P89, DOI 10.1038/271089a0; ROY R, 1992, PHYS REV LETT, V68, P1259, DOI 10.1103/PhysRevLett.68.1259; SHINBROT T, 1992, PHYS REV LETT, V68, P2863, DOI 10.1103/PhysRevLett.68.2863; SHINBROT T, 1990, PHYS REV LETT, V65, P3215, DOI 10.1103/PhysRevLett.65.3215; WEISS J, 1982, AM J PHYSIOL, V243, pH318, DOI 10.1152/ajpheart.1982.243.2.H318; WEISS JN, 1987, CARDIAC ARRHYTHMIAS, P83	23	702	726	3	42	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 28	1992	257	5074					1230	1235		10.1126/science.1519060	http://dx.doi.org/10.1126/science.1519060			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL050	1519060	Green Submitted			2022-12-01	WOS:A1992JL05000019
J	IZUMI, Y; CLIFFORD, DB; ZORUMSKI, CF				IZUMI, Y; CLIFFORD, DB; ZORUMSKI, CF			INHIBITION OF LONG-TERM POTENTIATION BY NMDA-MEDIATED NITRIC-OXIDE RELEASE	SCIENCE			English	Article							RAT HIPPOCAMPUS; L-ARGININE; INTERCELLULAR MESSENGER; SYNAPTIC TRANSMISSION; RECEPTOR ACTIVATION; RELAXING FACTOR; AMINO-ACIDS; INDUCTION; BRAIN; ENHANCEMENT	Activation of N-methyl-D-aspartate (NMDA) receptors before tetanic stimulation blocks long-term potentiation (LTP) in the CA1 region of the hippocampus. This NMDA-mediated inhibition of LTP can be reversed by the nitric oxide (NO) inhibitors L-N(G)-monomethyl-arginine or hemoglobin and mimicked by sodium nitroprusside. These results indicate that the timing of NO release relative to high-frequency activation of CA1 synapses may be an important determinant of LTP generation and suggest that NO may play a positive or negative modulatory role in LTP depending on prior events at the tetanized synapse and the ambient concentration of excitatory amino acids.	WASHINGTON UNIV,SCH MED,DEPT NEUROL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT ANAT & NEUROBIOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)	IZUMI, Y (corresponding author), WASHINGTON UNIV,SCH MED,DEPT PSYCHIAT,ST LOUIS,MO 63110, USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [K02MH000964, R01MH045493, R29MH045493] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P50AG005681] Funding Source: NIH RePORTER; NIA NIH HHS [AG05681] Funding Source: Medline; NIMH NIH HHS [MH00964, MH45493] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BOHME GA, 1991, EUR J PHARMACOL, V199, P379, DOI 10.1016/0014-2999(91)90505-K; BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; BREDT DS, 1991, NEURON, V7, P615, DOI 10.1016/0896-6273(91)90374-9; COAN EJ, 1989, NEUROSCI LETT, V105, P205, DOI 10.1016/0304-3940(89)90038-4; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6368, DOI 10.1073/pnas.88.14.6368; EAST SJ, 1991, NEUROSCI LETT, V123, P17, DOI 10.1016/0304-3940(91)90147-L; ERRINGTON ML, 1987, NEUROSCIENCE, V20, P279, DOI 10.1016/0306-4522(87)90019-4; Foster T C, 1991, Hippocampus, V1, P79, DOI 10.1002/hipo.450010108; GALLY JA, 1990, P NATL ACAD SCI USA, V87, P3547, DOI 10.1073/pnas.87.9.3547; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; GARTHWAITE J, 1989, EUR J PHARM-MOLEC PH, V172, P413, DOI 10.1016/0922-4106(89)90023-0; HALEY JE, 1992, NEURON, V8, P211, DOI 10.1016/0896-6273(92)90288-O; HUANG YY, 1992, SCIENCE, V255, P730, DOI 10.1126/science.1346729; IZUMI Y, 1992, NEUROSCI LETT, V135, P227, DOI 10.1016/0304-3940(92)90442-A; IZUMI Y, 1992, NEUROSCI LETT, V137, P245, DOI 10.1016/0304-3940(92)90414-3; IZUMI Y, UNPUB; KAUER JA, 1988, NATURE, V334, P250, DOI 10.1038/334250a0; LERMA J, 1986, BRAIN RES, V384, P145, DOI 10.1016/0006-8993(86)91230-8; LYNCH G, 1983, NATURE, V305, P719, DOI 10.1038/305719a0; MALENKA RC, 1991, NEURON, V6, P53, DOI 10.1016/0896-6273(91)90121-F; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MANABE T, 1992, NATURE, V355, P50, DOI 10.1038/355050a0; MANZONI O, 1992, NEURON, V8, P653, DOI 10.1016/0896-6273(92)90087-T; MARTIN W, 1986, BRIT J PHARMACOL, V89, P563, DOI 10.1111/j.1476-5381.1986.tb11157.x; MONCADA S, 1991, PHARMACOL REV, V43, P109; MOORE PK, 1990, BRIT J PHARMACOL, V99, P408, DOI 10.1111/j.1476-5381.1990.tb14717.x; ODELL TJ, 1991, P NATL ACAD SCI USA, V88, P11285, DOI 10.1073/pnas.88.24.11285; PALMER RMJ, 1988, BIOCHEM BIOPH RES CO, V153, P1251, DOI 10.1016/S0006-291X(88)81362-7; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; SCHUMAN EM, 1991, SCIENCE, V254, P1503, DOI 10.1126/science.1720572; van Sande M, 1970, J Neurochem, V17, P125	33	217	219	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 28	1992	257	5074					1273	1276		10.1126/science.1519065	http://dx.doi.org/10.1126/science.1519065			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL050	1519065				2022-12-01	WOS:A1992JL05000032
J	JAVIER, R; RASKA, K; SHENK, T				JAVIER, R; RASKA, K; SHENK, T			REQUIREMENT FOR THE ADENOVIRUS TYPE-9 E4 REGION IN PRODUCTION OF MAMMARY-TUMORS	SCIENCE			English	Article							E2F TRANSCRIPTION FACTOR; DNA-BINDING ACTIVITY; RETINOBLASTOMA GENE-PRODUCT; TRANSFORMED RAT-CELLS; NATURAL-KILLER CELLS; INFECTED-CELLS; NUCLEOTIDE-SEQUENCE; E1A PROTEINS; CYCLIN-A; EXPRESSION	Oncogenic viruses demonstrating a strict tropism for the mammary gland provide special opportunities to study the susceptibility of this tissue to neoplasia. In rats, human adenovirus type 9 (Ad9) elicits mammary fibroadenomas that are similar to common breast tumors in women, as well as phyllodes-like tumors and mammary sarcomas. By constructing recombinant adenoviruses between Ad9 and Ad26 (a related nontumorigenic virus), it was shown that the Ad9 E4 region was absolutely required to produce these mammary tumors. This indicates that an adenovirus gene located outside the classic transforming region (E1) can significantly influence the in vivo oncogenicity of an adenovirus. Consistent with a direct role in mammary gland oncogenesis, the Ad9 E4 region also exhibited transforming properties in vitro. Therefore, the Ad9 E4 region is a viral oncogene specifically involved in mammary gland tumorigenesis.	PRINCETON UNIV,HOWARD HUGHES MED INST,DEPT MOLEC BIOL,PRINCETON,NJ 08544; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT PATHOL,NEW BRUNSWICK,NJ 08903; ST PETERS MED CTR,NEW BRUNSWICK,NJ 08903	Howard Hughes Medical Institute; Princeton University; Rutgers State University New Brunswick; Rutgers State University Medical Center					NATIONAL CANCER INSTITUTE [P01CA041086, R01CA021196, T32CA009528] Funding Source: NIH RePORTER; NCI NIH HHS [CA 21196, CA 41086, T32 CA09528] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANKERST J, 1974, INT J CANCER, V13, P286, DOI 10.1002/ijc.2910130303; ANKERST J, 1989, J NATL CANCER I, V81, P294, DOI 10.1093/jnci/81.4.294; BABISS LE, 1984, J VIROL, V49, P731, DOI 10.1128/JVI.49.3.731-740.1984; BABISS LE, 1989, J VIROL, V63, P2709, DOI 10.1128/JVI.63.6.2709-2717.1989; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BERNARDS R, 1982, VIROLOGY, V120, P422, DOI 10.1016/0042-6822(82)90042-3; BERNARDS R, 1984, J VIROL, V50, P847, DOI 10.1128/JVI.50.3.847-853.1984; BERNARDS R, 1983, NATURE, V305, P776, DOI 10.1038/305776a0; BRIDGE E, 1989, J VIROL, V63, P631, DOI 10.1128/JVI.63.2.631-638.1989; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHINNADURAI G, 1979, J VIROL, V32, P623, DOI 10.1128/JVI.32.2.623-628.1979; COOK JL, 1987, J VIROL, V61, P3510, DOI 10.1128/JVI.61.11.3510-3520.1987; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; FISHER PB, 1982, P NATL ACAD SCI-BIOL, V79, P3527, DOI 10.1073/pnas.79.11.3527; GRAHAM FL, 1984, ADENOVIRUSES, P339; GREEN M, 1979, VIROLOGY, V93, P481, DOI 10.1016/0042-6822(79)90251-4; HALBERT DN, 1985, J VIROL, V56, P250, DOI 10.1128/JVI.56.1.250-257.1985; HANAHAN D, 1984, MOL CELL BIOL, V4, P302, DOI 10.1128/MCB.4.2.302; HARDY S, 1989, MOL CELL BIOL, V9, P4495, DOI 10.1128/MCB.9.10.4495; HARDY S, 1989, GENE DEV, V3, P1062, DOI 10.1101/gad.3.7.1062; HEMSTROM C, 1988, J VIROL, V62, P3258; HERISSE J, 1981, NUCLEIC ACIDS RES, V9, P4023, DOI 10.1093/nar/9.16.4023; HOGENKAMP T, 1990, NUCLEIC ACIDS RES, V18, P3065, DOI 10.1093/nar/18.10.3065; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; HUANG MM, 1989, GENE DEV, V3, P1699, DOI 10.1101/gad.3.11.1699; HUANG MM, 1989, J VIROL, V63, P2605, DOI 10.1128/JVI.63.6.2605-2615.1989; JANNUN R, 1987, VIRUS RES, V7, P33, DOI 10.1016/0168-1702(87)90056-6; JAVIER R, 1991, J VIROL, V65, P192; JAVIER R, UNPUB; MARTON MJ, 1990, J VIROL, V64, P2345, DOI 10.1128/JVI.64.5.2345-2359.1990; MELLOW GH, 1984, VIROLOGY, V134, P460, DOI 10.1016/0042-6822(84)90313-1; MUNGER K, 1991, J VIROL, V65, P3943; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; NEILL SD, 1990, P NATL ACAD SCI USA, V87, P2008, DOI 10.1073/pnas.87.5.2008; NEILL SD, 1991, J VIROL, V65, P5364, DOI 10.1128/JVI.65.10.5364-5373.1991; PILDER S, 1986, MOL CELL BIOL, V6, P470, DOI 10.1128/MCB.6.2.470; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; RAYCHAUDHURI P, 1990, J VIROL, V64, P2702, DOI 10.1128/JVI.64.6.2702-2710.1990; REICHEL R, 1989, J VIROL, V63, P3643, DOI 10.1128/JVI.63.9.3643-3650.1989; SANDLER AB, 1989, J VIROL, V63, P624, DOI 10.1128/JVI.63.2.624-630.1989; SARNOW P, 1984, J VIROL, V49, P692, DOI 10.1128/JVI.49.3.692-700.1984; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SAWADA Y, 1985, VIROLOGY, V147, P413, DOI 10.1016/0042-6822(85)90143-6; SAWADA Y, 1988, VIROLOGY, V166, P281, DOI 10.1016/0042-6822(88)90175-4; SCHRIER PI, 1983, NATURE, V305, P771, DOI 10.1038/305771a0; SHELLABARGER C, COMMUNICATION; SHIROKI K, 1984, J VIROL, V50, P854, DOI 10.1128/JVI.50.3.854-863.1984; STILLMAN B, 1986, CANCER SURV, V5, P389; TRENTIN JJ, 1962, SCIENCE, V137, P835, DOI 10.1126/science.137.3533.835; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YODER SS, 1986, J VIROL, V60, P779, DOI 10.1128/JVI.60.2.779-781.1986	53	54	54	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 28	1992	257	5074					1267	1271		10.1126/science.1519063	http://dx.doi.org/10.1126/science.1519063			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL050	1519063				2022-12-01	WOS:A1992JL05000030
J	LI, M; JAN, YN; JAN, LY				LI, M; JAN, YN; JAN, LY			SPECIFICATION OF SUBUNIT ASSEMBLY BY THE HYDROPHILIC AMINO-TERMINAL DOMAIN OF THE SHAKER POTASSIUM CHANNEL	SCIENCE			English	Article							MUSCLE ACETYLCHOLINE-RECEPTOR; DELAYED-RECTIFIER PROPERTIES; K+ CHANNEL; FUNCTIONAL EXPRESSION; RAT-BRAIN; XENOPUS-OOCYTES; HETEROMULTIMERIC CHANNELS; EXCITABLE CELLS; MAMMALIAN BRAIN; EPSILON SUBUNIT	The functional heterogeneity of potassium channels in eukaryotic cells arises not only from the multiple potassium channel genes and splice variants but also from the combinatorial mixing of different potassium channel polypeptides to form heteromultimeric channels with distinct properties. One structural element that determines the compatibility of different potassium channel polypeptides in subunit assembly has now been localized to the hydrophilic amino-terminal domain. A Drosophila Shaker B (ShB) potassium channel truncated polypeptide that contains only the hydrophilic amino-terminal domain can form a homomultimer; the minimal requirement for the homophilic interaction has been localized to a fragment of 114 amino acids. Substitution of the amino-terminal domain of a distantly related mammalian potassium channel polypeptide (DRK1) with that of ShB permits the chimeric DRK1 polypeptide to coassemble with ShB.	UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco	LI, M (corresponding author), UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143, USA.			Jan, Yuh Nung/0000-0003-1367-6299; Jan, Lily/0000-0003-3938-8498				BALDWIN TJ, 1991, NEURON, V7, P471, DOI 10.1016/0896-6273(91)90299-F; BEZANILLA F, 1977, J GEN PHYSIOL, V70, P567; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; CHANDY KG, 1991, NATURE, V352, P26, DOI 10.1038/352026b0; CHANDY KG, 1990, SCIENCE, V247, P973, DOI 10.1126/science.2305265; CHRISTIE MJ, 1990, NEURON, V4, P405, DOI 10.1016/0896-6273(90)90052-H; COOPER E, 1991, NATURE, V350, P235, DOI 10.1038/350235a0; COPELAND BR, 1982, J BIOL CHEM, V257, P5065; COVARRUBIAS M, 1991, NEURON, V7, P763, DOI 10.1016/0896-6273(91)90279-9; DOUGLASS J, 1990, J IMMUNOL, V144, P4841; DREWE JA, 1992, J NEUROSCI, V12, P538; FERRELL JE, 1989, J BIOL CHEM, V264, P20723; FRECH GC, 1989, NATURE, V340, P642, DOI 10.1038/340642a0; GRISSMER S, 1990, P NATL ACAD SCI USA, V87, P9411, DOI 10.1073/pnas.87.23.9411; GRUPE A, 1990, EMBO J, V9, P1749, DOI 10.1002/j.1460-2075.1990.tb08299.x; GU Y, 1991, NEURON, V6, P879, DOI 10.1016/0896-6273(91)90228-R; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; HEGINBOTHAM L, 1992, NEURON, V8, P483, DOI 10.1016/0896-6273(92)90276-J; Hille B., 1991, IONIC CHANNELS EXCIT; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; HWANG PM, 1992, NEURON, V8, P473, DOI 10.1016/0896-6273(92)90275-I; ISACOFF EY, 1991, NATURE, V353, P86, DOI 10.1038/353086a0; ISACOFF EY, 1990, NATURE, V345, P530, DOI 10.1038/345530a0; JAN LY, 1989, CELL, V56, P13, DOI 10.1016/0092-8674(89)90979-3; KAMB A, 1988, NEURON, V1, P421, DOI 10.1016/0896-6273(88)90192-4; KAVANAUGH MP, 1992, NEURON, V8, P493, DOI 10.1016/0896-6273(92)90277-K; KIRSCH GE, 1992, NEURON, V8, P499, DOI 10.1016/0896-6273(92)90278-L; KLAIBER K, 1990, NEURON, V5, P221, DOI 10.1016/0896-6273(90)90311-3; LATORRE R, 1984, ANNU REV PHYSIOL, V46, P485; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; Li M., UNPUB; LIMAN ER, 1991, NATURE, V353, P752, DOI 10.1038/353752a0; LOPEZ GA, 1991, NEURON, V7, P327, DOI 10.1016/0896-6273(91)90271-Z; LUNEAU C, 1991, FEBS LETT, V288, P163, DOI 10.1016/0014-5793(91)81026-5; LUNEAU CJ, 1991, P NATL ACAD SCI USA, V88, P3932, DOI 10.1073/pnas.88.9.3932; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MCCORMACK K, 1990, BIOCHEM BIOPH RES CO, V171, P1361, DOI 10.1016/0006-291X(90)90836-C; MCCORMACK T, 1990, P NATL ACAD SCI USA, V87, P5227, DOI 10.1073/pnas.87.13.5227; MCKINNON D, 1989, J BIOL CHEM, V264, P8230; MISKIMINS WK, 1985, P NATL ACAD SCI USA, V82, P6741, DOI 10.1073/pnas.82.20.6741; PAK MD, 1991, J NEUROSCI, V11, P869; PAK MD, 1991, P NATL ACAD SCI USA, V88, P4386, DOI 10.1073/pnas.88.10.4386; PAPAZIAN DM, 1991, NATURE, V349, P305, DOI 10.1038/349305a0; PFAFFINGER PJ, 1991, J NEUROSCI, V11, P918; PHILIPSON LH, 1991, P NATL ACAD SCI USA, V88, P53, DOI 10.1073/pnas.88.1.53; PONGS O, 1988, EMBO J, V7, P1087, DOI 10.1002/j.1460-2075.1988.tb02917.x; RAWLINS DR, 1985, CELL, V42, P859, DOI 10.1016/0092-8674(85)90282-X; ROBERDS SL, 1991, P NATL ACAD SCI USA, V88, P1798, DOI 10.1073/pnas.88.5.1798; ROGAWSKI MA, 1985, TRENDS NEUROSCI, V8, P214, DOI 10.1016/0166-2236(85)90082-7; RUDY B, 1988, NEUROSCIENCE, V25, P729, DOI 10.1016/0306-4522(88)90033-4; RUPPERSBERG JP, 1991, NATURE, V352, P711, DOI 10.1038/352711a0; RUPPERSBERG JP, 1990, NATURE, V345, P535, DOI 10.1038/345535a0; SALKOFF L, 1992, TRENDS NEUROSCI, V15, P161, DOI 10.1016/0166-2236(92)90165-5; SCHROTER KH, 1991, FEBS LETT, V278, P211, DOI 10.1016/0014-5793(91)80119-N; SCHWARZ TL, 1988, NATURE, V331, P137, DOI 10.1038/331137a0; STUHMER W, 1989, EMBO J, V8, P3235, DOI 10.1002/j.1460-2075.1989.tb08483.x; SWANSON R, 1990, NEURON, V4, P929, DOI 10.1016/0896-6273(90)90146-7; TEMPEL BL, 1988, NATURE, V332, P837, DOI 10.1038/332837a0; TEMPEL BL, 1987, SCIENCE, V237, P770, DOI 10.1126/science.2441471; UNWIN N, 1989, NEURON, V3, P665, DOI 10.1016/0896-6273(89)90235-3; VANDONGEN AMJ, 1990, NEURON, V5, P433, DOI 10.1016/0896-6273(90)90082-Q; VERRALL S, 1992, CELL, V68, P23, DOI 10.1016/0092-8674(92)90203-O; WEI A, 1990, SCIENCE, V248, P599, DOI 10.1126/science.2333511; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; YOKOYAMA S, 1989, FEBS LETT, V259, P37, DOI 10.1016/0014-5793(89)81488-7; YOOL AJ, 1991, NATURE, V349, P700, DOI 10.1038/349700a0; YU XM, 1991, NATURE, V352, P64, DOI 10.1038/352064a0; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520	69	413	423	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 28	1992	257	5074					1225	1230		10.1126/science.1519059	http://dx.doi.org/10.1126/science.1519059			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL050	1519059				2022-12-01	WOS:A1992JL05000018
J	MALMBERG, AB; YAKSH, TL				MALMBERG, AB; YAKSH, TL			HYPERALGESIA MEDIATED BY SPINAL GLUTAMATE OR SUBSTANCE-P RECEPTOR BLOCKED BY SPINAL CYCLOOXYGENASE INHIBITION	SCIENCE			English	Article							ASPIRIN-LIKE DRUGS; EXCITATORY AMINO-ACIDS; PROSTAGLANDIN SYNTHESIS; ARACHIDONIC-ACID; NEURONS; RAT; ACTIVATION; CORD; SENSITIZATION; STIMULATION	Inhibition of cyclooxygenase by nonsteroidal anti-inflammatory drugs (NSAIDs) in the periphery is commonly accepted as the primary mechanism by which these agents produce a selective attenuation of pain (analgesia). NSAIDs are now shown to exert a direct spinal action by blocking the excessive sensitivity to pain (hyperalgesia) induced by the activation of spinal glutamate and substance P receptors. These findings demonstrate that the analgesic effects of NSAIDs can be dissociated from their anti-inflammatory actions. Spinal prostanoids are thus critical for the augmented processing of pain information at the spinal level.			MALMBERG, AB (corresponding author), UNIV CALIF SAN DIEGO, DEPT ANESTHESIOL 0818, LA JOLLA, CA 92093 USA.		Yaksh, Tony/D-4119-2009		NATIONAL INSTITUTE ON DRUG ABUSE [R01DA002110] Funding Source: NIH RePORTER; NIDA NIH HHS [DA02110] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		AANONSEN LM, 1990, PAIN, V41, P309, DOI 10.1016/0304-3959(90)90008-2; AANONSEN LM, 1991, PAIN, V131, P71; BRUNE K, 1991, EXPERIENTIA, V47, P257, DOI 10.1007/BF01958153; CODERRE TJ, 1991, NEUROSCI LETT, V131, P71, DOI 10.1016/0304-3940(91)90339-U; DICKENSON AH, 1987, NEUROSCI LETT, V83, P207, DOI 10.1016/0304-3940(87)90242-4; DOUGHERTY PM, 1991, BRAIN RES, V542, P15, DOI 10.1016/0006-8993(91)90991-4; DROWER EJ, 1987, EUR J PHARMACOL, V133, P249, DOI 10.1016/0014-2999(87)90020-3; DUMUIS A, 1988, NATURE, V336, P68, DOI 10.1038/336068a0; FERREIRA SH, 1973, BRIT J PHARMACOL, V49, P86, DOI 10.1111/j.1476-5381.1973.tb08270.x; GUZMAN F, 1964, ARCH INT PHARMACOD T, V149, P571; HAGEN AA, 1977, STROKE, V8, P672, DOI 10.1161/01.STR.8.6.672; HARGREAVES K, 1988, PAIN, V32, P77, DOI 10.1016/0304-3959(88)90026-7; HEAPY C G, 1987, British Journal of Pharmacology, V90, p164P; Janis R.A., 1987, ADV DRUG RES, V16, P309; KURAISHI Y, 1989, NEUROSCIENCE, V30, P241, DOI 10.1016/0306-4522(89)90369-2; Lim R K, 1970, Annu Rev Physiol, V32, P269, DOI 10.1146/annurev.ph.32.030170.001413; LIM RKS, 1964, ARCH INT PHARMACOD T, V152, P25; MACDERMOTT AB, 1986, NATURE, V321, P519, DOI 10.1038/321519a0; MALMBERG AB, 1977, PAIN, V4, P161; MALMBERG AB, IN PRESS J PHARM EXP; MARRIOTT D, 1991, ADV PROSTAG THROMB L, V21, P739; MCCORMACK K, 1991, DRUGS, V41, P533, DOI 10.2165/00003495-199141040-00003; MONCADA S, 1979, INFLAMMATION HDB EXP, P588; NICOL GD, 1992, J NEUROSCI, V12, P1917; PELLERIN L, 1991, NEUROCHEM RES, V16, P983, DOI 10.1007/BF00965841; RAMWELL PW, 1966, AM J PHYSIOL, V211, P998, DOI 10.1152/ajplegacy.1966.211.4.998; SCHAIBLE HG, 1988, J PHYSIOL-LONDON, V403, P91, DOI 10.1113/jphysiol.1988.sp017240; SKILLING SR, 1988, J NEUROCHEM, V51, P127, DOI 10.1111/j.1471-4159.1988.tb04845.x; SORKIN LS, UNPUB; TAIWO YO, 1986, BRAIN RES, V373, P81, DOI 10.1016/0006-8993(86)90317-3; TALLARIDA RJ, 1987, MANUAL PHARM CALCULA, P137; UDA R, 1990, BRAIN RES, V510, P26, DOI 10.1016/0006-8993(90)90723-O; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0; WOOD PL, 1984, ANALGESICS NEUROCHEM, P175; WOOLF CJ, 1991, PAIN, V44, P293, DOI 10.1016/0304-3959(91)90100-C; YAKSH TL, 1976, PHYSIOL BEHAV, V17, P1031, DOI 10.1016/0031-9384(76)90029-9; YAKSH TL, 1982, ACETYLSALICYLIC ACID, P137; YAMAMOTO T, 1991, LIFE SCI, V49, P1955, DOI 10.1016/0024-3205(91)90637-Q; YAMAMOTO T, IN PRESS ANESTHESIOL	39	520	532	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 28	1992	257	5074					1276	1279		10.1126/science.1381521	http://dx.doi.org/10.1126/science.1381521			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL050	1381521				2022-12-01	WOS:A1992JL05000033
J	MEADOR, WE; MEANS, AR; QUIOCHO, FA				MEADOR, WE; MEANS, AR; QUIOCHO, FA			TARGET ENZYME RECOGNITION BY CALMODULIN - 2.4-ANGSTROM STRUCTURE OF A CALMODULIN-PEPTIDE COMPLEX	SCIENCE			English	Article							LIGHT-CHAIN KINASE; BINDING DOMAIN; CENTRAL HELIX; TROPONIN-C; MYOSIN; ACTIVATION; SEQUENCE; SITE	The crystal structure of calcium-bound calmodulin (Ca2+-CaM) bound to a peptide analog of the CaM-binding region of chicken smooth muscle myosin light chain kinase has been determined and refined to a resolution of 2.4 angstroms (angstrom). The structure is compact and has the shape of an ellipsoid (axial ratio approximately 2:1). The bound CaM forms a tunnel diagonal to its long axis that engulfs the helical peptide, with the hydrophobic regions of CaM melded into a single area that closely covers the hydrophobic side of the peptide. There is a remarkably high pseudo-twofold symmetry between the closely associated domains. The central helix of the native CaM is unwound and expanded into a bend between residues 73 and 77. About 185 contacts (<4 angstrom) are formed between CaM and the peptide, with van der Waals contacts comprising approximately 80% of this total.	BAYLOR COLL MED,HOWARD HUGHES MED INST,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT BIOCHEM,HOUSTON,TX 77030; DUKE UNIV,MED CTR,DEPT PHARMACOL,DURHAM,NC 27710	Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine; Duke University								BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; BAGCHI IC, 1992, J BIOL CHEM, V267, P3024; BLUMENTHAL DK, 1985, P NATL ACAD SCI USA, V82, P3187, DOI 10.1073/pnas.82.10.3187; BRUNGER AT, 1990, XPLOR VERSION 2 1 SY; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CHATTOPADHYAYA R, IN PRESS J MOL BIOL; COX JA, 1985, J BIOL CHEM, V260, P2527; HANLEY RM, 1987, SCIENCE, V237, P293, DOI 10.1126/science.3037704; HEIDORN DB, 1988, BIOCHEMISTRY-US, V27, P909, DOI 10.1021/bi00403a011; IKURA M, 1991, BIOCHEMISTRY-US, V30, P5498, DOI 10.1021/bi00236a024; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; ITO M, 1991, BIOCHEMISTRY-US, V30, P3498, DOI 10.1021/bi00228a021; KATAOKA M, 1991, BIOCHEMISTRY-US, V30, P6247, DOI 10.1021/bi00239a024; KEMP BE, 1987, J BIOL CHEM, V262, P2542; KLEE CB, 1982, ADV PROTEIN CHEM, V35, P213, DOI 10.1016/S0065-3233(08)60470-2; LEACHMAN SA, 1992, J BIOL CHEM, V267, P4930; LUKAS TJ, 1986, BIOCHEMISTRY-US, V25, P1458, DOI 10.1021/bi00354a041; LUKAS TS, 1988, COLD SPRING HARB SYM, V63, P185; MCDOWELL L, 1985, BIOCHEMISTRY-US, V24, P2979, DOI 10.1021/bi00333a026; MEANS AR, 1991, PHARMACOL THERAPEUT, V50, P255, DOI 10.1016/0163-7258(91)90017-G; ONEIL KT, 1989, J BIOL CHEM, V264, P14571; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; PEARSON RB, 1988, SCIENCE, V241, P970, DOI 10.1126/science.3406746; PERSECHINI A, 1989, J BIOL CHEM, V264, P8052; PERSECHINI A, 1988, J BIOL CHEM, V263, P12175; PERSECHINI A, 1988, J CARDIOVASC PHARM, V12, P501; PUTKEY JA, 1988, J BIOL CHEM, V263, P11242; ROTH SM, 1992, BIOCHEMISTRY-US, V31, P1443, DOI 10.1021/bi00120a022; Sack J. S., 1988, J MOL GRAPHICS, V6, P244; Seeholzer S.H., 1987, CALCIUM BINDING PROT, P360; SHOEMAKER MO, 1990, J CELL BIOL, V111, P1107, DOI 10.1083/jcb.111.3.1107; STEIGEMANN W, 1974, THESIS TU MUNCHEN; STRYNADKA NCJ, 1990, PROTEINS, V7, P234, DOI 10.1002/prot.340070305; TOROK K, 1992, BIOCHEMISTRY-US, V31, P3452, DOI 10.1021/bi00128a020; VANBERKUM MF, 1990, J BIOL CHEM, V265, P3950; VANBERKUM MFA, 1991, J BIOL CHEM, V266, P21488; VORHERR T, 1992, EUR J BIOCHEM, V204, P931, DOI 10.1111/j.1432-1033.1992.tb16714.x; VORHERR T, 1990, BIOCHEMISTRY, V29	38	978	985	0	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 28	1992	257	5074					1251	1255		10.1126/science.1519061	http://dx.doi.org/10.1126/science.1519061			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL050	1519061				2022-12-01	WOS:A1992JL05000025
J	MOUNTJOY, KG; ROBBINS, LS; MORTRUD, MT; CONE, RD				MOUNTJOY, KG; ROBBINS, LS; MORTRUD, MT; CONE, RD			THE CLONING OF A FAMILY OF GENES THAT ENCODE THE MELANOCORTIN RECEPTORS	SCIENCE			English	Article							MELANOCYTE STIMULATING HORMONE; POTENT ALPHA-MELANOTROPIN; FUNCTIONAL EXPRESSION; CANNABINOID RECEPTOR; CELLS; CDNA; SEQUENCE; PROTEIN; BINDING; DNA	Melanocyte-stimulating hormone (MSH) and adrenocorticotropic hormone (ACTH) regulate pigmentation and adrenal cortical function, respectively. These peptides also have a variety of biological activities in other areas, including the brain, the pituitary, and the immune system. A complete understanding of the biological activities of these hormones requires the isolation and characterization of their corresponding receptors. The murine and human MSH receptors (MSH-Rs) and a human ACTH receptor (ACTH-R) were cloned. These receptors define a subfamily of receptors coupled to guanine nucleotide-binding proteins that may include the cannabinoid receptor.	OREGON HLTH SCI UNIV,VOLLUM INST ADV BIOMED RES,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT CELL BIOL & ANAT,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT BIOCHEM & MOLEC BIOL,PORTLAND,OR 97201	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University			Mountjoy, Kathy/L-4473-2019		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043859] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK43859-02] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		APPLEBURY ML, 1986, VISION RES, V26, P1881, DOI 10.1016/0042-6989(86)90115-X; BUCKLEY DI, 1981, P NATL ACAD SCI-BIOL, V78, P7431, DOI 10.1073/pnas.78.12.7431; CANNON JG, 1986, J IMMUNOL, V137, P2232; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5924; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DEWIED D, 1982, PHYSIOL REV, V62, P977; DIXON RAF, 1987, EMBO J, V6, P3269, DOI 10.1002/j.1460-2075.1987.tb02645.x; ELLERKMANN E, 1992, ENDOCRINOLOGY, V130, P133, DOI 10.1210/en.130.1.133; GERARD C, 1990, NUCLEIC ACIDS RES, V18, P7142, DOI 10.1093/nar/18.23.7142; GERST JE, 1988, ENDOCRINOLOGY, V123, P1792, DOI 10.1210/endo-123-4-1792; GILMAN AG, 1970, P NATL ACAD SCI USA, V67, P305, DOI 10.1073/pnas.67.1.305; GRAHAMES.DG, 1967, J BIOL CHEM, V242, P5535; HANNEMAN E, 1989, PEPTIDE HORMONES PRO, P53; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; KARNIK SS, 1988, P NATL ACAD SCI USA, V85, P8459, DOI 10.1073/pnas.85.22.8459; KOBILKA BK, 1987, P NATL ACAD SCI USA, V84, P46, DOI 10.1073/pnas.84.1.46; LIN HY, 1991, SCIENCE, V254, P1022, DOI 10.1126/science.1658940; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; MASU Y, 1987, NATURE, V329, P836, DOI 10.1038/329836a0; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; MERTZ LM, 1991, P NATL ACAD SCI USA, V88, P8525, DOI 10.1073/pnas.88.19.8525; MOUNTJOY KG, UNPUB; MURPHY MT, 1983, SCIENCE, V221, P192, DOI 10.1126/science.6602381; PAWELEK J, 1976, J INVEST DERMATOL, V66, P210; PAWELEK JM, 1985, YALE J BIOL MED, V58, P571; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAWYER TK, 1980, P NATL ACAD SCI-BIOL, V77, P5754, DOI 10.1073/pnas.77.10.5754; SLOMINSKI A, 1992, LIFE SCI, V50, P1103, DOI 10.1016/0024-3205(92)90347-R; SOLCA F, 1989, J BIOL CHEM, V264, P14277; SPINDEL ER, 1990, MOL ENDOCRINOL, V4, P1956, DOI 10.1210/mend-4-12-1956; TATRO JB, 1990, J CLIN INVEST, V85, P1825, DOI 10.1172/JCI114642; TATRO JB, 1990, BRAIN RES, V536, P124, DOI 10.1016/0006-8993(90)90016-5; TATRO JB, 1990, CANCER RES, V50, P1237; ZHOU QY, 1990, NATURE, V347, P76, DOI 10.1038/347076a0	37	1398	1471	1	48	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 28	1992	257	5074					1248	1251		10.1126/science.1325670	http://dx.doi.org/10.1126/science.1325670			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL050	1325670				2022-12-01	WOS:A1992JL05000024
J	PITCHER, JA; INGLESE, J; HIGGINS, JB; ARRIZA, JL; CASEY, PJ; KIM, C; BENOVIC, JL; KWATRA, MM; CARON, MG; LEFKOWITZ, RJ				PITCHER, JA; INGLESE, J; HIGGINS, JB; ARRIZA, JL; CASEY, PJ; KIM, C; BENOVIC, JL; KWATRA, MM; CARON, MG; LEFKOWITZ, RJ			ROLE OF BETA-GAMMA-SUBUNITS OF G-PROTEINS IN TARGETING THE BETA-ADRENERGIC-RECEPTOR KINASE TO MEMBRANE-BOUND RECEPTORS	SCIENCE			English	Article							MAMMALIAN BETA-2-ADRENERGIC RECEPTOR; AGONIST-DEPENDENT PHOSPHORYLATION; NUCLEOTIDE-BINDING-PROTEIN; ROD OUTER SEGMENTS; ADENYLYL CYCLASE; RHODOPSIN KINASE; GTP-BINDING; TRANSDUCIN; INHIBITION; PURIFICATION	The rate and extent of the agonist-dependent phosphorylation of beta-2-adrenergic receptors and rhodopsin by beta-adrenergic receptor kinase (beta-ARK) are markedly enhanced on addition of G protein beta-gamma subunits. With a model peptide substrate it was demonstrated that direct activation of the kinase could not account for this effect. G protein beta-gamma subunits were shown to interact directly with the COOH-terminal region of beta-ARK, and formation of this beta-ARK-beta-gamma complex resulted in receptor-facilitated membrane localization of the enzyme. The beta-gamma subunits of transducin were less effective at both enhancing the rate of receptor phosphorylation and binding to the COOH-terminus of beta-ARK, suggesting that the enzyme preferentially binds specific beta-gamma complexes. The beta-gamma-mediated membrane localization of beta-ARK serves to intimately link receptor activation to beta-ARK-mediated desensitization.	DUKE UNIV,MED CTR,HOWARD HUGHES MED RES INST,DEPT MED,DURHAM,NC 27710; DUKE UNIV,MED CTR,HOWARD HUGHES MED RES INST,DEPT BIOCHEM,DURHAM,NC 27710; DUKE UNIV,MED CTR,HOWARD HUGHES MED RES INST,DEPT CELL BIOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,CELL GROWTH REGULAT & ONCOGENESIS SECT,DURHAM,NC 27710; THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,DEPT PHARMACOL,PHILADELPHIA,PA 19107	Duke University; Duke University; Duke University; Duke University; Jefferson University			Pitcher, Julie/ABH-2078-2020; Lefkowitz, Robert/AAW-2649-2021; Kwatra, Madan/ABD-2008-2020	Casey, Patrick/0000-0002-7366-9309	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044944] Funding Source: NIH RePORTER; NHLBI NIH HHS [4R37-HL16039] Funding Source: Medline; NIGMS NIH HHS [GM 44944] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENOVIC JL, 1984, BIOCHEMISTRY-US, V23, P4510, DOI 10.1021/bi00315a002; BENOVIC JL, 1988, ANNU REV CELL BIOL, V4, P405, DOI 10.1146/annurev.cb.04.110188.002201; BENOVIC JL, 1987, J BIOL CHEM, V262, P17251; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; BENOVIC JL, 1986, P NATL ACAD SCI USA, V83, P2797, DOI 10.1073/pnas.83.9.2797; BENOVIC JL, 1986, NATURE, V322, P869; BIRNBAUMER L, 1990, ANNU REV PHARMACOL, V30, P675; CASEY PJ, 1989, BIOCHEMISTRY-US, V28, P611, DOI 10.1021/bi00428a029; CERIONE RA, 1984, BIOCHEMISTRY-US, V23, P4519, DOI 10.1021/bi00315a003; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; FUKADA Y, 1990, NATURE, V346, P658, DOI 10.1038/346658a0; GAUTAM N, 1990, P NATL ACAD SCI USA, V87, P7973, DOI 10.1073/pnas.87.20.7973; GAUTAM N, 1989, SCIENCE, V244, P971, DOI 10.1126/science.2499046; GIERSCHIK P, 1984, FEBS LETT, V172, P321, DOI 10.1016/0014-5793(84)81149-7; HAGA K, 1992, J BIOL CHEM, V267, P2222; HAGA K, 1990, FEBS LETT, V268, P43, DOI 10.1016/0014-5793(90)80968-O; HURLEY JB, 1984, P NATL ACAD SCI-BIOL, V81, P6948, DOI 10.1073/pnas.81.22.6948; INGLESE J, 1992, J BIOL CHEM, V267, P1422; INGLESE J, IN PRESS NATURE; JELSEMA CL, 1987, P NATL ACAD SCI USA, V84, P3623, DOI 10.1073/pnas.84.11.3623; KELLEHER DJ, 1988, MOL PHARMACOL, V34, P452; KUHN H, 1978, BIOCHEMISTRY-US, V17, P4389; Kuhn H, 1984, PROGR RETINAL RES, V3, P123; KWATRA MM, 1989, BIOCHEMISTRY-US, V28, P4543, DOI 10.1021/bi00437a005; LAI RK, 1990, P NATL ACAD SCI USA, V87, P7673, DOI 10.1073/pnas.87.19.7673; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; LOHSE MJ, 1989, P NATL ACAD SCI USA, V86, P3011, DOI 10.1073/pnas.86.9.3011; LORENZ W, 1991, P NATL ACAD SCI USA, V88, P8715, DOI 10.1073/pnas.88.19.8715; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; ONORATO JJ, 1991, BIOCHEMISTRY-US, V30, P5118, DOI 10.1021/bi00235a002; PHILLIPS WJ, 1989, J BIOL CHEM, V264, P16679; PITCHER JA, UNPUB; ROBISHAW JD, 1989, J BIOL CHEM, V264, P15758; SHICHI H, 1978, J BIOL CHEM, V253, P7040; SIMONDS WF, 1991, J BIOL CHEM, V266, P5363; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STRASSER RH, 1986, P NATL ACAD SCI USA, V83, P6362, DOI 10.1073/pnas.83.17.6362; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; WILDEN U, 1982, BIOCHEMISTRY-US, V21, P3014, DOI 10.1021/bi00541a032; YAMANE HK, 1990, P NATL ACAD SCI USA, V87, P5868, DOI 10.1073/pnas.87.15.5868	42	625	630	1	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 28	1992	257	5074					1264	1267		10.1126/science.1325672	http://dx.doi.org/10.1126/science.1325672			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL050	1325672				2022-12-01	WOS:A1992JL05000029
J	TROTTER, Y; CELEBRINI, S; STRICANNE, B; THORPE, S; IMBERT, M				TROTTER, Y; CELEBRINI, S; STRICANNE, B; THORPE, S; IMBERT, M			MODULATION OF NEURAL STEREOSCOPIC PROCESSING IN PRIMATE AREA-V1 BY THE VIEWING DISTANCE	SCIENCE			English	Article							BINOCULAR INTERACTION; VISUAL-CORTEX; PERCEPTION; DISPARITIES; STRIATE; NEURONS; MONKEY; LIGHT	Accurate binocular depth perception requires information about both stereopsis (relative depth) and distance (absolute depth). It is unclear how these two types of information are integrated in the visual system. In alert, behaving monkeys the responsiveness of a large majority of neurons in the primary visual cortex (area V1) was modulated by the viewing distance. This phenomenon affected particularly disparity-related activity and background activity and was not dependent on the pattern of retinal stimulation. Therefore, extraretinal factors, probably related to ocular vergence or accommodation, or both, can affect processing early in the visual pathway. Such modulations could be useful for (i) judging true distance and (ii) scaling retinal disparity to give information about three-dimensional shape.			TROTTER, Y (corresponding author), UNIV PARIS 06,INST NEUROSCI,NEUROSCI VIS LAB,9 QUAI ST BERNARD,F-75230 PARIS 05,FRANCE.		celebrini, simona/H-2169-2011; Trotter, Yves/G-7333-2011; THORPE, Simon J/A-5661-2008	THORPE, Simon J/0000-0003-4997-3367				ANDERSEN RA, 1983, J NEUROSCI, V3, P532; BARLOW HB, 1967, J PHYSIOL-LONDON, V193, P327, DOI 10.1113/jphysiol.1967.sp008360; CUMMING BG, 1991, NATURE, V349, P411, DOI 10.1038/349411a0; FOLEY JM, 1980, PSYCHOL REV, V87, P411, DOI 10.1037/0033-295X.87.5.411; GAUTHIER GM, 1990, SCIENCE, V249, P58, DOI 10.1126/science.2367852; GNADT JW, 1991, SOC NEUR ABSTR, V2, P1113; JOSHUA DE, 1970, EXP BRAIN RES, V10, P389, DOI 10.1007/BF02324766; JULESZ B, 1960, AT&T TECH J, V39, P1125, DOI 10.1002/j.1538-7305.1960.tb03954.x; LEHKY SR, 1990, COLD SPRING HARB SYM, V55, P765; MAZZONI P, 1991, P NATL ACAD SCI USA, V88, P4433, DOI 10.1073/pnas.88.10.4433; MORRISON JD, 1984, PERCEPTION, V13, P555, DOI 10.1068/p130555; NIKARA T, 1968, EXP BRAIN RES, V6, P353; POGGIO GF, 1984, ANNU REV NEUROSCI, V7, P379, DOI 10.1146/annurev.ne.07.030184.002115; POGGIO GF, 1988, J NEUROSCI, V8, P4531; POGGIO GF, 1977, J NEUROPHYSIOL, V40, P1392, DOI 10.1152/jn.1977.40.6.1392; POGGIO GF, 1985, VISION RES, V25, P397, DOI 10.1016/0042-6989(85)90065-3; Wheatstone C., 1838, 18 CONTRIBUTIONS PHY, P371	17	112	112	1	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 28	1992	257	5074					1279	1281		10.1126/science.1519066	http://dx.doi.org/10.1126/science.1519066			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL050	1519066				2022-12-01	WOS:A1992JL05000034
J	TSARFATY, I; RESAU, JH; SHEN, RL; KEYDAR, I; FALETTO, DL; VANDEWOUDE, GF				TSARFATY, I; RESAU, JH; SHEN, RL; KEYDAR, I; FALETTO, DL; VANDEWOUDE, GF			THE MET PROTOONCOGENE RECEPTOR AND LUMEN FORMATION	SCIENCE			English	Article							HEPATOCYTE GROWTH-FACTOR; C-MET; SCATTER FACTOR; MOLECULAR-CLONING; KINASE-ACTIVITY; CELL-LINE; EXPRESSION; PROTOONCOGENE; IDENTIFICATION; ACTIVATION	The met proto-oncogene product (Met) and its ligand, hepatocyte growth factor/scatter factor (HGF/SF), have been implicated in cell mitogenic response, cell motility, and the promotion of the ordered spatial arrangement of tissue. By means of confocal laser-scanning microscopy, it was shown that Met is expressed in cells bordering lumen-like structures that resemble ducts in the human mammary cell line T47D. In human breast tissue biopsies, Met staining was intense in normal cells bordering mammary ducts but was reduced in adjacent tumor tissue. Met staining in lumen-forming organs colocalizes with staining of antibody to phosphotyrosine, which suggests that the Met receptor and its substrates may be activated in lumen structures or ducts. HGF/SF treatment of human epithelial carcinoma cell lines resulted in the formation of lumen-like structures in vitro. Reduced expression of Met could be related to the extent ot tumor cell differentiation.	NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,FREDERICK,MD 21702; NCI,DIV CANC ETIOL,MOLEC ONCOL LAB,BETHESDA,MD 20892; UNIV MARYLAND,SCH MED,DEPT PATHOL,BALTIMORE,MD 21201; TEL AVIV UNIV,DEPT CELL RES & IMMUNOL,IL-69978 TEL AVIV,ISRAEL	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University System of Maryland; University of Maryland Baltimore; Tel Aviv University			Shen, Rulong/E-4079-2011	Tsarfaty, Ilan/0000-0002-5230-7093	PHS HHS [N01-C0-74101] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BASLER K, 1989, SCIENCE, V243, P931, DOI 10.1126/science.2493159; BIECHE I, 1992, LANCET, V339, P139, DOI 10.1016/0140-6736(92)90208-K; Bissell M. J., 1987, The mammary gland. Development, regulation, and function., P97; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BOWTELL DDL, 1989, CELL, V56, P931, DOI 10.1016/0092-8674(89)90626-0; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; DEAN M, 1985, NATURE, V318, P385, DOI 10.1038/318385a0; DIRENZO MF, 1991, ONCOGENE, V6, P1997; FALETTO DL, 1992, ONCOGENE, V7, P1149; FALETTO DL, UNPUB; Freshney RI, 1987, CULTURE ANIMAL CELLS, P57; GERARDI E, 1991, CANCER CELLS, V3, P227; GIORDANO S, 1989, ONCOGENE, V4, P1383; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; IYER A, 1990, CELL GROWTH DIFFER, V1, P87; KEYDAR I, 1979, EUR J CANCER, V15, P659, DOI 10.1016/0014-2964(79)90139-7; MICHALOPOULOS GK, 1990, FASEB J, V4, P176, DOI 10.1096/fasebj.4.2.2404819; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NALDINI L, 1991, ONCOGENE, V6, P501; Naldini L., 1991, EMBO J, V10, P2876; PADAWER J, 1968, Journal of the Royal Microscopical Society, V88, P305; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PRAT M, 1991, INT J CANCER, V49, P323, DOI 10.1002/ijc.2910490302; ROSEN EM, 1991, CELL GROWTH DIFFER, V2, P603; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; STREULI CH, 1991, J CELL BIOL, V115, P1383, DOI 10.1083/jcb.115.5.1383; TAJIMA H, 1991, FEBS LETT, V291, P229, DOI 10.1016/0014-5793(91)81291-F; TASHIRO K, 1990, P NATL ACAD SCI USA, V87, P3200, DOI 10.1073/pnas.87.8.3200; TSARFATY I, UNPUB; VANDEWOUDE GF, 1992, JPN J CANCER RES, V83; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001	35	251	263	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 28	1992	257	5074					1258	1261		10.1126/science.1387731	http://dx.doi.org/10.1126/science.1387731			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL050	1387731				2022-12-01	WOS:A1992JL05000027
J	COWAN, SW; SCHIRMER, T; RUMMEL, G; STEIERT, M; GHOSH, R; PAUPTIT, RA; JANSONIUS, JN; ROSENBUSCH, JP				COWAN, SW; SCHIRMER, T; RUMMEL, G; STEIERT, M; GHOSH, R; PAUPTIT, RA; JANSONIUS, JN; ROSENBUSCH, JP			CRYSTAL-STRUCTURES EXPLAIN FUNCTIONAL-PROPERTIES OF 2 ESCHERICHIA-COLI PORINS	NATURE			English	Article							PHOTOSYNTHETIC REACTION CENTER; INTEGRAL MEMBRANE-PROTEIN; ESCHERICHIA-COLI; OUTER-MEMBRANE; MACROMOLECULAR CRYSTALLOGRAPHY; RHODOPSEUDOMONAS-VIRIDIS; RHODOBACTER-CAPSULATUS; ELECTRON-MICROSCOPY; BACTERIAL PORIN; PHOE PORIN	Porins form aqueous channels that aid the diffusion of small hydrophilic molecules across the outer membrane of Gram-negative bacteria. The crystal structures of matrix porin and phosphoporin both reveal trimers of identical subunits, each subunit consisting of a 16-stranded anti-parallel beta-barrel containing a pore. A long loop inside the barrel contributes to a constriction of the channel where the charge distribution affects ion selectivity. The structures explain at the molecular level functional characteristics and their alterations by known mutations.	UNIV BASEL,BIOCTR,DEPT STRUCT BIOL,CH-4056 BASEL,SWITZERLAND; UNIV BASEL,BIOCTR,DEPT MICROBIOL,CH-4056 BASEL,SWITZERLAND	University of Basel; University of Basel								BAUER K, 1989, J BIOL CHEM, V264, P16393; BENSON SA, 1988, J MOL BIOL, V203, P961, DOI 10.1016/0022-2836(88)90121-0; BENZ R, 1985, J BACTERIOL, V162, P722, DOI 10.1128/JB.162.2.722-727.1985; BOSCH D, 1989, MOL GEN GENET, V216, P144, DOI 10.1007/BF00332243; BRUNGER AT, 1990, XPLOR MANUAL; BUHLER LK, 1991, J BIOL CHEM, V266, P24446; DARGENT B, 1986, EMBO J, V5, P773, DOI 10.1002/j.1460-2075.1986.tb04280.x; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; DEISENHOFER J, 1989, SCIENCE, V245, P1463, DOI 10.1126/science.245.4925.1463; ENGEL A, 1985, NATURE, V317, P643, DOI 10.1038/317643a0; GARAVITO RM, 1980, J CELL BIOL, V86, P327, DOI 10.1083/jcb.86.1.327; GARAVITO RM, 1983, J MOL BIOL, V164, P313, DOI 10.1016/0022-2836(83)90079-7; HANCOCK REW, 1987, J BACTERIOL, V169, P929, DOI 10.1128/jb.169.3.929-933.1987; HENDERSON R, 1990, J MOL BIOL, V213, P899, DOI 10.1016/S0022-2836(05)80271-2; HENDERSON R, 1975, NATURE, V257, P28, DOI 10.1038/257028a0; HONGER A, 1990, J STRUCT BIOL, V103, P185; JAP BK, 1991, NATURE, V350, P167, DOI 10.1038/350167a0; JAP BK, 1990, Q REV BIOPHYS, V23, P367, DOI 10.1017/S003358350000559X; JAP BK, 1989, J MOL BIOL, V205, P407, DOI 10.1016/0022-2836(89)90351-3; JAP BK, 1990, J STRUCT BIOL, V103, P57, DOI 10.1016/1047-8477(90)90086-R; JEANTEUR D, 1991, MOL MICROBIOL, V5, P2153, DOI 10.1111/j.1365-2958.1991.tb02145.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JONES TA, 1990, MANUAL O; KLEBBA PE, 1990, J BIOL CHEM, V265, P6800; KORTELAND J, 1985, EUR J BIOCHEM, V152, P691, DOI 10.1111/j.1432-1033.1985.tb09249.x; LAKEY JH, 1991, FEBS LETT, V278, P31, DOI 10.1016/0014-5793(91)80076-F; LESK AM, 1989, PROTEINS, V5, P139, DOI 10.1002/prot.340050208; LEWIS BA, 1983, J MOL BIOL, V166, P211, DOI 10.1016/S0022-2836(83)80007-2; MESSERSCHMIDT A, 1987, J APPL CRYSTALLOGR, V20, P306, DOI 10.1107/S002188988708662X; MICHEL H, 1983, TRENDS BIOCHEM SCI, V8, P56, DOI 10.1016/0968-0004(83)90390-0; MISRA R, 1988, J BACTERIOL, V170, P3611, DOI 10.1128/jb.170.8.3611-3617.1988; MIZUNO T, 1983, J BIOL CHEM, V258, P6932; NIKAIDO H, 1981, J GEN PHYSIOL, V77, P121, DOI 10.1085/jgp.77.2.121; NIKAIDO H, 1983, J BACTERIOL, V153, P241, DOI 10.1128/JB.153.1.241-252.1983; NIKAIDO H, 1992, MOL MICROBIOL, V6, P435, DOI 10.1111/j.1365-2958.1992.tb01487.x; PAUPTIT RA, 1991, J MOL BIOL, V218, P505, DOI 10.1016/0022-2836(91)90696-4; PAUPTIT RA, 1991, J STRUCT BIOL, V107, P136, DOI 10.1016/1047-8477(91)90017-Q; PRIESTLE JP, 1988, J APPL CRYSTALLOGR, V21, P572, DOI 10.1107/S0021889888005746; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; ROCQUE WJ, 1990, BIOCHEMISTRY-US, V29, P5344, DOI 10.1021/bi00474a020; ROSENBUSCH JP, 1974, J BIOL CHEM, V249, P8019; ROSENBUSCH JP, 1990, EXPERIENTIA, V46, P167; ROSENBUSCH JP, 1977, SOLUBILIZATION LIPOP, P59; Rossmann M. G., 1972, MOL REPLACEMENT METH; SASS HJ, 1989, J MOL BIOL, V209, P171, DOI 10.1016/0022-2836(89)90180-0; SCHINDLER H, 1978, P NATL ACAD SCI USA, V75, P3751, DOI 10.1073/pnas.75.8.3751; Schirmer T, 1991, CURR OPIN STRUC BIOL, V1, P539, DOI 10.1016/S0959-440X(05)80075-2; SPURLINO JC, 1991, J BIOL CHEM, V266, P5202; STEIERT M, 1992, Experientia (Basel), V48, pA22; STEVEN AC, 1977, J CELL BIOL, V72, P292, DOI 10.1083/jcb.72.2.292; STRUYVE M, 1991, J MOL BIOL, V218, P141, DOI 10.1016/0022-2836(91)90880-F; VANDERLEY P, 1986, J BIOL CHEM, V261, P2222; VOGEL H, 1986, J MOL BIOL, V190, P191, DOI 10.1016/0022-2836(86)90292-5; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WEISS MS, 1990, FEBS LETT, V267, P268, DOI 10.1016/0014-5793(90)80942-C; WEISS MS, 1991, FEBS LETT, V280, P379, DOI 10.1016/0014-5793(91)80336-2; WEISS MS, 1991, SCIENCE, V254, P1627, DOI 10.1126/science.1721242; 1979, SERC UK4 DAR LAB COL	58	1345	1370	0	72	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 27	1992	358	6389					727	733		10.1038/358727a0	http://dx.doi.org/10.1038/358727a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JK699	1380671				2022-12-01	WOS:A1992JK69900043
J	DENNING, GM; ANDERSON, MP; AMARA, JF; MARSHALL, J; SMITH, AE; WELSH, MJ				DENNING, GM; ANDERSON, MP; AMARA, JF; MARSHALL, J; SMITH, AE; WELSH, MJ			PROCESSING OF MUTANT CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR IS TEMPERATURE-SENSITIVE	NATURE			English	Article							CFTR CHLORIDE CHANNEL; INTRACELLULAR-TRANSPORT; R-DOMAIN; GENE; IDENTIFICATION; EXPRESSION; CELLS; PHOSPHORYLATION; EXERCISE	CYSTIC fibrosis transmembrane conductance regulator (CFTR) is a plasma membrane Cl- channel regulated by cyclic AMP-dependent phosphorylation and by intracellular ATP1-7. Mutations in CFTR cause cystic fibrosis8-10 partly through loss of cAMP-regulated Cl- permeability from the plasma membrane of affected epithelia11,12. The most common mutation in cystic fibrosis is deletion of phenylalanine at residue 508 (CFTR-DELTA-F508) (ref. 10). Studies on the biosynthesis13,14 and localization15 of CFTR-DELTA-F508 indicate that the mutant protein is not processed correctly and, as a result, is not delivered to the plasma membrane. These conclusions are consistent with earlier functional studies which failed to detect cAMP-stimulated Cl- channels in cells expressing CFTR-DELTA-F508 (refs 16, 17). Chloride channel activity was detected, however, when CFTR-DELTA-F508 was expressed in Xenopus oocytes18, Vero cells19 and Sf9 insect cells20. Because oocytes and Sf9 cells are typically maintained at lower temperatures than mammalian cells, and because processing of nascent proteins can be sensitive to temperature21, we tested the effect of temperature on the processing of CFTR-DELTA-F508. Here we show that the processing of CFTR-DELTA-F508 reverts towards that of wild-type as the incubation temperature is reduced. When the processing defect is corrected, cAMP-regulated Cl- channels appear in the plasma membrane. These results reconcile previous contradictory observations and suggest that the mutant most commonly associated with cystic fibrosis is temperature-sensitive.	UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242; GENZYME CORP,FRAMINGHAM,MA 01701	Howard Hughes Medical Institute; University of Iowa; Sanofi-Aventis; Genzyme Corporation	DENNING, GM (corresponding author), UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,DEPT INTERNAL MED,IOWA CITY,IA 52242, USA.		Denning, Gerene M/D-1077-2009	Marshall, John/0000-0003-1361-2869; Anderson, Matthew/0000-0003-4602-1811; Welsh, Michael/0000-0002-1646-6206; Denning, Gerene/0000-0002-2334-993X				ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; BEAR C E, 1992, Biophysical Journal, V61, pA127; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BERGER HA, 1991, J CLIN INVEST, V88, P1422, DOI 10.1172/JCI115450; BOAT TF, 1989, METABOLIC BASIS INHE, V6, P2649; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; DALEMANS W, 1991, NATURE, V354, P52; DEAL EC, 1979, J APPL PHYSIOL, V46, P484, DOI 10.1152/jappl.1979.46.3.484; DENNING GM, 1992, J CELL BIOL, V118, P551, DOI 10.1083/jcb.118.3.551; DRUMM ML, 1991, SCIENCE, V254, P1797, DOI 10.1126/science.1722350; GILBERT IA, 1987, J APPL PHYSIOL, V63, P1681, DOI 10.1152/jappl.1987.63.4.1681; GREGORY RJ, 1991, MOL CELL BIOL, V11, P3886, DOI 10.1128/MCB.11.8.3886; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; MACHAMER CE, 1988, J BIOL CHEM, V263, P5955; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; RICH DP, 1991, SCIENCE, V253, P205, DOI 10.1126/science.1712985; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0	25	1065	1094	0	72	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 27	1992	358	6389					761	764		10.1038/358761a0	http://dx.doi.org/10.1038/358761a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JK699	1380673				2022-12-01	WOS:A1992JK69900055
J	FERRERA, VP; NEALEY, TA; MAUNSELL, JHR				FERRERA, VP; NEALEY, TA; MAUNSELL, JHR			MIXED PARVOCELLULAR AND MAGNOCELLULAR GENICULATE SIGNALS IN VISUAL AREA V4	NATURE			English	Article							MACAQUE STRIATE CORTEX; BROAD-BAND CHANNELS; REVERSIBLE INACTIVATION; INTRINSIC CONNECTIONS; GANGLION-CELLS; COLOR-OPPONENT; LAMINA 4C; PERCEPTION; VISION	VISUAL information from the retina is transmitted to the cerebral cortex by way of the lateral geniculate nucleus (LGN) in the thalamus. In primates, most of the retinal ganglion cells that project to the LGN belong to one of two classes, P and M, whose axons terminate in the parvocellular or magnocellular subdivisions of the LGN. These cell classes give rise to two channels that have been distinguished anatomically, physiologically and behaviourally1-3,16,17. The visual cortex also can be subdivided into two pathways, one specialized for motion processing and the other for colour and form information4. Several lines of indirect evidence have suggested a close correspondence between the subcortical and cortical pathways, such that the M channel provides input to the motion pathway and the P channel drives the colour/form pathway5-7. This hypothesis was tested directly by selectively inactivating either the magnocellular or parvocellular subdivision of the LGN and recording the effects on visual responses in the cortex. We have previously reported that, in accordance with the hypothesis, responses in the motion pathway in the cortex depend primarily on magnocellular LGN8. We now report that in the colour/form pathway, visual responses depend on both P and M input. These results argue against a simple correspondence between the subcortical and cortical pathways.	UNIV ROCHESTER,DEPT PHYSIOL,ROCHESTER,NY 14642; UNIV ROCHESTER,CTR VISUAL SCI,ROCHESTER,NY 14642	University of Rochester; University of Rochester			Maunsell, John/G-5702-2010	Maunsell, John/0000-0003-0018-4439; Ferrera, Vincent/0000-0002-6599-7740				BLASDEL GG, 1985, J NEUROSCI, V5, P3350; Felleman DJ, 1991, CEREB CORTEX, V1, P1, DOI 10.1093/cercor/1.1.1; FITZPATRICK D, 1985, J NEUROSCI, V5, P3329; LACHICA EA, 1992, P NATL ACAD SCI USA, V89, P3566, DOI 10.1073/pnas.89.8.3566; LIVINGSTONE M, 1988, SCIENCE, V240, P740, DOI 10.1126/science.3283936; MALPELI JG, 1979, J NEUROSCI METH, V1, P143, DOI 10.1016/0165-0270(79)90011-6; MALPELI JG, 1981, J NEUROPHYSIOL, V46, P1102, DOI 10.1152/jn.1981.46.5.1102; MAUNSELL JHR, 1990, J NEUROSCI, V10, P3323; MAUNSELL JHR, 1987, ANNU REV NEUROSCI, V10, P363, DOI 10.1146/annurev.ne.10.030187.002051; MAUNSELL JHR, 1987, MATTERS INTELLIGENCE; MERIGAN WH, 1991, J NEUROSCI, V11, P3422; MERIGAN WH, 1991, J NEUROSCI, V11, P994; NEALEY TA, 1991, INVEST OPHTH VIS SCI, V32, P1117; SCHILLER PH, 1990, VISUAL NEUROSCI, V5, P321, DOI 10.1017/S0952523800000420; SHAPLEY R, 1986, TRENDS NEUROSCI, V9, P229, DOI 10.1016/0166-2236(86)90064-0; SILVEIRA LCL, 1991, NEUROSCIENCE, V40, P217, DOI 10.1016/0306-4522(91)90186-R; UNGERLEIDER LG, 1982, ANAL VISUAL BEHAVIOR	17	141	143	1	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 27	1992	358	6389					756	758		10.1038/358756a0	http://dx.doi.org/10.1038/358756a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JK699	1508271				2022-12-01	WOS:A1992JK69900053
J	HEALY, B				HEALY, B			ON GENE PATENTING	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											HEALY, B (corresponding author), NIH,BETHESDA,MD 20892, USA.							ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; 1991, OTABA494 OFF TECHN A; 1991, REPORT NATIONAL BIOT; 1992, IBA POSITION PAPER R	5	29	29	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 27	1992	327	9					664	668		10.1056/NEJM199208273270930	http://dx.doi.org/10.1056/NEJM199208273270930			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JK204	1640972	Bronze			2022-12-01	WOS:A1992JK20400034
J	JOHNSON, NA; PEREZ, DE; CABOT, EL; HOLLOCHER, H; WU, CI				JOHNSON, NA; PEREZ, DE; CABOT, EL; HOLLOCHER, H; WU, CI			A TEST OF RECIPROCAL X-Y INTERACTIONS AS A CAUSE OF HYBRID STERILITY IN DROSOPHILA	NATURE			English	Article							HALDANE RULE; CHROMOSOME; PSEUDOOBSCURA; MELANOGASTER; PERSIMILIS	ELUCIDATION of the nature of the gene interactions that underly the sterility of interspecific hybrids is important in evolutionary biology1,2. The interactions between the heterospecific X and Y (or Z and W) chromosomes are often used as an explanation for two reasons. First, the fertility of the hybrids of the heterogametic sex is much more often affected than that of the homogametic sex (Haldane's rule3) and X-Y interactions are specific to the heterogametic sex. Second, sex chromosomes, especially the X chromosome, are often considered to be of special importance in determining the fertility of hybrids1,2,4. X-Y interactions have been addressed in studies of males with a heterospecific Y chromosome in a mixed genetic background5-8. A more stringent test of the X-Y interaction model requires each X chromosome sterility factor to be tested separately for its interaction with the Y chromosome in a homogeneous background of the pure species. Here we report such a test of the X-Y interaction model and conclude that X-Y interactions should not be assumed to be the only or even the most common cause of hybrid sterility.	UNIV CHICAGO,DEPT ECOL & EVOLUT,CHICAGO,IL 60637; UNIV ROCHESTER,DEPT BIOL,ROCHESTER,NY 14627	University of Chicago; University of Rochester								CLARK AG, 1987, GENETICS, V115, P143; COYNE JA, 1985, NATURE, V314, P736, DOI 10.1038/314736a0; COYNE JA, 1989, HEREDITY, V62, P97, DOI 10.1038/hdy.1989.13; COYNE JA, 1989, SPECIATION ITS CONSE, P181; Dobzhansky T, 1936, GENETICS, V21, P113; Haldane JBS, 1922, J GENET, V12, P101, DOI 10.1007/BF02983075; HENNIG W, 1977, ADV ENZYME REGUL, V15, P363, DOI 10.1016/0065-2571(77)90025-5; JOHNSON NA, 1992, GENETICS, V130, P507; JONES JS, 1985, NATURE, V314, P668, DOI 10.1038/314668a0; LIVAK KJ, 1984, GENETICS, V107, P611; Muller HJ., 1940, NEW SYSTEMATICS, P185; OKA HI, 1974, GENETICS, V77, P521; ORR HA, 1987, GENETICS, V116, P555; PANTAZIDIS AC, 1988, HEREDITY, V60, P299, DOI 10.1038/hdy.1988.46; WU CI, 1983, GENETICS, V105, P71; WU CI, IN PRESS MOL PALEOPO	16	47	47	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 27	1992	358	6389					751	753		10.1038/358751a0	http://dx.doi.org/10.1038/358751a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JK699	1508270				2022-12-01	WOS:A1992JK69900051
J	KLIEWER, SA; UMESONO, K; NOONAN, DJ; HEYMAN, RA; EVANS, RM				KLIEWER, SA; UMESONO, K; NOONAN, DJ; HEYMAN, RA; EVANS, RM			CONVERGENCE OF 9-CIS RETINOIC ACID AND PEROXISOME PROLIFERATOR SIGNALING PATHWAYS THROUGH HETERODIMER FORMATION OF THEIR RECEPTORS	NATURE			English	Article							HORMONE; GENE; RAT	PEROXISOMES are cytoplasmic organelles which are important in mammals in modulation of lipid homeostasis, including the metabolism of long-chain fatty acids and conversion or cholesterol to bile salts (reviewed in refs 1 and 2). Amphipathic carboxylates such as clofibric acid have been used in man as hypolipidaemic agents and in rodents they stimulate the proliferation of peroxisomes. These agents, termed peroxisome proliferators, and all-trans retinoic acid activate genes involved in peroxisomal-mediated beta-oxidation of fatty acids1-4. Here we show that the receptor activated by peroxisome proliferators5 and the retinoid X receptor-alpha (ref. 6) form a heterodimer that activates acyl-CoA oxidase gene expression in response to either clofibric acid or the retinoid X receptor-alpha ligand, 9-cis retinoic acid, an all-trans retinoic acid metabolite7,8; simultaneous exposure to both activators results in a synergistic induction of gene expression. These data demonstrate the coupling of the peroxisome proliferator and retinoid signalling pathways and provide evidence for a physiological role for 9-cis retinoic acid in modulating lipid metabolism.	LIGAND PHARMACEUT,SAN DIEGO,CA 92121	Ligand Pharmaceuticals	KLIEWER, SA (corresponding author), SALK INST BIOL STUDIES,HOWARD HUGHES MED INST,LA JOLLA,CA 92037, USA.		Evans, Ronald/AAF-4001-2019	Evans, Ronald/0000-0002-9986-5965	Howard Hughes Medical Institute Funding Source: Medline	Howard Hughes Medical Institute(Howard Hughes Medical Institute)		DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; HERTZ R, 1992, BIOCHEM J, V281, P41, DOI 10.1042/bj2810041; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HIJKATA M, 1990, J BIOL CHEM, V265, P4600; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448, DOI 10.1073/pnas.89.4.1448; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; LAZAROW PB, 1985, ANNU REV CELL BIOL, V1, P489, DOI 10.1146/annurev.cb.01.110185.002421; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; NEMALI MR, 1988, CANCER RES, V48, P5316; OSUMI T, 1991, BIOCHEM BIOPH RES CO, V175, P866, DOI 10.1016/0006-291X(91)91645-S; REDDY JK, 1983, CRC CR REV TOXICOL, V12, P1, DOI 10.3109/10408448309029317; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; Vamecq J, 1989, Essays Biochem, V24, P115; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	20	1528	1603	3	41	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 27	1992	358	6389					771	774		10.1038/358771a0	http://dx.doi.org/10.1038/358771a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JK699	1324435	Green Accepted			2022-12-01	WOS:A1992JK69900058
J	RAMAKRISHNAN, V; WHITE, SW				RAMAKRISHNAN, V; WHITE, SW			THE STRUCTURE OF RIBOSOMAL PROTEIN-S5 REVEALS SITES OF INTERACTION WITH 16S RIBOSOMAL-RNA	NATURE			English	Article							BACILLUS-STEAROTHERMOPHILUS RIBOSOME; ESCHERICHIA-COLI RIBOSOME; RNA-BINDING DOMAIN; CRYSTAL-STRUCTURE; SUBUNITS; S5; GENES; RECONSTITUTION; MUTATIONS; SEQUENCE	UNDERSTANDING the process whereby the ribosome translates the genetic code into protein molecules will ultimately require high-resolution structural information, and we report here the first crystal structure of a protein from the small ribosomal subunit. This protein, S5, has a molecular mass of 17,500 and is highly conserved in all lifeforms1-4. The molecule contains two distinct alpha/beta-domains that have structural similarities to several other proteins that are components of ribonucleoprotein complexes. Mutations in S5 result in several phenotypes which suggest that S5 may have a role in translational fidelity and translocation. These include ribosome ambiguity or ram5, reversion from streptomycin dependence6 and resistance to spectinomycin6. Also, a cold-sensitive, spectinomycin-resistant mutant of S5 has been identified which is defective in initiation7. Here we show that these mutations map to two distinct regions of the molecule which seem to be sites of interaction with ribosomal RNA. A structure/function analysis of the molecule reveals discrepancies with current models8,9 of the 30S subunit.	MRC,MOLEC BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND; DUKE UNIV,MED CTR,DEPT MICROBIOL,DURHAM,NC 27710	MRC Laboratory Molecular Biology; Duke University	RAMAKRISHNAN, V (corresponding author), BROOKHAVEN NATL LAB,DEPT BIOL,UPTON,NY 11973, USA.		White, Stephen W/N-8164-2018	Ramakrishnan, V/0000-0002-4699-2194				ALLROBYN JA, 1990, MOL CELL BIOL, V10, P6544, DOI 10.1128/MCB.10.12.6544; APPELT K, 1983, J BIOL CHEM, V258, P3328; ARNDT UW, 1985, METHOD ENZYMOL, V114, P472; BRIMACOMBE R, 1988, J MOL BIOL, V199, P115, DOI 10.1016/0022-2836(88)90383-X; BRIMACOMBE R, 1991, BIOCHIMIE, V73, P927, DOI 10.1016/0300-9084(91)90134-M; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; CAPEL MS, 1987, SCIENCE, V238, P1403, DOI 10.1126/science.3317832; DONTSOVA O, 1991, EMBO J, V10, P2613, DOI 10.1002/j.1460-2075.1991.tb07803.x; FUREY W, 1990, AM CRYSTALLOGR ASS 2, V18, P73; HELD WA, 1973, J BIOL CHEM, V248, P5720; HOFFMAN DW, 1991, P NATL ACAD SCI USA, V88, P2495, DOI 10.1073/pnas.88.6.2495; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIMURA M, 1984, J BIOL CHEM, V259, P1051; LAMBERT JM, 1983, BIOCHEMISTRY-US, V22, P3913, DOI 10.1021/bi00285a029; LEIJONMARCK M, 1987, J MOL BIOL, V195, P555, DOI 10.1016/0022-2836(87)90183-5; LEIJONMARCK M, 1988, PROTEINS, V3, P243, DOI 10.1002/prot.340030405; MOAZED D, 1987, NATURE, V327, P389, DOI 10.1038/327389a0; MONTANDON PE, 1986, EMBO J, V5, P3705, DOI 10.1002/j.1460-2075.1986.tb04703.x; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; NOLLER HF, 1991, ANNU REV BIOCHEM, V60, P191, DOI 10.1146/annurev.biochem.60.1.191; NOMURA M, 1987, COLD SPRING HARB SYM, V52, P653, DOI 10.1101/SQB.1987.052.01.075; OLLIS DL, 1987, CHEM REV, V87, P981, DOI 10.1021/cr00081a006; OSSWALD M, 1987, NUCLEIC ACIDS RES, V15, P3221, DOI 10.1093/nar/15.8.3221; PIEPERSBERG W, 1975, MOL GEN GENET, V143, P43, DOI 10.1007/BF00269419; PIEPERSBERG W, 1975, MOL GEN GENET, V140, P91, DOI 10.1007/BF00329777; RAMAKRISHNAN V, 1991, J BIOL CHEM, V266, P880; SCHOLZEN T, 1991, MOL GEN GENET, V228, P70, DOI 10.1007/BF00282450; SIGMUND CD, 1984, NUCLEIC ACIDS RES, V12, P4653, DOI 10.1093/nar/12.11.4653; STERN S, 1989, SCIENCE, V244, P783, DOI 10.1126/science.2658053; STERN S, 1988, J MOL BIOL, V204, P447, DOI 10.1016/0022-2836(88)90588-8; WHITE SW, 1983, FEBS LETT, V163, P73, DOI 10.1016/0014-5793(83)81166-1; WILSON KS, 1986, P NATL ACAD SCI USA, V83, P7251, DOI 10.1073/pnas.83.19.7251; WITTMANNLIEBOLD B, 1978, FEBS LETT, V95, P91, DOI 10.1016/0014-5793(78)80059-3	33	147	155	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 27	1992	358	6389					768	771		10.1038/358768a0	http://dx.doi.org/10.1038/358768a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JK699	1508272				2022-12-01	WOS:A1992JK69900057
J	SCHNEIDER, A; MONTAGUE, P; GRIFFITHS, I; FANARRAGA, M; KENNEDY, PGE; BROPHY, P; NAVE, KA				SCHNEIDER, A; MONTAGUE, P; GRIFFITHS, I; FANARRAGA, M; KENNEDY, PGE; BROPHY, P; NAVE, KA			UNCOUPLING OF HYPOMYELINATION AND GLIAL-CELL DEATH BY A MUTATION IN THE PROTEOLIPID PROTEIN GENE	NATURE			English	Article							JIMPY MUTANT MOUSE; MESSENGER-RNA; MYELIN; MICE; EXPRESSION; PLP; OLIGODENDROCYTES; BACKGROUNDS; MEMBRANES; DEFECT	PROTEOLIPID protein (PLP; M(r) 30,000) is a highly conserved major polytopic membrane protein in myelin but its cellular function remains obscure. Neurological mutant mice can often provide model systems for human genetic disorders. Mutations of the X-chromosome-linked PLP gene are lethal, identified first in the jimpy mouse1,2 and subsequently in patients with Pelizaeus-Merzbacher disease3,4. The unexplained phenotype of these mutations includes degeneration and premature cell death of oligodendrocytes with associated hypomyelination5. Here we show that a new mouse mutant rumpshaker6 is defined by the amino-acid substitution Ile-to-Thr at residue 186 in a membrane-embedded domain of PLP. Surprisingly, rumpshaker mice, although myelin-deficient, have normal longevity and a full complement of morphologically normal oligodendrocytes7. Hypomyelination can thus be genetically separated from the PLP-dependent oligodendrocyte degeneration. We suggest that PLP has a vital function in glial cell development, distinct from its later role in myelin assembly, and that this dichotomy of action may explain the clinical spectrum8 of Pelizaeus-Merzbacher disease.	UNIV HEIDELBERG, ZENTRUM MOLEK BIOL, W-6900 HEIDELBERG, GERMANY; UNIV GLASGOW, APPL NEUROBIOL GRP, GLASGOW G61 1QH, SCOTLAND; UNIV STIRLING, DEPT BIOL & MOLEC SCI, STIRLING FK9 4LA, SCOTLAND	Ruprecht Karls University Heidelberg; University of Glasgow; University of Stirling			Nave, Klaus-Armin/C-8883-2011; Fanarraga, Monica/AAE-5804-2019; Fanarraga, Mónica L./M-6177-2014	Fanarraga, Monica/0000-0003-4754-311X; Fanarraga, Mónica L./0000-0003-4754-311X				BARTLETT WP, 1988, GLIA, V1, P253, DOI 10.1002/glia.440010404; BILLINGSGAGLIARDI S, 1980, BRAIN RES, V194, P325, DOI 10.1016/0006-8993(80)91215-9; BOISON D, 1989, EMBO J, V8, P3295, DOI 10.1002/j.1460-2075.1989.tb08490.x; CHALFIE M, 1990, NATURE, V345, P410, DOI 10.1038/345410a0; DAUTIGNY A, 1986, NATURE, V321, P867, DOI 10.1038/321867a0; DIEHL HJ, 1986, P NATL ACAD SCI USA, V83, P9807, DOI 10.1073/pnas.83.24.9807; FANARRAGA ML, 1992, GLIA, V5, P161, DOI 10.1002/glia.440050302; GENCIC S, 1990, J NEUROSCI, V10, P117; GRIFFITHS IR, 1990, J NEUROCYTOL, V19, P273, DOI 10.1007/BF01217305; HELYNCK G, 1983, EUR J BIOCHEM, V133, P689, DOI 10.1111/j.1432-1033.1983.tb07518.x; HUDSON LD, 1987, P NATL ACAD SCI USA, V84, P1454, DOI 10.1073/pnas.84.5.1454; HUDSON LD, 1989, P NATL ACAD SCI USA, V86, P8128, DOI 10.1073/pnas.86.20.8128; HUDSON LD, 1990, ANN NY ACAD SCI, V605, P155, DOI 10.1111/j.1749-6632.1990.tb42390.x; IKENAKA K, 1992, J NEUROCHEM, V58, P2248, DOI 10.1111/j.1471-4159.1992.tb10970.x; KNAPP PE, 1986, J NEUROSCI, V6, P2813; KTIMMERMAN V, IN PRESS NATURE GENE; MANFIOLETTI G, 1990, MOL CELL BIOL, V10, P2924, DOI 10.1128/MCB.10.6.2924; MEYER C, 1974, J NEUROPATHOL EXP NE, V33, P343; MILNER RJ, 1985, CELL, V42, P931, DOI 10.1016/0092-8674(85)90289-2; MITCHELL LS, IN PRESS J NEUROSCI; NAVE KA, 1987, P NATL ACAD SCI USA, V84, P5665, DOI 10.1073/pnas.84.16.5665; NAVE KA, 1989, CRIT REV NEUROBIOL, V5, P65; NAVE KA, 1986, P NATL ACAD SCI USA, V83, P9264, DOI 10.1073/pnas.83.23.9264; POPOT JL, 1991, J MEMBRANE BIOL, V120, P233, DOI 10.1007/BF01868534; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Sambrook J., 1989, MOL CLONING; SIDMAN RL, 1964, SCIENCE, V144, P309, DOI 10.1126/science.144.3616.309; SIETELBERGER F, 1970, HDB CLIN NEUROLOGY, P150; SKOFF RP, 1976, NATURE, V264, P560, DOI 10.1038/264560a0; SUTER U, 1992, NATURE, V356, P241, DOI 10.1038/356241a0; VERMEESCH MK, 1990, DEV NEUROSCI-BASEL, V12, P303, DOI 10.1159/000111859; WOLF MK, 1983, BRAIN RES, V271, P121, DOI 10.1016/0006-8993(83)91371-9	32	182	185	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 27	1992	358	6389					758	761		10.1038/358758a0	http://dx.doi.org/10.1038/358758a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JK699	1380672				2022-12-01	WOS:A1992JK69900054
J	SHENTON, ME; KIKINIS, R; JOLESZ, FA; POLLAK, SD; LEMAY, M; WIBLE, CG; HOKAMA, H; MARTIN, J; METCALF, D; COLEMAN, M; MCCARLEY, RW				SHENTON, ME; KIKINIS, R; JOLESZ, FA; POLLAK, SD; LEMAY, M; WIBLE, CG; HOKAMA, H; MARTIN, J; METCALF, D; COLEMAN, M; MCCARLEY, RW			ABNORMALITIES OF THE LEFT TEMPORAL-LOBE AND THOUGHT-DISORDER IN SCHIZOPHRENIA - A QUANTITATIVE MAGNETIC-RESONANCE-IMAGING STUDY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ENTORHINAL CORTEX; PARAHIPPOCAMPAL GYRUS; CEREBRAL ASYMMETRY; VENTRICULAR VOLUME; PLANUM TEMPORALE; MR IMAGES; BRAIN; MONKEY; SYMPTOMS; SYSTEM	Background. Data from postmortem, CT, and magnetic resonance imaging (MRI) studies indicate that patients with schizophrenia may have anatomical abnormalities of the left temporal lobe, but it is unclear whether these abnormalities are related to the thought disorder characteristic of schizophrenia. Methods. We used new MRI neuroimaging techniques to derive (without knowledge of the diagnosis) volume measurements and three-dimensional reconstructions of temporal-lobe structures in vivo in 15 right-handed men with chronic schizophrenia and 15 matched controls. Results. As compared with the controls, the patients had significant reductions in the volume of gray matter in the left anterior hippocampus-amygdala (by 19 percent [95 percent confidence interval, 3 to 36 percent]), the left parahippocampal gyrus (by 13 percent [95 percent confidence interval, 3 to 23 percent], vs. 8 percent on the right), and the left superior temporal gyrus (by 15 percent [95 percent confidence interval, 5 to 25 percent]). The volume of the left posterior superior temporal gyrus correlated with the score on the thought-disorder index in the 13 patients evaluated (r = -0.81, P = 0.001). None of these regional volume decreases were accompanied by a decrease in the volume of the overall brain or temporal lobe. The volume of gray matter in a control region (the superior frontal gyrus) was essentially the same in the patients and controls. Conclusions. Schizophrenia involves localized reductions in the gray matter of the left temporal lobe. The degree of thought disorder is related to the size of the reduction in volume of the left posterior superior temporal gyrus.	HARVARD UNIV,SCH MED,DEPT PSYCHIAT,BOSTON,MA 02115; BROCKTON VET AFFAIRS MED CTR,BROCKTON,MA; BRIGHAM & WOMENS HOSP,MAGNET RESONANCE IMAGING CTR,BOSTON,MA 02115; MASSACHUSETTS MENTAL HLTH CTR,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT RADIOL,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School			Pollak, Seth D/G-2345-2011; Shenton, Martha/V-8780-2019		NIMH NIH HHS [K01-MH-00746-04, R01 MH040799] Funding Source: Medline; NINDS NIH HHS [K04-NS-01083] Funding Source: Medline; PHS HHS [40,799] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH040799, K01MH000746] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K04NS001083] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMARAL DG, 1983, BRAIN RES, V275, P263, DOI 10.1016/0006-8993(83)90987-3; Andreasen N., 1984, SCALE ASSESSMENT POS; Andreasen N.C, 1981, SCALE ASSESSMENT NEG; ARNOLD SE, 1991, ARCH GEN PSYCHIAT, V48, P625; BARTA PE, 1990, AM J PSYCHIAT, V147, P1457; BLEULER E, 1950, MONOGRAPH SERIES SCH, V1; BOGERTS B, 1990, PSYCHIAT RES-NEUROIM, V35, P1; BOGERTS B, 1985, ARCH GEN PSYCHIAT, V42, P784; BOGERTS B, 1984, FORTSCHR NEUROL PSYC, V52, P428, DOI 10.1055/s-2007-1002212; Boyd E, 1962, BIOL HDB, P346; BROWN R, 1986, ARCH GEN PSYCHIAT, V43, P36; CARLSSON A, 1988, NEUROPSYCHOPHARMACOL, V1, P179, DOI 10.1016/0893-133X(88)90012-7; CLINE HE, 1987, MAGN RESON IMAGING, V5, P345, DOI 10.1016/0730-725X(87)90124-X; CLINE HE, 1991, J COMPUT ASSIST TOMO, V15, P344, DOI 10.1097/00004728-199103000-00035; CLINE HE, 1988, MED PHYS, V15, P320, DOI 10.1118/1.596225; CLINE HE, 1990, J COMPUT ASSIST TOMO, V14, P1037, DOI 10.1097/00004728-199011000-00041; COLTER N, 1987, ARCH GEN PSYCHIAT, V44, P1023; CROW TJ, 1990, BRIT J PSYCHIAT, V156, P788, DOI 10.1192/bjp.156.6.788; CROW TJ, 1990, SCHIZOPHRENIA BULL, V16, P433, DOI 10.1093/schbul/16.3.433; CROW TJ, 1989, ARCH GEN PSYCHIAT, V46, P1145; Daniels DL, 1987, CRANIAL SPINAL MAGNE; DEGREEF G, 1991, INT C SCHIZOPHRENIA; DELISI LE, 1988, SCHIZOPHRENIA BULL, V14, P185, DOI 10.1093/schbul/14.2.185; DELISI LE, 1991, BIOL PSYCHIAT, V29, P159, DOI 10.1016/0006-3223(91)90044-M; DELISI LE, 1989, BIOL PSYCHIAT, V25, P835, DOI 10.1016/0006-3223(89)90263-1; DELISI LE, 1991, BIOL PSYCHIAT, V29, P519; Duvernoy HM, 1988, HUMAN HIPPOCAMPUS; FALKAI P, 1986, EUR ARCH PSY CLIN N, V236, P154, DOI 10.1007/BF00380943; FALKAI P, 1988, BIOL PSYCHIAT, V24, P515, DOI 10.1016/0006-3223(88)90162-X; FAUX SF, 1990, ELECTROEN CLIN NEURO, V75, P378, DOI 10.1016/0013-4694(90)90083-V; FILIPEK PA, 1989, ANN NEUROL, V25, P61, DOI 10.1002/ana.410250110; GALABURDA AM, 1987, NEUROPSYCHOLOGIA, V25, P853, DOI 10.1016/0028-3932(87)90091-1; GALABURDA AM, 1984, CEREBRAL DOMINANCE B, P11; GERIG G, 1990, BIWIITR124 ETH EIDG; GESCHWIND N, 1968, SCIENCE, V161, P186, DOI 10.1126/science.161.3837.186; GRANT R, 1987, MAGN RESON IMAGING, V5, P465, DOI 10.1016/0730-725X(87)90380-8; GUR RE, 1991, ARCH GEN PSYCHIAT, V48, P407; Hollingshead AB, 1965, 2 FACTOR INDEX SOCIA; Holzman, 1979, ASSESSING SCHIZOPHRE; JAKOB H, 1986, J NEURAL TRANSM, V65, P303, DOI 10.1007/BF01249090; JAKOB H, 1989, J ROY SOC MED, V82, P466, DOI 10.1177/014107688908200808; JESTE DV, 1989, ARCH GEN PSYCHIAT, V46, P1019; JOHNSTONE EC, 1989, J NEUROL NEUROSUR PS, V52, P736, DOI 10.1136/jnnp.52.6.736; KELSOE JR, 1988, ARCH GEN PSYCHIAT, V45, P533; KIKINIS R, 1990, NATO ADV SCI I F-COM, V60, P441; KOVELMAN JA, 1984, BIOL PSYCHIAT, V19, P1601; MCCARLEY RW, 1991, SCHIZOPHR RES, V4, P209, DOI 10.1016/0920-9964(91)90034-O; MCCARLEY RW, 1989, ARCH GEN PSYCHIAT, V46, P698; OJEMANN GA, 1991, J NEUROSCI, V11, P2281; OJEMANN GA, 1988, BRAIN, V111, P1383, DOI 10.1093/brain/111.6.1383; PENFIELD W, 1963, BRAIN, V86, P595, DOI 10.1093/brain/86.4.595; PERONA P, 1987, 1987 P IEEE WORKSH C, P16; PFEFFERBAUM A, 1990, SCHIZOPHRENIA BULL, V16, P453, DOI 10.1093/schbul/16.3.453; POSNER MI, 1988, ARCH GEN PSYCHIAT, V45, P814; Rosene D. L., 1987, CEREB CORTEX, V6, P345, DOI DOI 10.1007/978-1-4615-6616-8_9; ROSSI A, 1990, BIOL PSYCHIAT, V27, P61, DOI 10.1016/0006-3223(90)90020-3; SANGHERA MK, 1979, EXP NEUROL, V63, P610, DOI 10.1016/0014-4886(79)90175-4; SAUNDERS RC, 1988, J COMP NEUROL, V271, P185, DOI 10.1002/cne.902710203; SCHWARZKOPF SB, 1991, SCHIZOPHR RES, V4, P412, DOI 10.1016/0920-9964(91)90367-Z; SHELTON RC, 1986, HDB SCHIZOPHRENIA, V1, P207; SHENTON ME, 1989, BIOL PSYCHIAT, V25, P710, DOI 10.1016/0006-3223(89)90242-4; SHENTON ME, 1991, SCHIZOPHR RES, V5, P103, DOI 10.1016/0920-9964(91)90037-R; SHENTON ME, 1987, ARCH GEN PSYCHIAT, V44, P21; SHENTON ME, 1990, 145TH AM PSYCH ASS A; SOLOVAY MR, 1986, SCHIZOPHRENIA BULL, V12, P483; Spitzer R.L., 1978, SCHEDULE AFFECTIVE D; SQUIRE LR, 1991, SCIENCE, V253, P1380, DOI 10.1126/science.1896849; STEINMETZ H, 1989, J COMPUT ASSIST TOMO, V13, P996, DOI 10.1097/00004728-198911000-00011; SUDDATH RL, 1990, NEW ENGL J MED, V322, P789, DOI 10.1056/NEJM199003223221201; Wechsler D, 1981, ADULT INTELLIGENCE S; WEINBERGER DR, 1986, HDB SCHIZOPHRENIA, V1, P397; Wernicke C., 1874, APHASISCHE SYMPTOMEN; WIESEL FA, 1987, ACTA PSYCHIAT SCAND, V76, P628, DOI 10.1111/j.1600-0447.1987.tb02933.x; WITTER MP, 1991, J COMP NEUROL, V307, P437, DOI 10.1002/cne.903070308; WYPER DJ, 1979, J NEUROL NEUROSUR PS, V42, P345, DOI 10.1136/jnnp.42.4.345; YOUNG AH, 1991, BRIT J PSYCHIAT, V158, P158, DOI 10.1192/bjp.158.2.158; ZIPURSKY RB, 1992, ARCH GEN PSYCHIAT, V49, P195; 1987, DIAGNOSTIC STATISTIC	78	1002	1010	1	44	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 27	1992	327	9					604	612		10.1056/NEJM199208273270905	http://dx.doi.org/10.1056/NEJM199208273270905			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JK204	1640954	Green Published			2022-12-01	WOS:A1992JK20400005
J	STODDARD, BL; KOSHLAND, DE				STODDARD, BL; KOSHLAND, DE			PREDICTION OF THE STRUCTURE OF A RECEPTOR PROTEIN COMPLEX USING A BINARY DOCKING METHOD	NATURE			English	Article							MALTOSE-BINDING; ASPARTATE; CHEMORECEPTOR; CHEMOTAXIS	TO validate procedures of rational drug design, it is important to develop computational methods that predict binding sites between a protein and a ligand molecule. Many small molecules have been tested using such programs, but examination of protein-protein and peptide-protein interactions has been sparse. We were able to test such applications once the structures of both the maltose-binding protein1 (MBP) and the ligand-binding domain of the aspartate receptor2, which binds MBP, became available. Here we predict the binding site of MBP to its receptor using a 'binary docking' technique in which two MBP octapeptide sequences containing mutations that eliminate maltose chemotaxis are independently docked to the receptor. The peptides in the docked solutions superimpose on their original positions in the structure of MBP and allow the formation of an MBP-receptor complex. The consistency of the computational and biological results supports this approach for predicting protein-protein and peptide-protein interactions.			STODDARD, BL (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELLULAR BIOL,DIV BIOCHEM,534 BARKER HALL,BERKELEY,CA 94720, USA.							FALKE JJ, 1987, SCIENCE, V237, P1596, DOI 10.1126/science.2820061; GARDINA P, 1992, J BACTERIOL, V174, P1528, DOI 10.1128/jb.174.5.1528-1536.1992; GASTEIGER J, 1978, TETRAHEDRON LETT, V34, P3181; GOODFORD PJ, 1985, J MED CHEM, V28, P849, DOI 10.1021/jm00145a002; GOODSELL D, 1991, PROTEIN-STRUCT FUNCT, V8, P195; KIRKPATRICK S, 1983, SCIENCE, V220, P671, DOI 10.1126/science.220.4598.671; KOSSMANN M, 1988, J BACTERIOL, V170, P4516, DOI 10.1128/jb.170.10.4516-4521.1988; MANSON MD, 1986, J BACTERIOL, V165, P34, DOI 10.1128/jb.165.1.34-40.1986; MILBURN MV, 1991, SCIENCE, V254, P1342, DOI 10.1126/science.1660187; MILLIGAN DL, 1991, SCIENCE, V254, P1651, DOI 10.1126/science.1661030; MOWBRAY SL, 1987, CELL, V50, P171, DOI 10.1016/0092-8674(87)90213-3; SPURLINO JC, 1991, J BIOL CHEM, V266, P5202	12	67	68	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 27	1992	358	6389					774	776		10.1038/358774a0	http://dx.doi.org/10.1038/358774a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JK699	1324436				2022-12-01	WOS:A1992JK69900059
J	CHRISTEN, WG; MANSON, JE; SEDDON, JM; GLYNN, RJ; BURING, JE; ROSNER, B; HENNEKENS, CH				CHRISTEN, WG; MANSON, JE; SEDDON, JM; GLYNN, RJ; BURING, JE; ROSNER, B; HENNEKENS, CH			A PROSPECTIVE-STUDY OF CIGARETTE-SMOKING AND RISK OF CATARACT IN MEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POSTERIOR SUBCAPSULAR CATARACTS; LENS OPACITIES; NUCLEAR; PREVALENCE; ALCOHOL; PLASMA; EYES	Objective.-To examine the association between cigarette smoking and the incidence of cataract. Design, Setting, and Participants.-The design was a prospective cohort study using data from the Physicians' Health Study, a randomized trial of aspirin and beta carotene among 22 071 US male physicians aged 40 to 84 years that began in 1982. This analysis includes the 17 824 physicians who did not report cataract at baseline and did provide complete risk factor information. Based on information reported at baseline, 10% were current smokers, 39% were past smokers, and 51% were never smokers. Main Outcome Measure.-An incident cataract was defined as a self-report confirmed by medical record review to have been first diagnosed after randomization, age-related in origin, and responsible for a decrease in best corrected visual acuity to 20/30 or worse. Main Results.-During 60 months of follow-up, 557 incident cataracts among 371 participants were confirmed. Compared with never smokers, current smokers of 20 or more cigarettes per day had a statistically significant increase in the risk of cataract (relative fisk [RR], 2.16; 95% confidence interval [CI], 1.46 to 3.20; P<.001). Similar results were obtained after simultaneously controlling for other potential cataract risk factors in a logistic regression model (RR, 2.05; 95% CI, 1.38 to 3.05; P<.001). Among the 557 eyes with cataract, nuclear sclerotic changes were present in 442 while posterior subcapsular changes were present in 204. After controlling for other potential cataract risk factors, current smokers of 20 or more cigarettes per day had statistically significant increases in nuclear sclerosis (RR, 2.24; 95% CI, 1.47 to 3.41; P<.001) and posterior subcapsular (RR, 3.17; 95% CI, 1.81 to 5.53; P<.001) cataract. Past smokers had an elevated risk of posterior subcapsular (RR, 1.44; 95% CI, 0.97 to 2.13; P=.07) but not nuclear sclerosis cataract. For current smokers of fewer than 20 cigarettes per day, no increased risks were observed of total, nuclear sclerosis, or posterior subcapsular cataract. Conclusions.-These data provide support for the hypothesis that cigarette smoking increases the risk of developing both nuclear sclerosis and posterior subcapsular cataract.	HARVARD UNIV,SCH MED,DEPT MED,CHANNING LAB,PHYSICIANS HLTH STUDY,900 COMMONWEALTH AVE E,BOSTON,MA 02215; BRIGHAM & WOMENS HOSP,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PREVENT MED,BOSTON,MA 02115; HARVARD UNIV,MASSACHUSETTS EYE & EAR INFIRM,SCH MED,DEPT OPHTHALMOL,EPIDEMIOL UNIT,BOSTON,MA 02114	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary					NEI NIH HHS [EY03355] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		[Anonymous], 1991, AM J EPIDEMIOL, V133, P541; [Anonymous], 1989, NEW ENGL J MED, V321, P129; BOCHOW TW, 1989, ARCH OPHTHALMOL-CHIC, V107, P369, DOI 10.1001/archopht.1989.01070010379027; BUNCE GE, 1990, ANNU REV NUTR, V10, P233, DOI 10.1146/annurev.nu.10.070190.001313; CHOW CK, 1986, J AM COLL NUTR, V5, P305; CLAYTON RM, 1982, T OPHTHAL SOC UK, V102, P331; EDERER F, 1973, ARCH OPHTHALMOL-CHIC, V89, P1; FLAYE DE, 1989, EYE, V3, P379, DOI 10.1038/eye.1989.56; HANKINSON SE, 1992, JAMA-J AM MED ASSOC, V268, P994, DOI 10.1001/jama.268.8.994; HARDING JJ, 1988, BRIT J OPHTHALMOL, V72, P809, DOI 10.1136/bjo.72.11.809; HILLER R, 1986, AM J EPIDEMIOL, V124, P916, DOI 10.1093/oxfordjournals.aje.a114481; JACQUES PF, 1988, ARCH OPHTHALMOL-CHIC, V106, P337, DOI 10.1001/archopht.1988.01060130363022; KLEIN BEK, 1985, OPHTHALMOLOGY, V92, P1191; LESKE MC, 1991, ARCH OPHTHALMOL-CHIC, V109, P244, DOI 10.1001/archopht.1991.01080020090051; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.2307/2336267; MOHAN M, 1989, ARCH OPHTHALMOL-CHIC, V107, P670, DOI 10.1001/archopht.1989.01070010688028; PERKINS ES, 1984, BRIT J OPHTHALMOL, V68, P293, DOI 10.1136/bjo.68.5.293; ROSNER B, 1982, BIOMETRICS, V38, P105, DOI 10.2307/2530293; SPERDUTO RD, 1984, OPHTHALMOLOGY, V91, P815; STARK WJ, 1989, ARCH OPHTHALMOL-CHIC, V107, P1441, DOI 10.1001/archopht.1989.01070020515030; STRYKER WS, 1988, AM J EPIDEMIOL, V127, P283, DOI 10.1093/oxfordjournals.aje.a114804; WEST S, 1989, ARCH OPHTHALMOL-CHIC, V107, P1166, DOI 10.1001/archopht.1989.01070020232031; 1983, DHHS NIH822469 PUBL, P7; 1980, WORLD BLINDNESS ITS	24	167	167	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 26	1992	268	8					989	993						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JK129	1501324				2022-12-01	WOS:A1992JK12900022
J	HANKINSON, SE; WILLETT, WC; COLDITZ, GA; SEDDON, JM; ROSNER, B; SPEIZER, FE; STAMPFER, MJ				HANKINSON, SE; WILLETT, WC; COLDITZ, GA; SEDDON, JM; ROSNER, B; SPEIZER, FE; STAMPFER, MJ			A PROSPECTIVE-STUDY OF CIGARETTE-SMOKING AND RISK OF CATARACT-SURGERY IN WOMEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POSTERIOR SUBCAPSULAR CATARACTS; EPIDEMIOLOGY; ALCOHOL; NUCLEAR; PLASMA	Objective.-To examine prospectively the association between cigarette smoking and the risk of cataract extraction in women. Design.-Prospective cohort study beginning in 1980 with 8 years of follow-up. Setting.-United States, multistate. Participants.-Registered nurses 45 to 67 years of age and free of diagnosed cancer. There were 50 828 women included in 1980 and others were added as they became 45 years of age. Main Outcome Measure.-Incidence of senile cataract extraction. Results.-We documented 493 incident senile cataracts diagnosed and extracted during 470302 person-years of follow-up. The age-adjusted relative risk (RR) among women who smoked at least 65 pack-years was 1.63 (95% confidence interval [CI], 1.18 to 2.26; P for trend, .02). A similar increase in RR was noted when smoking was assessed in terms of number of cigarettes currently smoked or number of cigarettes smoked by past smokers. Results were also similar after adjusting for other potential risk factors for cataract. Smoking was also strongly associated with posterior subcapsular cataract specifically (RR, 2.59; 95% CI, 1.49 to 4.50 for greater-than-or-equal-to 65-pack-year smokers relative to nonsmokers). Conclusion.-Smoking appears to increase the risk of cataract extraction.	BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT OPHTHALMOL, BOSTON, MA 02115 USA; MASSACHUSETTS EYE & EAR INFIRM, BOSTON, MA 02114 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Massachusetts Eye & Ear Infirmary	HANKINSON, SE (corresponding author), HARVARD UNIV, SCH MED, CHANNING LAB, DEPT MED, 180 LONGWOOD AVE, BOSTON, MA 02115 USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NCI NIH HHS [CA40356] Funding Source: Medline; PHS HHS [5T32 E507069] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA040356, R01CA040356] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BLACKMAN BC, 1984, ANN NY ACAD SCI, V435, P385, DOI 10.1111/j.1749-6632.1984.tb13828.x; BOCHOW TW, 1989, ARCH OPHTHALMOL-CHIC, V107, P369, DOI 10.1001/archopht.1989.01070010379027; BUNCE GE, 1990, ANNU REV NUTR, V10, P233, DOI 10.1146/annurev.nu.10.070190.001313; BUNCE GE, 1988, NUTR TODAY, V4, P6; CHRISTEN WG, 1991, INVEST OPHTH VIS SCI, V32, P1244; COPELAND KT, 1977, AM J EPIDEMIOL, V105, P488, DOI 10.1093/oxfordjournals.aje.a112408; COX DR, 1972, J R STAT SOC B, V34, P187; DAGOSTINO RB, 1990, STAT MED, V9, P1501, DOI 10.1002/sim.4780091214; FLAYE DE, 1989, EYE, V3, P379, DOI 10.1038/eye.1989.56; HANKINSON SE, IN PRESS BMJ; HARDING JJ, 1987, EYE, V1, P537, DOI 10.1038/eye.1987.82; HARDING JJ, 1988, BRIT J OPHTHALMOL, V72, P809, DOI 10.1136/bjo.72.11.809; HILLER R, 1986, AM J EPIDEMIOL, V124, P916, DOI 10.1093/oxfordjournals.aje.a114481; KLEIN BEK, 1985, OPHTHALMOLOGY, V92, P1191; LESKE MC, 1983, AM J EPIDEMIOL, V118, P152, DOI 10.1093/oxfordjournals.aje.a113625; LESKE MC, 1991, ARCH OPHTHALMOL-CHIC, V109, P244, DOI 10.1001/archopht.1991.01080020090051; MARAINI G, 1991, AM J EPIDEMIOL, V133, P541; MOHAN M, 1989, ARCH OPHTHALMOL-CHIC, V107, P670, DOI 10.1001/archopht.1989.01070010688028; ROBERTSON JM, 1989, ANN NY ACAD SCI, V570, P372; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P87; SCHECTMAN G, 1989, AM J PUBLIC HEALTH, V79, P158, DOI 10.2105/AJPH.79.2.158; SCHWAB IR, 1988, ARCH OPHTHALMOL-CHIC, V106, P1062, DOI 10.1001/archopht.1988.01060140218027; STARK WJ, 1989, ARCH OPHTHALMOL-CHIC, V107, P1441, DOI 10.1001/archopht.1989.01070020515030; STRYKER WS, 1988, AM J EPIDEMIOL, V127, P283, DOI 10.1093/oxfordjournals.aje.a114804; VARMA SD, 1991, AM J CLIN NUTR, V53, pS335, DOI 10.1093/ajcn/53.1.335S; WEST S, 1989, ARCH OPHTHALMOL-CHIC, V107, P1166, DOI 10.1001/archopht.1989.01070020232031; WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366; WILLETT WC, 1987, NEW ENGL J MED, V316, P22, DOI 10.1056/NEJM198701013160105; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086	29	124	124	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 26	1992	268	8					994	998		10.1001/jama.268.8.994	http://dx.doi.org/10.1001/jama.268.8.994			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JK129	1501325				2022-12-01	WOS:A1992JK12900023
J	MACKENZIE, WR; DAVIS, JP; PETERSON, DE; HIBBARD, AJ; BECKER, G; ZARVAN, BS				MACKENZIE, WR; DAVIS, JP; PETERSON, DE; HIBBARD, AJ; BECKER, G; ZARVAN, BS			MULTIPLE FALSE-POSITIVE SEROLOGIC TESTS FOR HIV, HTLV-1, AND HEPATITIS-C FOLLOWING INFLUENZA VACCINATION, 1991	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note								Objective.-(1) To assess factors associated with the occurrence of multiple false-positive viral enzyme-linked immunosorbent assays (ELISAs) for human immunodeficiency virus (HIV), human T-cell lymphotrophic virus type 1 (HTLV-1), and hepatitis C virus (HCV) among individual blood donors and (2) to determine the frequency and time course of this phenomenon. Design.-Case-control study. Setting.-A regional blood center. Participants.-Blood donors found to have multiple false-positive viral ELISAs (case donors) and randomly selected seronegative controls (control donors) who donated between October 31, 1991, and December 15, 1991. An additional random sample of 262 donation records was reviewed to calculate the proportion of donors who received influenza vaccine. Main Outcome Measures.-Multiple false-positive viral ELISAs, receipt of influenza vaccination formulated for the 1991-1992 influenza season, and follow-up ELISA results on serum samples obtained from case donors. Results.-Among 17941 donors, 10 case donors were identified. Nine of the 10 case donors received influenza vaccine, compared with three of 30 control donors (odds ratio [OR]=81; 95% confidence interval [CI], 6 to 3670; P<.001). Among nine case donors, the mean time between vaccination and blood donation was 26 days (range, 9 to 68 days). Follow-up ELISAs of serum samples from seven case donors obtained 52 to 130 days (mean, 75 days) after vaccination demonstrated reversion to HIV and HTLV-1 seronegativity in all but one specimen, with persistence of positive HCV ELISAs in four specimens. We estimate between 0.6% and 1.7% of blood donors who received influenza vaccine this season had multiple false-positive viral ELISAs. Conclusions.-The occurrence of multiple false-positive viral ELISAs among blood donors was associated with influenza vaccination, but was infrequent among vaccinees. This phenomenon is of short duration for HIV and HTLV-1, but may persist longer for HCV. We recommend influenza vaccinees not be deferred from blood donation. Blood donors with multiple false-positive viral ELISAs should be considered for future reentry as blood donors.	CTR DIS CONTROL,DIV FIELD EPIDEMIOL,ATLANTA,GA 30333; AMER RED CROSS,BLOOD SERV,BADGER REG,MADISON,WI	Centers for Disease Control & Prevention - USA; American Red Cross	MACKENZIE, WR (corresponding author), WISCONSIN DEPT HLTH & SOCIAL SERV,BUR PUBL HLTH,1400 & WASHINGTON AVE,ROOM 96,MADISON,WI 53703, USA.		Kenzie, William R Mac/F-1528-2013	Kenzie, William R Mac/0000-0001-7723-0339				Colton T, 1974, STAT MED, P160; FANG CT, 1988, TRANSFUSION, V28, P179, DOI 10.1046/j.1537-2995.1988.28288179027.x; MENTA CR, 1985, J AM STAT ASSOC, V78, P969; 1985, MMWR, V34, P1; 1991, MMWR, V40, P1	5	58	60	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 26	1992	268	8					1015	1017		10.1001/jama.268.8.1015	http://dx.doi.org/10.1001/jama.268.8.1015			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JK129	1501307				2022-12-01	WOS:A1992JK12900028
J	MORSE, RM; FLAVIN, DK				MORSE, RM; FLAVIN, DK			THE DEFINITION OF ALCOHOLISM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DEPENDENCE; ABUSE	To establish a more precise use of the term alcoholism, a 23-member multidisciplinary committee of the National Council on Alcoholism and Drug Dependence and the American Society of Addiction Medicine conducted a 2-year study of the definition of alcoholism in the light of current concepts. The goals of the committee were to create by consensus a revised definition that is (1) scientifically valid, (2) clinically useful, and (3) understandable by the general public. Therefore, the committee agreed to define alcoholism as a primary, chronic disease with genetic, psychosocial, and environmental factors influencing its development and manifestations. The disease is often progressive and fatal. It is characterized by impaired control over drinking, preoccupation with the drug alcohol, use of alcohol despite adverse consequences, and distortions in thinking, most notably denial. Each of these symptoms may be continuous or periodic.	NATL COUNCIL ALCOHOLISM & DRUG DEPENDENCE,12 W 21ST ST,NEW YORK,NY 10010									CAMPBELL EJM, 1979, BMJ-BRIT MED J, V2, P757, DOI 10.1136/bmj.2.6193.757; CLONINGER CR, 1987, SCIENCE, V236, P410, DOI 10.1126/science.2882604; CLONINGER CR, 1981, ARCH GEN PSYCHIAT, V38, P861; EDWARDS G, 1976, BRIT MED J, V1, P1058, DOI 10.1136/bmj.1.6017.1058; GORDIS E, 1989, ALCOHOL HLTH RES WOR, V13, P298; GRANT BF, 1989, INT REV PSYCHIATR, V1, P21; JELLINEK EM, 1960, DIS CONCEPT ALCOHOL, P33; KLEBER HD, 1990, J PSYCHIAT RES, V24, P57, DOI 10.1016/0022-3956(90)90036-P; LE AD, 1981, PSYCHOPHARMACOLOGY, V75, P231, DOI 10.1007/BF00432429; MEYER RE, 1988, ALCOHOLISM ORIGINS O, P1; MORSE RM, 1989, SUBST ABUSE, V10, P75; NARANJO CA, 1986, J CLIN PSYCHIAT, V47, P16; WIKLER A, 1973, ARCH GEN PSYCHIAT, V28, P611; 1972, ANN INTERN MED, V77, P249; 1978, MENTAL DISORDERS GLO; 1976, ANN INTERN MED, V85, P764; 1972, AM J PSYCHIAT, V129, P127; 1980, DIAGNOSTIC STATISTIC; 1990, 7TH SPECF REP US C A; 1987, DIAGNOSTIC STATISTIC; 1981, B WORLD HEALTH ORGAN, V59, P225	21	155	162	0	16	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 26	1992	268	8					1012	1014		10.1001/jama.268.8.1012	http://dx.doi.org/10.1001/jama.268.8.1012			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JK129	1501306				2022-12-01	WOS:A1992JK12900027
J	PHILEN, RM; ORTIZ, DI; AUERBACH, SB; FALK, H				PHILEN, RM; ORTIZ, DI; AUERBACH, SB; FALK, H			SURVEY OF ADVERTISING FOR NUTRITIONAL SUPPLEMENTS IN HEALTH AND BODYBUILDING MAGAZINES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EOSINOPHILIA-MYALGIA SYNDROME; L-TRYPTOPHAN	The use of food supplements by the general public is poorly quantified, and little information on this subject is available in the medical literature. We surveyed 12 recent issues of popular health and bodybuilding magazines (1) to quantify the number of advertisements for food supplements, the number of products advertised, and the number and type of ingredients in these products; (2) to identify the purported health benefits of these products; and (3) as a preliminary effort to identify areas for future research. We counted 89 brands, 311 products, and 235 unique ingredients, the most frequent of which were unspecified amino acids; the most frequently promoted health benefit was muscle growth. We also found many unusual or unidentifiable ingredients, and 22.2% of the products had no ingredients listed in their advertisements. Health professionals may not be aware of how popular food supplements are or of a particular supplement's potential effects or side effects. In addition, patients may be reluctant to discuss their use of these products with traditional medical practitioners. We recommend that routine history taking include specific questions about patients' use of food supplements and that any possible adverse effects or side effects be reported to public health authorities.	UNIV TURABO, DEPT CIENCIAS & TECHNOL, UNIV STN, PR USA		PHILEN, RM (corresponding author), CTR DIS CONTROL, NATL CTR ENVIRONM HLTH & INJURY CONTROL, ATLANTA, GA 30333 USA.							AMOS RJ, 1987, J AM DIET ASSOC, V87, P1063; ARENA JM, 1979, POISONING; BLUHM R, 1990, JAMA-J AM MED ASSOC, V264, P1141, DOI 10.1001/jama.264.9.1141; CHERNOFF N, 1988, TOXICOLOGY, V51, P57, DOI 10.1016/0300-483X(88)90080-7; CLARK HW, 1988, J PSYCHOACTIVE DRUGS, V20, P355, DOI 10.1080/02791072.1988.10472505; EIDSON M, 1990, LANCET, V335, P645, DOI 10.1016/0140-6736(90)90421-Z; Ellenhorn MJ., 1997, MED TOXICOLOGY DIAGN, P610; GIANNINI JA, 1982, HDB OVERDOSE DETOXIF; Gilman A., 1985, PHARM BASIS THERAPEU, Vseventh; HENDEE WR, 1987, JAMA-J AM MED ASSOC, V257, P1929; HERTZMAN PA, 1990, NEW ENGL J MED, V322, P869, DOI 10.1056/NEJM199003293221301; KAMB ML, 1992, JAMA-J AM MED ASSOC, V267, P77, DOI 10.1001/jama.267.1.77; KAUFMAN J, 1983, OVER COUNTER PILLS D; KESSLER DA, 1992, NEW ENGL J MED, V326, P70; KURMUKOV A G, 1991, Farmakologiya i Toksikologiya (Moscow), V54, P27; Lentner C, 1981, GEIGY SCI TABLES, V1; LENTNER C, 1986, GEIGY SCI TABLES, V4; LUBY S, 1992, AM J PUBLIC HEALTH, V82, P128, DOI 10.2105/AJPH.82.1.128-a; Mahler H.R., 1971, BIOL CHEM, V2nd; MAIRESSE M, 1981, HLTH SECRETS MED HER; MIRKIN G, 1991, JAMA-J AM MED ASSOC, V265, P912; Mirkin G, 1987, Semin Adolesc Med, V3, P177; ROBINSON T, 1975, ORGANIC CONSTITUENTS; SCHNEIDERHELMERT D, 1986, PSYCHOPHARMACOLOGY, V89, P1; SHIFF CJ, 1991, TROP MED PARASITOL, V42, P11; SWYGERT LA, 1990, JAMA-J AM MED ASSOC, V264, P1698, DOI 10.1001/jama.264.13.1698; TAKEI M, 1991, J PHARM SCI, V80, P309, DOI 10.1002/jps.2600800403; WIDGER NH, 1979, WIDGER GUIDE OVER CO; ZHU DPQ, 1987, AM J CHINESE MED, V15, P117, DOI 10.1142/S0192415X87000151; ZIMMERMAN DR, 1983, ESSENTIAL GUIDE NONP; 1990, MMWR, V39, P789; 1991, MUSCLE MAG INT   AUG, P49; 1991, MUSCLE MAG INT   AUG, P121; 1990, MMWR, V39, P47; 1991, NATURES WAY HLTH CAR, P13; 1991, MUSCLE MAG INT   AUG, P163; 1990, NATURAL PHYSIQUE JUL, P92; 1989, MMWR, V38, P765; 1982, HDB NONPRESCRIPTION	39	41	42	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 26	1992	268	8					1008	1011		10.1001/jama.268.8.1008	http://dx.doi.org/10.1001/jama.268.8.1008			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JK129	1501305				2022-12-01	WOS:A1992JK12900026
J	SAFER, DJ; KRAGER, JM				SAFER, DJ; KRAGER, JM			EFFECT OF A MEDIA BLITZ AND A THREATENED LAWSUIT ON STIMULANT TREATMENT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RITALIN	Objective.-To enumerate and evaluate changes in the rate of medication treatment for hyperactive/inattentive students subsequent to negative media publicity about methylphenidate (Ritalin) and related lawsuits threatened or initiated from late 1987 to early 1989. Design.-Biennial 1971 to 1991 school nurse surveys of medication treatment for hyperactive/inattentive students; a 1989 school nurse questionnaire on parent attitudes about medication; annual 1984 through 1991 hyperkinetic clinic treatment data; annual 1986 through 1990 Drug Enforcement Administration estimates of retail sales of methylphenidate, nationally and locally. Primary Setting.-All public and private elementary and secondary schools in Baltimore County, Maryland. Patients.-Students receiving medication for hyperactivity/inattentiveness. Results.-Whereas the medication rate for the treatment of hyperactive/inattentive students in Baltimore County doubled every 4 to 7 years from 1971 through 1987, it declined 39% in the 1989 and 1991 surveys from its 1987 peak. This drop occurred after the 1987 through 1989 media blitz against methylphenidate and after a well-publicized threatened lawsuit locally. Parents became fearful of media-reported medication "side effects" and school staff hesitated to refer restless, impulsive, and inattentive students to physicians. Most inhibited from the prospect of medication treatment were less affluent parents and parents of hyperactive/inattentive elementary schoolchildren who had never received medication. Drug Enforcement Administration data revealed that the Baltimore metropolitan area had a far greater decline in methylphenidate use than that which occurred nationally. Conclusion.-Strong circumstantial evidence suggests that the prominent 1989 and 1991 declines in the initiation of stimulant medication for hyperactive/inattentive students were related to the apprehension of parents and involved professionals. generated by the methylphenidate media blitz and the threatened lawsuit.	JOHNS HOPKINS UNIV,SCH MED,BALTIMORE,MD 21205	Johns Hopkins University	SAFER, DJ (corresponding author), BALTIMORE CTY DEPT HLTH,9100 FRANKLIN SQ DR,BALTIMORE,MD 21237, USA.							BORNEMANN A, 1989, NE TIMES REP    0111, P8; Burton Thomas M., 1991, WALL STREET J; BURTON TM, 1991, WALL ST J       0419, pA2; CALLAHAM M, 1985, ANN EMERG MED, V14, P1, DOI 10.1016/S0196-0644(85)80725-3; COLINO S, 1988, BALTIMORE MAG, V81, P66; COLINO S, 1988, BALTIMORE MAG, V81, P96; COWART VS, 1988, JAMA-J AM MED ASSOC, V259, P2521; DIVOKY D, 1989, PHI DELTA KAPPAN, V70, P599; DUNN SG, 1988, TOWSON TIMES    0525, P19; KOHN A, 1989, ATLANTIC MONTHLY, V264, P90; KRAGER JM, 1979, J SCHOOL HEALTH, V49, P317, DOI 10.1111/j.1746-1561.1979.tb07722.x; MORGAN M, 1980, J BROADCASTING, V24, P117, DOI 10.1080/08838158009363973; MOSS DC, 1988, ABA J, V74, P19; NORTON M, 1989, BALTIMORE EVENI 0104, pD3; NORTON M, 1989, BALTIMORE EVENI 0104, pD1; PRESKORN SH, 1991, J CLIN PSYCHIAT, V52, P23; SAFER DJ, 1988, JAMA-J AM MED ASSOC, V260, P2256, DOI 10.1001/jama.260.15.2256; SAPPEL J, 1990, BALTIMORE SUN   0807, P8; SHERMAN SL, 1988, BALTIMORE DAILY 0518, P1; SHERMAN SL, 1988, BALTIMORE DAILY 0518, P11; SPRAGUE RL, 1991, OCT WORLD C PSYCH AT, V6, P569; THOMPSON K, 1987, BALTIMORE SUN   1211, P1; TREADWELL D, 1987, BALTIMORE SUN   1230, pC8; TREADWELL D, 1987, BALTIMORE SUN   1230, pC1; WELKE R, 1990, DET CL REV, P125; Wright JC, 1990, TELEVISION AM FAMILY, P227; 1989, BALTIMORE SUN   0104, pD1; 1970, NEWSWEEK        0209, P52; 1991, ARCOS DATA BASE 1986	29	42	42	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 26	1992	268	8					1004	1007		10.1001/jama.268.8.1004	http://dx.doi.org/10.1001/jama.268.8.1004			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JK129	1501304				2022-12-01	WOS:A1992JK12900025
J	BIRKHEAD, JS				BIRKHEAD, JS			TIME DELAYS IN PROVISION OF THROMBOLYTIC TREATMENT IN 6 DISTRICT HOSPITALS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ACUTE MYOCARDIAL-INFARCTION; SYMPTOMS; THERAPY	Objective-To measure the delays between onset of symptoms and admission to hospital and provision of thrombolysis in patients with possible acute myocardial infarction. Design-Observational study of patients admitted with suspected myocardial infarction during six months. Setting- Six district general hospitals in Britain. Subjects-1934 patients admitted with suspected myocardial infarction. Main outcome measures-Route of admission to hospital and time to admission and thrombolysis. Results-Patients who made emergency calls did so sooner after onset of symptoms than those who called their doctor (median time 40 (95% confidence interval 30 to 52) minutes v 70 (60 to 90) minutes). General practitioners took a median of 20 (20 to 25) minutes to visit patients, rising to 30 (20 to 30) minutes during 0800-1200. The median time from call to arrival in hospital was 41 (38 to 47) minutes for patients who called an ambulance from home and 90 (90 to 94) minutes for those who contacted their doctor. The median time from arrival at hospital to thrombolysis was 80 (75 to 85) minutes for patients who were treated in the cardiac care unit and 31 (25 to 35) minutes for those treated in the accident and emergency department. Conclusion-The time from onset of symptoms to thrombolysis could be reduced substantially by more effective use of emergency services and faster provision of thrombolysis in accident and emergency departments.			BIRKHEAD, JS (corresponding author), NORTHAMPTON GEN HOSP, DEPT MED, NORTHAMPTON NN1 5BD, ENGLAND.							[Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, Lancet, V1, P397; CAMERON M, 1975, BRIT MED J, V1, P384, DOI 10.1136/bmj.1.5954.384; COLLING A, 1976, BRIT MED J, V2, P1169, DOI 10.1136/bmj.2.6045.1169; EMERSON PA, 1989, Q J MED, V70, P213; KENNEDY JW, 1989, AM J CARDIOL, V64, pA8, DOI 10.1016/0002-9149(89)90922-3; KEREIAKES DJ, 1990, AM HEART J, V120, P773, DOI 10.1016/0002-8703(90)90192-Z; KOREN G, 1985, NEW ENGL J MED, V313, P1384, DOI 10.1056/NEJM198511283132204; LEIZOROVICZ A, 1988, EUR HEART J, V9, P118; MATHEY DG, 1985, J AM COLL CARDIOL, V6, P518, DOI 10.1016/S0735-1097(85)80107-8; PANTRIDG.JF, 1967, LANCET, V2, P271; PARRY G, 1991, BRIT HEART J, V66, P39; PELL ACH, 1992, BMJ-BRIT MED J, V304, P83, DOI 10.1136/bmj.304.6819.83; RAWLES JM, 1990, EUR HEART J, V11, P643, DOI 10.1093/oxfordjournals.eurheartj.a059770; RAWLES JM, 1989, ABERDEEN POSTGRAD ME, V23, P1; ROWLEY JM, 1992, BRIT HEART J, V67, P255; SCHROEDER JS, 1978, AM J MED, V64, P742, DOI 10.1016/0002-9343(78)90512-0; SHARKEY SW, 1989, JAMA-J AM MED ASSOC, V262, P3171, DOI 10.1001/jama.262.22.3171; SMYLLIE HC, 1972, BRIT MED J, V1, P34, DOI 10.1136/bmj.1.5791.34; WILCOX RG, 1988, LANCET, V2, P525; 1987, LANCET, V1, P871	21	109	109	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 22	1992	305	6851					445	448		10.1136/bmj.305.6851.445	http://dx.doi.org/10.1136/bmj.305.6851.445			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JK680	1392956	Bronze, Green Published, Green Submitted			2022-12-01	WOS:A1992JK68000020
J	EYSENCK, HJ				EYSENCK, HJ			PSYCHOSOCIAL FACTORS, CANCER, AND ISCHEMIC-HEART-DISEASE	BRITISH MEDICAL JOURNAL			English	Article							PERSONALITY; PREDICTOR; STRESS				EYSENCK, HJ (corresponding author), UNIV LONDON,INST PSYCHIAT,LONDON SE5 8AF,ENGLAND.							EYSENCK H J, 1991, Integrative Physiological and Behavioral Science, V26, P309, DOI 10.1007/BF02691067; Eysenck H.J., 1991, SMOKING PERSONALITY; EYSENCK HJ, 1990, PERCEPT MOTOR SKILL, V71, P216; EYSENCK HJ, 1991, BEHAV RES THER, V29, P17, DOI 10.1016/S0005-7967(09)80003-X; EYSENCK HJ, 1991, PSYCHOL INQUIRY, V2, P320; GROSSARTHMATICE.R, 1991, PSYCHOL REP, V65, P1027; GROSSARTHMATICEK R, 1991, PSYCHOL REP, V68, P1083, DOI 10.2466/PR0.68.4.1083-1087; GROSSARTHMATICEK R, 1988, PERS INDIV DIFFER, V9, P479, DOI 10.1016/0191-8869(88)90125-0; GROSSHANS EM, 1990, J AM ACAD DERMATOL, V23, P153, DOI 10.1016/S0190-9622(08)81224-8; KISSEN DM, 1992, J PSYCHOSOM RES, V6, P123; PELOSI AJ, 1992, BRIT MED J, V303, P1295; QUANDERBLAZNIK J, 1991, PERS INDIV DIFFER, V12, P125, DOI 10.1016/0191-8869(91)90095-S; SCHMALE AH, 1971, SOC SCI MED, V5, P95, DOI 10.1016/0037-7856(71)90090-4; SCHMITZ PG, 1992, PERS INDIV DIFFER, V13, P683, DOI 10.1016/0191-8869(92)90239-L; SPIEGEL D, 1989, LANCET, V2, P888; VETTER H, 1991, PSYCHOL INQUIRY, V2, P322; Vetter H, 1991, PSYCHOL INQ, V2, P286	17	18	18	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 22	1992	305	6851					457	459		10.1136/bmj.305.6851.457	http://dx.doi.org/10.1136/bmj.305.6851.457			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JK680	1392961	Bronze, Green Published, Green Submitted			2022-12-01	WOS:A1992JK68000025
J	FARLOW, M; GHETTI, B; BENSON, MD; FARROW, JS; VANNOSTRAND, WE; WAGNER, SL				FARLOW, M; GHETTI, B; BENSON, MD; FARROW, JS; VANNOSTRAND, WE; WAGNER, SL			LOW CEREBROSPINAL-FLUID CONCENTRATIONS OF SOLUBLE AMYLOID BETA-PROTEIN PRECURSOR IN HEREDITARY ALZHEIMERS-DISEASE	LANCET			English	Note							CEREBRAL-HEMORRHAGE; MUTATION	In Alzheimer's disease, deposits of amyloid beta-protein are apparently derived from intracellular processing of a large precursor protein. We have measured concentrations of this precursor in cerebrospinal fluid (CSF) from six members of a family affected by presenile Alzheimer's disease associated with a point mutation of the precursor gene. One gene carrier with clinical signs of the disorder had low CSF concentrations of the precursor, similar to those of three patients with sporadic Alzheimer's disease subsequently confirmed at necropsy. Two symptom-free gene carriers had CSF precursor concentrations similar to those of non-demented controls, though the value was lower in one, who had deficits revealed on neuropsychological testing, than in the other. These findings suggest that low concentrations of soluble amyloid precursor proteins in the CSF reflect the process that results in amyloid plaque formation and vascular deposition in Alzheimer's disease.	SALK INST BIOTECHNOL IND ASSOCIATES INC,505 COAST BLVD S,LA JOLLA,CA 92037; INDIANA UNIV,SCH MED,DEPT NEUROL,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,DEPT PATHOL,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,DEPT MED,INDIANAPOLIS,IN 46202; UNIV CALIF IRVINE,DEPT MICROBIOL & MOLEC GENET,IRVINE,CA 92717	Salk Institute; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; University of California System; University of California Irvine					NIA NIH HHS [P30 AG10133] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P30AG010133] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		GHETTI B, 1992, BRAIN RES, V571, P133, DOI 10.1016/0006-8993(92)90519-F; GHISO J, 1986, P NATL ACAD SCI USA, V83, P2974, DOI 10.1073/pnas.83.9.2974; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; GRUBB A, 1984, NEW ENGL J MED, V311, P1547, DOI 10.1056/NEJM198412133112406; LEVY E, 1990, SCIENCE, V248, P1124, DOI 10.1126/science.2111584; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; VANDUINEN SG, 1987, P NATL ACAD SCI USA, V84, P5991; VANNOSTRAND WE, 1989, NATURE, V341, P546; VANNOSTRAND WE, 1992, P NATL ACAD SCI USA, V89, P2251; VANNOSTRAND WE, IN PRESS ANN NEUROL	10	57	61	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 22	1992	340	8817					453	454		10.1016/0140-6736(92)91771-Y	http://dx.doi.org/10.1016/0140-6736(92)91771-Y			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JJ877	1354785				2022-12-01	WOS:A1992JJ87700005
J	FISHERHOCH, SP; PEREZORONOZ, GI; JACKSON, EL; HERMANN, LM; BROWN, BG				FISHERHOCH, SP; PEREZORONOZ, GI; JACKSON, EL; HERMANN, LM; BROWN, BG			FILOVIRUS CLEARANCE IN NONHUMAN-PRIMATES	LANCET			English	Article							EBOLA; MONKEYS; VIRUS	There has been concern in the USA and Europe about filovirus outbreaks in recently imported monkeys, and possible transmission to human beings. Healthy monkeys have been found to have low-titre immunofluorescence antibody (IFA) to Asian filoviruses (Reston and Pennsylvania viruses) as well as to the African filoviruses that caused fulminating human outbreaks in the 1970s (Ebola [Zaire] and Sudan viruses). We have assessed whether such monkeys are a risk to man. We studied 42 non-human primates; 31 were experimentally infected with African and Asian filoviruses, 6 were infected during a documented Reston filovirus outbreak, and 5 had serological evidence suggestive of recent filovirus infection. During the first 15 days after infection, virus could be routinely recovered from serum or biopsy or necropsy tissue, and Asian filovirus RNA could be detected by polymerase chain reaction. 20 to 600 days after challenge, filovirus could no longer be recovered nor viral RNA detected in 141 serum, liver, spleen, or kidney specimens. Animals surviving filovirus infection develop high-titre, cross-reacting filovirus-specific antibody 14 to 21 days after infection, and this coincides with virus clearance. Healthy monkeys with low-titre filovirus antibody may be regarded as uninfected.	CTR DIS CONTROL,NATL CTR INFECT DIS,DIV VIRAL & RICKETTSIAL DIS,ATLANTA,GA 30333; CTR DIS CONTROL,NATL CTR INFECT DIS,ANIM RESOURCES BRANCH,ATLANTA,GA 30333	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA								[Anonymous], 1978, Bull World Health Organ, V56, P271; FISHERHOCH SP, IN PRESS J INFECT DI; HENRICKSON RV, 1983, LANCET, V2, P388; HEYMANN DL, 1980, J INFECT DIS, V142, P372, DOI 10.1093/infdis/142.3.372; JAHRLING PB, 1990, LANCET, V335, P502, DOI 10.1016/0140-6736(90)90737-P; JOHNSON BK, 1982, T ROY SOC TROP MED H, V76, P307, DOI 10.1016/0035-9203(82)90175-4; MARTINI G A, 1971, P1; MIRANDA MEG, 1991, LANCET, V337, P425, DOI 10.1016/0140-6736(91)91199-5; SANCHEZ A, 1992, J GEN VIROL, V73, P347, DOI 10.1099/0022-1317-73-2-347; STEGALL MD, 1989, TRANSPLANTATION, V48, P944, DOI 10.1097/00007890-198912000-00009; TOMORI O, 1988, AM J TROP MED HYG, V38, P407, DOI 10.4269/ajtmh.1988.38.407; 1990, MMWR, V39, P296; 1978, B WEHO, V56, P247; 1992, WEEKLY EPIDEMIOL REP, V67, P142; 1989, MMWR, V38, P831; 1990, MMWR, V39, P22	16	29	29	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 22	1992	340	8817					451	453		10.1016/0140-6736(92)91770-9	http://dx.doi.org/10.1016/0140-6736(92)91770-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JJ877	1354784				2022-12-01	WOS:A1992JJ87700004
J	GOBBI, G; BOUQUET, F; GRECO, L; LAMBERTINI, A; TASSINARI, CA; VENTURA, A; ZANIBONI, MG				GOBBI, G; BOUQUET, F; GRECO, L; LAMBERTINI, A; TASSINARI, CA; VENTURA, A; ZANIBONI, MG			CELIAC-DISEASE, EPILEPSY, AND CEREBRAL CALCIFICATIONS	LANCET			English	Article							STURGE-WEBER SYNDROME; CELIAC-DISEASE; FACIAL NEVUS	There have been anecdotal reports of an association between coeliac disease and epilepsy with cerebral calcifications that resemble those of the Sturge-Weber syndrome. A series of patients who had epilepsy with calcifications, in whom coeliac disease (CD) was incidentally observed, prompted us to study this association. 43 patients (15 male, age range 4.6-30.7 years) were selected from two series. 31 patients with cerebral calcifications of unexplained origin and epilepsy (series A) underwent intestinal biopsy. 12 patients with CD and epilepsy (series B) underwent computed tomography. Antibodies to gluten, folic acid serum concentrations, were measured, and HLA typing was done in most patients. 24 of the series A patients were identified as having CD on the basis of a flat intestinal mucosa (15/22 with a high concentration of serum antigluten), and 5 series B patients showed cerebral calcifications, giving a total of 29 cases with the combination of CD, epilepsy, and cerebral calcifications (CEC). In 27 of these CEC patients, calcifications were located in the parieto-occipital regions. Only 2 of the series A patients had gastrointestinal symptoms at the time of intestinal biopsy; most patients had recurrent diarrhoea, anaemia, and other symptoms suggestive of CD in the first 3 years of life. The epilepsy in CEC patients was poorly responsive to antiepileptic drugs. Gluten-free diet beneficially affected the course of epilepsy only when started soon after epilepsy onset. Cases of "atypical Sturge-Weber syndrome" (characterised by serpiginous cerebral calcifications and epilepsy without facial port-wine naevus) should be reviewed, and CD should be ruled out in all cases of epilepsy and cerebral calcifications of unexplained origin.	UNIV TRIESTE,DIV NEUROPSICHIAT INFANTILE,I-34100 TRIESTE,ITALY; UNIV TRIESTE,PEDIAT CLIN,I-34100 TRIESTE,ITALY; NAPLES UNIV,FAC MED & CHIRURG 2,PEDIAT CLIN,I-80138 NAPLES,ITALY; OSPED MAGGIORE BOLOGNA,DIV PEDIAT,BOLOGNA,ITALY; UNIV BOLOGNA,OSPED BELLARIA,CATTEDRA NEUROL,DIV NEUROL 2,I-40126 BOLOGNA,ITALY	University of Trieste; University of Trieste; University of Naples Federico II; AUSL di Bologna; University of Bologna	GOBBI, G (corresponding author), SERV NEUROPSYCHIAT INFANTILE,USL 9,VIA AMENDOLA 2,I-42100 REGGIO EMILIA,ITALY.			Ventura, Alessandro/0000-0002-4657-1760; Tassinari, Carlo Alberto/0000-0002-4183-5165				ALEXANDER GL, 1972, HDB CLIN NEUROLOGY, P223; AMBROSETTO P, 1983, CHILD BRAIN, V10, P387; [Anonymous], 1981, EPILEPSIA, V22, P489; [Anonymous], 1989, EPILEPSIA, V30, P389; Auricchio S, 1988, GASTROENTEROL INT, V1, P25; BATTISTELLA PA, 1986, RIV ITAL PED, V12, P417; BURGINWOLFF A, 1991, ARCH DIS CHILD, V66, P941, DOI 10.1136/adc.66.8.941; CHAPMAN RWG, 1978, BRIT MED J, V2, P250, DOI 10.1136/bmj.2.6132.250; COPPER BT, 1978, BMJ, V1, P537; CORAZZA GR, 1985, GUT, V26, P1210, DOI 10.1136/gut.26.11.1210; CORBEEL L, 1985, EUR J PEDIATR, V143, P284, DOI 10.1007/BF00442302; DELGIUDICE E, 1984, NEUROPEDIATRICS, V15, P218, DOI 10.1055/s-2008-1052371; DELLACELLA G, 1991, MED SURG PEDIATR, V13, P427; DEMARCHI M, 1983, GUT, V24, P706, DOI 10.1136/gut.24.8.706; DUNNILL MS, 1972, J CLIN PATHOL, V25, P243, DOI 10.1136/jcp.25.3.243; Garwicz S, 1976, Pediatr Radiol, V5, P5, DOI 10.1007/BF00988654; GIROUD M, 1990, REV NEUROL, V4, P288; GOBBI G, 1988, NEUROLOGY, V38, P9103; HAUSER RA, 1988, ARCH NEUROL-CHICAGO, V45, P1078, DOI 10.1001/archneur.1988.00520340032007; ITO M, 1990, BRAIN DEV-JPN, V12, P473, DOI 10.1016/S0387-7604(12)80210-5; JASPER HH, 1958, ELECTROENCEPHALOGRAP, V10, P370, DOI DOI 10.1016/0013-4694(58)90053-1; LAIDLOW JM, 1977, GUT, V18, pA943; LOGAN RFA, 1983, BMJ-BRIT MED J, V286, P95, DOI 10.1136/bmj.286.6359.95; MAKI M, 1990, ARCH DIS CHILD, V65, P1137, DOI 10.1136/adc.65.10.1137; MAKI M, 1991, LANCET, V338, P724, DOI 10.1016/0140-6736(91)91445-Z; MAKI Y, 1979, CHILD BRAIN, V5, P51; MCNEISH AS, 1979, ARCH DIS CHILD, V54, P783, DOI 10.1136/adc.54.10.783; MOLTENI N, 1988, AM J GASTROENTEROL, V83, P992; NAMAGUCHI Y, 1975, AM J ROENTGENOL, V123, P27; REYNOLDS EH, 1973, LANCET, V1, P1376; SAMMARITANO M, 1988, Neurology, V38, P239; TALY AB, 1987, NEUROLOGY, V37, P1063, DOI 10.1212/WNL.37.6.1063; TOSI R, 1983, CLIN IMMUNOL IMMUNOP, V28, P395, DOI 10.1016/0090-1229(83)90106-X; VENTURA A, 1991, ACTA PAEDIATR SCAND, V80, P552; YOUNG LW, 1977, AM J DIS CHILD, V131, P1283, DOI 10.1001/archpedi.1977.02120240101022; ZANIBONI MG, 1989, 1ST JOINT M BRIT SOC, P54	36	280	283	1	10	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 22	1992	340	8817					439	443						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JJ877	1354781				2022-12-01	WOS:A1992JJ87700001
J	LINDQUIST, M; EDWARDS, IR				LINDQUIST, M; EDWARDS, IR			ENDOCRINE ADVERSE-EFFECTS OF OMEPRAZOLE	BRITISH MEDICAL JOURNAL			English	Article							GYNECOMASTIA; THERAPY				LINDQUIST, M (corresponding author), WHO,COLLABORATING CTR INT DRUG MONITORING,BOX 26,S-75103 UPPSALA,SWEDEN.							CONVENS C, 1991, LANCET, V338, P1153, DOI 10.1016/0140-6736(91)92018-W; GUGLER R, 1984, LANCET, V1, P969; JENSEN JC, 1986, BRIT J CLIN PHARMACO, V21, P328, DOI 10.1111/j.1365-2125.1986.tb05199.x; SANTUCCI L, 1991, NEW ENGL J MED, V324, P635	4	46	47	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 22	1992	305	6851					451	452		10.1136/bmj.305.6851.451	http://dx.doi.org/10.1136/bmj.305.6851.451			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JK680	1392958	Green Published, Green Submitted, Bronze			2022-12-01	WOS:A1992JK68000022
J	MOSES, S; MANJI, F; BRADLEY, JE; NAGELKERKE, NJD; MALISA, MA; PLUMMER, FA				MOSES, S; MANJI, F; BRADLEY, JE; NAGELKERKE, NJD; MALISA, MA; PLUMMER, FA			IMPACT OF USER FEES ON ATTENDANCE AT A REFERRAL CENTER FOR SEXUALLY-TRANSMITTED DISEASES IN KENYA	LANCET			English	Article							HEALTH-SERVICES; PRICE; PAY	We investigated the impact of a short-lived policy of charging fees to patients attending public-sector outpatient health facilities in Kenya by collecting data on attendance at Nairobi's Special Treatment Clinic for sexually transmitted diseases (STDs) before (23 months), during (9 months), and after (15 months) the user-charge period. During the user-charge period, the seasonally adjusted total mean monthly attendance of men decreased significantly to 40% (95% CI 36-45) of that before fees were levied. Attendance rose in the post-user-charge period, but reached only 64% (59-68) of the pre-user-charge level. For women, the adjusted total mean monthly attendance during the user-charge period was reduced significantly to 65% (55-77) of the pre-user-charge level. Mean monthly attendance by women rose in the post-user-charge period to 22% (9-37) above the pre-user-charge level. There was no evidence of an increase in attendance over the course of the user-charge period among either men or women. The introduction of user fees probably increased the number of untreated STDs in the population, with potentially serious long-term health implications. The user-fee experience in Kenya should be carefully evaluated before similar measures are introduced elsewhere.	UNIV NAIROBI, DEPT MED MICROBIOL, NAIROBI, KENYA; UNIV MANITOBA, DEPT COMMUNITY HLTH SCI, WINNIPEG R3T 2N2, MANITOBA, CANADA; UNIV MANITOBA, DEPT MED MICROBIOL, WINNIPEG R3T 2N2, MANITOBA, CANADA; UNIV MANITOBA, DEPT MED, WINNIPEG R3T 2N2, MANITOBA, CANADA; INT DEV RES CTR, DIV HLTH SCI, REG OFF EASTERN & SOUTHERN AFRICA, NAIROBI, KENYA; NAIROBI CITY COMMISS, SPECIAL TREATMENT CLIN, NAIROBI, KENYA	University of Nairobi; University of Manitoba; University of Manitoba; University of Manitoba	MOSES, S (corresponding author), UNIV NAIROBI, DEPT COMMUNITY HLTH, POB 19676, NAIROBI, KENYA.							Abel-Smith B, 1991, World Health Forum, V12, P191; ABELSMITH B, 1989, DISCUSSION PAPER ISS; BECK RG, 1980, MED CARE, V18, P787, DOI 10.1097/00005650-198008000-00001; BENNET S, 1989, LESOTHO EPIDEMIOL B, V4; De Bethune X., 1989, Health Policy and Planning, V4, P76, DOI 10.1093/heapol/4.1.76; CAMERON DW, 1989, LANCET, V2, P403; Creese Andrew L., 1990, USER CHARGES HLTH CA; de Ferranti D, 1984, World Health Stat Q, V37, P428; DEFERRANTI D, 1985, 721 WORLD BAND STAFF; GRIFFIN C, 1988, 37 EC DEV I SEM PAP; KANJI N, 1991, SOC SCI MED, V33, P985, DOI 10.1016/0277-9536(91)90003-U; Kanji N., 1989, Health Policy and Planning, V4, P110, DOI 10.1093/heapol/4.2.110; MWABU GM, 1986, SOC SCI MED, V22, P763, DOI 10.1016/0277-9536(86)90228-5; ODADA JE, 1990, SOCIOECONOMIC PROFIL; PEPIN J, 1989, AIDS, V3, P3; STANTON B, 1989, SOC SCI MED, V29, P1119; TEMMERMAN M, 1991, 6TH INT C AIDS AFR D; Waddington C., 1990, International Journal of Health Planning and Management, V5, P287, DOI 10.1002/hpm.4740050405; Waddington C. J., 1989, International Journal of Health Planning and Management, V4, P17, DOI 10.1002/hpm.4740040104; YODER RA, 1989, SOC SCI MED, V29, P35, DOI 10.1016/0277-9536(89)90125-1; 1987, FINANCING HLTH SERVI; 1988, NAIROBI AREA STUDY	22	89	89	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 22	1992	340	8817					463	466		10.1016/0140-6736(92)91778-7	http://dx.doi.org/10.1016/0140-6736(92)91778-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JJ877	1354792				2022-12-01	WOS:A1992JJ87700012
J	RUTTER, DR; CALNAN, M; VAILE, MSB; FIELD, S; WADE, KA				RUTTER, DR; CALNAN, M; VAILE, MSB; FIELD, S; WADE, KA			DISCOMFORT AND PAIN DURING MAMMOGRAPHY - DESCRIPTION, PREDICTION, AND PREVENTION	BRITISH MEDICAL JOURNAL			English	Article							PATIENT	Objective-To identify the nature of pain and discomfort experienced during mammography and how it can be ameliorated. Design-Questionnaire survey before invitation for mammography and immediately after mammography. Responses before screening were related to experience of discomfort. Setting-Health district in South East Thames region. Subjects-1160 women aged 50-64 invited routinely for screening; 774 completed first questionnaire, of whom 617 had mammography. 597 completed the second questionnaire. Main outcome measures-Reported discomfort and pain, comparisons of discomfort with that experienced during other medical procedures, qualitative description of pain with adjective checklist. Results-35% (206/597) of the women reported discomfort and 6% (37/595) pain. 10 minutes after mammography these figures were 4% (24/595) and 0.7% (4/595) respectively. More than two thirds of women ranked having a tooth drilled, having a smear test, and giving blood as more uncomfortable than mammography. The most important predictor of discomfort was previous expectation of pain (discomfort was reported by 21/32 (66%) women who expected pain and 186/531 (35%) who did not). Discomfort had little effect on satisfaction or intention to reattend. Conclusions-The low levels of reported pain and discomfort shortly after mammography and the favourable comparisons with other investigations suggest that current procedures are acceptable. Since two thirds of the women experienced less pain than expected health education and promotion must ensure that accurate information is made available and publicised.	UNIV KENT,CTR HLTH SERV STUDIES,CANTERBURY CT2 7LZ,ENGLAND; KENT & CANTERBURY HOSP,KENT BREAST SCREENING SERV,CANTERBURY,ENGLAND	University of Kent; University of Kent	RUTTER, DR (corresponding author), UNIV KENT,INST SOCIAL & APPL PSYCHOL,CTR RES HLTH BEHAV,CANTERBURY CT2 7LZ,ENGLAND.							EARDLEY A, 1990, SOC SCI MED, V30, P693, DOI 10.1016/0277-9536(88)90254-7; JACKSON VP, 1988, RADIOLOGY, V168, P421, DOI 10.1148/radiology.168.2.3393659; MELZACK R, 1987, PAIN, V30, P191, DOI 10.1016/0304-3959(87)91074-8; ORTON M, 1991, BRIT J GEN PRACT, V41, P320; SPIELBERGER CD, 1970, MANUAL STATE TRAIT A; STOMPER PC, 1988, ARCH INTERN MED, V148, P521, DOI 10.1001/archinte.148.3.521; VAILE MSB, IN PRESS J PUBLIC HL	7	52	53	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 22	1992	305	6851					443	445		10.1136/bmj.305.6851.443	http://dx.doi.org/10.1136/bmj.305.6851.443			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JK680	1392955	Green Published, Bronze, Green Submitted			2022-12-01	WOS:A1992JK68000019
J	SHIELD, JPH; STROBEL, S; LEVINSKY, RJ; MORGAN, G				SHIELD, JPH; STROBEL, S; LEVINSKY, RJ; MORGAN, G			IMMUNODEFICIENCY PRESENTING AS HYPERGAMMAGLOBULINEMIA WITH IGG2 SUBCLASS DEFICIENCY	LANCET			English	Article							IGA DEFICIENCY	Recurrent bacterial infections, lymphadenopathy, and failure to thrive are unlikely to be attributed to immune deficiency if they occur in the presence of hypergammaglobulinaemia, and other explanations will usually be sought. We describe eight patients who presented with all these features in infancy or early childhood. Deficiencies of immunoglobulin and antibody production were initially discounted, and the children were referred for investigation of possible lymphoma, autoimmune disease, or chronic viral infection. The patients were later referred to us for more detailed immunological investigation, which revealed low levels of IgG2 and poor specific antibody production to common pathogens. Treatment with intravenous immunoglobulin resulted in resolution of signs and symptoms in all patients. Thus we have shown that hypergammaglobulinaemia does not preclude the presence of immunoglobulin/antibody deficiency. We suggest that investigation of children with high levels of IgG and features of immunodeficiency should include IgG subclass analysis.	INST CHILD HLTH,HOST DEF UNIT,30 GUILFORD ST,LONDON WC1N 1EH,ENGLAND; INST CHILD HLTH,MOLEC IMMUNOL UNIT,LONDON WC1N 1EH,ENGLAND; HOSP SICK CHILDREN,LONDON WC1N 3JH,ENGLAND	Imperial College London; University of London; University College London; University of London; University College London; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust			Shield, Julian PH/D-6297-2014	Shield, Julian PH/0000-0003-2601-7575				Aucouturier P, 1986, Monogr Allergy, V20, P62; BIRD D, 1985, ARCH DIS CHILD, V60, P204, DOI 10.1136/adc.60.3.204; GOLDBLATT D, 1989, R SOC MED SER INT C, V143, P19; MORGAN G, 1988, ARCH DIS CHILD, V63, P579, DOI 10.1136/adc.63.6.579; MORGAN G, 1985, ARCH DIS CHILD, V63, P771; OXELIUS VA, 1981, NEW ENGL J MED, V304, P1476, DOI 10.1056/NEJM198106113042408; Rosen F S, 1989, Semin Immunol, V1, P87; SCHUR PH, 1970, NEW ENGL J MED, V283, P631, DOI 10.1056/NEJM197009172831205; SHAKELFORD PG, 1990, PAEDIATR RES, V17, P16; 1991, NEW ENGL J MED, V325, P73	10	24	25	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 22	1992	340	8817					448	450						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JJ877	1354783				2022-12-01	WOS:A1992JJ87700003
J	SLEVIN, ML				SLEVIN, ML			CURRENT ISSUES IN CANCER - QUALITY-OF-LIFE - PHILOSOPHICAL QUESTION OR CLINICAL REALITY	BRITISH MEDICAL JOURNAL			English	Article							ADVANCED BREAST-CANCER; OF-LIFE; CHEMOTHERAPY; MASTECTOMY; RESECTION; CARCINOMA; SURVIVAL; THERAPY				SLEVIN, ML (corresponding author), ST BARTHOLOMEWS HOSP,IMPERIAL CANC RES FUND,DEPT MED ONCOL,LONDON EC1A 7BE,ENGLAND.							Aaronson N K, 1988, Recent Results Cancer Res, V111, P231; BECKMANN J, 1983, DAN MED BULL, V30, P10; BRINKLEY D, 1985, BRIT MED J, V291, P685, DOI 10.1136/bmj.291.6497.685; BUHL K, 1990, EUR J SURG ONCOL, V16, P404; CASSILETH BR, 1991, NEW ENGL J MED, V324, P1180, DOI 10.1056/NEJM199104253241706; COATES A, 1987, NEW ENGL J MED, V317, P1490, DOI 10.1056/NEJM198712103172402; DEHAES JCJM, 1990, BRIT J CANCER, V62, P1034, DOI 10.1038/bjc.1990.434; GELBER RD, 1991, ANN INTERN MED, V114, P621, DOI 10.7326/0003-4819-114-8-621; GLIMELIUS B, 1989, EUR J CANCER CLIN ON, V25, P829, DOI 10.1016/0277-5379(89)90128-4; GOUGH IR, 1981, CLIN ONCOL, V7, P5; GREER S, 1992, BRIT MED J, V304, P675, DOI 10.1136/bmj.304.6828.675; Harris J., 1985, VALUE LIFE INTRO MED, P87; KAASA S, 1988, ACTA ONCOL, V27, P335, DOI 10.3109/02841868809093551; KIEBERT GM, 1991, J CLIN ONCOL, V9, P1059, DOI 10.1200/JCO.1991.9.6.1059; MAGUIRE P, 1989, BRIT J CANCER, V60, P437, DOI 10.1038/bjc.1989.301; MAGUIRE P, 1988, BRIT MED J, V297, P907, DOI 10.1136/bmj.297.6653.907; PRIESTMAN TJ, 1976, LANCET, V1, P899; SLEVIN ML, 1990, BRIT MED J, V300, P1458, DOI 10.1136/bmj.300.6737.1458; SLEVIN ML, 1988, BRIT J CANCER, V57, P109, DOI 10.1038/bjc.1988.20; SLEVIN ML, 1991, BR J CANC S8, V63, P11; SPIEGEL D, 1989, LANCET, V2, P888; STEINBERG MD, 1985, AM J PSYCHIAT, V142, P34; TAYLOR SE, 1985, CANCER, V55, P2506, DOI 10.1002/1097-0142(19850515)55:10<2506::AID-CNCR2820551033>3.0.CO;2-0; WOLBERG WH, 1989, CANCER-AM CANCER SOC, V63, P1645, DOI 10.1002/1097-0142(19890415)63:8<1645::AID-CNCR2820630835>3.0.CO;2-8; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	25	65	66	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 22	1992	305	6851					466	469		10.1136/bmj.305.6851.466	http://dx.doi.org/10.1136/bmj.305.6851.466			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JK680	1392964	Bronze, Green Published, Green Submitted			2022-12-01	WOS:A1992JK68000030
J	VELHO, G; FROGUEL, P; CLEMENT, K; PUEYO, ME; RAKOTOAMBININA, B; ZOUALI, H; PASSA, P; COHEN, D; ROBERT, JJ				VELHO, G; FROGUEL, P; CLEMENT, K; PUEYO, ME; RAKOTOAMBININA, B; ZOUALI, H; PASSA, P; COHEN, D; ROBERT, JJ			PRIMARY PANCREATIC BETA-CELL SECRETORY DEFECT CAUSED BY MUTATIONS IN GLUCOKINASE GENE IN KINDREDS OF MATURITY ONSET DIABETES OF THE YOUNG	LANCET			English	Article							INSULIN RELEASE; GLUCOSE; HUMANS	Maturity-onset diabetes of the young (MODY), characterised by non-insulin-dependent diabetes mellitus (NIDDM) with an early age of onset, is a genetically heterogeneous disorder. In most MODY kindreds described in France, chronic hyperglycaemia is caused by mutations in the gene encoding pancreatic beta-cell and liver glucokinase (GCK). We here report the beta-cell secretory profiles of nine patients from four GCK-linked MODY kindreds. First-phase insulin secretion assessed by an intravenous glucose test was comparable in patients and seven controls. However, beta-cell secretory response to continuous glucose stimulus during a hyperglycaemic glucose clamp was significantly reduced: mean plasma insulin values of 12 (SD 7) vs 40 (11) mU/l (p=0.0001) and mean plasma C-peptide values 1.20 (0.30) vs 2.61 (0.37) (p=0.0001).This secretory profile is different from those for NIDDM with late age of onset or MODY not linked to GCK. Fasting plasma insulin and C-peptide in patients were inappropriately low in relation to concomitant plasma glucose level. Furthermore, during a hyperinsulinaemic euglycaemic clamp, endogenous insulin secretion at euglycaemia (5 mmol/l) was suppressed in patients but not in controls. These results suggest that mutant GCK may lead to chronic hyperglycaemia by raising the threshold of circulating glucose level which induces insulin secretion. These data provide the first demonstration of a primary pancreatic secretory defect associated with a form of NIDDM.	HOP ST LOUIS,SERV ENDOCRINOL,F-75010 PARIS,FRANCE; HOP NECKER ENFANTS MALAD,UNITE ENDOCRINOL & DIABETOL PEDIAT,INSERM,U30,F-75730 PARIS 15,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	VELHO, G (corresponding author), CTR ETUD POLYMORPHISME HUMAIN,27 RUE JULIETTE DODU,F-75010 PARIS,FRANCE.		Clément, karine/R-1120-2017; FROGUEL, Philippe/O-6799-2017; Velho, Gilberto/Q-6724-2017	FROGUEL, Philippe/0000-0003-2972-0784; Velho, Gilberto/0000-0001-8811-363X				ASHCROFT SJH, 1980, DIABETOLOGIA, V18, P5, DOI 10.1007/BF01228295; BELL GI, 1991, P NATL ACAD SCI USA, V88, P1484, DOI 10.1073/pnas.88.4.1484; BRUNZELL JD, 1976, J CLIN ENDOCR METAB, V42, P222, DOI 10.1210/jcem-42-2-222; CALLESESCANDON J, 1987, DIABETES, V36, P1167, DOI 10.2337/diabetes.36.10.1167; DEFRONZO RA, 1992, DIABETES CARE, V15, P318, DOI 10.2337/diacare.15.3.318; DEFRONZO RA, 1979, AM J PHYSIOL, V237, pE214; Efendic S, 1988, Adv Exp Med Biol, V246, P167; FAJANS S S, 1986, Diabetes Metabolism Reviews, V2, P347; FAJANS SS, 1990, DIABETES CARE, V13, P49, DOI 10.2337/diacare.13.1.49; FROGUEL P, 1992, NATURE, V356, P162, DOI 10.1038/356162a0; HOLROYDE MJ, 1976, BIOCHEM J, V153, P363, DOI 10.1042/bj1530363; LATHROP GM, 1984, AM J HUM GENET, V36, P460; LESTRADET H, 1989, ARCH FR PEDIATR, V46, P19; LUZI L, 1989, AM J PHYSIOL, V257, pE241, DOI 10.1152/ajpendo.1989.257.2.E241; MAGNUSON MA, 1989, J BIOL CHEM, V264, P15936; MATSCHINSKY FM, 1990, DIABETES, V39, P647, DOI 10.2337/diabetes.39.6.647; MEGLASSON M D, 1986, Diabetes Metabolism Reviews, V2, P163; MEGLASSON MD, 1984, AM J PHYSIOL, V246, pE1, DOI 10.1152/ajpendo.1984.246.1.E1; NAIDOO C, 1986, DIABETES CARE, V9, P57, DOI 10.2337/diacare.9.1.57; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; STOFFEL M, 1992, IN PRESS P NATL ACAD, V89; TCHHOBROUTSKY G, 1991, DIABETOLOGIA, V34, P67; VIONNET N, 1992, NATURE, V356, P721, DOI 10.1038/356721a0; 1985, TECH REP SER WHO, V727	24	200	202	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 22	1992	340	8817					444	448		10.1016/0140-6736(92)91768-4	http://dx.doi.org/10.1016/0140-6736(92)91768-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JJ877	1354782				2022-12-01	WOS:A1992JJ87700002
J	CLARKE, LL; GRUBB, BR; GABRIEL, SE; SMITHIES, O; KOLLER, BH; BOUCHER, RC				CLARKE, LL; GRUBB, BR; GABRIEL, SE; SMITHIES, O; KOLLER, BH; BOUCHER, RC			DEFECTIVE EPITHELIAL CHLORIDE TRANSPORT IN A GENE-TARGETED MOUSE MODEL OF CYSTIC-FIBROSIS	SCIENCE			English	Article							POTENTIAL DIFFERENCE; AIRWAY EPITHELIUM; INTESTINAL TRANSPORT; TRACHEAL EPITHELIUM; ADENYLATE-CYCLASE; RECTAL MUCOSA; ION-TRANSPORT; SECRETION; ACTIVATION; CHANNELS	The cystic fibrosis transmembrane conductance regulator (CFTR) gene encodes an adenosine 3',5'-monophosphate (cyclic AMP)-activated chloride channel. In cystic fibrosis (CF) patients, loss of CFTR function because of a genetic mutation results in defective cyclic AMP-mediated chloride secretion across epithelia. Because of their potential role as an animal model for CF, mice with targeted disruption of the murine CFTR gene [CFTR(-/-)] were tested for abnormalities in epithelial chloride transport. In both freshly excised tissue from the intestine and in cultured epithelia from the proximal airways, the cyclic AMP-activated chloride secretory response was absent in CFTR(-/-) mice as compared to littermate controls. Thus, disruption of the murine CFTR gene results in the chloride transport abnormalities predicted from studies of human CF epithelia.	UNIV N CAROLINA,DEPT MED,DIV PULM DIS,CHAPEL HILL,NC 27514	University of North Carolina; University of North Carolina Chapel Hill			Clarke, Lane L/AAK-2866-2020	Clarke, Lane L/0000-0002-4938-6261	NHLBI NIH HHS [HL 42384] Funding Source: Medline; NIGMS NIH HHS [GM20069] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL042384] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM020069, R01GM020069] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; BAXTER P, 1990, GUT, V31, P817, DOI 10.1136/gut.31.7.817; BAXTER PS, 1989, LANCET, V1, P464; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BERSCHNEIDER HM, 1988, FASEB J, V2, P2625, DOI 10.1096/fasebj.2.10.2838365; BERSCHNEIDER HM, 1987, GASTROENTEROLOGY, V92, P1315; Boat TF., 1989, CYSTIC FIBROSIS META, V6th, P2649; BOUCHER RC, 1986, J CLIN INVEST, V78, P1245, DOI 10.1172/JCI112708; CAREY HV, 1989, AM J PHYSIOL, V256, pR481, DOI 10.1152/ajpregu.1989.256.2.R481; CAREY HV, 1989, DIGEST DIS SCI, V34, P185, DOI 10.1007/BF01536049; CLARKE LL, IN PRESS AM J PHYSL; DEJONGE HR, 1989, BIOCHEM SOC T, V17, P816, DOI 10.1042/bst0170816; EGGERMONT E, 1991, EUR J PEDIATR, V150, P824, DOI 10.1007/BF01954999; FRIZZELL RA, 1986, SCIENCE, V233, P558, DOI 10.1126/science.2425436; GOLDSTEIN JL, 1991, GASTROENTEROLOGY, V101, P1012, DOI 10.1016/0016-5085(91)90728-4; HAAS M, 1989, ANNU REV PHYSIOL, V51, P443, DOI 10.1146/annurev.physiol.51.1.443; HARDCASTLE J, 1991, GUT, V32, P1035, DOI 10.1136/gut.32.9.1035; HARDCASTLE J, 1987, MED SCI RES-BIOCHEM, V15, P471; HWANG TC, 1989, SCIENCE, V244, P1351, DOI 10.1126/science.2472005; JORIS L, 1989, PFLUG ARCH EUR J PHY, V415, P118, DOI 10.1007/BF00373149; KNOWLES MR, 1983, SCIENCE, V221, P1067, DOI 10.1126/science.6308769; KNOWLES MR, 1991, NEW ENGL J MED, V325, P533, DOI 10.1056/NEJM199108223250802; MASON SJ, 1991, BRIT J PHARMACOL, V103, P1649, DOI 10.1111/j.1476-5381.1991.tb09842.x; OLOUGHLIN EV, 1991, AM J PHYSIOL, V260, pG758, DOI 10.1152/ajpgi.1991.260.5.G758; ORLANDO RC, 1989, GASTROENTEROLOGY, V96, P1041, DOI 10.1016/0016-5085(89)91621-1; SEAMON KB, 1981, P NATL ACAD SCI-BIOL, V78, P3363, DOI 10.1073/pnas.78.6.3363; SHELDON RJ, 1989, J PHARMACOL EXP THER, V249, P572; SNOUWAERT J, 1992, SCIENCE, V253, P257; STUTTS MJ, 1992, P NATL ACAD SCI USA, V89, P1621, DOI 10.1073/pnas.89.5.1621; TAYLOR CJ, 1988, GUT, V29, P957, DOI 10.1136/gut.29.7.957; WELSH MJ, 1990, FASEB J, V4, P2718, DOI 10.1096/fasebj.4.10.1695593; WIDDICOMBE JH, 1985, P NATL ACAD SCI USA, V82, P6167, DOI 10.1073/pnas.82.18.6167; WILLUMSEN NJ, 1989, AM J PHYSIOL, V256, pC1045, DOI 10.1152/ajpcell.1989.256.5.C1045; WILLUMSEN NJ, 1989, AM J PHYSIOL, V256, pC1033, DOI 10.1152/ajpcell.1989.256.5.C1033; Willumsen NJ, 1989, AM J PHYSIOL, V256, pC1054, DOI 10.1152/ajpcell.1989.256.5.C1054; Yankaskas J R, 1987, Prog Clin Biol Res, V254, P139	36	275	293	1	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 21	1992	257	5073					1125	1128		10.1126/science.257.5073.1125	http://dx.doi.org/10.1126/science.257.5073.1125			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JJ884	1380724				2022-12-01	WOS:A1992JJ88400035
J	DELSAL, G; RUARO, ME; PHILIPSON, L; SCHNEIDER, C				DELSAL, G; RUARO, ME; PHILIPSON, L; SCHNEIDER, C			THE GROWTH ARREST-SPECIFIC GENE, GAS1, IS INVOLVED IN GROWTH SUPPRESSION	CELL			English	Article							RETINOBLASTOMA SUSCEPTIBILITY GENE; HUMAN TRANSFERRIN RECEPTOR; LARGE TUMOR-ANTIGEN; MESSENGER-RNA; CELL-CYCLE; 3T3 CELLS; WILD-TYPE; TRANSCRIPTIONAL ACTIVATION; SV40-TRANSFORMED CELLS; TRANSFORMED-CELLS	This report describes the structure of the mRNA, the protein product, and the growth-regulating activity of one of the growth arrest-specific genes, gas1. From the predicted amino acid sequence, in vitro translation of gas1 mRNA, and immunofluorescence of cells in culture, it appears that the gas1 protein is an integral plasma membrane protein whose expression is linked to growth arrest. When gas1 is overexpressed from a constitutive promoter in quiescent cells, the serum-induced transition from the G0 to the S phase of the cell cycle is inhibited without affecting the normal early serum response. Ectopic expression of the gas1 gene by microinjection in normal and transformed NIH 3T3 cell lines with the notable exception of SV40-transformed 3T3 cells leads to inhibition of DNA synthesis. Thus, gas1 appears to be one component of a negative circuit that governs growth suppression. Its effect is, however, abolished in SV40-transformed cells.	EUROPEAN MOLEC BIOL LAB, W-6900 HEIDELBERG, GERMANY	European Molecular Biology Laboratory (EMBL)	DELSAL, G (corresponding author), INT CTR GENET ENGN & BIOTECHNOL, CONSORTIUM INTERUNIV BIOTECHNOL LABS, AREA SCI PK, 99 PADRICIANO, I-34012 TRIESTE, ITALY.			DEL SAL, GIANNINO/0000-0003-2185-6003				AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BIGNAMI M, 1988, ONCOGENE, V2, P509; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BRANCOLINI C, 1991, P NATL ACAD SCI USA, V88, P6936, DOI 10.1073/pnas.88.16.6936; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DASSO MC, 1989, NUCLEIC ACIDS RES, V17, P3129, DOI 10.1093/nar/17.8.3129; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DELSAL G, 1989, BIOTECHNIQUES, V7, P514; DETOGNI P, 1988, MOL CELL BIOL, V8, P2251, DOI 10.1128/MCB.8.5.2251; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GOLDSTEIN S, 1990, SCIENCE, V249, P1129, DOI 10.1126/science.2204114; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARLOW E, 1988, ANTIBODIES LABORATOR; Harris H., 1970, CELL FUSION; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; KOZAK M, 1988, MOL CELL BIOL, V8, P2737, DOI 10.1128/MCB.8.7.2737; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LAU JTY, 1983, J BIOL CHEM, V258, P5255; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MANFIOLETTI G, 1990, MOL CELL BIOL, V10, P2924, DOI 10.1128/MCB.10.6.2924; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; OHARA O, 1989, P NATL ACAD SCI USA, V86, P5673, DOI 10.1073/pnas.86.15.5673; PARKS GD, 1986, J VIROL, V60, P376, DOI 10.1128/JVI.60.2.376-384.1986; PEPPERKOK R, 1988, P NATL ACAD SCI USA, V85, P6748, DOI 10.1073/pnas.85.18.6748; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; RAO JKM, 1986, BIOCHIM BIOPHYS ACTA, V869, P197, DOI 10.1016/0167-4838(86)90295-5; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SAUNDERS S, 1989, J CELL BIOL, V108, P1547, DOI 10.1083/jcb.108.4.1547; SAXON PJ, 1986, EMBO J, V5, P3461, DOI 10.1002/j.1460-2075.1986.tb04670.x; SCHEDL T, 1984, J CELL BIOL, V99, P155, DOI 10.1083/jcb.99.1.155; SCHNEIDER C, 1984, NATURE, V311, P675, DOI 10.1038/311675b0; SCHNEIDER C, 1988, CELL, V54, P787, DOI 10.1016/S0092-8674(88)91065-3; Schneider C, 1991, CURR OPIN CELL BIOL, V3, P276, DOI 10.1016/0955-0674(91)90152-O; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHEETS MD, 1990, NUCLEIC ACIDS RES, V18, P5799, DOI 10.1093/nar/18.19.5799; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; VANDENHEUVEL SJL, 1990, EMBO J, V9, P2621, DOI 10.1002/j.1460-2075.1990.tb07444.x; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZERIAL M, 1987, EMBO J, V6, P2661, DOI 10.1002/j.1460-2075.1987.tb02557.x	72	248	257	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 21	1992	70	4					595	607		10.1016/0092-8674(92)90429-G	http://dx.doi.org/10.1016/0092-8674(92)90429-G			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JJ886	1505026				2022-12-01	WOS:A1992JJ88600009
J	DICKINSON, LA; JOH, T; KOHWI, Y; KOHWISHIGEMATSU, T				DICKINSON, LA; JOH, T; KOHWI, Y; KOHWISHIGEMATSU, T			A TISSUE-SPECIFIC MAR/SAR DNA-BINDING PROTEIN WITH UNUSUAL BINDING-SITE RECOGNITION	CELL			English	Article							SCAFFOLD-ATTACHED REGIONS; CHROMOSOMAL LOOP ANCHORAGE; BETA-GLOBIN GENE; ESCHERICHIA-COLI; TOPOISOMERASE-II; NUCLEAR SCAFFOLD; DROSOPHILA-MELANOGASTER; NUCLEOTIDE-SEQUENCE; CONSENSUS SEQUENCE; CRYSTAL-STRUCTURE	A human cDNA was cloned that encodes a DNA-binding protein (SATB1) that is expressed predominantly in thymus and binds selectively to the nuclear matrix/scaffold-associating DNAs (MARs/SARs). Missing nucleoside experiments showed that SATB1 selectively binds in a special AT-rich sequence context where one strand consists of mixed A's, T's, and C's, excluding G's (ATC sequences). When this feature is destroyed by mutation, SATB1 binding is greatly reduced even if the direct contact sequence remains intact. Conjunctional SATB1-binding sequences become stably unpaired in supercoiled DNA. Specific mutations that diminish the unwinding potential greatly reduce SATB1 binding. However, SATB1 does not bind single-stranded DNA. Chemical interference assays show that SATB1 binds along the minor groove with very little contact with the bases. This suggests that SATB1 recognizes the ATC sequence indirectly through the altered sugar-phosphate backbone structure present in the double-stranded DNA.			DICKINSON, LA (corresponding author), LA JOLLA CANC RES FDN,LA JOLLA,CA 92037, USA.				NCI NIH HHS [R01 CA51377, R01 CA39681] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039681, R01CA051377] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADACHI Y, 1989, EMBO J, V8, P3997, DOI 10.1002/j.1460-2075.1989.tb08582.x; AMATI BB, 1988, CELL, V54, P967, DOI 10.1016/0092-8674(88)90111-0; ANDERSON JN, 1986, NUCLEIC ACIDS RES, V14, P8513, DOI 10.1093/nar/14.21.8513; BARRIO JR, 1972, BIOCHEM BIOPH RES CO, V46, P597, DOI 10.1016/S0006-291X(72)80181-5; BEREZNEY R, 1974, BIOCHEM BIOPH RES CO, V60, P1410, DOI 10.1016/0006-291X(74)90355-6; BODE J, 1988, BIOCHEMISTRY-US, V27, P4706, DOI 10.1021/bi00413a019; BODE J, 1992, SCIENCE, V255, P195, DOI 10.1126/science.1553545; BOUTON AH, 1986, MOL CELL BIOL, V6, P2354, DOI 10.1128/MCB.6.7.2354; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BROTHERTON T, 1991, BIOCHEMISTRY-US, V30, P5845, DOI 10.1021/bi00238a006; BROWN DG, 1990, EMBO J, V9, P1329, DOI 10.1002/j.1460-2075.1990.tb08242.x; BRUNELLE A, 1987, P NATL ACAD SCI USA, V84, P6673, DOI 10.1073/pnas.84.19.6673; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHURCHILL MEA, 1991, TRENDS BIOCHEM SCI, V16, P92, DOI 10.1016/0968-0004(91)90040-3; COCKERILL PN, 1987, J BIOL CHEM, V262, P5394; COCKERILL PN, 1986, CELL, V44, P273, DOI 10.1016/0092-8674(86)90761-0; COLL M, 1987, P NATL ACAD SCI USA, V84, P8385, DOI 10.1073/pnas.84.23.8385; DIJKWEL PA, 1988, MOL CELL BIOL, V8, P5398, DOI 10.1128/MCB.8.12.5398; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FEDOROFF NV, 1978, CELL, V13, P701, DOI 10.1016/0092-8674(78)90220-9; FITZGERALDHAYES M, 1982, CELL, V29, P235, DOI 10.1016/0092-8674(82)90108-8; FORRESTER WC, 1987, NUCLEIC ACIDS RES, V15, P10159, DOI 10.1093/nar/15.24.10159; GASSER SM, 1987, TRENDS GENET, V3, P16, DOI 10.1016/0168-9525(87)90156-9; GASSER SM, 1986, EMBO J, V5, P511, DOI 10.1002/j.1460-2075.1986.tb04240.x; GASSER SM, 1986, CELL, V46, P521, DOI 10.1016/0092-8674(86)90877-9; GEARING DP, 1989, BIO-TECHNOL, V7, P1157; GILLIES SD, 1983, CELL, V33, P717, DOI 10.1016/0092-8674(83)90014-4; GOODRICH JA, 1990, NUCLEIC ACIDS RES, V18, P4993, DOI 10.1093/nar/18.17.4993; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; HAYES JJ, 1989, BIOCHEMISTRY-US, V28, P9521, DOI 10.1021/bi00450a041; HOFMANN JFX, 1991, CELL, V64, P951, DOI 10.1016/0092-8674(91)90319-T; HOFMANN JFX, 1989, CELL, V57, P725, DOI 10.1016/0092-8674(89)90788-5; HOFMANN MC, 1989, CANCER RES, V49, P4696; HOMBERGER HP, 1989, CHROMOSOMA, V98, P99, DOI 10.1007/BF00291044; JARMAN AP, 1988, EMBO J, V7, P3337, DOI 10.1002/j.1460-2075.1988.tb03205.x; KELLUM R, 1991, CELL, V64, P941, DOI 10.1016/0092-8674(91)90318-S; KELLUM R, 1992, MOL CELL BIOL, V12, P2424, DOI 10.1128/MCB.12.5.2424; KLEHR D, 1991, BIOCHEMISTRY-US, V30, P1264, DOI 10.1021/bi00219a015; KOCHETKOV N K, 1971, Tetrahedron Letters, V22, P1993; KOHWI Y, 1988, P NATL ACAD SCI USA, V85, P3781, DOI 10.1073/pnas.85.11.3781; KOHWISHIGEMATSU T, 1990, BIOCHEMISTRY-US, V29, P9551, DOI 10.1021/bi00493a009; KOHWISHIGEMATSU T, 1983, P NATL ACAD SCI-BIOL, V80, P4389, DOI 10.1073/pnas.80.14.4389; KOHWISHIGEMATSU T, 1985, CELL, V43, P199, DOI 10.1016/0092-8674(85)90024-8; KOO HS, 1987, BIOCHEMISTRY-US, V26, P3745, DOI 10.1021/bi00386a070; KOPKA ML, 1985, P NATL ACAD SCI USA, V82, P1376, DOI 10.1073/pnas.82.5.1376; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KUMAMOTO AA, 1987, GENE DEV, V1, P556, DOI 10.1101/gad.1.6.556; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE DK, 1991, CELL, V67, P1241, DOI 10.1016/0092-8674(91)90300-N; LEVYWILSON B, 1989, J BIOL CHEM, V264, P21196; Maniatis T., 1982, MOL CLONING; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MIELKE C, 1990, BIOCHEMISTRY-US, V29, P7475, DOI 10.1021/bi00484a017; MIRKOVITCH J, 1984, CELL, V39, P223, DOI 10.1016/0092-8674(84)90208-3; MULLER MT, 1988, BIOCHEMISTRY-US, V27, P8369, DOI 10.1021/bi00422a012; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; PHIVAN L, 1988, EMBO J, V7, P655, DOI 10.1002/j.1460-2075.1988.tb02860.x; PHIVAN L, 1990, MOL CELL BIOL, V10, P2302, DOI 10.1128/MCB.10.5.2302; PHIVAN L, 1990, PROG MOL SUBCELL BIO, V11, P1; SANDER M, 1985, NUCLEIC ACIDS RES, V13, P1057, DOI 10.1093/nar/13.4.1057; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOLOMON MJ, 1986, P NATL ACAD SCI USA, V83, P1276, DOI 10.1073/pnas.83.5.1276; SPITZNER JR, 1988, NUCLEIC ACIDS RES, V16, P5533, DOI 10.1093/nar/16.12.5533; STARR DB, 1991, CELL, V67, P1231, DOI 10.1016/0092-8674(91)90299-E; STIEF A, 1989, NATURE, V341, P343, DOI 10.1038/341343a0; STOCKHAUS J, 1987, NUCLEIC ACIDS RES, V15, P3479, DOI 10.1093/nar/15.8.3479; STRUHL K, 1989, TRENDS BIOCHEM SCI, V14, P137, DOI 10.1016/0968-0004(89)90145-X; TUAN D, 1985, P NATL ACAD SCI USA, V82, P6384, DOI 10.1073/pnas.82.19.6384; UMEK RM, 1988, CELL, V52, P559, DOI 10.1016/0092-8674(88)90469-2; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; VONKRIES JP, 1991, CELL, V64, P123, DOI 10.1016/0092-8674(91)90214-J; VONKRIES JP, 1990, NUCLEIC ACIDS RES, V18, P3881; WEEKS KM, 1991, CELL, V66, P577, DOI 10.1016/0092-8674(81)90020-9; YANG CC, 1989, CELL, V57, P869, DOI 10.1016/0092-8674(89)90801-5	77	447	488	0	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 21	1992	70	4					631	645		10.1016/0092-8674(92)90432-C	http://dx.doi.org/10.1016/0092-8674(92)90432-C			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JJ886	1505028				2022-12-01	WOS:A1992JJ88600012
J	FERGUSON, M; TORRI, AF; WARD, DC; ENGLUND, PT				FERGUSON, M; TORRI, AF; WARD, DC; ENGLUND, PT			INSITU HYBRIDIZATION TO THE CRITHIDIA-FASCICULATA KINETOPLAST REVEALS 2 ANTIPODAL SITES INVOLVED IN KINETOPLAST DNA-REPLICATION	CELL			English	Article							TRYPANOSOMA-BRUCEI; GUIDE RNAS; MINICIRCLES; MITOCHONDRIA; NETWORKS; LOCALIZATION; ORGANIZATION; TRANSCRIPT; PROTOZOA; CLONING	Kinetoplast DNA is a network of interlocked minicircles and maxicircles. In situ hybridization, using probes detected by digital fluorescence microscopy, has clarified the in vivo structure and replication mechanism of the network. The probe recognizes only nicked minicircles. Hybridization reveals prereplication kinetoplasts (with closed minicircles), donut-shaped replicating kinetoplasts (with nicked minicircles on the periphery and closed minicircles in the center), and postreplication kinetoplasts (with nicked minicircles). Replicating kinetoplasts are associated with two peripheral structures containing free minicircle replication intermediates and DNA polymerase. Replication may involve release of closed minicircles from the center of the kinetoplast and their migration to the peripheral structures, replication of the free minicircles therein, and then peripheral reattachment of the progeny minicircles to the kinetoplast.	YALE UNIV,DEPT BIOCHEM & GENE,NEW HAVEN,CT 06510; JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21205	Yale University; Johns Hopkins University	FERGUSON, M (corresponding author), YALE UNIV,DEPT MOLEC BIOPHYS,NEW HAVEN,CT 06510, USA.				NIGMS NIH HHS [GM13604-02, GM-40115, GM-27608] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040115, R37GM027608, F32GM013604, R01GM027608] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON W, 1969, J CELL SCI, V4, P611; BENNE R, 1986, CELL, V46, P819, DOI 10.1016/0092-8674(86)90063-2; BIRKENMEYER L, 1987, J BIOL CHEM, V262, P2384; BLUM B, 1990, CELL, V60, P189, DOI 10.1016/0092-8674(90)90735-W; BOYLE AR, 1990, CURRENT PROTOCOLS S, V12; COSGROVE WB, 1970, J PROTOZOOL, V17, P172, DOI 10.1111/j.1550-7408.1970.tb02350.x; DELAIN E, 1969, CR ACAD SCI D NAT, V268, P1225; ENGLUND PT, 1978, CELL, V14, P157, DOI 10.1016/0092-8674(78)90310-0; ENGLUND PT, 1979, J BIOL CHEM, V254, P4895; ENGLUND PT, 1982, MITOCHONDRIAL GENES, P423; ENGMAN DM, 1989, MOL CELL BIOL, V9, P5163, DOI 10.1128/MCB.9.11.5163; FEAGIN JE, 1990, J BIOL CHEM, V265, P19373; FEAGIN JE, 1988, CELL, V53, P413, DOI 10.1016/0092-8674(88)90161-4; GONZALEZ A, 1990, MOL BIOCHEM PARASIT, V40, P233, DOI 10.1016/0166-6851(90)90045-N; KITCHIN PA, 1986, J BIOL CHEM, V261, P1302; KUSEL JP, 1967, J PROTOZOOL, V14, P283, DOI 10.1111/j.1550-7408.1967.tb01999.x; LICHTER P, 1988, HUM GENET, V80, P224, DOI 10.1007/BF01790090; MARINI JC, 1980, J BIOL CHEM, V255, P4976; MELENDY T, 1988, CELL, V55, P1083, DOI 10.1016/0092-8674(88)90252-8; POLLARD VW, 1990, CELL, V63, P783, DOI 10.1016/0092-8674(90)90144-4; RAY DS, 1987, PLASMID, V17, P177, DOI 10.1016/0147-619X(87)90026-6; RYAN KA, 1988, ANNU REV MICROBIOL, V42, P339, DOI 10.1146/annurev.mi.42.100188.002011; SHELINE C, 1989, MOL CELL BIOL, V9, P169, DOI 10.1128/MCB.9.1.169; SILVER LE, 1986, CELL, V47, P537, DOI 10.1016/0092-8674(86)90618-5; SIMPSON AM, 1976, J PROTOZOOL, V23, P583, DOI 10.1111/j.1550-7408.1976.tb03846.x; SIMPSON L, 1989, CELL, V57, P355, DOI 10.1016/0092-8674(89)90911-2; SIMPSON L, 1990, SCIENCE, V250, P512, DOI 10.1126/science.1700474; SIMPSON L, 1987, ANNU REV MICROBIOL, V41, P363, DOI 10.1146/annurev.mi.41.100187.002051; SIMPSON L, 1974, BIOCHIM BIOPHYS ACTA, V349, P161, DOI 10.1016/0005-2787(74)90077-X; STUART K, 1983, MOL BIOCHEM PARASIT, V9, P93, DOI 10.1016/0166-6851(83)90103-2; STURM NR, 1990, CELL, V61, P879, DOI 10.1016/0092-8674(90)90198-N; SUGISAKI H, 1987, MOL BIOCHEM PARASIT, V23, P253, DOI 10.1016/0166-6851(87)90032-6; TORRI AF, 1992, J BIOL CHEM, V267, P4786	33	114	114	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 21	1992	70	4					621	629		10.1016/0092-8674(92)90431-B	http://dx.doi.org/10.1016/0092-8674(92)90431-B			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JJ886	1324122				2022-12-01	WOS:A1992JJ88600011
J	GARDNER, JM; NAKATSU, Y; GONDO, Y; LEE, S; LYON, MF; KING, RA; BRILLIANT, MH				GARDNER, JM; NAKATSU, Y; GONDO, Y; LEE, S; LYON, MF; KING, RA; BRILLIANT, MH			THE MOUSE PINK-EYED DILUTION GENE - ASSOCIATION WITH HUMAN PRADER-WILLI AND ANGELMAN SYNDROMES	SCIENCE			English	Article							PARENTAL ORIGIN; CDNA CLONES; P-LOCUS; HYPOPIGMENTATION; IDENTIFICATION; DELETION; MUTANTS; ABNORMALITIES; CHROMOSOME-7; EXPRESSION	Complementary DNA clones from the pink-eyed dilution (p) locus of mouse chromosome 7 were isolated from murine melanoma and melanocyte libraries. The transcript from this gene is missing or altered in six independent mutant alleles of the p locus, suggesting that disruption of this gene results in the hypopigmentation phenotype that defines mutant p alleles. Characterization of the human homolog revealed that it is localized to human chromosome 15 at q11.2-q12, a region associated with Prader-Willi and Angelman syndromes, suggesting that altered expression of this gene may be responsible for the hypopigmentation phenotype exhibited by certain individuals with these disorders.	FOX CHASE CANC INST,INST CANC RES,PHILADELPHIA,PA 19111; MRC,RADIOBIOL UNIT,DIDCOT 0X11 0RD,OXON,ENGLAND; UNIV MINNESOTA,DEPT MED,MINNEAPOLIS,MN 55455	Fox Chase Cancer Center; University of Minnesota System; University of Minnesota Twin Cities			Gondo, Yoichi/A-5375-2016	Gondo, Yoichi/0000-0003-2184-6489; Nakatsu, Yoshimichi/0000-0001-7408-7071	NATIONAL CANCER INSTITUTE [P30CA006927] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043840, P01GM022167] Funding Source: NIH RePORTER; NCI NIH HHS [CA06927] Funding Source: Medline; NIGMS NIH HHS [GM22167, GM43840] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APKARIAN P, 1989, DOC OPHTHALMOL, V71, P355, DOI 10.1007/BF00152762; BRAY GA, 1983, MEDICINE, V62, P59, DOI 10.1097/00005792-198303000-00001; BRILLIANT MH, 1992, MAMM GENOME, V3, P187, DOI 10.1007/BF00355717; BRILLIANT MH, 1991, SCIENCE, V252, P566, DOI 10.1126/science.1673574; BRILLIANT MH, UNPUB; BUTLER MG, 1989, AM J HUM GENET, V45, P140; CHAILLET JR, 1991, GENOMICS, V11, P773, DOI 10.1016/0888-7543(91)90090-2; CREEL DJ, 1986, NEW ENGL J MED, V314, P1606, DOI 10.1056/NEJM198606193142503; DONLON TA, 1986, P NATL ACAD SCI USA, V83, P4408, DOI 10.1073/pnas.83.12.4408; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; FIDLER IJ, 1973, NATURE-NEW BIOL, V242, P148, DOI 10.1038/newbio242148a0; FRYBURG JS, 1991, AM J MED GENET, V38, P58, DOI 10.1002/ajmg.1320380114; GONDO Y, UNPUB; Green MC., 1989, GENETIC VARIANTS STR, P12; HAMABE J, 1991, AM J MED GENET, V41, P54, DOI 10.1002/ajmg.1320410116; HEARING VJ, 1973, J ULTRA MOL STRUCT R, V43, P88, DOI 10.1016/S0022-5320(73)90072-5; HITTNER HM, 1982, AM J OPHTHALMOL, V94, P328, DOI 10.1016/0002-9394(82)90358-0; HUNT DM, 1971, J EMBRYOL EXP MORPH, V26, P111; JOHNSON DR, 1975, J REPROD FERTIL, V42, P51, DOI 10.1530/jrf.0.0420051; KNOLL JHM, 1990, AM J HUM GENET, V47, P149; KNOLL JHM, 1989, AM J MED GENET, V32, P285, DOI 10.1002/ajmg.1320320235; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LARUE L, 1990, SOMAT CELL MOLEC GEN, V16, P361, DOI 10.1007/BF01232464; LYON MF, IN PRESS P NATL ACAD; MAGENIS RE, 1990, AM J MED GENET, V35, P333, DOI 10.1002/ajmg.1320350307; MARKERT CL, 1956, GENETICS, V41, P429; MELVOLD RW, 1971, MUTAT RES, V12, P171, DOI 10.1016/0027-5107(71)90138-2; MELVOLD RW, 1974, GENET RES, V23, P319, DOI 10.1017/S0016672300014956; MEYUHAS O, 1980, GENE, V10, P113, DOI 10.1016/0378-1119(80)90129-8; MONACO AP, 1986, NATURE, V323, P646, DOI 10.1038/323646a0; NAKATSU Y, 1992, MAMM GENOME, V2, P69, DOI 10.1007/BF00570442; NEVE RL, 1986, MOL BRAIN RES, V1, P271, DOI 10.1016/0169-328X(86)90033-1; NICHOLLS RD, 1989, AM J MED GENET, V33, P66, DOI 10.1002/ajmg.1320330109; NICHOLLS RD, 1989, MOUSE NEWS LETT, V84, P87; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PHILLIPS RJS, 1977, MOUSE NEWS LETT, V57, P18; PHILLIPS RJS, 1977, MOUSE NEWS LETT, V56, P38; REITH AD, 1991, GENE DEV, V5, P1115, DOI 10.1101/gad.5.7.1115; ROBINSON WP, 1991, AM J HUM GENET, V49, P1219; RUSSELL ES, 1949, GENETICS, V34, P146; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SILVERS WK, 1979, COAT COLORS MICE, P90; STEPHENSON DA, 1985, J EMBRYOL EXP MORPH, V87, P65; TANTRAVAHI U, 1989, AM J MED GENET, V33, P78, DOI 10.1002/ajmg.1320330110; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WAGSTAFF J, 1991, GENOMICS, V11, P1071, DOI 10.1016/0888-7543(91)90034-C; WALLIS CE, 1989, J MED GENET, V26, P337, DOI 10.1136/jmg.26.5.337; WIESNER GL, 1987, AM J HUM GENET, V40, P431; WILLIAMS CA, 1990, AM J MED GENET, V35, P350, DOI 10.1002/ajmg.1320350308; WOLFE HG, 1963, 11TH P INT C GEN, P251	50	198	200	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 21	1992	257	5073					1121	1124		10.1126/science.257.5073.1121	http://dx.doi.org/10.1126/science.257.5073.1121			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JJ884	1509264				2022-12-01	WOS:A1992JJ88400034
J	GRUENEBERG, DA; NATESAN, S; ALEXANDRE, C; GILMAN, MZ				GRUENEBERG, DA; NATESAN, S; ALEXANDRE, C; GILMAN, MZ			HUMAN AND DROSOPHILA HOMEODOMAIN PROTEINS THAT ENHANCE THE DNA-BINDING ACTIVITY OF SERUM RESPONSE FACTOR	SCIENCE			English	Article							YEAST TRANSCRIPTION ACTIVATOR; TERNARY COMPLEX-FORMATION; C-FOS PROMOTER; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; MAT-ALPHA-1 PROTEIN; ANTIRRHINUM-MAJUS; RECOGNITION HELIX; CRYSTAL-STRUCTURE; HOMEOBOX GENES	Cells with distinct developmental histories can respond differentially to identical signals, suggesting that signals are interpreted in a fashion that reflects a cell's identity. How this might occur is suggested by the observation that proteins of the homeodomain family, including a newly identified human protein, enhance the DNA-binding activity of serum response factor, a protein required for the induction of genes by growth and differentiation factors. Interaction with proteins of the serum response factor family may allow homeodomain proteins to specify the transcriptional response to inductive signals. Moreover, because the ability to enhance the binding of serum response factor to DNA resides within the homeodomain but is independent of homeodomain DNA-binding activity, this additional activity of the homeodomain may account for some of the specificity of action of homeodomain proteins in development.	COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724	Cold Spring Harbor Laboratory					NATIONAL CANCER INSTITUTE [R01CA045642] Funding Source: NIH RePORTER; NCI NIH HHS [CA08968, CA45642] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMMERER G, 1990, GENE DEV, V4, P299, DOI 10.1101/gad.4.2.299; ATTAR RM, 1992, MOL CELL BIOL, V12, P2432, DOI 10.1128/MCB.12.5.2432; ATTAR RM, UNPUB; BENDER A, 1986, CELL, V47, P929, DOI 10.1016/0092-8674(86)90808-1; BENDER A, 1987, CELL, V50, P681, DOI 10.1016/0092-8674(87)90326-6; BERKOWITZ LA, 1989, MOL CELL BIOL, V9, P4272, DOI 10.1128/MCB.9.10.4272; BLUMBERG B, 1991, SCIENCE, V253, P194, DOI 10.1126/science.1677215; BOPP D, 1986, CELL, V47, P1033, DOI 10.1016/0092-8674(86)90818-4; COLICELLI J, 1991, P NATL ACAD SCI USA, V88, P2913, DOI 10.1073/pnas.88.7.2913; CSERJESI P, IN PRESS DEVELOPMENT; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FIELDS S, 1990, TRENDS BIOCHEM SCI, V15, P270, DOI 10.1016/0968-0004(90)90052-D; FINKELSTEIN R, 1990, GENE DEV, V4, P1516, DOI 10.1101/gad.4.9.1516; FRIGERIO G, 1986, CELL, V47, P735, DOI 10.1016/0092-8674(86)90516-7; GEARING DP, 1989, BIO-TECHNOL, V7, P1157; GERSTER T, 1988, P NATL ACAD SCI USA, V85, P6347, DOI 10.1073/pnas.85.17.6347; GIBSON G, 1990, CELL, V62, P1087, DOI 10.1016/0092-8674(90)90386-S; GILMAN MZ, 1988, GENE DEV, V2, P394, DOI 10.1101/gad.2.4.394; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; GREENBERG ME, 1987, MOL CELL BIOL, V7, P1217, DOI 10.1128/MCB.7.3.1217; GRUENEBERG DA, UNPUB; HAGEN DC, 1986, P NATL ACAD SCI USA, V83, P1418, DOI 10.1073/pnas.83.5.1418; HANES SD, 1991, SCIENCE, V251, P426, DOI 10.1126/science.1671176; HANES SD, 1989, CELL, V57, P1275, DOI 10.1016/0092-8674(89)90063-9; HAWKINS NC, 1990, NUCLEIC ACIDS RES, V18, P6101, DOI 10.1093/nar/18.20.6101; HAYASHI S, 1990, CELL, V63, P883, DOI 10.1016/0092-8674(90)90492-W; HENIKOFF S, 1990, NUCLEIC ACIDS RES, V18, P2961, DOI 10.1093/nar/18.10.2961; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; JACK T, 1992, CELL, V68, P683, DOI 10.1016/0092-8674(92)90144-2; JANKNECHT R, 1992, EMBO J, V11, P1045, DOI 10.1002/j.1460-2075.1992.tb05143.x; JARVIS EE, 1989, GENE DEV, V3, P936, DOI 10.1101/gad.3.7.936; JARVIS EE, 1988, MOL CELL BIOL, V8, P309, DOI 10.1128/MCB.8.1.309; JOSTES B, 1991, MECH DEVELOP, V33, P27; KELEHER CA, 1988, CELL, V53, P927, DOI 10.1016/S0092-8674(88)90449-7; KELLY M, 1988, EMBO J, V7, P1537, DOI 10.1002/j.1460-2075.1988.tb02973.x; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KONGSUWAN K, 1988, EMBO J, V7, P2131, DOI 10.1002/j.1460-2075.1988.tb03052.x; KRISTIE TM, 1990, GENE DEV, V4, P2383, DOI 10.1101/gad.4.12b.2383; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KURET J, 1988, J BIOL CHEM, V263, P9149; KUZIORA MA, 1989, CELL, V59, P563, DOI 10.1016/0092-8674(89)90039-1; LIN L, 1992, GENE DEV, V6, P1071, DOI 10.1101/gad.6.6.1071; MANN RS, 1990, CELL, V60, P597, DOI 10.1016/0092-8674(90)90663-Y; MARAIS RM, 1992, EMBO J, V11, P97, DOI 10.1002/j.1460-2075.1992.tb05032.x; MUELLER CGF, 1991, EMBO J, V10, P4219, DOI 10.1002/j.1460-2075.1991.tb05000.x; NAKAYAMA N, 1987, EMBO J, V6, P249, DOI 10.1002/j.1460-2075.1987.tb04746.x; NAKAYAMA N, 1985, EMBO J, V4, P2643, DOI 10.1002/j.1460-2075.1985.tb03982.x; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; OHARE P, 1988, CELL, V52, P435, DOI 10.1016/S0092-8674(88)80036-9; OPSTELTEN DJE, 1991, MECH DEVELOP, V34, P29, DOI 10.1016/0925-4773(91)90089-O; OTTING G, 1990, EMBO J, V9, P3085, DOI 10.1002/j.1460-2075.1990.tb07505.x; PABO CO, 1984, ANNU REV BIOCHEM, V53, P293, DOI 10.1146/annurev.bi.53.070184.001453; PASSMORE S, 1989, GENE DEV, V3, P921, DOI 10.1101/gad.3.7.921; PASSMORE S, 1988, J MOL BIOL, V204, P593, DOI 10.1016/0022-2836(88)90358-0; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; PRIMIG M, 1991, EMBO J, V10, P4209, DOI 10.1002/j.1460-2075.1991.tb04999.x; RIVERA VM, 1990, GENE DEV, V4, P255, DOI 10.1101/gad.4.2.255; ROSA FM, 1989, CELL, V57, P965, DOI 10.1016/0092-8674(89)90335-8; RYAN WE, UNPUB; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHROTER H, 1990, EMBO J, V9, P1123, DOI 10.1002/j.1460-2075.1990.tb08218.x; SCHULZ B, 1990, CELL, V60, P295, DOI 10.1016/0092-8674(90)90744-Y; SCHWARZSOMMER Z, 1990, SCIENCE, V250, P931, DOI 10.1126/science.250.4983.931; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SIEGFRIED Z, 1989, ONCOGENE, V4, P3; SIMON K, UNPUB; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH DL, 1992, CELL, V68, P133, DOI 10.1016/0092-8674(92)90212-U; SOMMER H, 1990, EMBO J, V9, P605, DOI 10.1002/j.1460-2075.1990.tb08152.x; Sprague G F Jr, 1990, Adv Genet, V27, P33; STERN S, 1991, GENE DEV, V5, P2555, DOI 10.1101/gad.5.12b.2555; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; STRUHL K, 1982, P NATL ACAD SCI-BIOL, V79, P7385, DOI 10.1073/pnas.79.23.7385; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; TANAKA M, 1988, GENE DEV, V2, P1764, DOI 10.1101/gad.2.12b.1764; TATCHELL K, 1981, CELL, V27, P25, DOI 10.1016/0092-8674(81)90357-3; TREISMAN J, 1989, CELL, V59, P553; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; VERSHON AK, COMMUNICATION; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5; YANOFSKY MF, 1990, NATURE, V346, P35, DOI 10.1038/346035a0; YUAN YLO, 1991, MOL CELL BIOL, V11, P5910, DOI 10.1128/MCB.11.12.5910	90	299	305	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 21	1992	257	5073					1089	1095		10.1126/science.257.5073.1089	http://dx.doi.org/10.1126/science.257.5073.1089			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JJ884	1509260				2022-12-01	WOS:A1992JJ88400025
J	HAAF, T; WARBURTON, PE; WILLARD, HF				HAAF, T; WARBURTON, PE; WILLARD, HF			INTEGRATION OF HUMAN ALPHA-SATELLITE DNA INTO SIMIAN CHROMOSOMES - CENTROMERE PROTEIN-BINDING AND DISRUPTION OF NORMAL CHROMOSOME SEGREGATION	CELL			English	Article							DOUBLE MINUTE CHROMOSOMES; SYRIAN-HAMSTER CELLS; ADRENAL-TUMOR CELLS; ANTIGEN CENP-B; MAMMALIAN CHROMOSOMES; GENE AMPLIFICATION; LOCATED BENEATH; Y-CHROMOSOME; CAD GENES; SEQUENCES	Centromeres of mammalian and other complex eukaryotic chromosomes are dominated by one or more classes of satellite DNA. To test the hypothesis that alpha-satellite DNA, the major centromeric satellite of primate chromosomes, is involved in centromere structure and/or function, human alpha-satellite DNA was introduced into African green monkey (AGM) cells. Centromere protein binding was apparent at the sites of integrated human alpha-satellite DNA. In the presence of an AGM centromere on the same chromosome, human alpha-satellite was associated with bridges between the separating sets of chromatids at anaphase and an increased number of lagging chromosomes at meta-phase, both features consistent with the integrated alpha-satellite disrupting normal chromosome segregation. These experiments suggest that alpha-satellite DNA provides the primary sequence information for centromere protein binding and for at least some functional aspect(s) of a mammalian centromere, playing a role either in kinetochore formation or in sister chromatid apposition.	UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5S 1A8,ONTARIO,CANADA	University of Toronto	HAAF, T (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DEPT GENET,STANFORD,CA 94305, USA.				NHGRI NIH HHS [HG00107] Funding Source: Medline	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		BERNAT RL, 1991, CELL, V66, P1229, DOI 10.1016/0092-8674(91)90045-Z; BERNAT RL, 1990, J CELL BIOL, V111, P1519, DOI 10.1083/jcb.111.4.1519; Brinkley B.R., 1989, MITOSIS MOL MECHANIS, P77; BROWN PC, 1981, MOL CELL BIOL, V1, P1077, DOI 10.1128/MCB.1.12.1077; CHU G, 1986, SCIENCE, V234, P1582, DOI 10.1126/science.3538420; COOKE CA, 1990, J CELL BIOL, V110, P1475, DOI 10.1083/jcb.110.5.1475; COOKE CA, 1987, J CELL BIOL, V105, P2053, DOI 10.1083/jcb.105.5.2053; EARNSHAW WC, 1987, P NATL ACAD SCI USA, V84, P4979, DOI 10.1073/pnas.84.14.4979; EARNSHAW WC, 1991, J CELL SCI, V99, P1; EARNSHAW WC, 1985, CHROMOSOMA, V91, P313, DOI 10.1007/BF00328227; EARNSHAW WC, 1989, CHROMOSOMA, V98, P1, DOI 10.1007/BF00293329; FORD JH, 1989, MECHANISMS CHROMOSOM, P231; GEORGE DL, 1982, P NATL ACAD SCI-BIOL, V79, P1597, DOI 10.1073/pnas.79.5.1597; GEORGE DL, 1985, EMBO J, V4, P1199, DOI 10.1002/j.1460-2075.1985.tb03760.x; GRADY DL, 1992, P NATL ACAD SCI USA, V89, P1695, DOI 10.1073/pnas.89.5.1695; GROSVELD FG, 1982, NUCLEIC ACIDS RES, V10, P6715, DOI 10.1093/nar/10.21.6715; HAAF T, 1988, CANCER GENET CYTOGEN, V30, P73, DOI 10.1016/0165-4608(88)90094-5; HAAF T, 1990, EXP CELL RES, V191, P157, DOI 10.1016/0014-4827(90)90051-B; HAAF T, 1990, CYTOGENET CELL GENET, V53, P40, DOI 10.1159/000132892; HAAF T, 1990, HUM GENET, V85, P486; HAAF T, 1991, P223; HADLACZKY G, 1991, P NATL ACAD SCI USA, V88, P8106, DOI 10.1073/pnas.88.18.8106; HAMKALO BA, 1985, P NATL ACAD SCI USA, V82, P1126, DOI 10.1073/pnas.82.4.1126; HEARTLEIN MW, 1988, MOL CELL BIOL, V8, P3611, DOI 10.1128/MCB.8.9.3611; HSU TC, 1975, CYTOGENET CELL GENET, V15, P41, DOI 10.1159/000130497; KAUFMAN RJ, 1983, MOL CELL BIOL, V3, P699, DOI 10.1128/MCB.3.4.699; LIN CC, 1990, CANCER GENET CYTOGEN, V48, P271, DOI 10.1016/0165-4608(90)90131-S; MANUELIDIS L, 1976, NUCLEIC ACIDS RES, V3, P3063, DOI 10.1093/nar/3.11.3063; MASUMOTO H, 1989, EXP CELL RES, V181, P181, DOI 10.1016/0014-4827(89)90192-4; MASUMOTO H, 1989, J CELL BIOL, V109, P1963, DOI 10.1083/jcb.109.5.1963; Miklos GLG, 1985, MOL EVOLUTIONARY GEN, P241; MOLEBAJER J, 1990, P NATL ACAD SCI USA, V87, P3599, DOI 10.1073/pnas.87.9.3599; MOROI Y, 1980, P NATL ACAD SCI-BIOL, V77, P1627, DOI 10.1073/pnas.77.3.1627; MOYZIS RK, 1989, GENOMICS, V4, P273, DOI 10.1016/0888-7543(89)90331-5; MURO Y, 1992, J CELL BIOL, V116, P585, DOI 10.1083/jcb.116.3.585; NELSON DL, 1989, P NATL ACAD SCI USA, V86, P6686, DOI 10.1073/pnas.86.17.6686; OAKEY R, 1990, GENOMICS, V7, P325, DOI 10.1016/0888-7543(90)90165-Q; PALMER DK, 1991, P NATL ACAD SCI USA, V88, P3734, DOI 10.1073/pnas.88.9.3734; PERETTI D, 1986, HUM GENET, V73, P12, DOI 10.1007/BF00292655; PERUCHO M, 1980, CELL, V22, P9; PLUTA AF, 1990, TRENDS BIOCHEM SCI, V15, P181, DOI 10.1016/0968-0004(90)90158-8; PLUTA AF, 1992, J CELL BIOL, V116, P1081, DOI 10.1083/jcb.116.5.1081; PRAZNOVSZKY T, 1991, P NATL ACAD SCI USA, V88, P11042, DOI 10.1073/pnas.88.24.11042; ROSENBERG H, 1978, SCIENCE, V200, P394, DOI 10.1126/science.205944; SCHIMKE RT, 1988, J BIOL CHEM, V263, P5989; SIMERLY C, 1990, J CELL BIOL, V111, P1491, DOI 10.1083/jcb.111.4.1491; SMITH KA, 1990, CELL, V63, P1219, DOI 10.1016/0092-8674(90)90417-D; STARK GR, 1990, FRONTIERS MOL BIOL, P99; STENMAN S, 1975, EXP CELL RES, V90, P87, DOI 10.1016/0014-4827(75)90360-2; SUMNER AT, 1991, CHROMOSOMA, V100, P410, DOI 10.1007/BF00337519; THERMAN E, 1986, HUM GENET, V72, P191, DOI 10.1007/BF00291876; TYLERSMITH C, 1987, J MOL BIOL, V195, P457, DOI 10.1016/0022-2836(87)90175-6; VISSING H, 1987, NUCLEIC ACIDS RES, V15, P1363, DOI 10.1093/nar/15.4.1363; WAHL GM, 1983, MOL CELL BIOL, V3, P2066, DOI 10.1128/MCB.3.11.2066; WARBURTON PE, 1990, J MOL BIOL, V216, P3, DOI 10.1016/S0022-2836(05)80056-7; WARBURTON PE, 1991, GENOMICS, V11, P324, DOI 10.1016/0888-7543(91)90139-6; WAYE JS, 1989, P NATL ACAD SCI USA, V86, P6250, DOI 10.1073/pnas.86.16.6250; WAYE JS, 1986, MOL CELL BIOL, V6, P315; WEVRICK R, 1990, MOL CELL BIOL, V10, P6374, DOI 10.1128/MCB.10.12.6374; WEVRICK R, 1989, P NATL ACAD SCI USA, V86, P9394, DOI 10.1073/pnas.86.23.9394; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; WILLARD HF, 1987, TRENDS GENET, V3, P192, DOI 10.1016/0168-9525(87)90232-0; WILLARD HF, 1990, TRENDS GENET, V6, P410, DOI 10.1016/0168-9525(90)90302-M; WINDLE B, 1991, GENE DEV, V5, P160, DOI 10.1101/gad.5.2.160; YUNIS JJ, 1971, SCIENCE, V174, P1200, DOI 10.1126/science.174.4015.1200	66	191	206	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 21	1992	70	4					681	696		10.1016/0092-8674(92)90436-G	http://dx.doi.org/10.1016/0092-8674(92)90436-G			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JJ886	1505032				2022-12-01	WOS:A1992JJ88600016
J	HENRY, MF; CRONAN, JE				HENRY, MF; CRONAN, JE			A NEW MECHANISM OF TRANSCRIPTIONAL REGULATION - RELEASE OF AN ACTIVATOR TRIGGERED BY SMALL MOLECULE-BINDING	CELL			English	Article							FATTY-ACID DEGRADATION; ESCHERICHIA-COLI K-12; POSITIVE CONTROL; PRIMARY SEQUENCE; OPERON FUSION; DNA FRAGMENTS; GENE; CLONING; PROTEIN; SYSTEM	The FadR protein of E. coli activates transcription of the fabA gene, a key enzyme of fatty acid synthesis. We report that FadR binds to a DNA sequence positioned at -40 relative to the start site of the FadR-regulated fabA transcript (the location favored by positive activators). This binding was found to be specifically antagonized by long chain acyl-CoAs. The chain length specificity of the disassociation of the FadR-DNA complex by acyl-CoAs observed in vitro reflects that seen in the repression of fabA transcription observed upon addition of fatty acids to bacterial cultures. Acyl-CoA antagonism of FadR-DNA interactions is readily reversible. These data indicate that repression of fabA transcription by fatty acids is the first reported example of a repression system mediated by positive control.	UNIV ILLINOIS, DEPT MICROBIOL, URBANA, IL 61801 USA; UNIV ILLINOIS, DEPT BIOCHEM, URBANA, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign			Cronan, John/V-6626-2019		NIAID NIH HHS [AI15650] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI015650, R01AI015650] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADHYA S, 1990, J BIOL CHEM, V265, P10797; ARPS PJ, 1987, J BACTERIOL, V169, P1061, DOI 10.1128/jb.169.3.1061-1070.1987; BACHMANN BJ, 1972, BACTERIOL REV, V36, P525, DOI 10.1128/MMBR.36.4.525-557.1972; BLACK PN, 1991, J BACTERIOL, V173, P435, DOI 10.1128/jb.173.2.435-442.1991; CASADABAN MJ, 1975, P NATL ACAD SCI USA, V72, P809, DOI 10.1073/pnas.72.3.809; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; CHANG YY, 1988, J BACTERIOL, V170, P3937, DOI 10.1128/jb.170.9.3937-3945.1988; CHUNG CT, 1989, P NATL ACAD SCI USA, V86, P2172, DOI 10.1073/pnas.86.7.2172; CLARK D, 1981, J BACTERIOL, V148, P521, DOI 10.1128/JB.148.2.521-526.1981; CLARK DP, 1983, BIOCHEMISTRY-US, V22, P5897, DOI 10.1021/bi00294a032; COLLADOVIDES J, 1991, MICROBIOL REV, V55, P371, DOI 10.1128/MMBR.55.3.371-394.1991; CRONAN JE, 1984, J BACTERIOL, V159, P773, DOI 10.1128/JB.159.2.773-775.1984; CRONAN JE, 1988, J BIOL CHEM, V263, P4641; CRONAN JE, 1975, BACTERIOL REV, V39, P232, DOI 10.1128/MMBR.39.3.232-256.1975; CRONAN JE, 1973, J BIOL CHEM, V248, P1188; CRONAN JE, 1984, J BACTERIOL, V158, P357, DOI 10.1128/JB.158.1.357-361.1984; CRONAN JE, 1987, CELLULAR MOL BIOL, V1, P474; Davis R., 1980, ADV BACTERIAL GENETI; DIRUSSO CC, 1988, NUCLEIC ACIDS RES, V16, P7995, DOI 10.1093/nar/16.16.7995; DIRUSSO CC, 1990, J BACTERIOL, V172, P6459, DOI 10.1128/jb.172.11.6459-6468.1990; DRETZEN G, 1981, ANAL BIOCHEM, V112, P295, DOI 10.1016/0003-2697(81)90296-7; HENRY MF, 1989, J BACTERIOL, V171, P5254, DOI 10.1128/jb.171.10.5254-5261.1989; HENRY MF, 1991, J MOL BIOL, V222, P843, DOI 10.1016/0022-2836(91)90574-P; HILL FF, 1972, MOL GEN GENET, V117, P143, DOI 10.1007/BF00267611; HUGHES KT, 1988, J BACTERIOL, V170, P1666, DOI 10.1128/jb.170.4.1666-1671.1988; JASIN M, 1984, J BACTERIOL, V159, P783, DOI 10.1128/JB.159.2.783-786.1984; KINGSTON RE, 1987, CURRENT PROTOCOLS MO; KLEIN K, 1971, EUR J BIOCHEM, V19, P442, DOI 10.1111/j.1432-1033.1971.tb01334.x; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LEWIN B, 1990, GENES, V4, P257; Maniatis T., 1982, MOL CLONING; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; MULLIGAN ME, 1984, NUCLEIC ACIDS RES, V12, P789, DOI 10.1093/nar/12.1Part2.789; NAGGERT J, 1991, J BIOL CHEM, V266, P11044; NAKAHIGASHI K, 1990, NUCLEIC ACIDS RES, V18, P4937, DOI 10.1093/nar/18.16.4937; NUNN WD, 1983, J BACTERIOL, V154, P554, DOI 10.1128/JB.154.2.554-560.1983; NUNN WD, 1987, CELLULAR MOL BIOL, V1, P31; OVERATH P, 1969, EUR J BIOCHEM, V7, P559; POWELL GL, 1981, J BIOL CHEM, V256, P2740; RAIBAUD O, 1984, ANNU REV GENET, V18, P173, DOI 10.1146/annurev.ge.18.120184.001133; SALLUS L, 1983, J BACTERIOL, V155, P1450, DOI 10.1128/JB.155.3.1450-1454.1983; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAVAGEAU MA, 1989, THEORETICAL BIOLOGY, P42; SAVAGEAU MA, 1979, BIOL REGUL DEV, V1, P57; SHAPIRA SK, 1983, GENE, V25, P71, DOI 10.1016/0378-1119(83)90169-5; Silhavy T.J., 1984, EXPT GENE FUSIONS; SIMONS RW, 1980, J BACTERIOL, V142, P621, DOI 10.1128/JB.142.2.621-632.1980; SMITH RH, 1986, ARCH BIOCHEM BIOPHYS, V244, P357, DOI 10.1016/0003-9861(86)90124-4; STRUHL K, 1989, CURRENT PROTOCOLS MO, V2; TABOR S, 1987, CURRENT PROTOCOLS MO, V1; TAKETA K, 1966, J BIOL CHEM, V241, P720; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4	52	133	135	2	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 21	1992	70	4					671	679		10.1016/0092-8674(92)90435-F	http://dx.doi.org/10.1016/0092-8674(92)90435-F			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JJ886	1505031				2022-12-01	WOS:A1992JJ88600015
J	JONGENS, TA; HAY, B; JAN, LY; JAN, YN				JONGENS, TA; HAY, B; JAN, LY; JAN, YN			THE GERM CELL-LESS GENE-PRODUCT - A POSTERIORLY LOCALIZED COMPONENT NECESSARY FOR GERM-CELL DEVELOPMENT IN DROSOPHILA	CELL			English	Article							MEDIATED ENHANCER DETECTION; MATERNAL-EFFECT MUTATIONS; POLAR GRANULES; SEQUENCE SIMILARITY; DETERMINANT NANOS; CYCLIN-B; MELANOGASTER; EMBRYOS; PROTEIN; RNA	The first cell fate specification process in the Drosophila embryo, formation of the germline precursors, requires posteriorly localized germ plasm. We have cloned a gene, germ cell-less (gcl), required for germline formation. Posterior localization of the gcl messenger RNA (mRNA) requires the function of those genes essential for the localization of both nanos RNA, which specifies the abdomen, and the germ cell determinants. Mothers with reduced gcl function give rise to sterile adult progeny that lack germ cells. In embryos with reduced maternal gcl product, the germ cell precursors fail to form properly. Consistent with this phenotype, gcl protein specifically associates with those nuclei that later become the nuclei of the germ cell precursors. These observations suggest that gcl functions in the germ cell specification pathway.	UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT BIOCHEM,SAN FRANCISCO,CA 94143; UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,DEPT MOLEC CELLULAR & DEV BIOL,BERKELEY,CA 94720	Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California Berkeley	JONGENS, TA (corresponding author), UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT PHYSIOL,SAN FRANCISCO,CA 94143, USA.			Jan, Lily/0000-0003-3938-8498; Jan, Yuh Nung/0000-0003-1367-6299	NIGMS NIH HHS [GM PHS2271] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BEAMS HW, 1974, INT REV CYTOL, V39, P413, DOI 10.1016/S0074-7696(08)60944-4; BELLEN HJ, 1989, GENE DEV, V3, P1288, DOI 10.1101/gad.3.9.1288; BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; BODMER R, 1987, ROUX ARCH DEV BIOL, V196, P69, DOI 10.1007/BF00402027; BOSWELL RE, 1985, CELL, V43, P97, DOI 10.1016/0092-8674(85)90015-7; BOULAY JL, 1987, NATURE, V330, P395, DOI 10.1038/330395a0; CABRERA CV, 1987, CELL, V50, P659, DOI 10.1016/0092-8674(87)90039-0; Campos-Ortega JA., 1997, EMBRYONIC DEV DROSOP; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Davidson E. H., 1986, GENE ACTIVITY EARLY; DIECKMANN CL, 1985, J BIOL CHEM, V260, P1513; ENGSTROM E, 1982, DEV BIOL, V91, P163; EPHRUSSI A, 1991, CELL, V66, P37, DOI 10.1016/0092-8674(91)90137-N; FOE VE, 1983, J CELL SCI, V61, P31; Frohman MA, 1990, PCR PROTOCOLS GUIDE, P28; GROSSNIKLAUS U, 1989, DEVELOPMENT, V107, P189; HAY B, 1988, DEVELOPMENT, V103, P625; HAY B, 1990, DEVELOPMENT, V109, P425; HAY B, 1988, CELL, V55, P577, DOI 10.1016/0092-8674(88)90216-4; ILLMENSEE K, 1976, DEV BIOL, V49, P40, DOI 10.1016/0012-1606(76)90257-8; ILLMENSEE K, 1974, P NATL ACAD SCI USA, V71, P1016, DOI 10.1073/pnas.71.4.1016; JOWETT T, 1986, DROSOPHILA PRACTICAL; KALFAYAN L, 1982, CELL, V29, P91, DOI 10.1016/0092-8674(82)90093-9; KIMHA J, 1991, CELL, V66, P23, DOI 10.1016/0092-8674(91)90136-M; King RC., 1970, OVARIAN DEV DROSOPHI; LASKO PF, 1990, GENE DEV, V4, P905, DOI 10.1101/gad.4.6.905; LASKO PF, 1988, NATURE, V335, P611, DOI 10.1038/335611a0; LEHMANN R, 1991, DEVELOPMENT, V112, P679; LEHMANN R, 1986, CELL, V47, P141, DOI 10.1016/0092-8674(86)90375-2; LEHMANN R, 1987, NATURE, V329, P167, DOI 10.1038/329167a0; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; LINDSLEY DL, 1968, CARNEGIE I WASH PUBL, V627; Mahowald A.P., 1980, Genetics and Biology of Drosophila, V2d, P141; MAHOWALD AP, 1983, DEV BIOL, V98, P437, DOI 10.1016/0012-1606(83)90373-1; MAHOWALD AP, 1968, J EXP ZOOL, V167, P237, DOI 10.1002/jez.1401670211; MAHOWALD AP, 1962, J EXP ZOOL, V151, P201, DOI 10.1002/jez.1401510302; MAHOWALD AP, 1979, DEV BIOL, V69, P118, DOI 10.1016/0012-1606(79)90279-3; MANSEAU LJ, 1989, GENE DEV, V3, P1437, DOI 10.1101/gad.3.9.1437; MCKNIGHT SL, 1982, SCIENCE, V217, P316, DOI 10.1126/science.6283634; MOHLER J, 1986, GENETICS, V112, P803; NIKI Y, 1984, DEV BIOL, V103, P182, DOI 10.1016/0012-1606(84)90019-8; NIKI Y, 1986, DEV BIOL, V113, P255, DOI 10.1016/0012-1606(86)90127-2; OLIVER B, 1987, GENE DEV, V1, P913, DOI 10.1101/gad.1.9.913; PIRROTTA V, 1986, DROSOPHILA PRACTICAL; RAFF JW, 1990, DEVELOPMENT, V110, P1249; ROBERTSON HM, 1988, GENETICS, V118, P461; ROSENBERG UB, 1985, NATURE, V313, P703, DOI 10.1038/313703a0; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SCHUPBACH T, 1986, ROUX ARCH DEV BIOL, V195, P302, DOI 10.1007/BF00376063; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; STJOHNSTON D, 1991, CELL, V66, P51, DOI 10.1016/0092-8674(91)90138-O; SUTER B, 1989, GENE DEV, V3, P1957, DOI 10.1101/gad.3.12a.1957; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TECHNAU GM, 1986, ROUX ARCH DEV BIOL, V195, P489, DOI 10.1007/BF00375889; THERKAUF WE, 1992, IN PRESS J CELL BIOL, V116; UNDERWOOD EM, 1980, DEV BIOL, V77, P303, DOI 10.1016/0012-1606(80)90476-5; VAESSIN H, 1987, EMBO (European Molecular Biology Organization) Journal, V6, P3431; VANDERKROL AR, 1988, BIOTECHNIQUES, V6, P958; WANG C, 1991, CELL, V66, P637, DOI 10.1016/0092-8674(91)90110-K; WHARTON RP, 1989, CELL, V59, P881, DOI 10.1016/0092-8674(89)90611-9; WHITFIELD WGF, 1989, NATURE, V338, P337, DOI 10.1038/338337a0	63	147	151	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 21	1992	70	4					569	584		10.1016/0092-8674(92)90427-E	http://dx.doi.org/10.1016/0092-8674(92)90427-E			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JJ886	1380406				2022-12-01	WOS:A1992JJ88600007
J	KANG, SM; BEVERLY, B; TRAN, AC; BRORSON, K; SCHWARTZ, RH; LENARDO, MJ				KANG, SM; BEVERLY, B; TRAN, AC; BRORSON, K; SCHWARTZ, RH; LENARDO, MJ			TRANSACTIVATION BY AP-1 IS A MOLECULAR TARGET OF T-CELL CLONAL ANERGY	SCIENCE			English	Article							LYMPHOCYTE-SPECIFIC FACTORS; HUMAN IL-2 GENE; INTERLEUKIN-2 GENE; CYCLOSPORINE-A; COSTIMULATORY SIGNAL; ANTIGEN RECEPTOR; SELF-TOLERANCE; ACTIVATION; EXPRESSION; ENHANCER	Anergy is a mechanism of T lymphocyte tolerance induced by antigen receptor stimulation in the absence of co-stimulation. Anergic T cells were shown to have a defect in antigen-induced transcription of the interleukin-2 gene. Analysis of the promoter indicated that the transcription factor AP-1 and its corresponding cis element were specifically down-regulated. Exposure of anergic T cells to interleukin-2 restored both antigen responsiveness and activity of the AP-1 element.	NIAID,IMMUNOL LAB,BETHESDA,MD 20892; NIAID,CELLULAR & MOLEC IMMUNOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)								ALONSO S, 1986, J MOL EVOL, V23, P11, DOI 10.1007/BF02100994; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ASHWELL JD, 1987, J EXP MED, V165, P173, DOI 10.1084/jem.165.1.173; Ausubel F. M, 1987, CURRENT PROTOCOLS MO, V1; AUSUBEL FM, 1987, CURRENT PROTOCOLS MO, V2; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; BEVERLY B, 1992, INT IMMUNOL, V4, P661, DOI 10.1093/intimm/4.6.661; BEVERLY B, IN PRESS MOL MECHANI; BILLINGHAM RE, 1956, PHILOS T R SOC B, V239, P357, DOI 10.1098/rstb.1956.0006; BLACKMAN MA, 1990, NATURE, V345, P540, DOI 10.1038/345540a0; BONNEVILLE M, 1990, NATURE, V344, P163, DOI 10.1038/344163a0; BRABLETZ T, 1991, NUCLEIC ACIDS RES, V19, P61, DOI 10.1093/nar/19.1.61; BRETSCHER P, 1970, SCIENCE, V169, P1042, DOI 10.1126/science.169.3950.1042; BRORSON KA, 1991, J IMMUNOL, V147, P3601; BRUNVAND MW, 1988, J BIOL CHEM, V263, P18904; BURKLY LC, 1990, SCIENCE, V248, P1364, DOI 10.1126/science.1694042; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; DESILVA DR, 1991, J IMMUNOL, V147, P3261; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DRESSER DW, 1962, IMMUNOLOGY, V5, P378; DURAND DB, 1987, J EXP MED, V165, P395, DOI 10.1084/jem.165.2.395; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; ESSERY G, 1988, IMMUNOLOGY, V64, P413; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; FORSDYKE DR, 1968, LANCET, V1, P281; FRASER JD, 1991, SCIENCE, V251, P313, DOI 10.1126/science.1846244; FUGITA T, 1986, CELL, V46, P401; GOODNOW CC, 1990, SCIENCE, V248, P1373, DOI 10.1126/science.2356469; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRILLI M, IN PRESS INT REV CYT; HARDING FA, 1992, NATURE, V356, P607, DOI 10.1038/356607a0; HECHT TT, 1983, J IMMUNOL, V131, P1049; HUBBARD SC, 1986, P NATL ACAD SCI USA, V83, P1852, DOI 10.1073/pnas.83.6.1852; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; JAIN J, 1992, J EXP MED, V175, P853, DOI 10.1084/jem.175.3.853; JENKINS MK, 1991, J IMMUNOL, V147, P2461; JENKINS MK, 1987, J EXP MED, V165, P302, DOI 10.1084/jem.165.2.302; KAMPS MP, 1990, MOL CELL BIOL, V10, P5464, DOI 10.1128/MCB.10.10.5464; Kang S.-G., UNPUB; KANG SM, 1992, SCIENCE, V256, P1452, DOI 10.1126/science.1604322; KANG SM, 1992, MOL CELL BIOL, V12, P3149, DOI 10.1128/MCB.12.7.3149; KOULOVA L, 1991, J EXP MED, V173, P759, DOI 10.1084/jem.173.3.759; KRONKE M, 1985, J EXP MED, V161, P1593, DOI 10.1084/jem.161.6.1593; LAFFERTY KJ, 1983, ANNU REV IMMUNOL, V1, P143, DOI 10.1146/annurev.iy.01.040183.001043; LAFFERTY KJ, 1975, AUST J EXP BIOL MED, V53, P27, DOI 10.1038/icb.1975.3; LAMB JR, 1983, J EXP MED, V157, P1434, DOI 10.1084/jem.157.5.1434; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LENARDO M, UNPUB; LENARDO MJ, 1988, P NATL ACAD SCI USA, V85, P8825, DOI 10.1073/pnas.85.23.8825; LINDSTEN T, 1989, SCIENCE, V244, P339, DOI 10.1126/science.2540528; LINSLEY PS, 1990, P NATL ACAD SCI USA, V87, P5031, DOI 10.1073/pnas.87.13.5031; LIU Y, 1992, J EXP MED, V175, P437, DOI 10.1084/jem.175.2.437; LO D, 1989, J EXP MED, V170, P87, DOI 10.1084/jem.170.1.87; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MARTIN PJ, 1986, J IMMUNOL, V136, P3282; MORAHAN G, 1989, NATURE, V339, P622, DOI 10.1038/339622a0; MUEGGE K, 1989, SCIENCE, V246, P249, DOI 10.1126/science.2799385; MUELLER DL, 1989, ANNU REV IMMUNOL, V7, P445, DOI 10.1146/annurev.iy.07.040189.002305; MUELLER DL, 1989, J IMMUNOL, V142, P2617; NOSSAL GJV, 1980, P NATL ACAD SCI USA, V77, P16026; OTTEN GR, 1991, SCIENCE, V251, P1228, DOI 10.1126/science.1900952; PIERCE JW, 1988, P NATL ACAD SCI USA, V85, P1482, DOI 10.1073/pnas.85.5.1482; QUILL H, 1987, J IMMUNOL, V138, P3704; RADLER-POHL A, 1990, New Biologist, V2, P566; RAMMENSEE HG, 1989, NATURE, V339, P541, DOI 10.1038/339541a0; RAMSDELL F, 1989, SCIENCE, V246, P1038, DOI 10.1126/science.2511629; RANDAK C, 1990, EMBO J, V9, P2529, DOI 10.1002/j.1460-2075.1990.tb07433.x; REISER H, 1992, P NATL ACAD SCI USA, V89, P271, DOI 10.1073/pnas.89.1.271; ROCHA B, 1991, SCIENCE, V251, P1225, DOI 10.1126/science.1900951; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SERFLING E, 1989, EMBO J, V8, P465, DOI 10.1002/j.1460-2075.1989.tb03399.x; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; SHIBUYA H, 1989, NUCLEIC ACIDS RES, V17, P9173, DOI 10.1093/nar/17.22.9173; SHIBUYA H, 1989, INT IMMUNOL, V1, P143; SITKOVSKY MV, 1982, J IMMUNOL, V129, P1372; TOMONARI K, 1985, CELL IMMUNOL, V96, P147, DOI 10.1016/0008-8749(85)90347-8; ULLMAN KS, 1991, SCIENCE, V254, P558, DOI 10.1126/science.1683003; WILLIAMS TM, 1988, J IMMUNOL, V141, P662	79	336	357	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 21	1992	257	5073					1134	1138		10.1126/science.257.5073.1134	http://dx.doi.org/10.1126/science.257.5073.1134			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JJ884	1509265				2022-12-01	WOS:A1992JJ88400038
J	LAI, ZC; RUBIN, GM				LAI, ZC; RUBIN, GM			NEGATIVE CONTROL OF PHOTORECEPTOR DEVELOPMENT IN DROSOPHILA BY THE PRODUCT OF THE YAN GENE, AN ETS DOMAIN PROTEIN	CELL			English	Article							CELL-CELL-INTERACTION; TYROSINE-KINASE; DNA-BINDING; SEVENLESS PROTEIN; FATE; EYE; EXPRESSION; RECEPTOR; MELANOGASTER; ONCOGENE	Loss-of-function mutations in the yan gene result in the differentiation of supernumerary photoreceptors in the Drosophila eye. The yan gene encodes a protein with an ETS DNA-binding domain that accumulates in the nuclei of undifferentiated cells during the early stages of eye development. Our data suggest that yan functions as a cell-autonomous negative regulator of photoreceptor development; in the presumptive R7 and cone cells, yan appears to act antagonistically to the proneural signal mediated by sevenless and Ras1.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley	LAI, ZC (corresponding author), UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,BERKELEY,CA 94720, USA.			Rubin, Gerald/0000-0001-8762-8703				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BANERJEE U, 1987, CELL, V49, P281, DOI 10.1016/0092-8674(87)90569-1; BANERJEE U, 1990, NEURON, V4, P177, DOI 10.1016/0896-6273(90)90093-U; BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; BIER E, 1988, SCIENCE, V240, P913, DOI 10.1126/science.3129785; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; CAGAN RL, 1989, DEV BIOL, V136, P346, DOI 10.1016/0012-1606(89)90261-3; CARTHEW RW, 1990, CELL, V63, P561, DOI 10.1016/0092-8674(90)90452-K; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; FISCHERVIZE JA, 1992, DEVELOPMENT, V115, P89; FORTINI ME, 1992, NATURE, V355, P559, DOI 10.1038/355559a0; FORTINI ME, 1990, GENE DEV, V4, P444, DOI 10.1101/gad.4.3.444; FREEMAN M, 1992, CELL, V69, P963, DOI 10.1016/0092-8674(92)90615-J; FREEMAN M, 1992, IN PRESS DEVELOPMENT; GAUL U, 1992, CELL, V68, P1007, DOI 10.1016/0092-8674(92)90073-L; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HAFEN E, 1987, SCIENCE, V236, P55, DOI 10.1126/science.2882603; HART AC, 1990, GENE DEV, V4, P1835, DOI 10.1101/gad.4.11.1835; KIMMEL BE, 1990, GENE DEV, V4, P712, DOI 10.1101/gad.4.5.712; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KRAMER H, 1991, NATURE, V352, P207, DOI 10.1038/352207a0; LAI ZC, 1991, MECH DEVELOP, V34, P123, DOI 10.1016/0925-4773(91)90049-C; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LOWY DR, 1991, TRENDS GENET, V7, P346, DOI 10.1016/0168-9525(91)90253-M; MLODZIK M, 1992, METHODS NEUROSCIENCE, V9, P397; PATEL NH, 1989, GENE DEV, V3, P890, DOI 10.1101/gad.3.6.890; PRIBYL LJ, 1988, DEV BIOL, V127, P45, DOI 10.1016/0012-1606(88)90187-X; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; REDDY ESP, 1988, ONCOGENE RES, V3, P239; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; REINKE R, 1988, CELL, V55, P321, DOI 10.1016/0092-8674(88)90055-4; ROBERTSON HM, 1988, GENETICS, V118, P461; ROBINOW S, 1991, J NEUROBIOL, V22, P443, DOI 10.1002/neu.480220503; ROGGE RD, 1991, CELL, V64, P39, DOI 10.1016/0092-8674(91)90207-F; RUBIN GM, 1991, TRENDS GENET, V7, P372, DOI 10.1016/0168-9525(91)90258-R; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; TOMLINSON A, 1987, DEV BIOL, V120, P366, DOI 10.1016/0012-1606(87)90239-9; TOMLINSON A, 1987, DEV BIOL, V123, P264, DOI 10.1016/0012-1606(87)90448-9; TOMLINSON A, 1986, SCIENCE, V231, P400, DOI 10.1126/science.231.4736.400; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; VANVACTOR DL, 1991, CELL, V67, P1145, DOI 10.1016/0092-8674(91)90291-6; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862	50	235	238	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 21	1992	70	4					609	620		10.1016/0092-8674(92)90430-K	http://dx.doi.org/10.1016/0092-8674(92)90430-K			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JJ886	1505027				2022-12-01	WOS:A1992JJ88600010
J	LANKER, S; BUSHMAN, JL; HINNEBUSCH, AG; TRACHSEL, H; MUELLER, PP				LANKER, S; BUSHMAN, JL; HINNEBUSCH, AG; TRACHSEL, H; MUELLER, PP			AUTOREGULATION OF THE YEAST LYSYL-TRANSFER RNA-SYNTHETASE GENE GCD5/KRS1 BY TRANSLATIONAL AND TRANSCRIPTIONAL CONTROL MECHANISMS	CELL			English	Article							AMINO-ACID BIOSYNTHESIS; GCN4 MESSENGER-RNA; SACCHAROMYCES-CEREVISIAE; INITIATION-FACTOR; PROTEIN-SYNTHESIS; MUTATIONS; DNA; SPECIFICITY; EXPRESSION; REPRESSOR	We cloned the GCD5 gene of S. cerevisiae and found it to be identical to KRS1, which encodes lysyl-tRNA synthetase (LysRS). The mutation gcd5-1 changes a conserved residue in the putative lysine-binding domain of LysRS. This leads to a defect in lysine binding and, consequently, to reduced charging of tRNA(Lys). Mutant gcd5-1 cells compensate for the defect in LysRS by increasing GCN4 expression at the translational level. GCN4 protein in turn stimulates transcription of GCD5, leading to increased LysRS activity. We propose an autoregulatory model in which uncharged tRNA(Lys) stimulates the protein kinase GCN2, a translational activator of GCN4, and thereby increases transcription of GCD5 and other genes regulated by GCN4.	NICHHD,MOLEC GENET LOWER EUKARYOTES SECT,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	LANKER, S (corresponding author), UNIV BERN,INST BIOCHEM & MOLEC BIOL,CH-3000 BERN 9,SWITZERLAND.		Mueller, Peter P./H-8656-2019	Mueller, Peter P./0000-0002-1209-7546				ABASTADO JP, 1991, MOL CELL BIOL, V11, P486, DOI 10.1128/MCB.11.1.486; ANSELME J, 1991, FEBS LETT, V280, P163, DOI 10.1016/0014-5793(91)80228-U; BURBAUM JJ, 1991, J BIOL CHEM, V266, P16965; CIGAN AM, 1991, MOL CELL BIOL, V11, P3217, DOI 10.1128/MCB.11.6.3217; CIRAKOGLU B, 1985, EUR J BIOCHEM, V149, P353; COLTHURST DR, 1987, EUR J BIOCHEM, V166, P357, DOI 10.1111/j.1432-1033.1987.tb13523.x; CUSACK S, 1991, NUCLEIC ACIDS RES, V19, P3489, DOI 10.1093/nar/19.13.3489; CUSACK S, 1990, NATURE, V347, P249, DOI 10.1038/347249a0; DELFORGE J, 1975, EUR J BIOCHEM, V57, P231, DOI 10.1111/j.1432-1033.1975.tb02295.x; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; FOIANI M, 1991, MOL CELL BIOL, V11, P3203, DOI 10.1128/MCB.11.6.3203; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HINNEBUSCH AG, 1984, P NATL ACAD SCI-BIOL, V81, P6442, DOI 10.1073/pnas.81.20.6442; HINNEBUSCH AG, 1985, MOL CELL BIOL, V5, P2349, DOI 10.1128/MCB.5.9.2349; HINNEBUSCH AG, 1990, TRENDS BIOCHEM SCI, V15, P148, DOI 10.1016/0968-0004(90)90215-W; HINNEBUSCH AG, 1988, MICROBIOL REV, V52, P248, DOI 10.1128/MMBR.52.2.248-273.1988; HINNEBUSCH AG, 1991, TRANSLATION EUKARYOT, P243; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; KAST P, 1991, J MOL BIOL, V222, P99, DOI 10.1016/0022-2836(91)90740-W; MARTINEZ R, 1991, MOL GEN GENET, V227, P149, DOI 10.1007/BF00260720; MIRANDE M, 1988, J BIOL CHEM, V263, P18443; MOLDAVE K, 1985, ANNU REV BIOCHEM, V54, P1109, DOI 10.1146/annurev.bi.54.070185.005333; MUELLER PP, 1986, CELL, V45, P201, DOI 10.1016/0092-8674(86)90384-3; MUESSDOERFFER F, 1983, J BIOL CHEM, V258, P6293; NIEDERBERGER P, 1986, CURR GENET, V10, P657, DOI 10.1007/BF00410913; PADDON CJ, 1989, GENETICS, V122, P543; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; Sherman F., 1986, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; THIEROS B, 1984, P NATL ACAD SCI USA, V81, P5096; TZAMARIAS D, 1989, CELL, V57, P947, DOI 10.1016/0092-8674(89)90333-4; WEK RC, 1989, P NATL ACAD SCI USA, V86, P4579, DOI 10.1073/pnas.86.12.4579; WILLIAMS NP, 1989, P NATL ACAD SCI USA, V86, P7515, DOI 10.1073/pnas.86.19.7515; WOLFNER M, 1975, J MOL BIOL, V96, P273, DOI 10.1016/0022-2836(75)90348-4	39	48	52	1	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 21	1992	70	4					647	657		10.1016/0092-8674(92)90433-D	http://dx.doi.org/10.1016/0092-8674(92)90433-D			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JJ886	1505029				2022-12-01	WOS:A1992JJ88600013
J	LIU, YJ; PETER, D; ROGHANI, A; SCHULDINER, S; PRIVE, GG; EISENBERG, D; BRECHA, N; EDWARDS, RH				LIU, YJ; PETER, D; ROGHANI, A; SCHULDINER, S; PRIVE, GG; EISENBERG, D; BRECHA, N; EDWARDS, RH			A CDNA THAT SUPPRESSES MPP+ TOXICITY ENCODES A VESICULAR AMINE TRANSPORTER	CELL			English	Article							ORGAN SYNAPTIC VESICLES; GAMMA-AMINOBUTYRIC ACID; CHROMAFFIN GRANULES; PARKINSONS-DISEASE; ESCHERICHIA-COLI; RAT-BRAIN; RESERPINE BINDING; NEUROTOXIN 1-METHYL-4-PHENYLPYRIDINIUM; DIHYDROTETRABENAZINE BINDING; TETRACYCLINE-RESISTANCE	Classical neurotransmitters are transported into synaptic vesicles so that their release can be regulated by neural activity. In addition, the vesicular transport of biogenic amines modulates susceptibility to N-methyl-4-phenylpyridinium (MPP+), the active metabolite of the neurotoxin N-methyl-1,2,3,6-tetrahydropyridine that produces a model of Parkinson's disease. Taking advantage of selection in MPP+, we have used gene transfer followed by plasmid rescue to identify a cDNA clone that encodes a vesicular amine transporter. The sequence predicts a novel mammalian protein with 12 transmembrane domains and homology to a class of bacterial drug resistance transporters. We have detected messenger RNA transcripts for this transporter only in the adrenal gland. Monoamine cell populations in the brain stem express a distinct but highly related protein.	HEBREW UNIV JERUSALEM,INST LIFE SCI,IL-91904 JERUSALEM,ISRAEL; VET ADM MED CTR BRENTWOOD,LOS ANGELES,CA 90073; UNIV CALIF LOS ANGELES,SCH MED,INST MOLEC BIOL,DEPT MICROBIOL & IMMUNOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,INST MOLEC BIOL,DEPT CHEM & BIOCHEM,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,INST MOLEC BIOL,DEPT ANAT,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,INST EXTRATERR PHYS,DEPT CELL BIOL & MED,LOS ANGELES,CA 90024	Hebrew University of Jerusalem; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	LIU, YJ (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,INST MOLEC BIOL,DEPT NEUROL,LOS ANGELES,CA 90024, USA.		Liu, Yongjian/J-7852-2018; Schuldiner, Shimon/F-7628-2012	Schuldiner, Shimon/0000-0002-4874-6237; Prive, Gilbert/0000-0002-0712-4319	NATIONAL EYE INSTITUTE [R01EY004067] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY004067] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANDERSON DC, 1983, MOL PHARMACOL, V24, P48; ANDERSON DC, 1982, BIOCHEMISTRY-US, V21, P3037, DOI 10.1021/bi00256a001; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; AXELROD J, 1961, SCIENCE, V133, P383, DOI 10.1126/science.133.3450.383; BLAKELY RD, 1991, NATURE, V354, P66, DOI 10.1038/354066a0; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BURGER PM, 1991, NEURON, V7, P287, DOI 10.1016/0896-6273(91)90267-4; CALAMIA J, 1990, P NATL ACAD SCI USA, V87, P4937, DOI 10.1073/pnas.87.13.4937; CARLSON MD, 1989, J BIOL CHEM, V264, P7369; CARLSSON A, 1963, ACTA PHYSL SCAND S, V215, P1; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHRISTENSEN H, 1990, J NEUROCHEM, V54, P1142, DOI 10.1111/j.1471-4159.1990.tb01941.x; COHEN G, 1990, J NEURAL TRANSM-SUPP, V32, P229; COX KH, 1984, DEV BIOL, V101, P485, DOI 10.1016/0012-1606(84)90162-3; DANIELS AJ, 1988, J BIOL CHEM, V263, P5034; DARCHEN F, 1989, BIOCHEMISTRY-US, V28, P1692, DOI 10.1021/bi00430a040; DECAMILLI P, 1990, ANNU REV PHYSIOL, V52, P625, DOI 10.1146/annurev.ph.52.030190.003205; DELATORRE JC, 1980, J NEUROSCI METH, V3, P1, DOI 10.1016/0165-0270(80)90029-1; DENTON T, 1987, J NEUROCHEM, V49, P622, DOI 10.1111/j.1471-4159.1987.tb02909.x; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; Frize E.D., 1954, NEW ENGL J MED, V251, P1006; FYKSE EM, 1988, J NEUROCHEM, V50, P1237, DOI 10.1111/j.1471-4159.1988.tb10599.x; GIROS B, 1991, FEBS LETT, V295, P149, DOI 10.1016/0014-5793(91)81406-X; GREENE LA, 1977, BRAIN RES, V129, P247, DOI 10.1016/0006-8993(77)90005-1; GRIBSKOV M, 1987, P NATL ACAD SCI USA, V84, P4355, DOI 10.1073/pnas.84.13.4355; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; HEIKKILA RE, 1984, NATURE, V311, P467, DOI 10.1038/311467a0; HELL JW, 1988, EMBO J, V7, P3023, DOI 10.1002/j.1460-2075.1988.tb03166.x; HOFFMAN BJ, 1991, SCIENCE, V254, P579, DOI 10.1126/science.1948036; Hokfelt T., 1984, HDB CHEM NEUROANATOM; ISAMBERT MF, 1992, BIOCHEMISTRY-US, V31, P1980, DOI 10.1021/bi00122a012; JAVITCH JA, 1985, P NATL ACAD SCI USA, V82, P2173, DOI 10.1073/pnas.82.7.2173; JOHANNESSEN JN, 1985, LIFE SCI, V36, P219, DOI 10.1016/0024-3205(85)90062-1; JOHNSON RG, 1988, PHYSIOL REV, V68, P232, DOI 10.1152/physrev.1988.68.1.232; KABACK HR, 1990, TRENDS BIOCHEM SCI, V15, P309; KANEKO M, 1985, FEBS LETT, V193, P194, DOI 10.1016/0014-5793(85)80149-6; KANNER BI, 1987, CRIT REV BIOCHEM MOL, V22, P1, DOI 10.3109/10409238709082546; KELLY R B, 1991, Current Opinion in Cell Biology, V3, P654, DOI 10.1016/0955-0674(91)90037-Y; KILTY JE, 1991, SCIENCE, V254, P578, DOI 10.1126/science.1948035; KIRSHNER N, 1962, J BIOL CHEM, V237, P2311; KISH PE, 1989, P NATL ACAD SCI USA, V86, P3877, DOI 10.1073/pnas.86.10.3877; KNIGGE KM, 1977, BRAIN RES, V120, P393, DOI 10.1016/0006-8993(77)90394-8; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KRUEGER MJ, 1990, BIOCHEM BIOPH RES CO, V169, P123, DOI 10.1016/0006-291X(90)91442-U; LANGSTON JW, 1983, SCIENCE, V219, P979, DOI 10.1126/science.6823561; LANGSTON JW, 1984, SCIENCE, V225, P1480, DOI 10.1126/science.6332378; LIU Y, 1992, IN PRESS P NATL ACAD, V89; MARKEY SP, 1984, NATURE, V311, P464, DOI 10.1038/311464a0; MAYCOX PR, 1988, J BIOL CHEM, V263, P15423; MICHEL PP, 1990, J NEUROSCI RES, V26, P428, DOI 10.1002/jnr.490260405; MIZUNO Y, 1989, BIOCHEM BIOPH RES CO, V163, P1450, DOI 10.1016/0006-291X(89)91141-8; NAITO S, 1983, J BIOL CHEM, V258, P696; NEYFAKH AA, 1991, P NATL ACAD SCI USA, V88, P4781, DOI 10.1073/pnas.88.11.4781; NGUYEN TT, 1983, GENE, V25, P83, DOI 10.1016/0378-1119(83)90170-1; OZAWA T, 1990, BIOCHEM BIOPH RES CO, V172, P483, DOI 10.1016/0006-291X(90)90698-M; PACHOLCZYK T, 1991, NATURE, V350, P350, DOI 10.1038/350350a0; PARKER WD, 1989, ANN NEUROL, V26, P719, DOI 10.1002/ana.410260606; RAMSAY RR, 1986, J BIOL CHEM, V261, P7585; RAMSAY RR, 1991, J NEUROCHEM, V56, P1184, DOI 10.1111/j.1471-4159.1991.tb11409.x; REINHARD JF, 1987, P NATL ACAD SCI USA, V84, P8160, DOI 10.1073/pnas.84.22.8160; ROSENBERG PA, 1988, J NEUROSCI, V8, P2887, DOI 10.1523/jneurosci.08-08-02887.1988; RUDNICK G, 1990, BIOCHEMISTRY-US, V29, P603, DOI 10.1021/bi00455a002; RUDNICK G, 1992, P NATL ACAD SCI USA, V89, P1817, DOI 10.1073/pnas.89.5.1817; RUDNICK G, 1986, ANNU REV PHYSIOL, V48, P403; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHERMAN D, 1986, J NEUROCHEM, V47, P331; SCHERMAN D, 1984, MOL PHARMACOL, V25, P113; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SHIMADA S, 1991, SCIENCE, V254, P576, DOI 10.1126/science.1948034; SHOFFNER JM, 1991, ANN NEUROL, V30, P332, DOI 10.1002/ana.410300304; SNYDER SH, 1986, MPTP NEUROTOXIN PROD, P191; STERNBACH Y, 1990, J BIOL CHEM, V265, P3961; STERNINI C, 1989, GASTROENTEROLOGY, V97, P348, DOI 10.1016/0016-5085(89)90070-X; SULZER D, 1990, NEURON, V5, P797, DOI 10.1016/0896-6273(90)90339-H; TANNER CM, 1990, NEUROLOGY, V40, P17; TRIMBLE WS, 1991, ANNU REV NEUROSCI, V14, P93, DOI 10.1146/annurev.ne.14.030191.000521; VINCENT MS, 1991, MOL PHARMACOL, V40, P889; WEAVER JA, 1982, EUR J PHARMACOL, V80, P437, DOI 10.1016/0014-2999(82)90093-0; YAMAGUCHI A, 1990, J BIOL CHEM, V265, P15525; [No title captured]; 1989, NEW ENGL J MED, V321, P1364	85	527	543	1	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 21	1992	70	4					539	551		10.1016/0092-8674(92)90425-C	http://dx.doi.org/10.1016/0092-8674(92)90425-C			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JJ886	1505023				2022-12-01	WOS:A1992JJ88600005
J	MEZARD, C; POMPON, D; NICOLAS, A				MEZARD, C; POMPON, D; NICOLAS, A			RECOMBINATION BETWEEN SIMILAR BUT NOT IDENTICAL DNA-SEQUENCES DURING YEAST TRANSFORMATION OCCURS WITHIN SHORT STRETCHES OF IDENTITY	CELL			English	Article							DOUBLE-STRAND BREAKS; HUMAN ARGININOSUCCINATE LYASE; AMINO-ACID-SEQUENCES; MISMATCH REPAIR GENE; MOUSE L-CELLS; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; STREPTOCOCCUS-PNEUMONIAE; HOMOLOGOUS RECOMBINATION	Interactions between similar but not identical (homeologous) DNA sequences play an important biological role in the evolution of genes and genomes. To gain insight into the underlying molecular mechanism(s) of genetic recombination, we have studied inter- and intramolecular homeologous recombination in S. cerevisiae during transformation. We found that homeologous DNAs recombine efficiently. Hybrid sequences were obtained between two mammalian cytochrome P450 cDNAs, sharing 73% identity, and between the yeast ARG4 gene and its human homeologous cDNA, sharing 52% identity. Sequencing data showed that the preferred recombination events are those corresponding to the overall alignment of the DNA sequences and that the junctions are within stretches of identity of variable length (2-21 nt). We suggest that these events occur by a conventional homologous recombination mechanism.	UNIV PIERRE & MARIE CURIE,PROPRE ASSOCIE LAB,CNRS,CTR GENET MOLEC,F-91190 GIF SUR YVETTE,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Saclay	MEZARD, C (corresponding author), UNIV PARIS 11,INST GENET & MICROBIOL,F-91405 ORSAY,FRANCE.							AHN BY, 1988, MOL CELL BIOL, V8, P2442, DOI 10.1128/MCB.8.6.2442; AUASUBEL FM, 1987, CURRENT PROTOCOLS MO; BAILIS AM, 1990, GENETICS, V126, P535; BAUER GA, 1988, J BIOL CHEM, V263, P917; BEACHAM IR, 1984, GENE, V29, P271, DOI 10.1016/0378-1119(84)90056-8; BOYER HW, 1969, J MOL BIOL, V41, P459, DOI 10.1016/0022-2836(69)90288-5; BURGERS PMJ, 1988, J BIOL CHEM, V263, P8099; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; CHEVALLIER MR, 1979, FEBS LETT, V108, P179, DOI 10.1016/0014-5793(79)81204-1; CLAVERYS JP, 1986, MICROBIOL REV, V50, P133, DOI 10.1128/MMBR.50.2.133-165.1986; CULLIN C, 1988, GENE, V65, P203, DOI 10.1016/0378-1119(88)90457-X; DOUTRIAUX MP, 1986, P NATL ACAD SCI USA, V83, P2576, DOI 10.1073/pnas.83.8.2576; DOWSON CG, 1989, P NATL ACAD SCI USA, V86, P8842, DOI 10.1073/pnas.86.22.8842; DYKSTRA CC, 1990, J BIOL CHEM, V265, P10968; ERNST JF, 1981, P NATL ACAD SCI-BIOL, V78, P6334, DOI 10.1073/pnas.78.10.6334; FISHMANLOBELL J, 1992, MOL CELL BIOL, V12, P1292, DOI 10.1128/MCB.12.3.1292; GLICKMAN BW, 1980, P NATL ACAD SCI-BIOL, V77, P1063, DOI 10.1073/pnas.77.2.1063; GOGUEL V, 1992, MOL CELL BIOL, V12, P696, DOI 10.1128/MCB.12.2.696; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; HSIAO CL, 1979, P NATL ACAD SCI USA, V76, P3829, DOI 10.1073/pnas.76.8.3829; IOANNIDES C, 1990, DRUG METAB REV, V22, P1, DOI 10.3109/03602539008991444; JACOBSEN H, 1974, EUR J BIOCHEM, V45, P623, DOI 10.1111/j.1432-1033.1974.tb03588.x; JOHNSON AW, 1991, J BIOL CHEM, V266, P14046; KARIMOVA GA, 1985, MOL GENET MIKROBIOL, V10, P29; KIMURA S, 1984, J BIOL CHEM, V259, P705; KOLODNER R, 1987, P NATL ACAD SCI USA, V84, P5560, DOI 10.1073/pnas.84.16.5560; KRAMER W, 1989, J BACTERIOL, V171, P5339, DOI 10.1128/jb.171.10.5339-5346.1989; KUCHERLAPATI R, 1988, GENETIC RECOMBINATIO; KUNES S, 1984, COLD SPRING HARB SYM, V49, P617, DOI 10.1101/SQB.1984.049.01.070; LAU PP, 1979, NUCLEIC ACIDS RES, V6, P331, DOI 10.1093/nar/6.1.331; LIN FL, 1984, MOL CELL BIOL, V4, P1020, DOI 10.1128/MCB.4.6.1020; LIN FLM, 1990, MOL CELL BIOL, V10, P103, DOI 10.1128/MCB.10.1.103; LISKAY RM, 1987, GENETICS, V115, P161; MANKOVICH JA, 1989, J BACTERIOL, V171, P5325, DOI 10.1128/jb.171.10.5325-5331.1989; MARYON E, 1991, MOL CELL BIOL, V11, P3278, DOI 10.1128/MCB.11.6.3278; MATUO S, 1988, FEBS LETT, V234, P395, DOI 10.1016/0014-5793(88)80124-8; MAUTNER V, 1984, VIROLOGY, V139, P43, DOI 10.1016/0042-6822(84)90328-3; Miller JH., 1972, EXPT MOL GENETICS; MUNZ P, 1981, A BENZON S, V16, P264; NICKOLOFF JA, 1989, J MOL BIOL, V207, P527, DOI 10.1016/0022-2836(89)90462-2; OBRIEN WE, 1986, P NATL ACAD SCI USA, V83, P7211, DOI 10.1073/pnas.83.19.7211; ORRWEAVER TL, 1985, MICROBIOL REV, V49, P33, DOI 10.1128/MMBR.49.1.33-58.1985; ORRWEAVER TL, 1981, P NATL ACAD SCI-BIOL, V78, P6354, DOI 10.1073/pnas.78.10.6354; OZENBERGER BA, 1991, MOL CELL BIOL, V11, P1222, DOI 10.1128/MCB.11.3.1222; POMPON D, 1989, GENE, V83, P15, DOI 10.1016/0378-1119(89)90399-5; POMPON D, 1988, EUR J BIOCHEM, V177, P285, DOI 10.1111/j.1432-1033.1988.tb14375.x; PRUDHOMME M, 1989, J BACTERIOL, V171, P5332, DOI 10.1128/jb.171.10.5332-5338.1989; RADMAN M, 1988, GENETIC RECOMBINATIO, P169; RAYSSIGUIER C, 1989, NATURE, V342, P396, DOI 10.1038/342396a0; RAYSSIGUIER C, 1990, BIOCHIMIE, V73, P371; RESNICK MA, 1989, P NATL ACAD SCI USA, V86, P2276, DOI 10.1073/pnas.86.7.2276; RUBNITZ J, 1984, MOL CELL BIOL, V5, P529; RUDIN N, 1989, GENETICS, V122, P519; RUDOLPH H, 1985, GENE, V36, P87, DOI 10.1016/0378-1119(85)90072-1; Sambrook J., 1989, MOL CLONING LAB MANU; SCHIESTL RH, 1991, P NATL ACAD SCI USA, V88, P7585, DOI 10.1073/pnas.88.17.7585; SHEN P, 1986, GENETICS, V112, P441; SHEN P, 1989, MOL GEN GENET, V218, P358, DOI 10.1007/BF00331291; Sherman F., 1986, METHODS YEAST GENETI; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SUGAWARA N, 1992, MOL CELL BIOL, V12, P563, DOI 10.1128/MCB.12.2.563; SUN H, 1991, CELL, V64, P1155, DOI 10.1016/0092-8674(91)90270-9; SUN H, 1989, NATURE, V338, P87, DOI 10.1038/338087a0; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WALDMAN AS, 1987, P NATL ACAD SCI USA, V84, P5340, DOI 10.1073/pnas.84.15.5340; WALDMAN AS, 1988, MOL CELL BIOL, V8, P5350, DOI 10.1128/MCB.8.12.5350; WATT VM, 1985, P NATL ACAD SCI USA, V82, P4766; WHEELER CJ, 1990, NATURE, V347, P192, DOI 10.1038/347192a0; WHITE CI, 1990, EMBO J, V9, P663, DOI 10.1002/j.1460-2075.1990.tb08158.x; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	72	110	124	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 21	1992	70	4					659	670		10.1016/0092-8674(92)90434-E	http://dx.doi.org/10.1016/0092-8674(92)90434-E			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JJ886	1505030				2022-12-01	WOS:A1992JJ88600014
J	NAKAMURA, Y; KOMATSU, N; NAKAUCHI, H				NAKAMURA, Y; KOMATSU, N; NAKAUCHI, H			A TRUNCATED ERYTHROPOIETIN RECEPTOR THAT FAILS TO PREVENT PROGRAMMED CELL-DEATH OF ERYTHROID-CELLS	SCIENCE			English	Article							BONE-MARROW; CLONING; EXPRESSION; GENE; MEGAKARYOCYTES; ESTABLISHMENT; GROWTH; LINE; RAT	A form of the human erythropoietin receptor (EPOR) was identified in which the cytoplasmic region is truncated by alternative splicing. The truncated form of the receptor (EPOR-T) is the most prevalent form of EPOR in early-stage erythroid progenitor cells, but the full-length EPOR (EPOR-F) becomes the most prevalent form in late-stage progenitors. EPOR-T can transduce a mitogenic signal. However, cells transfected with EPOR-T are more prone to programmed cell death than those expressing EPOR-F. EPOR-F may transduce a signal to prevent programmed cell death that is independent of the mitogenic signal, and alternative splicing of the EPOR gene may have an important role in erythropoiesis.	INST PHYS & CHEM RES RIKEN, TSUKUBA LIFE SCI CTR, CELL GROWTH & DIFFERENTIAT LAB, 3-1-1 KOYADAI, TSUKUBA, JAPAN	RIKEN			Nakamura, Yukio/A-5263-2016	Nakamura, Yukio/0000-0001-8056-4946				BERRIDGE MV, 1988, BLOOD, V72, P970; DANDREA AD, 1991, MOL CELL BIOL, V11, P1980, DOI 10.1128/MCB.11.4.1980; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; FERNANDEZBOTRAN R, 1991, J EXP MED, V174, P673, DOI 10.1084/jem.174.3.673; FRASER JK, 1989, EXP HEMATOL, V17, P10; GREGORY CJ, 1976, J CELL PHYSIOL, V89, P289, DOI 10.1002/jcp.1040890212; HEATH DS, 1976, BLOOD, V47, P777; JONES SS, 1990, BLOOD, V76, P31; KOMATSU N, 1991, CANCER RES, V51, P341; KOURY MJ, 1988, J CELL PHYSIOL, V137, P65, DOI 10.1002/jcp.1041370108; KOURY MJ, 1990, SCIENCE, V248, P378, DOI 10.1126/science.2326648; LANDSCHULZ KT, 1989, BLOOD, V73, P1476; LOKEN MR, 1987, BLOOD, V69, P255; MAOUCHE L, 1991, BLOOD, V78, P2557; NOGUCHI CT, 1991, BLOOD, V78, P2548; OKUNO Y, 1990, CANCER, V66, P1544, DOI 10.1002/1097-0142(19901001)66:7<1544::AID-CNCR2820660719>3.0.CO;2-9; PARACIOS R, 1985, CELL, V41, P727; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; WINKELMANN JC, 1990, BLOOD, V76, P24; YOSHIMURA A, 1990, NATURE, V348, P647, DOI 10.1038/348647a0; [No title captured]	21	161	166	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 21	1992	257	5073					1138	1141		10.1126/science.257.5073.1138	http://dx.doi.org/10.1126/science.257.5073.1138			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JJ884	1324524				2022-12-01	WOS:A1992JJ88400039
J	NOSE, A; MAHAJAN, VB; GOODMAN, CS				NOSE, A; MAHAJAN, VB; GOODMAN, CS			CONNECTIN - A HOMOPHILIC CELL-ADHESION MOLECULE EXPRESSED ON A SUBSET OF MUSCLES AND THE MOTONEURONS THAT INNERVATE THEM IN DROSOPHILA	CELL			English	Article							MEMBRANE GLYCOPROTEIN-IB; AMINO-ACID SEQUENCE; LEUCINE-RICH ALPHA-2-GLYCOPROTEIN; SELECT APPROPRIATE PATHWAYS; VENTRAL PATTERN-FORMATION; CENTRAL-NERVOUS-SYSTEM; FACTOR-BINDING DOMAIN; GROWTH CONE GUIDANCE; GRASSHOPPER EMBRYO; VONWILLEBRAND-FACTOR	Each abdominal hemisegment in the Drosophila embryo contains a stereotyped array of 30 muscles, each specifically innervated by one or a few motoneurons. We screened 11,000 enhancer trap lines, isolated several expressing beta-galactosidase in small subsets of muscle fibers prior to innervation, and identified two of these as inserts in connectin and Toll, members of the leucine-rich repeat gene family. Connectin contains a signal sequence, ten leucine-rich repeats, and a putative phosphatidylinositol membrane linkage; in S2 cells, connectin can mediate homophilic cell adhesion. Connectin is expressed on the surface of eight muscles, the motoneurons that innervate them, and several glial cells along the pathways leading to them. During synapse formation, the protein localizes to synaptic sites; afterward, it largely disappears. Thus, connectin is a novel cell adhesion molecule whose expression suggests a role in target recognition.			NOSE, A (corresponding author), UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720, USA.				PHS HHS [18366] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANDERSON KV, 1985, CELL, V42, P779, DOI 10.1016/0092-8674(85)90274-0; BALL EE, 1985, DEV BIOL, V111, P383, DOI 10.1016/0012-1606(85)90492-0; BALL EE, 1985, J NEUROSCI, V5, P1808; BALL EE, 1985, DEV BIOL, V111, P399, DOI 10.1016/0012-1606(85)90493-2; BALL EE, 1985, DEV BIOL, V111, P417, DOI 10.1016/0012-1606(85)90494-4; BASTIANI MJ, 1987, CELL, V48, P745, DOI 10.1016/0092-8674(87)90072-9; BATE M, 1990, DEVELOPMENT, V110, P791; BELLEN HJ, 1989, GENE DEV, V3, P1288, DOI 10.1101/gad.3.9.1288; BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; BUNCH TA, 1988, NUCLEIC ACIDS RES, V16, P1043, DOI 10.1093/nar/16.3.1043; BURNS FR, 1991, NEURON, V7, P209, DOI 10.1016/0896-6273(91)90259-3; Campos-Ortega JA., 1997, EMBRYONIC DEV DROSOP; CASH S, 1992, J NEUROSCI, V12, P2051; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; Crossley AC, 1978, GENETICS BIOL DROS B, V2, P499; DOHRMANN C, 1990, GENE DEV, V4, P2098, DOI 10.1101/gad.4.12a.2098; EISEN JS, 1991, NEURON, V6, P767, DOI 10.1016/0896-6273(91)90173-W; EISEN JS, 1989, NEURON, V2, P1097, DOI 10.1016/0896-6273(89)90234-1; EISEN JS, 1986, NATURE, V320, P269, DOI 10.1038/320269a0; ELKINS T, 1990, CELL, V60, P565, DOI 10.1016/0092-8674(90)90660-7; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; FREDIEU JR, 1989, DEVELOPMENT, V106, P739; FURLEY AJ, 1990, CELL, V61, P157, DOI 10.1016/0092-8674(90)90223-2; GERTTULA S, 1988, GENETICS, V119, P123; GOULD AP, 1990, NATURE, V348, P308, DOI 10.1038/348308a0; GRENNINGLOH G, 1991, CELL, V67, P45, DOI 10.1016/0092-8674(91)90571-F; GRENNINGLOH G, 1990, COLD SH Q B, V55, P327; HALPERN ME, 1991, J NEUROSCI, V11, P3227; HANDA M, 1986, J BIOL CHEM, V261, P2579; HASHIMOTO C, 1991, DEVELOPMENT, V111, P1021; HASHIMOTO C, 1988, CELL, V52, P26; HATTA K, 1990, SCIENCE, V250, P802, DOI 10.1126/science.1978412; HO RK, 1983, NATURE, V301, P66, DOI 10.1038/301066a0; HORTSCH M, 1991, ANNU REV CELL BIOL, V7, P505, DOI 10.1146/annurev.cellbio.7.1.505; JESSELL TM, 1988, NEURON, V1, P3, DOI 10.1016/0896-6273(88)90204-8; JOHANSEN J, 1989, J NEUROSCI, V9, P710; JOHANSEN J, 1989, J NEUROSCI, V9, P4318; JOKERST RS, 1989, MOL GEN GENET, V215, P266, DOI 10.1007/BF00339727; KATAOKA T, 1985, CELL, V43, P493, DOI 10.1016/0092-8674(85)90179-5; KEITH FJ, 1990, EMBO J, V9, P4299, DOI 10.1002/j.1460-2075.1990.tb07878.x; KLAMBT C, 1991, CELL, V64, P801, DOI 10.1016/0092-8674(91)90509-W; KLAMBT C, 1991, GLIA, V4, P205, DOI 10.1002/glia.440040212; KRANTZ DE, 1990, EMBO J, V9, P1969, DOI 10.1002/j.1460-2075.1990.tb08325.x; LANCEJONES C, 1981, PROC R SOC SER B-BIO, V214, P19, DOI 10.1098/rspb.1981.0080; LANDMESSER LT, 1980, ANNU REV NEUROSCI, V3, P279, DOI 10.1146/annurev.ne.03.030180.001431; LEISS D, 1988, DEVELOPMENT, V104, P525; LIU DWC, 1990, J NEUROSCI, V10, P3947, DOI 10.1523/JNEUROSCI.10-12-03947.1990; LOPEZ JA, 1987, P NATL ACAD SCI USA, V84, P5615, DOI 10.1073/pnas.84.16.5615; LOPEZ JA, 1988, P NATL ACAD SCI USA, V85, P2135, DOI 10.1073/pnas.85.7.2135; MANIATIS T, 1978, CELL, V15, P687, DOI 10.1016/0092-8674(78)90036-3; MIKOL DD, 1990, J CELL BIOL, V110, P471, DOI 10.1083/jcb.110.2.471; MLODZIK M, 1990, CELL, V60, P211, DOI 10.1016/0092-8674(90)90737-Y; OKANE CJ, 1987, P NATL ACAD SCI USA, V84, P9123, DOI 10.1073/pnas.84.24.9123; PATEL NH, 1987, CELL, V48, P975, DOI 10.1016/0092-8674(87)90706-9; PIKE SH, 1990, J NEUROSCI, V10, P44; REINKE R, 1988, CELL, V52, P291, DOI 10.1016/0092-8674(88)90518-1; ROTHBERG JM, 1990, GENE DEV, V4, P2169, DOI 10.1101/gad.4.12a.2169; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEIDER DS, 1991, GENE DEV, V5, P797, DOI 10.1101/gad.5.5.797; SINK H, 1991, DEVELOPMENT, V113, P701; SINK H, 1991, J NEUROBIOL, V22, P298, DOI 10.1002/neu.480220309; SINK H, 1991, DEVELOPMENT, V112, P307; SNOW PM, 1989, CELL, V59, P313, DOI 10.1016/0092-8674(89)90293-6; SPINDLER KR, 1984, J VIROL, V49, P132, DOI 10.1128/JVI.49.1.132-141.1984; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; TAKAHASHI N, 1985, P NATL ACAD SCI USA, V82, P1906, DOI 10.1073/pnas.82.7.1906; TITANI K, 1987, P NATL ACAD SCI USA, V84, P5610, DOI 10.1073/pnas.84.16.5610; TOSNEY KW, 1985, J NEUROSCI, V5, P2345; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WICKI AN, 1985, EUR J BIOCHEM, V153, P1, DOI 10.1111/j.1432-1033.1985.tb09259.x; ZINN K, 1988, CELL, V53, P577, DOI 10.1016/0092-8674(88)90574-0	73	268	271	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 21	1992	70	4					553	567		10.1016/0092-8674(92)90426-D	http://dx.doi.org/10.1016/0092-8674(92)90426-D			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JJ886	1505024				2022-12-01	WOS:A1992JJ88600006
J	OVERDUIN, M; RIOS, CB; MAYER, BJ; BALTIMORE, D; COWBURN, D				OVERDUIN, M; RIOS, CB; MAYER, BJ; BALTIMORE, D; COWBURN, D			3-DIMENSIONAL SOLUTION STRUCTURE OF THE SRC HOMOLOGY-2 DOMAIN OF C-ABL	CELL			English	Article							NUCLEAR-MAGNETIC-RESONANCE; PROTEIN STRUCTURES; SH2 DOMAIN; ACTIVATION; P60C-SRC; BINDING; SITE; GAP	SH2 regions are protein motifs capable of binding target protein sequences that contain a phosphotyrosine. The solution structure of the abl SH2 product, a protein of 109 residues and 12.1 kd, has been determined by multidimensional nuclear magnetic resonance spectroscopy. It is a compact spherical domain with a pair of three-stranded antiparallel beta-sheets and a C-terminal alpha-helix enclosing the hydrophobic core. Three arginines project from a short N-terminal alpha-helix and one beta-sheet into the putative phosphotyrosine-binding site, which lies on a face distal from the termini. Comparison with other SH2 sequences supports a common global fold and mode of phosphotyrosine binding for this family.			OVERDUIN, M (corresponding author), ROCKEFELLER UNIV LABS, NEW YORK, NY 10021 USA.			Overduin, Michael/0000-0002-3114-6585; Cowburn, David/0000-0001-6770-7172	NCI NIH HHS [CA-51462] Funding Source: Medline; NIDDK NIH HHS [DK-20357] Funding Source: Medline; NIGMS NIH HHS [GM-47021] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051462] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK020357] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047021] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BRUNGER AT, 1992, XPLOR VERSION 3 0 MA; CLORE GM, 1989, CRIT REV BIOCHEM MOL, V24, P479, DOI 10.3109/10409238909086962; DALEY GQ, 1991, ADV CANCER RES, V57, P151; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; GUNTERT P, 1991, Journal of Biomolecular NMR, V1, P447, DOI 10.1007/BF02192866; GUNTERT P, 1991, J MOL BIOL, V217, P517, DOI 10.1016/0022-2836(91)90754-T; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KLIPPEL A, 1992, MOL CELL BIOL, V12, P1451, DOI 10.1128/MCB.12.4.1451; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; MARGOLIS B, 1992, CELL GROWTH DIFFER, V3, P73; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MATSUDA M, 1991, MOL CELL BIOL, V11, P1607, DOI 10.1128/MCB.11.3.1607; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; NILGES M, 1988, FEBS LETT, V239, P129, DOI 10.1016/0014-5793(88)80559-3; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; OBRIEN MC, 1990, MOL CELL BIOL, V10, P2855, DOI 10.1128/MCB.10.6.2855; OVERDUIN M, 1992, IN PRESS P NATL ACAD; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; ROSENBERG N, 1988, ADV VIRUS RES, V35, P39; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; WAGNER G, 1987, J MOL BIOL, V196, P611, DOI 10.1016/0022-2836(87)90037-4; WUTHRICK K, 1986, NMR PROTEINS NUCLEIC	29	163	170	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 21	1992	70	4					697	704		10.1016/0092-8674(92)90437-H	http://dx.doi.org/10.1016/0092-8674(92)90437-H			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JJ886	1505033				2022-12-01	WOS:A1992JJ88600017
J	PFAFFLE, RW; DIMATTIA, GE; PARKS, JS; BROWN, MR; WIT, JM; JANSEN, M; VANDERNAT, H; VANDENBRANDE, JL; ROSENFELD, MG; INGRAHAM, HA				PFAFFLE, RW; DIMATTIA, GE; PARKS, JS; BROWN, MR; WIT, JM; JANSEN, M; VANDERNAT, H; VANDENBRANDE, JL; ROSENFELD, MG; INGRAHAM, HA			MUTATION OF THE POU-SPECIFIC DOMAIN OF PIT-1 AND HYPOPITUITARISM WITHOUT PITUITARY HYPOPLASIA	SCIENCE			English	Article							THYROID STIMULATING HORMONE; TRANSCRIPTION FACTOR; GROWTH-HORMONE; GENE-EXPRESSION; DNA-BINDING; PROLACTIN; PROTEIN	A point mutation in the POU-specific portion of the human gene that encodes the tissue-specific POU-domain transcription factor, Pit-1, results in hypopituitarism, with deficiencies of growth hormone, prolactin, and thyroid-stimulating hormone. In two unrelated Dutch families, a mutation in Pit-1 that altered an alanine in the first putative alpha-helix of the POU-specific domain to proline was observed. This mutation generated a protein capable of binding to DNA response elements but unable to effectively activate its known target genes, growth hormone and prolactin. The phenotype of the affected individuals suggests that the mutant Pit-1 protein is competent to initiate other programs of gene activation required for normal proliferation of somatotrope, lactotrope, and thyrotrope cell types. Thus, a mutation in the POU-specific domain of Pit- 1 has a selective effect on a subset of Pit-1 target genes.	EMORY UNIV,SCH MED,DEPT PEDIAT,DIV PEDIAT ENDOCRINOL,2040 RIDGEWOOD DR,ATLANTA,GA 30322; UNIV CALIF SAN DIEGO,HOWARD HUGHES MED INST,LA JOLLA,CA 92093; UNIV UTRECHT,DEPT PEDIAT,UTRECHT,NETHERLANDS; NATL INST PUBL HLTH & ENVIRONM PROTECT,VIROL LAB,BILTHOVEN,NETHERLANDS	Emory University; Howard Hughes Medical Institute; University of California System; University of California San Diego; Utrecht University; Netherlands National Institute for Public Health & the Environment			Parks, John/F-8570-2011		NICHD NIH HHS [HD24960, HD2697] Funding Source: Medline; NIDDK NIH HHS [NIDDK 18477] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD024960] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018477] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASA SL, 1991, ENDOCRINE SOC ANN M; BODNER M, 1988, CELL, V55, P505, DOI 10.1016/0092-8674(88)90037-2; CHEN RP, 1990, NATURE, V346, P583, DOI 10.1038/346583a0; DIMATTIA GE, 1990, J BIOL CHEM, V265, P16412; DIMATTIA GE, UNPUB; INGRAHAM HA, 1990, CELL, V61, P1021, DOI 10.1016/0092-8674(90)90067-O; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; KONZAK KE, 1992, MOL ENDOCRINOL, V6, P241, DOI 10.1210/me.6.2.241; LEW AM, 1991, NUCLEIC ACIDS RES, V19, P6329, DOI 10.1093/nar/19.22.6329; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; MANGALAM HJ, 1989, GENE DEV, V3, P946, DOI 10.1101/gad.3.7.946; MCCORMICK A, 1990, NATURE, V345, P829, DOI 10.1038/345829a0; NELSON C, 1988, SCIENCE, V239, P1400, DOI 10.1126/science.2831625; ROGOL AD, 1976, J PEDIATR-US, V88, P953, DOI 10.1016/S0022-3476(76)81048-7; ROSENFELD MG, 1991, GENE DEV, V5, P897, DOI 10.1101/gad.5.6.897; STEINFELDER HJ, 1992, J CLIN INVEST, V89, P409, DOI 10.1172/JCI115600; TANSEY WP, 1991, J BIOL CHEM, V266, P9805; TATSUMI K, 1992, NAT GENET, V1, P56, DOI 10.1038/ng0492-56; VANBUULOFFERS SC, 1984, THESIS U UTRECHT; VERRIJZER CP, 1990, EMBO J, V9, P1883, DOI 10.1002/j.1460-2075.1990.tb08314.x; WINTER JSD, 1974, J CLIN ENDOCR METAB, V39, P356, DOI 10.1210/jcem-39-2-356; WIT JM, 1989, HORM RES, V32, P170, DOI 10.1159/000181284; YOSHIMOTO M, 1990, ACTA PAEDIATR SCAND, V79, P1247	23	378	387	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 21	1992	257	5073					1118	1121		10.1126/science.257.5073.1118	http://dx.doi.org/10.1126/science.257.5073.1118			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JJ884	1509263				2022-12-01	WOS:A1992JJ88400033
J	RAMSDELL, F; FOWLKES, BJ				RAMSDELL, F; FOWLKES, BJ			MAINTENANCE OF INVIVO TOLERANCE BY PERSISTENCE OF ANTIGEN	SCIENCE			English	Article							T-CELL-RECEPTOR; MAMMARY-TUMOR VIRUS; TRANSGENIC MICE; CLONAL ANERGY; TRANSPLANTATION TOLERANCE; NEGATIVE SELECTION; DELETION; INDUCTION; INACTIVATION; ELIMINATION	T cells of the immune system respond only to foreign antigens because those cells with reactivity for self proteins are either deleted during their development or rendered nonresponsive (anergic). The maintenance of the nonresponsive state was found to require the continual exposure of the anergic T cells to antigen. When anergic T cells were removed from the self antigen by adoptive transfer to a mouse strain lacking the antigen or by in vitro culture, nonresponsiveness was reversed and the anergic cells returned to normal functional status.	NIAID,CELLULAR & MOLEC IMMUNOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)								ALTERS SE, 1991, J EXP MED, V173, P491, DOI 10.1084/jem.173.2.491; BLACKMAN M, 1990, SCIENCE, V248, P1335, DOI 10.1126/science.1972592; BLACKMAN MA, 1991, P NATL ACAD SCI USA, V88, P6682, DOI 10.1073/pnas.88.15.6682; DYSON PJ, 1991, NATURE, V349, P531, DOI 10.1038/349531a0; FRANKEL WN, 1991, NATURE, V349, P526, DOI 10.1038/349526a0; GLIMCHER LH, 1992, ANNU REV IMMUNOL, V10, P13, DOI 10.1146/annurev.iy.10.040192.000305; GRAY D, 1991, INT IMMUNOL, V3, P141, DOI 10.1093/intimm/3.2.141; JENKINS MK, 1987, P NATL ACAD SCI USA, V84, P5409, DOI 10.1073/pnas.84.15.5409; KANAGAWA O, 1989, CELL IMMUNOL, V119, P412, DOI 10.1016/0008-8749(89)90255-4; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KAWABE Y, 1990, J EXP MED, V172, P1065, DOI 10.1084/jem.172.4.1065; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; KUBO RT, 1989, J IMMUNOL, V142, P2736; LO D, 1989, J EXP MED, V170, P87, DOI 10.1084/jem.170.1.87; MACDONALD HR, 1988, NATURE, V332, P40, DOI 10.1038/332040a0; MARKMANN J, 1988, NATURE, V336, P476, DOI 10.1038/336476a0; MARRACK P, 1991, NATURE, V349, P524, DOI 10.1038/349524a0; MUELLER DL, 1989, ANNU REV IMMUNOL, V7, P445, DOI 10.1146/annurev.iy.07.040189.002305; QIN SX, 1990, EUR J IMMUNOL, V20, P2737, DOI 10.1002/eji.1830201231; QIN SX, 1989, J EXP MED, V169, P779, DOI 10.1084/jem.169.3.779; RAMMENSEE HG, 1989, NATURE, V339, P541, DOI 10.1038/339541a0; RAMSDELL F, 1989, SCIENCE, V246, P1038, DOI 10.1126/science.2511629; RAMSDELL F, UNPUB; RELLAHAN BL, 1990, J EXP MED, V172, P1071; ROBERTS JL, 1990, J EXP MED, V171, P935, DOI 10.1084/jem.171.3.935; SHA WC, 1988, NATURE, V336, P73, DOI 10.1038/336073a0; TEW JG, 1980, IMMUNOL REV, V53, P29; WEBB S, 1990, CELL, V63, P1249, DOI 10.1016/0092-8674(90)90420-J; WIETIES K, 1990, P NATL ACAD SCI USA, V87, P6604, DOI 10.1073/pnas.87.17.6604; WOODLAND DL, 1991, NATURE, V349, P529, DOI 10.1038/349529a0	30	212	222	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 21	1992	257	5073					1130	1134		10.1126/science.257.5073.1130	http://dx.doi.org/10.1126/science.257.5073.1130			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JJ884	1354889				2022-12-01	WOS:A1992JJ88400037
J	ROTHNAGEL, JA; DOMINEY, AM; DEMPSEY, LD; LONGLEY, MA; GREENHALGH, DA; GAGNE, TA; HUBER, M; FRENK, E; HOHL, D; ROOP, DR				ROTHNAGEL, JA; DOMINEY, AM; DEMPSEY, LD; LONGLEY, MA; GREENHALGH, DA; GAGNE, TA; HUBER, M; FRENK, E; HOHL, D; ROOP, DR			MUTATIONS IN THE ROD DOMAINS OF KERATIN-1 AND KERATIN-10 IN EPIDERMOLYTIC HYPERKERATOSIS	SCIENCE			English	Article							INTERMEDIATE FILAMENTS; HUMAN CHROMOSOME-12; GENE-EXPRESSION; MOUSE EPIDERMIS; CELLS; SEQUENCE; ACID; CYTOKERATIN-18; ULTRASTRUCTURE; KERATINIZATION	Epidermolytic hyperkeratosis is a hereditary skin disorder characterized by blistering and a marked thickening of the stratum corneum. In one family, affected individuals exhibited a mutation in the highly conserved carboxyl terminal of the rod domain of keratin 1. In two other families, affected individuals had mutations in the highly conserved amino terminal of the rod domain of keratin 10. Structural analysis of these mutations predicts that heterodimer formation would be unaffected, although filament assembly and elongation would be severely compromised. These data imply that an intact keratin intermediate filament network is required for the maintenance of both cellular and tissue integrity.	BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT DERMATOL,HOUSTON,TX 77030; CHU VAUDOIS,HOP BEAUMONT,DEPT DERMATOL,CH-1011 LAUSANNE,SWITZERLAND	Baylor College of Medicine; Baylor College of Medicine; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)			Hohl, Daniel M/N-7554-2016; Rothnagel, Joe/A-4874-2010; Huber, Marcel/M-8822-2016	Rothnagel, Joe/0000-0002-6710-3165; Huber, Marcel/0000-0003-3821-2378	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD025479] Funding Source: NIH RePORTER; NICHD NIH HHS [HD25479] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ACKERMAN AB, 1970, ARCH DERMATOL, V102, P253, DOI 10.1001/archderm.102.3.253; ANTONLAMPRECHT I, 1974, ARCH DERMATOL FORSCH, V250, P207, DOI 10.1007/BF00561188; BADER BL, 1988, EUR J CELL BIOL, V47, P300; BONIFAS JM, 1991, SCIENCE, V254, P1202, DOI 10.1126/science.1720261; BONIFAS JM, 1992, J INVEST DERMATOL, V98, P573; Brocq L, 1902, ANN DERMATOL SYPHIL, V4, P1; COLOUMBE PA, 1991, CELL, V66, P1301; COMPTON JG, 1992, NAT GENET, V1, P301, DOI 10.1038/ng0792-301; CONWAY JF, 1988, INT J BIOL MACROMOL, V10, P79, DOI 10.1016/0141-8130(88)90015-3; COULOMBE PA, 1990, J CELL BIOL, V111, P153, DOI 10.1083/jcb.111.1.153; EPSTEIN EH, 1992, SCIENCE, V256, P799, DOI 10.1126/science.1375393; FRASER RDB, 1986, P NATL ACAD SCI USA, V83, P1179, DOI 10.1073/pnas.83.5.1179; FRITSCH EFJ, 1989, MOL CLONING LABORATO; FROST P, 1966, ARCH DERMATOL, V94, P113, DOI 10.1001/archderm.94.2.113; FROST P, 1966, J INVEST DERMATOL, V47, P561, DOI 10.1038/jid.1966.185; FUCHS E, 1980, CELL, V19, P1033, DOI 10.1016/0092-8674(80)90094-X; GEISLER N, 1982, NATURE, V296, P448, DOI 10.1038/296448a0; GIBBS RA, 1990, GENOMICS, V7, P235, DOI 10.1016/0888-7543(90)90545-6; HATZFELD M, 1991, J CELL SCI, V99, P351; HATZFELD M, 1990, J CELL BIOL, V110, P119; HEALD R, 1990, CELL, V61, P579, DOI 10.1016/0092-8674(90)90470-Y; HEATH P, 1990, HUM GENET, V85, P669; HIRONE T, 1969, Journal of Electron Microscopy, V18, P63; HOHL D, 1991, J INVEST DERMATOL, V96, P414, DOI 10.1111/1523-1747.ep12469779; HOLBROOK KA, 1983, J INVEST DERMATOL, V80, P222, DOI 10.1111/1523-1747.ep12534504; ISHIDAYAMAMOTO A, 1992, J INVEST DERMATOL, V99, P19, DOI 10.1111/1523-1747.ep12611391; JACKSON DP, 1990, J CLIN PATHOL, V43, P499, DOI 10.1136/jcp.43.6.499; JOHNSON LD, 1985, P NATL ACAD SCI USA, V82, P1896, DOI 10.1073/pnas.82.7.1896; KANITAKIS J, 1987, BRIT J DERMATOL, V117, P479, DOI 10.1111/j.1365-2133.1987.tb04928.x; KORGE BP, 1992, P NATL ACAD SCI USA, V89, P910, DOI 10.1073/pnas.89.3.910; LANE EB, 1992, NATURE, V356, P244, DOI 10.1038/356244a0; LAPIERE S, 1932, ANN DERMATOL SYPHIL, V3, P401; LESSIN SR, 1988, J INVEST DERMATOL, V91, P572, DOI 10.1111/1523-1747.ep12477087; LETAI A, 1992, J CELL BIOL, V116, P1181, DOI 10.1083/jcb.116.5.1181; MAGIN TM, 1987, EMBO J, V6, P2607, DOI 10.1002/j.1460-2075.1987.tb02551.x; MALI JWH, 1976, BRIT J DERMATOL, V95, P627, DOI 10.1111/j.1365-2133.1976.tb07035.x; OGAWA H, 1979, ARCH DERMATOL RES, V266, P109, DOI 10.1007/BF00694618; PARRY D A D, 1992, Current Opinion in Cell Biology, V4, P94, DOI 10.1016/0955-0674(92)90064-J; PARRY DAD, 1987, INT J BIOL MACROMOL, V9, P137, DOI 10.1016/0141-8130(87)90041-9; POPESCU NC, 1989, HUM GENET, V82, P109, DOI 10.1007/BF00284039; RIEGER M, 1988, J MOL BIOL, V204, P841, DOI 10.1016/0022-2836(88)90045-9; ROMANO V, 1988, CYTOGENET CELL GENET, V48, P148, DOI 10.1159/000132612; ROOP DR, 1983, P NATL ACAD SCI-BIOL, V80, P716, DOI 10.1073/pnas.80.3.716; ROSENBERG M, 1991, CYTOGENET CELL GENET, V57, P33, DOI 10.1159/000133109; ROTHNAGEL JA, UNPUB; SCHWEIZER J, 1984, CELL, V37, P159, DOI 10.1016/0092-8674(84)90311-8; STEINERT PM, 1990, J BIOL CHEM, V265, P8766; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; WILGRAM GF, 1966, ARCH DERMATOL, V94, P127, DOI 10.1001/archderm.94.2.127; WILLIAMS ML, 1988, PEDIAT DERMATOLOGY, V1, P400; WOODCOCKMITCHELL J, 1982, J CELL BIOL, V95, P580, DOI 10.1083/jcb.95.2.580	51	323	328	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 21	1992	257	5073					1128	1130		10.1126/science.257.5073.1128	http://dx.doi.org/10.1126/science.257.5073.1128			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JJ884	1380725				2022-12-01	WOS:A1992JJ88400036
J	SCHLICK, T; OLSON, WK				SCHLICK, T; OLSON, WK			TREFOIL KNOTTING REVEALED BY MOLECULAR-DYNAMICS SIMULATIONS OF SUPERCOILED DNA	SCIENCE			English	Article							CONFORMATIONAL CHANGE; CIRCULAR DNAS; B-DNA; TOPOISOMERASES; RECOMBINATION; GYRASE; COMPLEX; PBR322; MUTANT; SCHEME	Computer simulations of the supercoiling of DNA, largely limited to stochastic search techniques, can offer important information to complement analytical models and experimental data. Through association of an energy function, minimum-energy supercoiled conformations, fluctuations about these states, and interconversions among forms may be sought. In theory, the observation of such large-scale conformational changes is possible, but modeling and numerical considerations limit the picture obtained in practice. A new computational approach is reported that combines an idealized elastic energy model, a compact B-spline representation of circular duplex DNA, and deterministic minimization and molecular dynamics algorithms. A trefoil knotting result, made possible by a large time-step dynamics scheme, is described. The simulated strand passage supports and details a supercoiled-directed knotting mechanism. This process may be associated with collective bending and twisting motions involved in supercoiling propagation and interwound branching. The results also demonstrate the potential effectiveness of the Langevin/implicit-Euler dynamics scheme for studying biomolecular folding and reactions over biologically interesting time scales.	NYU, COURANT INST MATH SCI, NEW YORK, NY 10012 USA; RUTGERS STATE UNIV, WRIGHT RIEMAN LABS, DEPT CHEM, NEW BRUNSWICK, NJ 08903 USA	New York University; Rutgers State University New Brunswick	SCHLICK, T (corresponding author), NYU, DEPT CHEM, 251 MERCER ST, NEW YORK, NY 10012 USA.			Schlick, Tamar/0000-0002-2392-2062	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034809] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 34809] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADRIAN M, 1990, EMBO J, V9, P4551, DOI 10.1002/j.1460-2075.1990.tb07907.x; ANDERSON BF, 1990, NATURE, V344, P784, DOI 10.1038/344784a0; Bartels RH, 1987, INTRO SPLINES USE CO; BAUER WR, 1980, SCI AM, V243, P118; BENHAM CJ, 1989, PHYS REV A, V39, P2852; BENJAMIN HW, 1986, P RA WELCH F C CHEM, V29, P107; COZZARELLI NR, 1980, SCIENCE, V207, P953, DOI 10.1126/science.6243420; Dahlquist G., 1974, NUMERICAL METHODS; FABER HR, 1990, NATURE, V348, P263, DOI 10.1038/348263a0; Frank-Kamenetskii M. D., 1981, Soviet Physics - Uspekhi, V24, P679, DOI 10.1070/PU1981v024n08ABEH004835; FULLER FB, 1971, P NATL ACAD SCI USA, V68, P815, DOI 10.1073/pnas.68.4.815; HAGERMAN PJ, 1988, ANNU REV BIOPHYS BIO, V17, P265; HAO MH, 1989, BIOPOLYMERS, V28, P873, DOI 10.1002/bip.360280407; JOSEPH D, 1990, SCIENCE, V249, P1425, DOI 10.1126/science.2402636; KLENIN KV, 1991, J MOL BIOL, V217, P413, DOI 10.1016/0022-2836(91)90745-R; KRUEGER S, 1990, J MOL BIOL, V211, P211, DOI 10.1016/0022-2836(90)90021-D; LANDAU LD, 1975, THEORY ELASTICITY, pCH2; LEBRET M, 1979, BIOPOLYMERS, V18, P1709, DOI 10.1002/bip.1979.360180710; LEBRET M, 1984, BIOPOLYMERS, V23, P1835, DOI 10.1002/bip.360231004; LIU LF, 1980, CELL, V19, P697, DOI 10.1016/S0092-8674(80)80046-8; LIVOLANT F, 1989, NATURE, V339, P724, DOI 10.1038/339724a0; Love A.E.H., 1944, TREATISE MATH THEORY; MANDELKERN M, 1981, J MOL BIOL, V152, P153, DOI 10.1016/0022-2836(81)90099-1; McCammon JA., 1987, DYNAMICS PROTEINS NU; MUZARD G, 1990, EMBO J, V9, P1289, DOI 10.1002/j.1460-2075.1990.tb08238.x; NYBERG A, IN PRESS CHEM PHYS L; NYBERG AM, 1991, J CHEM PHYS, V95, P4986, DOI 10.1063/1.461715; OLSON WK, 1991, METHODS ENZYMOLOGY M, V203, P403; OSHEROFF N, 1991, BIOESSAYS, V13, P269, DOI 10.1002/bies.950130603; PESKIN CS, 1989, COMMUN PUR APPL MATH, V42, P1001, DOI 10.1002/cpa.3160420706; RAU DC, 1984, P NATL ACAD SCI-BIOL, V81, P2621, DOI 10.1073/pnas.81.9.2621; RAU DC, 1987, J MOL BIOL, V193, P555, DOI 10.1016/0022-2836(87)90266-X; SCHLICK T, 1989, COMMUN PUR APPL MATH, V42, P1141, DOI 10.1002/cpa.3160420807; SCHLICK T, 1992, J MOL BIOL, V223, P1089, DOI 10.1016/0022-2836(92)90263-J; SCHLICK T, 1992, ACM T MATH SOFTWARE, V18, P46, DOI 10.1145/128745.150973; SCHLICK T, 1987, J COMPUT CHEM, V8, P1025, DOI 10.1002/jcc.540080711; SCHLICK T, 1991, J CHEM PHYS, V94, P2118, DOI 10.1063/1.459935; SHISHIDO K, 1989, NUCLEIC ACIDS RES, V17, P9749, DOI 10.1093/nar/17.23.9749; SPENGLER SJ, 1985, CELL, V42, P325, DOI 10.1016/S0092-8674(85)80128-8; SUMNERS DW, 1990, MATH INTELL, V12, P71, DOI 10.1007/BF03024022; TAN RKZ, 1991, THEORETICAL BIOCH MO, V1, P125; TELEMAN O, 1986, J COMPUT CHEM, V7, P58, DOI 10.1002/jcc.540070108; TIMSIT Y, 1989, NATURE, V341, P459, DOI 10.1038/341459a0; TIMSIT Y, 1991, NATURE, V354, P167, DOI 10.1038/354167a0; TIMSIT Y, 1991, J MOL BIOL, V221, P919, DOI 10.1016/0022-2836(91)80184-V; TUCKERMAN ME, 1991, J CHEM PHYS, V94, P1465, DOI 10.1063/1.460004; VANGUNSTEREN WF, 1980, MOL PHYS, V40, P1015, DOI 10.1080/00268978000102101; VINOGRAD J, 1966, J GEN PHYSIOL, V49, P103, DOI 10.1085/jgp.49.6.103; WANG JC, 1982, SCI AM, V247, P94, DOI 10.1038/scientificamerican0782-94; WANG JC, 1991, J BIOL CHEM, V266, P6659; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WANG JC, 1986, CYCLIC POLYM, P225; WASSERMAN SA, 1985, SCIENCE, V229, P171, DOI 10.1126/science.2990045; WASSERMAN SA, 1991, J BIOL CHEM, V266, P20567; WASSERMAN SA, 1986, SCIENCE, V232, P951, DOI 10.1126/science.3010458; WHITE JH, 1969, AM J MATH, V91, P693, DOI 10.2307/2373348; WHITE JH, 1989, MATH METHODS DNA SEQ, pCH9; WIGLEY DB, 1991, NATURE, V351, P624, DOI 10.1038/351624a0	58	89	90	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 21	1992	257	5073					1110	1115		10.1126/science.257.5073.1110	http://dx.doi.org/10.1126/science.257.5073.1110			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JJ884	1509261				2022-12-01	WOS:A1992JJ88400031
J	SNOUWAERT, JN; BRIGMAN, KK; LATOUR, AM; MALOUF, NN; BOUCHER, RC; SMITHIES, O; KOLLER, BH				SNOUWAERT, JN; BRIGMAN, KK; LATOUR, AM; MALOUF, NN; BOUCHER, RC; SMITHIES, O; KOLLER, BH			AN ANIMAL-MODEL FOR CYSTIC-FIBROSIS MADE BY GENE TARGETING	SCIENCE			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; IDENTIFICATION; PANCREAS; CLONING; CELLS	Cystic fibrosis results from defects in the gene encoding a cyclic adenosine monophosphate-dependent chloride ion channel known as the cystic fibrosis transmembrane conductance regulator (CFTR). To create an animal model for cystic fibrosis, mice were generated from embryonic stem cells in which the CFTR gene was disrupted by gene targeting. Mice homozygous for the disrupted gene display many features common to young human cystic fibrosis patients, including failure to thrive, meconium ileus, alteration of mucous and serous glands, and obstruction of glandlike structures with inspissated eosinophilic material. Death resulting from intestinal obstruction usually occurs before 40 days of age.	UNIV N CAROLINA,DEPT MED,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT PATHOL,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL042384] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM020069, R01GM020069] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 42384] Funding Source: Medline; NIGMS NIH HHS [GM20069] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andersen DH, 1938, AM J DIS CHILD, V56, P344, DOI 10.1001/archpedi.1938.01980140114013; BARASCH J, 1991, NATURE, V352, P70, DOI 10.1038/352070a0; Boat TF., 1989, CYSTIC FIBROSIS META, V6th, P2649; BRADBURY NA, 1992, SCIENCE, V256, P530, DOI 10.1126/science.1373908; COLLINS FS, 1992, SCIENCE, V256, P774, DOI 10.1126/science.1375392; DISANTAGNESE PA, 1984, CYSTIC FIBROSIS, P212; DONNISON AB, 1966, PEDIATRICS, V37, P833; Dorin Julia R., 1992, Transgenic Research, V1, P101, DOI 10.1007/BF02513027; Farber S, 1944, ARCH PATHOL, V37, P0238; FOX WW, 1976, PEDIATRICS, V54, P293; GILMAN M, 1989, CURRENT PROTOCOLS MO; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KNOWLES ME, COMMUNICATION; KOLLER BH, 1991, P NATL ACAD SCI USA, V88, P10730, DOI 10.1073/pnas.88.23.10730; MARINO CR, 1991, J CLIN INVEST, V88, P712, DOI 10.1172/JCI115358; MCCARTHY VP, 1984, GASTROENTEROLOGY, V86, P564; Oppenheimer E H, 1975, Perspect Pediatr Pathol, V2, P241; OPPENHEIMER EH, 1973, ARCH PATHOL, V96, P149; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; STURGESS J, 1982, AM J PATHOL, V106, P303; TATA F, 1991, GENOMICS, V10, P301, DOI 10.1016/0888-7543(91)90312-3; TAUSSIG LM, 1984, CYSTIC FIBROSIS, P115; TREZISE AEO, 1991, NATURE, V353, P434, DOI 10.1038/353434a0	25	780	826	2	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 21	1992	257	5073					1083	1088		10.1126/science.257.5073.1083	http://dx.doi.org/10.1126/science.257.5073.1083			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JJ884	1380723				2022-12-01	WOS:A1992JJ88400024
J	STRAUS, DB; WEISS, A				STRAUS, DB; WEISS, A			GENETIC-EVIDENCE FOR THE INVOLVEMENT OF THE ICK TYROSINE KINASE IN SIGNAL TRANSDUCTION THROUGH THE T-CELL ANTIGEN RECEPTOR	CELL			English	Article							PROTEIN-KINASE; ZETA-CHAIN; PHOSPHOLIPASE C-GAMMA-1; SURFACE MOLECULES; CROSS-LINKING; CD4 RECEPTOR; SRC FAMILY; ACTIVATION; P56LCK; PHOSPHORYLATION	Signaling through the T cell antigen receptor (TCR) results both in rapid increases in tyrosine phosphorylation on a number of proteins and in the activation of the phosphatidylinositol pathway. It is not clear how stimulation of the TCR leads to these signaling events. Mutants of the Jurkat T cell line have been previously isolated that fail to show increases in calcium following receptor stimulation. Analysis of one of these mutants, JCaM1, which is defective in the induction of tyrosine phosphorylation, revealed a defect in the expression of functional lck tyrosine kinase. The lack of lck activity was caused in part by a splicing defect. Expression of the lck cDNA in JCaM1 restores the ability of the cell to respond to TCR stimulation. These results indicate that lck is required for normal signal transduction through the TCR.			STRAUS, DB (corresponding author), UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT MED,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039553] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM39553] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; ANSOTEGUI IJ, 1991, SCAND J IMMUNOL, V33, P375, DOI 10.1111/j.1365-3083.1991.tb01784.x; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.biochem.56.1.159; BURGESS KE, 1991, EUR J IMMUNOL, V21, P1663, DOI 10.1002/eji.1830210712; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; CAMPBELL MA, 1992, MOL CELL BIOL, V12, P2315, DOI 10.1128/MCB.12.5.2315; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COOKE M P, 1989, New Biologist, V1, P66; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; DAVIDSON D, 1992, J EXP MED, V175, P1483, DOI 10.1084/jem.175.6.1483; DEMBIC Z, 1986, NATURE, V320, P232, DOI 10.1038/320232a0; DRUCKER BJ, 1989, NEW ENGL J MED, V321, P1383; GASSMANN M, 1992, EUR J IMMUNOL, V22, P283, DOI 10.1002/eji.1830220142; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; GOLDSMITH MA, 1988, P NATL ACAD SCI USA, V85, P8613, DOI 10.1073/pnas.85.22.8613; GOLDSMITH MA, 1989, J BIOL CHEM, V264, P17190; GOLDSMITH MA, 1987, P NATL ACAD SCI USA, V84, P6879, DOI 10.1073/pnas.84.19.6879; GOLDSMITH MA, 1988, SCIENCE, V240, P1029, DOI 10.1126/science.3259335; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAMBOR JE, 1988, P NATL ACAD SCI USA, V85, P4010, DOI 10.1073/pnas.85.11.4010; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARA T, 1985, J EXP MED, V161, P641, DOI 10.1084/jem.161.4.641; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; IMBODEN JB, 1985, J EXP MED, V161, P446, DOI 10.1084/jem.161.3.446; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; JONGSTRA J, 1987, J EXP MED, V165, P601, DOI 10.1084/jem.165.3.601; JUNE CH, 1990, J IMMUNOL, V144, P1591; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LEDBETTER JA, 1988, EUR J IMMUNOL, V18, P525, DOI 10.1002/eji.1830180406; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; LUO KX, 1990, MOL CELL BIOL, V10, P5305, DOI 10.1128/MCB.10.10.5305; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; ORLOFF DG, 1989, J BIOL CHEM, V264, P14812; OSHEA JJ, 1991, P NATL ACAD SCI USA, V88, P1741, DOI 10.1073/pnas.88.5.1741; PARK DJ, 1991, P NATL ACAD SCI USA, V88, P5453, DOI 10.1073/pnas.88.12.5453; PERLMUTTER RM, 1988, J CELL BIOCHEM, V38, P117, DOI 10.1002/jcb.240380206; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; ROMEO C, 1991, CELL, V64, P1037, DOI 10.1016/0092-8674(91)90327-U; ROUER E, 1989, GENE, V84, P105, DOI 10.1016/0378-1119(89)90144-3; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SAITO T, 1987, NATURE, V325, P125, DOI 10.1038/325125a0; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; TESTI R, 1989, J IMMUNOL, V142, P1854; TRUNEH A, 1985, NATURE, V313, P318, DOI 10.1038/313318a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VEILLETTE A, 1988, ONCOGENE RES, V2, P385; WEISS A, 1984, P NATL ACAD SCI-BIOL, V81, P4169, DOI 10.1073/pnas.81.13.4169; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484; WEISS A, 1984, J EXP MED, V160, P1284, DOI 10.1084/jem.160.5.1284; WEISS A, 1989, FUNDAMENTAL IMMUNOLO, P359; WEISSMAN AM, 1989, EMBO J, V8, P3651, DOI 10.1002/j.1460-2075.1989.tb08539.x	57	1009	1046	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 21	1992	70	4					585	593		10.1016/0092-8674(92)90428-F	http://dx.doi.org/10.1016/0092-8674(92)90428-F			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JJ886	1505025				2022-12-01	WOS:A1992JJ88600008
J	ARNAIZVILLENA, A; TIMON, M; CORELL, A; PEREZACIEGO, P; MARTINVILLA, JM; REGUEIRO, JR				ARNAIZVILLENA, A; TIMON, M; CORELL, A; PEREZACIEGO, P; MARTINVILLA, JM; REGUEIRO, JR			PRIMARY IMMUNODEFICIENCY CAUSED BY MUTATIONS IN THE GENE ENCODING THE CD3-GAMMA SUBUNIT OF THE LYMPHOCYTE-T RECEPTOR	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							SURFACE EXPRESSION; FAMILIAL DEFECT; COMPLEX		UNIV VALLADOLID,SCH MED,DEPT PEDIAT,VALLADOLID,SPAIN	Universidad de Valladolid	ARNAIZVILLENA, A (corresponding author), UNIV COMPLUTENSE MADRID,HOSP 12 OCTUBRE,DEPT IMMUNOL,E-28041 MADRID,SPAIN.		Regueiro, José R./B-5499-2014; Martin-Villa, Jose M./K-2522-2019; Corell, Alfredo/E-1903-2011; Martin-Villa, Jose M. M/F-9234-2013; Corell, Alfredo/AAE-2133-2020	Regueiro, José R./0000-0001-8442-7762; Martin-Villa, Jose M./0000-0002-2436-8585; Martin-Villa, Jose M. M/0000-0002-2436-8585; Corell, Alfredo/0000-0001-5797-7814				ALARCON B, 1990, Immunodeficiency Reviews, V2, P1; ALARCON B, 1988, NEW ENGL J MED, V319, P1203, DOI 10.1056/NEJM198811033191806; ARNAIZVILLENA A, 1991, LAB INVEST, V64, P675; CLEVERS H, 1988, ANNU REV IMMUNOL, V6, P629, DOI 10.1146/annurev.iy.06.040188.003213; CORELL A, 1990, MOL IMMUNOL, V27, P313, DOI 10.1016/0161-5890(90)90145-P; CORELL A, 1991, MOL IMMUNOL, V28, P533, DOI 10.1016/0161-5890(91)90168-J; CORELL J, 1990, MOL IMMUNOL, V27, P471; Davis R W, 1980, Methods Enzymol, V65, P404; GELFAND EW, 1990, NEW ENGL J MED, V322, P1741, DOI 10.1056/NEJM199006143222410; PEREZACIEGO P, 1991, J EXP MED, V174, P319, DOI 10.1084/jem.174.2.319; REGUEIRO JR, 1990, EUR J IMMUNOL, V20, P2411, DOI 10.1002/eji.1830201108; REGUEIRO JR, 1986, LANCET, V1, P1274; REGUEIRO JR, 1992, SCAND J IMMUNOL, V36, P363; REGUEIRO JR, 1987, SCAND J IMMUNOL, V26, P699, DOI 10.1111/j.1365-3083.1987.tb02306.x; ROSEN FS, 1984, NEW ENGL J MED, V311, P235, DOI 10.1056/NEJM198407263110406; TUNNACLIFFE A, 1987, EMBO J, V6, P2953, DOI 10.1002/j.1460-2075.1987.tb02600.x	16	179	183	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 20	1992	327	8					529	533		10.1056/NEJM199208203270805	http://dx.doi.org/10.1056/NEJM199208203270805			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JJ457	1635567				2022-12-01	WOS:A1992JJ45700005
J	BOOKER, GW; BREEZE, AL; DOWNING, AK; PANAYOTOU, G; GOUT, I; WATERFIELD, MD; CAMPBELL, ID				BOOKER, GW; BREEZE, AL; DOWNING, AK; PANAYOTOU, G; GOUT, I; WATERFIELD, MD; CAMPBELL, ID			STRUCTURE OF AN SH2 DOMAIN OF THE P85-ALPHA SUBUNIT OF PHOSPHATIDYLINOSITOL-3-OH KINASE	NATURE			English	Article							NUCLEAR-MAGNETIC-RESONANCE; 3-DIMENSIONAL STRUCTURES; SIGNAL TRANSDUCTION; PROTEIN STRUCTURES; DISTANCE DATA; PROGRAM; CONFORMATIONS; DYNAMICS	RECEPTOR protein-tyrosine kinases, through phosphorylation of specific tyrosine residues, generate high-affinity binding sites which direct assembly of multienzyme signalling complexes1,2. Many of these signalling proteins, including phospholipase C-gamma, GTPase-activating protein and phosphatidylinositol-3-OH kinase, contain src-homology 2 (SH2) domains, which bind with high affinity and specificity to tyrosine-phosphorylated sequences3,4. The critical role played by SH2 domains in signalling has been highlighted by recent studies showing that mutation of specific phosphorylation sites on the platelet-derived growth factor receptor impair its association with phosphatidylinositol-3-OH kinase, preventing growth factor-induced mitogenesis5,6. Here we report the solution structure of an isolated SH2 domain from the 85K regulatory subunit of phosphatidylinositol-3-OH kinase, determined using multidimensional nuclear magnetic resonance spectroscopy. The structure is characterized by a central region of beta-sheet flanked by two alpha-helices, with a highly flexible loop close to functionally important residues previously identified by site-directed mutagenesis7,8.	UNIV OXFORD,DEPT BIOCHEM,OXFORD OX1 3QU,ENGLAND; ICI PLC,PHARMACEUT,PROT STRUCT FUNCT,MACCLESFIELD SK10 4TG,CHESHIRE,ENGLAND; LUDWIG INST CANC RES,LONDON W1P 8BT,ENGLAND	University of Oxford; Ludwig Institute for Cancer Research				Breeze, Alexander/0000-0001-9723-3350				BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUNGER AT, 1987, PROTEIN ENG, V1, P399, DOI 10.1093/protein/1.5.399; BRUNGER AT, 1988, XPLOR MANUAL; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; DOWNING AK, 1992, J MOL BIOL, V225, P821, DOI 10.1016/0022-2836(92)90403-7; DRISCOLL PC, 1990, BIOCHEMISTRY-US, V29, P3542, DOI 10.1021/bi00466a018; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; GUNTERT P, 1991, J MOL BIOL, V217, P517, DOI 10.1016/0022-2836(91)90754-T; HILES I, IN PRESS CELL; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KAY LE, 1990, J MAGN RESON, V86, P110, DOI 10.1016/0022-2364(90)90215-U; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Maniatis T., 1982, MOL CLONING; MARION D, 1989, BIOCHEMISTRY-US, V28, P6150, DOI 10.1021/bi00441a004; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MAYER BJ, 1990, J VIROL, V64, P3581, DOI 10.1128/JVI.64.8.3581-3589.1990; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; NILGES M, 1988, PROTEIN ENG, V2, P27, DOI 10.1093/protein/2.1.27; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; Pawson T., 1992, CURR OPIN STRUC BIOL, V2, P432; RUSSELL RB, 1992, FEBS LETT, V304, P15, DOI 10.1016/0014-5793(92)80579-6; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; WUTHRICH K, 1983, J MOL BIOL, V169, P949, DOI 10.1016/S0022-2836(83)80144-2; WUTHRICH K, 1991, FEBS LETT, V285, P327	28	169	171	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 20	1992	358	6388					684	687		10.1038/358684a0	http://dx.doi.org/10.1038/358684a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JJ882	1323062				2022-12-01	WOS:A1992JJ88200059
J	GUAN, JL; SHALLOWAY, D				GUAN, JL; SHALLOWAY, D			REGULATION OF FOCAL ADHESION-ASSOCIATED PROTEIN TYROSINE KINASE BY BOTH CELLULAR ADHESION AND ONCOGENIC TRANSFORMATION	NATURE			English	Article							PHOSPHORYLATION; PP60C-SRC; CELLS; ANTIBODIES; SITES	INCREASING evidence indicates that the integrin family of cell adhesion receptors can transduce biochemical signals from the extracellular matrix to the cell interior to modulate cell growth and differentiation1. We have shown that integrin/ligand interactions can trigger tyrosine phosphorylation of a protein of M(r) 120,000 (pp120), so it is possible that signal transduction by integrins might involve activation of intracellular protein tyrosine kinases as an early event in cell binding to the extracellular matrix2. Here we report that pp120 is identical to the focal adhesion-associated protein tyrosine kinase pp125FAK (refs 3,4). We show that tyrosine phosphorylation of this protein is modulated both by cell adhesion and transformation by pp60v-src, and that these changes in phosphorylation are correlated with increased pp125FAK tyrosine kinase activity. A model is proposed to relate these findings to the molecular basis of anchorage-independent growth of transformed cells.	CORNELL UNIV,BIOCHEM MOLEC & CELL BIOL SECT,ITHACA,NY 14853	Cornell University	GUAN, JL (corresponding author), CORNELL UNIV,COLL VET MED,DEPT PATHOL,CANC BIOL LABS,ITHACA,NY 14853, USA.							GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JOHNSON PJ, 1985, MOL CELL BIOL, V5, P1073, DOI 10.1128/MCB.5.5.1073; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; TUCKER R W, 1981, Journal of Supramolecular Structure and Cellular Biochemistry, V15, P29, DOI 10.1002/jsscb.1981.380150104; WANG JYJ, 1985, MOL CELL BIOL, V5, P3640, DOI 10.1128/MCB.5.12.3640; WITTELSBERGER SC, 1981, CELL, V24, P859, DOI 10.1016/0092-8674(81)90111-2	14	791	804	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 20	1992	358	6388					690	692		10.1038/358690a0	http://dx.doi.org/10.1038/358690a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JJ882	1379699				2022-12-01	WOS:A1992JJ88200061
J	HAGLUND, MM; OJEMANN, GA; HOCHMAN, DW				HAGLUND, MM; OJEMANN, GA; HOCHMAN, DW			OPTICAL IMAGING OF EPILEPTIFORM AND FUNCTIONAL-ACTIVITY IN HUMAN CEREBRAL-CORTEX	NATURE			English	Article							SALAMANDER OLFACTORY-BULB; INTRINSIC-SIGNALS; NEURONAL-ACTIVITY; VISUAL-CORTEX; ORGANIZATION; ARCHITECTURE; BRAIN; STIMULATION; VOLUNTARY; MOVEMENTS	OPTICAL imaging of animal somatosensory, olfactory and visual cortices has revealed maps of functional activity1-12. In non-human primates, high-resolution maps of the visual cortex have been obtained using only an intrinsic reflection signal3,4,6,13,14. Although the time course of the signal is slower than membrane potential changes, the maximum optical changes correspond to the maximal neuronal activity3,6. The intrinsic optical signal may represent the flow of ionic currents, oxygen delivery, changes in blood volume, potassium accumulation or glial swelling3,4,6,8,15-18. Here we use similar techniques to obtain maps from human cortex during stimulation-evoked epileptiform afterdischarges and cognitively evoked functional activity. Optical changes increased in magnitude as the intensity and duration of the afterdischarges increased. In areas surrounding the afterdischarge activity, optical changes were in the opposite direction and possibly represent an inhibitory surround. Large optical changes were found in the sensory cortex during tongue movement and in Broca's and Wernicke's language areas during naming exercises. The adaptation of high-resolution optical imaging for use on human cortex provides a new technique for investigation of the organization of the sensory and motor cortices, language, and other cognitive processes.	UNIV WASHINGTON,DEPT NEUROL SURG,RI-20,SEATTLE,WA 98195	University of Washington; University of Washington Seattle								BLASDEL GG, 1986, NATURE, V321, P579, DOI 10.1038/321579a0; BONHOEFFER T, 1991, NATURE, V353, P429, DOI 10.1038/353429a0; COHEN LB, 1973, PHYSIOL REV, V53, P373; COHEN LB, 1972, J PHYSIOL-LONDON, V224, P727, DOI 10.1113/jphysiol.1972.sp009920; COLEBATCH JG, 1991, J NEUROPHYSIOL, V65, P1392, DOI 10.1152/jn.1991.65.6.1392; FRITH CD, 1991, J NEUROPSYCHOLOGIA, V29, P1137; FROSTIG RD, 1990, P NATL ACAD SCI USA, V87, P6082, DOI 10.1073/pnas.87.16.6082; Gonzalez R. C., 1987, DIGITAL IMAGE PROCES; GRINVALD A, 1988, PHYSIOL REV, V68, P1285, DOI 10.1152/physrev.1988.68.4.1285; GRINVALD A, 1991, P NATL ACAD SCI USA, V88, P11559, DOI 10.1073/pnas.88.24.11559; GRINVALD A, 1986, NATURE, V324, P361, DOI 10.1038/324361a0; HAGLUND MM, 1991, MONITORING NEURONAL, P85; KAUER JS, 1988, NATURE, V331, P166, DOI 10.1038/331166a0; LEE BI, 1986, ANN NEUROL, V20, P32, DOI 10.1002/ana.410200107; LIEKE EE, 1989, ANNU REV PHYSIOL, V51, P543, DOI 10.1146/annurev.physiol.51.1.543; LIPTON P, 1973, J PHYSIOL-LONDON, V231, P365, DOI 10.1113/jphysiol.1973.sp010238; LONDON JA, 1989, J NEUROSCI, V9, P2182; MACVICAR BA, 1991, J NEUROSCI, V11, P1458; OJEMANN GA, 1983, BEHAV BRAIN SCI, V6, P189, DOI 10.1017/S0140525X00015491; OJEMANN GA, 1991, J NEUROSCI, V11, P2281; ORBACH HS, 1983, J NEUROSCI, V3, P2251; ORBACH HS, 1985, J NEUROSCI, V5, P1886; PETERSEN SE, 1988, NATURE, V331, P585, DOI 10.1038/331585a0; POSNER MI, 1988, SCIENCE, V240, P1627, DOI 10.1126/science.3289116; Raichle M. E., 1987, HDB PHYSL NERVOUS SY, V1, P643; RATZLAFF EH, 1991, J NEUROSCI METH, V36, P127, DOI 10.1016/0165-0270(91)90038-2; TSO DY, 1990, SCIENCE, V249, P417, DOI 10.1126/science.2165630; WOHLBERG G, 1988, DIGITAL IMAGING WARP; [No title captured]	29	253	276	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 20	1992	358	6388					668	671		10.1038/358668a0	http://dx.doi.org/10.1038/358668a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JJ882	1495561				2022-12-01	WOS:A1992JJ88200053
J	LU, H; ZAWEL, L; FISHER, L; EGLY, JM; REINBERG, D				LU, H; ZAWEL, L; FISHER, L; EGLY, JM; REINBERG, D			HUMAN GENERAL TRANSCRIPTION FACTOR-IIH PHOSPHORYLATES THE C-TERMINAL DOMAIN OF RNA POLYMERASE-II	NATURE			English	Article							PREINITIATION COMPLEX; LARGEST SUBUNIT; REPEAT DOMAIN; INITIATION; PURIFICATION; PROTEIN; PROMOTER; INVITRO; KINASE; FORM	Phosphorylation of the carboxy-terminal domain of the largest subunit of RNA polymerase II is believed to control the transition from transcription initiation to elongation. The general transcription factor IIH (TFIIH) contains a kinase activity capable of phosphorylating this domain. Factors that promote the association of RNA polymerase II with the preinitiation complex stimulate this activity. The transcription factor IIE, which is required for the stable association of TFIIH with the preinitiation complex, affects the processivity of TFIIH kinase.	UNIV MED & DENT NEW JERSEY, ROBERT WOOD JOHNSON MED SCH, DEPT BIOCHEM, 675 HOES LANE, PISCATAWAY, NJ 08854 USA; FAC MED STRASBOURG, CNRS, GENET MOLEC LAB, INSERM, U184, F-67085 STRASBOURG, FRANCE	Rutgers State University New Brunswick; Rutgers State University Medical Center; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg				Reinberg, Danny/0000-0003-4288-2016				ARIAS JA, 1991, J BIOL CHEM, V266, P8055; BUNICK D, 1982, CELL, V29, P877, DOI 10.1016/0092-8674(82)90449-4; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CADENA DL, 1987, J BIOL CHEM, V262, P12468; CHO KWY, 1985, J BIOL CHEM, V260, P5204; CISEK LJ, 1989, NATURE, V339, P679, DOI 10.1038/339679a0; CISEK LJ, 1991, METHOD ENZYMOL, V200, P301; CONAWAY JW, 1992, J BIOL CHEM, V267, P10142; CORDEN JL, 1990, TRENDS BIOCHEM SCI, V15, P383, DOI 10.1016/0968-0004(90)90236-5; CORTES P, 1992, MOL CELL BIOL, V12, P413, DOI 10.1128/MCB.12.1.413; DAHMUS M, IN PRESS TRANSCRIPTI; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; FISCHER L, IN PRESS SCIENCE; FLORES O, 1990, J BIOL CHEM, V265, P5629; FLORES O, 1991, P NATL ACAD SCI USA, V88, P9999, DOI 10.1073/pnas.88.22.9999; FLORES O, 1992, J BIOL CHEM, V267, P2786; GERARD M, 1991, J BIOL CHEM, V266, P20940; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; KIM WY, 1989, J BIOL CHEM, V264, P3169; LAYBOURN PJ, 1990, J BIOL CHEM, V265, P13165; LEE JM, 1991, GENE EXPRESSION, V1, P149; LEE JM, 1989, P NATL ACAD SCI USA, V86, P3624, DOI 10.1073/pnas.86.10.3624; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; PAYNE JM, 1989, J BIOL CHEM, V264, P19621; PETERSON MG, 1991, NATURE, V354, P369; PETERSON SR, 1992, GENE DEV, V6, P426, DOI 10.1101/gad.6.3.426; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; STONE N, 1992, J BIOL CHEM, V267, P6353; THOMPSON NE, 1990, J BIOL CHEM, V265, P7069; USHEVA A, 1992, CELL, V69, P871, DOI 10.1016/0092-8674(92)90297-P; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.bi.60.070191.003353; ZAWEL L, IN PRESS PROG NUCLEI; ZEHRING WA, 1988, P NATL ACAD SCI USA, V85, P3698, DOI 10.1073/pnas.85.11.3698	35	367	370	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 20	1992	358	6388					641	645		10.1038/358641a0	http://dx.doi.org/10.1038/358641a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JJ882	1495560				2022-12-01	WOS:A1992JJ88200045
J	MAGID, D; SCHWARTZ, B; CRAFT, J; SCHWARTZ, JS				MAGID, D; SCHWARTZ, B; CRAFT, J; SCHWARTZ, JS			PREVENTION OF LYME-DISEASE AFTER TICK BITES - A COST-EFFECTIVENESS ANALYSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LINKED IMMUNOSORBENT-ASSAY; WHITE-TAILED DEER; BORRELIA-BURGDORFERI; ENDEMIC AREA; MANIFESTATIONS; SPIROCHETE; ABNORMALITIES; CEFTRIAXONE; PREVALENCE; DIAGNOSIS	Background. In areas of endemic disease, the probability of Lyme disease after a tick bite ranges from about 0.012 to 0.05. Early treatment with oral antibiotics prevents most complications of Lyme disease, but antibiotics are generally not prescribed until rash or other symptoms develop. Methods. We used decision analysis to evaluate the outcomes, costs, and cost effectiveness of three alternative strategies to treat patients bitten by ixodes ticks in areas of endemic Lyme disease: empirically treat all patients with two weeks of doxycycline, treat only patients in whom erythema migrans develops, and treat only patients with erythema migrans or a positive serologic test for Lyme disease one month after exposure. Results. Empirical treatment is the least expensive strategy and results in the fewest cases of Lyme disease and the fewest complications when the probability of Borrelia burgdorferi infection after a tick bite is 0.036 or higher. For probabilities of infection below 0.036, empirical therapy prevents most major complications, sequelae, and adverse events, but it incurs additional minor complications, especially as the probability of infection falls below 0.01. Conclusions. Empirical treatment of patients with tick bites is indicated when the probability of B. burgdorferi infection after a bite is 0.036 or higher, and this treatment may be preferred when the probability of infection ranges from 0.01 to 0.035. When the probability of infection after a tick bite is less than 0.01, empirical therapy is not warranted.	UNIV PENN, LEONARD DAVIS INST HLTH ECON, 3641 LOCUST WALK, PHILADELPHIA, PA 19104 USA; DENVER GEN HOSP, EMERGENCY MED SERV, DENVER, CO 80204 USA; UNIV COLORADO, HLTH SCI CTR, EMERGENCY MED RES CTR, DENVER, CO 80262 USA; JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, DEPT ENVIRONM HLTH SCI, DIV OCCUPAT HLTH, BALTIMORE, MD 21218 USA; YALE UNIV, SCH MED, DEPT MED, RHEUMATOL SECT, NEW HAVEN, CT 06510 USA; UNIV PENN, SCH MED, DIV GEN INTERNAL MED, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, DEPT MED, CLIN EPIDEMIOL UNIT, PHILADELPHIA, PA 19104 USA; UNIV PENN, WHARTON SCH, DEPT HLTH CARE SYST, PHILADELPHIA, PA 19104 USA	University of Pennsylvania; Denver Health Medical Center; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Johns Hopkins University; Yale University; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI026853] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 26853] Funding Source: Medline; NIAMS NIH HHS [AR 4007] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AGRE F, 1991, AM J DIS CHILD, V145, P391; ASBRINK E, 1988, ANN NY ACAD SCI, V539, P4, DOI 10.1111/j.1749-6632.1988.tb31833.x; BERARDI VP, 1988, J INFECT DIS, V158, P754, DOI 10.1093/infdis/158.4.754; BOSLER EM, 1984, YALE J BIOL MED, V57, P651; BOWEN GS, 1984, YALE J BIOL MED, V57, P661; BURGDORFER W, 1985, AM J TROP MED HYG, V34, P925, DOI 10.4269/ajtmh.1985.34.925; BURGDORFER W, 1989, RHEUM DIS CLIN N AM, V15, P775; Centers for Disease Control (CDC), 1988, MMWR Suppl, V37, P1; CLARK JR, 1985, LARYNGOSCOPE, V95, P1341; COCKBURN J, 1987, BRIT MED J, V295, P814, DOI 10.1136/bmj.295.6602.814; COSTELLO CM, 1989, J INFECT DIS, V159, P136, DOI 10.1093/infdis/159.1.136; CRAFT JE, 1984, J INFECT DIS, V149, P789, DOI 10.1093/infdis/149.5.789; DATTWYLER RJ, 1988, LANCET, V1, P1191; FALCO RC, 1988, ANN NY ACAD SCI, V539, P456, DOI 10.1111/j.1749-6632.1988.tb31905.x; GELMAN CR, 1992, DOXYCYCLINE DRUG EVA, V72; GELMAN CR, 1992, CEFTRIAXONE DRUG EVA, V72; HANRAHAN JP, 1984, J INFECT DIS, V150, P489, DOI 10.1093/infdis/150.4.489; LACOMBE E, 1992, 5TH INT C LYM BORR W, pA49; LANE RS, 1988, ANN NY ACAD SCI, V539, P192, DOI 10.1111/j.1749-6632.1988.tb31853.x; LASTAVICA CC, 1989, NEW ENGL J MED, V320, P133, DOI 10.1056/NEJM198901193200301; LEVINE JF, 1985, AM J TROP MED HYG, V34, P355, DOI 10.4269/ajtmh.1985.34.355; LIU N Y, 1989, Arthritis and Rheumatism, V32, pS46; MAGNARELLI LA, 1988, J CLIN MICROBIOL, V26, P1482, DOI 10.1128/JCM.26.8.1482-1486.1988; MAGNARELLI LA, 1984, J WILDLIFE DIS, V20, P21, DOI 10.7589/0090-3558-20.1.21; MAGNARELLI LA, 1984, J CLIN MICROBIOL, V20, P181, DOI 10.1128/JCM.20.2.181-184.1984; MAGNARELLI LA, 1988, ANN NY ACAD SCI, V539, P154, DOI 10.1111/j.1749-6632.1988.tb31848.x; MALAWISTA SE, 1986, ADV INTERNAL MED, V31, P147; MATHER TN, 1992, 5TH INT C LYM BORR W, pA49; MCALISTER HF, 1989, ANN INTERN MED, V110, P339, DOI 10.7326/0003-4819-110-5-339; MOSKOVITZ BL, 1984, AM J MED, V77, P84; NADELMAN RB, 1992, 5TH INT C LYM BORR W, pA80; NEU HC, 1988, ANN NY ACAD SCI, V539, P314, DOI 10.1111/j.1749-6632.1988.tb31865.x; PACHNER AR, 1985, NEUROLOGY, V35, P47, DOI 10.1212/WNL.35.1.47; PIESMAN J, 1987, J CLIN MICROBIOL, V25, P557, DOI 10.1128/JCM.25.3.557-558.1987; RAHN DW, 1991, ANN INTERN MED, V114, P472, DOI 10.7326/0003-4819-114-6-472; REIK L, 1979, MEDICINE, V58, P281, DOI 10.1097/00005792-197907000-00001; RUSSELL H, 1984, J INFECT DIS, V149, P465, DOI 10.1093/infdis/149.3.465; SCHEIFE RT, 1976, DRUG EFFECTS HOSPITA, P263; Schoen R T, 1989, Conn Med, V53, P335; SHAPIRO ED, 1992, 5TH P INT C LYM BORR, pA47; SHRESTHA M, 1985, AM J MED, V78, P235, DOI 10.1016/0002-9343(85)90432-2; STEERE AC, 1983, ANN INTERN MED, V99, P76, DOI 10.7326/0003-4819-99-1-76; STEERE AC, 1979, ANN INTERN MED, V91, P730, DOI 10.7326/0003-4819-91-5-730; STEERE AC, 1980, ANN INTERN MED, V93, P8, DOI 10.7326/0003-4819-93-1-8; STEERE AC, 1989, NEW ENGL J MED, V321, P586, DOI 10.1056/NEJM198908313210906; STEERE AC, 1986, J INFECT DIS, V154, P295, DOI 10.1093/infdis/154.2.295; STEERE AC, 1983, ANN INTERN MED, V99, P22, DOI 10.7326/0003-4819-99-1-22; STEERE AC, 1983, NEW ENGL J MED, V308, P733, DOI 10.1056/NEJM198303313081301; STEERE AC, 1987, ANN INTERN MED, V107, P725, DOI 10.7326/0003-4819-107-5-725; 1989, MED LETT DRUGS THER, V31, P57; 1991, LYME DISEASE SURVEIL, V2, P1	51	137	139	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 20	1992	327	8					534	541		10.1056/NEJM199208203270806	http://dx.doi.org/10.1056/NEJM199208203270806			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JJ457	1298217	Bronze			2022-12-01	WOS:A1992JJ45700006
J	MALINSKI, T; TAHA, Z				MALINSKI, T; TAHA, Z			NITRIC-OXIDE RELEASE FROM A SINGLE CELL MEASURED INSITU BY A PORPHYRINIC-BASED MICROSENSOR	NATURE			English	Article							RELAXING FACTOR; ACETYLCHOLINE; RELAXATION	NITRIC oxide is an important bioregulatory molecule, being responsible, for example, for activity of endothelium-derived relaxing factor (EDRF)1-4. Acute hypertension5, diabetes6, ischaemia7 and atherosclerosis8 are associated with abnormalities of EDRF. Nitric oxide is thought to be a retrograde messenger in the central nervous system9. The technology is not yet available for rapid detection of NO released by a single cell in the presence of oxygen and/or nitrite, so the release, distribution and reactivity of endogenous NO in biological systems cannot be analysed. Here we describe a porphyrinic microsensor that we have developed and applied to monitoring NO release in a microsystem. We selectively measured in situ the NO released from a single cell with a response time of less than 10 ms. The microsensor consists of p-type semiconducting polymeric porphyrin and a cationic exchanger (Nafion) deposited on a thermally sharpened carbon fibre with a tip diameter of approximately 0.5-mu-m. The microsensor, which can be operated in either the amperometric or voltammetric mode, is characterized by a linear response up to 300-mu-M and a detection limit of 10 nM. Nitric oxide at the level of 10(-20) mols can be detected in a single cell.			MALINSKI, T (corresponding author), OAKLAND UNIV,DEPT CHEM,ROCHESTER,MI 48309, USA.							BAILEY F, 1991, ANAL CHEM, V63, P395, DOI 10.1021/ac00004a018; BENNETT JE, 1991, CHEM MATER, V3, P490, DOI 10.1021/cm00015a025; DOWNES MJ, 1976, ANALYST, V101, P742, DOI 10.1039/an9760100742; ENGSTROM RC, 1988, ANAL CHEM, V60, P652, DOI 10.1021/ac00158a010; FREIMAN PC, 1986, CIRC RES, V58, P783, DOI 10.1161/01.RES.58.6.783; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; FURCHGOTT RF, 1988, MECHANISM VASODILATI, V4, P101; GERHARDT GA, 1984, BRAIN RES, V290, P390, DOI 10.1016/0006-8993(84)90963-6; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; KANNER J, 1991, ARCH BIOCHEM BIOPHYS, V289, P130, DOI 10.1016/0003-9861(91)90452-O; MALINSKI T, 1991, J ELECTROCHEM SOC, V138, P2008, DOI 10.1149/1.2085915; MARLETTA MA, 1989, TRENDS BIOCHEM SCI, V14, P488, DOI 10.1016/0968-0004(89)90181-3; MONCADA S, 1991, PHARMACOL REV, V43, P109; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PIPER GM, 1988, AM J PHYSIOL, V24, P4825; Rosenthal AM, 1990, CELL CULTURE TECHNIQ, P117; SCHUMAN EM, 1991, SCIENCE, V254, P1503, DOI 10.1126/science.1720572; SHIBUKI K, 1990, NEUROSCI RES, V9, P69, DOI 10.1016/0168-0102(90)90048-J; VANBENTHUYSEN KM, 1987, J CLIN INVEST, V79, P265, DOI 10.1172/JCI112793; WEI EP, 1985, CIRC RES, V57, P781, DOI 10.1161/01.RES.57.5.781	20	1030	1088	3	97	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 20	1992	358	6388					676	678		10.1038/358676a0	http://dx.doi.org/10.1038/358676a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JJ882	1495562				2022-12-01	WOS:A1992JJ88200056
J	MATUSCHKA, FR; SPIELMAN, A				MATUSCHKA, FR; SPIELMAN, A			THE VECTOR OF THE LYME-DISEASE SPIROCHETE	NEW ENGLAND JOURNAL OF MEDICINE			English	Note									HARVARD UNIV,SCH PUBL HLTH,BOSTON,MA 02115	Harvard University; Harvard T.H. Chan School of Public Health	MATUSCHKA, FR (corresponding author), FREE UNIV BERLIN,W-1000 BERLIN 33,GERMANY.								0	5	5	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 20	1992	327	8					542	542						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JJ457	1635568				2022-12-01	WOS:A1992JJ45700007
J	MOHAMMADI, M; DIONNE, CA; LI, W; LI, N; SPIVAK, T; HONEGGER, AM; JAYE, M; SCHLESSINGER, J				MOHAMMADI, M; DIONNE, CA; LI, W; LI, N; SPIVAK, T; HONEGGER, AM; JAYE, M; SCHLESSINGER, J			POINT MUTATION IN FGF RECEPTOR ELIMINATES PHOSPHATIDYLINOSITOL HYDROLYSIS WITHOUT AFFECTING MITOGENESIS	NATURE			English	Article							PHOSPHOLIPASE-C-GAMMA; FIBROBLAST GROWTH-FACTOR; STIMULATES TYROSINE PHOSPHORYLATION; PDGF RECEPTOR; EGF RECEPTOR; SIGNAL TRANSDUCTION; BINDING-SITE; KINASE; EXPRESSION; ASSOCIATION	STIMULATION of growth factor receptors with tyrosine kinase activity is followed by rapid receptor dimerization, tyrosine autophosphorylation and phosphorylation of signalling molecules such as phospholipase C(gamma)(PLC-gamma) and the ras GTPase-activating protein1,2. PLC-gamma and GTPase-activating protein bind to specific tyrosine-phosphorylated regions in growth factor receptors3-9 through their src-homologous SH2 domains7,8,10,11. Growth factor-induced tyrosine phosphorylation of PLC-gamma is essential for stimulation of phosphatidylinositol hydrolysis in vitro12 and in vivo13. We have shown that a short phosphorylated peptide containing tyrosine at position 766 from a conserved region14-18 of the fibroblast growth factor (FGF) receptor is a binding site for the SH2 domain of PLC-gamma (ref. 8). Here we show that an FGF receptor point mutant in which Tyr 766 is replaced by a phenylalanine residue (Y766F) is unable to associate with and tyrosine-phosphorylate PLC-gamma or to stimulate hydrolysis of phosphatidylinositol. Nevertheless, the Y766F FGF receptor mutant can be autophosphorylated, and can phosphorylate several cellular proteins and stimulate DNA synthesis. Our data show that phosphorylation of the conserved Tyr 766 of the FGF receptor is essential for phosphorylation of PLC-gamma and for hydrolysis of phosphatidylinositol, but that elimination of this hydrolysis does not affect FGF-induced mitogenesis.	RHONE POULENC RORER CENT RES,COLLEGEVILLE,PA 19426		MOHAMMADI, M (corresponding author), NYU MED CTR,DEPT PHARMACOL,550 1ST AVE,NEW YORK,NY 10016, USA.		kasaei, fahime/T-7197-2018; Mohammadi, Moosa/ABA-6745-2020	Mohammadi, Moosa/0000-0003-2434-9437; Honegger, Annemarie/0000-0002-3378-3967				AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BERRIDGE MJ, 1989, CELL, V59, P411, DOI 10.1016/0092-8674(89)90026-3; BURGESS WH, 1990, MOL CELL BIOL, V10, P4770, DOI 10.1128/MCB.10.9.4770; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CUADRADO A, 1990, MOL CELL BIOL, V10, P6069, DOI 10.1128/MCB.10.11.6069; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; DOWNING JR, 1989, EMBO J, V8, P3345, DOI 10.1002/j.1460-2075.1989.tb08496.x; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; JAYE M, 1988, EMBO J, V7, P963, DOI 10.1002/j.1460-2075.1988.tb02902.x; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KORNBLUTH S, 1988, MOL CELL BIOL, V8, P5541, DOI 10.1128/MCB.8.12.5541; KUMJIAN DA, 1989, P NATL ACAD SCI USA, V86, P8232, DOI 10.1073/pnas.86.21.8232; KUMJIAN DA, 1991, J BIOL CHEM, V266, P3973; LEE PL, 1989, SCIENCE, V245, P5760; MARGOLIS B, 1990, SCIENCE, V248, P607, DOI 10.1126/science.2333512; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; PATERNO GD, 1989, DEVELOPMENT, V106, P79; RUTA M, 1988, ONCOGENE, V3, P9; SMITH MR, 1990, SCIENCE, V247, P1074, DOI 10.1126/science.2408147; SMITH MR, 1989, P NATL ACAD SCI USA, V86, P3659, DOI 10.1073/pnas.86.10.3659; SUTZLMAN L, 1991, MOL CELL BIOL, V11, P2018; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568	34	393	408	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 20	1992	358	6388					681	684		10.1038/358681a0	http://dx.doi.org/10.1038/358681a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JJ882	1379698				2022-12-01	WOS:A1992JJ88200058
J	MORI, H; MASAKI, H; YAMAKURA, T; MISHINA, M				MORI, H; MASAKI, H; YAMAKURA, T; MISHINA, M			IDENTIFICATION BY MUTAGENESIS OF A MG2+-BLOCK SITE OF THE NMDA RECEPTOR CHANNEL	NATURE			English	Article							METHYL-D-ASPARTATE; EXCITATORY AMINO-ACIDS; MOUSE CENTRAL NEURONS; SPINAL-CORD NEURONS; ANTICONVULSANT MK-801; ACTIVATED CHANNELS; CORTICAL-NEURONS; RESPONSES; ZINC; PERMEABILITY	THE N-methyl-D-aspartate (NMDA) receptor channel is highly permeable to Ca2+ but is blocked by Mg2+ in a voltage-dependent manner1-4. These characteristics are essential for the NMDA receptor channel to mediate the induction of long-term potentiation of synaptic efficacy, a form of activity-dependent synaptic plasticity thought to underlie memory, learning and development5-8. Recent studies have revealed the molecular and functional diversity of the NMDA receptor channel subunits, which are classified into the epsilon and zeta families according to the amino-acid sequence homology9-12. Here we report that replacement by glutamine of asparagine 598 in putative transmembrane segment M2 of the zeta-1 subunit, strongly reduces the sensitivity of the heteromeric epsilon-2/zeta-1 NMDA receptor channel to Mg2+ block. The corresponding mutation of the epsilon-2 subunit has a similar effect. Furthermore, the heteromeric epsilon-2/zeta-1 NMDA receptor channel with the mutation on both subunits shows greatly reduced sensitivity to MK-801, a channel blocker of the NMDA receptor channel13,14, but is still susceptible to inhibition by Zn2+ 15,16. These findings suggest that the conserved asparagine residue in segment M2 constitutes a Mg2+-block site of the NMDA receptor channel, and that the MK-801 site overlaps the Mg2+ site.	NIIGATA UNIV, BRAIN RES INST, DEPT NEUROPHARMACOL, ASAHIMACHI 1, NIIGATA 95021, JAPAN	Niigata University								ASCHER P, 1988, J PHYSIOL-LONDON, V399, P247; ASHCER P, 1986, J PHYSIOL-LONDON, V377, pP35; BURNASHEV N, 1992, NEURON, V8, P189, DOI 10.1016/0896-6273(92)90120-3; CHRISTINE CW, 1990, J NEUROSCI, V10, P108; COLLINGRIDGE GL, 1987, TRENDS NEUROSCI, V10, P288, DOI 10.1016/0166-2236(87)90175-5; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; HERRON CE, 1986, NATURE, V322, P265, DOI 10.1038/322265a0; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUETTNER JE, 1988, P NATL ACAD SCI USA, V85, P1307, DOI 10.1073/pnas.85.4.1307; HUME RI, 1991, SCIENCE, V253, P1028, DOI 10.1126/science.1653450; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; LEGENDRE P, 1990, J PHYSIOL-LONDON, V429, P429, DOI 10.1113/jphysiol.1990.sp018266; LEONARD JP, 1990, NEURON, V4, P53, DOI 10.1016/0896-6273(90)90443-J; MACDERMOTT AB, 1986, NATURE, V321, P519, DOI 10.1038/321519a0; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MCDONALD JW, 1990, BRAIN RES REV, V15, P41, DOI 10.1016/0165-0173(90)90011-C; MEGURO H, 1992, NATURE, V357, P70, DOI 10.1038/357070a0; MISHINA M, 1991, BIOCHEM BIOPH RES CO, V180, P813, DOI 10.1016/S0006-291X(05)81137-4; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; PETERS S, 1987, SCIENCE, V236, P589, DOI 10.1126/science.2883728; SAKIMURA K, 1990, FEBS LETT, V272, P73, DOI 10.1016/0014-5793(90)80452-O; WESTBROOK GL, 1987, NATURE, V328, P640, DOI 10.1038/328640a0; WONG EHF, 1986, P NATL ACAD SCI USA, V83, P7104, DOI 10.1073/pnas.83.18.7104; YAMAZAKI M, 1992, FEBS LETT, V300, P39, DOI 10.1016/0014-5793(92)80160-I	25	218	220	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 20	1992	358	6388					673	675		10.1038/358673a0	http://dx.doi.org/10.1038/358673a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JJ882	1386653				2022-12-01	WOS:A1992JJ88200055
J	PETERS, KG; MARIE, J; WILSON, E; IVES, HE; ESCOBEDO, J; DELROSARIO, M; MIRDA, D; WILLIAMS, LT				PETERS, KG; MARIE, J; WILSON, E; IVES, HE; ESCOBEDO, J; DELROSARIO, M; MIRDA, D; WILLIAMS, LT			POINT MUTATION OF AN FGF RECEPTOR ABOLISHES PHOSPHATIDYLINOSITOL TURNOVER AND CA2+ FLUX BUT NOT MITOGENESIS	NATURE			English	Article							PHOSPHOLIPASE-C-GAMMA; GROWTH-FACTOR RECEPTOR; TYROSINE PHOSPHORYLATION; EGF RECEPTOR; KINASE-ACTIVITY; BINDING-SITE; PDGF; HYDROLYSIS; SUBSTRATE; C-GAMMA-1	STIMULATION of certain receptor tyrosine kinases results in the tyrosine phosphorylation and activation of phospholipase C(gamma)(PLC-gamma), an enzyme that catalyses the hydrolysis of phosphatidylinositol ( PtdIns)1-8. This hydrolysis generates diacylglycerol and free inositol phosphate, which in turn activate protein kinase C and increase intracellular Ca2+, respectively. PLC-gamma physically associates with activated receptor tyrosine kinases, suggesting that it is a substrate for direct phosphorylation by these kinases7-10. Here we report that a fibroblast growth factor (FGF) receptor with a single point mutation at residue 766 replacing tyrosine with phenylalanine fails to associate with PLC-gamma in response to FGF. This mutant receptor also failed to mediate PtdIns hydrolysis and Ca2+ mobilization after FGF stimulation. However, the mutant receptor phosphorylated itself and several other cellular proteins, and it mediated mitogenesis in response to FGF. These findings show that a point mutation in the FGF receptor selectively eliminates activation of PLC-gamma and that neither Ca2+ mobilization nor PtdIns hydrolysis are required for FGF-induced mitogenesis.	UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,PROGRAM EXCELLENCE MOLEC BIOL,533 PARNASSUS AVE,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DIV NEPHROL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco								BROWN KD, 1989, FEBS LETT, V247, P227, DOI 10.1016/0014-5793(89)81340-7; BURGESS WH, 1990, MOL CELL BIOL, V10, P4770, DOI 10.1128/MCB.10.9.4770; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; COCHET C, 1984, J BIOL CHEM, V259, P2553; CUADRADO A, 1990, MOL CELL BIOL, V10, P6069, DOI 10.1128/MCB.10.11.6069; DECKER SJ, 1992, J BIOL CHEM, V267, P1104; DOWNING JR, 1989, EMBO J, V8, P3345, DOI 10.1002/j.1460-2075.1989.tb08496.x; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FRIEDMAN B, 1989, P NATL ACAD SCI USA, V86, P812, DOI 10.1073/pnas.86.3.812; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; HUANG CL, 1991, J BIOL CHEM, V266, P4045; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KUMJIAN DA, 1991, J BIOL CHEM, V266, P3973; MARGOLIS B, 1990, SCIENCE, V248, P607, DOI 10.1126/science.2333512; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MASLANSKI JA, 1992, SCIENCE, V256, P243, DOI 10.1126/science.1314424; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; OLWIN BB, 1989, J CELL BIOCHEM, V39, P443, DOI 10.1002/jcb.240390410; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; SULTZMAN L, 1991, MOL CELL BIOL, V11, P2018, DOI 10.1128/MCB.11.4.2018; VEGA QC, 1992, MOL CELL BIOL, V12, P128, DOI 10.1128/MCB.12.1.128; VETTER ML, 1991, P NATL ACAD SCI USA, V88, P5650, DOI 10.1073/pnas.88.13.5650; WAHL MI, 1989, MOL CELL BIOL, V9, P2934, DOI 10.1128/MCB.9.7.2934; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263	30	365	376	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 20	1992	358	6388					678	681		10.1038/358678a0	http://dx.doi.org/10.1038/358678a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JJ882	1379697				2022-12-01	WOS:A1992JJ88200057
J	SEGREDO, V; CALDWELL, JE; MATTHAY, MA; SHARMA, ML; GRUENKE, LD; MILLER, RD				SEGREDO, V; CALDWELL, JE; MATTHAY, MA; SHARMA, ML; GRUENKE, LD; MILLER, RD			PERSISTENT PARALYSIS IN CRITICALLY ILL PATIENTS AFTER LONG-TERM ADMINISTRATION OF VECURONIUM	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ORG NC 45; RENAL-FAILURE; BLOCKING ACTIONS; PHARMACOKINETICS; PANCURONIUM; BROMIDE; CAT; 3-DESACETYLVECURONIUM; PHARMACODYNAMICS; PHARMACOLOGY	Background. The muscle relaxant vecuronium is sometimes administered to facilitate mechanical ventilation. Neuromuscular paralysis lasting up to seven days may occur after the termination of long-term administration (i.e., more than two days) of vecuronium in critically ill patients. We investigated the role of clinical factors and plasma concentrations of vecuronium and its metabolite in causing this prolonged neuromuscular blockade. Methods. We studied 16 critically ill adult patients (8 women and 8 men) who had received vecuronium to facilitate mechanical ventilation for at least two consecutive days. Clinical factors and plasma concentrations of vecuronium and 3-desacetylvecuronium, the active metabolite of vecuronium, were compared in patients with and without prolonged neuromuscular blockade. In addition, we performed detailed pharmacokinetic studies in the patients without prolonged neuromuscular blockade. Results. Seven of the 16 patients had prolonged neuromuscular blockade, lasting from six hours to more than seven days, after the termination of vecuronium therapy. These seven patients, six of whom were women, had higher plasma magnesium concentrations and lower arterial blood pH values than the nine patients without prolonged neuromuscular blockade. They also had higher plasma concentrations of 3-desacetylvecuronium and a higher frequency of renal failure (seven of seven patients vs. four of nine patients, P<0.03). In the patients without prolonged neuromuscular blockade, the mean (+/-SD) plasma clearance, elimination half-life, and volume of distribution of vecuronium were 2.5+/-1.0 ml per kilogram of body weight per minute, 299+/-154 minutes, and 1.1+/-0.6 liters per kilogram, respectively. Conclusions. Prolonged neuromuscular blockade after the termination of long-term treatment with vecuronium is associated with metabolic acidosis, elevated plasma magnesium concentrations, female sex, and probably more important, the presence of renal failure and high plasma concentrations of 3-desacetylvecuronium.	UNIV CALIF SAN FRANCISCO,DEPT ANESTHESIA,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco					NIGMS NIH HHS [R0I GM 26403-0648] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026403] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARDEN JR, 1988, ANESTHESIOLOGY, V68, P771, DOI 10.1097/00000542-198805000-00016; BENCINI AF, 1985, BRIT J ANAESTH, V57, P782, DOI 10.1093/bja/57.8.782; BENCINI AF, 1985, BRIT J ANAESTH, V57, P789, DOI 10.1093/bja/57.8.789; CANNON JE, 1987, ANESTHESIOLOGY, V67, P503, DOI 10.1097/00000542-198710000-00010; COURSIN DB, 1989, ANESTH ANALG, V69, P518; DANON MJ, 1991, MUSCLE NERVE, V14, P1131, DOI 10.1002/mus.880141115; DARRAH WC, 1989, CRIT CARE MED, V17, P1297, DOI 10.1097/00003246-198912000-00010; DIXON WJ, 1985, BMDP STATISTICAL SOF, P237; FAHEY MR, 1981, BRIT J ANAESTH, V53, P1049, DOI 10.1093/bja/53.10.1049; FUNK DI, 1980, ACTA ANAESTH SCAND, V24, P119, DOI 10.1111/j.1399-6576.1980.tb01518.x; FURUTA T, 1988, J CHROMATOGR-BIOMED, V427, P41, DOI 10.1016/0378-4347(88)80103-8; GIBALDI M, 1975, PHARMACOKINETICS, P27; HANSENFLASCHEN JH, 1991, JAMA-J AM MED ASSOC, V266, P2870, DOI 10.1001/jama.266.20.2870; KOPMAN AF, 1984, ANESTHESIOLOGY, V61, P83, DOI 10.1097/00000542-198461010-00015; LEBRAULT C, 1985, ANESTHESIOLOGY, V62, P601, DOI 10.1097/00000542-198505000-00010; LYNAM DP, 1988, ANESTHESIOLOGY, V69, P227, DOI 10.1097/00000542-198808000-00012; MARSHALL IG, 1983, BRIT J ANAESTH, V55, P703, DOI 10.1093/bja/55.8.703; MATTHAY MA, 1989, TXB PULMONARY DISEAS, V2, P1055; MEISTELMAN C, 1986, EUR J ANAESTH, V3, P153; MILLER RD, 1984, ANESTHESIOLOGY, V61, P444, DOI 10.1097/00000542-198410000-00014; MURRAY JF, 1988, AM REV RESPIR DIS, V138, P720, DOI 10.1164/ajrccm/138.3.720; MURRAY JF, 1989, AM REV RESPIR DIS, V139, P1065; ONO K, 1988, ANESTHESIOLOGY, V68, P357, DOI 10.1097/00000542-198803000-00006; RUBIN DB, 1990, J CLIN INVEST, V86, P474, DOI 10.1172/JCI114733; SEGREDO V, 1991, ANESTHESIOLOGY, V74, P1052, DOI 10.1097/00000542-199106000-00013; SEGREDO V, 1990, ANESTHESIOLOGY, V72, P566, DOI 10.1097/00000542-199003000-00030; SHEARER ES, 1991, BRIT J ANAESTH, V67, P569, DOI 10.1093/bja/67.5.569; SMITH CL, 1987, ANAESTHESIA, V42, P387, DOI 10.1111/j.1365-2044.1987.tb03980.x; SMITH CL, 1987, ANAESTHESIA, V42, P925; UPTON RA, 1982, ANESTH ANALG, V61, P313; VIBYMOGENSEN J, 1982, BRIT J ANAESTH, V54, P209, DOI 10.1093/bja/54.2.209; WASER PG, 1987, BRIT J ANAESTH, V59, P1044, DOI 10.1093/bja/59.8.1044; WITT NJ, 1991, CHEST, V99, P176, DOI 10.1378/chest.99.1.176	33	336	342	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 20	1992	327	8					524	528		10.1056/NEJM199208203270804	http://dx.doi.org/10.1056/NEJM199208203270804			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JJ457	1353252				2022-12-01	WOS:A1992JJ45700004
J	VANDERWINDEN, JM; MAILLEUX, P; SCHIFFMANN, SN; VANDERHAEGHEN, JJ; DELAET, MH				VANDERWINDEN, JM; MAILLEUX, P; SCHIFFMANN, SN; VANDERHAEGHEN, JJ; DELAET, MH			NITRIC-OXIDE SYNTHASE ACTIVITY IN INFANTILE HYPERTROPHIC PYLORIC-STENOSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NEURONAL NADPH-DIAPHORASE; INHIBITORY TRANSMISSION; NERVOUS-SYSTEM; 2ND MESSENGER; GUINEA-PIG; MUSCLE; INVOLVEMENT; PEPTIDE; BRAIN; NO	Background. Hypertrophic pyloric stenosis is a common infantile disorder characterized by enlarged pyloric musculature and gastric-outlet obstruction. Its physiopathologic mechanism is not known, but a defect in pyloric relaxation (pylorospasm) has been postulated. Nitric oxide is a mediator of relaxation in the mammalian digestive tract, raising the possibility that pylorospasm could be caused by a defect in nitric oxide production. Since neuronal nitric oxide synthase and NADPH diaphorase are identical, we used the NADPH diaphorase histochemical reaction to study the distribution of nitric oxide synthase in pyloric tissue from patients with infantile hypertrophic pyloric stenosis. Methods. We studied pyloric tissue from nine infants with infantile hypertrophic pyloric stenosis and seven control infants and children. Cryostat sections were processed for NADPH diaphorase histochemical analysis. A polyclonal tau antiserum was used to identify the enteric nervous system by immunohistochemical methods. Results. NADPH diaphorase activity was restricted to the enteric nervous system and blood vessels. In the pyloric tissues from the control patients, intense diaphorase activity was present in the nerve fibers of the circular musculature, in the neurons and nerve bundles of the myenteric plexus, and in some nerve fibers of the longitudinal musculature. In the pyloric tissues from patients with infantile hypertrophic pyloric stenosis, the enteric nerve fibers in the hypertrophied circular musculature were enlarged and distorted and did not contain diaphorase activity, whereas the activity in the myenteric plexus and the longitudinal musculature was preserved. Conclusions. We suggest that a lack of nitric oxide synthase in pyloric tissue is responsible for pylorospasm in infantile hypertrophic pyloric stenosis.	ERASME ACAD HOSP,DEPT SURG,BRUSSELS,BELGIUM; ERASME ACAD HOSP,NEUROPATHOL & NEUROPEPTIDE RES LAB,BRUSSELS,BELGIUM; FREE UNIV BRUSSELS,CHILDRENS HOSP,DEPT PEDIAT SURG,B-1050 BRUSSELS,BELGIUM; UNIV LIBRE BRUXELLES,FAC MED,B-1050 BRUSSELS,BELGIUM	Universite Libre de Bruxelles; Universite Libre de Bruxelles; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles				Schiffmann, Serge/0000-0002-0118-9816				BRANCHEK TA, 1989, J COMP NEUROL, V285, P262, DOI 10.1002/cne.902850208; BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BRION JP, 1991, BIOCHEM J, V273, P127, DOI 10.1042/bj2730127; BULT H, 1990, NATURE, V345, P346, DOI 10.1038/345346a0; COLLIER J, 1989, TRENDS PHARMACOL SCI, V10, P427, DOI 10.1016/S0165-6147(89)80001-X; CROSSIN KL, 1991, TRENDS BIOCHEM SCI, V16, P81, DOI 10.1016/0968-0004(91)90036-U; DALZIEL HH, 1991, AM J PHYSIOL, V260, pG789, DOI 10.1152/ajpgi.1991.260.5.G789; DAWSON TM, 1991, P NATL ACAD SCI USA, V88, P7797, DOI 10.1073/pnas.88.17.7797; DESAI KM, 1991, NATURE, V351, P477, DOI 10.1038/351477a0; DIELER R, 1990, ACTA NEUROPATHOL, V80, P295, DOI 10.1007/BF00294648; DIELER R, 1989, ACTA NEUROPATHOL, V78, P649, DOI 10.1007/BF00691292; GARTHWAITE J, 1991, TRENDS NEUROSCI, V14, P60, DOI 10.1016/0166-2236(91)90022-M; GUSTAFSSON LE, 1990, BIOCHEM BIOPH RES CO, V173, P106, DOI 10.1016/S0006-291X(05)81028-9; HAYES MA, 1957, INT ABSTR SURG, V104, P105; HOPE BT, 1991, P NATL ACAD SCI USA, V88, P2811, DOI 10.1073/pnas.88.7.2811; HOPE BT, 1989, J HISTOCHEM CYTOCHEM, V37, P653, DOI 10.1177/37.5.2703701; LEHMANN W, 1931, Z KINDERHEILKD, V50, P691; LI CG, 1990, EUR J PHARMACOL, V191, P303; LYNN HB, 1960, ARCH SURG-CHICAGO, V81, P453; MONCADA S, 1991, EUR J CLIN INVEST, V21, P361, DOI 10.1111/j.1365-2362.1991.tb01383.x; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; SHUTTLEWORTH CWR, 1991, NEUROSCI LETT, V130, P77, DOI 10.1016/0304-3940(91)90231-H; SNYDER SH, 1991, TRENDS PHARMACOL SCI, V12, P125, DOI 10.1016/0165-6147(91)90526-X; Tam P K, 1985, Ann Acad Med Singap, V14, P523; TAM PKH, 1990, GASTROENTEROLOGY, V99, P1841, DOI 10.1016/0016-5085(90)90499-Q; TOTTRUP A, 1991, AM J PHYSIOL, V260, pG385, DOI 10.1152/ajpgi.1991.260.3.G385; UKABIALA O, 1987, J PEDIATR SURG, V22, P200, DOI 10.1016/S0022-3468(87)80326-3; WATTCHOW DA, 1987, GASTROENTEROLOGY, V92, P443, DOI 10.1016/0016-5085(87)90140-5; YAMASHIRO Y, 1981, EUR J PEDIATR, V136, P187, DOI 10.1007/BF00441922	30	284	290	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 20	1992	327	8					511	515		10.1056/NEJM199208203270802	http://dx.doi.org/10.1056/NEJM199208203270802			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JJ457	1378938				2022-12-01	WOS:A1992JJ45700002
J	BAKKEN, LL; CASE, KL; CALLISTER, SM; BOURDEAU, NJ; SCHELL, RF				BAKKEN, LL; CASE, KL; CALLISTER, SM; BOURDEAU, NJ; SCHELL, RF			PERFORMANCE OF 45 LABORATORIES PARTICIPATING IN A PROFICIENCY TESTING PROGRAM FOR LYME-DISEASE SEROLOGY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LINKED IMMUNOSORBENT-ASSAY; BORRELIA-BURGDORFERI; ANTIBODY; SERODIAGNOSIS	Objective.-We show that significant interlaboratory and intralaboratory variations exist in Lyme disease proficiency testing. Design.-Six case-defined Lyme serum samples and three serum samples from individuals with no history of Lyme disease were randomized in four shipments and distributed to 45 participating laboratories. Results.-Interlaboratory and intralaboratory performances were highly variable. Approximately 4% to 21% of laboratories failed to identify correctly positive serum samples with titers of 512 or more using polyvalent serum or immunoglobulin G conjugates. With lower levels of anti-Borrelia burgdorferi antibody in the serum sample, approximately 55% of participating laboratories did not identify a case-defined serum. There was also a striking inability of many laboratories to reproduce their results on split samples from the same individual. In addition, 2% to 7% of laboratories identified serum samples from individuals with no known exposure to B burgdorferi as positive using polyvalent serum. The false positivity rate increased to 27% with the use of immunoglobulin G conjugate. Conclusions.-Our results indicate that there is an urgent need for standardization of current testing methodologies. Until a national commitment is made, serological testing for Lyme disease will be of questionable value for the diagnosis of the disease.	UNIV WISCONSIN,WISCONSIN STATE LAB HYG,465 HENRY MALL,MADISON,WI 53706; UNIV WISCONSIN,DEPT MED MICROBIOL & IMMUNOL,MADISON,WI 53706; UNIV WISCONSIN,DEPT BACTERIOL,MADISON,WI 53706; GUNDERSON MED FDN,LA CROSSE,WI; LUTHERAN HOSP,LA CROSSE,WI	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Gundersen Lutheran Medical Center								AFZELIUS A, 1990, ARCH DERAMTOL SYPH, V101, P405; BERGSTROM S, 1991, EUR J CLIN MICROBIOL, V10, P422, DOI 10.1007/BF01968022; CALLISTER SM, 1988, J CLIN MICROBIOL, V26, P2632, DOI 10.1128/JCM.26.12.2632-2636.1988; HEDBERG CW, 1987, J INFECT DIS, V155, P1325, DOI 10.1093/infdis/155.6.1325; HEDBERG CW, 1990, ARCH INTERN MED, V150, P732; JONES JM, 1991, ANN INTERN MED, V114, P1064, DOI 10.7326/0003-4819-114-12-1064_1; LANE RS, 1990, J CLIN MICROBIOL, V28, P1774, DOI 10.1128/JCM.28.8.1774-1779.1990; LUGER SW, 1990, ARCH INTERN MED, V150, P761, DOI 10.1001/archinte.150.4.761; MAGNARELLI LA, 1984, J CLIN MICROBIOL, V20, P181, DOI 10.1128/JCM.20.2.181-184.1984; QUAN TJ, 1991, 1ST P NAT C LYM DIS, P61; RUSSELL H, 1984, J INFECT DIS, V149, P465, DOI 10.1093/infdis/149.3.465; SCHWARTZ BS, 1989, JAMA-J AM MED ASSOC, V262, P3431, DOI 10.1001/jama.262.24.3431; SCRIMENTI RJ, 1970, ARCH DERMATOL, V102, P104, DOI 10.1001/archderm.102.1.104; STEERE AC, 1983, ANN INTERN MED, V99, P76, DOI 10.7326/0003-4819-99-1-76; STEERE AC, 1989, NEW ENGL J MED, V321, P586, DOI 10.1056/NEJM198908313210906; STEERE AC, 1983, NEW ENGL J MED, V308, P733, DOI 10.1056/NEJM198303313081301; 1991, MMWR, V40, P417	17	119	119	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 19	1992	268	7					891	895		10.1001/jama.268.7.891	http://dx.doi.org/10.1001/jama.268.7.891			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JH588	1640618				2022-12-01	WOS:A1992JH58800040
J	JOHNSON, E				JOHNSON, E			ALCOHOLS IMPACT ON FETAL CNS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											JOHNSON, E (corresponding author), US ALCOHOL DRUG ABUSE & MENTAL HLTH ADM,PUBL AFFAIRS,PARKLAWN BLDG,5600 FISHERS LANE,ROCKVILLE,MD 20857, USA.							1992, ALCOHOLISM CLIN EXPT, V16, P295	1	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 19	1992	268	7					854	854						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JH588	1640596				2022-12-01	WOS:A1992JH58800010
J	JOHNSON, E				JOHNSON, E			ELEVATED VASOPRESSIN AND BULIMIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											JOHNSON, E (corresponding author), US ALCOHOL DRUG ABUSE & MENTAL HLTH ADM,PUBL AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1992, J CLIN ENDOCRINOLOGY, V74, P1277	1	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 19	1992	268	7					854	854						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JH588	1640596				2022-12-01	WOS:A1992JH58800011
J	JOHNSON, E				JOHNSON, E			NEUROPSYCHOLOGICAL IMPAIRMENT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											JOHNSON, E (corresponding author), US ALCOHOL DRUG ABUSE & MENTAL HLTH ADM,PUBL AFFAIRS,PARKLAWN BLDG,5600 FISHERS LANE,ROCKVILLE,MD 20857, USA.							1992, AM J DRUG ALCOHOL AB, V192, P131	1	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 19	1992	268	7					854	854						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JH588	1640596				2022-12-01	WOS:A1992JH58800009
J	MILUNSKY, A; ULCICKAS, M; ROTHMAN, KJ; WILLETT, W; JICK, SS; JICK, H				MILUNSKY, A; ULCICKAS, M; ROTHMAN, KJ; WILLETT, W; JICK, SS; JICK, H			MATERNAL HEAT EXPOSURE AND NEURAL-TUBE DEFECTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EARLY-PREGNANCY; HYPERTHERMIA; SAUNA; TERATOGEN; FEVER; ABNORMALITIES; EMBRYOS; WOMEN	Objective.-To determine if exposure to hot tub, sauna, fever, or electric blanket during early pregnancy was associated with an increased risk for neural tube defects (NTDs). Design.-Prospective follow-up study. Setting.-Mostly private obstetric practices, primarily in New England. Participants.-A cohort of 23491 women having serum alpha-fetoprotein screening or an amniocentesis were identified. Complete exposure and outcome information was available for 97% of these women. Outcome Measures.-Relative risks (RRs) were used to compare incidence of NTD in those exposed to heat with those who were not exposed to any heat. Crude RRs were calculated directly from the data. Unconfounded RRs were calculated using logistic regression. Results.-Women reporting any heat exposure (sauna, hot tub, fever, or electric blanket) in early pregnancy had a crude risk of their fetuses developing NTD of 1.6 (95% CI [confidence interval], 0.9 to 2.9). Women reporting exposure to sauna, hot tub, or fever in early pregnancy had a crude risk of their fetuses developing NTD 2.2 times that of women without heat exposure (95% CI, 1.2 to 4.1). For hot tub use, the crude RR was 2.9 (95% CI, 1.4 to 6.3); for sauna, 2.6 (95% CI, 0.7 to 10.1); for fever, 1.9 (95% CI, 0.8 to 4.1); and for electric blanket, 1.2 (95% CI, 0.5 to 2.6). Multivariate adjusted RRs for individual heat sources, after controlling for maternal age, folic acid supplements, family history of NTD, and exposure to other heat sources, were for hot tub use, 2.8 (95% CI, 1.2 to 6.5); sauna, 1.8 (95% CI, 0.4 to 7.9); fever, 1.8 (95% CI, 0.8 to 4.1); and electric blanket, 1.2 (95% CI, 0.5 to 2.6). When only hot tub, sauna, and fever were considered and the women's exposure to each tallied, compared with no heat exposure, the RR for NTDs increased from 1.9 (95% CI, 0.9 to 3.7) after one type of heat exposure to 6.2 (95% CI, 2.2 to 17.2) after two types of heat exposure. Conclusions.-Exposure to heat in the form of hot tub, sauna, or fever in the first trimester of pregnancy was associated with an increased risk for NTDs. Hot tub exposure appeared to have the strongest effect of any single heat exposure. Exposure to electric blanket was not materially associated with increased risk for NTDs.	BOSTON UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02118; BOSTON UNIV,SCH MED,BOSTON COLLABORAT DRUG SURVEILLANCE PROGRAM,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT MED & EPIDEMIOL,BOSTON,MA 02118; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,BOSTON,MA 02115; HARVARD UNIV,SCH MED,CHANNING LAB,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,BOSTON,MA 02115	Boston University; Boston University; Boston University; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	MILUNSKY, A (corresponding author), BOSTON UNIV,SCH MED,CTR HUMAN GENET,80 E CONCORD ST,BOSTON,MA 02118, USA.			Rothman, Kenneth/0000-0003-2398-1705; Jick, Hershel/0000-0003-4270-5992; Jick, Susan/0000-0002-2215-1067; Milunsky, Aubrey/0000-0003-2114-4823	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019561] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 19561] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARORA KL, 1979, TERATOLOGY, V19, P251, DOI 10.1002/tera.1420190216; BRINSMADE A B, 1957, Beitr Pathol Anat, V117, P154; CHANCE PF, 1978, LANCET, V1, P769; COCKROFT DL, 1978, TERATOLOGY, V17, P277, DOI 10.1002/tera.1420170306; EDWARDS MJ, 1972, LANCET, V1, P320; EDWARDS MJ, 1974, J EMBRYOL EXP MORPH, V32, P593; EDWARDS MJ, 1967, ARCH PATHOL, V84, P42; EDWARDS MJ, 1986, TERATOGEN CARCIN MUT, V6, P563, DOI 10.1002/tcm.1770060610; FISHER NL, 1981, PEDIATRICS, V68, P480; FRASER FC, 1978, LANCET, V2, P634; GERMAN J, 1984, AM J MED, V76, P293, DOI 10.1016/0002-9343(84)90788-5; GRAHAM JM, 1988, TERATOLOGY, V37, P461; HARTLEY WJ, 1974, TERATOLOGY, V9, P299, DOI 10.1002/tera.1420090309; HARVEY MAS, 1981, CAN MED ASSOC J, V125, P50; HENDRICKX AG, 1979, TERATOLOGY, V19, P177, DOI 10.1002/tera.1420190208; HUNTER AGW, 1984, AM J MED GENET, V19, P45, DOI 10.1002/ajmg.1320190108; KILHAM L, 1976, TERATOLOGY, V14, P323, DOI 10.1002/tera.1420140307; KLEINEBRECHT J, 1979, LANCET, V1, P1403; LAYDE PM, 1980, TERATOLOGY, V21, P105, DOI 10.1002/tera.1420210114; LIPSON A, 1988, AM J MED GENET, V29, P117, DOI 10.1002/ajmg.1320290114; MIETTINEN O, 1976, AM J EPIDEMIOL, V103, P226, DOI 10.1093/oxfordjournals.aje.a112220; MILLER P, 1978, LANCET, V1, P519; MILUNSKY A, 1989, JAMA-J AM MED ASSOC, V262, P2847, DOI 10.1001/jama.262.20.2847; NILSEN NO, 1984, TERATOLOGY, V30, P237, DOI 10.1002/tera.1420300211; PLEET H, 1981, PEDIATRICS, V67, P785; SAXEN L, 1982, TERATOLOGY, V25, P309, DOI 10.1002/tera.1420250307; SHIOTA K, 1982, AM J MED GENET, V12, P281, DOI 10.1002/ajmg.1320120306; SMITH DW, 1978, J PEDIATR-US, V92, P878, DOI 10.1016/S0022-3476(78)80352-7; SOHAR E, 1976, ISRAEL J MED SCI, V12, P1275; SPRAGGETT K, 1982, TERATOLOGY, V25, pA78; SUPERNEAU DW, 1985, AM J MED GENET, V21, P575, DOI 10.1002/ajmg.1320210319; UHARI M, 1979, BRIT MED J, V1, P1216, DOI 10.1136/bmj.1.6172.1216; UMPIERRE CC, 1978, TERATOLOGY, V16, P155; WANNER RA, 1976, J PATHOL, V118, P235, DOI 10.1002/path.1711180406; WARKANY J, 1986, TERATOLOGY, V33, P365, DOI 10.1002/tera.1420330316; WEBSTER WS, 1984, TERATOLOGY, V29, P417, DOI 10.1002/tera.1420290313; 1978, BMJ, V2, P1586; 1978, LANCET, V2, P560	38	187	193	0	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 19	1992	268	7					882	885		10.1001/jama.268.7.882	http://dx.doi.org/10.1001/jama.268.7.882			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JH588	1640616				2022-12-01	WOS:A1992JH58800038
J	NICHOLAS, R; OMEARA, PD; CALONGE, N				NICHOLAS, R; OMEARA, PD; CALONGE, N			IS SYNCOPE RELATED TO MODERATE ALTITUDE EXPOSURE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							BLOOD-PRESSURE; CIRCULATORY ADJUSTMENTS; DIAGNOSTIC EVALUATION; FOLLOW-UP; HYPOXIA	Study Objective.-To investigate factors related to syncope occurring on recent ascent to moderate altitude. Design.-A 1-year retrospective case-control study, using local acclimatized residents as a control group. Setting.-The two main ambulance destinations for Summit County, Colorado (elevation, 2770 m). Patients.-All patients with a diagnosis of syncope, near-syncope, or fainting whose medical records were available for review. Results.-There was a significant relationship (P<.05) between syncope of unknown origin and recent arrival at altitude (<24 hours), and a significant inverse relationship (P<.05) between syncope of unknown origin and arterial oxygen saturation as measured by pulse oximetry. Conclusions.-Short-term exposure to moderate altitude may be related to otherwise unexplained syncope in healthy young adults. We suggest the name high-altitude syncope for this entity and encourage further research in this area.	UNIV COLORADO,HLTH SCI CTR,DEPT FAMILY MED,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,AF WILLIAMS FAMILY MED RESIDENCY,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	NICHOLAS, R (corresponding author), SNAKE RIVER HLTH SERV,COLORADO ALTITUDE RES INST,POB 38,KEYSTONE,CO 80435, USA.							ABBOUD FM, 1989, NEW ENGL J MED, V320, P390, DOI 10.1056/NEJM198902093200609; APPLETON F, 1967, CIRCULATION S, V36, P55; BRINCHMANNHANSEN O, 1989, AVIAT SPACE ENVIR MD, V60, P970; CLEGG EJ, 1970, P R SOC LOND, V194, P83; DAY SC, 1982, AM J MED, V73, P15, DOI 10.1016/0002-9343(82)90913-5; DOHERTY JU, 1985, AM J CARDIOL, V55, P703, DOI 10.1016/0002-9149(85)90140-7; HEISTAD DD, 1980, CIRCULATION, V61, P463, DOI 10.1161/01.CIR.61.3.463; HOUSTON CS, 1980, GOING HIGHER; KAPOOR W, 1984, ANN INTERN MED, V100, P755, DOI 10.7326/0003-4819-100-5-755; KAPOOR W, 1986, AM J MED, V80, P419, DOI 10.1016/0002-9343(86)90716-3; KAPOOR WN, 1983, NEW ENGL J MED, V309, P197, DOI 10.1056/NEJM198307283090401; MANOLIS AS, 1990, ANN INTERN MED, V112, P850, DOI 10.7326/0003-4819-112-11-850; MARTICOR.E, 1969, AM J CARDIOL, V23, P364, DOI 10.1016/0002-9149(69)90516-5; MARTIN GJ, 1984, ANN EMERG MED, V13, P499, DOI 10.1016/S0196-0644(84)80511-9; PALATINI P, 1989, AM J CARDIOL, V64, P1379, DOI 10.1016/0002-9149(89)90587-0; PIERCE EC, 1962, J APPL PHYSIOL, V17, P899, DOI 10.1152/jappl.1962.17.6.899; STULTS BM, 1986, WESTERN J MED, V144, P234; Thoren P, 1979, Rev Physiol Biochem Pharmacol, V86, P1, DOI 10.1007/BFb0031531; WEITZ CA, 1982, SOC SCI MED, V16, P223, DOI 10.1016/0277-9536(82)90026-0; 1988, SUMMIT COUNTY STATIS	20	34	35	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 19	1992	268	7					904	906		10.1001/jama.268.7.904	http://dx.doi.org/10.1001/jama.268.7.904			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JH588	1640621				2022-12-01	WOS:A1992JH58800043
J	STAMPFER, MJ; MALINOW, MR; WILLETT, WC; NEWCOMER, LM; UPSON, B; ULLMANN, D; TISHLER, PV; HENNEKENS, CH				STAMPFER, MJ; MALINOW, MR; WILLETT, WC; NEWCOMER, LM; UPSON, B; ULLMANN, D; TISHLER, PV; HENNEKENS, CH			A PROSPECTIVE-STUDY OF PLASMA HOMOCYST(E)INE AND RISK OF MYOCARDIAL-INFARCTION IN UNITED-STATES PHYSICIANS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY-ARTERY DISEASE; BETA-SYNTHASE DEFICIENCY; PERFORMANCE LIQUID-CHROMATOGRAPHY; ENDOTHELIAL-CELL INJURY; VASCULAR-DISEASE; HOMOCYSTEINE; HOMOCYSTINURIA; HYPERHOMOCYST(E)INEMIA; PREVALENCE; CAROTENE	Objective.-To assess prospectively the risk of coronary heart disease associated with elevated plasma levels of homocyst(e)ine. Design.-Nested case-control study using prospectively collected blood samples. Setting.-Participants in the Physicians' Health Study. Participants.-A total of 14916 male physicians, aged 40 to 84 years, with no prior myocardial infarction (MI) or stroke provided plasma samples at baseline and were followed up for 5 years. Samples from 271 men who subsequently developed MI were analyzed for homocyst(e)ine levels together with paired controls, matched by age and smoking. Main Outcome Measure.-Acute MI or death due to coronary disease. Results.-Levels of homocyst(e)ine were higher in cases than in controls (11.1+/-4.0 [SD] vs 10.5+/-2.8 nmol/mL; P=.03). The difference was attributable to an excess of high values among men who later had MIs. The relative risk for the highest 5% vs the bottom 90% of homocyst(e)ine levels was 3.1 (95% confidence interval, 1.4 to 6.9; P=.005). After additional adjustment for diabetes, hypertension, aspirin assignment, Quetelet's Index, and total/high-density lipoprotein cholesterol, this relative risk was 3.4 (95% confidence interval, 1.3 to 8.8) (P=.01). Thirteen controls and 31 cases (11%) had values above the 95th percentile of the controls. Conclusions.- Moderately high levels of plasma homocyst(e)ine are associated with subsequent risk of MI independent of other coronary risk factors. Because high levels can often be easily treated with vitamin supplements, homocyst(e)ine may be an independent, modifiable risk factor.	HARVARD UNIV,SCH MED,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,BOSTON,MA 02115; OREGON REG PRIMATE RES CTR,BEAVERTON,OR 97006; OREGON HLTH SCI UNIV,DEPT MED,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT COMMUNITY & PREVENT MED,PORTLAND,OR 97201; BROCKTON W ROXBURY VET AFFAIRS MED CTR,BROCKTON,MA; HARVARD UNIV,SCH MED,DEPT PREVENT MED,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Oregon Health & Science University; Oregon National Primate Research Center; Oregon Health & Science University; Oregon Health & Science University; Harvard University; Harvard University; Harvard Medical School	STAMPFER, MJ (corresponding author), BRIGHAM & WOMENS HOSP,DEPT MED,CHANNING LAB,180 LONGWOOD AVE,BOSTON,MA 02115, USA.				NCI NIH HHS [CA42182] Funding Source: Medline; NHLBI NIH HHS [HL34595, HL26490] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042182] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034595] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1989, NEW ENGL J MED, V321, P129; BRATTSTROM L, 1988, METABOLISM, V37, P175, DOI 10.1016/S0026-0495(98)90014-2; BRATTSTROM LE, 1988, SCAND J CLIN LAB INV, V48, P215, DOI 10.3109/00365518809167487; CLARKE R, 1991, NEW ENGL J MED, V324, P1149, DOI 10.1056/NEJM199104253241701; DEGROOT PG, 1983, EUR J CLIN INVEST, V13, P405, DOI 10.1111/j.1365-2362.1983.tb00121.x; GENEST JJ, 1990, J AM COLL CARDIOL, V16, P1114, DOI 10.1016/0735-1097(90)90542-W; GENEST JJ, 1991, ARTERIOSCLER THROMB, V11, P1129, DOI 10.1161/01.ATV.11.5.1129; ISRAELSSON B, 1988, ATHEROSCLEROSIS, V71, P227, DOI 10.1016/0021-9150(88)90147-5; KANG SS, 1991, AM J HUM GENET, V48, P536; KANG SS, 1986, J CLIN INVEST, V77, P1482, DOI 10.1172/JCI112461; KANG SS, 1987, METABOLISM, V36, P458, DOI 10.1016/0026-0495(87)90043-6; KATRANGI N, 1984, J LIPID RES, V25, P400; MALINOW MR, 1990, CIRCULATION, V81, P2004, DOI 10.1161/01.CIR.81.6.2004; MALINOW MR, 1989, CIRCULATION, V79, P1180, DOI 10.1161/01.CIR.79.6.1180; MALINOW MR, 1990, CORONARY ARTERY DIS, V1, P215, DOI 10.1097/00019501-199003000-00010; MALINOW MR, 1992, NUTR METAB CARDIOVAS, V1, P166; MANORE MM, 1989, AM J CLIN NUTR, V50, P339, DOI 10.1093/ajcn/50.2.339; MEREAURICHARD C, 1991, CLIN CHEM, V37, P126; Mudd Sh, 1989, METABOLIC BASIS INHE, V1, P693; MURPHYCHUTORIAN DR, 1985, J AM COLL CARDIOL, V6, P725, DOI 10.1016/S0735-1097(85)80473-3; Polansky M. M., 1985, METHODS VITAMIN ASSA, P417; REED T, 1991, CLIN GENET, V39, P425; RUBBA P, 1990, METABOLISM, V39, P1191, DOI 10.1016/0026-0495(90)90093-R; SMOLIN LA, 1981, J PEDIATR-US, V99, P467, DOI 10.1016/S0022-3476(81)80352-6; SMOLIN LA, 1988, ANAL BIOCHEM, V168, P374, DOI 10.1016/0003-2697(88)90332-6; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P373, DOI 10.1056/NEJM199108083250601; STAMPFER MJ, 1985, STAT MED, V4, P111, DOI 10.1002/sim.4780040202; STARKEBAUM G, 1986, J CLIN INVEST, V77, P1370, DOI 10.1172/JCI112442; STORER BE, 1983, APPL STAT-J ROY ST C, V32, P172; SUBAR AF, 1989, AM J CLIN NUTR, V50, P508, DOI 10.1093/ajcn/50.3.508; UELAND PM, 1989, J LAB CLIN MED, V114, P473; WALL RT, 1980, THROMB RES, V18, P113, DOI 10.1016/0049-3848(80)90175-9; WILCKEN DEL, 1985, METABOLISM, V34, P1115, DOI 10.1016/0026-0495(85)90156-8; WILCKEN DEL, 1976, J CLIN INVEST, V57, P1079, DOI 10.1172/JCI108350; WILLIAMS RR, 1990, CORONARY ARTERY DIS, V1, P681, DOI 10.1097/00019501-199011000-00008; 1971, 5TH WORK GROUP COP	36	1391	1455	1	18	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 19	1992	268	7					877	881		10.1001/jama.268.7.877	http://dx.doi.org/10.1001/jama.268.7.877			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JH588	1640615				2022-12-01	WOS:A1992JH58800037
J	AABY, P				AABY, P			INFLUENCE OF CROSS-SEX TRANSMISSION ON MEASLES MORTALITY IN RURAL SENEGAL	LANCET			English	Article							INTENSIVE EXPOSURE; CHILD-MORTALITY; INFECTION; PATTERN	Previous studies of measles mortality in West Africa have shown a significantly higher case-fatality rate (CFR) among girls than among boys. This study aimed to find out whether the male/female difference in CFR is related to different risks for boys and girls of being infected as secondary rather than index cases and of transmission from someone of the same or the opposite sex. The study was conducted in Niakhar, a rural area of Senegal (population 24 000). All cases of measles reported between March, 1983, and December, 1986, were investigated to determine source of infection and pattern of transmission. For each case, the closest source of infection was judged the most likely. Death was attributed to measles if it occurred within 6 weeks of the onset of rash. Girls had a higher measles CFR than boys (53 deaths/722 cases [7.3%] vs 45/778 [5.8%]); the relative risk of death was 1.30 (95% confidence interval [CI] 0.89-1.90). Secondary cases infected by a child of the opposite sex had a 2.44 (1.48-4.02) times higher risk of death than did secondary cases infected by a child of the same sex. The risk of cross-sex transmission of infection was significantly greater for female than for male secondary cases (1.26 [1.09-1.47]). When this difference in risk of exposure to infection from the opposite sex was taken into account, the difference in risk of death between girls and boys disappeared (1.06 [0.66-1.69]). Within families, the CFR was higher in huts with 1 boy and 1 girl affected than in huts of either 2 boys or 2 girls affected (relative risk 2.16 [0.99-4.70]). Measles infection contracted from a person of the opposite sex is more severe. Variation in exposure may be an important determinant of sex differences in case fatality.	ORSTOM,UNITE RECH POPULAT & SANTE,DAKAR,SENEGAL; STATENS SERUM INST,DEPT EPIDEMIOL,DK-2300 COPENHAGEN,DENMARK	Institut de Recherche pour le Developpement (IRD); Statens Serum Institut				Aaby, Peter/0000-0001-8331-1389				AABY P, 1991, LANCET, V338, P1518, DOI 10.1016/0140-6736(91)92330-5; AABY P, 1991, J INFECTION, V22, P287, DOI 10.1016/S0163-4453(05)80014-3; AABY P, 1988, REV INFECT DIS, V10, P478; AABY P, 1991, ANN TROP PAEDIATR, V11, P397, DOI 10.1080/02724936.1991.11747537; AABY P, 1991, INT J EPIDEMIOL, V20, P504, DOI 10.1093/ije/20.2.504; AABY P, 1984, REV INFECT DIS, V6, P239; AABY P, 1990, BRIT MED J, V301, P143, DOI 10.1136/bmj.301.6744.143; AABY P, 1986, REV INFECT DIS, V8, P138; AABY P, 1983, ANTHR SOC, V7, P47; ARGUES P, 1988, DOUZE ANS MORTALITE; BABBOTT FL, 1954, AM J MED SCI, V228, P334; BHUIYA A, 1984, SOC SCI MED, V24, P439; GARENNE M, 1990, J INFECT DIS, V161, P1088, DOI 10.1093/infdis/161.6.1088; Garenne M. L, 1982, THESIS U PENNSYLVANI; MCGREGOR I A, 1964, West Afr Med J, V13, P251; MONASTIRI H, 1961, Tunis Med, V39, P179; PISON G, 1992, BRIT MED J, V304, P284, DOI 10.1136/bmj.304.6822.284; Rothman KJ, 1986, MODERN EPIDEMIOLOGY; 1991, WKLY EPIDEMIOL REC, V66, P249; IN PRESS WKLY EPIDEM	20	30	31	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 15	1992	340	8816					388	391		10.1016/0140-6736(92)91470-S	http://dx.doi.org/10.1016/0140-6736(92)91470-S			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JJ449	1353555				2022-12-01	WOS:A1992JJ44900003
J	COOKSON, WOCM; YOUNG, RP; SANDFORD, AJ; MOFFATT, MF; SHIRAKAWA, T; SHARP, PA; FAUX, JA; JULIER, C; LESOUEF, PN; NAKAMURA, Y; LATHROP, GM; HOPKIN, JM				COOKSON, WOCM; YOUNG, RP; SANDFORD, AJ; MOFFATT, MF; SHIRAKAWA, T; SHARP, PA; FAUX, JA; JULIER, C; LESOUEF, PN; NAKAMURA, Y; LATHROP, GM; HOPKIN, JM			MATERNAL INHERITANCE OF ATOPIC IGE RESPONSIVENESS ON CHROMOSOME-11Q	LANCET			English	Article							SERUM IGE; ALLERGY; RESPONSES; GENETICS; ASTHMA; TWINS	Atopy is a common familial state underlying allergic asthma and rhinitis. Lately, we have assigned a gene for atopy to chromosome 11 q by linkage to the marker D11S97. Since previous studies have suggested that the risk of atopy is higher for children of atopic mothers than for those of atopic fathers, we sought differences between maternal and paternal patterns of transmission at the 11q13 locus among pairs of siblings in families affected by atopy. When we defined atopy as the presence of a positive skinprick test (greater-than-or-equal-to 2 mm) to any of a panel of common allergens, a higher than normal concentration of total serum IgE, or a positive radioallergosorbent test for a specific IgE, we found that 125 (62%) of the sibling-pairs affected by atopy shared the maternal 11q13 allele and 78 (38%) did not. This distribution differs significantly from the expected 50/50 distribution (p=0.001). Of paternally derived alleles, 83 (46%) were shared and 96 (54%) were not (not significantly different from 50/50). The result was similar whatever definition of atopy was used and with other genetic markers on 11q. These findings show that transmission of atopy at the chromosome 11q locus is detectable only through the maternal line. The pattern of inheritance is consistent either with paternal genomic imprinting or with maternal modification of developing immune responses.	CTR ETUD POLYMORPHISME HUMAINE,PARIS,FRANCE; CHURCHILL HOSP,OLSER CHEST UNIT,OXFORD OX3 7LJ,ENGLAND; JAPANESE FDN CANC RES,INST CANC,DIV BIOCHEM,TOKYO 170,JAPAN	University of Oxford; Japanese Foundation for Cancer Research	COOKSON, WOCM (corresponding author), JOHN RADCLIFFE HOSP,NUFFIELD DEPT MED,OXFORD OX3 9DU,ENGLAND.		Le Souef, Peter N/H-5256-2014; JULIER, Cécile/M-9824-2017	JULIER, Cécile/0000-0002-1538-0240; Le Souef, Peter/0000-0003-0930-1654	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAZARAL M, 1974, J ALLERGY CLIN IMMUN, V54, P288, DOI 10.1016/0091-6749(74)90015-3; BLACKWELDER W C, 1985, Genetic Epidemiology, V2, P85, DOI 10.1002/gepi.1370020109; BLUMENTHAL MN, 1981, AM J MED GENET, V10, P219, DOI 10.1002/ajmg.1320100304; BORECKI I B, 1985, Genetic Epidemiology, V2, P327, DOI 10.1002/gepi.1370020402; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; CATTANACH BM, 1985, NATURE, V315, P496, DOI 10.1038/315496a0; CLINE MG, 1989, THORAX, V44, P425, DOI 10.1136/thx.44.5.425; COOKSON WOCM, 1988, LANCET, V1, P86; COOKSON WOCM, 1989, LANCET, V1, P1292; HALL JG, 1990, ARCH DIS CHILD-FETAL, V65, P1013, DOI 10.1136/adc.65.10_Spec_No.1013; HANSON B, 1985, J ALLERGY CLIN IMMUN, V75, P155, DOI 10.1016/0091-6749(85)90337-9; HAPPLE R, 1982, INT ARCH ALLER A IMM, V68, P90, DOI 10.1159/000233072; HEUTINK P, 1992, HUM MOL GENET, V1, P7, DOI 10.1093/hmg/1.1.7; HOLFORDSTREVENS V, 1984, J ALLERGY CLIN IMMUN, V73, P516, DOI 10.1016/0091-6749(84)90363-4; HOLT PG, 1990, IMMUNOLOGY, V1, P3; ISHIZAKA K, 1966, J IMMUNOL, V97, P75; JULIER C, 1990, GENOMICS, V7, P335, DOI 10.1016/0888-7543(90)90167-S; KJELLMAN NIM, 1976, CLIN ALLERGY, V6, P51, DOI 10.1111/j.1365-2222.1976.tb01411.x; MAGNUSSON CGM, 1988, ALLERGY, V43, P241, DOI 10.1111/j.1398-9995.1988.tb00896.x; MARSH DG, 1981, NEW ENGL J MED, V305, P1551, DOI 10.1056/NEJM198112243052603; PEAT JK, 1987, CLIN ALLERGY, V17, P271; RUIZ RGG, 1991, SCHWEIZ MED WSCH S40, V121, P129; SETTIPANE RA, 1989, ALLERGY PROC, V9, P555; SHIRAKAWA T, 1991, CYTOGENET CELL GENET, V58, P1970; SHIRAKAWA T, IN PRESS AM J EPIDEM; SOLTER D, 1988, ANNU REV GENET, V22, P127; TOKINO T, 1991, AM J HUM GENET, V48, P258; WAYE JS, 1987, HUM GENET, V77, P151, DOI 10.1007/BF00272383; YOUNG RP, 1992, J MED GENET, V29, P236, DOI 10.1136/jmg.29.4.236	29	297	309	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 15	1992	340	8816					381	384		10.1016/0140-6736(92)91468-N	http://dx.doi.org/10.1016/0140-6736(92)91468-N			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JJ449	1353553				2022-12-01	WOS:A1992JJ44900001
J	HEDLUND, JU; ORTQVIST, AB; KALIN, M; SCALIATOMBA, G; GIESECKE, J				HEDLUND, JU; ORTQVIST, AB; KALIN, M; SCALIATOMBA, G; GIESECKE, J			RISK OF PNEUMONIA IN PATIENTS PREVIOUSLY TREATED IN HOSPITAL FOR PNEUMONIA	LANCET			English	Note							COMMUNITY-ACQUIRED PNEUMONIA; PNEUMOCOCCAL VACCINE; IMMUNIZATION; CARE	Although elderly patients who are admitted to hospital for any disease have a higher risk of pneumonia subsequently, whether those treated in hospital for pneumonia are at even greater risk is unknown. Therefore we retrospectively assessed morbidity and mortality due to pneumonia after discharge in 573 consecutive patients admitted to hospital for pneumonia, gastrointestinal infection, renal infection, or erysipelas. Average follow-up was 34 months. The incidence rate for pneumonia was 5.45 times higher in the group of patients discharged after pneumonia than in the other groups combined (95% confidence interval 2.89-10.26; p<0.001), and this group also had more deaths due to pneumonia (p=0.06). For patients 50 years or older Streptococcus pneumoniae is the main cause of pneumonia. Pneumococcal vaccination after hospital treatment for an episode of pneumonia might be a cost-effective means of preventing disease in this group.	KAROLINSKA INST,DEPT INFECT DIS,S-10401 STOCKHOLM 60,SWEDEN; UNIV STOCKHOLM,DEPT MATH STAT,S-10691 STOCKHOLM,SWEDEN	Karolinska Institutet; Stockholm University	HEDLUND, JU (corresponding author), KAROLINSKA INST,DANDERYD HOSP,UNIV CLIN INFECT DIS,S-18288 DANDERYD,SWEDEN.							AUSTRIAN R, 1964, ANN INTERN MED, V60, P759, DOI 10.7326/0003-4819-60-5-759; FEDSON D, 1989, INFECTION, V17, P437, DOI 10.1007/BF01645568; FEDSON DS, 1990, JAMA-J AM MED ASSOC, V264, P1117; FEDSON DS, 1982, JAMA-J AM MED ASSOC, V248, P1989; HOOK EW, 1983, JAMA-J AM MED ASSOC, V249, P1055, DOI 10.1001/jama.249.8.1055; ORTQVIST A, 1990, EUR RESPIR J, V3, P1105; ORTQVIST A, 1988, SCAND J INFECT DIS, V20, P163, DOI 10.3109/00365548809032433; VENKATESAN P, 1990, THORAX, V45, P254, DOI 10.1136/thx.45.4.254; 1989, JAMA-J AM MED ASSOC, V261, P1265	9	37	37	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 15	1992	340	8816					396	397		10.1016/0140-6736(92)91473-L	http://dx.doi.org/10.1016/0140-6736(92)91473-L			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JJ449	1353558				2022-12-01	WOS:A1992JJ44900006
J	HENRY, JA; JEFFREYS, KJ; DAWLING, S				HENRY, JA; JEFFREYS, KJ; DAWLING, S			TOXICITY AND DEATHS FROM 3,4-METHYLENEDIOXYMETHAMPHETAMINE (ECSTASY)	LANCET			English	Article							MDMA ECSTASY; METHYLENEDIOXYMETHAMPHETAMINE MDMA; HYPERTHERMIA; PSYCHOSIS; NEUROTOXICITY; TERMINALS	The risk of adverse reactions to 3,4-methylenedioxymethamphetamine (MDMA), more commonly known as ''ecstasy'', is now widely known in both the USA and UK, but the patterns of illness remain varied. We report our experience during 1990 and 1991. There has been a recent increase in cases of severe toxicity following recreational misuse of small amounts of MDMA. Among 7 fatalities, the pattern of toxicity included fulminant hyperthermia, convulsions, disseminated intravascular coagulation, rhabdomyolysis, and acute renal failure. Until now, there have been few reports of this type of toxicity from MDMA, which may be related both to the potential of the drug to alter thermoregulation and to the circumstances of misuse. In addition, we have monitored 7 cases of hepatotoxicity and suspect that the frequency of this complication is increasing; a history of MDMA misuse should be sought in young people presenting with unexplained jaundice or hepatomegaly. We also describe 5 subjects involved in road traffic accidents in whom MDMA was identified. Misuse of MDMA can have severe acute toxic effects; few data are available concerning long-term morbidity, and this deserves close monitoring in future.			HENRY, JA (corresponding author), GUYS HOSP,NATL POISONS UNIT,LONDON SE1 9RT,ENGLAND.							BENAZZI F, 1991, LANCET, V338, P1520, DOI 10.1016/0140-6736(91)92332-V; BROWN C, 1987, JAMA-J AM MED ASSOC, V258, P780, DOI 10.1001/jama.258.6.780; CAMPKIN NTA, 1992, J ROY SOC MED, V85, P61; CHADWICK IS, 1991, J ROY SOC MED, V84, P371, DOI 10.1177/014107689108400622; CREIGHTON FJ, 1991, BRIT J PSYCHIAT, V159, P713, DOI 10.1192/bjp.159.5.713; DOWLING GP, 1987, JAMA-J AM MED ASSOC, V257, P1615, DOI 10.1001/jama.257.12.1615; FAHAL IH, 1992, BRIT MED J, V305, P29, DOI 10.1136/bmj.305.6844.29; GINSBERG MD, 1970, ANN INTERN MED, V73, P81, DOI 10.7326/0003-4819-73-1-81; GORDON CJ, 1991, PHARMACOL BIOCHEM BE, V38, P339, DOI 10.1016/0091-3057(91)90288-D; HOPKINS PM, 1991, LANCET, V338, P1491, DOI 10.1016/0140-6736(91)92304-K; MCGUIRE P, 1991, BRIT MED J, V302, P697, DOI 10.1136/bmj.302.6778.697; OHEARN E, 1988, J NEUROSCI, V8, P2788; PEROUTKA SJ, 1987, NEW ENGL J MED, V317, P1542; RICAURTE G, 1985, SCIENCE, V229, P986, DOI 10.1126/science.4023719; SCHIFANO F, 1991, LANCET, V338, P1335, DOI 10.1016/0140-6736(91)92633-D; SCHMIDT CJ, 1990, BRAIN RES, V529, P85, DOI 10.1016/0006-8993(90)90813-Q; SUAREZ RV, 1988, AM J FOREN MED PATH, V9, P339, DOI 10.1097/00000433-198812000-00015; WHITAKERAZMITIA PM, 1989, AM J PSYCHIAT, V146, P119	18	547	556	0	66	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 15	1992	340	8816					384	387		10.1016/0140-6736(92)91469-O	http://dx.doi.org/10.1016/0140-6736(92)91469-O			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JJ449	1353554				2022-12-01	WOS:A1992JJ44900002
J	HESSOL, NA; KATZ, MH; LIU, JY; BUCHBINDER, SP; RUBINO, CJ; HOLMBERG, SD				HESSOL, NA; KATZ, MH; LIU, JY; BUCHBINDER, SP; RUBINO, CJ; HOLMBERG, SD			INCREASED INCIDENCE OF HODGKIN DISEASE IN HOMOSEXUAL MEN WITH HIV-INFECTION	ANNALS OF INTERNAL MEDICINE			English	Article						HUMAN IMMUNODEFICIENCY VIRUS; HODGKINS DISEASE; HOMOSEXUALITY; ACQUIRED IMMUNODEFICIENCY SYNDROME; NON-HODGKIN LYMPHOMA	HUMAN-IMMUNODEFICIENCY-VIRUS; BISEXUAL MEN; COHORT; AIDS	Objective: To evaluate the incidence of Hodgkin disease and non-Hodgkin lymphoma among homosexual men infected with human immunodeficiency virus (HIV). Design: Cohort study with computer-matched identification of participants with the Northern California Cancer Center registry. Population rate comparisons were made with data from the Surveillance, Epidemiology, and End Results (SEER) cancer registry. Participants: The 6704 homosexual men in the San Francisco City Clinic Cohort study. Measurements: Incidence of Hodgkin disease, non-Hodgkin lymphoma, HIV infection, and the acquired immunodeficiency syndrome (AIDS); calculation of sex and age-adjusted standardized morbidity ratios and attributable risk. Results: Eight cases of Hodgkin disease and 90 cases of non-Hodgkin lymphoma were identified through computer matching among cohort members residing in the San Francisco Bay area from 1978 through 1989. Among the HIV-infected men, the age-adjusted standardized morbidity ratio was 5.0 (95% Cl, 2.0 to 10.3) for Hodgkin disease and 37.7 (Cl, 30.3 to 46.7) for non-Hodgkin lymphoma. The excess risk attributable to HIV infection was 19.3 cases of Hodgkin disease per 100 000 person-years and 224.9 cases of non-Hodgkin lymphoma per 100 000 person-years. Conclusion: An excess incidence of Hodgkin disease was found in HIV-infected homosexual men. Additional well-designed epidemiologic studies are needed to determine whether Hodgkin disease should be considered an HIV-related malignancy.	SAN FRANCISCO DEPT PUBL HLTH, SAN FRANCISCO, CA USA; CTR DIS CONTROL, CTR INFECT DIS, DIV HIV AIDS, ATLANTA, GA 30333 USA	San Francisco Department of Public Health; Centers for Disease Control & Prevention - USA					PHS HHS [U64/CCU900523-08] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BUCHBINDER S, 1991, 7 INT C AIDS FLOR, P33; BYERS RH, 1988, AIDS, V2, P207; GARNIER G, 1991, ANN INTERN MED, V115, P233, DOI 10.7326/0003-4819-115-3-233_1; HESSOL NA, 1989, AM J EPIDEMIOL, V130, P1167, DOI 10.1093/oxfordjournals.aje.a115445; MONFARDINI S, 1988, JNCI-J NATL CANCER I, V80, P855, DOI 10.1093/jnci/80.11.855; MUNOZ A, 1989, AM J EPIDEMIOL, V130, P530, DOI 10.1093/oxfordjournals.aje.a115367; RABKIN CS, 1991, INT J CANCER, V47, P692, DOI 10.1002/ijc.2910470511; RABKIN CS, 1992, JAMA-J AM MED ASSOC, V267, P1090, DOI 10.1001/jama.267.8.1090; ROITHMANN S, 1990, NEW ENGL J MED, V323, P275; RUTHERFORD GW, 1990, BRIT MED J, V301, P1183, DOI 10.1136/bmj.301.6762.1183; SERRANO M, 1990, CANCER-AM CANCER SOC, V65, P2248, DOI 10.1002/1097-0142(19900515)65:10<2248::AID-CNCR2820651015>3.0.CO;2-W; TIRELLI U, 1988, ANN INTERN MED, V108, P309, DOI 10.7326/0003-4819-108-2-309_2; 1987, MMWR, V36, pS1; 1990, SEER CANCER REGISTRY	14	138	138	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1992	117	4					309	311		10.7326/0003-4819-117-4-309	http://dx.doi.org/10.7326/0003-4819-117-4-309			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JH464	1637026				2022-12-01	WOS:A1992JH46400007
J	LUNNISS, PJ; ARMSTRONG, P; BARKER, PG; REZNEK, RH; PHILLIPS, RKS				LUNNISS, PJ; ARMSTRONG, P; BARKER, PG; REZNEK, RH; PHILLIPS, RKS			MAGNETIC-RESONANCE-IMAGING OF ANAL FISTULAS	LANCET			English	Note							IN-ANO	Success of surgery for an anal fistula depends on accurate assessment of the fistula; however, such assessment is technically difficult. We have done a prospective study that determined the accuracy of magnetic resonance imaging (MRI) in demonstrating the course of fistulae, by comparing MRI scan interpretations with subsequent operative findings. 16 patients (mean [range] age 42 [24-66] years) had MRI followed by surgery within a mean of 22 (1-101) days. MRI scan interpretations agreed precisely with independently documented operative findings in 14 of 16 patients. MRI is an accurate method of delineating anal fistulae, and should be considered for patients with difficult fistulae that recur despite skilled attention because it demonstrates abnormalities that might otherwise be missed.	ST MARKS HOSP,CITY RD,LONDON EC1V 2PS,ENGLAND; LONDON CLIN,LONDON,ENGLAND; ST BARTHOLOMEWS HOSP,PROF SURG UNIT,LONDON EC1A 7BE,ENGLAND; ST BARTHOLOMEWS HOSP,DEPT RADIOL,LONDON EC1A 7BE,ENGLAND	Imperial College London; University of London; University College London; University of London; Queen Mary University London; University of London; Queen Mary University London								COEN S, 1991, BRIT J SURG, V78, P445; KUIJPERS HC, 1985, DIS COLON RECTUM, V28, P103, DOI 10.1007/BF02552656; LAW PJ, 1989, BRIT J SURG, V76, P752, DOI 10.1002/bjs.1800760737; PARKS AG, 1976, BRIT J SURG, V63, P1, DOI 10.1002/bjs.1800630102; POMMERI F, 1988, RADIOL MED, V75, P632; SAINIO P, 1984, ANN CHIR GYNAECOL FE, V73, P219; SEOWCHOEN F, 1991, BRIT J SURG, V78, P539; SHOULER PJ, 1986, INT J COLORECTAL DIS, V1, P113, DOI 10.1007/BF01648418	8	141	144	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 15	1992	340	8816					394	396		10.1016/0140-6736(92)91472-K	http://dx.doi.org/10.1016/0140-6736(92)91472-K			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JJ449	1353557				2022-12-01	WOS:A1992JJ44900005
J	MCCLELLAN, WM; FLANDERS, WD; GUTMAN, RA				MCCLELLAN, WM; FLANDERS, WD; GUTMAN, RA			VARIABLE MORTALITY-RATES AMONG DIALYSIS TREATMENT CENTERS	ANNALS OF INTERNAL MEDICINE			English	Article						KIDNEY FAILURE, CHRONIC; DIALYSIS; AGE FACTORS; DIABETIC NEPHROPATHY	STAGE RENAL-DISEASE; LONG-TERM DIALYSIS; SURVIVAL; HEMODIALYSIS; PATIENT; RISK	Objective: To examine the variation in the risk for mortality among patients treated at renal dialysis facilities within a defined geographic area. Setting: All free-standing and hospital-based dialysis facilities in a single southeastern state reported to the registry. Design: Cohort of dialysis patients followed for 1 year by an end-stage renal disease registry. Patients: Patients (n = 3612) aged 20 years and older receiving treatment at the dialysis facilities reporting to the registry during 1987. Measurements: Demographic, comorbid, and severity of illness indicators were abstracted from patient records. Facility-specific risk estimates were derived from a Cox proportional hazards model. Results: Facility-specific mortality rates ranged between 2.0 and 10.5 deaths per 10 000 patient days. Mortality rates were higher among older persons; whites; those with a history of diabetic nephropathy, angina, or congestive heart failure; and patients with either nutritional or functional status impairment. Facility-specific prevalence of each mortality risk factor varied widely. The unadjusted risk for death in a facility at the 75th percentile of risk was 1.3 times that of a facility at the median, whereas at the 25th percentile, it was 0.68 times as likely-a twofold range of risk. Controlling for differences in the prevalence of patient characteristics did not change the interquartile range in risks, and a facility's adjusted risk estimate showed a strong correlation with its unadjusted estimate (R2, 0.566; P < 0.0001). Conclusions: Patient attributes associated with increased risk for mortality vary widely among dialysis facilities. Adjustment for these differences did not, however, substantially change either the degree of variation in mortality risks or the relative ranking of a facility's mortality.	EMORY UNIV, SCH MED, ATLANTA, GA 30322 USA; EMORY UNIV, SCH PUBL HLTH, DIV EPIDEMIOL, ATLANTA, GA 30322 USA; DURHAM REG HOSP, DURHAM, NC USA; DUKE UNIV, SCH MED, DURHAM, NC 27706 USA	Emory University; Emory University; Duke University	MCCLELLAN, WM (corresponding author), CLARK HOLDER CLIN, 303 SMITH ST, LA GRANGE, GA 30240 USA.							Acchiardo S R, 1983, Kidney Int Suppl, V16, pS199; BURTON BT, 1971, J AMER MED ASSOC, V218, P718, DOI 10.1001/jama.218.5.718; Degoulet P, 1980, Proc Eur Dial Transplant Assoc, V17, P149; GARCIAGARCIA G, 1985, AM J KIDNEY DIS, V5, P10, DOI 10.1016/S0272-6386(85)80129-3; GROSS JB, 1973, ANN INTERN MED, V78, P341, DOI 10.7326/0003-4819-78-3-341; GUTMAN RA, 1981, NEW ENGL J MED, V304, P309, DOI 10.1056/NEJM198102053040601; HELD PJ, 1991, JAMA-J AM MED ASSOC, V265, P871, DOI 10.1001/jama.265.7.871; HELD PJ, 1987, JAMA-J AM MED ASSOC, V257, P645, DOI 10.1001/jama.257.5.645; HELLERSTEDT WL, 1984, MAYO CLIN PROC, V59, P776, DOI 10.1016/S0025-6196(12)65589-X; HUSEBYE DG, 1987, ARCH INTERN MED, V147, P1921, DOI 10.1001/archinte.147.11.1921; HUTCHINSON TA, 1982, ANN INTERN MED, V96, P417, DOI 10.7326/0003-4819-96-4-417; HUTCHINSON TA, 1984, KIDNEY INT, V26, P44, DOI 10.1038/ki.1984.132; LEWIS EJ, 1969, ANN INTERN MED, V70, P311, DOI 10.7326/0003-4819-70-2-311; LOWRIE EG, 1990, AM J KIDNEY DIS, V15, P458, DOI 10.1016/S0272-6386(12)70364-5; MAIORCA R, 1988, KIDNEY INT, V34, P518, DOI 10.1038/ki.1988.212; MCCLELLAN WM, 1991, J CLIN EPIDEMIOL, V44, P83, DOI 10.1016/0895-4356(91)90204-M; PROWANT B, 1983, AM J KIDNEY DIS, V3, P27, DOI 10.1016/S0272-6386(83)80006-7; RADECKI SE, 1988, AM J KIDNEY DIS, V11, P7, DOI 10.1016/S0272-6386(88)80167-7; ROBERTS JL, 1976, KIDNEY INT, V9, P363, DOI 10.1038/ki.1976.43; UMEN AJ, 1986, STAT MED, V5, P637, DOI 10.1002/sim.4780050611; WALKER JV, 1988, AM J NEPHROL, V8, P40, DOI 10.1159/000167551; WELLER JM, 1982, KIDNEY INT, V21, P78, DOI 10.1038/ki.1982.11; 1991, USRDS1991  NAT I DIA; 1985, EGRET MANUAL STATIST; 1991, USRDS1991 NAT I DIAB	25	73	73	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1992	117	4					332	336		10.7326/0003-4819-117-4-332	http://dx.doi.org/10.7326/0003-4819-117-4-332			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JH464	1637029				2022-12-01	WOS:A1992JH46400011
J	MCINTOSH, EDG; MENSER, MA				MCINTOSH, EDG; MENSER, MA			A 50-YEAR FOLLOW-UP OF CONGENITAL-RUBELLA	LANCET			English	Article							DIABETES-MELLITUS	50 patients with congenital rubella, born in 1939-43, were reviewed in 1967. Here we report their outcome in 1 991. Since 1 967, there have been 7 deaths (3 cardiovascular, 3 malignant disease, 1 AIDS). 40 had full clinical assessment. The prevalence of diabetes mellitus is similar to that in 1967: 4 of the 5 reported diabetic then, remain so, and there is 1 new case. 1 subject has malignant melanoma and 3 have died from cancer. Although the incidence of malignant disease is not increased, the death rate is (standardised mortality rate 6.0, 95% CI 1.24-17.57). Longer follow-up will be required to confirm this observation.	ROYAL ALEXANDRA HOSP CHILDREN,DEPT MED,POB 34,CAMPERDOWN,NSW 2050,AUSTRALIA									FINE PEM, 1985, BRIT MED J, V290, P509, DOI 10.1136/bmj.290.6467.509; FORREST JM, 1971, LANCET, V2, P332; Gregg NM, 1941, T OPHTHALMOL SOC AUS, V3, P35; GREGG NM, 1945, MED J AUSTRALIA, V2, P122; MENSER MA, 1978, LANCET, V1, P57; MENSER MA, 1967, LANCET, V2, P1347; 1991, LANCET, V337, P668	7	57	57	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 15	1992	340	8816					414	415		10.1016/0140-6736(92)91483-O	http://dx.doi.org/10.1016/0140-6736(92)91483-O			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JJ449	1353568				2022-12-01	WOS:A1992JJ44900016
J	OKAMOTO, Y				OKAMOTO, Y			HEALTH-CARE FOR THE ELDERLY IN JAPAN - MEDICINE AND WELFARE IN AN AGING SOCIETY FACING A CRISIS IN LONG-TERM CARE	BRITISH MEDICAL JOURNAL			English	Article											OKAMOTO, Y (corresponding author), HANNAN CHUO HOSP,DEPT INTERNAL MED & HOME CARE,3-3-28 MINAMISHINMACHI,MATSUBARA,OSAKA 580,JAPAN.							ANDERSEN BR, 1990, KOSEIFUKUSHI J, P2; CHARLTON JRH, 1986, BRIT MED J, V292, P295, DOI 10.1136/bmj.292.6516.295; HASEGAWA T, 1990, J HLTH WELFARE STATI, V36, P23; HENDRICS J, 1986, AGING MASS SOC MYTHS; HIATT HH, 1987, AM HLTH BALANCE CHOI; IGLEHEART JK, 1989, NEW ENGL J MED, V319, P1166; IGLEHEART JK, 1989, NEW ENGL J MED, V319, P807; MARMOT MG, 1989, BMJ, V99, P23; MENDERSON MA, 1975, TENDER LOVING GREED; MUNDINGWER MO, 1983, HOME CARE CONTROVERS; OKAMOTO Y, 1984, AM NO IRYO TO KANGO; PEGLES CC, 1981, HLTH CARE ELDERLY; SHIEBER G, 1989, HLTH AFF         FAL, P169; SHIMAMOTO T, 1989, CIRCULATION, V79, P503, DOI 10.1161/01.CIR.79.3.503; SHIRAISHI M, 1986, J HLTH WELFARE STATI, V33, P200; SUGAYA Y, 1990, J HLTH WELFARE STATI, V137, P8; Vladeck B.C., 1980, UNLOVING CARE NURSIN; YAMAMOTO M, 1989, J HLTH WELFARE STATI, V36, P13; 1987, OECD SOCIAL POLICY S, P37; 1992, ANN REPORT 1990 91; 1989, NETAKIRI ZERO MEZASH; 1989, J HLTH WELFARE STATI, V36, P91; 1992, NIPPON CHARTED SURVE; 1991, SHAKAI HOKEN JUNPO J, P28	24	26	26	2	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 15	1992	305	6850					403	405		10.1136/bmj.305.6850.403	http://dx.doi.org/10.1136/bmj.305.6850.403			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JK314	1392924	Green Published, Bronze, Green Submitted			2022-12-01	WOS:A1992JK31400020
J	ROSOVE, MH; BREWER, PMC				ROSOVE, MH; BREWER, PMC			ANTIPHOSPHOLIPID THROMBOSIS - CLINICAL COURSE AFTER THE 1ST THROMBOTIC EVENT IN 70 PATIENTS	ANNALS OF INTERNAL MEDICINE			English	Article						FIBRINOLYTIC AGENTS; THROMBOEMBOLISM; ANTIPHOSPHOLIPID SYNDROME; LUPUS ERYTHEMATOSUS, SYSTEMIC PURPURA, THROMBOCYTOPENIC, IDIOPATHIC	SYSTEMIC LUPUS-ERYTHEMATOSUS; ANTI-CARDIOLIPIN ANTIBODIES; ANTICARDIOLIPIN ANTIBODIES; CIRCULATING ANTICOAGULANT; HABITUAL ABORTION; FETAL LOSSES; PREVALENCE; ASSOCIATION; WOMEN; PREDNISONE	Objective: To determine the clinical course and influence of antithrombotic therapy in patients with lupus anticoagulant or anticardiolipin antibodies, or both, after the first thromboembolic event. Design: Retrospective survey of consecutive patients treated according to their physician's best judgment. Setting: Secondary and tertiary referral practice. Patients: Seventy patients (48 women [69%]) with a mean age (+/-SD) of 45.5 +/- 17.3 years. The antiphospholipid syndrome was primary in 51 patients (73%) and secondary to systemic lupus erythematosus in 14 patients (20%) and to chronic idiopathic thrombocytopenic purpura in 5 patients (7%). Measurements: Site of initial and recurrent thrombotic events (venous or arterial), as well as kind (aspiring, heparin, or warfarin) and intensity of anticoagulation. Results: Total follow-up after the first thrombotic event was 361.0 patient-years (mean [+/-SD], 5.2 +/- 5.6 years per patient). Thirty-seven patients (53%) had 54 recurrent events, with 2 patients experiencing fatal events. Arterial events were followed by arterial events, and venous events by venous events, in 49 of 54 instances (91%). Recurrence rates during "no treatment;" aspirin therapy; or low-, intermediate-, or high-intensity warfarin therapy (international normalized ratios [INRs] less-than-or-equal-to 1.9, 2.0 to 2.9, and greater-than-or-equal-to 3.0, respectively, or rabbit brain thromboplastin prothrombin time ratios of approximately <1.3, 1.3 to 1.5, and >1.5, respectively) were 0.19, 0.32, 0.57, 0.07 (P = 0.12), and 0.00 (P < 0.001) per patient-year. The follow-up periods for the five types of therapy were 161.2, 37.8, 11.3, 40.9, and 110.2 patient-years, respectively. The highest INR coincident with thrombosis was 2.6. Five warfarin-treated patients had five significant bleeding events (0.031 per patient-year). Conclusions: Recurrent thrombosis is a potentially serious problem for patients with lupus anticoagulant or anticardiolipin antibodies or both. The site of the first event (arterial or venous) tended to predict the site of subsequent events. Intermediate- to high-intensity warfarin therapy may confer better antithrombotic protection than low- to intermediate-intensity warfarin therapy or aspirin therapy. Further studies are needed to define more precisely the rethrombosis rate and optimal type, intensity, and duration of antithrombotic therapy.			ROSOVE, MH (corresponding author), UNIV CALIF LOS ANGELES, SCH MED, 100 UCLA MED PLAZA, SUITE 550, LOS ANGELES, CA 90024 USA.							ALARCONSEGOVIA D, 1989, MEDICINE, V68, P353, DOI 10.1097/00005792-198911000-00003; BOEY ML, 1983, BMJ-BRIT MED J, V287, P1021, DOI 10.1136/bmj.287.6398.1021; BRANCH DW, 1985, NEW ENGL J MED, V313, P1322, DOI 10.1056/NEJM198511213132104; BREY RL, 1990, NEUROLOGY, V40, P1190, DOI 10.1212/WNL.40.8.1190; CANOSO RT, 1988, AM J HEMATOL, V27, P272, DOI 10.1002/ajh.2830270408; CARRERAS LO, 1982, THROMB HAEMOSTASIS, V48, P38; CERVERA R, 1990, ANN RHEUM DIS, V49, P109, DOI 10.1136/ard.49.2.109; COWCHOCK S, 1986, AM J OBSTET GYNECOL, V155, P1002, DOI 10.1016/0002-9378(86)90335-2; DERKSEN RHWM, 1986, ARTHRITIS RHEUM, V29, P1295, DOI 10.1002/art.1780291021; EDELMAN P, 1986, HUM REPROD, V1, P295, DOI 10.1093/oxfordjournals.humrep.a136408; ELDRUPJORGENSEN J, 1989, J VASC SURG, V9, P334, DOI 10.1067/mva.1989.vs0090334; ELIAS M, 1984, ARCH INTERN MED, V144, P510, DOI 10.1001/archinte.144.3.510; FEINSTEIN DI, 1985, NEW ENGL J MED, V313, P1348, DOI 10.1056/NEJM198511213132109; FRANCOIS A, 1988, ANN INTERN MED, V109, P993, DOI 10.7326/0003-4819-109-12-993; HARRIS EN, 1987, CLIN EXP IMMUNOL, V68, P215; HARRIS EN, 1983, LANCET, V2, P1211; ISHII Y, 1990, ANN RHEUM DIS, V49, P387, DOI 10.1136/ard.49.6.387; KALUNIAN KC, 1988, AM J MED, V85, P602; KHAMASHTA MA, 1990, LANCET, V335, P1541, DOI 10.1016/0140-6736(90)91373-I; LEUNG WH, 1990, AM J MED, V89, P411, DOI 10.1016/0002-9343(90)90368-N; LOCKSHIN MD, 1985, NEW ENGL J MED, V313, P152, DOI 10.1056/NEJM198507183130304; LOCKSHIN MD, 1989, AM J OBSTET GYNECOL, V160, P439, DOI 10.1016/0002-9378(89)90468-7; LOCKWOOD CJ, 1989, AM J OBSTET GYNECOL, V161, P369, DOI 10.1016/0002-9378(89)90522-X; LOVE PE, 1990, ANN INTERN MED, V112, P682, DOI 10.7326/0003-4819-112-9-682; LUBBE WF, 1983, LANCET, V1, P1361; MCNEIL HP, 1989, BRIT J HAEMATOL, V73, P506, DOI 10.1111/j.1365-2141.1989.tb00289.x; MUEH JR, 1980, ANN INTERN MED, V92, P156, DOI 10.7326/0003-4819-92-2-156; NILSSON IM, 1975, ACTA MED SCAND, V197, P153; PALARETI G, 1991, THROMB HAEMOSTASIS, V65, P452; PETRI M, 1987, ARTHRITIS RHEUM, V30, P601, DOI 10.1002/art.1780300601; ROSOVE MH, 1986, BLOOD, V68, P472; ROSOVE MH, 1990, OBSTET GYNECOL, V75, P630; ROSOVE MH, 1989, AM J HEMATOL, V32, P148, DOI 10.1002/ajh.2830320215; SANTIAGO MB, 1989, CLIN RHEUMATOL, V8, P23, DOI 10.1007/BF02031064; SHAPIRO SS, 1982, PROG HEMOST THROMB, V6, P263; SHI W, 1990, AUST NZ J MED, V20, P231, DOI 10.1111/j.1445-5994.1990.tb01025.x; STEGNAR M, 1991, THROMB RES, V63, P433, DOI 10.1016/0049-3848(91)90230-T; STIMMLER MM, 1989, ARCH INTERN MED, V149, P1833, DOI 10.1001/archinte.149.8.1833; TAYLOR M, 1990, AM J REPROD IMMUNOL, V23, P33, DOI 10.1111/j.1600-0897.1990.tb00666.x; UNANDER AM, 1987, AM J OBSTET GYNECOL, V156, P114, DOI 10.1016/0002-9378(87)90218-3; WANG Y, 1990, RHEUMATOL INT, V10, P75, DOI 10.1007/BF02274787	41	579	586	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1992	117	4					303	308		10.7326/0003-4819-117-4-303	http://dx.doi.org/10.7326/0003-4819-117-4-303			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JH464	1637025				2022-12-01	WOS:A1992JH46400006
J	SCHLUEDERBERG, A; STRAUS, SE; PETERSON, P; BLUMENTHAL, S; KOMAROFF, AL; SPRING, SB; LANDAY, A; BUCHWALD, D				SCHLUEDERBERG, A; STRAUS, SE; PETERSON, P; BLUMENTHAL, S; KOMAROFF, AL; SPRING, SB; LANDAY, A; BUCHWALD, D			CHRONIC FATIGUE SYNDROME RESEARCH - DEFINITION AND MEDICAL OUTCOME ASSESSMENT	ANNALS OF INTERNAL MEDICINE			English	Article						FATIGUE SYNDROME, CHRONIC; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PSYCHIATRIC STATUS RATING SCALES; DIAGNOSIS, DIFFERENTIAL; SLEEP DISORDERS	BARR VIRUS-INFECTION; FIBROMYALGIA; POPULATION	A workshop was held 18 to 19 March 1991 at the National Institutes of Health to address critical issues in research concerning the chronic fatigue syndrome (CFS). Case definition, confounding diagnoses, and medical outcome assessment by laboratory and other means were considered from the perspectives of key medical specialties involved in CFS research. It was recommended that published Centers for Disease Control (CDC) case-definition criteria be modified to exclude fewer patients from analysis because of a history of psychiatric disorder. Specific recommendations were made concerning the inclusion or exclusion of other major confounding diagnoses, and a standard panel of laboratory tests was specified for initial patient evaluation. The workshop emphasized the importance of recognizing other conditions that could explain the patient's symptoms and that may be treatable. It was viewed as essential for the investigator to screen for psychiatric disorder using a combination of self-report instruments followed by at least one structured interview to identity patients who should be excluded from studies or considered as a separate subgroup in data analysis. Because CFS is not a homogeneous abnormality and because there is no single pathogenic mechanism, research progress may depend upon delineation of these and other patient subgroups for separate data analysis. Despite preliminary data, no physical finding or laboratory test was deemed confirmatory of the diagnosis of CFS. For assessment of clinical status, investigators must rely on the use of standardized instruments for patient self-reporting of fatigue, mood disturbance, functional status, sleep disorder, global well-being, and pain. Further research is needed to develop better instruments for quantifying these domains in patients with CFS.	NIMH, BETHESDA, MD 20892 USA; UNIV MINNESOTA, MINNEAPOLIS, MN 55455 USA; BRIGHAM & WOMENS HOSP, DIV GEN MED, BOSTON, MA 02115 USA; RUSH UNIV, MED CTR, DEPT IMMUNOL MICROBIOL, CHICAGO, IL 60612 USA; UNIV WASHINGTON, HARBORVIEW MED CTR, SEATTLE, WA 98104 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); University of Minnesota System; University of Minnesota Twin Cities; Harvard University; Brigham & Women's Hospital; Rush University; Harborview Medical Center; University of Washington; University of Washington Seattle	SCHLUEDERBERG, A (corresponding author), NIAID, DMID, VIROL BRANCH, ROOM 3A-16, SOLAR BLDG, BETHESDA, MD 20892 USA.							BAROFSKY I, 1991, REV INFECT DIS, V13, pS94; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; BEYAERT R, 1991, CYTOKINE, V3, P284, DOI 10.1016/1043-4666(91)90496-Z; BUCHWALD D, 1992, ANN INTERN MED, V116, P103, DOI 10.7326/0003-4819-116-2-103; BUCHWALD D, 1991, REV INFECT DIS, V13, pS12; BUCHWALD D, 1987, ARTHRITIS RHEUM, V30, P1132, DOI 10.1002/art.1780301007; CANNON JG, 1985, SCIENCE, V227, P1247, DOI 10.1126/science.3871966; COLBURN TR, 1976, ISA T, V15, P149; DEMITRACK MA, 1991, BIOL PSYCHIAT, V30, P747, DOI 10.1016/0006-3223(91)90231-A; DEMITRACK MA, 1991, J CLIN ENDOCR METAB, V73, P1224, DOI 10.1210/jcem-73-6-1224; ENDRES S, 1989, EUR J IMMUNOL, V19, P2327, DOI 10.1002/eji.1830191222; First M.B., 1989, STRUCTURED CLIN INTE; GOLDBERG DP, 1979, PSYCHOL MED, V9, P139, DOI 10.1017/S0033291700021644; GOLDENBERG DL, 1990, ARTHRITIS RHEUM, V33, P381, DOI 10.1002/art.1780330311; HERBERMAN RB, 1991, REV INFECT DIS, V13, pS84; HOLMES GP, 1988, ANN INTERN MED, V109, P512; HOLMES GP, 1988, ANN INTERN MED, V108, P387, DOI 10.7326/0003-4819-108-3-387; HOLMES GP, 1991, REV INFECT DIS, V13, pS53; JONES JF, 1987, ANNU REV MED, V38, P195, DOI 10.1146/annurev.med.38.1.195; KATON W, 1992, IN PRESS ARCH INTERN; KOMAROFF AL, 1991, REV INFECT DIS, V13, pS8; KRUPP LB, 1989, ARCH NEUROL-CHICAGO, V46, P1121, DOI 10.1001/archneur.1989.00520460115022; LANDAY AL, 1991, LANCET, V338, P707, DOI 10.1016/0140-6736(91)91440-6; LANE TJ, 1991, AM J MED, V91, P335, DOI 10.1016/0002-9343(91)90150-V; LEWIS SF, 1991, REV INFECT DIS, V13, pS98; LLOYD AR, 1990, MED J AUSTRALIA, V153, P522, DOI 10.5694/j.1326-5377.1990.tb126191.x; MILLER AH, 1986, J CLIN PSYCHIAT, V47, P529; PETERSON PK, 1991, MINN MED, V74, P21; PETERSON PK, 1990, AM J MED, V89, P554, DOI 10.1016/0002-9343(90)90172-A; REDMOND CK, 1991, REV INFECT DIS, V13, pS90; ROBINS LN, 1985, NIMH DIAGNOSTIC INTE; SCHULTE PA, 1991, REV INFECT DIS, V13, pS87; SHARPE MC, 1991, J ROY SOC MED, V84, P118, DOI 10.1177/014107689108400224; STEWART AL, 1988, MED CARE, V26, P724, DOI 10.1097/00005650-198807000-00007; STRAUS SE, 1988, J ALLERGY CLIN IMMUN, V81, P791, DOI 10.1016/0091-6749(88)90933-5; WOLFE F, 1989, Arthritis and Rheumatism, V32, pS47; 1989, NCCLS H42P NAT COMM	37	258	259	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1992	117	4					325	331		10.7326/0003-4819-117-4-325	http://dx.doi.org/10.7326/0003-4819-117-4-325			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JH464	1322076				2022-12-01	WOS:A1992JH46400010
J	SLEMENDA, CW; CHRISTIAN, JC; REED, T; REISTER, TK; WILLIAMS, CJ; JOHNSTON, CC				SLEMENDA, CW; CHRISTIAN, JC; REED, T; REISTER, TK; WILLIAMS, CJ; JOHNSTON, CC			LONG-TERM BONE LOSS IN MEN - EFFECTS OF GENETIC AND ENVIRONMENTAL-FACTORS	ANNALS OF INTERNAL MEDICINE			English	Article						OSTEOPOROSIS; TWINS; ALCOHOL DRINKING; SMOKING	NHLBI TWIN; CIGARETTE-SMOKING; RISK-FACTORS; MASS; FRACTURES; OSTEOPOROSIS; WOMEN; HIP; AGE; HERITABILITY	Objective: To identity environmental factors associated with bone loss in adult male twins and to determine the extent to which shared environmental characteristics affect estimates of the genetic influence on bone loss. Design: A 16-year cohort study. Setting: A midwestern university hospital. Participants:One hundred and eleven male veterans of World War II or the Korean conflict, born between 1916 and 1927. All were twins, with the sample comprising 48 pairs and 15 persons whose twin brothers were deceased or seriously ill. Measurements: Bone mass and environmental characteristics (cigarette smoking, alcohol consumption, physical activity, dietary calcium intake, use of thiazide diuretics) measured at baseline and 16 years later. Results: Rates of radial bone loss averaged 0.45% per year. Those who both smoked and used alcohol at levels greater than the median for the population had a rate of bone loss (10% in 16 years) twice the rate of those who were below the median level for both variables (5% bone loss, P = 0.003). Rates of bone loss were correlated within twin pairs, and these correlations were diminished 25% to 35% by adjustments for environmental influences on bone loss. However, statistically significant within-pair correlations remained (r congruent-to 0.4), which did not differ between monozygotic and dizygotic twin pairs after adjustments for smoking, alcohol use, dietary calcium intake, and exercise. Conclusions: Bone loss in men during mid-life is determined, at least in part, by environmental factors, including smoking, alcohol intake, and, possibly, physical activity. Rates of bone loss were similar within twin pairs, apparently because of a shared environment.			SLEMENDA, CW (corresponding author), INDIANA UNIV, SCH MED, DEPT MED, DIV BIOSTAT, 702 BARNHILL DR, INDIANAPOLIS, IN 46202 USA.			Williams, Christopher/0000-0001-6346-8100	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC055027] Funding Source: NIH RePORTER; NCRR NIH HHS [MO1 RR750] Funding Source: Medline; NHLBI NIH HHS [HC 55027] Funding Source: Medline; NIA NIH HHS [AG 05793] Funding Source: Medline	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BACON WE, 1989, AM J PUBLIC HEALTH, V79, P1556, DOI 10.2105/AJPH.79.11.1556; CHRISTIAN JC, 1989, AM J HUM GENET, V44, P429; CHRISTIAN JC, 1974, AM J HUM GENET, V26, P154; CHRISTIANSEN C, 1987, LANCET, V1, P1106; CUMMINGS SR, 1985, EPIDEMIOL REV, V7, P178, DOI 10.1093/oxfordjournals.epirev.a036281; CUMMINGS SR, 1990, JAMA-J AM MED ASSOC, V263, P665, DOI 10.1001/jama.263.5.665; DANIELL HW, 1976, ARCH INTERN MED, V136, P298, DOI 10.1001/archinte.136.3.298; DEVERNEJOUL MC, 1983, CLIN ORTHOP RELAT R, V179, P107; FABSITZ R, 1985, J CHRON DIS, V38, P165, DOI 10.1016/0021-9681(85)90089-X; FABSITZ RR, 1988, ACTA GENET MED GEMEL, V37, P217, DOI 10.1017/S0001566000003822; FEINLEIB M, 1977, AM J EPIDEMIOL, V106, P284, DOI 10.1093/oxfordjournals.aje.a112464; GIOVANNUCCI E, 1991, AM J EPIDEMIOL, V133, P810; HUI SL, 1989, ANN INTERN MED, V111, P355, DOI 10.7326/0003-4819-111-5-355; HUTCHINSON TA, 1979, LANCET, V2, P705; KLATSKY AL, 1981, ANN INTERN MED, V95, P139, DOI 10.7326/0003-4819-95-2-139; KRALL EA, 1991, J BONE MINER RES, V6, P331; MEIER DE, 1984, ANN INTERN MED, V101, P605, DOI 10.7326/0003-4819-101-5-605; NILSSON BE, 1970, ACTA CHIR SCAND, V136, P383; PAFFENBARGER RS, 1978, AM J EPIDEMIOL, V108, P161, DOI 10.1093/oxfordjournals.aje.a112608; PEDERSEN N, 1981, TWIN RES G, V3, P37; POCOCK NA, 1987, J CLIN INVEST, V80, P706, DOI 10.1172/JCI113125; SEEMAN E, 1983, AM J MED, V75, P977, DOI 10.1016/0002-9343(83)90878-1; SLEMENDA C, 1987, J CLIN INVEST, V80, P1261, DOI 10.1172/JCI113201; SLEMENDA CW, 1989, J BONE MINER RES, V4, P737, DOI 10.1002/jbmr.5650040513; SLEMENDA CW, 1991, J BONE MINER RES, V6, P561; SMITH DM, 1973, J CLIN INVEST, V52, P2800, DOI 10.1172/JCI107476; SUZUKI DT, 1981, INTRO GENETIC ANAL; Swan G E, 1990, J Subst Abuse, V2, P39; TYLAVSKY FA, 1989, CALCIFIED TISSUE INT, V45, P265, DOI 10.1007/BF02556017; VASSART G, 1987, SCIENCE, V235, P683, DOI 10.1126/science.2880398; WASNICH RD, 1985, AM J OBSTET GYNECOL, V153, P745, DOI 10.1016/0002-9378(85)90338-2; 1989, REDUCING HLTH CONSEQ	32	181	188	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1992	117	4					286	291		10.7326/0003-4819-117-4-286	http://dx.doi.org/10.7326/0003-4819-117-4-286			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JH464	1637023				2022-12-01	WOS:A1992JH46400003
J	TEMPLE, JMF; SYKES, AM				TEMPLE, JMF; SYKES, AM			ASTHMA AND OPEN CAST MINING	BRITISH MEDICAL JOURNAL			English	Article									UNIV COLL SWANSEA,SWANSEA SA2 8PP,W GLAM,WALES	Swansea University								KIRN TF, 1988, JAMA-J AM MED ASSOC, V260, P455; LLOYD OL, 1978, LANCET, V1, P318; NEWHOUSE ML, 1965, BRIT J IND MED, V22, P261; WILLIAMS SM, 1992, BRIT MED J, V304, P1359, DOI 10.1136/bmj.304.6838.1359; 1985, OFFICIAL J EUROPEAN, V175, P40	5	25	25	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 15	1992	305	6850					396	397		10.1136/bmj.305.6850.396	http://dx.doi.org/10.1136/bmj.305.6850.396			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JK314	1392920	Green Published, Bronze, Green Submitted			2022-12-01	WOS:A1992JK31400015
J	WALD, NJ; KENNARD, A; DENSEM, JW; CUCKLE, HS; CHARD, T; BUTLER, L				WALD, NJ; KENNARD, A; DENSEM, JW; CUCKLE, HS; CHARD, T; BUTLER, L			ANTENATAL MATERNAL SERUM SCREENING FOR DOWNS-SYNDROME - RESULTS OF A DEMONSTRATION PROJECT	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PREGNANCY; AGE	Objectives-To assess the implementation of antenatal screening for Down's syndrome in practice, using individual risk estimates based on maternal age and the three serum markers: alpha-fetoprotein, unconjugated oestriol, and human chorionic gonadotrophin. Design-Demonstration project of Down's syndrome screening; women with a risk estimate at term of 1 in 250 or greater were classified as "screen positive" and offered diagnostic amniocentesis. Setting-Hospital and community antenatal clinics in four health districts in London. Subjects-12 603 women of all ages with singleton pregnancies seen between February 1989 and the end of May 1991, with follow up of the outcome of pregnancy completed to the end of 1991. Main outcome measures-Uptake of screening, detection rate for Down's syndrome, false positive rate, odds of being affected given a positive result, and uptake of amniocentesis in women with positive screening results, together with the costs of the screening programme. Results-The uptake of screening was 74%. The detection rate was 48% (12/25), and the false positive rate was 4.1%, consistent with results expected from previous work based on observational studies. There was a loss of detection due to thc selective use of ultrasound scans among women with positive screening results. One affected pregnancy occurred among 205 reclassified as negative; this illustrated the danger of false negatives occurring in this group and lends weight to the view that if an ultrasound estimate of gestational age is used it should be carried out routinely on all women rather than selectively among those with positive results. The estimated cost of avoiding the birth of a baby with Down's syndrome was about 38000 pounds, substantially less than the lifetime costs of care. Conclusion-Antenatal maternal serum screening for Down's syndrome is effective in practice and can be readily integrated into routine antenatal care. It is cost effective and performs better than selection for amniocentesis on the basis of maternal age alone.	ST BARTHOLOMEWS HOSP, DEPT REPROD PHYSIOL, LONDON EC1M 6EQ, ENGLAND; QUEEN ELIZABETH HOSP, REG CYTOGENET LAB, LONDON E2 8PS, ENGLAND	University of London; Queen Mary University London	WALD, NJ (corresponding author), ST BARTHOLOMEWS HOSP, COLL MED, WOLFSON INST PREVENT MED, DEPT ENVIRONM & PREVENT MED, LONDON EC1M 6BQ, ENGLAND.		Wald, Nicholas/AAY-2814-2021; Wald, Nicholas/AAY-8924-2021					[Anonymous], 1977, LANCET, V1, P1323; CUCKLE H, 1991, PRENATAL DIAG, V11, P29, DOI 10.1002/pd.1970110106; CUCKLE HS, 1987, BRIT J OBSTET GYNAEC, V94, P387, DOI 10.1111/j.1471-0528.1987.tb03115.x; GILL M, 1987, SOC SCI MED, V24, P725, DOI 10.1016/0277-9536(87)90109-2; HADDOW JE, IN PRESS N ENGL J ME; SHELDON TA, 1991, BRIT MED J, V302, P1133, DOI 10.1136/bmj.302.6785.1133; WALD NJ, 1992, BRIT J OBSTET GYNAEC, V99, P144, DOI 10.1111/j.1471-0528.1992.tb14474.x; WALD NJ, 1988, BRIT MED J, V297, P883, DOI 10.1136/bmj.297.6653.883; WALD NJ, IN PRESS PRENATAL DI	9	240	254	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 15	1992	305	6850					391	394		10.1136/bmj.305.6850.391	http://dx.doi.org/10.1136/bmj.305.6850.391			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JK314	1382768	Green Published, Bronze, Green Submitted			2022-12-01	WOS:A1992JK31400013
J	WILSON, RG; MACINTYRE, IMC; NIXON, SJ; SAUNDERS, JH; VARMA, JS; KING, PM				WILSON, RG; MACINTYRE, IMC; NIXON, SJ; SAUNDERS, JH; VARMA, JS; KING, PM			LAPAROSCOPIC CHOLECYSTECTOMY AS A SAFE AND EFFECTIVE TREATMENT FOR SEVERE ACUTE CHOLECYSTITIS	BRITISH MEDICAL JOURNAL			English	Article							EXPERIENCE	Objective-To evaluate the feasibility and safety of laparoscopic cholecystectomy in severe acute cholecystitis. Design-Analysis of data collected prospectively from a consecutive series of 350 laparoscopic operations. Setting-Two general surgical units in a teaching hospital. Subjects-31 patients with a diagnosis of severe acute cholecystitis based on clinical examination, investigation results, and operative findings. Interventions-Initial intravenous fluids and broad spectrum antibiotics followed by laparoscopic cholecystectomy within 72 hours of presentation. Main outcome measures-Failure to complete the operation laparoscopically, length of postoperative stay in hospital, early postoperative morbidity, interval from operation to full activity, and return to work. Results-Laparoscopic cholecystectomy was attempted in 19 patients with empyema of the gall bladder and 12 who had severe cholecystitis which failed to settle on medical management. A total of 29 operations were successfully completed with two conversions to open surgery. Two minor postoperative complications occurred, and one case of retained common bile duct stones with jaundice was treated by endoscopic retrograde cholangio-pancreatography and papillotomy. Median postoperative hospital stay was two days, with return to normal activity in seven days and to work in two weeks. There were no deaths related to the operation. Conclusions-In the presence of severe acute cholecystitis laparoscopic cholecystectomy is feasible in most patients, with minimal risk of injury to surrounding structures and considerable benefits. It is recommended that laparoscopic cholecystectomy should be attempted in these patients when appropriate surgical skill is available.			WILSON, RG (corresponding author), WESTERN GEN HOSP,DEPT SURG,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.			Macintyre, Iain/0000-0003-2716-8500				Cooperman A M, 1990, J Laparoendosc Surg, V1, P37, DOI 10.1089/lps.1990.1.37; CUSCHIERI A, 1991, AM J SURG, V161, P385, DOI 10.1016/0002-9610(91)90603-B; DUBOIS F, 1990, ANN SURG, V211, P60, DOI 10.1097/00000658-199001000-00010; FLOWERS JL, 1991, AM J SURG, V161, P388, DOI 10.1016/0002-9610(91)90604-C; HOLOHAN TV, 1991, LANCET, V338, P801, DOI 10.1016/0140-6736(91)90678-I; MCARTHUR P, 1975, BRIT J SURG, V62, P850, DOI 10.1002/bjs.1800621025; MEYERS WC, 1991, NEW ENGL J MED, V324, P1073; REDDICK EJ, 1989, SURG ENDOSC-ULTRAS, V3, P1333; REISS R, 1990, WORLD J SURG, V14, P567, DOI 10.1007/BF01658790; Unger S W, 1991, Surg Laparosc Endosc, V1, P14; WILSON P, 1991, LANCET, V338, P795, DOI 10.1016/0140-6736(91)90674-E; ZUCKER KA, 1991, AM J SURG, V161, P36, DOI 10.1016/0002-9610(91)90358-K	12	101	103	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 15	1992	305	6850					394	396		10.1136/bmj.305.6850.394	http://dx.doi.org/10.1136/bmj.305.6850.394			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JK314	1392919	Green Published, Green Submitted, Bronze			2022-12-01	WOS:A1992JK31400014
J	ZENZES, MT; WANG, P; CASPER, RF				ZENZES, MT; WANG, P; CASPER, RF			CHROMOSOME STATUS OF UNTRANSFERRED (SPARE) EMBRYOS AND PROBABILITY OF PREGNANCY AFTER INVITRO FERTILIZATION	LANCET			English	Article							FERTILIZATION	Many spontaneous abortions are associated with chromosomal abnormality of the fetus. In in-vitro fertilisation (IVF) the chromosome status of untransferred (''spare'') embryos and subsequent fate (pregnancy or not) of the transferred sibling embryos might be related. Since the spare and transferred embryos of a patient's cycle genetically are full siblings, the inherited chromosomal abnormalities in spare embryos have a 50% probability of also appearing in transferred embryos. We have tested whether chromosome analysis of spare embryos has predictive power for transferred embryos. 48 couples with a total of 437 embryos were selected because their spare embryos (1-4 per couple; 76 total) were successfully analysed for chromosome status. 16 patients became pregnant. These women produced a higher proportion of chromosomally normal spare embryos (9/24; 37.5%) than those who did not achieve pregnancy (1/52; 1.9%). The proportion of patients who had only normal embryos was significantly higher (p=0.012) in the pregnant group than in the non-pregnant group, and the proportion of patients who had only abnormal embryos was significantly higher (p=0.001) in the non-pregnant group. Patients with preclinical and clinical pregnancy losses had only chromosomally abnormal spare embryos; by contrast, 50% of spare embryos from patients with ectopic pregnancies were normal. The proportion of spare embryos that were normal (13%, 10/76), was similar to the livebirth rate of 11% per transferred embryo (19 infants from 171 transferred embryos). These results suggest that chromosome analysis of spare embryos may have predictive value for their transferred sibling embryos. We conclude that improving detection of chromosomally normal embryos for transfer should improve the success rate in IVF.	UNIV TORONTO, DEPT OBSTET & GYNAECOL, TORONTO M5S 1A1, ONTARIO, CANADA	University of Toronto			Casper, Robert F./E-3775-2013	Casper, Robert F./0000-0002-6249-462X				Angell R R, 1988, J Reprod Fertil Suppl, V36, P73; BEIER H, 1991, GUIDELINES ESHRE ETH, V1, P21; BELSEY MA, 1980, LABORATORY MANUAL EX, P9; BRAUDE RR, 1986, HUMAN EMBRYO RES YES, P63; BREED ASPM, 1990, PRENATAL DIAG, V10, P101, DOI 10.1002/pd.1970100206; EDMONDS DK, 1982, FERTIL STERIL, V38, P447; EIBEN B, 1990, AM J HUM GENET, V47, P656; GONEN Y, 1990, FERTIL STERIL, V53, P282; HARNDEN DG, 1985, CYTOGENET CELL GENET; HERTIG AT, 1949, AM J OBSTET GYNECOL, V58, P968, DOI 10.1016/0002-9378(49)90203-3; HOOK EB, IN PRESS PRENATAL DI; KLINE J, 1989, CONCEPTION BIRTH EPI, P81; LOPATA A, 1983, FERTIL STERIL, V40, P289; MILLER JF, 1980, LANCET, V2, P554; PLACHOT M, 1988, ANN NY ACAD SCI, V541, P384, DOI 10.1111/j.1749-6632.1988.tb22275.x; QUINN P, 1984, FERTIL STERIL, V41, P202; SUTTON HE, 1988, INTRO HUMAN GENETICS, P147; TARKOWSKI AK, 1966, CYTOGENETICS, V5, P394, DOI 10.1159/000129914; VANBLERKOM J, 1988, HUM REPROD, V3, P777, DOI 10.1093/oxfordjournals.humrep.a136783; WILCOX AJ, 1988, NEW ENGL J MED, V319, P189, DOI 10.1056/NEJM198807283190401; WRAMSBY H, 1987, HUM REPROD, V2, P233, DOI 10.1093/oxfordjournals.humrep.a136519; ZENZES MT, 1990, HUM REPROD, V5, P842, DOI 10.1093/oxfordjournals.humrep.a137195; ZENZES MT, 1992, FERTIL STERIL, V57, P143; ZENZES MT, 1992, HUM GENET, V88, P367, DOI 10.1007/BF00215667	24	17	17	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 15	1992	340	8816					391	394		10.1016/0140-6736(92)91471-J	http://dx.doi.org/10.1016/0140-6736(92)91471-J			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JJ449	1353556				2022-12-01	WOS:A1992JJ44900004
J	ADLER, RG				ADLER, RG			GENOME RESEARCH - FULFILLING THE PUBLICS EXPECTATIONS FOR KNOWLEDGE AND COMMERCIALIZATION	SCIENCE			English	Article							BIOTECHNOLOGY; PROJECT; PATENTS	This article provides a historical perspective for the patenting of gene sequences and describes the fundamentals and evolution of patent law. It summarizes federal technology transfer law and policy and assesses the impacts of patenting on academic research. The patentability of gene sequences is then considered along with potential impacts that published sequence data may have on obtaining patent protection for downstream products. Industry's position on gene patenting is summarized and perspectives from the emerging public record on these issues are presented. The article discussing points at which the filing of patent applications and the licensing of patents may be appropriate. It concludes that technology transfer policies for genome research must be adopted carefully so that they remain viable in a time of rapid technological change.			ADLER, RG (corresponding author), NIH,OFF TECHNOL TRANSFER,BETHESDA,MD 20892, USA.			Adler, Reid/0000-0002-4998-4034				ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; ADLER R, 1988, HARVARD J LAW TECH, V1, P1; ADLER R, 1989, AM INTELECT PROP LAW, V16, P287; ADLER RG, 1984, SCIENCE, V224, P357, DOI 10.1126/science.6584975; Beier David, 1991, DENVER U LAW REV, V68, P173; BENT S, 1992, GENET ENG NEWS   JAN, P4; BURRILL GS, 1990, BIOTECH 91 CHANGING, P5; Cohen Stanley N, 1980, US Patent, Patent No. [4,237,224, 4237224]; CURIEN H, 1991, SCIENCE, V254, P1710; Eisenberg Rebecca S, 1990, Emory Law J, V39, P721; EISENBERG RS, 1989, U CHICAGO LAW REV, V56, P1017, DOI 10.2307/1599761; FEIT, 1989, J PAT TRADEMARK OFF, V71, P819; GREENLEE LL, 1991, DENVER U LAW REV, V68, P127; HEALY B, 1992, IN PRESS N ENGL J ME; ISRAELSEN N, 1988, AM INTELECT PROP L A, V16, P457; JARJALA DS, 1992, JURIMETRICS, V32, P121; KELLY PD, 1992, BIO-TECHNOL, V10, P52, DOI 10.1038/nbt0192-52; KOSHLAND DE, 1992, SCIENCE, V255, P1189, DOI 10.1126/science.255.5049.1189; MANSFIELD E, 1979, REV EC STATISTIC FEB, P49; MERGES RP, 1990, COLUMBIA LAW REV, V90, P839, DOI 10.2307/1122920; MOSSINGHOFF GJ, 1992, COMMUNICATION   0528; Pasteur L., 1871, REV SCI; RAINES L, 1992, MAY PUBL M FCCSET CO; RAINES LJ, 1991, ISSUES SCI TECHNOL, V8, P33; Santayana George, 1905, LIFE REASON, VII; Schwaab Richard L., 1987, INTELLECTUAL PROPERT; Solzhenitsyn Aleksandr, 1978, NAT REV, V30; VAGELOS PR, 1991, SCIENCE, V252, P1080, DOI 10.1126/science.252.5009.1080; WATSON JD, 1981, DNA STORY DOCUMENTAR, pCH16; Winslow Ron, WALL STREET J; 1992, OTATCT527E OFF TECHN; 1991, OTABA495 OFF TECHN A, P203; 1991, REPORT NATIONAL BIOT, P17; 1984, OTAB2218 US C OFF TE; 1988, OTABA373 US C OFF TE, pCH16; 1991, OTABA494 US C OFF TE, P17; 1992, WASHINGTON POST 0501; [No title captured]; 1988, IMPLICATIONS SOC, P91	40	32	32	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 14	1992	257	5072					908	914		10.1126/science.1502557	http://dx.doi.org/10.1126/science.1502557			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	JH827	1502557				2022-12-01	WOS:A1992JH82700022
J	ECKER, DJ; VICKERS, TA; BRUICE, TW; FREIER, SM; JENISON, RD; MANOHARAN, M; ZOUNES, M				ECKER, DJ; VICKERS, TA; BRUICE, TW; FREIER, SM; JENISON, RD; MANOHARAN, M; ZOUNES, M			PSEUDO HALF-KNOT FORMATION WITH RNA	SCIENCE			English	Article							TAR RNA; BINDING; PROTEIN; SEQUENCE	A pseudo-half-knot can be formed by binding an oligonucleotide asymmetrically to an RNA hairpin loop. This binding motif was used to target the human immunodeficiency virus TAR element, an important viral RNA structure that is the receptor for Tat, the major viral transactivator protein. Oligonucleotides complementary to different halves of the TAR structure bound with greater affinity than molecules designed to bind symmetrically around the hairpin. The pseudo-half-knot-forming oligonucleotides altered the TAR structure so that specific recognition and binding of a Tat-derived peptide was disrupted. This general binding motif may be used to disrupt the structure of regulatory RNA hairpins.			ECKER, DJ (corresponding author), ISIS PHARMACEUT, 2280 FARADAY AVE, CARLSBAD, CA 92008 USA.			Ecker, David/0000-0003-4350-9037				CASEY JL, 1988, SCIENCE, V240, P924, DOI 10.1126/science.2452485; CHEN CHB, 1988, J AM CHEM SOC, V110, P6570, DOI 10.1021/ja00227a052; CROOKE ST, 1992, ANNU REV PHARMACOL, V32, P329; DINGWALL C, 1989, P NATL ACAD SCI USA, V86, P6925, DOI 10.1073/pnas.86.18.6925; ECKER D, UNPUB ANTISENSE RES; ECKER DJ, UNPUB; EGUCHI Y, 1991, ANNU REV BIOCHEM, V60, P631, DOI 10.1146/annurev.bi.60.070191.003215; HALL KB, 1991, BIOCHEMISTRY-US, V30, P10606, DOI 10.1021/bi00108a002; INOUE H, 1987, NUCLEIC ACIDS RES, V15, P6131, DOI 10.1093/nar/15.15.6131; JUNKERNIEPMANN M, 1990, EMBO J, V9, P3389, DOI 10.1002/j.1460-2075.1990.tb07540.x; PLEIJ CWA, 1985, NUCLEIC ACIDS RES, V13, P1717, DOI 10.1093/nar/13.5.1717; PLEIJ CWA, 1989, METHOD ENZYMOL, V180, P289; PLEIJ CWA, 1990, TRENDS BIOCHEM SCI, V15, P143, DOI 10.1016/0968-0004(90)90214-V; PUGLISI JD, 1991, ACCOUNTS CHEM RES, V24, P152, DOI 10.1021/ar00005a005; PYLE AM, 1990, P NATL ACAD SCI USA, V87, P8187, DOI 10.1073/pnas.87.21.8187; ROSEN CA, 1990, AIDS, V4, P499, DOI 10.1097/00002030-199006000-00002; ROY S, 1990, GENE DEV, V4, P1365, DOI 10.1101/gad.4.8.1365; WEEKS KM, 1990, SCIENCE, V249, P1281, DOI 10.1126/science.2205002; WITHERELL GW, 1990, BIOCHEMISTRY-US, V29, P11051, DOI 10.1021/bi00502a006	19	89	94	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 14	1992	257	5072					958	961		10.1126/science.1502560	http://dx.doi.org/10.1126/science.1502560			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JH827	1502560				2022-12-01	WOS:A1992JH82700033
J	EISENBERG, RS				EISENBERG, RS			GENES, PATENTS, AND PRODUCT DEVELOPMENT	SCIENCE			English	Article								In the past year,the National Institutes of Health (NIH) has filed patent applications on more than 2750 partial complementary DNA sequences of unknown function. The rationale for the filings-that patent protection may be necessary to ensure that private firms are willing to invest in developing related products-rests on two premises: first, that NIH may obtain patent rights that will offer effective product monopolies to licensee firms, and second, that unless NIH obtains these rights now, firms will be unable to obtain a comparable degree of exclusivity by other means, such as by obtaining patents on their own subsequent innovations. Neither premise is clearly wrong, although both are subject to doubt in view of statements from industry representatives that the NIH patenting strategy will deter rather than promote product development.			EISENBERG, RS (corresponding author), UNIV MICHIGAN,SCH LAW,ANN ARBOR,MI 48109, USA.							Eisenberg Rebecca S, 1990, Emory Law J, V39, P721; EISENBERG RS, 1989, U CHICAGO LAW REV, V56, P1017, DOI 10.2307/1599761; HEALY B, 1992, MAY PUBL M FED COORD; MERGES RP, 1990, COLUMBIA LAW REV, V90, P839, DOI 10.2307/1122920; MOSSINGHOFF GJ, 1992, COMMUNICATION   0528; 1991, POSITION PAPER PATEN; 1992, IBA POSITION PAPER R	7	46	46	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 14	1992	257	5072					903	908		10.1126/science.1502556	http://dx.doi.org/10.1126/science.1502556			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	JH827	1502556				2022-12-01	WOS:A1992JH82700021
J	FREMONT, DH; MATSUMURA, M; STURA, EA; PETERSON, PA; WILSON, IA				FREMONT, DH; MATSUMURA, M; STURA, EA; PETERSON, PA; WILSON, IA			CRYSTAL-STRUCTURES OF 2 VIRAL PEPTIDES IN COMPLEX WITH MURINE MHC CLASS-I H-2K(B)	SCIENCE			English	Article							ANTIGEN-BINDING SITE; T-CELL RECOGNITION; HISTOCOMPATIBILITY ANTIGEN; MOLECULES; RECEPTOR; RESOLUTION; ANTIBODY; HLA-B27; HLA-A2	The x-ray structures of a murine MHC class I molecule (H-2K(b)) were determined in complex with two different viral peptides, derived from the vesicular stomatitis virus nucleoprotein(52-59), VSV-8, and the Sendai virus nucleoprotein(324-332), SEV-9. The H-2K(b) complexes were refined at 2.3 angstrom for VSV-8 and 2.5 angstrom for SEV-9. The structure of H-2K(b) exhibits a high degree of similarity with human HLA class I, although the individual domains can have slightly altered dispositions. Both peptides bind in extended conformations with most of their surfaces buried in the H-2K(b) binding groove. The nonamer peptide maintains the same amino- and carboxyl-terminal interactions as the octamer primarily by the insertion of a bulge in the center of an otherwise beta-conformation. Most of the specific interactions are between side-chain atoms of H-2K(b) and main-chain atoms of peptide. This binding scheme accounts in large part for the enormous diversity of peptide sequences that bind with high affinity to class I molecules. Small but significant conformational changes in H-2K(b) are associated with peptide binding, and these synergistic movements may be an integral part of the T cell receptor recognition process.	SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA; UNIV CALIF SAN DIEGO, DEPT CHEM, LA JOLLA, CA 92093 USA	Scripps Research Institute; Scripps Research Institute; University of California System; University of California San Diego			Stura, Enrico A./A-2793-2010	Stura, Enrico A./0000-0001-6718-2118; Fremont, Daved/0000-0002-8544-2689	NCI NIH HHS [CA-09523, CA-97489] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMIT AG, 1986, SCIENCE, V233, P747, DOI 10.1126/science.2426778; BJORKMAN PJ, 1990, ANNU REV BIOCHEM, V59, P253, DOI 10.1146/annurev.biochem.59.1.253; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BLUESTONE JA, UNPUB; BROWN JH, 1988, NATURE, V332, P845, DOI 10.1038/332845a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CARBONE FR, 1989, J EXP MED, V169, P603, DOI 10.1084/jem.169.3.603; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CHEN BP, 1989, NATURE, V337, P743, DOI 10.1038/337743a0; CHEN Y, TUBES WERE GENERATED; CHOTHIA C, 1988, EMBO J, V7, P3745, DOI 10.1002/j.1460-2075.1988.tb03258.x; CONNOLLY ML, 1985, J MOL GRAPHICS, V3, P19, DOI 10.1016/0263-7855(85)80009-6; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985; CONNOLLY ML, CALCULATE SOLVENT AC; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.biochem.59.1.439; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FILMAN D, PROGRAM HARADA; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; FREMONT DH, CALCULATE PSEUDO ROT; FREMONT DH, UNPUB; GARRETT TPJ, 1989, NATURE, V342, P692, DOI 10.1038/342692a0; HARADA Y, 1981, ACTA CRYSTALLOGR A, V37, P398, DOI 10.1107/S0567739481000867; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; HUNT DF, 1992, SCIENCE, V255, P1261, DOI 10.1126/science.1546328; JACKSON MR, IN PRESS P NATL ACAD; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; JARDETZKY TS, 1990, EMBO J, V9, P1797, DOI 10.1002/j.1460-2075.1990.tb08304.x; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KAST WM, 1991, P NATL ACAD SCI USA, V88, P2283, DOI 10.1073/pnas.88.6.2283; KOURILSKY P, 1989, ADV IMMUNOL, V45, P107, DOI 10.1016/S0065-2776(08)60693-8; KOZLOWSKI S, 1991, NATURE, V349, P74, DOI 10.1038/349074a0; LEAHY DJ, 1992, CELL, V68, P1145, DOI 10.1016/0092-8674(92)90085-Q; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; MADDEN DR, IN PRESS CELL; MARRACK P, 1987, SCIENCE, V238, P1073, DOI 10.1126/science.3317824; MARYANSKI JL, 1990, CELL, V60, P63, DOI 10.1016/0092-8674(90)90716-R; MATSUI K, 1991, SCIENCE, V254, P1788, DOI 10.1126/science.1763329; MATSUMURA M, 1992, SCIENCE, V257, P927, DOI 10.1126/science.1323878; MATSUMURA M, IN PRESS J BIOL CHEM; RINI JM, 1992, SCIENCE, V255, P959, DOI 10.1126/science.1546293; ROGNAN D, 1992, PROTEINS, V13, P70, DOI 10.1002/prot.340130107; ROSSMANN MG, 1975, J BIOL CHEM, V250, P7525; SAPER MA, 1991, J MOL BIOL, V219, P277, DOI 10.1016/0022-2836(91)90567-P; SCHUMACHER TNM, 1991, NATURE, V350, P703, DOI 10.1038/350703a0; SHERIFF S, 1987, J MOL BIOL, V197, P273, DOI 10.1016/0022-2836(87)90124-0; SHIBATA K, 1992, P NATL ACAD SCI USA, V89, P3135, DOI 10.1073/pnas.89.7.3135; STANFIELD RL, 1990, SCIENCE, V248, P712, DOI 10.1126/science.2333521; STURA EA, IN PRESS J MOL BIOL; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; TSOMIDES TJ, 1991, J BIOL CHEM, V266, P3357; UPSON C, 1989, IEEE COMPUT GRAPH, V9, P30, DOI 10.1109/38.31462; VANBLEEK GM, 1990, NATURE, V348, P213; VITIELLO A, 1990, SCIENCE, V250, P1423, DOI 10.1126/science.2124002; WILSON IA, 1991, METHOD ENZYMOL, V203, P153	59	892	925	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 14	1992	257	5072					919	927		10.1126/science.1323877	http://dx.doi.org/10.1126/science.1323877			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JH827	1323877				2022-12-01	WOS:A1992JH82700024
J	KILEY, TD				KILEY, TD			PATENTS ON RANDOM COMPLEMENTARY-DNA FRAGMENTS	SCIENCE			English	Article								The proposal by the National Institutes of Health (NIH) to patent products resulting merely from sequencing the human genome is a mistake: at worst, it is wrong in patent law; at best, it relies on deficiencies in law concerning what is "useful" as a requirement for patents. The proposal is symptomatic of a problem besieging biotechnology-attempts to control the raw material of scientific experimentation before research has determined the practical value of such material-that needs curing on many fronts. Corrective measures are proposed for adoption by the Executive branch, the Congress, and the courts.										ROBERTS L, 1991, SCIENCE, V254, P184, DOI 10.1126/science.1925568; ROBERTS L, 1991, SCIENCE, V254, P1104, DOI 10.1126/science.1957160; USDIN S, 1992, BIOWORLD TODAY, V3, P1	3	26	26	1	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 14	1992	257	5072					915	918		10.1126/science.1502558	http://dx.doi.org/10.1126/science.1502558			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JH827	1502558				2022-12-01	WOS:A1992JH82700023
J	LATRON, F; PAZMANY, L; MORRISON, J; MOOTS, R; SAPER, MA; MCMICHAEL, A; STROMINGER, JL				LATRON, F; PAZMANY, L; MORRISON, J; MOOTS, R; SAPER, MA; MCMICHAEL, A; STROMINGER, JL			A CRITICAL ROLE FOR CONSERVED RESIDUES IN THE CLEFT OF HLA-A2 IN PRESENTATION OF A NONAPEPTIDE TO T-CELLS	SCIENCE			English	Article							ANTIGEN-BINDING SITE; TOXIC LYMPHOCYTES-T; HISTOCOMPATIBILITY ANTIGEN; PEPTIDE; RECOGNITION; MOLECULES	The peptide binding cleft of the class I human histocompatibility antigen, HLA-A2, contains conserved amino acid residues clustered in the two ends of the cleft in pockets A and F as well as polymorphic residues. The function of two conserved tyrosines in the A pocket was investigated by mutating them to phenylalanines and of a conserved tyrosine and threonine in the F pocket by mutating them to phenylalanine and valine, respectively. Presentation of influenza virus peptides and of intact virus to cytolytic T lymphocytes (CTLs) was then examined. The magnitude of the reduction seen by the mutation of the two tyrosines in the A pocket suggests that hydrogen bonds involving them have a critical function in the binding of the NH2-terminal NH3+ of the peptide nonamer and possibly of all bound peptide nonamers. In contrast, the mutations in the F pocket had no effect on CTL recognition.	UNIV OXFORD,INST MOLEC MED,OXFORD OX3 9DU,ENGLAND; HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138	University of Oxford; Harvard University	LATRON, F (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115, USA.		Moots, Robert/AAM-8091-2020; Morrison, Jo/AAK-2858-2020	Morrison, Jo/0000-0003-0000-520X	NATIONAL CANCER INSTITUTE [R35CA047554] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020182] Funding Source: NIH RePORTER; NCI NIH HHS [CA 47554] Funding Source: Medline; NIAID NIH HHS [AI 20182] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BEDNAREK MA, 1991, J IMMUNOL, V147, P4047; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BODMER HC, 1989, NATURE, V337, P653, DOI 10.1038/337653a0; BROWN JH, 1988, NATURE, V332, P845, DOI 10.1038/332845a0; CERUNDOLO V, 1991, EUR J IMMUNOL, V21, P2069, DOI 10.1002/eji.1830210915; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FERSHT AR, 1985, NATURE, V314, P235, DOI 10.1038/314235a0; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; GARRETT TPJ, 1989, NATURE, V342, P692, DOI 10.1038/342692a0; GOTCH F, 1987, NATURE, V326, P653; LATRON F, 1991, P NATL ACAD SCI USA, V88, P11325, DOI 10.1073/pnas.88.24.11325; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; MADDEN DR, IN PRESS CELL; MCMICHAEL AJ, 1988, P NATL ACAD SCI USA, V85, P9194, DOI 10.1073/pnas.85.23.9194; MORRISON J, 1992, EUR J IMMUNOL, V22, P903, DOI 10.1002/eji.1830220404; ROBBINS PA, 1989, J IMMUNOL, V143, P4098; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; SANTOSAGUADO J, 1989, P NATL ACAD SCI USA, V86, P8936, DOI 10.1073/pnas.86.22.8936; SAPER MA, 1991, J MOL BIOL, V219, P277, DOI 10.1016/0022-2836(91)90567-P; VANBLEEK GM, 1990, NATURE, V348, P213	21	77	79	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 14	1992	257	5072					964	967		10.1126/science.1380181	http://dx.doi.org/10.1126/science.1380181			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JH827	1380181				2022-12-01	WOS:A1992JH82700035
J	LIANG, P; PARDEE, AB				LIANG, P; PARDEE, AB			DIFFERENTIAL DISPLAY OF EUKARYOTIC MESSENGER-RNA BY MEANS OF THE POLYMERASE CHAIN-REACTION	SCIENCE			English	Article							CELL-CYCLE; MOLECULAR-CLONING; CDNA SEQUENCES; KINASE; TUMOR; EXPRESSION; CANDIDATE; GENES; G1	Effective methods are needed to identify and isolate those genes that are differentially expressed in various cells or under altered conditions. This report describes a method to separate and clone individual messenger RNAs (mRNAs) by means of the polymerase chain reaction. The key element is to use a set of oligonucleotide primers, one being anchored to the polyadenylate tail of a subset of mRNAs, the other being short and arbitrary in sequence so that it anneals at different positions relative to the first primer. The mRNA subpopulations defined by these primer pairs were amplified after reverse transcription and resolved on a DNA sequencing gel. When multiple primer sets were used, reproducible patterns of amplified complementary DNA fragments were obtained that showed strong dependence on sequence specificity of either primer.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV CELL GROWTH & REGULAT,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	LIANG, P (corresponding author), HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115, USA.							ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; Alberts B., 1989, MOL BIOL CELL; BAND V, 1990, CANCER RES, V50, P7351; Bothwell A., 1990, METHODS CLONING ANAL; COPPOCK DL, 1987, MOL CELL BIOL, V7, P2925, DOI 10.1128/MCB.7.8.2925; CROY RG, 1983, P NATL ACAD SCI-BIOL, V80, P4699, DOI 10.1073/pnas.80.15.4699; HOFBAUER R, 1987, NUCLEIC ACIDS RES, V15, P741, DOI 10.1093/nar/15.2.741; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; KEYOMARSI K, 1991, CANCER RES, V51, P3602; KHAN AS, 1991, NUCLEIC ACIDS RES, V19, P1715, DOI 10.1093/nar/19.7.1715; LEE SW, 1991, P NATL ACAD SCI USA, V88, P2825, DOI 10.1073/pnas.88.7.2825; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; LIANG P, UNPUB; LIN PF, 1985, MOL CELL BIOL, V5, P3149, DOI 10.1128/MCB.5.11.3149; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MASIAKOWSKI P, 1982, NUCLEIC ACIDS RES, V10, P7895, DOI 10.1093/nar/10.24.7895; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; SU JY, 1991, NUCLEIC ACIDS RES, V19, P823, DOI 10.1093/nar/19.4.823; VARMUS H, 1989, ONCOGENES MOL ORIGIN, P3; WILLIAMS JGK, 1990, NUCLEIC ACIDS RES, V18, P6531, DOI 10.1093/nar/18.22.6531	21	4592	5472	2	212	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 14	1992	257	5072					967	971		10.1126/science.1354393	http://dx.doi.org/10.1126/science.1354393			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JH827	1354393				2022-12-01	WOS:A1992JH82700036
J	LOCKHART, DJ; KIM, PS				LOCKHART, DJ; KIM, PS			INTERNAL STARK-EFFECT MEASUREMENT OF THE ELECTRIC-FIELD AT THE AMINO TERMINUS OF AN ALPHA-HELIX	SCIENCE			English	Article							DIELECTRIC-CONSTANT; DIPOLE MODEL; PROTEINS; STABILITY; STABILIZATION; RESONANCE; PEPTIDES; ALANINE; CHARGE	The strengths of electrostatic interactions in biological molecules are difficult to calculate or predict because they occur in complicated, inhomogeneous environments. The electric field at the amino terminus of an alpha-helix in water has been determined by measuring the shift in the absorption band for a covalently attached, neutral probe molecule with an electric dipole moment difference between the ground and excited electronic states (an internal Stark effect). The field at the interface between the helix and the solvent is found to be an order of magnitude stronger than expected from the dielectric properties of bulk water. Furthermore, although the total electric dipole moment of the helix increases with length, the electric field at the amino terminus does not.			LOCKHART, DJ (corresponding author), MIT,HOWARD HUGHES MED INST,WHITEHEAD INST BIOMED RES,DEPT BIOL,CAMBRIDGE,MA 02142, USA.							AQVIST J, 1991, P NATL ACAD SCI USA, V88, P2026, DOI 10.1073/pnas.88.5.2026; BASHFORD D, 1990, BIOCHEMISTRY-US, V29, P10219, DOI 10.1021/bi00496a010; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; CHAKRABARTTY A, 1991, NATURE, V351, P586, DOI 10.1038/351586a0; FAIRMAN R, 1989, PROTEINS, V5, P1, DOI 10.1002/prot.340050102; FIELDS C G, 1991, Peptide Research, V4, P95; GILSON MK, 1986, BIOPOLYMERS, V25, P2097, DOI 10.1002/bip.360251106; GILSON MK, 1988, PROTEINS, V3, P32, DOI 10.1002/prot.340030104; GILSON MK, 1985, J MOL BIOL, V183, P503; HEMANT SK, 1991, J AM CHEM SOC, V113, P6062; HOL WGJ, 1981, NATURE, V294, P532, DOI 10.1038/294532a0; HOL WGJ, 1978, NATURE, V273, P443, DOI 10.1038/273443a0; LIFF MI, 1991, J AM CHEM SOC, V113, P1014, DOI 10.1021/ja00003a041; Liptay W., 1974, Excited states. Vol.1, P129; LOCKHART DJ, 1987, BIOCHEMISTRY-US, V26, P664, DOI 10.1021/bi00377a001; LOCKHART DJ, UNPUB; MARQUSEE S, 1989, P NATL ACAD SCI USA, V86, P5286, DOI 10.1073/pnas.86.14.5286; MATHIES R, 1976, P NATL ACAD SCI USA, V73, P2169, DOI 10.1073/pnas.73.7.2169; MERUTKA G, 1991, BIOCHEMISTRY-US, V30, P1591, DOI 10.1021/bi00220a021; MIICK SM, 1991, BIOCHEMISTRY-US, V30, P9498, DOI 10.1021/bi00103a016; NICHOLSON H, 1991, BIOCHEMISTRY-US, V30, P9816, DOI 10.1021/bi00105a002; NICHOLSON H, 1988, NATURE, V336, P651, DOI 10.1038/336651a0; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; REES DC, 1980, J MOL BIOL, V141, P323, DOI 10.1016/0022-2836(80)90184-9; RODGERS KK, 1991, J AM CHEM SOC, V113, P9419, DOI 10.1021/ja00024a087; ROHL CA, 1992, BIOCHEMISTRY-US, V31, P1263, DOI 10.1021/bi00120a001; RUSSELL AJ, 1987, NATURE, V328, P496, DOI 10.1038/328496a0; SALI D, 1991, J MOL BIOL, V220, P779, DOI 10.1016/0022-2836(91)90117-O; SALI D, 1988, NATURE, V335, P740, DOI 10.1038/335740a0; SANCHO J, 1992, BIOCHEMISTRY-US, V31, P2253, DOI 10.1021/bi00123a006; SERRANO L, 1989, NATURE, V342, P296, DOI 10.1038/342296a0; SHOEMAKER KR, 1987, NATURE, V326, P563, DOI 10.1038/326563a0; Wada A, 1976, Adv Biophys, P1; Woody RW, 1985, PEPTIDES ANAL SYNTHE, P15	34	189	192	0	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 14	1992	257	5072					947	951		10.1126/science.1502559	http://dx.doi.org/10.1126/science.1502559			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JH827	1502559				2022-12-01	WOS:A1992JH82700030
J	MATSUMURA, M; FREMONT, DH; PETERSON, PA; WILSON, IA				MATSUMURA, M; FREMONT, DH; PETERSON, PA; WILSON, IA			EMERGING PRINCIPLES FOR THE RECOGNITION OF PEPTIDE ANTIGENS BY MHC CLASS-I MOLECULES	SCIENCE			English	Article							CYTOTOXIC LYMPHOCYTES-T; HISTOCOMPATIBILITY ANTIGEN; BINDING SITE; CELLS; IDENTIFICATION; HLA-B27; COMPLEX; HLA-A2	Class I major histocompatibility complex (MHC) molecules interact with self and foreign peptides of diverse amino acid sequences yet exhibit distinct allele-specific selectivity for peptide binding. The structures of the peptide-binding specificity pockets (subsites) in the groove of murine H-2K(b) as well as human histocompatibility antigen class I molecules have been analyzed. Deep but highly conserved pockets at each end of the groove bind the amino and carboxyl termini of peptide through extensive hydrogen bonding and, hence, dictate the orientation of peptide binding. A deep polymorphic pocket in the middle of the groove provides the chemical and structural complementarity for one of the peptide's anchor residues, thereby playing a major role in allele-specific peptide binding. Although one or two shallow pockets in the groove may also interact with specific peptide side chains, their role in the selection of peptide is minor. Thus, usage of a limited number of both deep and shallow pockets in multiple combinations appears to allow the binding of a broad range of peptides. This binding occurs with high affinity, primarily because of extensive interactions with the peptide backbone and the conserved hydrogen bonding network at both termini of the peptide. Interactions between the anchor residue (or residues) and the corresponding allele-specific pocket provide sufficient extra binding affinity not only to enhance specificity but also to endure the presentation of the peptide at the cell surface for recognition by T cells.	SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; UNIV CALIF SAN DIEGO, DEPT CHEM, LA JOLLA, CA 92093 USA	Scripps Research Institute; University of California System; University of California San Diego	MATSUMURA, M (corresponding author), SCRIPPS RES INST, DEPT IMMUNOL, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.			Fremont, Daved/0000-0002-8544-2689	NCI NIH HHS [CA-09523, CA-97489] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBER T, 1987, BIOCHEMISTRY-US, V26, P3754, DOI 10.1021/bi00387a002; BJORKMAN PJ, 1990, ANNU REV BIOCHEM, V59, P253, DOI 10.1146/annurev.biochem.59.1.253; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BROWN JH, 1988, NATURE, V332, P845, DOI 10.1038/332845a0; CARBONE FR, 1989, J EXP MED, V169, P603, DOI 10.1084/jem.169.3.603; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.biochem.59.1.439; ERIKSSON AE, 1992, SCIENCE, V255, P178, DOI 10.1126/science.1553543; FALK K, 1990, NATURE, V348, P248, DOI 10.1038/348248a0; FALK K, 1991, J EXP MED, V174, P425, DOI 10.1084/jem.174.2.425; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; Fersht A., 1985, ENZYME STRUCTURE MEC; FREMONT DH, 1992, SCIENCE, V257, pR30; GARRETT TPJ, 1989, NATURE, V342, P692, DOI 10.1038/342692a0; HENDERSON RA, 1992, SCIENCE, V255, P1264, DOI 10.1126/science.1546329; HUNT DF, 1992, SCIENCE, V255, P1261, DOI 10.1126/science.1546328; JANIN J, 1990, J BIOL CHEM, V265, P16027; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; JARDETZKY TS, 1990, EMBO J, V9, P1797, DOI 10.1002/j.1460-2075.1990.tb08304.x; KARPUSAS M, 1989, P NATL ACAD SCI USA, V86, P8237, DOI 10.1073/pnas.86.21.8237; KAST WM, 1991, P NATL ACAD SCI USA, V88, P2283, DOI 10.1073/pnas.88.6.2283; Klein J., 1986, NATURAL HIST MAJOR H; KOURILSKY P, 1989, ADV IMMUNOL, V45, P107, DOI 10.1016/S0065-2776(08)60693-8; LANGLADE P, UNPUB; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; MATSUMURA M, 1988, NATURE, V334, P406, DOI 10.1038/334406a0; MATSUMURA M, IN PRESS J BIOL CHEM; RINI JM, 1992, SCIENCE, V255, P959, DOI 10.1126/science.1546293; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; RUDENSKY AY, 1991, NATURE, V353, P622, DOI 10.1038/353622a0; SAITO Y, UNPUB; SAPER MA, 1991, J MOL BIOL, V219, P277, DOI 10.1016/0022-2836(91)90567-P; SAPER MA, IN PRESS CELL; SCHUMACHER TNM, 1991, NATURE, V350, P703, DOI 10.1038/350703a0; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; STANFIELD RL, 1990, SCIENCE, V248, P712, DOI 10.1126/science.2333521; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; TSOMIDES TJ, 1991, J BIOL CHEM, V266, P3357; VANBLEEK GM, 1990, NATURE, V348, P213; WANG CR, 1991, CELL, V66, P335, DOI 10.1016/0092-8674(91)90623-7	43	685	754	0	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 14	1992	257	5072					927	934		10.1126/science.1323878	http://dx.doi.org/10.1126/science.1323878			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JH827	1323878				2022-12-01	WOS:A1992JH82700025
J	MEYERS, C; FRATTINI, MG; HUDSON, JB; LAIMINS, LA				MEYERS, C; FRATTINI, MG; HUDSON, JB; LAIMINS, LA			BIOSYNTHESIS OF HUMAN PAPILLOMAVIRUS FROM A CONTINUOUS CELL-LINE UPON EPITHELIAL DIFFERENTIATION	SCIENCE			English	Article							VIRUS-INFECTION; TERMINAL DIFFERENTIATION; MOLECULAR MARKERS; UTERINE CERVIX; EXPRESSION; PROTEINS; INVITRO; KERATINOCYTE; REPLICATION; FILAGGRIN	The study of the human pathogen papillomaviruses (HPVs) has been hampered by the inability to propagate the virus in tissue culture. The addition of 12-O-tetradecanoyl phorbol-13-acetate to the media of organotypic (raft) cultures increased expression of physiological markers of keratinocyte differentiation and concomitantly induced production of virions. Capsid production was detected in differentiated suprabasal cells. Virions approximately 54 nanometers in size were observed by electron microscopy in raft tissue cross sections in the suprabasal layers. Virions purified through isopycnic gradients were found to contain type 31b DNA and exhibited an icosahedral shape similar to that of papillomaviruses found in clinical samples.	UNIV CHICAGO,HOWARD HUGHES MED INST,DEPT MOLEC GENET & CELL BIOL,CHICAGO,IL 60637; UNIV CHICAGO,DEPT BIOCHEM & MOLEC BIOL,CHICAGO,IL 60637	Howard Hughes Medical Institute; University of Chicago; University of Chicago								ASSELINEAU D, 1986, J INVEST DERMATOL, V86, P181, DOI 10.1111/1523-1747.ep12284237; BALL RD, 1978, J BIOL CHEM, V253, P5861; BEDELL MA, 1991, J VIROL, V65, P2254, DOI 10.1128/JVI.65.5.2254-2260.1991; CRAWFORD DH, 1986, IMMUNOLOGY, V59, P405; CULLEN BR, 1989, CELL, V58, P423, DOI 10.1016/0092-8674(89)90420-0; DALE BA, 1987, J INVEST DERMATOL, V88, P306, DOI 10.1111/1523-1747.ep12466185; DALE BA, 1985, ANN NY ACAD SCI, V455, P330, DOI 10.1111/j.1749-6632.1985.tb50420.x; DAVIES AH, 1991, J VIROL, V65, P6838, DOI 10.1128/JVI.65.12.6838-6844.1991; DUNN AEG, 1968, J ULTRA MOL STRUCT R, V22, P282, DOI 10.1016/S0022-5320(68)90021-X; FAVRE M, 1975, J VIROL, V15, P1239, DOI 10.1128/JVI.15.5.1239-1247.1975; FUCHS E, 1980, CELL, V19, P1033, DOI 10.1016/0092-8674(80)90094-X; KOPAN R, 1987, J CELL BIOL, V105, P427, DOI 10.1083/jcb.105.1.427; KREIDER JW, 1990, VIROLOGY, V177, P415, DOI 10.1016/0042-6822(90)90503-J; KREIDER JW, 1987, J VIROL, V61, P590, DOI 10.1128/JVI.61.2.590-593.1987; LAURENCE J, 1990, BLOOD, V75, P696; LAVERTY CR, 1978, ACTA CYTOL, V22, P195; LEWIS RM, 1989, REV INFECT DIS, V11, P736; LI QX, 1992, NATURE, V356, P347, DOI 10.1038/356347a0; MCCANCE DJ, 1988, P NATL ACAD SCI USA, V85, P7169, DOI 10.1073/pnas.85.19.7169; MEYERS C, 1992, PAPILLOMAVIRUS RES, V3, P1; MEYERS CLF, UNPUB; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; MORIN C, 1980, ACTA CYTOL, V24, P82; NELSON WG, 1983, J CELL BIOL, V97, P244, DOI 10.1083/jcb.97.1.244; PFISTER H, 1987, PAPILLOMAVIRUSES HUM, P1; PILOTTI S, 1981, J CLIN PATHOL, V34, P532, DOI 10.1136/jcp.34.5.532; POLYAK SJ, 1991, J VIROL, V65, P3575, DOI 10.1128/JVI.65.7.3575-3582.1991; RADER JS, 1990, ONCOGENE, V5, P571; SALZMAN NP, 1987, PAPOVAVIRIDAE, V2; STERLING J, 1990, J VIROL, V64, P6305, DOI 10.1128/JVI.64.12.6305-6307.1990; SYRJANEN K, 1987, PAPILLOMAVIRUSES HUM; Taichman L.B., 1987, PAPOVAVIRIDEA, P109; VIAC J, 1978, J INVEST DERMATOL, V70, P263, DOI 10.1111/1523-1747.ep12541415; WEINSHENKER BG, 1988, J IMMUNOL, V140, P1626; WU YJ, 1982, CELL, V31, P693, DOI 10.1016/0092-8674(82)90324-5	35	374	389	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 14	1992	257	5072					971	973		10.1126/science.1323879	http://dx.doi.org/10.1126/science.1323879			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JH827	1323879				2022-12-01	WOS:A1992JH82700037
J	PRICE, DJ; GROVE, JR; CALVO, V; AVRUCH, J; BIERER, BE				PRICE, DJ; GROVE, JR; CALVO, V; AVRUCH, J; BIERER, BE			RAPAMYCIN-INDUCED INHIBITION OF THE 70-KILODALTON S6 PROTEIN-KINASE	SCIENCE			English	Article							PEPTIDYL-PROLYL ISOMERASE; IMMUNOSUPPRESSANT FK506; RIBOSOMAL PROTEIN-S6; DISTINCT; PHOSPHORYLATION; ACTIVATION; CELLS; PURIFICATION; CYCLOSPORINE; CYCLOPHILIN	The immunosuppressant rapamycin inhibited proliferation of the H4IIEC hepatoma cell line. Rapamycin, but not its structural analog FK506, also inhibited the basal and insulin-stimulated activity of the p70 ribosomal protein S6 kinase. By contrast, insulin stimulation of the p85 Rsk S6 kinase and mitogen-activated protein (MAP) kinase activity were unaffected by drug. Rapamycin treatment of COS cells transfected with recombinant p70 S6 kinase completely inhibited the appearance of the hyperphosphorylated form of p70 S6 kinase concomitant with the inhibition of enzyme activity toward 40S subunits. Thus, rapamycin inhibits a signal transduction element that is necessary for the activation of p70 S6 kinase and mitogenesis but unnecessary for activation of p85 Rsk S6 kinase or MAP kinase.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV PEDIAT ONCOL,BOSTON,MA 02115; MASSACHUSETTS GEN HOSP,DIABET UNIT,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,MED SERV,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT MED,DIV HEMATOL ONCOL,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital			Calvo, Victor/L-5024-2014; Izquierdo, Manuel/D-2971-2017	Calvo, Victor/0000-0002-5913-7058; Bierer, Barbara/0000-0001-6448-8170; Izquierdo, Manuel/0000-0002-7701-1002	NATIONAL CANCER INSTITUTE [P01CA039542] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK017776] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA39542] Funding Source: Medline; NIDDK NIH HHS [R01 DK17776] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHN NG, 1990, J BIOL CHEM, V265, P11495; ALCORTA DA, 1989, MOL CELL BIOL, V9, P3850, DOI 10.1128/MCB.9.9.3850; BANERJEE P, 1990, P NATL ACAD SCI USA, V87, P8550, DOI 10.1073/pnas.87.21.8550; BANERJEE P, UNPUB; BARRETT CB, 1992, J BIOL CHEM, V267, P4408; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; CALVO V, IN PRESS P NATL ACAD; CHUNG J, 1991, P NATL ACAD SCI USA, V88, P4981, DOI 10.1073/pnas.88.11.4981; DUMONT FJ, 1990, J IMMUNOL, V144, P251; ERIKSON E, 1986, J BIOL CHEM, V261, P350; ERIKSON RL, 1991, J BIOL CHEM, V266, P6007; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FRUMAN DA, 1992, P NATL ACAD SCI USA, V89, P3686, DOI 10.1073/pnas.89.9.3686; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GORDON J, 1982, CURR TOP CELL REGUL, V21, P89; GROVE JF, UNPUB; GROVE JR, 1991, MOL CELL BIOL, V11, P2159; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; JENO P, 1988, P NATL ACAD SCI USA, V85, P406, DOI 10.1073/pnas.85.2.406; JIN YJ, 1992, J BIOL CHEM, V26, P10942; JONES SW, 1988, P NATL ACAD SCI USA, V85, P3377, DOI 10.1073/pnas.85.10.3377; KAY JE, 1991, IMMUNOLOGY, V72, P544; KOZMA SC, 1990, P NATL ACAD SCI USA, V87, P7365, DOI 10.1073/pnas.87.19.7365; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; METCALFE SM, 1990, TRANSPLANTATION, V49, P798, DOI 10.1097/00007890-199004000-00028; MUKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; NEMENOFF RA, 1986, ARCH BIOCHEM BIOPHYS, V245, P196, DOI 10.1016/0003-9861(86)90205-5; PRICE DJ, 1989, J BIOL CHEM, V264, P13825; PRICE DJ, 1990, P NATL ACAD SCI USA, V87, P7944, DOI 10.1073/pnas.87.20.7944; PRICE DJ, 1991, J BIOL CHEM, V266, P16821; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0	35	619	632	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 14	1992	257	5072					973	977		10.1126/science.1380182	http://dx.doi.org/10.1126/science.1380182			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JH827	1380182				2022-12-01	WOS:A1992JH82700038
J	SHAANAN, B; GRONENBORN, AM; COHEN, GH; GILLILAND, GL; VEERAPANDIAN, B; DAVIES, DR; CLORE, GM				SHAANAN, B; GRONENBORN, AM; COHEN, GH; GILLILAND, GL; VEERAPANDIAN, B; DAVIES, DR; CLORE, GM			COMBINING EXPERIMENTAL INFORMATION FROM CRYSTAL AND SOLUTION STUDIES - JOINT X-RAY AND NMR REFINEMENT	SCIENCE			English	Article							NUCLEAR-MAGNETIC-RESONANCE; INTERPROTON DISTANCE RESTRAINTS; AMYLASE INHIBITOR TENDAMISTAT; MOLECULAR-DYNAMICS; SINGLE-CRYSTALS; R-FACTOR; PROTEINS; INTERLEUKIN-1-BETA; DIFFRACTION; RESOLUTION	Joint refinement of macromolecules against crystallographic and nuclear magnetic resonance (NMR) observations is presented as a way of combining experimental information from the two methods. The model of interleukin-1-beta derived by the joint x-ray and NMR refinement is shown to be consistent with the experimental observations of both methods and to have crystallographic R value and geometrical parameters that are of the same quality as or better than those of models obtained by conventional crystallographic studies. The few NMR observations that are violated by the model serve as an indicator for genuine differences between the crystal and solution structures. The joint x-ray-NMR refinement can resolve structural ambiguities encountered in studies of multidomain proteins, in which low- to medium-resolution diffraction data can be complemented by higher resolution NMR data obtained for the individual domains.	NIDDKD,MOLEC BIOL LAB,BETHESDA,MD 20892; NIDDKD,CHEM PHYS LAB,BETHESDA,MD 20892; NATL INST STAND & TECHNOL,ROCKVILLE,MD 20850; UNIV MARYLAND,MARYLAND BIOTECHNOL INST,CTR ADV RES BIOTECHNOL,SHADY GROVE,MD	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institute of Standards & Technology (NIST) - USA			Shaanan, Boaz/F-1202-2012; Clore, G Marius/L-2546-2018; Clore, G. Marius/A-3511-2008	Shaanan, Boaz/0000-0001-8925-4362; Clore, G Marius/0000-0003-3809-1027; Clore, G. Marius/0000-0003-3809-1027; Gronenborn, Angela M/0000-0001-9072-3525				BALDWIN ET, 1991, P NATL ACAD SCI USA, V88, P502, DOI 10.1073/pnas.88.2.502; BHAT TN, 1984, J APPL CRYSTALLOGR, V17, P244, DOI 10.1107/S0021889884011456; BILLETER M, 1989, J MOL BIOL, V206, P677, DOI 10.1016/0022-2836(89)90575-5; BRAUN W, 1989, J MOL BIOL, V206, P669, DOI 10.1016/0022-2836(89)90574-3; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, SCIENCE, V235, P1049, DOI 10.1126/science.235.4792.1049; BRUNGER AT, 1987, PROTEIN ENG, V1, P399, DOI 10.1093/protein/1.5.399; BRUNGER AT, 1986, P NATL ACAD SCI USA, V83, P3801, DOI 10.1073/pnas.83.11.3801; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BRUNGER AT, 1990, XPLOR VERSION 21; CHOTHIA C, 1976, J MOL BIOL, V105, P1, DOI 10.1016/0022-2836(76)90191-1; CLORE GM, 1991, J MOL BIOL, V217, P611, DOI 10.1016/0022-2836(91)90518-B; CLORE GM, 1991, SCIENCE, V252, P1390, DOI 10.1126/science.2047852; CLORE GM, 1991, J MOL BIOL, V221, P47, DOI 10.1016/0022-2836(91)90802-D; CLORE GM, 1991, BIOCHEMISTRY-US, V30, P2316; FINZEL BC, 1989, J MOL BIOL, V209, P779, DOI 10.1016/0022-2836(89)90606-2; HENDRICKSON WA, 1980, COMPUTING CRYSTALLOG; HOCH JC, 1991, COMPUTATIONAL ASPECT, P57; HOLAK TA, 1989, J MOL BIOL, V210, P649, DOI 10.1016/0022-2836(89)90138-1; JACK A, 1978, ACTA CRYSTALLOGR A, V34, P931, DOI 10.1107/S0567739478001904; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; PRIESTLE JP, 1989, P NATL ACAD SCI USA, V86, P9667, DOI 10.1073/pnas.86.24.9667; VEERAPANDIAN B, 1992, PROTEINS, V12, P10, DOI 10.1002/prot.340120103; WLODAWER A, 1982, ACTA CRYSTALLOGR A, V38, P239, DOI 10.1107/S0567739482000527; WUTHRICH K, 1989, SCIENCE, V243, P45, DOI 10.1126/science.2911719	25	60	62	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 14	1992	257	5072					961	964		10.1126/science.1502561	http://dx.doi.org/10.1126/science.1502561			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JH827	1502561				2022-12-01	WOS:A1992JH82700034
J	STEITZ, JA				STEITZ, JA			SPLICING TAKES A HOLIDAY	SCIENCE			English	Editorial Material							PRE-MESSENGER-RNA; MITOCHONDRIAL TRANSFER-RNAS; JUNCTION SEQUENCES; MAMMALIAN INTRONS; GROUP-II; SITE; YEAST; CLEAVAGE; RIBONUCLEOPROTEIN; SPLICEOSOME				STEITZ, JA (corresponding author), YALE UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT MOLEC BIOPHYS & BIOCHEM,295 CONGRESS AVE,NEW HAVEN,CT 06536, USA.							AGABIAN N, 1990, CELL, V61, P1157, DOI 10.1016/0092-8674(90)90674-4; BARRELL BG, 1980, P NATL ACAD SCI-BIOL, V77, P3164, DOI 10.1073/pnas.77.6.3164; BRUZIK JP, 1988, NATURE, V335, P559, DOI 10.1038/335559a0; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; HECKMAN JE, 1980, P NATL ACAD SCI-BIOL, V77, P3159, DOI 10.1073/pnas.77.6.3159; HOLBROOK SR, 1991, NATURE, V353, P579, DOI 10.1038/353579a0; HOLLIDAY R, 1964, GENET RES, V5, P282, DOI 10.1017/S0016672300001233; JACQUIER A, 1991, J MOL BIOL, V219, P415, DOI 10.1016/0022-2836(91)90183-7; JACQUIER A, 1990, TRENDS BIOCHEM SCI, V15, P351, DOI 10.1016/0968-0004(90)90075-M; LECUYER K, UNPUB; LERNER MR, 1980, NATURE, V283, P220, DOI 10.1038/283220a0; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; MURCHIE AIH, 1990, NUCLEIC ACIDS RES, V18, P2599, DOI 10.1093/nar/18.9.2599; NEWMAN A, 1991, CELL, V65, P115, DOI 10.1016/0092-8674(91)90413-S; NEWMAN AJ, 1992, CELL, V68, P1; NILSEN TW, 1989, EXP PARASITOL, V69, P413, DOI 10.1016/0014-4894(89)90191-4; OHSHIMA Y, 1987, J MOL BIOL, V195, P247, DOI 10.1016/0022-2836(87)90647-4; REED R, 1989, GENE DEV, V3, P2113, DOI 10.1101/gad.3.12b.2113; REICH CI, 1992, CELL, V69, P1159, DOI 10.1016/0092-8674(92)90637-R; ROGERS J, 1980, P NATL ACAD SCI-BIOL, V77, P1877, DOI 10.1073/pnas.77.4.1877; RYMOND BC, 1988, GENE DEV, V2, P428, DOI 10.1101/gad.2.4.428; RYMOND BC, 1985, NATURE, V317, P735, DOI 10.1038/317735a0; SAWA H, 1991, NUCLEIC ACIDS RES, V19, P3953, DOI 10.1093/nar/19.14.3953; SMITH CWJ, 1989, NATURE, V342, P243, DOI 10.1038/342243a0	24	107	111	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 14	1992	257	5072					888	889		10.1126/science.1386941	http://dx.doi.org/10.1126/science.1386941			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JH827	1386941				2022-12-01	WOS:A1992JH82700019
J	SURPRENANT, A; HORSTMAN, DA; AKBARALI, H; LIMBIRD, LE				SURPRENANT, A; HORSTMAN, DA; AKBARALI, H; LIMBIRD, LE			A POINT MUTATION OF THE ALPHA-2-ADRENOCEPTOR THAT BLOCKS COUPLING TO POTASSIUM BUT NOT CALCIUM CURRENTS	SCIENCE			English	Article							SITE-DIRECTED MUTAGENESIS; BETA-ADRENERGIC RECEPTORS; BINDING PROTEIN; ADENYLYL CYCLASE; LIGAND-BINDING; ALPHA-SUBUNITS; INHIBITION; IDENTIFICATION; GI2; SOMATOSTATIN	The alpha-2A-adrenergic receptor (adrenoceptor) was stably expressed in AtT20 mouse pituitary tumor cells; adrenoceptor agonists inhibited adenylyl cyclase, inhibited voltage-dependent calcium currents, and increased inwardly rectifying potassium currents. An aspartic acid residue (Asp79) highly conserved among guanine nucleotide-binding protein (G protein)-coupled receptors was mutated to asparagine; in cells transfected with the mutant alpha-2-receptor, agonists inhibited adenylyl cyclase and calcium currents but did not increase potassium currents. Because distinct G proteins appear to couple adrenoceptors to potassium and calcium currents, the present findings suggest that the mutant alpha-2-adrenoceptor cannot achieve the conformation necessary to activate G proteins that mediate potassium channel activation.	UNIV CALGARY, DEPT MED PHYSIOL, CALGARY T2N 4N1, ALBERTA, CANADA; VANDERBILT UNIV, DEPT PHARMACOL, NASHVILLE, TN 37232 USA	University of Calgary; Vanderbilt University	SURPRENANT, A (corresponding author), OREGON HLTH SCI UNIV, VOLLUM INST, PORTLAND, OR 97201 USA.		Akbarali, Hamid/Q-9344-2019; Akbarali, Hamid I/B-3236-2012	Akbarali, Hamid/0000-0003-1423-0774				BENOVIC JL, 1988, ANNU REV CELL BIOL, V4, P405, DOI 10.1146/annurev.cb.04.110188.002201; BROWN AM, 1990, ANNU REV PHYSIOL, V52, P197, DOI 10.1146/annurev.ph.52.030190.001213; BROWN DA, 1989, ANN NY ACAD SCI, V560, P358; BROWN DA, 1990, ANNU REV PHYSIOL, V52, P215; CHUNG FZ, 1988, J BIOL CHEM, V263, P4052; EWALD DA, 1988, P NATL ACAD SCI USA, V85, P3633, DOI 10.1073/pnas.85.10.3633; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FRASER CM, 1989, MOL PHARMACOL, V36, P840; GERHARDT MA, 1990, MOL PHARMACOL, V38, P214; GUYER CA, 1990, J BIOL CHEM, V265, P17307; HAGIWARA S, 1978, J PHYSIOL-LONDON, V279, P167, DOI 10.1113/jphysiol.1978.sp012338; HARRIS GC, 1992, J PHARMACOL EXP THER, V261, P476; HESCHELER J, 1987, NATURE, V325, P445, DOI 10.1038/325445a0; HORSTMAN DA, 1990, J BIOL CHEM, V265, P21590; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; LAW SF, 1991, J BIOL CHEM, V266, P17885; LEFKOWITZ RJ, 1987, RECENT PROG HORM RES, V43, P469; LLEDO PM, 1992, NEURON, V8, P455, DOI 10.1016/0896-6273(92)90273-G; LUINI A, 1986, J NEUROSCI, V6, P3128; LUINI A, 1990, J NEUROCHEM, V54, P30, DOI 10.1111/j.1471-4159.1990.tb13279.x; MCKENZIE FR, 1990, BIOCHEM J, V267, P391, DOI 10.1042/bj2670391; MILLIGAN G, 1991, J BIOL CHEM, V266, P6447; NORTH RA, 1989, BRIT J PHARMACOL, V98, P13, DOI 10.1111/j.1476-5381.1989.tb16855.x; PENNEFATHER PS, 1988, BRAIN RES, V444, P346, DOI 10.1016/0006-8993(88)90944-4; REISINE T, 1985, ENDOCRINOLOGY, V116, P2259, DOI 10.1210/endo-116-6-2259; SHEN KZ, 1990, BRIT J PHARMACOL, V101, P925, DOI 10.1111/j.1476-5381.1990.tb14182.x; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; STACK J, 1990, THESIS OREGON HLTH S; STANDEN NB, 1978, J PHYSIOL-LONDON, V280, P169, DOI 10.1113/jphysiol.1978.sp012379; STARKE K, 1987, REV PHYSIOL BIOCH P, V107, P73, DOI 10.1007/BFb0027645; STRADER CD, 1987, P NATL ACAD SCI USA, V84, P4384, DOI 10.1073/pnas.84.13.4384; SURPRENANT A, 1988, PROC R SOC SER B-BIO, V234, P85, DOI 10.1098/rspb.1988.0039; SURPRENANT A, 1989, SEMIN NEUROSCI, V1, P126; TALLENT M, 1992, MOL PHARMACOL, V41, P452; WANG CD, 1991, MOL PHARMACOL, V40, P168; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0; YATANI A, 1988, NATURE, V336, P680, DOI 10.1038/336680a0	37	131	133	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 14	1992	257	5072					977	980		10.1126/science.1354394	http://dx.doi.org/10.1126/science.1354394			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JH827	1354394				2022-12-01	WOS:A1992JH82700039
J	BROWN, J; MACKINNON, D; KING, A; VANDERBUSH, E				BROWN, J; MACKINNON, D; KING, A; VANDERBUSH, E			ELEVATED ARTERIAL BLOOD-PRESSURE IN CARDIAC-TAMPONADE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VENTRICULAR DIASTOLIC COLLAPSE; VASCULAR SMOOTH-MUSCLE; ECHOCARDIOGRAPHIC SIGN; PERICARDIAL TAMPONADE; PULSUS PARADOXUS; MEDICAL PATIENTS; HYPERTENSION; COMPRESSION; RESISTANCE	Background. In cardiac tamponade cardiac output falls, but peripheral vascular resistance increases, so that systemic blood pressure may be maintained at normal or near-normal levels. We recently observed a patient with cardiac tamponade whose blood pressure was markedly elevated. Methods. To determine the frequency of elevated blood pressure in patients with cardiac tamponade and their hemodynamic characteristics, we studied 18 consecutive patients with cardiac tamponade from a variety of causes using right heart catheterization. Results. Six of the 18 patients had systolic arterial blood pressures ranging from 150 to 210 mm Hg (mean [+/-SD], 176+/-26) and diastolic pressures ranging from 100 to 130 mm Hg (mean, 113+/-14). All six had previously been hypertensive. After pericardiocentesis there was a significant decrease in blood pressure (to 139+/-13 mm Hg systolic, P<0.05; and 83+/-6 mm Hg diastolic, P<0.01) and peripheral vascular resistance (from 2150+/-588 to 1207+/-345 dyn . sec . cm-5, P<0.01). Cardiac output increased in all six. The other 12 patients, 3 of whom had a history of hypertension, had significant increases in cardiac output and systolic blood pressure (from 119+/-13 to 127+/-7 mm Hg, P<0.05) after pericardiocentesis, whereas peripheral vascular resistance decreased. Both groups had similar degrees of cardiac tamponade, as indicated by measurements of cardiac output and intrapericardial, right atrial, and pulmonary-artery wedge pressures. Conclusions. Elevated blood pressure may occur in some patients with cardiac tamponade who have preexisting hypertension. Moreover, blood pressure may fall after pericardiocentesis in patients who have elevated blood pressure associated with tamponade.			BROWN, J (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,HARLEM HOSP CTR,DEPT MED,DIV CARDIOL,506 LENOX AVE,NEW YORK,NY 10032, USA.							ARMSTRONG WF, 1982, CIRCULATION, V65, P1491, DOI 10.1161/01.CIR.65.7.1491; Beck CS, 1935, J AMER MED ASSOC, V104, P714, DOI 10.1001/jama.1935.02760090018005; BOHR DF, 1984, AM J MED, V77, P3, DOI 10.1016/S0002-9343(84)80032-7; COGSWELL TL, 1985, CIRCULATION, V72, P1076, DOI 10.1161/01.CIR.72.5.1076; COGSWELL TL, 1986, AM J PHYSIOL, V251, pR916, DOI 10.1152/ajpregu.1986.251.5.R916; ENGEL PJ, 1982, AM J CARDIOL, V50, P1018, DOI 10.1016/0002-9149(82)90411-8; FOWLER NO, 1969, J CLIN INVEST, V48, P502, DOI 10.1172/JCI106007; FOWLER NO, 1978, MOD CONC CARDIOV DIS, V47, P115; FOWLER NO, 1978, CIRCULATION, V57, P563, DOI 10.1161/01.CIR.57.3.563; GASCHO JA, 1981, AM J PHYSIOL, V240, pH49, DOI 10.1152/ajpheart.1981.240.1.H49; GEER M, 1984, CLIN RES, V32, pA331; GILLAM LD, 1983, CIRCULATION, V68, P294, DOI 10.1161/01.CIR.68.2.294; GUBERMAN BA, 1981, CIRCULATION, V64, P633, DOI 10.1161/01.CIR.64.3.633; HANCOCK EW, 1971, CIRCULATION, V43, P183, DOI 10.1161/01.CIR.43.2.183; HOLLOWAY ET, 1973, CIRC RES, V33, P678, DOI 10.1161/01.RES.33.6.678; INGELFINGER JA, 1987, BIOSTATISTICS CLIN M, P105; KERBER RE, 1982, NEW ENGL J MED, V307, P929, DOI 10.1056/NEJM198210073071506; KRONZON I, 1983, J AM COLL CARDIOL, V2, P770, DOI 10.1016/S0735-1097(83)80318-0; KULKARNI P, 1986, CHEST, V89, pS496; LEIMGRUBER PP, 1983, CIRCULATION, V68, P612, DOI 10.1161/01.CIR.68.3.612; LEVINE MJ, 1991, J AM COLL CARDIOL, V17, P59, DOI 10.1016/0735-1097(91)90704-D; LORELL BH, 1988, HEART DISEASE TXB CA, P1497; MILLER SW, 1982, AM J CARDIOL, V50, P1287, DOI 10.1016/0002-9149(82)90465-9; NYBORG NCB, 1988, HYPERTENSION, V11, P635, DOI 10.1161/01.HYP.11.6.635; PEGRAM BL, 1975, CARDIOVASC RES, V9, P707, DOI 10.1093/cvr/9.6.707; REDDY PS, 1978, CIRCULATION, V58, P265, DOI 10.1161/01.CIR.58.2.265; SCHILLER NB, 1977, CIRCULATION, V56, P774, DOI 10.1161/01.CIR.56.5.774; SCHULTE KL, 1988, HYPERTENSION, V11, P320, DOI 10.1161/01.HYP.11.4.320; SHABETAI R, 1979, PROG CARDIOVASC DIS, V22, P107, DOI 10.1016/0033-0620(79)90017-3; SHARP JT, 1960, AM J MED, V29, P640, DOI 10.1016/0002-9343(60)90097-8; SHEBATAI R, 1970, AM J CARDIOL, V26, P480; SINGH S, 1984, CIRCULATION, V70, P966, DOI 10.1161/01.CIR.70.6.966; SINGH S, 1986, AM J CARDIOL, V57, P652, DOI 10.1016/0002-9149(86)90853-2; SIVERTSSON R, 1968, LIFE SCI PT 1 PHYSI, V7, P1291, DOI 10.1016/0024-3205(68)90244-0; SPODICK DH, 1968, DIS CHEST, V54, P62, DOI 10.1378/chest.54.1.62	35	34	35	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 13	1992	327	7					463	466		10.1056/NEJM199208133270704	http://dx.doi.org/10.1056/NEJM199208133270704			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JH340	1625736				2022-12-01	WOS:A1992JH34000004
J	CATES, W; HINMAN, AR				CATES, W; HINMAN, AR			AIDS AND ABSOLUTISM - THE DEMAND FOR PERFECTION IN PREVENTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							HUMAN-IMMUNODEFICIENCY-VIRUS; METHADONE TREATMENT; HIV INFECTION; NOTIFICATION; RISK				CATES, W (corresponding author), CTR DIS CONTROL,ATLANTA,GA 30333, USA.							ADLER MW, 1988, BRIT MED J, V296, P1420, DOI 10.1136/bmj.296.6634.1420; ANGELL M, 1991, NEW ENGL J MED, V325, P811; BRANDT EN, 1988, PUBLIC HEALTH REP, V103, P339; COOPER JR, 1989, JAMA-J AM MED ASSOC, V262, P1664, DOI 10.1001/jama.262.12.1664; EVANS L, 1986, ACCIDENT ANAL PREV, V18, P229, DOI 10.1016/0001-4575(86)90007-2; Francois-Marie Arouet, 1764, DICT PHILOS; Gerstein D., 1990, TREATING DRUG PROBLE; HOUSTON S, 1991, NEW ENGL J MED, V325, P810; LAMBERT B, 1990, NY TIMES, P1; LANDIS SE, 1992, NEW ENGL J MED, V326, P101, DOI 10.1056/NEJM199201093260205; MARKS G, 1991, AM J PUBLIC HEALTH, V81, P1321, DOI 10.2105/AJPH.81.10.1321; NEWMAN RG, 1987, NEW ENGL J MED, V317, P447, DOI 10.1056/NEJM198708133170710; NEWMEYER JA, 1988, J PSYCHOACTIVE DRUGS, V20, P159, DOI 10.1080/02791072.1988.10524488; NOBLE RC, 1991, NEWSWEEK        0401, P8; OHI G, 1988, LANCET, V2, P947; PERRY S, 1989, HOSP COMMUNITY PSYCH, V40, P158; RAMSTEDT K, 1990, SEX TRANSM DIS, V17, P37, DOI 10.1097/00007435-199017010-00008; ROTHENBERG RB, 1990, SEXUALLY TRANSMITTED, P1081; RUTHERFORD GW, 1988, JAMA-J AM MED ASSOC, V259, P3609, DOI 10.1001/jama.259.24.3609; SCHLESINGER AM, 1989, BROWN ALUMNI MONTHLY, V42, P37; SIEGEL JE, 1991, AM J PUBLIC HEALTH, V81, P1273, DOI 10.2105/AJPH.81.10.1273; TOOMEY KE, 1988, NEW ENGL J MED, V319, P442; TOOMEY KE, 1989, AIDS, V3, pS57, DOI 10.1097/00002030-198901001-00009; VANDENHOEK JAR, 1989, AM J PUBLIC HEALTH, V79, P1355, DOI 10.2105/AJPH.79.10.1355; VLAHOV D, 1991, EPIDEMIOLOGY, V2, P444, DOI 10.1097/00001648-199111000-00010; WYKOFF RF, 1991, SEX TRANSM DIS, V18, P217, DOI 10.1097/00007435-199110000-00004; YANCOVITZ SR, 1991, AM J PUBLIC HEALTH, V81, P1185, DOI 10.2105/AJPH.81.9.1185; 1990, METHADONE MAINTENANC, P30; 1991, MMWR MORB MORTAL WKL, V40	29	43	44	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 13	1992	327	7					492	494		10.1056/NEJM199208133270711	http://dx.doi.org/10.1056/NEJM199208133270711			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JH340	1625740				2022-12-01	WOS:A1992JH34000011
J	EGAN, M; FLOTTE, T; AFIONE, S; SOLOW, R; ZEITLIN, PL; CARTER, BJ; GUGGINO, WB				EGAN, M; FLOTTE, T; AFIONE, S; SOLOW, R; ZEITLIN, PL; CARTER, BJ; GUGGINO, WB			DEFECTIVE REGULATION OF OUTWARDLY RECTIFYING CL- CHANNELS BY PROTEIN KINASE-A CORRECTED BY INSERTION OF CFTR	NATURE			English	Article							CYSTIC-FIBROSIS GENE; CHLORIDE CHANNELS; EPITHELIAL-CELLS; EXPRESSION; CONDUCTANCE; ACTIVATION; DISEASE	CYSTIC fibrosis (CF) is a lethal genetic disease resulting in a reduced Cl- permeability1, increased mucous sulphation2, increased Na+ absorption3 and defective acidification of lysosomal vesicles4. The CF gene encodes a protein (the cystic fibrosis transmembrane conductance regulator, CFTR5) that can function as a low-conductance Cl- channel with a linear current-voltage relationship whose regulation is defective in CF patients6-8. Larger conductance, outwardly rectifying Cl- channels are also defective in CF and fail to activate when exposed either to cyclic AMP-dependent protein kinase A or to protein kinase C9-13. The role of the outwardly rectifying Cl- channel in CF has been questioned14. We report here that expression of recombinant CF genes using adeno-associated virus vectors in CF bronchial epithelial cells corrects defective Cl- secretion, that it induces the appearance of small, linear conductance Cl- channels, and restores protein kinase A activation of outwardly rectifying Cl- channels. These results re-establish an involvement of outwardly rectifying Cl- channels in CF and suggest that CFTR regulates more than one conductance pathway in airway tissues.	JOHNS HOPKINS UNIV,SCH MED,DEPT PHYSIOL & BIOPHYS,BALTIMORE,MD 21205; NIDDKD,MOLEC & CELLULAR BIOL LAB,BETHESDA,MD	Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)				Zeitlin, Pamela/0000-0002-2719-1834				ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ANDERSON MP, 1991, P NATL ACAD SCI USA, V88, P6003, DOI 10.1073/pnas.88.14.6003; BARASCH J, 1991, NATURE, V352, P70, DOI 10.1038/352070a0; BEAR CE, 1991, J BIOL CHEM, V266, P19142; BRIDGES RJ, 1989, AM J PHYSIOL, V256, pC902, DOI 10.1152/ajpcell.1989.256.4.C902; CHEN JH, 1989, SCIENCE, V243, P657, DOI 10.1126/science.2464852; CHENG PW, 1989, J CLIN INVEST, V84, P68, DOI 10.1172/JCI114171; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; FLOTTE T, 1991, PEDIATR PULM, V6, P247; FLOTTE TR, IN PRESS AM J RESPIR; FRIZZELL RA, 1987, TRENDS NEUROSCI, V10, P190, DOI 10.1016/0166-2236(87)90144-5; HWANG TC, 1989, SCIENCE, V244, P1351, DOI 10.1126/science.2472005; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; LI M, 1989, SCIENCE, V244, P1353, DOI 10.1126/science.2472006; LI M, 1988, NATURE, V331, P358, DOI 10.1038/331358a0; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; SCHOUMACHER RA, 1987, NATURE, V330, P752, DOI 10.1038/330752a0; TRAPNELL BC, 1991, J BIOL CHEM, V266, P10319; WARD CL, 1991, P NATL ACAD SCI USA, V88, P5277, DOI 10.1073/pnas.88.12.5277; WELSH MJ, 1989, J CLIN INVEST, V84, P2002, DOI 10.1172/JCI114391; ZEITLIN PL, 1992, P NATL ACAD SCI USA, V89, P344, DOI 10.1073/pnas.89.1.344; ZEITLIN PL, 1991, AM J RESP CELL MOL, V4, P313, DOI 10.1165/ajrcmb/4.4.313	25	401	410	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 13	1992	358	6387					581	584		10.1038/358581a0	http://dx.doi.org/10.1038/358581a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JH829	1380129				2022-12-01	WOS:A1992JH82900059
J	FOLLAND, ED; KRIEGEL, BJ; HENDERSON, WG; HAMMERMEISTER, KE; SETHI, GK				FOLLAND, ED; KRIEGEL, BJ; HENDERSON, WG; HAMMERMEISTER, KE; SETHI, GK			IMPLICATIONS OF 3RD HEART SOUNDS IN PATIENTS WITH VALVULAR HEART-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LEFT-VENTRICULAR VOLUME; ORIGIN; FAILURE; DOGS	Background. The presence of third heart sounds in patients with valvular heart disease is often regarded as a sign of heart failure, but it may also depend on the type of valvular disease. Methods. We assessed the prevalence of third heart sounds and the relation between third heart sounds and cardiac function in 1281 patients with six types of valvular heart disease. Results. The prevalence of third heart sounds was higher in patients with mitral regurgitation (46 percent) or aortic regurgitation (28 percent) than in those with aortic stenosis (11 percent) or mitral stenosis (8 percent). The left ventricular ejection fraction was significantly lower (P<0.001) when a third heart sound was detected in patients with aortic stenosis (0.38, vs. 0.56 in those without third heart sounds) or mixed aortic valve disease (0.40 vs. 0.55). However, the ejection fraction was only slightly lower in patients with mitral regurgitation and third heart sounds (0.51 vs. 0.57, P = 0.03). The pulmonary-capillary wedge pressure was higher (P<0.001) when a third heart sound was detected in patients with aortic stenosis (18.6 mm Hg, vs. 12.1 mm Hg in those without third heart sounds). There was no association between the wedge pressure and third heart sounds in patients with mitral regurgitation. The prevalence of third heart sounds increased with the severity of mitral regurgitation. Conclusions. In patients with mitral regurgitation, third heart sounds are common but do not necessarily reflect left ventricular systolic dysfunction or increased filling pressure. In patients with aortic stenosis, third heart sounds are uncommon but usually indicate the presence of systolic dysfunction and elevated filling pressure.	VET AFFAIRS MED CTR,RES SERV,BOSTON,MA; VET AFFAIRS MED CTR,RES SERV,HINES,IL; VET AFFAIRS MED CTR,RES SERV,DENVER,CO; VET AFFAIRS MED CTR,RES SERV,TUCSON,AZ	US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); Southern Arizona Veterans Affairs Health Care System								ABDULLA AM, 1981, CIRCULATION, V64, P464, DOI 10.1161/01.CIR.64.3.464; BRAUNWALD E, 1988, HEART DISEASE TXB CA, P1040; DODGE HT, 1960, AM HEART J, V60, P762, DOI 10.1016/0002-8703(60)90359-8; GOLDMAN L, 1977, NEW ENGL J MED, V297, P845, DOI 10.1056/NEJM197710202971601; GRAYZEL J, 1960, AM J MED, V28, P578, DOI 10.1016/0002-9343(60)90152-2; HAMMERMEISTER KE, 1974, CIRCULATION, V49, P739; ISHIMITSU T, 1985, J AM COLL CARDIOL, V5, P268, DOI 10.1016/S0735-1097(85)80046-2; ISHMAIL AA, 1987, CHEST, V91, P870, DOI 10.1378/chest.91.6.870; KENNEDY JW, 1970, AM HEART J, V80, P343, DOI 10.1016/0002-8703(70)90099-2; KUO PT, 1957, J CLIN INVEST, V36, P1035, DOI 10.1172/JCI103499; LEE DCS, 1982, NEW ENGL J MED, V306, P699, DOI 10.1056/NEJM198203253061202; NIXON PG, 1961, BRIT HEART J, V23, P677; OZAWA Y, 1983, CIRCULATION, V67, P399, DOI 10.1161/01.CIR.67.2.399; OZAWA Y, 1983, CIRCULATION, V67, P393, DOI 10.1161/01.CIR.67.2.393; SHAH PM, 1968, NEW ENGL J MED, V278, P753, DOI 10.1056/NEJM196804042781402; SHAH PM, 1969, AM HEART J, V78, P823, DOI 10.1016/0002-8703(69)90450-5; VANDEWERF F, 1984, J CLIN INVEST, V73, P1400, DOI 10.1172/JCI111344; VANDEWERF F, 1984, CIRCULATION, V69, P1070, DOI 10.1161/01.CIR.69.6.1070; 1985, CONTROLLED CLIN TRIA, V6, P51	19	34	35	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 13	1992	327	7					458	462		10.1056/NEJM199208133270703	http://dx.doi.org/10.1056/NEJM199208133270703			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JH340	1625735				2022-12-01	WOS:A1992JH34000003
J	JANSSEN, RS; STLOUIS, ME; SATTEN, GA; CRITCHLEY, SE; PETERSEN, LR; STAFFORD, RS; WARD, JW; HANSON, DL; OLIVO, N; SCHABLE, CA; DONDERO, TJ				JANSSEN, RS; STLOUIS, ME; SATTEN, GA; CRITCHLEY, SE; PETERSEN, LR; STAFFORD, RS; WARD, JW; HANSON, DL; OLIVO, N; SCHABLE, CA; DONDERO, TJ			HIV-INFECTION AMONG PATIENTS IN UNITED-STATES ACUTE CARE HOSPITALS - STRATEGIES FOR THE COUNSELING AND TESTING OF HOSPITAL PATIENTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; SENTINEL HOSPITALS; RISK; SURVEILLANCE; EPIDEMIOLOGY; EMERGENCY; WORKERS	Background. Routine, voluntary testing of hospital patients for the human immunodeficiency virus (HIV) has been proposed in order to identify those with early HIV infection in a setting where there is ready access to counseling, appropriate clinical referral, evaluation, and therapy. We studied the pattern of HIV infection among patients in 20 U.S. hospitals, in order to evaluate possible national strategies for the routine, voluntary HIV counseling and testing of hospital patients. Methods. Blood specimens remaining after clinical use from a systematically selected sample of patients at 20 hospitals in 15 U.S. cities were tested anonymously for antibody to HIV type 1 (HIV-1). Multivariate regression was used to determine which variables best predicted HIV seroprevalence in individual hospitals. Using these data, we estimated the number of HIV-positive patients in all U.S. hospitals and considered the efficiency of routine counseling and testing in different subgroups of patients and hospitals. Results. From September 1989 through October 1991, 9286 of 195,829 specimens (4.7 percent) were positive for HIV-1 in the 20 hospitals. The seroprevalence of HIV at these institutions ranged from 0.2 percent to 14.2 percent. Among HIV-positive patients, 32 percent had symptomatic HIV infection or the acquired immunodeficiency syndrome (AIDS) at the time of admission or evaluation. In the 20 hospitals, HIV seroprevalence was 10.4 times (95 percent confidence interval, 8.8 to 12.0) the AIDS-diagnosis rate (the annual number of patients with new diagnoses of AIDS per 1000 discharges in 1990). In a multivariate model that included 13 hospital-specific variables, only the AIDS-diagnosis rate was associated with the hospital-specific HIV-seroprevalence rate (P<0.001). Using these data and the AIDS-diagnosis rates for all U.S. acute care hospitals, we estimated that 225,000 HIV-positive persons were hospitalized (95 percent confidence interval, 190,000 to 260,000) in all 5558 such hospitals in 1990, including 163,000 persons presenting with conditions other than HIV or AIDS (95 percent confidence interval, 130,000 to 196,000). In 1990, in 593 U.S. hospitals with AIDS-diagnosis rates of 1.0 or more per 1000 discharges, HIV testing of patients 15 to 54 years old (3 million patients, or 12.0 percent of all patients in U.S. acute care hospitals) would have identified an estimated 68 percent of all HIV-positive patients (110,000 patients) who were admitted with conditions other than symptomatic HIV infection or AIDS. Conclusions. We estimate that about 225,000 HIV-positive persons were hospitalized in 1990, of whom only one third were admitted for symptomatic HIV infection or AIDS. Routine, voluntary HIV testing of patients 15 to 54 years old in hospitals with 1 or more patients with newly diagnosed AIDS per 1000 discharges per year could potentially have identified as many as 110,000 patients with HIV infection that was previously unrecognized.	CTR DIS CONTROL,DIV HUMAN IMMUNODEFICIENCY VIRUS AID,ATLANTA,GA 30333; CTR DIS CONTROL,DIV HUMAN IMMUNODEFICIENCY VIRUS AIDS,ATLANTA,GA 30333; CTR DIS CONTROL,DIV HUMAN IMMUNODEFICIENCY VIRUS AIDS,AIDS SURVEILLANCE BRANCH,ATLANTA,GA 30333; CTR DIS CONTROL,DIV HUMAN IMMUNODEFICIENCY VIRUS AIDS,LAB INVEST BRANCH,ATLANTA,GA 30333	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA			Stafford, Randall/F-3974-2017	Stafford, Randall/0000-0003-1805-1271; Satten, Glen/0000-0001-7275-5371				ANGELL M, 1991, NEW ENGL J MED, V324, P1498, DOI 10.1056/NEJM199105233242110; BERKELMAN RL, 1989, AM J MED, V86, P761, DOI 10.1016/0002-9343(89)90470-1; BRENNAN TA, 1991, NEW ENGL J MED, V324, P1504, DOI 10.1056/NEJM199105233242112; CASTRO KG, 1988, JAMA-J AM MED ASSOC, V259, P1338, DOI 10.1001/jama.259.9.1338; Centers for Disease Control (CDC), 1986, MMWR Morb Mortal Wkly Rep, V35, P334; FARIZO KM, 1992, JAMA-J AM MED ASSOC, V267, P1798, DOI 10.1001/jama.267.13.1798; GORDIN FM, 1990, J INFECT DIS, V161, P14, DOI 10.1093/infdis/161.1.14; HARRIS RL, 1990, INFECT CONT HOSP EP, V11, P628; HENRY K, 1992, PUBLIC HEALTH REP, V107, P138; HIGGINS DL, 1991, JAMA-J AM MED ASSOC, V266, P2419, DOI 10.1001/jama.266.17.2419; KELEN GD, 1989, JAMA-J AM MED ASSOC, V262, P516, DOI 10.1001/jama.262.4.516; KELEN GD, 1988, NEW ENGL J MED, V318, P1645, DOI 10.1056/NEJM198806233182503; LINDSAY MK, 1989, OBSTET GYNECOL, V74, P289; LOMBARDO JM, 1991, ARCH INTERN MED, V151, P965, DOI 10.1001/archinte.151.5.965; MARCUS R, 1990, 6TH INT C AIDS SAN F, V1, P276; RHAME FS, 1989, NEW ENGL J MED, V320, P1248, DOI 10.1056/NEJM198905113201905; RISI GF, 1989, SOUTHERN MED J, V82, P1079, DOI 10.1097/00007611-198909000-00005; STLOUIS ME, 1990, NEW ENGL J MED, V323, P213, DOI 10.1056/NEJM199007263230401; STLOUIS ME, 1990, PUBLIC HEALTH REP, V105, P140; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; 1990, MMWR MORB MORT SRR8, V39; 1991, MMWR MORB MOTAL WKLY, V40, P1; 1992, HIV AIDS SURVEIL JAN; 1987, MMWR MORB MORTAL S1S, V36, pS1; 1989, MMWR MORB MORTAL SS7, V38; 1991, AHA ANN SURVEY HOSPI; 1990, NATIONAL HLTH INTERV; 1990, MMWR MORB MORT SRR16, V39, P1; 1989, MMWR MORB MORTAL SS5, V38; 1990, SAS STAT USERS GUIDE, V2; 1986, MMWR MORB MOTAL WKLY, V35, P152	31	109	109	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 13	1992	327	7					445	452		10.1056/NEJM199208133270701	http://dx.doi.org/10.1056/NEJM199208133270701			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JH340	1625734				2022-12-01	WOS:A1992JH34000001
J	PAN, T; UHLENBECK, OC				PAN, T; UHLENBECK, OC			A SMALL METALLORIBOZYME WITH A 2-STEP MECHANISM	NATURE			English	Article							PHENYLALANINE TRANSFER-RNA; YEAST TRANSFER RNAPHE; SELF-SPLICING RNA; CLEAVAGE; HYDROLYSIS	An RNA molecule consisting of an asymmetric internal loop of six nucleotides can be rapidly and specifically cleaved by Pb2+ in the presence of Mg2+. The 5' cleavage product terminates with a 3' phosphomonoester generated from a 2',3'-cyclic phosphodiester reaction intermediate. This two-step reaction mechanism resembles that of many protein ribonucleases but has not previously been observed for reactions catalysed by RNA.			PAN, T (corresponding author), UNIV COLORADO, DEPT CHEM & BIOCHEM, BOULDER, CO 80309 USA.							Altman S., 1989, ADV ENZYMOL RAMB, V62, P1; BEHLEN LS, 1990, BIOCHEMISTRY-US, V29, P2515, DOI 10.1021/bi00462a013; BROWN RS, 1983, NATURE, V303, P543, DOI 10.1038/303543a0; BROWN RS, 1985, BIOCHEMISTRY-US, V24, P4785, DOI 10.1021/bi00339a012; CECH TR, 1986, ANNU REV BIOCHEM, V55, P599, DOI 10.1146/annurev.biochem.55.1.599; CECH TR, 1987, SCIENCE, V236, P1532, DOI 10.1126/science.2438771; CECH TR, 1990, REV BIOCH, V59, P5543; DAHM SC, 1991, BIOCHEMISTRY-US, V30, P9464, DOI 10.1021/bi00103a011; FARKAS WR, 1968, BIOCHIM BIOPHYS ACTA, V155, P401, DOI 10.1016/0005-2787(68)90184-6; FORSTER AC, 1987, CELL, V50, P9, DOI 10.1016/0092-8674(87)90657-X; KAO TH, 1980, P NATL ACAD SCI-BIOL, V77, P3360, DOI 10.1073/pnas.77.6.3360; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; PACE NR, 1990, J BIOL CHEM, V265, P3587; PAN T, 1992, BIOCHEMISTRY-US, V31, P3887, DOI 10.1021/bi00131a001; PERROTTA AT, 1992, BIOCHEMISTRY-US, V31, P16, DOI 10.1021/bi00116a004; PRODY GA, 1986, SCIENCE, V231, P1577, DOI 10.1126/science.231.4745.1577; RUBIN JR, 1983, J BIOMOL STRUCT DYN, V1, P639, DOI 10.1080/07391102.1983.10507471; SUNDARALINGAM M, 1984, INT J QUANTUM CHEM, P355; UHLENBECK OC, 1987, NATURE, V328, P596, DOI 10.1038/328596a0	19	205	216	2	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 13	1992	358	6387					560	563		10.1038/358560a0	http://dx.doi.org/10.1038/358560a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JH829	1501711				2022-12-01	WOS:A1992JH82900050
J	STEINER, JP; DAWSON, TM; FOTUHI, M; GLATT, CE; SNOWMAN, AM; COHEN, N; SNYDER, SH				STEINER, JP; DAWSON, TM; FOTUHI, M; GLATT, CE; SNOWMAN, AM; COHEN, N; SNYDER, SH			HIGH BRAIN DENSITIES OF THE IMMUNOPHILIN FKBP COLOCALIZED WITH CALCINEURIN	NATURE			English	Article							CIS-TRANS ISOMERASE; A-BINDING-PROTEIN; T-CELL ACTIVATION; CYCLOPHILIN-CYCLOSPORINE-A; PEPTIDYL-PROLYL ISOMERASE; IMMUNOSUPPRESSANT FK506; FK506-BINDING PROTEIN; SIGNAL TRANSDUCTION; MOLECULAR-CLONING; B-50 GAP-43	THE immunophilins cyclophilin and FK506 binding protein (FKBP) are small, predominantly soluble proteins that bind the immunosuppressant drugs cyclosporin A and FK506, respectively, with high affinity, and which seem to mediate their pharmacological actions1,2. The Ca2+-dependent protein phosphatase, calcineurin, binds the cyclophilin-cyclosporin A and FKBP-FK506 complexes, indicating that calcineurin might mediate the actions of these drugs3. A physiological role for the immunophilins in the nervous system is implied by a close homology between the structure of NINA A, a protein in the neural retina of Drosophila, and cyclophilin4,5, as well as by the high density of FKBP messenger RNA in brain tissue6. Here we report that the levels of FKBP and mRNA in rat brain are extraordinarily high and that their regional localization is virtually identical to that of calcineurin, indicating that there may be a physiological link between calcineurin and the immunophilins. We also show that at low concentrations FK506 and cyclosporin A enhance the phosphorylation of endogenous protein substrates in brain tissue and in intact PC12 cells, indicating that these drugs may inhibit phosphatase activity by interacting with the immunophilin-calcineurin complexes.	JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,725 N WOLFE ST,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PHARMACOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT BLOOD BANK,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PSYCHIAT & BEHAV SCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROL,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University				Fotuhi, Majid/0000-0002-0980-1176; Cohen, Noam/0000-0002-9462-3932				ANDREASEN TJ, 1983, BIOCHEMISTRY-US, V22, P4618; BENOWITZ LI, 1987, TRENDS NEUROSCI, V10, P527, DOI 10.1016/0166-2236(87)90135-4; BIERER BE, 1991, EUR J IMMUNOL, V21, P439, DOI 10.1002/eji.1830210228; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COGGINS PJ, 1991, J NEUROCHEM, V56, P1095, DOI 10.1111/j.1471-4159.1991.tb11398.x; DEKKER LV, 1989, NATURE, V342, P74, DOI 10.1038/342074a0; DUMONT FJ, 1990, J IMMUNOL, V144, P251; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; GOLDSMITH MA, 1988, SCIENCE, V240, P1029, DOI 10.1126/science.3259335; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; HULTSCH T, 1991, P NATL ACAD SCI USA, V88, P6229, DOI 10.1073/pnas.88.14.6229; ITO A, 1989, BIOCHEM BIOPH RES CO, V163, P1492, DOI 10.1016/0006-291X(89)91148-0; KIMBALL PM, 1988, CELL IMMUNOL, V113, P107, DOI 10.1016/0008-8749(88)90010-X; KUNO T, 1989, BIOCHEM BIOPH RES CO, V165, P1352, DOI 10.1016/0006-291X(89)92752-6; LAD RP, 1991, MOL BRAIN RES, V9, P239, DOI 10.1016/0169-328X(91)90007-K; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MAKI N, 1990, P NATL ACAD SCI USA, V87, P5440, DOI 10.1073/pnas.87.14.5440; ROSS CA, 1989, P NATL ACAD SCI USA, V86, P2923, DOI 10.1073/pnas.86.8.2923; SCHNEUWLY S, 1989, P NATL ACAD SCI USA, V86, P5390, DOI 10.1073/pnas.86.14.5390; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SCHWARCZ R, 1983, SCIENCE, V219, P316, DOI 10.1126/science.6849138; SHIEH BH, 1989, NATURE, V338, P67, DOI 10.1038/338067a0; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; SKENE JHP, 1989, ANNU REV NEUROSCI, V12, P127, DOI 10.1146/annurev.ne.12.030189.001015; STANDAERT RF, 1990, NATURE, V346, P671, DOI 10.1038/346671a0; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; THOMSON AW, 1989, IMMUNOL TODAY, V10, P6, DOI 10.1016/0167-5699(89)90057-1; TRENN G, 1989, J IMMUNOL, V142, P3796; TRIGGIANI M, 1989, INT ARCH ALLER A IMM, V88, P253, DOI 10.1159/000234801	31	324	376	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 13	1992	358	6387					584	587		10.1038/358584a0	http://dx.doi.org/10.1038/358584a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JH829	1380130				2022-12-01	WOS:A1992JH82900060
J	WULCZYN, FG; NAUMANN, M; SCHEIDEREIT, C				WULCZYN, FG; NAUMANN, M; SCHEIDEREIT, C			CANDIDATE PROTOONCOGENE BCL-3 ENCODES A SUBUNIT-SPECIFIC INHIBITOR OF TRANSCRIPTION FACTOR NF-KAPPA-B	NATURE			English	Article							DNA-BINDING PROTEIN; REL-ASSOCIATED PP40; C-REL; GENE; CLONING; DORSAL; PURIFICATION; DROSOPHILA; COMPLEX; MOTIFS	THE NF-kappa-B subunits p50 and p65 and the product of the rel proto-oncogene are members Of a growing class of transcription factors with a unique DNA-binding and dimerization domain1-13. Nuclear transfer of each of these factors is controlled by cytoplasmic inhibitors, and regulated by specific stimuli. The inhibitors I-kappa-B-alpha and -beta and pp40 recognize either p65 or the c-rel protein14-16. We show here that the proto-oncogene bcl-3, believed to be involved in certain human B-cell leukaemias17, encodes a protein that functions as an I-kappa-B-like molecule for native NF-kappa-B but is specific for the p50 subunit. The ankyrin repeat domain of the bcl-3 product is shown to mediate complex formation with NF-kappa-B dimers by contacting the conserved dimerization domain of NF-kappa-B.	MAX PLANCK INST MOLEC GENET,OTTO WARBURG LAB,IHNESTR 73,W-1000 BERLIN 33,GERMANY	Max Planck Society			Naumann, Michael/B-5285-2011	Naumann, Michael/0000-0002-8060-2313				BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; DAVIS LH, 1991, J BIOL CHEM, V266, P11163; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GILMORE TD, 1990, CELL, V62, P841, DOI 10.1016/0092-8674(90)90257-F; GOSH S, 1990, CELL, V62, P1019; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HATADA EN, 1992, P NATL ACAD SCI USA, V89, P2489, DOI 10.1073/pnas.89.6.2489; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; IP YT, 1991, CELL, V64, P439; KAWAKAMI K, 1988, P NATL ACAD SCI USA, V85, P4700, DOI 10.1073/pnas.85.13.4700; KERR LD, 1991, GENE DEV, V5, P1464, DOI 10.1101/gad.5.8.1464; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LOGEAT F, 1991, EMBO J, V10, P1827, DOI 10.1002/j.1460-2075.1991.tb07708.x; MEYER R, 1991, P NATL ACAD SCI USA, V88, P966, DOI 10.1073/pnas.88.3.966; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; POGNONEC P, 1991, NUCLEIC ACIDS RES, V19, P6650, DOI 10.1093/nar/19.23.6650; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P	29	214	215	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 13	1992	358	6387					597	599		10.1038/358597a0	http://dx.doi.org/10.1038/358597a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JH829	1501714				2022-12-01	WOS:A1992JH82900064
J	ZHANG, XK; LEHMANN, J; HOFFMANN, B; DAWSON, MI; CAMERON, J; GRAUPNER, G; HERMANN, T; TRAN, P; PFAHL, M				ZHANG, XK; LEHMANN, J; HOFFMANN, B; DAWSON, MI; CAMERON, J; GRAUPNER, G; HERMANN, T; TRAN, P; PFAHL, M			HOMODIMER FORMATION OF RETINOID X-RECEPTOR INDUCED BY 9-CIS RETINOIC ACID	NATURE			English	Article							THYROID-HORMONE; RESPONSIVE ELEMENT; GENE; IDENTIFICATION; BINDING; ISOFORM; GAMMA	RETINOID response pathways are mediated by two classes of receptors, the retinoic acid receptors (RARs)1-6 and the retinoid X receptors (RXRs)7-11. A central question is whether distinct response pathways are regulated by these two classes of receptors. The observation that the stereoisomer 9-cis-retinoic acid binds with high affinity to RXRs12,13 suggested that this retinoid has a distinct role in controlling RXR activity, but it was almost simultaneously discovered that RXRs function as auxiliary receptors for RARs and related receptors, and are essential for DNA binding and function of those receptors9,10,14-17. Hence, although RARs seem to operate effectively only as heterodimeric RAR/RXR complexes, RXRs themselves apparently function predominantly, if not exclusively, as auxiliary receptors. Here we report that 9-cis-retinoic acid induces RXR homodimer formation. Our results demonstrate a new mechanism for retinoid action by which a ligand-induced homodimer mediates a distinct retinoid response pathway.	LA JOLLA CANC RES FDN,CTR CANC,10901 N TORREY PINES RD,LA JOLLA,CA 92037; SRI INT,DIV LIFE SCI,MENLO PK,CA 94025	Sanford Burnham Prebys Medical Discovery Institute; SRI International								BENBROOK D, 1988, NATURE, V333, P669, DOI 10.1038/333669a0; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; DESVERGNE B, 1991, J BIOL CHEM, V266, P1008; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; FLINK IL, 1990, J BIOL CHEM, V265, P11233; GIGUERE V, 1990, MOL CELL BIOL, V10, P2335, DOI 10.1128/MCB.10.5.2335; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; HAMADA K, 1989, P NATL ACAD SCI USA, V86, P8289, DOI 10.1073/pnas.86.21.8289; HERMANN T, 1991, CELL REGUL, V2, P565, DOI 10.1091/mbc.2.7.565; HERMANN T, IN PRESS MOL ENDOCR; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HOFFMANN B, 1990, MOL ENDOCRINOL, V4, P1734; HUSMANN M, 1991, MOL CELL BIOL, V11, P4097, DOI 10.1128/MCB.11.8.4097; KLEINHITPASS L, 1986, CELL, V46, P1053, DOI 10.1016/0092-8674(86)90705-1; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; ROTTMAN JN, 1991, MOL CELL BIOL, V11, P3814, DOI 10.1128/MCB.11.7.3814; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG X, 1991, MOL ENDOCRINOL, V5, P1909, DOI 10.1210/mend-5-12-1909; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	30	563	575	1	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 13	1992	358	6387					587	591		10.1038/358587a0	http://dx.doi.org/10.1038/358587a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JH829	1323763				2022-12-01	WOS:A1992JH82900061
J	ZHANG, Y; HEYM, B; ALLEN, B; YOUNG, D; COLE, S				ZHANG, Y; HEYM, B; ALLEN, B; YOUNG, D; COLE, S			THE CATALASE PEROXIDASE GENE AND ISONIAZID RESISTANCE OF MYCOBACTERIUM-TUBERCULOSIS	NATURE			English	Article							ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; EXPRESSION; TRANSFORMATION; SUPEROXIDE; EXTRACTS; CLONING; STRAINS	TUBERCULOSIS is responsible for one in four of all avoidable adult deaths in developing countries1. Increased frequency and accelerated fatality of the disease among individuals infected with human immunodeficiency virus has raised worldwide concern that control programmes may be inadequate2, and the emergence of multidrug-resistant strains of Mycobacterium tuberculosis has resulted in several recent fatal outbreaks in the United States3. Isonicotinic acid hydrazide (isoniazid, INH) forms the core of antituberculosis regimens; however, clinical isolates that are resistant to INH show reduced catalase activity and a relative lack of virulence in guinea-pigs4-7. Here we use mycobacterial genetics8,9 to study the molecular basis of INH resistance. A single M. tuberculosis gene, katG, encoding both catalase and peroxidase, restored sensitivity to INH in a resistant mutant of Mycobacterium smegmatis, and conferred INH susceptibility in some strains of Escherichia coli. Deletion of katG from the chromosome was associated with INH resistance in two patient isolates of M. tuberculosis.	HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT BACTERIOL,LONDON W12 0HS,ENGLAND; INST PASTEUR,GENET MOLEC BACTERIENNE LAB,F-75724 PARIS 15,FRANCE; CHU PITIE SALPETRIERE,SERV BACTERIOL VIROL,F-75634 PARIS 13,FRANCE	Imperial College London; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite	ZHANG, Y (corresponding author), HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,MRC,TB & RELATED INFECT UNIT,LONDON W12 0HS,ENGLAND.							COHN ML, 1954, AM REV TUBERC PULM, V70, P641; DEVI BG, 1975, BIOCHEM J, V149, P187, DOI 10.1042/bj1490187; HEYM B, IN PRESS RES MICROBI; JACKETT PS, 1978, J GEN MICROBIOL, V104, P37, DOI 10.1099/00221287-104-1-37; LOPRASERT S, 1989, J BACTERIOL, V171, P4871, DOI 10.1128/jb.171.9.4871-4875.1989; MIDDLEBROOK G, 1954, AM REV TUBERC PULM, V70, P852; MITCHISON DA, 1963, J PATHOL BACTERIOL, V86, P377, DOI 10.1002/path.1700860213; MULVEY MR, 1988, GENE, V73, P337, DOI 10.1016/0378-1119(88)90498-2; Murray C J, 1990, Bull Int Union Tuberc Lung Dis, V65, P6; PERRIENS JH, 1991, AM REV RESPIR DIS, V144, P750, DOI 10.1164/ajrccm/144.4.750; QUEMARD A, 1991, ANTIMICROB AGENTS CH, V35, P1035, DOI 10.1128/AAC.35.6.1035; SHOEB HA, 1985, ANTIMICROB AGENTS CH, V27, P404, DOI 10.1128/AAC.27.3.404; SNAPPER SB, 1988, P NATL ACAD SCI USA, V85, P6987, DOI 10.1073/pnas.85.18.6987; SNAPPER SB, 1990, MOL MICROBIOL, V4, P1911, DOI 10.1111/j.1365-2958.1990.tb02040.x; SNIDER DE, 1992, NEW ENGL J MED, V326, P703, DOI 10.1056/NEJM199203053261011; TRIGGSRAINE BL, 1988, J BACTERIOL, V170, P4415, DOI 10.1128/jb.170.9.4415-4419.1988; WAYNE LG, 1986, ANAL BIOCHEM, V157, P89, DOI 10.1016/0003-2697(86)90200-9; Winder F. G., 1982, The biology of the mycobacteria. Volume 1, P353; YOUATT J, 1969, AM REV RESPIR DIS, V99, P729; ZHANG Y, 1992, INFECT IMMUN, V60, P2160, DOI 10.1128/IAI.60.6.2160-2165.1992; ZHANG Y, 1991, MOL MICROBIOL, V5, P381, DOI 10.1111/j.1365-2958.1991.tb02120.x	21	1041	1116	4	99	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 13	1992	358	6387					591	593		10.1038/358591a0	http://dx.doi.org/10.1038/358591a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JH829	1501713				2022-12-01	WOS:A1992JH82900062
J	BARBEE, RA				BARBEE, RA			BRONCHIAL REACTIVITY - HYPORESPONSIVENESS VS HYPERRESPONSIVENESS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							POPULATION; RESPONSIVENESS; METHACHOLINE				BARBEE, RA (corresponding author), UNIV ARIZONA,ARIZONA HLTH SCI CTR,TUCSON,AZ 85724, USA.							COCKCROFT DW, 1983, CHEST, V83, P751, DOI 10.1378/chest.83.5.751; HOPP RJ, 1985, J ALLERGY CLIN IMMUN, V76, P609, DOI 10.1016/0091-6749(85)90783-3; MALO JL, 1983, AM REV RESPIR DIS, V128, P8, DOI 10.1164/arrd.1983.128.1.8; RIJCKEN B, 1987, AM REV RESPIR DIS, V136, P62, DOI 10.1164/ajrccm/136.1.62	4	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 12	1992	268	6					802	802						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG666	1640589				2022-12-01	WOS:A1992JG66600041
J	DANIELSON, C; LYON, JL; EGGER, M; GOODENOUGH, GK				DANIELSON, C; LYON, JL; EGGER, M; GOODENOUGH, GK			HIP-FRACTURES AND FLUORIDATION IN UTAH ELDERLY POPULATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							WATER FLUORIDATION; BONE; COMMUNITIES; WOMEN; OSTEOPOROSIS; DENSITY; OLDER	Objective.-To test the effect of water fluoridated to 1 ppm on the incidence of hip fractures in the elderly. Design.-Ecological cohort. Setting.-The incidence of femoral neck fractures in patients 65 years of age or older was compared in three communities in Utah, one with and two without water fluoridated to 1 ppm. Patients.-All patients with hip fractures who were 65 years of age and older over a 7-year period in the three communities, excluding (1) those with revisions of hip fractures, (2) those in whom the hip fracture was anything but a first diagnosis, (3) those in whom metastatic disease was present, or (4) those in whom the fracture was a second fracture (n=246). Outcome Measure.-Rate of hospital discharge for hip fracture. Results.-The relative risk for hip fracture for women in the fluoridated area was 1.27 (95% confidence interval [Cl]=1.08 to 1.46) and for men was 1.41 (95% Cl=1.00 to 1.81) relative to the nonfluoridated areas. Conclusions.-We found a small but significant increase in the risk of hip fracture in both men and women exposed to artificial fluoridation at 1 ppm, suggesting that low levels of fluoride may increase the risk of hip fracture in the elderly.			DANIELSON, C (corresponding author), UNIV UTAH,DEPT FAMILY & PREVENT MED,50 N MED DR,SALT LAKE CITY,UT 84132, USA.							ALHAVA EM, 1980, ACTA ORTHOP SCAND, V51, P413, DOI 10.3109/17453678008990817; ANSEL BM, 1965, ANN RHEUM DIS, V25, P67; ARNALA I, 1986, ACTA ORTHOP SCAND, V57, P433; BERNSTEI.DS, 1966, J AMER MED ASSOC, V198, P499, DOI 10.1001/jama.198.5.499; Chiang C, 1961, VITAL STAT SPEC REP, P47; COOPER C, 1990, J EPIDEMIOL COMMUN H, V44, P17, DOI 10.1136/jech.44.1.17; COOPER C, 1991, JAMA-J AM MED ASSOC, V266, P513, DOI 10.1001/jama.266.4.513; EVANS FG, 1976, ACTA ORTHOP SCAND, V47, P489, DOI 10.3109/17453677608988726; ISKRANT AP, 1968, AM J PUBLIC HEALTH N, V58, P485, DOI 10.2105/AJPH.58.3.485; JACOBSEN SJ, 1990, JAMA-J AM MED ASSOC, V264, P500, DOI 10.1001/jama.264.4.500; KENDALL MG, 1977, ADV THEORY STATISTIC, V1; LACROIX AZ, 1991, NEW ENGL J MED, V324, P1619, DOI 10.1056/NEJM199106063242303; LEONE NC, 1955, AMER J ROENTGENOL RA, V74, P874; Lindsay R, 1988, Clin Geriatr Med, V4, P411; MADANS J, 1983, AM J PUBLIC HEALTH, V73, P296, DOI 10.2105/AJPH.73.3.296; MELTON LJ, 1987, CALCIFIED TISSUE INT, V41, P57; PHIPPS KR, 1990, J DENT RES, V69, P1256, DOI 10.1177/00220345900690060601; PIANTADOSI S, 1988, AM J EPIDEMIOL, V127, P893, DOI 10.1093/oxfordjournals.aje.a114892; RIGGS BL, 1990, NEW ENGL J MED, V322, P802, DOI 10.1056/NEJM199003223221203; SAVILLE PD, 1966, JAMA-J AM MED ASSOC, V199, P105; SIMONEN O, 1985, LANCET, V2, P432; SOWERS MR, 1991, AM J EPIDEMIOL, V133, P649, DOI 10.1093/oxfordjournals.aje.a115940; 1989, CDC898411 US DEP HLT, P76	23	78	79	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 12	1992	268	6					746	748						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG666	1640574				2022-12-01	WOS:A1992JG66600015
J	GRIFO, JA; TANG, YX; COHEN, J; GILBERT, F; SANYAL, MK; ROSENWAKS, Z				GRIFO, JA; TANG, YX; COHEN, J; GILBERT, F; SANYAL, MK; ROSENWAKS, Z			PREGNANCY AFTER EMBRYO BIOPSY AND COAMPLIFICATION OF DNA FROM X-CHROMOSOME AND Y-CHROMOSOME	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							HUMAN PREIMPLANTATION EMBRYOS; AMPLIFICATION; FERTILIZATION		YALE UNIV,SCH MED,DEPT OBSTET & GYNECOL,NEW HAVEN,CT 06510	Yale University	GRIFO, JA (corresponding author), CORNELL UNIV,MED CTR,COLL MED,CTR REPROD MED & INFERTIL,DEPT OBSTET & GYNECOL,505 E 70TH ST,NEW YORK,NY 10021, USA.			Grifo, James/0000-0003-0439-2374				COHEN J, 1992, MICROMANIPULATION HU; GORDON JW, 1986, J EXP ZOOL, V239, P347, DOI 10.1002/jez.1402390306; GRIFO JA, 1991, 30TH ANN M SOC GYN I; GRIFO JA, 1990, J IN VITRO FERTIL EM, V1, P92; HANDYSIDE AH, 1989, LANCET, V1, P347; HANDYSIDE AH, 1990, NATURE, V344, P768, DOI 10.1038/344768a0; PIETERS MHEC, 1992, J ASSIST REPROD GEN, V9, P68, DOI 10.1007/BF01204118; PLACHOT M, 1988, HUM REPROD, V3, P125, DOI 10.1093/oxfordjournals.humrep.a136644; STROM CM, 1991, J IN VITRO FERTIL EM, V8, P225, DOI 10.1007/BF01130810; WAYE JS, 1985, NUCLEIC ACIDS RES, V13, P2731, DOI 10.1093/nar/13.8.2731	10	92	93	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 12	1992	268	6					727	729		10.1001/jama.268.6.727	http://dx.doi.org/10.1001/jama.268.6.727			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG666	1640572				2022-12-01	WOS:A1992JG66600012
J	MCGOVERN, PG; BURKE, GL; SPRAFKA, JM; XUE, SL; FOLSOM, AR; BLACKBURN, H				MCGOVERN, PG; BURKE, GL; SPRAFKA, JM; XUE, SL; FOLSOM, AR; BLACKBURN, H			TRENDS IN MORTALITY, MORBIDITY, AND RISK FACTOR LEVELS FOR STROKE FROM 1960 THROUGH 1990 - THE MINNESOTA HEART SURVEY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CEREBROVASCULAR-DISEASE; SURVEY EXPERIENCE; DECLINE; POPULATION; SURVIVAL	Objective.-The Minnesota Heart Survey is a population-based study designed to monitor and explain trends in cardiovascular mortality, morbidity, and risk factors. Design.-Surveillance time-trends study. Methods.-The following trends were examined among men and women aged 25 to 74 years living in Minneapolis-St Paul, Minn: (1) stroke mortality from 1960 through 1990; (2) risk factors in population-based surveys conducted in 1973 through 1974, 1980 through 1982, and 1985 through 1987; and (3) morbidity in a 50% sample of hospitalized discharges for acute-stroke in 1970, 1980, and 1985. Results.-Stroke mortality in Minneapolis-St Paul declined slowly from 1960 through 1972 (average fall, 2.4% per year), dropped sharply from 1972 through 1984 (average fall, 6.5% per year), but exhibited little change thereafter (average fall, 1.5% per year). The average level of cardiovascular disease risk factors fell from 1973-1974 to 1985-1987, with the exception of body mass index. In particular, hypertension diagnosis, treatment, and control levels improved substantially between 1973-1974 and 1980-1982, although there was little improvement after 1980-1982. While discharge rates for hospital-coded acute stroke declined substantially between 1970 and 1985 in both sexes, no clear trend was observed in definite stroke rates as validated using standard clinical criteria. Twenty-eight-day case fatality rates of definite stroke improved significantly from 1970 to 1985. Conclusions.-The substantial decline in stroke mortality of more than 50% from 1960 through 1990 appears to have been attributable to both primary and secondary prevention. These data suggest that the long decline in stroke mortality and morbidity in Minneapolis-St Paul has plateaued, although improved detection of stroke with computed tomography prevents an unequivocal conclusion.	WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT PUBL HLTH SCI,WINSTON SALEM,NC 27103	Wake Forest University; Wake Forest Baptist Medical Center	MCGOVERN, PG (corresponding author), UNIV MINNESOTA,SCH PUBL HLTH,DIV EPIDEMIOL,1300 S 2ND ST,SUITE 300,MINNEAPOLIS,MN 55454, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL023727] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL-23727] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BILLER J, 1991, SEMIN NEUROL, V11, P353, DOI 10.1055/s-2008-1041240; Bonita R, 1989, HYPERTENSION S1, V3; BRODERICK JP, 1989, STROKE, V20, P577, DOI 10.1161/01.STR.20.5.577; CAPLAN LR, 1991, JAMA-J AM MED ASSOC, V266, P2413, DOI 10.1001/jama.266.17.2413; DAWSON DA, 1987, VITAL HLTH STAT, V10, P164; EDLAVITCH SA, 1988, AM J EPIDEMIOL, V127, P1164, DOI 10.1093/oxfordjournals.aje.a114910; FOLSOM AR, 1983, JAMA-J AM MED ASSOC, V250, P916, DOI 10.1001/jama.250.7.916; GILLUM RF, 1986, STROKE, V17, P656, DOI 10.1161/01.STR.17.4.656; GILLUM RF, 1985, J CHRON DIS, V38, P8911; GRAVES EJ, 1984, PHS100 US DEP HLTH H; HOWARD G, 1989, STROKE, V20, P345, DOI 10.1161/01.STR.20.3.345; JACOBS DR, 1980, J CHRON DIS, V33, P395, DOI 10.1016/0021-9681(80)90037-5; JEFFERY RW, 1984, AM J PUBLIC HEALTH, V74, P349, DOI 10.2105/AJPH.74.4.349; KLAG MJ, 1989, STROKE, V20, P14, DOI 10.1161/01.STR.20.1.14; LUEPKER RV, 1988, J CLIN EPIDEMIOL, V41, P825, DOI 10.1016/0895-4356(88)90098-4; MCGOVERN PG, 1992, CIRCULATION, V85, P172, DOI 10.1161/01.CIR.85.1.172; ROSE G, 1991, CIRCULATION, V84, P1405, DOI 10.1161/01.CIR.84.3.1405; ROTHROCK JF, 1991, ANN INTERN MED, V115, P885, DOI 10.7326/0003-4819-115-11-885; SPRAFKA JM, 1990, AM J EPIDEMIOL, V132, P489, DOI 10.1093/oxfordjournals.aje.a115685; TILLINGHAST SJ, 1991, AM J EPIDEMIOL, V134, P851, DOI 10.1093/oxfordjournals.aje.a116160; WHISNANT JP, 1984, STROKE, V15, P160, DOI 10.1161/01.STR.15.1.160; 1976, PHS871232 US DEP HLT, P125; 1967, MANUAL INT STATISTIC; 1957, MANUAL INT STATISTIC; 1990, WORLD HLTH STATISTIC; 1975, INT CLASSIFICATION 2, V66; [No title captured]; 1987, JAMA-J AM MED ASSOC, V257, P937; 1980, MONTHLY VITAL STAT S, V28, P1; 1992, MONTHLY VITAL STA S2, V40, P1; 1989, SAS STAT GUIDE; 1989, MMWR, V38, P194; 1972, PHS861684 US DEP 11	33	128	131	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 12	1992	268	6					753	759						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG666	1640576				2022-12-01	WOS:A1992JG66600017
J	MEIER, B; URBAN, P; DORSAZ, PA; FAVRE, J				MEIER, B; URBAN, P; DORSAZ, PA; FAVRE, J			SURGICAL STANDBY FOR CORONARY BALLOON ANGIOPLASTY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARDIAC-SURGERY; TASK-FORCE; COMPLICATIONS; OCCLUSION; GUIDELINES; CARDIOLOGY; HEART	Objective.-To assess the predictability of need for emergency surgery after coronary balloon angioplasty. Design.-Nonrandomized intervention study. Setting.-Nonprofit university hospital. Patients.-Prior to balloon angioplasty, 1000 consecutive patients were assigned to either the "standby" group (189 patients [19%]) or the "no-standby" group (811 patients [81%]). Patients in the standby group (intervention coordinated with cardiac surgery) included all operable patients undergoing angioplasty of their largest coronary arteries that were not currently or previously totally occluded or collateralized; the no-standby group consisted of the remainder of patients. Intervention.-Allocation to coronary angioplasty with or without surgical standby. Main Outcome Measures.-Need for bypass surgery, occurrence of myocardial infarction, and mortality from complications of angioplasty. Results.-Bypass surgery immediately after angioplasty was done in one patient in each group (standby, 0.5%, vs no-standby, 0.1%). The frequency of infarction was 5% vs 4%, respectively. All eight deaths occurred in the no-standby group (1.0%), but none of them were consequences of a lack of surgical standby. They occurred in situations in which bypass surgery would not have changed the outcome (two cardiac failures late after technically successful angioplasty for postinfarct cardiogenic shock, one in-laboratory rupture of an unrecognized ventricular pseudoaneurysm, and one protamine reaction), secondary to acute problems late after successful angioplasty (two sudden deaths and one vessel occlusion in an inoperable patient), or despite surgery (one patient with left main stem dissection). Conclusions.-Performing roughly 80% of coronary angioplasties without surgical standby did not increase patient risk. Coronary angioplasty without surgical backup, albeit not an ideal setting, appears ethically feasible in selected patients if dictated by logistic considerations.			MEIER, B (corresponding author), UNIV GENEVA,HOP CANTONAL,CTR CARDIOL,CH-1211 GENEVA 4,SWITZERLAND.							BOURASSA M G, 1988, European Heart Journal, V9, P1034; CAMERON DE, 1990, ANN THORAC SURG, V50, P35, DOI 10.1016/0003-4975(90)90078-K; CAMPEAU L, 1976, CIRCULATION, V54, P522, DOI 10.1161/circ.54.3.947585; DETRE KM, 1990, CIRCULATION, V82, P739, DOI 10.1161/01.CIR.82.3.739; Deutsche Gessellschaft fur Herz- und Kreislaufforschung, 1987, Z KARDIOL, V76, P382; GRUENTZIG AR, 1979, NEW ENGL J MED, V301, P61; MEIER B, 1991, J AM COLL CARDIOL, V17, pB50; MEIER B, 1987, CORONARY ANGIOPLASTY, P146; REIFART N, 1990, Z KARDIOL, V79, P446; RENNER U, 1991, HERZ KREISLAUF, V23, P409; RICHARDSON SG, 1990, BRIT MED J, V300, P355, DOI 10.1136/bmj.300.6721.355; RYAN TJ, 1988, CIRCULATION, V78, P486, DOI 10.1161/01.CIR.78.2.486; RYAN TJ, 1990, J AM COLL CARDIOL, V15, P1469, DOI 10.1016/0735-1097(90)92812-G; SERRUYS PW, 1991, NEW ENGL J MED, V324, P13, DOI 10.1056/NEJM199101033240103; SIGWART U, 1988, CIRCULATION, V78, P1121, DOI 10.1161/01.CIR.78.5.1121; STEFFENINO G, 1988, BRIT HEART J, V59, P151; STEWART JT, 1990, BRIT HEART J, V63, P74; ULLYOT DJ, 1987, CIRCULATION, V76, P149; WEAVER WF, 1985, CATHETER CARDIO DIAG, V11, P109, DOI 10.1002/ccd.1810110117; 1988, CATHET CARDIOVASC DI, V15, P136	20	42	42	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 12	1992	268	6					741	745		10.1001/jama.268.6.741	http://dx.doi.org/10.1001/jama.268.6.741			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG666	1640573				2022-12-01	WOS:A1992JG66600014
J	NIGHTINGALE, SL				NIGHTINGALE, SL			WARNINGS ISSUED ON NONSEDATING ANTIHISTAMINES TERFENADINE AND ASTEMIZOLE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	46	47	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 12	1992	268	6					705	705		10.1001/jama.268.6.705	http://dx.doi.org/10.1001/jama.268.6.705			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG666	1322467				2022-12-01	WOS:A1992JG66600004
J	NIGHTINGALE, SL				NIGHTINGALE, SL			ZALCITABINE APPROVED FOR USE IN COMBINATION WITH ZIDOVUDINE FOR HIV-INFECTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1992, JAMA-J AM MED ASSOC, V267, P3262	1	46	47	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 12	1992	268	6					705	705		10.1001/jama.268.6.705	http://dx.doi.org/10.1001/jama.268.6.705			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG666	1322467				2022-12-01	WOS:A1992JG66600005
J	BLAU, JN				BLAU, JN			CLASSICAL MIGRAINE - SYMPTOMS BETWEEN VISUAL AURA AND HEADACHE ONSET	LANCET			English	Article								The gap between the end of the visual aura and headache onset in classical migraine has been called the free interval. In a retrospective study of twenty-five migraineurs who had noted a gap, only three reported feeling normal at that time: twenty-two described alterations in mood, detachment from the environment or other people, fears, disturbances of speech or thought, or somatic symptoms. The interval lasted less than an hour in seventeen of the twenty-two but in five persisted for 1 to 5 hours. These symptoms suggest involvement of the frontal and temporal cortices as well as the hypothalamus; they do not conform to Leao's spreading depression or a vascular mechanism, but are in keeping with a diffuse cerebral process with focal manifestations.			BLAU, JN (corresponding author), UCL NATL HOSP NEUROL & NEUROSURG, QUEEN SQ, LONDON WC1N 3BG, ENGLAND.							BLAU JN, 1992, LANCET, V339, P1202, DOI 10.1016/0140-6736(92)91140-4; BLAU JN, 1986, PRELUDE MIGRAINE ATT, P39; LAURITZEN M, 1984, BRAIN, V107, P457; PATON L, 1919, P ROY SOC MED, V12, P53; SELBY DK, 1983, GERIATRICS, V38, P42; WOLFF HG, 1963, HEADACHE OTHER HEAD, P230; 1988, CEPHALALGIA S7, V8, P21	7	24	25	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	AUG 8	1992	340	8815					355	356		10.1016/0140-6736(92)91415-5	http://dx.doi.org/10.1016/0140-6736(92)91415-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JH125	1353815				2022-12-01	WOS:A1992JH12500014
J	EGGER, M; SMITH, GD; TEUSCHER, A				EGGER, M; SMITH, GD; TEUSCHER, A			FOR DEBATE - HUMAN INSULIN AND UNAWARENESS OF HYPOGLYCEMIA - NEED FOR A LARGE RANDOMIZED TRIAL	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DEPENDENT DIABETES-MELLITUS; SEMISYNTHETIC HUMAN INSULIN; BLIND CROSSOVER TRIAL; PURIFIED PORK INSULIN; PORCINE INSULIN; INDUCED HYPOGLYCEMIA; RECOMBINANT DNA; COUNTERREGULATORY RESPONSES; GLUCOSE COUNTERREGULATION; SYMPTOMATIC AWARENESS		UNIV GLASGOW, DEPT PUBL HLTH, GLASGOW G12 8RZ, SCOTLAND; UNIV LONDON UNIV COLL, DEPT EPIDEMIOL & PUBL HLTH, LONDON WC1E 6BT, ENGLAND; UNIV BERN, DEPT ENDOCRINOL & DIABET, CH-3000 BERN, SWITZERLAND	University of Glasgow; University of London; University College London; University of Bern			Davey Smith, George/A-7407-2013	Davey Smith, George/0000-0002-1407-8314; Egger, Matthias/0000-0001-7462-5132				AMIEL SA, 1987, NEW ENGL J MED, V316, P1376, DOI 10.1056/NEJM198705283162205; [Anonymous], 1991, LANCET, V338, P853; BENDTSON I, 1991, J INTERN MED, V229, P293, DOI 10.1111/j.1365-2796.1991.tb00348.x; BERGER M, 1987, DIABETOLOGIA, V30, P829; BERGER W, 1989, LANCET, V1, P1041, DOI 10.1016/S0140-6736(89)92444-6; BERGER WG, 1987, DIABETES CARE, V10, P260, DOI 10.2337/diacare.10.2.260; BOLLI G, 1983, DIABETES, V32, P134, DOI 10.2337/diabetes.32.2.134; CLARK AJL, 1982, LANCET, V2, P354; DCCT Res Grp, 1986, DIABETES, V35, P530; DCCT Res Grp, 1991, AM J MED, V90, P450, DOI 10.1016/0002-9343(91)80085-Z; DUNCAN C, 1990, PRACTICAL DIABETES, V7, P18; EGGER M, 1988, DIABETOLOGIA, V31, P453, DOI 10.1007/BF00271592; EGGER M, 1990, DIABETIC MED, V7, P269, DOI 10.1111/j.1464-5491.1990.tb01385.x; EGGER M, 1991, BMJ-BRIT MED J, V303, P617, DOI 10.1136/bmj.303.6803.617; EGGER M, 1991, BMJ-BRIT MED J, V303, P622, DOI 10.1136/bmj.303.6803.622; EGGER M, 1991, BMJ-BRIT MED J, V303, P1267, DOI 10.1136/bmj.303.6812.1267-a; EGGER M, 1991, LANCET, V338, P950, DOI 10.1016/0140-6736(91)91820-K; FISHER BM, 1988, DIABETES RES CLIN EX, V8, P1; FRIER BM, 1991, BMJ-BRIT MED J, V303, P1266, DOI 10.1136/bmj.303.6812.1266-b; GERICH JE, 1973, SCIENCE, V182, P171, DOI 10.1126/science.182.4108.171; GORDEN P, 1990, NEW ENGL J MED, V322, P1007; HAUPT E, 1991, HYPOGLYCAEMIA HUMAN, P119; HEINE RJ, 1990, LANCET, V335, P62, DOI 10.1016/0140-6736(90)90203-H; HEINE RJ, 1989, LANCET, V2, P946; HELLER SR, 1987, LANCET, V2, P359; HEPBURN DA, 1989, LANCET, V1, P1394; HEPBURN DA, 1989, DIABETIC MED, V6, P586, DOI 10.1111/j.1464-5491.1989.tb01233.x; Home P D, 1984, Diabet Med, V1, P93; HOME PD, 1982, DRUGS, V24, P401, DOI 10.2165/00003495-198224050-00003; KAREM JH, 1991, CLIN DIABETES    NOV, P94; KEEN H, 1980, LANCET, V2, P398; KEEN H, 1981, MED INT, V1, P330; KERN W, 1989, LANCET, V2, P485; LANDGRAFLEURS MMC, 1984, KLIN WOCHENSCHR, V62, P659, DOI 10.1007/BF01716462; MANN NP, 1983, BMJ-BRIT MED J, V387, P1580; MARAN A, 1991, DIABETES, V40, pA544; ORCHARD TJ, 1991, DIABETIC MED, V8, P469, DOI 10.1111/j.1464-5491.1991.tb01634.x; OWENS DR, 1988, DIABETES RES CLIN EX, V8, P17; PARR JH, 1982, LANCET, V2, P831; PATRICK AW, 1991, LANCET, V338, P528, DOI 10.1016/0140-6736(91)91098-F; PATRICK AW, 1991, BRIT MED J, V303, P1266, DOI 10.1136/bmj.303.6812.1266-a; PICKUP J, 1986, BRIT MED J, V292, P155, DOI 10.1136/bmj.292.6514.155; REDMOND S, 1988, BALANCE          AUG, P66; ROSAK C, 1982, DIABETES CARE, V5, P82, DOI 10.2337/diacare.5.2.S82; Rothman K J, 1990, Epidemiology, V1, P43, DOI 10.1097/00001648-199001000-00010; SCHLUTER KJ, 1982, DIABETES CARE, V5, P78, DOI 10.2337/diacare.5.2.S78; SIEBER P, 1974, HELV CHIM ACTA, V57, P2617, DOI 10.1002/hlca.19740570839; SJOBOM NC, 1990, DIABETIC MED, V7, P775; SONNENBERG GE, 1983, DIABETOLOGIA, V25, P457; SPRAUL M, 1990, AKTUELLE ENDOKRINOLO, V11, P169; STEPHENSON J, 1990, LANCET, V335, P661, DOI 10.1016/0140-6736(90)90448-E; SWTOCKS AE, 1991, MED J AUSTRALIA, V154, P295; TATTERSALL RB, 1991, DIABETIC MED, V8, P49, DOI 10.1111/j.1464-5491.1991.tb01516.x; TATTERSALL RB, 1989, BRIT MED J, V299, P1339, DOI 10.1136/bmj.299.6711.1339-b; TEUSCHER A, 1987, LANCET, V2, P382; TEUSCHER A, 1979, SCHWEIZ MED WSCHR, V109, P743; TEUSCHER A, 1980, LANCET, V2, P1186; 1992, SCRIP           0207, P22	58	9	9	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 8	1992	305	6849					351	355		10.1136/bmj.305.6849.351	http://dx.doi.org/10.1136/bmj.305.6849.351			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JJ032	1392889	Green Published, Bronze, Green Submitted			2022-12-01	WOS:A1992JJ03200025
J	GEORGE, JR; OU, CY; PAREKH, B; BRATTEGAARD, K; BROWN, V; BOATENG, E; DECOCK, KM				GEORGE, JR; OU, CY; PAREKH, B; BRATTEGAARD, K; BROWN, V; BOATENG, E; DECOCK, KM			PREVALENCE OF HIV-1 AND HIV-2 MIXED INFECTIONS IN COTE-DIVOIRE	LANCET			English	Note							POLYMERASE CHAIN-REACTION; WESTERN BLOTS; DNA	We have investigated the cause of dual serological reactivity to human immunodeficiency virus (HIV) types 1 and 2, a common occurrence in West Africa. Serum specimens from 111 individuals from cote d'Ivoire classified by commercial western blot as HIV-1 (n = 15), HIV-2 (32), and dually reactive (64) were further tested by more specific serological tests (a synthetic peptide enzyme immunoassay [Pepti-LAV 1/2] and western blots prepared from antigen in which oligomeric forms of the transmembrane protein were disrupted by trichloroacetic acid [WB-TCA]). Peripheral blood mononuclear cells were tested for HIV-1 and HIV-2 with the polymerase chain reaction (PCR) and virus culture. Of 104 samples that were concordant by both WB-TCA and Pepti-LAV, 82 (79%) were confirmed by PCR results. Virus culture was concordant with serology for specimens (35/38) in which any virus was detected. Our findings indicate that mixed HIV-1/HIV-2 infections are common in Cote d'Ivoire, and suggest that natural infection by one HIV type does not prevent heterologous infection.	CTR DIS CONTROL,NATL CTR INFECT DIS,DIV HIV AIDS,INT ACT,ATLANTA,GA 30333; PROJECT RETROCI,ABIDJAN,COTE IVOIRE	Centers for Disease Control & Prevention - USA	GEORGE, JR (corresponding author), CTR DIS CONTROL,NATL CTR INFECT DIS,DIV HIV AIDS,LAB INVEST BRANCH,ATLANTA,GA 30333, USA.		Brown, Verity/X-6637-2019	Brown, Verity/0000-0001-5762-1797; PAREKH, BHARAT/0000-0002-1088-4263				DECOCK KM, 1991, AIDS, V5, P859, DOI 10.1097/00002030-199107000-00010; DECOCK KM, 1991, AIDS, V5, pS21; GUERN ML, 1992, P NATL ACAD SCI USA, V89, P363; JACKSON J, 1990, ARCH PATHOL LAB MED, V144, P249; OU CY, 1988, SCIENCE, V239, P295, DOI 10.1126/science.3336784; OU CY, 1990, AIDS RES HUM RETROV, V6, P1323, DOI 10.1089/aid.1990.6.1323; PAREKH BS, 1991, AIDS, V5, P1009, DOI 10.1097/00002030-199108000-00013; PIENIAZEK D, 1991, AIDS, V5, P1293, DOI 10.1097/00002030-199111000-00002; RAYFIELD M, 1988, J INFECT DIS, V158, P1170, DOI 10.1093/infdis/158.6.1170; 1989, MMWR, V38, P17	10	82	82	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 8	1992	340	8815					337	339		10.1016/0140-6736(92)91406-X	http://dx.doi.org/10.1016/0140-6736(92)91406-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JH125	1353806				2022-12-01	WOS:A1992JH12500005
J	GOLDING, J; GREENWOOD, R; BIRMINGHAM, K; MOTT, M				GOLDING, J; GREENWOOD, R; BIRMINGHAM, K; MOTT, M			CHILDHOOD-CANCER, INTRAMUSCULAR VITAMIN-K, AND PETHIDINE GIVEN DURING LABOR	BRITISH MEDICAL JOURNAL			English	Article							BENZO(A)PYRENE METABOLISM; DEFICIENCY; LEUKEMIA	Objective-To assess unexpected associations between childhood cancer and pethidine given in labour and the neonatal administration of vitamin K that had emerged in a study performed in the 1970 national birth cohort. Design and setting-195 children with cancer diagnosed in 1971-March 1991 and born in the two major Bristol maternity hospitals in 1965-87 were compared with 558 controls identified from the delivery books for the use of pethidine during labour and administration of vitamin K. Main outcome measures-Odds ratios for cancer in the presence of administration of pethidine or of intramuscular vitamin K. Both logistic regression and Mantel-Haenszel techniques were used for statistical analyses. Results-Children of mothers given pethidine in labour were not at increased risk of cancer (odds ratio 1.05, 95% confidence interval 0.7 to 1.5) after allowing for year and hospital of delivery, but there was a significant association (p=0.002) with intramuscular vitamin K (odds ratio 1.97, 95% confidence interval 1.3 to 3.0) when compared with oral vitamin K or no vitamin K. There was no significantly increased risk for children who had been given oral vitamin K when compared with no vitamin K (odds ratio 1.15, 95% confidence interval 0.5 to 2.7). These results could not be accounted for by other factors associated with administration of intramuscular vitamin K, such as type of delivery or admission to a special care baby unit. Conclusions-The only two studies so far to have examined the relation between childhood cancer and intramuscular vitamin K have shown similar results, and the relation is biologically plausible. The prophylactic benefits against haemorrhagic disease are unlikely to exceed the potential adverse effects from intramuscular vitamin K. Since oral vitamin K has major benefits but no obvious adverse effects this could be the prophylaxis of choice.			GOLDING, J (corresponding author), ROYAL HOSP SICK CHILDREN,INST CHILD HLTH,BRISTOL BS2 8BJ,ENGLAND.			Golding, Jean/0000-0003-2826-3307				BUTLER NR, 1982, J ROY SOC MED, V75, P781; Butler NR, 1986, BIRTH 5 STUDY HLTH B; Chamberlain R., 1975, BRIT BIRTHS, V1; CORNELISSEN M, 1991, PEDIATR RES, V30, P550, DOI 10.1203/00006450-199112000-00011; DOGRA SC, 1987, INT J BIOCHEM, V19, P471, DOI 10.1016/0020-711X(87)90070-X; Elwood M, 1988, CAUSAL RELATIONSHIPS; Gilman E A, 1989, Paediatr Perinat Epidemiol, V3, P66, DOI 10.1111/j.1365-3016.1989.tb00371.x; GILMAN EA, 1988, J SOC RADIOLOGICAL P, V3, P3; Golding J, 1990, West Engl Med J, V105, P80; GOLDING J, 1990, BRIT J CANCER, V62, P304, DOI 10.1038/bjc.1990.283; HILGARD P, 1977, BRIT J CANCER, V35, P891, DOI 10.1038/bjc.1977.135; ISRAELS LG, 1987, PEDIATR RES, V22, P405, DOI 10.1203/00006450-198710000-00008; ISRAELS LG, 1983, J CLIN INVEST, V71, P1130, DOI 10.1172/JCI110863; KNEALE GW, 1976, J NATL CANCER I, V56, P879, DOI 10.1093/jnci/56.5.879; MCKINNEY PA, 1987, ARCH DIS CHILD, V62, P279, DOI 10.1136/adc.62.3.279; MCNINCH AW, 1985, ARCH DIS CHILD, V60, P814, DOI 10.1136/adc.60.9.814; MCNINCH AW, 1991, BRIT MED J, V303, P1105, DOI 10.1136/bmj.303.6810.1105; ROBINS J, 1986, AM J EPIDEMIOL, V124, P719, DOI 10.1093/oxfordjournals.aje.a114447; STILLER CA, 1982, BRIT J CANCER, V45, P543, DOI 10.1038/bjc.1982.90; STJERNFELDT M, 1986, LANCET, V2, P687; von Kries R, 1992, Paediatr Perinat Epidemiol, V6, P7	21	224	229	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 8	1992	305	6849					341	346		10.1136/bmj.305.6849.341	http://dx.doi.org/10.1136/bmj.305.6849.341			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JJ032	1392886	Green Submitted, Green Published, Bronze			2022-12-01	WOS:A1992JJ03200022
J	HANKINSON, SE; STAMPFER, MJ; SEDDON, JM; COLDITZ, GA; ROSNER, B; SPEIZER, FE; WILLETT, WC				HANKINSON, SE; STAMPFER, MJ; SEDDON, JM; COLDITZ, GA; ROSNER, B; SPEIZER, FE; WILLETT, WC			NUTRIENT INTAKE AND CATARACT-EXTRACTION IN WOMEN - A PROSPECTIVE-STUDY	BMJ-BRITISH MEDICAL JOURNAL			English	Article							FOOD FREQUENCY QUESTIONNAIRE; PLASMA BETA-CAROTENE; VITAMIN-C STATUS; CIGARETTE-SMOKING; ASCORBIC-ACID; NUTRITIONAL-STATUS; ALPHA-TOCOPHEROL; SENILE CATARACT; LENS; RISK	Objective-To examine prospectively the association between dietary intake of vitamins C and E, carotene, and riboflavin and cataract extraction in women. Design-Prospective cohort study beginning in 1980 with eight years of follow up. Setting- 11 states of the United States. Participants - Female registered nurses who were 45 to 67 years of age. 50 828 women were included in 1980 and others were added as they became 45 years of age. Main outcome measure-Incidence of extraction of senile cataracts. Results-493 cataracts were extracted during 470 302 person years of follow up. Intake of carotene and vitamin A was inversely associated with cataract: in multivariate analyses, women in the highest fifth of total vitamin A intake (excluding supplements) had a 39% lower risk of cataract relative to women in the lowest fifth (relative risk 0.61; 95% confidence interval 0.45 to 0.81). Neither riboflavin nor dietary vitamins E or C were associated with cataract in a multivariate analysis. Among specific food items spinach (rather than carrots, the greatest source of beta-carotene) was most consistently associated with a lower relative risk. The risk of cataract was 45% lower among women who used vitamin C supplements for 10 or more years (relative risk 0.55 (0.32 to 0.96)), but no association was noted for multivitamin intake. Conclusion-Dietary carotenoids, although not necessarily beta-carotene, and long term vitamin C supplementation may decrease the risk of cataracts severe enough to require extraction.	BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, BOSTON, MA 02115 USA; MASSACHUSETTS EYE & EAR INFIRM, BOSTON, MA 02114 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Massachusetts Eye & Ear Infirmary	HANKINSON, SE (corresponding author), HARVARD UNIV, SCH MED, CHANNING LAB, DEPT MED, 180 LONGWOOD AVE, BOSTON, MA 02115 USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NATIONAL CANCER INSTITUTE [R37CA040356, R01CA040356] Funding Source: NIH RePORTER; NCI NIH HHS [CA40356] Funding Source: Medline; PHS HHS [5T32 E507069] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADAMS CF, 1975, NUTRITIVE VALUES AM; BHAT KS, 1987, NUTR REP INT, V36, P685; BHUYAN KC, 1984, CURR EYE RES, V3, P67, DOI 10.3109/02713688408997188; BLACKMAN BC, 1984, ANN NY ACAD SCI, V435, P385, DOI 10.1111/j.1749-6632.1984.tb13828.x; BLONDIN J, 1986, Journal of Free Radicals in Biology and Medicine, V2, P275; BUNCE GE, 1990, ANNU REV NUTR, V10, P233, DOI 10.1146/annurev.nu.10.070190.001313; BUNCE GE, 1988, NUTR TODAY, V4, P6; COX DR, 1972, J R STAT SOC B, V34, P187; CREIGHTON MO, 1985, EXP EYE RES, V40, P213, DOI 10.1016/0014-4835(85)90006-5; DAGOSTINO RB, 1990, STAT MED, V9, P1501, DOI 10.1002/sim.4780091214; DI MASCIO P, 1989, ARCH BIOCHEM BIOPHYS, V274, P532, DOI 10.1016/0003-9861(89)90467-0; FLAYE DE, 1989, EYE, V3, P379, DOI 10.1038/eye.1989.56; GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P904; JACOB RA, 1987, AM J CLIN NUTR, V46, P818, DOI 10.1093/ajcn/46.5.818; JACQUES PF, 1988, ARCH OPHTHALMOL-CHIC, V106, P337, DOI 10.1001/archopht.1988.01060130363022; JACQUES PF, 1991, AM J CLIN NUTR, V53, pS352, DOI 10.1093/ajcn/53.1.352S; JACQUES PF, 1988, AM J CLIN NUTR, V48, P152, DOI 10.1093/ajcn/48.1.152; KAHN HA, 1977, AM J EPIDEMIOL, V106, P17, DOI 10.1093/oxfordjournals.aje.a112428; KRINSKY NI, 1989, FREE RADICAL BIO MED, V7, P617, DOI 10.1016/0891-5849(89)90143-3; LESKE MC, 1991, ARCH OPHTHALMOL-CHIC, V109, P244, DOI 10.1001/archopht.1991.01080020090051; MARAINI G, 1991, AM J EPIDEMIOL, V133, P541; MCLAUGHLIN PJ, 1979, J AM DIET ASSOC, V75, P647; MILLER ER, 1954, J NUTR, V52, P405; MOHAN M, 1989, ARCH OPHTHALMOL-CHIC, V107, P670, DOI 10.1001/archopht.1989.01070010688028; NISHIGORI H, 1985, EXP EYE RES, V40, P445, DOI 10.1016/0014-4835(85)90157-5; OGINO S, 1957, AM J OPHTHALMOL, V43, P936, DOI 10.1016/0002-9394(57)91798-1; ROBERTSON JM, 1989, ANN NY ACAD SCI, V570, P372; ROMIEU I, 1990, AM J EPIDEMIOL, V131, P864, DOI 10.1093/oxfordjournals.aje.a115577; Rothman KJ, 1986, MODERN EPIDEMIOLOGY; SCHECTMAN G, 1989, AM J PUBLIC HEALTH, V79, P158, DOI 10.2105/AJPH.79.2.158; SRIVASTAVA SK, 1972, BIOCHEM MED METAB B, V6, P372, DOI 10.1016/0006-2944(72)90023-3; STARK WJ, 1989, ARCH OPHTHALMOL-CHIC, V107, P1441, DOI 10.1001/archopht.1989.01070020515030; STEPHENS RJ, 1988, EXP EYE RES, V47, P237, DOI 10.1016/0014-4835(88)90007-3; STRYKER WS, 1988, AM J EPIDEMIOL, V127, P283, DOI 10.1093/oxfordjournals.aje.a114804; TAYLOR A, 1991, CURR EYE RES, V10, P751, DOI 10.3109/02713689109013869; TREVITHICK JR, 1989, ANN NY ACAD SCI, V570, P358; VARMA SD, 1987, ANN NY ACAD SCI, V498, P280, DOI 10.1111/j.1749-6632.1987.tb23768.x; VARMA SD, 1991, AM J CLIN NUTR, V53, pS335, DOI 10.1093/ajcn/53.1.335S; WEST S, 1989, ARCH OPHTHALMOL-CHIC, V107, P1166, DOI 10.1001/archopht.1989.01070020232031; WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366; WILLETT WC, 1987, NEW ENGL J MED, V316, P22, DOI 10.1056/NEJM198701013160105; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; WU SY, 1991, 3RD NEI S EYE DIS EP; NIH832473 US DEP H 3; 1982, USDA HDB SERIES, V1	45	214	220	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 8	1992	305	6849					335	339		10.1136/bmj.305.6849.335	http://dx.doi.org/10.1136/bmj.305.6849.335			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JJ032	1392884	Green Published, Green Submitted			2022-12-01	WOS:A1992JJ03200020
J	KUMARESAN, JA; MAGANU, ET				KUMARESAN, JA; MAGANU, ET			CASE HOLDING IN PATIENTS WITH TUBERCULOSIS IN BOTSWANA	BRITISH MEDICAL JOURNAL			English	Article								Objective-To evaluate the effectiveness of daily supervised short course chemotherapy in a national tuberculosis programme. Design-Observation of programme during 1984-90. In October 1986 short course chemotherapy was introduced with patients receiving treatment daily from staff in their nearest health facility. Setting-Botswana national tuberculosis programme. Subjects - All patients with tuberculosis. Main outcome measures-Proportions of patients complying with and defaulting from treatment (missing greater-than-or-equal-to 43 days' treatment). Results-2938 cases of tuberculosis were recorded in 1990, 1528 of which were of sputum positive pulmonary disease. 2711 (92.3%) patients complied with treatment and 227 (7.7%) defaulted. Before introduction of short course chemotherapy compliance was about 60% compared with over 90% in 1987-90. Conclusions-A programme using daily supervised short course chemotherapy integrated into the primary health care system is an effective method of treating tuberculosis. The costs of the programme need to be evaluated.	MINIST HLTH,GABORONE,BOTSWANA		KUMARESAN, JA (corresponding author), COMMUNITY HLTH SERV DIV,EPIDEMIOL UNIT,PRIVATE BAG 00269,GABORONE,BOTSWANA.							ARMSTRONG RH, 1984, CENT AFR J MED, V30, P144; Bailey W C, 1988, Am Rev Respir Dis, V138, P1075; BARNUM HN, 1986, SOC SCI MED, V23, P847, DOI 10.1016/0277-9536(86)90212-1; Iseman M D, 1986, Semin Respir Infect, V1, P213; Murray C J, 1990, Bull Int Union Tuberc Lung Dis, V65, P6; REED JB, 1990, J EPIDEMIOL COMMUN H, V44, P20, DOI 10.1136/jech.44.1.20; RIEDER HL, 1985, TUBERCLE, V66, P179, DOI 10.1016/0041-3879(85)90034-0; TACHEZY P, 1985, NATIONAL TUBERCULOSI, P17; TEFUARANI N, 1989, PAPUA NEW GUINEA MED, V32, P177	9	10	10	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 8	1992	305	6849					340	341		10.1136/bmj.305.6849.340	http://dx.doi.org/10.1136/bmj.305.6849.340			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JJ032	1392885	Green Published, Green Submitted, Bronze			2022-12-01	WOS:A1992JJ03200021
J	PEETERS, M; GERSHYDAMET, GM; FRANSEN, K; KOFFI, K; COULIBALY, M; DELAPORTE, E; PIOT, P; VANDERGROEN, G				PEETERS, M; GERSHYDAMET, GM; FRANSEN, K; KOFFI, K; COULIBALY, M; DELAPORTE, E; PIOT, P; VANDERGROEN, G			VIROLOGICAL AND POLYMERASE CHAIN-REACTION STUDIES OF HIV-1 HIV-2 DUAL INFECTION IN COTE-DIVOIRE	LANCET			English	Note							IVORY-COAST; ABIDJAN; AIDS	Dual serological reactivity to the human immunodeficiency virus (HIV) types 1 and 2 is common in Cote d'Ivoire. To assess whether dual infection is the reason for dual seropositivity we sought HIV-1 and HIV-2 proviral DNA in primary uncultured peripheral blood mononuclear cells from selected seropositive patients in Cote d'Ivoire with the polymerase chain reaction (PCR). PCR on primary lymphocytes in 36 dually seropositive samples revealed the presence of both HIV-1 and HIV-2 proviral DNA in 12 cases and the presence of HIV-1 only in 24 cases. In 18 of these 36 samples a virus was isolated and identified by PCR. HIV-1 was isolated from the 9 specimens with only HIV-1 proviral DNA in the primary lymphocytes. Among dually PCR-positive samples, 2 viral isolates reacted with both HIV-1 and HIV-2 primers; and only HIV-2 (n = 1) or HIV-1 (n = 6) strains were isolated from the other samples. The findings show that surveys based on serology may overestimate the prevalence of mixed infections in areas where both HIV-1 and HIV-2 occur.	INST PASTEUR,ABIDJAN,COTE IVOIRE; INST MED & EPIDEMIOL AFRICAINES,INSERM,U13,PARIS,FRANCE; CHU TREICHVILLE,ABIDJAN,COTE IVOIRE	Institut National de la Sante et de la Recherche Medicale (Inserm)	PEETERS, M (corresponding author), INST TROP MED PRINCE LEOPOLD,WHO,COLLABORATING CTR AIDS,NATL ST 455,B-2000 ANTWERP,BELGIUM.		Delaporte, Eric/J-5397-2018	Delaporte, Eric/0000-0002-1822-9853				DECOCK KM, 1991, BMJ-BRIT MED J, V302, P496, DOI 10.1136/bmj.302.6775.496; DECOCK KM, 1989, LANCET, V2, P408; EVANS LA, 1988, LANCET, V2, P1389; LEONARD G, 1991, 6TH INT C AIDS AFR D; PEETERS M, 1989, AIDS, V3, P625, DOI 10.1097/00002030-198910000-00001; PEPIN JM, 1991, 7 INT C AIDS FLOR; PIENIAZEK D, 1991, AIDS, V5, P1293, DOI 10.1097/00002030-199111000-00002; RAYFIELD M, 1988, J INFECT DIS, V158, P1170, DOI 10.1093/infdis/158.6.1170; RAYFIELD M, 1991, 6TH INT C AIDS DAK	9	65	68	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 8	1992	340	8815					339	340		10.1016/0140-6736(92)91407-Y	http://dx.doi.org/10.1016/0140-6736(92)91407-Y			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JH125	1353807				2022-12-01	WOS:A1992JH12500006
J	STEHOUWER, CDA; NAUTA, JJP; ZELDENRUST, GC; HACKENG, WHL; DONKER, AJM; DENOTTOLANDER, GJH				STEHOUWER, CDA; NAUTA, JJP; ZELDENRUST, GC; HACKENG, WHL; DONKER, AJM; DENOTTOLANDER, GJH			URINARY ALBUMIN EXCRETION, CARDIOVASCULAR-DISEASE, AND ENDOTHELIAL DYSFUNCTION IN NON-INSULIN-DEPENDENT DIABETES-MELLITUS	LANCET			English	Article							CORONARY HEART-DISEASE; VONWILLEBRAND-FACTOR; RISK-FACTORS; MICROALBUMINURIA PREDICTS; NEPHROPATHY; MORTALITY; PROTEINURIA; PLASMA; ABNORMALITIES; KIDNEY	Raised urinary albumin excretion (UAE) is associated with an increased risk of cardiovascular disease in non-insulin-dependent diabetes mellitus (NIDDM). We have examined the role of endothelial dysfunction as a possible explanation for this association in 94 NIDDM patients by investigating UAE, new cardiovascular events, and plasma concentration of von Willebrand factor (vWF), an indicator of endothelial dysfunction. At baseline, 66 patients had normal UAE (< 15-mu-g/min), which remained normal in 33 (group 1) and increased in 33 (to median 31.5-mu-g/min, group 2). In 28 patients, baseline UAE was abnormal (67.1-mu-g/min, group 3). Follow-up ranged between 9 and 53 months. vWF did not change in group 1 (median 128% at baseline and 123% at follow-up), but increased in group 2 (from 116 to 219%, p < 0.0001) and group 3 (from 157 to 207%, p = 0.0005). Baseline level of and change in vWF were strongly related to the development of microalbuminuria (R2 = 0.60, p < 0.0001), but cardiovascular risk factors were not (R2 = 0.14). Raised baseline UAE was associated with an increased risk of new cardiovascular events only in patients with vWF concentrations above the median (relative risk 3.66, 95% Cl 1.3-11.9) and not in patients with lower vWF (0.19, 0.01-1.33). In addition, the cardiovascular risk associated with increased UAE was modified by low compared with high concentrations of serum high density lipoprotein cholesterol (2.86 [1.03-8.48] vs 0.15 [0.01-1.43]). Dysfunction of vascular endothelium may be a link between albuminuria and atherosclerotic cardiovascular disease in NIDDM.	BERGWEG HOSP,ENDOCRINOL LAB,ROTTERDAM,NETHERLANDS; FREE UNIV AMSTERDAM HOSP,DEPT INTERNAL MED,1081 HV AMSTERDAM,NETHERLANDS; FREE UNIV AMSTERDAM HOSP,DEPT THEORY MED EPIDEMIOL & BIOSTAT,1081 HV AMSTERDAM,NETHERLANDS	Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER	STEHOUWER, CDA (corresponding author), BERGWEG HOSP,DEPT INTERNAL MED,ROTTERDAM,NETHERLANDS.		Stehouwer, Coen/AAB-3435-2021					BORCHJOHNSEN K, 1987, BMJ-BRIT MED J, V294, P1651, DOI 10.1136/bmj.294.6588.1651; BULPITT CJ, 1979, LANCET, V2, P134; DAMSGAARD EM, 1990, BRIT MED J, V300, P297, DOI 10.1136/bmj.300.6720.297; ELLIS D, 1989, AM J KIDNEY DIS, V13, P321, DOI 10.1016/S0272-6386(89)80039-3; FITZGERALD AP, 1991, DIABETIC MED, V8, P475, DOI 10.1111/j.1464-5491.1991.tb01635.x; IWASHIMA Y, 1990, DIABETES, V39, P983, DOI 10.2337/diabetes.39.8.983; JAFFE EA, 1974, P NATL ACAD SCI USA, V71, P1906, DOI 10.1073/pnas.71.5.1906; JANSSON JH, 1991, BRIT HEART J, V66, P351; Jarrett R J, 1984, Diabet Med, V1, P17; JENSEN T, 1987, DIABETOLOGIA, V30, P144, DOI 10.1007/BF00274218; JENSEN T, 1989, LANCET, V1, P461; KANWAR YS, 1984, LAB INVEST, V51, P7; KROLEWSKI AS, 1987, AM J CARDIOL, V59, P750, DOI 10.1016/0002-9149(87)91086-1; MATTOCK MB, 1988, DIABETOLOGIA, V31, P82, DOI 10.1007/BF00395552; MOGENSEN CE, 1984, NEW ENGL J MED, V310, P356, DOI 10.1056/NEJM198402093100605; NISKANEN L, 1990, DIABETOLOGIA, V33, P237, DOI 10.1007/BF00404802; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; Rothman KJ, 1986, MODERN EPIDEMIOLOGY; SCHMITZ A, 1990, DIABETIC MED, V7, P521, DOI 10.1111/j.1464-5491.1990.tb01435.x; SEAQUIST ER, 1989, NEW ENGL J MED, V320, P1161, DOI 10.1056/NEJM198905043201801; STEHHOUWER CDA, 1991, DIABETES, V40, P1746; STEHOUWER CDA, 1991, DIABETES, V40, P971, DOI 10.2337/diabetes.40.8.971; STEHOUWER CDA, 1992, DIABETOLOGIA, V35, P555, DOI 10.1007/BF00400484; STEHOUWER CDA, 1990, ARCH INTERN MED, V150, P373, DOI 10.1001/archinte.150.2.373; SUFFREDINI AF, 1989, NEW ENGL J MED, V320, P1165, DOI 10.1056/NEJM198905043201802; VANE JR, 1990, NEW ENGL J MED, V323, P27; VIBERTI GC, 1986, CLIN ENDOCRINOL META, V15, P753, DOI 10.1016/S0300-595X(86)80073-1; VUKOVICH TC, 1989, J CLIN ENDOCR METAB, V69, P84, DOI 10.1210/jcem-69-1-84; YUDKIN JS, 1988, LANCET, V2, P530	29	522	531	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 8	1992	340	8815					319	323		10.1016/0140-6736(92)91401-S	http://dx.doi.org/10.1016/0140-6736(92)91401-S			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JH125	1353802				2022-12-01	WOS:A1992JH12500001
J	TONNESEN, H; PETERSEN, KR; HOJGAARD, L; STOKHOLM, KH; NIELSEN, HJ; KNIGGE, U; KEHLET, H				TONNESEN, H; PETERSEN, KR; HOJGAARD, L; STOKHOLM, KH; NIELSEN, HJ; KNIGGE, U; KEHLET, H			POSTOPERATIVE MORBIDITY AMONG SYMPTOM-FREE ALCOHOL MISUSERS	LANCET			English	Article							DELAYED-HYPERSENSITIVITY; ETHANOL; DYSFUNCTION; WITHDRAWAL; SURGERY; INJURY	Retrospective studies suggest that there is an increased postoperative morbidity among alcohol misusers. We have prospectively studied the risk of alcohol intake among patients undergoing surgery. We investigated 15 symptom-free subjects who required colorectal surgery and who were drinking at least 60 g of alcohol per day. These patients were matched for sex, nutrition, age, weight, cardiovascular and pulmonary disease, diagnosis, anaesthesia, and surgery to 15 control subjects who were consuming below 25 g of alcohol daily. Those drinking at least 60 g of alcohol per day developed more postoperative complications than controls (67% vs 20%, p < 0.05) and hospital stay was prolonged (20 vs 12 days, p < 0.05). Preoperatively, alcohol misusers had reduced left ventricular ejection fraction (median, 54% vs 68%, p<0.01). Delayed hypersensitivity responses were smaller in the alcohol group before (53 mm2 vs 78 mm2, p < 0.05) and after (18 mm2 vs 55 mm2, p < 0.01) surgery. Alcohol misusers had longer bleeding times during the first postoperative week (p < 0.01). Surgical stress responses, as assessed by changes in plasma cortisol and catecholamines, were higher among alcoholics (p < 0.05). Postoperative morbidity is increased in symptom-free alcohol misusers. The mechanism is probably subclinical cardiac insufficiency, immunosuppression, and decreased haemostatic function. Preoperative alcohol consumption may be a more important risk factor than previously thought.	UNIV COPENHAGEN,HVIDOVRE HOSP,DEPT CLIN PHYSIOL NUCL MED,DK-2650 HVIDOVRE,DENMARK; UNIV COPENHAGEN,PANUM INST,DEPT MED PHYSIOL C,DK-2200 COPENHAGEN,DENMARK	University of Copenhagen; University of Copenhagen	TONNESEN, H (corresponding author), UNIV COPENHAGEN,HVIDOVRE HOSP,DEPT SURG GASTROENTEROL,DK-2650 HVIDOVRE,DENMARK.		Højgaard, Liselotte/AAK-8329-2020	Tonnesen, Hanne/0000-0002-7161-3416; Kehlet, Henrik/0000-0002-2209-1711				BENJOHATHAN N, 1976, ENDOCRINOLOGY, V98, P1447; BRAUTBAR N, 1987, ALCOHOL CLIN EXP RES, V11, P118, DOI 10.1111/j.1530-0277.1987.tb01274.x; CREGLER LL, 1989, CLIN CARDIOL, V12, P122, DOI 10.1002/clc.4960120302; GOLDMAN L, 1977, NEW ENGL J MED, V297, P845, DOI 10.1056/NEJM197710202971601; GRIBALDO RS, 1985, AM J CARDIOL, V56, P825, DOI 10.1016/0002-9149(85)91159-2; HJORTSO NC, 1986, ACTA CHIR SCAND, V152, P175; KATZ AM, 1985, J MOL CELL CARDIOL, V17, P11, DOI 10.1016/0022-2828(85)90004-5; KAWAKAMI M, 1990, J TRAUMA, V30, P27, DOI 10.1097/00005373-199001000-00004; KNIKER WT, 1979, ANN ALLERGY, V43, P73; KRANTZ T, 1990, Ugeskrift for Laeger, V152, P1168; LINNOILA M, 1987, ANN INTERN MED, V107, P875, DOI 10.7326/0003-4819-107-6-875; MACLEAN LD, 1988, SURG GYNECOL OBSTET, V166, P285; MARVING J, 1985, CIRCULATION, V72, P502, DOI 10.1161/01.CIR.72.3.502; MIKHAILIDIS DP, 1986, BRIT MED J, V293, P715, DOI 10.1136/bmj.293.6549.715; MORGAN MY, 1988, P NUTR SOC, V47, P85, DOI 10.1079/PNS19880017; NEIMAN J, 1988, RES EXP MED, V188, P175, DOI 10.1007/BF01852318; SELZER ML, 1971, AM J PSYCHIAT, V127, P1653, DOI 10.1176/ajp.127.12.1653; Simms J M, 1982, Clin Nutr, V1, P71, DOI 10.1016/0261-5614(82)90007-3; SMITH AJ, 1990, ALCOHOL CLIN EXP RES, V14, P497, DOI 10.1111/j.1530-0277.1990.tb01187.x; SUN GY, 1985, ALCOHOL CLIN EXP RES, V9, P164, DOI 10.1111/j.1530-0277.1985.tb05543.x; TIERNAN JM, 1985, INT J BIOCHEM, V17, P793, DOI 10.1016/0020-711X(85)90266-6; TONNESEN H, 1988, SCAND J UROL NEPHROL, V22, P175, DOI 10.1080/00365599.1988.11690408; TONNESEN H, 1987, DIS COLON RECTUM, V30, P549, DOI 10.1007/BF02554788; TONNESEN H, 1987, Ugeskrift for Laeger, V149, P285; URBANOMARQUEZ A, 1989, NEW ENGL J MED, V320, P409, DOI 10.1056/NEJM198902163200701	25	127	128	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 8	1992	340	8815					334	337						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JH125	1353805				2022-12-01	WOS:A1992JH12500004
J	WILLIAMS, G; PATRICK, AW				WILLIAMS, G; PATRICK, AW			HUMAN INSULIN AND HYPOGLYCEMIA - BURNING ISSUE OR HOT AIR	BRITISH MEDICAL JOURNAL			English	Article							HYPOGLYCEMIA UNAWARENESS; AWARENESS; SYMPTOMS; IDDM				WILLIAMS, G (corresponding author), UNIV LIVERPOOL,DEPT MED,POB 147,LIVERPOOL L69 3BX,ENGLAND.							COLAGIURI S, 1992, LANCET, V339, P1432, DOI 10.1016/0140-6736(92)92028-E; CORP E, 1986, NEUROSCI LETT, V79, P17; COX DJ, 1991, PSYCHOSOM MED, V53, P453, DOI 10.1097/00006842-199107000-00010; DIAMOND MP, 1991, J CLIN ENDOCR METAB, V72, P1388, DOI 10.1210/jcem-72-6-1388; EGGER M, 1991, DIABETES CARE, V14, P1001, DOI 10.2337/diacare.14.11.1001; EGGER M, 1991, BMJ-BRIT MED J, V303, P617, DOI 10.1136/bmj.303.6803.617; EGGER M, 1991, BMJ-BRIT MED J, V303, P622, DOI 10.1136/bmj.303.6803.622; GALE EAM, 1989, LANCET, V2, P1264; GERICH JE, 1991, ENDOCR REV, V12, P356, DOI 10.1210/edrv-12-4-356; KERN W, 1990, DIABETES, V39, P1091, DOI 10.2337/diabetes.39.9.1091; KERR D, 1991, DIABETES, V40, P1057, DOI 10.2337/diabetes.40.8.1057; Lawrence RD, 1941, LANCET, V2, P602; LINDE B, 1991, TXB DIABETES, P371; MARAN A, 1992, DIABETIC MED S1, V9, pA11; PATRICK AW, 1991, LANCET, V338, P528, DOI 10.1016/0140-6736(91)91098-F; PATRICK AW, 1992, DIABETIC MED, V9, P579, DOI 10.1111/j.1464-5491.1992.tb01843.x; SCHWARTZ MW, 1990, AM J PHYSIOL, V259, pE378, DOI 10.1152/ajpendo.1990.259.3.E378; TEUSCHER A, 1987, LANCET, V2, P382; 1991, LANCET, V338, P950; 1991, BMJ, V303, P1265	20	8	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 8	1992	305	6849					355	357		10.1136/bmj.305.6849.355	http://dx.doi.org/10.1136/bmj.305.6849.355			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JJ032	1294086	Green Published, Bronze, Green Submitted			2022-12-01	WOS:A1992JJ03200026
J	BERSTEIN, G; BLANK, JL; JHON, DY; EXTON, JH; RHEE, SG; ROSS, EM				BERSTEIN, G; BLANK, JL; JHON, DY; EXTON, JH; RHEE, SG; ROSS, EM			PHOSPHOLIPASE C-BETA-1 IS A GTPASE-ACTIVATING PROTEIN FOR GQ/11, ITS PHYSIOLOGICAL REGULATOR	CELL			English	Article								Purified M1 muscarinic cholinergic receptor and G(q/11) were coreconstituted in lipid vesicles. Addition of purified phospholipase C-beta-1 (PLC-beta-1) further stimulated the receptor-promoted steady-state GTPase activity of G(q/11) up to 20-fold. Stimulation depended upon receptor-mediated GTP-GDP exchange. Addition of PLC-beta-1 caused a rapid burst of hydrolysis of G(q/11)-bound GTP that was at least 50-fold faster than in its absence. Thus, PLC-beta-1 stimulates hydrolysis of G(q/11)-bound GTP and acts as a GTPase-activating protein (GAP) for its physiologic regulator, G(q/11). GTPase-stimulating activity was specific both for PLC-beta-1 and G(g/11). Such GAP activity by an effector coupled to a trimeric G protein can reconcile slow GTP hydrolysis by pure G proteins in vitro with fast physiologic deactivation of G protein-mediated signaling.	VANDERBILT UNIV, MED CTR,SCH MED,HOWARD HUGHES MED INST, DEPT MOLEC PHYSIOL & BIOPHYS, NASHVILLE, TN 37232 USA; NHLBI, BIOCHEM LAB, BETHESDA, MD 20892 USA	Howard Hughes Medical Institute; Vanderbilt University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	BERSTEIN, G (corresponding author), UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, DALLAS, TX 75235 USA.				FIC NIH HHS [TW04475] Funding Source: Medline; NIGMS NIH HHS [GM30355] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [F05TW004475] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030355, R01GM030355] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; ARSHAVSKY VY, 1991, J BIOL CHEM, V266, P18530; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; BLANK JL, 1991, J BIOL CHEM, V266, P18206; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRANDT DR, 1985, J BIOL CHEM, V260, P266; BRANDT DR, 1986, J BIOL CHEM, V261, P1656; BREITWIESER GE, 1988, J GEN PHYSIOL, V91, P469, DOI 10.1085/jgp.91.4.469; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CASEY PJ, 1990, J BIOL CHEM, V265, P2383; CASSEL D, 1977, J CYCLIC NUCL PROT, V3, P393; DRATZ EA, 1987, BIOCHEM BIOPH RES CO, V146, P379, DOI 10.1016/0006-291X(87)90540-7; FLORIO VA, 1989, J BIOL CHEM, V264, P3909; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.biochem.56.1.615; HAGA K, 1985, J BIOL CHEM, V260, P7927; HALL A, 1990, CELL, V61, P921, DOI 10.1016/0092-8674(90)90054-I; HALL A, 1992, CELL, V69, P389, DOI 10.1016/0092-8674(92)90441-E; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P757; HIGASHIJIMA T, 1990, J BIOL CHEM, V265, P14176; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; LEE KY, 1987, P NATL ACAD SCI USA, V84, P5540, DOI 10.1073/pnas.84.16.5540; MAY DC, 1985, J BIOL CHEM, V260, P5829; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; NAVON SE, 1984, J BIOL CHEM, V259, P6686; PARK D, 1992, IN PRESS J BIOL CHEM; PARKER EM, 1991, J BIOL CHEM, V266, P519; PEDERSEN SE, 1982, P NATL ACAD SCI-BIOL, V79, P7228, DOI 10.1073/pnas.79.23.7228; ROSS EM, 1989, NEURON, V3, P141, DOI 10.1016/0896-6273(89)90027-5; ROSS EM, 1991, BETA ADRENERGIC RECE, P125; RYU SH, 1987, P NATL ACAD SCI USA, V84, P6649, DOI 10.1073/pnas.84.19.6649; RYU SH, 1987, J BIOL CHEM, V262, P12511; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; STERNWEIS PC, 1981, J BIOL CHEM, V256, P1517; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; SUH PG, 1988, J BIOL CHEM, V263, P14497; TANAKA K, 1990, CELL, V60, P803, DOI 10.1016/0092-8674(90)90094-U; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; TSAI MH, 1989, MOL CELL BIOL, V9, P5260, DOI 10.1128/MCB.9.11.5260; TSAI MH, 1989, SCIENCE, V243, P522, DOI 10.1126/science.2536192; VUONG TM, 1990, NATURE, V346, P71, DOI 10.1038/346071a0; VUONG TM, 1991, P NATL ACAD SCI USA, V88, P9813, DOI 10.1073/pnas.88.21.9813; YATANI A, 1988, NATURE, V336, P680, DOI 10.1038/336680a0; YATANI A, 1989, SCIENCE, V245, P71, DOI 10.1126/science.2544999	45	350	354	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 7	1992	70	3					411	418		10.1016/0092-8674(92)90165-9	http://dx.doi.org/10.1016/0092-8674(92)90165-9			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JH124	1322796				2022-12-01	WOS:A1992JH12400006
J	CENCIARELLI, C; HOU, D; HSU, KC; RELLAHAN, BL; WIEST, DL; SMITH, HT; FRIED, VA; WEISSMAN, AM				CENCIARELLI, C; HOU, D; HSU, KC; RELLAHAN, BL; WIEST, DL; SMITH, HT; FRIED, VA; WEISSMAN, AM			ACTIVATION-INDUCED UBIQUITINATION OF THE T-CELL ANTIGEN RECEPTOR	SCIENCE			English	Article							ZETA-CHAIN; COMPLEX; PHOSPHORYLATION; IDENTIFICATION; POLYPEPTIDE; DEGRADATION; COMPONENT; ANTIBODY; PROTEIN; SUBUNIT	The zeta-subunit of the T cell antigen receptor (TCR) exists primarily as a disulfide-linked homodimer. This receptor subunit is important in TCR-mediated signal transduction and is a substrate for a TCR-activated protein tyrosine kinase. The zeta-chain was found to undergo ubiquitination in response to receptor engagement. This posttranslational modification occurred in normal T cells and tumor lines. Both nonphosphorylated and phosphorylated zeta-molecules were modified, and at least one other TCR subunit, CD3-delta, was also ubiquitinated after activation of the receptor. These findings suggest an expanded role for ubiquitination in transmembrane receptor function.	NCI,DIV CANC BIOL DIAG & CTR,EXPTL IMMUNOL BRANCH,BETHESDA,MD 20892; NEW YORK MED COLL,DEPT CELL BIOL & ANAT,VALHALLA,NY 10595	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); New York Medical College				Wiest, David/0000-0002-0792-3188				ASHWELL JD, 1990, ANNU REV IMMUNOL, V8, P139, DOI 10.1146/annurev.immunol.8.1.139; BANIYASH M, 1988, J BIOL CHEM, V263, P18225; CENCIARELLI C, UNPUB; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; CIECHANOVER A, 1990, New Biologist, V2, P227; FINLEY D, 1991, ANNU REV CELL BIOL, V7, P25, DOI 10.1146/annurev.cb.07.110191.000325; FRANK SJ, 1992, J BIOL CHEM, V267, P13656; Fried V A, 1989, Prog Clin Biol Res, V317, P733; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; HEDRICK SM, 1982, CELL, V30, P141, DOI 10.1016/0092-8674(82)90020-4; HOCHSTRASSER M, 1991, P NATL ACAD SCI USA, V88, P4606, DOI 10.1073/pnas.88.11.4606; KAPPLER J, 1982, P NATL ACAD SCI-BIOL, V79, P3604, DOI 10.1073/pnas.79.11.3604; KOYASU S, 1992, J BIOL CHEM, V267, P3375; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; MORI H, 1987, SCIENCE, V235, P1641, DOI 10.1126/science.3029875; MORI S, 1992, J BIOL CHEM, V267, P6429; MURTI KG, 1988, P NATL ACAD SCI USA, V85, P3019, DOI 10.1073/pnas.85.9.3019; OETTGEN HC, 1986, NATURE, V320, P272, DOI 10.1038/320272a0; ORLOFF DG, 1989, J BIOL CHEM, V264, P14812; PATEL MD, 1987, J BIOL CHEM, V262, P5831; SAMELSON LE, 1985, CELL, V43, P223, DOI 10.1016/0092-8674(85)90027-3; SAMELSON LE, 1986, J IMMUNOL, V137, P3254; SAMELSON LE, 1983, P NATL ACAD SCI-BIOL, V80, P6972, DOI 10.1073/pnas.80.22.6972; SAMELSON LE, 1986, CELL, V46, P1083, DOI 10.1016/0092-8674(86)90708-7; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SIEGELMAN M, 1986, SCIENCE, V231, P823, DOI 10.1126/science.3003913; VIJAYKUMAR S, 1987, J BIOL CHEM, V262, P6396; Weissman A M, 1989, Year Immunol, V4, P74; WEISSMAN AM, 1988, SCIENCE, V239, P1018, DOI 10.1126/science.3278377; WEISSMAN AM, 1986, NATURE, V324, P480, DOI 10.1038/324480a0; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	32	197	198	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 7	1992	257	5071					795	797		10.1126/science.1323144	http://dx.doi.org/10.1126/science.1323144			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JG851	1323144				2022-12-01	WOS:A1992JG85100034
J	CHOI, GH; NUSS, DL				CHOI, GH; NUSS, DL			HYPOVIRULENCE OF CHESTNUT BLIGHT FUNGUS CONFERRED BY AN INFECTIOUS VIRAL CDNA	SCIENCE			English	Article							DOUBLE-STRANDED-RNA; ENDOTHIA-PARASITICA; BIOLOGICAL-CONTROL; CRYPHONECTRIA-PARASITICA; VEGETATIVE COMPATIBILITY; TRANSMISSIBLE HYPOVIRULENCE; GENE-EXPRESSION; VIRUS; AUTOPROTEOLYSIS; STRAINS	Strains of the chestnut blight fungus Cryphonectria parasitica that contain viral double-stranded RNAs often exhibit reduced virulence. Such hypovirulent strains act as biocontrol agents by virtue of their ability to convert virulent strains to hypovirulence after anastomosis. Transformation of virulent C. parasitica strains with a full-length complementary DNA copy of a hypovirulence-associated viral RNA conferred the complete hypovirulence phenotype. Cytoplasmic double-stranded RNA was resurrected from the chromosomally integrated complementary DNA copy and was able to convert compatible virulent strains to hypovirulence. These results establish viral double-stranded RNA as the causal agent of hypovirulence and demonstrate the feasibility of engineering hypovirulent fungal strains.	ROCHE RES CTR,ROCHE INST MOLEC BIOL,DEPT MOLEC ONCOL & VIROL,NUTLEY,NJ 07110	Roche Holding								ANAGNOSTAKIS SL, 1977, EXP MYCOL, V1, P306, DOI 10.1016/S0147-5975(77)80006-6; ANAGNOSTAKIS SL, 1986, PLANT DIS, V70, P536, DOI 10.1094/PD-70-536; ANAGNOSTAKIS SL, 1982, SCIENCE, V215, P466, DOI 10.1126/science.215.4532.466; ANAGNOSTAKIS SL, 1982, GENETICS, V102, P25; ANAGNOSTAKIS SL, 1983, MYCOLOGIA, V75, P777, DOI 10.2307/3792770; ANAGNOSTAKIS SL, 1984, ECOLOGY PHYSL FUNGAL, P499; Buck K.W., 1986, FUNGAL VIROLOGY, P1, DOI [10.1201/9781351072205-1, DOI 10.1201/9781351072205-1]; CHOI GH, 1992, EMBO J, V11, P473, DOI 10.1002/j.1460-2075.1992.tb05077.x; CHOI GH, 1991, VIROLOGY, V183, P747, DOI 10.1016/0042-6822(91)91004-Z; CHOI GH, 1991, P NATL ACAD SCI USA, V88, P1167, DOI 10.1073/pnas.88.4.1167; CULLEN D, 1987, GENE, V57, P21, DOI 10.1016/0378-1119(87)90172-7; DAY PR, 1977, PHYTOPATHOLOGY, V67, P1393, DOI 10.1094/Phyto-67-1393; Elliston JE, 1978, P AM CHESTNUT S, P95; ELSHERBEINI M, 1984, MOL CELL BIOL, V4, P2818, DOI 10.1128/MCB.4.12.2818; Grente J, 1978, P AM CHESTNUT S, P30; GRENTE M. J., 1965, COMPT REND HEBD SEANCES ACAD AGR FRANCE, V51, P1033; Griffin G. J., 1986, Horticultural Reviews, V8, P291, DOI 10.1002/9781118060810.ch8; HILLMAN BI, 1992, J GEN VIROL, V73, P681, DOI 10.1099/0022-1317-73-3-681; HILLMAN BI, 1990, PHYTOPATHOLOGY, V80, P950, DOI 10.1094/Phyto-80-950; HIREMATH S, 1986, NUCLEIC ACIDS RES, V14, P9877; JAYNES RA, 1980, PHYTOPATHOLOGY, V70, P453, DOI 10.1094/Phyto-70-453; KOONIN EV, 1991, P NATL ACAD SCI USA, V88, P10647, DOI 10.1073/pnas.88.23.10647; MACDONALD WL, 1991, PLANT DIS, V75, P656, DOI 10.1094/PD-75-053; Roane MK, 1986, CHESTNUT BLIGHT OTHE, P1; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SHAPIRA R, 1991, EMBO J, V10, P731, DOI 10.1002/j.1460-2075.1991.tb08004.x; SHAPIRA R, 1991, EMBO J, V10, P741, DOI 10.1002/j.1460-2075.1991.tb08005.x; SHAPIRA R, 1991, J BIOL CHEM, V266, P19419; VANALFEN NK, 1975, SCIENCE, V189, P890, DOI 10.1126/science.189.4206.890; WICKNER RB, 1989, FASEB J, V3, P2257, DOI 10.1096/fasebj.3.11.2550303	30	267	296	4	63	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 7	1992	257	5071					800	803		10.1126/science.1496400	http://dx.doi.org/10.1126/science.1496400			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JG851	1496400				2022-12-01	WOS:A1992JG85100036
J	DANIELS, DL; PLUNKETT, G; BURLAND, V; BLATTNER, FR				DANIELS, DL; PLUNKETT, G; BURLAND, V; BLATTNER, FR			ANALYSIS OF THE ESCHERICHIA-COLI GENOME - DNA-SEQUENCE OF THE REGION FROM 84.5 TO 86.5 MINUTES	SCIENCE			English	Article							DETERMINE ANTIGENIC SPECIFICITY; COMPLETE NUCLEOTIDE-SEQUENCE; DEPENDENT RNA HELICASE; GROUP-D SALMONELLAE; SACCHAROMYCES-CEREVISIAE; GENE-CLUSTER; MOLECULAR CHARACTERIZATION; TRANSCRIPTIONAL ACTIVITY; POSITIVE REGULATOR; BACILLUS-SUBTILIS	The DNA sequence of 91.4 kilobases of the Escherichia coli K-12 genome, spanning the region between rrnC at 84.5 minutes and rrnA at 86.5 minutes on the genetic map (85 to 87 percent on the physical map), is described. Analysis of this sequence identified 82 potential coding regions (open reading frames) covering 84 percent of the sequenced interval. The arrangement of these open reading frames, together with the consensus promoter sequences and terminator-like sequences found by computer searches, made it possible to assign them to proposed transcriptional units. More than half the open reading frames correlated with known genes or functions suggested by similarity to other sequences. Those remaining encode still unidentified proteins. The sequenced region also contains several RNA genes and two types of repeated sequence elements were found. Intergenic regions include three "gray holes," 0.6 to 0.8 kilobases, with no recognizable functions.			DANIELS, DL (corresponding author), UNIV WISCONSIN, GENET LAB, 445 HENRY MALL, MADISON, WI 53706 USA.		Plunkett, Guy/B-8058-2009	Plunkett, Guy/0000-0003-1422-469X	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000301] Funding Source: NIH RePORTER; NHGRI NIH HHS [HG00301] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		ADAMS CW, 1988, J BACTERIOL, V170, P203, DOI 10.1128/jb.170.1.203-212.1988; AIBA H, 1984, NUCLEIC ACIDS RES, V12, P9427, DOI 10.1093/nar/12.24.9427; Bachmann B. J., 1987, ESCHERICHIA COLI SAL, V2, P807; Bachmann B.J., 1987, ESCHERICHIA COLI SAL, P1190; BACHMANN BJ, 1990, MICROBIOL REV, V54, P130, DOI 10.1128/MMBR.54.2.130-197.1990; BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; BARTLETT DH, 1988, J BACTERIOL, V170, P1575, DOI 10.1128/jb.170.4.1575-1581.1988; BERLYN M, COMMUNICATION; BOELKER M, 1989, EMBO (European Molecular Biology Organization) Journal, V8, P2403; BOYD J, 1990, UNPUB; CASHEL M, COMMUNICATION; CHRISTMAN MF, 1989, P NATL ACAD SCI USA, V86, P3484, DOI 10.1073/pnas.86.10.3484; Church George, COMMUNICATION, V207; COPPOLA G, 1991, GENE, V97, P21, DOI 10.1016/0378-1119(91)90005-V; Daniels D L, 1983, Cold Spring Harb Symp Quant Biol, V47 Pt 2, P1009; DANIELS DL, 1990, BACTERIAL CHROMOSOME, P43; DANIELS DL, 1990, NUCLEIC ACIDS RES, V18, P2649, DOI 10.1093/nar/18.9.2649; DANIELS DL, 1987, NATURE, V325, P831, DOI 10.1038/325831a0; DANIELS DL, 1990, STRUCTURE METHODS, V1, P29; DERETIC V, 1987, NUCLEIC ACIDS RES, V15, P4567, DOI 10.1093/nar/15.11.4567; DHILLON N, 1989, MOL MICROBIOL, V3, P1405, DOI 10.1111/j.1365-2958.1989.tb00123.x; DISTLER J, 1987, NUCLEIC ACIDS RES, V15, P8041, DOI 10.1093/nar/15.19.8041; DORER DR, 1990, NUCLEIC ACIDS RES, V18, P5489, DOI 10.1093/nar/18.18.5489; DUNN JJ, 1981, J MOL BIOL, V148, P303, DOI 10.1016/0022-2836(81)90178-9; ENDO F, 1989, J BIOL CHEM, V264, P4476; GILCHRIST CA, 1987, NUCLEIC ACIDS RES, V15, P465, DOI 10.1093/nar/15.2.465; GOLDMAN RC, 1986, J BIOL CHEM, V261, P5831; GOSS TJ, 1985, MOL GEN GENET, V201, P308, DOI 10.1007/BF00425676; GRIBSKOV M, 1984, NUCLEIC ACIDS RES, V12, P539, DOI 10.1093/nar/12.1Part2.539; HAGSTROM R, COMMUNICATION; HAY B, 1988, CELL, V55, P577, DOI 10.1016/0092-8674(88)90216-4; HENIKOFF S, 1988, P NATL ACAD SCI USA, V85, P6602, DOI 10.1073/pnas.85.18.6602; HENIKOFF SJC, 1990, METHOD ENZYMOL, V183, P111; HENNER DJ, 1988, J BACTERIOL, V170, P5102, DOI 10.1128/jb.170.11.5102-5109.1988; HIRATSUKA J, 1989, MOL GEN GENET, V217, P185, DOI 10.1007/BF02464880; HLOCH P, 1990, NUCLEIC ACIDS RES, V18, P3045, DOI 10.1093/nar/18.10.3045; HOFFMANN W, 1985, J BIOL CHEM, V260, P1831; HONORE N, 1990, NUCLEIC ACIDS RES, V18, P653, DOI 10.1093/nar/18.3.653; HULTON CSJ, 1991, MOL MICROBIOL, V5, P825, DOI 10.1111/j.1365-2958.1991.tb00755.x; IGGO R, 1990, NUCLEIC ACIDS RES, V18, P5413, DOI 10.1093/nar/18.18.5413; IKEDA M, 1990, NUCLEIC ACIDS RES, V18, P1058, DOI 10.1093/nar/18.4.1058; KALMAN M, 1991, NEW BIOL, V3, P886; KOBAYASHI T, 1985, J BIOCHEM-TOKYO, V98, P1017, DOI 10.1093/oxfordjournals.jbchem.a135347; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; KROGER M, 1991, NUCLEIC ACIDS RES, V19, P2023, DOI 10.1093/nar/19.suppl.2023; KROGER M, 1989, NUCLEIC ACIDS RES S, V17, P283; LASKO PF, 1988, NATURE, V335, P611, DOI 10.1038/335611a0; LAWTHER RP, 1981, P NATL ACAD SCI-BIOL, V78, P922, DOI 10.1073/pnas.78.2.922; LEROY P, 1989, CELL, V57, P549, DOI 10.1016/0092-8674(89)90125-6; LEVENE SD, 1983, J BIOMOL STRUCT DYN, V1, P429, DOI 10.1080/07391102.1983.10507452; LINDER P, 1988, NUCLEIC ACIDS RES, V16, P10359, DOI 10.1093/nar/16.21.10359; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; MAGIURE M, COMMUNICATION; MATSUMOTO Y, 1986, J BACTERIOL, V166, P945, DOI 10.1128/jb.166.3.945-958.1986; MAXON ME, 1990, P NATL ACAD SCI USA, V87, P7076, DOI 10.1073/pnas.87.18.7076; MAXON ME, 1989, P NATL ACAD SCI USA, V86, P85, DOI 10.1073/pnas.86.1.85; MEIERDIETER U, 1992, J BIOL CHEM, V267, P746; MEIGHEN EA, 1991, MICROBIOL REV, V55, P123, DOI 10.1128/MMBR.55.1.123-142.1991; MOYLE H, 1991, J BACTERIOL, V173, P1944, DOI 10.1128/jb.173.6.1944-1950.1991; MUROOKA Y, 1990, J BACTERIOL, V172, P2131, DOI 10.1128/jb.172.4.2131-2140.1990; NAKAHIGASHI K, 1990, NUCLEIC ACIDS RES, V18, P6439, DOI 10.1093/nar/18.21.6439; NIELSEN PJ, 1985, NUCLEIC ACIDS RES, V13, P6867, DOI 10.1093/nar/13.19.6867; NIKAIDO H, 1987, ESCHERICHIA COLI SAL, P7; NISHI K, 1988, NATURE, V336, P496, DOI 10.1038/336496a0; NISHI K, 1989, NATURE, V340, P246, DOI 10.1038/340246a0; OHTA M, 1991, MOL MICROBIOL, V5, P1853, DOI 10.1111/j.1365-2958.1991.tb00809.x; OHTAKE Y, 1988, AGR BIOL CHEM TOKYO, V52, P2753, DOI 10.1080/00021369.1988.10869126; OLIVER SG, 1992, NATURE, V357, P38, DOI 10.1038/357038a0; OLSON C H, 1991, Methods (Orlando), V3, P27, DOI 10.1016/S1046-2023(05)80160-4; OSTROWSKI J, 1987, J BIOL CHEM, V262, P5999; PARK MH, 1976, J BACTERIOL, V126, P1096, DOI 10.1128/JB.126.3.1096-1103.1976; PEGUES JC, 1990, J BACTERIOL, V172, P4652, DOI 10.1128/jb.172.8.4652-4660.1990; PINKHAM JL, 1983, NUCLEIC ACIDS RES, V11, P3531, DOI 10.1093/nar/11.11.3531; REHEMTULLA A, 1986, J BACTERIOL, V166, P651, DOI 10.1128/jb.166.2.651-657.1986; ROTHMEL RK, 1990, J BACTERIOL, V172, P922, DOI 10.1128/jb.172.2.922-931.1990; RUDD KE, 1991, NUCLEIC ACIDS RES, V19, P637, DOI 10.1093/nar/19.3.637; RUDD KE, 1992, SHORT COURSE BACTERI; SANGER F, 1977, NATURE, V265, P687, DOI 10.1038/265687a0; SANGER F, 1982, J MOL BIOL, V162, P729, DOI 10.1016/0022-2836(82)90546-0; SASARMAN A, 1988, J BACTERIOL, V170, P1575; SEOL W, 1991, P NATL ACAD SCI USA, V88, P3802, DOI 10.1073/pnas.88.9.3802; SERAPHIN B, 1989, NATURE, V337, P84, DOI 10.1038/337084a0; SHARMA RC, 1983, J BACTERIOL, V154, P743, DOI 10.1128/JB.154.2.743-747.1983; SHARMA RC, 1987, MUTAT RES, V184, P23, DOI 10.1016/0167-8817(87)90032-0; SHARPLES GJ, 1990, NUCLEIC ACIDS RES, V18, P6503, DOI 10.1093/nar/18.22.6503; SHAVLIK J, 1990, 988 U WISC COMP SCI; SMITH CL, 1987, SCIENCE, V236, P1448, DOI 10.1126/science.3296194; SOPHIANOPOULOU V, 1989, MOL MICROBIOL, V3, P705, DOI 10.1111/j.1365-2958.1989.tb00219.x; SPARROW CP, 1983, J BIOL CHEM, V258, P9963; SPYROU G, 1991, J BACTERIOL, V173, P3673, DOI 10.1128/JB.173.12.3673-3679.1991; STADEN R, 1982, NUCLEIC ACIDS RES, V10, P141, DOI 10.1093/nar/10.1.141; STAINTHORPE AC, 1990, GENE, V91, P27, DOI 10.1016/0378-1119(90)90158-N; STEIN C, 1989, J BIOL CHEM, V264, P1252; STRAGIER P, 1983, J MOL BIOL, V168, P333, DOI 10.1016/S0022-2836(83)80022-9; SUTCLIFFE JG, 1979, COLD SPRING HARB SYM, V43, P77, DOI 10.1101/SQB.1979.043.01.013; SUZUKI M, 1991, J BACTERIOL, V173, P1690, DOI 10.1128/jb.173.5.1690-1695.1991; SWARTZMAN E, 1990, J BACTERIOL, V172, P6797, DOI 10.1128/jb.172.12.6797-6802.1990; SWARTZMAN E, 1990, J BIOL CHEM, V265, P3513; TAKAGI M, 1990, J BACTERIOL, V172, P411, DOI 10.1128/JB.172.1.411-418.1990; TOONE WM, 1991, J BACTERIOL, V173, P3291, DOI 10.1128/jb.173.11.3291-3302.1991; VANDENBOL M, 1989, GENE, V83, P153, DOI 10.1016/0378-1119(89)90413-7; VERMA N, 1989, J BACTERIOL, V171, P5694, DOI 10.1128/jb.171.10.5694-5701.1989; WASSARMAN DA, 1991, NATURE, V349, P463, DOI 10.1038/349463a0; WEBSTER TD, 1988, NUCLEIC ACIDS RES, V16, P8192, DOI 10.1093/nar/16.16.8192; WEK RC, 1986, J BIOL CHEM, V261, P2441; YAMADA T, 1978, J BACTERIOL, V133, P536, DOI 10.1128/JB.133.2.536-541.1978; YAMAMOTO Y, 1986, J BIOCHEM-TOKYO, V99, P1579, DOI 10.1093/oxfordjournals.jbchem.a135631; YANG Y, 1990, BACTERIAL CHROMOSOME, P211	108	235	319	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 7	1992	257	5071					771	778		10.1126/science.1379743	http://dx.doi.org/10.1126/science.1379743			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JG851	1379743				2022-12-01	WOS:A1992JG85100027
J	DAVID, M; LARNER, AC				DAVID, M; LARNER, AC			ACTIVATION OF TRANSCRIPTION FACTORS BY INTERFERON-ALPHA IN A CELL-FREE SYSTEM	SCIENCE			English	Article							ISGF3; INDUCTION; GENES	The signal transduction mechanisms of interferons (IFNs) remain unclear partly because no effect of IFN has been reproducible in a cell-free system. IFN-alpha rapidly induces the transcription of a set of early response genes, and a multicomponent transcriptional activator, interferon stimulated gene factor 3 (ISGF3), is activated within minutes after binding of IFN-alpha to its receptor. A system was developed in which IFN-alpha activated ISGF3 in homogenates of HeLa cells. Subcellular fractionation revealed that incubation of a plasma membrane-enriched fraction with IFN-alpha was sufficient to activate the regulatory subcomponent of ISGF3.	CTR BIOL EVALUAT & RES, DIV CYTOKINE BIOL, BETHESDA, MD 20892 USA	US Food & Drug Administration (FDA)								DALE TC, 1989, P NATL ACAD SCI USA, V86, P1203, DOI 10.1073/pnas.86.4.1203; DAVID M, UNPUB; FRIEDMAN RL, 1985, NATURE, V314, P637, DOI 10.1038/314637a0; FU XY, 1990, P NATL ACAD SCI USA, V87, P8555, DOI 10.1073/pnas.87.21.8555; KESSLER DS, 1991, J BIOL CHEM, V266, P23471; KESSLER DS, 1990, GENE DEV, V4, P1753, DOI 10.1101/gad.4.10.1753; LARNER AC, 1984, P NATL ACAD SCI-BIOL, V81, P6733, DOI 10.1073/pnas.81.21.6733; LEVY D, 1990, New Biologist, V2, P923; LEVY DE, 1988, GENE DEV, V2, P383, DOI 10.1101/gad.2.4.383; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; LEW DJ, 1989, MOL CELL BIOL, V9, P5404, DOI 10.1128/MCB.9.12.5404; TAMAOKI T, 1991, METHOD ENZYMOL, V201, P340; TIWARI RK, 1988, MOL CELL BIOL, V8, P4289, DOI 10.1128/MCB.8.10.4289	13	70	72	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 7	1992	257	5071					813	815		10.1126/science.1496402	http://dx.doi.org/10.1126/science.1496402			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JG851	1496402				2022-12-01	WOS:A1992JG85100040
J	DOMBROSKI, AJ; WALTER, WA; RECORD, MT; SIEGELE, DA; GROSS, CA				DOMBROSKI, AJ; WALTER, WA; RECORD, MT; SIEGELE, DA; GROSS, CA			POLYPEPTIDES CONTAINING HIGHLY CONSERVED REGIONS OF TRANSCRIPTION INITIATION-FACTOR SIGMA-70 EXHIBIT SPECIFICITY OF BINDING TO PROMOTER DNA	CELL			English	Article								The sigma-70 subunit of E. coli RNA polymerase is required for sequence-specific recognition of promoter DNA. Genetic studies and sequence analysis have indicated that sigma-70 contains two specific DNA-binding domains that recognize the two conserved portions of the prokaryotic promoter. However, intact sigma-70 does not bind to DNA. Using C-terminal and internal polypeptides of sigma-70, carrying one or both putative DNA-binding domains, we demonstrate that sigma-70 does contain two DNA-binding domains, but that N-terminal sequences inhibit the ability of intact sigma-70 to bind to DNA. Thus, we propose that sigma-70 is a sequence-specific DNA-binding protein that normally functions through an allosteric interaction with the core subunits of RNA polymerase.	UNIV WISCONSIN, DEPT BIOCHEM, MADISON, WI 53706 USA; HARVARD UNIV, SCH MED, DEPT MICROBIOL & MOLEC GENET, BOSTON, MA 02115 USA	University of Wisconsin System; University of Wisconsin Madison; Harvard University; Harvard Medical School	DOMBROSKI, AJ (corresponding author), UNIV WISCONSIN, DEPT BACTERIOL, MADISON, WI 53706 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019635] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM023467, R01GM023467] Funding Source: NIH RePORTER; NIAID NIH HHS [AI19635] Funding Source: Medline; NIGMS NIH HHS [GM23467] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGGARWAL AK, 1990, ANNU REV BIOCHEM, V53, P293; AMANN E, 1983, GENE, V25, P167, DOI 10.1016/0378-1119(83)90222-6; BUC H, 1985, BIOCHEMISTRY-US, V24, P2712, DOI 10.1021/bi00332a018; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; BURGESS RR, 1969, NATURE, V221, P43, DOI 10.1038/221043a0; BURGESS RR, 1970, FED PROC, V29, P1164; Chamberlin M.J., 1976, RNA POLYMERASE, P159; CHENCHICK A, 1981, FEBS LETT, V128, P46, DOI 10.1016/0014-5793(81)81076-9; CHENCHIK AA, 1982, MOL BIOL+, V16, P26; CONAWAY JW, 1990, SCIENCE, V248, P1550, DOI 10.1126/science.2193400; DANIELS D, 1990, P NATL ACAD SCI USA, V87, P8075, DOI 10.1073/pnas.87.20.8075; DEBOER HA, 1983, P NATL ACAD SCI-BIOL, V80, P21; DEHASETH P L, 1978, Biochemistry, V17, P1612, DOI 10.1021/bi00602a006; GARDELLA T, 1989, J MOL BIOL, V206, P579, DOI 10.1016/0022-2836(89)90567-6; GRIBSKOV M, 1983, GENE, V26, P109, DOI 10.1016/0378-1119(83)90180-4; GRIBSKOV M, 1986, NUCLEIC ACIDS RES, V14, P6745, DOI 10.1093/nar/14.16.6745; GROSS CA, 1992, IN PRESS TRANSCRIPTI; GUNSALUS RP, 1980, P NATL ACAD SCI-BIOL, V77, P7117, DOI 10.1073/pnas.77.12.7117; HARLEY CB, 1987, NUCLEIC ACIDS RES, V15, P2343, DOI 10.1093/nar/15.5.2343; HAWLEY DK, 1983, NUCLEIC ACIDS RES, V11, P2237, DOI 10.1093/nar/11.8.2237; HELMANN JD, 1988, ANNU REV BIOCHEM, V57, P839, DOI 10.1146/annurev.bi.57.070188.004203; HILTON MD, 1985, J BIOL CHEM, V260, P8121; HINKLE DC, 1972, J MOL BIOL, V70, P157, DOI 10.1016/0022-2836(72)90531-1; HU JC, 1988, J MOL BIOL, V203, P15, DOI 10.1016/0022-2836(88)90087-3; KILLEEN MT, 1992, MOL CELL BIOL, V12, P30, DOI 10.1128/MCB.12.1.30; KOBAYASHI M, 1990, NUCLEIC ACIDS RES, V18, P7367, DOI 10.1093/nar/18.24.7367; KROOS L, 1989, SCIENCE, V243, P526, DOI 10.1126/science.2492118; KUDO T, 1981, MOL GEN GENET, V181, P63, DOI 10.1007/BF00339006; KUDO T, 1981, J BIOL CHEM, V256, P9778; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LABELL TL, 1987, P NATL ACAD SCI USA, V84, P1784, DOI 10.1073/pnas.84.7.1784; LEDERER H, 1991, J MOL BIOL, V219, P747, DOI 10.1016/0022-2836(91)90669-W; LESLEY SA, 1989, BIOCHEMISTRY-US, V28, P7728, DOI 10.1021/bi00445a031; LOHMAN TM, 1980, BIOCHEMISTRY-US, V19, P3516, DOI 10.1021/bi00556a016; LONETTO M, 1992, J BACTERIOL, V174, P3843, DOI 10.1128/jb.174.12.3843-3849.1992; LOSICK R, 1981, CELL, V25, P582, DOI 10.1016/0092-8674(81)90164-1; LU SJ, 1990, P NATL ACAD SCI USA, V87, P9722, DOI 10.1073/pnas.87.24.9722; Maniatis T., 1982, MOL CLONING; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.biochem.54.1.171; MCCRACKEN S, 1991, SCIENCE, V253, P900, DOI 10.1126/science.1652156; MOYLE H, 1991, J BACTERIOL, V173, P1944, DOI 10.1128/jb.173.6.1944-1950.1991; MULLIGAN ME, 1984, NUCLEIC ACIDS RES, V12, P789, DOI 10.1093/nar/12.1Part2.789; RAMESH U, 1989, BIOCHEM BIOPH RES CO, V160, P121, DOI 10.1016/0006-291X(89)91629-X; RIGGS AD, 1970, J MOL BIOL, V48, P67, DOI 10.1016/0022-2836(70)90219-6; ROE JH, 1985, J MOL BIOL, V184, P441, DOI 10.1016/0022-2836(85)90293-1; SAXE SA, 1979, BIOCHEMISTRY-US, V18, P255, DOI 10.1021/bi00569a003; SHANER SL, 1982, COLD SPRING HARB SYM, V47, P463; SIEGELE DA, 1989, J MOL BIOL, V206, P591, DOI 10.1016/0022-2836(89)90568-8; SIMPSON RB, 1979, CELL, V18, P277, DOI 10.1016/0092-8674(79)90047-3; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOPTA M, 1989, NATURE, V341, P410, DOI 10.1038/341410a0; STRAGIER P, 1985, FEBS LETT, V187, P11, DOI 10.1016/0014-5793(85)81203-5; STRAGIER P, 1989, SCIENCE, V243, P507, DOI 10.1126/science.2536191; STRAUSS HS, 1980, BIOCHEMISTRY-US, V19, P3504, DOI 10.1021/bi00556a015; STRICKLAND MS, 1988, BIOCHEMISTRY-US, V27, P5755, DOI 10.1021/bi00415a054; TREMPY JE, 1985, MOL BIOL MICROBIAL D, P162; WALDBURGER C, 1990, J MOL BIOL, V215, P267, DOI 10.1016/S0022-2836(05)80345-6; WELLMAN A, 1991, BIOCHEM BIOPH RES CO, V177, P140, DOI 10.1016/0006-291X(91)91959-G; WITHERELL GW, 1989, BIOCHEMISTRY-US, V28, P71, DOI 10.1021/bi00427a011; WU CW, 1975, P NATL ACAD SCI USA, V72, P3019, DOI 10.1073/pnas.72.8.3019; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YOUDERIAN P, 1982, CELL, V30, P843, DOI 10.1016/0092-8674(82)90289-6; ZAGURSKY RJ, 1984, GENE, V27, P183, DOI 10.1016/0378-1119(84)90139-2; ZILLIG W, 1970, COLD SPRING HARB SYM, V35, P47, DOI 10.1101/SQB.1970.035.01.010; ZUBER P, 1989, J MOL BIOL, V206, P605, DOI 10.1016/0022-2836(89)90569-X	65	296	302	1	16	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 7	1992	70	3					501	512		10.1016/0092-8674(92)90174-B	http://dx.doi.org/10.1016/0092-8674(92)90174-B			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JH124	1643661	Bronze			2022-12-01	WOS:A1992JH12400015
J	FOREJT, J; GREGOROVA, S				FOREJT, J; GREGOROVA, S			GENETIC-ANALYSIS OF GENOMIC IMPRINTING - AN IMPRINTOR-1 GENE CONTROLS INACTIVATION OF THE PATERNAL COPY OF THE MOUSE TME LOCUS	CELL			English	Article								The T(hP) deletion on mouse chromosome 17 is lethal when inherited from the mother, because it deletes the T.associated maternal effect (Tme) locus, the paternal copy of which is inactivated by genomic imprinting. We have found a paternally nonimprinted Tme variant in crosses of T(hp) females with Mus m. musculus males. The data are consistent with the existence of a single Tme-unlinked gene, Imprintor-1 (Imp-1), with two alleles, one of which only causes imprinting at the Tme locus. Imp-1 is unlinked to the gene for cation-dependent Man-6-P receptor and acts prezygotically. Although Tme and Igf2r were thought to be identical, they show different patterns of imprinting in interspecies hybrids. The apparent nonequivalence of the Igf2r gene and Tme results in occurrence of viable mice lacking an active Igf2r gene. These mice are bigger at birth than their normal littermates, in accord with the proposed function of the IGF-II/Man-6-P receptor.			FOREJT, J (corresponding author), CZECHOSLOVAK ACAD SCI, INST MOLEC GENET, VIDENSKA 1083, CS-14220 PRAGUE 4, CZECH REPUBLIC.		Forejt, Jiri/G-7719-2012; Forejt, Jiri/AAF-5276-2019	Forejt, Jiri/0000-0002-2793-3623; Forejt, Jiri/0000-0002-2793-3623				AGULNIK AI, 1991, J HERED, V82, P351, DOI 10.1093/oxfordjournals.jhered.a111099; ALLEN ND, 1990, CELL, V61, P853, DOI 10.1016/0092-8674(90)90195-K; ARTZT K, 1984, CELL, V39, P565, DOI 10.1016/0092-8674(84)90463-X; BARLOW DP, 1991, NATURE, V349, P84, DOI 10.1038/349084a0; BARTOLOMEI MS, 1991, NATURE, V351, P153, DOI 10.1038/351153a0; BRUNKOW ME, 1991, GENE DEV, V5, P1092, DOI 10.1101/gad.5.6.1092; CATTANACH BM, 1990, DEVELOPMENT, P63; CATTANACH BM, 1985, NATURE, V315, P496, DOI 10.1038/315496a0; CHAILLET JR, 1991, CELL, V66, P77, DOI 10.1016/0092-8674(91)90140-T; CHANDRA HS, 1990, DEVELOPMENT, P47; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; DOERFLER W, 1991, BIOL CHEM H-S, V372, P557; ENGLER P, 1991, CELL, V65, P939, DOI 10.1016/0092-8674(91)90546-B; FASANO O, 1984, MOL CELL BIOL, V4, P1695, DOI 10.1128/MCB.4.9.1695; FERGUSONSMITH AC, 1990, CANCER SURV, V9, P487; FOREJT J, 1988, GENET RES, V51, P111, DOI 10.1017/S0016672300024125; FOREJT J, 1980, GENET RES, V35, P165, DOI 10.1017/S0016672300014026; FOREJT J, 1991, MAMM GENOME, V1, P84, DOI 10.1007/BF02443783; FOREJT J, 1981, CURRENT TRENDS HISTO, V1, P103; GOODFELLOW P N, 1991, Current Biology, V1, P11, DOI 10.1016/0960-9822(91)90111-9; HADCHOUEL M, 1987, NATURE, V329, P454, DOI 10.1038/329454a0; HAIG D, 1991, PHILOS T ROY SOC B, V333, P1, DOI 10.1098/rstb.1991.0057; HAIG D, 1991, CELL, V64, P1045; HARVEY MB, 1991, DEVELOPMENT, V111, P1057; HENRY I, 1991, NATURE, V351, P665, DOI 10.1038/351665a0; HUMBEL RE, 1990, EUR J BIOCHEM, V190, P445, DOI 10.1111/j.1432-1033.1990.tb15595.x; JOHNSON DR, 1974, GENETICS, V76, P795; JOHNSON DR, 1974, GENET RES, V24, P207, DOI 10.1017/S0016672300015226; KIESS W, 1987, J BIOL CHEM, V262, P12745; KRICKER MC, 1992, P NATL ACAD SCI USA, V89, P1075, DOI 10.1073/pnas.89.3.1075; Lewontin R. C., 1974, The genetic basis of evolutionary change.; MONK M, 1988, GENE DEV, V2, P921, DOI 10.1101/gad.2.8.921; MOORE T, 1991, TRENDS GENET, V7, P45, DOI 10.1016/0168-9525(91)90230-N; MOTTOLA C, 1984, J BIOL CHEM, V259, P2705; MURAYAMA Y, 1990, J BIOL CHEM, V265, P17456; NICHOLLS RD, 1989, NATURE, V342, P281, DOI 10.1038/342281a0; NISHIMOTO I, 1987, J BIOL CHEM, V262, P12120; PAVLJUKOVA H, 1981, MOUSE NEWS LETT, V65, P44; Peters JA, 1959, CLASSIC PAPERS GENET; PIRROTTA V, 1990, BIOESSAYS, V12, P409, DOI 10.1002/bies.950120903; REIK W, 1987, NATURE, V328, P248, DOI 10.1038/328248a0; REIK W, 1990, DEVELOPMENT, P99; REIK W, 1989, TRENDS GENET, V5, P331, DOI 10.1016/0168-9525(89)90138-8; RIDLEY RM, 1991, J MED GENET, V28, P224, DOI 10.1136/jmg.28.4.224; ROTH RA, 1990, KAR INS NCS, P73; RUVINSKY AO, 1990, DEV GENET, V11, P263, DOI 10.1002/dvg.1020110404; Sambrook J., 1989, MOL CLONING LAB MANU; SAPIENZA C, 1989, ANN NY ACAD SCI, V564, P24, DOI 10.1111/j.1749-6632.1989.tb25885.x; SAPIENZA C, 1989, DEVELOPMENT, V107, P165; SAPIENZA C, 1990, SCI AM, V263, P52, DOI 10.1038/scientificamerican1090-52; SAPIENZA C, 1991, BIOCHIM BIOPHYS ACTA, V1072, P51, DOI 10.1016/0304-419X(91)90006-7; SASAKI H, 1991, DEVELOPMENT, V111, P573; SCHIMENTI J, 1987, J MOL BIOL, V194, P583, DOI 10.1016/0022-2836(87)90235-X; SEARLE AG, 1978, CYTOGENET CELL GENET, V20, P282, DOI 10.1159/000130859; SEARLE AG, 1990, GENET RES, V56, P237, DOI 10.1017/S0016672300035333; SENIOR PV, 1990, DEVELOPMENT, V109, P67; SILVER LM, 1987, MOL BIOL EVOL, V4, P473; SOLTER D, 1988, ANNU REV GENET, V22, P127; SWAIN JL, 1987, CELL, V50, P719, DOI 10.1016/0092-8674(87)90330-8; TSAI JY, 1991, GENETICS, V129, P1159; VONDEIMLING OH, 1988, LAB ANIM-UK, V22, P61, DOI 10.1258/002367788780746610; VONFIGURA K, 1986, ANNU REV BIOCHEM, V55, P167, DOI 10.1146/annurev.biochem.55.1.167; WASHBURN LL, 1983, NATURE, V303, P338, DOI 10.1038/303338a0; WINKING H, 1984, GENETICS, V108, P1013	65	107	107	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 7	1992	70	3					443	450		10.1016/0092-8674(92)90168-C	http://dx.doi.org/10.1016/0092-8674(92)90168-C			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JH124	1322799	Bronze			2022-12-01	WOS:A1992JH12400009
J	GLUCKSMANN, MA; MARKIEWICZ, P; MALONE, C; ROTHMANDENES, LB				GLUCKSMANN, MA; MARKIEWICZ, P; MALONE, C; ROTHMANDENES, LB			SPECIFIC SEQUENCES AND A HAIRPIN STRUCTURE IN THE TEMPLATE STRAND ARE REQUIRED FOR N4-VIRION RNA-POLYMERASE PROMOTER RECOGNITION	CELL			English	Article							DNA-BINDING PROTEINS; TRANSCRIPTION INITIATION; OPEN COMPLEX; IDENTIFICATION; PURIFICATION; MECHANISM; KINETICS; INTERACT; ELEMENTS; LOOP	Coliphage N4 virion-encapsidated, DNA-dependent RNA polymerase (vRNAP) is inactive on double-stranded N4 DNA; however, denatured promoter-containing templates are accurately transcribed. We report that all determinants of vRNAP promoter recognition exist in the template strand, indicating that this enzyme is a site-specific, single-stranded DNA-binding protein. We show that conserved sequences and the integrity of inverted repeats present at the promoters are essential for activity, suggesting the necessity for specific secondary structure. Evidence for such a structure is presented. We propose a model for in vivo utilization of vRNAP promoters in which template negative supercoiling yields single-strandedness at the promoter to reveal the determinants of vRNAP binding. This structure is stabilized by the binding of E. coli single-stranded DNA-binding protein to yield an "activated promoter."	UNIV CHICAGO,DEPT BIOCHEM & MOLEC BIOL,CHICAGO,IL 60637; UNIV CHICAGO,DEPT MOLEC GENET & CELL BIOL,CHICAGO,IL 60637	University of Chicago; University of Chicago					NIAID NIH HHS [AI 07099, AI 12575] Funding Source: Medline; NIGMS NIH HHS [5T32 GM07183] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI012575] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007183] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEEN MD, 1983, METHOD ENZYMOL, V101, P90; BOROWIEC JA, 1987, J MOL BIOL, V196, P101, DOI 10.1016/0022-2836(87)90513-4; BUC H, 1985, BIOCHEMISTRY-US, V24, P2712, DOI 10.1021/bi00332a018; Chamberlin M., 1982, ENZYMES, V15, P87; COWING DW, 1989, J MOL BIOL, V210, P521, DOI 10.1016/0022-2836(89)90128-9; CRICK F, 1971, NATURE, V234, P25, DOI 10.1038/234025a0; DEMASSY B, 1987, J MOL BIOL, V193, P359, DOI 10.1016/0022-2836(87)90224-5; DREW HR, 1984, CELL, V37, P491, DOI 10.1016/0092-8674(84)90379-9; FALCO SC, 1978, P NATL ACAD SCI USA, V75, P3220, DOI 10.1073/pnas.75.7.3220; FALCO SC, 1980, J BIOL CHEM, V255, P4339; FALCO SC, 1977, P NATL ACAD SCI USA, V74, P520, DOI 10.1073/pnas.74.2.520; FEAVERS IM, 1989, J BIOL CHEM, V264, P9114; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GAILLARD C, 1990, J MOL BIOL, V215, P245, DOI 10.1016/S0022-2836(05)80343-2; GEIDER K, 1974, J BIOL CHEM, V249, P3999; GERMANN MW, 1990, NUCLEIC ACIDS RES, V18, P1489, DOI 10.1093/nar/18.6.1489; GRACHEV MA, 1986, FEBS LETT, V200, P287, DOI 10.1016/0014-5793(86)81154-1; GUALBERTO A, 1992, GENE DEV, V6, P815, DOI 10.1101/gad.6.5.815; GUINTA D, 1986, VIROLOGY, V150, P33, DOI 10.1016/0042-6822(86)90263-1; HARTMANN GR, 1988, BIOL CHEM H-S, V369, P775; HAWLEY DK, 1983, NUCLEIC ACIDS RES, V11, P2237, DOI 10.1093/nar/11.8.2237; HAYNES LL, 1985, CELL, V41, P597, DOI 10.1016/S0092-8674(85)80032-5; HIASA H, 1990, NUCLEIC ACIDS RES, V18, P4825, DOI 10.1093/nar/18.16.4825; HOFMANN JFX, 1991, CELL, V64, P951, DOI 10.1016/0092-8674(91)90319-T; KIINO DR, 1988, BACTERIOPHAGES, V2, P457; Kornberg A., 1991, DNA REPLICATION; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANNIGAN DA, 1989, P NATL ACAD SCI USA, V86, P863, DOI 10.1073/pnas.86.3.863; Maniatis T., 1982, MOL CLONING; MARKIEWICZ P, 1988, NUCLEIC ACIDS RES, V16, P1011, DOI 10.1093/nar/16.3.1011; MARKIEWICZ P, 1992, IN PRESS GENES DEV; Maxam A M, 1980, Methods Enzymol, V65, P499; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.biochem.54.1.171; MENDELMAN LV, 1991, J BIOL CHEM, V266, P23240; Nagai K., 1992, CURR OPIN STRUC BIOL, V2, P131; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTORO IM, 1991, MOL CELL BIOL, V11, P1944, DOI 10.1128/MCB.11.4.1944; SCHMIDT AMA, 1991, EMBO J, V10, P981, DOI 10.1002/j.1460-2075.1991.tb08032.x; SENIOR MM, 1988, P NATL ACAD SCI USA, V85, P6242, DOI 10.1073/pnas.85.17.6242; STEFANO JE, 1982, P NATL ACAD SCI-BIOL, V79, P1069, DOI 10.1073/pnas.79.4.1069; TAKASE H, 1991, BIOCHEM BIOPH RES CO, V176, P1593, DOI 10.1016/0006-291X(91)90470-R; VANDERLAAN K, 1977, VIROLOGY, V76, P596, DOI 10.1016/0042-6822(77)90241-0; VOS JC, 1991, CELL, V65, P105, DOI 10.1016/0092-8674(91)90412-R; WILKISON WO, 1990, J BIOL CHEM, V265, P477; YEE HA, 1991, NUCLEIC ACIDS RES, V19, P949, DOI 10.1093/nar/19.4.949; YOUDERIAN P, 1982, CELL, V30, P843, DOI 10.1016/0092-8674(82)90289-6; ZEHRING WA, 1983, J BIOL CHEM, V258, P8074; ZIVIN R, 1981, J MOL BIOL, V152, P335, DOI 10.1016/0022-2836(81)90246-1	49	74	76	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 7	1992	70	3					491	500		10.1016/0092-8674(92)90173-A	http://dx.doi.org/10.1016/0092-8674(92)90173-A			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JH124	1643660				2022-12-01	WOS:A1992JH12400014
J	HILES, ID; OTSU, M; VOLINIA, S; FRY, MJ; GOUT, I; DHAND, R; PANAYOTOU, G; RUIZLARREA, F; THOMPSON, A; TOTTY, NF; HSUAN, JJ; COURTNEIDGE, SA; PARKER, PJ; WATERFIELD, MD				HILES, ID; OTSU, M; VOLINIA, S; FRY, MJ; GOUT, I; DHAND, R; PANAYOTOU, G; RUIZLARREA, F; THOMPSON, A; TOTTY, NF; HSUAN, JJ; COURTNEIDGE, SA; PARKER, PJ; WATERFIELD, MD			PHOSPHATIDYLINOSITOL 3-KINASE - STRUCTURE AND EXPRESSION OF THE 110KD CATALYTIC SUBUNIT	CELL			English	Article							RECEPTOR TYROSINE KINASES; DEPENDENT PROTEIN-KINASE; FACTOR-I RECEPTOR; MIDDLE T-ANTIGEN; PDGF RECEPTOR; BOVINE BRAIN; SACCHAROMYCES-CEREVISIAE; SIGNAL TRANSDUCTION; ACTIVATED NEUTROPHILS; PHOSPHOLIPASE-C	Purified bovine brain phosphatidylinositol 3-kinase (Pl3-kinase) is composed of 85 kd and 110 kd subunits. The 85 kd subunit (p85-alpha) lacks Pl3-kinase activity and acts as an adaptor, coupling the 110 kd subunit (p110) to activated protein tyrosine kinases. Here the characterization of the p110 subunit is presented. cDNA cloning reveals p110 to be a 1068 aa protein related to Vps34p, a S. cerevisiae protein involved in the sorting of proteins to the vacuole. p110 expressed in insect cells possesses Pl3-kinase activity and associates with p85-alpha into an active p85-alpha-p110 complex that binds the activated colony-stimulating factor 1 receptor. p110 expressed in COS-1 cells is catalytically active only when complexed with p85-alpha.	UNIV LONDON UNIV COLL,DEPT BIOCHEM & MOLEC BIOL,LONDON WC1E 6BT,ENGLAND; EUROPEAN MOLEC BIOL LAB,DIFFERENTIAT PROGRAMME,W-6900 HEIDELBERG,GERMANY; IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND	University of London; University College London; European Molecular Biology Laboratory (EMBL); Cancer Research UK	HILES, ID (corresponding author), LUDWIG INST CANC RES,LONDON W1P 8BT,ENGLAND.		Hsuan, Justin/C-8825-2009; Volinia, Stefano/AAA-9264-2019; Parker, Peter j/D-5192-2013; Volinia, Stefano/A-3029-2010	Hsuan, Justin/0000-0001-6083-7564; Volinia, Stefano/0000-0003-0910-3893; Volinia, Stefano/0000-0003-0910-3893; Ruiz Larrea, Fernanda/0000-0001-5610-7745; Fry, Michael/0000-0001-8518-1370; parker, peter/0000-0002-6218-2933				ASHMUN RA, 1989, BLOOD, V73, P827; AUGER KR, 1989, J BIOL CHEM, V264, P20181; AUGER KR, 1991, CANCER CELL-MON REV, V3, P263; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P294; COUGHLIN SR, 1989, SCIENCE, V243, P1191; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOWNES CP, 1991, CELL SIGNAL, V3, P501, DOI 10.1016/0898-6568(91)90027-R; DOWNES CP, 1990, EUR J BIOCHEM, V193, P1, DOI 10.1111/j.1432-1033.1990.tb19297.x; ENDEMANN G, 1987, BIOCHEMISTRY-US, V26, P6845, DOI 10.1021/bi00395a039; ESCOBEDO JA, 1988, NATURE, V335, P85, DOI 10.1038/335085a0; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARVEY RJ, 1991, NUCLEIC ACIDS RES, V19, P4002, DOI 10.1093/nar/19.14.4002; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HERMAN PK, 1990, MOL CELL BIOL, V10, P6742, DOI 10.1128/MCB.10.12.6742; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; KAPLAN DR, 1986, P NATL ACAD SCI USA, V83, P3624, DOI 10.1073/pnas.83.11.3624; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KAZLAUSKAS A, 1990, EMBO J, V9, P3279, DOI 10.1002/j.1460-2075.1990.tb07527.x; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KAZLAUSKAS A, 1991, CELL REGUL, V2, P413, DOI 10.1091/mbc.2.6.413; KELLY KL, 1992, J BIOL CHEM, V267, P3423; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KUCERA GL, 1990, J BIOL CHEM, V265, P5345; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LIPS DL, 1989, J BIOL CHEM, V264, P8759; MAJERUS PW, 1990, CELL, V63, P459, DOI 10.1016/0092-8674(90)90442-H; Maniatis T., 1982, MOL CLONING; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; MORGAN SJ, 1990, EUR J BIOCHEM, V191, P761, DOI 10.1111/j.1432-1033.1990.tb19185.x; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PAGE MJ, 1989, NUCLEIC ACIDS RES, V17, P454, DOI 10.1093/nar/17.1.454; RHEE SG, 1991, TRENDS BIOCHEM SCI, V16, P297, DOI 10.1016/0968-0004(91)90122-C; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SERUNIAN LA, 1989, J BIOL CHEM, V264, P17809; SHIBASAKI F, 1991, J BIOL CHEM, V266, P8108; SHURTLEFF SA, 1990, EMBO J, V9, P2415, DOI 10.1002/j.1460-2075.1990.tb07417.x; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; Summers MD, 1987, TEXAS AGR EXP STATIO, V1555; TALMAGE DA, 1989, CELL, V59, P55, DOI 10.1016/0092-8674(89)90869-6; TOTTY NF, 1992, IN PRESS PROTEIN SCI, V1; TRAYNORKAPLAN AE, 1988, NATURE, V334, P353, DOI 10.1038/334353a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ULUG ET, 1990, J VIROL, V64, P3895, DOI 10.1128/JVI.64.8.3895-3904.1990; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; WHITLEY GSJ, 1987, MOL CELL ENDOCRINOL, V52, P279, DOI 10.1016/0303-7207(87)90056-6; WHITMAN M, 1987, BIOCHEM J, V247, P165, DOI 10.1042/bj2470165; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	63	643	814	1	16	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 7	1992	70	3					419	429		10.1016/0092-8674(92)90166-A	http://dx.doi.org/10.1016/0092-8674(92)90166-A			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JH124	1322797	Bronze			2022-12-01	WOS:A1992JH12400007
J	INOSTROZA, JA; MERMELSTEIN, FH; HA, I; LANE, WS; REINBERG, D				INOSTROZA, JA; MERMELSTEIN, FH; HA, I; LANE, WS; REINBERG, D			DR1, A TATA-BINDING PROTEIN ASSOCIATED PHOSPHOPROTEIN AND INHIBITOR OF CLASS-II GENE-TRANSCRIPTION	CELL			English	Article								We have discovered a protein termed Dr1 that interacts with the TATA-binding protein, TBP. The association of Dr1 with TBP results in repression of both basal and activated levels of transcription. The interaction of Dr1 with TBP precludes the formation of a transcription-competent complex by inhibiting the association of TFIIA and/or TFIIB with TBP. Dr1 activity is associated with a 19 kd protein. A cDNA clone encoding Dr1 was isolated. Dr1 is phosphorylated in vivo and phosphorylation of Dr1 affected its interaction with TBP. Our results suggest a regulatory role for Dr1 in repression of transcription mediated via phosphorylation.			INOSTROZA, JA (corresponding author), UNIV MED & DENT NEW JERSEY, ROBERT WOOD JOHNSON MED SCH, DEPT BIOCHEM, PISCATAWAY, NJ 08854 USA.			Reinberg, Danny/0000-0003-4288-2016	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM037120, R01GM037120] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM37120] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BIGGIN MD, 1989, CELL, V58, P433, DOI 10.1016/0092-8674(89)90424-8; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; CORTES P, 1992, MOL CELL BIOL, V12, P413, DOI 10.1128/MCB.12.1.413; CROSTON GE, 1991, SCIENCE, V251, P643, DOI 10.1126/science.1899487; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; FLORES O, 1992, J BIOL CHEM, V267, P2786; GILL G, 1992, IN PRESS CURR OPIN G; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; HAHN S, 1988, MOL CELL BIOL, V8, P655, DOI 10.1128/MCB.8.2.655; HAN KH, 1989, CELL, V56, P573, DOI 10.1016/0092-8674(89)90580-1; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; HORIKOSHI N, 1991, P NATL ACAD SCI USA, V88, P5124, DOI 10.1073/pnas.88.12.5124; INOSTROZA J, 1991, J BIOL CHEM, V266, P9304; JAYNES JB, 1988, NATURE, V336, P744, DOI 10.1038/336744a0; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANE WS, 1991, J PROTEIN CHEM, V10, P151, DOI 10.1007/BF01024778; LAYBOURN PJ, 1991, SCIENCE, V254, P238, DOI 10.1126/science.1718039; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; LICHT JD, 1990, NATURE, V346, P76, DOI 10.1038/346076a0; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; MACDONALD PM, 1986, CELL, V47, P721, DOI 10.1016/0092-8674(86)90515-5; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NEVINS JR, 1989, ADV VIRUS RES, V37, P35; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; POOLE SJ, 1985, CELL, V40, P37, DOI 10.1016/0092-8674(85)90306-X; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; REINBERG D, 1987, J BIOL CHEM, V262, P3322; ROSENBERG UB, 1986, NATURE, V319, P336, DOI 10.1038/319336a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; TIMMERS HTM, 1991, GENE DEV, V5, P1946, DOI 10.1101/gad.5.11.1946; ZAWEL L, 1992, IN PRESS PROG NUCL A	45	338	341	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 7	1992	70	3					477	489						13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JH124	1339312				2022-12-01	WOS:A1992JH12400013
J	KHAN, AA; STEINER, JP; KLEIN, MG; SCHNEIDER, MF; SNYDER, SH				KHAN, AA; STEINER, JP; KLEIN, MG; SCHNEIDER, MF; SNYDER, SH			IP3 RECEPTOR - LOCALIZATION TO PLASMA-MEMBRANE OF T-CELLS AND COCAPPING WITH THE T-CELL RECEPTOR	SCIENCE			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; CEREBELLAR PURKINJE-CELLS; LYMPHOCYTES-T; RAT-LIVER; ENDOPLASMIC-RETICULUM; INSP3 RECEPTOR; ACINAR-CELLS; K+ CHANNELS; PATCH CLAMP; ACTIVATION	Immune responses in lymphocytes require cellular accumulation of large amounts of calcium (Ca2+) from extracellular sources. In the T cell tumor line Jurkat, receptors for the Ca2+-releasing messenger inositol 1,4,5-trisphosphate (IP3) were localized to the plasma membrane (PM). Capping of the T cell receptor-CD3 complex, which is associated with signal transduction, was accompanied by capping of IP3 receptors. The IP3 receptor on T cells appears to be responsible for the entry of Ca2+ that initiates proliferative responses.	JOHNS HOPKINS UNIV, SCH MED, DEPT NEUROSCI, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT PSYCHIAT, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT PHARMACOL & MOLEC SCI, BALTIMORE, MD 21205 USA; UNIV MARYLAND, SCH MED, DEPT BIOL CHEM, BALTIMORE, MD 21201 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; University System of Maryland; University of Maryland Baltimore					NHLBI NIH HHS [P01-HL27867] Funding Source: Medline; NIDA NIH HHS [DA-00074] Funding Source: Medline; NIMH NIH HHS [MH-18501] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL027867] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH018501, R01MH018501] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AGARD DA, 1984, ANNU REV BIOPHYS BIO, V13, P191; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BIRD GS, 1991, NATURE, V352, P162, DOI 10.1038/352162a0; BOURGUIGNON LYW, 1984, INT REV CYTOL, V87, P195, DOI 10.1016/S0074-7696(08)62443-2; BOURGUIGNON LYW, 1988, SIGNAL TRANSDUCTION, P111; Castleman KR., 1979, DIGITAL IMAGE PROCES; CUNNINGHAM A, UNPUB; DANOFF SK, 1991, P NATL ACAD SCI USA, V88, P2951, DOI 10.1073/pnas.88.7.2951; DARGEMONT C, 1988, BIOCHEM J, V256, P117, DOI 10.1042/bj2560117; DECOURSEY TE, 1984, NATURE, V307, P465, DOI 10.1038/307465a0; FERRIS CD, 1992, ANNU REV PHYSIOL, V54, P469, DOI 10.1146/annurev.physiol.54.1.469; GARDNER P, 1989, J BIOL CHEM, V264, P1068; GARDNER P, 1990, ANNU REV IMMUNOL, V8, P231, DOI 10.1146/annurev.iy.08.040190.001311; GOLDSMITH MA, 1988, SCIENCE, V240, P1029, DOI 10.1126/science.3259335; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUILLEMETTE G, 1988, J BIOL CHEM, V263, P4541; HILL TD, 1988, SCIENCE, V242, P1176, DOI 10.1126/science.2847317; HIRAOKA Y, 1990, BIOPHYS J, V57, P325, DOI 10.1016/S0006-3495(90)82534-0; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; IRVINE RF, 1986, BIOCHEM J, V240, P917, DOI 10.1042/bj2400917; KHAN AA, 1992, P NATL ACAD SCI USA, V89, P2849, DOI 10.1073/pnas.89.7.2849; KHAN AT, UNPUB; KIMBALL PM, 1988, CELL IMMUNOL, V113, P107, DOI 10.1016/0008-8749(88)90010-X; KLEIN DP, 1990, J IMMUNOL, V145, P2967; KUNO M, 1986, NATURE, V323, P269, DOI 10.1038/323269a0; KUNO M, 1987, NATURE, V326, P301, DOI 10.1038/326301a0; LUCKHOFF A, 1992, NATURE, V355, P356, DOI 10.1038/355356a0; MASON MJ, 1991, J BIOL CHEM, V266, P10872; MASON MJ, 1991, J BIOL CHEM, V266, P20856; MATTESON DR, 1984, NATURE, V307, P468, DOI 10.1038/307468a0; MONCK JR, 1992, J CELL BIOL, V116, P745, DOI 10.1083/jcb.116.3.745; MORRIS AP, 1987, NATURE, V330, P653, DOI 10.1038/330653a0; NAKAGAWA T, 1991, P NATL ACAD SCI USA, V88, P6244, DOI 10.1073/pnas.88.14.6244; OTSU H, 1990, CELL STRUCT FUNCT, V15, P163, DOI 10.1247/csf.15.163; PENG YW, 1991, NEURON, V6, P525, DOI 10.1016/0896-6273(91)90055-5; ROSS CA, 1989, NATURE, V339, P468, DOI 10.1038/339468a0; ROSS CA, 1992, P NATL ACAD SCI USA, V89, P4265, DOI 10.1073/pnas.89.10.4265; ROSSIER MF, 1991, BIOCHEM J, V274, P643, DOI 10.1042/bj2740643; SATOH T, 1990, J CELL BIOL, V111, P615, DOI 10.1083/jcb.111.2.615; SHARP AH, 1992, J BIOL CHEM, V267, P7444; SHARP AH, 1991, BIOPHYS J, V59, P525; STREB H, 1983, NATURE, V306, P67, DOI 10.1038/306067a0; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; TAYLOR RB, 1971, NATURE-NEW BIOL, V233, P225, DOI 10.1038/newbio233225a0; TSIEN RY, 1990, CELL CALCIUM, V11, P93, DOI 10.1016/0143-4160(90)90063-Z; WARREN G, 1987, NATURE, V327, P17, DOI 10.1038/327017a0; WEISS A, 1986, ANNU REV IMMUNOL, V4, P593, DOI 10.1146/annurev.iy.04.040186.003113; WEISS A, 1984, P NATL ACAD SCI-BIOL, V81, P4169, DOI 10.1073/pnas.81.13.4169	49	204	205	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 7	1992	257	5071					815	818		10.1126/science.1323146	http://dx.doi.org/10.1126/science.1323146			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JG851	1323146				2022-12-01	WOS:A1992JG85100041
J	KOMURO, H; RAKIC, P				KOMURO, H; RAKIC, P			SELECTIVE ROLE OF N-TYPE CALCIUM CHANNELS IN NEURONAL MIGRATION	SCIENCE			English	Article							CEREBELLAR GRANULE CELLS; VERTEBRATE CELLS; EXPLANT CULTURES; CA2+ CHANNELS; RECEPTOR; DIFFERENTIATION; ACTIVATION; CURRENTS; DEPOLARIZATION; ASTROTACTIN	Analysis of neuronal migration in mouse cerebellar slice preparations by a laser scanning confocal microscope revealed that postmitotic granule cells initiate their migration only after the expression of N-type calcium channels on their plasmalemmal surface. Furthermore, selective blockade of these channels by addition of omega-conotoxin to the incubation medium curtailed cell movement. In contrast, inhibitors of L- and T-type calcium channels, as well as those of sodium and potassium channels, had no effect on the rate of granule cell migration. These results suggest that N-type calcium channels, which have been predominantly associated with neurotransmitter release in adult brain, also play a transient but specific developmental role in directed migration of immature neurons before the establishment of their synaptic circuits.			KOMURO, H (corresponding author), YALE UNIV, SCH MED, NEUROBIOL SECT, NEW HAVEN, CT 06510 USA.							ANTONICEK H, 1988, J NEUROSCI, V8, P2961; ARTALEJO CR, 1992, NEURON, V8, P85, DOI 10.1016/0896-6273(92)90110-Y; CAVINESS VS, 1978, ANNU REV NEUROSCI, V1, P297, DOI 10.1146/annurev.ne.01.030178.001501; CHUONG CM, 1987, J CELL BIOL, V104, P331, DOI 10.1083/jcb.104.2.331; CHUONG CM, 1990, EXPERIENTIA, V46, P892, DOI 10.1007/BF01939381; CONNOR JA, 1987, J NEUROSCI, V7, P1384; COURTNEY MJ, 1990, J NEUROSCI, V10, P3873, DOI 10.1523/JNEUROSCI.10-12-03873.1990; CULLCANDY SG, 1989, J PHYSIOL-LONDON, V414, P179, DOI 10.1113/jphysiol.1989.sp017683; DOHERTY P, 1991, CELL, V67, P21, DOI 10.1016/0092-8674(91)90569-K; EDMONDSON JC, 1988, J CELL BIOL, V106, P505, DOI 10.1083/jcb.106.2.505; FISHELL G, 1991, DEVELOPMENT, V113, P755; FORSCHER P, 1989, TRENDS NEUROSCI, V12, P468, DOI 10.1016/0166-2236(89)90098-2; FUJITA S, 1967, J CELL BIOL, V32, P277, DOI 10.1083/jcb.32.2.277; HESS P, 1990, ANNU REV NEUROSCI, V13, P337, DOI 10.1146/annurev.ne.13.030190.002005; HOCKBERGER PE, 1987, J NEUROSCI, V7, P1370; HOLLIDAY J, 1990, DEV BIOL, V141, P13, DOI 10.1016/0012-1606(90)90098-4; HORNE WA, 1991, J BIOL CHEM, V266, P13719; JONES OT, 1989, SCIENCE, V244, P1189, DOI 10.1126/science.2543080; KATER SB, 1991, J NEUROSCI, V11, P891; LOTURCO JJ, 1991, J NEUROSCI, V11, P792; MARCHETTI C, 1991, NEUROSCIENCE, V43, P121, DOI 10.1016/0306-4522(91)90422-K; MARTINMOUTOT N, 1990, NEUROSCI LETT, V115, P300, DOI 10.1016/0304-3940(90)90472-L; MILLER RJ, 1987, SCIENCE, V235, P46, DOI 10.1126/science.2432656; MORAN D, 1991, AM J ANAT, V192, P14, DOI 10.1002/aja.1001920103; NEWGREEN DF, 1985, CELL TISSUE RES, V239, P329; NOWYCKY MC, 1985, NATURE, V316, P440, DOI 10.1038/316440a0; OLIVERA BM, 1991, J BIOL CHEM, V266, P22067; RAKIC P, 1971, J COMP NEUROL, V141, P283, DOI 10.1002/cne.901410303; RAKIC P, 1990, EXPERIENTIA, V46, P882, DOI 10.1007/BF01939380; RAKIC P, 1971, BRAIN RES, V33, P471, DOI 10.1016/0006-8993(71)90119-3; Rakic P, 1985, CELL CONTACT ADHESIO, P67; RAKIC P, 1988, PROG BRAIN RES, V73, P15; ROBSON SJ, 1989, NEUROSCI LETT, V104, P110, DOI 10.1016/0304-3940(89)90338-8; SHER E, 1991, NEUROSCIENCE, V42, P301, DOI 10.1016/0306-4522(91)90376-Y; SLESINGER PA, 1991, J PHYSIOL-LONDON, V435, P101, DOI 10.1113/jphysiol.1991.sp018500; TSIEN RW, 1988, TRENDS NEUROSCI, V11, P431, DOI 10.1016/0166-2236(88)90194-4; VIGERS AJ, 1991, DEV BRAIN RES, V60, P197, DOI 10.1016/0165-3806(91)90048-N; WAGNER JA, 1988, J NEUROSCI, V8, P3354	38	320	326	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 7	1992	257	5071					806	809		10.1126/science.1323145	http://dx.doi.org/10.1126/science.1323145			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JG851	1323145				2022-12-01	WOS:A1992JG85100038
J	LENSCHOW, DJ; ZENG, YJ; THISTLETHWAITE, JR; MONTAG, A; BRADY, W; GIBSON, MG; LINSLEY, PS; BLUESTONE, JA				LENSCHOW, DJ; ZENG, YJ; THISTLETHWAITE, JR; MONTAG, A; BRADY, W; GIBSON, MG; LINSLEY, PS; BLUESTONE, JA			LONG-TERM SURVIVAL OF XENOGENEIC PANCREATIC-ISLET GRAFTS INDUCED BY CTLA4IG	SCIENCE			English	Article							ANTIGEN-PRESENTING CELLS; T-CELL; REJECTION; CTLA-4; TRANSPLANTATION; ACTIVATION; RECEPTOR; MOUSE	Antigen-specific T cell activation depends on T cell receptor-ligand interaction and co-stimulatory signals generated when accessory molecules bind to their ligands, such as CD28 to the B7 (also called BB1) molecule. A soluble fusion protein of human CTLA-4 (a protein homologous to CD28) and the immunoglobulin (Ig) G1 Fc region (CTLA4Ig) binds to human and murine B7 with high avidity and blocks T cell activation in vitro. CTLA4Ig therapy blocked human pancreatic islet rejection in mice by directly affecting T cell recognition of B7+ antigen-presenting cells. In addition, CTLA4Ig induced long-term, donor-specific tolerance, which may have applications to human organic transplantation.	UNIV CHICAGO,BEN MAY INST,CHICAGO,IL 60637; UNIV CHICAGO,COMM IMMUNOL,CHICAGO,IL 60637; UNIV CHICAGO,DEPT SURG,CHICAGO,IL 60637; UNIV CHICAGO,DEPT PATHOL,CHICAGO,IL 60637; BRISTOL MYERS SQUIBB PHARMACEUT RES INST,SEATTLE,WA 98121	University of Chicago; University of Chicago; University of Chicago; University of Chicago; Bristol-Myers Squibb					NIAID NIH HHS [AI29531] Funding Source: Medline; NIDDK NIH HHS [R29 DK40092] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI029531] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK040092] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRUNET JF, 1987, NATURE, V328, P267, DOI 10.1038/328267a0; DAMLE NK, 1992, J IMMUNOL, V148, P1985; FAUSTMAN D, 1991, SCIENCE, V252, P1700, DOI 10.1126/science.1710828; GILL RG, 1989, J IMMUNOL, V143, P2176; HAO L, 1987, J IMMUNOL, V139, P4022; HARDING FA, 1992, NATURE, V356, P607, DOI 10.1038/356607a0; HARPER K, 1991, J IMMUNOL, V147, P1037; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; JENKINS MK, 1991, J IMMUNOL, V147, P2461; JUNE CH, 1990, IMMUNOL TODAY, V11, P211, DOI 10.1016/0167-5699(90)90085-N; LAFFERTY KJ, 1983, ANNU REV IMMUNOL, V1, P143, DOI 10.1146/annurev.iy.01.040183.001043; LENSCHOW DJ, UNPUB; LINSLEY PS, 1991, J EXP MED, V174, P561, DOI 10.1084/jem.174.3.561; LINSLEY PS, 1992, SCIENCE, V257, P792, DOI 10.1126/science.1496399; LUCAS PJ, 1990, J IMMUNOL, V144, P4548; MOSES RD, 1992, TRANSPLANTATION, V53, P203, DOI 10.1097/00007890-199201000-00039; MOSES RD, 1990, J EXP MED, V172, P567, DOI 10.1084/jem.172.2.567; REISER H, 1992, P NATL ACAD SCI USA, V89, P271, DOI 10.1073/pnas.89.1.271; RICORDI C, 1988, DIABETES, V37, P413, DOI 10.2337/diabetes.37.4.413; RICORDI C, 1991, TRANSPLANTATION, V52, P519, DOI 10.1097/00007890-199109000-00026; TAN PH, UNPUB; TZAKIS AG, 1990, LANCET, V336, P402, DOI 10.1016/0140-6736(90)91946-8; YOKOCHI T, 1982, J IMMUNOL, V128, P823; ZENG YJ, 1992, TRANSPLANTATION, V53, P277, DOI 10.1097/00007890-199202010-00005	24	1157	1269	0	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 7	1992	257	5071					789	792		10.1126/science.1323143	http://dx.doi.org/10.1126/science.1323143			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JG851	1323143				2022-12-01	WOS:A1992JG85100032
J	LINSLEY, PS; WALLACE, PM; JOHNSON, J; GIBSON, MG; GREENE, JL; LEDBETTER, JA; SINGH, C; TEPPER, MA				LINSLEY, PS; WALLACE, PM; JOHNSON, J; GIBSON, MG; GREENE, JL; LEDBETTER, JA; SINGH, C; TEPPER, MA			IMMUNOSUPPRESSION INVIVO BY A SOLUBLE FORM OF THE CTLA-4 T-CELL ACTIVATION MOLECULE	SCIENCE			English	Article							COSTIMULATORY SIGNAL; ANTIGEN-B7; INTERLEUKIN-2; EXPRESSION; ANTIBODIES; RECEPTOR; ADHESION	In vitro, when the B7 molecule on the surface of antigen-presenting cells binds to the T cell surface molecules CD28 and CTLA-4, a costimulatory signal for T cell activation is generated. CTLA4Ig is a soluble form of the extracellular domain of CTLA-4 and binds B7 with high avidity. CTLA4Ig treatment in vivo suppressed T cell-dependent antibody responses to sheep erythrocytes or keyhole limpet hemocyanin. Large doses of CTLA4Ig suppressed responses to a second immunization. Thus, costimulation by B7 is important for humoral immune responses in vivo, and interference with costimulation may be useful for treatment of antibody-mediated autoimmune disease.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST, WALLINGFORD, CT 06492 USA	Bristol-Myers Squibb	LINSLEY, PS (corresponding author), BRISTOL MYERS SQUIBB PHARMACEUT RES INST, SEATTLE, WA 98121 USA.							BIERER BE, 1991, ADV CANCER RES, V56, P49; BRUNET JF, 1987, NATURE, V328, P267, DOI 10.1038/328267a0; BURSTEIN HJ, 1992, J IMMUNOL, V148, P3687; DAMLE NK, 1991, EUR J IMMUNOL, V21, P1277, DOI 10.1002/eji.1830210527; FREEMAN GJ, 1991, J EXP MED, V174, P625, DOI 10.1084/jem.174.3.625; GIMMI CD, 1991, P NATL ACAD SCI USA, V88, P6575, DOI 10.1073/pnas.88.15.6575; GUCKEL B, 1991, J EXP MED, V174, P957, DOI 10.1084/jem.174.5.957; HARDING FA, 1992, NATURE, V356, P607, DOI 10.1038/356607a0; ISOBE M, 1992, SCIENCE, V255, P1125, DOI 10.1126/science.1347662; JENKINS MK, 1991, J IMMUNOL, V147, P2461; Jerne N.K., 1963, CELL BOUND ANTIBODIE, P109; KOULOVA L, 1991, J EXP MED, V173, P759, DOI 10.1084/jem.173.3.759; LAFFERTY KJ, 1983, ANNU REV IMMUNOL, V1, P143, DOI 10.1146/annurev.iy.01.040183.001043; LENSCHOW DJ, 1992, SCIENCE, V257, P789, DOI 10.1126/science.1323143; LENSCHOW DJ, UNPUB; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LINSLEY PS, 1991, J EXP MED, V173, P721, DOI 10.1084/jem.173.3.721; LINSLEY PS, 1990, P NATL ACAD SCI USA, V87, P5031, DOI 10.1073/pnas.87.13.5031; LINSLEY PS, 1991, J EXP MED, V174, P561, DOI 10.1084/jem.174.3.561; LIU Y, 1992, J EXP MED, V175, P437, DOI 10.1084/jem.175.2.437; LIU Y, IN PRESS CURR OPIN I; LIU YJ, IN PRESS EUR J IMMUN; MUELLER DL, 1989, ANNU REV IMMUNOL, V7, P445, DOI 10.1146/annurev.iy.07.040189.002305; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SUBRAMANI S, 1981, MOL CELL BIOL, V1, P854, DOI 10.1128/MCB.1.9.854; TAN PH, UNPUB; VANSEVENTER GA, 1991, CURR OPIN IMMUNOL, V3, P294, DOI 10.1016/0952-7915(91)90027-X; WALDMANN H, 1989, ANNU REV IMMUNOL, V7, P407, DOI 10.1146/annurev.iy.07.040189.002203	28	765	848	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 7	1992	257	5071					792	795		10.1126/science.1496399	http://dx.doi.org/10.1126/science.1496399			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JG851	1496399				2022-12-01	WOS:A1992JG85100033
J	LOWENSTEIN, EJ; DALY, RJ; BATZER, AG; LI, W; MARGOLIS, B; LAMMERS, R; ULLRICH, A; SKOLNIK, EY; BARSAGI, D; SCHLESSINGER, J				LOWENSTEIN, EJ; DALY, RJ; BATZER, AG; LI, W; MARGOLIS, B; LAMMERS, R; ULLRICH, A; SKOLNIK, EY; BARSAGI, D; SCHLESSINGER, J			THE SH2 AND SH3 DOMAIN CONTAINING PROTEIN GRB2 LINKS RECEPTOR TYROSINE KINASES TO RAS SIGNALING	CELL			English	Article							PHOSPHOLIPASE-C-GAMMA; GROWTH-FACTOR RECEPTOR; EGF RECEPTOR; BINDING-SITE; PHOSPHATIDYLINOSITOL-3 KINASE; SUBSTRATE-SPECIFICITY; CYTOPLASMIC PROTEIN; SYNTHETIC PEPTIDES; ESCHERICHIA-COLI; PDGF RECEPTOR	A cDNA clone encoding a novel, widely expressed protein (called growth factor receptor-bound protein 2 or GRB2) containing one src homology 2 (SH2) domain and two SH3 domains was isolated. Immunoblotting experiments indicate that GRB2 associates with tyrosine-phosphorylated epidermal growth factor receptors (EGFRs) and platelet-derived growth factor receptors (PDGFRs) via its SH2 domain. Interestingly, GRB2 exhibits striking structural and functional homology to the C. elegans protein sem-5. It has been shown that sem-5 and two other genes called let-23 (EGFR like) and let-60 (ras like) lie along the same signal transduction pathway controlling C. elegans vulval induction. To examine whether GRB2 is also a component of ras signaling in mammalian cells, microinjection studies were performed. While injection of GRB2 or H-ras proteins alone into quiescent rat fibroblasts did not have mitogenic effect, microinjection of GRB2 together with H-ras protein stimulated DNA synthesis. These results suggest that GRB2/sem-5 plays a crucial role in a highly conserved mechanism for growth factor control of ras signaling.	MAX PLANCK INST BIOCHEM,W-8033 MARTINSRIED,GERMANY; COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724	Max Planck Society; Cold Spring Harbor Laboratory	LOWENSTEIN, EJ (corresponding author), NYU MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016, USA.		Daly, Roger J/C-8179-2009	Daly, Roger/0000-0002-5739-8027; Bar-Sagi, Dafna/0000-0003-2597-8948	NCI NIH HHS [CA 46370, CA 55360] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055360, P01CA046370, R37CA055360] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BELLOT F, 1990, J CELL BIOL, V110, P491, DOI 10.1083/jcb.110.2.491; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGESS WH, 1990, MOL CELL BIOL, V10, P4770, DOI 10.1128/MCB.10.9.4770; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FERAMISCO JR, 1984, CELL, V38, P109, DOI 10.1016/0092-8674(84)90531-2; FICKETT JW, 1982, NUCLEIC ACIDS RES, V10, P5303, DOI 10.1093/nar/10.17.5303; GROSS M, 1985, MOL CELL BIOL, V5, P1015, DOI 10.1128/MCB.5.5.1015; HELDIN CH, 1991, TRENDS BIOCHEM SCI, V16, P450, DOI 10.1016/0968-0004(91)90175-U; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HORVITZ HR, 1991, NATURE, V351, P535, DOI 10.1038/351535a0; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; KAZLAUSKAS A, 1990, EMBO J, V9, P3279, DOI 10.1002/j.1460-2075.1990.tb07527.x; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KISHIMOTO A, 1985, J BIOL CHEM, V260, P2492; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUENZEL EA, 1987, J BIOL CHEM, V262, P9136; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; LI W, 1991, J BIOL CHEM, V266, P6808; MARGOLIS B, 1992, CELL GROWTH DIFFER, V3, P73; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MARGOLIS B, 1990, MOL CELL BIOL, V10, P435, DOI 10.1128/MCB.10.2.435; MARIN O, 1986, EUR J BIOCHEM, V160, P239, DOI 10.1111/j.1432-1033.1986.tb09962.x; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MOHAMMADI M, 1992, IN PRESS NATURE; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; ROTIN D, 1992, J BIOL CHEM, V267, P9676; RUOSLAHTI E, 1986, CELL, V44, P517, DOI 10.1016/0092-8674(86)90259-X; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SCHLESSINGER J, 1988, TRENDS BIOCHEM SCI, V13, P443, DOI 10.1016/0968-0004(88)90219-8; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; SUH PG, 1988, P NATL ACAD SCI USA, V85, P5419, DOI 10.1073/pnas.85.15.5419; TRAHEY MG, 1988, SCIENCE, V242, P1696; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; WANG K, 1982, METHOD ENZYMOL, V85, P514; WOODGETT JR, 1986, EUR J BIOCHEM, V161, P177, DOI 10.1111/j.1432-1033.1986.tb10139.x	56	1512	1566	2	103	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 7	1992	70	3					431	442		10.1016/0092-8674(92)90167-B	http://dx.doi.org/10.1016/0092-8674(92)90167-B			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JH124	1322798	Bronze			2022-12-01	WOS:A1992JH12400008
J	MACASKIE, LE; EMPSON, RM; CHEETHAM, AK; GREY, CP; SKARNULIS, AJ				MACASKIE, LE; EMPSON, RM; CHEETHAM, AK; GREY, CP; SKARNULIS, AJ			URANIUM BIOACCUMULATION BY A CITROBACTER SP AS A RESULT OF ENZYMATICALLY MEDIATED GROWTH OF POLYCRYSTALLINE HUO2PO4	SCIENCE			English	Article							URANYL PHOSPHATE TETRAHYDRATE; P-31 NMR; ACCUMULATION; WASTES	A Citrobacter sp. accumulates heavy deposits of metal phosphate, derived from an enzymatically liberated phosphate ligand. The cells are not subject to saturation constraints and can accumulate several times their own weight of precipitated metal. This high capacity is attributable to biomineralization; uranyl phosphate accumulates as polycrystalline HUO2PO4 at the cell surface. The precipitated metal is indistinguishable from crystalline HUO2PO4.4H2O grown by chemical methods.	ST MARYS HOSP,SCH MED,LONDON W2 1NY,ENGLAND; UNIV OXFORD,CHEM CRYSTALLOG LAB,OXFORD OX1 3PD,ENGLAND	Imperial College London; University of Oxford	MACASKIE, LE (corresponding author), UNIV BIRMINGHAM,SCH BIOL SCI,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND.		Grey, Clare P/Q-8860-2017	Grey, Clare P/0000-0001-5572-192X; Empson, Ruth/0000-0002-0415-6083				AICKIN RM, 1979, MICROBIOS LETT, V9, P7; CHEETHAM AK, 1986, J CHEM SOC CHEM COMM, P195, DOI 10.1039/c39860000195; CLIFF G, 1975, J MICROSC-OXFORD, V103, P203, DOI 10.1111/j.1365-2818.1975.tb03895.x; DUNCAN TM, 1984, CHEM PHYS, V87, P339, DOI 10.1016/0301-0104(84)85115-0; DUNN HW, 1956, ORNL PUBL, V2092; GREAVES C, 1973, INORG CHEM, V12, P3003, DOI 10.1021/ic50130a054; GRIMMER AR, 1983, CHEM PHYS LETT, V99, P487, DOI 10.1016/0009-2614(83)80180-8; HERZFELD J, 1980, J CHEM PHYS, V73, P6021, DOI 10.1063/1.440136; HOWE AT, 1980, J SOLID STATE CHEM, V34, P149, DOI 10.1016/0022-4596(80)90217-0; Macaskie L E, 1989, Adv Biotechnol Processes, V12, P159; MACASKIE LE, 1988, FEMS MICROBIOL LETT, V55, P157, DOI 10.1111/j.1574-6968.1988.tb13926.x; MACASKIE LE, 1987, J GEN MICROBIOL, V133, P539; MACASKIE LE, 1991, CRIT REV BIOTECHNOL, V11, P41, DOI 10.3109/07388559109069183; MACASKIE LE, 1990, J CHEM TECHNOL BIOT, V49, P357; MOROSIN B, 1978, ACTA CRYSTALLOGR B, V34, P3732, DOI 10.1107/S0567740878011991; PLUMMER EJ, 1990, B ENVIRON CONTAM TOX, V44, P173, DOI 10.1007/BF01700133; ROTHWELL WP, 1980, J AM CHEM SOC, V102, P2637, DOI 10.1021/ja00528a020; STRACHAN L, 1991, 201ST P AM CHEM SOC, V31, P128; WEIGEL F, 1976, J LESS-COMMON MET, V44, P99, DOI 10.1016/0022-5088(76)90121-1	19	230	242	4	74	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 7	1992	257	5071					782	784		10.1126/science.1496397	http://dx.doi.org/10.1126/science.1496397			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JG851	1496397				2022-12-01	WOS:A1992JG85100029
J	MASLOV, DA; SIMPSON, L				MASLOV, DA; SIMPSON, L			THE POLARITY OF EDITING WITHIN A MULTIPLE GRNA-MEDIATED DOMAIN IS DUE TO FORMATION OF ANCHORS FOR UPSTREAM GRNAS BY DOWNSTREAM EDITING	CELL			English	Article							KINETOPLAST DNA MINICIRCLES; LEISHMANIA-TARENTOLAE; GUIDE RNAS; CRITHIDIA-FASCICULATA; MESSENGER-RNAS; CYTOCHROME-OXIDASE; SEQUENCE CLASSES; SUBUNIT-III; MITOCHONDRIA; REPLICATION	Seventeen kinetoplast minicircle-encoded and nine maxicircle-encoded gRNA genes have been identified. Six overlapping minicircle-encoded gRNAs mediate editing for the 5'-pan-edited MURF4 gene and two for the 5-edited COIII gene. The pan-edited RPS12 mRNA is edited by seven minicircle-encoded gRNAs and one maxicircle-encoded gRNA. The 3'-most gRNA in each domain forms an anchor with unedited mRNA, whereas upstream gRNAs form anchors only with edited mRNA, thereby explaining the observed 3' to 5' polarity of editing within an editing domain. We suggest that a role of G-U base pairs is to allow breathing of the edited mRNA-gRNA hybrid and formation of the upstream anchor hybrid.	UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,HOWARD HUGHES MED INST,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; Howard Hughes Medical Institute; University of California System; University of California Los Angeles	MASLOV, DA (corresponding author), UNIV CALIF LOS ANGELES,DEPT BIOL,LOS ANGELES,CA 90024, USA.				NIAID NIH HHS [AI09102] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI009102, R37AI009102] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAHAM JM, 1988, CELL, V55, P267, DOI 10.1016/0092-8674(88)90049-9; BENNE R, 1989, BIOCHIM BIOPHYS ACTA, V1007, P131, DOI 10.1016/0167-4781(89)90031-6; BHAT GJ, 1990, CELL, V61, P885, DOI 10.1016/0092-8674(90)90199-O; BHAT GJ, 1991, MOL BIOCHEM PARASIT, V48, P139, DOI 10.1016/0166-6851(91)90110-R; BIRKENMEYER L, 1986, J BIOL CHEM, V261, P2362; BLUM B, 1991, CELL, V65, P543, DOI 10.1016/0092-8674(91)90087-F; BLUM B, 1990, CELL, V60, P189, DOI 10.1016/0092-8674(90)90735-W; BLUM B, 1990, CELL, V62, P391, DOI 10.1016/0092-8674(90)90375-O; BRALY P, 1974, J PROTOZOOL, V21, P782, DOI 10.1111/j.1550-7408.1974.tb03752.x; DECKER CJ, 1990, CELL, V61, P1001, DOI 10.1016/0092-8674(90)90065-M; GOMEZEICHELMANN MC, 1988, MOL BIOCHEM PARASIT, V27, P143, DOI 10.1016/0166-6851(88)90034-5; HOLBROOK SR, 1991, NATURE, V353, P579, DOI 10.1038/353579a0; KIDANE GZ, 1984, GENE, V27, P265, DOI 10.1016/0378-1119(84)90071-4; KOSLOWSKY DJ, 1991, CELL, V67, P537, DOI 10.1016/0092-8674(91)90528-7; MASLOV DA, 1992, MOL CELL BIOL, V12, P56, DOI 10.1128/MCB.12.1.56; MUHICH ML, 1985, NUCLEIC ACIDS RES, V13, P3241, DOI 10.1093/nar/13.9.3241; MUHICH ML, 1986, NUCLEIC ACIDS RES, V14, P5531, DOI 10.1093/nar/14.13.5531; PARKER RC, 1977, P NATL ACAD SCI USA, V74, P851, DOI 10.1073/pnas.74.3.851; Parrot L., 1939, Arch Inst Pasteur Alger, V17, P231; POLLARD VW, 1990, CELL, V63, P783, DOI 10.1016/0092-8674(90)90144-4; RAY DS, 1989, MOL CELL BIOL, V9, P1365, DOI 10.1128/MCB.9.3.1365; RAY DS, 1987, PLASMID, V17, P177, DOI 10.1016/0147-619X(87)90026-6; RYAN KA, 1988, ANNU REV MICROBIOL, V42, P339, DOI 10.1146/annurev.mi.42.100188.002011; Sambrook J., 1989, MOL CLONING LAB MANU; SHAW JM, 1988, CELL, V53, P401, DOI 10.1016/0092-8674(88)90160-2; SIMPSON L, 1970, J PROTOZOOL, V17, P511, DOI 10.1111/j.1550-7408.1970.tb04719.x; SIMPSON L, 1989, CELL, V57, P355, DOI 10.1016/0092-8674(89)90911-2; SIMPSON L, 1990, SCIENCE, V250, P512, DOI 10.1126/science.1700474; SIMPSON L, 1978, CELL, V14, P169, DOI 10.1016/0092-8674(78)90311-2; SIMPSON L, 1987, ANNU REV MICROBIOL, V41, P363, DOI 10.1146/annurev.mi.41.100187.002051; SIMPSON L, 1974, BIOCHIM BIOPHYS ACTA, V349, P161, DOI 10.1016/0005-2787(74)90077-X; SIMPSON L, 1979, P NATL ACAD SCI USA, V76, P1585, DOI 10.1073/pnas.76.4.1585; SOUZA AE, 1992, MOL CELL BIOL, V12, P2100, DOI 10.1128/MCB.12.5.2100; STUART K, 1991, ANNU REV MICROBIOL, V45, P327, DOI 10.1146/annurev.mi.45.100191.001551; STURM NR, 1992, CELL, V70, P469, DOI 10.1016/0092-8674(92)90171-8; STURM NR, 1990, CELL, V61, P879, DOI 10.1016/0092-8674(90)90198-N; STURM NR, 1990, CELL, V61, P871, DOI 10.1016/0092-8674(90)90197-M; STURM NR, 1991, NUCLEIC ACIDS RES, V19, P6277, DOI 10.1093/nar/19.22.6277; TRAGER W, 1957, J PROTOZOOL, V4, P269, DOI 10.1111/j.1550-7408.1957.tb02519.x; VANDERSPEK H, 1990, EMBO J, V9, P257, DOI 10.1002/j.1460-2075.1990.tb08103.x	40	128	129	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 7	1992	70	3					459	467		10.1016/0092-8674(92)90170-H	http://dx.doi.org/10.1016/0092-8674(92)90170-H			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JH124	1379519	Bronze			2022-12-01	WOS:A1992JH12400011
J	RIDLEY, AJ; HALL, A				RIDLEY, AJ; HALL, A			THE SMALL GTP-BINDING PROTEIN RHO REGULATES THE ASSEMBLY OF FOCAL ADHESIONS AND ACTIN STRESS FIBERS IN RESPONSE TO GROWTH-FACTORS	CELL			English	Article							LYSOPHOSPHATIDIC ACID; CLOSTRIDIUM-BOTULINUM; ACTIVATING PROTEIN; MOLECULAR-CLONING; PHOSPHATIDIC-ACID; ESCHERICHIA-COLI; GENE-PRODUCT; R-RAS; CELLS; IDENTIFICATION	Actin stress fibers are one of the major cytoskeletal structures in fibroblasts and are linked to the plasma membrane at focal adhesions. rho, a ras-related GTP-binding protein, rapidly stimulated stress fiber and focal adhesion formation when microinjected into serum-starved Swiss 3T3 cells. Readdition of serum produced a similar response, detectable within 2 min. This activity was due to a lysophospholipid, most likely lysophosphatidic acid, bound to serum albumin. Other growth factors including PDGF induced actin reorganization initially to form membrane ruff les, and later, after 5 to 10 min, stress fibers. For all growth factors tested the stimulation of focal adhesion and stress fiber assembly was inhibited when endogenous rho function was blocked, whereas membrane ruffling was unaffected. These data imply that rho is essential specifically for the coordinated assembly of focal adhesions and stress fibers induced by growth factors.			RIDLEY, AJ (corresponding author), CHESTER BEATTY RES INST,INST CANC RES,FULHAM RD,LONDON SW3 6JB,ENGLAND.			Ridley, Anne/0000-0001-8186-5708				AKTORIES K, 1989, BIOCHEM BIOPH RES CO, V158, P209, DOI 10.1016/S0006-291X(89)80199-8; BALCH WE, 1990, TRENDS BIOCHEM SCI, V15, P473, DOI 10.1016/0968-0004(90)90301-Q; BENTON AM, 1982, BLOOD, V60, P642; BOCKUS BJ, 1984, EXP CELL RES, V153, P186, DOI 10.1016/0014-4827(84)90460-9; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; BRETSCHER A, 1991, ANNU REV CELL BIOL, V7, P337, DOI 10.1146/annurev.cb.07.110191.002005; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; CHEN LB, 1975, P NATL ACAD SCI USA, V72, P131, DOI 10.1073/pnas.72.1.131; DEPASQUALE JA, 1987, J CELL BIOL, V105, P2803, DOI 10.1083/jcb.105.6.2803; DEPASQUALE JA, 1991, J CELL BIOL, V113, P1352; DEVREOTES PN, 1988, ANNU REV CELL BIOL, V4, P649, DOI 10.1146/annurev.cellbio.4.1.649; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; DOWNWARD J, 1990, TRENDS BIOCHEM SCI, V15, P469, DOI 10.1016/0968-0004(90)90300-Z; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; GARRETT MD, 1991, BIOCHEM J, V276, P833, DOI 10.1042/bj2760833; GARRETT MD, 1989, J BIOL CHEM, V264, P10; GERRARD JM, 1984, BIOCHIM BIOPHYS ACTA, V795, P487, DOI 10.1016/0005-2760(84)90177-2; GERRARD JM, 1989, BIOCHIM BIOPHYS ACTA, V1001, P282, DOI 10.1016/0005-2760(89)90112-4; GREENBERG S, 1991, J CELL BIOL, V113, P757, DOI 10.1083/jcb.113.4.757; HALL A, 1986, J BIOL CHEM, V261, P963; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HALL AL, 1989, J CELL BIOL, V109, P2207, DOI 10.1083/jcb.109.5.2207; HERMAN B, 1985, J CELL BIOL, V100, P1031, DOI 10.1083/jcb.100.4.1031; HIRAOKA K, 1992, BIOCHEM BIOPH RES CO, V182, P921, DOI 10.1016/0006-291X(92)91820-G; ISOMURA M, 1990, BIOCHEM BIOPH RES CO, V169, P652, DOI 10.1016/0006-291X(90)90380-6; JALINK K, 1990, J BIOL CHEM, V265, P12232; JENNINGS LK, 1981, J BIOL CHEM, V256, P6927; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; KADOWAKI T, 1986, J BIOL CHEM, V261, P6141; KAHN RA, 1991, J BIOL CHEM, V266, P2606; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPETINA EG, 1981, NATURE, V292, P373; MELLSTROM K, 1988, EXP CELL RES, V177, P347, DOI 10.1016/0014-4827(88)90468-5; MELLSTROM K, 1983, J MUSCLE RES CELL M, V4, P589, DOI 10.1007/BF00712117; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; RIDLEY AJ, 1992, IN PRESS CELL, V70; RUBIN EJ, 1988, MOL CELL BIOL, V8, P418, DOI 10.1128/MCB.8.1.418; Salmon ED, 1989, CURR OPIN CELL BIOL, V1, P541, DOI 10.1016/0955-0674(89)90018-5; SEKINE A, 1989, J BIOL CHEM, V264, P8602; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SHAAFI RI, 1986, J CELL BIOL, V102, P1459, DOI 10.1083/jcb.102.4.1459; SHINJO K, 1990, P NATL ACAD SCI USA, V87, P9853, DOI 10.1073/pnas.87.24.9853; Small J V, 1988, Electron Microsc Rev, V1, P155; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STOSSEL TP, 1989, J BIOL CHEM, V264, P18261; SWITZER S, 1965, J LIPID RES, V6, P506; TSAI MH, 1989, MOL CELL BIOL, V9, P5260, DOI 10.1128/MCB.9.11.5260; Turner CE, 1991, CURR OPIN CELL BIOL, V3, P849, DOI 10.1016/0955-0674(91)90059-8; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; WANG YL, 1984, J CELL BIOL, V99, P1478, DOI 10.1083/jcb.99.4.1478	53	3918	3995	7	169	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 7	1992	70	3					389	399		10.1016/0092-8674(92)90163-7	http://dx.doi.org/10.1016/0092-8674(92)90163-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JH124	1643657				2022-12-01	WOS:A1992JH12400004
J	RIDLEY, AJ; PATERSON, HF; JOHNSTON, CL; DIEKMANN, D; HALL, A				RIDLEY, AJ; PATERSON, HF; JOHNSTON, CL; DIEKMANN, D; HALL, A			THE SMALL GTP-BINDING PROTEIN RAC REGULATES GROWTH-FACTOR INDUCED MEMBRANE RUFFLING	CELL			English	Article								The function of rac, a ras-related GTP-binding protein, was investigated in fibroblasts by microinjection. In confluent serum-starved Swiss 3T3 cells, rac1 rapidly stimulated actin filament accumulation at the plasma membrane, forming membrane ruffles. Several growth factors and activated H-ras also induced membrane ruffling, and this response was prevented by a dominant inhibitory mutant rac protein, N17rac1. This suggests that endogenous rac proteins are required for growth factor-induced membrane ruffling. In addition to membrane ruffling, a later response to both rac1 microinjection and some growth factors was the formation of actin stress fibers, a process requiring endogenous rho proteins. Using N17rac1 we have shown that these growth factors act through rac to stimulate this rho-dependent response. We propose that rac and rho are essential components of signal transduction pathways linking growth factors to the organization of polymerized actin.			RIDLEY, AJ (corresponding author), CHESTER BEATTY RES INST, INST CANC RES, FULHAM RD, LONDON SW3 6JB, ENGLAND.			Ridley, Anne/0000-0001-8186-5708; Tapon, Dagmar/0000-0003-3837-4764				ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; BARSAGI D, 1987, J CELL PHYSIOL, P69; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BATTEY JF, 1991, P NATL ACAD SCI USA, V88, P395, DOI 10.1073/pnas.88.2.395; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CANO ML, 1991, J CELL BIOL, V115, P677, DOI 10.1083/jcb.115.3.677; CARSON M, 1986, J CELL BIOL, V103, P2707, DOI 10.1083/jcb.103.6.2707; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; DOWNEY GP, 1992, J CELL BIOL, V116, P695, DOI 10.1083/jcb.116.3.695; DOWNWARD J, 1990, TRENDS BIOCHEM SCI, V15, P469, DOI 10.1016/0968-0004(90)90300-Z; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; HALL A, 1986, J BIOL CHEM, V261, P963; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HIRAOKA K, 1992, BIOCHEM BIOPH RES CO, V182, P921, DOI 10.1016/0006-291X(92)91820-G; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; KELLER HU, 1990, J CELL SCI, V96, P99; KELLER HU, 1990, J CELL PHYSIOL, V145, P465, DOI 10.1002/jcp.1041450311; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; LLOYD AC, 1989, EMBO J, V8, P1099, DOI 10.1002/j.1460-2075.1989.tb03479.x; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; MILLER J, 1986, J EXP MED, V164, P1478, DOI 10.1084/jem.164.5.1478; MOLL J, 1991, ONCOGENE, V6, P863; MOREL F, 1991, EUR J BIOCHEM, V201, P523, DOI 10.1111/j.1432-1033.1991.tb16312.x; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; OMANN GM, 1987, PHYSIOL REV, V67, P285, DOI 10.1152/physrev.1987.67.1.285; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; RIDLEY AJ, 1992, IN PRESS CELL, V70; ROZENGURT E, 1989, BRIT MED BULL, V45, P515, DOI 10.1093/oxfordjournals.bmb.a072339; SEKINE A, 1989, J BIOL CHEM, V264, P8602; SHIRSAT NV, 1990, ONCOGENE, V5, P769; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOBUE K, 1988, P NATL ACAD SCI USA, V85, P482, DOI 10.1073/pnas.85.2.482; STACEY DW, 1991, ONCOGENE, V6, P2297; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; YU CL, 1988, CELL, V52, P63, DOI 10.1016/0092-8674(88)90531-4	45	3166	3233	5	102	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 7	1992	70	3					401	410		10.1016/0092-8674(92)90164-8	http://dx.doi.org/10.1016/0092-8674(92)90164-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JH124	1643658	Bronze			2022-12-01	WOS:A1992JH12400005
J	SAUNDERS, WS; HOYT, MA				SAUNDERS, WS; HOYT, MA			KINESIN-RELATED PROTEINS REQUIRED FOR STRUCTURAL INTEGRITY OF THE MITOTIC SPINDLE	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; MICROBEAM IRRADIATIONS; GENE; DROSOPHILA; MOTOR; MICROTUBULES; SEGREGATION	For S. cerevisiae cells, the assembly of a bipolar mitotic spindle requires the action of either Cin8p or Kip1p, gene products related to the mechanochemical enzyme kinesin. In this paper we demonstrate that the activity of either one of these proteins is also required following spindle assembly. When their function was eliminated, preanaphase bipolar spindles rapidly collapsed, with previously separated poles being drawn together. In contrast, anaphase spindles were apparently resistant to collapse. Deletion of kinesin-related KAR3 partially suppressed the phenotypes associated with loss of Cin8p/Kip1p function. Our findings suggest that the structure of the preanaphase bipolar spindle is maintained by counteracting forces produced by kinesin-related proteins.			SAUNDERS, WS (corresponding author), JOHNS HOPKINS UNIV,DEPT BIOL,BALTIMORE,MD 21218, USA.				NIGMS NIH HHS [GM40714] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040714] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ENDOW SA, 1990, NATURE, V345, P81, DOI 10.1038/345081a0; ENOS AP, 1990, CELL, V60, P1019, DOI 10.1016/0092-8674(90)90350-N; HAGAN I, 1990, NATURE, V347, P563, DOI 10.1038/347563a0; HOGAN CJ, 1990, CELL MOTIL CYTOSKEL, V16, P99, DOI 10.1002/cm.970160203; HOYT MA, 1992, IN PRESS J CELL BIOL; HYAMS JS, 1989, MITOSIS MOL MECHANIS; INOUE S, 1981, J CELL BIOL, V91, pS131, DOI 10.1083/jcb.91.3.131s; JACOBS CW, 1988, J CELL BIOL, V107, P1409, DOI 10.1083/jcb.107.4.1409; KILMARTIN JV, 1982, J CELL BIOL, V93, P576, DOI 10.1083/jcb.93.3.576; LAFOUNTAIN JR, 1972, J CELL SCI, V10, P79; LESLIE RJ, 1983, J CELL BIOL, V96, P548, DOI 10.1083/jcb.96.2.548; MCDONALD HB, 1990, CELL, V63, P1159, DOI 10.1016/0092-8674(90)90412-8; MCDONALD HB, 1990, CELL, V61, P991, DOI 10.1016/0092-8674(90)90064-L; McDonald K., 1989, MITOSIS MOL MECHANIS, P1; MCDONALD KL, 1979, J CELL BIOL, V83, P443, DOI 10.1083/jcb.83.2.443; MCINTOSH JR, 1991, J CELL BIOL, V115, P577, DOI 10.1083/jcb.115.3.577; MCNEILL PA, 1981, J CELL BIOL, V88, P543, DOI 10.1083/jcb.88.3.543; MELUH PB, 1990, CELL, V60, P1029, DOI 10.1016/0092-8674(90)90351-E; NICKLAS RB, 1988, ANNU REV BIOPHYS BIO, V17, P431, DOI 10.1146/annurev.bb.17.060188.002243; PRINGLE JR, 1981, MOL BIOL YEAST SACCH, P97; ROOF DM, 1992, IN PRESS J CELL BIOL; ROSE MD, 1992, IN PRESS GUIDEBOOK C; ROUT MP, 1990, J CELL BIOL, V111, P1913, DOI 10.1083/jcb.111.5.1913; Salmon ED, 1989, MITOSIS MOL MECHANIS, P119; Sherman F., 1983, METHODS YEAST GENETI; SNYDER J A, 1985, European Journal of Cell Biology, V39, P373; SPURCK TP, 1990, J CELL BIOL, V111, P1505, DOI 10.1083/jcb.111.4.1505; STEARNS T, 1990, GENETICS, V124, P251; TAYLOR EW, 1960, ANN NY ACAD SCI, V90, P430, DOI 10.1111/j.1749-6632.1960.tb23261.x; WALKER RA, 1990, NATURE, V347, P780, DOI 10.1038/347780a0; WICKNER RB, 1987, YEAST, V3, P51, DOI 10.1002/yea.320030108	31	330	335	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 7	1992	70	3					451	458		10.1016/0092-8674(92)90169-D	http://dx.doi.org/10.1016/0092-8674(92)90169-D			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JH124	1643659				2022-12-01	WOS:A1992JH12400010
J	SCHINDLER, C; SHUAI, K; PREZIOSO, VR; DARNELL, JE				SCHINDLER, C; SHUAI, K; PREZIOSO, VR; DARNELL, JE			INTERFERON-DEPENDENT TYROSINE PHOSPHORYLATION OF A LATENT CYTOPLASMIC TRANSCRIPTION FACTOR	SCIENCE			English	Article							HUMAN LYMPHOCYTES-T; PROTEIN-KINASE; ALPHA-INTERFERON; GAMMA-INTERFERON; CYCLIC-AMP; RECEPTOR; GENE; EXPRESSION; CELLS; ISGF3	The interferon-alpha (IFN-alpha)-stimulated gene factor 3 (ISGF3), a transcriptional activator, contains three proteins, termed ISGF3-alpha-proteins,that reside in the cell cytoplasm until they are activated in response to IFN-alpha. Treatment of cells with IFN-alpha caused these three proteins to be phosphorylated on tyrosine and to translocate to the cell nucleus where they stimulate transcription through binding to IFN-alpha-stimulated response elements in DNA. IFN-gamma, which activates transcription through a different receptor and different DNA binding sites, also caused tyrosine phosphorylation of one of these proteins. The ISGF3-alpha-proteins may be substrates for one or more kinases activated by ligand binding to the cell surface and may link occupation of a specific polypeptide receptor with activation of transcription of a set of specific genes.	ROCKEFELLER UNIV,MOLEC CELL BIOL LAB,NEW YORK,NY 10021	Rockefeller University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032489] Funding Source: NIH RePORTER; NIAID NIH HHS [AI32489] Funding Source: Medline; NIGMS NIH HHS [GM07982-10] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGUET M, 1988, CELL, V55, P273, DOI 10.1016/0092-8674(88)90050-5; Bourne H.D., 1990, ONCOGENES MOL ORIGIN, P97; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CHAO MV, 1992, CELL, V68, P995, DOI 10.1016/0092-8674(92)90068-N; DECKER T, 1989, EMBO J, V8, P2009, DOI 10.1002/j.1460-2075.1989.tb03608.x; DECKER T, 1991, EMBO J, V10, P927, DOI 10.1002/j.1460-2075.1991.tb08026.x; DRAETTA G, 1988, NATURE, V336, P738, DOI 10.1038/336738a0; FU XY, 1990, P NATL ACAD SCI USA, V87, P8555, DOI 10.1073/pnas.87.21.8555; FU XY, IN PRESS P NATL ACAD; Gill G., 1990, ONCOGENES MOL ORIGIN, P67; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.biochem.56.1.615; GLENNY JR, 1991, J IMMUNOCHEM, V5, P1; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; Hunter T., 1990, ONCOGENES MOL ORIGIN, P142; KESSLER DS, 1991, J BIOL CHEM, V266, P23471; KESSLER DS, 1990, GENE DEV, V4, P1753, DOI 10.1101/gad.4.10.1753; LARNER AC, 1984, P NATL ACAD SCI-BIOL, V81, P6733, DOI 10.1073/pnas.81.21.6733; LEE TH, 1990, MOL CELL BIOL, V10, P1982, DOI 10.1128/MCB.10.5.1982; LEONARD WJ, 1985, P NATL ACAD SCI USA, V82, P6281, DOI 10.1073/pnas.82.18.6281; LEVY D, 1990, New Biologist, V2, P923; LEVY DE, 1988, GENE DEV, V2, P383, DOI 10.1101/gad.2.4.383; LEVY DE, 1990, EMBO J, V9, P1105, DOI 10.1002/j.1460-2075.1990.tb08216.x; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; LEW DJ, 1989, MOL CELL BIOL, V9, P5404, DOI 10.1128/MCB.9.12.5404; MURDOCH GH, 1982, SCIENCE, V218, P1315, DOI 10.1126/science.6293056; REICH N, 1987, P NATL ACAD SCI USA, V84, P6394, DOI 10.1073/pnas.84.18.6394; REICH NC, 1990, P NATL ACAD SCI USA, V87, P8761, DOI 10.1073/pnas.87.22.8761; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SCHINDLER C, IN PRESS P NATL ACAD; SCHINDLER C, UNPUB; SHUAI K, UNPUB; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; VEALS S, IN PRESS MOL CELL BI; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WALAAS SI, 1989, J MOL NEUROSCI, V1, P117, DOI 10.1007/BF02918897	35	791	819	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 7	1992	257	5071					809	813		10.1126/science.1496401	http://dx.doi.org/10.1126/science.1496401			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JG851	1496401				2022-12-01	WOS:A1992JG85100039
J	SHEAN, CS; GOTTESMAN, ME				SHEAN, CS; GOTTESMAN, ME			TRANSLATION OF THE PROPHAGE-LAMBDA CL TRANSCRIPT	CELL			English	Article								Mutations in rpsB that reduce the levels of the ribosomal protein S2 enhance the translation of cl in lambda lysogens. Two features of the cl transcript are required for enhanced translation: the absence of a leader and the presence of a downstream box, a sequence within the cl coding region that is complementary to the 16S rRNA. 30S ribosomal subunits deficient in S2 form ternary complexes with the cl transcript more efficiently than wild-type subunits. The absence of S2 may change the structure of the 16S rRNA, improving contacts with the cl downstream box.			SHEAN, CS (corresponding author), COLUMBIA UNIV COLL PHYS & SURG, INST CANC RES, 701 W 168TH ST, NEW YORK, NY 10032 USA.				NIGMS NIH HHS [5 R01 GM 37219] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037219] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AN G, 1981, NUCLEIC ACIDS RES, V9, P4163, DOI 10.1093/nar/9.16.4163; BAYLIS HA, 1987, NUCLEIC ACIDS RES, V15, P7176, DOI 10.1093/nar/15.17.7176; BOLLEN A, 1979, J MOL BIOL, V132, P219, DOI 10.1016/0022-2836(79)90392-9; BRIMACOMBE R, 1988, J MOL BIOL, V199, P115, DOI 10.1016/0022-2836(88)90383-X; CAM K, 1991, J BACTERIOL, V173, P734, DOI 10.1128/jb.173.2.734-740.1991; DANIELS DL, 1983, LAMBDA, V2, P519; DEBOER HA, 1983, P NATL ACAD SCI-BIOL, V80, P21; DREYFUS M, 1988, J MOL BIOL, V204, P79, DOI 10.1016/0022-2836(88)90601-8; FAXEN M, 1991, NUCLEIC ACIDS RES, V19, P5247, DOI 10.1093/nar/19.19.5247; GOLD L, 1988, ANNU REV BIOCHEM, V57, P199, DOI 10.1146/annurev.bi.57.070188.001215; HARLOW E, 1988, ANTIBODIES LABORATOR; HARTZ D, 1991, J MOL BIOL, V218, P83, DOI 10.1016/0022-2836(91)90875-7; HORINOUCHI S, 1987, J BACTERIOL, V169, P1929, DOI 10.1128/jb.169.5.1929-1937.1987; HOWARD BH, 1982, EUKARYOTIC VIRAL VEC, P211; JACOB WF, 1987, P NATL ACAD SCI USA, V84, P4757, DOI 10.1073/pnas.84.14.4757; JANSSEN GR, 1989, GENE DEV, V3, P415, DOI 10.1101/gad.3.3.415; JONES MO, 1979, P NATL ACAD SCI USA, V76, P150, DOI 10.1073/pnas.76.1.150; KING TC, 1987, ESCHERICHIA COLI SAL, V1, P703; KLOCK G, 1986, J MOL BIOL, V189, P633, DOI 10.1016/0022-2836(86)90493-6; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LAUGHREA M, 1978, J MOL BIOL, V121, P411, DOI 10.1016/0022-2836(78)90391-1; LOPEZCABRERA M, 1989, J BACTERIOL, V171, P321, DOI 10.1128/jb.171.1.321-328.1989; MEYER BJ, 1980, J MOL BIOL, V139, P163, DOI 10.1016/0022-2836(80)90303-4; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; MIZUSAWA S, 1982, GENE, V20, P317, DOI 10.1016/0378-1119(82)90200-1; MURRAY IA, 1989, GENE, V85, P283, DOI 10.1016/0378-1119(89)90420-4; NAGAI H, 1991, P NATL ACAD SCI USA, V88, P10515, DOI 10.1073/pnas.88.23.10515; Noller H. F, 1987, ESCHERICHIA COLI SAL, P104; OBERTO J, 1989, J MOL BIOL, V207, P675, DOI 10.1016/0022-2836(89)90237-4; OCONNOR M, 1989, EMBO J, V8, P4315, DOI 10.1002/j.1460-2075.1989.tb08618.x; OHTSUBO H, 1978, P NATL ACAD SCI USA, V75, P615, DOI 10.1073/pnas.75.2.615; POWERS T, 1988, J MOL BIOL, V201, P697, DOI 10.1016/0022-2836(88)90468-8; PTASHNE M, 1976, SCIENCE, V194, P156, DOI 10.1126/science.959843; REICHARDT L, 1971, P NATL ACAD SCI USA, V68, P2185, DOI 10.1073/pnas.68.9.2185; REICHARDT LF, 1975, J MOL BIOL, V93, P289, DOI 10.1016/0022-2836(75)90133-3; SCHERER GFE, 1980, NUCLEIC ACIDS RES, V8, P3895, DOI 10.1093/nar/8.17.3895; SCHNEIDER TD, 1986, J MOL BIOL, V188, P415, DOI 10.1016/0022-2836(86)90165-8; SHIMATAKE H, 1981, NATURE, V292, P128, DOI 10.1038/292128a0; SHINEDLING S, 1987, MOL GEN GENET, V207, P224, DOI 10.1007/BF00331582; Silhavy T.J., 1984, EXPT GENE FUSIONS; SIMONS RW, 1987, GENE, V53, P85, DOI 10.1016/0378-1119(87)90095-3; SPRENGART ML, 1990, NUCLEIC ACIDS RES, V18, P1719, DOI 10.1093/nar/18.7.1719; STEITZ JA, 1969, NATURE, V224, P957, DOI 10.1038/224957a0; STERN S, 1989, SCIENCE, V244, P783, DOI 10.1126/science.2658053; STORMO GD, 1982, NUCLEIC ACIDS RES, V10, P2971, DOI 10.1093/nar/10.9.2971; WAY JC, 1984, GENE, V32, P369, DOI 10.1016/0378-1119(84)90012-X; Zimmermann R A, 1979, Methods Enzymol, V59, P551	48	90	93	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 7	1992	70	3					513	522		10.1016/0092-8674(92)90175-C	http://dx.doi.org/10.1016/0092-8674(92)90175-C			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JH124	1386558				2022-12-01	WOS:A1992JH12400016
J	STOCK, DW; WHITT, GS				STOCK, DW; WHITT, GS			EVIDENCE FROM 18S RIBOSOMAL-RNA SEQUENCES THAT LAMPREYS AND HAGFISHES FORM A NATURAL GROUP	SCIENCE			English	Article							DNA; EVOLUTION; PHYLOGENY	Lampreys and hagfishes (cyclostomes) traditionally were considered to be a natural (monophyletic) group. Recently, the consensus of opinion, based largely on morphological analyses, has shifted to a view that lampreys are more closely related to jawed vertebrates (gnathostomes) than to hagfishes. Phylogenetic comparisons of 18S ribosomal RNA sequences from two hagfishes, two lampreys, a tunicate, a lancelet, and a number of gnathostomes support the monophyly of the cyclostomes. These data force a reassessment of several features of early vertebrate evolution.	UNIV ILLINOIS, DEPT ECOL ETHOL & EVOLUT, URBANA, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign								AJUH PM, 1991, P ROY SOC B-BIOL SCI, V245, P65, DOI 10.1098/rspb.1991.0089; BARDACK D, 1991, SCIENCE, V254, P701, DOI 10.1126/science.254.5032.701; CEDERGREN R, 1988, J MOL EVOL, V28, P98, DOI 10.1007/BF02143501; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; Felsenstein J, 1989, PHYLIP MANUAL VERSIO; FIELD KG, 1988, SCIENCE, V239, P748, DOI 10.1126/science.3277277; Forey P.L., 1984, Journal of Vertebrate Paleontology, V4, P330; GOODMAN M, 1988, J MOL EVOL, V27, P236, DOI 10.1007/BF02100080; GOODMAN M M, 1987, P141; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; Hardisty M.W., 1979, BIOL CYCLOSTOMES; HARDISTY MW, 1982, BIOL LAMPREYS B, V4, pCH36; HENDY MD, 1989, SYST ZOOL, V38, P297, DOI 10.2307/2992396; JANVIER P, 1981, Journal of Vertebrate Paleontology, V1, P121; JANVIER P, 1983, Journal of Vertebrate Paleontology, V2, P407; Jarvik E., 1980, BASIC STRUCTURE EVOL, DOI [10.1126/science.214.4519.431.b, DOI 10.1126/SCIENCE.214.4519.431.B]; Jefferies R.P.S., 1986, ANCESTRY VERTEBRATES; LAKE JA, 1990, P NATL ACAD SCI USA, V87, P763, DOI 10.1073/pnas.87.2.763; Lovtrup S., 1977, PHYLOGENY VERTEBRATA; MAISEY J G, 1986, Cladistics, V2, P201, DOI 10.1111/j.1096-0031.1986.tb00462.x; MCCALLUM FS, 1985, BIOCHEM J, V232, P725, DOI 10.1042/bj2320725; Nelson JS, 1984, FISHES WORLD; OLSEN GJ, 1991, NUCLEIC ACIDS RES, V19, P4817, DOI 10.1093/nar/19.17.4817; PATTERSON C, 1989, INT CONGR SER, V824, P471; REPETSKI JE, 1978, SCIENCE, V200, P529, DOI 10.1126/science.200.4341.529-a; Romer AS, 1966, VERTEBRATE PALEONTOL; SCHAEFFER B, 1987, EVOL BIOL, V21, P179; Schaeffer B., 1980, P19; SCHULTZE H.-P., 1979, HDB PALEOICHTHYOLOGY, V5; SMITH MW, 1992, J MOL EVOL, V34, P175; STOCK DW, 1991, ENVIRON BIOL FISH, V32, P99, DOI 10.1007/BF00007447; Swofford DL., 1991, PAUP PHYLOGENETIC AN; WILSON AC, 1977, ANNU REV BIOCHEM, V46, P573, DOI 10.1146/annurev.bi.46.070177.003041; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987; YALDEN DW, 1985, ZOOL J LINN SOC-LOND, V84, P291, DOI 10.1111/j.1096-3642.1985.tb01802.x	35	142	144	1	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 7	1992	257	5071					787	789		10.1126/science.1496398	http://dx.doi.org/10.1126/science.1496398			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JG851	1496398				2022-12-01	WOS:A1992JG85100031
J	STURM, NR; MASLOV, DA; BLUM, B; SIMPSON, L				STURM, NR; MASLOV, DA; BLUM, B; SIMPSON, L			GENERATION OF UNEXPECTED EDITING PATTERNS IN LEISHMANIA TARENTOLAE MITOCHONDRIAL MESSENGER-RNAS - MISEDITING PRODUCED BY MISGUIDING	CELL			English	Article							ENCODE GUIDE RNAS; CYTOCHROME-OXIDASE; SUBUNIT-III; MINICIRCLES; MOLECULES; REGION; GENES; GRNA	We have analyzed the generation of unexpected patterns of RNA editing, i.e., those not following a strict 3' to 5' progression, which occur in junction regions between fully edited and preedited sequences. Evidence is presented that these patterns are generated by misediting due to specific events of misguiding. Misediting can occur through the interaction of inappropriate gRNAs with mRNAs or appropriate gRNAs in an incorrect fashion. Four possible mechanisms for the generation of misedited sequences are presented. Chimeric molecules have been detected in steady-state mitochondrial RNAs that are composed of misguiding gRNAs covalently linked to mRNAs at misediting sites by the 3' oligo(U) tail. We propose that misediting within junction regions can be corrected by appropriately acting gRNAs.	UNIV CALIF LOS ANGELES,DEPT BIOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,HOWARD HUGHES MED INST,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Howard Hughes Medical Institute; University of California System; University of California Los Angeles					NIAID NIH HHS [AI-09102] Funding Source: Medline; NIGMS NIH HHS [GM-07104] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI009102, R37AI009102] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAHAM JM, 1988, CELL, V55, P267, DOI 10.1016/0092-8674(88)90049-9; BAKALARA N, 1989, J BIOL CHEM, V264, P18679; BENNE R, 1989, BIOCHIM BIOPHYS ACTA, V1007, P131, DOI 10.1016/0167-4781(89)90031-6; BLUM B, 1991, CELL, V65, P543, DOI 10.1016/0092-8674(91)90087-F; BLUM B, 1990, CELL, V60, P189, DOI 10.1016/0092-8674(90)90735-W; BRALY P, 1974, J PROTOZOOL, V21, P782, DOI 10.1111/j.1550-7408.1974.tb03752.x; CECH TR, 1991, CELL, V64, P667, DOI 10.1016/0092-8674(91)90494-J; DECKER CJ, 1990, CELL, V61, P1001, DOI 10.1016/0092-8674(90)90065-M; FEAGIN JE, 1990, J BIOL CHEM, V265, P1; HARRIS ME, 1992, CELL, V68, P1091, DOI 10.1016/0092-8674(92)90080-V; KOSLOWSKY DJ, 1991, CELL, V67, P537, DOI 10.1016/0092-8674(91)90528-7; KOSLOWSKY DJ, 1992, NATURE, V356, P807, DOI 10.1038/356807a0; MASLOV DA, 1992, MOL CELL BIOL, V12, P56, DOI 10.1128/MCB.12.1.56; MASLOV DA, 1992, CELL, V70, P459, DOI 10.1016/0092-8674(92)90170-H; POLLARD VW, 1990, CELL, V63, P783, DOI 10.1016/0092-8674(90)90144-4; SIMPSON L, 1970, J PROTOZOOL, V17, P511, DOI 10.1111/j.1550-7408.1970.tb04719.x; SIMPSON L, 1989, CELL, V57, P355, DOI 10.1016/0092-8674(89)90911-2; SIMPSON L, 1990, SCIENCE, V250, P512, DOI 10.1126/science.1700474; SIMPSON L, 1978, CELL, V14, P169, DOI 10.1016/0092-8674(78)90311-2; STURM NR, 1990, CELL, V61, P879, DOI 10.1016/0092-8674(90)90198-N; STURM NR, 1990, CELL, V61, P871, DOI 10.1016/0092-8674(90)90197-M; STURM NR, 1991, NUCLEIC ACIDS RES, V19, P6277, DOI 10.1093/nar/19.22.6277; VANDERSPEK H, 1991, EMBO J, V10, P1217, DOI 10.1002/j.1460-2075.1991.tb08063.x	23	62	63	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 7	1992	70	3					469	476		10.1016/0092-8674(92)90171-8	http://dx.doi.org/10.1016/0092-8674(92)90171-8			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JH124	1379520				2022-12-01	WOS:A1992JH12400012
J	AUBRY, JP; POCHON, S; GRABER, P; JANSEN, KU; BONNEFOY, JY				AUBRY, JP; POCHON, S; GRABER, P; JANSEN, KU; BONNEFOY, JY			CD21 IS A LIGAND FOR CD23 AND REGULATES IGE PRODUCTION	NATURE			English	Article							HUMAN LYMPHOCYTES-B; MHC CLASS-II; C3D RECEPTOR; SOLUBLE CD23; MONOCLONAL-ANTIBODIES; SEQUENCE HOMOLOGY; EBV/C3D RECEPTOR; INTERFERON-ALPHA; CELLS EXPRESS; ANTIGEN	THE molecule CD23, a low-affinity receptor for IgE (Fc-epsilon-R2)1,2, is a type II transmembrane molecule expressed on many haemopoietic cell types3,4. CD23 has pleiotropic roles in the control of lymphocyte behaviour5-9, suggesting that CD23 may interact with another ligand in addition to IgE. To identify such a CD23 ligand, we expressed and purified full-length recombinant CD23, incorporated it into fluorescent liposomes and used these as a probe. We report here that fluorescent liposomes carrying CD23 interact specifically with the cell-surface protein CD21, identified as the receptor for Epstein-Barr virus and the complement receptor-2 on B cells, some T cells and follicular dendritic cells. In addition, fluorescent CD23-liposomes were shown to bind to hamster kidney cells (BHK-21) transfected with CD21 complementary DNA. The interaction between fluorescent CD23-liposomes and B cells or CD21-transfected BHK-21 cells was specifically inhibited by anti-CD21 and anti-CD23 monoclonal antibodies. Western blotting analysis revealed that C-14-labelled liposomes carrying CD23, in contrast to anti-CD21 antibodies, reacted with a subtype of CD21 molecules. Triggering of CD21 either with an anti-CD21 antibody or with recombinant soluble CD23 was shown to increase specifically interleukin-4-induced IgE production from blood mononuclear cells. These results demonstrate that the cell-surface protein CD21 is a ligand for CD23 and that the pairing of these molecules may participate in the control of IgE production.	GLAXO INST MOLEC BIOL,14 CHEMIN AULX,CH-1228 PLAN LES OUATES,SWITZERLAND	GlaxoSmithKline								BILLAUD M, 1989, J VIROL, V63, P4121, DOI 10.1128/JVI.63.10.4121-4128.1989; BONNEFOY JY, 1987, J IMMUNOL, V138, P2970; BONNEFOY JY, 1988, J EXP MED, V167, P57, DOI 10.1084/jem.167.1.57; BONNEFOY JY, 1990, EUR J IMMUNOL, V20, P139, DOI 10.1002/eji.1830200120; CAIRNS J, 1990, EUR J IMMUNOL, V20, P534; CANTALOUBE JF, 1990, EUR J IMMUNOL, V20, P409, DOI 10.1002/eji.1830200226; DELCAYRE AX, 1991, EMBO J, V10, P919, DOI 10.1002/j.1460-2075.1991.tb08025.x; DELESPESSE G, 1989, IMMUNOL TODAY, V10, P159, DOI 10.1016/0167-5699(89)90173-4; DORKEN B, 1989, LEUCOCYTE TYPING, V4, P99; FISCHER E, 1991, J IMMUNOL, V146, P865; FLORESROMO L, 1990, EUR J IMMUNOL, V20, P2465, DOI 10.1002/eji.1830201116; FRADE R, 1985, P NATL ACAD SCI USA, V82, P1490, DOI 10.1073/pnas.82.5.1490; GORDON J, 1986, EUR J IMMUNOL, V16, P1075, DOI 10.1002/eji.1830160908; GORDON J, 1989, IMMUNOL TODAY, V10, P153, DOI 10.1016/0167-5699(89)90171-0; GRABER P, 1992, J IMMUNOL METHODS, V149, P215, DOI 10.1016/0022-1759(92)90253-P; HUTTFLECHER LM, 1987, J VIROL, V651, P774; IKUTA K, 1987, P NATL ACAD SCI USA, V84, P819, DOI 10.1073/pnas.84.3.819; JANSEN KU, 1991, J RECEPTOR RES, V11, P507, DOI 10.3109/10799899109066424; KOLB JP, 1990, J IMMUNOL, V145, P429; LIU YJ, 1991, EUR J IMMUNOL, V21, P1107, DOI 10.1002/eji.1830210504; MELCHERS F, 1985, NATURE, V317, P264, DOI 10.1038/317264a0; MOSSALAYI MD, 1990, BLOOD, V75, P1924; MOSSALAYI MD, 1990, J EXP MED, V171, P959, DOI 10.1084/jem.171.3.959; NADLER LM, 1981, J IMMUNOL, V126, P1941; NEMEROW GR, 1987, J VIROL, V61, P1416, DOI 10.1128/JVI.61.5.1416-1420.1987; PENE J, 1988, EUR J IMMUNOL, V18, P929, DOI 10.1002/eji.1830180615; PENE J, 1988, P NATL ACAD SCI USA, V85, P6880, DOI 10.1073/pnas.85.18.6880; POCHON S, IN PRESS J EXP MED; REYNES M, 1985, J IMMUNOL, V135, P2687; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; TANNER J, 1987, CELL, V50, P203, DOI 10.1016/0092-8674(87)90216-9; TEW JG, 1979, IMMUNOLOGY, V37, P69; VERCELLI D, 1989, J EXP MED, V169, P1295, DOI 10.1084/jem.169.4.1295; WEIS JJ, 1984, P NATL ACAD SCI-BIOL, V81, P881, DOI 10.1073/pnas.81.3.881; WILSON BS, 1985, BLOOD, V66, P824; YOUNG LS, 1986, LANCET, V1, P240; YUKAWA K, 1987, J IMMUNOL, V138, P2576	37	450	467	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 6	1992	358	6386					505	507		10.1038/358505a0	http://dx.doi.org/10.1038/358505a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JG739	1386409				2022-12-01	WOS:A1992JG73900050
J	BENJAMIN, EJ; PLEHN, JF; DAGOSTINO, RB; BELANGER, AJ; COMAI, K; FULLER, DL; WOLF, PA; LEVY, D				BENJAMIN, EJ; PLEHN, JF; DAGOSTINO, RB; BELANGER, AJ; COMAI, K; FULLER, DL; WOLF, PA; LEVY, D			MITRAL ANNULAR CALCIFICATION AND THE RISK OF STROKE IN AN ELDERLY COHORT	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MATCHED CONTROL SUBJECTS; ANULAR CALCIUM; CARDIAC ABNORMALITIES; ISCHEMIC ATTACKS; ECHOCARDIOGRAPHY; DISEASE; FIBROSUS; VALVE	Background. Previous clinical studies have suggested that there is an association between mitral annular calcification and the risk of stroke, but it is unclear whether this association is independent of the traditional risk factors for stroke. We examined the relation between mitral annular calcification and the incidence of stroke in a population-based study. Methods. Subjects in the Framingham Study receiving a routine examination underwent M-mode echocardiography to determine the presence and severity (thickness in millimeters) of mitral annular calcification. The incidence of stroke during eight years of follow-up was analyzed with a proportional-hazards model adjusting for the calcification, age, sex, systolic blood pressure, diabetes mellitus, cigarette smoking, atrial fibrillation, and coronary heart disease or congestive heart failure. Results. Among 1159 subjects whose echocardiograms could be assessed for mitral annular calcification and who had no history or current evidence of stroke at the index examination (51 percent of all subjects), the prevalence of mitral annular calcification was 10.3 percent in the men and 15.8 percent in the women. Multivariate analysis demonstrated that the presence of mitral annular calcification was associated with a relative risk of stroke of 2.10 (95 percent confidence interval, 1.24 to 3.57; P = 0.006). There was a continuous relation between the incidence of stroke and the severity of mitral annular calcification; each millimeter of thickening as shown on the echocardiogram represented a relative risk of stroke of 1.24 (95 percent confidence interval, 1.1 2 to 1.37; P<0.001). Furthermore, even when subjects with coronary heart disease or congestive heart failure were excluded from the analysis, subjects with mitral annular calcification still had twice the risk of stroke. Conclusions. In an elderly, longitudinally followed population-based cohort, mitral annular calcification was associated with a doubled risk of stroke, independently of traditional risk factors for stroke. Whether such calcification contributes causally to the risk of stroke or is merely a marker of increased risk because of its association with other precursors of stroke remains unknown.	BOSTON CITY HOSP,DEPT CARDIOL,BOSTON,MA 02118; BOSTON UNIV,DEPT MATH,BOSTON,MA 02215; NHLBI,BETHESDA,MD 20892; BOSTON UNIV,SCH MED,DEPT NEUROL,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT PREVENT MED,BOSTON,MA 02118; BETH ISRAEL HOSP,DIV CARDIOL,BOSTON,MA 02215; BETH ISRAEL HOSP,DIV CLIN EPIDEMIOL,BOSTON,MA 02215; DARTMOUTH HITCHCOCK MED CTR,CARDIOL SECT,LEBANON,NH	Boston Medical Center; Boston University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Boston University; Boston University; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Dartmouth College	BENJAMIN, EJ (corresponding author), FRAMINGHAM HEART DIS EPIDEMIOL STUDY,5 THURBER ST,FRAMINGHAM,MA 01701, USA.		Levy, Daniel/ABF-6873-2021; Benjamin, Emelia/E-7103-2011; Levy, Daniel/ABB-2752-2021	Levy, Daniel/0000-0003-1843-8724; Benjamin, Emelia/0000-0003-4076-2336; Wolf, Philip/0000-0002-3628-301X	NHLBI NIH HHS [N01-HC-38038] Funding Source: Medline; NINDS NIH HHS [2-R01-NS-17950-09] Funding Source: Medline; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC038038] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017950] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALWLESS JF, 1982, STATISTICAL MODELS M, P359; Barnett H J, 1983, Neurol Clin, V1, P291; BOGOUSSLAVSKY J, 1986, ARCH NEUROL-CHICAGO, V43, P223, DOI 10.1001/archneur.1986.00520030015005; Bonniger M, 1908, DEUT MED WOCHENSCHR, V34, P2292; BONNIGER M, 1908, DTSCH MED WCHNSCHR, V34, P2293; BURNSIDE JW, 1972, ANN INTERN MED, V76, P615, DOI 10.7326/0003-4819-76-4-615; CUPPLES LA, 1988, NIH882969 PUBL; DAWBER TR, 1963, ANN NY ACAD SCI, V107, P539, DOI 10.1111/j.1749-6632.1963.tb13299.x; DAWBER TR, 1951, AM J PUBLIC HEALTH, V41, P279; DEBONO DP, 1979, LANCET, V2, P383; FULKERSON PK, 1979, AM J MED, V66, P967, DOI 10.1016/0002-9343(79)90452-2; FURLAN AJ, 1984, STROKE, V15, P801, DOI 10.1161/01.STR.15.5.801; GOOD DC, 1986, STROKE, V17, P6, DOI 10.1161/01.STR.17.1.6; GREENLAND P, 1981, ANN INTERN MED, V95, P51, DOI 10.7326/0003-4819-95-1-51; GUTHRIE J, 1963, BRIT HEART J, V25, P137; JESPERSEN CM, 1987, ACTA MED SCAND, V222, P37; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI, P70; KANNEL WB, 1983, JAMA-J AM MED ASSOC, V250, P2942, DOI 10.1001/jama.250.21.2942; KIRK RS, 1969, BRIT HEART J, V31, P684; KORN D, 1962, NEW ENGL J MED, V267, P900, DOI 10.1056/NEJM196211012671802; LIN CS, 1987, ARCH PATHOL LAB MED, V111, P411; MELLINO M, 1982, AM HEART J, V103, P222, DOI 10.1016/0002-8703(82)90495-1; NAIR CK, 1989, AM J CARDIOL, V63, P465, DOI 10.1016/0002-9149(89)90321-4; NAIR CK, 1984, AM J CARDIOL, V54, P1286, DOI 10.1016/S0002-9149(84)80082-X; NISHIDE M, 1983, STROKE, V14, P541, DOI 10.1161/01.STR.14.4.541; POMERANCE A, 1970, J CLIN PATHOL, V23, P354, DOI 10.1136/jcp.23.4.354; REM JA, 1985, STROKE, V16, P950, DOI 10.1161/01.STR.16.6.950; RIDOLFI RL, 1976, ARCH PATHOL LAB MED, V100, P117; ROBERTS WC, 1972, ANN INTERN MED, V77, P939, DOI 10.7326/0003-4819-77-6-939; RYTAND DA, 1946, ARCH INTERN MED, V78, P544, DOI 10.1001/archinte.1946.00220050049003; SACCO RL, 1989, ANN NEUROL, V25, P382, DOI 10.1002/ana.410250410; SAVAGE DD, 1983, AM J CARDIOL, V51, P1375, DOI 10.1016/0002-9149(83)90315-6; SAVAGE DD, 1987, HYPERTENSION, V9, P40; SHURTLEFF D, 1974, DHEW NIH74599 PUBL; TODNEM K, 1986, ACTA NEUROL SCAND, V74, P323; ZAK FG, 1949, AM J MED SCI, V218, P510, DOI 10.1097/00000441-194911000-00004; 1992, ANN INTERN MED, V116, P6; 1988, APPLIED REGRESSION A, P297; 1990, NEW ENGL J MED, V323, P1505	39	300	305	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 6	1992	327	6					374	379		10.1056/NEJM199208063270602	http://dx.doi.org/10.1056/NEJM199208063270602			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG356	1625711				2022-12-01	WOS:A1992JG35600002
J	BERRY, M; GROSVELD, F; DILLON, N				BERRY, M; GROSVELD, F; DILLON, N			A SINGLE POINT MUTATION IS THE CAUSE OF THE GREEK FORM OF HEREDITARY PERSISTENCE OF FETAL HEMOGLOBIN	NATURE			English	Article							GAMMA-GLOBIN GENE; ERYTHROID-SPECIFIC PROTEIN; DISTAL CCAAT BOX; TRANSGENIC MICE; DEVELOPMENTAL EXPRESSION; BINDING; HEMOGLOBIN; REGION; DNA; BREAKPOINT	IN normal humans the fetal stage-specific gamma-globin genes are silenced after birth and not expressed in the adult. Exceptions are seen in cases of hereditary persistence of fetal haemoglobin (HPFH). These are clinically important because the elevated levels of gamma-globin can alleviate beta-thalassaemia and sickle cell anaemia. One class of mutations is associated with point mutations in the promoter of the gamma-globin genes (non-deletion HPFH), whereas others seem to be caused by large deletions 3' to the gamma-globin genes1. To test whether the point mutation found in the Greek non-deletion HPFH2,3 (guanine to adenine at nucleotide position -117) is the cause of the raised gamma-globin levels in the adult stage and is not just a linked polymorphism, we engineered this mutation into a gamma-globin gene. When this gene was introduced into mice, the presence of the -117 mutation results in persistence of gamma-globin expression at a high level and a concomitant decrease in beta-globin expression in fetal and adult mice. We show that these changes correlate with the loss of binding of the transcription factor GATA1 to the gamma-globin promoter, suggesting that it may act as a negative regulator of the gamma-globin gene in adults.			BERRY, M (corresponding author), NATL INST MED RES,GENE STRUCT & EXPRESS LAB,RIDGEWAY,LONDON NW7 1AA,ENGLAND.							ANAGNOU NP, 1990, CLIN RES, V38, pA301; BEHRINGER RR, 1990, GENE DEV, V4, P380, DOI 10.1101/gad.4.3.380; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; COLLINS FS, 1985, NATURE, V313, P325, DOI 10.1038/313325a0; DIGNAM J, 1983, NUCLEIC ACIDS RES, V113, P1475; DILLON N, 1991, NATURE, V350, P252, DOI 10.1038/350252a0; ENVER T, 1990, NATURE, V344, P309, DOI 10.1038/344309a0; EVANS T, 1991, MOL CELL BIOL, V11, P843, DOI 10.1128/MCB.11.2.843; FEINGOLD EA, 1989, BLOOD, V74, P2178; GELINAS R, 1985, NATURE, V313, P323, DOI 10.1038/313323a0; GIGLIONI B, 1984, EMBO J, V3, P2641, DOI 10.1002/j.1460-2075.1984.tb02187.x; GILMAN J, 1988, NUCLEIC ACIDS RES, V18, P10635; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; HANSCOMBE O, 1991, GENE DEV, V5, P1387, DOI 10.1101/gad.5.8.1387; MANTOVANI R, 1989, NUCLEIC ACIDS RES, V17, P6681, DOI 10.1093/nar/17.16.6681; MARTIN DIK, 1990, GENE DEV, V4, P1886, DOI 10.1101/gad.4.11.1886; MORLEY BJ, 1992, MOL CELL BIOL, V12, P2057, DOI 10.1128/MCB.12.5.2057; PHILIPSEN S, 1990, EMBO J, V9, P2159, DOI 10.1002/j.1460-2075.1990.tb07385.x; PONCZ M, 1989, OXFORD SURVEYS EUKAR, P163; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; STAMATOYANNOPOU.G, 1991, REGULATION HEMOGLOBI, pCH6; SUPERTIFURGA G, 1988, EMBO J, V7, P3099, DOI 10.1002/j.1460-2075.1988.tb03176.x; WALL L, 1988, GENE DEV, V2, P1089, DOI 10.1101/gad.2.9.1089; Weatherall DJ., 2008, THALASSAEMIA SYNDROM; WHITELAW E, 1990, MOL CELL BIOL, V10, P6596, DOI 10.1128/MCB.10.12.6596	25	123	126	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 6	1992	358	6386					499	502		10.1038/358499a0	http://dx.doi.org/10.1038/358499a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JG739	1379347	Green Submitted			2022-12-01	WOS:A1992JG73900048
J	BOMAN, AL; TAYLOR, TC; MELANCON, P; WILSON, KL				BOMAN, AL; TAYLOR, TC; MELANCON, P; WILSON, KL			A ROLE FOR ADP-RIBOSYLATION FACTOR IN NUCLEAR VESICLE DYNAMICS	NATURE			English	Article							GTP-BINDING PROTEINS; BREFELDIN-A; MEMBRANE-VESICLES; FORMATION INVITRO; GOLGI-APPARATUS; ENVELOPE; COMPONENTS; TRANSPORT; TARGETS; EGGS	Two distinct steps in nuclear envelope assembly can be assayed in vitro1-3: the protein-mediated binding4 of nuclear-specific vesicles to chromatin, and the subsequent fusion5 of these vesicles to enclose the chromatin within a double nuclear membrane. Nuclear vesicle fusion, like fusion in the secretory pathway6,7, requires ATP8,9 and cytosol1,3,5 and is inhibited by nonhydrolysable GTP analogues1,2. The sensitivity of nuclear vesicle fusion to GTP-gamma-S requires a GTP-dependent soluble factor, the properties of which are strikingly similar to a GTP-dependent Golgi binding factor (GCBF) that inhibits Golgi vesicle fusion in the presence of GTP-gamma-S and belongs to the ADP-ribosylation factor (ARF) family of small GTPases10,11. In the presence of GTP-gamma-S, ARF proteins and alpha-, beta-, gamma-, delta-COP ('coatomer') subunits are associated with Golgi transport vesicles 6,12,13, but the exact roles of ARF proteins in secretion are not vet understood. We report here that purified ARF1 and GGBF have GTP-dependent soluble factor activity in the nuclear vesicle fusion assay. Our results show that the function of ARF is not limited to the Golgi apparatus, and indicate that there may be a link between the formation of nuclear vesicles during mitosis and proteins involved in secretion.	JOHNS HOPKINS UNIV,SCH MED,DEPT CELL BIOL & ANAT,725 N WOLFE ST,BALTIMORE,MD 21205; UNIV COLORADO,DEPT CHEM & BIOCHEM,BOULDER,CO 80309	Johns Hopkins University; University of Colorado System; University of Colorado Boulder			Melancon, Paul/P-1304-2018	Melancon, Paul/0000-0002-8085-3032				BALCH WE, 1992, J BIOL CHEM, V267, P13053; BECKERS CJM, 1989, J CELL BIOL, V108, P1245, DOI 10.1083/jcb.108.4.1245; BOMAN AL, 1992, J CELL BIOL, V116, P281, DOI 10.1083/jcb.116.2.281; DONALDSON JG, 1991, J CELL BIOL, V112, P579, DOI 10.1083/jcb.112.4.579; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; DONALDSON JG, IN PRESS P NATN ACAD; ERCOLANI L, 1990, P NATL ACAD SCI USA, V87, P4637; KAHN RA, 1991, J BIOL CHEM, V266, P15595; KAHN RA, 1992, J BIOL CHEM, V267, P13039; KAHN RA, 1991, J BIOL CHEM, V266, P2606; LENHARD JM, 1992, J BIOL CHEM, V267, P13047; LOHKA MJ, 1983, SCIENCE, V220, P719, DOI 10.1126/science.6601299; LOHKA MJ, 1984, J CELL BIOL, V98, P1222, DOI 10.1083/jcb.98.4.1222; MAYORGA LS, 1989, SCIENCE, V244, P1475, DOI 10.1126/science.2499930; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; MELLMAN I, 1992, CELL, V68, P829, DOI 10.1016/0092-8674(92)90027-A; NEWMEYER DD, 1986, EMBO J, V5, P501, DOI 10.1002/j.1460-2075.1986.tb04239.x; NEWPORT J, 1992, J CELL BIOL, V116, P295, DOI 10.1083/jcb.116.2.295; ORCI L, 1991, CELL, V64, P1183; PELHAM HRB, 1991, CELL, V67, P449, DOI 10.1016/0092-8674(91)90517-3; PFALLER R, 1991, CELL, V65, P209, DOI 10.1016/0092-8674(91)90155-R; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SCHLEIFER LS, 1982, J BIOL CHEM, V257, P20; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; TAYLOR TC, 1992, CELL, V70, P69, DOI 10.1016/0092-8674(92)90534-J; VIGERS GPA, 1991, J CELL BIOL, V112, P545, DOI 10.1083/jcb.112.4.545; WARREN G, 1985, TRENDS BIOCHEM SCI, V10, P439, DOI 10.1016/0968-0004(85)90027-1; WEISS O, 1989, J BIOL CHEM, V264, P21066; WILSON KL, 1988, J CELL BIOL, V107, P57, DOI 10.1083/jcb.107.1.57	30	104	105	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 6	1992	358	6386					512	514		10.1038/358512a0	http://dx.doi.org/10.1038/358512a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JG739	1641041				2022-12-01	WOS:A1992JG73900053
J	DAVIES, K				DAVIES, K			MOVING STRAIGHT TO THE TARGET	NATURE			English	Article							GENE											ANDERSON WF, 1992, SCIENCE, V256, P808, DOI 10.1126/science.1589762; JAFFE HA, 1992, NAT GENET, V1, P372, DOI 10.1038/ng0892-372; LEMARCHAND P, 1992, P NATL ACAD SCI USA, V89, P6482, DOI 10.1073/pnas.89.14.6482; MILLER AD, 1992, NATURE, V357, P455, DOI 10.1038/357455a0; ROSENFELD MA, 1992, CELL, V68, P143, DOI 10.1016/0092-8674(92)90213-V; STRATFORDPERRICAUDET LD, 1990, HUM GENE THER, V1, P241, DOI 10.1089/hum.1990.1.3-241; TRAVIS GH, 1992, NEURON, V9, P113, DOI 10.1016/0896-6273(92)90226-4; VERMA IM, 1990, SCI AM, V263, P68, DOI 10.1038/scientificamerican1190-68; WOLFE JH, 1992, NAT GENET, V1, P379, DOI 10.1038/ng0892-379	9	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 6	1992	358	6386					519	519		10.1038/358519a0	http://dx.doi.org/10.1038/358519a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JG739	1641042	Bronze			2022-12-01	WOS:A1992JG73900055
J	DONAHUE, JG; MUNOZ, A; NESS, PM; BROWN, DE; YAWN, DH; MCALLISTER, HA; REITZ, BA; NELSON, KE				DONAHUE, JG; MUNOZ, A; NESS, PM; BROWN, DE; YAWN, DH; MCALLISTER, HA; REITZ, BA; NELSON, KE			THE DECLINING RISK OF POSTTRANSFUSION HEPATITIS-C VIRUS-INFECTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NON-B-HEPATITIS; NON-A; POSTTRANSFUSION HEPATITIS; TRANSMITTED VIRUSES; CARDIAC-SURGERY; BLOOD-DONORS; ANTIBODY; RECIPIENTS; TRANSMISSION; ANTIGEN	Background. The most common serious complication of blood transfusion is post-transfusion hepatitis from the hepatitis C virus (HCV). Blood banks now screen blood donors for surrogate markers of non-A, non-B hepatitis and antibodies to HCV, but the current risk of post-transfusion hepatitis C is unknown. Methods. From 1985 through 1991, blood samples and medical information were obtained prospectively from patients before and at least six months after cardiac surgery. The stored serum samples were tested for antibodies to HCV by enzyme immunoassay, and by recombinant immunoblotting if positive. Results. Of the 912 patients who received transfusions before donors were screened for surrogate markers, 35 seroconverted to HCV, for a risk of 3.84 percent per patient (0.45 percent per unit transfused). For the 976 patients who received transfusions after October 1986 with blood screened for surrogate markers, the risk of seroconversion was 1.54 percent per patient (0.19 percent per unit). For the 522 patients receiving transfusions since the addition in May 1990 of screening for antibodies to HCV, the risk was 0.57 percent per patient (0.03 percent per unit). The trend toward decreasing risk with increasingly stringent screening of donors was statistically significant (P<0.001). After we controlled for the method of donor screening, the risk of seroconversion was strongly associated (P<0.001) with the volume of blood transfused, but not with the use of particular blood components. Conclusions. The incidence of post-transfusion hepatitis C has decreased markedly since the implementation of donor screening for surrogate markers and antibodies to HCV. The current risk of post-transfusion hepatitis is about 3 per 10,000 units transfused.	JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT EPIDEMIOL,624 N BROADWAY,RM 763,BALTIMORE,MD 21205; BAYLOR COLL MED,DEPT PATHOL,HOUSTON,TX 77030; ST LUKES EPISCOPAL HOSP,DEPT CARDIAC PATHOL,HOUSTON,TX 77030; JOHNS HOPKINS UNIV HOSP,DEPT PATHOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV HOSP,DEPT CARDIAC SURG,BALTIMORE,MD 21205; METHODIST HOSP,HOUSTON,TX 77030	Johns Hopkins University; Baylor College of Medicine; Saint Lukes Episcopal Hospital; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; The Methodist Hospital System; The Methodist Hospital - Houston					NCRR NIH HHS [5M01RR00722] Funding Source: Medline; NHLBI NIH HHS [N01-HB-86-7025, R01-HL-45333-01A2] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000722] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045333] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AACH RD, 1991, NEW ENGL J MED, V325, P1325, DOI 10.1056/NEJM199111073251901; AACH RD, 1981, NEW ENGL J MED, V304, P989, DOI 10.1056/NEJM198104233041701; Aach RD, 1978, VIRAL HEPATITIS, P383; ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; ALTER HJ, 1981, JAMA-J AM MED ASSOC, V246, P630, DOI 10.1001/jama.246.6.630; ALTER HJ, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P396; BOVE JR, 1987, NEW ENGL J MED, V317, P242, DOI 10.1056/NEJM198707233170411; BRADLEY DW, 1986, SEMIN LIVER DIS, V6, P56, DOI 10.1055/s-2008-1040794; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; COHEN ND, 1989, NEW ENGL J MED, V320, P1172, DOI 10.1056/NEJM198905043201803; Cox D.R., 1989, MONOGRAPHS STAT APPL, V2nd ed.; DIENSTAG JL, 1986, SEMIN LIVER DIS, V6, P67, DOI 10.1055/s-2008-1040795; DIENSTAG JL, 1983, GASTROENTEROLOGY, V85, P743; ESTEBAN JI, 1989, LANCET, V2, P294; ESTEBAN JI, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P431; HANSON MR, 1987, TRANSFUSION, V27, P107, DOI 10.1046/j.1537-2995.1987.27187121451.x; KOZIOL DE, 1986, ANN INTERN MED, V104, P488, DOI 10.7326/0003-4819-104-4-488; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; LARSEN J, 1990, TRANSFUSION, V30, P431, DOI 10.1046/j.1537-2995.1990.30590296376.x; LEE SD, 1991, J INFECT DIS, V163, P1354, DOI 10.1093/infdis/163.6.1354; NAGACHINTA T, 1987, J INFECT DIS, V156, P967, DOI 10.1093/infdis/156.6.967; SHIBATA M, 1991, BLOOD, V77, P1157; STEVENS CE, 1984, ANN INTERN MED, V101, P733, DOI 10.7326/0003-4819-101-6-733; TREMOLADA F, 1991, ANN INTERN MED, V114, P277, DOI 10.7326/0003-4819-114-4-277; WILLIAMS AE, 1990, ANN CLIN LAB SCI, V20, P192; 1982, MMWR, V31, P652; 1991, LANCET, V338, P1040	27	628	631	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 6	1992	327	6					369	373		10.1056/NEJM199208063270601	http://dx.doi.org/10.1056/NEJM199208063270601			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG356	1320736				2022-12-01	WOS:A1992JG35600001
J	GAO, F; YUE, L; WHITE, AT; PAPPAS, PG; BARCHUE, J; HANSON, AP; GREENE, BM; SHARP, PM; SHAW, GM; HAHN, BH				GAO, F; YUE, L; WHITE, AT; PAPPAS, PG; BARCHUE, J; HANSON, AP; GREENE, BM; SHARP, PM; SHAW, GM; HAHN, BH			HUMAN INFECTION BY GENETICALLY DIVERSE SIVSM-RELATED HIV-2 IN WEST AFRICA	NATURE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-2; GENOMIC DIVERGENCE; SOOTY MANGABEY; MONKEYS; AIDS; VARIABILITY; ISOLATE	OUR understanding of the biology and origins of human immunodeficiency virus type 2 (HIV-2) derives from studies of cultured isolates from urban populations experiencing epidemic infection and disease1-8. To test the hypothesis that such isolates might represent only a subset of a larger, genetically more diverse group of viruses, we used nested polymerase chain reactions to characterize HIV-2 sequences in uncultured mononuclear blood cells of two healthy Liberian agricultural workers, from whom virus isolation was repeatedly unsuccessful, and from a culture-positive symptomatic urban dweller. Analysis of pol, env and long terminal repeat regions revealed the presence of three highly divergent HIV-2 strains, one of which (from one of the healthy subjects) was significantly more closely related to simian immunodeficiency viruses infecting sooty mangabeys and rhesus macaques (SIV(SM)/SIV(MAC)) than to any virus of human derivation. This subject also harboured multiply defective viral genotypes that resulted from hypermutation of G to A bases. Our results indicate that HIV-2, SIV(SM) and SIV(MAC) comprise a single, highly diverse group of lentiviruses which cannot be separated into distinct phylogenetic lineages according to species of origin.	UNIV ALABAMA,DIV GEOG MED,BIRMINGHAM,AL 35294; UNIV ALABAMA,DIV INFECT DIS,BIRMINGHAM,AL 35294; LIBERIAN INST BIOMED RES,ROBERTSFIELD,LIBERIA; UNIV DUBLIN TRINITY COLL,DEPT GENET,DUBLIN 2,IRELAND	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Trinity College Dublin	GAO, F (corresponding author), UNIV ALABAMA,DEPT MED,DIV HEMATOL ONCOL,BIRMINGHAM,AL 35294, USA.		Sharp, Paul/Y-3787-2019; Sharp, Paul M/GPX-1497-2022; Sharp, Paul M/F-5783-2010	Sharp, Paul M/0000-0001-9771-543X; Sharp, Paul M/0000-0001-9771-543X; Hahn, Beatrice/0000-0002-9400-9887				ALLAN JS, 1991, J VIROL, V65, P2816, DOI 10.1128/JVI.65.6.2816-2828.1991; CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404; DIETRICH U, 1989, NATURE, V342, P948, DOI 10.1038/342948a0; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; FIENNES TW, 1978, ZOONOSES ORIGINS ECO; FITCH WM, 1971, SYST ZOOL, V20, P406, DOI 10.2307/2412116; FRANCHINI G, 1989, P NATL ACAD SCI USA, V86, P2433, DOI 10.1073/pnas.86.7.2433; FULTZ PN, 1990, AIDS, V4, P619, DOI 10.1097/00002030-199007000-00002; GILKS C, 1991, NATURE, V354, P262, DOI 10.1038/354262a0; GUYADER M, 1987, NATURE, V326, P662, DOI 10.1038/326662a0; HASEGAWA A, 1989, AIDS RES HUM RETROV, V5, P593, DOI 10.1089/aid.1989.5.593; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; HIRSCH VM, 1989, NATURE, V339, P389, DOI 10.1038/339389a0; JOHNSON PR, 1991, VIROLOGY, V185, P217, DOI 10.1016/0042-6822(91)90769-8; KHAN AS, 1991, J VIROL, V65, P7061, DOI 10.1128/JVI.65.12.7061-7065.1991; KIMURA M, 1980, J MOL EVOL, V16, P111, DOI 10.1007/BF01731581; KIRCHHOFF F, 1990, AIDS, V4, P847, DOI 10.1097/00002030-199009000-00003; KUMAR P, 1990, J VIROL, V64, P890, DOI 10.1128/JVI.64.2.890-901.1990; LETVIN NL, 1985, SCIENCE, V230, P71, DOI 10.1126/science.2412295; LI YX, 1991, J VIROL, V65, P3973, DOI 10.1128/JVI.65.8.3973-3985.1991; MARX PA, 1991, J VIROL, V65, P4480, DOI 10.1128/JVI.65.8.4480-4485.1991; MEYERHANS A, 1989, CELL, V58, P901, DOI 10.1016/0092-8674(89)90942-2; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; MYERS G, 1991, HUMAN RETROVIRUSES A; NOVEMBRE FJ, 1992, VIROLOGY, V186, P783, DOI 10.1016/0042-6822(92)90047-S; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SCHULZ TF, 1990, J VIROL, V64, P5177, DOI 10.1128/JVI.64.10.5177-5182.1990; SWOFFORD DL, 1991, PAUP PHYLOGENETIC AN; VARTANIAN JP, 1991, J VIROL, V65, P1779, DOI 10.1128/JVI.65.4.1779-1788.1991; ZAGURY JF, 1988, P NATL ACAD SCI USA, V85, P5941, DOI 10.1073/pnas.85.16.5941	30	355	362	0	28	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 6	1992	358	6386					495	499		10.1038/358495a0	http://dx.doi.org/10.1038/358495a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JG739	1641038				2022-12-01	WOS:A1992JG73900047
J	HILL, RJ; STERNBERG, PW				HILL, RJ; STERNBERG, PW			THE GENE LIN-3 ENCODES AN INDUCTIVE SIGNAL FOR VULVAR DEVELOPMENT IN C-ELEGANS	NATURE			English	Article							EPIDERMAL GROWTH-FACTOR; NEMATODE CAENORHABDITIS-ELEGANS; SPECIFIES CELL FATES; FACTOR-ALPHA; TYROSINE KINASE; MYXOMA VIRUS; SEQUENCE; EGF; EXPRESSION; LINEAGES	The lin-3 gene is necessary for induction of the Caenorhabditis elegans vulva by the anchor cell. It encodes a molecule similar to epidermal growth factor and to transforming growth factor-alpha and acts through the epidermal growth factor receptor homologue let-23. Expression of lin-3 in the anchor cell stimulates vulval induction; lin-3 may encode the vulval inducing signal.	CALTECH,DIV BIOL,PASADENA,CA 91125	California Institute of Technology	HILL, RJ (corresponding author), CALTECH,HOWARD HUGHES MED INST,PASADENA,CA 91125, USA.			Sternberg, Paul/0000-0002-7699-0173				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AROIAN RV, 1991, GENETICS, V128, P251; AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; AVERY L, 1987, CELL, V51, P1071, DOI 10.1016/0092-8674(87)90593-9; BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; BRENNER S, 1974, GENETICS, V77, P71; CARPENTER G, 1990, HDB EXPT PHARM, V95, P69; CHANG W, 1987, MOL CELL BIOL, V7, P535, DOI 10.1128/MCB.7.1.535; CLARK DV, 1988, GENETICS, V119, P345; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COULSON A, 1986, P NATL ACAD SCI USA, V83, P7821, DOI 10.1073/pnas.83.20.7821; DAVIS C G, 1990, New Biologist, V2, P410; DERYNCK R, 1984, CELL, V38, P287, DOI 10.1016/0092-8674(84)90550-6; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FERGUSON EL, 1989, GENETICS, V123, P109; FERGUSON EL, 1987, NATURE, V326, P259, DOI 10.1038/326259a0; FERGUSON EL, 1985, GENETICS, V110, P17; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; GREENWALD IS, 1983, CELL, V34, P435, DOI 10.1016/0092-8674(83)90377-X; GREGORY H, 1975, NATURE, V257, P325, DOI 10.1038/257325a0; HAN M, 1990, GENETICS, V126, P899; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; HERMAN RK, 1990, NATURE, V348, P169, DOI 10.1038/348169a0; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HORVITZ HR, 1991, NATURE, V351, P535, DOI 10.1038/351535a0; HORVITZ HR, 1980, GENETICS, V96, P435; KIM SK, 1990, GENE DEV, V4, P357, DOI 10.1101/gad.4.3.357; KIMBLE J, 1981, DEV BIOL, V87, P286, DOI 10.1016/0012-1606(81)90152-4; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LIN YZ, 1991, BIOCHEMISTRY-US, V30, P3310, DOI 10.1021/bi00227a020; MASSAGUE J, 1990, J BIOL CHEM, V265, P21393; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MORI I, 1988, GENETICS, V120, P397; OCHMAN H, 1988, GENETICS, V120, P621; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; REES DJG, 1988, EMBO J, V7, P2053, DOI 10.1002/j.1460-2075.1988.tb03045.x; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROSENZWEIG B, 1983, NUCLEIC ACIDS RES, V11, P4201, DOI 10.1093/nar/11.12.4201; RUVKUN G, 1989, GENETICS, V121, P501; Sambrook J., 1989, MOL CLONING LAB MANU; SAVAGE CR, 1972, J BIOL CHEM, V247, P7612; SHOYAB M, 1989, SCIENCE, V243, P1074, DOI 10.1126/science.2466334; STERNBERG PW, 1986, CELL, V44, P761, DOI 10.1016/0092-8674(86)90842-1; STERNBERG PW, 1989, CELL, V58, P679, DOI 10.1016/0092-8674(89)90103-7; STERNBERG PW, 1988, NATURE, V335, P551, DOI 10.1038/335551a0; STROOBANT P, 1985, CELL, V42, P383, DOI 10.1016/S0092-8674(85)80133-1; SULSTON JE, 1981, DEV BIOL, V82, P41, DOI 10.1016/0012-1606(81)90427-9; SULSTON JE, 1980, DEV BIOL, V78, P577, DOI 10.1016/0012-1606(80)90353-X; TEPASS U, 1990, CELL, V61, P787, DOI 10.1016/0092-8674(90)90189-L; THOMAS JH, 1990, CELL, V62, P1041, DOI 10.1016/0092-8674(90)90382-O; UPTON C, 1987, J VIROL, V61, P1271, DOI 10.1128/JVI.61.4.1271-1275.1987; VENKATESAN S, 1982, J VIROL, V44, P637, DOI 10.1128/JVI.44.2.637-646.1982; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; Wood WB, 1988, NEMATODE CAENORHABDI; YOCHEM J, 1988, NATURE, V335, P547, DOI 10.1038/335547a0	58	321	339	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 6	1992	358	6386					470	476		10.1038/358470a0	http://dx.doi.org/10.1038/358470a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JG739	1641037				2022-12-01	WOS:A1992JG73900039
J	LAFON, M; LAFAGE, M; MARTINEZARENDS, A; RAMIREZ, R; VUILLIER, F; CHARRON, D; LOTTEAU, V; SCOTTALGARA, D				LAFON, M; LAFAGE, M; MARTINEZARENDS, A; RAMIREZ, R; VUILLIER, F; CHARRON, D; LOTTEAU, V; SCOTTALGARA, D			EVIDENCE FOR A VIRAL SUPERANTIGEN IN HUMANS	NATURE			English	Article							T-CELL; MONOCLONAL-ANTIBODIES; STAPHYLOCOCCAL ENTEROTOXINS; N-PROTEIN; HLA-DR; STIMULATION; MOLECULES; ANTIGEN; NUCLEOPROTEIN; EXPRESSION	SUPERANTIGENS1-4 bind class II major histocompatibility proteins5,6 and stimulate powerful proliferative responses of T lymphocytes bearing particular V-beta sequences as part of their alpha-beta antigen receptor7. Exogenous bacterial superantigens are responsible for food poisoning and toxic shock syndrome. Murine virus-encoded self-superantigens induce clonal deletion of T lymphocytes. Although superantigen-like properties have been suggested for human immunodeficiency virus-1, no viral superantigen has been identified in humans8. Here we report that the nucleocapsid of the rabies virus is an exogenous superantigen specific for V-beta-8 human T lymphocytes which binds to HLA class II alpha-chains.	INST BIOMED CORDELIERS,IMMUNOGENET LAB,F-75006 PARIS,FRANCE; INST PASTEUR,UNITE IMMUNOHEMATOL & IMMUNOPATHOL,F-75724 PARIS 15,FRANCE	UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	LAFON, M (corresponding author), INST PASTEUR,UNITE RAGE,25-28 RUE DOCTEUR ROUX,F-75724 PARIS 15,FRANCE.		Scott, Daniel/AFK-5428-2022; lotteau, vincent/M-8143-2014; Vuillier, Françoise/T-4699-2019	Vuillier, Francoise/0000-0002-5551-9876; Lafon, Monique/0000-0002-4423-7996; Scott-Algara, Daniel/0000-0003-1851-503X; Rafael, Ramirez/0000-0003-4598-339X; Lotteau, Vincent/0000-0003-0997-3282				BANKAMP B, 1991, J VIROL, V65, P1695, DOI 10.1128/JVI.65.4.1695-1700.1991; BARNSTABLE CJ, 1978, CELL, V14, P9, DOI 10.1016/0092-8674(78)90296-9; CARREL S, 1981, MOL IMMUNOL, V18, P403, DOI 10.1016/0161-5890(81)90102-4; CHARRON DJ, 1979, P NATL ACAD SCI USA, V76, P6567, DOI 10.1073/pnas.76.12.6567; COLE BC, 1991, IMMUNOL TODAY, V12, P271, DOI 10.1016/0167-5699(91)90125-D; DEMARS R, 1984, DIS MARKERS, V2, P175; DIETZSCHOLD B, 1987, P NATL ACAD SCI USA, V84, P9165, DOI 10.1073/pnas.84.24.9165; DIETZSCHOLD B, 1987, VIRUS RES, V8, P103, DOI 10.1016/0168-1702(87)90023-2; FLEISCHER B, 1988, J EXP MED, V167, P1697, DOI 10.1084/jem.167.5.1697; FLEISCHER B, 1991, IMMUNOL RES, V10, P349, DOI 10.1007/BF02919720; HERZOG M, 1992, VIRUS RES, V24, P77, DOI 10.1016/0168-1702(92)90032-5; HERZOG M, 1991, CLIN EXP IMMUNOL, V85, P224, DOI 10.1111/j.1365-2249.1991.tb05709.x; JANEWAY C, 1991, NATURE, V349, P459, DOI 10.1038/349459a0; JANEWAY CA, 1989, IMMUNOL REV, V107, P61, DOI 10.1111/j.1600-065X.1989.tb00003.x; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KARP DR, 1990, NATURE, V346, P474, DOI 10.1038/346474a0; LAFON M, 1985, J GEN VIROL, V66, P2125, DOI 10.1099/0022-1317-66-10-2125; LAFON M, 1990, J GEN VIROL, V71, P1689, DOI 10.1099/0022-1317-71-8-1689; LIBEAU G, 1983, BIOL STANDARD, V57, P213; LIU H, 1991, P NATL ACAD SCI USA, V88, P8705, DOI 10.1073/pnas.88.19.8705; MACDONALD HR, 1988, NATURE, V332, P40, DOI 10.1038/332040a0; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; ONO SJ, 1991, J EXP MED, V173, P629, DOI 10.1084/jem.173.3.629; PREHAUD C, 1990, VIROLOGY, V178, P486, DOI 10.1016/0042-6822(90)90346-S; RUSSELL SM, 1979, NATURE, V280, P147, DOI 10.1038/280147a0; SALTER RD, 1985, IMMUNOGENETICS, V21, P235, DOI 10.1007/BF00375376; SHERLE PA, 1986, J EXP MED, V169, P1114; WATSON AJ, 1983, NATURE, V304, P358, DOI 10.1038/304358a0; WHITE J, 1989, CELL, V56, P27, DOI 10.1016/0092-8674(89)90980-X	29	146	154	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 6	1992	358	6386					507	510		10.1038/358507a0	http://dx.doi.org/10.1038/358507a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JG739	1386410				2022-12-01	WOS:A1992JG73900051
J	SAMPSON, HA; MENDELSON, L; ROSEN, JP				SAMPSON, HA; MENDELSON, L; ROSEN, JP			FATAL AND NEAR-FATAL ANAPHYLACTIC REACTIONS TO FOOD IN CHILDREN AND ADOLESCENTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NECROSIS-FACTOR-ALPHA; MAST-CELLS; ALLERGY; INFANTS; RELEASE; MICE	Background and Methods. Reports of fatal or near-fatal anaphylactic reactions to foods in children and adolescents are rare. We identified six children and adolescents who died of anaphylactic reactions to foods and seven others who nearly died and required intubation. All the cases but one occurred in one of three metropolitan areas over a period of 14 months. Our investigations included a review of emergency medical care reports, medical records, and depositions by witnesses to the events, as well as interviews with parents (and some patients). Results. Of the 13 children and adolescents (age range, 2 to 17 years), 12 had asthma that was well controlled. All had known food allergies, but had unknowingly ingested the foods responsible for the reactions. The reactions were to peanuts (four patients), nuts (six patients), eggs (one patient), and milk (two patients), all of which were contained in foods such as candy, cookies, and pastry. The six patients who died had symptoms within 3 to 30 minutes of the ingestion of the allergen, but only two received epinephrine in the first hour. All the patients who survived had symptoms within 5 minutes of allergen ingestion, and all but one received epinephrine within 30 minutes. The course of anaphylaxis was rapidly progressive and uniphasic in seven patients; biphasic, with a relatively symptom-free interval in three; and protracted in three, requiring intubation for 3 to 21 days. Conclusions. Dangerous anaphylactic reactions to food occur in children and adolescents. The failure to recognize the severity of these reactions and to administer epinephrine promptly increases the risk of a fatal outcome.	UNIV CONNECTICUT,HARTFORD HOSP,HARTFORD,CT 06112; JOHNS HOPKINS UNIV,SCH MED,DIV PEDIAT ALLERGY & IMMUNOL,BALTIMORE,MD 21205	Hartford Hospital; University of Connecticut; Johns Hopkins University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024439] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00052] Funding Source: Medline; NIAID NIH HHS [AI24439] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOCHNER BS, 1991, NEW ENGL J MED, V324, P1785, DOI 10.1056/NEJM199106203242506; BOCK SA, 1989, J ALLERGY CLIN IMMUN, V83, P900, DOI 10.1016/0091-6749(89)90103-6; BOCK SA, 1987, PEDIATRICS, V79, P683; GERN JE, 1991, NEW ENGL J MED, V324, P976, DOI 10.1056/NEJM199104043241407; HA TY, 1987, EXP CELL BIOL, V5, P63; HIDE DW, 1983, BRIT J CLIN PRACT, V37, P285; HOST A, 1990, ALLERGY, V45, P587, DOI 10.1111/j.1398-9995.1990.tb00944.x; NATANSON C, 1989, J EXP MED, V169, P823, DOI 10.1084/jem.169.3.823; SAMPSON HA, 1988, J ALLERGY CLIN IMMUN, V81, P635, DOI 10.1016/0091-6749(88)91033-0; SCHWARTZ LB, 1989, J CLIN INVEST, V83, P1551, DOI 10.1172/JCI114051; SLOAN AE, 1986, J ALLERGY CLIN IMMUN, V78, P127, DOI 10.1016/0091-6749(86)90002-3; SMITH PL, 1980, J CLIN INVEST, V66, P1072, DOI 10.1172/JCI109936; STARK BJ, 1986, J ALLERGY CLIN IMMUN, V78, P76, DOI 10.1016/0091-6749(86)90117-X; STARNES HF, 1990, J IMMUNOL, V145, P4185; TAKEISHI T, 1991, J CLIN INVEST, V88, P598, DOI 10.1172/JCI115344; VECCHIARELLI A, 1992, CLIN EXP ALLERGY, V22, P365, DOI 10.1111/j.1365-2222.1992.tb03097.x; WALSH LJ, 1991, P NATL ACAD SCI USA, V88, P4220, DOI 10.1073/pnas.88.10.4220; YUNGINGER JW, 1991, J FORENSIC SCI, V36, P857; YUNGINGER JW, 1988, JAMA-J AM MED ASSOC, V260, P1450, DOI 10.1001/jama.260.10.1450	19	1263	1303	1	98	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 6	1992	327	6					380	384		10.1056/NEJM199208063270603	http://dx.doi.org/10.1056/NEJM199208063270603			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG356	1294076				2022-12-01	WOS:A1992JG35600003
J	SANDVIG, K; GARRED, O; PRYDZ, K; KOZLOV, JV; HANSEN, SH; VANDEURS, B				SANDVIG, K; GARRED, O; PRYDZ, K; KOZLOV, JV; HANSEN, SH; VANDEURS, B			RETROGRADE TRANSPORT OF ENDOCYTOSED SHIGA TOXIN TO THE ENDOPLASMIC-RETICULUM	NATURE			English	Article							INTERNALIZED RICIN; PSEUDOMONAS EXOTOXIN; SHIGELLA TOXIN; GOLGI NETWORK; CELLS; SEQUENCE; PROTEIN	SHIGA toxin and some other protein toxins that act on targets in the cytosol have previously been shown to enter the trans-Golgi network1-9. Transport by this route may be necessary for translocation of the toxin to the cytosol and for intoxication5-9, but it is not known whether the enzymatically active part of the toxins actually enters the cytosol from the trans-Golgi network. It has been suggested that such toxins are transported in a retrograde manner to the endoplasmic reticulum and that translocation occurs in this organelle10, but retrograde transport of endocytosed material beyond the trans-Golgi network has never been demonstrated. Here we show that in butyric acid-treated A431 cells endocytosed Shiga toxin is not only transported to the trans-Golgi network, but also to all Golgi stacks, to the endoplasmic reticulum and to the nuclear envelope. Furthermore, butyric acid sensitizes the cells to Shiga toxin, which is consistent with the possibility that retrograde transport is required for translocation of the toxin to the cytosol.	WA ENGELHARDT MOLEC BIOL INST, MOSCOW 117984, USSR; UNIV COPENHAGEN, PANUM INST, DEPT ANAT, STRUCT CELL BIOL UNIT, DK-2200 COPENHAGEN, DENMARK	Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS; University of Copenhagen	SANDVIG, K (corresponding author), NORWEGIAN RADIUM HOSP, INST CANC RES, N-0310 OSLO 3, NORWAY.			Hansen, Steen/0000-0002-9408-4676				CHAUDHARY VK, 1990, P NATL ACAD SCI USA, V87, P308, DOI 10.1073/pnas.87.1.308; HANSEN SH, 1989, EXP CELL RES, V185, P373, DOI 10.1016/0014-4827(89)90307-8; KARTENBECK J, 1989, J CELL BIOL, V109, P2721, DOI 10.1083/jcb.109.6.2721; KOZLOV YV, 1988, GENE, V67, P213, DOI 10.1016/0378-1119(88)90398-8; LEWIS MJ, 1992, CELL, V68, P353, DOI 10.1016/0092-8674(92)90476-S; OLSNES S, 1988, IMMUNOTOXINS, V1, P39; PELHAM H R B, 1992, Trends in Cell Biology, V2, P183, DOI 10.1016/0962-8924(92)90230-K; SANDVIG K, 1986, CANCER RES, V46, P6418; SANDVIG K, 1991, J CELL BIOL, V113, P553, DOI 10.1083/jcb.113.3.553; SANDVIG K, 1989, J CELL BIOL, V108, P1331, DOI 10.1083/jcb.108.4.1331; SEETHARAM S, 1991, J BIOL CHEM, V266, P17376; SEIDAH NG, 1986, J BIOL CHEM, V261, P13928; STROCKBINE NA, 1988, J BACTERIOL, V170, P1116, DOI 10.1128/jb.170.3.1116-1122.1988; VAN PN, 1989, J BIOL CHEM, V264, P17494; VANDEURS B, 1988, J CELL BIOL, V106, P253, DOI 10.1083/jcb.106.2.253; VANDEURS B, 1989, INT REV CYTOL, V117, P131; VANDEURS B, 1986, J CELL BIOL, V102, P37, DOI 10.1083/jcb.102.1.37; YOULE RJ, 1987, J BIOL CHEM, V262, P4676	18	381	394	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 6	1992	358	6386					510	512		10.1038/358510a0	http://dx.doi.org/10.1038/358510a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JG739	1641040				2022-12-01	WOS:A1992JG73900052
J	SENDTNER, M; SCHMALBRUCH, H; STOCKLI, KA; CARROLL, P; KREUTZBERG, GW; THOENEN, H				SENDTNER, M; SCHMALBRUCH, H; STOCKLI, KA; CARROLL, P; KREUTZBERG, GW; THOENEN, H			CILIARY NEUROTROPHIC FACTOR PREVENTS DEGENERATION OF MOTOR NEURONS IN MOUSE MUTANT PROGRESSIVE MOTOR NEURONOPATHY	NATURE			English	Article							NERVE GROWTH-FACTOR; SPINAL-CORD; FACTOR CNTF; EXPRESSION; SURVIVAL; RAT; SEQUENCE; CULTURE; CLONING	CILIARY neurotrophic factor (CNTF) supports the survival of embryonic motor neurons in vitro1,2 and in vivo3, and prevents lesion-mediated degeneration of rat motor neurons during early post-natal stages4. Here we report that CNTF greatly reduces all the functional and morphological changes in pmn/pmn mice5, an autosomal recessive mutant leading to progressive caudo-cranial motor neuron degeneration. The first manifestations of progressive motor neuronopathy in homozygous pmn/pmn mice become apparent in the hind limbs at the end of the third post-natal week, and all the mice die up to 6 or 7 weeks after birth from respiratory paralysis. Treatment with CNTF prolongs survival and greatly improves motor function of these mice. Moreover, morphological manifestations, such as loss of motor axons in the phrenic nerve and degeneration of facial motor neurons, were greatly reduced by CNTF, although the treatment did not start until the first symptoms of the disease had already become apparent and substantial degenerative changes were already present. The protective and restorative effects of CNTF in this mouse mutant give new perspectives for the treatment of human degenerative motor neuron diseases with CNTF.	MAX PLANCK INST PSYCHIAT,DEPT NEUROMORPHOL,W-8033 MARTINSRIED,GERMANY; UNIV COPENHAGEN,PANUM INST,INST NEUROPHYSIOL,DK-2200 COPENHAGEN,DENMARK	Max Planck Society; University of Copenhagen	SENDTNER, M (corresponding author), MAX PLANCK INST PSYCHIAT,DEPT NEUROCHEM,W-8033 MARTINSRIED,GERMANY.		Carroll, Patrick/AAL-7773-2021; Sendtner, Michael/M-8137-2014; Sendtner, Michael/J-1542-2012	Sendtner, Michael/0000-0002-4737-2974; Sendtner, Michael/0000-0002-4737-2974				ARAKAWA Y, 1990, J NEUROSCI, V10, P3507; DUCHEN LW, 1968, J NEUROL NEUROSUR PS, V31, P535, DOI 10.1136/jnnp.31.6.535; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; Hirano A., 1979, AMYOTROPHIC LATERAL, P107; HUGHES SM, 1988, NATURE, V335, P70, DOI 10.1038/335070a0; KAUPMANN K, 1992, GENOMICS, V13, P39, DOI 10.1016/0888-7543(92)90199-3; KLUVER H, 1953, J NEUROPATH EXP NEUR, V12, P400; LIN LFH, 1989, SCIENCE, V246, P1023, DOI 10.1126/science.2587985; MAGAL E, 1991, DEV BRAIN RES, V63, P141, DOI 10.1016/0165-3806(91)90074-S; MESSER A, 1987, J NEUROGENET, V4, P201, DOI 10.3109/01677068709102341; MESSER A, 1986, J NEUROGENET, V3, P345, DOI 10.3109/01677068609106858; OPPENHEIM RW, 1986, J COMP NEUROL, V246, P281, DOI 10.1002/cne.902460211; OPPENHEIM RW, 1991, SCIENCE, V251, P1616, DOI 10.1126/science.2011743; POLLIN MM, 1990, J NEUROCYTOL, V19, P29, DOI 10.1007/BF01188437; SCHMALBRUCH H, 1991, J NEUROPATH EXP NEUR, V50, P192, DOI 10.1097/00005072-199105000-00002; SCOTT J, 1983, NATURE, V302, P538, DOI 10.1038/302538a0; SENDTNER M, 1990, NATURE, V345, P440, DOI 10.1038/345440a0; SENDTNER M, IN PRESS J CELL BIOL; SENDTNER M, 1991, J CELL SCI S, V15, P103; STOCKLI KA, 1989, NATURE, V342, P920, DOI 10.1038/342920a0; ULLRICH A, 1983, NATURE, V303, P821, DOI 10.1038/303821a0	21	541	553	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 6	1992	358	6386					502	504		10.1038/358502a0	http://dx.doi.org/10.1038/358502a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JG739	1641039	Green Submitted			2022-12-01	WOS:A1992JG73900049
J	AMITAI, Y; ALMOG, S; SINGER, R; HAMMER, R; BENTUR, Y; DANON, YL				AMITAI, Y; ALMOG, S; SINGER, R; HAMMER, R; BENTUR, Y; DANON, YL			ATROPINE POISONING IN CHILDREN DURING THE PERSIAN GULF CRISIS - A NATIONAL SURVEY IN ISRAEL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							PHARMACOKINETICS	Objective.-To evaluate the effects of high doses of atropine in children accidentally injected with automatic atropine injectors. These were distributed in Israel during the Persian Gulf Crisis as an antidote for chemical warfare agents. Design and Setting.-A national survey in pediatric emergency departments in Israel, involving 22 medical centers, with prospective data collection in 14 centers. Patients.-Children (n=268) presenting to emergency departments following misuse of automatic atropine injectors. Main Outcome Measures.-Documentation of atropine dose and clinical manifestations; determination of a clinical severity score and its correlation with atropine dose; measurements of serum atropine levels in six patients. Results.-Over a period of 4 months, 268 cases were reported, of which 240 were clinically evaluated. The most common site of injection (75%) was the finger or palm. Doses were up to 17-fold higher than standard doses for age. In 116 children (48%), systemic effects of atropine were observed, and 20 (8%) had severe atropinization. Seizures and life-threatening arrhythmias were not reported, and there were no fatalities. The severity of atropinization was correlated with the dose following a classic nonlinear, dose-response relationship. Serum atropine levels (6.2 to 61.0 ng/mL) were much higher than those observed after administration of therapeutic doses. Conclusions.-The high incidence of injection in the hand implies accidental use of automatic atropine injectors among children. The lack of mortality or life-threatening complications from injection of large doses of atropine attests to its relative safety in children. The low risk from atropine injections weighed against expected benefit as a lifesaving antidote justifies the distribution of personal atropine injectors to children at risk of organophosphorus nerve agent attack.	CHAIM SHEBA MED CTR, INST CLIN PHARMACOL & TOXICOL, IL-52621 TEL HASHOMER, ISRAEL; SOROKA MED CTR, IL-84101 BEER SHEVA, ISRAEL; ISRAELS NATL POISON INFORMAT CTR, HAIFA, ISRAEL; CHILDRENS MED CTR ISRAEL, PETAH TIQWA, ISRAEL	Chaim Sheba Medical Center; Ben Gurion University; Soroka Medical Center	AMITAI, Y (corresponding author), HADASSAH UNIV HOSP, DEPT PEDIAT, MT SCOPUS, IL-91240 JERUSALEM, ISRAEL.							ADAMS RG, 1982, J CLIN PHARMACOL, V22, P477, DOI 10.1002/j.1552-4604.1982.tb02638.x; BERGHEM L, 1980, BRIT J ANAESTH, V52, P597, DOI 10.1093/bja/52.6.597; Brown JH, 1990, PHARM BASIS THERAPEU, V8th, P150; FASTH A, 1975, ACTA PHARM SUEC, V12, P311; HEATH WE, 1950, BRIT MED J, V2, P608, DOI 10.1136/bmj.2.4679.608; HINDERLING PH, 1985, J PHARM SCI-US, V74, P703, DOI 10.1002/jps.2600740702; HOLFORD NHG, 1982, PHARMACOL THERAPEUT, V16, P143, DOI 10.1016/0163-7258(82)90051-1; KETCHUM JS, 1973, PSYCHOPHARMACOLOGIA, V28, P121, DOI 10.1007/BF00421398; Morton HG, 1939, J PEDIATR-US, V14, P755, DOI 10.1016/S0022-3476(39)80097-X; Munns GF, 1929, J AMER MED ASSOC, V96, P171; OLSSON GL, 1983, ANAESTHESIA, V38, P1179, DOI 10.1111/j.1365-2044.1983.tb12521.x; Owens SM, 1890, LANCET, Vii, P443; Pilcher JD, 1934, J PHARMACOL EXP THER, V52, P196; SECORD E, 1991, AM J DIS CHILD, V145, P724	14	28	28	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 5	1992	268	5					630	632		10.1001/jama.268.5.630	http://dx.doi.org/10.1001/jama.268.5.630			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JF473	1629992				2022-12-01	WOS:A1992JF47300029
J	BLEICH, A; DYCIAN, A; KOSLOWSKY, M; SOLOMON, Z; WIENER, M				BLEICH, A; DYCIAN, A; KOSLOWSKY, M; SOLOMON, Z; WIENER, M			PSYCHIATRIC IMPLICATIONS OF MISSILE ATTACKS ON A CIVILIAN POPULATION - ISRAELI LESSONS FROM THE PERSIAN-GULF-WAR	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LEBANON WAR	Objective.-To determine the proportion of hospitalized patients who had stress reactions as a result of missile attacks during the Persian Gulf War and evaluate the factors that influenced their evacuation. Design.-Review of medical records of patients hospitalized as a result of missile attacks. Setting.-During the Persian Gulf War in the winter of 1991, Israel received 18 missile attacks involving 39 surface-to-surface Scud missiles. The uncertainty in time, place, and type of warhead, conventional or chemical, was a source of chronic stress and the immediate cause for many traumatic stress reactions at or near the missile attack sites. Participants.-Data from victims who were injured after each missile attack were available through a central hookup between 12 local hospitals and the Medical Corps of the Israeli Defence Force. Main Outcome Measure.-The number of persons diagnosed in the hospital as psychological casualties after each missile attack. Results.-Approximately 43% of the 773 casualties evacuated to hospitals were diagnosed as psychological casualties, and an additional 27% had mistakenly injected themselves with atropine. Data also indicated that triage of psychological casualties to hospitals was more a function of the rescue team's training and preparation than the severity or extent of injury or damage. Conclusions.-Optimal treatment during events that cause mass casualties requires proper preparation of rescue teams as well as reorganization of the hospital' s psychiatric services. The threat of chemical warfare affected the number and nature of stress reactions.	TEL AVIV UNIV,SACKLER SCH MED,TEL AVIV,ISRAEL; TEL AVIV UNIV,SHAPEL SCH SOCIAL WORK,IL-69978 TEL AVIV,ISRAEL; BAR ILAN UNIV,DEPT PSYCHOL,RAMAT GAN,ISRAEL	Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Bar Ilan University	BLEICH, A (corresponding author), ISRAEL DEF FORCES,MED CORPS,DEPT MENTAL HLTH,MIL POB 02149,JERUSALEM,ISRAEL.							BELENKY GL, 1987, PSYCHIAT ANN, V17, P528, DOI 10.3928/0048-5713-19870801-06; BURKLE F M JR, 1991, Emergency Medicine Clinics of North America, V9, P87; BUYDENSBRANCHEY L, 1990, J NERV MENT DIS, V178, P582, DOI 10.1097/00005053-199009000-00005; DUNN CL, 1952, EMERGENCY MED SERVIC, V1, P170; HISS J, 1992, BRIT MED J, V304, P92, DOI 10.1136/bmj.304.6819.92; KARSENTY E, 1991, ISRAEL J MED SCI, V27, P603; Kormos HR, 1978, STRESS DISORDERS VIE, P3; NEWHOUSE P, 1987, CONT STUDIES COMBAT, P185; NOY S, 1984, ISRAEL J MED SCI, V20, P360; OBALLANCE E, 1988, GULF WAR, P103; RACHMAN SJ, 1990, FEAR COURAGE, P25; SMITH EM, 1990, AM J PSYCHIAT, V147, P202; SOLOMON Z, 1986, AM J PSYCHIAT, V143, P613	13	66	66	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 5	1992	268	5					613	615		10.1001/jama.268.5.613	http://dx.doi.org/10.1001/jama.268.5.613			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JF473	1629988				2022-12-01	WOS:A1992JF47300025
J	BORTIN, MM; HOROWITZ, MM; GALE, RP; BARRETT, AJ; CHAMPLIN, RE; DICKE, KA; GLUCKMAN, E; KOLB, HJ; MARMONT, AM; MRSIC, M; SOBOCINSKI, KA; WEINER, RS; RIMM, AA				BORTIN, MM; HOROWITZ, MM; GALE, RP; BARRETT, AJ; CHAMPLIN, RE; DICKE, KA; GLUCKMAN, E; KOLB, HJ; MARMONT, AM; MRSIC, M; SOBOCINSKI, KA; WEINER, RS; RIMM, AA			CHANGING TRENDS IN ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR LEUKEMIA IN THE 1980S	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							VERSUS-HOST DISEASE; CYTOMEGALO-VIRUS INFECTION; TOTAL-BODY IRRADIATION; T-CELL DEPLETION; ACUTE NONLYMPHOBLASTIC LEUKEMIA; CHRONIC MYELOGENOUS LEUKEMIA; INTRAVENOUS IMMUNE GLOBULIN; ACUTE GRAFT; INCREASING UTILIZATION; APLASTIC-ANEMIA	Objective.-To identify changes in practice and outcome of bone marrow transplants for leukemia in the 1980s. Design.-Comparison of key explanatory and outcome variables in five 2-year cohorts, from 1980 through 1981 to 1988 through 1989, using a large database of detailed clinical information. Patients.-Recipients (7788) of bone marrow transplants for acute lymphoblastic, acute myelogenous, or chronic myelogenous leukemia reported to the International Bone Marrow Transplant Registry, Milwaukee, Wis, by 185 transplant teams worldwide. Results.-Linear increases occurred during the periods 1980 through 1981 to 1988 through 1989 as follows with 95% confidence intervals: (1) transplants for chronic myelogenous leukemia from 14%+/-2% to 35%+/-2%; (2) transplants from unrelated donors from 1%+/-1% to 7%+/-1%; (3) preparative regimens without radiation from 3%+/-1% to 30%+/-2%; and (4) use of methotrexate plus cyclosporine to prevent graft-vs-host disease from 2%+/-1% to 55%+/-2%. Among recipients of human lymphocyte antigen-identical sibling bone marrow, the 2-year probability of treatment-related mortality decreased by 6% to 22%. The probability of relapse decreased from 46%+/-6% to 38%+/-6% in intermediate leukemia but did not change appreciably in early or advanced leukemia. Probabilities of leukemia-free survival improved from 51%+/-4% to 57%+/-3% in early leukemia, from 28%+/-4% to 36%+/-5% in intermediate leukemia, and from 12%+/-4% to 18%+/-5% in advanced leukemia. A separate analysis of a homogenous population of patients indicated that improvements in outcome in the 1980s were due to improvements in transplant practice rather than improved patient selection. Conclusions.-Modest increases in leukemia-free survival rates occurred after human lymphocyte antigen-identical sibling bone marrow transplants in the 1980s. Improvements were due primarily to reductions in treatment-related mortality with little or no change in relapse risk. More effective antileukemia strategies and continued reductions in treatment-related toxic effects are needed.	MED COLL WISCONSIN, INT BONE MARROW TRANSPLANT REGISTRY, POB 26509, MILWAUKEE, WI 53226 USA; MED COLL WISCONSIN, DIV CANC & BLOOD DIS, MILWAUKEE, WI 53226 USA; MED COLL WISCONSIN, DIV BIOSTAT CLIN EPIDEMIOL, MILWAUKEE, WI 53226 USA; UNIV CALIF LOS ANGELES, CTR HLTH SCI, LOS ANGELES, CA 90024 USA; ROYAL POSTGRAD MED SCH, LONDON W12 0HS, ENGLAND; MD ANDERSON CANC CTR, HOUSTON, TX USA; CTR CANC PREVENT & TREATMENT, HOUSTON, TX USA; HOP ST LOUIS, F-75010 PARIS, FRANCE; UNIV MUNICH, W-8000 MUNICH 2, GERMANY; OSPED SAN MARTINO GENOVA, GENOA, ITALY; UNIV CROATIA, ZAGREB, CROATIA; UNIV FLORIDA, GAINESVILLE, FL 32611 USA	Medical College of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin; University of California System; University of California Los Angeles; Imperial College London; University of Texas System; UTMD Anderson Cancer Center; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; University of Munich; University of Genoa; IRCCS AOU San Martino IST; State University System of Florida; University of Florida			horowitz, Mary/ABH-2173-2021; eliane, Gluckman/AAA-5024-2021		NCI NIH HHS [P01-CA-40053] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA040053] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		APPERLEY JF, 1986, BONE MARROW TRANSPL, V1, P53; ASH RC, 1989, BLOOD, V74, pA163; ATKINSON K, 1991, EXP HEMATOL, V19, P578; BIGGS JC, 1986, TRANSPLANT P, V18, P253; BLUME KG, 1987, BLOOD, V69, P1015; BORTIN MM, 1989, TRANSPLANTATION, V48, P453, DOI 10.1097/00007890-198909000-00021; BORTIN MM, 1992, ANN INTERN MED, V116, P505, DOI 10.7326/0003-4819-116-6-505; BORTIN MM, 1986, TRANSPLANTATION, V42, P229, DOI 10.1097/00007890-198609000-00001; BROCHSTEIN JA, 1987, NEW ENGL J MED, V317, P1618, DOI 10.1056/NEJM198712243172602; CLIFT R, 1989, BONE MARROW TRANSPL, V4, P445; CLIFT RA, 1987, BONE MARROW TRANSPL, V2, P243; Cochran W.G., 1963, SAMPLING TECHNIQUES; DEEG HJ, 1985, BLOOD, V65, P1325, DOI 10.1182/blood.V65.6.1325.bloodjournal6561325; EMANUEL D, 1988, ANN INTERN MED, V109, P777, DOI 10.7326/0003-4819-109-10-777; FORMAN SJ, 1987, TRANSPLANT P, V19, P2605; GOLDMAN JM, 1988, ANN INTERN MED, V108, P806, DOI 10.7326/0003-4819-108-6-806; GOTTLIEB DJ, 1989, BLOOD, V74, P2335; GRATWOHL A, 1987, Bone Marrow Transplantation, V2, P15; HERZIG RH, 1985, SEMIN ONCOL, V12, P184; HOROWITZ MM, 1989, BONE MARROW TRANSPL, V4, P221; KLINTMALM G, 1985, SCAND J INFECT DIS, V17, P157, DOI 10.3109/inf.1985.17.issue-2.06; MARMONT AM, 1991, BLOOD, V78, P2120, DOI 10.1182/blood.V78.8.2120.bloodjournal7882120; MEYERS JD, 1988, NEW ENGL J MED, V318, P70, DOI 10.1056/NEJM198801143180202; NAVARI RM, 1984, AM J MED, V76, P564, DOI 10.1016/0002-9343(84)90274-2; PETERSEN FB, 1987, SCAND J INFECT DIS, V19, P559, DOI 10.3109/00365548709032423; PRENTICE HG, 1984, LANCET, V1, P472; REED EC, 1988, ANN INTERN MED, V109, P783, DOI 10.7326/0003-4819-109-10-783; RINGDEN O, 1986, BONE MARROW TRANSPL, V1, P41; SANTOS GW, 1983, NEW ENGL J MED, V309, P1347, DOI 10.1056/NEJM198312013092202; STORB R, 1985, BLOOD, V66, P698; STORB R, 1986, BLOOD, V68, P119; STORB R, 1986, NEW ENGL J MED, V314, P729, DOI 10.1056/NEJM198603203141201; STORB R, 1970, TRANSPLANTATION, V9, P240, DOI 10.1097/00007890-197003000-00007; THOMAS ED, 1982, INT J RADIAT ONCOL, V8, P817, DOI 10.1016/0360-3016(82)90083-9; THOMAS ED, 1986, ANN INTERN MED, V104, P155, DOI 10.7326/0003-4819-104-2-155; TORLONTANO G, 1981, EUR BONE MARROW TRAN, P41; TORRES A, 1989, BLUT, V58, P63, DOI 10.1007/BF00320650; TUTSCHKA PJ, 1986, VOX SANG, V51, P87, DOI 10.1111/j.1423-0410.1986.tb02014.x; WALDMANN H, 1984, LANCET, V2, P483; WINSTON DJ, 1987, ANN INTERN MED, V106, P12, DOI 10.7326/0003-4819-106-1-12	40	66	66	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 5	1992	268	5					607	612						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JF473	1321298				2022-12-01	WOS:A1992JF47300024
J	METTLER, FA; WILLIAMSON, MR; ROYAL, HD; HURLEY, JR; KHAFAGI, F; SHEPPARD, MC; BERAL, V; REEVES, G; SAENGER, EL; YOKOYAMA, N; PARSHIN, V; GRIAZNOVA, EA; TARANENKO, M; CHESIN, V; CHEBAN, A				METTLER, FA; WILLIAMSON, MR; ROYAL, HD; HURLEY, JR; KHAFAGI, F; SHEPPARD, MC; BERAL, V; REEVES, G; SAENGER, EL; YOKOYAMA, N; PARSHIN, V; GRIAZNOVA, EA; TARANENKO, M; CHESIN, V; CHEBAN, A			THYROID-NODULES IN THE POPULATION LIVING AROUND CHERNOBYL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DISEASE; ULTRASONOGRAPHY; NODULARITY; RADIATION; IRRADIATION; MANAGEMENT; CHILDHOOD; CHILDREN	Objective.-To determine the baseline incidence, prevalence, and characteristics of thyroid nodules in the population living around the Chernobyl nuclear power plant and to compare the findings with unexposed populations. Design.-Prevalence study. Population samples from seven highly contaminated villages were compared with six nearby control villages of the same size and type. The data were obtained as part of the International Chernobyl Project conducted in 1990. Setting.-The study was conducted 4.5 years after the Chernobyl reactor accident that released large quantities of radionuclides, including radioiodine. Patients or Other Participants.-Population samples of approximately 100 persons residing in both highly contaminated villages and control villages since the accident were compared. Individuals were selected on the basis of birth date as being 5, 10, 40, or 60 years old at the time of the study. All persons selected underwent a thyroid examination. Interventions.-None. Main Outcome Measures.-Two main outcome measures were used, both for thyroid nodularity: clinical palpation and high-resolution ultrasonography. Results.-There was no significant difference in thyroid nodularity between the study groups. Nodules were palpated in 0.7% of children and 2.9% of adults. Discrete nodules were found by ultrasonography in 0.5% of children and 14.9% of adults. Multinodular goiter was found in 3% of adults. Nodules were more common in females. Conclusions.-Four and a half years after the Chernobyl accident, the incidence, prevalence, and characteristics of thyroid nodules were the same in population samples from both highly contaminated and control settlements and similar to results reported for unexposed populations in other countries.	WASHINGTON UNIV,SCH MED,DEPT RADIOL,ST LOUIS,MO 63110; CORNELL UNIV,MED CTR,NEW YORK HOSP,SCH MED,DEPT NUCL MED,NEW YORK,NY 10021; ROYAL BRISBANE HOSP,SCH MED,DEPT NUCL MED,BRISBANE,QLD 4029,AUSTRALIA; UNIV BIRMINGHAM,SCH MED,DEPT MED,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND; RADCLIFFE INFIRM,CANC EPIDEMIOL UNIT,IMPERIAL CANC RES FUND,OXFORD OX2 6HE,ENGLAND; UNIV CINCINNATI HOSP,MED CTR RADIOISOTOPE LAB,CINCINNATI,OH; RADIAT EFFECT RES FDN,NAGASAKI,JAPAN; ACAD MED SCI OBINSK,INST MED RADIOL,OBNINSK,USSR; MINIST PUBL HLTH USSR,INST BIOPHYS,MOSCOW,USSR; KIEV UNION SCI CTR RADIAT MED,KIEV,UKRAINE,USSR	Washington University (WUSTL); Cornell University; NewYork-Presbyterian Hospital; Royal Brisbane & Women's Hospital; University of Birmingham; Radcliffe Infirmary; University of Oxford; University System of Ohio; University of Cincinnati; Radiation Effects Research Foundation - Japan; National Academy of Medical Sciences of Ukraine; National Research Center for Radiation Medicine of National Academy of Medical Sciences of Ukraine	METTLER, FA (corresponding author), UNIV NEW MEXICO,SCH MED,DEPT RADIOL,ALBUQUERQUE,NM 87131, USA.							ASHCRAFT MW, 1981, HEAD NECK SURG, V3, P216, DOI 10.1002/hed.2890030309; BANDER A, 1991, RADIOLOGY, V181, P683; Breslow NE., 1980, IARC SCI PUBLICATION, V32; CARROLL BA, 1982, AM J ROENTGENOL, V133, P499; HAY ID, 1984, LANCET, V1, P916; HAY ID, 1988, CURR MED, V5, P22; HAYASHI N, 1986, Acta Radiologica Diagnosis, V27, P403; HORLOCKER T, 1986, THYROIDOLOGY, P1309; ILYIN L A, 1990, Journal of Radiological Protection, V10, P3, DOI 10.1088/0952-4746/10/1/001; KAPLAN MM, 1988, J CLIN ENDOCR METAB, V66, P376, DOI 10.1210/jcem-66-2-376; KATZ JF, 1984, RADIOLOGY, V151, P741, DOI 10.1148/radiology.151.3.6718735; MAXON HR, 1977, AM J MED, V63, P967, DOI 10.1016/0002-9343(77)90552-6; MORTENSEN JD, 1955, J CLIN ENDOCR METAB, V15, P1270, DOI 10.1210/jcem-15-10-1270; NAGATAKI S, 1989, RAD THYROID, P1; POTTERN LM, 1990, J CLIN EPIDEMIOL, V43, P449, DOI 10.1016/0895-4356(90)90133-A; RALLISON ML, 1974, AM J MED, V56, P457, DOI 10.1016/0002-9343(74)90476-8; RALLISON ML, 1975, JAMA-J AM MED ASSOC, V233, P1069, DOI 10.1001/jama.233.10.1069; ROBBINS J, 1989, RAD THYROID, P11; ROJESKI MT, 1985, NEW ENGL J MED, V313, P428, DOI 10.1056/NEJM198508153130707; RON E, 1989, RADIAT RES, V120, P516, DOI 10.2307/3577801; SCHIBLE W, 1979, RADIOLOGY, V133, P413; SHORE R, 1984, J NATL CANCER I, V74, P1177; STARK DD, 1983, SURGERY, V94, P863; VANDER JB, 1968, ANN INTERN MED, V69, P537, DOI 10.7326/0003-4819-69-3-537; WANG ZY, 1990, JNCI-J NATL CANCER I, V82, P478, DOI 10.1093/jnci/82.6.478; WOESTYN J, 1985, BRIT J RADIOL, V58, P1179, DOI 10.1259/0007-1285-58-696-1179; 1991, TECHNICAL REPORT INT	27	59	60	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 5	1992	268	5					616	619		10.1001/jama.268.5.616	http://dx.doi.org/10.1001/jama.268.5.616			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JF473	1629989				2022-12-01	WOS:A1992JF47300026
J	BARNES, DM; HANBY, AM; GILLETT, CE; MOHAMMED, S; HODGSON, S; BOBROW, LG; LEIGH, IM; PURKIS, T; MACGEOCH, C; SPURR, NK; BARTEK, J; VOJTESEK, B; PICKSLEY, SM; LANE, DP				BARNES, DM; HANBY, AM; GILLETT, CE; MOHAMMED, S; HODGSON, S; BOBROW, LG; LEIGH, IM; PURKIS, T; MACGEOCH, C; SPURR, NK; BARTEK, J; VOJTESEK, B; PICKSLEY, SM; LANE, DP			ABNORMAL EXPRESSION OF WILD TYPE-P53 PROTEIN IN NORMAL-CELLS OF A CANCER FAMILY PATIENT	LANCET			English	Article							LI-FRAUMENI SYNDROME; SKIN FIBROBLASTS; P53; MUTATIONS; ONCOGENE; COLON; DNA	Mutations in the p53 gene are the commonest specific genetic change in human cancer. In normal tissues, p53 protein is present in such low quantities that it is not readily detectable by immunochemical techniques. However, in many tumour cells large amounts of p53 protein accumulate and can be seen by simple immunohistochemical staining; this is generally attributed to the accumulation of stabilised, mutant protein. We have found a mother and daughter, who both have a history of breast cancer, who show strong immunohistochemical staining of p53 in most of their normal epithelial and mesenchymal cells. Their family has a history of multiple cancers developing at an early age. Detailed protein analysis and gene sequencing of material obtained from cultured cells, grown from a skin biopsy taken from the daughter, suggest that her cells contained large quantities of normal (unmutated) p53. We suggest that this phenotype defines a new inherited cancer susceptibility syndrome that is distinct from the germ-line mutations in p53 found in some Li-Fraumeni families. This new syndrome affects p53 tumour suppressor function through an indirect mechanism that stabilises normal p53. It remains to be established whether this mechanism also contributes to the accumulation of p53 in sporadic cancers.	UNIV DUNDEE, DEPT BIOCHEM, CANC RES CAMPAIGN LABS, DUNDEE DD1 4HN, SCOTLAND; ROYAL LONDON HOSP, IMPERIAL CANC RES FUND, SKIN LAB, LONDON, ENGLAND; INST HEMATOL & BLOOD TRANSFUS, PRAGUE 10, CZECHOSLOVAKIA; GUYS HOSP, IMPERIAL CANC RES FUND, CLIN ONCOL UNIT, LONDON SE1 9RT, ENGLAND; IMPERIAL CANC RES FUND, HISTOPATHOL UNIT, LONDON WC2A 3PX, ENGLAND; GUYS HOSP, CLIN GENET UNIT, LONDON SE1 9RT, ENGLAND; CLARE HALL LABS, POTTERS BAR, ENGLAND	University of Dundee; Barts Health NHS Trust; Royal London Hospital; Cancer Research UK; Institute of Hematology Prague; Cancer Research UK; Guy's & St Thomas' NHS Foundation Trust; Cancer Research UK; Guy's & St Thomas' NHS Foundation Trust			Lane, David P/C-4920-2008; Bartek, Jiri/G-5870-2014					BARTEK J, 1990, ONCOGENE, V5, P893; BENNETT WP, 1991, ONCOGENE, V6, P1779; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HALL PA, 1991, LANCET, V338, P513, DOI 10.1016/0140-6736(91)90586-E; HARLOW E, 1988, ANTIBODIES LABORATOR; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; KASTAN MB, 1991, CANCER RES, V51, P6304; KOPELOVICH L, 1984, CANCER INVEST, V2, P333, DOI 10.3109/07357908409040309; KOPELOVICH L, 1986, J NATL CANCER I, V77, P1241; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MARKS JR, 1991, CANCER RES, V51, P2979; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; MIDGLEY CA, 1992, J CELL SCI, V101, P183; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; SANTIBANEZKOREF MF, 1991, LANCET, V338, P1490, DOI 10.1016/0140-6736(91)92303-J; SRIVASTAVA S, 1992, ONCOGENE, V7, P987; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; WARREN W, 1992, ONCOGENE, V7, P1043	23	230	230	0	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 1	1992	340	8814					259	263		10.1016/0140-6736(92)92354-I	http://dx.doi.org/10.1016/0140-6736(92)92354-I			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG665	1353190				2022-12-01	WOS:A1992JG66500002
J	BEEKEN, S; WATERSTON, T				BEEKEN, S; WATERSTON, T			HEALTH-SERVICE SUPPORT OF BREAST-FEEDING - ARE WE PRACTICING WHAT WE PREACH	BRITISH MEDICAL JOURNAL			English	Article								Objective-To ascertain the attitudes of health professionals and breast feeding mothers to breast feeding and their views on current practice. Design-Questionnaire to all midwives and health visitors and to breast feeding mothers in Newcastle upon Tyne. Setting-Maternity units and community in Newcastle upon Tyne. Subjects-127 hospital midwives, 23 community midwives, 63 health visitors, and 50 first time breast feeding mothers. Results-Optimum practice guidelines were not followed. 30 (60%) mothers said they were separated from their babies on the first night after birth. 82 (42%) professionals said that breast fed babies were frequently given water to drink. 28 (56%) babies in the mothers survey had received food or water other than breast milk; 19 of these had been given water. Professionals expressed mainly positive attitudes towards breast feeding in general but less positive attitudes to specific issues such as the beneficial effects on child health and the value of voluntary organisations in breast feeding promotion and management. Conclusions-Although many health workers are in favour of breast feeding there is conflict among the professions working most closely with breast feeding mothers. Good breast feeding support requires closer attention to monitoring hospital practices and continued training on good lactation management.	NEWCASTLE GEN HOSP,NEWCASTLE TYNE NE4 6BE,TYNE & WEAR,ENGLAND	Newcastle General Hospital								BLOOM K, 1982, ACTA PAEDIATR SC   S, V300, P9; CRUSE P, 1978, ARCH DIS CHILD, V53, P76, DOI 10.1136/adc.53.1.76; EMERY JL, 1990, ARCH DIS CHILD-FETAL, V65, P369, DOI 10.1136/adc.65.4_Spec_No.369; FRANK DA, 1987, PEDIATRICS, V80, P845; Grant J. Shaw, 1992, SHILLING YOUR SCOWL, P44; HOWIE PW, 1990, BRIT MED J, V300, P11, DOI 10.1136/bmj.300.6716.11; JELLIFE DB, 1988, PROGRAMMES PROMOTE B; LUCAS A, 1990, LANCET, V336, P1519, DOI 10.1016/0140-6736(90)93304-8; MARTIN J, 1988, INFANT FEEDING 1985; SALARIYA EM, 1978, LANCET, V2, P1141; WELLS N, 1987, PROGR CHILD HLTH, V3; 1988, C LAUNCH JOINT BREAS; 1988, SUCCESSFUL BREASTFEE	13	33	33	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 1	1992	305	6848					285	287		10.1136/bmj.305.6848.285	http://dx.doi.org/10.1136/bmj.305.6848.285			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG740	1392861	Green Published, Green Submitted, Bronze			2022-12-01	WOS:A1992JG74000019
J	CHUA, A; KEATING, J; HAMILTON, D; KEELING, PWN; DINAN, TG				CHUA, A; KEATING, J; HAMILTON, D; KEELING, PWN; DINAN, TG			CENTRAL SEROTONIN RECEPTORS AND DELAYED GASTRIC-EMPTYING IN NONULCER DYSPEPSIA	BRITISH MEDICAL JOURNAL			English	Article							NONULCER DYSPEPSIA; DIAGNOSIS; MOTILITY; GUT; EPIDEMIOLOGY; FENFLURAMINE; DISORDERS; RESPONSES; ANOREXIA; PATHWAYS	Objective-To determine whether central serotonin receptors are involved in the pathophysiology of non-ulcer dyspepsia. Design-Between subjects study of solid phase gastric emptying and prolactin response to buspirone challenge. Subjects-12 patients fulfilling criteria for non-ulcer dyspepsia and 12 age and sex matched controls. Main outcome measures-Solid phase gastric emptying measured by scintigraphic assessment of the movement of a standard meal labelled with technetium-99m and indium-111; responsiveness of central serotonin 1A receptors measured by the prolactin release following challenge with oral buspirone 60 mg. Results-Solid phase gastric emptying was significantly delayed in the patients with non-ulcer dyspepsia (t1/2=90.6 (SD 14.5) minutes in patients and 54.6 (10.7) minutes in controls; 95% confidence interval 24.7 to 46.7 minutes, p<0.001). Prolactin release was significantly greater in patients compared with controls (1272.7 (1039.9) mU/l v 292.9 (136.1) mU/l; 352.1 to 1607.5 mU/l, p<0.01). Gastric emptying and prolactin release were significantly correlated (r=0.59, p=0.04) in the patients but not in the controls (r=0.23). Conclusion-Central serotonin IA receptors may have a role in the pathophysiology of non-ulcer dyspepsia of the dysmotility subtype.	ST JAMES HOSP,TRINITY COLL,SCH MED,DEPT GASTROENTEROL,DUBLIN 8,IRELAND; ST JAMES HOSP,TRINITY COLL,SCH MED,DEPT NUCL MED,DUBLIN 8,IRELAND; ST JAMES HOSP,TRINITY COLL,SCH MED,DEPT PSYCHIAT,DUBLIN 8,IRELAND	Trinity College Dublin; Trinity College Dublin; Trinity College Dublin			Dinan, Timothy/ABA-8284-2020	Dinan, Timothy/0000-0002-2316-7220				ADAMI HO, 1984, SCAND J GASTROENTERO, V19, P216, DOI 10.1080/00365521.1984.12005712; BAKHEIT AMO, 1992, BRIT MED J, V304, P1010, DOI 10.1136/bmj.304.6833.1010; BLUNDELL JE, 1983, NUTR BRAIN, V6, P163; CAMILLERI M, 1986, DIGEST DIS SCI, V31, P1169, DOI 10.1007/BF01296514; CAMILLERI M, 1984, EUR J CLIN INVEST, V14, P420, DOI 10.1111/j.1365-2362.1984.tb01206.x; CAMILLERI M, 1985, GASTROENTEROLOGY, V88, P1852, DOI 10.1016/0016-5085(85)90010-1; CHECKLEY SA, 1980, PSYCHOL MED, V10, P35, DOI 10.1017/S0033291700039593; CHUA A, 1988, GUT, V29, pA1437; COCCARO EF, 1990, ARCH GEN PSYCHIAT, V47, P594; COLINJONES DG, 1988, LANCET, V1, P576; COLLINS PJ, 1983, GUT, V24, P1117, DOI 10.1136/gut.24.12.1117; COOTE JH, 1974, J PHYSIOL-LONDON, V241, P453, DOI 10.1113/jphysiol.1974.sp010666; DAVIES RF, 1983, PHYSIOL BEHAV, V30, P723, DOI 10.1016/0031-9384(83)90169-5; DINAN TG, 1990, INT CLIN PSYCHOPHARM, V5, P119, DOI 10.1097/00004850-199004000-00006; DINAN TG, 1990, SCAND J GASTROENTERO, V25, P541, DOI 10.3109/00365529009095527; DUHAULT J, 1980, PROG NEURO-PSYCHOPHA, V4, P341, DOI 10.1016/0364-7722(80)90004-1; ELIASSON S, 1953, ACTA PHYSL SCAND, V30, P199; GERSHON MD, 1981, GASTROENTEROLOGY, V80, P1571; Gilman AG, 1980, PHARM BASIS THERAPEU; HARRISON RJ, 1986, TXB INTERNAL MED; HARVEY RF, 1983, LANCET, V1, P632; HOPKINSON GB, 1989, SCAND J GASTROENTERO, V24, P923, DOI 10.3109/00365528909089236; KALIA M, 1980, J COMP NEUROL, V193, P467, DOI 10.1002/cne.901930211; KHURANA RK, 1980, NEUROLOGY, V30, P805, DOI 10.1212/WNL.30.8.805; LOEWY AD, 1981, J AUTONOM NERV SYST, V3, P265, DOI 10.1016/0165-1838(81)90068-0; MALAGELADA JR, 1985, GASTROENTEROLOGY, V88, P1223, DOI 10.1016/S0016-5085(85)80083-4; MANNING AP, 1978, BRIT MED J, V2, P653, DOI 10.1136/bmj.2.6138.653; PAGINI FD, 1984, AM J PHYSIOL, V246, pG253; ROWLAND N, 1984, LIFE SCI, V34, P2495, DOI 10.1016/0024-3205(84)90286-8; SILVERSTONE T, 1988, DRUG TREATMENT PSYCH; TALLEY NJ, 1985, SCAND J GASTROENTERO, V20, P896, DOI 10.3109/00365528509088842; THOMPSON WG, 1984, CAN MED ASSOC J, V130, P565; TIBBLIN G, 1985, SCAND J GASTROENTERO, V20, P29, DOI 10.3109/00365528509103932; VANPRAAG HM, 1980, COMPR PSYCHIAT, V21, P30, DOI 10.1016/0010-440X(80)90062-0; WOOD JR, 1985, GASTROENTEROLOGY, V89, P1411, DOI 10.1016/0016-5085(85)90663-8; YOU CH, 1981, ANN INTERN MED, V95, P449, DOI 10.7326/0003-4819-95-4-449; 1988, STAGRAPHICS 1988	37	40	43	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 1	1992	305	6848					280	282		10.1136/bmj.305.6848.280	http://dx.doi.org/10.1136/bmj.305.6848.280			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG740	1392859	Green Published, Green Submitted, Bronze			2022-12-01	WOS:A1992JG74000016
J	FISCHL, MA; UTTAMCHANDANI, RB; DAIKOS, GL; POBLETE, RB; MORENO, JN; REYES, RR; BOOTA, AM; THOMPSON, LM; CLEARY, TJ; LAI, SH				FISCHL, MA; UTTAMCHANDANI, RB; DAIKOS, GL; POBLETE, RB; MORENO, JN; REYES, RR; BOOTA, AM; THOMPSON, LM; CLEARY, TJ; LAI, SH			AN OUTBREAK OF TUBERCULOSIS CAUSED BY MULTIPLE-DRUG-RESISTANT TUBERCLE-BACILLI AMONG PATIENTS WITH HIV-INFECTION	ANNALS OF INTERNAL MEDICINE			English	Article						HUMAN IMMUNODEFICIENCY VIRUS; TUBERCULOSIS; DRUG RESISTANCE, MICROBIAL; CROSS INFECTION; MYCOBACTERIUM-TUBERCULOSIS; ACQUIRED IMMUNODEFICIENCY SYNDROME	ACQUIRED IMMUNODEFICIENCY SYNDROME; NON-HAITIAN PATIENTS; FLORIDA	Objective: To evaluate a nosocomial outbreak of tuberculosis caused by multiple-drug-resistant bacilli among patients with tuberculosis and HIV infection. Design: A case-control study. Patients: Patients with HIV infection and culture-proven tuberculosis. Measurements: Patient characteristics, date of diagnoses of HIV infection and disease, date of diagnosis of tuberculosis, Mycobacterium tuberculosis susceptibility results, and medical center contact. Results: Sixty-two patients who had tuberculosis caused by multiple-drug-resistant bacilli (cases) and 55 patients who had tuberculosis caused by susceptible or single-drug-resistant bacilli (controls) were identified. Controls were more likely to be black (odds ratio, 0.4; 95% Cl, 0.2 to 0.9) or Haitian (odds ratio, 0.2; Cl, 0.1 to 0.6) compared with cases, who were more likely to be homosexual men (odds ratio, 2.9; Cl, 1.3 to 6.4). Forty-four cases (71%) had previous contact with an HIV clinic compared with 15 controls (27%) (P < 0.0001). Cases were more likely to have had AIDS (odds ratio, 7.7; Cl, 1.5 to 53.7), to have been hospitalized on an HIV ward (odds ratio, 8.3; Cl, 2.3 to 29.7), to have been seen in an HIV clinic (odds ratio, 7.8; Cl, 3.4 to 18.1), to have received intravenous therapy in an HIV clinic (odds ratio, 13.0; Cl, 4.6 to 37.0), or to have received inhalation pentamidine in an HIV clinic before a diagnosis of tuberculosis was made. Multiple logistic regression analysis showed that a diagnosis of AIDS (odds ratio, 11.2; Cl, 3.1 to 40.6) and HIV clinic visits (odds ratio, 13.0; Cl, 2.7 to 63.7) before a diagnosis of tuberculosis were significantly associated with tuberculosis caused by multiple-drug-resistant bacilli. Using susceptibility patterns and appointment dates, we found that 22 cases had previous contact with a person who had tuberculosis caused by multiple-drug-resistant bacilli in the HIV clinic. Conclusions: Nosocomial transmission of M. tuberculosis from other HIV-infected patients with tuberculosis caused by multiple-drug-resistant bacilli can occur. These findings have serious public health implications and demand strict adherence to acid-fast bacilli isolation precautions.	F KEVIN MURPHY & ASSOCIATES, DALLAS, TX 75218 USA; CLEVELAND CLIN FLORIDA, FT LAUDERDALE, FL 33109 USA; UNIV MIAMI, SCH MED, DEPT MED, AIDS CLIN RES UNIT, MIAMI, FL 33101 USA; UNIV MIAMI, SCH MED, DEPT PATHOL, MIAMI, FL 33101 USA; UNIV MIAMI, SCH MED, COMPREHENS AIDS PROGRAM, MIAMI, FL 33101 USA	Cleveland Clinic Foundation; University of Miami; University of Miami; University of Miami	FISCHL, MA (corresponding author), UNIV MIAMI, SCH MED, DEPT MED, R-60A, POB 016960, MIAMI, FL 33101 USA.		Daikos, George L./ABD-8378-2021					BRAUN MM, 1989, JAMA-J AM MED ASSOC, V261, P393, DOI 10.1001/jama.261.3.393; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; DIPERRI G, 1989, LANCET, V2, P1502; HANDWERGER S, 1987, CHEST, V91, P176, DOI 10.1378/chest.91.2.176; LOUIE E, 1986, CHEST, V90, P542, DOI 10.1378/chest.90.4.542; PITCHENIK AE, 1982, NEW ENGL J MED, V307, P162, DOI 10.1056/NEJM198207153070306; PITCHENIK AE, 1984, ANN INTERN MED, V101, P641, DOI 10.7326/0003-4819-101-5-641; RIEDER HL, 1989, ARCH INTERN MED, V149, P1268, DOI 10.1001/archinte.149.6.1268; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; 1986, MMWR, V35, P587; 1991, MMWR, V40, P649; 1989, MMWR, V36, P795; 1989, MMWR, V36, P785; 1990, MMWR, V39, P718; 1991, MMWR, V40, P585; 1986, MMWR, V35, P74; 1991, MMWR, V40, P129; 1987, MMWR, V36, P133; 1990, MMWR, V39, P1	19	342	354	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1992	117	3					177	183		10.7326/0003-4819-117-3-177	http://dx.doi.org/10.7326/0003-4819-117-3-177			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JF304	1616211				2022-12-01	WOS:A1992JF30400001
J	FISCHL, MA; DAIKOS, GL; UTTAMCHANDANI, RB; POBLETE, RB; MORENO, JN; REYES, RR; BOOTA, AM; THOMPSON, LM; CLEARY, TJ; OLDHAM, SA; SALDANA, MJ; LAI, SH				FISCHL, MA; DAIKOS, GL; UTTAMCHANDANI, RB; POBLETE, RB; MORENO, JN; REYES, RR; BOOTA, AM; THOMPSON, LM; CLEARY, TJ; OLDHAM, SA; SALDANA, MJ; LAI, SH			CLINICAL PRESENTATION AND OUTCOME OF PATIENTS WITH HIV-INFECTION AND TUBERCULOSIS CAUSED BY MULTIPLE-DRUG-RESISTANT BACILLI	ANNALS OF INTERNAL MEDICINE			English	Article						HUMAN IMMUNODEFICIENCY VIRUS; TUBERCULOSIS; OUTCOME ASSESSMENT (HEALTH CARE); DRUG RESISTANCE, MICROBIAL; MYCOBACTERIUM-TUBERCULOSIS; ACQUIRED IMMUNODEFICIENCY SYNDROME	ACQUIRED-IMMUNODEFICIENCY-SYNDROME; NON-HAITIAN PATIENTS; VIRUS-INFECTION; SYNDROME AIDS; FLORIDA	Objective: To determine the clinical manifestations of patients with human immunodeficiency virus (HIV) infection and tuberculosis caused by multiple-drug-resistant bacilli compared with those with single-drug-resistant or susceptible bacilli. Design: Descriptive, case-control, and cohort studies. Setting: A large urban teaching hospital. Patients: Sixty-two patients with tuberculosis caused by multiple-drug-resistant bacilli (cases) and 55 patients with tuberculosis caused by single-drug-resistant or susceptible bacilli (controls). Measurements: Characteristics of clinical presentation, radiographs, pathologic abnormalities, antituberculosis treatment, and clinical course. Results: Twenty cases (32%) had concomitant pulmonary and extrapulmonary disease at presentation compared with 9 controls (16%; odds ratio, 2.4; 95% Cl, 1.0 to 5.9). More cases had alveolar infiltrates (76%; odds ratio, 3.6; Cl, 1.2 to 11.4), interstitial infiltrates with a reticular pattern (67%; odds ratio, 7.8; Cl, 1.0 to 83.5), and cavitations (18%; odds ratio, 6.6; Cl, 0.8 to 315.3) on initial chest radiographs compared with controls (49%, 19%, and 3%, respectively). Pathologic specimens from cases showed extensive necrosis, poor granuloma formation, marked inflammatory changes with a predominance of neutrophils, and abundant acid-fast bacilli. Twenty-five cases received two or more effective antituberculosis drugs for more than 2 months. Only 2 cases had three consecutive negative cultures for Mycobacterium tuberculosis, one patient died within 1 day of the last negative culture, and the other had positive cultures 496 days later. The remaining 23 cases had persistently or intermittently positive cultures despite therapy. The clinical course of these cases suggested overwhelming miliary tuberculosis with involvement of the lungs (77%), pleura (15%), stool (34%), meninges (13%), bone marrow (16%), blood (10%), lymph nodes (10%), and skin (8%). The median survival time was 2.1 months for cases compared with 14.6 months for controls (P = 0.001, log-rank test). Conclusions: Tuberculosis caused by multiple-drug resistant bacilli in patients with HIV infection is associated with widely disseminated disease, poor treatment response with an inability to eradicate the organism, and substantial mortality.	UNIV MIAMI, SCH MED, DEPT MED, AIDS CLIN RES UNIT, MIAMI, FL 33101 USA; UNIV MIAMI, SCH MED, DEPT PATHOL, MIAMI, FL 33101 USA; UNIV MIAMI, SCH MED, DEPT RADIOL, MIAMI, FL 33101 USA; UNIV MIAMI, SCH MED, COMPREHENS AIDS PROGRAM, MIAMI, FL 33101 USA	University of Miami; University of Miami; University of Miami; University of Miami	FISCHL, MA (corresponding author), UNIV MIAMI, SCH MED, DEPT MED, R-60A, POB 016960, MIAMI, FL 33101 USA.		Daikos, George L./ABD-8378-2021					BARNES PF, 1991, NEW ENGL J MED, V324, P1644, DOI 10.1056/NEJM199106063242307; BRAUN MM, 1989, JAMA-J AM MED ASSOC, V261, P393, DOI 10.1001/jama.261.3.393; CHAISSON RE, 1987, AM REV RESPIR DIS, V136, P570, DOI 10.1164/ajrccm/136.3.570; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; FISCHL MA, 1992, ANN INTERN MED, V117, P177, DOI 10.7326/0003-4819-117-3-177; HANDWERGER S, 1987, CHEST, V91, P176, DOI 10.1378/chest.91.2.176; HILL AR, 1991, AM REV RESPIR DIS, V144, P1164, DOI 10.1164/ajrccm/144.5.1164; KRAMER F, 1990, AM J MED, V89, P451, DOI 10.1016/0002-9343(90)90375-N; LOUIE E, 1986, CHEST, V90, P542, DOI 10.1378/chest.90.4.542; MEHTA CR, 1991, STATXART USER MANUEL; MODILEVSKY T, 1989, ARCH INTERN MED, V149, P2201, DOI 10.1001/archinte.149.10.2201; PITCHENIK AE, 1984, ANN INTERN MED, V101, P641, DOI 10.7326/0003-4819-101-5-641; PITCHENIK AE, 1985, AM REV RESPIR DIS, V131, P393; RIEDER HL, 1989, ARCH INTERN MED, V149, P1268, DOI 10.1001/archinte.149.6.1268; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; SMALL PM, 1991, NEW ENGL J MED, V324, P289, DOI 10.1056/NEJM199101313240503; SUNDERAM G, 1986, JAMA-J AM MED ASSOC, V256, P362, DOI 10.1001/jama.256.3.362; THEUER CP, 1990, J INFECT DIS, V162, P8, DOI 10.1093/infdis/162.1.8; 1986, MMWR, V35, P587; 1987, MMWR, V36, P785; 1990, MMWR, V39, P718; 1991, MMWR, V40, P585; 1986, MMWR, V35, P74; 1991, MMWR, V40, P129; 1987, MMWR, V36, P133	25	221	225	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1992	117	3					184	190		10.7326/0003-4819-117-3-184	http://dx.doi.org/10.7326/0003-4819-117-3-184			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JF304	1616212				2022-12-01	WOS:A1992JF30400002
J	ISEMAN, MD				ISEMAN, MD			A LEAP OF FAITH - WHAT CAN WE DO TO CURTAIL INTRAINSTITUTIONAL TRANSMISSION OF TUBERCULOSIS	ANNALS OF INTERNAL MEDICINE			English	Editorial Material						TUBERCULOSIS; ACQUIRED IMMUNODEFICIENCY SYNDROME; INFECTION CONTROL; ULTRAVIOLET RAYS; CROSS INFECTION	ULTRAVIOLET AIR DISINFECTION	Large-scale, epidemic transmission of tuberculosis to patients, nonprofessional staff, nurses, and physicians has been documented recently in hospitals, clinics, acquired immunodeficiency syndrome (AIDS) residencies, and correctional facilities. Prominent factors in these outbreaks have included human immunodeficiency virus (HIV) infection and AIDS, delayed diagnosis of tuberculosis, multidrug-resistant strains of tuberculosis that resulted in protracted shedding of mycobacteria, and ventilation patterns in buildings that resulted in the accumulation of infectious particles. Multiple deaths from tuberculosis have resulted. Various strategies, including vaccines, masks, augmented ventilation, air filters, and ultraviolet irradiation have been proposed to control this situation. Although no well-controlled studies exist to document the utility of any of these modalities, ultraviolet germicidal irradiation seems both the best theoretical model and the most practical tactic. Ultraviolet systems should be widely deployed throughout high-risk institutions.	UNIV COLORADO, SCH MED, DENVER, CO 80202 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	ISEMAN, MD (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED, DIV INFECT DIS, CLIN MYCOBACTERIOL SERV, 1400 JACKSON ST, DENVER, CO 80206 USA.							CLEMENS JD, 1983, JAMA-J AM MED ASSOC, V249, P2362, DOI 10.1001/jama.249.17.2362; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; DIPERRI G, 1989, LANCET, V2, P1502; EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302; FEREBEE SH, 1970, ADV TUBERC RES, V17, P28; GREENBERG PD, 1991, AM REV RESPIR DIS, V143, P490, DOI 10.1164/ajrccm/143.3.490; PONNIGHAUS JM, 1992, LANCET, V339, P636, DOI 10.1016/0140-6736(92)90794-4; Riley R.L., 1961, MOL MED MICROBIOLOGY, P1; RILEY RL, 1989, AM REV RESPIR DIS, V139, P1286, DOI 10.1164/ajrccm/139.5.1286; STEAD WW, 1989, AM REV RESPIR DIS, V140, P1832, DOI 10.1164/ajrccm/140.6.1832a; THOMPSON NJ, 1982, B WORLD HEALTH ORGAN, V60, P555; TORRES RA, 1990, ARCH INTERN MED, V150, P2030, DOI 10.1001/archinte.150.10.2030; 1991, MMWR, V40, P585; 1991, MMWR, V40, P129; 1980, B INT UNION TUBERC, V55, P14; 1990, MMWR, V39, P1	16	52	52	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1992	117	3					251	253		10.7326/0003-4819-117-3-251	http://dx.doi.org/10.7326/0003-4819-117-3-251			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JF304	1616220				2022-12-01	WOS:A1992JF30400013
J	KHABBAZ, RF; ROWE, T; MURPHEYCORB, M; HENEINE, WM; SCHABLE, CA; GEORGE, JR; PAU, CP; PAREKH, BS; LAIRMORE, MD; CURRAN, JW; KAPLAN, JE; SCHOCHETMAN, G; FOLKS, TM				KHABBAZ, RF; ROWE, T; MURPHEYCORB, M; HENEINE, WM; SCHABLE, CA; GEORGE, JR; PAU, CP; PAREKH, BS; LAIRMORE, MD; CURRAN, JW; KAPLAN, JE; SCHOCHETMAN, G; FOLKS, TM			SIMIAN IMMUNODEFICIENCY VIRUS NEEDLESTICK ACCIDENT IN A LABORATORY WORKER	LANCET			English	Note								The macaque monkey infected with simian immunodeficiency virus (SIV) is an animal model of the acquired immunodeficiency syndrome. We investigated a laboratory worker who was exposed by needlestick accident to blood from an SIV-infected macaque. Seroreactivity to SIV developed within 3 months of exposure, with antibody titres peaking from the third to the fifth month and declining thereafter. Polymerase chain reaction for SIV sequences and cultures of peripheral-blood mononuclear cells failed to show infection. Inoculation of an SIV-negative monkey with blood from the worker did not cause infection. Animal-care and laboratory workers should adhere strictly to recommended procedures to avoid accidental exposures when working with SIV-infected animals or specimens.	TULANE UNIV,DELTA REG PRIMATE RES CTR,COVINGTON,LA 70433; OHIO STATE UNIV,DEPT VET PATHOBIOL,COLUMBUS,OH 43210; CTR DIS CONTROL,CTR INFECT DIS,DIV HIV AIDS,ATLANTA,GA 30333	Tulane University; University System of Ohio; Ohio State University; Centers for Disease Control & Prevention - USA	KHABBAZ, RF (corresponding author), CTR DIS CONTROL,CTR INFECT DIS,DIV VIRAL & RICKETTSIAL DIS,RETROVIRUS DIS BRANCH,MS-G03,ATLANTA,GA 30333, USA.			PAREKH, BHARAT/0000-0002-1088-4263				ALLAN JS, 1991, J VIROL, V65, P2816, DOI 10.1128/JVI.65.6.2816-2828.1991; KANNAGI M, 1985, P NATL ACAD SCI USA, V82, P7053, DOI 10.1073/pnas.82.20.7053; KION TA, 1991, SCIENCE, V253, P1138, DOI 10.1126/science.1909456; MCLURE HM, 1989, VET IMMUNOL IMMUNOP, V21, P13; MURPHEYCORB M, 1986, NATURE, V321, P435, DOI 10.1038/321435a0; PAREKH BS, 1991, AIDS, V5, P1009, DOI 10.1097/00002030-199108000-00013; SHEN L, 1991, SCIENCE, V252, P440, DOI 10.1126/science.1708168; VILLINGER F, 1991, J VIROL, V65, P1855, DOI 10.1128/JVI.65.4.1855-1862.1991; 1988, MMWR, V37, P693	9	42	46	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 1	1992	340	8814					271	273		10.1016/0140-6736(92)92358-M	http://dx.doi.org/10.1016/0140-6736(92)92358-M			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG665	1353193				2022-12-01	WOS:A1992JG66500005
J	KHAW, KT; SNEYD, MJ; COMPSTON, J				KHAW, KT; SNEYD, MJ; COMPSTON, J			BONE-DENSITY PARATHYROID-HORMONE AND 25-HYDROXYVITAMIN-D CONCENTRATIONS IN MIDDLE-AGED WOMEN	BRITISH MEDICAL JOURNAL			English	Article							VITAMIN-D STATUS; HIP FRACTURE; POSTMENOPAUSAL OSTEOPOROSIS; PROXIMAL FEMUR; PHYSICAL-ACTIVITY; DIETARY CALCIUM; CALCITRIOL; SECRETION; RISK; 25-HYDROXYCHOLECALCIFEROL	Objective-To examine the relation between bone density and indices of calcium metabolism including parathyroid hormone and 25-hydroxyvitamin D concentrations in middle aged women. Design-A cross sectional study. Setting and subjects-138 women volunteers aged 45-65 with no known osteoporosis and unselected for disease status recruited for a dietary assessment study from the community using general practice registers. Volunteer rate was 20%. Main outcome measure-Bone mineral density measured with dual energy x ray absorptiometry. Results-Bone density at the lumbar spine and neck and trochanteric regions of the femur was inversely related to serum intact parathyroid hormone concentrations and positively related to serum 25-hydroxyvitamin D concentrations. These associations were independent of possible confounding factors, including age, body mass index, cigarette smoking habit, menopausal status, and use of diuretics and postmenopausal hormone replacement therapy. These associations were apparent throughout the whole distribution of bone density and 25-hydroxyvitamin D and parathyroid hormone concentrations within the normal range, suggesting a physiological relation. Conclusions-The findings are consistent with the hypothesis that parathyroid hormone and 25-hydroxyvitamin D concentrations influence bone density in middle aged women. Findings from this study together with other work suggest that the role of vitamin D in osteoporosis should not be neglected. The associations with parathyroid hormone also indicate plausible biological mechanisms. The roughly 5-10% difference in bone density between top and bottom tertiles of serum 25-hydroxyvitamin D concentrations, though not large in magnitude, may have considerable public health implications in terms of prevention of osteoporosis and its sequelae, fractures.			KHAW, KT (corresponding author), UNIV CAMBRIDGE,ADDENBROOKES HOSP,SCH CLIN MED,CLIN GERONTOL UNIT,CAMBRIDGE CB2 2QQ,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AIKEN JM, 1973, NATURE, V241, P59; ALOIA JF, 1988, AM J MED, V84, P401, DOI 10.1016/0002-9343(88)90259-8; BAKER MR, 1979, BRIT MED J, V1, P589, DOI 10.1136/bmj.1.6163.589; BOYCE WJ, 1985, LANCET, V1, P150; CALVO MS, 1991, J CLIN ENDOCR METAB, V72, P69, DOI 10.1210/jcem-72-1-69; CALVO MS, 1990, J CLIN ENDOCR METAB, V70, P1334, DOI 10.1210/jcem-70-5-1334; CUMMINGS SR, 1985, EPIDEMIOL REV, V7, P178, DOI 10.1093/oxfordjournals.epirev.a036281; CUMMINGS SR, 1990, JAMA-J AM MED ASSOC, V263, P665, DOI 10.1001/jama.263.5.665; FRAME B, 1978, ANN INTERN MED, V89, P966, DOI 10.7326/0003-4819-89-6-966; GALLAGHER JC, 1989, P SOC EXP BIOL MED, V191, P287; GLOTH FM, 1991, J AM GERIATR SOC, V39, P137, DOI 10.1111/j.1532-5415.1991.tb01615.x; Gregory F., 1990, DIETARY NUTR SURVEY; HOLBROOK TL, 1988, LANCET, V2, P1046, DOI 10.1016/S0140-6736(88)90065-7; HOLICK MF, 1985, ANN NY ACAD SCI, V453, P1, DOI 10.1111/j.1749-6632.1985.tb11793.x; HUI SL, 1988, J CLIN INVEST, V81, P1804, DOI 10.1172/JCI113523; JACOBSEN SJ, 1991, AM J EPIDEMIOL, V133, P996, DOI 10.1093/oxfordjournals.aje.a115819; KRALL EA, 1989, NEW ENGL J MED, V321, P1777, DOI 10.1056/NEJM198912283212602; LAU E, 1988, BRIT MED J, V297, P1441, DOI 10.1136/bmj.297.6661.1441; LAW MR, 1991, BMJ-BRIT MED J, V303, P453, DOI 10.1136/bmj.303.6800.453; LINDALL AW, 1983, J CLIN ENDOCR METAB, V57, P1007, DOI 10.1210/jcem-57-5-1007; LIPS P, 1987, AM J CLIN NUTR, V46, P1005, DOI 10.1093/ajcn/46.6.1005; LIPS P, 1988, J CLIN ENDOCR METAB, V67, P644, DOI 10.1210/jcem-67-4-644; LUND B, 1975, LANCET, V2, P300; MAZESS RB, 1989, P SOC EXP BIOL MED, V191, P261; OTT SM, 1989, ANN INTERN MED, V110, P267, DOI 10.7326/0003-4819-110-4-267; PARFITT AM, 1982, AM J CLIN NUTR, V36, P1014, DOI 10.1093/ajcn/36.5.1014; PARFITT AM, 1988, DRUGS, V36, P513, DOI 10.2165/00003495-198836050-00001; PREECE MA, 1974, CLIN CHIM ACTA, V54, P235, DOI 10.1016/0009-8981(74)90241-1; RAISZ LG, 1988, NEW ENGL J MED, V318, P818; RIGGS BL, 1983, AM J MED, V75, P889; ROSE G, 1981, BMJ-BRIT MED J, V282, P1847, DOI 10.1136/bmj.282.6279.1847; SCRAGG R, IN PRESS ANN EPIDEMI; SILVERBERG SJ, 1989, NEW ENGL J MED, V320, P277, DOI 10.1056/NEJM198902023200503; STEVENSON JC, 1982, BRIT MED J, V285, P585, DOI 10.1136/bmj.285.6342.585; TSAI KS, 1989, J CLIN ENDOCR METAB, V69, P1024, DOI 10.1210/jcem-69-5-1024; TSAI KS, 1984, J CLIN INVEST, V73, P1668, DOI 10.1172/JCI111373; VILLAREAL DT, 1991, J CLIN ENDOCR METAB, V72, P628, DOI 10.1210/jcem-72-3-628; WASNICH RD, 1985, AM J OBSTET GYNECOL, V153, P745, DOI 10.1016/0002-9378(85)90338-2; WICKHAM CAC, 1989, BMJ-BRIT MED J, V299, P889, DOI 10.1136/bmj.299.6704.889; 1991, FORTIFICATION YELLOW, V40	40	186	192	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 1	1992	305	6848					273	277		10.1136/bmj.305.6848.273	http://dx.doi.org/10.1136/bmj.305.6848.273			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG740	1392857	Green Submitted, Green Published, Bronze			2022-12-01	WOS:A1992JG74000014
J	KIM, SG; MANNINO, MM; CHOU, R; ROTH, S; ROTH, JA; DESAI, B; FERRICK, KJ; FISHER, JD				KIM, SG; MANNINO, MM; CHOU, R; ROTH, S; ROTH, JA; DESAI, B; FERRICK, KJ; FISHER, JD			RAPID SUPPRESSION OF SPONTANEOUS VENTRICULAR ARRHYTHMIAS DURING ORAL AMIODARONE LOADING	ANNALS OF INTERNAL MEDICINE			English	Article						AMIODARONE; ARRHYTHMIA; VENTRICULAR FIBRILLATION; TACHYCARDIA; EXTRASYSTOLE	CLASS-1A ANTIARRHYTHMIC AGENT; PROGRAMMED STIMULATION; MYOCARDIAL CONCENTRATIONS; TACHYCARDIA INDUCTION; CARDIAC-ARRHYTHMIAS; CLINICAL EFFICACY; THERAPY; COMBINATION; SAFETY; PLASMA	Objective: To determine the time course of effects of amiodarone during an oral loading period. Design: A prospective, nonrandomized study. Setting: Arrhythmia referral center at a university hospital. Patients: Fifty patients with refractory sustained ventricular tachycardia (n = 44) or ventricular fibrillation (n = 6) and frequent (greater-than-or-equal-to 30/h) ventricular premature complexes. Intervention: Oral amiodarone, 1200 mg/d for 14 days and 400 mg/d thereafter. Measurements: Ambulatory electrocardiographic monitorings, 12-lead electrocardiograms, and amiodarone blood levels on days 3, 5, 7, 9, 11, 13, and 28. Results: Dramatic reductions of ventricular arrhythmias were noted during the first 72 hours of the therapy. Average ventricular premature complexes/h, couplets/h, and nonsustained ventricular tachycardias/24 h were 524 +/- 1224/h, 16 +/- 61 /h, and 167 +/- 611/24 h, respectively, at baseline, and reduced to 140 +/- 243/h, 11 +/- 50/h, and 33 +/- 117/24 h, respectively, on day 3 (P < 0.05 for all). Subsequent reductions of ventricular arrhythmias from day 3 to day 13 were more gradual but were still significant (P < 0.05). A significant reduction of ventricular arrhythmias (greater-than-or-equal-to 70% reduction of ventricular premature complexes and greater-than-or-equal-to 90% reduction of nonsustained ventricular tachycardias) was noted in 50% of patients on day 3, in 65% on day 7, and in 83% on day 13. Prolongation of the OT interval exhibited a similar time course. There were no further differences in reduction of ventricular premature complexes or OT intervals between day 13 and day 28. Conclusions: Oral amiodarone given in loading doses produces rapid and dramatic reductions in spontaneous ventricular arrhythmias within 72 hours. Subsequent reductions of spontaneous arrhythmia were gradual and less dramatic.	MONTEFIORE MED CTR, DEPT MED, BRONX, NY 10467 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, BRONX, NY 10461 USA	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	KIM, SG (corresponding author), MONTEFIORE MED CTR, DIV CARDIOL, 111 E 210TH ST, BRONX, NY 10467 USA.			Fisher, John/0000-0003-2748-8715				[Anonymous], 1986, Am J Cardiol, V57, P91; Bazett HC, 1920, HEART-J STUD CIRC, V7, P353; BORBOLA J, 1988, AM HEART J, V115, P1202, DOI 10.1016/0002-8703(88)90009-9; DEBBAS NMG, 1984, BRIT HEART J, V51, P316; ESCOUBET B, 1985, AM J CARDIOL, V55, P696, DOI 10.1016/0002-9149(85)90139-0; GREENSPON AJ, 1988, J AM COLL CARDIOL, V11, P117, DOI 10.1016/0735-1097(88)90176-3; HAFFAJEE CI, 1983, AM HEART J, V106, P935, DOI 10.1016/0002-8703(83)90019-4; KIM SG, 1987, AM J CARDIOL, V60, P288, DOI 10.1016/0002-9149(87)90229-3; KIM SG, 1988, AM J CARDIOL, V62, P7; KIM SG, 1987, CIRCULATION, V76, P1, DOI 10.1161/01.CIR.76.1.1; KIM SG, 1985, AM J CARDIOL, V56, P84, DOI 10.1016/0002-9149(85)90571-5; KIM SG, 1987, J AM COLL CARDIOL, V9, P398, DOI 10.1016/S0735-1097(87)80395-9; KIM SG, 1987, AM J CARDIOL, V59, P1314, DOI 10.1016/0002-9149(87)90911-8; MARCHLINSKI FE, 1985, AM J CARDIOL, V55, P709, DOI 10.1016/0002-9149(85)90141-9; MASON JW, 1991, CIRCULATION, V84, P348; MITCHELL LB, 1989, CIRCULATION, V80, P34, DOI 10.1161/01.CIR.80.1.34; MITCHELL LB, 1987, NEW ENGL J MED, V317, P1681, DOI 10.1056/NEJM198712313172701; MORADY F, 1986, J AM COLL CARDIOL, V7, P148, DOI 10.1016/S0735-1097(86)80273-X; MORGANROTH J, 1978, CIRCULATION, V58, P408, DOI 10.1161/01.CIR.58.3.408; MOSTOW ND, 1984, AM J CARDIOL, V54, P569, DOI 10.1016/0002-9149(84)90250-9; MOSTOW ND, 1986, CIRCULATION, V73, P1231, DOI 10.1161/01.CIR.73.6.1231; NADEMANEE K, 1982, CIRCULATION, V66, P200; RAKITA L, 1983, JAMA-J AM MED ASSOC, V250, P1293, DOI 10.1001/jama.250.10.1293; ROSENBAUM MB, 1976, AM J CARDIOL, V38, P934, DOI 10.1016/0002-9149(76)90807-9; ROSENFELD LE, 1987, AM HEART J, V114, P1367, DOI 10.1016/0002-8703(87)90538-2; SIDDOWAY LA, 1983, AM HEART J, V106, P951, DOI 10.1016/0002-8703(83)90021-2; SINGH BN, 1984, PACE, V7, P109, DOI 10.1111/j.1540-8159.1984.tb04867.x; VELTRI EP, 1985, J AM COLL CARDIOL, V6, P806, DOI 10.1016/S0735-1097(85)80487-3; VELTRI EP, 1985, AM J CARDIOL, V55, P375, DOI 10.1016/0002-9149(85)90379-0; WELLENS HJJ, 1984, CIRCULATION, V69, P120, DOI 10.1161/01.CIR.69.1.120; WINKLE RA, 1978, CIRCULATION, V57, P1116, DOI 10.1161/01.CIR.57.6.1116	31	7	7	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1992	117	3					197	201		10.7326/0003-4819-117-3-197	http://dx.doi.org/10.7326/0003-4819-117-3-197			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JF304	1616213				2022-12-01	WOS:A1992JF30400004
J	LIMPER, AH; CARPENTER, PC; SCHEITHAUER, B; STAATS, BA				LIMPER, AH; CARPENTER, PC; SCHEITHAUER, B; STAATS, BA			THE CUSHING SYNDROME INDUCED BY BRONCHIAL CARCINOID-TUMORS	ANNALS OF INTERNAL MEDICINE			English	Article						DIARRHEA; NORFLOXACIN; CAMPYLOBACTER INFECTIONS; SALMONELLA INFECTIONS; DYSENTERY	ECTOPIC ACTH SYNDROME; CORTICOTROPIN; DIAGNOSIS; SECRETION; ADENOMA; LUNG	Objectives: To define the clinical spectrum of bronchial carcinoid tumors in patients presenting with the Cushing syndrome, to evaluate the role of chest radiographs and computed tomography in their diagnosis, to review the characteristic histologic features, and to determine patient outcome. Design: Retrospective analysis of consecutive patients. Setting. A referral-based medical center. Patients: Fifteen consecutive patients with the Cushing syndrome evaluated at the Mayo Clinic with histologically proven bronchial carcinoid tumors. Measurements: Clinical, radiographic, and histologic features. Results: The Cushing syndrome was the initial clinical presentation, and bronchial carcinoid tumors were found later in all 15 patients. The diagnosis of carcinoid tumor was proved histologically in all cases. Ten biopsies showed typical carcinoid tumors, three were histologically atypical, and three were metastatic. Corticotropin was detected by immunostaining in seven of these tumors. Biochemical analysis showed marked elevations of circulating corticotropin with a mean serum value of 156 +/- 58 pmol/L (normal, 4 to 22 pmol/L). Additional clinical features included hypokalemia in six patients and glucocorticoid response to either high-dose dexamethasone or metyrapone in 6 of 13. These hormonally active carcinoid tumors were frequently radiographically occult, with 10 of 15 patients initially having normal chest radiographs. Computed tomography was successful in locating carcinoid tumors in five patients with negative chest radiographs evaluated after 1980. All five remaining patients with normal chest radiographs evaluated before 1980 eventually developed nodular lesions on standard chest radiography from 1 to 10 years later. Ten patients achieved complete remission and two patients, partial remission of the Cushing syndrome after surgical resection. Three patients continued to have symptomatic glucocorticoid excess due to metastatic disease. Conclusions: Although uncommon, the Cushing syndrome may be the initial clinical manifestation of an otherwise indolent bronchial carcinoid tumor. Radiographic imaging of occult lesions can be successfully accomplished with computed tomography. Surgical resection is curative in most patients with this disorder.	MAYO CLIN & MAYO FDN, DIV ENDOCRINOL & INTERNAL MED, ROCHESTER, MN 55905 USA; MAYO CLIN & MAYO FDN, DEPT PATHOL & LAB MED, ROCHESTER, MN 55905 USA	Mayo Clinic; Mayo Clinic	LIMPER, AH (corresponding author), MAYO CLIN & MAYO FDN, DIV THORAC DIS & INTERNAL MED, E-18B, 200 1ST ST SW, ROCHESTER, MN 55905 USA.							ALTMAN RL, 1973, THORAX, V28, P433, DOI 10.1136/thx.28.4.433; ARRIGONI MG, 1972, J THORAC CARDIOV SUR, V64, P413; AZZOPARDI JG, 1968, CANCER-AM CANCER SOC, V22, P274, DOI 10.1002/1097-0142(196808)22:2<274::AID-CNCR2820220204>3.0.CO;2-W; CARPENTER PC, 1988, ENDOCRIN METAB CLIN, V17, P445, DOI 10.1016/S0889-8529(18)30412-2; DELGAUDIO A, 1988, INT SURG, V73, P44; DESTEPHANO DB, 1984, HUM PATHOL, V15, P890, DOI 10.1016/S0046-8177(84)80151-3; DOPPMAN JL, 1989, RADIOLOGY, V172, P115, DOI 10.1148/radiology.172.1.2544919; FINDLING JW, 1986, ARCH INTERN MED, V146, P929, DOI 10.1001/archinte.146.5.929; HOWLETT TA, 1986, CLIN ENDOCRINOL, V24, P699, DOI 10.1111/j.1365-2265.1986.tb01667.x; JEX RK, 1985, AM J SURG, V149, P276; KAO PC, 1979, CLIN CHEM, V25, P1267; KAYE TB, 1990, ANN INTERN MED, V112, P434, DOI 10.7326/0003-4819-76-3-112-6-434; LAWSON RM, 1976, THORAX, V31, P245, DOI 10.1136/thx.31.3.245; LEINUNG MC, 1990, MAYO CLIN PROC, V65, P1314, DOI 10.1016/S0025-6196(12)62142-9; LIDDLE GW, 1960, J CLIN ENDOCR METAB, V20, P1539, DOI 10.1210/jcem-20-12-1539; MALCHOFF CD, 1988, AM J MED, V84, P760, DOI 10.1016/0002-9343(88)90116-7; MASON A M S, 1972, Clinical Endocrinology, V1, P3, DOI 10.1111/j.1365-2265.1972.tb00374.x; MCDANIEL HG, 1980, SOUTHERN MED J, V73, P1194, DOI 10.1097/00007611-198009000-00008; MURRAY RJ, 1988, CHEST, V93, P1249, DOI 10.1378/chest.93.6.1249; OKIKE N, 1976, ANN THORAC SURG, V22, P270, DOI 10.1016/S0003-4975(10)64915-6; OLURIN EO, 1973, CANCER, V31, P1514, DOI 10.1002/1097-0142(197306)31:6<1514::AID-CNCR2820310631>3.0.CO;2-C; RAFF H, 1989, CLIN CHEM, V35, P596; Roberts L, 1985, WILLIAMS TXB ENDOCRI, P1363; ROZENMAN J, 1987, CHEST, V92, P145, DOI 10.1378/chest.92.1.145; SCHTEINGART DE, 1986, J CLIN ENDOCR METAB, V63, P770, DOI 10.1210/jcem-63-3-770; SKRABANEK P, 1978, CANCER, V42, P1263, DOI 10.1002/1097-0142(197809)42:3<1263::AID-CNCR2820420335>3.0.CO;2-O; STROTT CA, 1968, AM J MED, V44, P97, DOI 10.1016/0002-9343(68)90240-4; WHITE FE, 1982, BRIT MED J, V284, P771, DOI 10.1136/bmj.284.6318.771; ZARATE A, 1986, CLIN ENDOCRINOL, V24, P523, DOI 10.1111/j.1365-2265.1986.tb03281.x; 1981, NEW ENGL J MED, V305, P1637	30	109	112	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1992	117	3					209	214		10.7326/0003-4819-117-3-209	http://dx.doi.org/10.7326/0003-4819-117-3-209			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JF304	1319693				2022-12-01	WOS:A1992JF30400006
J	LINDBERG, G; RASTAM, L; GULLBERG, B; EKLUND, GA				LINDBERG, G; RASTAM, L; GULLBERG, B; EKLUND, GA			LOW SERUM-CHOLESTEROL CONCENTRATION AND SHORT-TERM MORTALITY FROM INJURIES IN MEN AND WOMEN	BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; ALCOHOL-CONSUMPTION; DEATH; RISK	Objective-To determine whether total serum cholesterol concentration predicts mortality from injuries including suicide. Design-Cohort study of men and women who had their serum cholesterol concentration measured as part of a general health survey in Varmland, Sweden in 1964 or 1965 and were followed up for an average of 20.5 years. Subjects-Adults participating in health screening in 1964-5 (26 693 men and 27 692 women). The study sample was restricted to subjects aged 45-74 years during any of the 20.5 years of follow up. Main outcome measures-Serum cholesterol concentration. Deaths from all injuries and suicides during three periods of follow up (0-6 years, 7-13 years, and 14-21 years) according to the Swedish mortality register in subjects aged 45-74. Adjustment was made for prevalent cancer (identified from the Swedish cancer register) at the time of a suicide. Results-A strong negative relation between cholesterol concentration and mortality from injuries was found in men during the first seven years of follow up. The relative risk in the lowest 25% of the cholesterol distribution was 2.8 (95% confidence interval 1.52 to 4.96) compared with the top 25%. Most of the excess risk was caused by suicide with a corresponding relative risk of 4.2 (p for trend=0.001). Correction for prevalent cancer did not change the results. Events occurring during the latter two thirds of the 20.5 years of follow up were not predicted. In women no relation between cholesterol concentration and mortality from injuries was found. Conclusions-Together with observations from intervention trials the findings support the existence of a relation between serum cholesterol concentration and suicide. The causality of such a relation is, however, not resolved.	UNIV LUND,DEPT COMMUNITY HLTH SCI,S-21401 MALMO,SWEDEN; KAROLINSKA HOSP,RADIUM HEMMET,DEPT CANC EPIDEMIOL,S-10401 STOCKHOLM,SWEDEN	Lund University; Karolinska Institutet; Karolinska University Hospital	LINDBERG, G (corresponding author), CTR PUBL HLTH RES,S-65182 KARLSTAD,SWEDEN.							BOLANDER AM, 1981, MED ASPECTS MORTALIT; CHEN ZM, 1991, BRIT MED J, V303, P276, DOI 10.1136/bmj.303.6797.276; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; FRIEDMAN LA, 1986, AM J EPIDEMIOL, V124, P481, DOI 10.1093/oxfordjournals.aje.a114418; GORDON T, 1986, ARCH INTERN MED, V146, P262, DOI 10.1001/archinte.146.2.262; HATCH FT, 1966, CIRCULATION, V33, P679, DOI 10.1161/01.CIR.33.5.679; JENKINS CD, 1969, PSYCHOSOM MED, V31, P115; KAPLAN JR, 1990, PSYCHOSOM MED, V52, P226; LINDBERG G, 1991, BRIT MED J, V302, P143, DOI 10.1136/bmj.302.6769.143; LINDBERG G, 1992, INT J EPIDEMIOL, V21, P253, DOI 10.1093/ije/21.2.253; MATTSSON B, 1984, ACTA RADIOL ONCOL, V23, P305, DOI 10.3109/02841868409136026; McCullagh P., 1989, STANDARD BOOK GEN LI, DOI DOI 10.1007/978-1-4899-3242-6; MULDOON MF, 1990, BMJ-BRIT MED J, V301, P309, DOI 10.1136/bmj.301.6747.309; PEKKANEN J, 1989, ARCH INTERN MED, V149, P1589, DOI 10.1001/archinte.149.7.1589; SMITH GD, 1992, BMJ-BRIT MED J, V304, P431, DOI 10.1136/bmj.304.6824.431; SMITH GD, 1990, BRIT MED J, V301, P552; TORNBERG SA, 1989, JNCI-J NATL CANCER I, V81, P1917, DOI 10.1093/jnci/81.24.1917; VIRKKUNEN M, 1979, NEUROPSYCHOBIOLOGY, V5, P27, DOI 10.1159/000117660; VIRKKUNEN M, 1984, BIOL PSYCHIAT, V19, P435; ZAK B, 1954, AM J CLIN PATHOL, V24, P1307, DOI 10.1093/ajcp/24.11_ts.1307; 1967, MANUAL INT STATISTIC; 1984, JAMA-J AM MED ASSOC, V251, P351	22	197	198	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 1	1992	305	6848					277	279		10.1136/bmj.305.6848.277	http://dx.doi.org/10.1136/bmj.305.6848.277			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG740	1392858	Green Submitted, Green Published, Bronze			2022-12-01	WOS:A1992JG74000015
J	MCGEE, HM; HORGAN, JH				MCGEE, HM; HORGAN, JH			CARDIAC REHABILITATION PROGRAMS - ARE WOMEN LESS LIKELY TO ATTEND	BRITISH MEDICAL JOURNAL			English	Article							EXERCISE				MCGEE, HM (corresponding author), BEAUMONT HOSP,DEPT CARDIOL,POB 1297,DUBLIN 9,IRELAND.		McGee, Hannah M/D-6480-2012	McGee, Hannah M/0000-0003-1417-993X				OCALLAGHAN WG, 1984, EUR HEART J, V5, P649, DOI 10.1093/oxfordjournals.eurheartj.a061721; OCONNOR GT, 1989, CIRCULATION, V80, P234, DOI 10.1161/01.CIR.80.2.234; OLDRIDGE MB, 1980, AM HEART J, V338, P1366; OLDRIDGE NB, 1978, CAN MED ASSOC J, V118, P361; 1991, LANCET, V338, P1366	5	52	52	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 1	1992	305	6848					283	284		10.1136/bmj.305.6848.283-a	http://dx.doi.org/10.1136/bmj.305.6848.283-a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG740	1285764	Green Submitted, Green Published, Bronze			2022-12-01	WOS:A1992JG74000018
J	PEARSON, ML; JEREB, JA; FRIEDEN, TR; CRAWFORD, JT; DAVIS, BJ; DOOLEY, SW; JARVIS, WR				PEARSON, ML; JEREB, JA; FRIEDEN, TR; CRAWFORD, JT; DAVIS, BJ; DOOLEY, SW; JARVIS, WR			NOSOCOMIAL TRANSMISSION OF MULTIDRUG-RESISTANT MYCOBACTERIUM-TUBERCULOSIS - A RISK TO PATIENTS AND HEALTH-CARE WORKERS	ANNALS OF INTERNAL MEDICINE			English	Article						TUBERCULOSIS; MYCOBACTERIUM-TUBERCULOSIS; DRUG RESISTANCE, MICROBIAL; CROSS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS; ACQUIRED IMMUNODEFICIENCY SYNDROME		Objective: To determine the factors associated with the development of multidrug-resistant tuberculosis among patients at a New York City Hospital and to investigate possible nosocomial transmission. Design: A retrospective case-control study and tuberculin skin test survey. Patients: Twenty-three patients with tuberculosis whose isolates were resistant to at least isoniazid and rifampin (case patients) were compared with patients with tuberculosis whose isolates were susceptible to all agents tested (controls). Tuberculin skin test conversion rates were compared among health care workers assigned to wards where patients with tuberculosis were frequently or rarely admitted. Setting: A large, teaching hospital in New York City. Measurements: Mycobacterium tuberculosis isolates from case patients and controls were typed by restriction fragment length polymorphism analysis. Results: Case patients were younger (median age, 34 compared with 42 years; P = 0.006), more likely to be seropositive for HIV (21 of 23 compared with 11 of 23 patients; odds ratio, 11.5; 95% Cl, 1.9 to 117), and more likely to have had a previous hospital admission within 7 months before the onset of tuberculosis (19 of 23 compared with 5 of 23 patients; odds ratio, 17.1; Cl, 3.3 to 97), particularly on one ward (12 of 23 compared with 0 of 23 patients; odds ratio, undefined; P = 0.002). Health care workers assigned to wards housing case patients were more likely to have tuberculin skin test conversions than were health care workers assigned to other wards (11 of 32 compared with 1 of 47 health care workers; P < 0.001). Few (6 of 23) case patients were placed in acid-fast bacilli isolation, and no rooms tested had negative pressure. Of 16 available multidrug-resistant isolates obtained from case patients, 14 had identical banding patterns by restriction fragment length polymorphism analysis. In contrast, M. tuberculosis isolates from controls with drug-susceptible tuberculosis had patterns distinct from each other and from those of case patients. Conclusions: These data suggest nosocomial transmission of multidrug-resistant tuberculosis occurred from patient to patient and from patient to health care worker and underscore the need for effective acid-fast bacilli isolation facilities and adherence to published infection control guidelines in health care institutions.	CTR DIS CONTROL, DIV TB ELIMINAT, ATLANTA, GA 30333 USA; CTR DIS CONTROL, NATL CTR ENVIRONM HLTH & INJURY CONTROL, OFF DIRECTOR, ATLANTA, GA 30333 USA; CTR DIS CONTROL, DIV BACTERIAL & MYCOT DIS, ATLANTA, GA 30333 USA; NEW YORK CITY DEPT HLTH, NEW YORK, NY 10013 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; New York City Department of Health & Mental Hygiene	PEARSON, ML (corresponding author), CTR DIS CONTROL, HOSP INFECT PROGRAM, MAILSTOP A-07, ATLANTA, GA 30333 USA.							CAVE MD, 1991, MOL CELL PROBE, V5, P73, DOI 10.1016/0890-8508(91)90040-Q; DEAN AG, 1991, EPI INFO VERSION 501; GURDIP FS, 1990, CHEST, V98, P1056; Jereb J A, 1991, MMWR CDC Surveill Summ, V40, P23; KENT PT, 1985, PUBLIC HLTH MYCOBACT, P166; NOBLE RC, 1981, AM J INFECT CONTROL, V9, P6, DOI 10.1016/S0196-6553(81)80003-X; SHAFER RW, 1991, AIDS, V5, P399, DOI 10.1097/00002030-199104000-00007; 1991, MMWR, V40, P585; 1991, MMWR, V40, P129; 1990, MMWR, V39, P1; 1991, LANCET, V337, P852	11	483	493	0	14	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1992	117	3					191	196		10.7326/0003-4819-117-3-191	http://dx.doi.org/10.7326/0003-4819-117-3-191			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JF304	1352093				2022-12-01	WOS:A1992JF30400003
J	ROBERTS, I; MARSHALL, R; NORTON, R				ROBERTS, I; MARSHALL, R; NORTON, R			CHILD PEDESTRIAN MORTALITY AND TRAFFIC VOLUME IN NEW-ZEALAND	BRITISH MEDICAL JOURNAL			English	Article											ROBERTS, I (corresponding author), UNIV AUCKLAND,INJURY PREVENT RES CTR,DEPT COMMUNITY HLTH,AUCKLAND,NEW ZEALAND.			Marshall, Roger/0000-0001-8278-167X				FROME EL, 1983, BIOMETRICS, V39, P665, DOI 10.2307/2531094; READ RC, 1990, BRIT MED J, V300, P761, DOI 10.1136/bmj.300.6727.761; ROSE G, 1985, INT J EPIDEMIOL, V14, P32, DOI 10.1093/ije/14.1.32; 1990, MORTALITY DEMOGRAPHI; 1990, NZ OFFICIAL YB 1990	5	27	27	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 1	1992	305	6848					283	283		10.1136/bmj.305.6848.283	http://dx.doi.org/10.1136/bmj.305.6848.283			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG740	1392860	Bronze, Green Submitted, Green Published			2022-12-01	WOS:A1992JG74000017
J	RUNYON, BA; MONTANO, AA; AKRIVIADIS, EA; ANTILLON, MR; IRVING, MA; MCHUTCHISON, JG				RUNYON, BA; MONTANO, AA; AKRIVIADIS, EA; ANTILLON, MR; IRVING, MA; MCHUTCHISON, JG			THE SERUM-ASCITES ALBUMIN GRADIENT IS SUPERIOR TO THE EXUDATE-TRANSUDATE CONCEPT IN THE DIFFERENTIAL-DIAGNOSIS OF ASCITES	ANNALS OF INTERNAL MEDICINE			English	Article						DIARRHEA; NORFLOXACIN; CAMPYLOBACTER INFECTIONS; SALMONELLA INFECTIONS; DYSENTERY	SPONTANEOUS BACTERIAL PERITONITIS; CHRONIC LIVER-DISEASE; PROTEIN-CONCENTRATION; CIRRHOTIC ASCITES; OPSONIC ACTIVITY; MENSTRUAL-CYCLE; FLUID; DIURESIS; BACTERASCITES; SPECTRUM	Objective: To compare the serum-ascites albumin gradient to the exudate-transudate concept in the classification of ascites. Design: Prospective collection of ascitic fluid data from patients with well-characterized causes of ascites. Setting. Hepatology inpatient and outpatient ward and consult service of a large, urban hospital. Patients: A total of 901 paired serum and ascitic fluid samples were collected from consecutive patients with all forms of ascites. Interventions: None. Main Outcome Measures: The utility of the serum-ascites albumin gradient and the old exudate-transudate concept (as defined by ascitic fluid total protein concentration [AFTP]) were compared for their ability in discriminating the cause for ascites formation. Results: The albumin gradient correctly differentiated causes of ascites due to portal hypertension from those that were not due to portal hypertension 96.7% of the time. The AFTP, when used as defined in the old exudate-transudate concept, classified the causes of ascites correctly only 55.6% of the time. This resulted in part because the AFTP of most spontaneously infected samples (traditionally expected to be exudates) was low, and the AFTP of most cardiac ascites samples (traditionally expected to be transudates) was high. Conclusions: The exudate-transudate concept should be discarded in the classification of ascites. The serum-ascites albumin gradient is far more useful than the AFTP as a marker for portal hypertension, but the latter remains a useful adjunct in the differential diagnosis of ascites.	UNIV IOWA, IOWA CITY, IA 52242 USA; UNIV SO CALIF, LIVER UNIT, LOS ANGELES, CA 90089 USA	University of Iowa; University of Southern California								AKRIVIADIS EA, 1990, GASTROENTEROLOGY, V98, P127, DOI 10.1016/0016-5085(90)91300-U; BOUCKAERT PXJM, 1986, J REPROD FERTIL, V77, P329; BOYER TD, 1978, ARCH INTERN MED, V138, P1103, DOI 10.1001/archinte.138.7.1103; BURACK WR, 1960, AM J MED, V28, P510, DOI 10.1016/0002-9343(60)90145-5; CHESON BD, 1985, CLIN LAB MED, V5, P195, DOI 10.1016/S0272-2712(18)30865-5; DOUMAS BT, 1971, CLIN CHIM ACTA, V31, P87, DOI 10.1016/0009-8981(71)90365-2; HOEFS JC, 1985, DM-DIS MON, V31, P1, DOI 10.1016/0011-5029(85)90002-1; HOEFS JC, 1983, J LAB CLIN MED, V102, P260; HOEFS JC, 1981, HEPATOLOGY, V1, P249, DOI 10.1002/hep.1840010310; KAJANI MA, 1990, DIGEST DIS SCI, V35, P33, DOI 10.1007/BF01537219; MAATHUIS JB, 1978, J ENDOCRINOL, V76, P123, DOI 10.1677/joe.0.0760123; MAUER K, 1988, DIGEST DIS SCI, V33, P1208, DOI 10.1007/BF01536667; MAUK PM, 1988, ARCH INTERN MED, V148, P1577, DOI 10.1001/archinte.148.7.1577; PARE P, 1983, GASTROENTEROLOGY, V85, P240; POCKROS PJ, 1988, HEPATOLOGY, V8, P1450; RANSOHOFF DF, 1978, NEW ENGL J MED, V299, P926, DOI 10.1056/NEJM197810262991705; RECTOR WG, 1984, AM J MED, V77, P83, DOI 10.1016/0002-9343(84)90440-6; ROCCO VK, 1986, ANN INTERN MED, V105, P573, DOI 10.7326/0003-4819-105-4-573; ROVELSTAD RA, 1958, GASTROENTEROLOGY, V34, P436; RUNYON BA, 1988, HEPATOLOGY, V8, P1104, DOI 10.1002/hep.1840080521; RUNYON BA, 1988, J CLIN GASTROENTEROL, V10, P410, DOI 10.1097/00004836-198808000-00013; RUNYON BA, 1986, ARCH INTERN MED, V146, P2173, DOI 10.1001/archinte.146.11.2173; RUNYON BA, 1986, GASTROENTEROLOGY, V91, P1343, DOI 10.1016/0016-5085(86)90185-X; RUNYON BA, 1985, HEPATOLOGY, V5, P257, DOI 10.1002/hep.1840050217; RUNYON BA, 1988, GASTROENTEROLOGY, V95, P1351, DOI 10.1016/0016-5085(88)90372-1; RUNYON BA, 1984, HEPATOLOGY, V4, P1209, DOI 10.1002/hep.1840040619; RUNYON BA, 1986, HEPATOLOGY, V6, P396, DOI 10.1002/hep.1840060311; RUNYON BA, 1989, GASTROENTEROLOGY, V97, P158, DOI 10.1016/0016-5085(89)91430-3; RUNYON BA, 1987, J CLIN GASTROENTEROL, V9, P172, DOI 10.1097/00004836-198704000-00012; RUNYON BA, 1990, HEPATOLOGY, V12, P710, DOI 10.1002/hep.1840120415; RUNYON BA, 1991, TXB GASTROENTEROLOGY, P846; SAMPLINER RE, 1974, AM J MED SCI, V267, P275, DOI 10.1097/00000441-197405000-00003; SORIANO G, 1991, GASTROENTEROLOGY, V100, P477, DOI 10.1016/0016-5085(91)90219-B; SPAK I, 1960, ACTA CHIR SCAND    S, V261, P7; STANLEY MM, 1989, NEW ENGL J MED, V321, P1632, DOI 10.1056/NEJM198912143212403	35	382	403	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1992	117	3					215	220		10.7326/0003-4819-117-3-215	http://dx.doi.org/10.7326/0003-4819-117-3-215			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JF304	1616215				2022-12-01	WOS:A1992JF30400007
J	SLYPER, AH				SLYPER, AH			A FRESH LOOK AT THE ATHEROGENIC REMNANT HYPOTHESIS	LANCET			English	Editorial Material							CORONARY-ARTERY DISEASE; HIGH-DENSITY LIPOPROTEIN; POSTPRANDIAL LIPEMIA; MYOCARDIAL-INFARCTION; METABOLISM; CHOLESTEROL; ASSOCIATION; MEN				SLYPER, AH (corresponding author), MED COLL WISCONSIN,DEPT PEDIAT,8701 WATERTOWN PLANK RD,MILWAUKEE,WI 53209, USA.							ALBERS JJ, 1989, CLIN LAB MED, V9, P137, DOI 10.1016/S0272-2712(18)30646-2; CARA L, 1992, AM J CLIN NUTR, V55, P81, DOI 10.1093/ajcn/55.1.81; DEGENNES JL, 1981, DIABETES METAB, V7, P161; GENEST J, 1986, ARTERIOSCLEROSIS, V6, P297, DOI 10.1161/01.ATV.6.3.297; GORDON DJ, 1989, NEW ENGL J MED, V321, P1311; HAMSTEN A, 1986, ATHEROSCLEROSIS, V59, P223, DOI 10.1016/0021-9150(86)90051-1; JONES HB, 1951, AM J MED, V11, P358, DOI 10.1016/0002-9343(51)90171-4; KAMEDA K, 1984, ATHEROSCLEROSIS, V5, P241; KRAUSS RM, 1987, LANCET, V2, P62; MAHLEY RW, 1983, BIOCHIM BIOPHYS ACTA, V737, P197, DOI 10.1016/0304-4157(83)90001-1; MAHLEY RW, 1989, METABOLIC BASIS INHE, V1, P1195; MERRILL JR, 1989, ARTERIOSCLEROSIS, V9, P217, DOI 10.1161/01.ATV.9.2.217; MOORJANI S, 1986, METABOLISM, V35, P311, DOI 10.1016/0026-0495(86)90146-0; NIKKILA EA, 1971, ACTA MED SCAND, V190, P49; PATSCH JR, 1990, CIRCULATION, V82, P284; PATSCH JR, 1983, P NATL ACAD SCI-BIOL, V80, P1449, DOI 10.1073/pnas.80.5.1449; SIMPSON HS, 1990, ATHEROSCLEROSIS, V85, P193, DOI 10.1016/0021-9150(90)90111-U; SNIDERMAN A, 1991, ATHEROSCLEROSIS, V89, P109, DOI 10.1016/0021-9150(91)90050-D; SNIDERMAN AD, 1990, ARTERIOSCLEROSIS, V10, P665, DOI 10.1161/01.ATV.10.5.665; STEINER G, 1987, CIRCULATION, V75, P124, DOI 10.1161/01.CIR.75.1.124; TALL AR, 1986, J LIPID RES, V27, P361; TALL AR, 1990, J CLIN INVEST, V86, P379, DOI 10.1172/JCI114722; TALL AR, 1984, J BIOL CHEM, V259, P9587; WEINTRAUB MS, 1987, J CLIN INVEST, V79, P1110, DOI 10.1172/JCI112926; WEINTRAUB MS, 1988, J CLIN INVEST, V82, P1884, DOI 10.1172/JCI113806; ZILVERSMIT DB, 1979, CIRCULATION, V60, P473, DOI 10.1161/01.CIR.60.3.473	26	61	64	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 1	1992	340	8814					289	291		10.1016/0140-6736(92)92368-P	http://dx.doi.org/10.1016/0140-6736(92)92368-P			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG665	1353203				2022-12-01	WOS:A1992JG66500015
J	SONNEVELD, P; DURIE, BGM; LOKHORST, HM; MARIE, JP; SOLBU, G; SUCIU, S; ZITTOUN, R; LOWENBERG, B; NOOTER, K				SONNEVELD, P; DURIE, BGM; LOKHORST, HM; MARIE, JP; SOLBU, G; SUCIU, S; ZITTOUN, R; LOWENBERG, B; NOOTER, K			MODULATION OF MULTIDRUG-RESISTANT MULTIPLE-MYELOMA BY CYCLOSPORINE	LANCET			English	Article							ACUTE MYELOCYTIC-LEUKEMIA; PLASMA-CELL MYELOMA; P-GLYCOPROTEIN; DRUG-RESISTANCE; MDR1 GENE; ACCUMULATION; EXPRESSION; CANCER; ANTHRACYCLINES; DOXORUBICIN	Resistance to chemotherapy in refractory multiple myeloma is frequently associated with expression of multidrug resistance (MDR). In resistant cells, intracellular accumulation of doxorubicin and vincristine does not occur because the MDR-1 gene product, a membrane glycoprotein (PgP), is an energy-dependent efflux pump. Cyclosporin is one of several non-cytotoxic drugs that can block the function of PgP. In a prospective study, we assessed the possibility that cyclosporin could be used clinically to modulate MDR. We studied 21 patients with multiple myeloma; disease had progressed during primary chemotherapy in 6 and was resistant to VAD (vincristine, doxorubicin, dexamethasone) in 15, The patients received cyclosporin by continuous infusion during VAD treatment; there were three cyclosporin dosage groups (5, 7.5, 10 mg/kg daily). Serum cyclosporin concentrations adequate for MDR modulation were reached in all patients receiving 7.5 or 10 mg/kg daily. 47% (7) of the VAD-refractory patients and 48% (10) of the whole group responded to VAD. Before treatment, MDR-1 expression was present in 12 patients. After VAD plus cyclosporin, no MDR-1-positive plasma cells were present in 6 of 8 patients tested. The response rate in MDR-1-positive patients was 58% compared with 33% in all our patients. Toxic effects were mild and reversible and did not include nephrotoxic or serious cardiovascular side-effects. 12 months after the start of treatment, survival was 85%, and disease-free survival at a median of 9 months after the response was 65%. Thus, in multiple myeloma clinical resistance to VAD can be circumvented by cyclosporin, which enables the cytotoxic drugs to eliminate resistant myeloma cells.	EUROPEAN ORG RES TREATMENT CANC,CTR DATA,DEPT HAEMATOL,BRUSSELS,BELGIUM; WESTMINSTER & CHARING CROSS MED SCH,DEPT HAEMATOL,LONDON,ENGLAND; INST APPL IMMUNOL & RADIOBIOL,DEPT HAEMATOL,RIJSWIJK,NETHERLANDS; UNIV UTRECHT HOSP,DEPT HAEMATOL,3511 GV UTRECHT,NETHERLANDS; HOP HOTEL DIEU,DEPT HAEMATOL,F-75181 PARIS 04,FRANCE	European Organisation for Research & Treatment of Cancer; Imperial College London; Utrecht University; Utrecht University Medical Center; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Hotel-Dieu - APHP; UDICE-French Research Universities; Universite Paris Cite	SONNEVELD, P (corresponding author), ERASMUS UNIV,HOSP DIJKZIGT,DEPT HAEMATOL,ROOM L407,DR MOLEWARTERPLEIN 40,3015 GD ROTTERDAM,NETHERLANDS.							ALEXANIAN R, 1990, AM J HEMATOL, V33, P86, DOI 10.1002/ajh.2830330203; ALEXANIAN R, 1985, ARCH INTERN MED, V145, P2073, DOI 10.1001/archinte.145.11.2073; BARLOGIE B, 1986, BLOOD, V67, P1298; BARLOGIE B, 1984, NEW ENGL J MED, V310, P1353, DOI 10.1056/NEJM198405243102104; BELCH A, 1988, BRIT J CANCER, V57, P94, DOI 10.1038/bjc.1988.17; BUZAID AC, 1988, J CLIN ONCOL, V6, P889, DOI 10.1200/JCO.1988.6.5.889; DALTON WS, 1989, BLOOD, V73, P747; DURIE BGM, 1975, CANCER, V36, P842, DOI 10.1002/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U; EPSTEIN J, 1989, BLOOD, V74, P913; GORE ME, 1989, LANCET, V2, P879; GOSLAND MP, 1991, P AM ASSOC CANC RES, P82; GROGAN T, 1990, LAB INVEST, V63, P815; HERWEIJER H, 1990, JNCI-J NATL CANCER I, V82, P1133, DOI 10.1093/jnci/82.13.1133; KYLE RA, 1986, PROG HEMATOL, V14, P257; NOOTER K, 1990, INT J CANCER, V45, P263, DOI 10.1002/ijc.2910450210; PASTAN I, 1987, NEW ENGL J MED, V316, P1388; SALMON SE, 1991, BLOOD, V78, P44; SALMON SE, 1989, J NATL CANCER I, V81, P696, DOI 10.1093/jnci/81.9.696; SONNEVELD P, 1990, BRIT J HAEMATOL, V75, P208, DOI 10.1111/j.1365-2141.1990.tb02650.x; SPETH PAJ, 1986, J CHROMATOGR, V377, P415, DOI 10.1016/S0378-4347(00)80803-8; TSURUO T, 1981, CANCER RES, V41, P1967; UEDA K, 1987, P NATL ACAD SCI USA, V84, P3004, DOI 10.1073/pnas.84.9.3004; VANKALKEN CK, 1991, EUR J CANCER, V27, P739, DOI 10.1016/0277-5379(91)90178-G	23	369	378	0	11	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 1	1992	340	8814					255	259		10.1016/0140-6736(92)92353-H	http://dx.doi.org/10.1016/0140-6736(92)92353-H			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG665	1353189				2022-12-01	WOS:A1992JG66500001
J	SPITERI, MA; KLENERMAN, P; SHEPPARD, MN; PADLEY, S; CLARK, TJK; NEWMANTAYLOR, A				SPITERI, MA; KLENERMAN, P; SHEPPARD, MN; PADLEY, S; CLARK, TJK; NEWMANTAYLOR, A			SEASONAL CRYPTOGENIC ORGANIZING PNEUMONIA WITH BIOCHEMICAL CHOLESTASIS - A NEW CLINICAL ENTITY	LANCET			English	Article							OBLITERANS-ORGANIZING PNEUMONIA; BRONCHIOLITIS OBLITERANS; BRONCHOALVEOLAR LAVAGE	The term crytogenic organising pneumonia has been used for the combination of dyspnoea, cough, pleuritic pain, widespread shadows on chest radiographs, and histological evidence of intra-alveolar organisation with buds of granulation tissue within the alveoli. We report 12 patients with seasonal recurrence of this disorder for between 3 and 11 years. In all 12 patients, symptoms recurred between late February and early May every year, tending to increase in severity each year, and resolved between June and January. Chest radiography and computed tomography showed bilateral consolidation. Lung biopsy samples showed intra-alveolar buds of granulation tissue. There were many neutrophils within the lumina of medium-sized airways and terminal bronchioles showed evidence of obstruction by granulation tissue. Functionally, the predominant defect was restrictive and only 2 patients (life-long non-smokers) had airflow limitation. All 12 patients had very high activities of liver enzymes, suggesting intrahepatic cholestasis, but no other evidence of liver disease. Cultures of blood, sputum, lung tissue, and bronchoalveolar lavage fluid, viral screening, and complement fixation tests were consistently negative. In all patients all abnormalities responded rapidly to oral steroid therapy. These findings suggest a seasonal syndrome of organising pneumonia and biochemical abnormalities indicative of intrahepatic cholestasis. No aetiological factor has been identified, but the nature and periodicity of the illness point to an inhaled agent present in the environment for a limited period every year.	ROYAL BROMPTON HOSP,LONDON,ENGLAND; NATL HEART & LUNG INST,LONDON,ENGLAND	Royal Brompton Hospital; Imperial College London			Sheppard, Mary N/AAB-3364-2019	Sheppard, Mary N/0000-0003-2724-3881; klenerman, paul/0000-0003-4307-9161				BELSEY R, 1960, BRIT J DIS CHEST, V54, P342, DOI 10.1016/S0007-0971(60)80068-X; BONKOWSKY HL, 1975, JAMA-J AM MED ASSOC, V1284, P233; CORDIER JF, 1989, CHEST, V96, P999, DOI 10.1378/chest.96.5.999; DAVISON AG, 1983, Q J MED, V207, P382; EPLER GR, 1985, NEW ENGL J MED, V312, P152, DOI 10.1056/NEJM198501173120304; FORCE MLG, 1987, AM REV RESPIR DIS, V133, P705; HASLAM P L, 1987, European Journal of Respiratory Diseases Supplement, V71, P120; JEDERLINIC PJ, 1988, MEDICINE, V67, P154, DOI 10.1097/00005792-198805000-00002; Laennec Rene-Theophile-Hyacinthe, 1826, TRAITE AUSCULTATION, V1; MCCARTHY D S, 1973, Clinical Allergy, V3, P339, DOI 10.1111/j.1365-2222.1973.tb01341.x; MCLOUD TC, 1986, RADIOLOGY, V159, P1; MULLER NL, 1990, AM J ROENTGENOL, V154, P983; NEVILLE E, 1975, POSTGRAD MED J, V51, P361, DOI 10.1136/pgmj.51.596.361; Nishimura K, 1989, Rinsho Hoshasen, V34, P127; PEYROL S, 1990, AM J PATHOL, V137, P155; REYNOLDS HY, 1987, AM REV RESPIR DIS, V135, P250; RUDD RM, 1981, AM REV RESPIR DIS, V124, P1; SULAVIK SB, 1989, CHEST, V96, P967, DOI 10.1378/chest.96.5.967; TESCHLER H, 1991, American Review of Respiratory Disease, V143, pA53; WOODHEAD MA, 1987, LANCET, V1, P671	20	48	48	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 1	1992	340	8814					281	284		10.1016/0140-6736(92)92366-N	http://dx.doi.org/10.1016/0140-6736(92)92366-N			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG665	1353201				2022-12-01	WOS:A1992JG66500013
J	THOMAIDES, TN; CHAUDHURI, KR; MAULE, S; WATSON, L; MARSDEN, CD; MATHIAS, CJ				THOMAIDES, TN; CHAUDHURI, KR; MAULE, S; WATSON, L; MARSDEN, CD; MATHIAS, CJ			GROWTH-HORMONE RESPONSE TO CLONIDINE IN CENTRAL AND PERIPHERAL PRIMARY AUTONOMIC FAILURE	LANCET			English	Article							SECRETION; HYPERGLYCEMIA; OUTFLOW	Patients with primary autonomic failure may have either pure autonomic failure (PAF) or multiple system atrophy (MSA) in which there is additional neurological involvement. Distinction between PAF and MSA at an early stage is important because a wide range of complications is associated with MSA, which has a poor response to drug therapy and a less favourable prognosis. We have investigated the growth hormone (GH) releasing effects of clonidine in patients with PAF and MSA to see whether this hormonal response could serve as a neuroendocrine marker to distinguish between the groups. Age-matched normal subjects were studied as controls. Both groups of patients had severe postural hypotension due to primary sympathetic failure of presumed central origin in MSA and peripheral origin in PAF. After clonidine, plasma GH concentrations increased in controls and PAF, with no change in MSA. Changes in plasma glucose and insulin concentrations were similar in all groups. Clonidine, therefore, stimulates growth hormone release in PAF but not MSA and may serve as a neuroendocrine marker in differentiating patients with MSA and a central autonomic defect from those with PAF with a peripheral defect.	UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,ST MARYS HOSP,SCH MED,DEPT MED,CARDIOVASC MED UNIT,LONDON SW7 2AZ,ENGLAND; NATL HOSP NEUROL & NEUROSURG,LONDON,ENGLAND; UNIV LONDON,INST NEUROL,DEPT CLIN NEUROL,AUTON UNIT,LONDON,ENGLAND	Imperial College London; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; University of London; University College London				Ray Chaudhuri, K/0000-0003-2815-0505	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALBAROTH J, 1989, CLIN ENDOCRINOL, V30, P485, DOI 10.1111/j.1365-2265.1989.tb01419.x; Armstrong E, 1991, Clin Auton Res, V1, P135, DOI 10.1007/BF01826210; BANNISTER R, 1988, AUTONOMIC FAILURE TX, P281; BANNISTER R, 1992, AUTONOMIC FAILURE TX, P255; BARBIERI C, 1980, J PHARMACOL EXP THER, V214, P433; BRAMNERT M, 1984, J CLIN ENDOCR METAB, V58, P374, DOI 10.1210/jcem-58-2-374; CHECKLEY SA, 1980, PSYCHOL MED, V10, P35, DOI 10.1017/S0033291700039593; CHEKLEY SA, 1981, BRIT J PSYCHIAT, V138, P51; DACOSTA DF, 1984, CLIN EXP HYPERTENS A, V6, P1843, DOI 10.3109/10641968409046089; DELITALA G, 1983, J CLIN ENDOCR METAB, V57, P1145, DOI 10.1210/jcem-57-6-1145; GEMMILL JD, 1988, LANCET, V1, P1018; GILAD I, 1979, LANCET, V2, P1242; HUGHES AJ, 1992, J NEUROL NEUROSUR PS, V55, P181, DOI 10.1136/jnnp.55.3.181; HUNT GE, 1986, PSYCHONEUROENDOCRINO, V11, P317, DOI 10.1016/0306-4530(86)90017-X; KOONER JS, 1991, CIRCULATION, V84, P75, DOI 10.1161/01.CIR.84.1.75; LAL S, 1981, HORM METAB RES, V13, P648, DOI 10.1055/s-2007-1019362; MAY CN, 1988, CLIN SCI, V75, P71, DOI 10.1042/cs0750071; MAY CN, 1990, NEUROPHARMACOLOGY, V29, P545, DOI 10.1016/0028-3908(90)90066-Z; MAZZA E, 1990, Endocrinologia Experimentalis, V24, P211; MULLER EE, 1988, ADV BIOSCI, V69, P173; POLINSKY RJ, 1992, AUTONOMIC FAILURE TX, P334; RAJPUT AH, 1990, CLIN NEUROPHARMACOL, V13, P553, DOI 10.1097/00002826-199012000-00007; REID JL, 1981, BRIT J CLIN PHARMACO, V12, P295, DOI 10.1111/j.1365-2125.1981.tb01217.x; REID JL, 1977, CLIN PHARMACOL THER, V21, P375; RUDMAN D, 1981, J CLIN INVEST, V67, P1364	25	35	35	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 1	1992	340	8814					263	266		10.1016/0140-6736(92)92355-J	http://dx.doi.org/10.1016/0140-6736(92)92355-J			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG665	1353191				2022-12-01	WOS:A1992JG66500003
J	ALDER, J; LU, B; VALTORTA, F; GREENGARD, P; POO, MM				ALDER, J; LU, B; VALTORTA, F; GREENGARD, P; POO, MM			CALCIUM-DEPENDENT TRANSMITTER SECRETION RECONSTITUTED IN XENOPUS OOCYTES - REQUIREMENT FOR SYNAPTOPHYSIN	SCIENCE			English	Article							SYNAPTIC VESICLE PROTEIN; MEMBRANE-PROTEIN; MESSENGER-RNA; NEUROMUSCULAR-JUNCTION; LAEVIS OOCYTES; AMINO-ACIDS; RAT-BRAIN; GLUTAMINE; RELEASE; NEUROTRANSMITTER	Calcium-dependent glutamate secretion was reconstituted in Xenopus oocytes by injecting the oocyte with total rat cerebellar messenger RNA (mRNA). Co-injection of total mRNA with antisense oligonucleotides to synaptophysin message decreased the expression of synaptophysin in the oocyte and reduced the calcium-dependent secretion. A similar effect on secretion was observed for oocytes injected with total mRNA together with an antibody to rat synaptophysin. These results indicate that synaptophysin is necessary for transmitter secretion and that the oocyte expression system may be useful for dissecting the molecular events associated with the secretory process.	COLUMBIA UNIV,DEPT BIOL SCI,NEW YORK,NY 10027; ROCKEFELLER UNIV,MOLEC & CELLULAR NEUROSCI LAB,NEW YORK,NY 10021; UNIV MILAN,NATL RES COUNCIL,CTR CYTOPHARMACOL,DEPT PHARMACOL,I-20129 MILAN,ITALY	Columbia University; Rockefeller University; University of Milan			Flavia, Valtorta/F-3450-2012; Lu, Bai/A-4018-2012	Flavia, Valtorta/0000-0001-9556-4746; Alder, Janet/0000-0002-5694-4946; Lu, Bai/0000-0001-5418-9759	NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH039327, R01MH039327] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS022764] Funding Source: NIH RePORTER; NIMH NIH HHS [MH 39327] Funding Source: Medline; NINDS NIH HHS [NS 22764] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADLER EM, 1991, J NEUROSCI, V11, P1496; BAUMERT M, 1989, EMBO J, V8, P379, DOI 10.1002/j.1460-2075.1989.tb03388.x; BLAKELY RD, 1988, P NATL ACAD SCI USA, V85, P9846, DOI 10.1073/pnas.85.24.9846; BLAKELY RD, 1991, J NEUROCHEM, V56, P860, DOI 10.1111/j.1471-4159.1991.tb02002.x; BRADFORD HF, 1978, J NEUROCHEM, V30, P1453, DOI 10.1111/j.1471-4159.1978.tb10477.x; BUCKLEY KM, 1987, J CELL BIOL, V105, P2447, DOI 10.1083/jcb.105.6.2447; CAVELLI A, 1991, EMBO J, V10, P1671; CAZENAVE C, 1987, NUCLEIC ACIDS RES, V15, P10507, DOI 10.1093/nar/15.24.10507; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COWAN D, 1990, BRAIN RES, V509, P1, DOI 10.1016/0006-8993(90)90301-Q; DASH P, 1987, P NATL ACAD SCI USA, V84, P7896, DOI 10.1073/pnas.84.22.7896; DECAMILLI P, 1990, ANNU REV PHYSIOL, V52, P625, DOI 10.1146/annurev.ph.52.030190.003205; DECAMILLI P, 1991, EMBO J, V10, P1275; HAMBERGER AC, 1979, BRAIN RES, V168, P513, DOI 10.1016/0006-8993(79)90306-8; JAHN R, 1985, P NATL ACAD SCI USA, V82, P4137, DOI 10.1073/pnas.82.12.4137; JOHNSON PA, 1989, J BIOL CHEM, V264, P1258; JOHNSTON PA, 1989, EMBO J, V8, P2863, DOI 10.1002/j.1460-2075.1989.tb08434.x; JOHNSTON PA, 1990, J BIOL CHEM, V264, P7849; KNAUS P, 1990, FEBS LETT, V261, P358, DOI 10.1016/0014-5793(90)80591-6; KUSHNER L, 1989, METHODS NEUROSCIENCE, V1, P3; LEUBE RE, 1987, EMBO J, V6, P3261, DOI 10.1002/j.1460-2075.1987.tb02644.x; LEUBE RE, 1989, CELL, V59, P433, DOI 10.1016/0092-8674(89)90028-7; LINSTEDT AD, 1991, NEURON, V7, P309, DOI 10.1016/0896-6273(91)90269-6; MCMAHON HT, 1990, J NEUROCHEM, V54, P373, DOI 10.1111/j.1471-4159.1990.tb01883.x; NICHOLLS DG, 1987, J NEUROCHEM, V49, P50, DOI 10.1111/j.1471-4159.1987.tb03393.x; NICHOLLS DG, 1986, NATURE, V321, P772, DOI 10.1038/321772a0; REHM H, 1986, EMBO J, V5, P535, DOI 10.1002/j.1460-2075.1986.tb04243.x; SHUTTLEWORTH J, 1988, GENE, V72, P267, DOI 10.1016/0378-1119(88)90152-7; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; SUDHOF TC, 1987, SCIENCE, V238, P1142, DOI 10.1126/science.3120313; SZERB JC, 1985, J NEUROCHEM, V44, P1724, DOI 10.1111/j.1471-4159.1985.tb07160.x; TAYLOR PM, 1989, J MEMBRANE BIOL, V112, P149, DOI 10.1007/BF01871276; THANKI CM, 1983, J NEUROCHEM, V41, P611, DOI 10.1111/j.1471-4159.1983.tb04785.x; THOMAS L, 1988, SCIENCE, V242, P1050, DOI 10.1126/science.2461586; THOMAS L, 1990, J CELL BIOL, V111, P2041, DOI 10.1083/jcb.111.5.2041; TORRITARELLI F, 1990, J CELL BIOL, V110, P449, DOI 10.1083/jcb.110.2.449; VALTORTA F, 1988, J CELL BIOL, V107, P2717, DOI 10.1083/jcb.107.6.2717; VALTORTA F, UNPUB; WARD HK, 1983, J NEUROCHEM, V40, P855, DOI 10.1111/j.1471-4159.1983.tb08058.x; WIEDENMANN B, 1985, CELL, V41, P1017, DOI 10.1016/S0092-8674(85)80082-9; YOUNG AB, 1974, BRAIN RES, V73, P1, DOI 10.1016/0006-8993(74)91002-6; 1990, PROMEGA PROTOCOLS AP, P116	42	123	137	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 31	1992	257	5070					657	661		10.1126/science.1353905	http://dx.doi.org/10.1126/science.1353905			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JF852	1353905				2022-12-01	WOS:A1992JF85200033
J	ARCH, R; WIRTH, K; HOFMANN, M; PONTA, H; MATZKU, S; HERRLICH, P; ZOLLER, M				ARCH, R; WIRTH, K; HOFMANN, M; PONTA, H; MATZKU, S; HERRLICH, P; ZOLLER, M			PARTICIPATION IN NORMAL IMMUNE-RESPONSES OF A METASTASIS-INDUCING SPLICE VARIANT OF CD44	SCIENCE			English	Article							ENDOTHELIAL-CELL RECOGNITION; MONOCLONAL-ANTIBODIES; RECEPTOR; ACTIVATION; TUMOR; ADHESION; MOLECULE; RAT	A variant of the glycoprotein CD44 (CD44v) that shares sequences with variants causally involved in metastasis formation is transiently expressed on B and T lymphocytes and macrophages after antigenic stimulation and in the postnatal period. Antibodies to the variant hinder in vivo activation of both B and T cells. The observation that a protein domain that is expressed on CD44 and required for the lymphatic spread of tumor cells can catalyze an essential step in the process of lymphocyte activation supports the idea that metastasizing tumor cells mimic lymphocyte behavior.	GERMAN CANC RES CTR,INST RADIOL & PATHOPHYSIOL,NEUENHEIMER FELD 280,W-6900 HEIDELBERG 1,GERMANY; KERNFORSCHUNGSZENTRUM KARLSRUHE GMBH,INST GENET & TOXIKOL,W-7500 KARLSRUHE 1,GERMANY; E MERCK & CO,W-6100 DARMSTADT,GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; Karlsruhe Institute of Technology; Merck KGaA			Hofmann-Apitius, Martin/E-6123-2018	Hofmann-Apitius, Martin/0000-0001-9012-6720				ARCH RH, UNPUB; DENNING SM, 1990, J IMMUNOL, V144, P7; ENGVALL E, 1972, J IMMUNOL, V109, P129; FIDLER JM, 1975, CELL IMMUNOL, V16, P223, DOI 10.1016/0008-8749(75)90114-8; GALLATIN WM, 1989, P NATL ACAD SCI USA, V86, P4654, DOI 10.1073/pnas.86.12.4654; GOWANS JL, 1964, P ROY SOC LOND A MAT, V159, P282; GUNTHERT U, 1991, INVAS METAST, V65, P13; HOFMANN M, 1991, CANCER RES, V51, P5292; HUET S, 1989, J IMMUNOL, V143, P798; IDZERDA RL, 1989, P NATL ACAD SCI USA, V86, P4659, DOI 10.1073/pnas.86.12.4659; ISOBE M, 1992, SCIENCE, V255, P1125, DOI 10.1126/science.1347662; JALKANEN S, 1986, SCIENCE, V233, P556, DOI 10.1126/science.3726548; JALKANEN ST, 1986, EUR J IMMUNOL, V16, P1195, DOI 10.1002/eji.1830161003; JERNE NK, 1963, SCIENCE, V140, P405, DOI 10.1126/science.140.3565.405; MATZKU S, 1983, INVAS METAST, V3, P109; REBER S, 1990, INT J CANCER, V46, P919, DOI 10.1002/ijc.2910460528; RITTENBERG MB, 1969, P SOC EXP BIOL MED, V132, P575; ROBINSON AP, 1986, IMMUNOLOGY, V57, P239; ROBINSON AP, 1985, IMMUNOLOGY, V55, P527; RUDY W, UNPUB; SEITER S, UNPUB; SHIMIZU Y, 1989, J IMMUNOL, V143, P2457; TOLG C, UNPUB; TROWBRIDGE IS, 1982, IMMUNOGENETICS, V15, P299, DOI 10.1007/BF00364338; ZOLLER M, 1990, SCAND J IMMUNOL, V31, P619, DOI 10.1111/j.1365-3083.1990.tb02813.x	25	444	464	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 31	1992	257	5070					682	685		10.1126/science.1496383	http://dx.doi.org/10.1126/science.1496383			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JF852	1496383				2022-12-01	WOS:A1992JF85200041
J	BEAUDRY, AA; JOYCE, GF				BEAUDRY, AA; JOYCE, GF			DIRECTED EVOLUTION OF AN RNA ENZYME	SCIENCE			English	Article							GROUP-I INTRON; SITE-SPECIFIC MUTAGENESIS; SELF-SPLICING INTRON; TETRAHYMENA RIBOZYME; RIBOSOMAL-RNA; CATALYTIC ACTIVITY; DNA-POLYMERASE; SATURATION MUTAGENESIS; SECONDARY STRUCTURE; STRANDED-DNA	An in vitro evolution procedure was used to obtain RNA enzymes with a particular catalytic function. A population of 10(13) variants of the, Tetrahynena ribozyme, a group I ribozyme that catalyzes sequence-specific cleavage of RNA via a phosphoester transfer mechanism, was generated. This enzyme has a limited ability to cleave DNA under conditions of high temperature or high MgCl2 concentration, or both. A selection constraint was imposed on the population of ribozyme variants such that only those individuals that carried out DNA cleavage under physiologic conditions were amplified to produce "progeny" ribozymes. Mutations were introduced during amplification to maintain heterogeneity in the population. This process was repeated for ten successive generations, resulting in enhanced (100 times) DNA cleavage activity.	SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute	BEAUDRY, AA (corresponding author), SCRIPPS RES INST, DEPT CHEM, LA JOLLA, CA 92037 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030882] Funding Source: NIH RePORTER; NIAID NIH HHS [AI30882] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARFOD ET, 1988, GENE DEV, V2, P652, DOI 10.1101/gad.2.6.652; BEAUDRY AA, 1990, BIOCHEMISTRY-US, V29, P6534, DOI 10.1021/bi00479a027; BEEN MD, 1988, SCIENCE, V239, P1412, DOI 10.1126/science.2450400; BURKE JM, 1987, NUCLEIC ACIDS RES, V15, P7217, DOI 10.1093/nar/15.18.7217; Cadwell R C, 1992, PCR Methods Appl, V2, P28, DOI 10.1101/gr.2.1.28; CECH TR, 1988, GENE, V73, P259, DOI 10.1016/0378-1119(88)90492-1; CELANDER DW, 1991, SCIENCE, V251, P401, DOI 10.1126/science.1989074; Chamberlin M., 1982, ENZYMES, V15, P87; CHOWRIRA BM, 1991, NATURE, V354, P320, DOI 10.1038/354320a0; CHU CT, 1979, VIROLOGY, V98, P168, DOI 10.1016/0042-6822(79)90535-X; COUTURE S, 1990, J MOL BIOL, V215, P345, DOI 10.1016/S0022-2836(05)80356-0; CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; DAVIES RW, 1982, NATURE, V300, P719, DOI 10.1038/300719a0; DERBYSHIRE KM, 1986, GENE, V46, P145, DOI 10.1016/0378-1119(86)90398-7; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; DOUDNA JA, 1989, NATURE, V339, P519, DOI 10.1038/339519a0; Eadie GS, 1942, J BIOL CHEM, V146, P85; EIGEN M, 1988, J PHYS CHEM-US, V92, P6881, DOI 10.1021/j100335a010; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; GREEN R, 1990, NATURE, V347, P406, DOI 10.1038/347406a0; GRUNSTEIN M, 1975, P NATL ACAD SCI USA, V72, P3961, DOI 10.1073/pnas.72.10.3961; GUATELLI JC, 1990, P NATL ACAD SCI USA, V87, P1874, DOI 10.1073/pnas.87.5.1874; Hanahan D., 1985, DNA CLONING PRACTICA, V1, P109; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10159, DOI 10.1021/bi00496a003; HERSCHLAG D, 1990, NATURE, V344, P405, DOI 10.1038/344405a0; HOFSTEE BHJ, 1952, J BIOL CHEM, V199, P357; HOLMES DS, 1981, ANAL BIOCHEM, V114, P193, DOI 10.1016/0003-2697(81)90473-5; HUTCHISON CA, 1986, P NATL ACAD SCI USA, V83, P710, DOI 10.1073/pnas.83.3.710; INOUE T, 1986, J MOL BIOL, V189, P143, DOI 10.1016/0022-2836(86)90387-6; JOHNSON KA, 1990, ENZYMES, V19, P159; JOYCE GF, 1989, GENE, V82, P83, DOI 10.1016/0378-1119(89)90033-4; JOYCE GF, 1987, NUCLEIC ACIDS RES, V15, P9825, DOI 10.1093/nar/15.23.9825; JOYCE GF, 1989, NUCLEIC ACIDS RES, V17, P7879, DOI 10.1093/nar/17.19.7879; JOYCE GF, 1989, NUCLEIC ACIDS RES, V17, P711, DOI 10.1093/nar/17.12.4885; JOYCE GF, 1992, ANTISENSE RNA DNA, P353; JOYCE GF, 1989, MOL BIOL RNA, P361; KAY PS, 1987, NATURE, V327, P343, DOI 10.1038/327343a0; KIM SH, 1987, P NATL ACAD SCI USA, V84, P8788, DOI 10.1073/pnas.84.24.8788; KNOWLES JR, 1987, SCIENCE, V236, P1252; KRUGER K, 1982, CELL, V31, P147, DOI 10.1016/0092-8674(82)90414-7; KWOH DY, 1989, P NATL ACAD SCI USA, V86, P1173, DOI 10.1073/pnas.86.4.1173; LAM KS, 1991, NATURE, V354, P82, DOI 10.1038/354082a0; LEHTOVAARA PM, 1988, PROTEIN ENG, V2, P63, DOI 10.1093/protein/2.1.63; Leung DW, 1989, TECHNIQUE, V1, P11; MATTEUCCI MD, 1983, NUCLEIC ACIDS RES, V11, P3113, DOI 10.1093/nar/11.10.3113; MCNEIL JB, 1985, MOL CELL BIOL, V5, P3545, DOI 10.1128/MCB.5.12.3545; MICHEL F, 1990, GENE DEV, V4, P777, DOI 10.1101/gad.4.5.777; MICHEL F, 1982, BIOCHIMIE, V64, P867, DOI 10.1016/S0300-9084(82)80349-0; MICHEL F, 1989, NATURE, V342, P391, DOI 10.1038/342391a0; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; MICHEL F, 1983, EMBO J, V2, P33, DOI 10.1002/j.1460-2075.1983.tb01376.x; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MILLS DR, 1967, P NATL ACAD SCI USA, V58, P217, DOI 10.1073/pnas.58.1.217; MORINAGA Y, 1984, BIO-TECHNOL, V2, P636, DOI 10.1038/nbt0784-636; MURPHY FL, 1989, P NATL ACAD SCI USA, V86, P9218, DOI 10.1073/pnas.86.23.9218; MYERS RM, 1985, SCIENCE, V229, P242, DOI 10.1126/science.2990046; PRICE JV, 1985, NUCLEIC ACIDS RES, V13, P1871, DOI 10.1093/nar/13.6.1871; Robertson D. W., UNPUB; ROBERTSON DL, 1990, NATURE, V344, P467, DOI 10.1038/344467a0; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SHORTLE D, 1983, METHOD ENZYMOL, V100, P457; SZOSTAK JW, 1986, NATURE, V322, P83, DOI 10.1038/322083a0; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; WELLS JA, 1985, GENE, V34, P315, DOI 10.1016/0378-1119(85)90140-4; WOODSON SA, 1989, CELL, V57, P335, DOI 10.1016/0092-8674(89)90971-9; YOUNG B, 1991, CELL, V67, P1007, DOI 10.1016/0092-8674(91)90373-7; ZAGURSKY RJ, 1985, GENE ANAL TECH, V2, P89, DOI 10.1016/0735-0651(85)90011-1; ZAKOUR RA, 1982, NATURE, V295, P708, DOI 10.1038/295708a0; ZAUG AJ, 1986, NATURE, V324, P429, DOI 10.1038/324429a0; ZAUG AJ, 1986, SCIENCE, V231, P470, DOI 10.1126/science.3941911; ZAUG AJ, 1988, BIOCHEMISTRY-US, V27, P8924, DOI 10.1021/bi00425a008; ZHOU YH, 1991, NUCLEIC ACIDS RES, V19, P6052, DOI 10.1093/nar/19.21.6052	75	347	443	1	76	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 31	1992	257	5070					635	641		10.1126/science.1496376	http://dx.doi.org/10.1126/science.1496376			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JF852	1496376				2022-12-01	WOS:A1992JF85200026
J	CHAN, HC; NELSON, DJ				CHAN, HC; NELSON, DJ			CHLORIDE-DEPENDENT CATION CONDUCTANCE ACTIVATED DURING CELLULAR SHRINKAGE	SCIENCE			English	Article							EPITHELIAL-CELLS; CHANNEL	A chloride (Cl-)-dependent, nonselective cation conductance was activated during cellular shrinkage and inhibited during cellular swelling or by extracellular gadolinium. The shrinking-induced, nonselective cation conductance and the swelling-induced anion conductance appear to function in the regulation of cell volume in airway epithelia. The shrinking-induced cation conductance had an unusual dependence on Cl-: partial replacement of extracellular Cl- with aspartate reduced the magnitude of the shrinking-enhanced current without accompanying changes in the reversal potential. The Cl- dependence of the nonselective cation conductance could provide a mechanism that tightly regulates Cl- secretion and sodium reabsorption in cells under osmotic stress.	UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637; UNIV CHICAGO,DEPT NEUROL,CHICAGO,IL 60637	University of Chicago; University of Chicago			Chan, Hsiao Chang/E-1507-2016					BUTT AG, 1990, AM J PHYSIOL, V258, P630; Chamberlin ME, 1989, AM J PHYSIOL, Vl257, P159; CHAN HC, 1992, AM J PHYSIOL, V262, pC1273, DOI 10.1152/ajpcell.1992.262.5.C1273; GOGELEIN H, 1989, PFLUG ARCH EUR J PHY, V413, P287, DOI 10.1007/BF00583543; GRAY MA, 1990, BIOCHIM BIOPHYS ACTA, V1029, P33, DOI 10.1016/0005-2736(90)90433-O; JORISSEN M, 1990, PFLUG ARCH EUR J PHY, V415, P617, DOI 10.1007/BF02583515; KROUSE ME, 1989, AM J PHYSIOL, V257, P129; OKADA Y, 1989, NEWS PHYSIOL SCI, V4, P238; ROTHSTEIN A, 1990, AM J PHYSIOL, V258, P827; SOEJIMA M, 1984, PFLUG ARCH EUR J PHY, V400, P424, DOI 10.1007/BF00587544; SOLC CK, 1991, AM J PHYSIOL, V261, P658; WONG MMY, 1991, SCIENCE, V254, P1014, DOI 10.1126/science.1948071; WORRELL RT, 1989, AM J PHYSIOL, V256, pC1111, DOI 10.1152/ajpcell.1989.256.6.C1111	13	64	64	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 31	1992	257	5070					669	671		10.1126/science.1379742	http://dx.doi.org/10.1126/science.1379742			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JF852	1379742				2022-12-01	WOS:A1992JF85200036
J	GIMENO, CJ; FINK, GR				GIMENO, CJ; FINK, GR			THE LOGIC OF CELL-DIVISION IN THE LIFE-CYCLE OF YEAST	SCIENCE			English	Editorial Material									MIT,DEPT BIOL,CAMBRIDGE,MA 02142	Massachusetts Institute of Technology (MIT)	GIMENO, CJ (corresponding author), MIT,WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040266, R37GM035010, R01GM035010] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM40266, GM35010] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		FREIFELDER D, 1960, J BACTERIOL, V80, P567, DOI 10.1128/JB.80.4.567-568.1960; GIMENO CJ, 1992, CELL, V68, P1077, DOI 10.1016/0092-8674(92)90079-R; HANSEN EC, 1886, C R TRAV LAB CARLS P, V2, P92; HAWTHORNE DC, 1955, GENETICS, V40, P511; HERSKOWITZ I, 1992, NATURE, V357, P190, DOI 10.1038/357190a0; HICKS JB, 1977, GENETICS, V85, P395; LODDER J, 1970, YEASTS TAXONOMIC STU, P51; MORTIMER RK, 1986, GENETICS, V113, P35; NASMYTH KA, 1982, ANNU REV GENET, V16, P439, DOI 10.1146/annurev.ge.16.120182.002255; SCHERR GH, 1953, BACTERIOL REV, V17, P51, DOI 10.1128/MMBR.17.1.51-92.1953; THOMAS JH, 1987, GENETICS, V115, P229	11	53	54	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 31	1992	257	5070					626	626		10.1126/science.1496375	http://dx.doi.org/10.1126/science.1496375			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JF852	1496375				2022-12-01	WOS:A1992JF85200024
J	KURLANDER, RJ; SHAWAR, SM; BROWN, ML; RICH, RR				KURLANDER, RJ; SHAWAR, SM; BROWN, ML; RICH, RR			SPECIALIZED ROLE FOR A MURINE CLASS-I-B MHC MOLECULE IN PROKARYOTIC HOST DEFENSES	SCIENCE			English	Article							N-FORMYLATED PEPTIDES; LISTERIA-MONOCYTOGENES; T-CELLS; LYMPHOCYTES-T; ANTIGEN; RECEPTOR; MICE; PROTECTION; IMMUNITY; PROTEINS	Although nonclassical (class I-b) gene products represent the majority of murine major histocompatibility complex (MHC) genes, the role of these relatively nonpolymorphic molecules remains uncertain. Recently, one such protein, H-2M3 (formerly designated Hmt), was shown to bind and specifically present N-formylated peptides to cytotoxic T lymphocytes. Because N-formylation is characteristic of prokaryotic proteins, this MHC molecule may be especially adapted for a role in the mammalian defense against bacterial attack. The current studies demonstrate that an MHC molecule, indistinguishable from H-2M3, presents antigens derived from the intracellular pathogen Listeria monocytogenes to Listeria-specific CD8+ cells.	BAYLOR COLL MED, DEPT MED, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DEPT MED, HOUSTON, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	KURLANDER, RJ (corresponding author), DUKE UNIV, MED CTR, DEPT MED, DURHAM, NC 27710 USA.			Shawar, Said/0000-0002-5281-1783	NIAID NIH HHS [R01 AI18882, R01 AI18073] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018073, R01AI018882] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BROWN ML, 1992, J IMMUNOL, V148, P555; BRUNT LM, 1990, J IMMUNOL, V145, P3540; Buetow D E, 1978, Subcell Biochem, V5, P1; COLLINGE J, 1991, NATURE, V353, P802, DOI 10.1038/353802a0; CZUPRYNSKI CJ, 1987, IMMUNOLOGY, V60, P287; DELIBERO G, 1988, EUR J IMMUNOL, V18, P59, DOI 10.1002/eji.1830180110; DELIBERO G, 1986, J IMMUNOL, V137, P2688; FISCHERLINDAHL K, 1985, TRENDS GENET, V1, P135; FISCHERLINDAHL K, 1983, NATURE, V306, P383; IMANI F, 1991, P NATL ACAD SCI USA, V88, P10475, DOI 10.1073/pnas.88.23.10475; KAUFMANN SHE, 1987, REV INFECT DIS, V9, pS650; KAUFMANN SHE, 1988, J IMMUNOL, V140, P3173; KLEIN J, 1990, IMMUNOGENETICS, V32, P147, DOI 10.1007/BF02114967; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LINDAHL KF, 1991, ANNU REV IMMUNOL, V9, P351, DOI 10.1146/annurev.iy.09.040191.002031; LOVELAND B, 1990, CELL, V60, P971, DOI 10.1016/0092-8674(90)90345-F; LUKACS K, 1989, J IMMUNOL, V142, P2879; LUKACS K, 1989, J IMMUNOL, V143, P3731; MIELKE MEA, 1988, INFECT IMMUN, V56, P1920, DOI 10.1128/IAI.56.8.1920-1925.1988; MILLIGAN GN, 1991, J EXP MED, V174, P133, DOI 10.1084/jem.174.1.133; PARISH CR, 1983, J IMMUNOL METHODS, V58, P225, DOI 10.1016/0022-1759(83)90277-6; Rodgers J R, 1986, Adv Immunol, V38, P313, DOI 10.1016/S0065-2776(08)60010-3; SHAWAR SM, 1991, J EXP MED, V174, P941, DOI 10.1084/jem.174.4.941; SHAWAR SM, 1990, J EXP MED, V171, P897, DOI 10.1084/jem.171.3.897; SHAWAR SM, 1991, IMMUNOL RES, V10, P365, DOI 10.1007/BF02919723; STROMINGER JL, 1989, CELL, V57, P895, DOI 10.1016/0092-8674(89)90326-7; WANG CR, 1991, CELL, V66, P335, DOI 10.1016/0092-8674(91)90623-7	27	140	141	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 31	1992	257	5070					678	679		10.1126/science.1496381	http://dx.doi.org/10.1126/science.1496381			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JF852	1496381				2022-12-01	WOS:A1992JF85200039
J	MOSS, SJ; SMART, TG; BLACKSTONE, CD; HUGANIR, RL				MOSS, SJ; SMART, TG; BLACKSTONE, CD; HUGANIR, RL			FUNCTIONAL MODULATION OF GABA(A) RECEPTORS BY CAMP-DEPENDENT PROTEIN-PHOSPHORYLATION	SCIENCE			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; A RECEPTOR; SUBUNIT COMPOSITION; MOLECULAR-BIOLOGY; KINASE-C; GAMMA-2-SUBUNIT; DESENSITIZATION; PHARMACOLOGY; POTENTIATION; EXPRESSION	Gamma-aminobutyric acid(A) (GABA(A)) receptors are ligand-gated ion channels that mediate inhibitory synaptic transmission in the central nervous system. The role of protein phosphorylation in the modulation of GABA(A) receptor function was examined with cells transiently transfected with GABA(A) receptor subunits. GABA(A) receptors consisting of the alpha-1 and beta-1 or the alpha-1, beta-1, and gamma-2, subunits were directly phosphorylated on the beta-1 subunit by adenosine 3',5'-monophosphate (cAMP)-dependent protein kinase (PKA). The phosphorylation decreased the amplitude of the GABA response of both receptor types and the extent of rapid desensitization of the GABA(A) receptor that consisted of the alpha-1 and beta-1 subunits. Site-specific mutagenesis of the serine residue phosphorylated by PKA completely eliminated the PKA phosphorylation and modulation of the GABA(A) receptor. In primary embryonic rat neuronal cell cultures, a similar regulation of GABA(A) receptors by PKA was observed. These results demonstrate that the GABA(A) receptor is directly modulated by protein phosphorylation and suggest that neurotransmitters or neuropeptides that regulate intracellular cAMP levels may modulate the responses of neurons to GABA and consequently have profound effects on synaptic excitability.	JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT NEUROSCI,BALTIMORE,MD 21205; UNIV LONDON,DEPT PHARMACOL,LONDON WC1N 1AX,ENGLAND	Howard Hughes Medical Institute; Johns Hopkins University; University of London					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BROWNING MD, 1990, P NATL ACAD SCI USA, V87, P1315, DOI 10.1073/pnas.87.4.1315; BURT DR, 1991, FASEB J, V5, P2916, DOI 10.1096/fasebj.5.14.1661244; DRAGUHN A, 1990, NEURON, V5, P781, DOI 10.1016/0896-6273(90)90337-F; HOPFIELD JF, 1988, NATURE, V336, P677, DOI 10.1038/336677a0; HUGANIR RL, 1986, NATURE, V321, P774, DOI 10.1038/321774a0; HUGANIR RL, 1984, P NATL ACAD SCI-BIOL, V81, P6968, DOI 10.1073/pnas.81.22.6968; KIRKNESS EF, 1989, BIOCHEM J, V259, P613, DOI 10.1042/bj2590613; KOFUJI P, 1991, J NEUROCHEM, V56, P713, DOI 10.1111/j.1471-4159.1991.tb08209.x; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEIDENHEIMER NJ, 1991, TRENDS PHARMACOL SCI, V12, P84, DOI 10.1016/0165-6147(91)90509-Q; LEIDENHEIMER NJ, 1991, J NEUROCHEM, V57, P722, DOI 10.1111/j.1471-4159.1991.tb03806.x; LEVITAN ES, 1988, NATURE, V335, P76, DOI 10.1038/335076a0; MOSS SJ, 1992, J BIOL CHEM, V267, P14470; MOSS SJ, 1991, NEUROSCI LETT, V123, P265, DOI 10.1016/0304-3940(91)90947-R; MOSS SJ, UNPUB; OLSEN RW, 1990, FASEB J, V4, P1469, DOI 10.1096/fasebj.4.5.2155149; PORTER NM, 1990, NEURON, V5, P789, DOI 10.1016/0896-6273(90)90338-G; PRITCHETT DB, 1988, SCIENCE, V242, P1306, DOI 10.1126/science.2848320; PRITCHETT DB, 1989, NATURE, V338, P582, DOI 10.1038/338582a0; SCHOFIELD PR, 1987, NATURE, V328, P221, DOI 10.1038/328221a0; SESSLER FM, 1989, BRAIN RES, V499, P27, DOI 10.1016/0006-8993(89)91132-3; SIGEL E, 1988, P NATL ACAD SCI USA, V85, P6192, DOI 10.1073/pnas.85.16.6192; SMART TG, 1991, BRIT J PHARMACOL, V103, P1837, DOI 10.1111/j.1476-5381.1991.tb12337.x; SMART TG, 1992, J PHYSIOL-LONDON, V447, P587, DOI 10.1113/jphysiol.1992.sp019020; SWOPE SL, 1992, FASEB J, V6, P2514, DOI 10.1096/fasebj.6.8.1375568; TICKU MK, 1990, MOL PHARMACOL, V38, P719; UHLER MD, 1986, P NATL ACAD SCI USA, V83, P1300, DOI 10.1073/pnas.83.5.1300; VERDOORN TA, 1990, NEURON, V4, P919, DOI 10.1016/0896-6273(90)90145-6; WANG JB, IN PRESS J MOL NEURO	29	267	270	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 31	1992	257	5070					661	665		10.1126/science.1323140	http://dx.doi.org/10.1126/science.1323140			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JF852	1323140				2022-12-01	WOS:A1992JF85200034
J	YANG, XO; HUBBARD, EJA; CARLSON, M				YANG, XO; HUBBARD, EJA; CARLSON, M			A PROTEIN-KINASE SUBSTRATE IDENTIFIED BY THE 2-HYBRID SYSTEM	SCIENCE			English	Article							YEAST TRANSCRIPTIONAL ACTIVATORS; SACCHAROMYCES-CEREVISIAE; SNF4 PROTEIN; GENE	A genetic method, the two-hybrid system, was used to identify four genes encoding proteins that interact with the SNF1 protein kinase from yeast. One of the genes, SIP1, was independently isolated as a multicopy suppressor of defects caused by reduced SNF1 kinase activity, and genetic evidence supports its function in the SNF1 pathyway. The SIP1 protein co-immunoprecipitated with SNF1 and was phosphorylated in vitro. Thus, the two-hybrid system, which is applicable to any cloned gene, can be used to detect physical interactions between protein kinases and functionally related substrate proteins.	COLUMBIA UNIV COLL PHYS & SURG,DEPT GENET & DEV,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,INST CANC RES,NEW YORK,NY 10032	Columbia University; Columbia University				Hubbard, E. Jane Albert/0000-0001-5893-7232	NATIONAL CANCER INSTITUTE [T32CA009503] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034095, R01GM034095] Funding Source: NIH RePORTER; NCI NIH HHS [CA09503] Funding Source: Medline; NIGMS NIH HHS [GM34095] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALDERSON A, 1991, P NATL ACAD SCI USA, V88, P8602, DOI 10.1073/pnas.88.19.8602; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; CELENZA JL, 1989, MOL CELL BIOL, V9, P5045, DOI 10.1128/MCB.9.11.5045; CELENZA JL, 1989, MOL CELL BIOL, V9, P5034, DOI 10.1128/MCB.9.11.5034; CELENZA JL, 1986, SCIENCE, V233, P1175, DOI 10.1126/science.3526554; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GILL G, 1987, CELL, V51, P121, DOI 10.1016/0092-8674(87)90016-X; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; HUBBARD EJA, 1992, GENETICS, V130, P71; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; Miller JH., 1972, EXPT MOL GENETICS; ROBINSON LC, 1992, P NATL ACAD SCI USA, V89, P28, DOI 10.1073/pnas.89.1.28; ROSE MD, 1990, METHODS YEAST GENETI; RUDEN DM, 1991, NATURE, V350, P250, DOI 10.1038/350250a0; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; THOMPSONJAEGER S, 1991, GENETICS, V129, P697	19	180	212	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 31	1992	257	5070					680	682		10.1126/science.1496382	http://dx.doi.org/10.1126/science.1496382			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JF852	1496382				2022-12-01	WOS:A1992JF85200040
J	YUSTE, R; PEINADO, A; KATZ, LC				YUSTE, R; PEINADO, A; KATZ, LC			NEURONAL DOMAINS IN DEVELOPING NEOCORTEX	SCIENCE			English	Article							CEREBRAL-CORTEX; VISUAL-CORTEX; STRIATE CORTEX; CALCIUM; CELLS; CAT; ORGANIZATION; ASTROCYTES; SYNAPSES; SYSTEM	The mammalian neocortex consists of a mosaic of columnar units whose development is poorly understood. Optical recordings of brain slices labeled with the fluorescent calcium indicator fura-2 revealed that the neonatal rat cortex was partitioned into distinct domains of spontaneously coactive neurons. In tangential slices, these domains were 50 to 120 micrometers in diameter; in coronal slices they spanned several cortical layers and resembled columns found in the adult cortex. In developing somatosensory cortex, domains were smaller than, and distinct from, the barrels, which represent sensory input from a single vibrissa. The neurons within each domain were coupled by gap junctions. Thus, nonsynaptic communication during cortical development defines discrete multicellular patterns that could presage adult functional architecture.			YUSTE, R (corresponding author), DUKE UNIV,MED CTR,DEPT NEUROBIOL,BOX 3209,DURHAM,NC 27710, USA.				NATIONAL EYE INSTITUTE [R01EY007960] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [T32MH015177] Funding Source: NIH RePORTER; NEI NIH HHS [EY07960] Funding Source: Medline; NIMH NIH HHS [MH15177] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ARMSTRONGJAMES M, 1975, J PHYSIOL-LONDON, V246, P501, DOI 10.1113/jphysiol.1975.sp010902; ARMSTRONGJAMES M, 1970, Z ZELLFORSCH MIK ANA, V110, P559, DOI 10.1007/BF00330104; CALLAWAY EM, 1991, P NATL ACAD SCI USA, V88, P745, DOI 10.1073/pnas.88.3.745; CONNORS BW, 1983, J NEUROSCI, V3, P773; CORNELLBELL AH, 1990, SCIENCE, V247, P470, DOI 10.1126/science.1967852; CRAGG BG, 1975, J COMP NEUROL, V160, P147, DOI 10.1002/cne.901600202; DELANEY KR, 1989, J NEUROSCI, V9, P3558; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUTHRIE SC, 1989, TRENDS NEUROSCI, V12, P12, DOI 10.1016/0166-2236(89)90150-1; GUTNICK MJ, 1981, SCIENCE, V211, P67, DOI 10.1126/science.7444449; Hebb DO, 1949, ORG BEHAVIOR, P62; HUBEL DH, 1963, J NEUROPHYSIOL, V26, P994, DOI 10.1152/jn.1963.26.6.994; HUBEL DH, 1977, PROC R SOC SER B-BIO, V198, P1, DOI 10.1098/rspb.1977.0085; HUBEL DH, 1977, PHILOS T ROY SOC B, V278, P377, DOI 10.1098/rstb.1977.0050; JENSEN AM, 1990, J NEUROSCI, V10, P1165; KATZ LC, 1989, J NEUROSCI, V9, P1389; KATZ LC, 1987, J NEUROSCI, V7, P1223; KATZ LC, 1984, NATURE, V310, P498, DOI 10.1038/310498a0; KAUR C, 1989, ACTA ANAT, V136, P204; LEVRAM V, 1987, BIOPHYS J, V52, P571, DOI 10.1016/S0006-3495(87)83246-0; Lorente de No R., 1949, PHYSL NERVOUS SYSTEM, P274; LOTURCO JJ, 1991, SCIENCE, V252, P563, DOI 10.1126/science.1850552; LOWEL S, 1992, SCIENCE, V255, P209, DOI 10.1126/science.1372754; MEISTER M, 1991, SCIENCE, V252, P939, DOI 10.1126/science.2035024; MISSON JP, 1991, GLIA, V4, P138, DOI 10.1002/glia.440040205; Mountcastle V., 1978, MINDFUL BRAIN, P7; RAKIC P, 1988, SCIENCE, V241, P170, DOI 10.1126/science.3291116; SAEZ JC, 1989, P NATL ACAD SCI USA, V86, P2708, DOI 10.1073/pnas.86.8.2708; STENT GS, 1973, P NATL ACAD SCI USA, V70, P997, DOI 10.1073/pnas.70.4.997; TANK DW, 1988, SCIENCE, V242, P773, DOI 10.1126/science.2847315; VANDERLO.H, 1973, SCIENCE, V179, P395, DOI 10.1126/science.179.4071.395; VANEY DI, 1991, NEUROSCI LETT, V125, P187, DOI 10.1016/0304-3940(91)90024-N; WIESEL TN, 1982, NATURE, V299, P583, DOI 10.1038/299583a0; WOOLSEY TA, 1970, BRAIN RES, V17, P205, DOI 10.1016/0006-8993(70)90079-X; YUESTE R, 1991, NEURON, V6, P333	35	365	370	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 31	1992	257	5070					666	669		10.1126/science.1496379	http://dx.doi.org/10.1126/science.1496379			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JF852	1496379				2022-12-01	WOS:A1992JF85200035
J	ZHANG, K; PAPAGEORGE, AG; LOWY, DR				ZHANG, K; PAPAGEORGE, AG; LOWY, DR			MECHANISTIC ASPECTS OF SIGNALING THROUGH RAS IN NIH-3T3 CELLS	SCIENCE			English	Article							GTPASE-ACTIVATING PROTEIN; SACCHAROMYCES-CEREVISIAE; TYROSINE PHOSPHORYLATION; NUCLEOTIDE BINDING; CYCLASE PATHWAY; GROWTH-FACTOR; KINASE-C; GENE; P21RAS; GAP	Serum and growth factors can increase the proportion of Ras in the active guanosine triphosphate (GTP)-bound form. Growth factors might stimulate guanine nucleotide exchange or decrease the activity of the guanosine triphosphatase-activating proteins GAP and neurofibromin (NF1). In NIH 3T3 cells that overexpress the mutant Ras protein His116, which releases bound guanine nucleotide at a constitutively high rate and retains sensitivity to GAP and NF1, the proportion of GTP bound to the His116 protein was not altered by serum or platelet-derived growth factor. However, these mitogens increased the proportion of Ras in the GTP-bound form in cells that overexpressed control Ras proteins with a normal intrinsic rate of guanine nucleotide release. The amount of GTP-bound His116 or control Ras proteins was higher in cells at low density than in cells at high density, which have more GAP-like activity. The lower proportion of GTP-bound Ras in NIH 3T3 cells at high density may result from increased GAP-like activity. By contrast, serum and platelet-derived growth factors appear to stimulate guanine nucleotide exchange.			ZHANG, K (corresponding author), NCI,CELLULAR ONCOL LAB,BLDG 37,ROOM 1B-26,BETHESDA,MD 20892, USA.							BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BROEK D, 1987, CELL, V48, P789, DOI 10.1016/0092-8674(87)90076-6; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; DECLUE JE, 1991, MOL CELL BIOL, V11, P2819, DOI 10.1128/MCB.11.5.2819; DER CJ, 1988, ONCOGENE, V3, P105; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; DOWNWARD J, 1990, P NATL ACAD SCI USA, V87, P5998, DOI 10.1073/pnas.87.15.5998; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; HOSHINO M, 1988, MOL CELL BIOL, V8, P4169, DOI 10.1128/MCB.8.10.4169; HUANG YK, 1990, P NATL ACAD SCI USA, V87, P8008, DOI 10.1073/pnas.87.20.8008; JONES S, 1991, MOL CELL BIOL, V11, P2641, DOI 10.1128/MCB.11.5.2641; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; LACAL JC, 1987, MOL CELL BIOL, V7, P4146, DOI 10.1128/MCB.7.11.4146; LOWY DR, 1991, TRENDS GENET, V7, P346, DOI 10.1016/0168-9525(91)90253-M; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; MORRIS JDH, 1989, ONCOGENE, V4, P27; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NORI M, 1991, MOL CELL BIOL, V11, P2812, DOI 10.1128/MCB.11.5.2812; PAPAGEORGE AG, UNPUB; PATEL G, 1992, ONCOGENE, V7, P283; ROBINSON LC, 1987, SCIENCE, V235, P1218, DOI 10.1126/science.3547648; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P952, DOI 10.1073/pnas.83.4.952; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; WOLFMAN A, 1990, SCIENCE, V248, P67, DOI 10.1126/science.2181667; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9	34	83	83	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 31	1992	257	5070					671	674		10.1126/science.1496380	http://dx.doi.org/10.1126/science.1496380			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JF852	1496380				2022-12-01	WOS:A1992JF85200037
J	BUCK, M; CANNON, W				BUCK, M; CANNON, W			SPECIFIC BINDING OF THE TRANSCRIPTION FACTOR SIGMA-54 TO PROMOTER DNA	NATURE			English	Article							ESCHERICHIA-COLI; RNA-POLYMERASE; PROTEIN NTRC; ACTIVATION; INITIATION; MECHANISM; ENHANCERS; INVIVO; GENES	A CENTRAL event in transcription is the assembly on DNA of specific complexes near the initiation sites for RNA synthesis. Activation of transcription by one class of enhancer-binding proteins requires an RNA polymerase holoenzyme1 containing the specialized transcription factor, sigma-54 (sigma-54). We report here that sigma-54 alone specifically binds to promoter DNA and is responsible for many of the close contacts between RNA polymerase holoenzyme and promoter DNA, a property proposed for the major sigma-70 protein family. Binding of simga-54 to promoter DNA is not equivalent to that of holoenzyme suggesting that there is a constraint on sigma-54 conformation when bound with core RNA polymerase. Footprints indicate sigma-54 is at the leading edge of DNA-bound holoenzyme. Like the holoenzyme1-4, sigma-54-binding to promoter DNA does not result in DNA strand separation. Instead the specific DNA-binding activity of sigma-54 assists assembly of a closed promoter complex. This complex can be isomerized to the open (DNA melted) complex by activator protein5,6, but promoter-bound sigma-54 alone cannot be induced to melt DNA. The pathway leading to productive transcription is similar to that proposed for eukaryotic RNA polymerase II systems.			BUCK, M (corresponding author), UNIV SUSSEX,AFRC,NITROGEN FIXAT LAB,BRIGHTON BN1 9RQ,E SUSSEX,ENGLAND.							AUSTIN S, 1991, NUCLEIC ACIDS RES, V19, P2281, DOI 10.1093/nar/19.9.2281; AUSTIN S, 1992, EMBO J, V6, P2219; BMORETT E, 1988, P NATL ACAD SCI USA, V8, P9401; BUCK M, 1986, NATURE, V320, P374, DOI 10.1038/320374a0; BUCK M, IN PRESS MOL MICROBI; CANNON W, 1992, J MOL BIOL, V225, P271, DOI 10.1016/0022-2836(92)90921-6; CLAVERIEMARTIN F, 1991, P NATL ACAD SCI USA, V88, P1631, DOI 10.1073/pnas.88.5.1631; COPPARD JR, 1991, MOL MICROBIOL, V5, P1309, DOI 10.1111/j.1365-2958.1991.tb00777.x; GREENBLATT J, 1991, CELL, V66, P1067, DOI 10.1016/0092-8674(91)90027-V; HELMANN JD, 1988, ANNU REV BIOCHEM, V57, P839, DOI 10.1146/annurev.bi.57.070188.004203; KUSTU S, 1989, MICROBIOL REV, V53, P367, DOI 10.1128/MMBR.53.3.367-376.1989; KUSTU S, 1986, REGULATION GENE EXPR, P139; LESLEY SA, 1991, J BIOL CHEM, V266, P2632; MORETT E, 1989, J MOL BIOL, V210, P65, DOI 10.1016/0022-2836(89)90291-X; NINFA AJ, 1987, CELL, V50, P1039, DOI 10.1016/0092-8674(87)90170-X; POPHAM D, 1991, J BIOL CHEM, V266, P19510; POPHAM DL, 1989, SCIENCE, V243, P629, DOI 10.1126/science.2563595; REITZER LJ, 1986, CELL, V45, P785, DOI 10.1016/0092-8674(86)90553-2; SASSEDWIGHT S, 1990, CELL, V62, P945, DOI 10.1016/0092-8674(90)90269-K; SASSEDWIGHT S, 1988, P NATL ACAD SCI USA, V85, P8934, DOI 10.1073/pnas.85.23.8934; WANG WD, 1992, SCIENCE, V255, P450, DOI 10.1126/science.1310361; WEISS DS, 1991, CELL, V67, P155, DOI 10.1016/0092-8674(91)90579-N	22	133	133	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 30	1992	358	6385					422	424		10.1038/358422a0	http://dx.doi.org/10.1038/358422a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JF853	1641025	Bronze			2022-12-01	WOS:A1992JF85300058
J	BURKHOLDER, JM; NOGA, EJ; HOBBS, CH; GLASGOW, HB				BURKHOLDER, JM; NOGA, EJ; HOBBS, CH; GLASGOW, HB			NEW PHANTOM DINOFLAGELLATE IS THE CAUSATIVE AGENT OF MAJOR ESTUARINE FISH KILLS	NATURE			English	Article							TOXINS	A WORLDWIDE increase in toxic phytoplankton blooms over the past 20 years1,2 has coincided with increasing reports of fish diseases and deaths of unknown cause3. Among estuaries that have been repeatedly associated with unexplained fish kills on the western Atlantic Coast are the Pamlico and Neuse Estuaries of the southeastern United States4. Here we describe a new toxic dinoflagellate with 'phantom-like' behaviour that has been identified as the causative agent of a significant portion of the fish kills in these estuaries, and which may also be active in other geographic regions. The alga requires live finfish or their fresh excreta for excystment and release of a potent toxin. Low cell densities cause neurotoxic signs and fish death, followed by rapid algal encystment and dormancy unless live fish are added. This dinoflagellate was abundant in the water during major fish kills in local estuaries, but only while fish were dying; within several hours of death where carcasses were still present, the flagellated vegetative algal population had encysted and settled back to the sediments. Isolates from each event were highly lethal to finfish and shellfish in laboratory bioassays. Given its broad temperature and salinity tolerance, and its stimulation by phosphate enrichment, this toxic phytoplankter may be a widespread but undetected source of fish mortality in nutrient-enriched estuaries.	N CAROLINA STATE UNIV,DEPT COMPAN ANIM & SPECIAL SPECIES MED,RALEIGH,NC 27606	University of North Carolina; North Carolina State University	BURKHOLDER, JM (corresponding author), N CAROLINA STATE UNIV,DEPT BOT,BOX 7612,RALEIGH,NC 27695, USA.							Gaines G, 1987, BIOL DINOFLAGELLATES; HALLEGRAEFF GM, 1988, J PLANKTON RES, V10, P533, DOI 10.1093/plankt/10.3.533; LAGLER KF, 1962, ICHTHYOLOGY, P268; MILLER KH, 1990, PAMLICO ENV RESPONSE; PALENIK B, 1988, Biological Oceanography, V6, P347; ROBERTS RJ, 1983, J MAR BIOL ASSOC UK, V63, P741, DOI 10.1017/S0025315400071186; ROBINEAU B, 1991, MAR BIOL, V108, P293, DOI 10.1007/BF01344344; RUDEK J, 1991, MAR ECOL PROG SER, V75, P133, DOI 10.3354/meps075133; RYTHER JH, 1954, ECOLOGY, V35, P522, DOI 10.2307/1931041; SHUMWAY S E, 1990, Journal of the World Aquaculture Society, V21, P65, DOI 10.1111/j.1749-7345.1990.tb00529.x; SMAYDA TJ, 1989, NOVEL PHYTOPLANKTON, P449; SMITH SA, 1988, 3RD P INT C PATH MAR, P167; Sokal R., 1981, BIOMETRY; SPERO HJ, 1982, J PHYCOL, V18, P357; STANLEY DH, 1988, S COASTAL WATER RESO, P155; Taylor FJR, 1987, BIOL DINOFLAGELLATES, P24; THORP JH, 1991, ECOLOGY CLASSIFICATI, P77; WHITE AW, 1981, MAR BIOL, V65, P255, DOI 10.1007/BF00397119; WHITE AW, 1988, 1987 P INT C IMP TOX, P9; 1987, 1986 N CAR DEP ENV H; 1990, 1990 N CAR DEP ENV H; 1988, 1987 N CAR DEP ENV H; 1989, 1988 N CAR DEP ENV H	23	290	300	2	73	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 30	1992	358	6385					407	410		10.1038/358407a0	http://dx.doi.org/10.1038/358407a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JF853	1641022				2022-12-01	WOS:A1992JF85300053
J	CUNLIFFE, V; SMITH, JC				CUNLIFFE, V; SMITH, JC			ECTOPIC MESODERM FORMATION IN XENOPUS EMBRYOS CAUSED BY WIDESPREAD EXPRESSION OF A BRACHYURY HOMOLOG	NATURE			English	Article							EARLY AMPHIBIAN EMBRYO; PATTERN; LAEVIS; CELLS; TRANSCRIPTION; ORGANIZATION; ACTIVATION; PROTEIN; MUSCLE; GENES	THE Brachyury (T) gene is required cell-autonomously for mesoderm formation in the posterior of the mouse embryo1,2, and both its complementary DNA sequence and expression pattern3 closely resemble those of a Xenopus homologue (Xbra)4, suggesting that these genes have an evolutionarily conserved function in vertebrate development. Strong expression of Xbra messenger RNA is found in the ring of involuting mesoderm during Xenopus gastrulation 4, and the expression of Xbra is an immediate-early response of animal pole blastomeres to mesoderm-inducing factors4. To assess the role of Xbra in mesoderm formation, we increased its domain of expression in the embryo by microinjection of Xbra transcripts into the animal pole of Xenopus embryos at the one-cell stage. We show that expression of Xbra by cells of the early embryo is sufficient to direct their development into differentiated mesodermal tissues. At the molecular level this response shows a sharp threshold of sensitivity to the dose of Xbra RNA delivered, and we suggest that Xbra may act as a genetic switch initiating posterior mesodermal specification during embryogenesis.			CUNLIFFE, V (corresponding author), NATL INST MED RES, DEV BIOL LAB, RIDGEWAY, MILL HILL, LONDON NW7 1AA, ENGLAND.		Cunliffe, Vincent/E-6170-2010	Smith, Jim/0000-0003-2413-9392; Cunliffe, Vincent/0000-0001-7483-7610				ALTABA ARI, 1989, DEVELOPMENT, V106, P173; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; CHO KWY, 1991, CELL, V65, P55, DOI 10.1016/0092-8674(91)90407-P; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; COOKE J, 1989, DEV BIOL, V131, P383, DOI 10.1016/S0012-1606(89)80012-0; COOKE J, 1987, DEVELOPMENT, V101, P893; COOKE J, 1979, J EMBRYOL EXP MORPH, V51, P165; DALE L, 1992, DEVELOPMENT, V115, P573; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; GREEN JBA, 1990, DEVELOPMENT, V108, P173; HERRMANN BG, 1990, NATURE, V343, P617, DOI 10.1038/343617a0; HOPWOOD ND, 1990, NATURE, V347, P197, DOI 10.1038/347197a0; JONAS E, 1985, P NATL ACAD SCI USA, V82, P5413, DOI 10.1073/pnas.82.16.5413; KINTNER CR, 1984, NATURE, V308, P67, DOI 10.1038/308067a0; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; MOHUN TJ, 1984, NATURE, V311, P716, DOI 10.1038/311716a0; Nieuwkoop P.D., 1994, NORMAL TABLES XENOPU; RASHBASS P, 1991, NATURE, V353, P348, DOI 10.1038/353348a0; RUIZ IA, 1989, CELL, V57, P317; SARGENT MG, 1990, DEVELOPMENT, V109, P967; SLACK JMW, 1984, J EMBRYOL EXP MORPH, V80, P289; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; WILKINSON DG, 1990, NATURE, V343, P657, DOI 10.1038/343657a0; [No title captured]	25	216	216	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 30	1992	358	6385					427	430		10.1038/358427a0	http://dx.doi.org/10.1038/358427a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JF853	1641026				2022-12-01	WOS:A1992JF85300060
J	EPHRUSSI, A; LEHMANN, R				EPHRUSSI, A; LEHMANN, R			INDUCTION OF GERM-CELL FORMATION BY OSKAR	NATURE			English	Article							POSTERIOR DETERMINANT NANOS; SEGMENTATION GENE HUNCHBACK; DROSOPHILA POLAR GRANULES; MATERNAL GENE; ANTERIOR PATTERN; MESSENGER-RNA; LOCALIZATION; PROTEIN; EMBRYO; PLASM	The oskar gene directs germ plasm assembly and controls the number of germ cell precursors formed at the posterior pole of the Drosophila embryo. Mislocalization of oskar RNA to the anterior pole leads to induction of germ cells at the anterior. Of the eight genes necessary for germ cell formation at the posterior, only three, oskar, vasa and tudor, are essential at an ectopic site.	MIT,HOWARD HUGHES MED INST,WHITEHEAD INST BIOMED RES,DEPT BIOL,CAMBRIDGE,MA 02142	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Whitehead Institute			Ephrussi, Anne/ABD-4393-2021; Ephrussi, Anne/AAG-4075-2020	Ephrussi, Anne/0000-0002-5061-4620; Lehmann, Ruth/0000-0002-8454-5651				BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; BOSWELL RE, 1985, CELL, V43, P97, DOI 10.1016/0092-8674(85)90015-7; BOSWELL RE, 1991, DEVELOPMENT, V113, P373; BULL AL, 1966, J EXP ZOOL, V161, P221, DOI 10.1002/jez.1401610207; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; EDDY EM, 1975, INT REV CYTOL, V43, P229; ELDON ED, 1991, DEVELOPMENT, V111, P367; EPHRUSSI A, 1991, CELL, V66, P37, DOI 10.1016/0092-8674(91)90137-N; FROHNHOFER HG, 1986, NATURE, V324, P120, DOI 10.1038/324120a0; GAUL U, 1987, CELL, V50, P639, DOI 10.1016/0092-8674(87)90037-7; HAY B, 1988, DEVELOPMENT, V103, P625; HAY B, 1990, DEVELOPMENT, V109, P425; ILLMENSEE K, 1974, P NATL ACAD SCI USA, V71, P1016, DOI 10.1073/pnas.71.4.1016; KIMHA J, 1991, CELL, V66, P23, DOI 10.1016/0092-8674(91)90136-M; KRAUT R, 1991, DEVELOPMENT, V111, P601; LASKO PF, 1990, GENE DEV, V4, P905, DOI 10.1101/gad.4.6.905; LASKO PF, 1988, NATURE, V335, P611, DOI 10.1038/335611a0; LEHMANN R, 1991, DEVELOPMENT, V112, P679; LEHMANN R, 1986, CELL, V47, P141, DOI 10.1016/0092-8674(86)90375-2; LEHMANN R, 1987, DEV BIOL, V119, P402, DOI 10.1016/0012-1606(87)90045-5; LEHMANN R, IN PRESS CURR OPIN G; MACDONALD PM, 1988, NATURE, V336, P595, DOI 10.1038/336595a0; MACDONALD PM, 1986, NATURE, V324, P672; MAHOWALD AP, 1971, J EXP ZOOL, V176, P329, DOI 10.1002/jez.1401760308; MANSEAU LJ, 1989, GENE DEV, V3, P1437, DOI 10.1101/gad.3.9.1437; MOHLER J, 1985, COLD SPRING HARB SYM, V50, P105, DOI 10.1101/SQB.1985.050.01.015; NAUBER U, 1988, NATURE, V336, P489, DOI 10.1038/336489a0; OLIVER B, 1987, GENE DEV, V1, P913, DOI 10.1101/gad.1.9.913; Rabinowitz M, 1941, J MORPHOL, V69, P1, DOI 10.1002/jmor.1050690102; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SCHUEPBACH T, 1986, Wilhelm Roux's Archives of Developmental Biology, V195, P302; SPRADLING AC, 1960, DROSOPHILA PRACTICAL, P175; STJOHNSTON D, 1991, CELL, V66, P51, DOI 10.1016/0092-8674(91)90138-O; STRUHL G, 1992, CELL, V69, P237, DOI 10.1016/0092-8674(92)90405-2; SUTER B, 1989, GENE DEV, V3, P1957, DOI 10.1101/gad.3.12a.1957; TAUTZ D, 1987, NATURE, V327, P383, DOI 10.1038/327383a0; TAUTZ D, 1988, NATURE, V332, P281, DOI 10.1038/332281a0; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; WANG C, 1991, CELL, V66, P637, DOI 10.1016/0092-8674(91)90110-K; WHARTON RP, 1989, CELL, V59, P881, DOI 10.1016/0092-8674(89)90611-9; WHARTON RP, 1991, CELL, V67, P955, DOI 10.1016/0092-8674(91)90368-9	41	513	521	1	31	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 30	1992	358	6385					387	392		10.1038/358387a0	http://dx.doi.org/10.1038/358387a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JF853	1641021				2022-12-01	WOS:A1992JF85300046
J	GILLE, H; SHARROCKS, AD; SHAW, PE				GILLE, H; SHARROCKS, AD; SHAW, PE			PHOSPHORYLATION OF TRANSCRIPTION FACTOR P62TCF BY MAP KINASE STIMULATES TERNARY COMPLEX-FORMATION AT C-FOS PROMOTER	NATURE			English	Article							EPIDERMAL GROWTH-FACTOR; SERUM RESPONSE ELEMENT; DIRECTED PROTEIN-KINASE; PROLIFERATIVE CELLS; LATE PHASE; S6 KINASE; ACTIVATION; IDENTIFICATION; P58CYCLIN; INSULIN	TRANSCRIPTION of the proto-oncogene c-fos is stimulated rapidly and transiently by serum growth factors and mitogens1. Critical for this response is the serum-response element which is bound in vivo in a ternary complex containing the transcription factors p67SRF and p62TCF (ref. 2). Disruption of the ternary complex correlates with impaired induction by serum and phorbol ester3,4. Mitogen-activated protein (MAP) kinase is a serine/threonine kinase which is activated 1-5 minutes after treatment of cells with mitogens and growth factors5-8 that induce re-entry into the cell cycle, making MAP kinase a candidate for the transmission of proliferative signals. Here we show that p62TCF is phosphorylated by MAP kinase in vitro and that phosphorylation results in enhanced ternary complex formation. Serum-starved Swiss 3T3 cells treated with epidermal growth factor, which induces MAP kinase in these cells9, are induced to express c-fos and yield p62TCF active in ternary complex formation. In contrast, treatment of Swiss 3T3 cells with insulin, which does not activate MAP kinase under these conditions9, does not lead to enhanced ternary complex formation nor does it induce c-fos transcription. Our results link the expression of the human c-fos proto-oncogene to signal transduction pathways known to be activated before its own induction.			GILLE, H (corresponding author), MAX PLANCK INST IMMUNBIOL, SPEMANN LABS, POSTFACH 1169, W-7800 FREIBURG, GERMANY.			SHAW, Peter/0000-0002-2598-4283				ACKERMAN P, 1990, P NATL ACAD SCI USA, V87, P821, DOI 10.1073/pnas.87.2.821; ACKERMAN P, 1989, J BIOL CHEM, V264, P11958; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; BALLOU LM, 1988, J BIOL CHEM, V263, P1188; BALLOU LM, 1991, NATURE, V349, P348, DOI 10.1038/349348a0; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BUHROW SA, 1983, J BIOL CHEM, V258, P7824; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHEN RH, 1990, MOL CELL BIOL, V10, P3204, DOI 10.1128/MCB.10.6.3204; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; FERRARI S, 1991, METHOD ENZYMOL, V200, P159; GOMEZ N, 1990, FEBS LETT, V271, P119, DOI 10.1016/0014-5793(90)80386-W; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; HALL FL, 1991, J BIOL CHEM, V266, P17430; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HIPSKIND RA, 1991, NATURE, V354, P31; HOSHI M, 1988, J BIOL CHEM, V263, P5396; MALIK RK, 1991, J BIOL CHEM, V266, P8576; MANAK JR, 1990, GENE DEV, V4, P955, DOI 10.1101/gad.4.6.955; MANAK JR, 1991, MOL CELL BIOL, V11, P3652, DOI 10.1128/MCB.11.7.3652; MARAIS RM, 1992, EMBO J, V11, P97, DOI 10.1002/j.1460-2075.1992.tb05032.x; PRYWES R, 1988, P NATL ACAD SCI USA, V85, P7206, DOI 10.1073/pnas.85.19.7206; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; SCHROTER H, 1990, EMBO J, V9, P1123, DOI 10.1002/j.1460-2075.1990.tb08218.x; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SUSA M, 1990, P NATL ACAD SCI USA, V87, P7040, DOI 10.1073/pnas.87.18.7040; SUSA M, 1989, CELL, V57, P817, DOI 10.1016/0092-8674(89)90796-4	31	917	932	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 30	1992	358	6385					414	417		10.1038/358414a0	http://dx.doi.org/10.1038/358414a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JF853	1322499				2022-12-01	WOS:A1992JF85300056
J	HOLLAND, KN; BRILL, RW; CHANG, RKC; SIBERT, JR; FOURNIER, DA				HOLLAND, KN; BRILL, RW; CHANG, RKC; SIBERT, JR; FOURNIER, DA			PHYSIOLOGICAL AND BEHAVIORAL THERMOREGULATION IN BIGEYE TUNA (THUNNUS-OBESUS)	NATURE			English	Article							FISH; MOVEMENTS	TUNA are unique among teleost fishes in being thermoconserving. Vascular counter-current heat exchangers maintain body temperatures above ambient water temperature, thereby improving locomotor muscle efficiency, especially at burst speeds and when pursuing prey below the thermocline1-6. Because tuna also occasionally swim rapidly in warm surface waters, it has been hypothesized that tuna thermoregulate to accommodate changing activity levels or ambient temperatures7. But previous field experiments have been unable to demonstrate definitively short-latency, mammalian-type physiological thermoregulation8,9. Here we show using telemetered data that free-ranging bigeye tuna (Thunnus obesus) can rapidly alter whole-body thermal conductivity by two orders of magnitude. The heat exchangers are disengaged to allow rapid warming as the tuna ascend from cold water into warmer surface waters, and are reactivated to conserve heat when they return into the depths. Combining physiological and behavioural thermoregulation expands the foraging space of bigeye tuna into otherwise prohibitively cold, deep water.	NATL MARINE FISHERIES SERV,HONOLULU LAB,HONOLULU,HI 96822; OTTER RES LTD,NANAIMO,BC,CANADA	National Aeronautics & Space Administration (NASA); National Oceanic Atmospheric Admin (NOAA) - USA	HOLLAND, KN (corresponding author), HAWAII INST MARINE BIOL,POB 1346,COCONUT ISL,KANEOHE,HI 96744, USA.		Holland, Kim/ABH-1490-2021					[Anonymous], 1978, FISH PHYSL; AXELSSON M, 1986, J EXP BIOL, V126, P225; CAREY FG, 1973, SCI AM, V228, P36, DOI 10.1038/scientificamerican0273-36; CAREY FG, 1973, COMP BIOCHEM PHYSIOL, V44, P375, DOI 10.1016/0300-9629(73)90490-8; CAREY FG, 1987, PHYSIOL ZOOL, V60, P138, DOI 10.1086/physzool.60.1.30158635; CAREY FG, 1990, MAR BIOL, V106, P329, DOI 10.1007/BF01344309; Carey FG, 1990, PLANNING FUTURE BILL, P103; DIZON AE, 1979, AM ZOOL, V19, P249; DIZON AE, 1976, J THERM BIOL, V1, P18; Graham J.B., 1978, P113; Graham J.B., 1983, P248; GRAHAM JB, 1975, FISH B-NOAA, V73, P219; GRAHAM JB, 1981, PHYSIOL ZOOL, V54, P470, DOI 10.1086/physzool.54.4.30155840; GREIWANK A, 1991, AUTOMATIC DIFFERENTI; HOLLAND K, 1985, MAR FISH REV, V47, P26; HOLLAND KN, 1990, FISH B-NOAA, V88, P493; NEILL W H, 1976, Environmental Biology of Fishes, V1, P61, DOI 10.1007/BF00761729; NEILL WS, 1974, SCIENCE, V184, P8; STEFFEL S, 1976, T AM FISH SOC, V105, P558; STEVENS ED, 1974, J EXP BIOL, V61, P145; 1991, AUTODIF A C PLUS PLU	21	180	190	6	57	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 30	1992	358	6385					410	412		10.1038/358410a0	http://dx.doi.org/10.1038/358410a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JF853	1641023				2022-12-01	WOS:A1992JF85300054
J	KARJALAINEN, J; MARTIN, JM; KNIP, M; ILONEN, J; ROBINSON, BH; SAVILAHTI, E; AKERBLOM, HK; DOSCH, HM				KARJALAINEN, J; MARTIN, JM; KNIP, M; ILONEN, J; ROBINSON, BH; SAVILAHTI, E; AKERBLOM, HK; DOSCH, HM			A BOVINE ALBUMIN PEPTIDE AS A POSSIBLE TRIGGER OF INSULIN-DEPENDENT DIABETES-MELLITUS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ISLET CELL ANTIBODIES; SERUM-ALBUMIN; NOD MICE; BB-RAT; IDDM; CHILDREN; AUTOANTIBODIES; SUSCEPTIBILITY; DESTRUCTION; CHILDHOOD	Background. Cow's milk has been implicated as a possible trigger of the autoimmune response that destroys pancreatic beta cells in genetically susceptible hosts, thus causing diabetes mellitus. Studies in animals have suggested that bovine serum albumin (BSA) is the milk protein responsible, and an albumin peptide containing 17 amino acids (ABBOS) may be the reactive epitope. Antibodies to this peptide react with p69, a beta-cell surface protein that may represent the target antigen for milk-induced beta-cell-specific immunity. Methods. We used immunoassays and Western blot analysis to analyze anti-BSA antibodies in the serum of 142 children with insulin-dependent diabetes mellitus, 79 healthy children, and 300 adult blood donors. Anti-ABBOS antibodies were measured in 44 diabetic patients at the time of diagnosis, three to four months later, and one to two years later. Results. All the diabetic patients had elevated serum concentrations of IgG anti-BSA antibodies (but not of antibodies to other milk proteins), the bulk of which were specific for ABBOS. The mean (+/-SE) concentration was 8.5+/-0.2 kilofluorescence units (kfU) per microliter, as compared with 1.3+/-0.1 kfU per microliter in the healthy children. IgA antibodies were elevated as well, but not IgM antibodies. The antibody concentrations declined after diagnosis, reaching normal levels in most patients within one to two years. The initial decline involved anti-ABBOS-specific antibodies almost exclusively. Much lower serum concentrations of anti-BSA antibodies were found in all 379 control subjects, but only 2.5 percent of them had small amounts of ABBOS-specific IgG. Conclusions. Patients with insulin-dependent diabetes mellitus have immunity to cow's-milk albumin, with antibodies to an albumin peptide that are capable of reacting with a beta-cell-specific surface protein. Such antibodies could participate in the development of islet dysfunction.	UNIV TORONTO,HOSP SICK CHILDREN,DEPT PEDIAT & IMMUNOL,TORONTO M5G 1X8,ONTARIO,CANADA; UNIV OULU,DEPT PEDIAT,SF-90100 OULU 10,FINLAND; UNIV OULU,DEPT MED MICROBIOL,SF-90100 OULU 10,FINLAND; UNIV TURKU,DEPT VIROL,SF-20500 TURKU 50,FINLAND; UNIV HELSINKI,CHILDRENS HOSP,DEPT PEDIAT 1,SF-00100 HELSINKI 10,FINLAND; UNIV HELSINKI,CHILDRENS HOSP,DEPT PEDIAT 2,SF-00100 HELSINKI 10,FINLAND	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Oulu; University of Oulu; University of Turku; University of Helsinki; University of Helsinki			Knip, Mikael/AAL-3773-2020	Knip, Mikael/0000-0003-0474-0033				BAISCH JM, 1990, NEW ENGL J MED, V322, P1836, DOI 10.1056/NEJM199006283222602; BARNETT AH, 1981, DIABETOLOGIA, V20, P87, DOI 10.1007/BF00262007; BEPPU H, 1987, DIABETES RES CLIN EX, V6, P67; BRUINING GJ, 1984, DIABETOLOGIA, V26, P24; DANEMAN D, 1987, DIABETES RES CLIN EX, V5, P93; DOSCH HM, 1992, PEDIAT AD E, V21, P202; DOSCH HM, 1988, PANDEX S PCFIA, P5; DRASH AL, 1990, SCHWEIZ MED WSCHR, V120, P39; ELLIOTT RB, 1984, DIABETOLOGIA, V26, P297, DOI 10.1007/BF00283653; ELLIOTT RB, 1988, DIABETOLOGIA, V31, P62; GLERUM M, 1989, DIABETES RES CLIN EX, V10, P103; GORSUCH AN, 1981, LANCET, V2, P1363; HANENBERG H, 1989, DIABETOLOGIA, V32, P126, DOI 10.1007/BF00505185; HUSBY S, 1985, INT ARCH ALLER A IMM, V77, P416, DOI 10.1159/000233819; IHM SH, 1990, DIABETES, V39, P1273, DOI 10.2337/diabetes.39.10.1273; ILONEN J, 1988, TISSUE ANTIGENS, V32, P139, DOI 10.1111/j.1399-0039.1988.tb01649.x; KARJALAINEN J, 1989, NEW ENGL J MED, V320, P881, DOI 10.1056/NEJM198904063201401; KARJALAINEN J, 1988, DIABETOLOGIA, V31, P129, DOI 10.1007/BF00276844; KARJALAINEN JK, 1990, DIABETES, V39, P1144, DOI 10.2337/diabetes.39.9.1144; KOLB H, 1988, DIABETOLOGIA, V31, P189, DOI 10.1007/BF00290583; MACKENZIE T, 1989, J EXP MED, V169, P407, DOI 10.1084/jem.169.2.407; MARTIN JM, 1991, ANN MED, V23, P447, DOI 10.3109/07853899109148088; MIGLIORESAMOUR D, 1988, EXPERIENTIA, V44, P188, DOI 10.1007/BF01941703; NERUP J, 1988, DIABETES CARE, V11, P16; PAGANO G, 1987, DIABETES, V36, P859, DOI 10.2337/diabetes.36.7.859; POCECCO M, 1991, HORM RES, V35, P67; REIJONEN H, 1991, DIABETES, V40, P1640, DOI 10.2337/diabetes.40.12.1640; SAVILAHTI E, 1988, DIABETES RES CLIN EX, V7, P137; SCOTT FW, 1990, AM J CLIN NUTR, V51, P489; SCOTT FW, 1989, DIABETES 1988, P763; TARN AC, 1988, LANCET, V1, P845; THIVOLET C, 1988, DIABETOLOGIA, V31, P741, DOI 10.1007/BF00274776; TODD JA, 1991, NATURE, V351, P542, DOI 10.1038/351542a0; VIRTANEN SM, 1991, DIABETES CARE, V14, P415, DOI 10.2337/diacare.14.5.415; WALTER MA, 1991, J EXP MED, V174, P335, DOI 10.1084/jem.174.2.335; YOKOTA A, 1990, DIABETES RES CLIN PR, V9, P211, DOI 10.1016/0168-8227(90)90047-W	36	366	373	2	11	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 30	1992	327	5					302	307		10.1056/NEJM199207303270502	http://dx.doi.org/10.1056/NEJM199207303270502			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JF655	1377788				2022-12-01	WOS:A1992JF65500002
J	KLEUSS, C; SCHERUBL, H; HESCHELER, J; SCHULTZ, G; WITTIG, B				KLEUSS, C; SCHERUBL, H; HESCHELER, J; SCHULTZ, G; WITTIG, B			DIFFERENT BETA-SUBUNITS DETERMINE G-PROTEIN INTERACTION WITH TRANSMEMBRANE RECEPTORS	NATURE			English	Article							GTP-BINDING PROTEINS; MUSCARINIC K+-CHANNEL; GAMMA-SUBUNITS; ADENYLATE-CYCLASE; INHIBITION; TRANSDUCIN; PHOSPHOLIPASE-A2; DIVERSITY; RHODOPSIN; ACTIVATE	REGULATORY GTP-binding proteins (G proteins) are membrane-attached heterotrimers (alpha, beta, gamma) that mediate cellular responses to a wide variety of extracellular stimuli1,2. They undergo a cycle of guanine-nucleotide exchange and GTP hydrolysis, during which they dissociate into alpha-subunit and beta-gamma-complex1. The roles of G-protein alpha-subunits in these processes and for the specificity of signal transduction are largely established; the beta- and gamma-subunits are essential for receptor-induced G-protein activation and seem to be less diverse and less specific. Although the complementary DNAs for several beta-subunits have been cloned2,5-8, isolated subunits have only been studied as beta-gamma-complexes3,9-12. Functional differences have been ascribed to the gamma-subunit on the basis of extensive sequence similarity among beta-subunits and apparent heterogeneity in gamma-subunit sequences13,14. Beta-gamma-complexes can inter act directly or indirectly with different effectors10,11,15-20. They seem to be interchangeable in their interaction with pertussis toxin-sensitive alpha-subunits3, so we tested this by microinjecting antisense oligonucleotides into nuclei of a rat pituitary cell line to suppress the synthesis of individual beta-subunits selectively. Here we show that two out of four subtypes of beta-subunits tested (beta-1 and beta-3) are selectively involved in the signal transduction cascades from muscarinic M4 (ref. 4) and somatostatin receptors, respectively, to voltage-dependent Ca2+ channels.	FREE UNIV BERLIN,INST PHARMAKOL,W-1000 BERLIN 33,GERMANY	Free University of Berlin	KLEUSS, C (corresponding author), FREE UNIV BERLIN,INST MOLEK BIOL & BIOCHEM,ARNIMALLEE 22,W-1000 BERLIN 33,GERMANY.							BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BOYER JL, 1989, J BIOL CHEM, V264, P13917; CERIONE RA, 1987, BIOCHEMISTRY-US, V26, P1485, DOI 10.1021/bi00379a041; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CODINA J, 1986, FEBS LETT, V207, P187, DOI 10.1016/0014-5793(86)81486-7; FAWZI AB, 1991, J BIOL CHEM, V266, P12194; FISHER KJ, 1992, MOL CELL BIOL, V12, P1585, DOI 10.1128/MCB.12.4.1585; GAO B, 1987, P NATL ACAD SCI USA, V84, P6122, DOI 10.1073/pnas.84.17.6122; HEKMAN M, 1987, EUR J BIOCHEM, V169, P431, DOI 10.1111/j.1432-1033.1987.tb13630.x; JELSEMA CL, 1987, P NATL ACAD SCI USA, V84, P3623, DOI 10.1073/pnas.84.11.3623; KANAHO Y, 1984, J BIOL CHEM, V259, P7378; KATADA T, 1987, J BIOL CHEM, V262, P11897; KIM D, 1989, NATURE, V337, P557, DOI 10.1038/337557a0; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; LAW SF, 1991, J BIOL CHEM, V266, P17885; LEVINE MA, 1990, P NATL ACAD SCI USA, V87, P2329, DOI 10.1073/pnas.87.6.2329; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; OKABE K, 1990, J BIOL CHEM, V265, P12854; PINKASKRAMARSKI R, 1990, NEUROSCI LETT, V108, P335, DOI 10.1016/0304-3940(90)90663-T; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SIMONDS WF, 1991, J BIOL CHEM, V266, P5363; TAMIR H, 1991, BIOCHEMISTRY-US, V30, P3929, DOI 10.1021/bi00230a018; VONWEIZSACKER E, 1992, BIOCHEM BIOPH RES CO, V183, P350, DOI 10.1016/0006-291X(92)91650-F	23	373	376	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 30	1992	358	6385					424	426		10.1038/358424a0	http://dx.doi.org/10.1038/358424a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JF853	1322501				2022-12-01	WOS:A1992JF85300059
J	KYRIAKIS, JM; APP, H; ZHANG, XF; BANERJEE, P; BRAUTIGAN, DL; RAPP, UR; AVRUCH, J				KYRIAKIS, JM; APP, H; ZHANG, XF; BANERJEE, P; BRAUTIGAN, DL; RAPP, UR; AVRUCH, J			RAF-1 ACTIVATES MAP KINASE-KINASE	NATURE			English	Article							THREONINE PROTEIN-KINASE; EPIDERMAL GROWTH-FACTOR; T-CELL ACTIVATION; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; INSULIN; PATHWAYS; CASCADE	THE normal cellular homologue of the acutely transforming oncogene v-raf is c-raf-1, which encodes a serine/threonine protein kinase that is activated by many extracellular stimuli1. The physiological substrates of the protein c-Raf-1 are unknown. The mitogen-activated protein (MAP) kinases Erk1 and 2 are also activated by mitogens through phosphorylation of Erk tyrosine and threonine residues catalysed by a protein kinase of relative molecular mass 50,000, MAP kinase-kinase (MAPK-K)2-7. Here we report that MAPK-K as well as Erk1 and 2 are constitutively active in v-raf-transformed cells. MAPK-K partially purified from v-raf-transformed cells or from mitogen-treated cells3 can be deactivated by phosphatase 2A. c-Raf-1 purified after mitogen stimulation can reactivate the phosphatase 2A-inactivated MAPK-K over 30-fold in vitro. c-Raf-1 reactivation of MAPK-K coincides with the selective phosphorylation at serine/threonine residues of a polypeptide with M(r) 50,000 which coelutes precisely on cation-exchange chromatography with the MAPK-K activatable by c-Raf-1. These results indicate that c-Raf-1 is an immediate upstream activator of MAPK-K in vivo. To our knowledge, MAPK-K is the first physiological substrate of the c-raf-1 protooncogene product to be identified.	HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; NCI,FREDERICK CANC RES & DEV CTR,VIRAL CARCINOGENESIS LAB,FREDERICK,MD 21702; BROWN UNIV,DIV BIOL & MED,PROVIDENCE,RI 02912	Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Brown University	KYRIAKIS, JM (corresponding author), MASSACHUSETTS GEN HOSP,MED SERV,DIABET UNIT,149 13TH ST,BOSTON,MA 02129, USA.							AHN NG, 1991, J BIOL CHEM, V266, P4220; AHN NG, 1990, J BIOL CHEM, V265, P11487; ALLEMAIN GL, 1992, MOL CELL BIOL, V12, P2222; ANDERSON NG, 1991, BIOCHEM J, V277, P573, DOI 10.1042/bj2770573; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GROVE JR, 1987, SCIENCE, V238, P530; HSI ED, 1989, J BIOL CHEM, V264, P10836; JONES SW, 1989, J BIOL CHEM, V264, P7747; KYRIAKIS JM, 1990, BIOCHIM BIOPHYS ACTA, V1054, P73, DOI 10.1016/0167-4889(90)90207-T; KYRIAKIS JM, 1990, J BIOL CHEM, V265, P17355; KYRIAKIS JM, 1991, J BIOL CHEM, V266, P10043; LEE RM, 1992, J BIOL CHEM, V267, P1088; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAPP UR, 1991, ONCOGENE, V6, P495; RAPP UR, 1983, J VIROL, V45, P914, DOI 10.1128/JVI.45.3.914-924.1983; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; TAKEDA M, 1988, J BIOL CHEM, V258, P10455; TROPPMAIR J, IN PRESS ONCOGENE	26	1187	1206	1	50	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 30	1992	358	6385					417	421		10.1038/358417a0	http://dx.doi.org/10.1038/358417a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JF853	1322500				2022-12-01	WOS:A1992JF85300057
J	RELMAN, DA; SCHMIDT, TM; MACDERMOTT, RP; FALKOW, S				RELMAN, DA; SCHMIDT, TM; MACDERMOTT, RP; FALKOW, S			IDENTIFICATION OF THE UNCULTURED BACILLUS OF WHIPPLES DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PHYLOGENETIC ANALYSIS; INFECTION; GRANULOMAS; ORGANISMS; EVOLUTION; BACTERIA; AGENT; AIDS	Background. Whipple's disease is a systemic disorder known for 85 years to be associated with an uncultured, and therefore unidentified, bacillus. Methods. We used a molecular genetic approach to identify this organism. The bacterial 16S ribosomal RNA (rRNA) sequence was amplified directly from tissues of five unrelated patients with Whipple's disease by means of the polymerase chain reaction, first with broad-range primers and then with specific primers. We determined and analyzed the nucleotide sequence of the amplification products. Results. A unique 1321-base bacterial 16S rRNA sequence was amplified from duodenal tissue of one patient. This sequence indicated the presence of a previously un characterized organism. We then detected this sequence in tissues from all 5 patients with Whipple's disease, but in none of those from 10 patients without the disorder. According to phylogenetic analysis, this bacterium is a gram-positive actinomycete that is not closely related to any known genus. Conclusions. We have identified the uncultured bacillus associated with Whipple's disease. The phylogenetic relations of this bacterium, its distinct morphologic characteristics, and the unusual features of the disease are sufficient grounds for naming this bacillus Tropheryma whippelii gen. nov. sp. nov. Our findings also provide a basis for a specific diagnostic test for this organism.	STANFORD UNIV, DEPT MED, STANFORD, CA 94305 USA; STANFORD UNIV, CTR DIGEST DIS, STANFORD, CA 94305 USA; STANFORD UNIV, DEPT MICROBIOL & IMMUNOL, STANFORD, CA 94305 USA; MIAMI UNIV, DEPT MICROBIOL, OXFORD, OH 45056 USA; UNIV PENN, DEPT MED, DIV GASTROENTEROL, PHILADELPHIA, PA 19104 USA	Stanford University; Stanford University; Stanford University; University System of Ohio; Miami University; University of Pennsylvania				Schmidt, Thomas/0000-0002-8209-6055; Relman, David A./0000-0001-8331-1354	NIAID NIH HHS [AI-26195] Funding Source: Medline; NIDDK NIH HHS [DK-21474, DK-38707] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026195] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK021474, R01DK021474, P30DK038707] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAUER HM, 1991, JAMA-J AM MED ASSOC, V265, P472, DOI 10.1001/jama.265.4.472; CHEARS WC, 1961, GASTROENTEROLOGY, V41, P129; CHO C, 1984, GASTROENTEROLOGY, V87, P941; CIMPRICH RE, 1977, VET PATHOL, V14, P95, DOI 10.1177/030098587701400201; CLANCY RL, 1975, BRIT MED J, V3, P568, DOI 10.1136/bmj.3.5983.568; Clark JB, 1972, CRIT REV MICROBIOL, V1, P521; COLLINS MD, 1989, INT J SYST BACTERIOL, V39, P1, DOI 10.1099/00207713-39-1-1; DOBBINS WO, 1981, GASTROENTEROLOGY, V80, P1468; DOBBINS WO, 1987, WHIPPLES DISEASE; EDEN PA, 1991, INT J SYST BACTERIOL, V41, P324, DOI 10.1099/00207713-41-2-324; FELDMAN M, 1989, GASTROENTEROLOGY, V96, P1207, DOI 10.1016/0016-5085(89)91643-0; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; FLEMING JL, 1988, MAYO CLIN PROC, V63, P539, DOI 10.1016/S0025-6196(12)64884-8; FOX GE, 1992, INT J SYST BACTERIOL, V42, P166, DOI 10.1099/00207713-42-1-166; GILLIN JS, 1983, GASTROENTEROLOGY, V85, P1187; GOODFELLOW M, 1989, BERGEYS MANUAL SYSTE, V4, P2333; GUPTA S, 1986, GASTROENTEROLOGY, V90, P1286, DOI 10.1016/0016-5085(86)90398-7; Jukes T.H., 1969, MAMMALIAN PROTEIN ME, P21, DOI DOI 10.1093/BIOINFORMATICS/BTM404; KHAVARI PA, 1991, ARCH DERMATOL, V127, P543, DOI 10.1001/archderm.127.4.543; LUSCOMBE BM, 1974, J GEN MICROBIOL, V82, P213, DOI 10.1099/00221287-82-2-213; OLSEN GJ, 1991, NUCLEIC ACIDS RES, V19, P2017, DOI 10.1093/nar/19.suppl.2017; OLSEN GJ, 1987, COLD SPRING HARB SYM, V52, P825, DOI 10.1101/SQB.1987.052.01.090; OLSEN GJ, 1986, ANNU REV MICROBIOL, V40, P337, DOI 10.1146/annurev.mi.40.100186.002005; RELMAN DA, 1990, NEW ENGL J MED, V323, P1573, DOI 10.1056/NEJM199012063232301; ROTH RI, 1983, NEW ENGL J MED, V309, P1324; SILVA MT, 1985, J GEN MICROBIOL, V131, P1001; SOUTHERN JF, 1989, JAMA-J AM MED ASSOC, V261, P1467, DOI 10.1001/jama.261.10.1467; SPAPEN HDM, 1989, DIGEST DIS SCI, V34, P640, DOI 10.1007/BF01536345; STACKEBRANDT E, 1983, J GEN MICROBIOL, V129, P1831; STAHL DA, 1990, J BACTERIOL, V172, P116, DOI 10.1128/JB.172.1.116-124.1990; STROM RL, 1983, NEW ENGL J MED, V309, P1323; TRACY TE, 1991, BIOTECHNIQUES, V11, P68; WANG HH, 1986, NEW ENGL J MED, V314, P1577; Whipple GH, 1907, B JOHNS HOPKINS HOSP, V18, P382; WILLIAMS ST, 1989, BERGEYS MANUAL SYSTE; WILSON KH, 1991, LANCET, V338, P474, DOI 10.1016/0140-6736(91)90545-Z; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987; YARDLEY JH, 1961, B JOHNS HOPKINS HOSP, V109, P80	39	901	922	0	20	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 30	1992	327	5					293	301		10.1056/NEJM199207303270501	http://dx.doi.org/10.1056/NEJM199207303270501			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JF655	1377787				2022-12-01	WOS:A1992JF65500001
J	SCHLUNEGGER, MP; GRUTTER, MG				SCHLUNEGGER, MP; GRUTTER, MG			AN UNUSUAL FEATURE REVEALED BY THE CRYSTAL-STRUCTURE AT 2.2-ANGSTROM RESOLUTION OF HUMAN TRANSFORMING GROWTH-FACTOR-BETA-2	NATURE			English	Article							FACTOR-BETA; MACROMOLECULAR CRYSTALLOGRAPHY; PROTEINS; REFINEMENT; COMPLEX; PATTERN; PROGRAM; MEMBER	TRANSFORMING growth factor type-beta-2 (TGF-beta-2)1 is a member of an expanding family of growth factors that regulate proliferation and differentiation of many different cell types2,3. TGF-beta-2 binds to various receptors4, one of which was shown to be a serine/threonine kinase5. TGF-beta-2 is involved in wound healing6, bone formation7 and modulation of immune functions8. We report here the crystal structure of TGF-beta-2 at 2.2 angstrom resolution, which reveals a novel monomer fold and dimer association. The monomer consists of two antiparallel pairs of beta-strands forming a flat curved surface and a separate, long alpha-helix. The disulphide-rich core has one disulphide bond pointing through a ring formed by the sequence motifs Cys-Ala-Gly-Ala-Cys and Cys-Lys-Cys, which are themselves connected through the cysteines. Two monomers are connected through a single disulphide bridge and associate such that the helix of one subunit interacts with the concave beta-sheet surface of the other. Four exposed loop regions might determine receptor specificity. The structure provides a suitable model for the TGF-beta-s and other members of the super-family9-11 and is the basis for the analysis of the TGF-beta-2 interactions with the receptor.			SCHLUNEGGER, MP (corresponding author), CIBA GEIGY AG,DIV PHARMACEUT,DEPT BIOTECHNOL,CH-4002 BASEL,SWITZERLAND.							BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CHEIFETZ S, 1991, J BIOL CHEM, V266, P20767; CHEIFETZ S, 1987, CELL, V48, P409, DOI 10.1016/0092-8674(87)90192-9; COX DA, 1992, ANGIOGENESIS KEY PRI, P287; IKEDA T, 1987, BIOCHEMISTRY-US, V26, P2406, DOI 10.1021/bi00383a002; JANIN J, 1978, J MOL BIOL, V125, P357, DOI 10.1016/0022-2836(78)90408-4; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JOYCE ME, 1990, J CELL BIOL, V110, P2195, DOI 10.1083/jcb.110.6.2195; LEE SJ, 1990, MOL ENDOCRINOL, V4, P1034, DOI 10.1210/mend-4-7-1034; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; MASON AJ, 1985, NATURE, V318, P659, DOI 10.1038/318659a0; Massague J., 1990, REV CELL BIOL, V6, P597; MESSERSCHMIDT A, 1987, J APPL CRYSTALLOGR, V20, P306, DOI 10.1107/S002188988708662X; OGAWA Y, 1992, J BIOL CHEM, V267, P2325; PRIESTLE JP, 1988, J APPL CRYSTALLOGR, V21, P572, DOI 10.1107/S0021889888005746; REES DC, 1980, P NATL ACAD SCI-BIOL, V77, P4633, DOI 10.1073/pnas.77.8.4633; ROBERTS AB, 1988, ADV CANCER RES, V51, P107, DOI 10.1016/S0065-230X(08)60221-3; SCHLUNEGGER MP, 1992, FEBS LETT, V303, P91, DOI 10.1016/0014-5793(92)80484-X; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; WHARTON KA, 1991, P NATL ACAD SCI USA, V88, P9214, DOI 10.1073/pnas.88.20.9214; Wozney J M, 1989, Prog Growth Factor Res, V1, P267, DOI 10.1016/0955-2235(89)90015-X; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; WRANN M, 1987, EMBO J, V6, P1633, DOI 10.1002/j.1460-2075.1987.tb02411.x	25	306	338	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 30	1992	358	6385					430	434		10.1038/358430a0	http://dx.doi.org/10.1038/358430a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JF853	1641027				2022-12-01	WOS:A1992JF85300061
J	STONER, GR; ALBRIGHT, TD				STONER, GR; ALBRIGHT, TD			NEURAL CORRELATES OF PERCEPTUAL MOTION COHERENCE	NATURE			English	Article								THE motions of overlapping contours in a visual scene may arise from the physical motion(s) of either a single or multiple surface(s). A central problem facing the visual motion system is that of assigning the most likely interpretation. The rules underlying this perceptual decision can be explored using a visual stimulus formed by superimposing two moving gratings. The resultant percept is either that of a single coherently moving 'plaid pattern' (coherent motion) or of the two component gratings sliding noncoherently across one another (noncoherent motion)1,2. When plaid patterns are configured to mimic one transparent grating overlying another, the percept of noncoherent motion dominates3. We now report that neurons in the visual cortex of rhesus monkeys exhibit changes in direction tuning that parallel this perceptual phenomenon: sensitivity to the motions of the component gratings is enhanced under conditions that favour the perception of noncoherent motion. These results challenge models of cortical visual processing that fail to take into account the contribution of figural image segmentation cues to the analysis of visual motion.			STONER, GR (corresponding author), SALK INST BIOL STUDIES,VIS CTR LAB,LA JOLLA,CA 92037, USA.							ADELSON EH, 1982, NATURE, V300, P523, DOI 10.1038/300523a0; ADELSON EH, 1984, J OPT SOC AM A, V1, P1266; BECK J, 1986, HUMAN MACHINE VISION, V2, P1; KOOI FL, IN PRESS PERCEPTION; KRAUSKOPF J, 1990, NATURE, V348, P328, DOI 10.1038/348328a0; METELLI F, 1974, SCI AM, V230, P91, DOI 10.1038/scientificamerican0474-90; MOVSHON JA, 1985, STUDY GROUP PATTERN; RODMAN HR, 1989, EXP BRAIN RES, V75, P53; STONER GR, 1990, NATURE, V344, P153, DOI 10.1038/344153a0; STONER GR, 1992, INVEST OPHTH VIS SCI, V33, P1050; VALLORTIGARA G, 1992, VISION RES, V31, P1967	11	147	147	1	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 30	1992	358	6385					412	414		10.1038/358412a0	http://dx.doi.org/10.1038/358412a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JF853	1641024				2022-12-01	WOS:A1992JF85300055
J	ALDOUS, J; HICKMAN, M; ELLAM, A; GAZZARD, B; HARGREAVES, S				ALDOUS, J; HICKMAN, M; ELLAM, A; GAZZARD, B; HARGREAVES, S			IMPACT OF HIV-INFECTION ON MORTALITY IN YOUNG MEN IN A LONDON HEALTH AUTHORITY	BRITISH MEDICAL JOURNAL			English	Article							AIDS; EPIDEMIC; ENGLAND; DEATHS; WALES	Objective-To determine the number of deaths attributable to HIV infection among men aged 15-64 in a geographically defined population in the United Kingdom. Design-Retrospective review of death certificates and linkage with local and national HIV and AIDS surveillance data. Setting-Riverside District Health Authority, London. Main outcome measures-Numbers of deaths attributed to HIV infection in male residents of Riverside aged 15-64 and 15-44 over a six month period. Proportion of attributed deaths were (i) identified from death certificates by the Office of Population Censuses and Surveys as being due to HIV infection and (ii) reported as cases of AIDS or HIV related deaths to the Public Health Laboratory Service Communicable Disease Surveillance Centre Results-34 of 213 (16%) deaths in men aged 15-64 and 27 of 69 (39%) deaths in men aged 15-44 were attributed to HIV infection. Six of 33 (18%) attributed deaths were identified by the Office of Population Censuses and Surveys and 32/34 (94%) were reported to the Communicable Disease Surveillance Centre. Conclusions-HIV infection was the leading cause of death in male residents of Riverside aged 15-44 and the third commonest cause of death in those aged 15-64. Most individuals dying of known HIV infection were reported to the Communicable Disease Surveillance Centre but identification of the true cause of death from the process of death certification was poor. Measures to improve the certification of HIV and AIDS or the use of AIDS surveillance information correctly to code the cause of death needs to be considered to ensure that the true impact of HIV infection is reflected in routine mortality statistics.	RIVERSIDE HLTH AUTHOR,DEPT PUBL HLTH,LONDON SW6 4UL,ENGLAND; WESTMINSTER MED SCH & HOSP,HIV GENITOURINARY MED UNIT,LONDON SW1P 2AP,ENGLAND	Imperial College London			Hickman, Matthew/Y-2400-2019	Hickman, Matthew/0000-0001-9864-459X				BOBBY JJ, 1988, PUBLIC HEALTH, V102, P519, DOI 10.1016/S0033-3506(88)80020-9; DECOCK KM, 1990, SCIENCE, V249, P793, DOI 10.1126/science.2167515; EVANS GE, 1991, BMJ, V302, P1351; FENNA D, 1984, COMPUT PROG BIOMED, V19, P31, DOI 10.1016/0010-468X(84)90035-7; HICKMAN M, 1990, LANCET, V336, P1328, DOI 10.1016/0140-6736(90)93020-P; HICKMAN M, 1991, BRIT MED J, V302, P1376, DOI 10.1136/bmj.302.6789.1376; MCCORMICK A, 1989, PHILOS T ROY SOC B, V325, P163, DOI 10.1098/rstb.1989.0081; MCCORMICK A, 1991, BRIT MED J, V302, P1365, DOI 10.1136/bmj.302.6789.1365; MCCORMICK A, 1988, BRIT MED J, V296, P1289, DOI 10.1136/bmj.296.6632.1289; MCCORMICK A, 1991, BRIT MED J, V302, P1375, DOI 10.1136/bmj.302.6789.1375; 1991, Q SURVEILLANCE TABLE; 1990, STATE PUBLIC HLTH YE; 1991, MMWR, V40, P41; 1987, MMWR S1, V36, P3; 1986, MMWR S2, V35, P1	15	12	12	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 25	1992	305	6847					219	221		10.1136/bmj.305.6847.219	http://dx.doi.org/10.1136/bmj.305.6847.219			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG112	1392823	Green Published, Green Submitted, Bronze			2022-12-01	WOS:A1992JG11200020
J	DAVIES, PH; FRANKLYN, JA; SHEPPARD, MC				DAVIES, PH; FRANKLYN, JA; SHEPPARD, MC			TREATMENT OF AMIODARONE INDUCED THYROTOXICOSIS WITH CARBIMAZOLE ALONE AND CONTINUATION OF AMIODARONE	BRITISH MEDICAL JOURNAL			English	Article							INDUCED HYPERTHYROIDISM				DAVIES, PH (corresponding author), UNIV BIRMINGHAM,QUEEN ELIZABETH HOSP,DEPT MED,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND.							GAMMAGE MD, 1987, Q J MED, V283, P83; MARTINO E, 1987, HORM RES, V26, P158, DOI 10.1159/000180696; MEHRA A, 1991, AM HEART J, V122, P1160, DOI 10.1016/0002-8703(91)90488-4; REICHERT LJM, 1989, BRIT MED J, V298, P1547, DOI 10.1136/bmj.298.6687.1547; WIMPFHEIMER C, 1982, BRIT MED J, V284, P1835, DOI 10.1136/bmj.284.6332.1835-a	5	23	23	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 25	1992	305	6847					224	225		10.1136/bmj.305.6847.224	http://dx.doi.org/10.1136/bmj.305.6847.224			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG112	1392826	Green Published, Green Submitted, Bronze			2022-12-01	WOS:A1992JG11200023
J	DEWIND, CM				DEWIND, CM			A TALE OF ONE CITY	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 25	1992	305	6847					260	260		10.1136/bmj.305.6847.260	http://dx.doi.org/10.1136/bmj.305.6847.260			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG112	1392851	Green Submitted, Bronze, Green Published			2022-12-01	WOS:A1992JG11200070
J	FFYTCHE, TJ; BRANDT, F; CERCHEZ, J; STOICESCU, S; STINGL, P; FILITIS, M				FFYTCHE, TJ; BRANDT, F; CERCHEZ, J; STOICESCU, S; STINGL, P; FILITIS, M			OCULAR COMPLICATIONS OBSERVED IN LEPROSY PATIENTS IN ROMANIA	BRITISH MEDICAL JOURNAL			English	Article									EYE CLIN HOSP,BUCHAREST,ROMANIA		FFYTCHE, TJ (corresponding author), ST THOMAS HOSP,LONDON SE1 7EH,ENGLAND.							BORTHEN L, 1902, BLINDENVERHALTNISSE; COURTRIGHT P, 1988, PREVENTION BLINDNESS; FFYTCHE TJ, 1983, LEPROSY REV, V54, P271; GIBSON J B G, 1950, Med J Aust, V1, P8; Hobbs H E, 1971, Lepr Rev, V42, P131; LOWE J, 1955, P ROY SOC MED, V48, P107, DOI 10.1177/003591575504800210; PENDERGAST JJ, 1940, ARCH OPHTHALMOL-CHIC, V23, P112; SHIELDS JA, 1974, AM J OPHTHALMOL, V77, P880, DOI 10.1016/0002-9394(74)90393-6; SUZUKI T, 1980, Folia Ophthalmologica Japonica, V31, P1719; WANGSPA S, 1976, T ASIA PACIFIC ACADE, V5, P153	10	5	5	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 25	1992	305	6847					240	242		10.1136/bmj.305.6847.240	http://dx.doi.org/10.1136/bmj.305.6847.240			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG112	1392833	Bronze, Green Submitted, Green Published			2022-12-01	WOS:A1992JG11200031
J	GODFREYFAUSSETT, P; MORTIMER, PR; JENKINS, PA; STOKER, NG				GODFREYFAUSSETT, P; MORTIMER, PR; JENKINS, PA; STOKER, NG			EVIDENCE OF TRANSMISSION OF TUBERCULOSIS BY DNA FINGERPRINTING	BRITISH MEDICAL JOURNAL			English	Article							IS6110	Objective-To determine whether a subject who had died of tuberculous meningitis had been infected by a neighbour. Design-Retrospective comparison of isolates of Mycobacterium tuberculosis from the two cases and from 10 controls by DNA fingerprinting. Setting-Public Health Service Reference Laboratory for Mycobacteria and bacterial molecular genetics unit of the London School of Hygiene and Tropical Medicine. Subjects-Deceased and neighbour; 10 controls from the same city, from whom isolates had been collected over three months before the subject's death. Main outcome measures-Identity and similarity values (S(AB)) between fingerprint patterns from different isolates obtained by hybridisation of restriction fragments produced by PvuII with a probe from the insertion element IS6110/986, present in multiple copies throughout the genome of M tuberculosis. Results-Isolates from the two cases under investigation had identical fingerprints whereas those from the controls were all distinct. Two clusters of isolates with a similarity coefficient >0.25 were identified: in one, four out of five patients were born in the midlands (the birth place of the fifth was not known) and in the other all three patients were born in the Indian subcontinent. Conclusions-The data are consistent with, but do not prove, transmission of tuberculosis from the neighbour to the deceased. Geographical separation of the pools of infection may have led to the evolution of distinct clusters of fingerprint patterns. DNA fingerprinting of M tuberculosis is a powerful new tool for study of the epidemiology and pathogenesis of tuberculosis.	UNIV LONDON LONDON SCH HYG & TROP MED,DEPT CLIN SCI,BACTERIAL MOLEC GENET UNIT,LONDON WC1E 7HT,ENGLAND; PUBL HLTH LABS,COVENTRY,ENGLAND; PUBL HLTH LABS,MYCOBACTERIUM REFERENCE UNIT,CARDIFF,WALES	University of London; London School of Hygiene & Tropical Medicine			Stoker, Neil G/L-8812-2016	Stoker, Neil G/0000-0001-7055-6184				BISHOP MJ, 1991, NUCLEIC ACID PROTEIN, P359; CAMPBELL A, 1981, ANNU REV MICROBIOL, V35, P55, DOI 10.1146/annurev.mi.35.100181.000415; GODFREYFAUSSETT P, 1991, LANCET, V337, P176, DOI 10.1016/0140-6736(91)90840-L; HERMANS PWM, 1990, J CLIN MICROBIOL, V28, P1204, DOI 10.1128/JCM.28.6.1204-1213.1990; HERMANS PWM, 1990, J CLIN MICROBIOL, V28, P2052; MAZUREK GH, 1991, J CLIN MICROBIOL, V29, P2030, DOI 10.1128/JCM.29.9.2030-2033.1991; OTAL I, 1991, J CLIN MICROBIOL, V29, P1252, DOI 10.1128/JCM.29.6.1252-1254.1991; SCHMID J, 1990, J CLIN MICROBIOL, V28, P1236, DOI 10.1128/JCM.28.6.1236-1243.1990; ZAINUDDIN ZF, 1989, J GEN MICROBIOL, V135, P2347	9	38	38	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 25	1992	305	6847					221	223		10.1136/bmj.305.6847.221	http://dx.doi.org/10.1136/bmj.305.6847.221			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG112	1392824	Green Submitted, Green Published, Bronze			2022-12-01	WOS:A1992JG11200021
J	HARDMAN, TC; DUBREY, SW; LESLIE, DG; HAFIZ, M; NOBLE, MI; LANT, AF				HARDMAN, TC; DUBREY, SW; LESLIE, DG; HAFIZ, M; NOBLE, MI; LANT, AF			ERYTHROCYTE SODIUM-LITHIUM COUNTERTRANSPORT AND BLOOD-PRESSURE IN IDENTICAL TWIN PAIRS DISCORDANT FOR INSULIN-DEPENDENT DIABETES	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RED-CELLS; ESSENTIAL-HYPERTENSION; MELLITUS; CHILDREN; NEPHROPATHY; EXCHANGE	Objective-To investigate whether insulin dependent diabetes is responsible for the abnormal behaviour of the carrier in sodium-lithium countertransport and whether the diabetic state is associated with rise in blood pressure. Design-Case-control study. Setting-London teaching hospital. Subjects-44 twin pairs discordant for insulin dependent diabetes living in United Kingdom and 44 healthy control subjects matched for age, sex, and body mass index. None of the twin pairs or the controls had evidence of microalbuminuria. Main outcome measures-Sodium-lithium countertransport activity in erythrocytes and arterial blood pressure. Results-The mean (95% confidence interval) sodium-lithium countertransport activity (mmol Li per litre of red blood cells per h) of the diabetic twins (0.291 (0.244 to 0.338)) was similar to that of their non-diabetic cotwins (0.247 (0.204 to 0.290)); both values were significantly higher than that of the controls (0.187 (0.157 to 0.216), p<0.05). In addition, systolic blood pressure was higher in those twins with diabetes (127 (122 to 133) mm Hg) than in the non-diabetic cotwins (122 (117 to 127) mm Hg; p<0.01). There were no significant differences in mean diastolic blood pressure between any of the groups studied. Conclusions-The raised erythrocyte sodium-lithium countertransport activity in the diabetic twins compared with the controls seems to be inherited rather than a consequence of overt diabetes. The higher systolic blood pressure in diabetic twins than non-diabetic cotwins indicates that insulin dependent diabetes does exert a small influence on systolic blood pressure.	WESTMINSTER MED SCH & HOSP, CHARING CROSS & WESTMINSTER MED SCH, ACAD UNIT CARDIOVASC MED, LONDON SW1P 2AP, ENGLAND	Imperial College London			Leslie, Richard/AAF-6977-2020	Leslie, Richard/0000-0002-1786-1531; Hardman, Tim/0000-0002-1417-9019	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARNETT AH, 1981, DIABETOLOGIA, V20, P87, DOI 10.1007/BF00262007; CANESSA M, 1980, NEW ENGL J MED, V302, P772, DOI 10.1056/NEJM198004033021403; CANESSA M, 1989, METHOD ENZYMOL, V173, P176; CARR S, 1990, NEW ENGL J MED, V322, P500, DOI 10.1056/NEJM199002223220803; EILERS RJ, 1967, AM J CLIN PATHOL, V47, P212, DOI 10.1093/ajcp/47.2.212; FERRARI P, 1990, J HYPERTENS, V8, P491, DOI 10.1097/00004872-199006000-00001; FOYLE WJ, 1991, J HYPERTENS, V9, P713, DOI 10.1097/00004872-199108000-00004; HALKIN A, 1991, CLIN SCI, V81, P223, DOI 10.1042/cs0810223; HUNT SC, 1991, HYPERTENSION, V17, P1; IBSEN KK, 1983, ACTA PAEDIATR SCAND, V72, P191, DOI 10.1111/j.1651-2227.1983.tb09695.x; JENSEN JS, 1990, DIABETOLOGIA, V33, P619, DOI 10.1007/BF00400206; KROLEWSKI AS, 1988, NEW ENGL J MED, V318, P140, DOI 10.1056/NEJM198801213180303; LAURENZI M, 1989, HYPERTENSION, V13, P408, DOI 10.1161/01.HYP.13.5.408; LEWITTER FI, 1985, AM J HUM GENET S, V36, pS172; MANGILI R, 1988, NEW ENGL J MED, V318, P146, DOI 10.1056/NEJM198801213180304; MATHIESEN ER, 1985, DIABETES, V34, P1301, DOI 10.2337/diabetes.34.12.1301; ROWE DJF, 1990, ANN CLIN BIOCHEM, V27, P297, DOI 10.1177/000456329002700404; RUTHERFORD PA, 1992, CLIN SCI, V82, P341, DOI 10.1042/cs0820341; RUTHERFORD PA, 1990, CLIN SCI, V79, P365, DOI 10.1042/cs0790365; SCHIEKEN RM, 1989, AM J CARDIOL, V64, P1333, DOI 10.1016/0002-9149(89)90577-8; SMITH JB, 1986, CLIN CHIM ACTA, V157, P317, DOI 10.1016/0009-8981(86)90308-6; SMITH JB, 1982, CLIN CHIM ACTA, V122, P327, DOI 10.1016/0009-8981(82)90135-8; TARN AC, 1986, DIABETOLOGIA, V29, P275, DOI 10.1007/BF00452062; TREVISAN M, 1981, CLIN CHIM ACTA, V116, P319, DOI 10.1016/0009-8981(81)90051-6; TURNER ST, 1989, HYPERTENSION, V13, P378, DOI 10.1161/01.HYP.13.4.378; WALKER JD, 1990, BMJ-BRIT MED J, V301, P633; WEDER AB, 1986, J HYPERTENS, V4, pS373; 1980, DIABETES, V28, P1039; 1979, WHO TECH REP SER, V628	29	27	27	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 25	1992	305	6847					215	219		10.1136/bmj.305.6847.215	http://dx.doi.org/10.1136/bmj.305.6847.215			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG112	1392822	Green Published, Bronze, Green Submitted			2022-12-01	WOS:A1992JG11200019
J	KABUKOBA, JJ; YOUNG, P				KABUKOBA, JJ; YOUNG, P			MIDWIFERY AND BODY-FLUID CONTAMINATION	BRITISH MEDICAL JOURNAL			English	Article							PRIMARY TARGET; HIV		ALL ST HOSP,OBSTET & GYNAECOL,CHATHAM,KENT,ENGLAND									BRAATHEN LR, 1987, LANCET, V2, P1094; CHAMBERLAIN G, 1991, LANCET, V337, P1219; JESSOP JH, 1990, BRIT MED J, V300, P49, DOI 10.1136/bmj.300.6716.49-a; NIEDECKEN H, 1987, LANCET, V2, P519; 1987, REPORT RCOG SUBCOMMI	5	18	18	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 25	1992	305	6847					226	226		10.1136/bmj.305.6847.226	http://dx.doi.org/10.1136/bmj.305.6847.226			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG112	1392828	Green Published, Green Submitted, Bronze			2022-12-01	WOS:A1992JG11200025
J	MENNIE, ME; GILFILLAN, A; COMPTON, M; CURTIS, L; LISTON, WA; PULLEN, I; WHYTE, DA; BROCK, DJH				MENNIE, ME; GILFILLAN, A; COMPTON, M; CURTIS, L; LISTON, WA; PULLEN, I; WHYTE, DA; BROCK, DJH			PRENATAL SCREENING FOR CYSTIC-FIBROSIS	LANCET			English	Article							IDENTIFICATION; GENE	Screening for carriers of CF (cystic fibrosis) is now possible but the best way of delivering such a service is unknown. In one model 4348 women attending antenatal clinics in an Edinburgh maternity hospital were invited to participate in a trial of prenatal screening. Mouthwash samples were tested for six CF alleles (85% of mutant genes) and when a woman was found to be a CF carrier her partner was also tested. Heterozygous couples were offered prenatal diagnosis. 609 (14%) women declined to enter the trial and another 574 (13%) were not screened, usually because of late booking. Among the remaining 3165 women there were 111 carriers of a CF gene (1 in 29). 4 of these 111 had carrier partners and these couples opted for prenatal diagnosis, the 1 pregnancy with an affected fetus being terminated. The psychological impact of screening was assessed by the general health questionnaire. There was a significant increase in stress at the time of the test result among women identified as carriers. However, this disappeared when their male partners tested normal and did not reappear later in the pregnancy. By providing time for couples to discuss the possibility of screening and by offering the test at a point (the antenatal booking clinic) at which most pregnant women are seen, this approach has advantages, provided that counselling is readily available.	UNIV EDINBURGH,HUMAN GENET UNIT,EDINBURGH EH8 9YL,MIDLOTHIAN,SCOTLAND; UNIV EDINBURGH,DEPT OBSTET & GYNAECOL,EDINBURGH EH8 9YL,MIDLOTHIAN,SCOTLAND; UNIV EDINBURGH,DEPT PSYCHIAT,EDINBURGH EH8 9YL,MIDLOTHIAN,SCOTLAND; UNIV EDINBURGH,DEPT NURSING STUDIES,EDINBURGH EH8 9YL,MIDLOTHIAN,SCOTLAND	University of Edinburgh; University of Edinburgh; University of Edinburgh; University of Edinburgh								BROCK DJH, 1991, LANCET, V338, P1151, DOI 10.1016/0140-6736(91)92013-R; FERRIE RM, 1991, AM J HUM GENET, V49, pA993; Goldberg DPW, 1988, USERS GUIDE GEN HLTH; KEREM B, 1989, SCIENCE, V345, P1073; MARI JD, 1985, PSYCHOL MED, V15, P651; MCINTOSH I, 1989, LANCET, V2, P1404; MENNIE ME, 1992, J MED GENET, V29, P308, DOI 10.1136/jmg.29.5.308; MODELL B, 1990, J MED GENET, V27, P475, DOI 10.1136/jmg.27.8.475; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SHAPIRO DA, 1989, NEW YORK STATE J MED, V89, P317; SHARP DJ, 1988, PSYCHOL MED, V18, P503, DOI 10.1017/S0033291700008047; SHRIMPTON AE, 1991, J MED GENET, V28, P317, DOI 10.1136/jmg.28.5.317; WALD NJ, 1991, LANCET, V338, P1318, DOI 10.1016/0140-6736(91)92605-2; WATSON EK, 1991, BRIT MED J, V303, P504, DOI 10.1136/bmj.303.6801.504; 1989, PRENATAL DIAGNOSIS G	16	121	123	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 25	1992	340	8813					214	216		10.1016/0140-6736(92)90476-J	http://dx.doi.org/10.1016/0140-6736(92)90476-J			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JE758	1353143				2022-12-01	WOS:A1992JE75800011
J	RANDALL, T; MUIR, J; MANT, D				RANDALL, T; MUIR, J; MANT, D			CHOOSING THE PREVENTIVE WORKLOAD IN GENERAL-PRACTICE - PRACTICAL APPLICATION OF THE CORONARY-PREVENTION-GROUP GUIDELINES AND DUNDEE CORONARY RISK-DISK	BRITISH MEDICAL JOURNAL			English	Article								Objective-To determine the workload implications for general practice of the Coronary Prevention Group and British Heart Foundation action plan for preventing heart disease. Design-Computer simulation of plan, including calculation of Dundee risk scores, with data from OXCHECK trial. Subjects-4759 patients aged 35-64 who had health checks during 1989-91. Main outcome measure-Effect of using different risk scores as thresholds on workload and coverage of patients at known risk. Thresholds of 6-20 were used for cholesterol screening (nearset) and 4-16 for special care (preset). Results-On the basis of workload a nearset of 8 and preset of 12 would be reasonable. This implies cholesterol measurement in 1794 (37.7%) patients and special care in 1074 (22.6%). However, many patients with single risk factors were not allocated to special care at these thresholds: 11 (37.9%) patients with cholesterol concentrations greater-than-or-equal-to 10 mmol/l, 21 (33.9%) with systolic pressure greater-than-or-equal-to 180 mm Hg, and 213 (40.7%) heavy smokers (>20 cigarettes/day) were missed. The distribution of scores was similar in those at established clinical risk, those with family history of heart disease, and others. Conclusion-The guidelines may help to make best use of resources within specific age-sex groups but sound protocols for unifactorial risk assessment and modification remain essential.	UNIV OXFORD,RADCLIFFE INFIRM,DEPT PUBL HLTH & PRIMARY CARE,OXFORD OX4 1SX,ENGLAND	Radcliffe Infirmary; University of Oxford			Mant, David CA/C-7763-2009					MANN JI, 1988, BRIT MED J, V296, P1702, DOI 10.1136/bmj.296.6638.1702; Scientific Steering Committee on behalf of the Simon Broome Register Group, 1991, BMJ, V303, P893; TUNSTALLPEDOE H, 1991, BRIT MED J, V303, P744, DOI 10.1136/bmj.303.6805.744; 1991, BMJ, V303, P748; 1980, EUR HEART J, V1, P73; 1989, BMJ; 1991, BMJ, V302, P1057	7	10	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 25	1992	305	6847					227	231		10.1136/bmj.305.6847.227	http://dx.doi.org/10.1136/bmj.305.6847.227			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG112	1392829	Green Submitted, Green Published, Bronze			2022-12-01	WOS:A1992JG11200027
